1	A	N	I-MajorClaim
2	combination	N	I-MajorClaim
3	of	N	I-MajorClaim
4	mitoxantrone	N	I-MajorClaim
5	plus	N	I-MajorClaim
6	prednisone	N	I-MajorClaim
7	is	N	I-MajorClaim
8	preferable	N	I-MajorClaim
9	to	N	I-MajorClaim
10	prednisone	N	I-MajorClaim
11	alone	N	I-MajorClaim
12	for	N	I-MajorClaim
13	reduction	N	I-MajorClaim
14	of	N	I-MajorClaim
15	pain	N	I-MajorClaim
16	in	N	I-MajorClaim
17	men	N	I-MajorClaim
18	with	N	I-MajorClaim
19	metastatic	N	I-MajorClaim
20	,	N	I-MajorClaim
21	hormone-resistant	N	I-MajorClaim
22	,	N	I-MajorClaim
23	prostate	N	I-MajorClaim
24	cancer	N	I-MajorClaim
25	.	N	I-MajorClaim

26	The	N	O
27	purpose	N	O
28	of	N	O
29	this	N	O
30	study	N	O
31	was	N	O
32	to	N	O
33	assess	N	O
34	the	N	O
35	effects	N	O
36	of	N	O
37	these	N	O
38	treatments	N	O
39	on	N	O
40	health-related	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	(	N	O
45	HQL	N	O
46	)	N	O
47	.	N	O

48	Men	N	O
49	with	N	O
50	metastatic	N	O
51	prostate	N	O
52	cancer	N	O
53	(	N	O
54	n	N	O
55	=	N	O
56	161	N	O
57	)	N	O
58	were	N	O
59	randomized	N	O
60	to	N	O
61	receive	N	O
62	either	N	O
63	daily	N	O
64	prednisone	N	O
65	alone	N	O
66	or	N	O
67	mitoxantrone	N	O
68	(	N	O
69	every	N	O
70	3	N	O
71	weeks	N	O
72	)	N	O
73	plus	N	O
74	prednisone	N	O
75	.	N	O

76	Those	N	O
77	who	N	O
78	received	N	O
79	prednisone	N	O
80	alone	N	O
81	could	N	O
82	have	N	O
83	mitoxantrone	N	O
84	added	N	O
85	after	N	O
86	6	N	O
87	weeks	N	O
88	if	N	O
89	there	N	O
90	was	N	O
91	no	N	O
92	improvement	N	O
93	in	N	O
94	pain	N	O
95	.	N	O

96	HQL	N	O
97	was	N	O
98	assessed	N	O
99	before	N	O
100	treatment	N	O
101	initiation	N	O
102	and	N	O
103	then	N	O
104	every	N	O
105	3	N	O
106	weeks	N	O
107	using	N	O
108	the	N	O
109	European	N	O
110	Organization	N	O
111	for	N	O
112	Research	N	O
113	and	N	O
114	Treatment	N	O
115	of	N	O
116	Cancer	N	O
117	Quality-of-Life	N	O
118	Questionnaire	N	O
119	C30	N	O
120	(	N	O
121	EORTC	N	O
122	QLQ-C30	N	O
123	)	N	O
124	and	N	O
125	the	N	O
126	Quality	N	O
127	of	N	O
128	Life	N	O
129	Module-Prostate	N	O
130	14	N	O
131	(	N	O
132	QOLM-P14	N	O
133	)	N	O
134	,	N	O
135	a	N	O
136	trial-specific	N	O
137	module	N	O
138	developed	N	O
139	for	N	O
140	this	N	O
141	study	N	O
142	.	N	O

143	An	N	O
144	intent-to-treat	N	O
145	analysis	N	O
146	was	N	O
147	used	N	O
148	to	N	O
149	determine	N	O
150	the	N	O
151	mean	N	O
152	duration	N	O
153	of	N	O
154	HQL	N	O
155	improvement	N	O
156	and	N	O
157	differences	N	O
158	in	N	O
159	improvement	N	O
160	duration	N	O
161	between	N	O
162	groups	N	O
163	of	N	O
164	patients	N	O
165	.	N	O

166	At	N	I-Premise
167	6	N	I-Premise
168	weeks	N	I-Premise
169	,	N	I-Premise
170	both	N	I-Premise
171	groups	N	I-Premise
172	showed	N	I-Premise
173	improvement	N	I-Premise
174	in	N	I-Premise
175	several	N	I-Premise
176	HQL	N	I-Premise
177	domains	N	I-Premise
178	,	N	I-Premise
179	and	N	O
180	only	N	I-Premise
181	physical	N	I-Premise
182	functioning	N	I-Premise
183	and	N	I-Premise
184	pain	N	I-Premise
185	were	N	I-Premise
186	better	N	I-Premise
187	in	N	I-Premise
188	the	N	I-Premise
189	mitoxantrone-plus-prednisone	N	I-Premise
190	group	N	I-Premise
191	than	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	prednisone-alone	N	I-Premise
195	group	N	I-Premise
196	.	N	I-Premise

197	After	N	I-Premise
198	6	N	I-Premise
199	weeks	N	I-Premise
200	,	N	I-Premise
201	patients	N	I-Premise
202	taking	N	I-Premise
203	prednisone	N	I-Premise
204	showed	N	I-Premise
205	no	N	I-Premise
206	improvement	N	I-Premise
207	in	N	I-Premise
208	HQL	N	I-Premise
209	scores	N	I-Premise
210	,	N	I-Premise
211	whereas	N	I-Premise
212	those	N	I-Premise
213	taking	N	I-Premise
214	mitoxantrone	N	I-Premise
215	plus	N	I-Premise
216	prednisone	N	I-Premise
217	showed	N	I-Premise
218	significant	N	I-Premise
219	improvements	N	I-Premise
220	in	N	I-Premise
221	global	N	I-Premise
222	quality	N	I-Premise
223	of	N	I-Premise
224	life	N	I-Premise
225	(	N	I-Premise
226	P	N	I-Premise
227	=.009	N	I-Premise
228	)	N	I-Premise
229	,	N	I-Premise
230	four	N	I-Premise
231	functioning	N	I-Premise
232	domains	N	I-Premise
233	,	N	I-Premise
234	and	N	I-Premise
235	nine	N	I-Premise
236	symptoms	N	I-Premise
237	(	N	I-Premise
238	.001	N	I-Premise
239	<	N	I-Premise
240	P	N	I-Premise
241	<	N	I-Premise
242	.	N	I-Premise

243	01	N	I-Premise
244	)	N	I-Premise
245	,	N	I-Premise
246	and	N	O
247	the	N	I-Premise
248	improvement	N	I-Premise
249	(	N	I-Premise
250	>	N	I-Premise
251	10	N	I-Premise
252	units	N	I-Premise
253	on	N	I-Premise
254	a	N	I-Premise
255	scale	N	I-Premise
256	of	N	I-Premise
257	0	N	I-Premise
258	to100	N	I-Premise
259	)	N	I-Premise
260	lasted	N	I-Premise
261	longer	N	I-Premise
262	than	N	I-Premise
263	in	N	I-Premise
264	the	N	I-Premise
265	prednisone-alone	N	I-Premise
266	group	N	I-Premise
267	(	N	I-Premise
268	.004	N	I-Premise
269	<	N	I-Premise
270	P	N	I-Premise
271	<	N	I-Premise
272	.05	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	The	N	I-Premise
276	addition	N	I-Premise
277	of	N	I-Premise
278	mitoxantrone	N	I-Premise
279	to	N	I-Premise
280	prednisone	N	I-Premise
281	after	N	I-Premise
282	failure	N	I-Premise
283	of	N	I-Premise
284	prednisone	N	I-Premise
285	alone	N	I-Premise
286	was	N	I-Premise
287	associated	N	I-Premise
288	with	N	I-Premise
289	improvements	N	I-Premise
290	in	N	I-Premise
291	pain	N	I-Premise
292	,	N	I-Premise
293	pain	N	I-Premise
294	impact	N	I-Premise
295	,	N	I-Premise
296	pain	N	I-Premise
297	relief	N	I-Premise
298	,	N	I-Premise
299	insomnia	N	I-Premise
300	,	N	I-Premise
301	and	N	I-Premise
302	global	N	I-Premise
303	quality	N	I-Premise
304	of	N	I-Premise
305	life	N	I-Premise
306	(	N	I-Premise
307	.001	N	I-Premise
308	<	N	I-Premise
309	P	N	I-Premise
310	<	N	I-Premise
311	.003	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	Treatment	N	I-Claim
315	with	N	I-Claim
316	mitoxantrone	N	I-Claim
317	plus	N	I-Claim
318	prednisone	N	I-Claim
319	was	N	I-Claim
320	associated	N	I-Claim
321	with	N	I-Claim
322	greater	N	I-Claim
323	and	N	I-Claim
324	longer-lasting	N	I-Claim
325	improvement	N	I-Claim
326	in	N	I-Claim
327	several	N	I-Claim
328	HQL	N	I-Claim
329	domains	N	I-Claim
330	and	N	I-Claim
331	symptoms	N	I-Claim
332	than	N	I-Claim
333	treatment	N	I-Claim
334	with	N	I-Claim
335	prednisone	N	I-Claim
336	alone	N	I-Claim
337	.	N	I-Claim

1	In	N	I-Claim
2	endocrine	N	I-Claim
3	therapy	N	I-Claim
4	trials	N	I-Claim
5	in	N	I-Claim
6	advanced	N	I-Claim
7	breast	N	I-Claim
8	cancer	N	I-Claim
9	,	N	I-Claim
10	patients	N	I-Claim
11	with	N	I-Claim
12	response	N	I-Claim
13	(	N	I-Claim
14	complete	N	I-Claim
15	response/partial	N	I-Claim
16	response	N	I-Claim
17	[	N	I-Claim
18	CR/PR	N	I-Claim
19	]	N	I-Claim
20	)	N	I-Claim
21	and	N	I-Claim
22	patients	N	I-Claim
23	with	N	I-Claim
24	stable	N	I-Claim
25	disease	N	I-Claim
26	for	N	I-Claim
27	at	N	I-Claim
28	least	N	I-Claim
29	6	N	I-Claim
30	months	N	I-Claim
31	(	N	I-Claim
32	SD	N	I-Claim
33	(	N	I-Claim
34	6m	N	I-Claim
35	)	N	I-Claim
36	)	N	I-Claim
37	have	N	I-Claim
38	shown	N	I-Claim
39	similar	N	I-Claim
40	survival	N	I-Claim
41	and	N	I-Claim
42	therefore	N	I-Claim
43	are	N	I-Claim
44	often	N	I-Claim
45	defined	N	I-Claim
46	as	N	I-Claim
47	a	N	I-Claim
48	population	N	I-Claim
49	with	N	I-Claim
50	clinical	N	I-Claim
51	benefit	N	I-Claim
52	(	N	I-Claim
53	patients	N	I-Claim
54	with	N	I-Claim
55	CR/PR	N	I-Claim
56	or	N	I-Claim
57	SD	N	I-Claim
58	(	N	I-Claim
59	6m	N	I-Claim
60	)	N	I-Claim
61	)	N	I-Claim
62	.	N	I-Claim

63	We	N	O
64	evaluated	N	O
65	the	N	O
66	impact	N	O
67	of	N	O
68	response	N	O
69	and/or	N	O
70	clinical	N	O
71	benefit	N	O
72	on	N	O
73	quality	N	O
74	of	N	O
75	life	N	O
76	(	N	O
77	QL	N	O
78	)	N	O
79	in	N	O
80	postmenopausal	N	O
81	patients	N	O
82	under	N	O
83	second-line	N	O
84	endocrine	N	O
85	treatment	N	O
86	after	N	O
87	failure	N	O
88	of	N	O
89	tamoxifen	N	O
90	.	N	O

91	One	N	O
92	hundred	N	O
93	twenty-eight	N	O
94	of	N	O
95	177	N	O
96	eligible	N	O
97	patients	N	O
98	of	N	O
99	a	N	O
100	randomized	N	O
101	trial	N	O
102	(	N	O
103	Swiss	N	O
104	Group	N	O
105	for	N	O
106	Clinical	N	O
107	Cancer	N	O
108	Research	N	O
109	20/90	N	O
110	)	N	O
111	receiving	N	O
112	either	N	O
113	formestane	N	O
114	(	N	O
115	250	N	O
116	mg	N	O
117	intramuscularly	N	O
118	biweekly	N	O
119	)	N	O
120	or	N	O
121	megestrol	N	O
122	acetate	N	O
123	(	N	O
124	160	N	O
125	mg	N	O
126	orally	N	O
127	daily	N	O
128	)	N	O
129	were	N	O
130	analyzed	N	O
131	.	N	O

132	The	N	O
133	baseline	N	O
134	characteristics	N	O
135	(	N	O
136	with	N	O
137	the	N	O
138	exception	N	O
139	of	N	O
140	site	N	O
141	of	N	O
142	metastases	N	O
143	)	N	O
144	were	N	O
145	balanced	N	O
146	among	N	O
147	patients	N	O
148	with	N	O
149	CR/PR	N	O
150	,	N	O
151	SD	N	O
152	(	N	O
153	6m	N	O
154	)	N	O
155	,	N	O
156	and	N	O
157	progressive	N	O
158	disease	N	O
159	(	N	O
160	PD	N	O
161	)	N	O
162	.	N	O

163	Patients	N	O
164	completed	N	O
165	QL	N	O
166	indicators	N	O
167	at	N	O
168	baseline	N	O
169	and	N	O
170	at	N	O
171	1	N	O
172	,	N	O
173	3	N	O
174	,	N	O
175	5	N	O
176	,	N	O
177	7	N	O
178	,	N	O
179	9	N	O
180	,	N	O
181	and	N	O
182	11	N	O
183	months	N	O
184	.	N	O

185	Responders	N	O
186	were	N	O
187	separately	N	O
188	compared	N	O
189	with	N	O
190	nonresponders	N	O
191	(	N	O
192	patients	N	O
193	with	N	O
194	SD	N	O
195	(	N	O
196	6m	N	O
197	)	N	O
198	or	N	O
199	PD	N	O
200	)	N	O
201	and	N	O
202	with	N	O
203	patients	N	O
204	with	N	O
205	SD	N	O
206	(	N	O
207	6m	N	O
208	)	N	O
209	,	N	O
210	and	N	O
211	patients	N	O
212	with	N	O
213	clinical	N	O
214	benefit	N	O
215	were	N	O
216	compared	N	O
217	with	N	O
218	patients	N	O
219	with	N	O
220	PD	N	O
221	by	N	O
222	analysis	N	O
223	of	N	O
224	covariance	N	O
225	with	N	O
226	adjustment	N	O
227	for	N	O
228	baseline	N	O
229	scores	N	O
230	.	N	O

231	Overall	N	O
232	,	N	O
233	88	N	O
234	%	N	O
235	(	N	O
236	557	N	O
237	of	N	O
238	634	N	O
239	)	N	O
240	of	N	O
241	expected	N	O
242	QL	N	O
243	forms	N	O
244	were	N	O
245	received	N	O
246	.	N	O

247	In	N	O
248	the	N	O
249	comparison	N	O
250	of	N	O
251	responders	N	O
252	versus	N	O
253	patients	N	O
254	with	N	O
255	both	N	O
256	SD	N	O
257	(	N	O
258	6m	N	O
259	)	N	O
260	and	N	O
261	PD	N	O
262	,	N	O
263	responders	N	I-Premise
264	indicated	N	I-Premise
265	better	N	I-Premise
266	physical	N	I-Premise
267	well-being	N	I-Premise
268	(	N	I-Premise
269	P	N	I-Premise
270	=	N	I-Premise
271	.	N	I-Premise

272	004	N	I-Premise
273	)	N	I-Premise
274	and	N	I-Premise
275	mood	N	I-Premise
276	(	N	I-Premise
277	P	N	I-Premise
278	=.02	N	I-Premise
279	)	N	I-Premise
280	at	N	I-Premise
281	month	N	I-Premise
282	3	N	I-Premise
283	.	N	I-Premise

284	Compared	N	I-Premise
285	only	N	I-Premise
286	with	N	I-Premise
287	patients	N	I-Premise
288	with	N	I-Premise
289	SD	N	I-Premise
290	(	N	I-Premise
291	6m	N	I-Premise
292	)	N	I-Premise
293	,	N	I-Premise
294	responders	N	I-Premise
295	showed	N	I-Premise
296	no	N	I-Premise
297	significant	N	I-Premise
298	difference	N	I-Premise
299	in	N	I-Premise
300	baseline	N	I-Premise
301	QL	N	I-Premise
302	and	N	I-Premise
303	time	N	I-Premise
304	to	N	I-Premise
305	treatment	N	I-Premise
306	failure	N	I-Premise
307	(	N	I-Premise
308	328.5	N	I-Premise
309	v	N	I-Premise
310	340	N	I-Premise
311	days	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	While	N	I-Premise
315	under	N	I-Premise
316	treatment	N	I-Premise
317	,	N	I-Premise
318	responders	N	I-Premise
319	reported	N	I-Premise
320	significantly	N	I-Premise
321	better	N	I-Premise
322	physical	N	I-Premise
323	well-being	N	I-Premise
324	(	N	I-Premise
325	months	N	I-Premise
326	3	N	I-Premise
327	to	N	I-Premise
328	11	N	I-Premise
329	)	N	I-Premise
330	,	N	I-Premise
331	mood	N	I-Premise
332	(	N	I-Premise
333	months	N	I-Premise
334	5	N	I-Premise
335	to	N	I-Premise
336	11	N	I-Premise
337	)	N	I-Premise
338	,	N	I-Premise
339	coping	N	I-Premise
340	(	N	I-Premise
341	months	N	I-Premise
342	5	N	I-Premise
343	to	N	I-Premise
344	9	N	I-Premise
345	)	N	I-Premise
346	,	N	I-Premise
347	and	N	I-Premise
348	appetite	N	I-Premise
349	(	N	I-Premise
350	months	N	I-Premise
351	7	N	I-Premise
352	to	N	I-Premise
353	11	N	I-Premise
354	)	N	I-Premise
355	and	N	I-Premise
356	less	N	I-Premise
357	dizziness	N	I-Premise
358	(	N	I-Premise
359	month	N	I-Premise
360	9	N	I-Premise
361	)	N	I-Premise
362	than	N	I-Premise
363	patients	N	I-Premise
364	with	N	I-Premise
365	SD	N	I-Premise
366	(	N	I-Premise
367	6m	N	I-Premise
368	)	N	I-Premise
369	.	N	I-Premise

370	The	N	I-Premise
371	changes	N	I-Premise
372	between	N	I-Premise
373	baseline	N	I-Premise
374	and	N	I-Premise
375	months	N	I-Premise
376	5	N	I-Premise
377	and	N	I-Premise
378	7	N	I-Premise
379	,	N	I-Premise
380	respectively	N	I-Premise
381	,	N	I-Premise
382	indicated	N	I-Premise
383	improvement	N	I-Premise
384	in	N	I-Premise
385	responders	N	I-Premise
386	but	N	I-Premise
387	heterogeneous	N	I-Premise
388	patterns	N	I-Premise
389	in	N	I-Premise
390	patients	N	I-Premise
391	with	N	I-Premise
392	SD	N	I-Premise
393	(	N	I-Premise
394	6m	N	I-Premise
395	)	N	I-Premise
396	.	N	I-Premise

397	Although	N	I-Premise
398	the	N	I-Premise
399	CR/PR	N	I-Premise
400	and	N	I-Premise
401	SD	N	I-Premise
402	(	N	I-Premise
403	6m	N	I-Premise
404	)	N	I-Premise
405	groups	N	I-Premise
406	had	N	I-Premise
407	similar	N	I-Premise
408	times	N	I-Premise
409	to	N	I-Premise
410	treatment	N	I-Premise
411	failure	N	I-Premise
412	,	N	I-Premise
413	patients	N	I-Claim
414	with	N	I-Claim
415	CR/PR	N	I-Claim
416	reported	N	I-Claim
417	better	N	I-Claim
418	QL	N	I-Claim
419	,	N	I-Claim
420	suggesting	N	I-Claim
421	more	N	I-Claim
422	beneficial	N	I-Claim
423	response	N	I-Claim
424	to	N	I-Claim
425	second-line	N	I-Claim
426	endocrine	N	I-Claim
427	treatment	N	I-Claim
428	.	N	I-Claim

429	Patients	N	O
430	'	N	O
431	subjective	N	O
432	perspective	N	O
433	should	N	O
434	be	N	O
435	taken	N	O
436	into	N	O
437	account	N	O
438	in	N	O
439	this	N	O
440	mainly	N	O
441	palliative	N	O
442	setting	N	O
443	.	N	O

444	Future	N	O
445	trials	N	O
446	should	N	O
447	be	N	O
448	designed	N	O
449	so	N	O
450	that	N	O
451	the	N	O
452	CR/PR	N	O
453	and	N	O
454	SD	N	O
455	(	N	O
456	6m	N	O
457	)	N	O
458	groups	N	O
459	are	N	O
460	investigated	N	O
461	separately	N	O
462	.	N	O

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	cisplatin-based	N	I-Claim
4	chemotherapy	N	I-Claim
5	provides	N	I-Claim
6	a	N	I-Claim
7	modest	N	I-Claim
8	survival	N	I-Claim
9	advantage	N	I-Claim
10	over	N	I-Claim
11	supportive	N	I-Claim
12	care	N	I-Claim
13	alone	N	I-Claim
14	in	N	I-Claim
15	advanced	N	I-Claim
16	non-small-cell	N	I-Claim
17	lung	N	I-Claim
18	cancer	N	I-Claim
19	(	N	I-Claim
20	NSCLC	N	I-Claim
21	)	N	I-Claim
22	.	N	I-Claim

23	To	N	O
24	determine	N	O
25	whether	N	O
26	a	N	O
27	new	N	O
28	agent	N	O
29	,	N	O
30	paclitaxel	N	O
31	,	N	O
32	would	N	O
33	further	N	O
34	improve	N	O
35	survival	N	O
36	in	N	O
37	NSCLC	N	O
38	,	N	O
39	the	N	O
40	Eastern	N	O
41	Cooperative	N	O
42	Oncology	N	O
43	Group	N	O
44	conducted	N	O
45	a	N	O
46	randomized	N	O
47	trial	N	O
48	comparing	N	O
49	paclitaxel	N	O
50	plus	N	O
51	cisplatin	N	O
52	to	N	O
53	a	N	O
54	standard	N	O
55	chemotherapy	N	O
56	regimen	N	O
57	consisting	N	O
58	of	N	O
59	cisplatin	N	O
60	and	N	O
61	etoposide	N	O
62	.	N	O

63	The	N	O
64	study	N	O
65	was	N	O
66	carried	N	O
67	out	N	O
68	by	N	O
69	a	N	O
70	multi-institutional	N	O
71	cooperative	N	O
72	group	N	O
73	in	N	O
74	chemotherapy-naive	N	O
75	stage	N	O
76	IIIB	N	O
77	to	N	O
78	IV	N	O
79	NSCLC	N	O
80	patients	N	O
81	randomized	N	O
82	to	N	O
83	receive	N	O
84	paclitaxel	N	O
85	plus	N	O
86	cisplatin	N	O
87	or	N	O
88	etoposide	N	O
89	plus	N	O
90	cisplatin	N	O
91	.	N	O

92	Paclitaxel	N	O
93	was	N	O
94	administered	N	O
95	at	N	O
96	two	N	O
97	different	N	O
98	dose	N	O
99	levels	N	O
100	(	N	O
101	135	N	O
102	mg/m	N	O
103	(	N	O
104	2	N	O
105	)	N	O
106	and	N	O
107	250	N	O
108	mg/m	N	O
109	(	N	O
110	2	N	O
111	)	N	O
112	)	N	O
113	,	N	O
114	and	N	O
115	etoposide	N	O
116	was	N	O
117	given	N	O
118	at	N	O
119	a	N	O
120	dose	N	O
121	of	N	O
122	100	N	O
123	mg/m	N	O
124	(	N	O
125	2	N	O
126	)	N	O
127	daily	N	O
128	on	N	O
129	days	N	O
130	1	N	O
131	to	N	O
132	3	N	O
133	.	N	O

134	Each	N	O
135	regimen	N	O
136	was	N	O
137	repeated	N	O
138	every	N	O
139	21	N	O
140	days	N	O
141	and	N	O
142	each	N	O
143	included	N	O
144	cisplatin	N	O
145	(	N	O
146	75	N	O
147	mg/m	N	O
148	(	N	O
149	2	N	O
150	)	N	O
151	)	N	O
152	.	N	O

153	The	N	O
154	characteristics	N	O
155	of	N	O
156	the	N	O
157	599	N	O
158	patients	N	O
159	were	N	O
160	well-balanced	N	O
161	across	N	O
162	the	N	O
163	three	N	O
164	treatment	N	O
165	groups	N	O
166	.	N	O

167	Superior	N	I-Premise
168	survival	N	I-Premise
169	was	N	I-Premise
170	observed	N	I-Premise
171	with	N	I-Premise
172	the	N	I-Premise
173	combined	N	I-Premise
174	paclitaxel	N	I-Premise
175	regimens	N	I-Premise
176	(	N	I-Premise
177	median	N	I-Premise
178	survival	N	I-Premise
179	time	N	I-Premise
180	,	N	I-Premise
181	9.9	N	I-Premise
182	months	N	I-Premise
183	;	N	I-Premise
184	1-year	N	I-Premise
185	survival	N	I-Premise
186	rate	N	I-Premise
187	,	N	I-Premise
188	38.9	N	I-Premise
189	%	N	I-Premise
190	)	N	I-Premise
191	compared	N	I-Premise
192	with	N	I-Premise
193	etoposide	N	I-Premise
194	plus	N	I-Premise
195	cisplatin	N	I-Premise
196	(	N	I-Premise
197	median	N	I-Premise
198	survival	N	I-Premise
199	time	N	I-Premise
200	,	N	I-Premise
201	7.6	N	I-Premise
202	months	N	I-Premise
203	;	N	I-Premise
204	1-year	N	I-Premise
205	survival	N	I-Premise
206	rate	N	I-Premise
207	,	N	I-Premise
208	31.8	N	I-Premise
209	%	N	I-Premise
210	;	N	I-Premise
211	P	N	I-Premise
212	=	N	I-Premise
213	.	N	I-Premise

214	048	N	I-Premise
215	)	N	I-Premise
216	.	N	I-Premise

217	Comparing	N	I-Premise
218	survival	N	I-Premise
219	for	N	I-Premise
220	the	N	I-Premise
221	two	N	I-Premise
222	dose	N	I-Premise
223	levels	N	I-Premise
224	of	N	I-Premise
225	paclitaxel	N	I-Premise
226	revealed	N	I-Premise
227	no	N	I-Premise
228	significant	N	I-Premise
229	difference	N	I-Premise
230	.	N	I-Premise

231	The	N	I-Premise
232	median	N	I-Premise
233	survival	N	I-Premise
234	duration	N	I-Premise
235	for	N	I-Premise
236	the	N	I-Premise
237	stage	N	I-Premise
238	IIIB	N	I-Premise
239	subgroup	N	I-Premise
240	was	N	I-Premise
241	7.9	N	I-Premise
242	months	N	I-Premise
243	for	N	I-Premise
244	etoposide	N	I-Premise
245	plus	N	I-Premise
246	cisplatin	N	I-Premise
247	patients	N	I-Premise
248	versus	N	I-Premise
249	13.1	N	I-Premise
250	months	N	I-Premise
251	for	N	I-Premise
252	all	N	I-Premise
253	paclitaxel	N	I-Premise
254	patients	N	I-Premise
255	(	N	I-Premise
256	P	N	I-Premise
257	=.152	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	For	N	I-Premise
261	the	N	I-Premise
262	stage	N	I-Premise
263	IV	N	I-Premise
264	subgroup	N	I-Premise
265	,	N	I-Premise
266	the	N	I-Premise
267	median	N	I-Premise
268	survival	N	I-Premise
269	time	N	I-Premise
270	for	N	I-Premise
271	etoposide	N	I-Premise
272	plus	N	I-Premise
273	cisplatin	N	I-Premise
274	was	N	I-Premise
275	7.6	N	I-Premise
276	months	N	I-Premise
277	compared	N	I-Premise
278	with	N	I-Premise
279	8.9	N	I-Premise
280	months	N	I-Premise
281	for	N	I-Premise
282	paclitaxel	N	I-Premise
283	(	N	I-Premise
284	P	N	I-Premise
285	=.246	N	I-Premise
286	)	N	I-Premise
287	.	N	I-Premise

288	With	N	I-Premise
289	the	N	I-Premise
290	exceptions	N	I-Premise
291	of	N	I-Premise
292	increased	N	I-Premise
293	granulocytopenia	N	I-Premise
294	on	N	I-Premise
295	the	N	I-Premise
296	low-dose	N	I-Premise
297	paclitaxel	N	I-Premise
298	regimen	N	I-Premise
299	and	N	I-Premise
300	increased	N	I-Premise
301	myalgias	N	I-Premise
302	,	N	I-Premise
303	neurotoxicity	N	I-Premise
304	,	N	I-Premise
305	and	N	I-Premise
306	,	N	I-Premise
307	possibly	N	I-Premise
308	,	N	I-Premise
309	increased	N	I-Premise
310	treatment-related	N	I-Premise
311	cardiac	N	I-Premise
312	events	N	I-Premise
313	with	N	I-Premise
314	high-dose	N	I-Premise
315	paclitaxel	N	I-Premise
316	,	N	I-Premise
317	toxicity	N	I-Premise
318	was	N	I-Premise
319	similar	N	I-Premise
320	across	N	I-Premise
321	all	N	I-Premise
322	three	N	I-Premise
323	arms	N	I-Premise
324	.	N	I-Premise

325	Quality	N	I-Premise
326	of	N	I-Premise
327	life	N	I-Premise
328	(	N	I-Premise
329	QOL	N	I-Premise
330	)	N	I-Premise
331	declined	N	I-Premise
332	significantly	N	I-Premise
333	over	N	I-Premise
334	the	N	I-Premise
335	6	N	I-Premise
336	months	N	I-Premise
337	.	N	I-Premise

338	However	N	O
339	,	N	O
340	QOL	N	I-Claim
341	scores	N	I-Claim
342	were	N	I-Claim
343	not	N	I-Claim
344	significantly	N	I-Claim
345	different	N	I-Claim
346	among	N	I-Claim
347	the	N	I-Claim
348	regimens	N	I-Claim
349	.	N	I-Claim

350	As	N	O
351	a	N	O
352	result	N	O
353	of	N	O
354	these	N	O
355	observations	N	O
356	,	N	O
357	paclitaxel	N	I-Claim
358	(	N	I-Claim
359	135	N	I-Claim
360	mg/m	N	I-Claim
361	(	N	I-Claim
362	2	N	I-Claim
363	)	N	I-Claim
364	)	N	I-Claim
365	combined	N	I-Claim
366	with	N	I-Claim
367	cisplatin	N	I-Claim
368	has	N	I-Claim
369	replaced	N	I-Claim
370	etoposide	N	I-Claim
371	plus	N	I-Claim
372	cisplatin	N	I-Claim
373	as	N	I-Claim
374	the	N	I-Claim
375	reference	N	I-Claim
376	regimen	N	I-Claim
377	in	N	I-Claim
378	our	N	I-Claim
379	recently	N	I-Claim
380	completed	N	I-Claim
381	phase	N	I-Claim
382	III	N	I-Claim
383	trial	N	I-Claim
384	.	N	I-Claim

1	Extracellular	N	O
2	adenosine	N	O
3	5'-triphosphate	N	O
4	(	N	O
5	ATP	N	O
6	)	N	O
7	is	N	O
8	involved	N	O
9	in	N	O
10	the	N	O
11	regulation	N	O
12	of	N	O
13	a	N	O
14	variety	N	O
15	of	N	O
16	biologic	N	O
17	processes	N	O
18	,	N	O
19	including	N	O
20	neurotransmission	N	O
21	,	N	O
22	muscle	N	O
23	contraction	N	O
24	,	N	O
25	and	N	O
26	liver	N	O
27	glucose	N	O
28	metabolism	N	O
29	,	N	O
30	via	N	O
31	purinergic	N	O
32	receptors	N	O
33	.	N	O

34	In	N	I-MajorClaim
35	nonrandomized	N	I-MajorClaim
36	studies	N	I-MajorClaim
37	involving	N	I-MajorClaim
38	patients	N	I-MajorClaim
39	with	N	I-MajorClaim
40	different	N	I-MajorClaim
41	tumor	N	I-MajorClaim
42	types	N	I-MajorClaim
43	including	N	I-MajorClaim
44	non-small-cell	N	I-MajorClaim
45	lung	N	I-MajorClaim
46	cancer	N	I-MajorClaim
47	(	N	I-MajorClaim
48	NSCLC	N	I-MajorClaim
49	)	N	I-MajorClaim
50	,	N	I-MajorClaim
51	ATP	N	I-MajorClaim
52	infusion	N	I-MajorClaim
53	appeared	N	I-MajorClaim
54	to	N	I-MajorClaim
55	inhibit	N	I-MajorClaim
56	loss	N	I-MajorClaim
57	of	N	I-MajorClaim
58	weight	N	I-MajorClaim
59	and	N	I-MajorClaim
60	deterioration	N	I-MajorClaim
61	of	N	I-MajorClaim
62	quality	N	I-MajorClaim
63	of	N	I-MajorClaim
64	life	N	I-MajorClaim
65	(	N	I-MajorClaim
66	QOL	N	I-MajorClaim
67	)	N	I-MajorClaim
68	and	N	I-MajorClaim
69	performance	N	I-MajorClaim
70	status	N	I-MajorClaim
71	.	N	I-MajorClaim

72	We	N	O
73	conducted	N	O
74	a	N	O
75	randomized	N	O
76	clinical	N	O
77	trial	N	O
78	to	N	O
79	evaluate	N	O
80	the	N	O
81	effects	N	O
82	of	N	O
83	ATP	N	O
84	in	N	O
85	patients	N	O
86	with	N	O
87	advanced	N	O
88	NSCLC	N	O
89	(	N	O
90	stage	N	O
91	IIIB	N	O
92	or	N	O
93	IV	N	O
94	)	N	O
95	.	N	O

96	Fifty-eight	N	O
97	patients	N	O
98	were	N	O
99	randomly	N	O
100	assigned	N	O
101	to	N	O
102	receive	N	O
103	either	N	O
104	10	N	O
105	intravenous	N	O
106	30-hour	N	O
107	ATP	N	O
108	infusions	N	O
109	,	N	O
110	with	N	O
111	the	N	O
112	infusions	N	O
113	given	N	O
114	at	N	O
115	2-	N	O
116	to	N	O
117	4-week	N	O
118	intervals	N	O
119	,	N	O
120	or	N	O
121	no	N	O
122	ATP	N	O
123	.	N	O

124	Outcome	N	O
125	parameters	N	O
126	were	N	O
127	assessed	N	O
128	every	N	O
129	4	N	O
130	weeks	N	O
131	until	N	O
132	28	N	O
133	weeks	N	O
134	.	N	O

135	Between-group	N	O
136	differences	N	O
137	were	N	O
138	tested	N	O
139	for	N	O
140	statistical	N	O
141	significance	N	O
142	by	N	O
143	use	N	O
144	of	N	O
145	repeated-measures	N	O
146	analysis	N	O
147	,	N	O
148	and	N	O
149	reported	N	O
150	P	N	O
151	values	N	O
152	are	N	O
153	two-sided	N	O
154	.	N	O

155	Twenty-eight	N	O
156	patients	N	O
157	were	N	O
158	allocated	N	O
159	to	N	O
160	receive	N	O
161	ATP	N	O
162	treatment	N	O
163	and	N	O
164	30	N	O
165	received	N	O
166	no	N	O
167	ATP	N	O
168	.	N	O

169	Mean	N	I-Premise
170	weight	N	I-Premise
171	changes	N	I-Premise
172	per	N	I-Premise
173	4-week	N	I-Premise
174	period	N	I-Premise
175	were	N	I-Premise
176	-1.0	N	I-Premise
177	kg	N	I-Premise
178	(	N	I-Premise
179	95	N	I-Premise
180	%	N	I-Premise
181	confidence	N	I-Premise
182	interval	N	I-Premise
183	[	N	I-Premise
184	CI	N	I-Premise
185	]	N	I-Premise
186	=	N	I-Premise
187	-1.5	N	I-Premise
188	to	N	I-Premise
189	-0.5	N	I-Premise
190	)	N	I-Premise
191	in	N	I-Premise
192	the	N	I-Premise
193	control	N	I-Premise
194	group	N	I-Premise
195	and	N	I-Premise
196	0.2	N	I-Premise
197	kg	N	I-Premise
198	(	N	I-Premise
199	95	N	I-Premise
200	%	N	I-Premise
201	CI	N	I-Premise
202	=	N	I-Premise
203	-0.2	N	I-Premise
204	to	N	I-Premise
205	+0.6	N	I-Premise
206	)	N	I-Premise
207	in	N	I-Premise
208	the	N	I-Premise
209	ATP	N	I-Premise
210	group	N	I-Premise
211	(	N	I-Premise
212	P	N	I-Premise
213	=.002	N	I-Premise
214	)	N	I-Premise
215	.	N	I-Premise

216	Serum	N	I-Premise
217	albumin	N	I-Premise
218	concentration	N	I-Premise
219	declined	N	I-Premise
220	by	N	I-Premise
221	-1.2	N	I-Premise
222	g/L	N	I-Premise
223	(	N	I-Premise
224	95	N	I-Premise
225	%	N	I-Premise
226	CI=	N	I-Premise
227	-2.0	N	I-Premise
228	to	N	I-Premise
229	-0.4	N	I-Premise
230	)	N	I-Premise
231	per	N	I-Premise
232	4	N	I-Premise
233	weeks	N	I-Premise
234	in	N	I-Premise
235	the	N	I-Premise
236	control	N	I-Premise
237	group	N	I-Premise
238	but	N	I-Premise
239	remained	N	I-Premise
240	stable	N	I-Premise
241	(	N	I-Premise
242	0.0	N	I-Premise
243	g/L	N	I-Premise
244	;	N	I-Premise
245	95	N	I-Premise
246	%	N	I-Premise
247	CI	N	I-Premise
248	=	N	I-Premise
249	-0.3	N	I-Premise
250	to	N	I-Premise
251	+0.3	N	I-Premise
252	)	N	I-Premise
253	in	N	I-Premise
254	the	N	I-Premise
255	ATP	N	I-Premise
256	group	N	I-Premise
257	(	N	I-Premise
258	P	N	I-Premise
259	=.006	N	I-Premise
260	)	N	I-Premise
261	.	N	I-Premise

262	Elbow	N	I-Premise
263	flexor	N	I-Premise
264	muscle	N	I-Premise
265	strength	N	I-Premise
266	declined	N	I-Premise
267	by	N	I-Premise
268	-5.5	N	I-Premise
269	%	N	I-Premise
270	(	N	I-Premise
271	95	N	I-Premise
272	%	N	I-Premise
273	CI	N	I-Premise
274	=	N	I-Premise
275	-9.6	N	I-Premise
276	%	N	I-Premise
277	to	N	I-Premise
278	-1	N	I-Premise
279	.	N	I-Premise

280	4	N	I-Premise
281	%	N	I-Premise
282	)	N	I-Premise
283	per	N	I-Premise
284	4	N	I-Premise
285	weeks	N	I-Premise
286	in	N	I-Premise
287	the	N	I-Premise
288	control	N	I-Premise
289	group	N	I-Premise
290	but	N	I-Premise
291	remained	N	I-Premise
292	stable	N	I-Premise
293	(	N	I-Premise
294	0.0	N	I-Premise
295	%	N	I-Premise
296	;	N	I-Premise
297	95	N	I-Premise
298	%	N	I-Premise
299	CI=	N	I-Premise
300	-1.4	N	I-Premise
301	%	N	I-Premise
302	to	N	I-Premise
303	+1.4	N	I-Premise
304	%	N	I-Premise
305	)	N	I-Premise
306	in	N	I-Premise
307	the	N	I-Premise
308	ATP	N	I-Premise
309	group	N	I-Premise
310	(	N	I-Premise
311	P	N	I-Premise
312	=.01	N	I-Premise
313	)	N	I-Premise
314	.	N	I-Premise

315	A	N	I-Premise
316	similar	N	I-Premise
317	pattern	N	I-Premise
318	was	N	I-Premise
319	observed	N	I-Premise
320	for	N	I-Premise
321	knee	N	I-Premise
322	extensor	N	I-Premise
323	muscles	N	I-Premise
324	(	N	I-Premise
325	P	N	I-Premise
326	=.02	N	I-Premise
327	)	N	I-Premise
328	.	N	I-Premise

329	The	N	I-Premise
330	effects	N	I-Premise
331	of	N	I-Premise
332	ATP	N	I-Premise
333	on	N	I-Premise
334	body	N	I-Premise
335	weight	N	I-Premise
336	,	N	I-Premise
337	muscle	N	I-Premise
338	strength	N	I-Premise
339	,	N	I-Premise
340	and	N	I-Premise
341	albumin	N	I-Premise
342	concentration	N	I-Premise
343	were	N	I-Premise
344	especially	N	I-Premise
345	marked	N	I-Premise
346	in	N	I-Premise
347	cachectic	N	I-Premise
348	patients	N	I-Premise
349	(	N	I-Premise
350	P	N	I-Premise
351	=.0002	N	I-Premise
352	,	N	I-Premise
353	P	N	I-Premise
354	=.0001	N	I-Premise
355	,	N	I-Premise
356	and	N	I-Premise
357	P	N	I-Premise
358	=	N	I-Premise
359	.	N	I-Premise

360	0001	N	I-Premise
361	,	N	I-Premise
362	respectively	N	I-Premise
363	,	N	I-Premise
364	for	N	I-Premise
365	ATP	N	I-Premise
366	versus	N	I-Premise
367	no	N	I-Premise
368	ATP	N	I-Premise
369	)	N	I-Premise
370	.	N	I-Premise

371	QOL	N	I-Premise
372	score	N	I-Premise
373	changes	N	I-Premise
374	per	N	I-Premise
375	4-week	N	I-Premise
376	period	N	I-Premise
377	in	N	I-Premise
378	the	N	I-Premise
379	ATP	N	I-Premise
380	group	N	I-Premise
381	showed	N	I-Premise
382	overall	N	I-Premise
383	less	N	I-Premise
384	deterioration	N	I-Premise
385	than	N	I-Premise
386	in	N	I-Premise
387	the	N	I-Premise
388	control	N	I-Premise
389	group-physical	N	I-Premise
390	scores	N	I-Premise
391	(	N	I-Premise
392	-0.2	N	I-Premise
393	%	N	I-Premise
394	versus	N	I-Premise
395	-2.4	N	I-Premise
396	%	N	I-Premise
397	;	N	I-Premise
398	P	N	I-Premise
399	=	N	I-Premise
400	.	N	I-Premise

401	0002	N	I-Premise
402	)	N	I-Premise
403	;	N	I-Premise
404	functional	N	I-Premise
405	scores	N	I-Premise
406	(	N	I-Premise
407	+0.4	N	I-Premise
408	%	N	I-Premise
409	versus	N	I-Premise
410	-5.5	N	I-Premise
411	%	N	I-Premise
412	;	N	I-Premise
413	P	N	I-Premise
414	=.02	N	I-Premise
415	)	N	I-Premise
416	;	N	I-Premise
417	psychologic	N	I-Premise
418	scores	N	I-Premise
419	(	N	I-Premise
420	-0.7	N	I-Premise
421	%	N	I-Premise
422	versus	N	I-Premise
423	-2.4	N	I-Premise
424	%	N	I-Premise
425	;	N	I-Premise
426	P	N	I-Premise
427	=.11	N	I-Premise
428	)	N	I-Premise
429	;	N	I-Premise
430	overall	N	I-Premise
431	QOL	N	I-Premise
432	score	N	I-Premise
433	(	N	I-Premise
434	+0.1	N	I-Premise
435	%	N	I-Premise
436	versus	N	I-Premise
437	-3.5	N	I-Premise
438	%	N	I-Premise
439	;	N	I-Premise
440	P	N	I-Premise
441	=.0001	N	I-Premise
442	)	N	I-Premise
443	.	N	I-Premise

444	This	N	O
445	randomized	N	O
446	trial	N	O
447	demonstrates	N	O
448	that	N	O
449	ATP	N	I-Claim
450	has	N	I-Claim
451	beneficial	N	I-Claim
452	effects	N	I-Claim
453	on	N	I-Claim
454	weight	N	I-Claim
455	,	N	I-Claim
456	muscle	N	I-Claim
457	strength	N	I-Claim
458	,	N	I-Claim
459	and	N	I-Claim
460	QOL	N	I-Claim
461	in	N	I-Claim
462	patients	N	I-Claim
463	with	N	I-Claim
464	advanced	N	I-Claim
465	NSCLC	N	I-Claim
466	.	N	I-Claim

1	This	N	O
2	phase	N	O
3	III	N	O
4	,	N	O
5	double-blind	N	O
6	,	N	O
7	randomized	N	O
8	,	N	O
9	multicenter	N	O
10	study	N	O
11	evaluated	N	O
12	the	N	O
13	efficacy	N	O
14	,	N	O
15	pharmacodynamics	N	O
16	,	N	O
17	and	N	O
18	safety	N	O
19	of	N	O
20	the	N	O
21	oral	N	O
22	aromatase	N	O
23	inactivator	N	O
24	exemestane	N	O
25	(	N	O
26	EXE	N	O
27	)	N	O
28	versus	N	O
29	megestrol	N	O
30	acetate	N	O
31	(	N	O
32	MA	N	O
33	)	N	O
34	in	N	O
35	postmenopausal	N	O
36	women	N	O
37	with	N	O
38	progressive	N	O
39	advanced	N	O
40	breast	N	O
41	cancer	N	O
42	who	N	O
43	experienced	N	O
44	failure	N	O
45	of	N	O
46	tamoxifen	N	O
47	.	N	O

48	A	N	O
49	total	N	O
50	of	N	O
51	769	N	O
52	patients	N	O
53	were	N	O
54	randomized	N	O
55	to	N	O
56	EXE	N	O
57	25	N	O
58	mg/d	N	O
59	(	N	O
60	n	N	O
61	=	N	O
62	366	N	O
63	)	N	O
64	or	N	O
65	MA	N	O
66	(	N	O
67	n	N	O
68	=	N	O
69	403	N	O
70	)	N	O
71	40	N	O
72	mg	N	O
73	four	N	O
74	times	N	O
75	daily	N	O
76	.	N	O

77	Tumor	N	O
78	response	N	O
79	,	N	O
80	duration	N	O
81	of	N	O
82	tumor	N	O
83	control	N	O
84	,	N	O
85	tumor-related	N	O
86	signs	N	O
87	and	N	O
88	symptoms	N	O
89	(	N	O
90	TRSS	N	O
91	)	N	O
92	,	N	O
93	quality	N	O
94	of	N	O
95	life	N	O
96	(	N	O
97	QOL	N	O
98	)	N	O
99	,	N	O
100	survival	N	O
101	,	N	O
102	and	N	O
103	tolerability	N	O
104	were	N	O
105	evaluated	N	O
106	.	N	O

107	Overall	N	I-Premise
108	objective	N	I-Premise
109	response	N	I-Premise
110	(	N	I-Premise
111	OR	N	I-Premise
112	)	N	I-Premise
113	rates	N	I-Premise
114	were	N	I-Premise
115	higher	N	I-Premise
116	in	N	I-Premise
117	patients	N	I-Premise
118	treated	N	I-Premise
119	with	N	I-Premise
120	EXE	N	I-Premise
121	than	N	I-Premise
122	in	N	I-Premise
123	those	N	I-Premise
124	treated	N	I-Premise
125	with	N	I-Premise
126	MA	N	I-Premise
127	(	N	I-Premise
128	15.0	N	I-Premise
129	%	N	I-Premise
130	v	N	I-Premise
131	12.4	N	I-Premise
132	%	N	I-Premise
133	)	N	I-Premise
134	;	N	I-Premise
135	a	N	I-Premise
136	similar	N	I-Premise
137	trend	N	I-Premise
138	was	N	I-Premise
139	noted	N	I-Premise
140	in	N	I-Premise
141	patients	N	I-Premise
142	with	N	I-Premise
143	visceral	N	I-Premise
144	metastases	N	I-Premise
145	(	N	I-Premise
146	13.5	N	I-Premise
147	%	N	I-Premise
148	v	N	I-Premise
149	10.5	N	I-Premise
150	%	N	I-Premise
151	)	N	I-Premise
152	.	N	I-Premise

153	Median	N	I-Premise
154	survival	N	I-Premise
155	time	N	I-Premise
156	was	N	I-Premise
157	significantly	N	I-Premise
158	longer	N	I-Premise
159	with	N	I-Premise
160	EXE	N	I-Premise
161	(	N	I-Premise
162	median	N	I-Premise
163	not	N	I-Premise
164	reached	N	I-Premise
165	)	N	I-Premise
166	than	N	I-Premise
167	with	N	I-Premise
168	MA	N	I-Premise
169	(	N	I-Premise
170	123.4	N	I-Premise
171	weeks	N	I-Premise
172	;	N	I-Premise
173	P	N	I-Premise
174	=.039	N	I-Premise
175	)	N	I-Premise
176	,	N	I-Premise
177	as	N	I-Premise
178	were	N	I-Premise
179	the	N	I-Premise
180	median	N	I-Premise
181	duration	N	I-Premise
182	of	N	I-Premise
183	overall	N	I-Premise
184	success	N	I-Premise
185	(	N	I-Premise
186	OR	N	I-Premise
187	or	N	I-Premise
188	stable	N	I-Premise
189	disease	N	I-Premise
190	>	N	I-Premise
191	or	N	I-Premise
192	=	N	I-Premise
193	24	N	I-Premise
194	weeks	N	I-Premise
195	;	N	I-Premise
196	60.1	N	I-Premise
197	v	N	I-Premise
198	49.1	N	I-Premise
199	weeks	N	I-Premise
200	;	N	I-Premise
201	P	N	I-Premise
202	=.025	N	I-Premise
203	)	N	I-Premise
204	,	N	I-Premise
205	time	N	I-Premise
206	to	N	I-Premise
207	tumor	N	I-Premise
208	progression	N	I-Premise
209	(	N	I-Premise
210	20.3	N	I-Premise
211	v	N	I-Premise
212	16.6	N	I-Premise
213	weeks	N	I-Premise
214	;	N	I-Premise
215	P	N	I-Premise
216	=.037	N	I-Premise
217	)	N	I-Premise
218	,	N	I-Premise
219	and	N	I-Premise
220	time	N	I-Premise
221	to	N	I-Premise
222	treatment	N	I-Premise
223	failure	N	I-Premise
224	(	N	I-Premise
225	16.3	N	I-Premise
226	v	N	I-Premise
227	15.7	N	I-Premise
228	weeks	N	I-Premise
229	;	N	I-Premise
230	P	N	I-Premise
231	=.042	N	I-Premise
232	)	N	I-Premise
233	.	N	I-Premise

234	Compared	N	I-Premise
235	with	N	I-Premise
236	MA	N	I-Premise
237	,	N	I-Premise
238	there	N	I-Premise
239	were	N	I-Premise
240	similar	N	I-Premise
241	or	N	I-Premise
242	greater	N	I-Premise
243	improvements	N	I-Premise
244	in	N	I-Premise
245	pain	N	I-Premise
246	,	N	I-Premise
247	TRSS	N	I-Premise
248	,	N	I-Premise
249	and	N	I-Premise
250	QOL	N	I-Premise
251	with	N	I-Premise
252	EXE	N	I-Premise
253	.	N	I-Premise

254	Both	N	I-Claim
255	drugs	N	I-Claim
256	were	N	I-Claim
257	well	N	I-Claim
258	tolerated	N	I-Claim
259	.	N	I-Claim

260	Grade	N	I-Premise
261	3	N	I-Premise
262	or	N	I-Premise
263	4	N	I-Premise
264	weight	N	I-Premise
265	changes	N	I-Premise
266	were	N	I-Premise
267	more	N	I-Premise
268	common	N	I-Premise
269	with	N	I-Premise
270	MA	N	I-Premise
271	(	N	I-Premise
272	17.1	N	I-Premise
273	%	N	I-Premise
274	v	N	I-Premise
275	7.6	N	I-Premise
276	%	N	I-Premise
277	;	N	I-Premise
278	P	N	I-Premise
279	=.001	N	I-Premise
280	)	N	I-Premise
281	.	N	I-Premise

282	EXE	N	I-Claim
283	prolongs	N	I-Claim
284	survival	N	I-Claim
285	time	N	I-Claim
286	,	N	I-Claim
287	time	N	I-Claim
288	to	N	I-Claim
289	tumor	N	I-Claim
290	progression	N	I-Claim
291	,	N	I-Claim
292	and	N	I-Claim
293	time	N	I-Claim
294	to	N	I-Claim
295	treatment	N	I-Claim
296	failure	N	I-Claim
297	compared	N	I-Claim
298	with	N	I-Claim
299	MA	N	I-Claim
300	and	N	I-Claim
301	offers	N	I-Claim
302	a	N	I-Claim
303	well-tolerated	N	I-Claim
304	treatment	N	I-Claim
305	option	N	I-Claim
306	for	N	I-Claim
307	postmenopausal	N	I-Claim
308	women	N	I-Claim
309	with	N	I-Claim
310	progressive	N	I-Claim
311	advanced	N	I-Claim
312	breast	N	I-Claim
313	cancer	N	I-Claim
314	who	N	I-Claim
315	experienced	N	I-Claim
316	failure	N	I-Claim
317	of	N	I-Claim
318	tamoxifen	N	I-Claim
319	.	N	I-Claim

1	This	N	O
2	phase	N	O
3	III	N	O
4	study	N	O
5	was	N	O
6	performed	N	O
7	to	N	O
8	determine	N	O
9	the	N	O
10	superiority	N	O
11	of	N	O
12	doxorubicin	N	O
13	(	N	O
14	DOX	N	O
15	)	N	O
16	and	N	O
17	vinorelbine	N	O
18	(	N	O
19	VNB	N	O
20	)	N	O
21	(	N	O
22	arm	N	O
23	1	N	O
24	)	N	O
25	versus	N	O
26	DOX	N	O
27	alone	N	O
28	(	N	O
29	arm	N	O
30	2	N	O
31	)	N	O
32	in	N	O
33	metastatic	N	O
34	breast	N	O
35	cancer	N	O
36	(	N	O
37	MBC	N	O
38	)	N	O
39	for	N	O
40	overall	N	O
41	survival	N	O
42	(	N	O
43	OS	N	O
44	)	N	O
45	,	N	O
46	time	N	O
47	to	N	O
48	treatment	N	O
49	failure	N	O
50	(	N	O
51	TTF	N	O
52	)	N	O
53	,	N	O
54	toxicity	N	O
55	,	N	O
56	and	N	O
57	quality	N	O
58	of	N	O
59	life	N	O
60	(	N	O
61	QOL	N	O
62	)	N	O
63	.	N	O

64	Three	N	O
65	hundred	N	O
66	three	N	O
67	patients	N	O
68	were	N	O
69	randomized	N	O
70	to	N	O
71	DOX	N	O
72	50	N	O
73	mg/m	N	O
74	(	N	O
75	2	N	O
76	)	N	O
77	intravenously	N	O
78	(	N	O
79	IV	N	O
80	)	N	O
81	on	N	O
82	day	N	O
83	1	N	O
84	and	N	O
85	VNB	N	O
86	25	N	O
87	mg/m	N	O
88	(	N	O
89	2	N	O
90	)	N	O
91	IV	N	O
92	on	N	O
93	days	N	O
94	1	N	O
95	and	N	O
96	8	N	O
97	(	N	O
98	arm	N	O
99	1	N	O
100	)	N	O
101	or	N	O
102	DOX	N	O
103	70	N	O
104	mg/m	N	O
105	(	N	O
106	2	N	O
107	)	N	O
108	IV	N	O
109	on	N	O
110	day	N	O
111	1	N	O
112	(	N	O
113	arm	N	O
114	2	N	O
115	)	N	O
116	.	N	O

117	Both	N	O
118	regimens	N	O
119	were	N	O
120	given	N	O
121	every	N	O
122	3	N	O
123	weeks	N	O
124	until	N	O
125	a	N	O
126	cumulative	N	O
127	DOX	N	O
128	dose	N	O
129	of	N	O
130	450	N	O
131	mg/m	N	O
132	(	N	O
133	2	N	O
134	)	N	O
135	.	N	O

136	After	N	O
137	16	N	O
138	of	N	O
139	the	N	O
140	first	N	O
141	65	N	O
142	randomized	N	O
143	patients	N	O
144	experienced	N	O
145	febrile	N	O
146	neutropenia	N	O
147	(	N	O
148	FN	N	O
149	)	N	O
150	,	N	O
151	the	N	O
152	doses	N	O
153	were	N	O
154	reduced	N	O
155	to	N	O
156	DOX	N	O
157	40	N	O
158	mg/m	N	O
159	(	N	O
160	2	N	O
161	)	N	O
162	on	N	O
163	day	N	O
164	1	N	O
165	and	N	O
166	VNB	N	O
167	20	N	O
168	mg/m	N	O
169	(	N	O
170	2	N	O
171	)	N	O
172	on	N	O
173	days	N	O
174	1	N	O
175	and	N	O
176	8	N	O
177	versus	N	O
178	DOX	N	O
179	60	N	O
180	mg/m	N	O
181	(	N	O
182	2	N	O
183	)	N	O
184	on	N	O
185	day	N	O
186	1	N	O
187	.	N	O

188	Eligible	N	O
189	patients	N	O
190	were	N	O
191	vinca	N	O
192	alkaloid	N	O
193	and	N	O
194	anthracycline	N	O
195	naive	N	O
196	.	N	O

197	Chemotherapy	N	O
198	was	N	O
199	first-line	N	O
200	or	N	O
201	second-line	N	O
202	for	N	O
203	MBC	N	O
204	.	N	O

205	Three	N	O
206	patients	N	O
207	were	N	O
208	ineligible	N	O
209	.	N	O

210	Thus	N	O
211	,	N	O
212	300	N	O
213	patients	N	O
214	were	N	O
215	assessable	N	O
216	for	N	O
217	toxicity	N	O
218	and	N	O
219	to	N	O
220	determine	N	O
221	time	N	O
222	to	N	O
223	disease	N	O
224	progression	N	O
225	(	N	O
226	TTP	N	O
227	)	N	O
228	,	N	O
229	TTF	N	O
230	,	N	O
231	and	N	O
232	OS	N	O
233	.	N	O

234	Two	N	O
235	hundred	N	O
236	eighty-nine	N	O
237	patients	N	O
238	were	N	O
239	assessable	N	O
240	for	N	O
241	response	N	O
242	,	N	O
243	and	N	O
244	99	N	O
245	responders	N	O
246	were	N	O
247	assessable	N	O
248	for	N	O
249	response	N	O
250	duration	N	O
251	(	N	O
252	RD	N	O
253	)	N	O
254	.	N	O

255	The	N	I-Premise
256	response	N	I-Premise
257	rates	N	I-Premise
258	,	N	I-Premise
259	QOL	N	I-Premise
260	,	N	I-Premise
261	and	N	I-Premise
262	median	N	I-Premise
263	RD	N	I-Premise
264	,	N	I-Premise
265	TTP	N	I-Premise
266	,	N	I-Premise
267	and	N	I-Premise
268	TTF	N	I-Premise
269	were	N	I-Premise
270	not	N	I-Premise
271	significantly	N	I-Premise
272	different	N	I-Premise
273	between	N	I-Premise
274	the	N	I-Premise
275	arms	N	I-Premise
276	.	N	I-Premise

277	Median	N	I-Premise
278	OS	N	I-Premise
279	was	N	I-Premise
280	13.8	N	I-Premise
281	months	N	I-Premise
282	for	N	I-Premise
283	arm	N	I-Premise
284	1	N	I-Premise
285	versus	N	I-Premise
286	14.4	N	I-Premise
287	months	N	I-Premise
288	for	N	I-Premise
289	arm	N	I-Premise
290	2	N	I-Premise
291	(	N	I-Premise
292	P	N	I-Premise
293	=.4	N	I-Premise
294	)	N	I-Premise
295	.	N	I-Premise

296	Grade	N	I-Premise
297	3	N	I-Premise
298	or	N	I-Premise
299	4	N	I-Premise
300	granulocytopenia	N	I-Premise
301	was	N	I-Premise
302	equivalent	N	I-Premise
303	in	N	I-Premise
304	both	N	I-Premise
305	arms	N	I-Premise
306	but	N	I-Premise
307	more	N	I-Premise
308	grade	N	I-Premise
309	3/4	N	I-Premise
310	neurotoxicity	N	I-Premise
311	,	N	I-Premise
312	mild	N	I-Premise
313	venous	N	I-Premise
314	toxicity	N	I-Premise
315	,	N	I-Premise
316	and	N	I-Premise
317	FN	N	I-Premise
318	were	N	I-Premise
319	seen	N	I-Premise
320	on	N	I-Premise
321	arm	N	I-Premise
322	1	N	I-Premise
323	.	N	I-Premise

324	The	N	I-Claim
325	survival	N	I-Claim
326	with	N	I-Claim
327	DOX	N	I-Claim
328	and	N	I-Claim
329	VNB	N	I-Claim
330	is	N	I-Claim
331	not	N	I-Claim
332	superior	N	I-Claim
333	to	N	I-Claim
334	DOX	N	I-Claim
335	alone	N	I-Claim
336	in	N	I-Claim
337	MBC	N	I-Claim
338	.	N	I-Claim

1	Menopausal	N	I-MajorClaim
2	symptoms	N	I-MajorClaim
3	(	N	I-MajorClaim
4	e.g.	N	I-MajorClaim
5	,	N	I-MajorClaim
6	hot	N	I-MajorClaim
7	flashes	N	I-MajorClaim
8	,	N	I-MajorClaim
9	vaginal	N	I-MajorClaim
10	dryness	N	I-MajorClaim
11	,	N	I-MajorClaim
12	and	N	I-MajorClaim
13	stress	N	I-MajorClaim
14	urinary	N	I-MajorClaim
15	incontinence	N	I-MajorClaim
16	)	N	I-MajorClaim
17	are	N	I-MajorClaim
18	very	N	I-MajorClaim
19	common	N	I-MajorClaim
20	in	N	I-MajorClaim
21	breast	N	I-MajorClaim
22	cancer	N	I-MajorClaim
23	survivors	N	I-MajorClaim
24	and	N	I-MajorClaim
25	can	N	I-MajorClaim
26	not	N	I-MajorClaim
27	be	N	I-MajorClaim
28	managed	N	I-MajorClaim
29	with	N	I-MajorClaim
30	standard	N	I-MajorClaim
31	estrogen	N	I-MajorClaim
32	replacement	N	I-MajorClaim
33	therapy	N	I-MajorClaim
34	(	N	I-MajorClaim
35	ERT	N	I-MajorClaim
36	)	N	I-MajorClaim
37	in	N	I-MajorClaim
38	these	N	I-MajorClaim
39	patients	N	I-MajorClaim
40	.	N	I-MajorClaim

41	The	N	O
42	purpose	N	O
43	of	N	O
44	this	N	O
45	study	N	O
46	was	N	O
47	to	N	O
48	test	N	O
49	the	N	O
50	efficacy	N	O
51	of	N	O
52	a	N	O
53	comprehensive	N	O
54	menopausal	N	O
55	assessment	N	O
56	(	N	O
57	CMA	N	O
58	)	N	O
59	intervention	N	O
60	program	N	O
61	in	N	O
62	achieving	N	O
63	relief	N	O
64	of	N	O
65	symptoms	N	O
66	,	N	O
67	the	N	O
68	improvement	N	O
69	in	N	O
70	quality	N	O
71	of	N	O
72	life	N	O
73	(	N	O
74	QOL	N	O
75	)	N	O
76	,	N	O
77	and	N	O
78	sexual	N	O
79	functioning	N	O
80	in	N	O
81	breast	N	O
82	cancer	N	O
83	survivors	N	O
84	.	N	O

85	Using	N	O
86	a	N	O
87	two-group	N	O
88	,	N	O
89	randomized	N	O
90	controlled	N	O
91	design	N	O
92	,	N	O
93	we	N	O
94	assigned	N	O
95	76	N	O
96	postmenopausal	N	O
97	breast	N	O
98	cancer	N	O
99	survivors	N	O
100	with	N	O
101	at	N	O
102	least	N	O
103	one	N	O
104	severe	N	O
105	target	N	O
106	symptom	N	O
107	either	N	O
108	to	N	O
109	the	N	O
110	intervention	N	O
111	group	N	O
112	or	N	O
113	to	N	O
114	a	N	O
115	usual-care	N	O
116	group	N	O
117	.	N	O

118	Seventy-two	N	O
119	women	N	O
120	were	N	O
121	evaluable	N	O
122	at	N	O
123	the	N	O
124	end	N	O
125	of	N	O
126	the	N	O
127	study	N	O
128	period	N	O
129	.	N	O

130	The	N	O
131	CMA	N	O
132	intervention	N	O
133	,	N	O
134	delivered	N	O
135	by	N	O
136	a	N	O
137	nurse	N	O
138	practitioner	N	O
139	,	N	O
140	focused	N	O
141	on	N	O
142	symptom	N	O
143	assessment	N	O
144	,	N	O
145	education	N	O
146	,	N	O
147	counseling	N	O
148	and	N	O
149	,	N	O
150	as	N	O
151	appropriate	N	O
152	,	N	O
153	specific	N	O
154	pharmacologic	N	O
155	and	N	O
156	behavioral	N	O
157	interventions	N	O
158	for	N	O
159	each	N	O
160	of	N	O
161	the	N	O
162	three	N	O
163	target	N	O
164	symptoms	N	O
165	.	N	O

166	Psychosocial	N	O
167	symptoms	N	O
168	were	N	O
169	assessed	N	O
170	with	N	O
171	the	N	O
172	use	N	O
173	of	N	O
174	a	N	O
175	self-report	N	O
176	screening	N	O
177	instrument	N	O
178	,	N	O
179	and	N	O
180	distressed	N	O
181	women	N	O
182	were	N	O
183	referred	N	O
184	for	N	O
185	counseling	N	O
186	if	N	O
187	needed	N	O
188	.	N	O

189	The	N	O
190	intervention	N	O
191	took	N	O
192	place	N	O
193	over	N	O
194	a	N	O
195	4-month	N	O
196	period	N	O
197	.	N	O

198	Outcomes	N	O
199	measured	N	O
200	were	N	O
201	scores	N	O
202	on	N	O
203	a	N	O
204	composite	N	O
205	menopausal	N	O
206	symptom	N	O
207	scale	N	O
208	,	N	O
209	the	N	O
210	RAND	N	O
211	Short	N	O
212	Form	N	O
213	Health	N	O
214	Survey	N	O
215	Vitality	N	O
216	Scale	N	O
217	,	N	O
218	and	N	O
219	the	N	O
220	Cancer	N	O
221	Rehabilitation	N	O
222	Evaluation	N	O
223	System	N	O
224	(	N	O
225	CARES	N	O
226	)	N	O
227	Sexual	N	O
228	Functioning	N	O
229	Scale	N	O
230	at	N	O
231	baseline	N	O
232	and	N	O
233	at	N	O
234	4-month	N	O
235	follow-up	N	O
236	.	N	O

237	All	N	O
238	statistical	N	O
239	tests	N	O
240	were	N	O
241	two-sided	N	O
242	and	N	O
243	were	N	O
244	performed	N	O
245	at	N	O
246	the	N	O
247	alpha	N	O
248	=	N	O
249	.	N	O

250	05	N	O
251	significance	N	O
252	level	N	O
253	.	N	O

254	Patients	N	I-Premise
255	receiving	N	I-Premise
256	the	N	I-Premise
257	intervention	N	I-Premise
258	demonstrated	N	I-Premise
259	statistically	N	I-Premise
260	significant	N	I-Premise
261	improvement	N	I-Premise
262	(	N	I-Premise
263	P	N	I-Premise
264	=.0004	N	I-Premise
265	)	N	I-Premise
266	in	N	I-Premise
267	menopausal	N	I-Premise
268	symptoms	N	I-Premise
269	but	N	I-Premise
270	no	N	I-Premise
271	significant	N	I-Premise
272	change	N	I-Premise
273	in	N	I-Premise
274	vitality	N	I-Premise
275	(	N	I-Premise
276	P	N	I-Premise
277	=.77	N	I-Premise
278	)	N	I-Premise
279	.	N	I-Premise

280	Sexual	N	I-Premise
281	functioning	N	I-Premise
282	was	N	I-Premise
283	statistically	N	I-Premise
284	significantly	N	I-Premise
285	improved	N	I-Premise
286	(	N	I-Premise
287	P	N	I-Premise
288	=.04	N	I-Premise
289	)	N	I-Premise
290	in	N	I-Premise
291	the	N	I-Premise
292	treatment	N	I-Premise
293	group	N	I-Premise
294	compared	N	I-Premise
295	with	N	I-Premise
296	the	N	I-Premise
297	usual-care	N	I-Premise
298	group	N	I-Premise
299	.	N	I-Premise

300	A	N	I-Claim
301	clinical	N	I-Claim
302	assessment	N	I-Claim
303	and	N	I-Claim
304	intervention	N	I-Claim
305	program	N	I-Claim
306	for	N	I-Claim
307	menopausal	N	I-Claim
308	symptom	N	I-Claim
309	management	N	I-Claim
310	in	N	I-Claim
311	breast	N	I-Claim
312	cancer	N	I-Claim
313	survivors	N	I-Claim
314	is	N	I-Claim
315	feasible	N	I-Claim
316	and	N	I-Claim
317	acceptable	N	I-Claim
318	to	N	I-Claim
319	patients	N	I-Claim
320	,	N	I-Claim
321	leading	N	I-Claim
322	to	N	I-Claim
323	reduction	N	I-Claim
324	in	N	I-Claim
325	symptoms	N	I-Claim
326	and	N	I-Claim
327	improvement	N	I-Claim
328	in	N	I-Claim
329	sexual	N	I-Claim
330	functioning	N	I-Claim
331	.	N	I-Claim

332	Measurable	N	I-Claim
333	improvement	N	I-Claim
334	in	N	I-Claim
335	a	N	I-Claim
336	general	N	I-Claim
337	QOL	N	I-Claim
338	measure	N	I-Claim
339	was	N	I-Claim
340	not	N	I-Claim
341	demonstrated	N	I-Claim
342	.	N	I-Claim

1	In	N	I-Claim
2	phase	N	I-Claim
3	II	N	I-Claim
4	trials	N	I-Claim
5	,	N	I-Claim
6	paclitaxel	N	I-Claim
7	has	N	I-Claim
8	been	N	I-Claim
9	shown	N	I-Claim
10	to	N	I-Claim
11	have	N	I-Claim
12	antitumor	N	I-Claim
13	activity	N	I-Claim
14	in	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	advanced	N	I-Claim
18	non-small-cell	N	I-Claim
19	lung	N	I-Claim
20	cancer	N	I-Claim
21	(	N	I-Claim
22	NSCLC	N	I-Claim
23	)	N	I-Claim
24	.	N	I-Claim

25	However	N	O
26	,	N	O
27	the	N	O
28	survival	N	O
29	and	N	O
30	quality-of-life	N	O
31	(	N	O
32	QOL	N	O
33	)	N	O
34	benefits	N	O
35	of	N	O
36	paclitaxel	N	O
37	used	N	O
38	as	N	O
39	a	N	O
40	single	N	O
41	agent	N	O
42	compared	N	O
43	with	N	O
44	supportive	N	O
45	care	N	O
46	alone	N	O
47	have	N	O
48	not	N	O
49	been	N	O
50	assessed	N	O
51	in	N	O
52	a	N	O
53	randomized	N	O
54	clinical	N	O
55	trial	N	O
56	.	N	O

57	A	N	O
58	total	N	O
59	of	N	O
60	157	N	O
61	patients	N	O
62	with	N	O
63	stage	N	O
64	IIIB	N	O
65	or	N	O
66	IV	N	O
67	NSCLC	N	O
68	who	N	O
69	had	N	O
70	received	N	O
71	no	N	O
72	prior	N	O
73	chemotherapy	N	O
74	were	N	O
75	randomly	N	O
76	assigned	N	O
77	to	N	O
78	receive	N	O
79	either	N	O
80	best	N	O
81	supportive	N	O
82	care	N	O
83	alone	N	O
84	(	N	O
85	78	N	O
86	patients	N	O
87	)	N	O
88	or	N	O
89	paclitaxel	N	O
90	plus	N	O
91	supportive	N	O
92	care	N	O
93	(	N	O
94	79	N	O
95	patients	N	O
96	)	N	O
97	.	N	O

98	Paclitaxel	N	O
99	was	N	O
100	administered	N	O
101	as	N	O
102	a	N	O
103	3-hour	N	O
104	intravenous	N	O
105	infusion	N	O
106	every	N	O
107	3	N	O
108	weeks	N	O
109	.	N	O

110	Supportive	N	O
111	care	N	O
112	included	N	O
113	palliative	N	O
114	radiotherapy	N	O
115	and	N	O
116	supportive	N	O
117	therapy	N	O
118	with	N	O
119	corticosteroids	N	O
120	,	N	O
121	antibiotics	N	O
122	,	N	O
123	analgesics	N	O
124	,	N	O
125	antiemetics	N	O
126	,	N	O
127	transfusions	N	O
128	,	N	O
129	and	N	O
130	other	N	O
131	symptomatic	N	O
132	therapy	N	O
133	as	N	O
134	required	N	O
135	.	N	O

136	The	N	O
137	primary	N	O
138	end	N	O
139	point	N	O
140	of	N	O
141	the	N	O
142	study	N	O
143	was	N	O
144	survival	N	O
145	.	N	O

146	Time	N	O
147	to	N	O
148	disease	N	O
149	progression	N	O
150	,	N	O
151	response	N	O
152	rate	N	O
153	,	N	O
154	adverse	N	O
155	events	N	O
156	,	N	O
157	and	N	O
158	QOL	N	O
159	were	N	O
160	secondary	N	O
161	end	N	O
162	points	N	O
163	.	N	O

164	Pretreatment	N	O
165	characteristics	N	O
166	were	N	O
167	evenly	N	O
168	distributed	N	O
169	between	N	O
170	the	N	O
171	two	N	O
172	arms	N	O
173	.	N	O

174	Survival	N	I-Premise
175	was	N	I-Premise
176	statistically	N	I-Premise
177	significantly	N	I-Premise
178	better	N	I-Premise
179	in	N	I-Premise
180	the	N	I-Premise
181	paclitaxel	N	I-Premise
182	plus	N	I-Premise
183	supportive	N	I-Premise
184	care	N	I-Premise
185	arm	N	I-Premise
186	than	N	I-Premise
187	in	N	I-Premise
188	the	N	I-Premise
189	supportive	N	I-Premise
190	care	N	I-Premise
191	alone	N	I-Premise
192	arm	N	I-Premise
193	(	N	I-Premise
194	two-sided	N	I-Premise
195	P	N	I-Premise
196	=.037	N	I-Premise
197	)	N	I-Premise
198	(	N	I-Premise
199	median	N	I-Premise
200	survival	N	I-Premise
201	=	N	I-Premise
202	6.8	N	I-Premise
203	months	N	I-Premise
204	versus	N	I-Premise
205	4.8	N	I-Premise
206	months	N	I-Premise
207	)	N	I-Premise
208	.	N	I-Premise

209	Cox	N	I-Premise
210	multivariate	N	I-Premise
211	analysis	N	I-Premise
212	showed	N	I-Premise
213	paclitaxel	N	I-Premise
214	plus	N	I-Premise
215	supportive	N	I-Premise
216	care	N	I-Premise
217	to	N	I-Premise
218	be	N	I-Premise
219	statistically	N	I-Premise
220	significantly	N	I-Premise
221	associated	N	I-Premise
222	with	N	I-Premise
223	improved	N	I-Premise
224	survival	N	I-Premise
225	(	N	I-Premise
226	two-sided	N	I-Premise
227	P	N	I-Premise
228	=.048	N	I-Premise
229	)	N	I-Premise
230	.	N	I-Premise

231	QOL	N	I-Premise
232	was	N	I-Premise
233	similar	N	I-Premise
234	for	N	I-Premise
235	both	N	I-Premise
236	treatment	N	I-Premise
237	arms	N	I-Premise
238	,	N	I-Premise
239	except	N	I-Premise
240	for	N	I-Premise
241	the	N	I-Premise
242	functional	N	I-Premise
243	activity	N	I-Premise
244	score	N	I-Premise
245	of	N	I-Premise
246	the	N	I-Premise
247	Rotterdam	N	I-Premise
248	Symptom	N	I-Premise
249	Checklist	N	I-Premise
250	,	N	I-Premise
251	where	N	I-Premise
252	QOL	N	I-Premise
253	data	N	I-Premise
254	statistically	N	I-Premise
255	significantly	N	I-Premise
256	favored	N	I-Premise
257	the	N	I-Premise
258	paclitaxel	N	I-Premise
259	plus	N	I-Premise
260	supportive	N	I-Premise
261	care	N	I-Premise
262	arm	N	I-Premise
263	(	N	I-Premise
264	two-sided	N	I-Premise
265	P	N	I-Premise
266	=.043	N	I-Premise
267	)	N	I-Premise
268	.	N	I-Premise

269	The	N	I-Claim
270	addition	N	I-Claim
271	of	N	I-Claim
272	paclitaxel	N	I-Claim
273	to	N	I-Claim
274	best	N	I-Claim
275	supportive	N	I-Claim
276	care	N	I-Claim
277	significantly	N	I-Claim
278	improved	N	I-Claim
279	survival	N	I-Claim
280	and	N	I-Claim
281	time	N	I-Claim
282	to	N	I-Claim
283	disease	N	I-Claim
284	progression	N	I-Claim
285	compared	N	I-Claim
286	with	N	I-Claim
287	best	N	I-Claim
288	supportive	N	I-Claim
289	care	N	I-Claim
290	in	N	I-Claim
291	patients	N	I-Claim
292	with	N	I-Claim
293	advanced	N	I-Claim
294	NSCLC	N	I-Claim
295	and	N	I-Claim
296	may	N	I-Claim
297	improve	N	I-Claim
298	some	N	I-Claim
299	aspects	N	I-Claim
300	of	N	I-Claim
301	QOL	N	I-Claim
302	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	project	N	O
6	was	N	O
7	to	N	O
8	identify	N	O
9	clinical	N	O
10	and	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	(	N	O
15	QL	N	O
16	)	N	O
17	factors	N	O
18	that	N	O
19	together	N	O
20	predict	N	O
21	survival	N	O
22	and	N	O
23	response	N	O
24	to	N	O
25	chemotherapy	N	O
26	in	N	O
27	advanced	N	O
28	breast	N	O
29	cancer	N	O
30	.	N	O

31	Potential	N	O
32	prognostic	N	O
33	factors	N	O
34	were	N	O
35	studied	N	O
36	in	N	O
37	187	N	O
38	women	N	O
39	with	N	O
40	baseline	N	O
41	QL	N	O
42	data	N	O
43	from	N	O
44	a	N	O
45	trial	N	O
46	of	N	O
47	paclitaxel	N	O
48	versus	N	O
49	doxorubicin	N	O
50	as	N	O
51	first-line	N	O
52	chemotherapy	N	O
53	.	N	O

54	Demographic	N	O
55	and	N	O
56	clinical	N	O
57	factors	N	O
58	studied	N	O
59	were	N	O
60	age	N	O
61	,	N	O
62	performance	N	O
63	status	N	O
64	,	N	O
65	dominant	N	O
66	site	N	O
67	of	N	O
68	disease	N	O
69	and	N	O
70	preceding	N	O
71	disease-free	N	O
72	interval	N	O
73	(	N	O
74	DFI	N	O
75	)	N	O
76	.	N	O

77	Factors	N	O
78	from	N	O
79	the	N	O
80	EORTC	N	O
81	QLQ-C30	N	O
82	were	N	O
83	all	N	O
84	function	N	O
85	scales	N	O
86	,	N	O
87	fatigue	N	O
88	,	N	O
89	nausea/vomiting	N	O
90	,	N	O
91	pain	N	O
92	,	N	O
93	dyspnoea	N	O
94	,	N	O
95	insomnia	N	O
96	,	N	O
97	loss	N	O
98	of	N	O
99	appetite	N	O
100	and	N	O
101	global	N	O
102	QL	N	O
103	.	N	O

104	The	N	O
105	proportional	N	O
106	hazards	N	O
107	regression	N	O
108	model	N	O
109	with	N	O
110	stratification	N	O
111	for	N	O
112	treatment	N	O
113	,	N	O
114	and	N	O
115	the	N	O
116	logistic	N	O
117	regression	N	O
118	model	N	O
119	adjusting	N	O
120	for	N	O
121	treatment	N	O
122	arm	N	O
123	were	N	O
124	used	N	O
125	for	N	O
126	univariate	N	O
127	and	N	O
128	multivariate	N	O
129	analyses	N	O
130	of	N	O
131	survival	N	O
132	and	N	O
133	response	N	O
134	to	N	O
135	treatment	N	O
136	,	N	O
137	respectively	N	O
138	.	N	O

139	For	N	I-Premise
140	survival	N	I-Premise
141	,	N	I-Premise
142	multiple	N	I-Premise
143	sites	N	I-Premise
144	of	N	I-Premise
145	visceral	N	I-Premise
146	disease	N	I-Premise
147	,	N	I-Premise
148	pain	N	I-Premise
149	,	N	I-Premise
150	global	N	I-Premise
151	QL	N	I-Premise
152	and	N	I-Premise
153	fatigue	N	I-Premise
154	were	N	I-Premise
155	significant	N	I-Premise
156	prognostic	N	I-Premise
157	factors	N	I-Premise
158	in	N	I-Premise
159	the	N	I-Premise
160	univariate	N	I-Premise
161	analysis	N	I-Premise
162	.	N	I-Premise

163	The	N	I-Premise
164	final	N	I-Premise
165	multivariate	N	I-Premise
166	model	N	I-Premise
167	predicted	N	I-Premise
168	poor	N	I-Premise
169	survival	N	I-Premise
170	with	N	I-Premise
171	multiple	N	I-Premise
172	sites	N	I-Premise
173	of	N	I-Premise
174	visceral	N	I-Premise
175	disease	N	I-Premise
176	(	N	I-Premise
177	P=0.003	N	I-Premise
178	)	N	I-Premise
179	,	N	I-Premise
180	DFI	N	I-Premise
181	<	N	I-Premise
182	/=2	N	I-Premise
183	years	N	I-Premise
184	(	N	I-Premise
185	P=0.026	N	I-Premise
186	)	N	I-Premise
187	and	N	I-Premise
188	pain	N	I-Premise
189	(	N	I-Premise
190	P=0.003	N	I-Premise
191	)	N	I-Premise
192	.	N	I-Premise

193	For	N	I-Premise
194	response	N	I-Premise
195	,	N	I-Premise
196	age	N	I-Premise
197	,	N	I-Premise
198	dyspnoea	N	I-Premise
199	,	N	I-Premise
200	fatigue	N	I-Premise
201	and	N	I-Premise
202	global	N	I-Premise
203	QL	N	I-Premise
204	were	N	I-Premise
205	significant	N	I-Premise
206	predictive	N	I-Premise
207	factors	N	I-Premise
208	in	N	I-Premise
209	the	N	I-Premise
210	univariate	N	I-Premise
211	analysis	N	I-Premise
212	.	N	I-Premise

213	The	N	I-Premise
214	final	N	I-Premise
215	multivariate	N	I-Premise
216	model	N	I-Premise
217	for	N	I-Premise
218	response	N	I-Premise
219	selected	N	I-Premise
220	DFI	N	I-Premise
221	(	N	I-Premise
222	P=0.009	N	I-Premise
223	)	N	I-Premise
224	,	N	I-Premise
225	multiple	N	I-Premise
226	sites	N	I-Premise
227	of	N	I-Premise
228	visceral	N	I-Premise
229	disease	N	I-Premise
230	(	N	I-Premise
231	P=0.037	N	I-Premise
232	)	N	I-Premise
233	and	N	I-Premise
234	dyspnoea	N	I-Premise
235	(	N	I-Premise
236	P=	N	I-Premise
237	<	N	I-Premise
238	0.001	N	I-Premise
239	)	N	I-Premise
240	using	N	I-Premise
241	forward	N	I-Premise
242	selection	N	I-Premise
243	,	N	I-Premise
244	but	N	I-Premise
245	model	N	I-Premise
246	instability	N	I-Premise
247	was	N	I-Premise
248	indicated	N	I-Premise
249	by	N	I-Premise
250	the	N	I-Premise
251	inclusion	N	I-Premise
252	of	N	I-Premise
253	fatigue	N	I-Premise
254	and	N	I-Premise
255	emotional	N	I-Premise
256	function	N	I-Premise
257	in	N	I-Premise
258	the	N	I-Premise
259	final	N	I-Premise
260	model	N	I-Premise
261	when	N	I-Premise
262	backward	N	I-Premise
263	selection	N	I-Premise
264	was	N	I-Premise
265	used	N	I-Premise
266	.	N	I-Premise

267	In	N	O
268	addition	N	O
269	to	N	O
270	known	N	O
271	clinical	N	O
272	factors	N	O
273	,	N	O
274	patient-assessed	N	I-Claim
275	QL	N	I-Claim
276	variables	N	I-Claim
277	appear	N	I-Claim
278	to	N	I-Claim
279	be	N	I-Claim
280	prognostic	N	I-Claim
281	for	N	I-Claim
282	survival	N	I-Claim
283	and	N	I-Claim
284	response	N	I-Claim
285	to	N	I-Claim
286	chemotherapy	N	I-Claim
287	in	N	I-Claim
288	women	N	I-Claim
289	with	N	I-Claim
290	advanced	N	I-Claim
291	breast	N	I-Claim
292	cancer	N	I-Claim
293	.	N	I-Claim

294	However	N	I-Claim
295	,	N	I-Claim
296	identification	N	I-Claim
297	of	N	I-Claim
298	prognostic	N	I-Claim
299	factors	N	I-Claim
300	from	N	I-Claim
301	responses	N	I-Claim
302	to	N	I-Claim
303	questionnaires	N	I-Claim
304	may	N	I-Claim
305	be	N	I-Claim
306	unstable	N	I-Claim
307	,	N	I-Claim
308	and	N	I-Claim
309	their	N	I-Claim
310	reliability	N	I-Claim
311	and	N	I-Claim
312	clinical	N	I-Claim
313	utility	N	I-Claim
314	should	N	I-Claim
315	be	N	I-Claim
316	tested	N	I-Claim
317	prospectively	N	I-Claim
318	.	N	I-Claim

1	In	N	O
2	a	N	O
3	previous	N	O
4	study	N	O
5	of	N	O
6	treatment	N	O
7	for	N	O
8	advanced	N	O
9	colorectal	N	O
10	cancer	N	O
11	,	N	O
12	the	N	O
13	LV5FU2	N	O
14	regimen	N	O
15	,	N	O
16	comprising	N	O
17	leucovorin	N	O
18	(	N	O
19	LV	N	O
20	)	N	O
21	plus	N	O
22	bolus	N	O
23	and	N	O
24	infusional	N	O
25	fluorouracil	N	O
26	(	N	O
27	5FU	N	O
28	)	N	O
29	every	N	O
30	2	N	O
31	weeks	N	O
32	,	N	O
33	was	N	O
34	superior	N	O
35	to	N	O
36	the	N	O
37	standard	N	O
38	North	N	O
39	Central	N	O
40	Cancer	N	O
41	Treatment	N	O
42	Group/Mayo	N	O
43	Clinic	N	O
44	5-day	N	O
45	bolus	N	O
46	5FU/LV	N	O
47	regimen	N	O
48	.	N	O

49	This	N	O
50	phase	N	O
51	III	N	O
52	study	N	O
53	investigated	N	O
54	the	N	O
55	effect	N	O
56	of	N	O
57	combining	N	O
58	oxaliplatin	N	O
59	with	N	O
60	LV5FU2	N	O
61	,	N	O
62	with	N	O
63	progression-free	N	O
64	survival	N	O
65	as	N	O
66	the	N	O
67	primary	N	O
68	end	N	O
69	point	N	O
70	.	N	O

71	Four	N	O
72	hundred	N	O
73	twenty	N	O
74	previously	N	O
75	untreated	N	O
76	patients	N	O
77	with	N	O
78	measurable	N	O
79	disease	N	O
80	were	N	O
81	randomized	N	O
82	to	N	O
83	receive	N	O
84	a	N	O
85	2-hour	N	O
86	infusion	N	O
87	of	N	O
88	LV	N	O
89	(	N	O
90	200	N	O
91	mg/m	N	O
92	(	N	O
93	2	N	O
94	)	N	O
95	/d	N	O
96	)	N	O
97	followed	N	O
98	by	N	O
99	a	N	O
100	5FU	N	O
101	bolus	N	O
102	(	N	O
103	400	N	O
104	mg/m	N	O
105	(	N	O
106	2	N	O
107	)	N	O
108	/d	N	O
109	)	N	O
110	and	N	O
111	22-hour	N	O
112	infusion	N	O
113	(	N	O
114	600	N	O
115	mg/m	N	O
116	(	N	O
117	2	N	O
118	)	N	O
119	/d	N	O
120	)	N	O
121	for	N	O
122	2	N	O
123	consecutive	N	O
124	days	N	O
125	every	N	O
126	2	N	O
127	weeks	N	O
128	,	N	O
129	either	N	O
130	alone	N	O
131	or	N	O
132	together	N	O
133	with	N	O
134	oxaliplatin	N	O
135	85	N	O
136	mg/m	N	O
137	(	N	O
138	2	N	O
139	)	N	O
140	as	N	O
141	a	N	O
142	2-hour	N	O
143	infusion	N	O
144	on	N	O
145	day	N	O
146	1	N	O
147	.	N	O

148	Patients	N	I-Premise
149	allocated	N	I-Premise
150	to	N	I-Premise
151	oxaliplatin	N	I-Premise
152	plus	N	I-Premise
153	LV5FU2	N	I-Premise
154	had	N	I-Premise
155	significantly	N	I-Premise
156	longer	N	I-Premise
157	progression-free	N	I-Premise
158	survival	N	I-Premise
159	(	N	I-Premise
160	median	N	I-Premise
161	,	N	I-Premise
162	9.0	N	I-Premise
163	v	N	I-Premise
164	6.2	N	I-Premise
165	months	N	I-Premise
166	;	N	I-Premise
167	P	N	I-Premise
168	=.0003	N	I-Premise
169	)	N	I-Premise
170	and	N	I-Premise
171	better	N	I-Premise
172	response	N	I-Premise
173	rate	N	I-Premise
174	(	N	I-Premise
175	50.7	N	I-Premise
176	%	N	I-Premise
177	v	N	I-Premise
178	22.3	N	I-Premise
179	%	N	I-Premise
180	;	N	I-Premise
181	P	N	I-Premise
182	=.0001	N	I-Premise
183	)	N	I-Premise
184	when	N	I-Premise
185	compared	N	I-Premise
186	with	N	I-Premise
187	the	N	I-Premise
188	control	N	I-Premise
189	arm	N	I-Premise
190	.	N	I-Premise

191	The	N	I-Premise
192	improvement	N	I-Premise
193	in	N	I-Premise
194	overall	N	I-Premise
195	survival	N	I-Premise
196	did	N	I-Premise
197	not	N	I-Premise
198	reach	N	I-Premise
199	significance	N	I-Premise
200	(	N	I-Premise
201	median	N	I-Premise
202	,	N	I-Premise
203	16.2	N	I-Premise
204	v	N	I-Premise
205	14.7	N	I-Premise
206	months	N	I-Premise
207	;	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	.	N	I-Premise

211	12	N	I-Premise
212	)	N	I-Premise
213	.	N	I-Premise

214	LV5FU2	N	I-Premise
215	plus	N	I-Premise
216	oxaliplatin	N	I-Premise
217	gave	N	I-Premise
218	higher	N	I-Premise
219	frequencies	N	I-Premise
220	of	N	I-Premise
221	National	N	I-Premise
222	Cancer	N	I-Premise
223	Institute	N	I-Premise
224	common	N	I-Premise
225	toxicity	N	I-Premise
226	criteria	N	I-Premise
227	grade	N	I-Premise
228	3/4	N	I-Premise
229	neutropenia	N	I-Premise
230	(	N	I-Premise
231	41	N	I-Premise
232	.	N	I-Premise

233	7	N	I-Premise
234	%	N	I-Premise
235	v	N	I-Premise
236	5.3	N	I-Premise
237	%	N	I-Premise
238	of	N	I-Premise
239	patients	N	I-Premise
240	)	N	I-Premise
241	,	N	I-Premise
242	grade	N	I-Premise
243	3/4	N	I-Premise
244	diarrhea	N	I-Premise
245	(	N	I-Premise
246	11.9	N	I-Premise
247	%	N	I-Premise
248	v	N	I-Premise
249	5.3	N	I-Premise
250	%	N	I-Premise
251	)	N	I-Premise
252	,	N	I-Premise
253	and	N	I-Premise
254	grade	N	I-Premise
255	3	N	I-Premise
256	neurosensory	N	I-Premise
257	toxicity	N	I-Premise
258	(	N	I-Premise
259	18.2	N	I-Premise
260	%	N	I-Premise
261	v	N	I-Premise
262	0	N	I-Premise
263	%	N	I-Premise
264	)	N	I-Premise
265	,	N	I-Premise
266	but	N	I-Premise
267	this	N	I-Premise
268	did	N	I-Premise
269	not	N	I-Premise
270	result	N	I-Premise
271	in	N	I-Premise
272	impairment	N	I-Premise
273	of	N	I-Premise
274	quality	N	I-Premise
275	of	N	I-Premise
276	life	N	I-Premise
277	(	N	I-Premise
278	QoL	N	I-Premise
279	)	N	I-Premise
280	.	N	I-Premise

281	Survival	N	I-Premise
282	without	N	I-Premise
283	disease	N	I-Premise
284	progression	N	I-Premise
285	or	N	I-Premise
286	deterioration	N	I-Premise
287	in	N	I-Premise
288	global	N	I-Premise
289	health	N	I-Premise
290	status	N	I-Premise
291	was	N	I-Premise
292	longer	N	I-Premise
293	in	N	I-Premise
294	patients	N	I-Premise
295	allocated	N	I-Premise
296	to	N	I-Premise
297	oxaliplatin	N	I-Premise
298	treatment	N	I-Premise
299	(	N	I-Premise
300	P	N	I-Premise
301	=.004	N	I-Premise
302	)	N	I-Premise
303	.	N	I-Premise

304	The	N	I-Claim
305	LV5FU2-oxaliplatin	N	I-Claim
306	combination	N	I-Claim
307	seems	N	I-Claim
308	beneficial	N	I-Claim
309	as	N	I-Claim
310	first-line	N	I-Claim
311	therapy	N	I-Claim
312	in	N	I-Claim
313	advanced	N	I-Claim
314	colorectal	N	I-Claim
315	cancer	N	I-Claim
316	,	N	I-Claim
317	demonstrating	N	I-Claim
318	a	N	I-Claim
319	prolonged	N	I-Claim
320	progression-free	N	I-Claim
321	survival	N	I-Claim
322	with	N	I-Claim
323	acceptable	N	I-Claim
324	tolerability	N	I-Claim
325	and	N	I-Claim
326	maintenance	N	I-Claim
327	of	N	I-Claim
328	QoL	N	I-Claim
329	.	N	I-Claim

1	A	N	O
2	randomized	N	O
3	phase	N	O
4	III	N	O
5	trial	N	O
6	was	N	O
7	conducted	N	O
8	to	N	O
9	determine	N	O
10	whether	N	O
11	combination	N	O
12	therapy	N	O
13	with	N	O
14	13-cis-retinoic	N	O
15	acid	N	O
16	(	N	O
17	13-CRA	N	O
18	)	N	O
19	plus	N	O
20	interferon	N	O
21	alfa-2a	N	O
22	(	N	O
23	IFNalpha2a	N	O
24	)	N	O
25	is	N	O
26	superior	N	O
27	to	N	O
28	IFNalpha2a	N	O
29	alone	N	O
30	in	N	O
31	patients	N	O
32	with	N	O
33	advanced	N	O
34	renal	N	O
35	cell	N	O
36	carcinoma	N	O
37	(	N	O
38	RCC	N	O
39	)	N	O
40	.	N	O

41	Two	N	O
42	hundred	N	O
43	eighty-four	N	O
44	patients	N	O
45	were	N	O
46	randomized	N	O
47	to	N	O
48	treatment	N	O
49	with	N	O
50	IFNalpha2a	N	O
51	plus	N	O
52	13-CRA	N	O
53	or	N	O
54	treatment	N	O
55	with	N	O
56	IFNalpha2a	N	O
57	alone	N	O
58	.	N	O

59	IFNalpha2a	N	O
60	was	N	O
61	given	N	O
62	daily	N	O
63	subcutaneously	N	O
64	,	N	O
65	starting	N	O
66	at	N	O
67	a	N	O
68	dose	N	O
69	of	N	O
70	3	N	O
71	million	N	O
72	units	N	O
73	(	N	O
74	MU	N	O
75	)	N	O
76	.	N	O

77	The	N	O
78	dose	N	O
79	was	N	O
80	escalated	N	O
81	every	N	O
82	7	N	O
83	days	N	O
84	from	N	O
85	3	N	O
86	to	N	O
87	9	N	O
88	MU	N	O
89	(	N	O
90	by	N	O
91	increments	N	O
92	of	N	O
93	3	N	O
94	MU	N	O
95	)	N	O
96	,	N	O
97	unless	N	O
98	>	N	O
99	/=	N	O
100	grade	N	O
101	2	N	O
102	toxicity	N	O
103	occurred	N	O
104	,	N	O
105	in	N	O
106	which	N	O
107	case	N	O
108	dose	N	O
109	escalation	N	O
110	was	N	O
111	stopped	N	O
112	.	N	O

113	Patients	N	O
114	randomized	N	O
115	to	N	O
116	combination	N	O
117	therapy	N	O
118	were	N	O
119	given	N	O
120	oral	N	O
121	13-CRA	N	O
122	1	N	O
123	mg/kg/d	N	O
124	plus	N	O
125	IFNalpha2a	N	O
126	.	N	O

127	Quality	N	O
128	of	N	O
129	life	N	O
130	(	N	O
131	QOL	N	O
132	)	N	O
133	was	N	O
134	assessed	N	O
135	.	N	O

136	Complete	N	I-Premise
137	or	N	I-Premise
138	partial	N	I-Premise
139	responses	N	I-Premise
140	were	N	I-Premise
141	achieved	N	I-Premise
142	by	N	I-Premise
143	12	N	I-Premise
144	%	N	I-Premise
145	of	N	I-Premise
146	patients	N	I-Premise
147	treated	N	I-Premise
148	with	N	I-Premise
149	IFNalpha2a	N	I-Premise
150	plus	N	I-Premise
151	13-CRA	N	I-Premise
152	and	N	I-Premise
153	6	N	I-Premise
154	%	N	I-Premise
155	of	N	I-Premise
156	patients	N	I-Premise
157	treated	N	I-Premise
158	with	N	I-Premise
159	IFNalpha2a	N	I-Premise
160	(	N	I-Premise
161	P	N	I-Premise
162	=.14	N	I-Premise
163	)	N	I-Premise
164	.	N	I-Premise

165	Median	N	I-Premise
166	duration	N	I-Premise
167	of	N	I-Premise
168	response	N	I-Premise
169	(	N	I-Premise
170	complete	N	I-Premise
171	and	N	I-Premise
172	partial	N	I-Premise
173	combined	N	I-Premise
174	)	N	I-Premise
175	in	N	I-Premise
176	the	N	I-Premise
177	group	N	I-Premise
178	treated	N	I-Premise
179	with	N	I-Premise
180	the	N	I-Premise
181	combination	N	I-Premise
182	was	N	I-Premise
183	33	N	I-Premise
184	months	N	I-Premise
185	(	N	I-Premise
186	range	N	I-Premise
187	,	N	I-Premise
188	9	N	I-Premise
189	to	N	I-Premise
190	50	N	I-Premise
191	months	N	I-Premise
192	)	N	I-Premise
193	,	N	I-Premise
194	versus	N	I-Premise
195	22	N	I-Premise
196	months	N	I-Premise
197	(	N	I-Premise
198	range	N	I-Premise
199	,	N	I-Premise
200	5	N	I-Premise
201	to	N	I-Premise
202	38	N	I-Premise
203	months	N	I-Premise
204	)	N	I-Premise
205	for	N	I-Premise
206	the	N	I-Premise
207	second	N	I-Premise
208	group	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	=.03	N	I-Premise
212	)	N	I-Premise
213	.	N	I-Premise

214	Nineteen	N	I-Premise
215	percent	N	I-Premise
216	of	N	I-Premise
217	patients	N	I-Premise
218	treated	N	I-Premise
219	with	N	I-Premise
220	IFNalpha2a	N	I-Premise
221	plus	N	I-Premise
222	13-CRA	N	I-Premise
223	were	N	I-Premise
224	progression-free	N	I-Premise
225	at	N	I-Premise
226	24	N	I-Premise
227	months	N	I-Premise
228	,	N	I-Premise
229	compared	N	I-Premise
230	with	N	I-Premise
231	10	N	I-Premise
232	%	N	I-Premise
233	of	N	I-Premise
234	patients	N	I-Premise
235	treated	N	I-Premise
236	with	N	I-Premise
237	IFNalpha2a	N	I-Premise
238	alone	N	I-Premise
239	(	N	I-Premise
240	P	N	I-Premise
241	=.05	N	I-Premise
242	)	N	I-Premise
243	.	N	I-Premise

244	Median	N	I-Premise
245	survival	N	I-Premise
246	time	N	I-Premise
247	for	N	I-Premise
248	all	N	I-Premise
249	patients	N	I-Premise
250	was	N	I-Premise
251	15	N	I-Premise
252	months	N	I-Premise
253	,	N	I-Premise
254	with	N	I-Premise
255	no	N	I-Premise
256	difference	N	I-Premise
257	in	N	I-Premise
258	survival	N	I-Premise
259	between	N	I-Premise
260	the	N	I-Premise
261	two	N	I-Premise
262	treatment	N	I-Premise
263	arms	N	I-Premise
264	(	N	I-Premise
265	P	N	I-Premise
266	=.26	N	I-Premise
267	)	N	I-Premise
268	.	N	I-Premise

269	QOL	N	I-Premise
270	decreased	N	I-Premise
271	during	N	I-Premise
272	the	N	I-Premise
273	first	N	I-Premise
274	8	N	I-Premise
275	weeks	N	I-Premise
276	of	N	I-Premise
277	treatment	N	I-Premise
278	,	N	I-Premise
279	and	N	I-Premise
280	a	N	I-Premise
281	partial	N	I-Premise
282	recovery	N	I-Premise
283	followed	N	I-Premise
284	.	N	I-Premise

285	Lower	N	I-Premise
286	scores	N	I-Premise
287	were	N	I-Premise
288	associated	N	I-Premise
289	with	N	I-Premise
290	the	N	I-Premise
291	combination	N	I-Premise
292	therapy	N	I-Premise
293	.	N	I-Premise

294	Response	N	I-Claim
295	proportion	N	I-Claim
296	and	N	I-Claim
297	survival	N	I-Claim
298	did	N	I-Claim
299	not	N	I-Claim
300	improve	N	I-Claim
301	significantly	N	I-Claim
302	with	N	I-Claim
303	the	N	I-Claim
304	addition	N	I-Claim
305	of	N	I-Claim
306	13-CRA	N	I-Claim
307	to	N	I-Claim
308	IFNalpha2a	N	I-Claim
309	therapy	N	I-Claim
310	in	N	I-Claim
311	patients	N	I-Claim
312	with	N	I-Claim
313	advanced	N	I-Claim
314	RCC	N	I-Claim
315	.	N	I-Claim

316	13-CRA	N	I-Claim
317	may	N	I-Claim
318	lengthen	N	I-Claim
319	response	N	I-Claim
320	to	N	I-Claim
321	IFNalpha2a	N	I-Claim
322	therapy	N	I-Claim
323	in	N	I-Claim
324	patients	N	I-Claim
325	with	N	I-Claim
326	IFNalpha2a-sensitive	N	I-Claim
327	tumors	N	I-Claim
328	.	N	I-Claim

329	Treatment	N	I-Claim
330	,	N	I-Claim
331	particularly	N	I-Claim
332	the	N	I-Claim
333	combination	N	I-Claim
334	therapy	N	I-Claim
335	,	N	I-Claim
336	was	N	I-Claim
337	associated	N	I-Claim
338	with	N	I-Claim
339	a	N	I-Claim
340	decrease	N	I-Claim
341	in	N	I-Claim
342	QOL	N	I-Claim
343	.	N	I-Claim

1	Postoperative	N	I-Claim
2	adjuvant	N	I-Claim
3	chemoradiation	N	I-Claim
4	treatment	N	I-Claim
5	after	N	I-Claim
6	curative	N	I-Claim
7	resection	N	I-Claim
8	for	N	I-Claim
9	rectal	N	I-Claim
10	cancer	N	I-Claim
11	was	N	I-Claim
12	needed	N	I-Claim
13	to	N	I-Claim
14	reduce	N	I-Claim
15	recurrence	N	I-Claim
16	and	N	I-Claim
17	improve	N	I-Claim
18	a	N	I-Claim
19	survival	N	I-Claim
20	rate	N	I-Claim
21	.	N	I-Claim

22	Intravenous	N	I-MajorClaim
23	5-fluorouracil	N	I-MajorClaim
24	(	N	I-MajorClaim
25	5-FU	N	I-MajorClaim
26	)	N	I-MajorClaim
27	and	N	I-MajorClaim
28	leucovorin	N	I-MajorClaim
29	has	N	I-MajorClaim
30	been	N	I-MajorClaim
31	a	N	I-MajorClaim
32	mainstay	N	I-MajorClaim
33	of	N	I-MajorClaim
34	chemotherapy	N	I-MajorClaim
35	,	N	I-MajorClaim
36	but	N	O
37	oral	N	I-MajorClaim
38	5-FU	N	I-MajorClaim
39	derivatives	N	I-MajorClaim
40	have	N	I-MajorClaim
41	been	N	I-MajorClaim
42	shown	N	I-MajorClaim
43	a	N	I-MajorClaim
44	comparable	N	I-MajorClaim
45	antitumor	N	I-MajorClaim
46	activity	N	I-MajorClaim
47	.	N	I-MajorClaim

48	Intravenous	N	O
49	5-FU	N	O
50	and	N	O
51	oral	N	O
52	doxifluridine	N	O
53	were	N	O
54	compared	N	O
55	with	N	O
56	respect	N	O
57	to	N	O
58	therapeutic	N	O
59	efficacy	N	O
60	,	N	O
61	drug	N	O
62	toxicity	N	O
63	,	N	O
64	and	N	O
65	quality	N	O
66	of	N	O
67	life	N	O
68	.	N	O

69	A	N	O
70	total	N	O
71	of	N	O
72	166	N	O
73	patients	N	O
74	were	N	O
75	randomized	N	O
76	to	N	O
77	receive	N	O
78	intravenous	N	O
79	5-FU	N	O
80	(	N	O
81	450	N	O
82	mg/m2/day	N	O
83	)	N	O
84	or	N	O
85	oral	N	O
86	doxifluridine	N	O
87	(	N	O
88	900	N	O
89	mg/m2/day	N	O
90	)	N	O
91	in	N	O
92	combination	N	O
93	with	N	O
94	leucovorin	N	O
95	(	N	O
96	20	N	O
97	mg/m2/day	N	O
98	)	N	O
99	for	N	O
100	depth	N	O
101	of	N	O
102	invasion	N	O
103	,	N	O
104	nodal	N	O
105	status	N	O
106	,	N	O
107	metastasis	N	O
108	(	N	O
109	TNM	N	O
110	)	N	O
111	stage	N	O
112	II	N	O
113	and	N	O
114	III	N	O
115	patients	N	O
116	between	N	O
117	October	N	O
118	1997	N	O
119	and	N	O
120	February	N	O
121	1999	N	O
122	.	N	O

123	Consecutive	N	O
124	daily	N	O
125	intravenous	N	O
126	infusion	N	O
127	for	N	O
128	5	N	O
129	days	N	O
130	per	N	O
131	every	N	O
132	month	N	O
133	for	N	O
134	a	N	O
135	total	N	O
136	of	N	O
137	12	N	O
138	cycles	N	O
139	(	N	O
140	IV	N	O
141	arm	N	O
142	,	N	O
143	n	N	O
144	=	N	O
145	74	N	O
146	)	N	O
147	and	N	O
148	oral	N	O
149	doxifluridine	N	O
150	daily	N	O
151	for	N	O
152	3	N	O
153	weeks	N	O
154	and	N	O
155	1	N	O
156	week	N	O
157	rest	N	O
158	for	N	O
159	a	N	O
160	total	N	O
161	of	N	O
162	12	N	O
163	cycles	N	O
164	(	N	O
165	oral	N	O
166	arm	N	O
167	,	N	O
168	n	N	O
169	=	N	O
170	92	N	O
171	)	N	O
172	.	N	O

173	Drug	N	O
174	toxicity	N	O
175	and	N	O
176	quality	N	O
177	of	N	O
178	life	N	O
179	were	N	O
180	observed	N	O
181	.	N	O

182	Quality	N	O
183	of	N	O
184	life	N	O
185	was	N	O
186	scored	N	O
187	according	N	O
188	to	N	O
189	22	N	O
190	daily	N	O
191	activity	N	O
192	items	N	O
193	(	N	O
194	good	N	O
195	,	N	O
196	>	N	O
197	or	N	O
198	=71	N	O
199	;	N	O
200	fair	N	O
201	,	N	O
202	<	N	O
203	70	N	O
204	;	N	O
205	poor	N	O
206	,	N	O
207	<	N	O
208	52	N	O
209	)	N	O
210	.	N	O

211	There	N	O
212	was	N	O
213	no	N	O
214	difference	N	O
215	of	N	O
216	sex	N	O
217	between	N	O
218	two	N	O
219	groups	N	O
220	(	N	O
221	IV	N	O
222	arm	N	O
223	:	N	O
224	male/female	N	O
225	=	N	O
226	45/29	N	O
227	,	N	O
228	oral	N	O
229	arm	N	O
230	:	N	O
231	male/female	N	O
232	=	N	O
233	59/33	N	O
234	)	N	O
235	.	N	O

236	The	N	O
237	mean	N	O
238	age	N	O
239	was	N	O
240	52.3	N	O
241	vs.	N	O
242	59.5	N	O
243	,	N	O
244	respectively	N	O
245	.	N	O

246	There	N	O
247	was	N	O
248	also	N	O
249	no	N	O
250	difference	N	O
251	of	N	O
252	TNM	N	O
253	stage	N	O
254	distribution	N	O
255	and	N	O
256	type	N	O
257	of	N	O
258	operation	N	O
259	between	N	O
260	groups	N	O
261	(	N	O
262	P	N	O
263	>	N	O
264	.05	N	O
265	)	N	O
266	.	N	O

267	Mean	N	I-Premise
268	numbers	N	I-Premise
269	of	N	I-Premise
270	chemotherapy	N	I-Premise
271	cycles	N	I-Premise
272	were	N	I-Premise
273	6.5+/-3.7	N	I-Premise
274	(	N	I-Premise
275	IV	N	I-Premise
276	arm	N	I-Premise
277	)	N	I-Premise
278	vs.	N	I-Premise
279	7.2+/-4.3	N	I-Premise
280	(	N	I-Premise
281	oral	N	I-Premise
282	arm	N	I-Premise
283	)	N	I-Premise
284	,	N	I-Premise
285	respectively	N	I-Premise
286	.	N	I-Premise

287	The	N	I-Premise
288	rate	N	I-Premise
289	of	N	I-Premise
290	recurrence	N	I-Premise
291	was	N	I-Premise
292	9/74	N	I-Premise
293	(	N	I-Premise
294	12.1	N	I-Premise
295	%	N	I-Premise
296	)	N	I-Premise
297	in	N	I-Premise
298	the	N	I-Premise
299	IV	N	I-Premise
300	arm	N	I-Premise
301	and	N	I-Premise
302	6/92	N	I-Premise
303	(	N	I-Premise
304	6.5	N	I-Premise
305	%	N	I-Premise
306	)	N	I-Premise
307	in	N	I-Premise
308	the	N	I-Premise
309	oral	N	I-Premise
310	arm	N	I-Premise
311	,	N	I-Premise
312	respectively	N	I-Premise
313	(	N	I-Premise
314	P	N	I-Premise
315	=	N	I-Premise
316	.937	N	I-Premise
317	)	N	I-Premise
318	.	N	I-Premise

319	Local	N	I-Premise
320	recurrence	N	I-Premise
321	was	N	I-Premise
322	2/74	N	I-Premise
323	(	N	I-Premise
324	stage	N	I-Premise
325	III	N	I-Premise
326	;	N	I-Premise
327	2.7	N	I-Premise
328	%	N	I-Premise
329	)	N	I-Premise
330	in	N	I-Premise
331	the	N	I-Premise
332	IV	N	I-Premise
333	arm	N	I-Premise
334	and	N	I-Premise
335	1/92	N	I-Premise
336	(	N	I-Premise
337	stage	N	I-Premise
338	II	N	I-Premise
339	;	N	I-Premise
340	1.1	N	I-Premise
341	%	N	I-Premise
342	)	N	I-Premise
343	in	N	I-Premise
344	the	N	I-Premise
345	oral	N	I-Premise
346	arm	N	I-Premise
347	,	N	I-Premise
348	respectively	N	I-Premise
349	.	N	I-Premise

350	Systemic	N	I-Premise
351	recurrence	N	I-Premise
352	was	N	I-Premise
353	7/74	N	I-Premise
354	(	N	I-Premise
355	stage	N	I-Premise
356	III	N	I-Premise
357	;	N	I-Premise
358	9.4	N	I-Premise
359	%	N	I-Premise
360	)	N	I-Premise
361	in	N	I-Premise
362	the	N	I-Premise
363	IV	N	I-Premise
364	arm	N	I-Premise
365	and	N	I-Premise
366	5/92	N	I-Premise
367	(	N	I-Premise
368	stage	N	I-Premise
369	III	N	I-Premise
370	;	N	I-Premise
371	5.4	N	I-Premise
372	%	N	I-Premise
373	)	N	I-Premise
374	in	N	I-Premise
375	the	N	I-Premise
376	oral	N	I-Premise
377	arm	N	I-Premise
378	,	N	I-Premise
379	respectively	N	I-Premise
380	.	N	I-Premise

381	The	N	I-Premise
382	most	N	I-Premise
383	common	N	I-Premise
384	site	N	I-Premise
385	of	N	I-Premise
386	systemic	N	I-Premise
387	recurrence	N	I-Premise
388	was	N	I-Premise
389	the	N	I-Premise
390	liver	N	I-Premise
391	.	N	I-Premise

392	Toxicity	N	I-Premise
393	profile	N	I-Premise
394	was	N	I-Premise
395	as	N	I-Premise
396	follows	N	I-Premise
397	:	N	I-Premise
398	leukopenia	N	I-Premise
399	(	N	I-Premise
400	30/74	N	I-Premise
401	vs.	N	I-Premise
402	17/92	N	I-Premise
403	)	N	I-Premise
404	and	N	I-Premise
405	alopecia	N	I-Premise
406	(	N	I-Premise
407	21/74	N	I-Premise
408	vs.	N	I-Premise
409	13/92	N	I-Premise
410	)	N	I-Premise
411	were	N	I-Premise
412	statistically	N	I-Premise
413	more	N	I-Premise
414	common	N	I-Premise
415	in	N	I-Premise
416	the	N	I-Premise
417	IV	N	I-Premise
418	arm	N	I-Premise
419	.	N	I-Premise

420	Diarrhea	N	I-Premise
421	was	N	I-Premise
422	more	N	I-Premise
423	common	N	I-Premise
424	in	N	I-Premise
425	the	N	I-Premise
426	oral	N	I-Premise
427	arm	N	I-Premise
428	.	N	I-Premise

429	Poor	N	I-Premise
430	quality	N	I-Premise
431	of	N	I-Premise
432	life	N	I-Premise
433	score	N	I-Premise
434	between	N	I-Premise
435	two	N	I-Premise
436	groups	N	I-Premise
437	was	N	I-Premise
438	observed	N	I-Premise
439	at	N	I-Premise
440	1	N	I-Premise
441	month	N	I-Premise
442	(	N	I-Premise
443	23.9	N	I-Premise
444	%	N	I-Premise
445	vs.	N	I-Premise
446	13	N	I-Premise
447	%	N	I-Premise
448	)	N	I-Premise
449	and	N	I-Premise
450	2	N	I-Premise
451	months	N	I-Premise
452	(	N	I-Premise
453	15.8	N	I-Premise
454	%	N	I-Premise
455	vs.	N	I-Premise
456	3.7	N	I-Premise
457	%	N	I-Premise
458	)	N	I-Premise
459	after	N	I-Premise
460	chemotherapy	N	I-Premise
461	.	N	I-Premise

462	Good	N	I-Premise
463	quality	N	I-Premise
464	of	N	I-Premise
465	life	N	I-Premise
466	score	N	I-Premise
467	was	N	I-Premise
468	observed	N	I-Premise
469	at	N	I-Premise
470	1	N	I-Premise
471	month	N	I-Premise
472	(	N	I-Premise
473	19.5	N	I-Premise
474	%	N	I-Premise
475	vs.	N	I-Premise
476	49	N	I-Premise
477	%	N	I-Premise
478	)	N	I-Premise
479	and	N	I-Premise
480	2	N	I-Premise
481	months	N	I-Premise
482	(	N	I-Premise
483	47	N	I-Premise
484	%	N	I-Premise
485	vs.	N	I-Premise
486	72	N	I-Premise
487	%	N	I-Premise
488	)	N	I-Premise
489	,	N	I-Premise
490	respectively	N	I-Premise
491	(	N	I-Premise
492	P	N	I-Premise
493	<	N	I-Premise
494	.05	N	I-Premise
495	)	N	I-Premise
496	.	N	I-Premise

497	Oral	N	I-Claim
498	doxifluridine	N	I-Claim
499	with	N	I-Claim
500	leucovorin	N	I-Claim
501	shows	N	I-Claim
502	a	N	I-Claim
503	comparable	N	I-Claim
504	therapeutic	N	I-Claim
505	efficacy	N	I-Claim
506	to	N	I-Claim
507	intravenous	N	I-Claim
508	5-FU	N	I-Claim
509	regimen	N	I-Claim
510	with	N	I-Claim
511	high	N	I-Claim
512	quality	N	I-Claim
513	of	N	I-Claim
514	life	N	I-Claim
515	as	N	I-Claim
516	postoperative	N	I-Claim
517	adjuvant	N	I-Claim
518	therapy	N	I-Claim
519	.	N	I-Claim

520	The	N	I-Claim
521	oral	N	I-Claim
522	regimen	N	I-Claim
523	also	N	I-Claim
524	can	N	I-Claim
525	be	N	I-Claim
526	safely	N	I-Claim
527	given	N	I-Claim
528	with	N	I-Claim
529	appropriate	N	I-Claim
530	toxicity	N	I-Claim
531	and	N	I-Claim
532	tolerability	N	I-Claim
533	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	randomised	N	O
6	trial	N	O
7	was	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	activity	N	O
12	and	N	O
13	toxicity	N	O
14	of	N	O
15	a	N	O
16	biweekly	N	O
17	regimen	N	O
18	including	N	O
19	6S-leucovorin-modulated	N	O
20	5-fluorouracil	N	O
21	(	N	O
22	LFA-5-FU	N	O
23	)	N	O
24	,	N	O
25	combined	N	O
26	with	N	O
27	either	N	O
28	irinotecan	N	O
29	(	N	O
30	CPT-11	N	O
31	+	N	O
32	LFA	N	O
33	5-FU	N	O
34	)	N	O
35	or	N	O
36	raltitrexed	N	O
37	(	N	O
38	Tomudex	N	O
39	)	N	O
40	(	N	O
41	TOM	N	O
42	+	N	O
43	LFA-5-FU	N	O
44	)	N	O
45	,	N	O
46	in	N	O
47	advanced	N	O
48	colorectal	N	O
49	cancer	N	O
50	patients	N	O
51	,	N	O
52	and	N	O
53	to	N	O
54	make	N	O
55	a	N	O
56	preliminary	N	O
57	comparison	N	O
58	of	N	O
59	both	N	O
60	these	N	O
61	experimental	N	O
62	regimens	N	O
63	with	N	O
64	a	N	O
65	biweekly	N	O
66	administration	N	O
67	of	N	O
68	LFA-5-FU	N	O
69	modulated	N	O
70	by	N	O
71	methotrexate	N	O
72	(	N	O
73	MTX	N	O
74	+	N	O
75	LFA-5-FU	N	O
76	)	N	O
77	.	N	O

78	One	N	O
79	hundred	N	O
80	fifty-nine	N	O
81	patients	N	O
82	with	N	O
83	advanced	N	O
84	colorectal	N	O
85	carcinoma	N	O
86	previously	N	O
87	untreated	N	O
88	for	N	O
89	the	N	O
90	metastatic	N	O
91	disease	N	O
92	(	N	O
93	34	N	O
94	of	N	O
95	them	N	O
96	previously	N	O
97	exposed	N	O
98	to	N	O
99	adjuvant	N	O
100	5-FU	N	O
101	)	N	O
102	were	N	O
103	randomly	N	O
104	allocated	N	O
105	to	N	O
106	receive	N	O
107	:	N	O
108	CPT-11	N	O
109	,	N	O
110	200	N	O
111	mg/m2	N	O
112	i.v	N	O
113	.	N	O

114	on	N	O
115	day	N	O
116	1	N	O
117	,	N	O
118	followed	N	O
119	on	N	O
120	day	N	O
121	2	N	O
122	by	N	O
123	LFA	N	O
124	,	N	O
125	250	N	O
126	mg/m2	N	O
127	i.v	N	O
128	.	N	O

129	infusion	N	O
130	and	N	O
131	5-FU	N	O
132	,	N	O
133	850	N	O
134	mg/m2	N	O
135	s	N	O
136	i.v	N	O
137	.	N	O

138	bolus	N	O
139	(	N	O
140	arm	N	O
141	A	N	O
142	)	N	O
143	;	N	O
144	TOM	N	O
145	,	N	O
146	3	N	O
147	mg/m2	N	O
148	i.v	N	O
149	.	N	O

150	on	N	O
151	day	N	O
152	1	N	O
153	,	N	O
154	followed	N	O
155	on	N	O
156	day	N	O
157	2	N	O
158	by	N	O
159	LFA	N	O
160	,	N	O
161	250	N	O
162	mg/m2	N	O
163	i.v	N	O
164	.	N	O

165	infusion	N	O
166	and	N	O
167	5-FU	N	O
168	,	N	O
169	1050	N	O
170	mg/m2	N	O
171	i.v	N	O
172	.	N	O

173	bolus	N	O
174	(	N	O
175	arm	N	O
176	B	N	O
177	)	N	O
178	;	N	O
179	or	N	O
180	MTX	N	O
181	,	N	O
182	750	N	O
183	mg/m2	N	O
184	i.v	N	O
185	.	N	O

186	on	N	O
187	day	N	O
188	1	N	O
189	,	N	O
190	followed	N	O
191	on	N	O
192	day	N	O
193	2	N	O
194	by	N	O
195	LFA	N	O
196	,	N	O
197	250	N	O
198	mg/m2	N	O
199	i.v	N	O
200	.	N	O

201	infusion	N	O
202	and	N	O
203	5-FU	N	O
204	,	N	O
205	800	N	O
206	mg/m2	N	O
207	i.v	N	O
208	.	N	O

209	bolus	N	O
210	(	N	O
211	arm	N	O
212	C	N	O
213	)	N	O
214	.	N	O

215	Courses	N	O
216	were	N	O
217	repeated	N	O
218	every	N	O
219	two	N	O
220	weeks	N	O
221	in	N	O
222	all	N	O
223	arms	N	O
224	of	N	O
225	the	N	O
226	trial	N	O
227	.	N	O

228	Response	N	O
229	rate	N	O
230	(	N	O
231	RR	N	O
232	)	N	O
233	was	N	O
234	evaluated	N	O
235	after	N	O
236	every	N	O
237	four	N	O
238	courses	N	O
239	.	N	O

240	The	N	O
241	sample	N	O
242	size	N	O
243	was	N	O
244	defined	N	O
245	to	N	O
246	have	N	O
247	an	N	O
248	80	N	O
249	%	N	O
250	power	N	O
251	to	N	O
252	detect	N	O
253	a	N	O
254	35	N	O
255	%	N	O
256	RR	N	O
257	for	N	O
258	each	N	O
259	experimental	N	O
260	treatment	N	O
261	,	N	O
262	and	N	O
263	to	N	O
264	show	N	O
265	a	N	O
266	difference	N	O
267	of	N	O
268	at	N	O
269	least	N	O
270	4	N	O
271	%	N	O
272	in	N	O
273	RR	N	O
274	with	N	O
275	the	N	O
276	standard	N	O
277	treatment	N	O
278	if	N	O
279	the	N	O
280	true	N	O
281	difference	N	O
282	is	N	O
283	15	N	O
284	%	N	O
285	or	N	O
286	more	N	O
287	.	N	O

288	The	N	O
289	RRs	N	O
290	were	N	O
291	:	N	O
292	34	N	O
293	%	N	O
294	(	N	O
295	95	N	O
296	%	N	O
297	confidence	N	O
298	interval	N	O
299	(	N	O
300	95	N	O
301	%	N	O
302	,	N	O
303	CI	N	O
304	)	N	O
305	:	N	O
306	21	N	O
307	%	N	O
308	-48	N	O
309	%	N	O
310	)	N	O
311	in	N	O
312	arm	N	O
313	A	N	O
314	,	N	O
315	including	N	O
316	3	N	O
317	complete	N	O
318	responses	N	O
319	(	N	O
320	CRs	N	O
321	)	N	O
322	and	N	O
323	15	N	O
324	partial	N	O
325	responses	N	O
326	(	N	O
327	PRs	N	O
328	)	N	O
329	,	N	O
330	24	N	O
331	%	N	O
332	(	N	O
333	95	N	O
334	%	N	O
335	CI	N	O
336	:	N	O
337	14	N	O
338	%	N	O
339	-38	N	O
340	%	N	O
341	)	N	O
342	in	N	O
343	arm	N	O
344	B	N	O
345	,	N	O
346	including	N	O
347	2	N	O
348	CRs	N	O
349	and	N	O
350	11	N	O
351	PRs	N	O
352	,	N	O
353	and	N	O
354	24	N	O
355	%	N	O
356	(	N	O
357	95	N	O
358	%	N	O
359	CI	N	O
360	:	N	O
361	14	N	O
362	%	N	O
363	-38	N	O
364	%	N	O
365	)	N	O
366	,	N	O
367	with	N	O
368	2	N	O
369	CRs	N	O
370	and	N	O
371	11	N	O
372	PRs	N	O
373	,	N	O
374	in	N	O
375	arm	N	O
376	C.	N	O
377	After	N	I-Premise
378	a	N	I-Premise
379	median	N	I-Premise
380	follow-up	N	I-Premise
381	time	N	I-Premise
382	of	N	I-Premise
383	62	N	I-Premise
384	(	N	I-Premise
385	range	N	I-Premise
386	18-108	N	I-Premise
387	)	N	I-Premise
388	weeks	N	I-Premise
389	,	N	I-Premise
390	the	N	I-Premise
391	median	N	I-Premise
392	time	N	I-Premise
393	to	N	I-Premise
394	progression	N	I-Premise
395	was	N	I-Premise
396	38	N	I-Premise
397	,	N	I-Premise
398	25	N	I-Premise
399	,	N	I-Premise
400	and	N	I-Premise
401	27	N	I-Premise
402	weeks	N	I-Premise
403	for	N	I-Premise
404	arm	N	I-Premise
405	A	N	I-Premise
406	,	N	I-Premise
407	B	N	I-Premise
408	,	N	I-Premise
409	and	N	I-Premise
410	C	N	I-Premise
411	,	N	I-Premise
412	respectively	N	I-Premise
413	.	N	I-Premise

414	With	N	I-Premise
415	94	N	I-Premise
416	patients	N	I-Premise
417	still	N	I-Premise
418	alive	N	I-Premise
419	,	N	I-Premise
420	the	N	I-Premise
421	one-year	N	I-Premise
422	probability	N	I-Premise
423	of	N	I-Premise
424	survival	N	I-Premise
425	was	N	I-Premise
426	61	N	I-Premise
427	%	N	I-Premise
428	,	N	I-Premise
429	54	N	I-Premise
430	%	N	I-Premise
431	,	N	I-Premise
432	and	N	I-Premise
433	59	N	I-Premise
434	%	N	I-Premise
435	,	N	I-Premise
436	respectively	N	I-Premise
437	.	N	I-Premise

438	WHO	N	I-Premise
439	grade	N	I-Premise
440	3	N	I-Premise
441	or	N	I-Premise
442	4	N	I-Premise
443	neutropenia	N	I-Premise
444	and	N	I-Premise
445	diarrhoea	N	I-Premise
446	affected	N	I-Premise
447	46	N	I-Premise
448	%	N	I-Premise
449	and	N	I-Premise
450	16	N	I-Premise
451	%	N	I-Premise
452	,	N	I-Premise
453	respectively	N	I-Premise
454	,	N	I-Premise
455	of	N	I-Premise
456	patients	N	I-Premise
457	treated	N	I-Premise
458	with	N	I-Premise
459	CPT-11	N	I-Premise
460	+	N	I-Premise
461	LFA	N	I-Premise
462	5-FU	N	I-Premise
463	.	N	I-Premise

464	Median	N	I-Premise
465	relative	N	I-Premise
466	dose	N	I-Premise
467	intensity	N	I-Premise
468	over	N	I-Premise
469	eight	N	I-Premise
470	cycles	N	I-Premise
471	(	N	I-Premise
472	DI8	N	I-Premise
473	)	N	I-Premise
474	was	N	I-Premise
475	78	N	I-Premise
476	%	N	I-Premise
477	for	N	I-Premise
478	CPT-11	N	I-Premise
479	and	N	I-Premise
480	82	N	I-Premise
481	%	N	I-Premise
482	for	N	I-Premise
483	5-FU	N	I-Premise
484	.	N	I-Premise

485	Severe	N	I-Premise
486	toxicities	N	I-Premise
487	of	N	I-Premise
488	TOM	N	I-Premise
489	+	N	I-Premise
490	LFA-5-FU	N	I-Premise
491	were	N	I-Premise
492	neutropenia	N	I-Premise
493	(	N	I-Premise
494	16	N	I-Premise
495	%	N	I-Premise
496	)	N	I-Premise
497	and	N	I-Premise
498	diarrhoea	N	I-Premise
499	(	N	I-Premise
500	16	N	I-Premise
501	%	N	I-Premise
502	)	N	I-Premise
503	,	N	I-Premise
504	but	N	I-Premise
505	median	N	I-Premise
506	relative	N	I-Premise
507	DI8	N	I-Premise
508	was	N	I-Premise
509	93	N	I-Premise
510	%	N	I-Premise
511	for	N	I-Premise
512	TOM	N	I-Premise
513	,	N	I-Premise
514	and	N	I-Premise
515	82	N	I-Premise
516	%	N	I-Premise
517	for	N	I-Premise
518	5-FU	N	I-Premise
519	.	N	I-Premise

520	CPT-11	N	I-Premise
521	+	N	I-Premise
522	LFA-5-FU	N	I-Premise
523	compares	N	I-Premise
524	favorably	N	I-Premise
525	in	N	I-Premise
526	term	N	I-Premise
527	of	N	I-Premise
528	activity	N	I-Premise
529	and	N	I-Premise
530	toxicity	N	I-Premise
531	with	N	I-Premise
532	other	N	I-Premise
533	combination	N	I-Premise
534	regimens	N	I-Premise
535	including	N	I-Premise
536	CPT-11	N	I-Premise
537	and	N	I-Premise
538	continuous	N	I-Premise
539	infusional	N	I-Premise
540	5-FU	N	I-Premise
541	.	N	I-Premise

542	The	N	I-Claim
543	hypothesis	N	I-Claim
544	of	N	I-Claim
545	a	N	I-Claim
546	RR	N	I-Claim
547	15	N	I-Claim
548	%	N	I-Claim
549	higher	N	I-Claim
550	than	N	I-Claim
551	the	N	I-Claim
552	MTX	N	I-Claim
553	+	N	I-Claim
554	LFA-5-FU	N	I-Claim
555	treatment	N	I-Claim
556	can	N	I-Claim
557	not	N	I-Claim
558	be	N	I-Claim
559	ruled	N	I-Claim
560	out	N	I-Claim
561	after	N	I-Claim
562	this	N	I-Claim
563	interim	N	I-Claim
564	analysis	N	I-Claim
565	.	N	I-Claim

566	The	N	I-Claim
567	TOM	N	I-Claim
568	+	N	I-Claim
569	LFA	N	I-Claim
570	5-FU	N	I-Claim
571	regimen	N	I-Claim
572	showed	N	I-Claim
573	a	N	I-Claim
574	RR	N	I-Claim
575	and	N	I-Claim
576	a	N	I-Claim
577	toxicity	N	I-Claim
578	profile	N	I-Claim
579	very	N	I-Claim
580	close	N	I-Claim
581	to	N	I-Claim
582	the	N	I-Claim
583	MTX	N	I-Claim
584	+	N	I-Claim
585	LFA	N	I-Claim
586	5-FU	N	I-Claim
587	combination	N	I-Claim
588	,	N	I-Claim
589	and	N	I-Claim
590	does	N	I-Claim
591	not	N	I-Claim
592	deserve	N	I-Claim
593	further	N	I-Claim
594	evaluation	N	I-Claim
595	in	N	I-Claim
596	advanced	N	I-Claim
597	colorectal	N	I-Claim
598	cancer	N	I-Claim
599	patients	N	I-Claim
600	.	N	I-Claim

1	We	N	O
2	have	N	O
3	recently	N	O
4	suggested	N	O
5	that	N	O
6	bolus	N	O
7	5-fluorouracil	N	O
8	(	N	O
9	5-FU	N	O
10	)	N	O
11	may	N	O
12	work	N	O
13	via	N	O
14	a	N	O
15	RNA	N	O
16	directed	N	O
17	mechanism	N	O
18	while	N	O
19	continuous	N	O
20	infusion	N	O
21	5-FU	N	O
22	may	N	O
23	kill	N	O
24	cells	N	O
25	via	N	O
26	a	N	O
27	thymidylate	N	O
28	synthase	N	O
29	related	N	O
30	pathway	N	O
31	.	N	O

32	It	N	O
33	may	N	O
34	thus	N	O
35	be	N	O
36	possible	N	O
37	to	N	O
38	selectively	N	O
39	modulate	N	O
40	each	N	O
41	schedule	N	O
42	biochemically	N	O
43	.	N	O

44	We	N	O
45	have	N	O
46	compared	N	O
47	an	N	O
48	alternating	N	O
49	regimen	N	O
50	of	N	O
51	bolus	N	O
52	and	N	O
53	continuous	N	O
54	infusion	N	O
55	5-FU	N	O
56	,	N	O
57	selectively	N	O
58	modulated	N	O
59	for	N	O
60	the	N	O
61	schedule	N	O
62	of	N	O
63	administration	N	O
64	,	N	O
65	with	N	O
66	modulated	N	O
67	bolus	N	O
68	5-FU	N	O
69	in	N	O
70	advanced	N	O
71	colorectal	N	O
72	cancer	N	O
73	patients	N	O
74	.	N	O

75	Two	N	O
76	hundred	N	O
77	fourteen	N	O
78	patients	N	O
79	from	N	O
80	nineteen	N	O
81	Italian	N	O
82	centers	N	O
83	were	N	O
84	randomized	N	O
85	to	N	O
86	the	N	O
87	control	N	O
88	arm	N	O
89	consisting	N	O
90	of	N	O
91	biweekly	N	O
92	cycles	N	O
93	of	N	O
94	MTX	N	O
95	,	N	O
96	200	N	O
97	mg/m2	N	O
98	on	N	O
99	day	N	O
100	1	N	O
101	,	N	O
102	followed	N	O
103	by	N	O
104	bolus	N	O
105	5-FU	N	O
106	600	N	O
107	mg/m2	N	O
108	on	N	O
109	day	N	O
110	2	N	O
111	and	N	O
112	6-S-leucovorin	N	O
113	rescue	N	O
114	,	N	O
115	or	N	O
116	to	N	O
117	the	N	O
118	experimental	N	O
119	arm	N	O
120	consisting	N	O
121	of	N	O
122	two	N	O
123	biweekly	N	O
124	cycles	N	O
125	of	N	O
126	the	N	O
127	same	N	O
128	regimen	N	O
129	as	N	O
130	in	N	O
131	the	N	O
132	control	N	O
133	arm	N	O
134	alternated	N	O
135	to	N	O
136	three	N	O
137	weeks	N	O
138	of	N	O
139	continuous	N	O
140	infusion	N	O
141	5-FU	N	O
142	(	N	O
143	200	N	O
144	mg/m2	N	O
145	day	N	O
146	)	N	O
147	+	N	O
148	weekly	N	O
149	bolus	N	O
150	6-S-leucovorin	N	O
151	,	N	O
152	20	N	O
153	mg/m2	N	O
154	.	N	O

155	Nine	N	I-Premise
156	CR	N	I-Premise
157	and	N	I-Premise
158	twenty-seven	N	I-Premise
159	PR	N	I-Premise
160	were	N	I-Premise
161	obtained	N	I-Premise
162	on	N	I-Premise
163	one	N	I-Premise
164	hundred	N	I-Premise
165	eleven	N	I-Premise
166	evaluable	N	I-Premise
167	patients	N	I-Premise
168	treated	N	I-Premise
169	in	N	I-Premise
170	experimental	N	I-Premise
171	arm	N	I-Premise
172	(	N	I-Premise
173	RR	N	I-Premise
174	=	N	I-Premise
175	32	N	I-Premise
176	%	N	I-Premise
177	,	N	I-Premise
178	95	N	I-Premise
179	%	N	I-Premise
180	confidence	N	I-Premise
181	interval	N	I-Premise
182	(	N	I-Premise
183	95	N	I-Premise
184	%	N	I-Premise
185	CI	N	I-Premise
186	)	N	I-Premise
187	:	N	I-Premise
188	24	N	I-Premise
189	%	N	I-Premise
190	-42	N	I-Premise
191	%	N	I-Premise
192	)	N	I-Premise
193	,	N	I-Premise
194	while	N	I-Premise
195	two	N	I-Premise
196	CR	N	I-Premise
197	and	N	I-Premise
198	eleven	N	I-Premise
199	PR	N	I-Premise
200	were	N	I-Premise
201	observed	N	I-Premise
202	among	N	I-Premise
203	one	N	I-Premise
204	hundred	N	I-Premise
205	three	N	I-Premise
206	evaluable	N	I-Premise
207	patients	N	I-Premise
208	in	N	I-Premise
209	control	N	I-Premise
210	arm	N	I-Premise
211	(	N	I-Premise
212	RR	N	I-Premise
213	=	N	I-Premise
214	13	N	I-Premise
215	%	N	I-Premise
216	,	N	I-Premise
217	95	N	I-Premise
218	%	N	I-Premise
219	CI	N	I-Premise
220	:	N	I-Premise
221	7	N	I-Premise
222	%	N	I-Premise
223	-21	N	I-Premise
224	%	N	I-Premise
225	)	N	I-Premise
226	.	N	I-Premise

227	WHO	N	I-Premise
228	grade	N	I-Premise
229	3-4	N	I-Premise
230	toxicity	N	I-Premise
231	occurred	N	I-Premise
232	in	N	I-Premise
233	13	N	I-Premise
234	%	N	I-Premise
235	of	N	I-Premise
236	cycles	N	I-Premise
237	of	N	I-Premise
238	experimental	N	I-Premise
239	arm	N	I-Premise
240	and	N	I-Premise
241	in	N	I-Premise
242	8	N	I-Premise
243	%	N	I-Premise
244	of	N	I-Premise
245	cycles	N	I-Premise
246	in	N	I-Premise
247	control	N	I-Premise
248	arm	N	I-Premise
249	.	N	I-Premise

250	The	N	I-Premise
251	PFS	N	I-Premise
252	was	N	I-Premise
253	significantly	N	I-Premise
254	longer	N	I-Premise
255	in	N	I-Premise
256	experimental	N	I-Premise
257	arm	N	I-Premise
258	(	N	I-Premise
259	6.2	N	I-Premise
260	vs.	N	I-Premise
261	4.3	N	I-Premise
262	months	N	I-Premise
263	,	N	I-Premise
264	odds	N	I-Premise
265	ratio	N	I-Premise
266	0.66	N	I-Premise
267	,	N	I-Premise
268	P	N	I-Premise
269	=	N	I-Premise
270	0.003	N	I-Premise
271	)	N	I-Premise
272	,	N	I-Premise
273	while	N	O
274	the	N	I-Premise
275	overall	N	I-Premise
276	survival	N	I-Premise
277	was	N	I-Premise
278	similar	N	I-Premise
279	in	N	I-Premise
280	both	N	I-Premise
281	arms	N	I-Premise
282	(	N	I-Premise
283	14.8	N	I-Premise
284	months	N	I-Premise
285	in	N	I-Premise
286	experimental	N	I-Premise
287	arm	N	I-Premise
288	vs.	N	I-Premise
289	14.1	N	I-Premise
290	months	N	I-Premise
291	in	N	I-Premise
292	control	N	I-Premise
293	arm	N	I-Premise
294	)	N	I-Premise
295	;	N	I-Premise
296	quality	N	I-Claim
297	of	N	I-Claim
298	life	N	I-Claim
299	was	N	I-Claim
300	similar	N	I-Claim
301	as	N	I-Claim
302	well	N	I-Claim
303	.	N	I-Claim

304	Eighty	N	I-Premise
305	percent	N	I-Premise
306	of	N	I-Premise
307	patients	N	I-Premise
308	receiving	N	I-Premise
309	second-line	N	I-Premise
310	chemotherapy	N	I-Premise
311	in	N	I-Premise
312	control	N	I-Premise
313	arm	N	I-Premise
314	were	N	I-Premise
315	treated	N	I-Premise
316	with	N	I-Premise
317	continuous	N	I-Premise
318	infusion	N	I-Premise
319	5-FU	N	I-Premise
320	.	N	I-Premise

321	Alternating	N	O
322	,	N	O
323	schedule-specific	N	I-Claim
324	biochemical	N	I-Claim
325	modulation	N	I-Claim
326	of	N	I-Claim
327	FU	N	I-Claim
328	is	N	I-Claim
329	more	N	I-Claim
330	active	N	I-Claim
331	than	N	I-Claim
332	MTX	N	I-Claim
333	--	N	I-Claim
334	>	N	I-Claim
335	5-FU	N	I-Claim
336	as	N	I-Claim
337	first-line	N	I-Claim
338	treatment	N	I-Claim
339	of	N	I-Claim
340	advanced	N	I-Claim
341	colorectal	N	I-Claim
342	cancer	N	I-Claim
343	.	N	I-Claim

344	However	N	I-Claim
345	,	N	I-Claim
346	the	N	I-Claim
347	overall	N	I-Claim
348	survival	N	I-Claim
349	was	N	I-Claim
350	similar	N	I-Claim
351	suggesting	N	I-Claim
352	that	N	I-Claim
353	alternating	N	I-Claim
354	bolus	N	I-Claim
355	and	N	I-Claim
356	infusional	N	I-Claim
357	5-FU	N	I-Claim
358	upfront	N	I-Claim
359	may	N	I-Claim
360	be	N	I-Claim
361	as	N	I-Claim
362	effective	N	I-Claim
363	as	N	I-Claim
364	giving	N	I-Claim
365	them	N	I-Claim
366	in	N	I-Claim
367	sequence	N	I-Claim
368	as	N	I-Claim
369	first-	N	I-Claim
370	and	N	I-Claim
371	second-line	N	I-Claim
372	treatment	N	I-Claim
373	.	N	I-Claim

1	The	N	I-MajorClaim
2	combination	N	I-MajorClaim
3	of	N	I-MajorClaim
4	etoposide	N	I-MajorClaim
5	plus	N	I-MajorClaim
6	cisplatin	N	I-MajorClaim
7	(	N	I-MajorClaim
8	EP	N	I-MajorClaim
9	)	N	I-MajorClaim
10	is	N	I-MajorClaim
11	considered	N	I-MajorClaim
12	to	N	I-MajorClaim
13	be	N	I-MajorClaim
14	standard	N	I-MajorClaim
15	therapy	N	I-MajorClaim
16	for	N	I-MajorClaim
17	small-cell	N	I-MajorClaim
18	lung	N	I-MajorClaim
19	cancer	N	I-MajorClaim
20	(	N	I-MajorClaim
21	SCLC	N	I-MajorClaim
22	)	N	I-MajorClaim
23	.	N	I-MajorClaim

24	To	N	O
25	determine	N	O
26	whether	N	O
27	drug	N	O
28	intensification	N	O
29	improves	N	O
30	survival	N	O
31	of	N	O
32	patients	N	O
33	with	N	O
34	extensive	N	O
35	SCLC	N	O
36	,	N	O
37	we	N	O
38	compared	N	O
39	this	N	O
40	treatment	N	O
41	with	N	O
42	a	N	O
43	four-drug	N	O
44	regimen	N	O
45	containing	N	O
46	EP	N	O
47	plus	N	O
48	cyclophosphamide	N	O
49	and	N	O
50	4'-epidoxorubicin	N	O
51	(	N	O
52	PCDE	N	O
53	)	N	O
54	.	N	O

55	In	N	O
56	a	N	O
57	phase	N	O
58	III	N	O
59	clinical	N	O
60	trial	N	O
61	organized	N	O
62	by	N	O
63	the	N	O
64	French	N	O
65	Federation	N	O
66	of	N	O
67	Cancer	N	O
68	Institutes	N	O
69	,	N	O
70	patients	N	O
71	were	N	O
72	randomly	N	O
73	assigned	N	O
74	to	N	O
75	receive	N	O
76	either	N	O
77	EP	N	O
78	(	N	O
79	n	N	O
80	=	N	O
81	109	N	O
82	;	N	O
83	etoposide	N	O
84	at	N	O
85	a	N	O
86	dose	N	O
87	of	N	O
88	100	N	O
89	mg/m	N	O
90	(	N	O
91	2	N	O
92	)	N	O
93	on	N	O
94	days	N	O
95	1-3	N	O
96	plus	N	O
97	cisplatin	N	O
98	at	N	O
99	100	N	O
100	mg/m	N	O
101	(	N	O
102	2	N	O
103	)	N	O
104	on	N	O
105	day	N	O
106	2	N	O
107	)	N	O
108	or	N	O
109	PCDE	N	O
110	(	N	O
111	n	N	O
112	=	N	O
113	117	N	O
114	;	N	O
115	etoposide	N	O
116	and	N	O
117	cisplatin	N	O
118	given	N	O
119	as	N	O
120	in	N	O
121	EP	N	O
122	plus	N	O
123	cyclophosphamide	N	O
124	at	N	O
125	400	N	O
126	mg/m	N	O
127	(	N	O
128	2	N	O
129	)	N	O
130	on	N	O
131	days	N	O
132	1-3	N	O
133	and	N	O
134	4'-epidoxorubicin	N	O
135	at	N	O
136	40	N	O
137	mg/m	N	O
138	(	N	O
139	2	N	O
140	)	N	O
141	on	N	O
142	day	N	O
143	1	N	O
144	)	N	O
145	every	N	O
146	4	N	O
147	weeks	N	O
148	.	N	O

149	Both	N	O
150	groups	N	O
151	received	N	O
152	a	N	O
153	total	N	O
154	of	N	O
155	six	N	O
156	cycles	N	O
157	.	N	O

158	Survival	N	O
159	differences	N	O
160	were	N	O
161	analyzed	N	O
162	by	N	O
163	Wilcoxon	N	O
164	and	N	O
165	log-rank	N	O
166	tests	N	O
167	.	N	O

168	Associations	N	O
169	of	N	O
170	treatment	N	O
171	group	N	O
172	and	N	O
173	putative	N	O
174	prognostic	N	O
175	variables	N	O
176	with	N	O
177	survival	N	O
178	were	N	O
179	tested	N	O
180	in	N	O
181	the	N	O
182	Cox	N	O
183	proportional	N	O
184	hazards	N	O
185	model	N	O
186	.	N	O

187	Quality	N	O
188	of	N	O
189	life	N	O
190	was	N	O
191	assessed	N	O
192	from	N	O
193	the	N	O
194	responses	N	O
195	to	N	O
196	the	N	O
197	European	N	O
198	Organization	N	O
199	for	N	O
200	Research	N	O
201	and	N	O
202	Treatment	N	O
203	of	N	O
204	Cancer	N	O
205	quality-of-life	N	O
206	questionnaire	N	O
207	(	N	O
208	C30	N	O
209	,	N	O
210	health	N	O
211	status	N	O
212	and	N	O
213	lung	N	O
214	cancer	N	O
215	module	N	O
216	13	N	O
217	)	N	O
218	.	N	O

219	All	N	O
220	statistical	N	O
221	tests	N	O
222	were	N	O
223	two-sided	N	O
224	.	N	O

225	Patients	N	I-Premise
226	in	N	I-Premise
227	the	N	I-Premise
228	PCDE	N	I-Premise
229	arm	N	I-Premise
230	had	N	I-Premise
231	a	N	I-Premise
232	statistically	N	I-Premise
233	significant	N	I-Premise
234	higher	N	I-Premise
235	frequency	N	I-Premise
236	of	N	I-Premise
237	combined	N	I-Premise
238	complete	N	I-Premise
239	plus	N	I-Premise
240	partial	N	I-Premise
241	responses	N	I-Premise
242	compared	N	I-Premise
243	with	N	I-Premise
244	those	N	I-Premise
245	in	N	I-Premise
246	the	N	I-Premise
247	EP	N	I-Premise
248	arm	N	I-Premise
249	(	N	I-Premise
250	21	N	I-Premise
251	%	N	I-Premise
252	plus	N	I-Premise
253	55	N	I-Premise
254	%	N	I-Premise
255	versus	N	I-Premise
256	13	N	I-Premise
257	%	N	I-Premise
258	plus	N	I-Premise
259	48	N	I-Premise
260	%	N	I-Premise
261	,	N	I-Premise
262	respectively	N	I-Premise
263	;	N	I-Premise
264	P	N	I-Premise
265	=.02	N	I-Premise
266	for	N	I-Premise
267	difference	N	I-Premise
268	in	N	I-Premise
269	combined	N	I-Premise
270	objective	N	I-Premise
271	responses	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	Patients	N	I-Premise
275	in	N	I-Premise
276	the	N	I-Premise
277	PCDE	N	I-Premise
278	arm	N	I-Premise
279	survived	N	I-Premise
280	longer	N	I-Premise
281	than	N	I-Premise
282	those	N	I-Premise
283	in	N	I-Premise
284	the	N	I-Premise
285	EP	N	I-Premise
286	arm	N	I-Premise
287	(	N	I-Premise
288	1-year	N	I-Premise
289	survival	N	I-Premise
290	rate	N	I-Premise
291	:	N	I-Premise
292	40	N	I-Premise
293	%	N	I-Premise
294	and	N	I-Premise
295	29	N	I-Premise
296	%	N	I-Premise
297	,	N	I-Premise
298	respectively	N	I-Premise
299	;	N	I-Premise
300	median	N	I-Premise
301	survival	N	I-Premise
302	:	N	I-Premise
303	10.5	N	I-Premise
304	and	N	I-Premise
305	9.3	N	I-Premise
306	months	N	I-Premise
307	,	N	I-Premise
308	respectively	N	I-Premise
309	;	N	I-Premise
310	log-rank	N	I-Premise
311	P	N	I-Premise
312	=.0067	N	I-Premise
313	)	N	I-Premise
314	.	N	I-Premise

315	In	N	I-Premise
316	the	N	I-Premise
317	Cox	N	I-Premise
318	model	N	I-Premise
319	,	N	I-Premise
320	the	N	I-Premise
321	relative	N	I-Premise
322	risk	N	I-Premise
323	of	N	I-Premise
324	death	N	I-Premise
325	for	N	I-Premise
326	patients	N	I-Premise
327	in	N	I-Premise
328	the	N	I-Premise
329	PCDE	N	I-Premise
330	arm	N	I-Premise
331	compared	N	I-Premise
332	with	N	I-Premise
333	those	N	I-Premise
334	in	N	I-Premise
335	the	N	I-Premise
336	EP	N	I-Premise
337	arm	N	I-Premise
338	was	N	I-Premise
339	0.70	N	I-Premise
340	(	N	I-Premise
341	95	N	I-Premise
342	%	N	I-Premise
343	confidence	N	I-Premise
344	interval	N	I-Premise
345	=	N	I-Premise
346	0.51	N	I-Premise
347	to	N	I-Premise
348	0.95	N	I-Premise
349	)	N	I-Premise
350	;	N	I-Premise
351	the	N	I-Premise
352	disease	N	I-Premise
353	also	N	I-Premise
354	progressed	N	I-Premise
355	more	N	I-Premise
356	slowly	N	I-Premise
357	in	N	I-Premise
358	patients	N	I-Premise
359	in	N	I-Premise
360	the	N	I-Premise
361	PCDE	N	I-Premise
362	arm	N	I-Premise
363	.	N	I-Premise

364	Hematologic	N	I-Premise
365	toxicity	N	I-Premise
366	was	N	I-Premise
367	higher	N	I-Premise
368	in	N	I-Premise
369	the	N	I-Premise
370	PCDE	N	I-Premise
371	arm	N	I-Premise
372	(	N	I-Premise
373	22	N	I-Premise
374	%	N	I-Premise
375	with	N	I-Premise
376	documented	N	I-Premise
377	infections	N	I-Premise
378	compared	N	I-Premise
379	with	N	I-Premise
380	8	N	I-Premise
381	%	N	I-Premise
382	in	N	I-Premise
383	the	N	I-Premise
384	EP	N	I-Premise
385	arm	N	I-Premise
386	;	N	I-Premise
387	P	N	I-Premise
388	=.0038	N	I-Premise
389	)	N	I-Premise
390	,	N	I-Premise
391	and	N	O
392	the	N	I-Premise
393	toxicity-related	N	I-Premise
394	death	N	I-Premise
395	rate	N	I-Premise
396	was	N	I-Premise
397	9	N	I-Premise
398	%	N	I-Premise
399	in	N	I-Premise
400	the	N	I-Premise
401	PCDE	N	I-Premise
402	arm	N	I-Premise
403	versus	N	I-Premise
404	5.5	N	I-Premise
405	%	N	I-Premise
406	in	N	I-Premise
407	the	N	I-Premise
408	EP	N	I-Premise
409	arm	N	I-Premise
410	(	N	I-Premise
411	P	N	I-Premise
412	=.22	N	I-Premise
413	)	N	I-Premise
414	.	N	I-Premise

415	The	N	I-Claim
416	global	N	I-Claim
417	health	N	I-Claim
418	status	N	I-Claim
419	showed	N	I-Claim
420	similar	N	I-Claim
421	improvement	N	I-Claim
422	in	N	I-Claim
423	both	N	I-Claim
424	arms	N	I-Claim
425	during	N	I-Claim
426	treatment	N	I-Claim
427	.	N	I-Claim

428	Compared	N	I-Claim
429	with	N	I-Claim
430	the	N	I-Claim
431	EP	N	I-Claim
432	regimen	N	I-Claim
433	,	N	I-Claim
434	the	N	I-Claim
435	PCDE	N	I-Claim
436	regimen	N	I-Claim
437	yielded	N	I-Claim
438	higher	N	I-Claim
439	response	N	I-Claim
440	rates	N	I-Claim
441	and	N	I-Claim
442	better	N	I-Claim
443	survival	N	I-Claim
444	rates	N	I-Claim
445	in	N	I-Claim
446	patients	N	I-Claim
447	with	N	I-Claim
448	extensive	N	I-Claim
449	SCLC	N	I-Claim
450	without	N	I-Claim
451	affecting	N	I-Claim
452	the	N	I-Claim
453	quality	N	I-Claim
454	of	N	I-Claim
455	life	N	I-Claim
456	of	N	I-Claim
457	the	N	I-Claim
458	patients	N	I-Claim
459	during	N	I-Claim
460	chemotherapy	N	I-Claim
461	.	N	I-Claim

1	To	N	O
2	test	N	O
3	the	N	O
4	equivalence	N	O
5	of	N	O
6	three	N	O
7	versus	N	O
8	four	N	O
9	cycles	N	O
10	of	N	O
11	bleomycin	N	O
12	,	N	O
13	etoposide	N	O
14	,	N	O
15	and	N	O
16	cisplatin	N	O
17	(	N	O
18	BEP	N	O
19	)	N	O
20	and	N	O
21	of	N	O
22	the	N	O
23	5-day	N	O
24	schedule	N	O
25	versus	N	O
26	3	N	O
27	days	N	O
28	per	N	O
29	cycle	N	O
30	in	N	O
31	good-prognosis	N	O
32	germ	N	O
33	cell	N	O
34	cancer	N	O
35	.	N	O

36	The	N	O
37	study	N	O
38	was	N	O
39	designed	N	O
40	as	N	O
41	a	N	O
42	2	N	O
43	x	N	O
44	2	N	O
45	factorial	N	O
46	trial	N	O
47	.	N	O

48	The	N	O
49	aim	N	O
50	was	N	O
51	to	N	O
52	rule	N	O
53	out	N	O
54	a	N	O
55	5	N	O
56	%	N	O
57	decrease	N	O
58	in	N	O
59	the	N	O
60	2-year	N	O
61	progression-free	N	O
62	survival	N	O
63	(	N	O
64	PFS	N	O
65	)	N	O
66	rate	N	O
67	.	N	O

68	The	N	O
69	study	N	O
70	included	N	O
71	the	N	O
72	assessment	N	O
73	of	N	O
74	patient	N	O
75	quality	N	O
76	of	N	O
77	life	N	O
78	.	N	O

79	A	N	O
80	cycle	N	O
81	of	N	O
82	BEP	N	O
83	consisted	N	O
84	of	N	O
85	etoposide	N	O
86	500	N	O
87	mg/m	N	O
88	(	N	O
89	2	N	O
90	)	N	O
91	,	N	O
92	administered	N	O
93	at	N	O
94	either	N	O
95	100	N	O
96	mg/m	N	O
97	(	N	O
98	2	N	O
99	)	N	O
100	days	N	O
101	1	N	O
102	through	N	O
103	5	N	O
104	or	N	O
105	165	N	O
106	mg/m	N	O
107	(	N	O
108	2	N	O
109	)	N	O
110	days	N	O
111	1	N	O
112	through	N	O
113	3	N	O
114	,	N	O
115	cisplatin	N	O
116	100	N	O
117	mg/m	N	O
118	(	N	O
119	2	N	O
120	)	N	O
121	,	N	O
122	administered	N	O
123	at	N	O
124	either	N	O
125	20	N	O
126	mg/m	N	O
127	(	N	O
128	2	N	O
129	)	N	O
130	days	N	O
131	1	N	O
132	through	N	O
133	5	N	O
134	or	N	O
135	50	N	O
136	mg/m	N	O
137	(	N	O
138	2	N	O
139	)	N	O
140	days	N	O
141	1	N	O
142	and	N	O
143	2	N	O
144	.	N	O

145	Bleomycin	N	O
146	30	N	O
147	mg	N	O
148	was	N	O
149	administered	N	O
150	on	N	O
151	days	N	O
152	1	N	O
153	,	N	O
154	8	N	O
155	,	N	O
156	and	N	O
157	15	N	O
158	during	N	O
159	cycles	N	O
160	1	N	O
161	through	N	O
162	3	N	O
163	.	N	O

164	The	N	O
165	randomization	N	O
166	procedure	N	O
167	allowed	N	O
168	some	N	O
169	investigators	N	O
170	to	N	O
171	participate	N	O
172	only	N	O
173	in	N	O
174	the	N	O
175	comparison	N	O
176	of	N	O
177	three	N	O
178	versus	N	O
179	four	N	O
180	cycles	N	O
181	.	N	O

182	From	N	O
183	March	N	O
184	1995	N	O
185	until	N	O
186	April	N	O
187	1998	N	O
188	,	N	O
189	812	N	O
190	patients	N	O
191	were	N	O
192	randomly	N	O
193	assigned	N	O
194	to	N	O
195	receive	N	O
196	three	N	O
197	or	N	O
198	four	N	O
199	cycles	N	O
200	:	N	O
201	of	N	O
202	these	N	O
203	,	N	O
204	681	N	O
205	were	N	O
206	also	N	O
207	randomly	N	O
208	assigned	N	O
209	to	N	O
210	the	N	O
211	5-day	N	O
212	or	N	O
213	the	N	O
214	3-day	N	O
215	schedule	N	O
216	.	N	O

217	Histology	N	O
218	,	N	O
219	marker	N	O
220	values	N	O
221	,	N	O
222	and	N	O
223	disease	N	O
224	extent	N	O
225	are	N	O
226	well	N	O
227	balanced	N	O
228	in	N	O
229	the	N	O
230	treatment	N	O
231	arms	N	O
232	of	N	O
233	the	N	O
234	two	N	O
235	comparisons	N	O
236	.	N	O

237	The	N	I-Premise
238	projected	N	I-Premise
239	2-year	N	I-Premise
240	PFS	N	I-Premise
241	is	N	I-Premise
242	90.4	N	I-Premise
243	%	N	I-Premise
244	on	N	I-Premise
245	three	N	I-Premise
246	cycles	N	I-Premise
247	and	N	I-Premise
248	89.4	N	I-Premise
249	%	N	I-Premise
250	on	N	I-Premise
251	four	N	I-Premise
252	cycles	N	I-Premise
253	.	N	I-Premise

254	The	N	I-Premise
255	difference	N	I-Premise
256	in	N	I-Premise
257	PFS	N	I-Premise
258	between	N	I-Premise
259	three	N	I-Premise
260	and	N	I-Premise
261	four	N	I-Premise
262	cycles	N	I-Premise
263	is	N	I-Premise
264	-1.0	N	I-Premise
265	%	N	I-Premise
266	(	N	I-Premise
267	80	N	I-Premise
268	%	N	I-Premise
269	confidence	N	I-Premise
270	limit	N	I-Premise
271	[	N	I-Premise
272	CL	N	I-Premise
273	]	N	I-Premise
274	,	N	I-Premise
275	-3.8	N	I-Premise
276	%	N	I-Premise
277	,	N	I-Premise
278	+1.8	N	I-Premise
279	%	N	I-Premise
280	)	N	I-Premise
281	.	N	I-Premise

282	Equivalence	N	I-Claim
283	for	N	I-Claim
284	three	N	I-Claim
285	versus	N	I-Claim
286	four	N	I-Claim
287	cycles	N	I-Claim
288	is	N	I-Claim
289	claimed	N	I-Claim
290	because	N	I-Claim
291	both	N	I-Claim
292	the	N	I-Claim
293	upper	N	I-Claim
294	and	N	I-Claim
295	lower	N	I-Claim
296	bounds	N	I-Claim
297	of	N	I-Claim
298	the	N	I-Claim
299	80	N	I-Claim
300	%	N	I-Claim
301	CL	N	I-Claim
302	are	N	I-Claim
303	less	N	I-Claim
304	than	N	I-Claim
305	5	N	I-Claim
306	%	N	I-Claim
307	.	N	I-Claim

308	In	N	I-Premise
309	the	N	I-Premise
310	5-	N	I-Premise
311	versus	N	I-Premise
312	3-day	N	I-Premise
313	comparison	N	I-Premise
314	,	N	I-Premise
315	the	N	I-Premise
316	projected	N	I-Premise
317	2-year	N	I-Premise
318	PFS	N	I-Premise
319	is	N	I-Premise
320	88.8	N	I-Premise
321	%	N	I-Premise
322	and	N	I-Premise
323	89.7	N	I-Premise
324	%	N	I-Premise
325	,	N	I-Premise
326	respectively	N	I-Premise
327	(	N	I-Premise
328	difference	N	I-Premise
329	,	N	I-Premise
330	-0.9	N	I-Premise
331	%	N	I-Premise
332	,	N	I-Premise
333	(	N	I-Premise
334	80	N	I-Premise
335	%	N	I-Premise
336	CL	N	I-Premise
337	,	N	I-Premise
338	-4.1	N	I-Premise
339	%	N	I-Premise
340	,	N	I-Premise
341	+2.2	N	I-Premise
342	%	N	I-Premise
343	)	N	I-Premise
344	.	N	I-Premise

345	Hence	N	O
346	,	N	O
347	equivalence	N	I-Claim
348	is	N	I-Claim
349	claimed	N	I-Claim
350	in	N	I-Claim
351	this	N	I-Claim
352	comparison	N	I-Claim
353	also	N	I-Claim
354	.	N	I-Claim

355	Frequencies	N	I-Premise
356	of	N	I-Premise
357	hematologic	N	I-Premise
358	and	N	I-Premise
359	nonhematologic	N	I-Premise
360	toxicities	N	I-Premise
361	were	N	I-Premise
362	essentially	N	I-Premise
363	similar	N	I-Premise
364	.	N	I-Premise

365	Quality	N	I-Premise
366	of	N	I-Premise
367	life	N	I-Premise
368	was	N	I-Premise
369	maintained	N	I-Premise
370	better	N	I-Premise
371	in	N	I-Premise
372	patients	N	I-Premise
373	receiving	N	I-Premise
374	three	N	I-Premise
375	cycles	N	I-Premise
376	;	N	I-Premise
377	no	N	I-Premise
378	differences	N	I-Premise
379	were	N	I-Premise
380	detected	N	I-Premise
381	between	N	I-Premise
382	3	N	I-Premise
383	and	N	I-Premise
384	5	N	I-Premise
385	days	N	I-Premise
386	of	N	I-Premise
387	treatment	N	I-Premise
388	.	N	I-Premise

389	We	N	O
390	conclude	N	O
391	that	N	O
392	three	N	I-Claim
393	cycles	N	I-Claim
394	of	N	I-Claim
395	BEP	N	I-Claim
396	,	N	I-Claim
397	with	N	I-Claim
398	etoposide	N	I-Claim
399	at	N	I-Claim
400	500	N	I-Claim
401	mg/m	N	I-Claim
402	(	N	I-Claim
403	2	N	I-Claim
404	)	N	I-Claim
405	,	N	I-Claim
406	is	N	I-Claim
407	sufficient	N	I-Claim
408	therapy	N	I-Claim
409	in	N	I-Claim
410	good-prognosis	N	I-Claim
411	germ	N	I-Claim
412	cell	N	I-Claim
413	cancer	N	I-Claim
414	and	N	O
415	that	N	O
416	the	N	I-Claim
417	administration	N	I-Claim
418	of	N	I-Claim
419	the	N	I-Claim
420	chemotherapy	N	I-Claim
421	in	N	I-Claim
422	3	N	I-Claim
423	days	N	I-Claim
424	has	N	I-Claim
425	no	N	I-Claim
426	detrimental	N	I-Claim
427	effect	N	I-Claim
428	on	N	I-Claim
429	the	N	I-Claim
430	effectiveness	N	I-Claim
431	of	N	I-Claim
432	the	N	I-Claim
433	BEP	N	I-Claim
434	regimen	N	I-Claim
435	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	topotecan	N	O
7	in	N	O
8	combination	N	O
9	with	N	O
10	standard	N	O
11	chemotherapy	N	O
12	in	N	O
13	previously	N	O
14	untreated	N	O
15	patients	N	O
16	with	N	O
17	extensive-stage	N	O
18	small-cell	N	O
19	lung	N	O
20	cancer	N	O
21	(	N	O
22	SCLC	N	O
23	)	N	O
24	,	N	O
25	the	N	O
26	Eastern	N	O
27	Cooperative	N	O
28	Oncology	N	O
29	Group	N	O
30	(	N	O
31	ECOG	N	O
32	)	N	O
33	conducted	N	O
34	a	N	O
35	phase	N	O
36	III	N	O
37	trial	N	O
38	.	N	O

39	Eligible	N	O
40	patients	N	O
41	had	N	O
42	measurable	N	O
43	or	N	O
44	assessable	N	O
45	disease	N	O
46	and	N	O
47	an	N	O
48	ECOG	N	O
49	performance	N	O
50	status	N	O
51	of	N	O
52	0	N	O
53	to	N	O
54	2	N	O
55	;	N	O
56	stable	N	O
57	brain	N	O
58	metastases	N	O
59	were	N	O
60	allowed	N	O
61	.	N	O

62	All	N	O
63	patients	N	O
64	received	N	O
65	four	N	O
66	cycles	N	O
67	of	N	O
68	cisplatin	N	O
69	and	N	O
70	etoposide	N	O
71	every	N	O
72	3	N	O
73	weeks	N	O
74	(	N	O
75	step	N	O
76	1	N	O
77	;	N	O
78	PE	N	O
79	)	N	O
80	.	N	O

81	Patients	N	O
82	with	N	O
83	stable	N	O
84	or	N	O
85	responding	N	O
86	disease	N	O
87	were	N	O
88	then	N	O
89	randomized	N	O
90	to	N	O
91	observation	N	O
92	or	N	O
93	four	N	O
94	cycles	N	O
95	of	N	O
96	topotecan	N	O
97	(	N	O
98	1.5	N	O
99	mg/m	N	O
100	(	N	O
101	2	N	O
102	)	N	O
103	/d	N	O
104	for	N	O
105	5	N	O
106	days	N	O
107	,	N	O
108	every	N	O
109	3	N	O
110	weeks	N	O
111	;	N	O
112	step	N	O
113	2	N	O
114	)	N	O
115	.	N	O

116	A	N	O
117	total	N	O
118	of	N	O
119	402	N	O
120	eligible	N	O
121	patients	N	O
122	were	N	O
123	registered	N	O
124	to	N	O
125	step	N	O
126	1	N	O
127	,	N	O
128	and	N	O
129	223	N	O
130	eligible	N	O
131	patients	N	O
132	were	N	O
133	registered	N	O
134	to	N	O
135	step	N	O
136	2	N	O
137	(	N	O
138	observation	N	O
139	,	N	O
140	n	N	O
141	=	N	O
142	111	N	O
143	;	N	O
144	topotecan	N	O
145	,	N	O
146	n	N	O
147	=	N	O
148	112	N	O
149	)	N	O
150	.	N	O

151	Complete	N	I-Premise
152	and	N	I-Premise
153	partial	N	I-Premise
154	response	N	I-Premise
155	rates	N	I-Premise
156	to	N	I-Premise
157	induction	N	I-Premise
158	PE	N	I-Premise
159	were	N	I-Premise
160	3	N	I-Premise
161	%	N	I-Premise
162	and	N	I-Premise
163	32	N	I-Premise
164	%	N	I-Premise
165	,	N	I-Premise
166	respectively	N	I-Premise
167	.	N	I-Premise

168	A	N	I-Premise
169	7	N	I-Premise
170	%	N	I-Premise
171	response	N	I-Premise
172	rate	N	I-Premise
173	was	N	I-Premise
174	observed	N	I-Premise
175	with	N	I-Premise
176	topotecan	N	I-Premise
177	(	N	I-Premise
178	complete	N	I-Premise
179	response	N	I-Premise
180	,	N	I-Premise
181	2	N	I-Premise
182	%	N	I-Premise
183	;	N	I-Premise
184	partial	N	I-Premise
185	response	N	I-Premise
186	,	N	I-Premise
187	5	N	I-Premise
188	%	N	I-Premise
189	)	N	I-Premise
190	.	N	I-Premise

191	The	N	I-Premise
192	median	N	I-Premise
193	survival	N	I-Premise
194	time	N	I-Premise
195	for	N	I-Premise
196	all	N	I-Premise
197	402	N	I-Premise
198	eligible	N	I-Premise
199	patients	N	I-Premise
200	was	N	I-Premise
201	9.6	N	I-Premise
202	months	N	I-Premise
203	.	N	I-Premise

204	Progression-free	N	I-Premise
205	survival	N	I-Premise
206	(	N	I-Premise
207	PFS	N	I-Premise
208	)	N	I-Premise
209	from	N	I-Premise
210	date	N	I-Premise
211	of	N	I-Premise
212	randomization	N	I-Premise
213	on	N	I-Premise
214	step	N	I-Premise
215	2	N	I-Premise
216	was	N	I-Premise
217	significantly	N	I-Premise
218	better	N	I-Premise
219	with	N	I-Premise
220	topotecan	N	I-Premise
221	compared	N	I-Premise
222	with	N	I-Premise
223	observation	N	I-Premise
224	(	N	I-Premise
225	3.6	N	I-Premise
226	months	N	I-Premise
227	v	N	I-Premise
228	2.3	N	I-Premise
229	months	N	I-Premise
230	;	N	I-Premise
231	P	N	I-Premise
232	<	N	I-Premise
233	.001	N	I-Premise
234	)	N	I-Premise
235	.	N	I-Premise

236	However	N	O
237	,	N	O
238	overall	N	I-Premise
239	survival	N	I-Premise
240	from	N	I-Premise
241	date	N	I-Premise
242	of	N	I-Premise
243	randomization	N	I-Premise
244	on	N	I-Premise
245	step	N	I-Premise
246	2	N	I-Premise
247	was	N	I-Premise
248	not	N	I-Premise
249	significantly	N	I-Premise
250	different	N	I-Premise
251	between	N	I-Premise
252	the	N	I-Premise
253	observation	N	I-Premise
254	and	N	I-Premise
255	topotecan	N	I-Premise
256	arms	N	I-Premise
257	(	N	I-Premise
258	8.9	N	I-Premise
259	months	N	I-Premise
260	v	N	I-Premise
261	9.3	N	I-Premise
262	months	N	I-Premise
263	;	N	I-Premise
264	P	N	I-Premise
265	=.43	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	Grade	N	I-Premise
269	4	N	I-Premise
270	neutropenia	N	I-Premise
271	and	N	I-Premise
272	thrombocytopenia	N	I-Premise
273	occurred	N	I-Premise
274	in	N	I-Premise
275	50	N	I-Premise
276	%	N	I-Premise
277	and	N	I-Premise
278	3	N	I-Premise
279	%	N	I-Premise
280	,	N	I-Premise
281	respectively	N	I-Premise
282	,	N	I-Premise
283	of	N	I-Premise
284	PE	N	I-Premise
285	patients	N	I-Premise
286	in	N	I-Premise
287	step	N	I-Premise
288	1	N	I-Premise
289	and	N	I-Premise
290	60	N	I-Premise
291	%	N	I-Premise
292	and	N	I-Premise
293	13	N	I-Premise
294	%	N	I-Premise
295	of	N	I-Premise
296	topotecan	N	I-Premise
297	patients	N	I-Premise
298	in	N	I-Premise
299	step	N	I-Premise
300	2	N	I-Premise
301	.	N	I-Premise

302	Grade	N	I-Premise
303	4/5	N	I-Premise
304	infection	N	I-Premise
305	was	N	I-Premise
306	observed	N	I-Premise
307	in	N	I-Premise
308	4.6	N	I-Premise
309	%	N	I-Premise
310	of	N	I-Premise
311	PE	N	I-Premise
312	patients	N	I-Premise
313	and	N	I-Premise
314	1.8	N	I-Premise
315	%	N	I-Premise
316	of	N	I-Premise
317	topotecan	N	I-Premise
318	patients	N	I-Premise
319	.	N	I-Premise

320	Grade	N	I-Premise
321	3/4	N	I-Premise
322	anemia	N	I-Premise
323	developed	N	I-Premise
324	in	N	I-Premise
325	22	N	I-Premise
326	%	N	I-Premise
327	of	N	I-Premise
328	patients	N	I-Premise
329	who	N	I-Premise
330	received	N	I-Premise
331	topotecan	N	I-Premise
332	.	N	I-Premise

333	No	N	I-Premise
334	difference	N	I-Premise
335	in	N	I-Premise
336	quality	N	I-Premise
337	of	N	I-Premise
338	life	N	I-Premise
339	between	N	I-Premise
340	topotecan	N	I-Premise
341	and	N	I-Premise
342	observation	N	I-Premise
343	was	N	I-Premise
344	observed	N	I-Premise
345	at	N	I-Premise
346	any	N	I-Premise
347	assessment	N	I-Premise
348	time	N	I-Premise
349	or	N	I-Premise
350	for	N	I-Premise
351	any	N	I-Premise
352	of	N	I-Premise
353	the	N	I-Premise
354	subscale	N	I-Premise
355	scores	N	I-Premise
356	.	N	I-Premise

357	Four	N	I-Claim
358	cycles	N	I-Claim
359	of	N	I-Claim
360	PE	N	I-Claim
361	induction	N	I-Claim
362	therapy	N	I-Claim
363	followed	N	I-Claim
364	by	N	I-Claim
365	four	N	I-Claim
366	cycles	N	I-Claim
367	of	N	I-Claim
368	topotecan	N	I-Claim
369	improved	N	I-Claim
370	PFS	N	I-Claim
371	but	N	I-Claim
372	failed	N	I-Claim
373	to	N	I-Claim
374	improve	N	I-Claim
375	overall	N	I-Claim
376	survival	N	I-Claim
377	or	N	I-Claim
378	quality	N	I-Claim
379	of	N	I-Claim
380	life	N	I-Claim
381	in	N	I-Claim
382	extensive-stage	N	I-Claim
383	SCLC	N	I-Claim
384	.	N	I-Claim

385	Four	N	I-Claim
386	cycles	N	I-Claim
387	of	N	I-Claim
388	standard	N	I-Claim
389	PE	N	I-Claim
390	remains	N	I-Claim
391	an	N	I-Claim
392	appropriate	N	I-Claim
393	first-line	N	I-Claim
394	treatment	N	I-Claim
395	for	N	I-Claim
396	extensive-stage	N	I-Claim
397	SCLC	N	I-Claim
398	patients	N	I-Claim
399	with	N	I-Claim
400	good	N	I-Claim
401	performance	N	I-Claim
402	status	N	I-Claim
403	.	N	I-Claim

1	The	N	I-MajorClaim
2	role	N	I-MajorClaim
3	of	N	I-MajorClaim
4	adjuvant	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	in	N	I-MajorClaim
7	postmenopausal	N	I-MajorClaim
8	patients	N	I-MajorClaim
9	with	N	I-MajorClaim
10	lymph	N	I-MajorClaim
11	node-negative	N	I-MajorClaim
12	breast	N	I-MajorClaim
13	cancer	N	I-MajorClaim
14	is	N	I-MajorClaim
15	controversial	N	I-MajorClaim
16	.	N	I-MajorClaim

17	After	N	O
18	demonstrating	N	O
19	the	N	O
20	efficacy	N	O
21	of	N	O
22	chemotherapy	N	O
23	combined	N	O
24	with	N	O
25	tamoxifen	N	O
26	for	N	O
27	postmenopausal	N	O
28	patients	N	O
29	with	N	O
30	lymph	N	O
31	node-positive	N	O
32	disease	N	O
33	,	N	O
34	the	N	O
35	International	N	O
36	Breast	N	O
37	Cancer	N	O
38	Study	N	O
39	Group	N	O
40	launched	N	O
41	a	N	O
42	randomized	N	O
43	trial	N	O
44	(	N	O
45	Trial	N	O
46	IX	N	O
47	)	N	O
48	to	N	O
49	evaluate	N	O
50	the	N	O
51	role	N	O
52	of	N	O
53	adjuvant	N	O
54	chemotherapy	N	O
55	preceding	N	O
56	treatment	N	O
57	with	N	O
58	tamoxifen	N	O
59	for	N	O
60	patients	N	O
61	with	N	O
62	lymph	N	O
63	node-negative	N	O
64	disease	N	O
65	.	N	O

66	After	N	O
67	stratification	N	O
68	by	N	O
69	estrogen	N	O
70	receptor	N	O
71	(	N	O
72	ER	N	O
73	)	N	O
74	status	N	O
75	,	N	O
76	patients	N	O
77	were	N	O
78	randomly	N	O
79	assigned	N	O
80	to	N	O
81	receive	N	O
82	three	N	O
83	28-day	N	O
84	courses	N	O
85	of	N	O
86	``	N	O
87	classical	N	O
88	''	N	O
89	adjuvant	N	O
90	CMF	N	O
91	chemotherapy	N	O
92	(	N	O
93	cyclophosphamide	N	O
94	at	N	O
95	100	N	O
96	mg/m	N	O
97	(	N	O
98	2	N	O
99	)	N	O
100	on	N	O
101	days	N	O
102	1-14	N	O
103	,	N	O
104	orally	N	O
105	;	N	O
106	methotrexate	N	O
107	at	N	O
108	40	N	O
109	mg/m	N	O
110	(	N	O
111	2	N	O
112	)	N	O
113	on	N	O
114	days	N	O
115	1	N	O
116	and	N	O
117	8	N	O
118	,	N	O
119	intravenously	N	O
120	;	N	O
121	and	N	O
122	5-fluorouracil	N	O
123	at	N	O
124	600	N	O
125	mg/m	N	O
126	(	N	O
127	2	N	O
128	)	N	O
129	on	N	O
130	days	N	O
131	1	N	O
132	and	N	O
133	8	N	O
134	,	N	O
135	intravenously	N	O
136	)	N	O
137	followed	N	O
138	by	N	O
139	tamoxifen	N	O
140	(	N	O
141	20	N	O
142	mg/day	N	O
143	,	N	O
144	orally	N	O
145	for	N	O
146	57	N	O
147	months	N	O
148	)	N	O
149	(	N	O
150	CMF	N	O
151	--	N	O
152	>	N	O
153	tamoxifen	N	O
154	)	N	O
155	or	N	O
156	to	N	O
157	receive	N	O
158	tamoxifen	N	O
159	alone	N	O
160	(	N	O
161	20	N	O
162	mg/day	N	O
163	,	N	O
164	orally	N	O
165	for	N	O
166	60	N	O
167	months	N	O
168	)	N	O
169	.	N	O

170	We	N	O
171	enrolled	N	O
172	1669	N	O
173	eligible	N	O
174	patients	N	O
175	,	N	O
176	382	N	O
177	(	N	O
178	23	N	O
179	%	N	O
180	)	N	O
181	with	N	O
182	ER-negative	N	O
183	tumors	N	O
184	,	N	O
185	1217	N	O
186	(	N	O
187	73	N	O
188	%	N	O
189	)	N	O
190	with	N	O
191	ER-positive	N	O
192	tumors	N	O
193	,	N	O
194	and	N	O
195	70	N	O
196	(	N	O
197	4	N	O
198	%	N	O
199	)	N	O
200	with	N	O
201	unknown	N	O
202	ER	N	O
203	status	N	O
204	.	N	O

205	The	N	O
206	median	N	O
207	follow-up	N	O
208	was	N	O
209	71	N	O
210	months	N	O
211	.	N	O

212	All	N	O
213	statistical	N	O
214	tests	N	O
215	were	N	O
216	two-sided	N	O
217	.	N	O

218	The	N	I-Premise
219	added	N	I-Premise
220	benefit	N	I-Premise
221	of	N	I-Premise
222	CMF	N	I-Premise
223	followed	N	I-Premise
224	by	N	I-Premise
225	tamoxifen	N	I-Premise
226	over	N	I-Premise
227	tamoxifen	N	I-Premise
228	alone	N	I-Premise
229	was	N	I-Premise
230	statistically	N	I-Premise
231	significantly	N	I-Premise
232	dependent	N	I-Premise
233	on	N	I-Premise
234	ER	N	I-Premise
235	status	N	I-Premise
236	(	N	I-Premise
237	tests	N	I-Premise
238	for	N	I-Premise
239	interaction	N	I-Premise
240	:	N	I-Premise
241	P	N	I-Premise
242	=.01	N	I-Premise
243	for	N	I-Premise
244	disease-free	N	I-Premise
245	survival	N	I-Premise
246	[	N	I-Premise
247	DFS	N	I-Premise
248	]	N	I-Premise
249	and	N	I-Premise
250	P	N	I-Premise
251	=.07	N	I-Premise
252	for	N	I-Premise
253	overall	N	I-Premise
254	survival	N	I-Premise
255	[	N	I-Premise
256	OS	N	I-Premise
257	]	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	For	N	I-Premise
261	patients	N	I-Premise
262	with	N	I-Premise
263	ER-negative	N	I-Premise
264	tumors	N	I-Premise
265	,	N	I-Premise
266	the	N	I-Premise
267	addition	N	I-Premise
268	of	N	I-Premise
269	CMF	N	I-Premise
270	statistically	N	I-Premise
271	significantly	N	I-Premise
272	improved	N	I-Premise
273	DFS	N	I-Premise
274	(	N	I-Premise
275	5-year	N	I-Premise
276	DFS	N	I-Premise
277	=	N	I-Premise
278	84	N	I-Premise
279	%	N	I-Premise
280	for	N	I-Premise
281	CMF	N	I-Premise
282	--	N	I-Premise
283	>	N	I-Premise
284	tamoxifen	N	I-Premise
285	versus	N	I-Premise
286	69	N	I-Premise
287	%	N	I-Premise
288	for	N	I-Premise
289	tamoxifen	N	I-Premise
290	alone	N	I-Premise
291	;	N	I-Premise
292	difference	N	I-Premise
293	=	N	I-Premise
294	15	N	I-Premise
295	%	N	I-Premise
296	;	N	I-Premise
297	95	N	I-Premise
298	%	N	I-Premise
299	confidence	N	I-Premise
300	interval	N	I-Premise
301	[	N	I-Premise
302	CI	N	I-Premise
303	]	N	I-Premise
304	=	N	I-Premise
305	6	N	I-Premise
306	%	N	I-Premise
307	to	N	I-Premise
308	24	N	I-Premise
309	%	N	I-Premise
310	;	N	I-Premise
311	risk	N	I-Premise
312	ratio	N	I-Premise
313	[	N	I-Premise
314	RR	N	I-Premise
315	]	N	I-Premise
316	=	N	I-Premise
317	0.52	N	I-Premise
318	;	N	I-Premise
319	95	N	I-Premise
320	%	N	I-Premise
321	CI	N	I-Premise
322	=	N	I-Premise
323	0.34	N	I-Premise
324	to	N	I-Premise
325	0.79	N	I-Premise
326	;	N	I-Premise
327	P	N	I-Premise
328	=.003	N	I-Premise
329	)	N	I-Premise
330	and	N	I-Premise
331	OS	N	I-Premise
332	(	N	I-Premise
333	5-year	N	I-Premise
334	OS	N	I-Premise
335	=	N	I-Premise
336	89	N	I-Premise
337	%	N	I-Premise
338	for	N	I-Premise
339	CMF	N	I-Premise
340	--	N	I-Premise
341	>	N	I-Premise
342	tamoxifen	N	I-Premise
343	versus	N	I-Premise
344	81	N	I-Premise
345	%	N	I-Premise
346	for	N	I-Premise
347	tamoxifen	N	I-Premise
348	alone	N	I-Premise
349	;	N	I-Premise
350	difference	N	I-Premise
351	=	N	I-Premise
352	8	N	I-Premise
353	%	N	I-Premise
354	;	N	I-Premise
355	95	N	I-Premise
356	%	N	I-Premise
357	CI	N	I-Premise
358	=	N	I-Premise
359	0	N	I-Premise
360	%	N	I-Premise
361	to	N	I-Premise
362	16	N	I-Premise
363	%	N	I-Premise
364	;	N	I-Premise
365	RR	N	I-Premise
366	=	N	I-Premise
367	0.51	N	I-Premise
368	;	N	I-Premise
369	95	N	I-Premise
370	%	N	I-Premise
371	CI	N	I-Premise
372	=	N	I-Premise
373	0.30	N	I-Premise
374	to	N	I-Premise
375	0.87	N	I-Premise
376	;	N	I-Premise
377	P	N	I-Premise
378	=.01	N	I-Premise
379	)	N	I-Premise
380	.	N	I-Premise

381	By	N	I-Premise
382	contrast	N	I-Premise
383	,	N	I-Premise
384	for	N	I-Premise
385	patients	N	I-Premise
386	with	N	I-Premise
387	ER-positive	N	I-Premise
388	tumors	N	I-Premise
389	,	N	I-Premise
390	addition	N	I-Premise
391	of	N	I-Premise
392	CMF	N	I-Premise
393	provided	N	I-Premise
394	no	N	I-Premise
395	benefit	N	I-Premise
396	in	N	I-Premise
397	terms	N	I-Premise
398	of	N	I-Premise
399	DFS	N	I-Premise
400	(	N	I-Premise
401	5-year	N	I-Premise
402	DFS	N	I-Premise
403	=	N	I-Premise
404	84	N	I-Premise
405	%	N	I-Premise
406	for	N	I-Premise
407	CMF	N	I-Premise
408	--	N	I-Premise
409	>	N	I-Premise
410	tamoxifen	N	I-Premise
411	versus	N	I-Premise
412	85	N	I-Premise
413	%	N	I-Premise
414	for	N	I-Premise
415	tamoxifen	N	I-Premise
416	alone	N	I-Premise
417	;	N	I-Premise
418	difference	N	I-Premise
419	=	N	I-Premise
420	-1	N	I-Premise
421	;	N	I-Premise
422	95	N	I-Premise
423	%	N	I-Premise
424	CI	N	I-Premise
425	=	N	I-Premise
426	-6	N	I-Premise
427	%	N	I-Premise
428	to	N	I-Premise
429	4	N	I-Premise
430	%	N	I-Premise
431	;	N	I-Premise
432	RR	N	I-Premise
433	=	N	I-Premise
434	0.99	N	I-Premise
435	;	N	I-Premise
436	95	N	I-Premise
437	%	N	I-Premise
438	CI	N	I-Premise
439	=	N	I-Premise
440	0.75	N	I-Premise
441	to	N	I-Premise
442	1.30	N	I-Premise
443	;	N	I-Premise
444	P	N	I-Premise
445	=.92	N	I-Premise
446	)	N	I-Premise
447	or	N	I-Premise
448	OS	N	I-Premise
449	(	N	I-Premise
450	5-year	N	I-Premise
451	OS	N	I-Premise
452	=	N	I-Premise
453	95	N	I-Premise
454	%	N	I-Premise
455	for	N	I-Premise
456	CMF	N	I-Premise
457	--	N	I-Premise
458	>	N	I-Premise
459	tamoxifen	N	I-Premise
460	versus	N	I-Premise
461	93	N	I-Premise
462	%	N	I-Premise
463	for	N	I-Premise
464	tamoxifen	N	I-Premise
465	alone	N	I-Premise
466	;	N	I-Premise
467	difference	N	I-Premise
468	=	N	I-Premise
469	2	N	I-Premise
470	%	N	I-Premise
471	;	N	I-Premise
472	95	N	I-Premise
473	%	N	I-Premise
474	CI	N	I-Premise
475	=	N	I-Premise
476	-1	N	I-Premise
477	%	N	I-Premise
478	to	N	I-Premise
479	5	N	I-Premise
480	%	N	I-Premise
481	;	N	I-Premise
482	RR	N	I-Premise
483	=	N	I-Premise
484	0.95	N	I-Premise
485	;	N	I-Premise
486	95	N	I-Premise
487	%	N	I-Premise
488	CI	N	I-Premise
489	=	N	I-Premise
490	0.64	N	I-Premise
491	to	N	I-Premise
492	1.40	N	I-Premise
493	;	N	I-Premise
494	P	N	I-Premise
495	=.80	N	I-Premise
496	)	N	I-Premise
497	.	N	I-Premise

498	Postmenopausal	N	I-Claim
499	patients	N	I-Claim
500	with	N	I-Claim
501	lymph	N	I-Claim
502	node-negative	N	I-Claim
503	breast	N	I-Claim
504	cancer	N	I-Claim
505	benefited	N	I-Claim
506	substantially	N	I-Claim
507	from	N	I-Claim
508	adjuvant	N	I-Claim
509	chemotherapy	N	I-Claim
510	if	N	I-Claim
511	their	N	I-Claim
512	cancer	N	I-Claim
513	was	N	I-Claim
514	ER-negative	N	I-Claim
515	(	N	I-Claim
516	i.e.	N	I-Claim
517	,	N	I-Claim
518	endocrine-nonresponsive	N	I-Claim
519	)	N	I-Claim
520	.	N	I-Claim

521	In	N	I-Claim
522	contrast	N	I-Claim
523	,	N	I-Claim
524	if	N	I-Claim
525	their	N	I-Claim
526	cancer	N	I-Claim
527	was	N	I-Claim
528	ER-positive	N	I-Claim
529	(	N	I-Claim
530	i.e.	N	I-Claim
531	,	N	I-Claim
532	endocrine-responsive	N	I-Claim
533	)	N	I-Claim
534	,	N	I-Claim
535	they	N	I-Claim
536	obtained	N	I-Claim
537	no	N	I-Claim
538	benefit	N	I-Claim
539	from	N	I-Claim
540	the	N	I-Claim
541	combination	N	I-Claim
542	treatment	N	I-Claim
543	compared	N	I-Claim
544	with	N	I-Claim
545	tamoxifen	N	I-Claim
546	alone	N	I-Claim
547	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	a	N	O
7	novel	N	O
8	coloplasty	N	O
9	colonic	N	O
10	pouch	N	O
11	design	N	O
12	in	N	O
13	optimizing	N	O
14	bowel	N	O
15	function	N	O
16	after	N	O
17	ultralow	N	O
18	anterior	N	O
19	resection	N	O
20	.	N	O

21	A	N	I-Claim
22	colonic	N	I-Claim
23	J-pouch	N	I-Claim
24	may	N	I-Claim
25	reduce	N	I-Claim
26	excessive	N	I-Claim
27	stool	N	I-Claim
28	frequency	N	I-Claim
29	and	N	I-Claim
30	incontinence	N	I-Claim
31	after	N	I-Claim
32	anterior	N	I-Claim
33	resection	N	I-Claim
34	,	N	I-Claim
35	but	N	I-Claim
36	at	N	I-Claim
37	the	N	I-Claim
38	risk	N	I-Claim
39	of	N	I-Claim
40	evacuation	N	I-Claim
41	problems	N	I-Claim
42	.	N	I-Claim

43	Experimental	N	I-Claim
44	surgery	N	I-Claim
45	on	N	I-Claim
46	pigs	N	I-Claim
47	has	N	I-Claim
48	suggested	N	I-Claim
49	that	N	I-Claim
50	a	N	I-Claim
51	coloplasty	N	I-Claim
52	pouch	N	I-Claim
53	(	N	I-Claim
54	CP	N	I-Claim
55	)	N	I-Claim
56	may	N	I-Claim
57	be	N	I-Claim
58	a	N	I-Claim
59	useful	N	I-Claim
60	alternative	N	I-Claim
61	.	N	O

62	Although	N	O
63	CP	N	O
64	has	N	O
65	recently	N	O
66	been	N	O
67	shown	N	O
68	to	N	O
69	be	N	O
70	feasible	N	O
71	in	N	O
72	patients	N	O
73	,	N	O
74	there	N	O
75	is	N	O
76	no	N	O
77	randomized	N	O
78	controlled	N	O
79	trial	N	O
80	comparing	N	O
81	bowel	N	O
82	function	N	O
83	with	N	O
84	the	N	O
85	J-pouch	N	O
86	.	N	O

87	After	N	O
88	anterior	N	O
89	resection	N	O
90	for	N	O
91	cancer	N	O
92	,	N	O
93	patients	N	O
94	were	N	O
95	allocated	N	O
96	to	N	O
97	either	N	O
98	J-pouch	N	O
99	or	N	O
100	CP-anal	N	O
101	anastomoses	N	O
102	.	N	O

103	Continence	N	O
104	scoring	N	O
105	,	N	O
106	anorectal	N	O
107	manometry	N	O
108	,	N	O
109	and	N	O
110	endoanal	N	O
111	ultrasound	N	O
112	assessments	N	O
113	were	N	O
114	made	N	O
115	before	N	O
116	surgery	N	O
117	.	N	O

118	All	N	O
119	complications	N	O
120	were	N	O
121	recorded	N	O
122	,	N	O
123	and	N	O
124	these	N	O
125	preoperative	N	O
126	assessments	N	O
127	were	N	O
128	repeated	N	O
129	at	N	O
130	4	N	O
131	months	N	O
132	.	N	O

133	The	N	O
134	assessments	N	O
135	were	N	O
136	repeated	N	O
137	again	N	O
138	at	N	O
139	1	N	O
140	year	N	O
141	,	N	O
142	and	N	O
143	a	N	O
144	quality	N	O
145	of	N	O
146	life	N	O
147	questionnaire	N	O
148	was	N	O
149	added	N	O
150	.	N	O

151	Eighty-eight	N	O
152	patients	N	O
153	were	N	O
154	recruited	N	O
155	from	N	O
156	October	N	O
157	1998	N	O
158	to	N	O
159	April	N	O
160	2000	N	O
161	.	N	O

162	Both	N	O
163	groups	N	O
164	were	N	O
165	well	N	O
166	matched	N	O
167	for	N	O
168	age	N	O
169	,	N	O
170	gender	N	O
171	,	N	O
172	staging	N	O
173	,	N	O
174	adjuvant	N	O
175	therapy	N	O
176	,	N	O
177	and	N	O
178	mean	N	O
179	follow-up	N	O
180	.	N	O

181	There	N	O
182	were	N	O
183	no	N	O
184	differences	N	O
185	in	N	O
186	the	N	O
187	intraoperative	N	O
188	time	N	O
189	and	N	O
190	hospital	N	O
191	stay	N	O
192	.	N	O

193	CP	N	I-Premise
194	resulted	N	I-Premise
195	in	N	I-Premise
196	more	N	I-Premise
197	anastomotic	N	I-Premise
198	leaks	N	I-Premise
199	.	N	I-Premise

200	At	N	I-Premise
201	4	N	I-Premise
202	months	N	I-Premise
203	,	N	I-Premise
204	J-pouch	N	I-Premise
205	patients	N	I-Premise
206	had	N	I-Premise
207	10.3	N	I-Premise
208	%	N	I-Premise
209	less	N	I-Premise
210	stool	N	I-Premise
211	fragmentation	N	I-Premise
212	but	N	I-Premise
213	poorer	N	I-Premise
214	stool	N	I-Premise
215	deferment	N	I-Premise
216	and	N	I-Premise
217	more	N	I-Premise
218	nocturnal	N	I-Premise
219	leakage	N	I-Premise
220	.	N	I-Premise

221	However	N	O
222	,	N	O
223	there	N	I-Premise
224	were	N	I-Premise
225	no	N	I-Premise
226	differences	N	I-Premise
227	in	N	I-Premise
228	the	N	I-Premise
229	bowel	N	I-Premise
230	function	N	I-Premise
231	,	N	I-Premise
232	continence	N	I-Premise
233	score	N	I-Premise
234	,	N	I-Premise
235	and	N	I-Premise
236	quality	N	I-Premise
237	of	N	I-Premise
238	life	N	I-Premise
239	at	N	I-Premise
240	1	N	I-Premise
241	year	N	I-Premise
242	.	N	I-Premise

243	There	N	I-Premise
244	were	N	I-Premise
245	no	N	I-Premise
246	differences	N	I-Premise
247	in	N	I-Premise
248	the	N	I-Premise
249	anorectal	N	I-Premise
250	manometry	N	I-Premise
251	and	N	I-Premise
252	endoanal	N	I-Premise
253	ultrasound	N	I-Premise
254	findings	N	I-Premise
255	.	N	I-Premise

256	Coloplasty	N	I-Claim
257	pouches	N	I-Claim
258	resulted	N	I-Claim
259	in	N	I-Claim
260	more	N	I-Claim
261	anastomotic	N	I-Claim
262	leaks	N	I-Claim
263	and	N	I-Claim
264	minimal	N	I-Claim
265	differences	N	I-Claim
266	in	N	I-Claim
267	bowel	N	I-Claim
268	function	N	I-Claim
269	.	N	I-Claim

270	At	N	O
271	present	N	O
272	,	N	O
273	the	N	I-Claim
274	J-pouch	N	I-Claim
275	remains	N	I-Claim
276	the	N	I-Claim
277	benchmark	N	I-Claim
278	for	N	I-Claim
279	routine	N	I-Claim
280	clinical	N	I-Claim
281	practice	N	I-Claim
282	,	N	I-Claim
283	and	N	O
284	due	N	I-Claim
285	care	N	I-Claim
286	(	N	I-Claim
287	including	N	I-Claim
288	defunctioning	N	I-Claim
289	stoma	N	I-Claim
290	)	N	I-Claim
291	should	N	I-Claim
292	be	N	I-Claim
293	exercised	N	I-Claim
294	in	N	I-Claim
295	situations	N	I-Claim
296	requiring	N	I-Claim
297	CP	N	I-Claim
298	.	N	I-Claim

1	Chemotherapy	N	I-Claim
2	is	N	I-Claim
3	moderately	N	I-Claim
4	efficient	N	I-Claim
5	as	N	I-Claim
6	a	N	I-Claim
7	treatment	N	I-Claim
8	for	N	I-Claim
9	pancreatic	N	I-Claim
10	adenocarcinoma	N	I-Claim
11	,	N	I-Claim
12	but	N	I-Claim
13	patient	N	I-Claim
14	survival	N	I-Claim
15	and	N	I-Claim
16	quality	N	I-Claim
17	of	N	I-Claim
18	life	N	I-Claim
19	has	N	I-Claim
20	improved	N	I-Claim
21	with	N	I-Claim
22	this	N	I-Claim
23	modality	N	I-Claim
24	in	N	I-Claim
25	some	N	I-Claim
26	trials	N	I-Claim
27	.	N	I-Claim

28	In	N	O
29	a	N	O
30	previous	N	O
31	phase	N	O
32	II	N	O
33	trial	N	O
34	,	N	O
35	5-fluorouracil	N	O
36	(	N	O
37	5-FU	N	O
38	)	N	O
39	plus	N	O
40	cisplatin	N	O
41	(	N	O
42	FUP	N	O
43	)	N	O
44	yielded	N	O
45	a	N	O
46	26.5	N	O
47	%	N	O
48	response	N	O
49	rate	N	O
50	and	N	O
51	a	N	O
52	29	N	O
53	%	N	O
54	survival	N	O
55	rate	N	O
56	at	N	O
57	1	N	O
58	year	N	O
59	.	N	O

60	The	N	O
61	present	N	O
62	study	N	O
63	aimed	N	O
64	to	N	O
65	compare	N	O
66	FUP	N	O
67	with	N	O
68	5-FU	N	O
69	alone	N	O
70	,	N	O
71	which	N	O
72	was	N	O
73	the	N	O
74	control	N	O
75	arm	N	O
76	in	N	O
77	former	N	O
78	Mayo	N	O
79	Clinic	N	O
80	trials	N	O
81	.	N	O

82	Patients	N	O
83	with	N	O
84	untreated	N	O
85	cytologically	N	O
86	or	N	O
87	histologically	N	O
88	proven	N	O
89	metastatic	N	O
90	or	N	O
91	locally	N	O
92	advanced	N	O
93	adenocarcinoma	N	O
94	of	N	O
95	the	N	O
96	pancreas	N	O
97	were	N	O
98	deemed	N	O
99	measurable	N	O
100	or	N	O
101	evaluable	N	O
102	.	N	O

103	Chemotherapy	N	O
104	regimens	N	O
105	consisted	N	O
106	of	N	O
107	a	N	O
108	control	N	O
109	FU	N	O
110	arm	N	O
111	(	N	O
112	5-FU	N	O
113	500	N	O
114	mg/m	N	O
115	(	N	O
116	2	N	O
117	)	N	O
118	/day	N	O
119	for	N	O
120	5	N	O
121	days	N	O
122	)	N	O
123	and	N	O
124	the	N	O
125	investigational	N	O
126	FUP	N	O
127	arm	N	O
128	(	N	O
129	continuous	N	O
130	5-FU	N	O
131	1000	N	O
132	mg/m	N	O
133	(	N	O
134	2	N	O
135	)	N	O
136	/day	N	O
137	for	N	O
138	5	N	O
139	days	N	O
140	plus	N	O
141	cisplatin	N	O
142	100	N	O
143	mg/m	N	O
144	(	N	O
145	2	N	O
146	)	N	O
147	on	N	O
148	day	N	O
149	1	N	O
150	or	N	O
151	day	N	O
152	2	N	O
153	)	N	O
154	.	N	O

155	In	N	O
156	both	N	O
157	arms	N	O
158	,	N	O
159	chemotherapy	N	O
160	was	N	O
161	repeated	N	O
162	at	N	O
163	day	N	O
164	29	N	O
165	.	N	O

166	Two-hundred	N	O
167	and	N	O
168	seven	N	O
169	patients	N	O
170	from	N	O
171	18	N	O
172	centres	N	O
173	were	N	O
174	randomised	N	O
175	:	N	O
176	103	N	O
177	in	N	O
178	the	N	O
179	FU	N	O
180	arm	N	O
181	and	N	O
182	104	N	O
183	in	N	O
184	FUP	N	O
185	arm	N	O
186	.	N	O

187	Treatment	N	O
188	arms	N	O
189	were	N	O
190	balanced	N	O
191	with	N	O
192	respect	N	O
193	to	N	O
194	performance	N	O
195	status	N	O
196	grade	N	O
197	0-1	N	O
198	(	N	O
199	83	N	O
200	%	N	O
201	versus	N	O
202	86	N	O
203	%	N	O
204	,	N	O
205	respectively	N	O
206	)	N	O
207	and	N	O
208	the	N	O
209	presence	N	O
210	of	N	O
211	metastases	N	O
212	(	N	O
213	92	N	O
214	%	N	O
215	versus	N	O
216	89	N	O
217	%	N	O
218	,	N	O
219	respectively	N	O
220	)	N	O
221	.	N	O

222	The	N	O
223	median	N	O
224	number	N	O
225	of	N	O
226	cycles	N	O
227	administered	N	O
228	was	N	O
229	two	N	O
230	in	N	O
231	both	N	O
232	arms	N	O
233	(	N	O
234	range	N	O
235	0-14	N	O
236	)	N	O
237	.	N	O

238	Five	N	O
239	patients	N	O
240	did	N	O
241	not	N	O
242	receive	N	O
243	any	N	O
244	chemotherapy	N	O
245	and	N	O
246	45	N	O
247	received	N	O
248	only	N	O
249	one	N	O
250	cycle	N	O
251	.	N	O

252	Toxicity	N	I-Premise
253	(	N	I-Premise
254	WHO	N	I-Premise
255	grade	N	I-Premise
256	3-4	N	I-Premise
257	)	N	I-Premise
258	was	N	I-Premise
259	lower	N	I-Premise
260	with	N	I-Premise
261	FU	N	I-Premise
262	than	N	I-Premise
263	with	N	I-Premise
264	FUP	N	I-Premise
265	(	N	I-Premise
266	20	N	I-Premise
267	%	N	I-Premise
268	versus	N	I-Premise
269	48	N	I-Premise
270	%	N	I-Premise
271	,	N	I-Premise
272	P	N	I-Premise
273	<	N	I-Premise
274	0.001	N	I-Premise
275	)	N	I-Premise
276	,	N	I-Premise
277	as	N	I-Premise
278	was	N	I-Premise
279	neutropenia	N	I-Premise
280	(	N	I-Premise
281	6	N	I-Premise
282	%	N	I-Premise
283	versus	N	I-Premise
284	23	N	I-Premise
285	%	N	I-Premise
286	)	N	I-Premise
287	,	N	I-Premise
288	vomiting	N	I-Premise
289	(	N	I-Premise
290	4	N	I-Premise
291	%	N	I-Premise
292	versus	N	I-Premise
293	17	N	I-Premise
294	%	N	I-Premise
295	)	N	I-Premise
296	and	N	I-Premise
297	toxicity-related	N	I-Premise
298	deaths	N	I-Premise
299	(	N	I-Premise
300	one	N	I-Premise
301	versus	N	I-Premise
302	four	N	I-Premise
303	early	N	I-Premise
304	in	N	I-Premise
305	the	N	I-Premise
306	trial	N	I-Premise
307	)	N	I-Premise
308	.	N	I-Premise

309	The	N	I-Premise
310	response	N	I-Premise
311	rate	N	I-Premise
312	was	N	I-Premise
313	low	N	I-Premise
314	in	N	I-Premise
315	both	N	I-Premise
316	arms	N	I-Premise
317	,	N	I-Premise
318	but	N	I-Premise
319	superior	N	I-Premise
320	in	N	I-Premise
321	the	N	I-Premise
322	FUP	N	I-Premise
323	arm	N	I-Premise
324	:	N	I-Premise
325	12	N	I-Premise
326	%	N	I-Premise
327	versus	N	I-Premise
328	0	N	I-Premise
329	%	N	I-Premise
330	(	N	I-Premise
331	intention-to-treat	N	I-Premise
332	analysis	N	I-Premise
333	,	N	I-Premise
334	P	N	I-Premise
335	<	N	I-Premise
336	0.01	N	I-Premise
337	)	N	I-Premise
338	.	N	I-Premise

339	The	N	I-Premise
340	survival	N	I-Premise
341	rates	N	I-Premise
342	at	N	I-Premise
343	6	N	I-Premise
344	months	N	I-Premise
345	were	N	I-Premise
346	28	N	I-Premise
347	%	N	I-Premise
348	and	N	I-Premise
349	38	N	I-Premise
350	%	N	I-Premise
351	for	N	I-Premise
352	the	N	I-Premise
353	FU	N	I-Premise
354	and	N	I-Premise
355	FUP	N	I-Premise
356	arms	N	I-Premise
357	,	N	I-Premise
358	respectively	N	I-Premise
359	,	N	I-Premise
360	and	N	I-Premise
361	1-year	N	I-Premise
362	survival	N	I-Premise
363	rates	N	I-Premise
364	were	N	I-Premise
365	9	N	I-Premise
366	%	N	I-Premise
367	and	N	I-Premise
368	17	N	I-Premise
369	%	N	I-Premise
370	(	N	I-Premise
371	log-rank	N	I-Premise
372	test	N	I-Premise
373	,	N	I-Premise
374	P	N	I-Premise
375	=	N	I-Premise
376	0.10	N	I-Premise
377	)	N	I-Premise
378	.	N	I-Premise

379	One-year	N	I-Premise
380	progression-free	N	I-Premise
381	survival	N	I-Premise
382	was	N	I-Premise
383	0	N	I-Premise
384	%	N	I-Premise
385	with	N	I-Premise
386	FU	N	I-Premise
387	versus	N	I-Premise
388	10	N	I-Premise
389	%	N	I-Premise
390	with	N	I-Premise
391	FUP	N	I-Premise
392	(	N	I-Premise
393	log-rank	N	I-Premise
394	test	N	I-Premise
395	,	N	I-Premise
396	P	N	I-Premise
397	=	N	I-Premise
398	0.0001	N	I-Premise
399	)	N	I-Premise
400	.	N	I-Premise

401	In	N	I-Claim
402	advanced	N	I-Claim
403	pancreatic	N	I-Claim
404	carcinomas	N	I-Claim
405	with	N	I-Claim
406	a	N	I-Claim
407	poor	N	I-Claim
408	prognosis	N	I-Claim
409	,	N	I-Claim
410	FUP	N	I-Claim
411	was	N	I-Claim
412	superior	N	I-Claim
413	to	N	I-Claim
414	FU	N	I-Claim
415	in	N	I-Claim
416	terms	N	I-Claim
417	of	N	I-Claim
418	response	N	I-Claim
419	and	N	I-Claim
420	progression-free	N	I-Claim
421	survival	N	I-Claim
422	,	N	I-Claim
423	but	N	I-Claim
424	not	N	I-Claim
425	in	N	I-Claim
426	terms	N	I-Claim
427	of	N	I-Claim
428	overall	N	I-Claim
429	survival	N	I-Claim
430	.	N	I-Claim

431	The	N	O
432	low	N	O
433	response	N	O
434	rate	N	O
435	is	N	O
436	partly	N	O
437	related	N	O
438	to	N	O
439	the	N	O
440	number	N	O
441	of	N	O
442	patients	N	O
443	who	N	O
444	received	N	O
445	only	N	O
446	one	N	O
447	cycle	N	O
448	of	N	O
449	chemotherapy	N	O
450	.	N	O

451	A	N	I-Claim
452	more	N	I-Claim
453	effective	N	I-Claim
454	,	N	I-Claim
455	better	N	I-Claim
456	tolerated	N	I-Claim
457	version	N	I-Claim
458	of	N	I-Claim
459	this	N	I-Claim
460	FUP	N	I-Claim
461	combination	N	I-Claim
462	is	N	I-Claim
463	needed	N	I-Claim
464	.	N	I-Claim

1	Amitriptyline	N	I-Claim
2	is	N	I-Claim
3	the	N	I-Claim
4	most	N	I-Claim
5	common	N	I-Claim
6	analgesic	N	I-Claim
7	adjuvant	N	I-Claim
8	used	N	I-Claim
9	in	N	I-Claim
10	cancer	N	I-Claim
11	patients	N	I-Claim
12	with	N	I-Claim
13	neuropathic	N	I-Claim
14	pain	N	I-Claim
15	,	N	I-Claim
16	even	N	O
17	though	N	O
18	no	N	I-Claim
19	specific	N	I-Claim
20	studies	N	I-Claim
21	have	N	I-Claim
22	demonstrated	N	I-Claim
23	a	N	I-Claim
24	benefit	N	I-Claim
25	.	N	I-Claim

26	A	N	O
27	randomized	N	O
28	placebo-controlled	N	O
29	,	N	O
30	double-blind	N	O
31	crossover	N	O
32	study	N	O
33	was	N	O
34	designed	N	O
35	to	N	O
36	evidence	N	O
37	the	N	O
38	effects	N	O
39	of	N	O
40	amitriptyline	N	O
41	in	N	O
42	patients	N	O
43	with	N	O
44	neuropathic	N	O
45	cancer	N	O
46	pain	N	O
47	.	N	O

48	Sixteen	N	O
49	advanced	N	O
50	cancer	N	O
51	patients	N	O
52	with	N	O
53	neuropathic	N	O
54	pain	N	O
55	on	N	O
56	systemic	N	O
57	morphine	N	O
58	therapy	N	O
59	,	N	O
60	no	N	O
61	longer	N	O
62	receiving	N	O
63	oncologic	N	O
64	treatment	N	O
65	,	N	O
66	presenting	N	O
67	moderate	N	O
68	pain	N	O
69	(	N	O
70	about	N	O
71	4	N	O
72	or	N	O
73	more	N	O
74	,	N	O
75	but	N	O
76	less	N	O
77	than	N	O
78	7	N	O
79	,	N	O
80	on	N	O
81	a	N	O
82	numerical	N	O
83	scale	N	O
84	of	N	O
85	0-10	N	O
86	)	N	O
87	in	N	O
88	the	N	O
89	last	N	O
90	week	N	O
91	,	N	O
92	and	N	O
93	given	N	O
94	a	N	O
95	stable	N	O
96	morphine	N	O
97	dose	N	O
98	in	N	O
99	the	N	O
100	last	N	O
101	2	N	O
102	days	N	O
103	were	N	O
104	admitted	N	O
105	to	N	O
106	the	N	O
107	study	N	O
108	.	N	O

109	During	N	O
110	the	N	O
111	first	N	O
112	week	N	O
113	of	N	O
114	study	N	O
115	,	N	O
116	patients	N	O
117	were	N	O
118	administered	N	O
119	25	N	O
120	mg	N	O
121	of	N	O
122	amitriptyline	N	O
123	or	N	O
124	equivalent	N	O
125	drops	N	O
126	of	N	O
127	placebo	N	O
128	at	N	O
129	night	N	O
130	for	N	O
131	3	N	O
132	days	N	O
133	and	N	O
134	50	N	O
135	mg	N	O
136	for	N	O
137	the	N	O
138	following	N	O
139	4	N	O
140	days	N	O
141	.	N	O

142	Doses	N	O
143	for	N	O
144	patients	N	O
145	aged	N	O
146	more	N	O
147	than	N	O
148	65	N	O
149	years	N	O
150	were	N	O
151	15	N	O
152	mg	N	O
153	(	N	O
154	first	N	O
155	3	N	O
156	days	N	O
157	)	N	O
158	and	N	O
159	30	N	O
160	mg	N	O
161	(	N	O
162	3	N	O
163	days	N	O
164	after	N	O
165	)	N	O
166	.	N	O

167	After	N	O
168	a	N	O
169	week	N	O
170	,	N	O
171	a	N	O
172	crossover	N	O
173	took	N	O
174	place	N	O
175	for	N	O
176	the	N	O
177	second	N	O
178	week	N	O
179	,	N	O
180	with	N	O
181	the	N	O
182	other	N	O
183	treatment	N	O
184	at	N	O
185	an	N	O
186	inverse	N	O
187	sequence	N	O
188	.	N	O

189	Opioid	N	O
190	consumption	N	O
191	,	N	O
192	pain	N	O
193	intensity	N	O
194	,	N	O
195	symptoms	N	O
196	and	N	O
197	adverse	N	O
198	effects	N	O
199	,	N	O
200	mood	N	O
201	,	N	O
202	sleep	N	O
203	,	N	O
204	patient	N	O
205	's	N	O
206	preference	N	O
207	,	N	O
208	quality	N	O
209	of	N	O
210	life	N	O
211	before	N	O
212	starting	N	O
213	the	N	O
214	study	N	O
215	,	N	O
216	the	N	O
217	first	N	O
218	week	N	O
219	after	N	O
220	and	N	O
221	the	N	O
222	second	N	O
223	week	N	O
224	after	N	O
225	were	N	O
226	recorded	N	O
227	.	N	O

228	No	N	I-Premise
229	significant	N	I-Premise
230	benefits	N	I-Premise
231	in	N	I-Premise
232	analgesia	N	I-Premise
233	were	N	I-Premise
234	found	N	I-Premise
235	in	N	I-Premise
236	the	N	I-Premise
237	global	N	I-Premise
238	pain	N	I-Premise
239	intensity	N	I-Premise
240	of	N	I-Premise
241	the	N	I-Premise
242	previous	N	I-Premise
243	week	N	I-Premise
244	of	N	I-Premise
245	treatment	N	I-Premise
246	,	N	I-Premise
247	the	N	I-Premise
248	least	N	I-Premise
249	pain	N	I-Premise
250	intensity	N	I-Premise
251	or	N	I-Premise
252	the	N	I-Premise
253	pain	N	I-Premise
254	evaluated	N	I-Premise
255	just	N	I-Premise
256	after	N	I-Premise
257	a	N	I-Premise
258	week	N	I-Premise
259	of	N	I-Premise
260	treatment	N	I-Premise
261	,	N	I-Premise
262	at	N	I-Premise
263	the	N	I-Premise
264	moment	N	I-Premise
265	of	N	I-Premise
266	the	N	I-Premise
267	visit	N	I-Premise
268	,	N	I-Premise
269	when	N	I-Premise
270	amitriptyline	N	I-Premise
271	was	N	I-Premise
272	compared	N	I-Premise
273	with	N	I-Premise
274	placebo	N	I-Premise
275	.	N	I-Premise

276	A	N	I-Premise
277	significant	N	I-Premise
278	difference	N	I-Premise
279	was	N	I-Premise
280	evidenced	N	I-Premise
281	for	N	I-Premise
282	the	N	I-Premise
283	worst	N	I-Premise
284	pain	N	I-Premise
285	(	N	I-Premise
286	P	N	I-Premise
287	<	N	I-Premise
288	0.035	N	I-Premise
289	)	N	I-Premise
290	.	N	I-Premise

291	No	N	I-Premise
292	differences	N	I-Premise
293	in	N	I-Premise
294	opioid	N	I-Premise
295	doses	N	I-Premise
296	during	N	I-Premise
297	the	N	I-Premise
298	period	N	I-Premise
299	of	N	I-Premise
300	study	N	I-Premise
301	were	N	I-Premise
302	found	N	I-Premise
303	.	N	I-Premise

304	Drowsiness	N	I-Premise
305	,	N	I-Premise
306	confusion	N	I-Premise
307	and	N	I-Premise
308	dry	N	I-Premise
309	mouth	N	I-Premise
310	were	N	I-Premise
311	significantly	N	I-Premise
312	more	N	I-Premise
313	intense	N	I-Premise
314	with	N	I-Premise
315	amitriptyline	N	I-Premise
316	than	N	I-Premise
317	with	N	I-Premise
318	placebo	N	I-Premise
319	(	N	I-Premise
320	P	N	I-Premise
321	<	N	I-Premise
322	0.036	N	I-Premise
323	,	N	I-Premise
324	0.003	N	I-Premise
325	,	N	I-Premise
326	and	N	I-Premise
327	0.034	N	I-Premise
328	,	N	I-Premise
329	respectively	N	I-Premise
330	)	N	I-Premise
331	.	N	I-Premise

332	There	N	I-Premise
333	were	N	I-Premise
334	no	N	I-Premise
335	substantial	N	I-Premise
336	differences	N	I-Premise
337	between	N	I-Premise
338	the	N	I-Premise
339	two	N	I-Premise
340	treatments	N	I-Premise
341	in	N	I-Premise
342	Spitzer	N	I-Premise
343	's	N	I-Premise
344	quality	N	I-Premise
345	of	N	I-Premise
346	life	N	I-Premise
347	score	N	I-Premise
348	and	N	I-Premise
349	for	N	I-Premise
350	each	N	I-Premise
351	item	N	I-Premise
352	.	N	I-Premise

353	No	N	I-Premise
354	differences	N	I-Premise
355	in	N	I-Premise
356	patients	N	I-Premise
357	'	N	I-Premise
358	preference	N	I-Premise
359	for	N	I-Premise
360	the	N	I-Premise
361	two	N	I-Premise
362	treatment	N	I-Premise
363	periods	N	I-Premise
364	were	N	I-Premise
365	found	N	I-Premise
366	.	N	I-Premise

367	The	N	I-Claim
368	analgesic	N	I-Claim
369	effects	N	I-Claim
370	of	N	I-Claim
371	amitriptyline	N	I-Claim
372	were	N	I-Claim
373	slight	N	I-Claim
374	and	N	I-Claim
375	associated	N	I-Claim
376	with	N	I-Claim
377	adverse	N	I-Claim
378	effects	N	I-Claim
379	.	N	I-Claim

380	In	N	O
381	light	N	O
382	of	N	O
383	the	N	O
384	results	N	O
385	obtained	N	O
386	in	N	O
387	the	N	O
388	study	N	O
389	,	N	O
390	the	N	I-Claim
391	extensive	N	I-Claim
392	use	N	I-Claim
393	of	N	I-Claim
394	the	N	I-Claim
395	drug	N	I-Claim
396	for	N	I-Claim
397	cancer	N	I-Claim
398	pain	N	I-Claim
399	should	N	I-Claim
400	be	N	I-Claim
401	questioned	N	I-Claim
402	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	patients	N	O
5	with	N	O
6	locally	N	O
7	advanced	N	O
8	non-small	N	O
9	cell	N	O
10	lung	N	O
11	cancer	N	O
12	unsuitable	N	O
13	for	N	O
14	resection	N	O
15	or	N	O
16	radical	N	O
17	radiotherapy	N	O
18	,	N	O
19	and	N	O
20	with	N	O
21	minimal	N	O
22	thoracic	N	O
23	symptoms	N	O
24	,	N	O
25	should	N	O
26	be	N	O
27	given	N	O
28	palliative	N	O
29	thoracic	N	O
30	radiotherapy	N	O
31	immediately	N	O
32	or	N	O
33	as	N	O
34	needed	N	O
35	to	N	O
36	treat	N	O
37	symptoms	N	O
38	.	N	O

39	Multicentre	N	O
40	randomised	N	O
41	controlled	N	O
42	trial	N	O
43	.	N	O

44	23	N	O
45	centres	N	O
46	in	N	O
47	the	N	O
48	United	N	O
49	Kingdom	N	O
50	,	N	O
51	Ireland	N	O
52	,	N	O
53	and	N	O
54	South	N	O
55	Africa	N	O
56	.	N	O

57	230	N	O
58	patients	N	O
59	with	N	O
60	previously	N	O
61	untreated	N	O
62	,	N	O
63	non-small	N	O
64	cell	N	O
65	lung	N	O
66	cancer	N	O
67	that	N	O
68	is	N	O
69	locally	N	O
70	too	N	O
71	advanced	N	O
72	for	N	O
73	resection	N	O
74	or	N	O
75	radical	N	O
76	radiotherapy	N	O
77	with	N	O
78	curative	N	O
79	intent	N	O
80	,	N	O
81	with	N	O
82	minimal	N	O
83	thoracic	N	O
84	symptoms	N	O
85	,	N	O
86	and	N	O
87	with	N	O
88	no	N	O
89	indication	N	O
90	for	N	O
91	immediate	N	O
92	thoracic	N	O
93	radiotherapy	N	O
94	.	N	O

95	All	N	O
96	patients	N	O
97	were	N	O
98	given	N	O
99	supportive	N	O
100	treatment	N	O
101	and	N	O
102	were	N	O
103	randomised	N	O
104	to	N	O
105	receive	N	O
106	palliative	N	O
107	thoracic	N	O
108	radiotherapy	N	O
109	either	N	O
110	immediately	N	O
111	or	N	O
112	delayed	N	O
113	until	N	O
114	needed	N	O
115	to	N	O
116	treat	N	O
117	symptoms	N	O
118	.	N	O

119	The	N	O
120	recommended	N	O
121	regimens	N	O
122	were	N	O
123	17	N	O
124	Gy	N	O
125	in	N	O
126	two	N	O
127	fractions	N	O
128	one	N	O
129	week	N	O
130	apart	N	O
131	or	N	O
132	10	N	O
133	Gy	N	O
134	as	N	O
135	a	N	O
136	single	N	O
137	dose	N	O
138	.	N	O

139	Primary	N	O
140	--	N	O
141	patients	N	O
142	alive	N	O
143	and	N	O
144	without	N	O
145	moderate	N	O
146	or	N	O
147	severe	N	O
148	cough	N	O
149	,	N	O
150	chest	N	O
151	pain	N	O
152	,	N	O
153	haemoptysis	N	O
154	,	N	O
155	or	N	O
156	dyspnoea	N	O
157	six	N	O
158	months	N	O
159	from	N	O
160	randomisation	N	O
161	,	N	O
162	as	N	O
163	recorded	N	O
164	by	N	O
165	clinicians	N	O
166	.	N	O

167	Secondary	N	O
168	--	N	O
169	quality	N	O
170	of	N	O
171	life	N	O
172	,	N	O
173	adverse	N	O
174	events	N	O
175	,	N	O
176	survival	N	O
177	.	N	O

178	From	N	O
179	December	N	O
180	1992	N	O
181	to	N	O
182	May	N	O
183	1999	N	O
184	,	N	O
185	230	N	O
186	patients	N	O
187	were	N	O
188	randomised	N	O
189	.	N	O

190	104/115	N	O
191	of	N	O
192	the	N	O
193	patients	N	O
194	in	N	O
195	the	N	O
196	immediate	N	O
197	treatment	N	O
198	group	N	O
199	received	N	O
200	thoracic	N	O
201	radiotherapy	N	O
202	(	N	O
203	90	N	O
204	received	N	O
205	one	N	O
206	of	N	O
207	the	N	O
208	recommended	N	O
209	regimens	N	O
210	)	N	O
211	.	N	O

212	In	N	O
213	the	N	O
214	delayed	N	O
215	treatment	N	O
216	group	N	O
217	,	N	O
218	48/115	N	O
219	(	N	O
220	42	N	O
221	%	N	O
222	)	N	O
223	patients	N	O
224	received	N	O
225	thoracic	N	O
226	radiotherapy	N	O
227	(	N	O
228	29	N	O
229	received	N	O
230	one	N	O
231	of	N	O
232	the	N	O
233	recommended	N	O
234	regimens	N	O
235	)	N	O
236	;	N	O
237	64	N	O
238	(	N	O
239	56	N	O
240	%	N	O
241	)	N	O
242	died	N	O
243	without	N	O
244	receiving	N	O
245	thoracic	N	O
246	radiotherapy	N	O
247	;	N	O
248	the	N	O
249	remaining	N	O
250	three	N	O
251	(	N	O
252	3	N	O
253	%	N	O
254	)	N	O
255	were	N	O
256	alive	N	O
257	at	N	O
258	the	N	O
259	end	N	O
260	of	N	O
261	the	N	O
262	study	N	O
263	without	N	O
264	having	N	O
265	received	N	O
266	the	N	O
267	treatment	N	O
268	.	N	O

269	For	N	O
270	patients	N	O
271	who	N	O
272	received	N	O
273	thoracic	N	O
274	radiotherapy	N	O
275	,	N	O
276	the	N	O
277	median	N	O
278	time	N	O
279	to	N	O
280	start	N	O
281	was	N	O
282	15	N	O
283	days	N	O
284	in	N	O
285	the	N	O
286	immediate	N	O
287	treatment	N	O
288	group	N	O
289	and	N	O
290	125	N	O
291	days	N	O
292	in	N	O
293	the	N	O
294	delayed	N	O
295	treatment	N	O
296	group	N	O
297	.	N	O

298	The	N	I-Premise
299	primary	N	I-Premise
300	outcome	N	I-Premise
301	measure	N	I-Premise
302	was	N	I-Premise
303	achieved	N	I-Premise
304	in	N	I-Premise
305	28	N	I-Premise
306	%	N	I-Premise
307	of	N	I-Premise
308	the	N	I-Premise
309	immediate	N	I-Premise
310	treatment	N	I-Premise
311	group	N	I-Premise
312	and	N	I-Premise
313	26	N	I-Premise
314	%	N	I-Premise
315	of	N	I-Premise
316	patients	N	I-Premise
317	from	N	I-Premise
318	the	N	I-Premise
319	delayed	N	I-Premise
320	treatment	N	I-Premise
321	group	N	I-Premise
322	(	N	I-Premise
323	27/97	N	I-Premise
324	and	N	I-Premise
325	27/103	N	I-Premise
326	,	N	I-Premise
327	respectively	N	I-Premise
328	;	N	I-Premise
329	absolute	N	I-Premise
330	difference	N	I-Premise
331	1.6	N	I-Premise
332	%	N	I-Premise
333	,	N	I-Premise
334	95	N	I-Premise
335	%	N	I-Premise
336	confidence	N	I-Premise
337	interval	N	I-Premise
338	-10.7	N	I-Premise
339	%	N	I-Premise
340	to	N	I-Premise
341	13.9	N	I-Premise
342	%	N	I-Premise
343	)	N	I-Premise
344	.	N	I-Premise

345	No	N	I-Premise
346	evidence	N	I-Premise
347	of	N	I-Premise
348	a	N	I-Premise
349	difference	N	I-Premise
350	was	N	I-Premise
351	observed	N	I-Premise
352	between	N	I-Premise
353	the	N	I-Premise
354	two	N	I-Premise
355	treatment	N	I-Premise
356	groups	N	I-Premise
357	in	N	I-Premise
358	terms	N	I-Premise
359	of	N	I-Premise
360	activity	N	I-Premise
361	level	N	I-Premise
362	,	N	I-Premise
363	anxiety	N	I-Premise
364	,	N	I-Premise
365	depression	N	I-Premise
366	,	N	I-Premise
367	and	N	I-Premise
368	psychological	N	I-Premise
369	distress	N	I-Premise
370	,	N	I-Premise
371	as	N	I-Premise
372	recorded	N	I-Premise
373	by	N	I-Premise
374	the	N	I-Premise
375	patients	N	I-Premise
376	.	N	I-Premise

377	Adverse	N	I-Premise
378	events	N	I-Premise
379	were	N	I-Premise
380	more	N	I-Premise
381	common	N	I-Premise
382	in	N	I-Premise
383	the	N	I-Premise
384	immediate	N	I-Premise
385	treatment	N	I-Premise
386	group	N	I-Premise
387	.	N	I-Premise

388	Neither	N	I-Premise
389	group	N	I-Premise
390	had	N	I-Premise
391	a	N	I-Premise
392	survival	N	I-Premise
393	advantage	N	I-Premise
394	(	N	I-Premise
395	hazard	N	I-Premise
396	ratio	N	I-Premise
397	0.95	N	I-Premise
398	,	N	I-Premise
399	0.73	N	I-Premise
400	to	N	I-Premise
401	1.24	N	I-Premise
402	;	N	I-Premise
403	P=0.71	N	I-Premise
404	)	N	I-Premise
405	.	N	I-Premise

406	Median	N	I-Premise
407	survival	N	I-Premise
408	was	N	I-Premise
409	8.3	N	I-Premise
410	months	N	I-Premise
411	and	N	I-Premise
412	7.9	N	I-Premise
413	months	N	I-Premise
414	,	N	I-Premise
415	and	N	O
416	the	N	I-Premise
417	survival	N	I-Premise
418	rates	N	I-Premise
419	were	N	I-Premise
420	31	N	I-Premise
421	%	N	I-Premise
422	and	N	I-Premise
423	29	N	I-Premise
424	%	N	I-Premise
425	at	N	I-Premise
426	12	N	I-Premise
427	months	N	I-Premise
428	,	N	I-Premise
429	for	N	I-Premise
430	the	N	I-Premise
431	immediate	N	I-Premise
432	and	N	I-Premise
433	delayed	N	I-Premise
434	treatment	N	I-Premise
435	groups	N	I-Premise
436	,	N	I-Premise
437	respectively	N	I-Premise
438	.	N	I-Premise

439	In	N	I-Claim
440	minimally	N	I-Claim
441	symptomatic	N	I-Claim
442	patients	N	I-Claim
443	with	N	I-Claim
444	locally	N	I-Claim
445	advanced	N	I-Claim
446	non-small	N	I-Claim
447	cell	N	I-Claim
448	lung	N	I-Claim
449	cancer	N	I-Claim
450	,	N	I-Claim
451	no	N	I-Claim
452	persuasive	N	I-Claim
453	evidence	N	I-Claim
454	was	N	I-Claim
455	found	N	I-Claim
456	to	N	I-Claim
457	indicate	N	I-Claim
458	that	N	I-Claim
459	giving	N	I-Claim
460	immediate	N	I-Claim
461	palliative	N	I-Claim
462	thoracic	N	I-Claim
463	radiotherapy	N	I-Claim
464	improves	N	I-Claim
465	symptom	N	I-Claim
466	control	N	I-Claim
467	,	N	I-Claim
468	quality	N	I-Claim
469	of	N	I-Claim
470	life	N	I-Claim
471	,	N	I-Claim
472	or	N	I-Claim
473	survival	N	I-Claim
474	when	N	I-Claim
475	compared	N	I-Claim
476	with	N	I-Claim
477	delaying	N	I-Claim
478	until	N	I-Claim
479	symptoms	N	I-Claim
480	require	N	I-Claim
481	treatment	N	I-Claim
482	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	outcome	N	O
5	of	N	O
6	treatment	N	O
7	of	N	O
8	mediastinoscopy-verified	N	O
9	N2	N	O
10	non-small-cell	N	O
11	lung	N	O
12	cancer	N	O
13	treated	N	O
14	with	N	O
15	induction	N	O
16	chemotherapy	N	O
17	followed	N	O
18	by	N	O
19	either	N	O
20	surgery	N	O
21	or	N	O
22	radiotherapy	N	O
23	(	N	O
24	RT	N	O
25	)	N	O
26	,	N	O
27	with	N	O
28	both	N	O
29	options	N	O
30	followed	N	O
31	by	N	O
32	consolidation	N	O
33	chemotherapy	N	O
34	.	N	O

35	A	N	O
36	randomized	N	O
37	Phase	N	O
38	III	N	O
39	trial	N	O
40	for	N	O
41	Stage	N	O
42	IIIA	N	O
43	(	N	O
44	T1-T3N2M0	N	O
45	)	N	O
46	non-small	N	O
47	cell	N	O
48	lung	N	O
49	cancer	N	O
50	was	N	O
51	conducted	N	O
52	by	N	O
53	the	N	O
54	Radiation	N	O
55	Therapy	N	O
56	Oncology	N	O
57	Group	N	O
58	(	N	O
59	RTOG	N	O
60	)	N	O
61	and	N	O
62	Eastern	N	O
63	Cooperative	N	O
64	Oncology	N	O
65	Group	N	O
66	between	N	O
67	April	N	O
68	1990	N	O
69	and	N	O
70	April	N	O
71	1994	N	O
72	.	N	O

73	After	N	O
74	documentation	N	O
75	of	N	O
76	N2	N	O
77	disease	N	O
78	by	N	O
79	mediastinoscopy	N	O
80	or	N	O
81	anterior	N	O
82	mediastinotomy	N	O
83	,	N	O
84	patients	N	O
85	received	N	O
86	induction	N	O
87	chemotherapy	N	O
88	with	N	O
89	cisplatin	N	O
90	,	N	O
91	vinblastine	N	O
92	,	N	O
93	and	N	O
94	mitomycin-C.	N	O
95	Mitomycin-C	N	O
96	was	N	O
97	later	N	O
98	dropped	N	O
99	from	N	O
100	the	N	O
101	induction	N	O
102	regimen	N	O
103	.	N	O

104	Patients	N	O
105	were	N	O
106	then	N	O
107	randomized	N	O
108	to	N	O
109	surgery	N	O
110	or	N	O
111	RT	N	O
112	(	N	O
113	64	N	O
114	Gy	N	O
115	in	N	O
116	7	N	O
117	weeks	N	O
118	)	N	O
119	followed	N	O
120	by	N	O
121	cisplatin	N	O
122	and	N	O
123	vinblastine	N	O
124	.	N	O

125	RTOG	N	O
126	89-01	N	O
127	accrued	N	O
128	75	N	O
129	patients	N	O
130	,	N	O
131	of	N	O
132	whom	N	O
133	73	N	O
134	were	N	O
135	eligible	N	O
136	and	N	O
137	analyzable	N	O
138	.	N	O

139	Twelve	N	O
140	patients	N	O
141	received	N	O
142	induction	N	O
143	chemotherapy	N	O
144	but	N	O
145	were	N	O
146	not	N	O
147	randomized	N	O
148	to	N	O
149	RT	N	O
150	or	N	O
151	surgery	N	O
152	thereafter	N	O
153	.	N	O

154	Forty-five	N	O
155	patients	N	O
156	were	N	O
157	randomized	N	O
158	to	N	O
159	postinduction	N	O
160	RT	N	O
161	or	N	O
162	surgery	N	O
163	.	N	O

164	Of	N	O
165	the	N	O
166	analyzable	N	O
167	patients	N	O
168	,	N	O
169	90	N	O
170	%	N	O
171	had	N	O
172	a	N	O
173	Karnofsky	N	O
174	performance	N	O
175	score	N	O
176	of	N	O
177	90-100	N	O
178	,	N	O
179	18	N	O
180	%	N	O
181	had	N	O
182	weight	N	O
183	loss	N	O
184	>	N	O
185	5	N	O
186	%	N	O
187	,	N	O
188	37	N	O
189	%	N	O
190	had	N	O
191	squamous	N	O
192	cell	N	O
193	histologic	N	O
194	features	N	O
195	,	N	O
196	and	N	O
197	54	N	O
198	%	N	O
199	had	N	O
200	bulky	N	O
201	N2	N	O
202	disease	N	O
203	.	N	O

204	The	N	O
205	distribution	N	O
206	of	N	O
207	bulky	N	O
208	N2	N	O
209	disease	N	O
210	was	N	O
211	uniform	N	O
212	among	N	O
213	the	N	O
214	treatment	N	O
215	arms	N	O
216	.	N	O

217	The	N	I-Premise
218	incidence	N	I-Premise
219	of	N	I-Premise
220	Grade	N	I-Premise
221	4	N	I-Premise
222	toxicity	N	I-Premise
223	was	N	I-Premise
224	56	N	I-Premise
225	%	N	I-Premise
226	in	N	I-Premise
227	patients	N	I-Premise
228	receiving	N	I-Premise
229	mitomycin-C	N	I-Premise
230	and	N	I-Premise
231	29	N	I-Premise
232	%	N	I-Premise
233	in	N	I-Premise
234	those	N	I-Premise
235	who	N	I-Premise
236	did	N	I-Premise
237	not	N	I-Premise
238	.	N	I-Premise

239	Only	N	I-Premise
240	1	N	I-Premise
241	patient	N	I-Premise
242	in	N	I-Premise
243	each	N	I-Premise
244	group	N	I-Premise
245	had	N	I-Premise
246	acute	N	I-Premise
247	nonhematologic	N	I-Premise
248	toxicity	N	I-Premise
249	greater	N	I-Premise
250	than	N	I-Premise
251	Grade	N	I-Premise
252	3	N	I-Premise
253	(	N	I-Premise
254	nausea	N	I-Premise
255	and	N	I-Premise
256	vomiting	N	I-Premise
257	)	N	I-Premise
258	.	N	I-Premise

259	No	N	I-Premise
260	acute	N	I-Premise
261	Grade	N	I-Premise
262	4	N	I-Premise
263	radiation	N	I-Premise
264	toxicity	N	I-Premise
265	developed	N	I-Premise
266	.	N	I-Premise

267	The	N	I-Premise
268	incidences	N	I-Premise
269	of	N	I-Premise
270	long-term	N	I-Premise
271	toxicity	N	I-Premise
272	were	N	I-Premise
273	equivalent	N	I-Premise
274	across	N	I-Premise
275	the	N	I-Premise
276	arms	N	I-Premise
277	.	N	I-Premise

278	Three	N	I-Premise
279	treatment-related	N	I-Premise
280	deaths	N	I-Premise
281	occurred	N	I-Premise
282	:	N	I-Premise
283	2	N	I-Premise
284	patients	N	I-Premise
285	in	N	I-Premise
286	the	N	I-Premise
287	surgical	N	I-Premise
288	arms	N	I-Premise
289	(	N	I-Premise
290	one	N	I-Premise
291	late	N	I-Premise
292	pulmonary	N	I-Premise
293	toxicity	N	I-Premise
294	and	N	I-Premise
295	one	N	I-Premise
296	pulmonary	N	I-Premise
297	embolus	N	I-Premise
298	)	N	I-Premise
299	,	N	I-Premise
300	and	N	I-Premise
301	1	N	I-Premise
302	patient	N	I-Premise
303	in	N	I-Premise
304	the	N	I-Premise
305	radiation	N	I-Premise
306	arm	N	I-Premise
307	(	N	I-Premise
308	radiation	N	I-Premise
309	pneumonitis	N	I-Premise
310	)	N	I-Premise
311	.	N	I-Premise

312	Induction	N	I-Premise
313	chemotherapy	N	I-Premise
314	was	N	I-Premise
315	completed	N	I-Premise
316	in	N	I-Premise
317	78	N	I-Premise
318	%	N	I-Premise
319	of	N	I-Premise
320	the	N	I-Premise
321	patients	N	I-Premise
322	.	N	I-Premise

323	Complete	N	I-Premise
324	resection	N	I-Premise
325	was	N	I-Premise
326	performed	N	I-Premise
327	in	N	I-Premise
328	73	N	I-Premise
329	%	N	I-Premise
330	of	N	I-Premise
331	26	N	I-Premise
332	patients	N	I-Premise
333	undergoing	N	I-Premise
334	thoracotomy	N	I-Premise
335	.	N	I-Premise

336	Consolidation	N	I-Premise
337	chemotherapy	N	I-Premise
338	was	N	I-Premise
339	completed	N	I-Premise
340	in	N	I-Premise
341	75	N	I-Premise
342	%	N	I-Premise
343	of	N	I-Premise
344	the	N	I-Premise
345	patients	N	I-Premise
346	.	N	I-Premise

347	No	N	I-Premise
348	statistically	N	I-Premise
349	significant	N	I-Premise
350	difference	N	I-Premise
351	was	N	I-Premise
352	found	N	I-Premise
353	among	N	I-Premise
354	the	N	I-Premise
355	treatment	N	I-Premise
356	arms	N	I-Premise
357	.	N	I-Premise

358	The	N	I-Premise
359	overall	N	I-Premise
360	progression-free	N	I-Premise
361	survival	N	I-Premise
362	rate	N	I-Premise
363	was	N	I-Premise
364	53	N	I-Premise
365	%	N	I-Premise
366	at	N	I-Premise
367	1	N	I-Premise
368	year	N	I-Premise
369	and	N	I-Premise
370	17	N	I-Premise
371	%	N	I-Premise
372	at	N	I-Premise
373	3	N	I-Premise
374	years	N	I-Premise
375	.	N	I-Premise

376	The	N	I-Premise
377	median	N	I-Premise
378	progression-free	N	I-Premise
379	survival	N	I-Premise
380	was	N	I-Premise
381	14	N	I-Premise
382	months	N	I-Premise
383	.	N	I-Premise

384	No	N	I-Premise
385	difference	N	I-Premise
386	in	N	I-Premise
387	the	N	I-Premise
388	1-year	N	I-Premise
389	survival	N	I-Premise
390	rate	N	I-Premise
391	(	N	I-Premise
392	70	N	I-Premise
393	%	N	I-Premise
394	vs.	N	I-Premise
395	66	N	I-Premise
396	%	N	I-Premise
397	)	N	I-Premise
398	or	N	I-Premise
399	median	N	I-Premise
400	survival	N	I-Premise
401	time	N	I-Premise
402	(	N	I-Premise
403	19.4	N	I-Premise
404	vs.	N	I-Premise
405	17.4	N	I-Premise
406	months	N	I-Premise
407	)	N	I-Premise
408	between	N	I-Premise
409	the	N	I-Premise
410	surgery	N	I-Premise
411	and	N	I-Premise
412	RT	N	I-Premise
413	arms	N	I-Premise
414	.	N	I-Premise

415	The	N	I-Premise
416	median	N	I-Premise
417	survival	N	I-Premise
418	in	N	I-Premise
419	the	N	I-Premise
420	patients	N	I-Premise
421	receiving	N	I-Premise
422	induction	N	I-Premise
423	chemotherapy	N	I-Premise
424	only	N	I-Premise
425	was	N	I-Premise
426	8.9	N	I-Premise
427	months	N	I-Premise
428	.	N	I-Premise

429	Mitomycin-C	N	I-Premise
430	had	N	I-Premise
431	no	N	I-Premise
432	impact	N	I-Premise
433	on	N	I-Premise
434	survival	N	I-Premise
435	(	N	I-Premise
436	p	N	I-Premise
437	=	N	I-Premise
438	0.75	N	I-Premise
439	)	N	I-Premise
440	.	N	I-Premise

441	No	N	I-Premise
442	statistically	N	I-Premise
443	significant	N	I-Premise
444	difference	N	I-Premise
445	was	N	I-Premise
446	noted	N	I-Premise
447	in	N	I-Premise
448	the	N	I-Premise
449	time	N	I-Premise
450	to	N	I-Premise
451	local	N	I-Premise
452	failure	N	I-Premise
453	between	N	I-Premise
454	the	N	I-Premise
455	surgical	N	I-Premise
456	and	N	I-Premise
457	RT	N	I-Premise
458	arms	N	I-Premise
459	.	N	I-Premise

460	The	N	I-Claim
461	patient	N	I-Claim
462	accrual	N	I-Claim
463	to	N	I-Claim
464	this	N	I-Claim
465	trial	N	I-Claim
466	made	N	I-Claim
467	its	N	I-Claim
468	results	N	I-Claim
469	inconclusive	N	I-Claim
470	,	N	I-Claim
471	but	N	O
472	several	N	O
473	observations	N	O
474	are	N	O
475	notable	N	O
476	.	N	O

477	In	N	O
478	this	N	O
479	trial	N	O
480	,	N	O
481	histologic	N	I-Claim
482	confirmation	N	I-Claim
483	of	N	I-Claim
484	N2	N	I-Claim
485	disease	N	I-Claim
486	in	N	I-Claim
487	the	N	I-Claim
488	surgical	N	I-Claim
489	and	N	I-Claim
490	nonsurgical	N	I-Claim
491	arms	N	I-Claim
492	eliminated	N	I-Claim
493	the	N	I-Claim
494	usual	N	I-Claim
495	biases	N	I-Claim
496	from	N	I-Claim
497	clinical	N	I-Claim
498	staging	N	I-Claim
499	.	N	I-Claim

500	In	N	O
501	this	N	O
502	setting	N	O
503	,	N	O
504	local	N	I-Claim
505	control	N	I-Claim
506	and	N	I-Claim
507	survival	N	I-Claim
508	were	N	I-Claim
509	essentially	N	I-Claim
510	equal	N	I-Claim
511	between	N	I-Claim
512	the	N	I-Claim
513	surgical	N	I-Claim
514	and	N	I-Claim
515	RT	N	I-Claim
516	arms	N	I-Claim
517	.	N	I-Claim

518	The	N	I-Claim
519	3-	N	I-Claim
520	and	N	I-Claim
521	5-year	N	I-Claim
522	survival	N	I-Claim
523	rates	N	I-Claim
524	of	N	I-Claim
525	nonsurgical	N	I-Claim
526	therapy	N	I-Claim
527	were	N	I-Claim
528	comparable	N	I-Claim
529	to	N	I-Claim
530	published	N	I-Claim
531	surgical	N	I-Claim
532	trials	N	I-Claim
533	of	N	I-Claim
534	N2	N	I-Claim
535	disease	N	I-Claim
536	.	N	I-Claim

1	Mucositis	N	I-Premise
2	occurs	N	I-Premise
3	in	N	I-Premise
4	almost	N	I-Premise
5	all	N	I-Premise
6	patients	N	I-Premise
7	treated	N	I-Premise
8	with	N	I-Premise
9	radiotherapy	N	I-Premise
10	for	N	I-Premise
11	head	N	I-Premise
12	and	N	I-Premise
13	neck	N	I-Premise
14	cancer	N	I-Premise
15	.	N	I-Premise

16	The	N	O
17	aim	N	O
18	of	N	O
19	this	N	O
20	multicenter	N	O
21	,	N	O
22	double-blind	N	O
23	,	N	O
24	prospective	N	O
25	,	N	O
26	randomized	N	O
27	trial	N	O
28	was	N	O
29	to	N	O
30	evaluate	N	O
31	the	N	O
32	clinical	N	O
33	efficacy	N	O
34	of	N	O
35	an	N	O
36	economically	N	O
37	viable	N	O
38	antimicrobial	N	O
39	lozenge	N	O
40	(	N	O
41	bacitracin	N	O
42	,	N	O
43	clotrimazole	N	O
44	,	N	O
45	and	N	O
46	gentamicin	N	O
47	[	N	O
48	BcoG	N	O
49	]	N	O
50	)	N	O
51	in	N	O
52	the	N	O
53	alleviation	N	O
54	of	N	O
55	radiation-induced	N	O
56	mucositis	N	O
57	in	N	O
58	patients	N	O
59	with	N	O
60	head	N	O
61	and	N	O
62	neck	N	O
63	cancer	N	O
64	.	N	O

65	One	N	O
66	hundred	N	O
67	thirty-seven	N	O
68	eligible	N	O
69	patients	N	O
70	were	N	O
71	randomized	N	O
72	to	N	O
73	treatment	N	O
74	with	N	O
75	either	N	O
76	antimicrobial	N	O
77	lozenge	N	O
78	(	N	O
79	69	N	O
80	patients	N	O
81	)	N	O
82	or	N	O
83	placebo	N	O
84	lozenge	N	O
85	(	N	O
86	68	N	O
87	patients	N	O
88	)	N	O
89	.	N	O

90	The	N	O
91	primary	N	O
92	end	N	O
93	point	N	O
94	of	N	O
95	the	N	O
96	study	N	O
97	was	N	O
98	the	N	O
99	time	N	O
100	to	N	O
101	development	N	O
102	of	N	O
103	severe	N	O
104	mucositis	N	O
105	from	N	O
106	the	N	O
107	start	N	O
108	of	N	O
109	radiotherapy	N	O
110	.	N	O

111	Secondary	N	O
112	end	N	O
113	points	N	O
114	included	N	O
115	severity	N	O
116	and	N	O
117	duration	N	O
118	of	N	O
119	mucositis	N	O
120	,	N	O
121	pain	N	O
122	measurement	N	O
123	,	N	O
124	radiation	N	O
125	therapy	N	O
126	interruption	N	O
127	,	N	O
128	and	N	O
129	quality	N	O
130	of	N	O
131	life	N	O
132	.	N	O

133	Mucositis	N	O
134	was	N	O
135	scored	N	O
136	using	N	O
137	a	N	O
138	validated	N	O
139	mucositis	N	O
140	scoring	N	O
141	system	N	O
142	.	N	O

143	Toxicity	N	I-Premise
144	profiles	N	I-Premise
145	were	N	I-Premise
146	similar	N	I-Premise
147	between	N	I-Premise
148	the	N	I-Premise
149	two	N	I-Premise
150	arms	N	I-Premise
151	of	N	I-Premise
152	the	N	I-Premise
153	study	N	I-Premise
154	.	N	I-Premise

155	The	N	I-Premise
156	median	N	I-Premise
157	time	N	I-Premise
158	to	N	I-Premise
159	development	N	I-Premise
160	of	N	I-Premise
161	severe	N	I-Premise
162	mucositis	N	I-Premise
163	from	N	I-Premise
164	the	N	I-Premise
165	start	N	I-Premise
166	of	N	I-Premise
167	radiotherapy	N	I-Premise
168	was	N	I-Premise
169	3.61	N	I-Premise
170	weeks	N	I-Premise
171	on	N	I-Premise
172	BCoG	N	I-Premise
173	and	N	I-Premise
174	3.96	N	I-Premise
175	weeks	N	I-Premise
176	on	N	I-Premise
177	placebo	N	I-Premise
178	(	N	I-Premise
179	P	N	I-Premise
180	=.61	N	I-Premise
181	)	N	I-Premise
182	.	N	I-Premise

183	There	N	I-Premise
184	were	N	I-Premise
185	no	N	I-Premise
186	statistically	N	I-Premise
187	significant	N	I-Premise
188	differences	N	I-Premise
189	between	N	I-Premise
190	the	N	I-Premise
191	arms	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	extent	N	I-Premise
195	of	N	I-Premise
196	severe	N	I-Premise
197	mucositis	N	I-Premise
198	as	N	I-Premise
199	measured	N	I-Premise
200	by	N	I-Premise
201	physician	N	I-Premise
202	,	N	I-Premise
203	in	N	I-Premise
204	oral	N	I-Premise
205	toxicities	N	I-Premise
206	as	N	I-Premise
207	recorded	N	I-Premise
208	by	N	I-Premise
209	patients	N	I-Premise
210	,	N	I-Premise
211	or	N	I-Premise
212	in	N	I-Premise
213	radiotherapy	N	I-Premise
214	delays	N	I-Premise
215	.	N	I-Premise

216	This	N	O
217	study	N	O
218	was	N	O
219	conducted	N	O
220	on	N	O
221	the	N	O
222	basis	N	O
223	of	N	O
224	a	N	O
225	pilot	N	O
226	study	N	O
227	that	N	O
228	demonstrated	N	O
229	the	N	O
230	BCoG	N	O
231	lozenge	N	O
232	to	N	O
233	be	N	O
234	tolerable	N	O
235	and	N	O
236	microbiologically	N	O
237	efficacious	N	O
238	.	N	O

239	A	N	O
240	validated	N	O
241	mucositis	N	O
242	scoring	N	O
243	system	N	O
244	was	N	O
245	used	N	O
246	.	N	O

247	However	N	O
248	,	N	O
249	in	N	I-Claim
250	this	N	I-Claim
251	group	N	I-Claim
252	of	N	I-Claim
253	patients	N	I-Claim
254	treated	N	I-Claim
255	with	N	I-Claim
256	conventional	N	I-Claim
257	radiotherapy	N	I-Claim
258	,	N	I-Claim
259	the	N	I-Claim
260	lozenge	N	I-Claim
261	did	N	I-Claim
262	not	N	I-Claim
263	impact	N	I-Claim
264	significantly	N	I-Claim
265	on	N	I-Claim
266	the	N	I-Claim
267	severity	N	I-Claim
268	of	N	I-Claim
269	mucositis	N	I-Claim
270	.	N	I-Claim

271	Whether	N	I-Claim
272	such	N	I-Claim
273	a	N	I-Claim
274	lozenge	N	I-Claim
275	would	N	I-Claim
276	be	N	I-Claim
277	beneficial	N	I-Claim
278	in	N	I-Claim
279	treatment	N	I-Claim
280	situations	N	I-Claim
281	where	N	I-Claim
282	rate	N	I-Claim
283	of	N	I-Claim
284	severe	N	I-Claim
285	mucositis	N	I-Claim
286	is	N	I-Claim
287	higher	N	I-Claim
288	(	N	I-Claim
289	ie	N	I-Claim
290	,	N	I-Claim
291	in	N	I-Claim
292	patients	N	I-Claim
293	treated	N	I-Claim
294	with	N	I-Claim
295	unconventional	N	I-Claim
296	fractionation	N	I-Claim
297	or	N	I-Claim
298	with	N	I-Claim
299	concomitant	N	I-Claim
300	chemotherapy	N	I-Claim
301	)	N	I-Claim
302	is	N	I-Claim
303	unknown	N	I-Claim
304	.	N	I-Claim

1	Bone	N	I-Claim
2	metastases	N	I-Claim
3	are	N	I-Claim
4	a	N	I-Claim
5	common	N	I-Claim
6	cause	N	I-Claim
7	of	N	I-Claim
8	morbidity	N	I-Claim
9	in	N	I-Claim
10	patients	N	I-Claim
11	with	N	I-Claim
12	prostate	N	I-Claim
13	carcinoma	N	I-Claim
14	.	N	I-Claim

15	We	N	O
16	studied	N	O
17	the	N	O
18	effect	N	O
19	of	N	O
20	a	N	O
21	new	N	O
22	bisphosphonate	N	O
23	,	N	O
24	zoledronic	N	O
25	acid	N	O
26	,	N	O
27	which	N	O
28	blocks	N	O
29	bone	N	O
30	destruction	N	O
31	,	N	O
32	on	N	O
33	skeletal	N	O
34	complications	N	O
35	in	N	O
36	prostate	N	O
37	cancer	N	O
38	patients	N	O
39	with	N	O
40	bone	N	O
41	metastases	N	O
42	.	N	O

43	Patients	N	O
44	with	N	O
45	hormone-refractory	N	O
46	prostate	N	O
47	cancer	N	O
48	and	N	O
49	a	N	O
50	history	N	O
51	of	N	O
52	bone	N	O
53	metastases	N	O
54	were	N	O
55	randomly	N	O
56	assigned	N	O
57	to	N	O
58	a	N	O
59	double-blind	N	O
60	treatment	N	O
61	regimen	N	O
62	of	N	O
63	intravenous	N	O
64	zoledronic	N	O
65	acid	N	O
66	at	N	O
67	4	N	O
68	mg	N	O
69	(	N	O
70	N	N	O
71	=	N	O
72	214	N	O
73	)	N	O
74	,	N	O
75	zoledronic	N	O
76	acid	N	O
77	at	N	O
78	8	N	O
79	mg	N	O
80	(	N	O
81	subsequently	N	O
82	reduced	N	O
83	to	N	O
84	4	N	O
85	mg	N	O
86	;	N	O
87	8/4	N	O
88	)	N	O
89	(	N	O
90	N	N	O
91	=	N	O
92	221	N	O
93	)	N	O
94	,	N	O
95	or	N	O
96	placebo	N	O
97	(	N	O
98	N	N	O
99	=	N	O
100	208	N	O
101	)	N	O
102	every	N	O
103	3	N	O
104	weeks	N	O
105	for	N	O
106	15	N	O
107	months	N	O
108	.	N	O

109	Proportions	N	O
110	of	N	O
111	patients	N	O
112	with	N	O
113	skeletal-related	N	O
114	events	N	O
115	,	N	O
116	time	N	O
117	to	N	O
118	the	N	O
119	first	N	O
120	skeletal-related	N	O
121	event	N	O
122	,	N	O
123	skeletal	N	O
124	morbidity	N	O
125	rate	N	O
126	,	N	O
127	pain	N	O
128	and	N	O
129	analgesic	N	O
130	scores	N	O
131	,	N	O
132	disease	N	O
133	progression	N	O
134	,	N	O
135	and	N	O
136	safety	N	O
137	were	N	O
138	assessed	N	O
139	.	N	O

140	All	N	O
141	statistical	N	O
142	tests	N	O
143	were	N	O
144	two-sided	N	O
145	.	N	O

146	Approximately	N	O
147	38	N	O
148	%	N	O
149	of	N	O
150	patients	N	O
151	who	N	O
152	received	N	O
153	zoledronic	N	O
154	acid	N	O
155	at	N	O
156	4	N	O
157	mg	N	O
158	,	N	O
159	28	N	O
160	%	N	O
161	who	N	O
162	received	N	O
163	zoledronic	N	O
164	acid	N	O
165	at	N	O
166	8/4	N	O
167	mg	N	O
168	,	N	O
169	and	N	O
170	31	N	O
171	%	N	O
172	who	N	O
173	received	N	O
174	placebo	N	O
175	completed	N	O
176	the	N	O
177	study	N	O
178	.	N	O

179	A	N	I-Premise
180	greater	N	I-Premise
181	proportion	N	I-Premise
182	of	N	I-Premise
183	patients	N	I-Premise
184	who	N	I-Premise
185	received	N	I-Premise
186	placebo	N	I-Premise
187	had	N	I-Premise
188	skeletal-related	N	I-Premise
189	events	N	I-Premise
190	than	N	I-Premise
191	those	N	I-Premise
192	who	N	I-Premise
193	received	N	I-Premise
194	zoledronic	N	I-Premise
195	acid	N	I-Premise
196	at	N	I-Premise
197	4	N	I-Premise
198	mg	N	I-Premise
199	(	N	I-Premise
200	44.2	N	I-Premise
201	%	N	I-Premise
202	versus	N	I-Premise
203	33.2	N	I-Premise
204	%	N	I-Premise
205	;	N	I-Premise
206	difference	N	I-Premise
207	=	N	I-Premise
208	-11.0	N	I-Premise
209	%	N	I-Premise
210	,	N	I-Premise
211	95	N	I-Premise
212	%	N	I-Premise
213	confidence	N	I-Premise
214	interval	N	I-Premise
215	[	N	I-Premise
216	CI	N	I-Premise
217	]	N	I-Premise
218	=	N	I-Premise
219	-20.3	N	I-Premise
220	%	N	I-Premise
221	to	N	I-Premise
222	-1.8	N	I-Premise
223	%	N	I-Premise
224	;	N	I-Premise
225	P	N	I-Premise
226	=.021	N	I-Premise
227	)	N	I-Premise
228	or	N	I-Premise
229	those	N	I-Premise
230	who	N	I-Premise
231	received	N	I-Premise
232	zoledronic	N	I-Premise
233	acid	N	I-Premise
234	at	N	I-Premise
235	8/4	N	I-Premise
236	mg	N	I-Premise
237	(	N	I-Premise
238	38.5	N	I-Premise
239	%	N	I-Premise
240	;	N	I-Premise
241	difference	N	I-Premise
242	versus	N	I-Premise
243	placebo	N	I-Premise
244	=	N	I-Premise
245	-5.8	N	I-Premise
246	%	N	I-Premise
247	,	N	I-Premise
248	95	N	I-Premise
249	%	N	I-Premise
250	CI	N	I-Premise
251	=	N	I-Premise
252	-15.1	N	I-Premise
253	%	N	I-Premise
254	to	N	I-Premise
255	3.6	N	I-Premise
256	%	N	I-Premise
257	;	N	I-Premise
258	P	N	I-Premise
259	=.222	N	I-Premise
260	)	N	I-Premise
261	.	N	I-Premise

262	Median	N	I-Premise
263	time	N	I-Premise
264	to	N	I-Premise
265	first	N	I-Premise
266	skeletal-related	N	I-Premise
267	event	N	I-Premise
268	was	N	I-Premise
269	321	N	I-Premise
270	days	N	I-Premise
271	for	N	I-Premise
272	patients	N	I-Premise
273	who	N	I-Premise
274	received	N	I-Premise
275	placebo	N	I-Premise
276	,	N	I-Premise
277	was	N	I-Premise
278	not	N	I-Premise
279	reached	N	I-Premise
280	for	N	I-Premise
281	patients	N	I-Premise
282	who	N	I-Premise
283	received	N	I-Premise
284	zoledronic	N	I-Premise
285	acid	N	I-Premise
286	at	N	I-Premise
287	4	N	I-Premise
288	mg	N	I-Premise
289	(	N	I-Premise
290	P	N	I-Premise
291	=.011	N	I-Premise
292	versus	N	I-Premise
293	placebo	N	I-Premise
294	)	N	I-Premise
295	,	N	I-Premise
296	and	N	I-Premise
297	was	N	I-Premise
298	363	N	I-Premise
299	days	N	I-Premise
300	for	N	I-Premise
301	those	N	I-Premise
302	who	N	I-Premise
303	received	N	I-Premise
304	zoledronic	N	I-Premise
305	acid	N	I-Premise
306	at	N	I-Premise
307	8/4	N	I-Premise
308	mg	N	I-Premise
309	(	N	I-Premise
310	P	N	I-Premise
311	=.491	N	I-Premise
312	versus	N	I-Premise
313	placebo	N	I-Premise
314	)	N	I-Premise
315	.	N	I-Premise

316	Compared	N	I-Premise
317	with	N	I-Premise
318	urinary	N	I-Premise
319	markers	N	I-Premise
320	in	N	I-Premise
321	patients	N	I-Premise
322	who	N	I-Premise
323	received	N	I-Premise
324	placebo	N	I-Premise
325	,	N	I-Premise
326	urinary	N	I-Premise
327	markers	N	I-Premise
328	of	N	I-Premise
329	bone	N	I-Premise
330	resorption	N	I-Premise
331	were	N	I-Premise
332	statistically	N	I-Premise
333	significantly	N	I-Premise
334	decreased	N	I-Premise
335	in	N	I-Premise
336	patients	N	I-Premise
337	who	N	I-Premise
338	received	N	I-Premise
339	zoledronic	N	I-Premise
340	acid	N	I-Premise
341	at	N	I-Premise
342	either	N	I-Premise
343	dose	N	I-Premise
344	(	N	I-Premise
345	P	N	I-Premise
346	=.001	N	I-Premise
347	)	N	I-Premise
348	.	N	I-Premise

349	Pain	N	I-Premise
350	and	N	I-Premise
351	analgesic	N	I-Premise
352	scores	N	I-Premise
353	increased	N	I-Premise
354	more	N	I-Premise
355	in	N	I-Premise
356	patients	N	I-Premise
357	who	N	I-Premise
358	received	N	I-Premise
359	placebo	N	I-Premise
360	than	N	I-Premise
361	in	N	I-Premise
362	patients	N	I-Premise
363	who	N	I-Premise
364	received	N	I-Premise
365	zoledronic	N	I-Premise
366	acid	N	I-Premise
367	,	N	I-Premise
368	but	N	O
369	there	N	I-Premise
370	were	N	I-Premise
371	no	N	I-Premise
372	differences	N	I-Premise
373	in	N	I-Premise
374	disease	N	I-Premise
375	progression	N	I-Premise
376	,	N	I-Premise
377	performance	N	I-Premise
378	status	N	I-Premise
379	,	N	I-Premise
380	or	N	I-Premise
381	quality-of-life	N	I-Premise
382	scores	N	I-Premise
383	among	N	I-Premise
384	the	N	I-Premise
385	groups	N	I-Premise
386	.	N	I-Premise

387	Zoledronic	N	I-Claim
388	acid	N	I-Claim
389	at	N	I-Claim
390	4	N	I-Claim
391	mg	N	I-Claim
392	given	N	I-Claim
393	as	N	I-Claim
394	a	N	I-Claim
395	15-minute	N	I-Claim
396	infusion	N	I-Claim
397	was	N	I-Claim
398	well	N	I-Claim
399	tolerated	N	I-Claim
400	,	N	I-Claim
401	but	N	O
402	the	N	I-Claim
403	8-mg	N	I-Claim
404	dose	N	I-Claim
405	was	N	I-Claim
406	associated	N	I-Claim
407	with	N	I-Claim
408	renal	N	I-Claim
409	function	N	I-Claim
410	deterioration	N	I-Claim
411	.	N	I-Claim

412	Zoledronic	N	I-Claim
413	acid	N	I-Claim
414	at	N	I-Claim
415	4	N	I-Claim
416	mg	N	I-Claim
417	reduced	N	I-Claim
418	skeletal-related	N	I-Claim
419	events	N	I-Claim
420	in	N	I-Claim
421	prostate	N	I-Claim
422	cancer	N	I-Claim
423	patients	N	I-Claim
424	with	N	I-Claim
425	bone	N	I-Claim
426	metastases	N	I-Claim
427	.	N	I-Claim

1	In	N	O
2	the	N	O
3	Asia-Pacific	N	O
4	region	N	O
5	and	N	O
6	elsewhere	N	O
7	,	N	O
8	almost	N	O
9	85	N	O
10	%	N	O
11	of	N	O
12	patients	N	O
13	with	N	O
14	hepatocellular	N	O
15	carcinoma	N	O
16	(	N	O
17	HCC	N	O
18	)	N	O
19	are	N	O
20	inoperable	N	O
21	at	N	O
22	diagnosis	N	O
23	and	N	O
24	have	N	O
25	a	N	O
26	dismal	N	O
27	prognosis	N	O
28	.	N	O

29	Tamoxifen	N	I-Claim
30	(	N	I-Claim
31	TMX	N	I-Claim
32	)	N	I-Claim
33	is	N	I-Claim
34	believed	N	I-Claim
35	to	N	I-Claim
36	inhibit	N	I-Claim
37	HCC	N	I-Claim
38	positive	N	I-Claim
39	for	N	I-Claim
40	estrogen	N	I-Claim
41	receptor	N	I-Claim
42	(	N	I-Claim
43	ER	N	I-Claim
44	)	N	I-Claim
45	,	N	I-Claim
46	but	N	I-Claim
47	most	N	I-Claim
48	HCCs	N	I-Claim
49	are	N	I-Claim
50	ER	N	I-Claim
51	negative	N	I-Claim
52	.	N	I-Claim

53	Results	N	I-Claim
54	of	N	I-Claim
55	previous	N	I-Claim
56	phase	N	I-Claim
57	3	N	I-Claim
58	trials	N	I-Claim
59	in	N	I-Claim
60	inoperable	N	I-Claim
61	HCC	N	I-Claim
62	have	N	I-Claim
63	been	N	I-Claim
64	conflicting	N	I-Claim
65	and	N	I-Claim
66	inconclusive	N	I-Claim
67	.	N	I-Claim

68	At	N	I-Claim
69	higher	N	I-Claim
70	doses	N	I-Claim
71	,	N	I-Claim
72	however	N	I-Claim
73	,	N	I-Claim
74	TMX	N	I-Claim
75	inhibits	N	I-Claim
76	HCC	N	I-Claim
77	through	N	I-Claim
78	ER-independent	N	I-Claim
79	mechanisms	N	I-Claim
80	.	N	I-Claim

81	A	N	O
82	multicenter	N	O
83	randomized	N	O
84	controlled	N	O
85	trial	N	O
86	was	N	O
87	performed	N	O
88	to	N	O
89	assess	N	O
90	the	N	O
91	role	N	O
92	of	N	O
93	high-dose	N	O
94	TMX	N	O
95	versus	N	O
96	placebo	N	O
97	(	N	O
98	P	N	O
99	)	N	O
100	in	N	O
101	the	N	O
102	treatment	N	O
103	of	N	O
104	patients	N	O
105	with	N	O
106	inoperable	N	O
107	HCC	N	O
108	with	N	O
109	respect	N	O
110	to	N	O
111	survival	N	O
112	and	N	O
113	quality	N	O
114	of	N	O
115	life	N	O
116	(	N	O
117	QoL	N	O
118	)	N	O
119	.	N	O

120	A	N	O
121	total	N	O
122	of	N	O
123	329	N	O
124	patients	N	O
125	from	N	O
126	10	N	O
127	centers	N	O
128	in	N	O
129	9	N	O
130	countries	N	O
131	in	N	O
132	the	N	O
133	Asia-Pacific	N	O
134	region	N	O
135	enrolled	N	O
136	in	N	O
137	a	N	O
138	double-blind	N	O
139	randomized	N	O
140	controlled	N	O
141	trial	N	O
142	of	N	O
143	TMX	N	O
144	120	N	O
145	mg/d	N	O
146	(	N	O
147	TMX120	N	O
148	)	N	O
149	against	N	O
150	P	N	O
151	as	N	O
152	a	N	O
153	control	N	O
154	arm	N	O
155	with	N	O
156	an	N	O
157	intermediate	N	O
158	dosage	N	O
159	of	N	O
160	TMX	N	O
161	60	N	O
162	mg/d	N	O
163	(	N	O
164	TMX60	N	O
165	)	N	O
166	to	N	O
167	assess	N	O
168	possible	N	O
169	dose	N	O
170	response	N	O
171	.	N	O

172	An	N	O
173	independent	N	O
174	data	N	O
175	monitoring	N	O
176	committee	N	O
177	reviewed	N	O
178	all	N	O
179	aspects	N	O
180	of	N	O
181	the	N	O
182	trial	N	O
183	.	N	O

184	QoL	N	O
185	was	N	O
186	assessed	N	O
187	using	N	O
188	the	N	O
189	European	N	O
190	Organization	N	O
191	for	N	O
192	Research	N	O
193	and	N	O
194	Treatment	N	O
195	of	N	O
196	Cancer	N	O
197	QLQ-C30	N	O
198	questionnaire	N	O
199	.	N	O

200	Three-month	N	I-Premise
201	survival	N	I-Premise
202	rates	N	I-Premise
203	for	N	I-Premise
204	the	N	I-Premise
205	P	N	I-Premise
206	,	N	I-Premise
207	TMX60	N	I-Premise
208	,	N	I-Premise
209	and	N	I-Premise
210	TMX120	N	I-Premise
211	groups	N	I-Premise
212	were	N	I-Premise
213	44	N	I-Premise
214	%	N	I-Premise
215	,	N	I-Premise
216	41	N	I-Premise
217	%	N	I-Premise
218	,	N	I-Premise
219	and	N	I-Premise
220	35	N	I-Premise
221	%	N	I-Premise
222	,	N	I-Premise
223	respectively	N	I-Premise
224	,	N	I-Premise
225	with	N	I-Premise
226	a	N	I-Premise
227	statistically	N	I-Premise
228	significant	N	I-Premise
229	trend	N	I-Premise
230	difference	N	I-Premise
231	in	N	I-Premise
232	survival	N	I-Premise
233	across	N	I-Premise
234	the	N	I-Premise
235	3	N	I-Premise
236	treatment	N	I-Premise
237	regimens	N	I-Premise
238	(	N	I-Premise
239	P	N	I-Premise
240	=.011	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	There	N	I-Premise
244	was	N	I-Premise
245	a	N	I-Premise
246	significantly	N	I-Premise
247	higher	N	I-Premise
248	risk	N	I-Premise
249	of	N	I-Premise
250	death	N	I-Premise
251	in	N	I-Premise
252	the	N	I-Premise
253	TMX120	N	I-Premise
254	group	N	I-Premise
255	compared	N	I-Premise
256	with	N	I-Premise
257	the	N	I-Premise
258	P	N	I-Premise
259	group	N	I-Premise
260	(	N	I-Premise
261	hazard	N	I-Premise
262	ratio	N	I-Premise
263	,	N	I-Premise
264	1.39	N	I-Premise
265	;	N	I-Premise
266	95	N	I-Premise
267	%	N	I-Premise
268	confidence	N	I-Premise
269	interval	N	I-Premise
270	,	N	I-Premise
271	1.07-1.81	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	Adverse	N	I-Premise
275	drug	N	I-Premise
276	reactions	N	I-Premise
277	were	N	I-Premise
278	reported	N	I-Premise
279	in	N	I-Premise
280	3	N	I-Premise
281	%	N	I-Premise
282	(	N	I-Premise
283	9	N	I-Premise
284	patients	N	I-Premise
285	)	N	I-Premise
286	,	N	I-Premise
287	and	N	O
288	8	N	I-Premise
289	patients	N	I-Premise
290	were	N	I-Premise
291	lost	N	I-Premise
292	to	N	I-Premise
293	follow-up	N	I-Premise
294	.	N	I-Premise

295	In	N	O
296	conclusion	N	O
297	,	N	O
298	TMX	N	I-Claim
299	does	N	I-Claim
300	not	N	I-Claim
301	prolong	N	I-Claim
302	survival	N	I-Claim
303	in	N	I-Claim
304	patients	N	I-Claim
305	with	N	I-Claim
306	inoperable	N	I-Claim
307	HCC	N	I-Claim
308	and	N	I-Claim
309	has	N	I-Claim
310	an	N	I-Claim
311	increasingly	N	I-Claim
312	negative	N	I-Claim
313	impact	N	I-Claim
314	with	N	I-Claim
315	increasing	N	I-Claim
316	dose	N	I-Claim
317	.	N	I-Claim

318	No	N	I-Claim
319	appreciable	N	I-Claim
320	advantage	N	I-Claim
321	to	N	I-Claim
322	QoL	N	I-Claim
323	with	N	I-Claim
324	TMX	N	I-Claim
325	was	N	I-Claim
326	observed	N	I-Claim
327	.	N	I-Claim

1	Increased	N	I-Claim
2	expression	N	I-Claim
3	of	N	I-Claim
4	metalloproteinases	N	I-Claim
5	is	N	I-Claim
6	associated	N	I-Claim
7	with	N	I-Claim
8	poor	N	I-Claim
9	prognosis	N	I-Claim
10	in	N	I-Claim
11	small-cell	N	I-Claim
12	lung	N	I-Claim
13	cancer	N	I-Claim
14	(	N	I-Claim
15	SCLC	N	I-Claim
16	)	N	I-Claim
17	.	N	I-Claim

18	This	N	O
19	trial	N	O
20	was	N	O
21	undertaken	N	O
22	to	N	O
23	determine	N	O
24	whether	N	O
25	adjuvant	N	O
26	treatment	N	O
27	with	N	O
28	the	N	O
29	metalloproteinase	N	O
30	inhibitor	N	O
31	marimastat	N	O
32	could	N	O
33	prolong	N	O
34	survival	N	O
35	in	N	O
36	responding	N	O
37	patients	N	O
38	with	N	O
39	SCLC	N	O
40	after	N	O
41	chemotherapy	N	O
42	.	N	O

43	SCLC	N	O
44	patients	N	O
45	in	N	O
46	complete	N	O
47	or	N	O
48	partial	N	O
49	remission	N	O
50	were	N	O
51	eligible	N	O
52	.	N	O

53	They	N	O
54	were	N	O
55	stratified	N	O
56	by	N	O
57	radiotherapy	N	O
58	(	N	O
59	early	N	O
60	,	N	O
61	late	N	O
62	,	N	O
63	or	N	O
64	none	N	O
65	)	N	O
66	,	N	O
67	stage	N	O
68	(	N	O
69	extensive	N	O
70	or	N	O
71	limited	N	O
72	)	N	O
73	,	N	O
74	response	N	O
75	(	N	O
76	complete	N	O
77	or	N	O
78	partial	N	O
79	)	N	O
80	,	N	O
81	and	N	O
82	cooperative	N	O
83	group	N	O
84	(	N	O
85	National	N	O
86	Cancer	N	O
87	Institute	N	O
88	of	N	O
89	Canada-Clinical	N	O
90	Trials	N	O
91	Group	N	O
92	or	N	O
93	European	N	O
94	Organization	N	O
95	for	N	O
96	Research	N	O
97	and	N	O
98	Treatment	N	O
99	of	N	O
100	Cancer	N	O
101	)	N	O
102	.	N	O

103	They	N	O
104	were	N	O
105	randomized	N	O
106	to	N	O
107	receive	N	O
108	marimastat	N	O
109	10	N	O
110	mg	N	O
111	or	N	O
112	placebo	N	O
113	orally	N	O
114	bid	N	O
115	for	N	O
116	up	N	O
117	to	N	O
118	2	N	O
119	years	N	O
120	.	N	O

121	There	N	O
122	were	N	O
123	532	N	O
124	eligible	N	O
125	patients	N	O
126	(	N	O
127	266	N	O
128	marimastat	N	O
129	and	N	O
130	266	N	O
131	placebo	N	O
132	)	N	O
133	.	N	O

134	Stage	N	O
135	was	N	O
136	limited	N	O
137	for	N	O
138	279	N	O
139	patients	N	O
140	(	N	O
141	52	N	O
142	%	N	O
143	)	N	O
144	and	N	O
145	extensive	N	O
146	for	N	O
147	253	N	O
148	(	N	O
149	48	N	O
150	%	N	O
151	)	N	O
152	.	N	O

153	Best	N	I-Premise
154	response	N	I-Premise
155	to	N	I-Premise
156	induction	N	I-Premise
157	therapy	N	I-Premise
158	was	N	I-Premise
159	complete	N	I-Premise
160	remission	N	I-Premise
161	for	N	I-Premise
162	176	N	I-Premise
163	patients	N	I-Premise
164	(	N	I-Premise
165	33	N	I-Premise
166	%	N	I-Premise
167	)	N	I-Premise
168	,	N	I-Premise
169	partial	N	I-Premise
170	remission	N	I-Premise
171	for	N	I-Premise
172	341	N	I-Premise
173	(	N	I-Premise
174	64	N	I-Premise
175	%	N	I-Premise
176	)	N	I-Premise
177	,	N	I-Premise
178	and	N	I-Premise
179	15	N	I-Premise
180	patients	N	I-Premise
181	(	N	I-Premise
182	3	N	I-Premise
183	%	N	I-Premise
184	)	N	I-Premise
185	had	N	I-Premise
186	undergone	N	I-Premise
187	surgical	N	I-Premise
188	resection	N	I-Premise
189	.	N	I-Premise

190	The	N	I-Premise
191	median	N	I-Premise
192	time	N	I-Premise
193	to	N	I-Premise
194	progression	N	I-Premise
195	for	N	I-Premise
196	marimastat	N	I-Premise
197	patients	N	I-Premise
198	was	N	I-Premise
199	4.3	N	I-Premise
200	months	N	I-Premise
201	compared	N	I-Premise
202	with	N	I-Premise
203	4.4	N	I-Premise
204	months	N	I-Premise
205	for	N	I-Premise
206	placebo	N	I-Premise
207	patients	N	I-Premise
208	(	N	I-Premise
209	P	N	I-Premise
210	=.81	N	I-Premise
211	)	N	I-Premise
212	.	N	I-Premise

213	Median	N	I-Premise
214	survivals	N	I-Premise
215	for	N	I-Premise
216	marimastat	N	I-Premise
217	and	N	I-Premise
218	placebo	N	I-Premise
219	patients	N	I-Premise
220	were	N	I-Premise
221	9.3	N	I-Premise
222	months	N	I-Premise
223	and	N	I-Premise
224	9.7	N	I-Premise
225	months	N	I-Premise
226	,	N	I-Premise
227	respectively	N	I-Premise
228	(	N	I-Premise
229	P	N	I-Premise
230	=.90	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	Toxicity	N	I-Premise
234	was	N	I-Premise
235	generally	N	I-Premise
236	limited	N	I-Premise
237	to	N	I-Premise
238	musculoskeletal	N	I-Premise
239	symptoms	N	I-Premise
240	(	N	I-Premise
241	18	N	I-Premise
242	%	N	I-Premise
243	grade	N	I-Premise
244	3/4	N	I-Premise
245	for	N	I-Premise
246	marimastat	N	I-Premise
247	)	N	I-Premise
248	.	N	I-Premise

249	Dose	N	I-Premise
250	modifications	N	I-Premise
251	for	N	I-Premise
252	musculoskeletal	N	I-Premise
253	toxicity	N	I-Premise
254	were	N	I-Premise
255	required	N	I-Premise
256	in	N	I-Premise
257	90	N	I-Premise
258	patients	N	I-Premise
259	(	N	I-Premise
260	33	N	I-Premise
261	%	N	I-Premise
262	)	N	I-Premise
263	on	N	I-Premise
264	the	N	I-Premise
265	marimastat	N	I-Premise
266	arm	N	I-Premise
267	,	N	I-Premise
268	and	N	I-Premise
269	87	N	I-Premise
270	(	N	I-Premise
271	32	N	I-Premise
272	%	N	I-Premise
273	)	N	I-Premise
274	permanently	N	I-Premise
275	stopped	N	I-Premise
276	marimastat	N	I-Premise
277	because	N	I-Premise
278	of	N	I-Premise
279	toxicity	N	I-Premise
280	.	N	I-Premise

281	Patients	N	I-Premise
282	on	N	I-Premise
283	marimastat	N	I-Premise
284	had	N	I-Premise
285	significantly	N	I-Premise
286	poorer	N	I-Premise
287	quality	N	I-Premise
288	of	N	I-Premise
289	life	N	I-Premise
290	at	N	I-Premise
291	3	N	I-Premise
292	and	N	I-Premise
293	6	N	I-Premise
294	months	N	I-Premise
295	.	N	I-Premise

296	Treatment	N	I-Claim
297	with	N	I-Claim
298	marimastat	N	I-Claim
299	after	N	I-Claim
300	induction	N	I-Claim
301	therapy	N	I-Claim
302	for	N	I-Claim
303	SCLC	N	I-Claim
304	did	N	I-Claim
305	not	N	I-Claim
306	result	N	I-Claim
307	in	N	I-Claim
308	improved	N	I-Claim
309	survival	N	I-Claim
310	and	N	I-Claim
311	had	N	I-Claim
312	a	N	I-Claim
313	negative	N	I-Claim
314	impact	N	I-Claim
315	on	N	I-Claim
316	quality	N	I-Claim
317	of	N	I-Claim
318	life	N	I-Claim
319	.	N	I-Claim

1	Morbidity	N	I-Claim
2	associated	N	I-Claim
3	with	N	I-Claim
4	wound	N	I-Claim
5	complications	N	I-Claim
6	may	N	I-Claim
7	translate	N	I-Claim
8	into	N	I-Claim
9	disability	N	I-Claim
10	and	N	I-Claim
11	quality-of-life	N	I-Claim
12	disadvantages	N	I-Claim
13	for	N	I-Claim
14	patients	N	I-Claim
15	treated	N	I-Claim
16	with	N	I-Claim
17	radiotherapy	N	I-Claim
18	(	N	I-Claim
19	RT	N	I-Claim
20	)	N	I-Claim
21	for	N	I-Claim
22	soft	N	I-Claim
23	tissue	N	I-Claim
24	sarcoma	N	I-Claim
25	(	N	I-Claim
26	STS	N	I-Claim
27	)	N	I-Claim
28	of	N	I-Claim
29	the	N	I-Claim
30	extremities	N	I-Claim
31	.	N	I-Claim

32	Functional	N	O
33	outcome	N	O
34	and	N	O
35	health	N	O
36	status	N	O
37	of	N	O
38	extremity	N	O
39	STS	N	O
40	patients	N	O
41	randomized	N	O
42	in	N	O
43	a	N	O
44	phase	N	O
45	III	N	O
46	trial	N	O
47	comparing	N	O
48	preoperative	N	O
49	versus	N	O
50	postoperative	N	O
51	RT	N	O
52	is	N	O
53	described	N	O
54	.	N	O

55	One	N	O
56	hundred	N	O
57	ninety	N	O
58	patients	N	O
59	with	N	O
60	extremity	N	O
61	STS	N	O
62	were	N	O
63	randomized	N	O
64	after	N	O
65	stratification	N	O
66	by	N	O
67	tumor	N	O
68	size	N	O
69	dichotomized	N	O
70	at	N	O
71	10	N	O
72	cm	N	O
73	.	N	O

74	Function	N	O
75	and	N	O
76	quality	N	O
77	of	N	O
78	life	N	O
79	were	N	O
80	measured	N	O
81	by	N	O
82	the	N	O
83	Musculoskeletal	N	O
84	Tumor	N	O
85	Society	N	O
86	Rating	N	O
87	Scale	N	O
88	(	N	O
89	MSTS	N	O
90	)	N	O
91	,	N	O
92	the	N	O
93	Toronto	N	O
94	Extremity	N	O
95	Salvage	N	O
96	Score	N	O
97	(	N	O
98	TESS	N	O
99	)	N	O
100	,	N	O
101	and	N	O
102	the	N	O
103	Short	N	O
104	Form-36	N	O
105	(	N	O
106	SF-36	N	O
107	)	N	O
108	at	N	O
109	randomization	N	O
110	,	N	O
111	6	N	O
112	weeks	N	O
113	,	N	O
114	and	N	O
115	3	N	O
116	,	N	O
117	6	N	O
118	,	N	O
119	12	N	O
120	,	N	O
121	and	N	O
122	24	N	O
123	months	N	O
124	after	N	O
125	surgery	N	O
126	.	N	O

127	One	N	O
128	hundred	N	O
129	eighty-five	N	O
130	patients	N	O
131	had	N	O
132	function	N	O
133	data	N	O
134	.	N	O

135	Patients	N	I-Premise
136	treated	N	I-Premise
137	with	N	I-Premise
138	postoperative	N	I-Premise
139	RT	N	I-Premise
140	had	N	I-Premise
141	better	N	I-Premise
142	function	N	I-Premise
143	with	N	I-Premise
144	higher	N	I-Premise
145	MSTS	N	I-Premise
146	(	N	I-Premise
147	25.8	N	I-Premise
148	v	N	I-Premise
149	21.3	N	I-Premise
150	,	N	I-Premise
151	P	N	I-Premise
152	<	N	I-Premise
153	.01	N	I-Premise
154	)	N	I-Premise
155	,	N	I-Premise
156	TESS	N	I-Premise
157	(	N	I-Premise
158	69.8	N	I-Premise
159	v	N	I-Premise
160	60.6	N	I-Premise
161	,	N	I-Premise
162	P	N	I-Premise
163	=.01	N	I-Premise
164	)	N	I-Premise
165	,	N	I-Premise
166	and	N	I-Premise
167	SF-36	N	I-Premise
168	bodily	N	I-Premise
169	pain	N	I-Premise
170	(	N	I-Premise
171	67.7	N	I-Premise
172	v	N	I-Premise
173	58.5	N	I-Premise
174	,	N	I-Premise
175	P	N	I-Premise
176	=.03	N	I-Premise
177	)	N	I-Premise
178	scores	N	I-Premise
179	at	N	I-Premise
180	6	N	I-Premise
181	weeks	N	I-Premise
182	after	N	I-Premise
183	surgery	N	I-Premise
184	.	N	I-Premise

185	There	N	O
186	were	N	O
187	no	N	O
188	differences	N	O
189	at	N	O
190	later	N	O
191	time	N	O
192	points	N	O
193	.	N	O

194	Scores	N	I-Premise
195	on	N	I-Premise
196	the	N	I-Premise
197	physical	N	I-Premise
198	function	N	I-Premise
199	,	N	I-Premise
200	role-physical	N	I-Premise
201	,	N	I-Premise
202	and	N	I-Premise
203	general	N	I-Premise
204	health	N	I-Premise
205	subscales	N	I-Premise
206	of	N	I-Premise
207	the	N	I-Premise
208	SF-36	N	I-Premise
209	were	N	I-Premise
210	significantly	N	I-Premise
211	lower	N	I-Premise
212	than	N	I-Premise
213	Canadian	N	I-Premise
214	normative	N	I-Premise
215	data	N	I-Premise
216	at	N	I-Premise
217	all	N	I-Premise
218	time	N	I-Premise
219	points	N	I-Premise
220	.	N	I-Premise

221	After	N	O
222	treatment	N	O
223	arm	N	O
224	was	N	O
225	controlled	N	O
226	for	N	O
227	,	N	O
228	MSTS	N	O
229	change	N	O
230	scores	N	O
231	were	N	O
232	predicted	N	O
233	by	N	O
234	a	N	O
235	lower-extremity	N	O
236	tumor	N	O
237	,	N	O
238	a	N	O
239	large	N	O
240	resection	N	O
241	specimen	N	O
242	,	N	O
243	and	N	O
244	motor	N	O
245	nerve	N	O
246	sacrifice	N	O
247	;	N	O
248	TESS	N	O
249	change	N	O
250	scores	N	O
251	were	N	O
252	predicted	N	O
253	by	N	O
254	lower-extremity	N	O
255	tumor	N	O
256	and	N	O
257	prior	N	O
258	incomplete	N	O
259	excision	N	O
260	.	N	O

261	When	N	I-Premise
262	wound	N	I-Premise
263	complication	N	I-Premise
264	was	N	I-Premise
265	included	N	I-Premise
266	in	N	I-Premise
267	the	N	I-Premise
268	model	N	I-Premise
269	,	N	I-Premise
270	patients	N	I-Premise
271	with	N	I-Premise
272	complications	N	I-Premise
273	had	N	I-Premise
274	lower	N	I-Premise
275	MSTS	N	I-Premise
276	and	N	I-Premise
277	TESS	N	I-Premise
278	scores	N	I-Premise
279	in	N	I-Premise
280	the	N	I-Premise
281	first	N	I-Premise
282	2	N	I-Premise
283	years	N	I-Premise
284	after	N	I-Premise
285	treatment	N	I-Premise
286	.	N	I-Premise

287	The	N	I-Claim
288	timing	N	I-Claim
289	of	N	I-Claim
290	RT	N	I-Claim
291	has	N	I-Claim
292	minimal	N	I-Claim
293	impact	N	I-Claim
294	on	N	I-Claim
295	the	N	I-Claim
296	function	N	I-Claim
297	of	N	I-Claim
298	STS	N	I-Claim
299	patients	N	I-Claim
300	in	N	I-Claim
301	the	N	I-Claim
302	first	N	I-Claim
303	year	N	I-Claim
304	after	N	I-Claim
305	surgery	N	I-Claim
306	.	N	O

307	Tumor	N	I-Claim
308	characteristics	N	I-Claim
309	and	N	I-Claim
310	wound	N	I-Claim
311	complications	N	I-Claim
312	have	N	I-Claim
313	a	N	I-Claim
314	detrimental	N	I-Claim
315	effect	N	I-Claim
316	on	N	I-Claim
317	patient	N	I-Claim
318	function	N	I-Claim
319	.	N	I-Claim

1	The	N	O
2	standard	N	O
3	doublet	N	O
4	,	N	O
5	vinorelbine-cisplatin	N	O
6	,	N	O
7	was	N	O
8	compared	N	O
9	with	N	O
10	a	N	O
11	triplet	N	O
12	of	N	O
13	vinorelbine-ifosfamide-cisplatin	N	O
14	,	N	O
15	in	N	O
16	terms	N	O
17	of	N	O
18	survival	N	O
19	,	N	O
20	in	N	O
21	patients	N	O
22	with	N	O
23	advanced	N	O
24	non-small-cell	N	O
25	lung	N	O
26	cancer	N	O
27	(	N	O
28	NSCLC	N	O
29	)	N	O
30	.	N	O

31	From	N	O
32	February	N	O
33	1998	N	O
34	to	N	O
35	June	N	O
36	1999	N	O
37	,	N	O
38	259	N	O
39	chemonave	N	O
40	patients	N	O
41	entered	N	O
42	the	N	O
43	study	N	O
44	and	N	O
45	were	N	O
46	randomised	N	O
47	to	N	O
48	receive	N	O
49	either	N	O
50	vinorelbine-cisplatin	N	O
51	(	N	O
52	NP	N	O
53	;	N	O
54	vinorelbine	N	O
55	30	N	O
56	mg/m	N	O
57	(	N	O
58	2	N	O
59	)	N	O
60	on	N	O
61	days	N	O
62	1	N	O
63	,	N	O
64	8	N	O
65	and	N	O
66	15	N	O
67	with	N	O
68	cisplatin	N	O
69	80	N	O
70	mg/m	N	O
71	(	N	O
72	2	N	O
73	)	N	O
74	on	N	O
75	day	N	O
76	1	N	O
77	)	N	O
78	or	N	O
79	vinorelbine-ifosfamide-cisplatin	N	O
80	(	N	O
81	NIP	N	O
82	;	N	O
83	vinorelbine	N	O
84	25	N	O
85	mg/m	N	O
86	(	N	O
87	2	N	O
88	)	N	O
89	on	N	O
90	days	N	O
91	1	N	O
92	and	N	O
93	8	N	O
94	,	N	O
95	ifosfamide	N	O
96	3	N	O
97	g/m	N	O
98	(	N	O
99	2	N	O
100	)	N	O
101	on	N	O
102	day	N	O
103	1	N	O
104	and	N	O
105	cisplatin	N	O
106	75	N	O
107	mg/m	N	O
108	(	N	O
109	2	N	O
110	)	N	O
111	on	N	O
112	day	N	O
113	1	N	O
114	)	N	O
115	,	N	O
116	with	N	O
117	both	N	O
118	regimens	N	O
119	being	N	O
120	repeated	N	O
121	every	N	O
122	3	N	O
123	weeks	N	O
124	.	N	O

125	All	N	O
126	patients	N	O
127	had	N	O
128	stage	N	O
129	IV	N	O
130	or	N	O
131	relapsed	N	O
132	disease	N	O
133	and	N	O
134	a	N	O
135	performance	N	O
136	score	N	O
137	of	N	O
138	0	N	O
139	or	N	O
140	1	N	O
141	.	N	O

142	The	N	I-Premise
143	overall	N	I-Premise
144	response	N	I-Premise
145	rate	N	I-Premise
146	was	N	I-Premise
147	34.6	N	I-Premise
148	%	N	I-Premise
149	for	N	I-Premise
150	NP	N	I-Premise
151	and	N	I-Premise
152	35.7	N	I-Premise
153	%	N	I-Premise
154	for	N	I-Premise
155	NIP	N	I-Premise
156	.	N	I-Premise

157	Median	N	I-Premise
158	and	N	I-Premise
159	1-year	N	I-Premise
160	survival	N	I-Premise
161	rates	N	I-Premise
162	were	N	I-Premise
163	10.0	N	I-Premise
164	months	N	I-Premise
165	and	N	I-Premise
166	38.4	N	I-Premise
167	%	N	I-Premise
168	for	N	I-Premise
169	NP	N	I-Premise
170	,	N	I-Premise
171	and	N	I-Premise
172	8.2	N	I-Premise
173	months	N	I-Premise
174	and	N	I-Premise
175	33.7	N	I-Premise
176	%	N	I-Premise
177	for	N	I-Premise
178	NIP	N	I-Premise
179	,	N	I-Premise
180	respectively	N	I-Premise
181	.	N	I-Premise

182	A	N	O
183	median	N	O
184	of	N	O
185	four	N	O
186	cycles	N	O
187	was	N	O
188	administered	N	O
189	in	N	O
190	each	N	O
191	arm	N	O
192	.	N	O

193	The	N	I-Premise
194	major	N	I-Premise
195	World	N	I-Premise
196	Health	N	I-Premise
197	Organization	N	I-Premise
198	grade	N	I-Premise
199	3-4	N	I-Premise
200	toxicities	N	I-Premise
201	for	N	I-Premise
202	NP	N	I-Premise
203	and	N	I-Premise
204	NIP	N	I-Premise
205	,	N	I-Premise
206	respectively	N	I-Premise
207	,	N	I-Premise
208	were	N	I-Premise
209	:	N	I-Premise
210	neutropenia	N	I-Premise
211	(	N	I-Premise
212	20.3	N	I-Premise
213	%	N	I-Premise
214	compared	N	I-Premise
215	with	N	I-Premise
216	9	N	I-Premise
217	%	N	I-Premise
218	of	N	I-Premise
219	cycles	N	I-Premise
220	)	N	I-Premise
221	,	N	I-Premise
222	anaemia	N	I-Premise
223	(	N	I-Premise
224	4.1	N	I-Premise
225	%	N	I-Premise
226	compared	N	I-Premise
227	with	N	I-Premise
228	5	N	I-Premise
229	%	N	I-Premise
230	of	N	I-Premise
231	cycles	N	I-Premise
232	)	N	I-Premise
233	,	N	I-Premise
234	nausea	N	I-Premise
235	and	N	I-Premise
236	vomiting	N	I-Premise
237	(	N	I-Premise
238	22.2	N	I-Premise
239	%	N	I-Premise
240	compared	N	I-Premise
241	with	N	I-Premise
242	19.4	N	I-Premise
243	%	N	I-Premise
244	of	N	I-Premise
245	patients	N	I-Premise
246	)	N	I-Premise
247	and	N	I-Premise
248	alopecia	N	I-Premise
249	(	N	I-Premise
250	5.6	N	I-Premise
251	%	N	I-Premise
252	compared	N	I-Premise
253	with	N	I-Premise
254	29.8	N	I-Premise
255	%	N	I-Premise
256	of	N	I-Premise
257	patients	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	Four	N	I-Premise
261	toxic	N	I-Premise
262	deaths	N	I-Premise
263	occurred	N	I-Premise
264	in	N	I-Premise
265	the	N	I-Premise
266	NP	N	I-Premise
267	arm	N	I-Premise
268	and	N	I-Premise
269	eight	N	I-Premise
270	in	N	I-Premise
271	the	N	I-Premise
272	NIP	N	I-Premise
273	arm	N	I-Premise
274	.	N	I-Premise

275	The	N	I-Premise
276	different	N	I-Premise
277	schedules	N	I-Premise
278	of	N	I-Premise
279	vinorelbine	N	I-Premise
280	in	N	I-Premise
281	the	N	I-Premise
282	two	N	I-Premise
283	arms	N	I-Premise
284	led	N	I-Premise
285	to	N	I-Premise
286	a	N	I-Premise
287	greater	N	I-Premise
288	survival	N	I-Premise
289	in	N	I-Premise
290	the	N	I-Premise
291	NP	N	I-Premise
292	arm	N	I-Premise
293	without	N	I-Premise
294	impairing	N	I-Premise
295	the	N	I-Premise
296	tolerance	N	I-Premise
297	profile	N	I-Premise
298	,	N	I-Premise
299	although	N	I-Premise
300	this	N	I-Premise
301	is	N	I-Premise
302	not	N	I-Premise
303	statistically	N	I-Premise
304	significant	N	I-Premise
305	.	N	I-Premise

306	This	N	I-Claim
307	confirms	N	I-Claim
308	that	N	I-Claim
309	the	N	I-Claim
310	two-drug	N	I-Claim
311	combination	N	I-Claim
312	NP	N	I-Claim
313	is	N	I-Claim
314	a	N	I-Claim
315	reference	N	I-Claim
316	treatment	N	I-Claim
317	for	N	I-Claim
318	metastatic	N	I-Claim
319	NSCLC	N	I-Claim
320	.	N	I-Claim

321	The	N	I-Claim
322	role	N	I-Claim
323	of	N	I-Claim
324	three-drug	N	I-Claim
325	combinations	N	I-Claim
326	remains	N	I-Claim
327	questionable	N	I-Claim
328	in	N	I-Claim
329	this	N	I-Claim
330	subset	N	I-Claim
331	of	N	I-Claim
332	patients	N	I-Claim
333	.	N	I-Claim

1	A	N	O
2	multicenter	N	O
3	trial	N	O
4	was	N	O
5	conducted	N	O
6	to	N	O
7	determine	N	O
8	the	N	O
9	efficacy	N	O
10	and	N	O
11	toxicity	N	O
12	of	N	O
13	escalating	N	O
14	dosages	N	O
15	of	N	O
16	liposomal	N	O
17	tretinoin	N	O
18	(	N	O
19	all-trans-retinoic	N	O
20	acid	N	O
21	)	N	O
22	administered	N	O
23	once	N	O
24	or	N	O
25	three	N	O
26	times	N	O
27	weekly	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	acquired	N	O
32	immunodeficiency	N	O
33	syndrome	N	O
34	(	N	O
35	AIDS	N	O
36	)	N	O
37	-associated	N	O
38	Kaposi	N	O
39	sarcoma	N	O
40	.	N	O

41	Seventy-six	N	O
42	patients	N	O
43	with	N	O
44	acquired	N	O
45	immunodeficiency	N	O
46	syndrome	N	O
47	(	N	O
48	AIDS	N	O
49	)	N	O
50	-associated	N	O
51	Kaposi	N	O
52	sarcoma	N	O
53	were	N	O
54	randomized	N	O
55	to	N	O
56	receive	N	O
57	the	N	O
58	study	N	O
59	drug	N	O
60	either	N	O
61	once	N	O
62	(	N	O
63	n	N	O
64	=	N	O
65	30	N	O
66	)	N	O
67	or	N	O
68	3	N	O
69	times	N	O
70	weekly	N	O
71	(	N	O
72	n	N	O
73	=	N	O
74	46	N	O
75	)	N	O
76	.	N	O

77	The	N	O
78	starting	N	O
79	dosage	N	O
80	was	N	O
81	60	N	O
82	mg/m	N	O
83	(	N	O
84	2	N	O
85	)	N	O
86	,	N	O
87	which	N	O
88	was	N	O
89	escalated	N	O
90	to	N	O
91	90	N	O
92	mg/m	N	O
93	(	N	O
94	2	N	O
95	)	N	O
96	and	N	O
97	then	N	O
98	120	N	O
99	mg/m	N	O
100	(	N	O
101	2	N	O
102	)	N	O
103	if	N	O
104	the	N	O
105	drug	N	O
106	was	N	O
107	well	N	O
108	tolerated	N	O
109	(	N	O
110	<	N	O
111	or=	N	O
112	Grade	N	O
113	2	N	O
114	toxicities	N	O
115	[	N	O
116	according	N	O
117	to	N	O
118	the	N	O
119	Southwest	N	O
120	Oncology	N	O
121	Group	N	O
122	toxicity	N	O
123	scale	N	O
124	]	N	O
125	)	N	O
126	.	N	O

127	Four	N	O
128	weeks	N	O
129	of	N	O
130	therapy	N	O
131	constituted	N	O
132	1	N	O
133	cycle	N	O
134	;	N	O
135	patients	N	O
136	could	N	O
137	receive	N	O
138	up	N	O
139	to	N	O
140	8	N	O
141	cycles	N	O
142	and	N	O
143	those	N	O
144	who	N	O
145	completed	N	O
146	8	N	O
147	cycles	N	O
148	were	N	O
149	given	N	O
150	the	N	O
151	option	N	O
152	of	N	O
153	receiving	N	O
154	extended	N	O
155	therapy	N	O
156	.	N	O

157	Clinical	N	O
158	response	N	O
159	was	N	O
160	defined	N	O
161	as	N	O
162	complete	N	O
163	response	N	O
164	(	N	O
165	CR	N	O
166	)	N	O
167	,	N	O
168	partial	N	O
169	response	N	O
170	(	N	O
171	PR	N	O
172	)	N	O
173	,	N	O
174	or	N	O
175	stable	N	O
176	disease	N	O
177	(	N	O
178	SD	N	O
179	)	N	O
180	.	N	O

181	Efficacy	N	O
182	was	N	O
183	assessed	N	O
184	after	N	O
185	the	N	O
186	completion	N	O
187	of	N	O
188	3	N	O
189	treatment	N	O
190	cycles	N	O
191	;	N	O
192	28.9	N	O
193	%	N	O
194	of	N	O
195	patients	N	O
196	(	N	O
197	22	N	O
198	of	N	O
199	76	N	O
200	patients	N	O
201	)	N	O
202	responded	N	O
203	(	N	O
204	no	N	O
205	CRs	N	O
206	,	N	O
207	1	N	O
208	PR	N	O
209	,	N	O
210	and	N	O
211	21	N	O
212	SDs	N	O
213	)	N	O
214	.	N	O

215	Among	N	I-Premise
216	the	N	I-Premise
217	patients	N	I-Premise
218	receiving	N	I-Premise
219	treatment	N	I-Premise
220	3	N	I-Premise
221	times	N	I-Premise
222	weekly	N	I-Premise
223	,	N	I-Premise
224	16	N	I-Premise
225	of	N	I-Premise
226	49	N	I-Premise
227	patients	N	I-Premise
228	(	N	I-Premise
229	32.7	N	I-Premise
230	%	N	I-Premise
231	)	N	I-Premise
232	achieved	N	I-Premise
233	a	N	I-Premise
234	clinical	N	I-Premise
235	response	N	I-Premise
236	at	N	I-Premise
237	the	N	I-Premise
238	end	N	I-Premise
239	of	N	I-Premise
240	the	N	I-Premise
241	third	N	I-Premise
242	treatment	N	I-Premise
243	cycle	N	I-Premise
244	(	N	I-Premise
245	no	N	I-Premise
246	CRs	N	I-Premise
247	,	N	I-Premise
248	1	N	I-Premise
249	PR	N	I-Premise
250	,	N	I-Premise
251	and	N	I-Premise
252	15	N	I-Premise
253	SDs	N	I-Premise
254	)	N	I-Premise
255	.	N	I-Premise

256	Concomitant	N	I-Premise
257	or	N	I-Premise
258	prior	N	I-Premise
259	use	N	I-Premise
260	of	N	I-Premise
261	protease	N	I-Premise
262	inhibitors	N	I-Premise
263	did	N	I-Premise
264	not	N	I-Premise
265	appear	N	I-Premise
266	to	N	I-Premise
267	affect	N	I-Premise
268	the	N	I-Premise
269	patient	N	I-Premise
270	's	N	I-Premise
271	response	N	I-Premise
272	to	N	I-Premise
273	treatment	N	I-Premise
274	(	N	I-Premise
275	P	N	I-Premise
276	=	N	I-Premise
277	0.183	N	I-Premise
278	)	N	I-Premise
279	.	N	I-Premise

280	Liposomal	N	I-Premise
281	tretinoin	N	I-Premise
282	is	N	I-Premise
283	a	N	I-Premise
284	new	N	I-Premise
285	therapeutic	N	I-Premise
286	agent	N	I-Premise
287	that	N	I-Premise
288	has	N	I-Premise
289	been	N	I-Premise
290	reported	N	I-Premise
291	to	N	I-Premise
292	have	N	I-Premise
293	some	N	I-Premise
294	clinical	N	I-Premise
295	activity	N	I-Premise
296	in	N	I-Premise
297	patients	N	I-Premise
298	with	N	I-Premise
299	AIDS-associated	N	I-Premise
300	Kaposi	N	I-Premise
301	sarcoma	N	I-Premise
302	.	N	I-Premise

303	A	N	I-Claim
304	three-times-per-week	N	I-Claim
305	dosing	N	I-Claim
306	schedule	N	I-Claim
307	was	N	I-Claim
308	noted	N	I-Claim
309	to	N	I-Claim
310	be	N	I-Claim
311	more	N	I-Claim
312	effective	N	I-Claim
313	compared	N	I-Claim
314	with	N	I-Claim
315	a	N	I-Claim
316	once-a-week	N	I-Claim
317	schedule	N	I-Claim
318	without	N	I-Claim
319	any	N	I-Claim
320	significant	N	I-Claim
321	difference	N	I-Claim
322	in	N	I-Claim
323	toxicity	N	I-Claim
324	reported	N	I-Claim
325	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	in	N	O
4	a	N	O
5	phase	N	O
6	III	N	O
7	study	N	O
8	the	N	O
9	safety	N	O
10	and	N	O
11	efficacy	N	O
12	of	N	O
13	fludarabine	N	O
14	to	N	O
15	that	N	O
16	of	N	O
17	cyclophosphamide	N	O
18	,	N	O
19	vincristine	N	O
20	,	N	O
21	and	N	O
22	prednisone	N	O
23	(	N	O
24	CVP	N	O
25	)	N	O
26	in	N	O
27	recurrent	N	O
28	,	N	O
29	low-grade	N	O
30	,	N	O
31	non-Hodgkin	N	O
32	's	N	O
33	lymphoma	N	O
34	after	N	O
35	previous	N	O
36	response	N	O
37	to	N	O
38	systemic	N	O
39	treatment	N	O
40	.	N	O

41	Patients	N	O
42	were	N	O
43	randomized	N	O
44	to	N	O
45	fludarabine	N	O
46	(	N	O
47	25	N	O
48	mg/m	N	O
49	(	N	O
50	2	N	O
51	)	N	O
52	intravenously	N	O
53	on	N	O
54	days	N	O
55	1	N	O
56	to	N	O
57	5	N	O
58	,	N	O
59	every	N	O
60	28	N	O
61	days	N	O
62	)	N	O
63	or	N	O
64	CVP	N	O
65	(	N	O
66	cyclophosphamide	N	O
67	750	N	O
68	mg/m	N	O
69	(	N	O
70	2	N	O
71	)	N	O
72	and	N	O
73	vincristine	N	O
74	1.2	N	O
75	mg/m	N	O
76	(	N	O
77	2	N	O
78	)	N	O
79	both	N	O
80	intravenously	N	O
81	on	N	O
82	day	N	O
83	1	N	O
84	and	N	O
85	prednisone	N	O
86	40	N	O
87	mg/m	N	O
88	(	N	O
89	2	N	O
90	)	N	O
91	orally	N	O
92	on	N	O
93	days	N	O
94	1	N	O
95	to	N	O
96	5	N	O
97	,	N	O
98	every	N	O
99	21	N	O
100	days	N	O
101	)	N	O
102	.	N	O

103	The	N	O
104	primary	N	O
105	outcome	N	O
106	assessed	N	O
107	was	N	O
108	progression-free	N	O
109	survival	N	O
110	(	N	O
111	PFS	N	O
112	)	N	O
113	;	N	O
114	secondary	N	O
115	outcomes	N	O
116	included	N	O
117	treatment-free	N	O
118	survival	N	O
119	(	N	O
120	TFS	N	O
121	)	N	O
122	,	N	O
123	overall	N	O
124	survival	N	O
125	(	N	O
126	OS	N	O
127	)	N	O
128	,	N	O
129	treatment-related	N	O
130	toxicity	N	O
131	,	N	O
132	and	N	O
133	quality	N	O
134	of	N	O
135	life	N	O
136	(	N	O
137	QoL	N	O
138	)	N	O
139	according	N	O
140	to	N	O
141	the	N	O
142	European	N	O
143	Organization	N	O
144	for	N	O
145	Research	N	O
146	and	N	O
147	Treatment	N	O
148	of	N	O
149	Cancer	N	O
150	's	N	O
151	Quality	N	O
152	of	N	O
153	Life	N	O
154	Questionnaire	N	O
155	C-30	N	O
156	version	N	O
157	1.0	N	O
158	instrument	N	O
159	.	N	O

160	Ninety-one	N	O
161	patients	N	O
162	were	N	O
163	randomized	N	O
164	,	N	O
165	47	N	O
166	to	N	O
167	fludarabine	N	O
168	and	N	O
169	44	N	O
170	to	N	O
171	CVP	N	O
172	.	N	O

173	There	N	I-Premise
174	was	N	I-Premise
175	no	N	I-Premise
176	difference	N	I-Premise
177	in	N	I-Premise
178	response	N	I-Premise
179	rates	N	I-Premise
180	,	N	I-Premise
181	with	N	I-Premise
182	64	N	I-Premise
183	%	N	I-Premise
184	(	N	I-Premise
185	complete	N	I-Premise
186	response	N	I-Premise
187	[	N	I-Premise
188	CR	N	I-Premise
189	]	N	I-Premise
190	,	N	I-Premise
191	9	N	I-Premise
192	%	N	I-Premise
193	)	N	I-Premise
194	for	N	I-Premise
195	fludarabine	N	I-Premise
196	versus	N	I-Premise
197	52	N	I-Premise
198	%	N	I-Premise
199	(	N	I-Premise
200	CR	N	I-Premise
201	,	N	I-Premise
202	7	N	I-Premise
203	%	N	I-Premise
204	)	N	I-Premise
205	for	N	I-Premise
206	CVP	N	I-Premise
207	(	N	I-Premise
208	P	N	I-Premise
209	=.72	N	I-Premise
210	)	N	I-Premise
211	.	N	I-Premise

212	With	N	I-Premise
213	a	N	I-Premise
214	median	N	I-Premise
215	follow-up	N	I-Premise
216	of	N	I-Premise
217	42	N	I-Premise
218	months	N	I-Premise
219	,	N	I-Premise
220	median	N	I-Premise
221	PFS	N	I-Premise
222	(	N	I-Premise
223	11	N	I-Premise
224	months	N	I-Premise
225	v	N	I-Premise
226	9.1	N	I-Premise
227	months	N	I-Premise
228	;	N	I-Premise
229	P	N	I-Premise
230	=.03	N	I-Premise
231	)	N	I-Premise
232	and	N	I-Premise
233	TFS	N	I-Premise
234	(	N	I-Premise
235	15	N	I-Premise
236	months	N	I-Premise
237	v	N	I-Premise
238	11	N	I-Premise
239	months	N	I-Premise
240	;	N	I-Premise
241	P	N	I-Premise
242	=.02	N	I-Premise
243	)	N	I-Premise
244	were	N	I-Premise
245	superior	N	I-Premise
246	in	N	I-Premise
247	patients	N	I-Premise
248	receiving	N	I-Premise
249	fludarabine	N	I-Premise
250	.	N	I-Premise

251	No	N	I-Premise
252	difference	N	I-Premise
253	in	N	I-Premise
254	median	N	I-Premise
255	overall	N	I-Premise
256	survival	N	I-Premise
257	was	N	I-Premise
258	detected	N	I-Premise
259	(	N	I-Premise
260	57	N	I-Premise
261	months	N	I-Premise
262	for	N	I-Premise
263	fludarabine	N	I-Premise
264	v	N	I-Premise
265	44	N	I-Premise
266	months	N	I-Premise
267	for	N	I-Premise
268	CVP	N	I-Premise
269	;	N	I-Premise
270	P	N	I-Premise
271	=.95	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	Three	N	I-Premise
275	patients	N	I-Premise
276	receiving	N	I-Premise
277	fludarabine	N	I-Premise
278	died	N	I-Premise
279	of	N	I-Premise
280	treatment-related	N	I-Premise
281	toxicity	N	I-Premise
282	compared	N	I-Premise
283	with	N	I-Premise
284	none	N	I-Premise
285	of	N	I-Premise
286	the	N	I-Premise
287	patients	N	I-Premise
288	receiving	N	I-Premise
289	CVP	N	I-Premise
290	.	N	I-Premise

291	Peripheral	N	I-Premise
292	neuropathy	N	I-Premise
293	and	N	I-Premise
294	alopecia	N	I-Premise
295	were	N	I-Premise
296	more	N	I-Premise
297	common	N	I-Premise
298	with	N	I-Premise
299	CVP	N	I-Premise
300	.	N	I-Premise

301	Patients	N	I-Premise
302	receiving	N	I-Premise
303	fludarabine	N	I-Premise
304	had	N	I-Premise
305	higher	N	I-Premise
306	scores	N	I-Premise
307	for	N	I-Premise
308	social	N	I-Premise
309	function	N	I-Premise
310	(	N	I-Premise
311	P	N	I-Premise
312	=.008	N	I-Premise
313	)	N	I-Premise
314	;	N	I-Premise
315	no	N	I-Premise
316	other	N	I-Premise
317	differences	N	I-Premise
318	in	N	I-Premise
319	QoL	N	I-Premise
320	were	N	I-Premise
321	detected	N	I-Premise
322	.	N	I-Premise

323	In	N	I-Claim
324	recurrent	N	I-Claim
325	low-grade	N	I-Claim
326	lymphoma	N	I-Claim
327	,	N	I-Claim
328	fludarabine	N	I-Claim
329	improves	N	I-Claim
330	PFS	N	I-Claim
331	,	N	I-Claim
332	TFS	N	I-Claim
333	,	N	I-Claim
334	and	N	I-Claim
335	social	N	I-Claim
336	function	N	I-Claim
337	scores	N	I-Claim
338	in	N	I-Claim
339	comparison	N	I-Claim
340	with	N	I-Claim
341	CVP	N	I-Claim
342	but	N	I-Claim
343	does	N	I-Claim
344	not	N	I-Claim
345	improve	N	I-Claim
346	OS	N	I-Claim
347	.	N	I-Claim

1	Anemia	N	I-Claim
2	,	N	I-Claim
3	highly	N	I-Claim
4	common	N	I-Claim
5	among	N	I-Claim
6	cancer	N	I-Claim
7	patients	N	I-Claim
8	,	N	I-Claim
9	is	N	I-Claim
10	often	N	I-Claim
11	an	N	I-Claim
12	underlying	N	I-Claim
13	cause	N	I-Claim
14	of	N	I-Claim
15	cancer-related	N	I-Claim
16	fatigue	N	I-Claim
17	and	N	I-Claim
18	other	N	I-Claim
19	quality-of-life	N	I-Claim
20	(	N	I-Claim
21	QOL	N	I-Claim
22	)	N	I-Claim
23	deficits	N	I-Claim
24	.	N	I-Claim

25	Although	N	O
26	randomized	N	O
27	clinical	N	O
28	trials	N	O
29	have	N	O
30	shown	N	O
31	that	N	O
32	treatment	N	O
33	with	N	O
34	epoetin	N	O
35	alfa	N	O
36	increases	N	O
37	hemoglobin	N	O
38	levels	N	O
39	,	N	O
40	reduces	N	O
41	fatigue	N	O
42	,	N	O
43	lessens	N	O
44	transfusion	N	O
45	requirements	N	O
46	,	N	O
47	and	N	O
48	improves	N	O
49	overall	N	O
50	QOL	N	O
51	,	N	O
52	cancer-related	N	O
53	anemia	N	O
54	and	N	O
55	fatigue	N	O
56	remain	N	O
57	undertreated	N	O
58	.	N	O

59	This	N	O
60	is	N	O
61	,	N	O
62	in	N	O
63	part	N	O
64	,	N	O
65	because	N	O
66	scales	N	O
67	and	N	O
68	measures	N	O
69	of	N	O
70	QOL	N	O
71	are	N	O
72	still	N	O
73	relatively	N	O
74	unfamiliar	N	O
75	to	N	O
76	most	N	O
77	clinicians	N	O
78	and	N	O
79	because	N	O
80	population-based	N	O
81	reference	N	O
82	ranges	N	O
83	are	N	O
84	lacking	N	O
85	,	N	O
86	thus	N	O
87	making	N	O
88	clinical	N	O
89	trial	N	O
90	results	N	O
91	difficult	N	O
92	to	N	O
93	interpret	N	O
94	.	N	O

95	To	N	O
96	aid	N	O
97	in	N	O
98	the	N	O
99	interpretation	N	O
100	of	N	O
101	QOL	N	O
102	results	N	O
103	from	N	O
104	clinical	N	O
105	trials	N	O
106	,	N	O
107	we	N	O
108	administered	N	O
109	the	N	O
110	Functional	N	O
111	Assessment	N	O
112	of	N	O
113	Cancer	N	O
114	Therapy-Anemia	N	O
115	(	N	O
116	FACT-An	N	O
117	)	N	O
118	QOL	N	O
119	instrument	N	O
120	to	N	O
121	a	N	O
122	nationally	N	O
123	representative	N	O
124	sample	N	O
125	of	N	O
126	1,400	N	O
127	people	N	O
128	using	N	O
129	an	N	O
130	Internet	N	O
131	survey	N	O
132	panel	N	O
133	in	N	O
134	the	N	O
135	United	N	O
136	States	N	O
137	.	N	O

138	We	N	O
139	then	N	O
140	compared	N	O
141	the	N	O
142	FACT-An	N	O
143	data	N	O
144	from	N	O
145	the	N	O
146	Internet	N	O
147	survey	N	O
148	with	N	O
149	the	N	O
150	QOL	N	O
151	data	N	O
152	of	N	O
153	a	N	O
154	375-patient	N	O
155	randomized	N	O
156	,	N	O
157	double-blind	N	O
158	clinical	N	O
159	trial	N	O
160	evaluating	N	O
161	epoetin	N	O
162	alfa	N	O
163	versus	N	O
164	placebo	N	O
165	in	N	O
166	anemic	N	O
167	cancer	N	O
168	patients	N	O
169	.	N	O

170	FACT-An	N	O
171	,	N	O
172	as	N	O
173	administered	N	O
174	to	N	O
175	the	N	O
176	survey	N	O
177	population	N	O
178	,	N	O
179	displayed	N	O
180	good	N	O
181	psychometric	N	O
182	properties	N	O
183	and	N	O
184	was	N	O
185	able	N	O
186	to	N	O
187	discriminate	N	O
188	between	N	O
189	respondents	N	O
190	with	N	O
191	histories	N	O
192	of	N	O
193	specified	N	O
194	illnesses	N	O
195	,	N	O
196	including	N	O
197	anemia	N	O
198	and	N	O
199	cancer	N	O
200	,	N	O
201	and	N	O
202	those	N	O
203	without	N	O
204	.	N	O

205	Comparison	N	I-Premise
206	of	N	I-Premise
207	the	N	I-Premise
208	population	N	I-Premise
209	norm	N	I-Premise
210	and	N	I-Premise
211	clinical	N	I-Premise
212	trial	N	I-Premise
213	data	N	I-Premise
214	showed	N	I-Premise
215	that	N	I-Premise
216	treatment	N	I-Premise
217	with	N	I-Premise
218	epoetin	N	I-Premise
219	alfa	N	I-Premise
220	resulted	N	I-Premise
221	in	N	I-Premise
222	clinically	N	I-Premise
223	meaningful	N	I-Premise
224	as	N	I-Premise
225	well	N	I-Premise
226	as	N	I-Premise
227	statistically	N	I-Premise
228	significant	N	I-Premise
229	improvements	N	I-Premise
230	in	N	I-Premise
231	QOL	N	I-Premise
232	(	N	I-Premise
233	P	N	I-Premise
234	<	N	I-Premise
235	.01	N	I-Premise
236	)	N	I-Premise
237	.	N	I-Premise

238	Reliable	N	O
239	population	N	O
240	norm	N	O
241	data	N	O
242	are	N	O
243	now	N	O
244	available	N	O
245	to	N	O
246	aid	N	O
247	in	N	O
248	the	N	O
249	interpretation	N	O
250	of	N	O
251	clinical	N	O
252	trial	N	O
253	results	N	O
254	where	N	O
255	the	N	O
256	FACT-An	N	O
257	questionnaire	N	O
258	is	N	O
259	administered	N	O
260	.	N	O

261	In	N	I-Claim
262	the	N	I-Claim
263	clinical	N	I-Claim
264	trial	N	I-Claim
265	,	N	I-Claim
266	treatment	N	I-Claim
267	with	N	I-Claim
268	epoetin	N	I-Claim
269	alfa	N	I-Claim
270	overcame	N	I-Claim
271	much	N	I-Claim
272	of	N	I-Claim
273	the	N	I-Claim
274	QOL	N	I-Claim
275	deficit	N	I-Claim
276	seen	N	I-Claim
277	in	N	I-Claim
278	anemic	N	I-Claim
279	cancer	N	I-Claim
280	patients	N	I-Claim
281	compared	N	I-Claim
282	with	N	I-Claim
283	the	N	I-Claim
284	norm	N	I-Claim
285	population	N	I-Claim
286	sample	N	I-Claim
287	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	a	N	O
7	progressive	N	O
8	upper-body	N	O
9	exercise	N	O
10	program	N	O
11	on	N	O
12	lymphedema	N	O
13	secondary	N	O
14	to	N	O
15	breast	N	O
16	cancer	N	O
17	treatment	N	O
18	.	N	O

19	Fourteen	N	O
20	breast	N	O
21	cancer	N	O
22	survivors	N	O
23	with	N	O
24	unilateral	N	O
25	upper	N	O
26	extremity	N	O
27	lymphedema	N	O
28	were	N	O
29	randomly	N	O
30	assigned	N	O
31	to	N	O
32	an	N	O
33	exercise	N	O
34	(	N	O
35	n	N	O
36	=	N	O
37	7	N	O
38	)	N	O
39	or	N	O
40	control	N	O
41	group	N	O
42	(	N	O
43	n	N	O
44	=	N	O
45	7	N	O
46	)	N	O
47	.	N	O

48	The	N	O
49	exercise	N	O
50	group	N	O
51	followed	N	O
52	a	N	O
53	progressive	N	O
54	,	N	O
55	8-week	N	O
56	upper-body	N	O
57	exercise	N	O
58	program	N	O
59	consisting	N	O
60	of	N	O
61	resistance	N	O
62	training	N	O
63	plus	N	O
64	aerobic	N	O
65	exercise	N	O
66	using	N	O
67	a	N	O
68	Monark	N	O
69	Rehab	N	O
70	Trainer	N	O
71	arm	N	O
72	ergometer	N	O
73	.	N	O

74	Lymphedema	N	O
75	was	N	O
76	assessed	N	O
77	by	N	O
78	arm	N	O
79	circumference	N	O
80	and	N	O
81	measurement	N	O
82	of	N	O
83	arm	N	O
84	volume	N	O
85	by	N	O
86	water	N	O
87	displacement	N	O
88	.	N	O

89	Patients	N	O
90	were	N	O
91	evaluated	N	O
92	on	N	O
93	five	N	O
94	occasions	N	O
95	over	N	O
96	the	N	O
97	experimental	N	O
98	period	N	O
99	.	N	O

100	The	N	O
101	Medical	N	O
102	Outcomes	N	O
103	Trust	N	O
104	Short-Form	N	O
105	36	N	O
106	Survey	N	O
107	was	N	O
108	used	N	O
109	to	N	O
110	measure	N	O
111	quality	N	O
112	of	N	O
113	life	N	O
114	before	N	O
115	and	N	O
116	after	N	O
117	the	N	O
118	intervention	N	O
119	.	N	O

120	Significance	N	O
121	was	N	O
122	set	N	O
123	at	N	O
124	alpha	N	O
125	<	N	O
126	or	N	O
127	=	N	O
128	0.01	N	O
129	.	N	O

130	No	N	I-Premise
131	changes	N	I-Premise
132	were	N	I-Premise
133	found	N	I-Premise
134	in	N	I-Premise
135	arm	N	I-Premise
136	circumference	N	I-Premise
137	or	N	I-Premise
138	arm	N	I-Premise
139	volume	N	I-Premise
140	as	N	I-Premise
141	a	N	I-Premise
142	result	N	I-Premise
143	of	N	I-Premise
144	the	N	I-Premise
145	exercise	N	I-Premise
146	program	N	I-Premise
147	.	N	I-Premise

148	Three	N	I-Premise
149	of	N	I-Premise
150	the	N	I-Premise
151	quality-of-life	N	I-Premise
152	domains	N	I-Premise
153	showed	N	I-Premise
154	trends	N	I-Premise
155	toward	N	I-Premise
156	increases	N	I-Premise
157	in	N	I-Premise
158	the	N	I-Premise
159	exercise	N	I-Premise
160	group	N	I-Premise
161	:	N	I-Premise
162	physical	N	I-Premise
163	functioning	N	I-Premise
164	(	N	I-Premise
165	P	N	I-Premise
166	=.050	N	I-Premise
167	)	N	I-Premise
168	,	N	I-Premise
169	general	N	I-Premise
170	health	N	I-Premise
171	(	N	I-Premise
172	P	N	I-Premise
173	=.048	N	I-Premise
174	)	N	I-Premise
175	,	N	I-Premise
176	and	N	I-Premise
177	vitality	N	I-Premise
178	(	N	I-Premise
179	P	N	I-Premise
180	=.023	N	I-Premise
181	)	N	I-Premise
182	.	N	I-Premise

183	Mental	N	I-Premise
184	health	N	I-Premise
185	increased	N	I-Premise
186	,	N	I-Premise
187	although	N	I-Premise
188	not	N	I-Premise
189	significantly	N	I-Premise
190	,	N	I-Premise
191	for	N	I-Premise
192	all	N	I-Premise
193	subjects	N	I-Premise
194	(	N	I-Premise
195	P	N	I-Premise
196	=.019	N	I-Premise
197	)	N	I-Premise
198	.	N	I-Premise

199	Arm	N	I-Premise
200	volume	N	I-Premise
201	measured	N	I-Premise
202	by	N	I-Premise
203	water	N	I-Premise
204	displacement	N	I-Premise
205	was	N	I-Premise
206	correlated	N	I-Premise
207	with	N	I-Premise
208	calculated	N	I-Premise
209	arm	N	I-Premise
210	volume	N	I-Premise
211	(	N	I-Premise
212	r	N	I-Premise
213	=.973	N	I-Premise
214	,	N	I-Premise
215	P	N	I-Premise
216	<	N	I-Premise
217	.001	N	I-Premise
218	)	N	I-Premise
219	,	N	I-Premise
220	although	N	I-Premise
221	the	N	I-Premise
222	exercise	N	I-Premise
223	and	N	I-Premise
224	control	N	I-Premise
225	group	N	I-Premise
226	means	N	I-Premise
227	were	N	I-Premise
228	significantly	N	I-Premise
229	different	N	I-Premise
230	(	N	I-Premise
231	P	N	I-Premise
232	<	N	I-Premise
233	.001	N	I-Premise
234	)	N	I-Premise
235	.	N	I-Premise

236	Participation	N	I-Claim
237	in	N	I-Claim
238	an	N	I-Claim
239	upper-body	N	I-Claim
240	exercise	N	I-Claim
241	program	N	I-Claim
242	caused	N	I-Claim
243	no	N	I-Claim
244	changes	N	I-Claim
245	in	N	I-Claim
246	arm	N	I-Claim
247	circumference	N	I-Claim
248	or	N	I-Claim
249	arm	N	I-Claim
250	volume	N	I-Claim
251	in	N	I-Claim
252	women	N	I-Claim
253	with	N	I-Claim
254	lymphedema	N	I-Claim
255	after	N	I-Claim
256	breast	N	I-Claim
257	cancer	N	I-Claim
258	,	N	I-Claim
259	and	N	I-Claim
260	they	N	I-Claim
261	may	N	I-Claim
262	have	N	I-Claim
263	experienced	N	I-Claim
264	an	N	I-Claim
265	increase	N	I-Claim
266	in	N	I-Claim
267	quality	N	I-Claim
268	of	N	I-Claim
269	life	N	I-Claim
270	.	N	I-Claim

271	Additional	N	I-Claim
272	studies	N	I-Claim
273	should	N	I-Claim
274	be	N	I-Claim
275	done	N	I-Claim
276	in	N	I-Claim
277	this	N	I-Claim
278	area	N	I-Claim
279	to	N	I-Claim
280	determine	N	I-Claim
281	the	N	I-Claim
282	optimum	N	I-Claim
283	training	N	I-Claim
284	program	N	I-Claim
285	.	N	I-Claim

1	Radiotherapy	N	I-Claim
2	is	N	I-Claim
3	an	N	I-Claim
4	effective	N	I-Claim
5	palliative	N	I-Claim
6	treatment	N	I-Claim
7	for	N	I-Claim
8	cancer	N	I-Claim
9	patients	N	I-Claim
10	with	N	I-Claim
11	painful	N	I-Claim
12	bone	N	I-Claim
13	metastases	N	I-Claim
14	.	N	I-Claim

15	Although	N	O
16	single-	N	O
17	and	N	O
18	multiple-fraction	N	O
19	radiotherapy	N	O
20	are	N	O
21	thought	N	O
22	to	N	O
23	provide	N	O
24	equal	N	O
25	palliation	N	O
26	,	N	O
27	which	N	O
28	treatment	N	O
29	schedule	N	O
30	provides	N	O
31	better	N	O
32	value	N	O
33	for	N	O
34	the	N	O
35	money	N	O
36	is	N	O
37	unknown	N	O
38	.	N	O

39	We	N	O
40	compared	N	O
41	quality-adjusted	N	O
42	life	N	O
43	expectancy	N	O
44	(	N	O
45	the	N	O
46	overall	N	O
47	valuation	N	O
48	of	N	O
49	the	N	O
50	health	N	O
51	of	N	O
52	the	N	O
53	patients	N	O
54	)	N	O
55	and	N	O
56	societal	N	O
57	costs	N	O
58	for	N	O
59	patients	N	O
60	receiving	N	O
61	either	N	O
62	single-	N	O
63	or	N	O
64	multiple-fraction	N	O
65	radiotherapy	N	O
66	.	N	O

67	A	N	O
68	societal	N	O
69	cost-utility	N	O
70	analysis	N	O
71	was	N	O
72	performed	N	O
73	on	N	O
74	a	N	O
75	Dutch	N	O
76	randomized	N	O
77	,	N	O
78	controlled	N	O
79	trial	N	O
80	of	N	O
81	1157	N	O
82	patients	N	O
83	with	N	O
84	painful	N	O
85	bone	N	O
86	metastases	N	O
87	that	N	O
88	compared	N	O
89	pain	N	O
90	responses	N	O
91	and	N	O
92	quality	N	O
93	of	N	O
94	life	N	O
95	from	N	O
96	a	N	O
97	single-fraction	N	O
98	treatment	N	O
99	schedule	N	O
100	of	N	O
101	8	N	O
102	Gy	N	O
103	with	N	O
104	a	N	O
105	treatment	N	O
106	schedule	N	O
107	of	N	O
108	six	N	O
109	fractions	N	O
110	of	N	O
111	4	N	O
112	Gy	N	O
113	each	N	O
114	.	N	O

115	The	N	O
116	societal	N	O
117	values	N	O
118	of	N	O
119	life	N	O
120	expectancies	N	O
121	were	N	O
122	assessed	N	O
123	with	N	O
124	the	N	O
125	EuroQol	N	O
126	classification	N	O
127	system	N	O
128	(	N	O
129	EQ-5D	N	O
130	)	N	O
131	questionnaire	N	O
132	.	N	O

133	A	N	O
134	subset	N	O
135	of	N	O
136	166	N	O
137	patients	N	O
138	also	N	O
139	answered	N	O
140	additional	N	O
141	questionnaires	N	O
142	to	N	O
143	estimate	N	O
144	nonradiotherapy	N	O
145	and	N	O
146	nonmedical	N	O
147	costs	N	O
148	.	N	O

149	Statistical	N	O
150	tests	N	O
151	were	N	O
152	two-sided	N	O
153	.	N	O

154	Comparing	N	I-Premise
155	the	N	I-Premise
156	single-	N	I-Premise
157	and	N	I-Premise
158	multiple-fraction	N	I-Premise
159	radiotherapy	N	I-Premise
160	schedules	N	I-Premise
161	,	N	I-Premise
162	no	N	I-Premise
163	differences	N	I-Premise
164	were	N	I-Premise
165	found	N	I-Premise
166	in	N	I-Premise
167	life	N	I-Premise
168	expectancy	N	I-Premise
169	(	N	I-Premise
170	43.0	N	I-Premise
171	versus	N	I-Premise
172	40.4	N	I-Premise
173	weeks	N	I-Premise
174	,	N	I-Premise
175	P	N	I-Premise
176	=.20	N	I-Premise
177	)	N	I-Premise
178	or	N	I-Premise
179	quality-adjusted	N	I-Premise
180	life	N	I-Premise
181	expectancy	N	I-Premise
182	(	N	I-Premise
183	17.7	N	I-Premise
184	versus	N	I-Premise
185	16.0	N	I-Premise
186	weeks	N	I-Premise
187	,	N	I-Premise
188	P	N	I-Premise
189	=.21	N	I-Premise
190	)	N	I-Premise
191	.	N	I-Premise

192	The	N	I-Premise
193	estimated	N	I-Premise
194	cost	N	I-Premise
195	of	N	I-Premise
196	radiotherapy	N	I-Premise
197	,	N	I-Premise
198	including	N	I-Premise
199	retreatments	N	I-Premise
200	and	N	I-Premise
201	nonmedical	N	I-Premise
202	costs	N	I-Premise
203	,	N	I-Premise
204	was	N	I-Premise
205	statistically	N	I-Premise
206	significantly	N	I-Premise
207	lower	N	I-Premise
208	for	N	I-Premise
209	the	N	I-Premise
210	single-fraction	N	I-Premise
211	schedule	N	I-Premise
212	than	N	I-Premise
213	for	N	I-Premise
214	the	N	I-Premise
215	multiple-fraction	N	I-Premise
216	schedule	N	I-Premise
217	(	N	I-Premise
218	$	N	I-Premise
219	2438	N	I-Premise
220	versus	N	I-Premise
221	$	N	I-Premise
222	3311	N	I-Premise
223	,	N	I-Premise
224	difference	N	I-Premise
225	=	N	I-Premise
226	$	N	I-Premise
227	873	N	I-Premise
228	,	N	I-Premise
229	95	N	I-Premise
230	%	N	I-Premise
231	confidence	N	I-Premise
232	interval	N	I-Premise
233	[	N	I-Premise
234	CI	N	I-Premise
235	]	N	I-Premise
236	on	N	I-Premise
237	the	N	I-Premise
238	difference	N	I-Premise
239	=	N	I-Premise
240	$	N	I-Premise
241	449	N	I-Premise
242	to	N	I-Premise
243	$	N	I-Premise
244	1297	N	I-Premise
245	;	N	I-Premise
246	P	N	I-Premise
247	<	N	I-Premise
248	.001	N	I-Premise
249	)	N	I-Premise
250	.	N	I-Premise

251	The	N	I-Premise
252	estimated	N	I-Premise
253	difference	N	I-Premise
254	in	N	I-Premise
255	total	N	I-Premise
256	societal	N	I-Premise
257	costs	N	I-Premise
258	was	N	I-Premise
259	larger	N	I-Premise
260	,	N	I-Premise
261	also	N	I-Premise
262	in	N	I-Premise
263	favor	N	I-Premise
264	of	N	I-Premise
265	the	N	I-Premise
266	single-fraction	N	I-Premise
267	schedule	N	I-Premise
268	,	N	I-Premise
269	but	N	I-Premise
270	it	N	I-Premise
271	was	N	I-Premise
272	not	N	I-Premise
273	statistically	N	I-Premise
274	significant	N	I-Premise
275	(	N	I-Premise
276	$	N	I-Premise
277	4700	N	I-Premise
278	versus	N	I-Premise
279	$	N	I-Premise
280	6453	N	I-Premise
281	,	N	I-Premise
282	difference	N	I-Premise
283	=	N	I-Premise
284	$	N	I-Premise
285	1753	N	I-Premise
286	,	N	I-Premise
287	95	N	I-Premise
288	%	N	I-Premise
289	CI	N	I-Premise
290	on	N	I-Premise
291	the	N	I-Premise
292	difference	N	I-Premise
293	=	N	I-Premise
294	-	N	I-Premise
295	$	N	I-Premise
296	99	N	I-Premise
297	to	N	I-Premise
298	$	N	I-Premise
299	3604	N	I-Premise
300	;	N	I-Premise
301	P	N	I-Premise
302	=.06	N	I-Premise
303	)	N	I-Premise
304	.	N	I-Premise

305	For	N	I-Premise
306	willingness-to-pay	N	I-Premise
307	between	N	I-Premise
308	$	N	I-Premise
309	5000	N	I-Premise
310	and	N	I-Premise
311	$	N	I-Premise
312	40	N	I-Premise
313	000	N	I-Premise
314	per	N	I-Premise
315	quality-adjusted	N	I-Premise
316	life	N	I-Premise
317	year	N	I-Premise
318	,	N	I-Premise
319	the	N	I-Premise
320	single-fraction	N	I-Premise
321	schedule	N	I-Premise
322	was	N	I-Premise
323	statistically	N	I-Premise
324	significantly	N	I-Premise
325	more	N	I-Premise
326	cost-effective	N	I-Premise
327	than	N	I-Premise
328	the	N	I-Premise
329	multiple-fraction	N	I-Premise
330	schedule	N	I-Premise
331	(	N	I-Premise
332	P	N	I-Premise
333	<	N	I-Premise
334	or	N	I-Premise
335	=.05	N	I-Premise
336	)	N	I-Premise
337	.	N	I-Premise

338	Compared	N	I-Claim
339	with	N	I-Claim
340	multiple-fraction	N	I-Claim
341	radiotherapy	N	I-Claim
342	,	N	I-Claim
343	single-fraction	N	I-Claim
344	radiotherapy	N	I-Claim
345	provides	N	I-Claim
346	equal	N	I-Claim
347	palliation	N	I-Claim
348	and	N	I-Claim
349	quality	N	I-Claim
350	of	N	I-Claim
351	life	N	I-Claim
352	and	N	I-Claim
353	has	N	I-Claim
354	lower	N	I-Claim
355	medical	N	I-Claim
356	and	N	I-Claim
357	societal	N	I-Claim
358	costs	N	I-Claim
359	,	N	I-Claim
360	at	N	I-Claim
361	least	N	I-Claim
362	in	N	I-Claim
363	The	N	I-Claim
364	Netherlands	N	I-Claim
365	.	N	I-Claim

366	Therefore	N	I-Claim
367	,	N	I-Claim
368	single-fraction	N	I-Claim
369	radiotherapy	N	I-Claim
370	should	N	I-Claim
371	be	N	I-Claim
372	considered	N	I-Claim
373	as	N	I-Claim
374	the	N	I-Claim
375	palliative	N	I-Claim
376	treatment	N	I-Claim
377	of	N	I-Claim
378	choice	N	I-Claim
379	for	N	I-Claim
380	cancer	N	I-Claim
381	patients	N	I-Claim
382	with	N	I-Claim
383	painful	N	I-Claim
384	bone	N	I-Claim
385	metastases	N	I-Claim
386	.	N	I-Claim

1	Randomized	N	I-Claim
2	trials	N	I-Claim
3	in	N	I-Claim
4	fluorouracil	N	I-Claim
5	(	N	I-Claim
6	FU	N	I-Claim
7	)	N	I-Claim
8	-refractory	N	I-Claim
9	colorectal	N	I-Claim
10	cancer	N	I-Claim
11	demonstrate	N	I-Claim
12	significant	N	I-Claim
13	survival	N	I-Claim
14	advantages	N	I-Claim
15	for	N	I-Claim
16	patients	N	I-Claim
17	receiving	N	I-Claim
18	irinotecan	N	I-Claim
19	.	N	I-Claim

20	We	N	O
21	prospectively	N	O
22	compared	N	O
23	the	N	O
24	efficacy	N	O
25	and	N	O
26	tolerability	N	O
27	of	N	O
28	two	N	O
29	irinotecan	N	O
30	regimens	N	O
31	(	N	O
32	once	N	O
33	a	N	O
34	week	N	O
35	for	N	O
36	4	N	O
37	weeks	N	O
38	followed	N	O
39	by	N	O
40	a	N	O
41	2-week	N	O
42	rest	N	O
43	period	N	O
44	[	N	O
45	weekly	N	O
46	]	N	O
47	v	N	O
48	once	N	O
49	every	N	O
50	3	N	O
51	weeks	N	O
52	)	N	O
53	in	N	O
54	such	N	O
55	patients	N	O
56	.	N	O

57	This	N	O
58	multicenter	N	O
59	,	N	O
60	open-label	N	O
61	,	N	O
62	phase	N	O
63	III	N	O
64	study	N	O
65	randomly	N	O
66	assigned	N	O
67	patients	N	O
68	in	N	O
69	a	N	O
70	1:2	N	O
71	ratio	N	O
72	to	N	O
73	irinotecan	N	O
74	given	N	O
75	either	N	O
76	weekly	N	O
77	(	N	O
78	125	N	O
79	mg/m	N	O
80	(	N	O
81	2	N	O
82	)	N	O
83	)	N	O
84	or	N	O
85	once	N	O
86	every	N	O
87	3	N	O
88	weeks	N	O
89	(	N	O
90	350	N	O
91	mg/m	N	O
92	(	N	O
93	2	N	O
94	)	N	O
95	,	N	O
96	or	N	O
97	300	N	O
98	mg/m	N	O
99	(	N	O
100	2	N	O
101	)	N	O
102	in	N	O
103	patients	N	O
104	who	N	O
105	were	N	O
106	>	N	O
107	/=	N	O
108	70	N	O
109	years	N	O
110	of	N	O
111	age	N	O
112	,	N	O
113	who	N	O
114	had	N	O
115	Eastern	N	O
116	Cooperative	N	O
117	Oncology	N	O
118	Group	N	O
119	performance	N	O
120	status	N	O
121	equal	N	O
122	to	N	O
123	2	N	O
124	,	N	O
125	or	N	O
126	who	N	O
127	had	N	O
128	prior	N	O
129	pelvic	N	O
130	irradiation	N	O
131	)	N	O
132	.	N	O

133	With	N	I-Premise
134	median	N	I-Premise
135	follow-up	N	I-Premise
136	of	N	I-Premise
137	15.8	N	I-Premise
138	months	N	I-Premise
139	,	N	I-Premise
140	there	N	I-Premise
141	was	N	I-Premise
142	no	N	I-Premise
143	significant	N	I-Premise
144	difference	N	I-Premise
145	in	N	I-Premise
146	1-year	N	I-Premise
147	survival	N	I-Premise
148	(	N	I-Premise
149	46	N	I-Premise
150	%	N	I-Premise
151	v	N	I-Premise
152	41	N	I-Premise
153	%	N	I-Premise
154	,	N	I-Premise
155	respectively	N	I-Premise
156	;	N	I-Premise
157	P	N	I-Premise
158	=.42	N	I-Premise
159	)	N	I-Premise
160	,	N	I-Premise
161	median	N	I-Premise
162	survival	N	I-Premise
163	(	N	I-Premise
164	9.9	N	I-Premise
165	v	N	I-Premise
166	9.9	N	I-Premise
167	months	N	I-Premise
168	,	N	I-Premise
169	respectively	N	I-Premise
170	;	N	I-Premise
171	P	N	I-Premise
172	=.43	N	I-Premise
173	)	N	I-Premise
174	,	N	I-Premise
175	or	N	I-Premise
176	median	N	I-Premise
177	time	N	I-Premise
178	to	N	I-Premise
179	progression	N	I-Premise
180	(	N	I-Premise
181	4.0	N	I-Premise
182	v	N	I-Premise
183	3.0	N	I-Premise
184	months	N	I-Premise
185	,	N	I-Premise
186	respectively	N	I-Premise
187	;	N	I-Premise
188	P	N	I-Premise
189	=.54	N	I-Premise
190	)	N	I-Premise
191	between	N	I-Premise
192	the	N	I-Premise
193	two	N	I-Premise
194	regimens	N	I-Premise
195	.	N	I-Premise

196	Grade	N	I-Premise
197	3/4	N	I-Premise
198	diarrhea	N	I-Premise
199	occurred	N	I-Premise
200	in	N	I-Premise
201	36	N	I-Premise
202	%	N	I-Premise
203	of	N	I-Premise
204	patients	N	I-Premise
205	treated	N	I-Premise
206	weekly	N	I-Premise
207	and	N	I-Premise
208	in	N	I-Premise
209	19	N	I-Premise
210	%	N	I-Premise
211	of	N	I-Premise
212	those	N	I-Premise
213	treated	N	I-Premise
214	once	N	I-Premise
215	every	N	I-Premise
216	3	N	I-Premise
217	weeks	N	I-Premise
218	(	N	I-Premise
219	P	N	I-Premise
220	=.002	N	I-Premise
221	)	N	I-Premise
222	.	N	I-Premise

223	Grade	N	I-Premise
224	3/4	N	I-Premise
225	neutropenia	N	I-Premise
226	occurred	N	I-Premise
227	in	N	I-Premise
228	29	N	I-Premise
229	%	N	I-Premise
230	of	N	I-Premise
231	patients	N	I-Premise
232	treated	N	I-Premise
233	weekly	N	I-Premise
234	and	N	I-Premise
235	34	N	I-Premise
236	%	N	I-Premise
237	of	N	I-Premise
238	those	N	I-Premise
239	treated	N	I-Premise
240	once	N	I-Premise
241	every	N	I-Premise
242	3	N	I-Premise
243	weeks	N	I-Premise
244	(	N	I-Premise
245	P	N	I-Premise
246	=.35	N	I-Premise
247	)	N	I-Premise
248	.	N	I-Premise

249	Treatment-related	N	I-Premise
250	mortality	N	I-Premise
251	occurred	N	I-Premise
252	in	N	I-Premise
253	five	N	I-Premise
254	patients	N	I-Premise
255	(	N	I-Premise
256	5.3	N	I-Premise
257	%	N	I-Premise
258	)	N	I-Premise
259	receiving	N	I-Premise
260	irinotecan	N	I-Premise
261	weekly	N	I-Premise
262	and	N	I-Premise
263	three	N	I-Premise
264	patients	N	I-Premise
265	(	N	I-Premise
266	1.6	N	I-Premise
267	%	N	I-Premise
268	)	N	I-Premise
269	given	N	I-Premise
270	therapy	N	I-Premise
271	once	N	I-Premise
272	every	N	I-Premise
273	3	N	I-Premise
274	weeks	N	I-Premise
275	(	N	I-Premise
276	P	N	I-Premise
277	=.12	N	I-Premise
278	)	N	I-Premise
279	.	N	I-Premise

280	Global	N	I-Premise
281	quality	N	I-Premise
282	of	N	I-Premise
283	life	N	I-Premise
284	was	N	I-Premise
285	not	N	I-Premise
286	statistically	N	I-Premise
287	different	N	I-Premise
288	between	N	I-Premise
289	treatment	N	I-Premise
290	groups	N	I-Premise
291	.	N	I-Premise

292	Irinotecan	N	I-Claim
293	schedules	N	I-Claim
294	of	N	I-Claim
295	weekly	N	I-Claim
296	and	N	I-Claim
297	of	N	I-Claim
298	once	N	I-Claim
299	every	N	I-Claim
300	3	N	I-Claim
301	weeks	N	I-Claim
302	demonstrated	N	I-Claim
303	similar	N	I-Claim
304	efficacy	N	I-Claim
305	and	N	I-Claim
306	quality	N	I-Claim
307	of	N	I-Claim
308	life	N	I-Claim
309	in	N	I-Claim
310	patients	N	I-Claim
311	with	N	I-Claim
312	FU-refractory	N	I-Claim
313	,	N	I-Claim
314	metastatic	N	I-Claim
315	colorectal	N	I-Claim
316	cancer	N	I-Claim
317	.	N	I-Claim

318	The	N	I-Claim
319	regimen	N	I-Claim
320	of	N	I-Claim
321	once	N	I-Claim
322	every	N	I-Claim
323	3	N	I-Claim
324	weeks	N	I-Claim
325	was	N	I-Claim
326	associated	N	I-Claim
327	with	N	I-Claim
328	a	N	I-Claim
329	significantly	N	I-Claim
330	lower	N	I-Claim
331	incidence	N	I-Claim
332	of	N	I-Claim
333	severe	N	I-Claim
334	diarrhea	N	I-Claim
335	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	a	N	O
7	standard	N	O
8	anthracycline-based	N	O
9	regimen	N	O
10	to	N	O
11	a	N	O
12	dose-intensified	N	O
13	anthracycline	N	O
14	regimen	N	O
15	in	N	O
16	locally	N	O
17	advanced	N	O
18	breast	N	O
19	cancer	N	O
20	.	N	O

21	Locally	N	O
22	advanced	N	O
23	breast	N	O
24	cancer	N	O
25	patients	N	O
26	were	N	O
27	randomly	N	O
28	assigned	N	O
29	onto	N	O
30	a	N	O
31	study	N	O
32	comparing	N	O
33	cyclophosphamide	N	O
34	(	N	O
35	C	N	O
36	;	N	O
37	75	N	O
38	mg/m	N	O
39	(	N	O
40	2	N	O
41	)	N	O
42	orally	N	O
43	days	N	O
44	1	N	O
45	to	N	O
46	14	N	O
47	)	N	O
48	,	N	O
49	epirubicin	N	O
50	(	N	O
51	E	N	O
52	;	N	O
53	60	N	O
54	mg/m	N	O
55	(	N	O
56	2	N	O
57	)	N	O
58	intravenously	N	O
59	[	N	O
60	IV	N	O
61	]	N	O
62	days	N	O
63	1	N	O
64	,	N	O
65	8	N	O
66	)	N	O
67	,	N	O
68	and	N	O
69	fluorouracil	N	O
70	(	N	O
71	F	N	O
72	;	N	O
73	500	N	O
74	mg/m	N	O
75	(	N	O
76	2	N	O
77	)	N	O
78	IV	N	O
79	days	N	O
80	1	N	O
81	,	N	O
82	8	N	O
83	)	N	O
84	six	N	O
85	cycles	N	O
86	every	N	O
87	28	N	O
88	days	N	O
89	versus	N	O
90	E	N	O
91	(	N	O
92	120	N	O
93	mg/m	N	O
94	(	N	O
95	2	N	O
96	)	N	O
97	IV	N	O
98	day	N	O
99	1	N	O
100	)	N	O
101	,	N	O
102	C	N	O
103	(	N	O
104	830	N	O
105	mg/m	N	O
106	(	N	O
107	2	N	O
108	)	N	O
109	IV	N	O
110	day	N	O
111	1	N	O
112	)	N	O
113	,	N	O
114	and	N	O
115	granulocyte	N	O
116	colony-stimulating	N	O
117	factor	N	O
118	(	N	O
119	filgrastim	N	O
120	;	N	O
121	5	N	O
122	micro	N	O
123	g/kg/d	N	O
124	subcutaneously	N	O
125	days	N	O
126	2	N	O
127	to	N	O
128	13	N	O
129	)	N	O
130	six	N	O
131	cycles	N	O
132	every	N	O
133	14	N	O
134	days	N	O
135	.	N	O

136	The	N	O
137	study	N	O
138	was	N	O
139	designed	N	O
140	to	N	O
141	detect	N	O
142	a	N	O
143	15	N	O
144	%	N	O
145	improvement	N	O
146	;	N	O
147	that	N	O
148	is	N	O
149	,	N	O
150	from	N	O
151	50	N	O
152	%	N	O
153	to	N	O
154	65	N	O
155	%	N	O
156	in	N	O
157	median	N	O
158	progression-free	N	O
159	survival	N	O
160	(	N	O
161	PFS	N	O
162	)	N	O
163	in	N	O
164	favor	N	O
165	of	N	O
166	the	N	O
167	dose-intensified	N	O
168	regimen	N	O
169	.	N	O

170	A	N	O
171	total	N	O
172	of	N	O
173	448	N	O
174	patients	N	O
175	were	N	O
176	enrolled	N	O
177	over	N	O
178	a	N	O
179	period	N	O
180	of	N	O
181	3	N	O
182	years	N	O
183	.	N	O

184	The	N	O
185	median	N	O
186	dose	N	O
187	intensity	N	O
188	delivered	N	O
189	for	N	O
190	C	N	O
191	and	N	O
192	E	N	O
193	reached	N	O
194	,	N	O
195	respectively	N	O
196	,	N	O
197	85	N	O
198	%	N	O
199	and	N	O
200	87	N	O
201	%	N	O
202	of	N	O
203	that	N	O
204	planned	N	O
205	in	N	O
206	the	N	O
207	CEF	N	O
208	arm	N	O
209	and	N	O
210	96	N	O
211	%	N	O
212	and	N	O
213	95	N	O
214	%	N	O
215	of	N	O
216	that	N	O
217	planned	N	O
218	in	N	O
219	the	N	O
220	EC	N	O
221	arm	N	O
222	.	N	O

223	The	N	I-Premise
224	dose-intensified	N	I-Premise
225	arm	N	I-Premise
226	was	N	I-Premise
227	slightly	N	I-Premise
228	more	N	I-Premise
229	emetogenic	N	I-Premise
230	and	N	I-Premise
231	generated	N	I-Premise
232	more	N	I-Premise
233	grade	N	I-Premise
234	3	N	I-Premise
235	to	N	I-Premise
236	4	N	I-Premise
237	anemia	N	I-Premise
238	but	N	I-Premise
239	less	N	I-Premise
240	febrile	N	I-Premise
241	neutropenia	N	I-Premise
242	episodes	N	I-Premise
243	.	N	I-Premise

244	After	N	O
245	a	N	O
246	median	N	O
247	follow-up	N	O
248	of	N	O
249	5.5	N	O
250	years	N	O
251	,	N	O
252	277	N	O
253	events	N	O
254	have	N	O
255	been	N	O
256	reported	N	O
257	.	N	O

258	The	N	I-Premise
259	median	N	I-Premise
260	PFS	N	I-Premise
261	was	N	I-Premise
262	34	N	I-Premise
263	and	N	I-Premise
264	33.7	N	I-Premise
265	months	N	I-Premise
266	for	N	I-Premise
267	CEF	N	I-Premise
268	and	N	I-Premise
269	EC	N	I-Premise
270	,	N	I-Premise
271	respectively	N	I-Premise
272	(	N	I-Premise
273	P	N	I-Premise
274	=.68	N	I-Premise
275	)	N	I-Premise
276	,	N	I-Premise
277	and	N	I-Premise
278	the	N	I-Premise
279	5-year	N	I-Premise
280	survival	N	I-Premise
281	rate	N	I-Premise
282	was	N	I-Premise
283	53	N	I-Premise
284	%	N	I-Premise
285	and	N	I-Premise
286	51	N	I-Premise
287	%	N	I-Premise
288	for	N	I-Premise
289	CEF	N	I-Premise
290	and	N	I-Premise
291	EC	N	I-Premise
292	,	N	I-Premise
293	respectively	N	I-Premise
294	(	N	I-Premise
295	P	N	I-Premise
296	=.94	N	I-Premise
297	)	N	I-Premise
298	.	N	I-Premise

299	Dose-intensified	N	I-Claim
300	EC	N	I-Claim
301	does	N	I-Claim
302	not	N	I-Claim
303	provide	N	I-Claim
304	a	N	I-Claim
305	measurable	N	I-Claim
306	therapeutic	N	I-Claim
307	benefit	N	I-Claim
308	over	N	I-Claim
309	CEF	N	I-Claim
310	as	N	I-Claim
311	neoadjuvant	N	I-Claim
312	chemotherapy	N	I-Claim
313	for	N	I-Claim
314	unselected	N	I-Claim
315	locally	N	I-Claim
316	advanced	N	I-Claim
317	breast	N	I-Claim
318	cancer	N	I-Claim
319	patients	N	I-Claim
320	.	N	I-Claim

1	Several	N	O
2	multicomponent	N	O
3	regimens	N	O
4	have	N	O
5	been	N	O
6	reported	N	O
7	to	N	O
8	be	N	O
9	useful	N	O
10	in	N	O
11	advanced	N	O
12	androgen-independent	N	O
13	prostate	N	O
14	cancer	N	O
15	.	N	O

16	We	N	O
17	used	N	O
18	a	N	O
19	randomized	N	O
20	phase	N	O
21	II	N	O
22	design	N	O
23	to	N	O
24	evaluate	N	O
25	and	N	O
26	compare	N	O
27	two	N	O
28	such	N	O
29	regimens	N	O
30	.	N	O

31	Patients	N	O
32	were	N	O
33	accrued	N	O
34	primarily	N	O
35	in	N	O
36	the	N	O
37	community	N	O
38	setting	N	O
39	.	N	O

40	Patients	N	O
41	with	N	O
42	progressive	N	O
43	,	N	O
44	androgen-independent	N	O
45	prostate	N	O
46	cancer	N	O
47	were	N	O
48	randomly	N	O
49	assigned	N	O
50	to	N	O
51	one	N	O
52	of	N	O
53	two	N	O
54	treatments	N	O
55	:	N	O
56	either	N	O
57	ketoconazole/doxorubicin	N	O
58	alternating	N	O
59	with	N	O
60	vinblastine/estramustine	N	O
61	(	N	O
62	KA/VE	N	O
63	)	N	O
64	or	N	O
65	paclitaxel	N	O
66	,	N	O
67	estramustine	N	O
68	,	N	O
69	and	N	O
70	oral	N	O
71	etoposide	N	O
72	(	N	O
73	TEE	N	O
74	)	N	O
75	.	N	O

76	Patients	N	O
77	were	N	O
78	prospectively	N	O
79	stratified	N	O
80	on	N	O
81	the	N	O
82	basis	N	O
83	of	N	O
84	disease	N	O
85	volume	N	O
86	.	N	O

87	The	N	O
88	primary	N	O
89	end	N	O
90	points	N	O
91	were	N	O
92	response	N	O
93	and	N	O
94	overall	N	O
95	survival	N	O
96	time	N	O
97	.	N	O

98	A	N	O
99	total	N	O
100	of	N	O
101	75	N	O
102	patients	N	O
103	were	N	O
104	registered	N	O
105	;	N	O
106	71	N	O
107	are	N	O
108	included	N	O
109	in	N	O
110	the	N	O
111	analysis	N	O
112	.	N	O

113	By	N	O
114	the	N	O
115	criterion	N	O
116	of	N	O
117	an	N	O
118	80	N	O
119	%	N	O
120	prostate-specific	N	O
121	antigen	N	O
122	reduction	N	O
123	maintained	N	O
124	for	N	O
125	at	N	O
126	least	N	O
127	8	N	O
128	weeks	N	O
129	,	N	O
130	11	N	O
131	(	N	O
132	30	N	O
133	%	N	O
134	)	N	O
135	of	N	O
136	37	N	O
137	patients	N	O
138	in	N	O
139	the	N	O
140	TEE	N	O
141	arm	N	O
142	responded	N	O
143	,	N	O
144	whereas	N	O
145	11	N	O
146	(	N	O
147	32	N	O
148	%	N	O
149	)	N	O
150	of	N	O
151	34	N	O
152	assigned	N	O
153	to	N	O
154	KA/VE	N	O
155	responded	N	O
156	.	N	O

157	Median	N	I-Premise
158	survival	N	I-Premise
159	was	N	I-Premise
160	16.9	N	I-Premise
161	months	N	I-Premise
162	(	N	I-Premise
163	95	N	I-Premise
164	%	N	I-Premise
165	confidence	N	I-Premise
166	interval	N	I-Premise
167	[	N	I-Premise
168	CI	N	I-Premise
169	]	N	I-Premise
170	,	N	I-Premise
171	10.5	N	I-Premise
172	to	N	I-Premise
173	21.2	N	I-Premise
174	months	N	I-Premise
175	)	N	I-Premise
176	in	N	I-Premise
177	the	N	I-Premise
178	TEE	N	I-Premise
179	arm	N	I-Premise
180	and	N	I-Premise
181	23.4	N	I-Premise
182	months	N	I-Premise
183	(	N	I-Premise
184	95	N	I-Premise
185	%	N	I-Premise
186	CI	N	I-Premise
187	,	N	I-Premise
188	12.9	N	I-Premise
189	to	N	I-Premise
190	30.6	N	I-Premise
191	months	N	I-Premise
192	)	N	I-Premise
193	for	N	I-Premise
194	patients	N	I-Premise
195	treated	N	I-Premise
196	with	N	I-Premise
197	KA/VE	N	I-Premise
198	.	N	I-Premise

199	Many	N	I-Premise
200	patients	N	I-Premise
201	(	N	I-Premise
202	24	N	I-Premise
203	%	N	I-Premise
204	)	N	I-Premise
205	failed	N	I-Premise
206	to	N	I-Premise
207	complete	N	I-Premise
208	at	N	I-Premise
209	least	N	I-Premise
210	6	N	I-Premise
211	weeks	N	I-Premise
212	of	N	I-Premise
213	therapy	N	I-Premise
214	,	N	I-Premise
215	including	N	I-Premise
216	five	N	I-Premise
217	(	N	I-Premise
218	8	N	I-Premise
219	%	N	I-Premise
220	)	N	I-Premise
221	treatment-related	N	I-Premise
222	early	N	I-Premise
223	deaths	N	I-Premise
224	.	N	I-Premise

225	Each	N	I-Claim
226	of	N	I-Claim
227	these	N	I-Claim
228	regimens	N	I-Claim
229	produced	N	I-Claim
230	clinically	N	I-Claim
231	significant	N	I-Claim
232	responses	N	I-Claim
233	,	N	I-Claim
234	and	N	O
235	the	N	I-Claim
236	observed	N	I-Claim
237	median	N	I-Claim
238	survival	N	I-Claim
239	(	N	I-Claim
240	18.9	N	I-Claim
241	months	N	I-Claim
242	for	N	I-Claim
243	all	N	I-Claim
244	71	N	I-Claim
245	patients	N	I-Claim
246	)	N	I-Claim
247	compares	N	I-Claim
248	favorably	N	I-Claim
249	with	N	I-Claim
250	previously	N	I-Claim
251	published	N	I-Claim
252	results	N	I-Claim
253	,	N	I-Claim
254	especially	N	I-Claim
255	in	N	I-Claim
256	the	N	I-Claim
257	community	N	I-Claim
258	setting	N	I-Claim
259	.	N	I-Claim

260	Nonetheless	N	I-Claim
261	,	N	I-Claim
262	it	N	I-Claim
263	is	N	I-Claim
264	apparent	N	I-Claim
265	that	N	I-Claim
266	these	N	I-Claim
267	first-generation	N	I-Claim
268	regimens	N	I-Claim
269	must	N	I-Claim
270	be	N	I-Claim
271	applied	N	I-Claim
272	judiciously	N	I-Claim
273	,	N	I-Claim
274	and	N	O
275	thus	N	I-Claim
276	we	N	I-Claim
277	view	N	I-Claim
278	efforts	N	I-Claim
279	at	N	I-Claim
280	better	N	I-Claim
281	patient	N	I-Claim
282	selection	N	I-Claim
283	and	N	I-Claim
284	the	N	I-Claim
285	development	N	I-Claim
286	of	N	I-Claim
287	more	N	I-Claim
288	tolerable	N	I-Claim
289	therapies	N	I-Claim
290	as	N	I-Claim
291	higher	N	I-Claim
292	priorities	N	I-Claim
293	than	N	I-Claim
294	carrying	N	I-Claim
295	either	N	I-Claim
296	of	N	I-Claim
297	these	N	I-Claim
298	regimens	N	I-Claim
299	to	N	I-Claim
300	phase	N	I-Claim
301	III	N	I-Claim
302	evaluation	N	I-Claim
303	in	N	I-Claim
304	the	N	I-Claim
305	cooperative	N	I-Claim
306	group	N	I-Claim
307	setting	N	I-Claim
308	.	N	I-Claim

1	Vinorelbine	N	I-Claim
2	prolongs	N	I-Claim
3	survival	N	I-Claim
4	and	N	I-Claim
5	improves	N	I-Claim
6	quality	N	I-Claim
7	of	N	I-Claim
8	life	N	I-Claim
9	in	N	I-Claim
10	elderly	N	I-Claim
11	patients	N	I-Claim
12	with	N	I-Claim
13	advanced	N	I-Claim
14	non-small-cell	N	I-Claim
15	lung	N	I-Claim
16	cancer	N	I-Claim
17	(	N	I-Claim
18	NSCLC	N	I-Claim
19	)	N	I-Claim
20	.	N	I-Claim

21	Some	N	I-Claim
22	studies	N	I-Claim
23	have	N	I-Claim
24	also	N	I-Claim
25	suggested	N	I-Claim
26	that	N	I-Claim
27	gemcitabine	N	I-Claim
28	is	N	I-Claim
29	well	N	I-Claim
30	tolerated	N	I-Claim
31	and	N	I-Claim
32	effective	N	I-Claim
33	in	N	I-Claim
34	such	N	I-Claim
35	patients	N	I-Claim
36	.	N	I-Claim

37	We	N	O
38	compared	N	O
39	the	N	O
40	effectiveness	N	O
41	and	N	O
42	toxicity	N	O
43	of	N	O
44	the	N	O
45	combination	N	O
46	of	N	O
47	vinorelbine	N	O
48	plus	N	O
49	gemcitabine	N	O
50	with	N	O
51	those	N	O
52	of	N	O
53	each	N	O
54	drug	N	O
55	given	N	O
56	alone	N	O
57	in	N	O
58	an	N	O
59	open-label	N	O
60	,	N	O
61	randomized	N	O
62	phase	N	O
63	III	N	O
64	trial	N	O
65	in	N	O
66	elderly	N	O
67	patients	N	O
68	with	N	O
69	advanced	N	O
70	NSCLC	N	O
71	.	N	O

72	Patients	N	O
73	aged	N	O
74	70	N	O
75	years	N	O
76	and	N	O
77	older	N	O
78	,	N	O
79	enrolled	N	O
80	between	N	O
81	December	N	O
82	1997	N	O
83	and	N	O
84	November	N	O
85	2000	N	O
86	,	N	O
87	were	N	O
88	randomly	N	O
89	assigned	N	O
90	to	N	O
91	receive	N	O
92	intravenous	N	O
93	vinorelbine	N	O
94	(	N	O
95	30	N	O
96	mg/m	N	O
97	(	N	O
98	2	N	O
99	)	N	O
100	of	N	O
101	body	N	O
102	surface	N	O
103	area	N	O
104	)	N	O
105	,	N	O
106	gemcitabine	N	O
107	(	N	O
108	1200	N	O
109	mg/m	N	O
110	(	N	O
111	2	N	O
112	)	N	O
113	)	N	O
114	,	N	O
115	or	N	O
116	vinorelbine	N	O
117	(	N	O
118	25	N	O
119	mg/m	N	O
120	(	N	O
121	2	N	O
122	)	N	O
123	)	N	O
124	plus	N	O
125	gemcitabine	N	O
126	(	N	O
127	1000	N	O
128	mg/m	N	O
129	(	N	O
130	2	N	O
131	)	N	O
132	)	N	O
133	.	N	O

134	All	N	O
135	treatments	N	O
136	were	N	O
137	delivered	N	O
138	on	N	O
139	days	N	O
140	1	N	O
141	and	N	O
142	8	N	O
143	every	N	O
144	3	N	O
145	weeks	N	O
146	for	N	O
147	a	N	O
148	maximum	N	O
149	of	N	O
150	six	N	O
151	cycles	N	O
152	.	N	O

153	The	N	O
154	primary	N	O
155	endpoint	N	O
156	was	N	O
157	survival	N	O
158	.	N	O

159	Survival	N	O
160	curves	N	O
161	were	N	O
162	drawn	N	O
163	using	N	O
164	the	N	O
165	Kaplan-Meier	N	O
166	method	N	O
167	and	N	O
168	analyzed	N	O
169	by	N	O
170	the	N	O
171	Mantel-Haenszel	N	O
172	test	N	O
173	.	N	O

174	Secondary	N	O
175	endpoints	N	O
176	were	N	O
177	quality	N	O
178	of	N	O
179	life	N	O
180	and	N	O
181	toxicity	N	O
182	.	N	O

183	Of	N	O
184	698	N	O
185	patients	N	O
186	available	N	O
187	for	N	O
188	intention-to-treat	N	O
189	analysis	N	O
190	,	N	O
191	233	N	O
192	were	N	O
193	assigned	N	O
194	to	N	O
195	receive	N	O
196	vinorelbine	N	O
197	,	N	O
198	233	N	O
199	to	N	O
200	gemcitabine	N	O
201	,	N	O
202	and	N	O
203	232	N	O
204	to	N	O
205	vinorelbine	N	O
206	plus	N	O
207	gemcitabine	N	O
208	.	N	O

209	Compared	N	I-Premise
210	with	N	I-Premise
211	each	N	I-Premise
212	single	N	I-Premise
213	drug	N	I-Premise
214	,	N	I-Premise
215	the	N	I-Premise
216	combination	N	I-Premise
217	treatment	N	I-Premise
218	did	N	I-Premise
219	not	N	I-Premise
220	improve	N	I-Premise
221	survival	N	I-Premise
222	.	N	I-Premise

223	The	N	I-Premise
224	hazard	N	I-Premise
225	ratio	N	I-Premise
226	of	N	I-Premise
227	death	N	I-Premise
228	for	N	I-Premise
229	patients	N	I-Premise
230	receiving	N	I-Premise
231	the	N	I-Premise
232	combination	N	I-Premise
233	treatment	N	I-Premise
234	was	N	I-Premise
235	1.17	N	I-Premise
236	(	N	I-Premise
237	95	N	I-Premise
238	%	N	I-Premise
239	confidence	N	I-Premise
240	interval	N	I-Premise
241	[	N	I-Premise
242	CI	N	I-Premise
243	]	N	I-Premise
244	=	N	I-Premise
245	0.95	N	I-Premise
246	to	N	I-Premise
247	1.44	N	I-Premise
248	)	N	I-Premise
249	that	N	I-Premise
250	of	N	I-Premise
251	patients	N	I-Premise
252	receiving	N	I-Premise
253	vinorelbine	N	I-Premise
254	and	N	I-Premise
255	1.06	N	I-Premise
256	(	N	I-Premise
257	95	N	I-Premise
258	%	N	I-Premise
259	CI	N	I-Premise
260	=	N	I-Premise
261	0.86	N	I-Premise
262	to	N	I-Premise
263	1.29	N	I-Premise
264	)	N	I-Premise
265	that	N	I-Premise
266	of	N	I-Premise
267	patients	N	I-Premise
268	receiving	N	I-Premise
269	gemcitabine	N	I-Premise
270	.	N	I-Premise

271	Although	N	I-Premise
272	quality	N	I-Premise
273	of	N	I-Premise
274	life	N	I-Premise
275	was	N	I-Premise
276	similar	N	I-Premise
277	across	N	I-Premise
278	the	N	I-Premise
279	three	N	I-Premise
280	treatment	N	I-Premise
281	arms	N	I-Premise
282	,	N	I-Premise
283	the	N	I-Premise
284	combination	N	I-Premise
285	treatment	N	I-Premise
286	was	N	I-Premise
287	more	N	I-Premise
288	toxic	N	I-Premise
289	than	N	I-Premise
290	the	N	I-Premise
291	two	N	I-Premise
292	drugs	N	I-Premise
293	given	N	I-Premise
294	singly	N	I-Premise
295	.	N	I-Premise

296	The	N	I-Claim
297	combination	N	I-Claim
298	of	N	I-Claim
299	vinorelbine	N	I-Claim
300	plus	N	I-Claim
301	gemcitabine	N	I-Claim
302	is	N	I-Claim
303	not	N	I-Claim
304	more	N	I-Claim
305	effective	N	I-Claim
306	than	N	I-Claim
307	single-agent	N	I-Claim
308	vinorelbine	N	I-Claim
309	or	N	I-Claim
310	gemcitabine	N	I-Claim
311	in	N	I-Claim
312	the	N	I-Claim
313	treatment	N	I-Claim
314	of	N	I-Claim
315	elderly	N	I-Claim
316	patients	N	I-Claim
317	with	N	I-Claim
318	advanced	N	I-Claim
319	NSCLC	N	I-Claim
320	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	,	N	O
4	multicenter	N	O
5	,	N	O
6	phase	N	O
7	III	N	O
8	study	N	O
9	compared	N	O
10	doxorubicin	N	O
11	and	N	O
12	docetaxel	N	O
13	(	N	O
14	AT	N	O
15	)	N	O
16	with	N	O
17	doxorubicin	N	O
18	and	N	O
19	cyclophosphamide	N	O
20	(	N	O
21	AC	N	O
22	)	N	O
23	as	N	O
24	first-line	N	O
25	chemotherapy	N	O
26	(	N	O
27	CT	N	O
28	)	N	O
29	in	N	O
30	metastatic	N	O
31	breast	N	O
32	cancer	N	O
33	(	N	O
34	MBC	N	O
35	)	N	O
36	.	N	O

37	Patients	N	O
38	(	N	O
39	n	N	O
40	=	N	O
41	429	N	O
42	)	N	O
43	were	N	O
44	randomly	N	O
45	assigned	N	O
46	to	N	O
47	receive	N	O
48	doxorubicin	N	O
49	50	N	O
50	mg/m	N	O
51	(	N	O
52	2	N	O
53	)	N	O
54	plus	N	O
55	docetaxel	N	O
56	75	N	O
57	mg/m	N	O
58	(	N	O
59	2	N	O
60	)	N	O
61	(	N	O
62	n	N	O
63	=	N	O
64	214	N	O
65	)	N	O
66	or	N	O
67	doxorubicin	N	O
68	60	N	O
69	mg/m	N	O
70	(	N	O
71	2	N	O
72	)	N	O
73	plus	N	O
74	cyclophosphamide	N	O
75	600	N	O
76	mg/m	N	O
77	(	N	O
78	2	N	O
79	)	N	O
80	(	N	O
81	n	N	O
82	=	N	O
83	215	N	O
84	)	N	O
85	on	N	O
86	day	N	O
87	1	N	O
88	,	N	O
89	every	N	O
90	3	N	O
91	weeks	N	O
92	for	N	O
93	up	N	O
94	to	N	O
95	eight	N	O
96	cycles	N	O
97	.	N	O

98	Time	N	I-Premise
99	to	N	I-Premise
100	progression	N	I-Premise
101	(	N	I-Premise
102	TTP	N	I-Premise
103	;	N	I-Premise
104	primary	N	I-Premise
105	end	N	I-Premise
106	point	N	I-Premise
107	)	N	I-Premise
108	and	N	I-Premise
109	time	N	I-Premise
110	to	N	I-Premise
111	treatment	N	I-Premise
112	failure	N	I-Premise
113	(	N	I-Premise
114	TTF	N	I-Premise
115	)	N	I-Premise
116	were	N	I-Premise
117	significantly	N	I-Premise
118	longer	N	I-Premise
119	with	N	I-Premise
120	AT	N	I-Premise
121	than	N	I-Premise
122	AC	N	I-Premise
123	(	N	I-Premise
124	median	N	I-Premise
125	TTP	N	I-Premise
126	,	N	I-Premise
127	37.3	N	I-Premise
128	v	N	I-Premise
129	31.9	N	I-Premise
130	weeks	N	I-Premise
131	;	N	I-Premise
132	log-rank	N	I-Premise
133	P	N	I-Premise
134	=.014	N	I-Premise
135	;	N	I-Premise
136	median	N	I-Premise
137	TTF	N	I-Premise
138	,	N	I-Premise
139	25.6	N	I-Premise
140	v	N	I-Premise
141	23.7	N	I-Premise
142	weeks	N	I-Premise
143	;	N	I-Premise
144	log-rank	N	I-Premise
145	P	N	I-Premise
146	=.048	N	I-Premise
147	)	N	I-Premise
148	.	N	I-Premise

149	The	N	I-Premise
150	overall	N	I-Premise
151	response	N	I-Premise
152	rate	N	I-Premise
153	(	N	I-Premise
154	ORR	N	I-Premise
155	)	N	I-Premise
156	was	N	I-Premise
157	significantly	N	I-Premise
158	greater	N	I-Premise
159	for	N	I-Premise
160	patients	N	I-Premise
161	taking	N	I-Premise
162	AT	N	I-Premise
163	(	N	I-Premise
164	59	N	I-Premise
165	%	N	I-Premise
166	,	N	I-Premise
167	with	N	I-Premise
168	10	N	I-Premise
169	%	N	I-Premise
170	complete	N	I-Premise
171	response	N	I-Premise
172	[	N	I-Premise
173	CR	N	I-Premise
174	]	N	I-Premise
175	,	N	I-Premise
176	49	N	I-Premise
177	%	N	I-Premise
178	partial	N	I-Premise
179	response	N	I-Premise
180	[	N	I-Premise
181	PR	N	I-Premise
182	]	N	I-Premise
183	)	N	I-Premise
184	than	N	I-Premise
185	for	N	I-Premise
186	those	N	I-Premise
187	taking	N	I-Premise
188	AC	N	I-Premise
189	(	N	I-Premise
190	47	N	I-Premise
191	%	N	I-Premise
192	,	N	I-Premise
193	with	N	I-Premise
194	7	N	I-Premise
195	%	N	I-Premise
196	CR	N	I-Premise
197	,	N	I-Premise
198	39	N	I-Premise
199	%	N	I-Premise
200	PR	N	I-Premise
201	)	N	I-Premise
202	(	N	I-Premise
203	P	N	I-Premise
204	=.009	N	I-Premise
205	)	N	I-Premise
206	.	N	I-Premise

207	The	N	I-Premise
208	ORR	N	I-Premise
209	was	N	I-Premise
210	also	N	I-Premise
211	higher	N	I-Premise
212	with	N	I-Premise
213	AT	N	I-Premise
214	in	N	I-Premise
215	patients	N	I-Premise
216	with	N	I-Premise
217	visceral	N	I-Premise
218	involvement	N	I-Premise
219	(	N	I-Premise
220	58	N	I-Premise
221	%	N	I-Premise
222	v	N	I-Premise
223	41	N	I-Premise
224	%	N	I-Premise
225	;	N	I-Premise
226	liver	N	I-Premise
227	,	N	I-Premise
228	62	N	I-Premise
229	%	N	I-Premise
230	v	N	I-Premise
231	42	N	I-Premise
232	%	N	I-Premise
233	;	N	I-Premise
234	lung	N	I-Premise
235	,	N	I-Premise
236	58	N	I-Premise
237	%	N	I-Premise
238	v	N	I-Premise
239	35	N	I-Premise
240	%	N	I-Premise
241	)	N	I-Premise
242	,	N	I-Premise
243	three	N	I-Premise
244	or	N	I-Premise
245	more	N	I-Premise
246	organs	N	I-Premise
247	involved	N	I-Premise
248	(	N	I-Premise
249	59	N	I-Premise
250	%	N	I-Premise
251	v	N	I-Premise
252	40	N	I-Premise
253	%	N	I-Premise
254	)	N	I-Premise
255	,	N	I-Premise
256	or	N	I-Premise
257	prior	N	I-Premise
258	adjuvant	N	I-Premise
259	CT	N	I-Premise
260	(	N	I-Premise
261	53	N	I-Premise
262	%	N	I-Premise
263	v	N	I-Premise
264	41	N	I-Premise
265	%	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	Overall	N	I-Premise
269	survival	N	I-Premise
270	(	N	I-Premise
271	OS	N	I-Premise
272	)	N	I-Premise
273	was	N	I-Premise
274	comparable	N	I-Premise
275	in	N	I-Premise
276	both	N	I-Premise
277	arms	N	I-Premise
278	.	N	I-Premise

279	Grade	N	I-Premise
280	3/4	N	I-Premise
281	neutropenia	N	I-Premise
282	was	N	I-Premise
283	frequent	N	I-Premise
284	in	N	I-Premise
285	both	N	I-Premise
286	groups	N	I-Premise
287	,	N	I-Premise
288	although	N	I-Premise
289	febrile	N	I-Premise
290	neutropenia	N	I-Premise
291	and	N	I-Premise
292	infections	N	I-Premise
293	were	N	I-Premise
294	more	N	I-Premise
295	frequent	N	I-Premise
296	for	N	I-Premise
297	patients	N	I-Premise
298	taking	N	I-Premise
299	AT	N	I-Premise
300	(	N	I-Premise
301	respectively	N	I-Premise
302	,	N	I-Premise
303	33	N	I-Premise
304	%	N	I-Premise
305	v	N	I-Premise
306	10	N	I-Premise
307	%	N	I-Premise
308	,	N	I-Premise
309	P	N	I-Premise
310	<	N	I-Premise
311	.001	N	I-Premise
312	;	N	I-Premise
313	8	N	I-Premise
314	%	N	I-Premise
315	v	N	I-Premise
316	2	N	I-Premise
317	%	N	I-Premise
318	,	N	I-Premise
319	P	N	I-Premise
320	=.01	N	I-Premise
321	)	N	I-Premise
322	.	N	I-Premise

323	Severe	N	I-Premise
324	nonhematologic	N	I-Premise
325	toxicity	N	I-Premise
326	was	N	I-Premise
327	infrequent	N	I-Premise
328	in	N	I-Premise
329	both	N	I-Premise
330	groups	N	I-Premise
331	,	N	I-Premise
332	including	N	I-Premise
333	grade	N	I-Premise
334	3/4	N	I-Premise
335	cardiac	N	I-Premise
336	events	N	I-Premise
337	(	N	I-Premise
338	AT	N	I-Premise
339	,	N	I-Premise
340	3	N	I-Premise
341	%	N	I-Premise
342	;	N	I-Premise
343	AC	N	I-Premise
344	,	N	I-Premise
345	4	N	I-Premise
346	%	N	I-Premise
347	)	N	I-Premise
348	.	N	I-Premise

349	AT	N	I-Claim
350	significantly	N	I-Claim
351	improves	N	I-Claim
352	TTP	N	I-Claim
353	and	N	I-Claim
354	ORR	N	I-Claim
355	compared	N	I-Claim
356	with	N	I-Claim
357	AC	N	I-Claim
358	in	N	I-Claim
359	patients	N	I-Claim
360	with	N	I-Claim
361	MBC	N	I-Claim
362	,	N	I-Claim
363	but	N	I-Claim
364	there	N	I-Claim
365	is	N	I-Claim
366	no	N	I-Claim
367	difference	N	I-Claim
368	in	N	I-Claim
369	OS	N	I-Claim
370	.	N	I-Claim

371	AT	N	I-Claim
372	represents	N	I-Claim
373	a	N	I-Claim
374	valid	N	I-Claim
375	option	N	I-Claim
376	for	N	I-Claim
377	the	N	I-Claim
378	treatment	N	I-Claim
379	of	N	I-Claim
380	MBC	N	I-Claim
381	.	N	I-Claim

1	Despite	N	I-MajorClaim
2	considerable	N	I-MajorClaim
3	improvement	N	I-MajorClaim
4	in	N	I-MajorClaim
5	the	N	I-MajorClaim
6	treatment	N	I-MajorClaim
7	of	N	I-MajorClaim
8	advanced	N	I-MajorClaim
9	ovarian	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	,	N	I-MajorClaim
12	the	N	I-MajorClaim
13	optimization	N	I-MajorClaim
14	of	N	I-MajorClaim
15	efficacy	N	I-MajorClaim
16	and	N	I-MajorClaim
17	tolerability	N	I-MajorClaim
18	remains	N	I-MajorClaim
19	an	N	I-MajorClaim
20	important	N	I-MajorClaim
21	issue	N	I-MajorClaim
22	.	N	I-MajorClaim

23	Therefore	N	O
24	,	N	O
25	we	N	O
26	performed	N	O
27	a	N	O
28	randomized	N	O
29	,	N	O
30	phase	N	O
31	III	N	O
32	non-inferiority	N	O
33	trial	N	O
34	comparing	N	O
35	paclitaxel	N	O
36	plus	N	O
37	cisplatin	N	O
38	(	N	O
39	PT	N	O
40	)	N	O
41	with	N	O
42	paclitaxel	N	O
43	plus	N	O
44	carboplatin	N	O
45	(	N	O
46	TC	N	O
47	)	N	O
48	in	N	O
49	patients	N	O
50	with	N	O
51	advanced	N	O
52	ovarian	N	O
53	cancer	N	O
54	.	N	O

55	A	N	O
56	total	N	O
57	of	N	O
58	798	N	O
59	patients	N	O
60	with	N	O
61	International	N	O
62	Federation	N	O
63	of	N	O
64	Gynecology	N	O
65	and	N	O
66	Obstetrics	N	O
67	stage	N	O
68	IIB-IV	N	O
69	were	N	O
70	randomly	N	O
71	assigned	N	O
72	to	N	O
73	receive	N	O
74	six	N	O
75	courses	N	O
76	of	N	O
77	either	N	O
78	PT	N	O
79	or	N	O
80	TC	N	O
81	at	N	O
82	3-week	N	O
83	intervals	N	O
84	.	N	O

85	The	N	O
86	primary	N	O
87	endpoint	N	O
88	was	N	O
89	the	N	O
90	proportion	N	O
91	of	N	O
92	patients	N	O
93	without	N	O
94	progression	N	O
95	at	N	O
96	2	N	O
97	years	N	O
98	.	N	O

99	Secondary	N	O
100	endpoints	N	O
101	included	N	O
102	toxicity	N	O
103	,	N	O
104	response	N	O
105	to	N	O
106	treatment	N	O
107	,	N	O
108	quality	N	O
109	of	N	O
110	life	N	O
111	,	N	O
112	and	N	O
113	overall	N	O
114	and	N	O
115	progression-free	N	O
116	survival	N	O
117	time	N	O
118	.	N	O

119	Quality	N	O
120	of	N	O
121	life	N	O
122	was	N	O
123	evaluated	N	O
124	using	N	O
125	the	N	O
126	European	N	O
127	Organization	N	O
128	for	N	O
129	Research	N	O
130	and	N	O
131	Treatment	N	O
132	of	N	O
133	Cancer	N	O
134	quality-of-life	N	O
135	questionnaire	N	O
136	(	N	O
137	QLQ	N	O
138	)	N	O
139	-C30	N	O
140	,	N	O
141	version	N	O
142	2.0	N	O
143	.	N	O

144	Survival	N	O
145	curves	N	O
146	were	N	O
147	calculated	N	O
148	using	N	O
149	the	N	O
150	Kaplan-Meier	N	O
151	method	N	O
152	,	N	O
153	and	N	O
154	hazard	N	O
155	ratios	N	O
156	were	N	O
157	estimated	N	O
158	using	N	O
159	the	N	O
160	Cox	N	O
161	proportional	N	O
162	hazards	N	O
163	model	N	O
164	.	N	O

165	The	N	I-Premise
166	proportion	N	I-Premise
167	of	N	I-Premise
168	patients	N	I-Premise
169	without	N	I-Premise
170	progression	N	I-Premise
171	at	N	I-Premise
172	2	N	I-Premise
173	years	N	I-Premise
174	was	N	I-Premise
175	not	N	I-Premise
176	statistically	N	I-Premise
177	significantly	N	I-Premise
178	different	N	I-Premise
179	between	N	I-Premise
180	the	N	I-Premise
181	two	N	I-Premise
182	treatment	N	I-Premise
183	arms	N	I-Premise
184	(	N	I-Premise
185	40.0	N	I-Premise
186	%	N	I-Premise
187	for	N	I-Premise
188	PT	N	I-Premise
189	versus	N	I-Premise
190	37.5	N	I-Premise
191	%	N	I-Premise
192	for	N	I-Premise
193	TC	N	I-Premise
194	,	N	I-Premise
195	difference	N	I-Premise
196	=	N	I-Premise
197	2.5	N	I-Premise
198	%	N	I-Premise
199	,	N	I-Premise
200	one-sided	N	I-Premise
201	95	N	I-Premise
202	%	N	I-Premise
203	confidence	N	I-Premise
204	interval	N	I-Premise
205	[	N	I-Premise
206	CI	N	I-Premise
207	]	N	I-Premise
208	=	N	I-Premise
209	-	N	I-Premise
210	infinity	N	I-Premise
211	to	N	I-Premise
212	8.2	N	I-Premise
213	%	N	I-Premise
214	)	N	I-Premise
215	.	N	I-Premise

216	Median	N	I-Premise
217	progression-free	N	I-Premise
218	survival	N	I-Premise
219	time	N	I-Premise
220	in	N	I-Premise
221	the	N	I-Premise
222	TC	N	I-Premise
223	arm	N	I-Premise
224	(	N	I-Premise
225	17.2	N	I-Premise
226	months	N	I-Premise
227	,	N	I-Premise
228	95	N	I-Premise
229	%	N	I-Premise
230	CI	N	I-Premise
231	=	N	I-Premise
232	15.2	N	I-Premise
233	to	N	I-Premise
234	19.3	N	I-Premise
235	months	N	I-Premise
236	)	N	I-Premise
237	and	N	I-Premise
238	the	N	I-Premise
239	PT	N	I-Premise
240	arm	N	I-Premise
241	(	N	I-Premise
242	19.1	N	I-Premise
243	months	N	I-Premise
244	,	N	I-Premise
245	95	N	I-Premise
246	%	N	I-Premise
247	CI	N	I-Premise
248	=	N	I-Premise
249	16.7	N	I-Premise
250	to	N	I-Premise
251	21.5	N	I-Premise
252	months	N	I-Premise
253	)	N	I-Premise
254	were	N	I-Premise
255	also	N	I-Premise
256	not	N	I-Premise
257	statistically	N	I-Premise
258	significantly	N	I-Premise
259	different	N	I-Premise
260	;	N	I-Premise
261	the	N	I-Premise
262	same	N	I-Premise
263	was	N	I-Premise
264	true	N	I-Premise
265	of	N	I-Premise
266	median	N	I-Premise
267	overall	N	I-Premise
268	survival	N	I-Premise
269	time	N	I-Premise
270	(	N	I-Premise
271	43.3	N	I-Premise
272	months	N	I-Premise
273	,	N	I-Premise
274	95	N	I-Premise
275	%	N	I-Premise
276	CI	N	I-Premise
277	=	N	I-Premise
278	37.2	N	I-Premise
279	to	N	I-Premise
280	47.8	N	I-Premise
281	months	N	I-Premise
282	versus	N	I-Premise
283	44.1	N	I-Premise
284	months	N	I-Premise
285	,	N	I-Premise
286	95	N	I-Premise
287	%	N	I-Premise
288	CI	N	I-Premise
289	=	N	I-Premise
290	40.2	N	I-Premise
291	to	N	I-Premise
292	49.4	N	I-Premise
293	months	N	I-Premise
294	,	N	I-Premise
295	for	N	I-Premise
296	the	N	I-Premise
297	TC	N	I-Premise
298	and	N	I-Premise
299	PT	N	I-Premise
300	arms	N	I-Premise
301	,	N	I-Premise
302	respectively	N	I-Premise
303	)	N	I-Premise
304	.	N	I-Premise

305	The	N	I-Premise
306	TC	N	I-Premise
307	regimen	N	I-Premise
308	was	N	I-Premise
309	associated	N	I-Premise
310	with	N	I-Premise
311	a	N	I-Premise
312	higher	N	I-Premise
313	frequency	N	I-Premise
314	of	N	I-Premise
315	hematologic	N	I-Premise
316	toxicity	N	I-Premise
317	,	N	I-Premise
318	but	N	I-Premise
319	a	N	I-Premise
320	lower	N	I-Premise
321	frequency	N	I-Premise
322	of	N	I-Premise
323	gastrointestinal	N	I-Premise
324	and	N	I-Premise
325	neurologic	N	I-Premise
326	toxicity	N	I-Premise
327	,	N	I-Premise
328	than	N	I-Premise
329	the	N	I-Premise
330	PT	N	I-Premise
331	regimen	N	I-Premise
332	.	N	I-Premise

333	Mean	N	I-Premise
334	global	N	I-Premise
335	quality-of-life	N	I-Premise
336	scores	N	I-Premise
337	at	N	I-Premise
338	the	N	I-Premise
339	end	N	I-Premise
340	of	N	I-Premise
341	treatment	N	I-Premise
342	were	N	I-Premise
343	statistically	N	I-Premise
344	significantly	N	I-Premise
345	better	N	I-Premise
346	in	N	I-Premise
347	the	N	I-Premise
348	TC	N	I-Premise
349	arm	N	I-Premise
350	than	N	I-Premise
351	in	N	I-Premise
352	the	N	I-Premise
353	PT	N	I-Premise
354	arm	N	I-Premise
355	(	N	I-Premise
356	65.25	N	I-Premise
357	versus	N	I-Premise
358	51.97	N	I-Premise
359	,	N	I-Premise
360	respectively	N	I-Premise
361	;	N	I-Premise
362	difference	N	I-Premise
363	=	N	I-Premise
364	-13.28	N	I-Premise
365	,	N	I-Premise
366	95	N	I-Premise
367	%	N	I-Premise
368	CI	N	I-Premise
369	=	N	I-Premise
370	-18.88	N	I-Premise
371	to	N	I-Premise
372	-7.68	N	I-Premise
373	)	N	I-Premise
374	.	N	I-Premise

375	The	N	I-Claim
376	TC	N	I-Claim
377	regimen	N	I-Claim
378	achieved	N	I-Claim
379	comparable	N	I-Claim
380	efficacy	N	I-Claim
381	to	N	I-Claim
382	the	N	I-Claim
383	PT	N	I-Claim
384	regimen	N	I-Claim
385	but	N	I-Claim
386	was	N	I-Claim
387	associated	N	I-Claim
388	with	N	I-Claim
389	better	N	I-Claim
390	tolerability	N	I-Claim
391	and	N	I-Claim
392	quality	N	I-Claim
393	of	N	I-Claim
394	life	N	I-Claim
395	,	N	I-Claim
396	and	N	I-Claim
397	should	N	I-Claim
398	,	N	I-Claim
399	therefore	N	I-Claim
400	,	N	I-Claim
401	be	N	I-Claim
402	considered	N	I-Claim
403	as	N	I-Claim
404	an	N	I-Claim
405	important	N	I-Claim
406	alternative	N	I-Claim
407	for	N	I-Claim
408	standard	N	I-Claim
409	first-line	N	I-Claim
410	chemotherapy	N	I-Claim
411	in	N	I-Claim
412	patients	N	I-Claim
413	with	N	I-Claim
414	advanced	N	I-Claim
415	ovarian	N	I-Claim
416	cancer	N	I-Claim
417	.	N	I-Claim

1	This	N	O
2	trial	N	O
3	was	N	O
4	conducted	N	O
5	to	N	O
6	determine	N	O
7	whether	N	O
8	high-dose	N	O
9	fluorouracil	N	O
10	(	N	O
11	FU	N	O
12	)	N	O
13	given	N	O
14	as	N	O
15	a	N	O
16	weekly	N	O
17	24-hour	N	O
18	infusion	N	O
19	is	N	O
20	more	N	O
21	active	N	O
22	than	N	O
23	bolus	N	O
24	FU	N	O
25	+	N	O
26	leucovorin	N	O
27	(	N	O
28	LV	N	O
29	)	N	O
30	,	N	O
31	and	N	O
32	whether	N	O
33	high-dose	N	O
34	infusional	N	O
35	FU	N	O
36	can	N	O
37	be	N	O
38	modulated	N	O
39	by	N	O
40	LV	N	O
41	.	N	O

42	A	N	O
43	total	N	O
44	of	N	O
45	497	N	O
46	patients	N	O
47	with	N	O
48	previously	N	O
49	untreated	N	O
50	metastatic	N	O
51	colorectal	N	O
52	cancer	N	O
53	were	N	O
54	randomly	N	O
55	assigned	N	O
56	to	N	O
57	receive	N	O
58	bolus	N	O
59	FU	N	O
60	425	N	O
61	mg/m2	N	O
62	intravenously	N	O
63	+	N	O
64	LV	N	O
65	20	N	O
66	mg/m2	N	O
67	on	N	O
68	days	N	O
69	1	N	O
70	to	N	O
71	5	N	O
72	and	N	O
73	repeated	N	O
74	on	N	O
75	day	N	O
76	28	N	O
77	(	N	O
78	FU	N	O
79	+	N	O
80	LV	N	O
81	)	N	O
82	,	N	O
83	or	N	O
84	FU	N	O
85	2600	N	O
86	mg/m2	N	O
87	as	N	O
88	a	N	O
89	24-hour	N	O
90	infusion	N	O
91	alone	N	O
92	(	N	O
93	FU24h	N	O
94	)	N	O
95	or	N	O
96	in	N	O
97	combination	N	O
98	with	N	O
99	500	N	O
100	mg/m2	N	O
101	LV	N	O
102	(	N	O
103	FU24h	N	O
104	+	N	O
105	LV	N	O
106	)	N	O
107	-all	N	O
108	given	N	O
109	weekly	N	O
110	x6	N	O
111	followed	N	O
112	by	N	O
113	a	N	O
114	2-week	N	O
115	rest	N	O
116	period	N	O
117	.	N	O

118	Survival	N	O
119	was	N	O
120	the	N	O
121	major	N	O
122	study	N	O
123	end	N	O
124	point	N	O
125	.	N	O

126	With	N	I-Premise
127	a	N	I-Premise
128	median	N	I-Premise
129	follow-up	N	I-Premise
130	of	N	I-Premise
131	more	N	I-Premise
132	than	N	I-Premise
133	3	N	I-Premise
134	years	N	I-Premise
135	,	N	I-Premise
136	survival	N	I-Premise
137	did	N	I-Premise
138	not	N	I-Premise
139	differ	N	I-Premise
140	among	N	I-Premise
141	the	N	I-Premise
142	treatment	N	I-Premise
143	groups	N	I-Premise
144	(	N	I-Premise
145	median	N	I-Premise
146	FU	N	I-Premise
147	+	N	I-Premise
148	LV	N	I-Premise
149	,	N	I-Premise
150	11.1	N	I-Premise
151	months	N	I-Premise
152	[	N	I-Premise
153	95	N	I-Premise
154	%	N	I-Premise
155	CI	N	I-Premise
156	,	N	I-Premise
157	10.2	N	I-Premise
158	to	N	I-Premise
159	15.0	N	I-Premise
160	months	N	I-Premise
161	]	N	I-Premise
162	;	N	I-Premise
163	FU24h	N	I-Premise
164	,	N	I-Premise
165	13.0	N	I-Premise
166	months	N	I-Premise
167	[	N	I-Premise
168	95	N	I-Premise
169	%	N	I-Premise
170	CI	N	I-Premise
171	,	N	I-Premise
172	10.4	N	I-Premise
173	to	N	I-Premise
174	15.4	N	I-Premise
175	months	N	I-Premise
176	]	N	I-Premise
177	;	N	I-Premise
178	FU24h	N	I-Premise
179	+	N	I-Premise
180	LV	N	I-Premise
181	,	N	I-Premise
182	13.7	N	I-Premise
183	months	N	I-Premise
184	[	N	I-Premise
185	95	N	I-Premise
186	%	N	I-Premise
187	CI	N	I-Premise
188	,	N	I-Premise
189	12.0	N	I-Premise
190	to	N	I-Premise
191	16.4	N	I-Premise
192	months	N	I-Premise
193	]	N	I-Premise
194	;	N	I-Premise
195	P	N	I-Premise
196	=.724	N	I-Premise
197	)	N	I-Premise
198	.	N	I-Premise

199	Progression-free	N	I-Premise
200	survival	N	I-Premise
201	(	N	I-Premise
202	PFS	N	I-Premise
203	)	N	I-Premise
204	was	N	I-Premise
205	significantly	N	I-Premise
206	longer	N	I-Premise
207	for	N	I-Premise
208	FU24h	N	I-Premise
209	+	N	I-Premise
210	LV	N	I-Premise
211	(	N	I-Premise
212	median	N	I-Premise
213	FU	N	I-Premise
214	+	N	I-Premise
215	LV	N	I-Premise
216	,	N	I-Premise
217	4.0	N	I-Premise
218	months	N	I-Premise
219	[	N	I-Premise
220	95	N	I-Premise
221	%	N	I-Premise
222	CI	N	I-Premise
223	,	N	I-Premise
224	3.4	N	I-Premise
225	to	N	I-Premise
226	4.9	N	I-Premise
227	]	N	I-Premise
228	;	N	I-Premise
229	FU24h	N	I-Premise
230	,	N	I-Premise
231	4.1	N	I-Premise
232	months	N	I-Premise
233	[	N	I-Premise
234	95	N	I-Premise
235	%	N	I-Premise
236	CI	N	I-Premise
237	,	N	I-Premise
238	3.4	N	I-Premise
239	to	N	I-Premise
240	5.0	N	I-Premise
241	]	N	I-Premise
242	;	N	I-Premise
243	FU24h	N	I-Premise
244	+	N	I-Premise
245	LV	N	I-Premise
246	5.6	N	I-Premise
247	months	N	I-Premise
248	[	N	I-Premise
249	95	N	I-Premise
250	%	N	I-Premise
251	CI	N	I-Premise
252	,	N	I-Premise
253	4.4	N	I-Premise
254	to	N	I-Premise
255	6.7	N	I-Premise
256	]	N	I-Premise
257	;	N	I-Premise
258	P	N	I-Premise
259	=.029	N	I-Premise
260	)	N	I-Premise
261	.	N	I-Premise

262	The	N	I-Premise
263	response	N	I-Premise
264	rates	N	I-Premise
265	in	N	I-Premise
266	the	N	I-Premise
267	subgroup	N	I-Premise
268	of	N	I-Premise
269	patients	N	I-Premise
270	with	N	I-Premise
271	measurable	N	I-Premise
272	disease	N	I-Premise
273	were	N	I-Premise
274	12	N	I-Premise
275	%	N	I-Premise
276	,	N	I-Premise
277	10	N	I-Premise
278	%	N	I-Premise
279	,	N	I-Premise
280	and	N	I-Premise
281	17	N	I-Premise
282	%	N	I-Premise
283	for	N	I-Premise
284	FU	N	I-Premise
285	+	N	I-Premise
286	LV	N	I-Premise
287	,	N	I-Premise
288	FU24h	N	I-Premise
289	,	N	I-Premise
290	and	N	I-Premise
291	FU24h	N	I-Premise
292	+	N	I-Premise
293	LV	N	I-Premise
294	,	N	I-Premise
295	respectively	N	I-Premise
296	(	N	I-Premise
297	not	N	I-Premise
298	significant	N	I-Premise
299	)	N	I-Premise
300	.	N	I-Premise

301	Occurrence	N	I-Premise
302	of	N	I-Premise
303	grade	N	I-Premise
304	3	N	I-Premise
305	and	N	I-Premise
306	4	N	I-Premise
307	diarrhea	N	I-Premise
308	was	N	I-Premise
309	higher	N	I-Premise
310	in	N	I-Premise
311	the	N	I-Premise
312	FU24h	N	I-Premise
313	+	N	I-Premise
314	LV	N	I-Premise
315	arm	N	I-Premise
316	(	N	I-Premise
317	22	N	I-Premise
318	%	N	I-Premise
319	)	N	I-Premise
320	compared	N	I-Premise
321	with	N	I-Premise
322	the	N	I-Premise
323	FU24h	N	I-Premise
324	(	N	I-Premise
325	6	N	I-Premise
326	%	N	I-Premise
327	)	N	I-Premise
328	or	N	I-Premise
329	FU	N	I-Premise
330	+	N	I-Premise
331	LV	N	I-Premise
332	(	N	I-Premise
333	9	N	I-Premise
334	%	N	I-Premise
335	)	N	I-Premise
336	arms	N	I-Premise
337	;	N	I-Premise
338	however	N	I-Premise
339	,	N	I-Premise
340	stomatitis	N	I-Premise
341	(	N	I-Premise
342	11	N	I-Premise
343	%	N	I-Premise
344	in	N	I-Premise
345	FU	N	I-Premise
346	+	N	I-Premise
347	LV	N	I-Premise
348	v	N	I-Premise
349	3	N	I-Premise
350	%	N	I-Premise
351	in	N	I-Premise
352	FU24h	N	I-Premise
353	v	N	I-Premise
354	5	N	I-Premise
355	%	N	I-Premise
356	in	N	I-Premise
357	FU24h	N	I-Premise
358	+	N	I-Premise
359	LV	N	I-Premise
360	arms	N	I-Premise
361	)	N	I-Premise
362	and	N	I-Premise
363	hematologic	N	I-Premise
364	toxicity	N	I-Premise
365	were	N	I-Premise
366	higher	N	I-Premise
367	in	N	I-Premise
368	the	N	I-Premise
369	bolus	N	I-Premise
370	FU	N	I-Premise
371	+	N	I-Premise
372	LV	N	I-Premise
373	arm	N	I-Premise
374	.	N	I-Premise

375	Global	N	I-Claim
376	quality	N	I-Claim
377	of	N	I-Claim
378	life	N	I-Claim
379	did	N	I-Claim
380	not	N	I-Claim
381	differ	N	I-Claim
382	within	N	I-Claim
383	the	N	I-Claim
384	three	N	I-Claim
385	arms	N	I-Claim
386	.	N	I-Claim

387	Neither	N	I-Claim
388	FU24h	N	I-Claim
389	+	N	I-Claim
390	LV	N	I-Claim
391	nor	N	I-Claim
392	FU24h	N	I-Claim
393	prolong	N	I-Claim
394	survival	N	I-Claim
395	,	N	I-Claim
396	relative	N	I-Claim
397	to	N	I-Claim
398	bolus	N	I-Claim
399	FU	N	I-Claim
400	+	N	I-Claim
401	LV	N	I-Claim
402	.	N	I-Claim

403	Leucovorin	N	I-Claim
404	increases	N	I-Claim
405	PFS	N	I-Claim
406	if	N	I-Claim
407	added	N	I-Claim
408	to	N	I-Claim
409	FU24h	N	I-Claim
410	,	N	I-Claim
411	but	N	I-Claim
412	increases	N	I-Claim
413	toxicity	N	I-Claim
414	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	patient-reported	N	O
4	prostate	N	O
5	cancer-specific	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	2	N	O
10	and	N	O
11	3	N	O
12	years	N	O
13	after	N	O
14	radiotherapy	N	O
15	to	N	O
16	the	N	O
17	prostate	N	O
18	in	N	O
19	a	N	O
20	randomized	N	O
21	dose-escalation	N	O
22	trial	N	O
23	of	N	O
24	70	N	O
25	versus	N	O
26	78	N	O
27	Gy	N	O
28	conducted	N	O
29	from	N	O
30	1993	N	O
31	to	N	O
32	1998	N	O
33	.	N	O

34	Two	N	O
35	years	N	O
36	after	N	O
37	completing	N	O
38	radiotherapy	N	O
39	,	N	O
40	a	N	O
41	questionnaire	N	O
42	that	N	O
43	assessed	N	O
44	bladder	N	O
45	,	N	O
46	rectal	N	O
47	,	N	O
48	and	N	O
49	sexual	N	O
50	function	N	O
51	was	N	O
52	sent	N	O
53	to	N	O
54	301	N	O
55	patients	N	O
56	in	N	O
57	the	N	O
58	study	N	O
59	.	N	O

60	Three	N	O
61	years	N	O
62	after	N	O
63	treatment	N	O
64	,	N	O
65	a	N	O
66	second	N	O
67	questionnaire	N	O
68	was	N	O
69	sent	N	O
70	to	N	O
71	the	N	O
72	175	N	O
73	patients	N	O
74	with	N	O
75	adequate	N	O
76	follow-up	N	O
77	.	N	O

78	Three	N	I-Premise
79	years	N	I-Premise
80	after	N	I-Premise
81	radiotherapy	N	I-Premise
82	,	N	I-Premise
83	urinary	N	I-Premise
84	incontinence	N	I-Premise
85	was	N	I-Premise
86	reported	N	I-Premise
87	by	N	I-Premise
88	35	N	I-Premise
89	%	N	I-Premise
90	of	N	I-Premise
91	patients	N	I-Premise
92	,	N	I-Premise
93	but	N	I-Premise
94	only	N	I-Premise
95	6	N	I-Premise
96	%	N	I-Premise
97	required	N	I-Premise
98	the	N	I-Premise
99	use	N	I-Premise
100	of	N	I-Premise
101	a	N	I-Premise
102	pad	N	I-Premise
103	or	N	I-Premise
104	other	N	I-Premise
105	protective	N	I-Premise
106	device	N	I-Premise
107	.	N	I-Premise

108	Patients	N	I-Premise
109	reported	N	I-Premise
110	increased	N	I-Premise
111	leakage	N	I-Premise
112	with	N	I-Premise
113	a	N	I-Premise
114	full	N	I-Premise
115	bladder	N	I-Premise
116	(	N	I-Premise
117	urge	N	I-Premise
118	incontinence	N	I-Premise
119	)	N	I-Premise
120	between	N	I-Premise
121	the	N	I-Premise
122	2	N	I-Premise
123	and	N	I-Premise
124	3-year	N	I-Premise
125	questionnaires	N	I-Premise
126	(	N	I-Premise
127	42	N	I-Premise
128	%	N	I-Premise
129	versus	N	I-Premise
130	50	N	I-Premise
131	%	N	I-Premise
132	;	N	I-Premise
133	P	N	I-Premise
134	=	N	I-Premise
135	0.03	N	I-Premise
136	)	N	I-Premise
137	.	N	I-Premise

138	At	N	I-Premise
139	3	N	I-Premise
140	years	N	I-Premise
141	,	N	I-Premise
142	33	N	I-Premise
143	%	N	I-Premise
144	of	N	I-Premise
145	patients	N	I-Premise
146	reported	N	I-Premise
147	rectal	N	I-Premise
148	bleeding	N	I-Premise
149	compared	N	I-Premise
150	with	N	I-Premise
151	47	N	I-Premise
152	%	N	I-Premise
153	at	N	I-Premise
154	2	N	I-Premise
155	years	N	I-Premise
156	(	N	I-Premise
157	P	N	I-Premise
158	=	N	I-Premise
159	0.006	N	I-Premise
160	)	N	I-Premise
161	.	N	I-Premise

162	Patients	N	I-Premise
163	in	N	I-Premise
164	the	N	I-Premise
165	78-Gy	N	I-Premise
166	arm	N	I-Premise
167	reported	N	I-Premise
168	more	N	I-Premise
169	frequent	N	I-Premise
170	bowel	N	I-Premise
171	movements	N	I-Premise
172	at	N	I-Premise
173	3	N	I-Premise
174	years	N	I-Premise
175	and	N	I-Premise
176	less	N	I-Premise
177	change	N	I-Premise
178	in	N	I-Premise
179	bowel	N	I-Premise
180	function	N	I-Premise
181	at	N	I-Premise
182	2	N	I-Premise
183	years	N	I-Premise
184	than	N	I-Premise
185	patients	N	I-Premise
186	in	N	I-Premise
187	the	N	I-Premise
188	70-Gy	N	I-Premise
189	arm	N	I-Premise
190	.	N	I-Premise

191	Before	N	I-Premise
192	radiotherapy	N	I-Premise
193	,	N	I-Premise
194	84	N	I-Premise
195	%	N	I-Premise
196	of	N	I-Premise
197	patients	N	I-Premise
198	reported	N	I-Premise
199	erections	N	I-Premise
200	adequate	N	I-Premise
201	for	N	I-Premise
202	intercourse	N	I-Premise
203	at	N	I-Premise
204	least	N	I-Premise
205	a	N	I-Premise
206	few	N	I-Premise
207	times	N	I-Premise
208	during	N	I-Premise
209	the	N	I-Premise
210	previous	N	I-Premise
211	year	N	I-Premise
212	.	N	I-Premise

213	After	N	I-Premise
214	2	N	I-Premise
215	and	N	I-Premise
216	3	N	I-Premise
217	years	N	I-Premise
218	,	N	I-Premise
219	this	N	I-Premise
220	had	N	I-Premise
221	decreased	N	I-Premise
222	to	N	I-Premise
223	49	N	I-Premise
224	%	N	I-Premise
225	and	N	I-Premise
226	41	N	I-Premise
227	%	N	I-Premise
228	,	N	I-Premise
229	respectively	N	I-Premise
230	(	N	I-Premise
231	P	N	I-Premise
232	<	N	I-Premise
233	0.02	N	I-Premise
234	)	N	I-Premise
235	.	N	I-Premise

236	By	N	I-Claim
237	patient-reported	N	I-Claim
238	questionnaire	N	I-Claim
239	,	N	I-Claim
240	78	N	I-Claim
241	Gy	N	I-Claim
242	produced	N	I-Claim
243	an	N	I-Claim
244	increase	N	I-Claim
245	in	N	I-Claim
246	bowel	N	I-Claim
247	movement	N	I-Claim
248	frequency	N	I-Claim
249	and	N	I-Claim
250	no	N	I-Claim
251	increase	N	I-Claim
252	in	N	I-Claim
253	bladder	N	I-Claim
254	or	N	I-Claim
255	sexual	N	I-Claim
256	side	N	I-Claim
257	effects	N	I-Claim
258	at	N	I-Claim
259	3	N	I-Claim
260	years	N	I-Claim
261	compared	N	I-Claim
262	with	N	I-Claim
263	70	N	I-Claim
264	Gy	N	I-Claim
265	.	N	I-Claim

266	Comparing	N	I-Claim
267	the	N	I-Claim
268	results	N	I-Claim
269	2	N	I-Claim
270	and	N	I-Claim
271	3	N	I-Claim
272	years	N	I-Claim
273	after	N	I-Claim
274	radiotherapy	N	I-Claim
275	,	N	I-Claim
276	the	N	I-Claim
277	symptoms	N	I-Claim
278	of	N	I-Claim
279	rectal	N	I-Claim
280	bleeding	N	I-Claim
281	had	N	I-Claim
282	improved	N	I-Claim
283	,	N	I-Claim
284	erectile	N	I-Claim
285	function	N	I-Claim
286	had	N	I-Claim
287	decreased	N	I-Claim
288	,	N	I-Claim
289	and	N	I-Claim
290	urinary	N	I-Claim
291	urge	N	I-Claim
292	incontinence	N	I-Claim
293	had	N	I-Claim
294	increased	N	I-Claim
295	.	N	I-Claim

1	In	N	I-Premise
2	a	N	I-Premise
3	multinational	N	I-Premise
4	trial	N	I-Premise
5	of	N	I-Premise
6	anaemic	N	I-Premise
7	patients	N	I-Premise
8	with	N	I-Premise
9	cancer	N	I-Premise
10	receiving	N	I-Premise
11	nonplatinum-containing	N	I-Premise
12	chemotherapy	N	I-Premise
13	,	N	I-Premise
14	epoetin-alfa	N	I-Premise
15	effectively	N	I-Premise
16	increased	N	I-Premise
17	haemoglobin	N	I-Premise
18	levels	N	I-Premise
19	,	N	I-Premise
20	reduced	N	I-Premise
21	red	N	I-Premise
22	blood	N	I-Premise
23	cell	N	I-Premise
24	transfusion	N	I-Premise
25	requirements	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	improved	N	I-Premise
29	QOL	N	I-Premise
30	.	N	I-Premise

31	Although	N	O
32	the	N	O
33	study	N	O
34	was	N	O
35	not	N	O
36	designed	N	O
37	or	N	O
38	powered	N	O
39	to	N	O
40	evaluate	N	O
41	survival	N	O
42	,	N	O
43	a	N	I-Premise
44	survival	N	I-Premise
45	trend	N	I-Premise
46	was	N	I-Premise
47	noted	N	I-Premise
48	favouring	N	I-Premise
49	epoetin-alfa	N	I-Premise
50	compared	N	I-Premise
51	with	N	I-Premise
52	placebo	N	I-Premise
53	(	N	I-Premise
54	median	N	I-Premise
55	survival	N	I-Premise
56	17	N	I-Premise
57	vs	N	I-Premise
58	11	N	I-Premise
59	months	N	I-Premise
60	[	N	I-Premise
61	p	N	I-Premise
62	=	N	I-Premise
63	0.126	N	I-Premise
64	]	N	I-Premise
65	)	N	I-Premise
66	.	N	I-Premise

67	To	N	O
68	determine	N	O
69	the	N	O
70	incremental	N	O
71	cost	N	O
72	utility	N	O
73	of	N	O
74	epoetin-alfa	N	O
75	versus	N	O
76	placebo	N	O
77	in	N	O
78	anaemic	N	O
79	patients	N	O
80	with	N	O
81	stage	N	O
82	IV	N	O
83	breast	N	O
84	cancer	N	O
85	from	N	O
86	a	N	O
87	UK	N	O
88	National	N	O
89	Health	N	O
90	Service	N	O
91	perspective	N	O
92	.	N	O

93	Patient	N	O
94	data	N	O
95	regarding	N	O
96	transfusions	N	O
97	,	N	O
98	epoetin-alfa	N	O
99	usage	N	O
100	,	N	O
101	chemotherapy	N	O
102	treatment	N	O
103	cycles	N	O
104	,	N	O
105	and	N	O
106	adverse	N	O
107	events	N	O
108	were	N	O
109	recorded	N	O
110	,	N	O
111	with	N	O
112	survival	N	O
113	follow-up	N	O
114	for	N	O
115	12-36	N	O
116	months	N	O
117	post-study	N	O
118	.	N	O

119	Stage	N	O
120	IV	N	O
121	breast	N	O
122	cancer	N	O
123	therapy	N	O
124	costs	N	O
125	were	N	O
126	collected	N	O
127	by	N	O
128	surveying	N	O
129	UK	N	O
130	oncologists	N	O
131	,	N	O
132	and	N	O
133	utilities	N	O
134	for	N	O
135	associated	N	O
136	health	N	O
137	states	N	O
138	were	N	O
139	from	N	O
140	published	N	O
141	sources	N	O
142	.	N	O

143	Costs	N	O
144	were	N	O
145	in	N	O
146	British	N	O
147	pounds	N	O
148	and	N	O
149	year	N	O
150	2000	N	O
151	values	N	O
152	.	N	O

153	Costs	N	O
154	and	N	O
155	benefits	N	O
156	were	N	O
157	jointly	N	O
158	determined	N	O
159	for	N	O
160	the	N	O
161	stage	N	O
162	IV	N	O
163	breast	N	O
164	cancer	N	O
165	subgroup	N	O
166	(	N	O
167	n	N	O
168	=	N	O
169	55	N	O
170	)	N	O
171	.	N	O

172	Incremental	N	O
173	cost-utility	N	O
174	ratios	N	O
175	(	N	O
176	ICURs	N	O
177	)	N	O
178	were	N	O
179	calculated	N	O
180	assuming	N	O
181	a	N	O
182	6	N	O
183	%	N	O
184	annual	N	O
185	discount	N	O
186	rate	N	O
187	for	N	O
188	costs	N	O
189	and	N	O
190	a	N	O
191	1.5	N	O
192	%	N	O
193	annual	N	O
194	discount	N	O
195	rate	N	O
196	for	N	O
197	benefits	N	O
198	.	N	O

199	Bootstrap	N	O
200	simulations	N	O
201	(	N	O
202	10,000	N	O
203	iterations	N	O
204	)	N	O
205	were	N	O
206	conducted	N	O
207	to	N	O
208	account	N	O
209	for	N	O
210	uncertainty	N	O
211	,	N	O
212	and	N	O
213	sensitivity	N	O
214	analyses	N	O
215	were	N	O
216	conducted	N	O
217	to	N	O
218	establish	N	O
219	robustness	N	O
220	.	N	O

221	The	N	I-Premise
222	ICUR	N	I-Premise
223	for	N	I-Premise
224	epoetin-alfa	N	I-Premise
225	treatment	N	I-Premise
226	was	N	I-Premise
227	pounds	N	I-Premise
228	8,851	N	I-Premise
229	per	N	I-Premise
230	QALY	N	I-Premise
231	,	N	I-Premise
232	with	N	I-Premise
233	a	N	I-Premise
234	99	N	I-Premise
235	%	N	I-Premise
236	probability	N	I-Premise
237	of	N	I-Premise
238	a	N	I-Premise
239	positive	N	I-Premise
240	net	N	I-Premise
241	benefit	N	I-Premise
242	in	N	I-Premise
243	QALYs	N	I-Premise
244	(	N	I-Premise
245	net	N	I-Premise
246	benefit	N	I-Premise
247	=	N	I-Premise
248	0.4805	N	I-Premise
249	years	N	I-Premise
250	of	N	I-Premise
251	perfect	N	I-Premise
252	life	N	I-Premise
253	)	N	I-Premise
254	and	N	I-Premise
255	a	N	I-Premise
256	94	N	I-Premise
257	%	N	I-Premise
258	probability	N	I-Premise
259	of	N	I-Premise
260	being	N	I-Premise
261	acceptable	N	I-Premise
262	using	N	I-Premise
263	a	N	I-Premise
264	threshold	N	I-Premise
265	ICUR	N	I-Premise
266	of	N	I-Premise
267	pounds	N	I-Premise
268	30,000/QALY	N	I-Premise
269	.	N	I-Premise

270	The	N	I-Premise
271	main	N	I-Premise
272	cost	N	I-Premise
273	drivers	N	I-Premise
274	distinguishing	N	I-Premise
275	epoetin-alfa	N	I-Premise
276	from	N	I-Premise
277	placebo	N	I-Premise
278	were	N	I-Premise
279	the	N	I-Premise
280	costs	N	I-Premise
281	of	N	I-Premise
282	drug	N	I-Premise
283	and	N	I-Premise
284	patient	N	I-Premise
285	care	N	I-Premise
286	due	N	I-Premise
287	to	N	I-Premise
288	increased	N	I-Premise
289	survival	N	I-Premise
290	.	N	I-Premise

291	The	N	I-Claim
292	available	N	I-Claim
293	data	N	I-Claim
294	suggest	N	I-Claim
295	a	N	I-Claim
296	high	N	I-Claim
297	probability	N	I-Claim
298	of	N	I-Claim
299	favourable	N	I-Claim
300	cost-utility	N	I-Claim
301	outcomes	N	I-Claim
302	with	N	I-Claim
303	epoetin-alfa	N	I-Claim
304	treatment	N	I-Claim
305	for	N	I-Claim
306	anaemia	N	I-Claim
307	in	N	I-Claim
308	patients	N	I-Claim
309	with	N	I-Claim
310	stage	N	I-Claim
311	IV	N	I-Claim
312	breast	N	I-Claim
313	cancer	N	I-Claim
314	receiving	N	I-Claim
315	nonplatinum-containing	N	I-Claim
316	chemotherapy	N	I-Claim
317	.	N	I-Claim

318	Additional	N	I-Claim
319	studies	N	I-Claim
320	are	N	I-Claim
321	warranted	N	I-Claim
322	.	N	I-Claim

1	In	N	I-Claim
2	advanced	N	I-Claim
3	not	N	I-Claim
4	selected	N	I-Claim
5	NSCLC	N	I-Claim
6	chemotherapy	N	I-Claim
7	achieved	N	I-Claim
8	an	N	I-Claim
9	advantage	N	I-Claim
10	of	N	I-Claim
11	approximately	N	I-Claim
12	1-2	N	I-Claim
13	months	N	I-Claim
14	on	N	I-Claim
15	median	N	I-Claim
16	survival	N	I-Claim
17	versus	N	I-Claim
18	best	N	I-Claim
19	supportive	N	I-Claim
20	care	N	I-Claim
21	.	N	I-Claim

22	Chemotherapy	N	I-Claim
23	seems	N	I-Claim
24	to	N	I-Claim
25	improve	N	I-Claim
26	symptoms	N	I-Claim
27	control	N	I-Claim
28	,	N	I-Claim
29	even	N	O
30	if	N	O
31	randomised	N	O
32	studies	N	O
33	with	N	O
34	quality	N	O
35	of	N	O
36	life	N	O
37	as	N	O
38	first	N	O
39	endpoint	N	O
40	are	N	O
41	lacking	N	O
42	and	N	O
43	often	N	O
44	chemotherapy	N	O
45	toxicity	N	O
46	compromises	N	O
47	the	N	O
48	frail	N	O
49	cost/benefit	N	O
50	ratio	N	O
51	.	N	O

52	The	N	O
53	aim	N	O
54	of	N	O
55	the	N	O
56	present	N	O
57	study	N	O
58	is	N	O
59	to	N	O
60	evaluate	N	O
61	the	N	O
62	impact	N	O
63	on	N	O
64	QoL	N	O
65	,	N	O
66	substituting	N	O
67	cisplatin	N	O
68	,	N	O
69	a	N	O
70	pivot	N	O
71	drug	N	O
72	in	N	O
73	NSCLC	N	O
74	therapy	N	O
75	,	N	O
76	with	N	O
77	carboplatin	N	O
78	,	N	O
79	an	N	O
80	analogue	N	O
81	with	N	O
82	an	N	O
83	improved	N	O
84	toxicity	N	O
85	profile	N	O
86	.	N	O

87	The	N	O
88	combination	N	O
89	of	N	O
90	cisplatin	N	O
91	with	N	O
92	Mitomycin	N	O
93	and	N	O
94	Vinblastine	N	O
95	was	N	O
96	one	N	O
97	of	N	O
98	the	N	O
99	most	N	O
100	frequently	N	O
101	used	N	O
102	in	N	O
103	the	N	O
104	palliative	N	O
105	setting	N	O
106	at	N	O
107	the	N	O
108	time	N	O
109	of	N	O
110	design	N	O
111	of	N	O
112	our	N	O
113	study	N	O
114	.	N	O

115	Patients	N	O
116	were	N	O
117	randomized	N	O
118	to	N	O
119	receive	N	O
120	MVP	N	O
121	regimen	N	O
122	(	N	O
123	Mitomycin-C	N	O
124	8	N	O
125	mg/m2	N	O
126	d1	N	O
127	,	N	O
128	Vinblastine	N	O
129	4	N	O
130	mg/m2	N	O
131	d	N	O
132	1-8	N	O
133	,	N	O
134	Cisplatin	N	O
135	100	N	O
136	mg/m2	N	O
137	d1	N	O
138	)	N	O
139	or	N	O
140	MVC	N	O
141	regimen	N	O
142	(	N	O
143	Mitomycin-C	N	O
144	8	N	O
145	mg/m2	N	O
146	d1	N	O
147	,	N	O
148	Vinblastine	N	O
149	4	N	O
150	mg/m2	N	O
151	d	N	O
152	1-8	N	O
153	,	N	O
154	Carboplatin	N	O
155	300	N	O
156	mg/m2	N	O
157	d1	N	O
158	)	N	O
159	every	N	O
160	3	N	O
161	weeks	N	O
162	.	N	O

163	The	N	O
164	QoL	N	O
165	was	N	O
166	evaluated	N	O
167	by	N	O
168	the	N	O
169	Spitzer	N	O
170	QL-Index	N	O
171	and	N	O
172	by	N	O
173	the	N	O
174	EORTC	N	O
175	QLQ-C30+LC	N	O
176	13	N	O
177	questionnaires	N	O
178	before	N	O
179	chemotherapy	N	O
180	,	N	O
181	after	N	O
182	one	N	O
183	cycle	N	O
184	,	N	O
185	after	N	O
186	three	N	O
187	cycles	N	O
188	,	N	O
189	and	N	O
190	then	N	O
191	every	N	O
192	6	N	O
193	weeks	N	O
194	in	N	O
195	the	N	O
196	first	N	O
197	6	N	O
198	months	N	O
199	and	N	O
200	every	N	O
201	3	N	O
202	months	N	O
203	thenafter	N	O
204	.	N	O

205	From	N	O
206	September	N	O
207	1994	N	O
208	to	N	O
209	July	N	O
210	1997	N	O
211	,	N	O
212	153	N	O
213	consecutive	N	O
214	patients	N	O
215	were	N	O
216	randomized	N	O
217	to	N	O
218	MVP	N	O
219	(	N	O
220	75	N	O
221	patients	N	O
222	)	N	O
223	or	N	O
224	MVC	N	O
225	arm	N	O
226	(	N	O
227	78	N	O
228	patients	N	O
229	)	N	O
230	.	N	O

231	Despite	N	I-Premise
232	difficulties	N	I-Premise
233	in	N	I-Premise
234	carrying	N	I-Premise
235	out	N	I-Premise
236	and	N	I-Premise
237	analysing	N	I-Premise
238	QoL	N	I-Premise
239	items	N	I-Premise
240	in	N	I-Premise
241	such	N	I-Premise
242	patients	N	I-Premise
243	,	N	I-Premise
244	the	N	I-Premise
245	global	N	I-Premise
246	QoL	N	I-Premise
247	evaluated	N	I-Premise
248	by	N	I-Premise
249	the	N	I-Premise
250	Spitzer	N	I-Premise
251	's	N	I-Premise
252	questionnaire	N	I-Premise
253	suggested	N	I-Premise
254	an	N	I-Premise
255	advantage	N	I-Premise
256	for	N	I-Premise
257	MVC	N	I-Premise
258	regimen	N	I-Premise
259	(	N	I-Premise
260	P=0.05	N	I-Premise
261	)	N	I-Premise
262	and	N	I-Premise
263	a	N	I-Premise
264	significant	N	I-Premise
265	difference	N	I-Premise
266	was	N	I-Premise
267	observed	N	I-Premise
268	in	N	I-Premise
269	global	N	I-Premise
270	health	N	I-Premise
271	subdomain	N	I-Premise
272	(	N	I-Premise
273	P=0.04	N	I-Premise
274	)	N	I-Premise
275	.	N	I-Premise

276	The	N	I-Premise
277	disease-related	N	I-Premise
278	symptoms	N	I-Premise
279	improved	N	I-Premise
280	with	N	I-Premise
281	time	N	I-Premise
282	,	N	I-Premise
283	and	N	O
284	the	N	I-Premise
285	benefits	N	I-Premise
286	lasted	N	I-Premise
287	for	N	I-Premise
288	the	N	I-Premise
289	entire	N	I-Premise
290	treatment	N	I-Premise
291	period	N	I-Premise
292	.	N	I-Premise

293	When	N	I-Premise
294	evaluated	N	I-Premise
295	with	N	I-Premise
296	the	N	I-Premise
297	EORTC	N	I-Premise
298	questionnaire	N	I-Premise
299	there	N	I-Premise
300	was	N	I-Premise
301	significantly	N	I-Premise
302	less	N	I-Premise
303	nausea	N	I-Premise
304	and	N	I-Premise
305	vomiting	N	I-Premise
306	(	N	I-Premise
307	P=0.0001	N	I-Premise
308	)	N	I-Premise
309	,	N	I-Premise
310	appetite	N	I-Premise
311	loss	N	I-Premise
312	(	N	I-Premise
313	P=0.01	N	I-Premise
314	)	N	I-Premise
315	,	N	I-Premise
316	insomnia	N	I-Premise
317	(	N	I-Premise
318	P=0.03	N	I-Premise
319	)	N	I-Premise
320	,	N	I-Premise
321	constipation	N	I-Premise
322	(	N	I-Premise
323	P=0.01	N	I-Premise
324	)	N	I-Premise
325	and	N	I-Premise
326	peripheral	N	I-Premise
327	neuropathy	N	I-Premise
328	(	N	I-Premise
329	P=0.01	N	I-Premise
330	)	N	I-Premise
331	in	N	I-Premise
332	favour	N	I-Premise
333	of	N	I-Premise
334	MVC	N	I-Premise
335	,	N	I-Premise
336	and	N	I-Premise
337	a	N	I-Premise
338	trend	N	I-Premise
339	for	N	I-Premise
340	less	N	I-Premise
341	hair	N	I-Premise
342	loss	N	I-Premise
343	(	N	I-Premise
344	P=0.05	N	I-Premise
345	)	N	I-Premise
346	.	N	I-Premise

347	The	N	I-Premise
348	advantage	N	I-Premise
349	lasted	N	I-Premise
350	for	N	I-Premise
351	all	N	I-Premise
352	the	N	I-Premise
353	duration	N	I-Premise
354	of	N	I-Premise
355	chemotherapy	N	I-Premise
356	.	N	I-Premise

357	No	N	I-Premise
358	differences	N	I-Premise
359	were	N	I-Premise
360	observed	N	I-Premise
361	in	N	I-Premise
362	global	N	I-Premise
363	quality	N	I-Premise
364	of	N	I-Premise
365	life	N	I-Premise
366	subdomain	N	I-Premise
367	(	N	I-Premise
368	P=0.40	N	I-Premise
369	)	N	I-Premise
370	between	N	I-Premise
371	the	N	I-Premise
372	two	N	I-Premise
373	regimen	N	I-Premise
374	.	N	I-Premise

375	QoL	N	O
376	was	N	O
377	the	N	O
378	first	N	O
379	endpoint	N	O
380	and	N	O
381	the	N	O
382	statistical	N	O
383	power	N	O
384	was	N	O
385	inadequate	N	O
386	to	N	O
387	assess	N	O
388	other	N	O
389	parameters	N	O
390	.	N	O

391	However	N	O
392	,	N	O
393	we	N	I-Premise
394	reported	N	I-Premise
395	a	N	I-Premise
396	response	N	I-Premise
397	rate	N	I-Premise
398	of	N	I-Premise
399	43.1	N	I-Premise
400	and	N	I-Premise
401	38.6	N	I-Premise
402	%	N	I-Premise
403	,	N	I-Premise
404	respectively	N	I-Premise
405	,	N	I-Premise
406	in	N	I-Premise
407	MVP	N	I-Premise
408	and	N	I-Premise
409	MVC	N	I-Premise
410	arm	N	I-Premise
411	(	N	I-Premise
412	P=0.59	N	I-Premise
413	)	N	I-Premise
414	and	N	I-Premise
415	a	N	I-Premise
416	median	N	I-Premise
417	survival	N	I-Premise
418	of	N	I-Premise
419	10.2	N	I-Premise
420	and	N	I-Premise
421	7.2	N	I-Premise
422	months	N	I-Premise
423	,	N	I-Premise
424	respectively	N	I-Premise
425	,	N	I-Premise
426	for	N	I-Premise
427	cisplatin	N	I-Premise
428	and	N	I-Premise
429	carboplatin	N	I-Premise
430	arm	N	I-Premise
431	(	N	I-Premise
432	P=0.39	N	I-Premise
433	)	N	I-Premise
434	.	N	I-Premise

435	The	N	I-Premise
436	carboplatin	N	I-Premise
437	containing	N	I-Premise
438	regimen	N	I-Premise
439	(	N	I-Premise
440	MVC	N	I-Premise
441	)	N	I-Premise
442	has	N	I-Premise
443	a	N	I-Premise
444	significant	N	I-Premise
445	better	N	I-Premise
446	toxicity	N	I-Premise
447	profile	N	I-Premise
448	than	N	I-Premise
449	the	N	I-Premise
450	cisplatin	N	I-Premise
451	containing	N	I-Premise
452	(	N	I-Premise
453	MVP	N	I-Premise
454	)	N	I-Premise
455	regimen	N	I-Premise
456	as	N	I-Premise
457	proven	N	I-Premise
458	both	N	I-Premise
459	by	N	I-Premise
460	the	N	I-Premise
461	EORTC	N	I-Premise
462	questionnaires	N	I-Premise
463	and	N	I-Premise
464	by	N	I-Premise
465	the	N	I-Premise
466	WHO	N	I-Premise
467	toxicity	N	I-Premise
468	data	N	I-Premise
469	reported	N	I-Premise
470	by	N	I-Premise
471	physicians	N	I-Premise
472	.	N	I-Premise

473	No	N	I-Claim
474	significant	N	I-Claim
475	differences	N	I-Claim
476	in	N	I-Claim
477	terms	N	I-Claim
478	of	N	I-Claim
479	response	N	I-Claim
480	rate	N	I-Claim
481	,	N	I-Claim
482	time	N	I-Claim
483	to	N	I-Claim
484	progression	N	I-Claim
485	and	N	I-Claim
486	overall	N	I-Claim
487	survival	N	I-Claim
488	were	N	I-Claim
489	observed	N	I-Claim
490	between	N	I-Claim
491	the	N	I-Claim
492	two	N	I-Claim
493	regimen	N	I-Claim
494	.	N	I-Claim

495	The	N	I-Claim
496	two	N	I-Claim
497	chemotherapy	N	I-Claim
498	regimen	N	I-Claim
499	showed	N	I-Claim
500	a	N	I-Claim
501	similar	N	I-Claim
502	effectiveness	N	I-Claim
503	in	N	I-Claim
504	symptom	N	I-Claim
505	palliation	N	I-Claim
506	when	N	I-Claim
507	evaluated	N	I-Claim
508	with	N	I-Claim
509	C30	N	I-Claim
510	addendum	N	I-Claim
511	of	N	I-Claim
512	EORTC	N	I-Claim
513	QOL	N	I-Claim
514	questionnaire	N	I-Claim
515	.	N	I-Claim

516	With	N	I-Premise
517	the	N	I-Premise
518	Spitzer	N	I-Premise
519	's	N	I-Premise
520	questionnaires	N	I-Premise
521	a	N	I-Premise
522	trend	N	I-Premise
523	towards	N	I-Premise
524	an	N	I-Premise
525	improved	N	I-Premise
526	quality	N	I-Premise
527	of	N	I-Premise
528	life	N	I-Premise
529	index	N	I-Premise
530	was	N	I-Premise
531	observed	N	I-Premise
532	during	N	I-Premise
533	treatment	N	I-Premise
534	with	N	I-Premise
535	the	N	I-Premise
536	carboplatin	N	I-Premise
537	combination	N	I-Premise
538	in	N	I-Premise
539	comparison	N	I-Premise
540	to	N	I-Premise
541	the	N	I-Premise
542	cisplatin	N	I-Premise
543	combination	N	I-Premise
544	.	N	I-Premise

545	This	N	I-Premise
546	difference	N	I-Premise
547	,	N	I-Premise
548	however	N	I-Premise
549	,	N	I-Premise
550	was	N	I-Premise
551	not	N	I-Premise
552	observed	N	I-Premise
553	when	N	I-Premise
554	the	N	I-Premise
555	global	N	I-Premise
556	quality	N	I-Premise
557	of	N	I-Premise
558	life	N	I-Premise
559	was	N	I-Premise
560	evaluated	N	I-Premise
561	with	N	I-Premise
562	the	N	I-Premise
563	EORTC	N	I-Premise
564	patients	N	I-Premise
565	compiled	N	I-Premise
566	questionnaires	N	I-Premise
567	.	N	I-Premise

568	A	N	I-Claim
569	carboplatin	N	I-Claim
570	containing	N	I-Claim
571	regimen	N	I-Claim
572	with	N	I-Claim
573	better	N	I-Claim
574	toxicity	N	I-Claim
575	profile	N	I-Claim
576	and	N	I-Claim
577	a	N	I-Claim
578	similar	N	I-Claim
579	potentiality	N	I-Claim
580	for	N	I-Claim
581	symptoms	N	I-Claim
582	control	N	I-Claim
583	offers	N	I-Claim
584	an	N	I-Claim
585	option	N	I-Claim
586	in	N	I-Claim
587	comparison	N	I-Claim
588	to	N	I-Claim
589	similar	N	I-Claim
590	cisplatin	N	I-Claim
591	containing	N	I-Claim
592	combinations	N	I-Claim
593	in	N	I-Claim
594	the	N	I-Claim
595	palliative	N	I-Claim
596	treatment	N	I-Claim
597	of	N	I-Claim
598	advanced	N	I-Claim
599	NSCLC	N	I-Claim
600	.	N	I-Claim

1	N	N	O
2	,	N	O
3	N-diethyl-2-	N	O
4	[	N	O
5	4-	N	O
6	(	N	O
7	phenylmethyl	N	O
8	)	N	O
9	phenoxy	N	O
10	]	N	O
11	ethanamine	N	O
12	(	N	O
13	DPPE	N	O
14	;	N	O
15	tesmilifene	N	O
16	)	N	O
17	is	N	O
18	a	N	O
19	novel	N	O
20	agent	N	O
21	that	N	O
22	augments	N	O
23	chemotherapy	N	O
24	cytotoxicity	N	O
25	in	N	O
26	vitro	N	O
27	and	N	O
28	in	N	O
29	vivo	N	O
30	.	N	O

31	A	N	O
32	phase	N	O
33	II	N	O
34	trial	N	O
35	combining	N	O
36	DPPE	N	O
37	and	N	O
38	doxorubicin	N	O
39	(	N	O
40	DOX	N	O
41	)	N	O
42	in	N	O
43	metastatic	N	O
44	breast	N	O
45	carcinoma	N	O
46	showed	N	O
47	increased	N	O
48	response	N	O
49	over	N	O
50	that	N	O
51	expected	N	O
52	with	N	O
53	DOX	N	O
54	.	N	O

55	We	N	O
56	report	N	O
57	a	N	O
58	phase	N	O
59	III	N	O
60	trial	N	O
61	comparing	N	O
62	DOX	N	O
63	with	N	O
64	DPPE	N	O
65	plus	N	O
66	DOX	N	O
67	in	N	O
68	metastatic	N	O
69	or	N	O
70	recurrent	N	O
71	breast	N	O
72	cancer	N	O
73	.	N	O

74	Anthracycline-naive	N	O
75	women	N	O
76	with	N	O
77	measurable	N	O
78	metastatic	N	O
79	disease	N	O
80	were	N	O
81	randomly	N	O
82	assigned	N	O
83	to	N	O
84	receive	N	O
85	,	N	O
86	every	N	O
87	21	N	O
88	days	N	O
89	,	N	O
90	either	N	O
91	DOX	N	O
92	60	N	O
93	mg/m	N	O
94	(	N	O
95	2	N	O
96	)	N	O
97	intravenously	N	O
98	or	N	O
99	DOX	N	O
100	during	N	O
101	the	N	O
102	last	N	O
103	20	N	O
104	minutes	N	O
105	of	N	O
106	an	N	O
107	80-minute	N	O
108	infusion	N	O
109	of	N	O
110	DPPE	N	O
111	(	N	O
112	5.3	N	O
113	mg/kg	N	O
114	)	N	O
115	,	N	O
116	in	N	O
117	both	N	O
118	cases	N	O
119	to	N	O
120	cumulative	N	O
121	DOX	N	O
122	doses	N	O
123	of	N	O
124	450	N	O
125	mg/m	N	O
126	(	N	O
127	2	N	O
128	)	N	O
129	.	N	O

130	Patients	N	O
131	receiving	N	O
132	DPPE	N	O
133	were	N	O
134	aggressively	N	O
135	premedicated	N	O
136	to	N	O
137	ameliorate	N	O
138	toxicity	N	O
139	.	N	O

140	End	N	O
141	points	N	O
142	included	N	O
143	progression-free	N	O
144	survival	N	O
145	(	N	O
146	PFS	N	O
147	)	N	O
148	,	N	O
149	response	N	O
150	rate	N	O
151	(	N	O
152	RR	N	O
153	)	N	O
154	,	N	O
155	and	N	O
156	response	N	O
157	duration	N	O
158	(	N	O
159	RD	N	O
160	)	N	O
161	,	N	O
162	quality	N	O
163	of	N	O
164	life	N	O
165	(	N	O
166	QOL	N	O
167	)	N	O
168	,	N	O
169	toxicity	N	O
170	,	N	O
171	and	N	O
172	overall	N	O
173	survival	N	O
174	(	N	O
175	OS	N	O
176	)	N	O
177	.	N	O

178	A	N	O
179	planned	N	O
180	interim	N	O
181	analysis	N	O
182	failed	N	O
183	to	N	O
184	detect	N	O
185	an	N	O
186	RR	N	O
187	difference	N	O
188	more	N	O
189	than	N	O
190	5	N	O
191	%	N	O
192	.	N	O

193	The	N	O
194	study	N	O
195	was	N	O
196	closed	N	O
197	to	N	O
198	additional	N	O
199	accrual	N	O
200	and	N	O
201	all	N	O
202	DPPE	N	O
203	was	N	O
204	discontinued	N	O
205	.	N	O

206	The	N	O
207	final	N	O
208	analysis	N	O
209	was	N	O
210	conducted	N	O
211	as	N	O
212	planned	N	O
213	after	N	O
214	256	N	O
215	progression	N	O
216	events	N	O
217	(	N	O
218	median	N	O
219	follow-up	N	O
220	,	N	O
221	20.5	N	O
222	months	N	O
223	)	N	O
224	.	N	O

225	There	N	I-Premise
226	was	N	I-Premise
227	no	N	I-Premise
228	significant	N	I-Premise
229	difference	N	I-Premise
230	in	N	I-Premise
231	RR	N	I-Premise
232	,	N	I-Premise
233	RD	N	I-Premise
234	,	N	I-Premise
235	or	N	I-Premise
236	PFS	N	I-Premise
237	between	N	I-Premise
238	arms	N	I-Premise
239	.	N	I-Premise

240	DPPE	N	I-Premise
241	plus	N	I-Premise
242	DOX	N	I-Premise
243	was	N	I-Premise
244	statistically	N	I-Premise
245	superior	N	I-Premise
246	to	N	I-Premise
247	DOX	N	I-Premise
248	in	N	I-Premise
249	OS	N	I-Premise
250	(	N	I-Premise
251	hazard	N	I-Premise
252	ratio	N	I-Premise
253	,	N	I-Premise
254	0.66	N	I-Premise
255	;	N	I-Premise
256	95	N	I-Premise
257	%	N	I-Premise
258	CI	N	I-Premise
259	,	N	I-Premise
260	0.48	N	I-Premise
261	to	N	I-Premise
262	0.91	N	I-Premise
263	;	N	I-Premise
264	P	N	I-Premise
265	=.021	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	DPPE	N	I-Premise
269	plus	N	I-Premise
270	DOX	N	I-Premise
271	was	N	I-Premise
272	associated	N	I-Premise
273	with	N	I-Premise
274	more	N	I-Premise
275	gastrointestinal	N	I-Premise
276	and	N	I-Premise
277	CNS	N	I-Premise
278	toxicity	N	I-Premise
279	.	N	I-Premise

280	No	N	I-Premise
281	consistent	N	I-Premise
282	influence	N	I-Premise
283	on	N	I-Premise
284	QOL	N	I-Premise
285	was	N	I-Premise
286	detected	N	I-Premise
287	.	N	I-Premise

288	This	N	I-Claim
289	study	N	I-Claim
290	demonstrated	N	I-Claim
291	no	N	I-Claim
292	advantage	N	I-Claim
293	in	N	I-Claim
294	RR	N	I-Claim
295	,	N	I-Claim
296	RD	N	I-Claim
297	,	N	I-Claim
298	or	N	I-Claim
299	PFS	N	I-Claim
300	but	N	I-Claim
301	significantly	N	I-Claim
302	superior	N	I-Claim
303	OS	N	I-Claim
304	for	N	I-Claim
305	DPPE	N	I-Claim
306	plus	N	I-Claim
307	DOX	N	I-Claim
308	.	N	I-Claim

309	Additional	N	I-Claim
310	studies	N	I-Claim
311	of	N	I-Claim
312	DPPE	N	I-Claim
313	are	N	I-Claim
314	warranted	N	I-Claim
315	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	whether	N	O
4	the	N	O
5	effect	N	O
6	of	N	O
7	hypofractionated	N	O
8	thoracic	N	O
9	radiotherapy	N	O
10	(	N	O
11	TRT	N	O
12	)	N	O
13	is	N	O
14	comparable	N	O
15	to	N	O
16	more	N	O
17	standard	N	O
18	fractionated	N	O
19	radiotherapy	N	O
20	(	N	O
21	RT	N	O
22	)	N	O
23	in	N	O
24	advanced	N	O
25	non-small-cell	N	O
26	lung	N	O
27	cancer	N	O
28	(	N	O
29	NSCLC	N	O
30	)	N	O
31	.	N	O

32	A	N	O
33	total	N	O
34	of	N	O
35	421	N	O
36	patients	N	O
37	with	N	O
38	locally	N	O
39	advanced	N	O
40	stage	N	O
41	III	N	O
42	or	N	O
43	stage	N	O
44	IV	N	O
45	NSCLC	N	O
46	tumors	N	O
47	were	N	O
48	included	N	O
49	.	N	O

50	Inclusion	N	O
51	criteria	N	O
52	were	N	O
53	inoperable	N	O
54	,	N	O
55	disease	N	O
56	too	N	O
57	advanced	N	O
58	for	N	O
59	curative	N	O
60	radiotherapy	N	O
61	,	N	O
62	and	N	O
63	chest	N	O
64	symptoms	N	O
65	or	N	O
66	central	N	O
67	tumor	N	O
68	threatening	N	O
69	the	N	O
70	airways	N	O
71	.	N	O

72	Patients	N	O
73	were	N	O
74	randomly	N	O
75	assigned	N	O
76	to	N	O
77	three	N	O
78	arms	N	O
79	:	N	O
80	A	N	O
81	,	N	O
82	17	N	O
83	Gy	N	O
84	per	N	O
85	two	N	O
86	fractions	N	O
87	(	N	O
88	n	N	O
89	=	N	O
90	146	N	O
91	)	N	O
92	;	N	O
93	B	N	O
94	,	N	O
95	42	N	O
96	Gy	N	O
97	per	N	O
98	15	N	O
99	fractions	N	O
100	(	N	O
101	n	N	O
102	=	N	O
103	145	N	O
104	)	N	O
105	;	N	O
106	and	N	O
107	C	N	O
108	,	N	O
109	50	N	O
110	Gy	N	O
111	per	N	O
112	25	N	O
113	fractions	N	O
114	(	N	O
115	n	N	O
116	=	N	O
117	130	N	O
118	)	N	O
119	.	N	O

120	Four	N	O
121	hundred	N	O
122	seven	N	O
123	patients	N	O
124	were	N	O
125	eligible	N	O
126	for	N	O
127	the	N	O
128	study	N	O
129	;	N	O
130	395	N	O
131	patients	N	O
132	(	N	O
133	97	N	O
134	%	N	O
135	)	N	O
136	participated	N	O
137	in	N	O
138	the	N	O
139	health-related	N	O
140	quality-of-life	N	O
141	(	N	O
142	HRQOL	N	O
143	)	N	O
144	study	N	O
145	.	N	O

146	The	N	O
147	European	N	O
148	Organization	N	O
149	for	N	O
150	Research	N	O
151	and	N	O
152	Treatment	N	O
153	of	N	O
154	Cancer	N	O
155	(	N	O
156	EORTC	N	O
157	)	N	O
158	Quality	N	O
159	of	N	O
160	Life	N	O
161	Questionnaire	N	O
162	(	N	O
163	QLQ	N	O
164	)	N	O
165	-C30	N	O
166	and	N	O
167	EORTC	N	O
168	QLQ-lung	N	O
169	cancer-specific	N	O
170	module	N	O
171	(	N	O
172	LC13	N	O
173	)	N	O
174	were	N	O
175	used	N	O
176	to	N	O
177	investigate	N	O
178	airway	N	O
179	symptom	N	O
180	relief	N	O
181	and	N	O
182	changes	N	O
183	in	N	O
184	HRQOL	N	O
185	.	N	O

186	Assessments	N	O
187	were	N	O
188	performed	N	O
189	before	N	O
190	TRT	N	O
191	and	N	O
192	until	N	O
193	week	N	O
194	54	N	O
195	.	N	O

196	Clinicians	N	O
197	'	N	O
198	assessments	N	O
199	of	N	O
200	symptom	N	O
201	improvement	N	O
202	were	N	O
203	at	N	O
204	2	N	O
205	,	N	O
206	6	N	O
207	,	N	O
208	and	N	O
209	14	N	O
210	weeks	N	O
211	after	N	O
212	completion	N	O
213	of	N	O
214	TRT	N	O
215	.	N	O

216	The	N	O
217	patients	N	O
218	were	N	O
219	observed	N	O
220	for	N	O
221	a	N	O
222	minimum	N	O
223	of	N	O
224	3	N	O
225	years	N	O
226	.	N	O

227	Results	N	O
228	Baseline	N	O
229	prognostic	N	O
230	data	N	O
231	were	N	O
232	equally	N	O
233	distributed	N	O
234	in	N	O
235	the	N	O
236	treatment	N	O
237	groups	N	O
238	.	N	O

239	Patient	N	O
240	compliance	N	O
241	with	N	O
242	respect	N	O
243	to	N	O
244	the	N	O
245	HRQOL	N	O
246	investigation	N	O
247	was	N	O
248	minimum	N	O
249	74	N	O
250	%	N	O
251	.	N	O

252	HRQOL	N	I-Premise
253	and	N	I-Premise
254	symptom	N	I-Premise
255	relief	N	I-Premise
256	were	N	I-Premise
257	equivalent	N	I-Premise
258	in	N	I-Premise
259	the	N	I-Premise
260	treatment	N	I-Premise
261	arms	N	I-Premise
262	.	N	I-Premise

263	No	N	I-Premise
264	significant	N	I-Premise
265	difference	N	I-Premise
266	in	N	I-Premise
267	survival	N	I-Premise
268	among	N	I-Premise
269	arms	N	I-Premise
270	A	N	I-Premise
271	,	N	I-Premise
272	B	N	I-Premise
273	,	N	I-Premise
274	and	N	I-Premise
275	C	N	I-Premise
276	was	N	I-Premise
277	found	N	I-Premise
278	,	N	I-Premise
279	with	N	I-Premise
280	median	N	I-Premise
281	survival	N	I-Premise
282	8.2	N	I-Premise
283	,	N	I-Premise
284	7.0	N	I-Premise
285	,	N	I-Premise
286	and	N	I-Premise
287	6.8	N	I-Premise
288	months	N	I-Premise
289	,	N	I-Premise
290	respectively	N	I-Premise
291	.	N	I-Premise

292	Our	N	I-Claim
293	data	N	I-Claim
294	indicate	N	I-Claim
295	that	N	I-Claim
296	protracted	N	I-Claim
297	palliative	N	I-Claim
298	TRT	N	I-Claim
299	renders	N	I-Claim
300	no	N	I-Claim
301	improvement	N	I-Claim
302	in	N	I-Claim
303	symptom	N	I-Claim
304	relief	N	I-Claim
305	,	N	I-Claim
306	HRQOL	N	I-Claim
307	,	N	I-Claim
308	or	N	I-Claim
309	survival	N	I-Claim
310	when	N	I-Claim
311	compared	N	I-Claim
312	with	N	I-Claim
313	short-term	N	I-Claim
314	hypofractionated	N	I-Claim
315	treatment	N	I-Claim
316	in	N	I-Claim
317	advanced	N	I-Claim
318	NSCLC	N	I-Claim
319	.	N	I-Claim

1	During	N	I-Premise
2	the	N	I-Premise
3	last	N	I-Premise
4	decade	N	I-Premise
5	,	N	I-Premise
6	survival	N	I-Premise
7	rates	N	I-Premise
8	for	N	I-Premise
9	breast	N	I-Premise
10	cancer	N	I-Premise
11	have	N	I-Premise
12	increased	N	I-Premise
13	as	N	I-Premise
14	a	N	I-Premise
15	result	N	I-Premise
16	of	N	I-Premise
17	earlier	N	I-Premise
18	detection	N	I-Premise
19	and	N	I-Premise
20	increased	N	I-Premise
21	use	N	I-Premise
22	of	N	I-Premise
23	adjuvant	N	I-Premise
24	therapy	N	I-Premise
25	.	N	I-Premise

26	Limited	N	O
27	data	N	O
28	exist	N	O
29	on	N	O
30	the	N	O
31	psychosocial	N	O
32	aspects	N	O
33	of	N	O
34	the	N	O
35	transitional	N	O
36	period	N	O
37	between	N	O
38	the	N	O
39	end	N	O
40	of	N	O
41	primary	N	O
42	treatment	N	O
43	and	N	O
44	survivorship	N	O
45	.	N	O

46	We	N	O
47	investigated	N	O
48	the	N	O
49	baseline	N	O
50	psychosocial	N	O
51	status	N	O
52	of	N	O
53	women	N	O
54	enrolled	N	O
55	in	N	O
56	a	N	O
57	randomized	N	O
58	trial	N	O
59	testing	N	O
60	two	N	O
61	psychosocial	N	O
62	interventions	N	O
63	for	N	O
64	women	N	O
65	at	N	O
66	the	N	O
67	end	N	O
68	of	N	O
69	primary	N	O
70	treatment	N	O
71	.	N	O

72	Participants	N	O
73	,	N	O
74	identified	N	O
75	within	N	O
76	1	N	O
77	month	N	O
78	after	N	O
79	surgery	N	O
80	(	N	O
81	registration	N	O
82	)	N	O
83	,	N	O
84	provided	N	O
85	demographic	N	O
86	information	N	O
87	and	N	O
88	limited	N	O
89	measures	N	O
90	of	N	O
91	quality	N	O
92	of	N	O
93	life	N	O
94	.	N	O

95	They	N	O
96	were	N	O
97	followed	N	O
98	until	N	O
99	they	N	O
100	finished	N	O
101	primary	N	O
102	treatment	N	O
103	(	N	O
104	enrollment	N	O
105	)	N	O
106	,	N	O
107	at	N	O
108	which	N	O
109	time	N	O
110	they	N	O
111	completed	N	O
112	a	N	O
113	mailed	N	O
114	baseline	N	O
115	survey	N	O
116	that	N	O
117	included	N	O
118	standardized	N	O
119	measures	N	O
120	of	N	O
121	quality	N	O
122	of	N	O
123	life	N	O
124	(	N	O
125	including	N	O
126	standardized	N	O
127	scales	N	O
128	of	N	O
129	physical	N	O
130	and	N	O
131	emotional	N	O
132	functioning	N	O
133	)	N	O
134	,	N	O
135	mood	N	O
136	,	N	O
137	symptoms	N	O
138	,	N	O
139	and	N	O
140	sexual	N	O
141	functioning	N	O
142	.	N	O

143	A	N	O
144	total	N	O
145	of	N	O
146	558	N	O
147	patients	N	O
148	(	N	O
149	mean	N	O
150	age	N	O
151	=	N	O
152	56.9	N	O
153	years	N	O
154	)	N	O
155	were	N	O
156	enrolled	N	O
157	in	N	O
158	the	N	O
159	study	N	O
160	between	N	O
161	July	N	O
162	1	N	O
163	,	N	O
164	1999	N	O
165	,	N	O
166	and	N	O
167	June	N	O
168	30	N	O
169	,	N	O
170	2002	N	O
171	.	N	O

172	Health	N	O
173	outcomes	N	O
174	were	N	O
175	examined	N	O
176	according	N	O
177	to	N	O
178	treatment	N	O
179	received	N	O
180	:	N	O
181	mastectomy	N	O
182	with	N	O
183	and	N	O
184	without	N	O
185	chemotherapy	N	O
186	,	N	O
187	and	N	O
188	lumpectomy	N	O
189	with	N	O
190	and	N	O
191	without	N	O
192	chemotherapy	N	O
193	.	N	O

194	All	N	O
195	statistical	N	O
196	tests	N	O
197	were	N	O
198	two-sided	N	O
199	.	N	O

200	Among	N	I-Premise
201	all	N	I-Premise
202	treatment	N	I-Premise
203	groups	N	I-Premise
204	,	N	I-Premise
205	patients	N	I-Premise
206	who	N	I-Premise
207	had	N	I-Premise
208	a	N	I-Premise
209	mastectomy	N	I-Premise
210	had	N	I-Premise
211	the	N	I-Premise
212	poorest	N	I-Premise
213	physical	N	I-Premise
214	functioning	N	I-Premise
215	at	N	I-Premise
216	registration	N	I-Premise
217	(	N	I-Premise
218	P	N	I-Premise
219	<	N	I-Premise
220	.001	N	I-Premise
221	)	N	I-Premise
222	and	N	I-Premise
223	at	N	I-Premise
224	enrollment	N	I-Premise
225	(	N	I-Premise
226	P=.05	N	I-Premise
227	)	N	I-Premise
228	.	N	I-Premise

229	At	N	I-Premise
230	enrollment	N	I-Premise
231	,	N	I-Premise
232	mood	N	I-Premise
233	and	N	I-Premise
234	emotional	N	I-Premise
235	functioning	N	I-Premise
236	were	N	I-Premise
237	similar	N	I-Premise
238	among	N	I-Premise
239	all	N	I-Premise
240	patients	N	I-Premise
241	,	N	I-Premise
242	with	N	I-Premise
243	no	N	I-Premise
244	differences	N	I-Premise
245	by	N	I-Premise
246	type	N	I-Premise
247	of	N	I-Premise
248	treatment	N	I-Premise
249	received	N	I-Premise
250	.	N	I-Premise

251	At	N	I-Premise
252	enrollment	N	I-Premise
253	,	N	I-Premise
254	symptoms	N	I-Premise
255	,	N	I-Premise
256	including	N	I-Premise
257	muscle	N	I-Premise
258	stiffness	N	I-Premise
259	,	N	I-Premise
260	breast	N	I-Premise
261	sensitivity	N	I-Premise
262	,	N	I-Premise
263	aches	N	I-Premise
264	and	N	I-Premise
265	pains	N	I-Premise
266	,	N	I-Premise
267	tendency	N	I-Premise
268	to	N	I-Premise
269	take	N	I-Premise
270	naps	N	I-Premise
271	,	N	I-Premise
272	and	N	I-Premise
273	difficulty	N	I-Premise
274	concentrating	N	I-Premise
275	,	N	I-Premise
276	were	N	I-Premise
277	common	N	I-Premise
278	among	N	I-Premise
279	patients	N	I-Premise
280	in	N	I-Premise
281	all	N	I-Premise
282	groups	N	I-Premise
283	and	N	I-Premise
284	were	N	I-Premise
285	statistically	N	I-Premise
286	significantly	N	I-Premise
287	associated	N	I-Premise
288	with	N	I-Premise
289	poor	N	I-Premise
290	physical	N	I-Premise
291	functioning	N	I-Premise
292	and	N	I-Premise
293	emotional	N	I-Premise
294	well-being	N	I-Premise
295	.	N	I-Premise

296	Sexual	N	I-Premise
297	functioning	N	I-Premise
298	was	N	I-Premise
299	worse	N	I-Premise
300	for	N	I-Premise
301	women	N	I-Premise
302	who	N	I-Premise
303	received	N	I-Premise
304	chemotherapy	N	I-Premise
305	than	N	I-Premise
306	for	N	I-Premise
307	those	N	I-Premise
308	who	N	I-Premise
309	did	N	I-Premise
310	not	N	I-Premise
311	,	N	I-Premise
312	regardless	N	I-Premise
313	of	N	I-Premise
314	type	N	I-Premise
315	of	N	I-Premise
316	surgery	N	I-Premise
317	(	N	I-Premise
318	P	N	I-Premise
319	<	N	I-Premise
320	.001	N	I-Premise
321	)	N	I-Premise
322	.	N	I-Premise

323	At	N	I-Claim
324	the	N	I-Claim
325	end	N	I-Claim
326	of	N	I-Claim
327	primary	N	I-Claim
328	treatment	N	I-Claim
329	for	N	I-Claim
330	breast	N	I-Claim
331	cancer	N	I-Claim
332	,	N	I-Claim
333	women	N	I-Claim
334	in	N	I-Claim
335	all	N	I-Claim
336	treatment	N	I-Claim
337	groups	N	I-Claim
338	report	N	I-Claim
339	good	N	I-Claim
340	emotional	N	I-Claim
341	functioning	N	I-Claim
342	but	N	I-Claim
343	report	N	I-Claim
344	decreased	N	I-Claim
345	physical	N	I-Claim
346	functioning	N	I-Claim
347	,	N	I-Claim
348	particularly	N	I-Claim
349	among	N	I-Claim
350	women	N	I-Claim
351	who	N	I-Claim
352	have	N	I-Claim
353	a	N	I-Claim
354	mastectomy	N	I-Claim
355	or	N	I-Claim
356	receive	N	I-Claim
357	chemotherapy	N	I-Claim
358	.	N	I-Claim

359	Clinical	N	I-Claim
360	interventions	N	I-Claim
361	to	N	I-Claim
362	address	N	I-Claim
363	common	N	I-Claim
364	symptoms	N	I-Claim
365	associated	N	I-Claim
366	with	N	I-Claim
367	treatment	N	I-Claim
368	should	N	I-Claim
369	be	N	I-Claim
370	considered	N	I-Claim
371	to	N	I-Claim
372	improve	N	I-Claim
373	physical	N	I-Claim
374	and	N	I-Claim
375	emotional	N	I-Claim
376	functioning	N	I-Claim
377	at	N	I-Claim
378	the	N	I-Claim
379	end	N	I-Claim
380	of	N	I-Claim
381	primary	N	I-Claim
382	treatment	N	I-Claim
383	for	N	I-Claim
384	breast	N	I-Claim
385	cancer	N	I-Claim
386	.	N	I-Claim

1	The	N	O
2	World	N	O
3	Health	N	O
4	Organization	N	O
5	(	N	O
6	WHO	N	O
7	)	N	O
8	guidelines	N	O
9	for	N	O
10	the	N	O
11	treatment	N	O
12	of	N	O
13	cancer	N	O
14	pain	N	O
15	recommend	N	O
16	nonopioid	N	O
17	analgesics	N	O
18	as	N	O
19	first-line	N	O
20	therapy	N	O
21	,	N	O
22	so-called	N	O
23	``	N	O
24	weak	N	O
25	''	N	O
26	analgesics	N	O
27	combined	N	O
28	with	N	O
29	nonopioid	N	O
30	analgesics	N	O
31	as	N	O
32	second-line	N	O
33	therapy	N	O
34	,	N	O
35	and	N	O
36	so-called	N	O
37	``	N	O
38	strong	N	O
39	''	N	O
40	opioids	N	O
41	(	N	O
42	with	N	O
43	nonopioid	N	O
44	analgesics	N	O
45	)	N	O
46	only	N	O
47	as	N	O
48	third-line	N	O
49	therapy	N	O
50	.	N	O

51	However	N	O
52	,	N	O
53	these	N	O
54	guidelines	N	O
55	can	N	O
56	be	N	O
57	questioned	N	O
58	with	N	O
59	regard	N	O
60	to	N	O
61	the	N	O
62	extent	N	O
63	of	N	O
64	efficacy	N	O
65	as	N	O
66	well	N	O
67	as	N	O
68	the	N	O
69	rationale	N	O
70	for	N	O
71	not	N	O
72	using	N	O
73	strong	N	O
74	opioids	N	O
75	as	N	O
76	first-line	N	O
77	treatment	N	O
78	,	N	O
79	especially	N	O
80	in	N	O
81	terminal	N	O
82	cancer	N	O
83	patients	N	O
84	.	N	O

85	The	N	O
86	purpose	N	O
87	of	N	O
88	this	N	O
89	randomized	N	O
90	study	N	O
91	was	N	O
92	to	N	O
93	prospectively	N	O
94	compare	N	O
95	the	N	O
96	efficacy	N	O
97	and	N	O
98	tolerability	N	O
99	of	N	O
100	strong	N	O
101	opioids	N	O
102	as	N	O
103	first-line	N	O
104	agents	N	O
105	with	N	O
106	the	N	O
107	recommendations	N	O
108	of	N	O
109	the	N	O
110	WHO	N	O
111	in	N	O
112	terminal	N	O
113	cancer	N	O
114	patients	N	O
115	.	N	O

116	One	N	O
117	hundred	N	O
118	patients	N	O
119	with	N	O
120	mild-moderate	N	O
121	pain	N	O
122	were	N	O
123	randomized	N	O
124	to	N	O
125	treatment	N	O
126	according	N	O
127	to	N	O
128	WHO	N	O
129	guidelines	N	O
130	or	N	O
131	to	N	O
132	treatment	N	O
133	with	N	O
134	strong	N	O
135	opioids	N	O
136	.	N	O

137	Evaluated	N	O
138	outcomes	N	O
139	included	N	O
140	pain	N	O
141	intensity	N	O
142	,	N	O
143	need	N	O
144	for	N	O
145	change	N	O
146	in	N	O
147	therapy	N	O
148	,	N	O
149	quality	N	O
150	of	N	O
151	life	N	O
152	,	N	O
153	Karnofsky	N	O
154	Performance	N	O
155	Status	N	O
156	,	N	O
157	general	N	O
158	condition	N	O
159	of	N	O
160	the	N	O
161	patient	N	O
162	,	N	O
163	and	N	O
164	adverse	N	O
165	events	N	O
166	.	N	O

167	No	N	I-Premise
168	between-treatment	N	I-Premise
169	differences	N	I-Premise
170	were	N	I-Premise
171	observed	N	I-Premise
172	for	N	I-Premise
173	changes	N	I-Premise
174	in	N	I-Premise
175	quality	N	I-Premise
176	of	N	I-Premise
177	life	N	I-Premise
178	or	N	I-Premise
179	performance	N	I-Premise
180	status	N	I-Premise
181	,	N	I-Premise
182	but	N	O
183	patients	N	I-Premise
184	started	N	I-Premise
185	on	N	I-Premise
186	strong	N	I-Premise
187	opioids	N	I-Premise
188	had	N	I-Premise
189	significantly	N	I-Premise
190	better	N	I-Premise
191	pain	N	I-Premise
192	relief	N	I-Premise
193	than	N	I-Premise
194	patients	N	I-Premise
195	treated	N	I-Premise
196	according	N	I-Premise
197	to	N	I-Premise
198	WHO	N	I-Premise
199	guidelines	N	I-Premise
200	(	N	I-Premise
201	P=0.041	N	I-Premise
202	)	N	I-Premise
203	.	N	I-Premise

204	Additionally	N	I-Premise
205	,	N	I-Premise
206	patients	N	I-Premise
207	started	N	I-Premise
208	on	N	I-Premise
209	strong	N	I-Premise
210	opioids	N	I-Premise
211	required	N	I-Premise
212	significantly	N	I-Premise
213	fewer	N	I-Premise
214	changes	N	I-Premise
215	in	N	I-Premise
216	therapy	N	I-Premise
217	,	N	I-Premise
218	had	N	I-Premise
219	greater	N	I-Premise
220	reduction	N	I-Premise
221	in	N	I-Premise
222	pain	N	I-Premise
223	when	N	I-Premise
224	a	N	I-Premise
225	change	N	I-Premise
226	was	N	I-Premise
227	initiated	N	I-Premise
228	,	N	I-Premise
229	and	N	I-Premise
230	reported	N	I-Premise
231	greater	N	I-Premise
232	satisfaction	N	I-Premise
233	with	N	I-Premise
234	treatment	N	I-Premise
235	than	N	I-Premise
236	the	N	I-Premise
237	comparator	N	I-Premise
238	group	N	I-Premise
239	(	N	I-Premise
240	P=0.041	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	Strong	N	I-Claim
244	opioids	N	I-Claim
245	were	N	I-Claim
246	safe	N	I-Claim
247	and	N	I-Claim
248	well-tolerated	N	I-Claim
249	,	N	I-Claim
250	with	N	I-Claim
251	no	N	I-Claim
252	development	N	I-Claim
253	of	N	I-Claim
254	tolerance	N	I-Claim
255	or	N	I-Claim
256	serious	N	I-Claim
257	adverse	N	I-Claim
258	events	N	I-Claim
259	.	N	I-Claim

260	These	N	I-Claim
261	data	N	I-Claim
262	suggest	N	I-Claim
263	the	N	I-Claim
264	utility	N	I-Claim
265	of	N	I-Claim
266	strong	N	I-Claim
267	opioids	N	I-Claim
268	for	N	I-Claim
269	first-line	N	I-Claim
270	treatment	N	I-Claim
271	of	N	I-Claim
272	pain	N	I-Claim
273	in	N	I-Claim
274	patients	N	I-Claim
275	with	N	I-Claim
276	terminal	N	I-Claim
277	cancer	N	I-Claim
278	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	if	N	O
4	the	N	O
5	type	N	O
6	of	N	O
7	embolic	N	O
8	material	N	O
9	used	N	O
10	for	N	O
11	uterine	N	O
12	artery	N	O
13	embolization	N	O
14	(	N	O
15	UAE	N	O
16	)	N	O
17	for	N	O
18	leiomyomas	N	O
19	has	N	O
20	an	N	O
21	impact	N	O
22	on	N	O
23	short-term	N	O
24	recovery	N	O
25	or	N	O
26	the	N	O
27	effectiveness	N	O
28	of	N	O
29	embolization	N	O
30	.	N	O

31	One	N	O
32	hundred	N	O
33	patients	N	O
34	were	N	O
35	randomly	N	O
36	assigned	N	O
37	to	N	O
38	undergo	N	O
39	UAE	N	O
40	with	N	O
41	polyvinyl	N	O
42	alcohol	N	O
43	(	N	O
44	PVA	N	O
45	)	N	O
46	particles	N	O
47	or	N	O
48	tris-acryl	N	O
49	gelatin	N	O
50	microspheres	N	O
51	.	N	O

52	Short-term	N	O
53	,	N	O
54	in-hospital	N	O
55	medication	N	O
56	use	N	O
57	and	N	O
58	pain	N	O
59	levels	N	O
60	were	N	O
61	recorded	N	O
62	.	N	O

63	After	N	O
64	discharge	N	O
65	,	N	O
66	symptom	N	O
67	severity	N	O
68	,	N	O
69	temperature	N	O
70	,	N	O
71	and	N	O
72	medications	N	O
73	used	N	O
74	were	N	O
75	recorded	N	O
76	daily	N	O
77	for	N	O
78	1	N	O
79	week	N	O
80	and	N	O
81	symptom	N	O
82	levels	N	O
83	were	N	O
84	measured	N	O
85	for	N	O
86	weeks	N	O
87	2-4	N	O
88	.	N	O

89	Three	N	O
90	months	N	O
91	after	N	O
92	embolization	N	O
93	,	N	O
94	contrast	N	O
95	material-enhanced	N	O
96	magnetic	N	O
97	resonance	N	O
98	imaging	N	O
99	examinations	N	O
100	were	N	O
101	evaluated	N	O
102	blindly	N	O
103	to	N	O
104	determine	N	O
105	the	N	O
106	extent	N	O
107	of	N	O
108	leiomyoma	N	O
109	infarction	N	O
110	.	N	O

111	Symptom	N	O
112	and	N	O
113	quality	N	O
114	of	N	O
115	life	N	O
116	(	N	O
117	QOL	N	O
118	)	N	O
119	status	N	O
120	was	N	O
121	determined	N	O
122	with	N	O
123	use	N	O
124	of	N	O
125	questionnaires	N	O
126	.	N	O

127	Analysis	N	O
128	was	N	O
129	completed	N	O
130	with	N	O
131	use	N	O
132	of	N	O
133	chi	N	O
134	(	N	O
135	2	N	O
136	)	N	O
137	analysis	N	O
138	,	N	O
139	Fisher	N	O
140	exact	N	O
141	tests	N	O
142	,	N	O
143	Student	N	O
144	t	N	O
145	tests	N	O
146	,	N	O
147	and	N	O
148	analysis	N	O
149	of	N	O
150	variance	N	O
151	as	N	O
152	appropriate	N	O
153	.	N	O

154	Regression	N	O
155	analysis	N	O
156	was	N	O
157	used	N	O
158	to	N	O
159	analyze	N	O
160	the	N	O
161	impact	N	O
162	on	N	O
163	outcome	N	O
164	of	N	O
165	baseline	N	O
166	factors	N	O
167	(	N	O
168	other	N	O
169	than	N	O
170	type	N	O
171	of	N	O
172	embolic	N	O
173	agent	N	O
174	)	N	O
175	.	N	O

176	No	N	O
177	significant	N	O
178	differences	N	O
179	were	N	O
180	noted	N	O
181	at	N	O
182	baseline	N	O
183	between	N	O
184	the	N	O
185	two	N	O
186	treatment	N	O
187	groups	N	O
188	.	N	O

189	On	N	I-Premise
190	average	N	I-Premise
191	,	N	I-Premise
192	there	N	I-Premise
193	were	N	I-Premise
194	significantly	N	I-Premise
195	higher	N	I-Premise
196	volumes	N	I-Premise
197	of	N	I-Premise
198	tris-acryl	N	I-Premise
199	microspheres	N	I-Premise
200	used	N	I-Premise
201	(	N	I-Premise
202	9.0	N	I-Premise
203	mL	N	I-Premise
204	vs	N	I-Premise
205	3.0	N	I-Premise
206	mL	N	I-Premise
207	;	N	I-Premise
208	P	N	I-Premise
209	=.0001	N	I-Premise
210	)	N	I-Premise
211	,	N	I-Premise
212	whereas	N	O
213	microcatheter	N	I-Premise
214	occlusion	N	I-Premise
215	was	N	I-Premise
216	more	N	I-Premise
217	common	N	I-Premise
218	with	N	I-Premise
219	PVA	N	I-Premise
220	(	N	I-Premise
221	28	N	I-Premise
222	%	N	I-Premise
223	vs	N	I-Premise
224	4	N	I-Premise
225	%	N	I-Premise
226	,	N	I-Premise
227	P	N	I-Premise
228	=.001	N	I-Premise
229	)	N	I-Premise
230	.	N	I-Premise

231	There	N	I-Premise
232	were	N	I-Premise
233	no	N	I-Premise
234	differences	N	I-Premise
235	in	N	I-Premise
236	pain	N	I-Premise
237	severity	N	I-Premise
238	,	N	I-Premise
239	other	N	I-Premise
240	postprocedural	N	I-Premise
241	symptoms	N	I-Premise
242	,	N	I-Premise
243	or	N	I-Premise
244	medication	N	I-Premise
245	use	N	I-Premise
246	between	N	I-Premise
247	the	N	I-Premise
248	two	N	I-Premise
249	treatment	N	I-Premise
250	groups	N	I-Premise
251	.	N	I-Premise

252	There	N	I-Premise
253	were	N	I-Premise
254	also	N	I-Premise
255	no	N	I-Premise
256	differences	N	I-Premise
257	in	N	I-Premise
258	the	N	I-Premise
259	frequency	N	I-Premise
260	of	N	I-Premise
261	incompletely	N	I-Premise
262	infarcted	N	I-Premise
263	leiomyomas	N	I-Premise
264	,	N	I-Premise
265	degree	N	I-Premise
266	of	N	I-Premise
267	improvement	N	I-Premise
268	in	N	I-Premise
269	symptom	N	I-Premise
270	score	N	I-Premise
271	,	N	I-Premise
272	patient	N	I-Premise
273	satisfaction	N	I-Premise
274	,	N	I-Premise
275	or	N	I-Premise
276	QOL	N	I-Premise
277	.	N	I-Premise

278	No	N	I-Claim
279	substantive	N	I-Claim
280	differences	N	I-Claim
281	were	N	I-Claim
282	detected	N	I-Claim
283	between	N	I-Claim
284	outcomes	N	I-Claim
285	of	N	I-Claim
286	embolization	N	I-Claim
287	with	N	I-Claim
288	PVA	N	I-Claim
289	particles	N	I-Claim
290	or	N	I-Claim
291	tris-acryl	N	I-Claim
292	gelatin	N	I-Claim
293	microspheres	N	I-Claim
294	.	N	I-Claim

1	Fatigue	N	O
2	is	N	O
3	a	N	O
4	frequent	N	O
5	problem	N	O
6	after	N	O
7	surgical	N	O
8	treatment	N	O
9	of	N	O
10	solid	N	O
11	tumours	N	O
12	.	N	O

13	Aerobic	N	I-Claim
14	exercise	N	I-Claim
15	and	N	I-Claim
16	psychosocial	N	I-Claim
17	interventions	N	I-Claim
18	have	N	I-Claim
19	been	N	I-Claim
20	shown	N	I-Claim
21	to	N	I-Claim
22	reduce	N	I-Claim
23	the	N	I-Claim
24	severity	N	I-Claim
25	of	N	I-Claim
26	this	N	I-Claim
27	symptom	N	I-Claim
28	in	N	I-Claim
29	cancer	N	I-Claim
30	patients	N	I-Claim
31	.	N	I-Claim

32	Therefore	N	O
33	,	N	O
34	we	N	O
35	compared	N	O
36	the	N	O
37	effect	N	O
38	of	N	O
39	the	N	O
40	two	N	O
41	therapies	N	O
42	on	N	O
43	fatigue	N	O
44	in	N	O
45	a	N	O
46	randomised	N	O
47	controlled	N	O
48	study	N	O
49	.	N	O

50	Seventy-two	N	O
51	patients	N	O
52	who	N	O
53	underwent	N	O
54	surgery	N	O
55	for	N	O
56	lung	N	O
57	(	N	O
58	n=27	N	O
59	)	N	O
60	or	N	O
61	gastrointestinal	N	O
62	tumours	N	O
63	(	N	O
64	n=42	N	O
65	)	N	O
66	were	N	O
67	assigned	N	O
68	to	N	O
69	an	N	O
70	aerobic	N	O
71	exercise	N	O
72	group	N	O
73	(	N	O
74	stationary	N	O
75	biking	N	O
76	30	N	O
77	min	N	O
78	five	N	O
79	times	N	O
80	weekly	N	O
81	)	N	O
82	or	N	O
83	a	N	O
84	progressive	N	O
85	relaxation	N	O
86	training	N	O
87	group	N	O
88	(	N	O
89	45	N	O
90	min	N	O
91	three	N	O
92	times	N	O
93	per	N	O
94	week	N	O
95	)	N	O
96	.	N	O

97	Both	N	O
98	interventions	N	O
99	were	N	O
100	carried	N	O
101	out	N	O
102	for	N	O
103	3	N	O
104	weeks	N	O
105	.	N	O

106	At	N	O
107	the	N	O
108	beginning	N	O
109	and	N	O
110	the	N	O
111	end	N	O
112	of	N	O
113	the	N	O
114	study	N	O
115	,	N	O
116	we	N	O
117	evaluated	N	O
118	physical	N	O
119	,	N	O
120	cognitive	N	O
121	and	N	O
122	emotional	N	O
123	status	N	O
124	and	N	O
125	somatic	N	O
126	complaints	N	O
127	with	N	O
128	the	N	O
129	European	N	O
130	Organization	N	O
131	for	N	O
132	Research	N	O
133	and	N	O
134	Treatment	N	O
135	of	N	O
136	Cancer	N	O
137	Quality	N	O
138	of	N	O
139	Life	N	O
140	Questionnaire	N	O
141	Core	N	O
142	Module	N	O
143	(	N	O
144	EORTC-QLQ-30	N	O
145	)	N	O
146	questionnaire	N	O
147	,	N	O
148	and	N	O
149	maximal	N	O
150	physical	N	O
151	performance	N	O
152	with	N	O
153	an	N	O
154	ergometric	N	O
155	stress	N	O
156	test	N	O
157	.	N	O

158	Physical	N	I-Premise
159	performance	N	I-Premise
160	of	N	I-Premise
161	the	N	I-Premise
162	training	N	I-Premise
163	group	N	I-Premise
164	improved	N	I-Premise
165	significantly	N	I-Premise
166	during	N	I-Premise
167	the	N	I-Premise
168	programme	N	I-Premise
169	(	N	I-Premise
170	9.4+/-20	N	I-Premise
171	watts	N	I-Premise
172	,	N	I-Premise
173	p=0.01	N	I-Premise
174	)	N	I-Premise
175	but	N	I-Premise
176	remained	N	I-Premise
177	unchanged	N	I-Premise
178	in	N	I-Premise
179	the	N	I-Premise
180	relaxation	N	I-Premise
181	group	N	I-Premise
182	(	N	I-Premise
183	1.5+/-14.8	N	I-Premise
184	watts	N	I-Premise
185	,	N	I-Premise
186	p=0.37	N	I-Premise
187	)	N	I-Premise
188	.	N	I-Premise

189	Fatigue	N	I-Premise
190	and	N	I-Premise
191	global	N	I-Premise
192	health	N	I-Premise
193	scores	N	I-Premise
194	improved	N	I-Premise
195	in	N	I-Premise
196	both	N	I-Premise
197	groups	N	I-Premise
198	during	N	I-Premise
199	the	N	I-Premise
200	intervention	N	I-Premise
201	(	N	I-Premise
202	fatigue	N	I-Premise
203	:	N	I-Premise
204	training	N	I-Premise
205	group	N	I-Premise
206	21	N	I-Premise
207	%	N	I-Premise
208	,	N	I-Premise
209	relaxation	N	I-Premise
210	group	N	I-Premise
211	19	N	I-Premise
212	%	N	I-Premise
213	;	N	I-Premise
214	global	N	I-Premise
215	health	N	I-Premise
216	of	N	I-Premise
217	both	N	I-Premise
218	groups	N	I-Premise
219	19	N	I-Premise
220	%	N	I-Premise
221	,	N	I-Premise
222	p	N	I-Premise
223	for	N	I-Premise
224	all	N	I-Premise
225	<	N	I-Premise
226	or	N	I-Premise
227	=0.01	N	I-Premise
228	)	N	I-Premise
229	;	N	I-Premise
230	however	N	I-Premise
231	,	N	I-Premise
232	there	N	I-Premise
233	was	N	I-Premise
234	no	N	I-Premise
235	significant	N	I-Premise
236	difference	N	I-Premise
237	between	N	I-Premise
238	changes	N	I-Premise
239	in	N	I-Premise
240	the	N	I-Premise
241	scores	N	I-Premise
242	of	N	I-Premise
243	both	N	I-Premise
244	groups	N	I-Premise
245	(	N	I-Premise
246	p=0.67	N	I-Premise
247	)	N	I-Premise
248	.	N	I-Premise

249	We	N	I-Claim
250	conclude	N	I-Claim
251	that	N	I-Claim
252	a	N	I-Claim
253	structured	N	I-Claim
254	aerobic	N	I-Claim
255	training	N	I-Claim
256	programme	N	I-Claim
257	improves	N	I-Claim
258	the	N	I-Claim
259	physical	N	I-Claim
260	performance	N	I-Claim
261	of	N	I-Claim
262	patients	N	I-Claim
263	recovering	N	I-Claim
264	from	N	I-Claim
265	surgery	N	I-Claim
266	for	N	I-Claim
267	solid	N	I-Claim
268	tumours	N	I-Claim
269	.	N	I-Claim

270	However	N	I-Claim
271	,	N	I-Claim
272	exercise	N	I-Claim
273	is	N	I-Claim
274	not	N	I-Claim
275	better	N	I-Claim
276	than	N	I-Claim
277	progressive	N	I-Claim
278	relaxation	N	I-Claim
279	training	N	I-Claim
280	for	N	I-Claim
281	the	N	I-Claim
282	treatment	N	I-Claim
283	of	N	I-Claim
284	fatigue	N	I-Claim
285	in	N	I-Claim
286	this	N	I-Claim
287	setting	N	I-Claim
288	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	a	N	O
7	seated	N	O
8	exercise	N	O
9	program	N	O
10	on	N	O
11	fatigue	N	O
12	and	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	(	N	O
17	QOL	N	O
18	)	N	O
19	in	N	O
20	women	N	O
21	with	N	O
22	metastatic	N	O
23	breast	N	O
24	cancer	N	O
25	.	N	O

26	Randomized	N	O
27	,	N	O
28	controlled	N	O
29	,	N	O
30	longitudinal	N	O
31	trial	N	O
32	.	N	O

33	Outpatient	N	O
34	clinic	N	O
35	of	N	O
36	a	N	O
37	comprehensive	N	O
38	cancer	N	O
39	center	N	O
40	.	N	O

41	Convenience	N	O
42	sample	N	O
43	of	N	O
44	38	N	O
45	women	N	O
46	who	N	O
47	were	N	O
48	beginning	N	O
49	outpatient	N	O
50	chemotherapy	N	O
51	.	N	O

52	Subjects	N	O
53	were	N	O
54	randomized	N	O
55	to	N	O
56	a	N	O
57	control	N	O
58	or	N	O
59	intervention	N	O
60	group	N	O
61	;	N	O
62	the	N	O
63	intervention	N	O
64	was	N	O
65	performance	N	O
66	of	N	O
67	a	N	O
68	seated	N	O
69	exercise	N	O
70	program	N	O
71	using	N	O
72	home	N	O
73	videotape	N	O
74	three	N	O
75	times	N	O
76	per	N	O
77	week	N	O
78	for	N	O
79	four	N	O
80	cycles	N	O
81	of	N	O
82	chemotherapy	N	O
83	.	N	O

84	All	N	O
85	subjects	N	O
86	completed	N	O
87	the	N	O
88	Functional	N	O
89	Assessment	N	O
90	of	N	O
91	Chronic	N	O
92	Illness	N	O
93	Therapy	N	O
94	Fatigue	N	O
95	Version	N	O
96	IV	N	O
97	(	N	O
98	FACIT	N	O
99	F	N	O
100	)	N	O
101	at	N	O
102	baseline	N	O
103	and	N	O
104	at	N	O
105	the	N	O
106	time	N	O
107	of	N	O
108	the	N	O
109	next	N	O
110	three	N	O
111	cycles	N	O
112	.	N	O

113	Subjects	N	O
114	were	N	O
115	asked	N	O
116	to	N	O
117	document	N	O
118	the	N	O
119	frequency	N	O
120	,	N	O
121	duration	N	O
122	,	N	O
123	and	N	O
124	intensity	N	O
125	of	N	O
126	all	N	O
127	exercise	N	O
128	participation	N	O
129	on	N	O
130	monthly	N	O
131	calendars	N	O
132	.	N	O

133	Exercise	N	O
134	,	N	O
135	fatigue	N	O
136	,	N	O
137	and	N	O
138	QOL	N	O
139	.	N	O

140	32	N	O
141	subjects	N	O
142	,	N	O
143	16	N	O
144	per	N	O
145	group	N	O
146	,	N	O
147	completed	N	O
148	the	N	O
149	study	N	O
150	follow-up	N	O
151	.	N	O

152	With	N	I-Premise
153	a	N	I-Premise
154	mixed	N	I-Premise
155	modeling	N	I-Premise
156	approach	N	I-Premise
157	,	N	I-Premise
158	total	N	I-Premise
159	FACIT	N	I-Premise
160	F	N	I-Premise
161	scores	N	I-Premise
162	for	N	I-Premise
163	the	N	I-Premise
164	entire	N	I-Premise
165	sample	N	I-Premise
166	declined	N	I-Premise
167	at	N	I-Premise
168	a	N	I-Premise
169	significant	N	I-Premise
170	rate	N	I-Premise
171	(	N	I-Premise
172	p	N	I-Premise
173	=	N	I-Premise
174	0.003	N	I-Premise
175	)	N	I-Premise
176	beginning	N	I-Premise
177	with	N	I-Premise
178	cycle	N	I-Premise
179	3	N	I-Premise
180	but	N	I-Premise
181	at	N	I-Premise
182	a	N	I-Premise
183	slower	N	I-Premise
184	rate	N	I-Premise
185	for	N	I-Premise
186	the	N	I-Premise
187	experimental	N	I-Premise
188	group	N	I-Premise
189	(	N	I-Premise
190	p	N	I-Premise
191	=	N	I-Premise
192	0.02	N	I-Premise
193	)	N	I-Premise
194	.	N	I-Premise

195	Fatigue	N	I-Premise
196	scores	N	I-Premise
197	indicated	N	I-Premise
198	less	N	I-Premise
199	increase	N	I-Premise
200	and	N	I-Premise
201	physical	N	I-Premise
202	well-being	N	I-Premise
203	subscale	N	I-Premise
204	scores	N	I-Premise
205	showed	N	I-Premise
206	less	N	I-Premise
207	decline	N	I-Premise
208	for	N	I-Premise
209	the	N	I-Premise
210	experimental	N	I-Premise
211	group	N	I-Premise
212	(	N	I-Premise
213	p	N	I-Premise
214	=	N	I-Premise
215	0.008	N	I-Premise
216	and	N	I-Premise
217	p	N	I-Premise
218	=	N	I-Premise
219	0.02	N	I-Premise
220	,	N	I-Premise
221	respectively	N	I-Premise
222	)	N	I-Premise
223	.	N	I-Premise

224	Women	N	I-Premise
225	with	N	I-Premise
226	advanced	N	I-Premise
227	breast	N	I-Premise
228	cancer	N	I-Premise
229	randomized	N	I-Premise
230	to	N	I-Premise
231	the	N	I-Premise
232	seated	N	I-Premise
233	exercise	N	I-Premise
234	intervention	N	I-Premise
235	had	N	I-Premise
236	a	N	I-Premise
237	slower	N	I-Premise
238	decline	N	I-Premise
239	in	N	I-Premise
240	total	N	I-Premise
241	and	N	I-Premise
242	physical	N	I-Premise
243	well-being	N	I-Premise
244	and	N	I-Premise
245	less	N	I-Premise
246	increase	N	I-Premise
247	in	N	I-Premise
248	fatigue	N	I-Premise
249	scores	N	I-Premise
250	starting	N	I-Premise
251	with	N	I-Premise
252	the	N	I-Premise
253	third	N	I-Premise
254	cycle	N	I-Premise
255	of	N	I-Premise
256	chemotherapy	N	I-Premise
257	.	N	I-Premise

258	Seated	N	I-Claim
259	exercise	N	I-Claim
260	may	N	I-Claim
261	be	N	I-Claim
262	a	N	I-Claim
263	feasible	N	I-Claim
264	exercise	N	I-Claim
265	program	N	I-Claim
266	for	N	I-Claim
267	women	N	I-Claim
268	with	N	I-Claim
269	advanced	N	I-Claim
270	cancer	N	I-Claim
271	for	N	I-Claim
272	controlling	N	I-Claim
273	fatigue	N	I-Claim
274	and	N	I-Claim
275	improving	N	I-Claim
276	physical	N	I-Claim
277	well-being	N	I-Claim
278	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	weekly	N	O
5	epoetin	N	O
6	alfa	N	O
7	could	N	O
8	improve	N	O
9	hemoglobin	N	O
10	(	N	O
11	HgB	N	O
12	)	N	O
13	levels	N	O
14	,	N	O
15	reduce	N	O
16	RBC	N	O
17	transfusions	N	O
18	,	N	O
19	and	N	O
20	improve	N	O
21	quality	N	O
22	of	N	O
23	life	N	O
24	(	N	O
25	QOL	N	O
26	)	N	O
27	in	N	O
28	patients	N	O
29	with	N	O
30	advanced	N	O
31	cancer	N	O
32	and	N	O
33	with	N	O
34	anemia	N	O
35	after	N	O
36	receiving	N	O
37	myelosuppressive	N	O
38	chemotherapy	N	O
39	.	N	O

40	This	N	O
41	double-blind	N	O
42	,	N	O
43	placebo-controlled	N	O
44	study	N	O
45	randomly	N	O
46	assigned	N	O
47	patients	N	O
48	to	N	O
49	placebo	N	O
50	or	N	O
51	epoetin	N	O
52	alfa	N	O
53	(	N	O
54	Ortho	N	O
55	Biotech	N	O
56	,	N	O
57	Bridgewater	N	O
58	,	N	O
59	NJ	N	O
60	)	N	O
61	40,000	N	O
62	U	N	O
63	subcutaneous	N	O
64	weekly	N	O
65	for	N	O
66	16	N	O
67	weeks	N	O
68	.	N	O

69	QOL	N	O
70	,	N	O
71	HgB	N	O
72	,	N	O
73	and	N	O
74	RBC	N	O
75	transfusions	N	O
76	were	N	O
77	measured	N	O
78	pretreatment	N	O
79	and	N	O
80	monthly	N	O
81	.	N	O

82	The	N	O
83	study	N	O
84	accrued	N	O
85	344	N	O
86	patients	N	O
87	;	N	O
88	330	N	O
89	were	N	O
90	assessable	N	O
91	for	N	O
92	efficacy	N	O
93	and	N	O
94	305	N	O
95	were	N	O
96	assessable	N	O
97	for	N	O
98	QOL	N	O
99	.	N	O

100	Placebo-treated	N	I-Premise
101	patients	N	I-Premise
102	had	N	I-Premise
103	a	N	I-Premise
104	mean	N	I-Premise
105	increase	N	I-Premise
106	in	N	I-Premise
107	HgB	N	I-Premise
108	of	N	I-Premise
109	0.9	N	I-Premise
110	g/dL	N	I-Premise
111	(	N	I-Premise
112	range	N	I-Premise
113	,	N	I-Premise
114	-3.8	N	I-Premise
115	to	N	I-Premise
116	+5.3	N	I-Premise
117	)	N	I-Premise
118	compared	N	I-Premise
119	with	N	I-Premise
120	2.8	N	I-Premise
121	g/dL	N	I-Premise
122	(	N	I-Premise
123	range	N	I-Premise
124	,	N	I-Premise
125	-2.2	N	I-Premise
126	to	N	I-Premise
127	+7.5	N	I-Premise
128	)	N	I-Premise
129	for	N	I-Premise
130	epoetin-treated	N	I-Premise
131	patients	N	I-Premise
132	(	N	I-Premise
133	P	N	I-Premise
134	<	N	I-Premise
135	.0001	N	I-Premise
136	)	N	I-Premise
137	.	N	I-Premise

138	During	N	I-Premise
139	the	N	I-Premise
140	study	N	I-Premise
141	,	N	I-Premise
142	31.7	N	I-Premise
143	%	N	I-Premise
144	of	N	I-Premise
145	placebo-treated	N	I-Premise
146	patients	N	I-Premise
147	achieved	N	I-Premise
148	a	N	I-Premise
149	>	N	I-Premise
150	or	N	I-Premise
151	=	N	I-Premise
152	2	N	I-Premise
153	g/dL	N	I-Premise
154	HgB	N	I-Premise
155	increase	N	I-Premise
156	compared	N	I-Premise
157	with	N	I-Premise
158	72.7	N	I-Premise
159	%	N	I-Premise
160	of	N	I-Premise
161	epoetin-treated	N	I-Premise
162	patients	N	I-Premise
163	(	N	I-Premise
164	P	N	I-Premise
165	<	N	I-Premise
166	.0001	N	I-Premise
167	)	N	I-Premise
168	.	N	I-Premise

169	The	N	I-Premise
170	incidence	N	I-Premise
171	of	N	I-Premise
172	RBC	N	I-Premise
173	transfusion	N	I-Premise
174	for	N	I-Premise
175	placebo	N	I-Premise
176	and	N	I-Premise
177	epoetin	N	I-Premise
178	treatment	N	I-Premise
179	arms	N	I-Premise
180	was	N	I-Premise
181	39.6	N	I-Premise
182	%	N	I-Premise
183	and	N	I-Premise
184	25.3	N	I-Premise
185	%	N	I-Premise
186	(	N	I-Premise
187	P	N	I-Premise
188	=	N	I-Premise
189	.005	N	I-Premise
190	)	N	I-Premise
191	,	N	I-Premise
192	respectively	N	I-Premise
193	.	N	I-Premise

194	The	N	O
195	placebo	N	O
196	group	N	O
197	received	N	O
198	256	N	O
199	units	N	O
200	of	N	O
201	RBCs	N	O
202	compared	N	O
203	with	N	O
204	127	N	O
205	units	N	O
206	in	N	O
207	the	N	O
208	epoetin	N	O
209	group	N	O
210	(	N	O
211	P	N	O
212	<	N	O
213	.0001	N	O
214	)	N	O
215	.	N	O

216	The	N	I-Premise
217	incidence	N	I-Premise
218	of	N	I-Premise
219	toxicity	N	I-Premise
220	in	N	I-Premise
221	the	N	I-Premise
222	groups	N	I-Premise
223	was	N	I-Premise
224	similar	N	I-Premise
225	.	N	I-Premise

226	Changes	N	I-Premise
227	in	N	I-Premise
228	the	N	I-Premise
229	average	N	I-Premise
230	QOL	N	I-Premise
231	scores	N	I-Premise
232	from	N	I-Premise
233	baseline	N	I-Premise
234	to	N	I-Premise
235	the	N	I-Premise
236	end	N	I-Premise
237	of	N	I-Premise
238	the	N	I-Premise
239	study	N	I-Premise
240	were	N	I-Premise
241	similar	N	I-Premise
242	in	N	I-Premise
243	the	N	I-Premise
244	two	N	I-Premise
245	groups	N	I-Premise
246	(	N	I-Premise
247	P	N	I-Premise
248	=	N	I-Premise
249	not	N	I-Premise
250	significant	N	I-Premise
251	)	N	I-Premise
252	.	N	I-Premise

253	The	N	I-Premise
254	HgB	N	I-Premise
255	responders	N	I-Premise
256	(	N	I-Premise
257	irrespective	N	I-Premise
258	of	N	I-Premise
259	treatment	N	I-Premise
260	arm	N	I-Premise
261	)	N	I-Premise
262	had	N	I-Premise
263	a	N	I-Premise
264	mean	N	I-Premise
265	change	N	I-Premise
266	in	N	I-Premise
267	Functional	N	I-Premise
268	Assessment	N	I-Premise
269	of	N	I-Premise
270	Cancer	N	I-Premise
271	Therapy	N	I-Premise
272	(	N	I-Premise
273	FACT	N	I-Premise
274	)	N	I-Premise
275	fatigue	N	I-Premise
276	score	N	I-Premise
277	from	N	I-Premise
278	a	N	I-Premise
279	baseline	N	I-Premise
280	of	N	I-Premise
281	+5.1	N	I-Premise
282	compared	N	I-Premise
283	with	N	I-Premise
284	-2.1	N	I-Premise
285	for	N	I-Premise
286	the	N	I-Premise
287	nonresponders	N	I-Premise
288	(	N	I-Premise
289	P	N	I-Premise
290	=	N	I-Premise
291	.006	N	I-Premise
292	)	N	I-Premise
293	.	N	I-Premise

294	Epoetin	N	I-Claim
295	alfa	N	I-Claim
296	significantly	N	I-Claim
297	improved	N	I-Claim
298	HgB	N	I-Claim
299	and	N	I-Claim
300	reduced	N	I-Claim
301	transfusions	N	I-Claim
302	in	N	I-Claim
303	this	N	I-Claim
304	patient	N	I-Claim
305	population	N	I-Claim
306	.	N	I-Claim

307	These	N	I-Claim
308	results	N	I-Claim
309	support	N	I-Claim
310	the	N	I-Claim
311	use	N	I-Claim
312	of	N	I-Claim
313	weekly	N	I-Claim
314	epoetin	N	I-Claim
315	alfa	N	I-Claim
316	as	N	I-Claim
317	an	N	I-Claim
318	ameliorative	N	I-Claim
319	agent	N	I-Claim
320	for	N	I-Claim
321	cancer-related	N	I-Claim
322	anemia	N	I-Claim
323	.	N	I-Claim

1	Epoetin	N	I-Claim
2	alfa	N	I-Claim
3	administered	N	I-Claim
4	at	N	I-Claim
5	40,000	N	I-Claim
6	U	N	I-Claim
7	once	N	I-Claim
8	weekly	N	I-Claim
9	(	N	I-Claim
10	qw	N	I-Claim
11	)	N	I-Claim
12	to	N	I-Claim
13	anemic	N	I-Claim
14	cancer	N	I-Claim
15	patients	N	I-Claim
16	receiving	N	I-Claim
17	chemotherapy	N	I-Claim
18	increases	N	I-Claim
19	hemoglobin	N	I-Claim
20	levels	N	I-Claim
21	,	N	I-Claim
22	improves	N	I-Claim
23	quality	N	I-Claim
24	of	N	I-Claim
25	life	N	I-Claim
26	(	N	I-Claim
27	QOL	N	I-Claim
28	)	N	I-Claim
29	,	N	I-Claim
30	and	N	I-Claim
31	reduces	N	I-Claim
32	transfusions	N	I-Claim
33	.	N	I-Claim

34	The	N	O
35	benefit	N	O
36	of	N	O
37	epoetin	N	O
38	alfa	N	O
39	in	N	O
40	maintaining	N	O
41	hemoglobin	N	O
42	levels	N	O
43	in	N	O
44	cancer	N	O
45	patients	N	O
46	with	N	O
47	hemoglobin	N	O
48	less	N	O
49	than	N	O
50	12	N	O
51	g/dL	N	O
52	has	N	O
53	not	N	O
54	been	N	O
55	evaluated	N	O
56	.	N	O

57	Breast	N	O
58	cancer	N	O
59	patients	N	O
60	(	N	O
61	N	N	O
62	=	N	O
63	354	N	O
64	)	N	O
65	receiving	N	O
66	chemotherapy	N	O
67	were	N	O
68	randomly	N	O
69	assigned	N	O
70	in	N	O
71	1:1	N	O
72	ratio	N	O
73	to	N	O
74	epoetin	N	O
75	alfa	N	O
76	(	N	O
77	40,000	N	O
78	U	N	O
79	qw	N	O
80	)	N	O
81	or	N	O
82	standard	N	O
83	of	N	O
84	care	N	O
85	(	N	O
86	SOC	N	O
87	)	N	O
88	.	N	O

89	QOL	N	O
90	was	N	O
91	assessed	N	O
92	at	N	O
93	baseline	N	O
94	and	N	O
95	week	N	O
96	12	N	O
97	.	N	O

98	Hemoglobin	N	O
99	responses	N	O
100	,	N	O
101	transfusion	N	O
102	requirements	N	O
103	,	N	O
104	and	N	O
105	prognostic	N	O
106	factors	N	O
107	for	N	O
108	responses	N	O
109	were	N	O
110	measured	N	O
111	.	N	O

112	At	N	I-Premise
113	week	N	I-Premise
114	12	N	I-Premise
115	,	N	I-Premise
116	Functional	N	I-Premise
117	Assessment	N	I-Premise
118	of	N	I-Premise
119	Cancer	N	I-Premise
120	Therapy-Anemia	N	I-Premise
121	(	N	I-Premise
122	FACT-An	N	I-Premise
123	;	N	I-Premise
124	mean	N	I-Premise
125	,	N	I-Premise
126	2.16	N	I-Premise
127	+/-	N	I-Premise
128	12.84	N	I-Premise
129	for	N	I-Premise
130	epoetin	N	I-Premise
131	alfa	N	I-Premise
132	v	N	I-Premise
133	-4.43	N	I-Premise
134	+/-	N	I-Premise
135	13.42	N	I-Premise
136	for	N	I-Premise
137	SOC	N	I-Premise
138	)	N	I-Premise
139	and	N	I-Premise
140	FACT-An	N	I-Premise
141	fatigue	N	I-Premise
142	(	N	I-Premise
143	mean	N	I-Premise
144	,	N	I-Premise
145	1.85	N	I-Premise
146	+/-	N	I-Premise
147	10.52	N	I-Premise
148	for	N	I-Premise
149	epoetin	N	I-Premise
150	alfa	N	I-Premise
151	v	N	I-Premise
152	-3.55	N	I-Premise
153	+/-	N	I-Premise
154	11.14	N	I-Premise
155	for	N	I-Premise
156	SOC	N	I-Premise
157	)	N	I-Premise
158	change	N	I-Premise
159	scores	N	I-Premise
160	were	N	I-Premise
161	significantly	N	I-Premise
162	higher	N	I-Premise
163	in	N	I-Premise
164	the	N	I-Premise
165	epoetin	N	I-Premise
166	alfa	N	I-Premise
167	group	N	I-Premise
168	(	N	I-Premise
169	P	N	I-Premise
170	<	N	I-Premise
171	.0001	N	I-Premise
172	)	N	I-Premise
173	.	N	I-Premise

174	Hemoglobin	N	I-Premise
175	responses	N	I-Premise
176	defined	N	I-Premise
177	as	N	I-Premise
178	mean	N	I-Premise
179	hemoglobin	N	I-Premise
180	>	N	I-Premise
181	or	N	I-Premise
182	=	N	I-Premise
183	12	N	I-Premise
184	g/dL	N	I-Premise
185	or	N	I-Premise
186	a	N	I-Premise
187	>	N	I-Premise
188	or	N	I-Premise
189	=	N	I-Premise
190	2	N	I-Premise
191	g/dL	N	I-Premise
192	increase	N	I-Premise
193	compared	N	I-Premise
194	with	N	I-Premise
195	baseline	N	I-Premise
196	were	N	I-Premise
197	significantly	N	I-Premise
198	higher	N	I-Premise
199	in	N	I-Premise
200	the	N	I-Premise
201	epoetin	N	I-Premise
202	alfa	N	I-Premise
203	group	N	I-Premise
204	versus	N	I-Premise
205	SOC	N	I-Premise
206	:	N	I-Premise
207	52.0	N	I-Premise
208	%	N	I-Premise
209	v	N	I-Premise
210	5.1	N	I-Premise
211	%	N	I-Premise
212	and	N	I-Premise
213	65.7	N	I-Premise
214	%	N	I-Premise
215	v	N	I-Premise
216	6.3	N	I-Premise
217	%	N	I-Premise
218	,	N	I-Premise
219	respectively	N	I-Premise
220	(	N	I-Premise
221	P	N	I-Premise
222	<	N	I-Premise
223	.0001	N	I-Premise
224	for	N	I-Premise
225	both	N	I-Premise
226	comparisons	N	I-Premise
227	)	N	I-Premise
228	.	N	I-Premise

229	Percentage	N	I-Premise
230	transfused	N	I-Premise
231	was	N	I-Premise
232	significantly	N	I-Premise
233	lower	N	I-Premise
234	in	N	I-Premise
235	the	N	I-Premise
236	epoetin	N	I-Premise
237	alfa	N	I-Premise
238	group	N	I-Premise
239	compared	N	I-Premise
240	with	N	I-Premise
241	SOC	N	I-Premise
242	(	N	I-Premise
243	8.6	N	I-Premise
244	%	N	I-Premise
245	v	N	I-Premise
246	22.9	N	I-Premise
247	%	N	I-Premise
248	)	N	I-Premise
249	.	N	I-Premise

250	More	N	I-Premise
251	than	N	I-Premise
252	90	N	I-Premise
253	%	N	I-Premise
254	of	N	I-Premise
255	patients	N	I-Premise
256	did	N	I-Premise
257	not	N	I-Premise
258	require	N	I-Premise
259	a	N	I-Premise
260	dose	N	I-Premise
261	increase	N	I-Premise
262	and	N	I-Premise
263	28.7	N	I-Premise
264	%	N	I-Premise
265	had	N	I-Premise
266	a	N	I-Premise
267	dose	N	I-Premise
268	reduction	N	I-Premise
269	.	N	I-Premise

270	Epoetin	N	I-Claim
271	alfa	N	I-Claim
272	administered	N	I-Claim
273	at	N	I-Claim
274	40,000	N	I-Claim
275	U	N	I-Claim
276	qw	N	I-Claim
277	is	N	I-Claim
278	effective	N	I-Claim
279	in	N	I-Claim
280	improving	N	I-Claim
281	QOL	N	I-Claim
282	,	N	I-Claim
283	maintaining	N	I-Claim
284	hemoglobin	N	I-Claim
285	level	N	I-Claim
286	,	N	I-Claim
287	and	N	I-Claim
288	reducing	N	I-Claim
289	transfusion	N	I-Claim
290	requirements	N	I-Claim
291	in	N	I-Claim
292	breast	N	I-Claim
293	cancer	N	I-Claim
294	patients	N	I-Claim
295	.	N	I-Claim

296	The	N	I-Claim
297	high	N	I-Claim
298	effectiveness	N	I-Claim
299	observed	N	I-Claim
300	could	N	I-Claim
301	be	N	I-Claim
302	attributed	N	I-Claim
303	in	N	I-Claim
304	part	N	I-Claim
305	to	N	I-Claim
306	early	N	I-Claim
307	treatment	N	I-Claim
308	with	N	I-Claim
309	epoetin	N	I-Claim
310	alfa	N	I-Claim
311	.	N	I-Claim

1	Increased	N	O
2	attention	N	O
3	has	N	O
4	focused	N	O
5	on	N	O
6	exercise	N	O
7	as	N	O
8	a	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	intervention	N	O
13	for	N	O
14	breast	N	O
15	cancer	N	O
16	survivors	N	O
17	during	N	O
18	and	N	O
19	after	N	O
20	adjuvant	N	O
21	therapy	N	O
22	.	N	O

23	Our	N	O
24	objective	N	O
25	was	N	O
26	to	N	O
27	examine	N	O
28	the	N	O
29	effects	N	O
30	of	N	O
31	an	N	O
32	oncologist	N	O
33	's	N	O
34	recommendation	N	O
35	to	N	O
36	exercise	N	O
37	on	N	O
38	self-reported	N	O
39	exercise	N	O
40	behavior	N	O
41	in	N	O
42	newly	N	O
43	diagnosed	N	O
44	breast	N	O
45	cancer	N	O
46	survivors	N	O
47	attending	N	O
48	their	N	O
49	first	N	O
50	adjuvant	N	O
51	therapy	N	O
52	consultation	N	O
53	.	N	O

54	Using	N	O
55	a	N	O
56	single-blinded	N	O
57	,	N	O
58	3-armed	N	O
59	,	N	O
60	randomized	N	O
61	controlled	N	O
62	trial	N	O
63	,	N	O
64	450	N	O
65	breast	N	O
66	cancer	N	O
67	survivors	N	O
68	were	N	O
69	randomly	N	O
70	assigned	N	O
71	to	N	O
72	receive	N	O
73	an	N	O
74	oncologist	N	O
75	exercise	N	O
76	recommendation	N	O
77	only	N	O
78	,	N	O
79	an	N	O
80	oncologist	N	O
81	exercise	N	O
82	recommendation	N	O
83	plus	N	O
84	referral	N	O
85	to	N	O
86	an	N	O
87	exercise	N	O
88	specialist	N	O
89	,	N	O
90	or	N	O
91	usual	N	O
92	care	N	O
93	.	N	O

94	The	N	O
95	primary	N	O
96	outcome	N	O
97	was	N	O
98	self-reported	N	O
99	total	N	O
100	exercise	N	O
101	(	N	O
102	in	N	O
103	metabolic	N	O
104	equivalent	N	O
105	[	N	O
106	MET	N	O
107	]	N	O
108	hours	N	O
109	per	N	O
110	week	N	O
111	)	N	O
112	at	N	O
113	5	N	O
114	weeks	N	O
115	postconsultation	N	O
116	.	N	O

117	The	N	O
118	follow-up	N	O
119	assessment	N	O
120	rate	N	O
121	was	N	O
122	73	N	O
123	%	N	O
124	(	N	O
125	329	N	O
126	of	N	O
127	450	N	O
128	)	N	O
129	.	N	O

130	Intention-to-treat	N	I-Premise
131	analysis	N	I-Premise
132	based	N	I-Premise
133	on	N	I-Premise
134	participants	N	I-Premise
135	with	N	I-Premise
136	follow-up	N	I-Premise
137	data	N	I-Premise
138	indicated	N	I-Premise
139	a	N	I-Premise
140	significant	N	I-Premise
141	difference	N	I-Premise
142	in	N	I-Premise
143	total	N	I-Premise
144	exercise	N	I-Premise
145	in	N	I-Premise
146	favor	N	I-Premise
147	of	N	I-Premise
148	the	N	I-Premise
149	recommendation-only	N	I-Premise
150	group	N	I-Premise
151	over	N	I-Premise
152	the	N	I-Premise
153	usual	N	I-Premise
154	care	N	I-Premise
155	group	N	I-Premise
156	(	N	I-Premise
157	mean	N	I-Premise
158	difference	N	I-Premise
159	,	N	I-Premise
160	3.4	N	I-Premise
161	MET	N	I-Premise
162	hr	N	I-Premise
163	per	N	I-Premise
164	week	N	I-Premise
165	;	N	I-Premise
166	95	N	I-Premise
167	%	N	I-Premise
168	confidence	N	I-Premise
169	interval	N	I-Premise
170	[	N	I-Premise
171	CI	N	I-Premise
172	]	N	I-Premise
173	,	N	I-Premise
174	0.7-6.1	N	I-Premise
175	MET	N	I-Premise
176	hr	N	I-Premise
177	per	N	I-Premise
178	week	N	I-Premise
179	;	N	I-Premise
180	p	N	I-Premise
181	=	N	I-Premise
182	.011	N	I-Premise
183	)	N	I-Premise
184	.	N	I-Premise

185	There	N	I-Premise
186	was	N	I-Premise
187	no	N	I-Premise
188	significant	N	I-Premise
189	difference	N	I-Premise
190	between	N	I-Premise
191	the	N	I-Premise
192	recommendation-plus-referral	N	I-Premise
193	group	N	I-Premise
194	and	N	I-Premise
195	the	N	I-Premise
196	usual	N	I-Premise
197	care	N	I-Premise
198	group	N	I-Premise
199	(	N	I-Premise
200	mean	N	I-Premise
201	difference	N	I-Premise
202	,	N	I-Premise
203	1.5	N	I-Premise
204	MET	N	I-Premise
205	hr	N	I-Premise
206	per	N	I-Premise
207	week	N	I-Premise
208	;	N	I-Premise
209	95	N	I-Premise
210	%	N	I-Premise
211	CI	N	I-Premise
212	,	N	I-Premise
213	-1.0	N	I-Premise
214	to	N	I-Premise
215	4.0	N	I-Premise
216	MET	N	I-Premise
217	hr	N	I-Premise
218	per	N	I-Premise
219	week	N	I-Premise
220	;	N	I-Premise
221	p	N	I-Premise
222	=	N	I-Premise
223	.244	N	I-Premise
224	)	N	I-Premise
225	.	N	I-Premise

226	Ancillary	N	I-Premise
227	``	N	I-Premise
228	on-treatment	N	I-Premise
229	''	N	I-Premise
230	analyzes	N	I-Premise
231	showed	N	I-Premise
232	that	N	I-Premise
233	participants	N	I-Premise
234	who	N	I-Premise
235	recalled	N	I-Premise
236	an	N	I-Premise
237	exercise	N	I-Premise
238	recommendation	N	I-Premise
239	reported	N	I-Premise
240	significantly	N	I-Premise
241	more	N	I-Premise
242	total	N	I-Premise
243	exercise	N	I-Premise
244	than	N	I-Premise
245	participants	N	I-Premise
246	who	N	I-Premise
247	did	N	I-Premise
248	not	N	I-Premise
249	recall	N	I-Premise
250	an	N	I-Premise
251	exercise	N	I-Premise
252	recommendation	N	I-Premise
253	(	N	I-Premise
254	mean	N	I-Premise
255	difference	N	I-Premise
256	,	N	I-Premise
257	4.1	N	I-Premise
258	MET	N	I-Premise
259	hr	N	I-Premise
260	per	N	I-Premise
261	week	N	I-Premise
262	:	N	I-Premise
263	95	N	I-Premise
264	%	N	I-Premise
265	CI	N	I-Premise
266	,	N	I-Premise
267	1.9-6.4	N	I-Premise
268	MET	N	I-Premise
269	hr	N	I-Premise
270	per	N	I-Premise
271	week	N	I-Premise
272	;	N	I-Premise
273	p	N	I-Premise
274	<	N	I-Premise
275	.001	N	I-Premise
276	)	N	I-Premise
277	.	N	I-Premise

278	Our	N	I-Claim
279	findings	N	I-Claim
280	suggest	N	I-Claim
281	that	N	I-Claim
282	an	N	I-Claim
283	oncologist	N	I-Claim
284	recommendation	N	I-Claim
285	may	N	I-Claim
286	increase	N	I-Claim
287	exercise	N	I-Claim
288	behavior	N	I-Claim
289	in	N	I-Claim
290	newly	N	I-Claim
291	diagnosed	N	I-Claim
292	breast	N	I-Claim
293	cancer	N	I-Claim
294	survivors	N	I-Claim
295	,	N	I-Claim
296	particularly	N	I-Claim
297	if	N	I-Claim
298	it	N	I-Claim
299	is	N	I-Claim
300	recalled	N	I-Claim
301	1	N	I-Claim
302	week	N	I-Claim
303	after	N	I-Claim
304	the	N	I-Claim
305	recommendation	N	I-Claim
306	.	N	I-Claim

1	Kaposi	N	O
2	's	N	O
3	sarcoma	N	O
4	is	N	O
5	currently	N	O
6	the	N	O
7	most	N	O
8	common	N	O
9	tumor	N	O
10	in	N	O
11	Zimbabwe	N	O
12	.	N	O

13	The	N	O
14	purpose	N	O
15	of	N	O
16	our	N	O
17	study	N	O
18	is	N	O
19	to	N	O
20	compare	N	O
21	the	N	O
22	effectiveness	N	O
23	of	N	O
24	supportive	N	O
25	care	N	O
26	vs.	N	O
27	3	N	O
28	intervention	N	O
29	approaches	N	O
30	,	N	O
31	namely	N	O
32	oral	N	O
33	Etoposide	N	O
34	,	N	O
35	a	N	O
36	3-drug	N	O
37	combination	N	O
38	,	N	O
39	and	N	O
40	radiotherapy	N	O
41	using	N	O
42	quality	N	O
43	of	N	O
44	life	N	O
45	(	N	O
46	QOL	N	O
47	)	N	O
48	as	N	O
49	the	N	O
50	primary	N	O
51	measure	N	O
52	of	N	O
53	success	N	O
54	.	N	O

55	In	N	O
56	addition	N	O
57	,	N	O
58	our	N	O
59	study	N	O
60	was	N	O
61	to	N	O
62	determine	N	O
63	whether	N	O
64	a	N	O
65	disease-specific	N	O
66	module	N	O
67	has	N	O
68	greater	N	O
69	sensitivity	N	O
70	to	N	O
71	group	N	O
72	differences	N	O
73	than	N	O
74	a	N	O
75	generic	N	O
76	QOL	N	O
77	questionnaire	N	O
78	and	N	O
79	to	N	O
80	determine	N	O
81	the	N	O
82	most	N	O
83	pragmatic	N	O
84	approach	N	O
85	to	N	O
86	treating	N	O
87	epidemic	N	O
88	Kaposi	N	O
89	's	N	O
90	sarcoma	N	O
91	(	N	O
92	EKS	N	O
93	)	N	O
94	in	N	O
95	Zimbabwe	N	O
96	.	N	O

97	Histologically	N	O
98	confirmed	N	O
99	HIV-positive	N	O
100	patients	N	O
101	with	N	O
102	Kaposi	N	O
103	's	N	O
104	sarcoma	N	O
105	were	N	O
106	randomized	N	O
107	to	N	O
108	receive	N	O
109	supportive	N	O
110	care	N	O
111	only	N	O
112	or	N	O
113	supportive	N	O
114	care	N	O
115	plus	N	O
116	either	N	O
117	radiotherapy	N	O
118	,	N	O
119	oral	N	O
120	Etoposide	N	O
121	or	N	O
122	a	N	O
123	3-drug	N	O
124	combination	N	O
125	consisting	N	O
126	of	N	O
127	actinomycin-D	N	O
128	,	N	O
129	vincristine	N	O
130	and	N	O
131	bleomycin	N	O
132	.	N	O

133	No	N	O
134	patient	N	O
135	received	N	O
136	antiretroviral	N	O
137	therapy	N	O
138	.	N	O

139	The	N	O
140	primary	N	O
141	outcome	N	O
142	was	N	O
143	QOL	N	O
144	measured	N	O
145	by	N	O
146	the	N	O
147	functional	N	O
148	living	N	O
149	index-cancer	N	O
150	(	N	O
151	FLI-C	N	O
152	)	N	O
153	and	N	O
154	supplemented	N	O
155	by	N	O
156	the	N	O
157	Kaposi	N	O
158	's	N	O
159	sarcoma	N	O
160	module	N	O
161	(	N	O
162	KSM	N	O
163	)	N	O
164	.	N	O

165	From	N	O
166	1994-1999	N	O
167	,	N	O
168	495	N	O
169	EKS	N	O
170	patients	N	O
171	were	N	O
172	accrued	N	O
173	,	N	O
174	and	N	O
175	470	N	O
176	were	N	O
177	evaluable	N	O
178	.	N	O

179	Of	N	O
180	these	N	O
181	,	N	O
182	433	N	O
183	are	N	O
184	known	N	O
185	to	N	O
186	be	N	O
187	dead	N	O
188	,	N	O
189	26	N	O
190	are	N	O
191	lost	N	O
192	to	N	O
193	follow-up	N	O
194	and	N	O
195	11	N	O
196	are	N	O
197	still	N	O
198	alive	N	O
199	.	N	O

200	The	N	I-Premise
201	group	N	I-Premise
202	treated	N	I-Premise
203	with	N	I-Premise
204	oral	N	I-Premise
205	Etoposide	N	I-Premise
206	had	N	I-Premise
207	a	N	I-Premise
208	significantly	N	I-Premise
209	better	N	I-Premise
210	QOL	N	I-Premise
211	than	N	I-Premise
212	the	N	I-Premise
213	radiotherapy	N	I-Premise
214	group	N	I-Premise
215	for	N	I-Premise
216	the	N	I-Premise
217	total	N	I-Premise
218	FLI-C	N	I-Premise
219	score	N	I-Premise
220	(	N	I-Premise
221	adjusted	N	I-Premise
222	mean	N	I-Premise
223	plus	N	I-Premise
224	standard	N	I-Premise
225	error	N	I-Premise
226	at	N	I-Premise
227	3-months	N	I-Premise
228	89	N	I-Premise
229	+/-	N	I-Premise
230	3	N	I-Premise
231	vs.	N	I-Premise
232	76	N	I-Premise
233	+/-	N	I-Premise
234	3	N	I-Premise
235	;	N	I-Premise
236	p	N	I-Premise
237	=	N	I-Premise
238	0.004	N	I-Premise
239	)	N	I-Premise
240	and	N	I-Premise
241	for	N	I-Premise
242	the	N	I-Premise
243	hardship	N	I-Premise
244	(	N	I-Premise
245	11	N	I-Premise
246	+/-	N	I-Premise
247	0.4	N	I-Premise
248	vs.	N	I-Premise
249	9	N	I-Premise
250	+/-	N	I-Premise
251	0.4	N	I-Premise
252	;	N	I-Premise
253	p	N	I-Premise
254	=	N	I-Premise
255	0.001	N	I-Premise
256	)	N	I-Premise
257	;	N	I-Premise
258	social	N	I-Premise
259	(	N	I-Premise
260	10	N	I-Premise
261	+/-	N	I-Premise
262	0.4	N	I-Premise
263	vs.	N	I-Premise
264	8	N	I-Premise
265	+/-	N	I-Premise
266	0.4	N	I-Premise
267	;	N	I-Premise
268	p	N	I-Premise
269	=	N	I-Premise
270	0.001	N	I-Premise
271	)	N	I-Premise
272	and	N	I-Premise
273	nausea	N	I-Premise
274	(	N	I-Premise
275	9	N	I-Premise
276	+/-	N	I-Premise
277	0.4	N	I-Premise
278	vs.	N	I-Premise
279	8	N	I-Premise
280	+/-	N	I-Premise
281	0.4	N	I-Premise
282	;	N	I-Premise
283	p	N	I-Premise
284	=	N	I-Premise
285	0.002	N	I-Premise
286	)	N	I-Premise
287	subscales	N	I-Premise
288	.	N	I-Premise

289	In	N	I-Premise
290	addition	N	I-Premise
291	,	N	I-Premise
292	on	N	I-Premise
293	the	N	I-Premise
294	physical	N	I-Premise
295	and	N	I-Premise
296	psychological	N	I-Premise
297	subscales	N	I-Premise
298	,	N	I-Premise
299	the	N	I-Premise
300	Etoposide	N	I-Premise
301	group	N	I-Premise
302	had	N	I-Premise
303	a	N	I-Premise
304	significantly	N	I-Premise
305	better	N	I-Premise
306	QOL	N	I-Premise
307	than	N	I-Premise
308	the	N	I-Premise
309	other	N	I-Premise
310	3	N	I-Premise
311	treatment	N	I-Premise
312	groups	N	I-Premise
313	(	N	I-Premise
314	p	N	I-Premise
315	<	N	I-Premise
316	0.04	N	I-Premise
317	)	N	I-Premise
318	.	N	I-Premise

319	The	N	I-Premise
320	3-drug	N	I-Premise
321	combination	N	I-Premise
322	,	N	I-Premise
323	supportive	N	I-Premise
324	care	N	I-Premise
325	and	N	I-Premise
326	radiotherapy	N	I-Premise
327	groups	N	I-Premise
328	did	N	I-Premise
329	not	N	I-Premise
330	differ	N	I-Premise
331	significantly	N	I-Premise
332	from	N	I-Premise
333	each	N	I-Premise
334	other	N	I-Premise
335	with	N	I-Premise
336	respect	N	I-Premise
337	to	N	I-Premise
338	the	N	I-Premise
339	total	N	I-Premise
340	FLI-C	N	I-Premise
341	score	N	I-Premise
342	or	N	I-Premise
343	its	N	I-Premise
344	subscales	N	I-Premise
345	.	N	I-Premise

346	There	N	I-Premise
347	were	N	I-Premise
348	no	N	I-Premise
349	group	N	I-Premise
350	differences	N	I-Premise
351	with	N	I-Premise
352	respect	N	I-Premise
353	to	N	I-Premise
354	survival	N	I-Premise
355	.	N	I-Premise

356	Oral	N	I-Claim
357	Etoposide	N	I-Claim
358	therapy	N	I-Claim
359	resulted	N	I-Claim
360	in	N	I-Claim
361	better	N	I-Claim
362	total	N	I-Claim
363	FLI-C	N	I-Claim
364	QOL	N	I-Claim
365	score	N	I-Claim
366	than	N	I-Claim
367	radiotherapy	N	I-Claim
368	.	N	I-Claim

369	As	N	O
370	well	N	O
371	,	N	O
372	Etoposide	N	I-Claim
373	resulted	N	I-Claim
374	in	N	I-Claim
375	better	N	I-Claim
376	physical	N	I-Claim
377	and	N	I-Claim
378	psychological	N	I-Claim
379	subscale	N	I-Claim
380	scores	N	I-Claim
381	than	N	I-Claim
382	radiotherapy	N	I-Claim
383	,	N	I-Claim
384	3-drugs	N	I-Claim
385	and	N	I-Claim
386	supportive	N	I-Claim
387	care	N	I-Claim
388	.	N	I-Claim

389	Thus	N	I-Claim
390	,	N	I-Claim
391	funds	N	I-Claim
392	permitting	N	I-Claim
393	,	N	I-Claim
394	oral	N	I-Claim
395	Etoposide	N	I-Claim
396	is	N	I-Claim
397	a	N	I-Claim
398	pragmatic	N	I-Claim
399	approach	N	I-Claim
400	to	N	I-Claim
401	treating	N	I-Claim
402	EKS	N	I-Claim
403	in	N	I-Claim
404	an	N	I-Claim
405	environment	N	I-Claim
406	where	N	I-Claim
407	antiretroviral	N	I-Claim
408	drugs	N	I-Claim
409	are	N	I-Claim
410	not	N	I-Claim
411	universally	N	I-Claim
412	available	N	I-Claim
413	.	N	I-Claim

414	The	N	I-MajorClaim
415	study	N	I-MajorClaim
416	underscores	N	I-MajorClaim
417	the	N	I-MajorClaim
418	value	N	I-MajorClaim
419	of	N	I-MajorClaim
420	undertaking	N	I-MajorClaim
421	studies	N	I-MajorClaim
422	in	N	I-MajorClaim
423	areas	N	I-MajorClaim
424	of	N	I-MajorClaim
425	disease	N	I-MajorClaim
426	prevalence	N	I-MajorClaim
427	and	N	I-MajorClaim
428	the	N	I-MajorClaim
429	necessity	N	I-MajorClaim
430	of	N	I-MajorClaim
431	selecting	N	I-MajorClaim
432	appropriate	N	I-MajorClaim
433	outcome	N	I-MajorClaim
434	measures	N	I-MajorClaim
435	.	N	I-MajorClaim

1	To	N	O
2	determine	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	safety	N	O
7	of	N	O
8	a	N	O
9	biweekly	N	O
10	regimen	N	O
11	of	N	O
12	leucovorin	N	O
13	(	N	O
14	LV	N	O
15	)	N	O
16	plus	N	O
17	fluorouracil	N	O
18	(	N	O
19	FU	N	O
20	)	N	O
21	alone	N	O
22	or	N	O
23	in	N	O
24	combination	N	O
25	with	N	O
26	cisplatin	N	O
27	or	N	O
28	irinotecan	N	O
29	in	N	O
30	patients	N	O
31	with	N	O
32	previously	N	O
33	untreated	N	O
34	metastatic	N	O
35	gastric	N	O
36	adenocarcinoma	N	O
37	and	N	O
38	to	N	O
39	select	N	O
40	the	N	O
41	best	N	O
42	arm	N	O
43	for	N	O
44	a	N	O
45	phase	N	O
46	III	N	O
47	study	N	O
48	.	N	O

49	One	N	O
50	hundred	N	O
51	thirty-six	N	O
52	patients	N	O
53	(	N	O
54	two	N	O
55	were	N	O
56	ineligible	N	O
57	)	N	O
58	were	N	O
59	enrolled	N	O
60	onto	N	O
61	the	N	O
62	randomized	N	O
63	multicenter	N	O
64	phase	N	O
65	II	N	O
66	trial	N	O
67	.	N	O

68	Patients	N	O
69	received	N	O
70	LV	N	O
71	200	N	O
72	mg/m	N	O
73	(	N	O
74	2	N	O
75	)	N	O
76	(	N	O
77	2-hour	N	O
78	infusion	N	O
79	)	N	O
80	followed	N	O
81	by	N	O
82	FU	N	O
83	400	N	O
84	mg/m	N	O
85	(	N	O
86	2	N	O
87	)	N	O
88	(	N	O
89	bolus	N	O
90	)	N	O
91	and	N	O
92	FU	N	O
93	600	N	O
94	mg/m	N	O
95	(	N	O
96	2	N	O
97	)	N	O
98	(	N	O
99	22-hour	N	O
100	continuous	N	O
101	infusion	N	O
102	)	N	O
103	on	N	O
104	days	N	O
105	1	N	O
106	and	N	O
107	2	N	O
108	every	N	O
109	14	N	O
110	days	N	O
111	(	N	O
112	LV5FU2	N	O
113	;	N	O
114	arm	N	O
115	A	N	O
116	)	N	O
117	,	N	O
118	LV5FU2	N	O
119	plus	N	O
120	cisplatin	N	O
121	50	N	O
122	mg/m	N	O
123	(	N	O
124	2	N	O
125	)	N	O
126	(	N	O
127	1-hour	N	O
128	infusion	N	O
129	)	N	O
130	on	N	O
131	day	N	O
132	1	N	O
133	or	N	O
134	2	N	O
135	(	N	O
136	arm	N	O
137	B	N	O
138	)	N	O
139	,	N	O
140	or	N	O
141	LV5FU2	N	O
142	plus	N	O
143	irinotecan	N	O
144	180	N	O
145	mg/m	N	O
146	(	N	O
147	2	N	O
148	)	N	O
149	(	N	O
150	2-hour	N	O
151	infusion	N	O
152	)	N	O
153	on	N	O
154	day	N	O
155	1	N	O
156	(	N	O
157	arm	N	O
158	C	N	O
159	)	N	O
160	.	N	O

161	The	N	I-Premise
162	overall	N	I-Premise
163	response	N	I-Premise
164	rates	N	I-Premise
165	,	N	I-Premise
166	which	N	I-Premise
167	were	N	I-Premise
168	confirmed	N	I-Premise
169	by	N	I-Premise
170	an	N	I-Premise
171	independent	N	I-Premise
172	expert	N	I-Premise
173	panel	N	I-Premise
174	,	N	I-Premise
175	were	N	I-Premise
176	13	N	I-Premise
177	%	N	I-Premise
178	(	N	I-Premise
179	95	N	I-Premise
180	%	N	I-Premise
181	CI	N	I-Premise
182	,	N	I-Premise
183	3.4	N	I-Premise
184	%	N	I-Premise
185	to	N	I-Premise
186	23.3	N	I-Premise
187	%	N	I-Premise
188	)	N	I-Premise
189	,	N	I-Premise
190	27	N	I-Premise
191	%	N	I-Premise
192	(	N	I-Premise
193	95	N	I-Premise
194	%	N	I-Premise
195	CI	N	I-Premise
196	,	N	I-Premise
197	14.1	N	I-Premise
198	%	N	I-Premise
199	to	N	I-Premise
200	40.4	N	I-Premise
201	%	N	I-Premise
202	)	N	I-Premise
203	,	N	I-Premise
204	and	N	I-Premise
205	40	N	I-Premise
206	%	N	I-Premise
207	(	N	I-Premise
208	95	N	I-Premise
209	%	N	I-Premise
210	CI	N	I-Premise
211	,	N	I-Premise
212	25.7	N	I-Premise
213	%	N	I-Premise
214	to	N	I-Premise
215	54.3	N	I-Premise
216	%	N	I-Premise
217	)	N	I-Premise
218	for	N	I-Premise
219	arms	N	I-Premise
220	A	N	I-Premise
221	,	N	I-Premise
222	B	N	I-Premise
223	,	N	I-Premise
224	and	N	I-Premise
225	C	N	I-Premise
226	,	N	I-Premise
227	respectively	N	I-Premise
228	.	N	I-Premise

229	Median	N	I-Premise
230	progression-free	N	I-Premise
231	survival	N	I-Premise
232	and	N	I-Premise
233	overall	N	I-Premise
234	survival	N	I-Premise
235	times	N	I-Premise
236	were	N	I-Premise
237	3.2	N	I-Premise
238	months	N	I-Premise
239	(	N	I-Premise
240	95	N	I-Premise
241	%	N	I-Premise
242	CI	N	I-Premise
243	,	N	I-Premise
244	1.8	N	I-Premise
245	to	N	I-Premise
246	4.6	N	I-Premise
247	months	N	I-Premise
248	)	N	I-Premise
249	and	N	I-Premise
250	6.8	N	I-Premise
251	months	N	I-Premise
252	(	N	I-Premise
253	95	N	I-Premise
254	%	N	I-Premise
255	CI	N	I-Premise
256	,	N	I-Premise
257	2.6	N	I-Premise
258	to	N	I-Premise
259	11.1	N	I-Premise
260	months	N	I-Premise
261	)	N	I-Premise
262	with	N	I-Premise
263	LV5FU2	N	I-Premise
264	,	N	I-Premise
265	respectively	N	I-Premise
266	;	N	I-Premise
267	4.9	N	I-Premise
268	months	N	I-Premise
269	(	N	I-Premise
270	95	N	I-Premise
271	%	N	I-Premise
272	CI	N	I-Premise
273	,	N	I-Premise
274	3.5	N	I-Premise
275	to	N	I-Premise
276	6.3	N	I-Premise
277	months	N	I-Premise
278	)	N	I-Premise
279	and	N	I-Premise
280	9.5	N	I-Premise
281	months	N	I-Premise
282	(	N	I-Premise
283	95	N	I-Premise
284	%	N	I-Premise
285	CI	N	I-Premise
286	,	N	I-Premise
287	6.9	N	I-Premise
288	to	N	I-Premise
289	12.2	N	I-Premise
290	months	N	I-Premise
291	)	N	I-Premise
292	with	N	I-Premise
293	LV5FU2-cisplatin	N	I-Premise
294	,	N	I-Premise
295	respectively	N	I-Premise
296	;	N	I-Premise
297	and	N	I-Premise
298	6.9	N	I-Premise
299	months	N	I-Premise
300	(	N	I-Premise
301	95	N	I-Premise
302	%	N	I-Premise
303	CI	N	I-Premise
304	,	N	I-Premise
305	5.5	N	I-Premise
306	to	N	I-Premise
307	8.3	N	I-Premise
308	months	N	I-Premise
309	)	N	I-Premise
310	and	N	I-Premise
311	11.3	N	I-Premise
312	months	N	I-Premise
313	(	N	I-Premise
314	95	N	I-Premise
315	%	N	I-Premise
316	CI	N	I-Premise
317	,	N	I-Premise
318	9.3	N	I-Premise
319	to	N	I-Premise
320	13.3	N	I-Premise
321	months	N	I-Premise
322	)	N	I-Premise
323	with	N	I-Premise
324	LV5FU2-irinotecan	N	I-Premise
325	,	N	I-Premise
326	respectively	N	I-Premise
327	.	N	I-Premise

328	Of	N	I-Claim
329	the	N	I-Claim
330	three	N	I-Claim
331	regimens	N	I-Claim
332	tested	N	I-Claim
333	,	N	I-Claim
334	the	N	I-Claim
335	combination	N	I-Claim
336	of	N	I-Claim
337	LV5FU2-irinotecan	N	I-Claim
338	is	N	I-Claim
339	the	N	I-Claim
340	most	N	I-Claim
341	promising	N	I-Claim
342	and	N	I-Claim
343	will	N	I-Claim
344	be	N	I-Claim
345	assessed	N	I-Claim
346	in	N	I-Claim
347	a	N	I-Claim
348	phase	N	I-Claim
349	III	N	I-Claim
350	trial	N	I-Claim
351	.	N	I-Claim

1	Treatment-induced	N	O
2	arm	N	O
3	lymphoedema	N	O
4	is	N	O
5	a	N	O
6	common	N	O
7	and	N	O
8	distressing	N	O
9	complication	N	O
10	of	N	O
11	curative	N	O
12	surgery	N	O
13	and	N	O
14	radiotherapy	N	O
15	for	N	O
16	early	N	O
17	breast	N	O
18	cancer	N	O
19	.	N	O

20	A	N	O
21	number	N	O
22	of	N	O
23	studies	N	O
24	testing	N	O
25	alpha-tocopherol	N	O
26	(	N	O
27	vitamin	N	O
28	E	N	O
29	)	N	O
30	and	N	O
31	pentoxifylline	N	O
32	suggest	N	O
33	evidence	N	O
34	of	N	O
35	clinical	N	O
36	regression	N	O
37	of	N	O
38	superficial	N	O
39	radiation-induced	N	O
40	fibrosis	N	O
41	but	N	O
42	there	N	O
43	is	N	O
44	only	N	O
45	very	N	O
46	limited	N	O
47	evidence	N	O
48	from	N	O
49	randomised	N	O
50	trials	N	O
51	.	N	O

52	Arm	N	O
53	lymphoedema	N	O
54	after	N	O
55	lymphatic	N	O
56	radiotherapy	N	O
57	and	N	O
58	surgery	N	O
59	has	N	O
60	been	N	O
61	used	N	O
62	in	N	O
63	the	N	O
64	present	N	O
65	study	N	O
66	as	N	O
67	a	N	O
68	clinical	N	O
69	system	N	O
70	for	N	O
71	testing	N	O
72	these	N	O
73	drugs	N	O
74	in	N	O
75	a	N	O
76	double-blind	N	O
77	placebo-controlled	N	O
78	randomised	N	O
79	phase	N	O
80	II	N	O
81	trial	N	O
82	.	N	O

83	Sixty-eight	N	O
84	eligible	N	O
85	research	N	O
86	volunteers	N	O
87	with	N	O
88	a	N	O
89	minimum	N	O
90	20	N	O
91	%	N	O
92	increase	N	O
93	in	N	O
94	arm	N	O
95	volume	N	O
96	at	N	O
97	a	N	O
98	median	N	O
99	15.5	N	O
100	years	N	O
101	(	N	O
102	range	N	O
103	2-41	N	O
104	)	N	O
105	after	N	O
106	axillary/supraclavicular	N	O
107	radiotherapy	N	O
108	(	N	O
109	plus	N	O
110	axillary	N	O
111	surgery	N	O
112	in	N	O
113	51/68	N	O
114	(	N	O
115	75	N	O
116	%	N	O
117	)	N	O
118	cases	N	O
119	)	N	O
120	were	N	O
121	randomised	N	O
122	to	N	O
123	active	N	O
124	drugs	N	O
125	or	N	O
126	placebo	N	O
127	.	N	O

128	All	N	O
129	volunteers	N	O
130	were	N	O
131	given	N	O
132	dl-alpha	N	O
133	tocopheryl	N	O
134	acetate	N	O
135	500	N	O
136	mg	N	O
137	twice	N	O
138	a	N	O
139	day	N	O
140	orally	N	O
141	plus	N	O
142	pentoxifylline	N	O
143	400	N	O
144	mg	N	O
145	twice	N	O
146	a	N	O
147	day	N	O
148	orally	N	O
149	,	N	O
150	or	N	O
151	corresponding	N	O
152	placebos	N	O
153	,	N	O
154	for	N	O
155	6	N	O
156	months	N	O
157	.	N	O

158	The	N	O
159	primary	N	O
160	endpoint	N	O
161	was	N	O
162	volume	N	O
163	of	N	O
164	the	N	O
165	ipsilateral	N	O
166	limb	N	O
167	measured	N	O
168	opto-electronically	N	O
169	using	N	O
170	a	N	O
171	perometer	N	O
172	and	N	O
173	expressed	N	O
174	as	N	O
175	a	N	O
176	percentage	N	O
177	of	N	O
178	the	N	O
179	contralateral	N	O
180	limb	N	O
181	volume	N	O
182	.	N	O

183	At	N	I-Premise
184	12	N	I-Premise
185	months	N	I-Premise
186	post-randomisation	N	I-Premise
187	,	N	I-Premise
188	there	N	I-Premise
189	was	N	I-Premise
190	no	N	I-Premise
191	significant	N	I-Premise
192	difference	N	I-Premise
193	between	N	I-Premise
194	treatment	N	I-Premise
195	and	N	I-Premise
196	control	N	I-Premise
197	groups	N	I-Premise
198	in	N	I-Premise
199	terms	N	I-Premise
200	of	N	I-Premise
201	arm	N	I-Premise
202	volume	N	I-Premise
203	.	N	I-Premise

204	Absolute	N	I-Premise
205	change	N	I-Premise
206	in	N	I-Premise
207	arm	N	I-Premise
208	volume	N	I-Premise
209	at	N	I-Premise
210	12	N	I-Premise
211	months	N	I-Premise
212	was	N	I-Premise
213	2.5	N	I-Premise
214	%	N	I-Premise
215	(	N	I-Premise
216	95	N	I-Premise
217	%	N	I-Premise
218	CI	N	I-Premise
219	-0.40	N	I-Premise
220	to	N	I-Premise
221	5.3	N	I-Premise
222	)	N	I-Premise
223	in	N	I-Premise
224	the	N	I-Premise
225	treatment	N	I-Premise
226	group	N	I-Premise
227	compared	N	I-Premise
228	to	N	I-Premise
229	1.2	N	I-Premise
230	%	N	I-Premise
231	(	N	I-Premise
232	95	N	I-Premise
233	%	N	I-Premise
234	CI	N	I-Premise
235	-2.8	N	I-Premise
236	to	N	I-Premise
237	5.1	N	I-Premise
238	)	N	I-Premise
239	in	N	I-Premise
240	the	N	I-Premise
241	placebo	N	I-Premise
242	group	N	I-Premise
243	.	N	I-Premise

244	The	N	I-Premise
245	difference	N	I-Premise
246	in	N	I-Premise
247	mean	N	I-Premise
248	volume	N	I-Premise
249	change	N	I-Premise
250	between	N	I-Premise
251	randomisation	N	I-Premise
252	groups	N	I-Premise
253	at	N	I-Premise
254	12	N	I-Premise
255	months	N	I-Premise
256	was	N	I-Premise
257	not	N	I-Premise
258	statistically	N	I-Premise
259	significant	N	I-Premise
260	(	N	I-Premise
261	P	N	I-Premise
262	=	N	I-Premise
263	0.6	N	I-Premise
264	)	N	I-Premise
265	,	N	I-Premise
266	-1.3	N	I-Premise
267	%	N	I-Premise
268	(	N	I-Premise
269	95	N	I-Premise
270	%	N	I-Premise
271	CI	N	I-Premise
272	-6.1	N	I-Premise
273	to	N	I-Premise
274	3.5	N	I-Premise
275	)	N	I-Premise
276	,	N	I-Premise
277	nor	N	I-Premise
278	was	N	I-Premise
279	there	N	I-Premise
280	a	N	I-Premise
281	significant	N	I-Premise
282	difference	N	I-Premise
283	in	N	I-Premise
284	response	N	I-Premise
285	at	N	I-Premise
286	6	N	I-Premise
287	months	N	I-Premise
288	(	N	I-Premise
289	P	N	I-Premise
290	=	N	I-Premise
291	0.7	N	I-Premise
292	)	N	I-Premise
293	,	N	I-Premise
294	where	N	I-Premise
295	mean	N	I-Premise
296	change	N	I-Premise
297	in	N	I-Premise
298	arm	N	I-Premise
299	volume	N	I-Premise
300	from	N	I-Premise
301	baseline	N	I-Premise
302	in	N	I-Premise
303	the	N	I-Premise
304	treatment	N	I-Premise
305	and	N	I-Premise
306	placebo	N	I-Premise
307	groups	N	I-Premise
308	was	N	I-Premise
309	-2.3	N	I-Premise
310	%	N	I-Premise
311	(	N	I-Premise
312	95	N	I-Premise
313	%	N	I-Premise
314	CI	N	I-Premise
315	-7.9	N	I-Premise
316	to	N	I-Premise
317	3.4	N	I-Premise
318	)	N	I-Premise
319	and	N	I-Premise
320	-1.1	N	I-Premise
321	%	N	I-Premise
322	(	N	I-Premise
323	95	N	I-Premise
324	%	N	I-Premise
325	CI	N	I-Premise
326	-3.9	N	I-Premise
327	to	N	I-Premise
328	1.7	N	I-Premise
329	)	N	I-Premise
330	,	N	I-Premise
331	respectively	N	I-Premise
332	.	N	I-Premise

333	There	N	I-Premise
334	were	N	I-Premise
335	no	N	I-Premise
336	significant	N	I-Premise
337	differences	N	I-Premise
338	between	N	I-Premise
339	randomised	N	I-Premise
340	groups	N	I-Premise
341	in	N	I-Premise
342	terms	N	I-Premise
343	of	N	I-Premise
344	secondary	N	I-Premise
345	endpoints	N	I-Premise
346	,	N	I-Premise
347	including	N	I-Premise
348	tissue	N	I-Premise
349	induration	N	I-Premise
350	(	N	I-Premise
351	fibrosis	N	I-Premise
352	)	N	I-Premise
353	in	N	I-Premise
354	the	N	I-Premise
355	irradiated	N	I-Premise
356	breast	N	I-Premise
357	or	N	I-Premise
358	chest	N	I-Premise
359	wall	N	I-Premise
360	,	N	I-Premise
361	pectoral	N	I-Premise
362	fold	N	I-Premise
363	or	N	I-Premise
364	supraclavicular	N	I-Premise
365	fossa	N	I-Premise
366	,	N	I-Premise
367	change	N	I-Premise
368	in	N	I-Premise
369	photographic	N	I-Premise
370	breast/chest	N	I-Premise
371	wall	N	I-Premise
372	appearance	N	I-Premise
373	or	N	I-Premise
374	patient	N	I-Premise
375	self-assessment	N	I-Premise
376	of	N	I-Premise
377	function	N	I-Premise
378	and	N	I-Premise
379	Quality	N	I-Premise
380	of	N	I-Premise
381	Life	N	I-Premise
382	at	N	I-Premise
383	either	N	I-Premise
384	6	N	I-Premise
385	or	N	I-Premise
386	12	N	I-Premise
387	months	N	I-Premise
388	.	N	I-Premise

389	The	N	I-Claim
390	study	N	I-Claim
391	fails	N	I-Claim
392	to	N	I-Claim
393	demonstrate	N	I-Claim
394	efficacy	N	I-Claim
395	of	N	I-Claim
396	dl-alpha	N	I-Claim
397	tocopheryl	N	I-Claim
398	acetate	N	I-Claim
399	plus	N	I-Claim
400	pentoxifylline	N	I-Claim
401	in	N	I-Claim
402	patients	N	I-Claim
403	with	N	I-Claim
404	arm	N	I-Claim
405	lymphoedema	N	I-Claim
406	following	N	I-Claim
407	axillary	N	I-Claim
408	surgery	N	I-Claim
409	and	N	I-Claim
410	lymphatic	N	I-Claim
411	radiotherapy	N	I-Claim
412	,	N	I-Claim
413	nor	N	I-Claim
414	does	N	I-Claim
415	it	N	I-Claim
416	suggest	N	I-Claim
417	any	N	I-Claim
418	benefits	N	I-Claim
419	of	N	I-Claim
420	these	N	I-Claim
421	drugs	N	I-Claim
422	in	N	I-Claim
423	radiation-induced	N	I-Claim
424	induration	N	I-Claim
425	(	N	I-Claim
426	fibrosis	N	I-Claim
427	)	N	I-Claim
428	in	N	I-Claim
429	the	N	I-Claim
430	breast	N	I-Claim
431	,	N	I-Claim
432	chest	N	I-Claim
433	wall	N	I-Claim
434	,	N	I-Claim
435	pectoral	N	I-Claim
436	fold	N	I-Claim
437	,	N	I-Claim
438	axilla	N	I-Claim
439	or	N	I-Claim
440	supraclavicular	N	I-Claim
441	fossa	N	I-Claim
442	.	N	I-Claim

1	Chemotherapy	N	O
2	with	N	O
3	a	N	O
4	platinum	N	O
5	agent	N	O
6	and	N	O
7	a	N	O
8	taxane	N	O
9	(	N	O
10	paclitaxel	N	O
11	)	N	O
12	is	N	O
13	considered	N	O
14	the	N	O
15	standard	N	O
16	of	N	O
17	care	N	O
18	for	N	O
19	treatment	N	O
20	of	N	O
21	ovarian	N	O
22	carcinoma	N	O
23	.	N	O

24	We	N	O
25	compared	N	O
26	the	N	O
27	combination	N	O
28	of	N	O
29	docetaxel-carboplatin	N	O
30	with	N	O
31	the	N	O
32	combination	N	O
33	of	N	O
34	paclitaxel-carboplatin	N	O
35	as	N	O
36	first-line	N	O
37	chemotherapy	N	O
38	for	N	O
39	stage	N	O
40	Ic-IV	N	O
41	epithelial	N	O
42	ovarian	N	O
43	or	N	O
44	primary	N	O
45	peritoneal	N	O
46	cancer	N	O
47	.	N	O

48	We	N	O
49	randomly	N	O
50	assigned	N	O
51	1077	N	O
52	patients	N	O
53	to	N	O
54	receive	N	O
55	docetaxel	N	O
56	at	N	O
57	75	N	O
58	mg/m2	N	O
59	of	N	O
60	body	N	O
61	surface	N	O
62	area	N	O
63	(	N	O
64	1-hour	N	O
65	intravenous	N	O
66	infusion	N	O
67	)	N	O
68	or	N	O
69	paclitaxel	N	O
70	at	N	O
71	175	N	O
72	mg/m2	N	O
73	(	N	O
74	3-hour	N	O
75	intravenous	N	O
76	infusion	N	O
77	)	N	O
78	.	N	O

79	Both	N	O
80	treatments	N	O
81	then	N	O
82	were	N	O
83	followed	N	O
84	by	N	O
85	carboplatin	N	O
86	to	N	O
87	an	N	O
88	area	N	O
89	under	N	O
90	the	N	O
91	plasma	N	O
92	concentration-time	N	O
93	curve	N	O
94	of	N	O
95	5	N	O
96	.	N	O

97	The	N	O
98	treatments	N	O
99	were	N	O
100	repeated	N	O
101	every	N	O
102	3	N	O
103	weeks	N	O
104	for	N	O
105	six	N	O
106	cycles	N	O
107	;	N	O
108	in	N	O
109	responding	N	O
110	patients	N	O
111	,	N	O
112	an	N	O
113	additional	N	O
114	three	N	O
115	cycles	N	O
116	of	N	O
117	single-agent	N	O
118	carboplatin	N	O
119	was	N	O
120	permitted	N	O
121	.	N	O

122	Survival	N	O
123	curves	N	O
124	were	N	O
125	calculated	N	O
126	by	N	O
127	the	N	O
128	Kaplan-Meier	N	O
129	method	N	O
130	,	N	O
131	and	N	O
132	hazard	N	O
133	ratios	N	O
134	were	N	O
135	estimated	N	O
136	with	N	O
137	the	N	O
138	Cox	N	O
139	proportional	N	O
140	hazards	N	O
141	model	N	O
142	.	N	O

143	All	N	O
144	statistical	N	O
145	tests	N	O
146	were	N	O
147	two-sided	N	O
148	.	N	O

149	After	N	I-Premise
150	a	N	I-Premise
151	median	N	I-Premise
152	follow-up	N	I-Premise
153	of	N	I-Premise
154	23	N	I-Premise
155	months	N	I-Premise
156	,	N	I-Premise
157	both	N	I-Premise
158	groups	N	I-Premise
159	had	N	I-Premise
160	similar	N	I-Premise
161	progression-free	N	I-Premise
162	survival	N	I-Premise
163	(	N	I-Premise
164	medians	N	I-Premise
165	of	N	I-Premise
166	15.0	N	I-Premise
167	months	N	I-Premise
168	for	N	I-Premise
169	docetaxel-carboplatin	N	I-Premise
170	and	N	I-Premise
171	14.8	N	I-Premise
172	months	N	I-Premise
173	for	N	I-Premise
174	paclitaxel-carboplatin	N	I-Premise
175	;	N	I-Premise
176	hazard	N	I-Premise
177	ratio	N	I-Premise
178	[	N	I-Premise
179	HR	N	I-Premise
180	]	N	I-Premise
181	docetaxel-paclitaxel	N	I-Premise
182	=	N	I-Premise
183	0.97	N	I-Premise
184	,	N	I-Premise
185	95	N	I-Premise
186	%	N	I-Premise
187	confidence	N	I-Premise
188	interval	N	I-Premise
189	[	N	I-Premise
190	CI	N	I-Premise
191	]	N	I-Premise
192	=	N	I-Premise
193	0.83	N	I-Premise
194	to	N	I-Premise
195	1.13	N	I-Premise
196	;	N	I-Premise
197	P	N	I-Premise
198	=	N	I-Premise
199	.707	N	I-Premise
200	)	N	I-Premise
201	,	N	I-Premise
202	overall	N	I-Premise
203	survival	N	I-Premise
204	rates	N	I-Premise
205	at	N	I-Premise
206	2	N	I-Premise
207	years	N	I-Premise
208	(	N	I-Premise
209	64.2	N	I-Premise
210	%	N	I-Premise
211	and	N	I-Premise
212	68.9	N	I-Premise
213	%	N	I-Premise
214	,	N	I-Premise
215	respectively	N	I-Premise
216	;	N	I-Premise
217	HR	N	I-Premise
218	=	N	I-Premise
219	1.13	N	I-Premise
220	,	N	I-Premise
221	95	N	I-Premise
222	%	N	I-Premise
223	CI	N	I-Premise
224	=	N	I-Premise
225	0.92	N	I-Premise
226	to	N	I-Premise
227	1.39	N	I-Premise
228	;	N	I-Premise
229	P	N	I-Premise
230	=	N	I-Premise
231	.238	N	I-Premise
232	)	N	I-Premise
233	,	N	I-Premise
234	and	N	I-Premise
235	objective	N	I-Premise
236	tumor	N	I-Premise
237	(	N	I-Premise
238	58.7	N	I-Premise
239	%	N	I-Premise
240	and	N	I-Premise
241	59.5	N	I-Premise
242	%	N	I-Premise
243	,	N	I-Premise
244	respectively	N	I-Premise
245	;	N	I-Premise
246	difference	N	I-Premise
247	between	N	I-Premise
248	docetaxel	N	I-Premise
249	and	N	I-Premise
250	paclitaxel	N	I-Premise
251	=	N	I-Premise
252	-0.8	N	I-Premise
253	%	N	I-Premise
254	,	N	I-Premise
255	95	N	I-Premise
256	%	N	I-Premise
257	CI	N	I-Premise
258	=	N	I-Premise
259	-8.6	N	I-Premise
260	%	N	I-Premise
261	to	N	I-Premise
262	7.1	N	I-Premise
263	%	N	I-Premise
264	;	N	I-Premise
265	P	N	I-Premise
266	=	N	I-Premise
267	.868	N	I-Premise
268	)	N	I-Premise
269	and	N	I-Premise
270	CA-125	N	I-Premise
271	(	N	I-Premise
272	75.8	N	I-Premise
273	%	N	I-Premise
274	and	N	I-Premise
275	76.8	N	I-Premise
276	%	N	I-Premise
277	,	N	I-Premise
278	respectively	N	I-Premise
279	;	N	I-Premise
280	difference	N	I-Premise
281	docetaxel-paclitaxel	N	I-Premise
282	=	N	I-Premise
283	-1.0	N	I-Premise
284	%	N	I-Premise
285	,	N	I-Premise
286	95	N	I-Premise
287	%	N	I-Premise
288	CI	N	I-Premise
289	=	N	I-Premise
290	-7.2	N	I-Premise
291	%	N	I-Premise
292	to	N	I-Premise
293	5.1	N	I-Premise
294	%	N	I-Premise
295	;	N	I-Premise
296	P	N	I-Premise
297	=	N	I-Premise
298	.794	N	I-Premise
299	)	N	I-Premise
300	response	N	I-Premise
301	rates	N	I-Premise
302	.	N	I-Premise

303	However	N	I-Premise
304	,	N	I-Premise
305	docetaxel-carboplatin	N	I-Premise
306	was	N	I-Premise
307	associated	N	I-Premise
308	with	N	I-Premise
309	substantially	N	I-Premise
310	less	N	I-Premise
311	overall	N	I-Premise
312	and	N	I-Premise
313	grade	N	I-Premise
314	2	N	I-Premise
315	or	N	I-Premise
316	higher	N	I-Premise
317	neurotoxicity	N	I-Premise
318	than	N	I-Premise
319	paclitaxel-carboplatin	N	I-Premise
320	(	N	I-Premise
321	grade	N	I-Premise
322	>	N	I-Premise
323	or	N	I-Premise
324	=2	N	I-Premise
325	neurosensory	N	I-Premise
326	toxicity	N	I-Premise
327	in	N	I-Premise
328	11	N	I-Premise
329	%	N	I-Premise
330	versus	N	I-Premise
331	30	N	I-Premise
332	%	N	I-Premise
333	,	N	I-Premise
334	difference	N	I-Premise
335	=	N	I-Premise
336	19	N	I-Premise
337	%	N	I-Premise
338	,	N	I-Premise
339	95	N	I-Premise
340	%	N	I-Premise
341	CI	N	I-Premise
342	=	N	I-Premise
343	15	N	I-Premise
344	%	N	I-Premise
345	to	N	I-Premise
346	24	N	I-Premise
347	%	N	I-Premise
348	;	N	I-Premise
349	P	N	I-Premise
350	<	N	I-Premise
351	.001	N	I-Premise
352	;	N	I-Premise
353	grade	N	I-Premise
354	>	N	I-Premise
355	or	N	I-Premise
356	=2	N	I-Premise
357	neuromotor	N	I-Premise
358	toxicity	N	I-Premise
359	in	N	I-Premise
360	3	N	I-Premise
361	%	N	I-Premise
362	versus	N	I-Premise
363	7	N	I-Premise
364	%	N	I-Premise
365	,	N	I-Premise
366	difference	N	I-Premise
367	=	N	I-Premise
368	4	N	I-Premise
369	%	N	I-Premise
370	,	N	I-Premise
371	95	N	I-Premise
372	%	N	I-Premise
373	CI	N	I-Premise
374	=	N	I-Premise
375	1	N	I-Premise
376	%	N	I-Premise
377	to	N	I-Premise
378	7	N	I-Premise
379	%	N	I-Premise
380	;	N	I-Premise
381	P	N	I-Premise
382	<	N	I-Premise
383	.001	N	I-Premise
384	)	N	I-Premise
385	.	N	I-Premise

386	Treatment	N	I-Premise
387	with	N	I-Premise
388	docetaxel-carboplatin	N	I-Premise
389	was	N	I-Premise
390	associated	N	I-Premise
391	with	N	I-Premise
392	statistically	N	I-Premise
393	significantly	N	I-Premise
394	more	N	I-Premise
395	grade	N	I-Premise
396	3-4	N	I-Premise
397	neutropenia	N	I-Premise
398	(	N	I-Premise
399	94	N	I-Premise
400	%	N	I-Premise
401	versus	N	I-Premise
402	84	N	I-Premise
403	%	N	I-Premise
404	,	N	I-Premise
405	difference	N	I-Premise
406	=	N	I-Premise
407	11	N	I-Premise
408	%	N	I-Premise
409	,	N	I-Premise
410	95	N	I-Premise
411	%	N	I-Premise
412	CI	N	I-Premise
413	=	N	I-Premise
414	7	N	I-Premise
415	%	N	I-Premise
416	to	N	I-Premise
417	14	N	I-Premise
418	%	N	I-Premise
419	;	N	I-Premise
420	P	N	I-Premise
421	<	N	I-Premise
422	.001	N	I-Premise
423	)	N	I-Premise
424	and	N	I-Premise
425	neutropenic	N	I-Premise
426	complications	N	I-Premise
427	than	N	I-Premise
428	treatment	N	I-Premise
429	with	N	I-Premise
430	paclitaxel-carboplatin	N	I-Premise
431	,	N	I-Premise
432	although	N	I-Premise
433	myelosuppression	N	I-Premise
434	did	N	I-Premise
435	not	N	I-Premise
436	influence	N	I-Premise
437	dose	N	I-Premise
438	delivery	N	I-Premise
439	or	N	I-Premise
440	patient	N	I-Premise
441	safety	N	I-Premise
442	.	N	I-Premise

443	Global	N	I-Premise
444	quality	N	I-Premise
445	of	N	I-Premise
446	life	N	I-Premise
447	was	N	I-Premise
448	similar	N	I-Premise
449	in	N	I-Premise
450	both	N	I-Premise
451	arms	N	I-Premise
452	,	N	I-Premise
453	but	N	I-Premise
454	substantive	N	I-Premise
455	differences	N	I-Premise
456	in	N	I-Premise
457	many	N	I-Premise
458	symptom	N	I-Premise
459	scores	N	I-Premise
460	favored	N	I-Premise
461	docetaxel	N	I-Premise
462	.	N	I-Premise

463	Docetaxel-carboplatin	N	I-Claim
464	appears	N	I-Claim
465	to	N	I-Claim
466	be	N	I-Claim
467	similar	N	I-Claim
468	to	N	I-Claim
469	paclitaxel-carboplatin	N	I-Claim
470	in	N	I-Claim
471	terms	N	I-Claim
472	of	N	I-Claim
473	progression-free	N	I-Claim
474	survival	N	I-Claim
475	and	N	I-Claim
476	response	N	I-Claim
477	,	N	I-Claim
478	although	N	I-Claim
479	longer	N	I-Claim
480	follow-up	N	I-Claim
481	is	N	I-Claim
482	required	N	I-Claim
483	for	N	I-Claim
484	a	N	I-Claim
485	definitive	N	I-Claim
486	statement	N	I-Claim
487	on	N	I-Claim
488	survival	N	I-Claim
489	.	N	I-Claim

490	Thus	N	I-MajorClaim
491	,	N	I-MajorClaim
492	docetaxel-carboplatin	N	I-MajorClaim
493	represents	N	I-MajorClaim
494	an	N	I-MajorClaim
495	alternative	N	I-MajorClaim
496	first-line	N	I-MajorClaim
497	chemotherapy	N	I-MajorClaim
498	regimen	N	I-MajorClaim
499	for	N	I-MajorClaim
500	patients	N	I-MajorClaim
501	with	N	I-MajorClaim
502	newly	N	I-MajorClaim
503	diagnosed	N	I-MajorClaim
504	ovarian	N	I-MajorClaim
505	cancer	N	I-MajorClaim
506	.	N	I-MajorClaim

1	This	N	O
2	phase	N	O
3	III	N	O
4	randomized	N	O
5	trial	N	O
6	compared	N	O
7	two	N	O
8	chemotherapy	N	O
9	regimens	N	O
10	,	N	O
11	gemcitabine	N	O
12	plus	N	O
13	carboplatin	N	O
14	and	N	O
15	mitomycin	N	O
16	,	N	O
17	ifosfamide	N	O
18	,	N	O
19	and	N	O
20	cisplatin	N	O
21	,	N	O
22	in	N	O
23	chemotherapy-naive	N	O
24	patients	N	O
25	with	N	O
26	advanced	N	O
27	non-small-cell	N	O
28	lung	N	O
29	cancer	N	O
30	(	N	O
31	NSCLC	N	O
32	)	N	O
33	.	N	O

34	The	N	O
35	regimens	N	O
36	were	N	O
37	compared	N	O
38	with	N	O
39	regard	N	O
40	to	N	O
41	effects	N	O
42	on	N	O
43	survival	N	O
44	,	N	O
45	response	N	O
46	rates	N	O
47	,	N	O
48	toxicity	N	O
49	,	N	O
50	and	N	O
51	quality	N	O
52	of	N	O
53	life	N	O
54	.	N	O

55	Eligible	N	O
56	patients	N	O
57	had	N	O
58	previously	N	O
59	untreated	N	O
60	stage	N	O
61	IIIB	N	O
62	or	N	O
63	IV	N	O
64	NSCLC	N	O
65	suitable	N	O
66	for	N	O
67	cisplatin-based	N	O
68	chemotherapy	N	O
69	.	N	O

70	Randomly	N	O
71	assigned	N	O
72	patients	N	O
73	were	N	O
74	to	N	O
75	receive	N	O
76	four	N	O
77	cycles	N	O
78	,	N	O
79	each	N	O
80	at	N	O
81	3-week	N	O
82	intervals	N	O
83	,	N	O
84	of	N	O
85	carboplatin	N	O
86	area	N	O
87	under	N	O
88	the	N	O
89	curve	N	O
90	of	N	O
91	5	N	O
92	on	N	O
93	day	N	O
94	1	N	O
95	plus	N	O
96	gemcitabine	N	O
97	1,200	N	O
98	mg/m	N	O
99	(	N	O
100	2	N	O
101	)	N	O
102	on	N	O
103	days	N	O
104	1	N	O
105	and	N	O
106	8	N	O
107	(	N	O
108	GCa	N	O
109	)	N	O
110	or	N	O
111	mitomycin	N	O
112	6	N	O
113	mg/m	N	O
114	(	N	O
115	2	N	O
116	)	N	O
117	,	N	O
118	ifosfamide	N	O
119	3g/m	N	O
120	(	N	O
121	2	N	O
122	)	N	O
123	,	N	O
124	and	N	O
125	cisplatin	N	O
126	50	N	O
127	mg/m	N	O
128	(	N	O
129	2	N	O
130	)	N	O
131	on	N	O
132	day	N	O
133	1	N	O
134	(	N	O
135	MIC	N	O
136	)	N	O
137	.	N	O

138	Between	N	O
139	February	N	O
140	1999	N	O
141	and	N	O
142	August	N	O
143	2001	N	O
144	,	N	O
145	422	N	O
146	patients	N	O
147	(	N	O
148	GCa	N	O
149	,	N	O
150	n	N	O
151	=	N	O
152	212	N	O
153	;	N	O
154	MIC	N	O
155	,	N	O
156	n	N	O
157	=	N	O
158	210	N	O
159	)	N	O
160	were	N	O
161	randomly	N	O
162	assigned	N	O
163	in	N	O
164	the	N	O
165	United	N	O
166	Kingdom	N	O
167	.	N	O

168	The	N	O
169	majority	N	O
170	of	N	O
171	patients	N	O
172	received	N	O
173	the	N	O
174	intended	N	O
175	four	N	O
176	cycles	N	O
177	(	N	O
178	GCa	N	O
179	,	N	O
180	64	N	O
181	%	N	O
182	;	N	O
183	MIC	N	O
184	,	N	O
185	61	N	O
186	%	N	O
187	)	N	O
188	.	N	O

189	There	N	I-Premise
190	was	N	I-Premise
191	a	N	I-Premise
192	significant	N	I-Premise
193	survival	N	I-Premise
194	advantage	N	I-Premise
195	for	N	I-Premise
196	GCa	N	I-Premise
197	compared	N	I-Premise
198	with	N	I-Premise
199	MIC	N	I-Premise
200	(	N	I-Premise
201	hazard	N	I-Premise
202	ratio	N	I-Premise
203	,	N	I-Premise
204	0.76	N	I-Premise
205	;	N	I-Premise
206	95	N	I-Premise
207	%	N	I-Premise
208	CI	N	I-Premise
209	,	N	I-Premise
210	0.61	N	I-Premise
211	to	N	I-Premise
212	0	N	I-Premise
213	.	N	I-Premise

214	93	N	I-Premise
215	;	N	I-Premise
216	P	N	I-Premise
217	=	N	I-Premise
218	.008	N	I-Premise
219	)	N	I-Premise
220	.	N	I-Premise

221	Median	N	I-Premise
222	survival	N	I-Premise
223	was	N	I-Premise
224	10	N	I-Premise
225	months	N	I-Premise
226	with	N	I-Premise
227	GCa	N	I-Premise
228	and	N	I-Premise
229	7.6	N	I-Premise
230	months	N	I-Premise
231	with	N	I-Premise
232	MIC	N	I-Premise
233	(	N	I-Premise
234	difference	N	I-Premise
235	,	N	I-Premise
236	2.4	N	I-Premise
237	months	N	I-Premise
238	;	N	I-Premise
239	95	N	I-Premise
240	%	N	I-Premise
241	CI	N	I-Premise
242	,	N	I-Premise
243	1.0	N	I-Premise
244	to	N	I-Premise
245	4.0	N	I-Premise
246	)	N	I-Premise
247	,	N	I-Premise
248	and	N	I-Premise
249	1-year	N	I-Premise
250	survival	N	I-Premise
251	was	N	I-Premise
252	40	N	I-Premise
253	%	N	I-Premise
254	with	N	I-Premise
255	GCa	N	I-Premise
256	and	N	I-Premise
257	30	N	I-Premise
258	%	N	I-Premise
259	with	N	I-Premise
260	MIC	N	I-Premise
261	(	N	I-Premise
262	difference	N	I-Premise
263	,	N	I-Premise
264	10	N	I-Premise
265	%	N	I-Premise
266	;	N	I-Premise
267	95	N	I-Premise
268	%	N	I-Premise
269	CI	N	I-Premise
270	,	N	I-Premise
271	3	N	I-Premise
272	%	N	I-Premise
273	to	N	I-Premise
274	18	N	I-Premise
275	%	N	I-Premise
276	)	N	I-Premise
277	.	N	I-Premise

278	Overall	N	I-Premise
279	response	N	I-Premise
280	rates	N	I-Premise
281	were	N	I-Premise
282	similar	N	I-Premise
283	(	N	I-Premise
284	42	N	I-Premise
285	%	N	I-Premise
286	for	N	I-Premise
287	GCa	N	I-Premise
288	v	N	I-Premise
289	41	N	I-Premise
290	%	N	I-Premise
291	for	N	I-Premise
292	MIC	N	I-Premise
293	;	N	I-Premise
294	P	N	I-Premise
295	=	N	I-Premise
296	.84	N	I-Premise
297	)	N	I-Premise
298	.	N	I-Premise

299	More	N	I-Premise
300	thrombocytopenia	N	I-Premise
301	occurred	N	I-Premise
302	with	N	I-Premise
303	GCa	N	I-Premise
304	(	N	I-Premise
305	P	N	I-Premise
306	=	N	I-Premise
307	.03	N	I-Premise
308	)	N	I-Premise
309	,	N	I-Premise
310	but	N	I-Premise
311	this	N	I-Premise
312	was	N	I-Premise
313	not	N	I-Premise
314	associated	N	I-Premise
315	with	N	I-Premise
316	increased	N	I-Premise
317	hospital	N	I-Premise
318	admission	N	I-Premise
319	or	N	I-Premise
320	fatality	N	I-Premise
321	.	N	I-Premise

322	GCa	N	I-Premise
323	caused	N	I-Premise
324	less	N	I-Premise
325	nausea	N	I-Premise
326	,	N	I-Premise
327	vomiting	N	I-Premise
328	,	N	I-Premise
329	constipation	N	I-Premise
330	,	N	I-Premise
331	and	N	I-Premise
332	alopecia	N	I-Premise
333	and	N	I-Premise
334	was	N	I-Premise
335	associated	N	I-Premise
336	with	N	I-Premise
337	fewer	N	I-Premise
338	admissions	N	I-Premise
339	for	N	I-Premise
340	administration	N	I-Premise
341	and	N	I-Premise
342	better	N	I-Premise
343	quality	N	I-Premise
344	of	N	I-Premise
345	life	N	I-Premise
346	.	N	I-Premise

347	In	N	I-Claim
348	patients	N	I-Claim
349	with	N	I-Claim
350	advanced	N	I-Claim
351	NSCLC	N	I-Claim
352	,	N	I-Claim
353	GCa	N	I-Claim
354	chemotherapy	N	I-Claim
355	was	N	I-Claim
356	shown	N	I-Claim
357	to	N	I-Claim
358	be	N	I-Claim
359	a	N	I-Claim
360	better-tolerated	N	I-Claim
361	treatment	N	I-Claim
362	that	N	I-Claim
363	conferred	N	I-Claim
364	a	N	I-Claim
365	survival	N	I-Claim
366	advantage	N	I-Claim
367	over	N	I-Claim
368	MIC	N	I-Claim
369	.	N	I-Claim

1	The	N	I-MajorClaim
2	role	N	I-MajorClaim
3	of	N	I-MajorClaim
4	high-dose	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	(	N	I-MajorClaim
7	HDCT	N	I-MajorClaim
8	)	N	I-MajorClaim
9	in	N	I-MajorClaim
10	metastatic	N	I-MajorClaim
11	breast	N	I-MajorClaim
12	cancer	N	I-MajorClaim
13	remains	N	I-MajorClaim
14	controversial	N	I-MajorClaim
15	.	N	I-MajorClaim

16	Trials	N	I-Claim
17	with	N	I-Claim
18	late	N	I-Claim
19	intensification	N	I-Claim
20	HDCT	N	I-Claim
21	have	N	I-Claim
22	failed	N	I-Claim
23	to	N	I-Claim
24	show	N	I-Claim
25	an	N	I-Claim
26	advantage	N	I-Claim
27	in	N	I-Claim
28	overall	N	I-Claim
29	survival	N	I-Claim
30	.	N	I-Claim

31	This	N	O
32	study	N	O
33	was	N	O
34	initiated	N	O
35	to	N	O
36	compare	N	O
37	up-front	N	O
38	tandem	N	O
39	HDCT	N	O
40	and	N	O
41	standard	N	O
42	combination	N	O
43	therapy	N	O
44	in	N	O
45	patients	N	O
46	with	N	O
47	metastatic	N	O
48	breast	N	O
49	cancer	N	O
50	.	N	O

51	Patients	N	O
52	without	N	O
53	prior	N	O
54	chemotherapy	N	O
55	for	N	O
56	metastatic	N	O
57	disease	N	O
58	were	N	O
59	randomly	N	O
60	assigned	N	O
61	to	N	O
62	standard	N	O
63	combination	N	O
64	therapy	N	O
65	with	N	O
66	doxorubicin	N	O
67	and	N	O
68	paclitaxel	N	O
69	(	N	O
70	AT	N	O
71	)	N	O
72	or	N	O
73	double	N	O
74	HDCT	N	O
75	with	N	O
76	cyclophosphamide	N	O
77	,	N	O
78	mitoxantrone	N	O
79	,	N	O
80	and	N	O
81	etoposide	N	O
82	followed	N	O
83	by	N	O
84	peripheral-blood	N	O
85	stem-cell	N	O
86	transplantation	N	O
87	.	N	O

88	HDCT	N	O
89	was	N	O
90	repeated	N	O
91	after	N	O
92	6	N	O
93	weeks	N	O
94	.	N	O

95	Patients	N	O
96	were	N	O
97	stratified	N	O
98	by	N	O
99	menopausal	N	O
100	and	N	O
101	hormone-receptor	N	O
102	status	N	O
103	.	N	O

104	The	N	O
105	primary	N	O
106	objective	N	O
107	was	N	O
108	to	N	O
109	compare	N	O
110	complete	N	O
111	response	N	O
112	(	N	O
113	CR	N	O
114	)	N	O
115	rates	N	O
116	.	N	O

117	A	N	O
118	total	N	O
119	of	N	O
120	93	N	O
121	patients	N	O
122	were	N	O
123	enrolled	N	O
124	onto	N	O
125	the	N	O
126	trial	N	O
127	.	N	O

128	Intent-to-treat	N	I-Premise
129	CR	N	I-Premise
130	rates	N	I-Premise
131	for	N	I-Premise
132	patients	N	I-Premise
133	randomized	N	I-Premise
134	to	N	I-Premise
135	HDCT	N	I-Premise
136	and	N	I-Premise
137	AT	N	I-Premise
138	were	N	I-Premise
139	12.5	N	I-Premise
140	%	N	I-Premise
141	and	N	I-Premise
142	11.1	N	I-Premise
143	%	N	I-Premise
144	,	N	I-Premise
145	respectively	N	I-Premise
146	(	N	I-Premise
147	P	N	I-Premise
148	=	N	I-Premise
149	.84	N	I-Premise
150	)	N	I-Premise
151	.	N	I-Premise

152	Objective	N	I-Premise
153	response	N	I-Premise
154	rates	N	I-Premise
155	were	N	I-Premise
156	66.7	N	I-Premise
157	%	N	I-Premise
158	for	N	I-Premise
159	patients	N	I-Premise
160	in	N	I-Premise
161	the	N	I-Premise
162	high-dose	N	I-Premise
163	group	N	I-Premise
164	and	N	I-Premise
165	64.4	N	I-Premise
166	%	N	I-Premise
167	for	N	I-Premise
168	patients	N	I-Premise
169	in	N	I-Premise
170	the	N	I-Premise
171	AT	N	I-Premise
172	arm	N	I-Premise
173	(	N	I-Premise
174	P	N	I-Premise
175	=	N	I-Premise
176	.82	N	I-Premise
177	)	N	I-Premise
178	.	N	I-Premise

179	In	N	I-Premise
180	an	N	I-Premise
181	intent-to-treat	N	I-Premise
182	analysis	N	I-Premise
183	,	N	I-Premise
184	there	N	I-Premise
185	were	N	I-Premise
186	no	N	I-Premise
187	significant	N	I-Premise
188	differences	N	I-Premise
189	between	N	I-Premise
190	the	N	I-Premise
191	two	N	I-Premise
192	treatments	N	I-Premise
193	in	N	I-Premise
194	median	N	I-Premise
195	time	N	I-Premise
196	to	N	I-Premise
197	progression	N	I-Premise
198	(	N	I-Premise
199	HDCT	N	I-Premise
200	,	N	I-Premise
201	11.1	N	I-Premise
202	months	N	I-Premise
203	;	N	I-Premise
204	AT	N	I-Premise
205	,	N	I-Premise
206	10.6	N	I-Premise
207	months	N	I-Premise
208	;	N	I-Premise
209	P	N	I-Premise
210	=	N	I-Premise
211	.67	N	I-Premise
212	)	N	I-Premise
213	,	N	I-Premise
214	duration	N	I-Premise
215	of	N	I-Premise
216	response	N	I-Premise
217	(	N	I-Premise
218	HDCT	N	I-Premise
219	,	N	I-Premise
220	13.9	N	I-Premise
221	months	N	I-Premise
222	;	N	I-Premise
223	AT	N	I-Premise
224	,	N	I-Premise
225	14.3	N	I-Premise
226	months	N	I-Premise
227	;	N	I-Premise
228	P	N	I-Premise
229	=	N	I-Premise
230	.98	N	I-Premise
231	)	N	I-Premise
232	,	N	I-Premise
233	and	N	I-Premise
234	overall	N	I-Premise
235	survival	N	I-Premise
236	(	N	I-Premise
237	HDCT	N	I-Premise
238	,	N	I-Premise
239	26.9	N	I-Premise
240	months	N	I-Premise
241	;	N	I-Premise
242	AT	N	I-Premise
243	,	N	I-Premise
244	23.4	N	I-Premise
245	months	N	I-Premise
246	;	N	I-Premise
247	P	N	I-Premise
248	=	N	I-Premise
249	.60	N	I-Premise
250	)	N	I-Premise
251	.	N	I-Premise

252	HDCT	N	I-Premise
253	was	N	I-Premise
254	associated	N	I-Premise
255	with	N	I-Premise
256	significantly	N	I-Premise
257	more	N	I-Premise
258	myelosuppression	N	I-Premise
259	,	N	I-Premise
260	infection	N	I-Premise
261	,	N	I-Premise
262	diarrhea	N	I-Premise
263	,	N	I-Premise
264	stomatitis	N	I-Premise
265	,	N	I-Premise
266	and	N	I-Premise
267	nausea	N	I-Premise
268	and	N	I-Premise
269	vomiting	N	I-Premise
270	,	N	I-Premise
271	whereas	N	I-Premise
272	patients	N	I-Premise
273	treated	N	I-Premise
274	with	N	I-Premise
275	AT	N	I-Premise
276	developed	N	I-Premise
277	more	N	I-Premise
278	neurotoxicity	N	I-Premise
279	.	N	I-Premise

280	This	N	I-Claim
281	trial	N	I-Claim
282	failed	N	I-Claim
283	to	N	I-Claim
284	show	N	I-Claim
285	a	N	I-Claim
286	benefit	N	I-Claim
287	for	N	I-Claim
288	up-front	N	I-Claim
289	tandem	N	I-Claim
290	HDCT	N	I-Claim
291	compared	N	I-Claim
292	with	N	I-Claim
293	standard	N	I-Claim
294	combination	N	I-Claim
295	therapy	N	I-Claim
296	.	N	I-Claim

297	HDCT	N	I-Claim
298	was	N	I-Claim
299	associated	N	I-Claim
300	with	N	I-Claim
301	more	N	I-Claim
302	acute	N	I-Claim
303	adverse	N	I-Claim
304	effects	N	I-Claim
305	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	efficacy	N	O
5	,	N	O
6	impact	N	O
7	on	N	O
8	quality-of-life	N	O
9	(	N	O
10	QoL	N	O
11	)	N	O
12	and	N	O
13	tolerability	N	O
14	of	N	O
15	two	N	O
16	different	N	O
17	irinotecan	N	O
18	administration	N	O
19	schedules	N	O
20	in	N	O
21	combination	N	O
22	with	N	O
23	capecitabine	N	O
24	as	N	O
25	first-line	N	O
26	treatment	N	O
27	of	N	O
28	metastatic	N	O
29	colorectal	N	O
30	cancer	N	O
31	.	N	O

32	We	N	O
33	carried	N	O
34	out	N	O
35	a	N	O
36	randomized	N	O
37	phase	N	O
38	II	N	O
39	trial	N	O
40	to	N	O
41	select	N	O
42	one	N	O
43	of	N	O
44	the	N	O
45	following	N	O
46	treatment	N	O
47	regimens	N	O
48	for	N	O
49	further	N	O
50	investigation	N	O
51	:	N	O
52	weekly	N	O
53	irinotecan	N	O
54	at	N	O
55	a	N	O
56	dose	N	O
57	of	N	O
58	70	N	O
59	mg/m	N	O
60	(	N	O
61	2	N	O
62	)	N	O
63	days	N	O
64	1	N	O
65	,	N	O
66	8	N	O
67	,	N	O
68	15	N	O
69	,	N	O
70	22	N	O
71	,	N	O
72	29	N	O
73	(	N	O
74	arm	N	O
75	A	N	O
76	)	N	O
77	or	N	O
78	3-weekly	N	O
79	irinotecan	N	O
80	at	N	O
81	a	N	O
82	dose	N	O
83	of	N	O
84	300/240	N	O
85	mg/m	N	O
86	(	N	O
87	2	N	O
88	)	N	O
89	day	N	O
90	1	N	O
91	and	N	O
92	days	N	O
93	22	N	O
94	(	N	O
95	arm	N	O
96	B	N	O
97	)	N	O
98	in	N	O
99	combination	N	O
100	with	N	O
101	capecitabine	N	O
102	1000	N	O
103	mg/m	N	O
104	(	N	O
105	2	N	O
106	)	N	O
107	twice	N	O
108	daily	N	O
109	days	N	O
110	1-14	N	O
111	and	N	O
112	days	N	O
113	22-35	N	O
114	every	N	O
115	6	N	O
116	weeks	N	O
117	.	N	O

118	Seventy-five	N	O
119	patients	N	O
120	with	N	O
121	good	N	O
122	performance	N	O
123	status	N	O
124	entered	N	O
125	the	N	O
126	trial	N	O
127	.	N	O

128	The	N	O
129	two	N	O
130	arms	N	O
131	were	N	O
132	well	N	O
133	balanced	N	O
134	for	N	O
135	relevant	N	O
136	patient	N	O
137	and	N	O
138	disease	N	O
139	characteristics	N	O
140	.	N	O

141	The	N	I-Premise
142	most	N	I-Premise
143	frequent	N	I-Premise
144	toxic	N	I-Premise
145	effects	N	I-Premise
146	were	N	I-Premise
147	grade	N	I-Premise
148	3/4	N	I-Premise
149	diarrhea	N	I-Premise
150	(	N	I-Premise
151	arm	N	I-Premise
152	A	N	I-Premise
153	:	N	I-Premise
154	34	N	I-Premise
155	%	N	I-Premise
156	,	N	I-Premise
157	B	N	I-Premise
158	:	N	I-Premise
159	19	N	I-Premise
160	%	N	I-Premise
161	)	N	I-Premise
162	,	N	I-Premise
163	grade	N	I-Premise
164	3/4	N	I-Premise
165	neutropenia	N	I-Premise
166	(	N	I-Premise
167	A	N	I-Premise
168	:	N	I-Premise
169	5	N	I-Premise
170	%	N	I-Premise
171	,	N	I-Premise
172	B	N	I-Premise
173	:	N	I-Premise
174	19	N	I-Premise
175	%	N	I-Premise
176	)	N	I-Premise
177	and	N	I-Premise
178	grade	N	I-Premise
179	2/3	N	I-Premise
180	alopecia	N	I-Premise
181	(	N	I-Premise
182	A	N	I-Premise
183	:	N	I-Premise
184	26	N	I-Premise
185	%	N	I-Premise
186	,	N	I-Premise
187	B	N	I-Premise
188	:	N	I-Premise
189	65	N	I-Premise
190	%	N	I-Premise
191	)	N	I-Premise
192	.	N	I-Premise

193	Other	N	I-Premise
194	grade	N	I-Premise
195	3/4	N	I-Premise
196	toxic	N	I-Premise
197	effects	N	I-Premise
198	were	N	I-Premise
199	rare	N	I-Premise
200	(	N	I-Premise
201	<	N	I-Premise
202	5	N	I-Premise
203	%	N	I-Premise
204	)	N	I-Premise
205	.	N	I-Premise

206	Response	N	I-Premise
207	rates	N	I-Premise
208	were	N	I-Premise
209	34	N	I-Premise
210	%	N	I-Premise
211	[	N	I-Premise
212	95	N	I-Premise
213	%	N	I-Premise
214	confidence	N	I-Premise
215	interval	N	I-Premise
216	(	N	I-Premise
217	CI	N	I-Premise
218	)	N	I-Premise
219	20	N	I-Premise
220	%	N	I-Premise
221	to	N	I-Premise
222	51	N	I-Premise
223	%	N	I-Premise
224	]	N	I-Premise
225	in	N	I-Premise
226	arm	N	I-Premise
227	A	N	I-Premise
228	and	N	I-Premise
229	35	N	I-Premise
230	%	N	I-Premise
231	(	N	I-Premise
232	95	N	I-Premise
233	%	N	I-Premise
234	CI	N	I-Premise
235	:	N	I-Premise
236	20	N	I-Premise
237	%	N	I-Premise
238	to	N	I-Premise
239	53	N	I-Premise
240	%	N	I-Premise
241	)	N	I-Premise
242	in	N	I-Premise
243	arm	N	I-Premise
244	B	N	I-Premise
245	.	N	I-Premise

246	Median	N	I-Premise
247	time	N	I-Premise
248	to	N	I-Premise
249	progression	N	I-Premise
250	was	N	I-Premise
251	6.9	N	I-Premise
252	(	N	I-Premise
253	4.6-10.1	N	I-Premise
254	)	N	I-Premise
255	and	N	I-Premise
256	9.2	N	I-Premise
257	(	N	I-Premise
258	7.9-11.5	N	I-Premise
259	)	N	I-Premise
260	months	N	I-Premise
261	and	N	I-Premise
262	median	N	I-Premise
263	overall	N	I-Premise
264	survival	N	I-Premise
265	was	N	I-Premise
266	17.4	N	I-Premise
267	(	N	I-Premise
268	12.6-23.0+	N	I-Premise
269	)	N	I-Premise
270	and	N	I-Premise
271	24.7	N	I-Premise
272	(	N	I-Premise
273	16.3-26.4+	N	I-Premise
274	)	N	I-Premise
275	months	N	I-Premise
276	.	N	I-Premise

277	Patients	N	I-Premise
278	with	N	I-Premise
279	an	N	I-Premise
280	objective	N	I-Premise
281	tumor	N	I-Premise
282	response	N	I-Premise
283	reported	N	I-Premise
284	better	N	I-Premise
285	physical	N	I-Premise
286	well-being	N	I-Premise
287	(	N	I-Premise
288	P	N	I-Premise
289	<	N	I-Premise
290	0.01	N	I-Premise
291	)	N	I-Premise
292	,	N	I-Premise
293	mood	N	I-Premise
294	(	N	I-Premise
295	P	N	I-Premise
296	<	N	I-Premise
297	0.05	N	I-Premise
298	)	N	I-Premise
299	,	N	I-Premise
300	functional	N	I-Premise
301	performance	N	I-Premise
302	(	N	I-Premise
303	P	N	I-Premise
304	<	N	I-Premise
305	0.05	N	I-Premise
306	)	N	I-Premise
307	and	N	I-Premise
308	less	N	I-Premise
309	effort	N	I-Premise
310	to	N	I-Premise
311	cope	N	I-Premise
312	(	N	I-Premise
313	P	N	I-Premise
314	<	N	I-Premise
315	0.05	N	I-Premise
316	)	N	I-Premise
317	compared	N	I-Premise
318	with	N	I-Premise
319	the	N	I-Premise
320	non-responders	N	I-Premise
321	and	N	I-Premise
322	stable	N	I-Premise
323	disease	N	I-Premise
324	patients	N	I-Premise
325	.	N	I-Premise

326	The	N	O
327	primary	N	O
328	end	N	O
329	point	N	O
330	of	N	O
331	this	N	O
332	study	N	O
333	was	N	O
334	the	N	O
335	objective	N	O
336	response	N	O
337	rate	N	O
338	and	N	O
339	based	N	O
340	on	N	O
341	the	N	O
342	statistical	N	O
343	design	N	O
344	of	N	O
345	the	N	O
346	trial	N	O
347	,	N	O
348	the	N	O
349	3-weekly	N	O
350	irinotecan	N	O
351	schedule	N	O
352	was	N	O
353	selected	N	O
354	over	N	O
355	weekly	N	O
356	irinotecan	N	O
357	administration	N	O
358	.	N	O

359	The	N	I-Claim
360	3-weekly	N	I-Claim
361	irinotecan	N	I-Claim
362	schedule	N	I-Claim
363	also	N	I-Claim
364	seemed	N	I-Claim
365	advantageous	N	I-Claim
366	in	N	I-Claim
367	terms	N	I-Claim
368	of	N	I-Claim
369	grade	N	I-Claim
370	3/4	N	I-Claim
371	diarrhea	N	I-Claim
372	,	N	I-Claim
373	time	N	I-Claim
374	to	N	I-Claim
375	progression	N	I-Claim
376	,	N	I-Claim
377	overall	N	I-Claim
378	survival	N	I-Claim
379	and	N	I-Claim
380	patient	N	I-Claim
381	convenience	N	I-Claim
382	,	N	I-Claim
383	but	N	I-Claim
384	the	N	I-Claim
385	study	N	I-Claim
386	was	N	I-Claim
387	not	N	I-Claim
388	designed	N	I-Claim
389	to	N	I-Claim
390	detect	N	I-Claim
391	differences	N	I-Claim
392	in	N	I-Claim
393	these	N	I-Claim
394	parameters	N	I-Claim
395	.	N	I-Claim

396	In	N	O
397	addition	N	O
398	,	N	O
399	tumor	N	I-Claim
400	response	N	I-Claim
401	was	N	I-Claim
402	shown	N	I-Claim
403	to	N	I-Claim
404	have	N	I-Claim
405	a	N	I-Claim
406	beneficial	N	I-Claim
407	effect	N	I-Claim
408	on	N	I-Claim
409	QoL	N	I-Claim
410	indicators	N	I-Claim
411	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	dietary	N	O
7	counseling	N	O
8	or	N	O
9	nutritional	N	O
10	supplements	N	O
11	on	N	O
12	outcomes	N	O
13	in	N	O
14	cancer	N	O
15	patients	N	O
16	:	N	O
17	nutritional	N	O
18	,	N	O
19	morbidity	N	O
20	,	N	O
21	and	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	(	N	O
26	QoL	N	O
27	)	N	O
28	during	N	O
29	and	N	O
30	3	N	O
31	months	N	O
32	after	N	O
33	radiotherapy	N	O
34	.	N	O

35	A	N	O
36	total	N	O
37	of	N	O
38	111	N	O
39	colorectal	N	O
40	cancer	N	O
41	outpatients	N	O
42	referred	N	O
43	for	N	O
44	radiotherapy	N	O
45	,	N	O
46	stratified	N	O
47	by	N	O
48	staging	N	O
49	,	N	O
50	were	N	O
51	randomly	N	O
52	assigned	N	O
53	:	N	O
54	group	N	O
55	1	N	O
56	(	N	O
57	G1	N	O
58	;	N	O
59	n	N	O
60	=	N	O
61	37	N	O
62	)	N	O
63	,	N	O
64	dietary	N	O
65	counseling	N	O
66	(	N	O
67	regular	N	O
68	foods	N	O
69	)	N	O
70	;	N	O
71	group	N	O
72	2	N	O
73	(	N	O
74	G2	N	O
75	;	N	O
76	n	N	O
77	=	N	O
78	37	N	O
79	)	N	O
80	,	N	O
81	protein	N	O
82	supplements	N	O
83	;	N	O
84	and	N	O
85	group	N	O
86	3	N	O
87	(	N	O
88	G3	N	O
89	;	N	O
90	n	N	O
91	=	N	O
92	37	N	O
93	)	N	O
94	,	N	O
95	ad	N	O
96	libitum	N	O
97	intake	N	O
98	.	N	O

99	Nutritional	N	O
100	intake	N	O
101	(	N	O
102	diet	N	O
103	history	N	O
104	)	N	O
105	,	N	O
106	status	N	O
107	(	N	O
108	Ottery	N	O
109	's	N	O
110	Subjective	N	O
111	Global	N	O
112	Assessment	N	O
113	)	N	O
114	,	N	O
115	and	N	O
116	QoL	N	O
117	(	N	O
118	European	N	O
119	Organisation	N	O
120	for	N	O
121	Research	N	O
122	and	N	O
123	Treatment	N	O
124	of	N	O
125	Cancer	N	O
126	Quality	N	O
127	of	N	O
128	Life	N	O
129	Questionnaire	N	O
130	version	N	O
131	3.0	N	O
132	)	N	O
133	were	N	O
134	evaluated	N	O
135	at	N	O
136	baseline	N	O
137	,	N	O
138	at	N	O
139	the	N	O
140	end	N	O
141	,	N	O
142	and	N	O
143	3	N	O
144	months	N	O
145	after	N	O
146	radiotherapy	N	O
147	.	N	O

148	At	N	I-Premise
149	radiotherapy	N	I-Premise
150	completion	N	I-Premise
151	,	N	I-Premise
152	energy	N	I-Premise
153	intake	N	I-Premise
154	increased	N	I-Premise
155	in	N	I-Premise
156	G1/G2	N	I-Premise
157	(	N	I-Premise
158	P	N	I-Premise
159	<	N	I-Premise
160	or	N	I-Premise
161	=	N	I-Premise
162	.04	N	I-Premise
163	)	N	I-Premise
164	,	N	I-Premise
165	G1	N	I-Premise
166	more	N	I-Premise
167	than	N	I-Premise
168	G2	N	I-Premise
169	(	N	I-Premise
170	P	N	I-Premise
171	=	N	I-Premise
172	.001	N	I-Premise
173	)	N	I-Premise
174	,	N	I-Premise
175	and	N	I-Premise
176	decreased	N	I-Premise
177	in	N	I-Premise
178	G3	N	I-Premise
179	(	N	I-Premise
180	P	N	I-Premise
181	<	N	I-Premise
182	.01	N	I-Premise
183	)	N	I-Premise
184	.	N	I-Premise

185	Protein	N	I-Premise
186	intake	N	I-Premise
187	increased	N	I-Premise
188	in	N	I-Premise
189	G1/G2	N	I-Premise
190	(	N	I-Premise
191	P	N	I-Premise
192	<	N	I-Premise
193	or	N	I-Premise
194	=	N	I-Premise
195	.007	N	I-Premise
196	)	N	I-Premise
197	,	N	I-Premise
198	G1	N	I-Premise
199	less	N	I-Premise
200	than	N	I-Premise
201	G2	N	I-Premise
202	(	N	I-Premise
203	not	N	I-Premise
204	significant	N	I-Premise
205	)	N	I-Premise
206	,	N	I-Premise
207	and	N	I-Premise
208	decreased	N	I-Premise
209	in	N	I-Premise
210	G3	N	I-Premise
211	(	N	I-Premise
212	P	N	I-Premise
213	<	N	I-Premise
214	.01	N	I-Premise
215	)	N	I-Premise
216	.	N	I-Premise

217	At	N	I-Premise
218	3	N	I-Premise
219	months	N	I-Premise
220	,	N	I-Premise
221	G1	N	I-Premise
222	maintained	N	I-Premise
223	nutritional	N	I-Premise
224	intake	N	I-Premise
225	and	N	I-Premise
226	G2/G3	N	I-Premise
227	returned	N	I-Premise
228	to	N	I-Premise
229	baseline	N	I-Premise
230	.	N	I-Premise

231	After	N	I-Premise
232	radiotherapy	N	I-Premise
233	and	N	I-Premise
234	at	N	I-Premise
235	3	N	I-Premise
236	months	N	I-Premise
237	,	N	I-Premise
238	rates	N	I-Premise
239	of	N	I-Premise
240	anorexia	N	I-Premise
241	,	N	I-Premise
242	nausea	N	I-Premise
243	,	N	I-Premise
244	vomiting	N	I-Premise
245	,	N	I-Premise
246	and	N	I-Premise
247	diarrhea	N	I-Premise
248	were	N	I-Premise
249	higher	N	I-Premise
250	in	N	I-Premise
251	G3	N	I-Premise
252	(	N	I-Premise
253	P	N	I-Premise
254	<	N	I-Premise
255	.05	N	I-Premise
256	)	N	I-Premise
257	.	N	I-Premise

258	At	N	I-Premise
259	radiotherapy	N	I-Premise
260	completion	N	I-Premise
261	,	N	I-Premise
262	in	N	I-Premise
263	G1	N	I-Premise
264	all	N	I-Premise
265	QoL	N	I-Premise
266	function	N	I-Premise
267	scores	N	I-Premise
268	improved	N	I-Premise
269	proportionally	N	I-Premise
270	to	N	I-Premise
271	adequate	N	I-Premise
272	intake	N	I-Premise
273	or	N	I-Premise
274	nutritional	N	I-Premise
275	status	N	I-Premise
276	(	N	I-Premise
277	P	N	I-Premise
278	<	N	I-Premise
279	.05	N	I-Premise
280	)	N	I-Premise
281	;	N	I-Premise
282	whereas	N	I-Premise
283	in	N	I-Premise
284	G2	N	I-Premise
285	only	N	I-Premise
286	three	N	I-Premise
287	of	N	I-Premise
288	six	N	I-Premise
289	function	N	I-Premise
290	scores	N	I-Premise
291	improved	N	I-Premise
292	proportionally	N	I-Premise
293	to	N	I-Premise
294	protein	N	I-Premise
295	intake	N	I-Premise
296	(	N	I-Premise
297	P	N	I-Premise
298	=	N	I-Premise
299	.04	N	I-Premise
300	)	N	I-Premise
301	,	N	I-Premise
302	and	N	I-Premise
303	in	N	I-Premise
304	G3	N	I-Premise
305	all	N	I-Premise
306	scores	N	I-Premise
307	worsened	N	I-Premise
308	(	N	I-Premise
309	P	N	I-Premise
310	<	N	I-Premise
311	.05	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	At	N	I-Premise
315	3	N	I-Premise
316	months	N	I-Premise
317	,	N	I-Premise
318	G1	N	I-Premise
319	patients	N	I-Premise
320	maintained/improved	N	I-Premise
321	function	N	I-Premise
322	,	N	I-Premise
323	symptoms	N	I-Premise
324	,	N	I-Premise
325	and	N	I-Premise
326	single-item	N	I-Premise
327	scores	N	I-Premise
328	(	N	I-Premise
329	P	N	I-Premise
330	<	N	I-Premise
331	.02	N	I-Premise
332	)	N	I-Premise
333	;	N	I-Premise
334	in	N	I-Premise
335	G2	N	I-Premise
336	,	N	I-Premise
337	only	N	I-Premise
338	few	N	I-Premise
339	function	N	I-Premise
340	and	N	I-Premise
341	symptom	N	I-Premise
342	scales	N	I-Premise
343	improved	N	I-Premise
344	(	N	I-Premise
345	P	N	I-Premise
346	<	N	I-Premise
347	.05	N	I-Premise
348	)	N	I-Premise
349	;	N	I-Premise
350	in	N	I-Premise
351	G3	N	I-Premise
352	,	N	I-Premise
353	QoL	N	I-Premise
354	remained	N	I-Premise
355	as	N	I-Premise
356	poor	N	I-Premise
357	as	N	I-Premise
358	after	N	I-Premise
359	radiotherapy	N	I-Premise
360	.	N	I-Premise

361	In	N	I-Premise
362	G1/G2	N	I-Premise
363	,	N	I-Premise
364	respectively	N	I-Premise
365	,	N	I-Premise
366	improvement/deterioration	N	I-Premise
367	of	N	I-Premise
368	QoL	N	I-Premise
369	correlated	N	I-Premise
370	with	N	I-Premise
371	better	N	I-Premise
372	or	N	I-Premise
373	poorer	N	I-Premise
374	intake	N	I-Premise
375	or	N	I-Premise
376	nutritional	N	I-Premise
377	status	N	I-Premise
378	(	N	I-Premise
379	P	N	I-Premise
380	<	N	I-Premise
381	.003	N	I-Premise
382	)	N	I-Premise
383	.	N	I-Premise

384	During	N	I-Claim
385	radiotherapy	N	I-Claim
386	,	N	I-Claim
387	both	N	I-Claim
388	interventions	N	I-Claim
389	positively	N	I-Claim
390	influenced	N	I-Claim
391	outcomes	N	I-Claim
392	;	N	I-Claim
393	dietary	N	I-Claim
394	counseling	N	I-Claim
395	was	N	I-Claim
396	of	N	I-Claim
397	similar	N	I-Claim
398	or	N	I-Claim
399	higher	N	I-Claim
400	benefit	N	I-Claim
401	,	N	I-Claim
402	whereas	N	I-Claim
403	even	N	I-Claim
404	3	N	I-Claim
405	months	N	I-Claim
406	after	N	I-Claim
407	RT	N	I-Claim
408	,	N	I-Claim
409	it	N	I-Claim
410	was	N	I-Claim
411	the	N	I-Claim
412	only	N	I-Claim
413	method	N	I-Claim
414	to	N	I-Claim
415	sustain	N	I-Claim
416	a	N	I-Claim
417	significant	N	I-Claim
418	impact	N	I-Claim
419	on	N	I-Claim
420	patient	N	I-Claim
421	outcomes	N	I-Claim
422	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	incidence	N	O
5	and	N	O
6	temporal	N	O
7	resolution	N	O
8	of	N	O
9	dysuria	N	O
10	after	N	O
11	permanent	N	O
12	prostate	N	O
13	brachytherapy	N	O
14	,	N	O
15	and	N	O
16	to	N	O
17	identify	N	O
18	predictors	N	O
19	of	N	O
20	brachytherapy-related	N	O
21	dysuria	N	O
22	.	N	O

23	The	N	O
24	study	N	O
25	included	N	O
26	130	N	O
27	patients	N	O
28	with	N	O
29	no	N	O
30	history	N	O
31	of	N	O
32	transurethral	N	O
33	resection	N	O
34	of	N	O
35	the	N	O
36	prostate	N	O
37	before	N	O
38	treatment	N	O
39	,	N	O
40	who	N	O
41	had	N	O
42	brachytherapy	N	O
43	on	N	O
44	one	N	O
45	of	N	O
46	two	N	O
47	prospective	N	O
48	randomized	N	O
49	trials	N	O
50	,	N	O
51	with	N	O
52	explicitly	N	O
53	planned	N	O
54	and	N	O
55	executed	N	O
56	urethral-sparing	N	O
57	techniques	N	O
58	(	N	O
59	100-150	N	O
60	%	N	O
61	minimum	N	O
62	peripheral	N	O
63	dose	N	O
64	)	N	O
65	using	N	O
66	either	N	O
67	103Pd	N	O
68	or	N	O
69	125I	N	O
70	for	N	O
71	clinical	N	O
72	T1c-T2c	N	O
73	prostate	N	O
74	cancer	N	O
75	.	N	O

76	The	N	O
77	median	N	O
78	follow-up	N	O
79	was	N	O
80	22.6	N	O
81	months	N	O
82	.	N	O

83	An	N	O
84	alpha-blocker	N	O
85	was	N	O
86	initiated	N	O
87	either	N	O
88	prophylactically	N	O
89	2	N	O
90	weeks	N	O
91	before	N	O
92	implantation	N	O
93	and	N	O
94	continued	N	O
95	at	N	O
96	least	N	O
97	until	N	O
98	the	N	O
99	International	N	O
100	Prostate	N	O
101	Symptom	N	O
102	Score	N	O
103	(	N	O
104	IPSS	N	O
105	)	N	O
106	returned	N	O
107	to	N	O
108	normal	N	O
109	,	N	O
110	or	N	O
111	withheld	N	O
112	until	N	O
113	the	N	O
114	onset	N	O
115	of	N	O
116	significant	N	O
117	brachytherapy-related	N	O
118	urinary	N	O
119	morbidity	N	O
120	.	N	O

121	Dysuria	N	O
122	was	N	O
123	evaluated	N	O
124	on	N	O
125	a	N	O
126	0-10	N	O
127	scale	N	O
128	,	N	O
129	before	N	O
130	brachytherapy	N	O
131	and	N	O
132	then	N	O
133	at	N	O
134	1	N	O
135	,	N	O
136	3	N	O
137	,	N	O
138	6	N	O
139	and	N	O
140	12	N	O
141	months	N	O
142	afterward	N	O
143	,	N	O
144	with	N	O
145	a	N	O
146	median	N	O
147	of	N	O
148	four	N	O
149	dysuria	N	O
150	questionnaires	N	O
151	per	N	O
152	patient	N	O
153	.	N	O

154	Clinical	N	O
155	,	N	O
156	treatment	N	O
157	and	N	O
158	dosimetric	N	O
159	variables	N	O
160	evaluated	N	O
161	included	N	O
162	alpha-blocker	N	O
163	,	N	O
164	age	N	O
165	,	N	O
166	IPSS	N	O
167	before	N	O
168	and	N	O
169	the	N	O
170	maximum	N	O
171	after	N	O
172	treatment	N	O
173	,	N	O
174	prostate	N	O
175	volume	N	O
176	on	N	O
177	ultrasonography	N	O
178	,	N	O
179	hormonal	N	O
180	status	N	O
181	,	N	O
182	supplemental	N	O
183	radiotherapy	N	O
184	,	N	O
185	isotope	N	O
186	,	N	O
187	urethral	N	O
188	dose	N	O
189	,	N	O
190	V	N	O
191	(	N	O
192	100/200	N	O
193	)	N	O
194	,	N	O
195	D90	N	O
196	,	N	O
197	and	N	O
198	time	N	O
199	to	N	O
200	obtaining	N	O
201	a	N	O
202	normal	N	O
203	IPSS	N	O
204	.	N	O

205	The	N	O
206	maximum	N	O
207	incidence	N	O
208	of	N	O
209	dysuria	N	O
210	was	N	O
211	85	N	O
212	%	N	O
213	at	N	O
214	1	N	O
215	month	N	O
216	after	N	O
217	brachytherapy	N	O
218	,	N	O
219	with	N	O
220	subsequent	N	O
221	resolution	N	O
222	over	N	O
223	time	N	O
224	.	N	O

225	The	N	I-Premise
226	use	N	I-Premise
227	of	N	I-Premise
228	prophylactic	N	I-Premise
229	tamsulosin	N	I-Premise
230	resulted	N	I-Premise
231	in	N	I-Premise
232	a	N	I-Premise
233	statistically	N	I-Premise
234	lower	N	I-Premise
235	dysuria	N	I-Premise
236	severity	N	I-Premise
237	score	N	I-Premise
238	(	N	I-Premise
239	difference	N	I-Premise
240	of	N	I-Premise
241	2.7	N	I-Premise
242	vs	N	I-Premise
243	4.2	N	I-Premise
244	,	N	I-Premise
245	P	N	I-Premise
246	<	N	I-Premise
247	0.005	N	I-Premise
248	)	N	I-Premise
249	at	N	I-Premise
250	1	N	I-Premise
251	month	N	I-Premise
252	,	N	I-Premise
253	with	N	I-Premise
254	no	N	I-Premise
255	discernible	N	I-Premise
256	differences	N	I-Premise
257	at	N	I-Premise
258	3	N	I-Premise
259	,	N	I-Premise
260	6	N	I-Premise
261	,	N	I-Premise
262	12	N	I-Premise
263	and	N	I-Premise
264	18	N	I-Premise
265	months	N	I-Premise
266	.	N	I-Premise

267	Patients	N	I-Premise
268	with	N	I-Premise
269	dysuria	N	I-Premise
270	had	N	I-Premise
271	a	N	I-Premise
272	statistically	N	I-Premise
273	higher	N	I-Premise
274	IPSS	N	I-Premise
275	.	N	I-Premise

276	The	N	I-Premise
277	dysuria	N	I-Premise
278	resolved	N	I-Premise
279	faster	N	I-Premise
280	in	N	I-Premise
281	patients	N	I-Premise
282	implanted	N	I-Premise
283	with	N	I-Premise
284	103Pd	N	I-Premise
285	but	N	I-Premise
286	was	N	I-Premise
287	unaffected	N	I-Premise
288	by	N	I-Premise
289	the	N	I-Premise
290	use	N	I-Premise
291	of	N	I-Premise
292	supplemental	N	I-Premise
293	radiotherapy	N	I-Premise
294	and/or	N	I-Premise
295	androgen	N	I-Premise
296	deprivation	N	I-Premise
297	therapy	N	I-Premise
298	.	N	I-Premise

299	In	N	I-Premise
300	multivariate	N	I-Premise
301	analysis	N	I-Premise
302	,	N	I-Premise
303	prophylactic	N	I-Premise
304	alpha-blockers	N	I-Premise
305	resulted	N	I-Premise
306	in	N	I-Premise
307	statistically	N	I-Premise
308	lower	N	I-Premise
309	maximum	N	I-Premise
310	dysuria	N	I-Premise
311	scores	N	I-Premise
312	,	N	I-Premise
313	while	N	I-Premise
314	the	N	I-Premise
315	maximum	N	I-Premise
316	IPSS	N	I-Premise
317	after	N	I-Premise
318	implantation	N	I-Premise
319	and	N	I-Premise
320	isotope	N	I-Premise
321	type	N	I-Premise
322	(	N	I-Premise
323	but	N	I-Premise
324	only	N	I-Premise
325	at	N	I-Premise
326	6	N	I-Premise
327	months	N	I-Premise
328	)	N	I-Premise
329	were	N	I-Premise
330	the	N	I-Premise
331	best	N	I-Premise
332	predictors	N	I-Premise
333	of	N	I-Premise
334	the	N	I-Premise
335	resolution	N	I-Premise
336	of	N	I-Premise
337	dysuria	N	I-Premise
338	.	N	I-Premise

339	Dysuria	N	I-Claim
340	is	N	I-Claim
341	common	N	I-Claim
342	after	N	I-Claim
343	brachytherapy	N	I-Claim
344	but	N	I-Claim
345	is	N	I-Claim
346	typically	N	I-Claim
347	mild	N	I-Claim
348	.	N	I-Claim

349	Prophylactic	N	I-Claim
350	alpha-blockers	N	I-Claim
351	gave	N	I-Claim
352	significantly	N	I-Claim
353	lower	N	I-Claim
354	maximum	N	I-Claim
355	dysuria	N	I-Claim
356	scores	N	I-Claim
357	but	N	I-Claim
358	did	N	I-Claim
359	not	N	I-Claim
360	affect	N	I-Claim
361	the	N	I-Claim
362	time	N	I-Claim
363	to	N	I-Claim
364	the	N	I-Claim
365	resolution	N	I-Claim
366	of	N	I-Claim
367	dysuria	N	I-Claim
368	.	N	I-Claim

369	The	N	I-Claim
370	maximum	N	I-Claim
371	IPSS	N	I-Claim
372	after	N	I-Claim
373	the	N	I-Claim
374	implant	N	I-Claim
375	was	N	I-Claim
376	the	N	I-Claim
377	best	N	I-Claim
378	predictor	N	I-Claim
379	of	N	I-Claim
380	the	N	I-Claim
381	resolution	N	I-Claim
382	of	N	I-Claim
383	dysuria	N	I-Claim
384	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	phase	N	O
4	II	N	O
5	study	N	O
6	compared	N	O
7	two	N	O
8	treatment	N	O
9	schedules	N	O
10	of	N	O
11	gemcitabine	N	O
12	in	N	O
13	patients	N	O
14	with	N	O
15	non-small-cell	N	O
16	lung	N	O
17	cancer	N	O
18	(	N	O
19	NSCLC	N	O
20	)	N	O
21	and	N	O
22	impaired	N	O
23	Karnofsky	N	O
24	performance	N	O
25	status	N	O
26	(	N	O
27	KP	N	O
28	)	N	O
29	.	N	O

30	Primary	N	O
31	objectives	N	O
32	were	N	O
33	to	N	O
34	record	N	O
35	changes	N	O
36	from	N	O
37	baseline	N	O
38	KP	N	O
39	and	N	O
40	to	N	O
41	assess	N	O
42	symptom	N	O
43	palliation	N	O
44	.	N	O

45	Secondary	N	O
46	objectives	N	O
47	were	N	O
48	overall	N	O
49	survival	N	O
50	,	N	O
51	tumor	N	O
52	response	N	O
53	,	N	O
54	and	N	O
55	toxicity	N	O
56	.	N	O

57	Patients	N	O
58	with	N	O
59	stage	N	O
60	IIIb	N	O
61	and	N	O
62	IV	N	O
63	NSCLC	N	O
64	and	N	O
65	KP	N	O
66	<	N	O
67	/=	N	O
68	70	N	O
69	were	N	O
70	randomly	N	O
71	assigned	N	O
72	to	N	O
73	receive	N	O
74	gemcitabine	N	O
75	1,000	N	O
76	mg/m	N	O
77	(	N	O
78	2	N	O
79	)	N	O
80	on	N	O
81	days	N	O
82	1	N	O
83	,	N	O
84	8	N	O
85	,	N	O
86	and	N	O
87	15	N	O
88	of	N	O
89	each	N	O
90	28-day	N	O
91	cycle	N	O
92	(	N	O
93	3w4	N	O
94	)	N	O
95	or	N	O
96	gemcitabine	N	O
97	1,500	N	O
98	mg/m	N	O
99	(	N	O
100	2	N	O
101	)	N	O
102	on	N	O
103	days	N	O
104	1	N	O
105	and	N	O
106	8	N	O
107	of	N	O
108	each	N	O
109	21-day	N	O
110	cycle	N	O
111	(	N	O
112	2w3	N	O
113	)	N	O
114	,	N	O
115	both	N	O
116	for	N	O
117	up	N	O
118	to	N	O
119	six	N	O
120	cycles	N	O
121	.	N	O

122	KP	N	O
123	,	N	O
124	toxicity	N	O
125	,	N	O
126	and	N	O
127	SS14	N	O
128	lung	N	O
129	cancer	N	O
130	specific	N	O
131	questions	N	O
132	were	N	O
133	recorded	N	O
134	before	N	O
135	each	N	O
136	cycle	N	O
137	of	N	O
138	treatment	N	O
139	.	N	O

140	Response	N	O
141	was	N	O
142	evaluated	N	O
143	4	N	O
144	weeks	N	O
145	after	N	O
146	the	N	O
147	last	N	O
148	cycle	N	O
149	.	N	O

150	One	N	O
151	hundred	N	O
152	seventy-four	N	O
153	patients	N	O
154	were	N	O
155	enrolled	N	O
156	.	N	O

157	There	N	I-Premise
158	was	N	I-Premise
159	significant	N	I-Premise
160	early	N	I-Premise
161	attrition	N	I-Premise
162	due	N	I-Premise
163	to	N	I-Premise
164	disease	N	I-Premise
165	progression	N	I-Premise
166	;	N	I-Premise
167	only	N	I-Premise
168	61.5	N	I-Premise
169	%	N	I-Premise
170	of	N	I-Premise
171	patients	N	I-Premise
172	were	N	I-Premise
173	alive	N	I-Premise
174	at	N	I-Premise
175	2	N	I-Premise
176	months	N	I-Premise
177	.	N	I-Premise

178	There	N	I-Premise
179	was	N	I-Premise
180	a	N	I-Premise
181	significant	N	I-Premise
182	improvement	N	I-Premise
183	in	N	I-Premise
184	KP	N	I-Premise
185	from	N	I-Premise
186	baseline	N	I-Premise
187	to	N	I-Premise
188	pre-cycle	N	I-Premise
189	3	N	I-Premise
190	in	N	I-Premise
191	both	N	I-Premise
192	arms	N	I-Premise
193	,	N	I-Premise
194	with	N	I-Premise
195	a	N	I-Premise
196	trend	N	I-Premise
197	in	N	I-Premise
198	favor	N	I-Premise
199	of	N	I-Premise
200	the	N	I-Premise
201	3w4	N	I-Premise
202	regimen	N	I-Premise
203	for	N	I-Premise
204	duration	N	I-Premise
205	and	N	I-Premise
206	faster	N	I-Premise
207	onset	N	I-Premise
208	of	N	I-Premise
209	improvement	N	I-Premise
210	.	N	I-Premise

211	Eight	N	I-Premise
212	of	N	I-Premise
213	the	N	I-Premise
214	17	N	I-Premise
215	quality-of-life	N	I-Premise
216	(	N	I-Premise
217	QOL	N	I-Premise
218	)	N	I-Premise
219	variables	N	I-Premise
220	assessed	N	I-Premise
221	showed	N	I-Premise
222	an	N	I-Premise
223	improvement	N	I-Premise
224	of	N	I-Premise
225	more	N	I-Premise
226	than	N	I-Premise
227	10	N	I-Premise
228	%	N	I-Premise
229	between	N	I-Premise
230	baseline	N	I-Premise
231	and	N	I-Premise
232	the	N	I-Premise
233	start	N	I-Premise
234	of	N	I-Premise
235	the	N	I-Premise
236	third	N	I-Premise
237	cycle	N	I-Premise
238	of	N	I-Premise
239	treatment	N	I-Premise
240	.	N	I-Premise

241	Response	N	I-Premise
242	rate	N	I-Premise
243	,	N	I-Premise
244	survival	N	I-Premise
245	,	N	I-Premise
246	and	N	I-Premise
247	duration	N	I-Premise
248	were	N	I-Premise
249	similar	N	I-Premise
250	in	N	I-Premise
251	both	N	I-Premise
252	arms	N	I-Premise
253	.	N	I-Premise

254	There	N	I-Claim
255	was	N	I-Claim
256	no	N	I-Claim
257	significant	N	I-Claim
258	difference	N	I-Claim
259	between	N	I-Claim
260	the	N	I-Claim
261	two	N	I-Claim
262	schedules	N	I-Claim
263	examined	N	I-Claim
264	in	N	I-Claim
265	terms	N	I-Claim
266	of	N	I-Claim
267	improvement	N	I-Claim
268	in	N	I-Claim
269	KP	N	I-Claim
270	or	N	I-Claim
271	QOL	N	I-Claim
272	,	N	I-Claim
273	but	N	I-Claim
274	there	N	I-Claim
275	seemed	N	I-Claim
276	to	N	I-Claim
277	be	N	I-Claim
278	a	N	I-Claim
279	trend	N	I-Claim
280	in	N	I-Claim
281	favor	N	I-Claim
282	of	N	I-Claim
283	the	N	I-Claim
284	3w4	N	I-Claim
285	schedule	N	I-Claim
286	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	palliation	N	O
5	of	N	O
6	chest	N	O
7	symptoms	N	O
8	from	N	O
9	a	N	O
10	10	N	O
11	Gy	N	O
12	single	N	O
13	fraction	N	O
14	(	N	O
15	regimen	N	O
16	1	N	O
17	)	N	O
18	was	N	O
19	equivalent	N	O
20	to	N	O
21	that	N	O
22	from	N	O
23	30	N	O
24	Gy	N	O
25	in	N	O
26	10	N	O
27	fractions	N	O
28	(	N	O
29	regimen	N	O
30	2	N	O
31	)	N	O
32	.	N	O

33	Patients	N	O
34	with	N	O
35	cytologically	N	O
36	proven	N	O
37	,	N	O
38	symptomatic	N	O
39	lung	N	O
40	cancer	N	O
41	not	N	O
42	amenable	N	O
43	to	N	O
44	curative	N	O
45	therapy	N	O
46	,	N	O
47	with	N	O
48	performance	N	O
49	status	N	O
50	0-3	N	O
51	,	N	O
52	were	N	O
53	randomised	N	O
54	to	N	O
55	receive	N	O
56	either	N	O
57	30	N	O
58	Gy	N	O
59	in	N	O
60	10	N	O
61	fractions	N	O
62	or	N	O
63	a	N	O
64	10	N	O
65	Gy	N	O
66	single	N	O
67	fraction	N	O
68	.	N	O

69	Local	N	O
70	symptoms	N	O
71	were	N	O
72	scored	N	O
73	on	N	O
74	a	N	O
75	physician-assessed	N	O
76	,	N	O
77	five-point	N	O
78	categorical	N	O
79	scale	N	O
80	and	N	O
81	summed	N	O
82	to	N	O
83	produce	N	O
84	a	N	O
85	total	N	O
86	symptom	N	O
87	score	N	O
88	(	N	O
89	TSS	N	O
90	)	N	O
91	.	N	O

92	This	N	O
93	,	N	O
94	performance	N	O
95	status	N	O
96	,	N	O
97	Hospital	N	O
98	Anxiety	N	O
99	and	N	O
100	Depression	N	O
101	(	N	O
102	HAD	N	O
103	)	N	O
104	score	N	O
105	and	N	O
106	Spitzer	N	O
107	's	N	O
108	quality-of-life	N	O
109	index	N	O
110	were	N	O
111	noted	N	O
112	before	N	O
113	treatment	N	O
114	,	N	O
115	at	N	O
116	1	N	O
117	month	N	O
118	after	N	O
119	treatment	N	O
120	and	N	O
121	every	N	O
122	2	N	O
123	months	N	O
124	thereafter	N	O
125	.	N	O

126	Palliation	N	O
127	was	N	O
128	defined	N	O
129	as	N	O
130	an	N	O
131	improvement	N	O
132	of	N	O
133	one	N	O
134	point	N	O
135	or	N	O
136	more	N	O
137	in	N	O
138	the	N	O
139	categorical	N	O
140	scale	N	O
141	.	N	O

142	Equivalence	N	O
143	was	N	O
144	defined	N	O
145	as	N	O
146	less	N	O
147	than	N	O
148	20	N	O
149	%	N	O
150	difference	N	O
151	in	N	O
152	the	N	O
153	number	N	O
154	achieving	N	O
155	an	N	O
156	improvement	N	O
157	in	N	O
158	the	N	O
159	TSS	N	O
160	.	N	O

161	We	N	O
162	randomised	N	O
163	149	N	O
164	patients	N	O
165	and	N	O
166	analysed	N	O
167	74	N	O
168	in	N	O
169	each	N	O
170	arm	N	O
171	.	N	O

172	According	N	O
173	to	N	O
174	the	N	O
175	design	N	O
176	criteria	N	O
177	,	N	O
178	palliation	N	O
179	was	N	O
180	equivalent	N	O
181	between	N	O
182	the	N	O
183	two	N	O
184	arms	N	O
185	.	N	O

186	TSS	N	I-Premise
187	improved	N	I-Premise
188	in	N	I-Premise
189	49	N	I-Premise
190	patients	N	I-Premise
191	(	N	I-Premise
192	77	N	I-Premise
193	%	N	I-Premise
194	)	N	I-Premise
195	on	N	I-Premise
196	regimen	N	I-Premise
197	1	N	I-Premise
198	,	N	I-Premise
199	and	N	I-Premise
200	in	N	I-Premise
201	57	N	I-Premise
202	(	N	I-Premise
203	92	N	I-Premise
204	%	N	I-Premise
205	)	N	I-Premise
206	patients	N	I-Premise
207	on	N	I-Premise
208	regimen	N	I-Premise
209	2	N	I-Premise
210	,	N	I-Premise
211	a	N	I-Premise
212	difference	N	I-Premise
213	of	N	I-Premise
214	15	N	I-Premise
215	%	N	I-Premise
216	(	N	I-Premise
217	95	N	I-Premise
218	%	N	I-Premise
219	confidence	N	I-Premise
220	interval	N	I-Premise
221	[	N	I-Premise
222	CI	N	I-Premise
223	]	N	I-Premise
224	3-28	N	I-Premise
225	)	N	I-Premise
226	in	N	I-Premise
227	the	N	I-Premise
228	proportion	N	I-Premise
229	improving	N	I-Premise
230	between	N	I-Premise
231	the	N	I-Premise
232	two	N	I-Premise
233	regimens	N	I-Premise
234	.	N	I-Premise

235	A	N	I-Premise
236	complete	N	I-Premise
237	resolution	N	I-Premise
238	of	N	I-Premise
239	all	N	I-Premise
240	symptoms	N	I-Premise
241	was	N	I-Premise
242	achieved	N	I-Premise
243	in	N	I-Premise
244	three	N	I-Premise
245	(	N	I-Premise
246	5	N	I-Premise
247	%	N	I-Premise
248	)	N	I-Premise
249	on	N	I-Premise
250	regimen	N	I-Premise
251	1	N	I-Premise
252	,	N	I-Premise
253	and	N	I-Premise
254	in	N	I-Premise
255	14	N	I-Premise
256	(	N	I-Premise
257	23	N	I-Premise
258	%	N	I-Premise
259	)	N	I-Premise
260	patients	N	I-Premise
261	on	N	I-Premise
262	regimen	N	I-Premise
263	2	N	I-Premise
264	(	N	I-Premise
265	P	N	I-Premise
266	<	N	I-Premise
267	0.001	N	I-Premise
268	)	N	I-Premise
269	,	N	I-Premise
270	a	N	I-Premise
271	difference	N	I-Premise
272	in	N	I-Premise
273	the	N	I-Premise
274	proportion	N	I-Premise
275	between	N	I-Premise
276	the	N	I-Premise
277	two	N	I-Premise
278	regimens	N	I-Premise
279	of	N	I-Premise
280	21	N	I-Premise
281	%	N	I-Premise
282	(	N	I-Premise
283	95	N	I-Premise
284	%	N	I-Premise
285	CI	N	I-Premise
286	10-33	N	I-Premise
287	)	N	I-Premise
288	.	N	I-Premise

289	A	N	I-Premise
290	significantly	N	I-Premise
291	higher	N	I-Premise
292	proportion	N	I-Premise
293	of	N	I-Premise
294	patients	N	I-Premise
295	experienced	N	I-Premise
296	palliation	N	I-Premise
297	and	N	I-Premise
298	complete	N	I-Premise
299	resolution	N	I-Premise
300	of	N	I-Premise
301	chest	N	I-Premise
302	pain	N	I-Premise
303	and	N	I-Premise
304	dyspnoea	N	I-Premise
305	with	N	I-Premise
306	regimen	N	I-Premise
307	2	N	I-Premise
308	.	N	I-Premise

309	No	N	I-Premise
310	differences	N	I-Premise
311	were	N	I-Premise
312	observed	N	I-Premise
313	in	N	I-Premise
314	toxicity	N	I-Premise
315	.	N	I-Premise

316	The	N	I-Premise
317	median	N	I-Premise
318	survival	N	I-Premise
319	was	N	I-Premise
320	22.7	N	I-Premise
321	weeks	N	I-Premise
322	for	N	I-Premise
323	regimen	N	I-Premise
324	1	N	I-Premise
325	and	N	I-Premise
326	28.3	N	I-Premise
327	weeks	N	I-Premise
328	for	N	I-Premise
329	regimen	N	I-Premise
330	2	N	I-Premise
331	(	N	I-Premise
332	P	N	I-Premise
333	=	N	I-Premise
334	0.197	N	I-Premise
335	)	N	I-Premise
336	.	N	I-Premise

337	Although	N	I-Claim
338	this	N	I-Claim
339	trial	N	I-Claim
340	met	N	I-Claim
341	the	N	I-Claim
342	pre-determined	N	I-Claim
343	criteria	N	I-Claim
344	for	N	I-Claim
345	equivalence	N	I-Claim
346	between	N	I-Claim
347	the	N	I-Claim
348	two	N	I-Claim
349	palliative	N	I-Claim
350	regimens	N	I-Claim
351	,	N	I-Claim
352	significantly	N	I-Claim
353	more	N	I-Claim
354	patients	N	I-Claim
355	achieved	N	I-Claim
356	complete	N	I-Claim
357	resolution	N	I-Claim
358	of	N	I-Claim
359	symptoms	N	I-Claim
360	and	N	I-Claim
361	palliation	N	I-Claim
362	of	N	I-Claim
363	chest	N	I-Claim
364	pain	N	I-Claim
365	and	N	I-Claim
366	dyspnoea	N	I-Claim
367	with	N	I-Claim
368	the	N	I-Claim
369	fractionated	N	I-Claim
370	regimen	N	I-Claim
371	.	N	I-Claim

1	Bevacizumab	N	I-Claim
2	,	N	I-Claim
3	a	N	I-Claim
4	monoclonal	N	I-Claim
5	antibody	N	I-Claim
6	against	N	I-Claim
7	vascular	N	I-Claim
8	endothelial	N	I-Claim
9	growth	N	I-Claim
10	factor	N	I-Claim
11	,	N	I-Claim
12	increases	N	I-Claim
13	survival	N	I-Claim
14	when	N	I-Claim
15	combined	N	I-Claim
16	with	N	I-Claim
17	irinotecan-based	N	I-Claim
18	chemotherapy	N	I-Claim
19	in	N	I-Claim
20	first-line	N	I-Claim
21	treatment	N	I-Claim
22	of	N	I-Claim
23	metastatic	N	I-Claim
24	colorectal	N	I-Claim
25	cancer	N	I-Claim
26	(	N	I-Claim
27	CRC	N	I-Claim
28	)	N	I-Claim
29	.	N	I-Claim

30	This	N	O
31	randomized	N	O
32	,	N	O
33	phase	N	O
34	II	N	O
35	trial	N	O
36	compared	N	O
37	bevacizumab	N	O
38	plus	N	O
39	fluorouracil	N	O
40	and	N	O
41	leucovorin	N	O
42	(	N	O
43	FU/LV	N	O
44	)	N	O
45	versus	N	O
46	placebo	N	O
47	plus	N	O
48	FU/LV	N	O
49	as	N	O
50	first-line	N	O
51	therapy	N	O
52	in	N	O
53	patients	N	O
54	considered	N	O
55	nonoptimal	N	O
56	candidates	N	O
57	for	N	O
58	first-line	N	O
59	irinotecan	N	O
60	.	N	O

61	Patients	N	O
62	had	N	O
63	metastatic	N	O
64	CRC	N	O
65	and	N	O
66	one	N	O
67	of	N	O
68	the	N	O
69	following	N	O
70	characteristics	N	O
71	:	N	O
72	age	N	O
73	>	N	O
74	or	N	O
75	=	N	O
76	65	N	O
77	years	N	O
78	,	N	O
79	Eastern	N	O
80	Cooperative	N	O
81	Oncology	N	O
82	Group	N	O
83	performance	N	O
84	status	N	O
85	1	N	O
86	or	N	O
87	2	N	O
88	,	N	O
89	serum	N	O
90	albumin	N	O
91	<	N	O
92	or	N	O
93	=	N	O
94	3.5	N	O
95	g/dL	N	O
96	,	N	O
97	or	N	O
98	prior	N	O
99	abdominal/pelvic	N	O
100	radiotherapy	N	O
101	.	N	O

102	Patients	N	O
103	were	N	O
104	randomly	N	O
105	assigned	N	O
106	to	N	O
107	FU/LV/placebo	N	O
108	(	N	O
109	n	N	O
110	=	N	O
111	105	N	O
112	)	N	O
113	or	N	O
114	FU/LV/bevacizumab	N	O
115	(	N	O
116	n	N	O
117	=	N	O
118	104	N	O
119	)	N	O
120	.	N	O

121	The	N	O
122	primary	N	O
123	end	N	O
124	point	N	O
125	was	N	O
126	overall	N	O
127	survival	N	O
128	.	N	O

129	Secondary	N	O
130	end	N	O
131	points	N	O
132	were	N	O
133	progression-free	N	O
134	survival	N	O
135	,	N	O
136	response	N	O
137	rate	N	O
138	,	N	O
139	response	N	O
140	duration	N	O
141	,	N	O
142	and	N	O
143	quality	N	O
144	of	N	O
145	life	N	O
146	.	N	O

147	Safety	N	O
148	was	N	O
149	also	N	O
150	assessed	N	O
151	.	N	O

152	Median	N	I-Premise
153	survival	N	I-Premise
154	was	N	I-Premise
155	16.6	N	I-Premise
156	months	N	I-Premise
157	for	N	I-Premise
158	the	N	I-Premise
159	FU/LV/bevacizumab	N	I-Premise
160	group	N	I-Premise
161	and	N	I-Premise
162	12.9	N	I-Premise
163	months	N	I-Premise
164	for	N	I-Premise
165	the	N	I-Premise
166	FU/LV/placebo	N	I-Premise
167	group	N	I-Premise
168	(	N	I-Premise
169	hazard	N	I-Premise
170	ratio	N	I-Premise
171	,	N	I-Premise
172	0.79	N	I-Premise
173	;	N	I-Premise
174	P	N	I-Premise
175	=	N	I-Premise
176	.16	N	I-Premise
177	)	N	I-Premise
178	.	N	I-Premise

179	Median	N	I-Premise
180	progression-free	N	I-Premise
181	survival	N	I-Premise
182	was	N	I-Premise
183	9.2	N	I-Premise
184	months	N	I-Premise
185	(	N	I-Premise
186	FU/LV/bevacizumab	N	I-Premise
187	)	N	I-Premise
188	and	N	I-Premise
189	5.5	N	I-Premise
190	months	N	I-Premise
191	(	N	I-Premise
192	FU/LV/placebo	N	I-Premise
193	)	N	I-Premise
194	;	N	I-Premise
195	hazard	N	I-Premise
196	ratio	N	I-Premise
197	was	N	I-Premise
198	0.50	N	I-Premise
199	;	N	I-Premise
200	P	N	I-Premise
201	=	N	I-Premise
202	.0002	N	I-Premise
203	.	N	O

204	Response	N	I-Premise
205	rates	N	I-Premise
206	were	N	I-Premise
207	26.0	N	I-Premise
208	%	N	I-Premise
209	(	N	I-Premise
210	FU/LV/bevacizumab	N	I-Premise
211	)	N	I-Premise
212	and	N	I-Premise
213	15.2	N	I-Premise
214	%	N	I-Premise
215	(	N	I-Premise
216	FU/LV/placebo	N	I-Premise
217	)	N	I-Premise
218	(	N	I-Premise
219	P	N	I-Premise
220	=	N	I-Premise
221	.055	N	I-Premise
222	)	N	I-Premise
223	;	N	I-Premise
224	duration	N	I-Premise
225	of	N	I-Premise
226	response	N	I-Premise
227	was	N	I-Premise
228	9.2	N	I-Premise
229	months	N	I-Premise
230	(	N	I-Premise
231	FU/LV/bevacizumab	N	I-Premise
232	)	N	I-Premise
233	and	N	I-Premise
234	6.8	N	I-Premise
235	months	N	I-Premise
236	(	N	I-Premise
237	FU/LV/placebo	N	I-Premise
238	)	N	I-Premise
239	;	N	I-Premise
240	hazard	N	I-Premise
241	ratio	N	I-Premise
242	was	N	I-Premise
243	0.42	N	I-Premise
244	;	N	I-Premise
245	P	N	I-Premise
246	=	N	I-Premise
247	.088	N	I-Premise
248	.	N	I-Premise

249	Grade	N	I-Premise
250	3	N	I-Premise
251	hypertension	N	I-Premise
252	was	N	I-Premise
253	more	N	I-Premise
254	common	N	I-Premise
255	with	N	I-Premise
256	bevacizumab	N	I-Premise
257	treatment	N	I-Premise
258	(	N	I-Premise
259	16	N	I-Premise
260	%	N	I-Premise
261	v	N	I-Premise
262	3	N	I-Premise
263	%	N	I-Premise
264	)	N	I-Premise
265	but	N	I-Premise
266	was	N	I-Premise
267	controlled	N	I-Premise
268	with	N	I-Premise
269	oral	N	I-Premise
270	medication	N	I-Premise
271	and	N	I-Premise
272	did	N	I-Premise
273	not	N	I-Premise
274	cause	N	I-Premise
275	study	N	I-Premise
276	drug	N	I-Premise
277	discontinuation	N	I-Premise
278	.	N	I-Premise

279	Addition	N	I-Claim
280	of	N	I-Claim
281	bevacizumab	N	I-Claim
282	to	N	I-Claim
283	FU/LV	N	I-Claim
284	as	N	I-Claim
285	first-line	N	I-Claim
286	therapy	N	I-Claim
287	in	N	I-Claim
288	CRC	N	I-Claim
289	patients	N	I-Claim
290	who	N	I-Claim
291	were	N	I-Claim
292	not	N	I-Claim
293	considered	N	I-Claim
294	optimal	N	I-Claim
295	candidates	N	I-Claim
296	for	N	I-Claim
297	first-line	N	I-Claim
298	irinotecan	N	I-Claim
299	treatment	N	I-Claim
300	provided	N	I-Claim
301	clinically	N	I-Claim
302	significant	N	I-Claim
303	patient	N	I-Claim
304	benefit	N	I-Claim
305	,	N	I-Claim
306	including	N	I-Claim
307	statistically	N	I-Claim
308	significant	N	I-Claim
309	improvement	N	I-Claim
310	in	N	I-Claim
311	progression-free	N	I-Claim
312	survival	N	I-Claim
313	.	N	I-Claim

1	Impaired	N	I-Claim
2	cognition	N	I-Claim
3	,	N	I-Claim
4	fatigue	N	I-Claim
5	,	N	I-Claim
6	and	N	I-Claim
7	diminished	N	I-Claim
8	quality	N	I-Claim
9	of	N	I-Claim
10	life	N	I-Claim
11	(	N	I-Claim
12	QOL	N	I-Claim
13	)	N	I-Claim
14	are	N	I-Claim
15	commonly	N	I-Claim
16	associated	N	I-Claim
17	with	N	I-Claim
18	breast	N	I-Claim
19	cancer	N	I-Claim
20	chemotherapy	N	I-Claim
21	.	N	I-Claim

22	This	N	O
23	randomized	N	O
24	,	N	O
25	double-blind	N	O
26	,	N	O
27	placebo-controlled	N	O
28	pilot	N	O
29	trial	N	O
30	assessed	N	O
31	the	N	O
32	feasibility	N	O
33	of	N	O
34	quantifying	N	O
35	the	N	O
36	effects	N	O
37	of	N	O
38	epoetin	N	O
39	alfa	N	O
40	on	N	O
41	cognitive	N	O
42	function	N	O
43	and	N	O
44	mood	N	O
45	,	N	O
46	and	N	O
47	evaluated	N	O
48	its	N	O
49	effects	N	O
50	on	N	O
51	fatigue	N	O
52	and	N	O
53	QOL	N	O
54	in	N	O
55	patients	N	O
56	with	N	O
57	breast	N	O
58	cancer	N	O
59	treated	N	O
60	with	N	O
61	anthracycline-based	N	O
62	adjuvant	N	O
63	or	N	O
64	neoadjuvant	N	O
65	chemotherapy	N	O
66	.	N	O

67	Patients	N	O
68	were	N	O
69	randomized	N	O
70	to	N	O
71	receive	N	O
72	epoetin	N	O
73	alfa	N	O
74	40,000	N	O
75	U	N	O
76	subcutaneously	N	O
77	once	N	O
78	weekly	N	O
79	or	N	O
80	placebo	N	O
81	at	N	O
82	the	N	O
83	beginning	N	O
84	of	N	O
85	4	N	O
86	cycles	N	O
87	of	N	O
88	chemotherapy	N	O
89	administered	N	O
90	over	N	O
91	12	N	O
92	weeks	N	O
93	.	N	O

94	Cognitive	N	O
95	function	N	O
96	was	N	O
97	assessed	N	O
98	by	N	O
99	Executive	N	O
100	Interview	N	O
101	(	N	O
102	EXIT25	N	O
103	)	N	O
104	and	N	O
105	Clock	N	O
106	Drawing	N	O
107	Tasks	N	O
108	;	N	O
109	mood	N	O
110	by	N	O
111	Profile	N	O
112	of	N	O
113	Mood	N	O
114	States	N	O
115	;	N	O
116	anemia-related	N	O
117	symptoms	N	O
118	,	N	O
119	including	N	O
120	fatigue	N	O
121	,	N	O
122	by	N	O
123	the	N	O
124	Functional	N	O
125	Assessment	N	O
126	of	N	O
127	Cancer	N	O
128	Therapy-Anemia	N	O
129	(	N	O
130	FACT-An	N	O
131	)	N	O
132	subscale	N	O
133	;	N	O
134	and	N	O
135	QOL	N	O
136	by	N	O
137	Linear	N	O
138	Analog	N	O
139	Scale	N	O
140	Assessment	N	O
141	.	N	O

142	Ninety-four	N	O
143	patients	N	O
144	were	N	O
145	evaluable	N	O
146	for	N	O
147	efficacy	N	O
148	and	N	O
149	safety	N	O
150	.	N	O

151	Mean	N	I-Premise
152	change	N	I-Premise
153	in	N	I-Premise
154	EXIT25	N	I-Premise
155	scores	N	I-Premise
156	from	N	I-Premise
157	baseline	N	I-Premise
158	to	N	I-Premise
159	cycle	N	I-Premise
160	4	N	I-Premise
161	in	N	I-Premise
162	the	N	I-Premise
163	epoetin	N	I-Premise
164	alfa	N	I-Premise
165	group	N	I-Premise
166	was	N	I-Premise
167	1.3	N	I-Premise
168	+/-	N	I-Premise
169	3.3	N	I-Premise
170	;	N	I-Premise
171	the	N	I-Premise
172	mean	N	I-Premise
173	change	N	I-Premise
174	was	N	I-Premise
175	0.3	N	I-Premise
176	+/-	N	I-Premise
177	2.4	N	I-Premise
178	in	N	I-Premise
179	the	N	I-Premise
180	placebo	N	I-Premise
181	group	N	I-Premise
182	(	N	I-Premise
183	a	N	I-Premise
184	negative	N	I-Premise
185	change	N	I-Premise
186	indicates	N	I-Premise
187	improved	N	I-Premise
188	executive	N	I-Premise
189	function	N	I-Premise
190	)	N	I-Premise
191	.	N	I-Premise

192	There	N	I-Premise
193	was	N	I-Premise
194	no	N	I-Premise
195	difference	N	I-Premise
196	between	N	I-Premise
197	groups	N	I-Premise
198	in	N	I-Premise
199	mean	N	I-Premise
200	change	N	I-Premise
201	in	N	I-Premise
202	EXIT25	N	I-Premise
203	score	N	I-Premise
204	from	N	I-Premise
205	baseline	N	I-Premise
206	to	N	I-Premise
207	6-month	N	I-Premise
208	follow-up	N	I-Premise
209	assessment	N	I-Premise
210	.	N	I-Premise

211	Mean	N	I-Premise
212	hemoglobin	N	I-Premise
213	levels	N	I-Premise
214	were	N	I-Premise
215	higher	N	I-Premise
216	in	N	I-Premise
217	the	N	I-Premise
218	epoetin	N	I-Premise
219	alfa	N	I-Premise
220	group	N	I-Premise
221	compared	N	I-Premise
222	with	N	I-Premise
223	the	N	I-Premise
224	placebo	N	I-Premise
225	group	N	I-Premise
226	after	N	I-Premise
227	4	N	I-Premise
228	cycles	N	I-Premise
229	of	N	I-Premise
230	chemotherapy	N	I-Premise
231	.	N	I-Premise

232	Epoetin	N	I-Premise
233	alfa	N	I-Premise
234	recipients	N	I-Premise
235	had	N	I-Premise
236	less	N	I-Premise
237	of	N	I-Premise
238	a	N	I-Premise
239	decrease	N	I-Premise
240	in	N	I-Premise
241	FACT-An	N	I-Premise
242	subscale	N	I-Premise
243	scores	N	I-Premise
244	from	N	I-Premise
245	baseline	N	I-Premise
246	to	N	I-Premise
247	cycle	N	I-Premise
248	4	N	I-Premise
249	and	N	I-Premise
250	improvement	N	I-Premise
251	in	N	I-Premise
252	FACT-An	N	I-Premise
253	subscale	N	I-Premise
254	scores	N	I-Premise
255	at	N	I-Premise
256	6-month	N	I-Premise
257	follow-up	N	I-Premise
258	assessment	N	I-Premise
259	compared	N	I-Premise
260	with	N	I-Premise
261	placebo	N	I-Premise
262	.	N	I-Premise

263	Epoetin	N	I-Claim
264	alfa	N	I-Claim
265	therapy	N	I-Claim
266	was	N	I-Claim
267	well	N	I-Claim
268	tolerated	N	I-Claim
269	.	N	I-Claim

270	These	N	I-Claim
271	data	N	I-Claim
272	suggest	N	I-Claim
273	that	N	I-Claim
274	epoetin	N	I-Claim
275	alfa	N	I-Claim
276	may	N	I-Claim
277	have	N	I-Claim
278	attenuated	N	I-Claim
279	the	N	I-Claim
280	cognitive	N	I-Claim
281	impairment	N	I-Claim
282	and	N	I-Claim
283	fatigue	N	I-Claim
284	that	N	I-Claim
285	occurred	N	I-Claim
286	during	N	I-Claim
287	adjuvant	N	I-Claim
288	breast	N	I-Claim
289	cancer	N	I-Claim
290	chemotherapy	N	I-Claim
291	.	N	I-Claim

1	To	N	O
2	pilot	N	O
3	an	N	O
4	investigation	N	O
5	of	N	O
6	individualized	N	O
7	homeopathy	N	O
8	for	N	O
9	symptoms	N	O
10	of	N	O
11	estrogen	N	O
12	withdrawal	N	O
13	in	N	O
14	breast	N	O
15	cancer	N	O
16	survivors	N	O
17	.	N	O

18	Randomized	N	O
19	,	N	O
20	double-blinded	N	O
21	,	N	O
22	placebo-controlled	N	O
23	trial	N	O
24	.	N	O

25	Outpatient	N	O
26	department	N	O
27	of	N	O
28	a	N	O
29	National	N	O
30	Health	N	O
31	Service	N	O
32	(	N	O
33	NHS	N	O
34	)	N	O
35	homeopathic	N	O
36	hospital	N	O
37	.	N	O

38	Fifty-seven	N	O
39	(	N	O
40	57	N	O
41	)	N	O
42	women	N	O
43	met	N	O
44	inclusion	N	O
45	criteria	N	O
46	and	N	O
47	53	N	O
48	were	N	O
49	randomized	N	O
50	to	N	O
51	the	N	O
52	study	N	O
53	.	N	O

54	After	N	O
55	2	N	O
56	weeks	N	O
57	of	N	O
58	baseline	N	O
59	assessment	N	O
60	,	N	O
61	all	N	O
62	participants	N	O
63	received	N	O
64	a	N	O
65	consultation	N	O
66	plus	N	O
67	either	N	O
68	oral	N	O
69	homeopathic	N	O
70	medicine	N	O
71	or	N	O
72	placebo	N	O
73	,	N	O
74	assessed	N	O
75	every	N	O
76	4	N	O
77	weeks	N	O
78	for	N	O
79	16	N	O
80	weeks	N	O
81	.	N	O

82	The	N	O
83	primary	N	O
84	outcome	N	O
85	measures	N	O
86	were	N	O
87	the	N	O
88	activity	N	O
89	score	N	O
90	and	N	O
91	profile	N	O
92	score	N	O
93	of	N	O
94	the	N	O
95	Measure	N	O
96	Yourself	N	O
97	Medical	N	O
98	Outcome	N	O
99	Profile	N	O
100	(	N	O
101	MYMOP	N	O
102	)	N	O
103	.	N	O

104	Eighty-five	N	O
105	percent	N	O
106	(	N	O
107	85	N	O
108	%	N	O
109	)	N	O
110	(	N	O
111	45/53	N	O
112	)	N	O
113	of	N	O
114	women	N	O
115	completed	N	O
116	the	N	O
117	study	N	O
118	.	N	O

119	There	N	I-Premise
120	was	N	I-Premise
121	no	N	I-Premise
122	evidence	N	I-Premise
123	of	N	I-Premise
124	a	N	I-Premise
125	difference	N	I-Premise
126	seen	N	I-Premise
127	between	N	I-Premise
128	groups	N	I-Premise
129	for	N	I-Premise
130	either	N	I-Premise
131	activity	N	I-Premise
132	(	N	I-Premise
133	adjusted	N	I-Premise
134	difference	N	I-Premise
135	=-0.4	N	I-Premise
136	,	N	I-Premise
137	95	N	I-Premise
138	%	N	I-Premise
139	confidence	N	I-Premise
140	interval	N	I-Premise
141	CI	N	I-Premise
142	-1.0	N	I-Premise
143	to	N	I-Premise
144	0.2	N	I-Premise
145	,	N	I-Premise
146	p	N	I-Premise
147	=	N	I-Premise
148	0.17	N	I-Premise
149	)	N	I-Premise
150	or	N	I-Premise
151	profile	N	I-Premise
152	scores	N	I-Premise
153	(	N	I-Premise
154	adjusted	N	I-Premise
155	difference	N	I-Premise
156	=	N	I-Premise
157	-0.4	N	I-Premise
158	,	N	I-Premise
159	95	N	I-Premise
160	%	N	I-Premise
161	CI	N	I-Premise
162	-0.9	N	I-Premise
163	to	N	I-Premise
164	0.1	N	I-Premise
165	,	N	I-Premise
166	p	N	I-Premise
167	=	N	I-Premise
168	0.13	N	I-Premise
169	)	N	I-Premise
170	using	N	I-Premise
171	this	N	I-Premise
172	trial	N	I-Premise
173	design	N	I-Premise
174	,	N	I-Premise
175	although	N	I-Claim
176	post	N	I-Claim
177	hoc	N	I-Claim
178	power	N	I-Claim
179	calculations	N	I-Claim
180	suggests	N	I-Claim
181	that	N	I-Claim
182	65-175	N	I-Claim
183	would	N	I-Claim
184	be	N	I-Claim
185	needed	N	I-Claim
186	per	N	I-Claim
187	group	N	I-Claim
188	to	N	I-Claim
189	detect	N	I-Claim
190	differences	N	I-Claim
191	of	N	I-Claim
192	this	N	I-Claim
193	magnitude	N	I-Claim
194	with	N	I-Claim
195	sufficient	N	I-Claim
196	precision	N	I-Claim
197	.	N	I-Claim

198	Clinically	N	I-Premise
199	relevant	N	I-Premise
200	improvements	N	I-Premise
201	in	N	I-Premise
202	symptoms	N	I-Premise
203	and	N	I-Premise
204	mood	N	I-Premise
205	disturbance	N	I-Premise
206	were	N	I-Premise
207	seen	N	I-Premise
208	for	N	I-Premise
209	both	N	I-Premise
210	groups	N	I-Premise
211	over	N	I-Premise
212	the	N	I-Premise
213	study	N	I-Premise
214	period	N	I-Premise
215	.	N	I-Premise

216	Improvements	N	I-Claim
217	were	N	I-Claim
218	seen	N	I-Claim
219	for	N	I-Claim
220	symptom	N	I-Claim
221	scores	N	I-Claim
222	over	N	I-Claim
223	the	N	I-Claim
224	study	N	I-Claim
225	period	N	I-Claim
226	.	N	I-Claim

227	However	N	I-Claim
228	,	N	I-Claim
229	presuming	N	I-Claim
230	these	N	I-Claim
231	improvements	N	I-Claim
232	were	N	I-Claim
233	caused	N	I-Claim
234	by	N	I-Claim
235	the	N	I-Claim
236	individualized	N	I-Claim
237	homeopathic	N	I-Claim
238	approach	N	I-Claim
239	,	N	I-Claim
240	the	N	I-Claim
241	study	N	I-Claim
242	failed	N	I-Claim
243	to	N	I-Claim
244	show	N	I-Claim
245	clearly	N	I-Claim
246	that	N	I-Claim
247	the	N	I-Claim
248	specific	N	I-Claim
249	effect	N	I-Claim
250	of	N	I-Claim
251	the	N	I-Claim
252	remedy	N	I-Claim
253	added	N	I-Claim
254	further	N	I-Claim
255	to	N	I-Claim
256	the	N	I-Claim
257	nonspecific	N	I-Claim
258	effects	N	I-Claim
259	of	N	I-Claim
260	the	N	I-Claim
261	consultation	N	I-Claim
262	.	N	I-Claim

263	Future	N	I-Claim
264	trial	N	I-Claim
265	design	N	I-Claim
266	must	N	I-Claim
267	ensure	N	I-Claim
268	adequate	N	I-Claim
269	power	N	I-Claim
270	to	N	I-Claim
271	account	N	I-Claim
272	for	N	I-Claim
273	the	N	I-Claim
274	nonspecific	N	I-Claim
275	impact	N	I-Claim
276	of	N	I-Claim
277	such	N	I-Claim
278	complex	N	I-Claim
279	individualized	N	I-Claim
280	interventions	N	I-Claim
281	while	N	I-Claim
282	pragmatic	N	I-Claim
283	designs	N	I-Claim
284	may	N	I-Claim
285	more	N	I-Claim
286	readily	N	I-Claim
287	answer	N	I-Claim
288	questions	N	I-Claim
289	of	N	I-Claim
290	clinical	N	I-Claim
291	and	N	I-Claim
292	cost	N	I-Claim
293	effectiveness	N	I-Claim
294	.	N	O

1	To	N	O
2	carry	N	O
3	out	N	O
4	a	N	O
5	preliminary	N	O
6	trial	N	O
7	evaluating	N	O
8	the	N	O
9	effectiveness	N	O
10	of	N	O
11	two	N	O
12	types	N	O
13	of	N	O
14	homeopathy	N	O
15	for	N	O
16	the	N	O
17	treatment	N	O
18	of	N	O
19	menopausal	N	O
20	symptoms	N	O
21	in	N	O
22	breast	N	O
23	cancer	N	O
24	survivors	N	O
25	.	N	O

26	Randomized	N	O
27	,	N	O
28	double-blinded	N	O
29	,	N	O
30	placebo-controlled	N	O
31	.	N	O

32	Private	N	O
33	medical	N	O
34	clinic	N	O
35	,	N	O
36	Seattle	N	O
37	,	N	O
38	WA	N	O
39	.	N	O

40	Women	N	O
41	with	N	O
42	a	N	O
43	history	N	O
44	of	N	O
45	breast	N	O
46	cancer	N	O
47	who	N	O
48	had	N	O
49	completed	N	O
50	all	N	O
51	surgery	N	O
52	,	N	O
53	chemotherapy	N	O
54	,	N	O
55	and	N	O
56	radiation	N	O
57	treatment	N	O
58	and	N	O
59	who	N	O
60	had	N	O
61	an	N	O
62	average	N	O
63	of	N	O
64	at	N	O
65	least	N	O
66	three	N	O
67	hot	N	O
68	flashes	N	O
69	per	N	O
70	day	N	O
71	for	N	O
72	the	N	O
73	previous	N	O
74	month	N	O
75	.	N	O

76	Subjects	N	O
77	were	N	O
78	randomized	N	O
79	to	N	O
80	receive	N	O
81	either	N	O
82	an	N	O
83	individualized	N	O
84	homeopathic	N	O
85	single	N	O
86	remedy	N	O
87	,	N	O
88	a	N	O
89	homeopathic	N	O
90	combination	N	O
91	medicine	N	O
92	,	N	O
93	or	N	O
94	placebo	N	O
95	.	N	O

96	Patients	N	O
97	were	N	O
98	seen	N	O
99	by	N	O
100	homeopathic	N	O
101	providers	N	O
102	every	N	O
103	2	N	O
104	months	N	O
105	for	N	O
106	1	N	O
107	year	N	O
108	.	N	O

109	Hot	N	O
110	flash	N	O
111	frequency	N	O
112	and	N	O
113	severity	N	O
114	,	N	O
115	Kupperman	N	O
116	Menopausal	N	O
117	Index	N	O
118	(	N	O
119	KMI	N	O
120	)	N	O
121	,	N	O
122	Short	N	O
123	Form	N	O
124	36	N	O
125	(	N	O
126	SF-36	N	O
127	)	N	O
128	.	N	O

129	There	N	I-Premise
130	was	N	I-Premise
131	no	N	I-Premise
132	significant	N	I-Premise
133	difference	N	I-Premise
134	found	N	I-Premise
135	in	N	I-Premise
136	the	N	I-Premise
137	primary	N	I-Premise
138	outcome	N	I-Premise
139	measure	N	I-Premise
140	,	N	I-Premise
141	the	N	I-Premise
142	hot	N	I-Premise
143	flash	N	I-Premise
144	severity	N	I-Premise
145	score	N	I-Premise
146	,	N	I-Premise
147	although	N	I-Premise
148	there	N	I-Premise
149	was	N	I-Premise
150	a	N	I-Premise
151	positive	N	I-Premise
152	trend	N	I-Premise
153	in	N	I-Premise
154	the	N	I-Premise
155	single	N	I-Premise
156	remedy	N	I-Premise
157	group	N	I-Premise
158	during	N	I-Premise
159	the	N	I-Premise
160	first	N	I-Premise
161	3	N	I-Premise
162	months	N	I-Premise
163	of	N	I-Premise
164	the	N	I-Premise
165	study	N	I-Premise
166	(	N	I-Premise
167	p	N	I-Premise
168	=	N	I-Premise
169	0.1	N	I-Premise
170	)	N	I-Premise
171	.	N	I-Premise

172	A	N	I-Premise
173	statistically	N	I-Premise
174	significant	N	I-Premise
175	improvement	N	I-Premise
176	in	N	I-Premise
177	general	N	I-Premise
178	health	N	I-Premise
179	score	N	I-Premise
180	in	N	I-Premise
181	both	N	I-Premise
182	homeopathy	N	I-Premise
183	groups	N	I-Premise
184	(	N	I-Premise
185	p	N	I-Premise
186	<	N	I-Premise
187	0.05	N	I-Premise
188	)	N	I-Premise
189	on	N	I-Premise
190	the	N	I-Premise
191	SF-36	N	I-Premise
192	after	N	I-Premise
193	1	N	I-Premise
194	year	N	I-Premise
195	was	N	I-Premise
196	found	N	I-Premise
197	.	N	I-Premise

198	Evidence	N	I-Premise
199	of	N	I-Premise
200	a	N	I-Premise
201	homeopathic	N	I-Premise
202	``	N	I-Premise
203	drug	N	I-Premise
204	proving	N	I-Premise
205	''	N	I-Premise
206	in	N	I-Premise
207	the	N	I-Premise
208	subjects	N	I-Premise
209	receiving	N	I-Premise
210	the	N	I-Premise
211	homeopathic	N	I-Premise
212	combination	N	I-Premise
213	medicine	N	I-Premise
214	who	N	I-Premise
215	were	N	I-Premise
216	not	N	I-Premise
217	taking	N	I-Premise
218	tamoxifen	N	I-Premise
219	also	N	I-Premise
220	was	N	I-Premise
221	found	N	I-Premise
222	.	N	I-Premise

223	Small	N	I-Claim
224	sample	N	I-Claim
225	size	N	I-Claim
226	precludes	N	I-Claim
227	definitive	N	I-Claim
228	answers	N	I-Claim
229	,	N	I-Claim
230	but	N	I-Claim
231	results	N	I-Claim
232	from	N	I-Claim
233	this	N	I-Claim
234	preliminary	N	I-Claim
235	trial	N	I-Claim
236	suggest	N	I-Claim
237	that	N	I-Claim
238	homeopathy	N	I-Claim
239	may	N	I-Claim
240	be	N	I-Claim
241	of	N	I-Claim
242	value	N	I-Claim
243	in	N	I-Claim
244	the	N	I-Claim
245	treatment	N	I-Claim
246	of	N	I-Claim
247	menopausal	N	I-Claim
248	symptoms	N	I-Claim
249	and	N	I-Claim
250	improving	N	I-Claim
251	quality	N	I-Claim
252	of	N	I-Claim
253	life	N	I-Claim
254	,	N	I-Claim
255	especially	N	I-Claim
256	in	N	I-Claim
257	those	N	I-Claim
258	women	N	I-Claim
259	not	N	I-Claim
260	on	N	I-Claim
261	tamoxifen	N	I-Claim
262	.	N	I-Claim

263	Larger	N	I-Claim
264	studies	N	I-Claim
265	should	N	I-Claim
266	be	N	I-Claim
267	carried	N	I-Claim
268	out	N	I-Claim
269	that	N	I-Claim
270	also	N	I-Claim
271	include	N	I-Claim
272	healthy	N	I-Claim
273	women	N	I-Claim
274	who	N	I-Claim
275	want	N	I-Claim
276	to	N	I-Claim
277	avoid	N	I-Claim
278	hormone	N	I-Claim
279	replacement	N	I-Claim
280	therapy	N	I-Claim
281	.	N	I-Claim

1	Proinflammatory	N	O
2	cytokines	N	O
3	,	N	O
4	especially	N	O
5	tumour	N	O
6	necrosis	N	O
7	factor	N	O
8	alpha	N	O
9	(	N	O
10	TNF-alpha	N	O
11	)	N	O
12	,	N	O
13	play	N	O
14	a	N	O
15	prominent	N	O
16	role	N	O
17	in	N	O
18	the	N	O
19	pathogenesis	N	O
20	of	N	O
21	cancer	N	O
22	cachexia	N	O
23	.	N	O

24	Thalidomide	N	I-MajorClaim
25	,	N	I-MajorClaim
26	which	N	I-MajorClaim
27	is	N	I-MajorClaim
28	an	N	I-MajorClaim
29	inhibitor	N	I-MajorClaim
30	of	N	I-MajorClaim
31	TNF-alpha	N	I-MajorClaim
32	synthesis	N	I-MajorClaim
33	,	N	I-MajorClaim
34	may	N	I-MajorClaim
35	represent	N	I-MajorClaim
36	a	N	I-MajorClaim
37	novel	N	I-MajorClaim
38	and	N	I-MajorClaim
39	rational	N	I-MajorClaim
40	approach	N	I-MajorClaim
41	to	N	I-MajorClaim
42	the	N	I-MajorClaim
43	treatment	N	I-MajorClaim
44	of	N	I-MajorClaim
45	cancer	N	I-MajorClaim
46	cachexia	N	I-MajorClaim
47	.	N	I-MajorClaim

48	To	N	O
49	assess	N	O
50	the	N	O
51	safety	N	O
52	and	N	O
53	efficacy	N	O
54	of	N	O
55	thalidomide	N	O
56	in	N	O
57	attenuating	N	O
58	weight	N	O
59	loss	N	O
60	in	N	O
61	patients	N	O
62	with	N	O
63	cachexia	N	O
64	secondary	N	O
65	to	N	O
66	advanced	N	O
67	pancreatic	N	O
68	cancer	N	O
69	.	N	O

70	Fifty	N	O
71	patients	N	O
72	with	N	O
73	advanced	N	O
74	pancreatic	N	O
75	cancer	N	O
76	who	N	O
77	had	N	O
78	lost	N	O
79	at	N	O
80	least	N	O
81	10	N	O
82	%	N	O
83	of	N	O
84	their	N	O
85	body	N	O
86	weight	N	O
87	were	N	O
88	randomised	N	O
89	to	N	O
90	receive	N	O
91	thalidomide	N	O
92	200	N	O
93	mg	N	O
94	daily	N	O
95	or	N	O
96	placebo	N	O
97	for	N	O
98	24	N	O
99	weeks	N	O
100	in	N	O
101	a	N	O
102	single	N	O
103	centre	N	O
104	,	N	O
105	double	N	O
106	blind	N	O
107	,	N	O
108	randomised	N	O
109	controlled	N	O
110	trial	N	O
111	.	N	O

112	The	N	O
113	primary	N	O
114	outcome	N	O
115	was	N	O
116	change	N	O
117	in	N	O
118	weight	N	O
119	and	N	O
120	nutritional	N	O
121	status	N	O
122	.	N	O

123	Thirty	N	O
124	three	N	O
125	patients	N	O
126	(	N	O
127	16	N	O
128	control	N	O
129	,	N	O
130	17	N	O
131	thalidomide	N	O
132	)	N	O
133	were	N	O
134	evaluated	N	O
135	at	N	O
136	four	N	O
137	weeks	N	O
138	,	N	O
139	and	N	O
140	20	N	O
141	patients	N	O
142	(	N	O
143	eight	N	O
144	control	N	O
145	,	N	O
146	12	N	O
147	thalidomide	N	O
148	)	N	O
149	at	N	O
150	eight	N	O
151	weeks	N	O
152	.	N	O

153	At	N	I-Premise
154	four	N	I-Premise
155	weeks	N	I-Premise
156	,	N	I-Premise
157	patients	N	I-Premise
158	who	N	I-Premise
159	received	N	I-Premise
160	thalidomide	N	I-Premise
161	had	N	I-Premise
162	gained	N	I-Premise
163	on	N	I-Premise
164	average	N	I-Premise
165	0.37	N	I-Premise
166	kg	N	I-Premise
167	in	N	I-Premise
168	weight	N	I-Premise
169	and	N	I-Premise
170	1.0	N	I-Premise
171	cm	N	I-Premise
172	(	N	I-Premise
173	3	N	I-Premise
174	)	N	I-Premise
175	in	N	I-Premise
176	arm	N	I-Premise
177	muscle	N	I-Premise
178	mass	N	I-Premise
179	(	N	I-Premise
180	AMA	N	I-Premise
181	)	N	I-Premise
182	compared	N	I-Premise
183	with	N	I-Premise
184	a	N	I-Premise
185	loss	N	I-Premise
186	of	N	I-Premise
187	2.21	N	I-Premise
188	kg	N	I-Premise
189	(	N	I-Premise
190	absolute	N	I-Premise
191	difference	N	I-Premise
192	-2.59	N	I-Premise
193	kg	N	I-Premise
194	(	N	I-Premise
195	95	N	I-Premise
196	%	N	I-Premise
197	confidence	N	I-Premise
198	interval	N	I-Premise
199	(	N	I-Premise
200	CI	N	I-Premise
201	)	N	I-Premise
202	-4.3	N	I-Premise
203	to	N	I-Premise
204	-0.8	N	I-Premise
205	)	N	I-Premise
206	;	N	I-Premise
207	p	N	I-Premise
208	=	N	I-Premise
209	0.005	N	I-Premise
210	)	N	I-Premise
211	and	N	I-Premise
212	4.46	N	I-Premise
213	cm	N	I-Premise
214	(	N	I-Premise
215	3	N	I-Premise
216	)	N	I-Premise
217	(	N	I-Premise
218	absolute	N	I-Premise
219	difference	N	I-Premise
220	-5.6	N	I-Premise
221	cm	N	I-Premise
222	(	N	I-Premise
223	3	N	I-Premise
224	)	N	I-Premise
225	(	N	I-Premise
226	95	N	I-Premise
227	%	N	I-Premise
228	CI	N	I-Premise
229	-8.9	N	I-Premise
230	to	N	I-Premise
231	-2.2	N	I-Premise
232	)	N	I-Premise
233	;	N	I-Premise
234	p	N	I-Premise
235	=	N	I-Premise
236	0.002	N	I-Premise
237	)	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	placebo	N	I-Premise
241	group	N	I-Premise
242	.	N	I-Premise

243	At	N	I-Premise
244	eight	N	I-Premise
245	weeks	N	I-Premise
246	,	N	I-Premise
247	patients	N	I-Premise
248	in	N	I-Premise
249	the	N	I-Premise
250	thalidomide	N	I-Premise
251	group	N	I-Premise
252	had	N	I-Premise
253	lost	N	I-Premise
254	0.06	N	I-Premise
255	kg	N	I-Premise
256	in	N	I-Premise
257	weight	N	I-Premise
258	and	N	I-Premise
259	0.5	N	I-Premise
260	cm	N	I-Premise
261	(	N	I-Premise
262	3	N	I-Premise
263	)	N	I-Premise
264	in	N	I-Premise
265	AMA	N	I-Premise
266	compared	N	I-Premise
267	with	N	I-Premise
268	a	N	I-Premise
269	loss	N	I-Premise
270	of	N	I-Premise
271	3.62	N	I-Premise
272	kg	N	I-Premise
273	(	N	I-Premise
274	absolute	N	I-Premise
275	difference	N	I-Premise
276	-3.57	N	I-Premise
277	kg	N	I-Premise
278	(	N	I-Premise
279	95	N	I-Premise
280	%	N	I-Premise
281	CI	N	I-Premise
282	-6.8	N	I-Premise
283	to	N	I-Premise
284	-0.3	N	I-Premise
285	)	N	I-Premise
286	;	N	I-Premise
287	p	N	I-Premise
288	=	N	I-Premise
289	0.034	N	I-Premise
290	)	N	I-Premise
291	and	N	I-Premise
292	8.4	N	I-Premise
293	cm	N	I-Premise
294	(	N	I-Premise
295	3	N	I-Premise
296	)	N	I-Premise
297	(	N	I-Premise
298	absolute	N	I-Premise
299	difference	N	I-Premise
300	-7.9	N	I-Premise
301	cm	N	I-Premise
302	(	N	I-Premise
303	3	N	I-Premise
304	)	N	I-Premise
305	(	N	I-Premise
306	95	N	I-Premise
307	%	N	I-Premise
308	CI	N	I-Premise
309	-14.0	N	I-Premise
310	to	N	I-Premise
311	-1.8	N	I-Premise
312	)	N	I-Premise
313	;	N	I-Premise
314	p	N	I-Premise
315	=	N	I-Premise
316	0.014	N	I-Premise
317	)	N	I-Premise
318	in	N	I-Premise
319	the	N	I-Premise
320	placebo	N	I-Premise
321	group	N	I-Premise
322	.	N	I-Premise

323	Improvement	N	I-Premise
324	in	N	I-Premise
325	physical	N	I-Premise
326	functioning	N	I-Premise
327	correlated	N	I-Premise
328	positively	N	I-Premise
329	with	N	I-Premise
330	weight	N	I-Premise
331	gain	N	I-Premise
332	(	N	I-Premise
333	r	N	I-Premise
334	=	N	I-Premise
335	0.56	N	I-Premise
336	,	N	I-Premise
337	p	N	I-Premise
338	=	N	I-Premise
339	0.001	N	I-Premise
340	)	N	I-Premise
341	.	N	I-Premise

342	Thalidomide	N	I-Claim
343	was	N	I-Claim
344	well	N	I-Claim
345	tolerated	N	I-Claim
346	and	N	I-Claim
347	effective	N	I-Claim
348	at	N	I-Claim
349	attenuating	N	I-Claim
350	loss	N	I-Claim
351	of	N	I-Claim
352	weight	N	I-Claim
353	and	N	I-Claim
354	lean	N	I-Claim
355	body	N	I-Claim
356	mass	N	I-Claim
357	in	N	I-Claim
358	patients	N	I-Claim
359	with	N	I-Claim
360	cachexia	N	I-Claim
361	due	N	I-Claim
362	to	N	I-Claim
363	advanced	N	I-Claim
364	pancreatic	N	I-Claim
365	cancer	N	I-Claim
366	.	N	I-Claim

1	To	N	O
2	test	N	O
3	the	N	O
4	ability	N	O
5	of	N	O
6	the	N	O
7	cytoprotectant	N	O
8	,	N	O
9	amifostine	N	O
10	,	N	O
11	to	N	O
12	reduce	N	O
13	chemoradiotherapy-induced	N	O
14	esophagitis	N	O
15	and	N	O
16	evaluate	N	O
17	its	N	O
18	influence	N	O
19	on	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QOL	N	O
25	)	N	O
26	and	N	O
27	swallowing	N	O
28	symptoms	N	O
29	.	N	O

30	A	N	O
31	total	N	O
32	of	N	O
33	243	N	O
34	patients	N	O
35	with	N	O
36	stage	N	O
37	II	N	O
38	to	N	O
39	IIIA/B	N	O
40	non-small-cell	N	O
41	lung	N	O
42	cancer	N	O
43	received	N	O
44	induction	N	O
45	paclitaxel	N	O
46	225	N	O
47	mg/m	N	O
48	(	N	O
49	2	N	O
50	)	N	O
51	intravenously	N	O
52	(	N	O
53	IV	N	O
54	)	N	O
55	days	N	O
56	1	N	O
57	and	N	O
58	22	N	O
59	and	N	O
60	carboplatin	N	O
61	area	N	O
62	under	N	O
63	the	N	O
64	curve	N	O
65	(	N	O
66	AUC	N	O
67	)	N	O
68	days	N	O
69	1	N	O
70	and	N	O
71	22	N	O
72	,	N	O
73	followed	N	O
74	by	N	O
75	concurrent	N	O
76	weekly	N	O
77	paclitaxel	N	O
78	(	N	O
79	50	N	O
80	mg/m	N	O
81	(	N	O
82	2	N	O
83	)	N	O
84	IV	N	O
85	)	N	O
86	and	N	O
87	carboplatin	N	O
88	(	N	O
89	AUC	N	O
90	2	N	O
91	)	N	O
92	,	N	O
93	and	N	O
94	hyperfractionated	N	O
95	radiation	N	O
96	therapy	N	O
97	(	N	O
98	69.6	N	O
99	Gy	N	O
100	at	N	O
101	1.2	N	O
102	Gy	N	O
103	bid	N	O
104	)	N	O
105	.	N	O

106	Patients	N	O
107	were	N	O
108	randomly	N	O
109	assigned	N	O
110	at	N	O
111	registration	N	O
112	to	N	O
113	amifostine	N	O
114	(	N	O
115	AM	N	O
116	)	N	O
117	500	N	O
118	mg	N	O
119	IV	N	O
120	four	N	O
121	times	N	O
122	per	N	O
123	week	N	O
124	or	N	O
125	no	N	O
126	AM	N	O
127	during	N	O
128	chemoradiotherapy	N	O
129	.	N	O

130	Beyond	N	O
131	standard	N	O
132	toxicity	N	O
133	end	N	O
134	points	N	O
135	,	N	O
136	physician	N	O
137	dysphagia	N	O
138	logs	N	O
139	(	N	O
140	PDLs	N	O
141	)	N	O
142	,	N	O
143	daily	N	O
144	patient	N	O
145	swallowing	N	O
146	diaries	N	O
147	,	N	O
148	and	N	O
149	QOL	N	O
150	(	N	O
151	EORTC	N	O
152	QLQ-C30/LC-13	N	O
153	)	N	O
154	were	N	O
155	also	N	O
156	collected	N	O
157	.	N	O

158	Swallowing	N	O
159	AUC	N	O
160	analyses	N	O
161	were	N	O
162	calculated	N	O
163	from	N	O
164	patient	N	O
165	diaries	N	O
166	and	N	O
167	PDLs	N	O
168	.	N	O

169	A	N	O
170	total	N	O
171	of	N	O
172	120	N	O
173	patients	N	O
174	were	N	O
175	randomly	N	O
176	assigned	N	O
177	to	N	O
178	receive	N	O
179	AM	N	O
180	,	N	O
181	and	N	O
182	122	N	O
183	,	N	O
184	to	N	O
185	receive	N	O
186	no	N	O
187	AM	N	O
188	(	N	O
189	one	N	O
190	patient	N	O
191	was	N	O
192	ineligible	N	O
193	)	N	O
194	;	N	O
195	72	N	O
196	%	N	O
197	received	N	O
198	AM	N	O
199	per	N	O
200	protocol	N	O
201	or	N	O
202	with	N	O
203	a	N	O
204	minor	N	O
205	deviation	N	O
206	.	N	O

207	AM	N	I-Premise
208	was	N	I-Premise
209	associated	N	I-Premise
210	with	N	I-Premise
211	higher	N	I-Premise
212	rates	N	I-Premise
213	of	N	I-Premise
214	acute	N	I-Premise
215	nausea	N	I-Premise
216	(	N	I-Premise
217	P	N	I-Premise
218	=	N	I-Premise
219	.03	N	I-Premise
220	)	N	I-Premise
221	,	N	I-Premise
222	vomiting	N	I-Premise
223	(	N	I-Premise
224	P	N	I-Premise
225	=	N	I-Premise
226	.007	N	I-Premise
227	)	N	I-Premise
228	,	N	I-Premise
229	cardiovascular	N	I-Premise
230	toxicity	N	I-Premise
231	(	N	I-Premise
232	P	N	I-Premise
233	=	N	I-Premise
234	.0001	N	I-Premise
235	)	N	I-Premise
236	,	N	I-Premise
237	and	N	I-Premise
238	infection	N	I-Premise
239	or	N	I-Premise
240	febrile	N	I-Premise
241	neutropenia	N	I-Premise
242	(	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	.03	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	The	N	I-Premise
249	rate	N	I-Premise
250	of	N	I-Premise
251	>	N	I-Premise
252	/=	N	I-Premise
253	grade	N	I-Premise
254	3	N	I-Premise
255	esophagitis	N	I-Premise
256	was	N	I-Premise
257	30	N	I-Premise
258	%	N	I-Premise
259	with	N	I-Premise
260	AM	N	I-Premise
261	versus	N	I-Premise
262	34	N	I-Premise
263	%	N	I-Premise
264	without	N	I-Premise
265	AM	N	I-Premise
266	(	N	I-Premise
267	P	N	I-Premise
268	=	N	I-Premise
269	.9	N	I-Premise
270	)	N	I-Premise
271	.	N	I-Premise

272	Patient	N	I-Premise
273	diaries	N	I-Premise
274	demonstrated	N	I-Premise
275	lower	N	I-Premise
276	swallowing	N	I-Premise
277	dysfunction	N	I-Premise
278	AUC	N	I-Premise
279	with	N	I-Premise
280	amifostine	N	I-Premise
281	(	N	I-Premise
282	z	N	I-Premise
283	test	N	I-Premise
284	P	N	I-Premise
285	=	N	I-Premise
286	.025	N	I-Premise
287	)	N	I-Premise
288	.	N	I-Premise

289	QOL	N	I-Premise
290	was	N	I-Premise
291	not	N	I-Premise
292	significantly	N	I-Premise
293	different	N	I-Premise
294	between	N	I-Premise
295	the	N	I-Premise
296	two	N	I-Premise
297	arms	N	I-Premise
298	,	N	I-Premise
299	except	N	I-Premise
300	for	N	I-Premise
301	pain	N	I-Premise
302	,	N	I-Premise
303	which	N	I-Premise
304	showed	N	I-Premise
305	more	N	I-Premise
306	clinically	N	I-Premise
307	meaningful	N	I-Premise
308	improvement	N	I-Premise
309	and	N	I-Premise
310	less	N	I-Premise
311	deterioration	N	I-Premise
312	at	N	I-Premise
313	6	N	I-Premise
314	weeks	N	I-Premise
315	follow-up	N	I-Premise
316	(	N	I-Premise
317	v	N	I-Premise
318	pretreatment	N	I-Premise
319	)	N	I-Premise
320	in	N	I-Premise
321	the	N	I-Premise
322	AM	N	I-Premise
323	arm	N	I-Premise
324	(	N	I-Premise
325	P	N	I-Premise
326	=	N	I-Premise
327	.003	N	I-Premise
328	)	N	I-Premise
329	.	N	I-Premise

330	The	N	I-Premise
331	median	N	I-Premise
332	survival	N	I-Premise
333	rates	N	I-Premise
334	for	N	I-Premise
335	both	N	I-Premise
336	arms	N	I-Premise
337	were	N	I-Premise
338	comparable	N	I-Premise
339	(	N	I-Premise
340	AM	N	I-Premise
341	,	N	I-Premise
342	17.3	N	I-Premise
343	v	N	I-Premise
344	no	N	I-Premise
345	AM	N	I-Premise
346	,	N	I-Premise
347	17.9	N	I-Premise
348	months	N	I-Premise
349	;	N	I-Premise
350	P	N	I-Premise
351	=	N	I-Premise
352	.87	N	I-Premise
353	)	N	I-Premise
354	.	N	I-Premise

355	AM	N	I-Claim
356	did	N	I-Claim
357	not	N	I-Claim
358	significantly	N	I-Claim
359	reduce	N	I-Claim
360	esophagitis	N	I-Claim
361	>	N	I-Claim
362	/=	N	I-Claim
363	grade	N	I-Claim
364	3	N	I-Claim
365	in	N	I-Claim
366	patients	N	I-Claim
367	receiving	N	I-Claim
368	hyperfractionated	N	I-Claim
369	radiation	N	I-Claim
370	and	N	I-Claim
371	chemotherapy	N	I-Claim
372	.	N	I-Claim

373	However	N	I-Claim
374	,	N	I-Claim
375	patient	N	I-Claim
376	self-assessments	N	I-Claim
377	suggested	N	I-Claim
378	a	N	I-Claim
379	possible	N	I-Claim
380	advantage	N	I-Claim
381	to	N	I-Claim
382	AM	N	I-Claim
383	that	N	I-Claim
384	is	N	I-Claim
385	being	N	I-Claim
386	explored	N	I-Claim
387	with	N	I-Claim
388	modified	N	I-Claim
389	dosing	N	I-Claim
390	route	N	I-Claim
391	strategies	N	I-Claim
392	.	N	I-Claim

1	Many	N	O
2	patients	N	O
3	with	N	O
4	advanced	N	O
5	ovarian	N	O
6	cancer	N	O
7	will	N	O
8	develop	N	O
9	recurrent	N	O
10	disease	N	O
11	.	N	O

12	For	N	I-Premise
13	those	N	I-Premise
14	patients	N	I-Premise
15	who	N	I-Premise
16	have	N	I-Premise
17	recurrence	N	I-Premise
18	of	N	I-Premise
19	disease	N	I-Premise
20	at	N	I-Premise
21	least	N	I-Premise
22	6	N	I-Premise
23	months	N	I-Premise
24	after	N	I-Premise
25	initial	N	I-Premise
26	therapy	N	I-Premise
27	,	N	I-Premise
28	the	N	I-Premise
29	paclitaxel-platinum	N	I-Premise
30	combination	N	I-Premise
31	has	N	I-Premise
32	been	N	I-Premise
33	shown	N	I-Premise
34	to	N	I-Premise
35	be	N	I-Premise
36	a	N	I-Premise
37	superior	N	I-Premise
38	treatment	N	I-Premise
39	to	N	I-Premise
40	platinum	N	I-Premise
41	monotherapy	N	I-Premise
42	.	N	I-Premise

43	However	N	I-Claim
44	,	N	I-Claim
45	many	N	I-Claim
46	patients	N	I-Claim
47	develop	N	I-Claim
48	clinically	N	I-Claim
49	relevant	N	I-Claim
50	neurotoxicity	N	I-Claim
51	,	N	I-Claim
52	frequently	N	I-Claim
53	resulting	N	I-Claim
54	in	N	I-Claim
55	treatment	N	I-Claim
56	discontinuation	N	I-Claim
57	.	N	I-Claim

58	The	N	O
59	efficacy	N	O
60	and	N	O
61	safety	N	O
62	of	N	O
63	an	N	O
64	alternative	N	O
65	regimen	N	O
66	that	N	O
67	does	N	O
68	not	N	O
69	show	N	O
70	significant	N	O
71	neurotoxicity	N	O
72	were	N	O
73	evaluated	N	O
74	by	N	O
75	comparing	N	O
76	gemcitabine-carboplatin	N	O
77	with	N	O
78	carboplatin	N	O
79	in	N	O
80	platinum-sensitive	N	O
81	recurrent	N	O
82	ovarian	N	O
83	cancer	N	O
84	patients	N	O
85	in	N	O
86	a	N	O
87	Gynecologic	N	O
88	Cancer	N	O
89	InterGroup	N	O
90	trial	N	O
91	of	N	O
92	the	N	O
93	Arbeitsgemeinschaft	N	O
94	Gynakologische	N	O
95	Onkologie	N	O
96	Ovarian	N	O
97	Cancer	N	O
98	Study	N	O
99	Group	N	O
100	,	N	O
101	the	N	O
102	National	N	O
103	Cancer	N	O
104	Institute	N	O
105	of	N	O
106	Canada	N	O
107	Clinical	N	O
108	Trials	N	O
109	Group	N	O
110	,	N	O
111	and	N	O
112	the	N	O
113	European	N	O
114	Organisation	N	O
115	for	N	O
116	Research	N	O
117	and	N	O
118	Treatment	N	O
119	of	N	O
120	Cancer	N	O
121	Gynaecological	N	O
122	Cancer	N	O
123	Group	N	O
124	.	N	O

125	Participants	N	O
126	with	N	O
127	recurrent	N	O
128	platinum-sensitive	N	O
129	ovarian	N	O
130	cancer	N	O
131	were	N	O
132	randomly	N	O
133	assigned	N	O
134	to	N	O
135	receive	N	O
136	either	N	O
137	gemcitabine-carboplatin	N	O
138	or	N	O
139	carboplatin	N	O
140	every	N	O
141	21	N	O
142	days	N	O
143	.	N	O

144	The	N	O
145	primary	N	O
146	objective	N	O
147	was	N	O
148	to	N	O
149	compare	N	O
150	progression-free	N	O
151	survival	N	O
152	(	N	O
153	PFS	N	O
154	)	N	O
155	between	N	O
156	the	N	O
157	groups	N	O
158	.	N	O

159	From	N	O
160	September	N	O
161	1999	N	O
162	to	N	O
163	April	N	O
164	2002	N	O
165	,	N	O
166	356	N	O
167	patients	N	O
168	(	N	O
169	178	N	O
170	participants	N	O
171	received	N	O
172	gemcitabine-carboplatin	N	O
173	,	N	O
174	178	N	O
175	received	N	O
176	carboplatin	N	O
177	only	N	O
178	)	N	O
179	were	N	O
180	randomized	N	O
181	to	N	O
182	treatment	N	O
183	.	N	O

184	Patients	N	O
185	received	N	O
186	six	N	O
187	cycles	N	O
188	of	N	O
189	either	N	O
190	gemcitabine-carboplatin	N	O
191	or	N	O
192	carboplatin	N	O
193	.	N	O

194	With	N	I-Premise
195	a	N	I-Premise
196	median	N	I-Premise
197	follow-up	N	I-Premise
198	of	N	I-Premise
199	17	N	I-Premise
200	months	N	I-Premise
201	,	N	I-Premise
202	median	N	I-Premise
203	PFS	N	I-Premise
204	was	N	I-Premise
205	8.6	N	I-Premise
206	months	N	I-Premise
207	for	N	I-Premise
208	gemcitabine-carboplatin	N	I-Premise
209	(	N	I-Premise
210	95	N	I-Premise
211	%	N	I-Premise
212	confidence	N	I-Premise
213	interval	N	I-Premise
214	[	N	I-Premise
215	CI	N	I-Premise
216	]	N	I-Premise
217	7.9-9.7	N	I-Premise
218	months	N	I-Premise
219	)	N	I-Premise
220	and	N	I-Premise
221	5.8	N	I-Premise
222	months	N	I-Premise
223	for	N	I-Premise
224	carboplatin	N	I-Premise
225	(	N	I-Premise
226	95	N	I-Premise
227	%	N	I-Premise
228	CI	N	I-Premise
229	5.2-7.1	N	I-Premise
230	months	N	I-Premise
231	;	N	I-Premise
232	hazard	N	I-Premise
233	ratio	N	I-Premise
234	[	N	I-Premise
235	HR	N	I-Premise
236	]	N	I-Premise
237	0.72	N	I-Premise
238	[	N	I-Premise
239	95	N	I-Premise
240	%	N	I-Premise
241	CI	N	I-Premise
242	0.58-0.90	N	I-Premise
243	;	N	I-Premise
244	P	N	I-Premise
245	=	N	I-Premise
246	0.0032	N	I-Premise
247	]	N	I-Premise
248	)	N	I-Premise
249	.	N	I-Premise

250	The	N	I-Premise
251	response	N	I-Premise
252	rate	N	I-Premise
253	for	N	I-Premise
254	the	N	I-Premise
255	gemcitabine-carboplatin	N	I-Premise
256	group	N	I-Premise
257	was	N	I-Premise
258	47.2	N	I-Premise
259	%	N	I-Premise
260	(	N	I-Premise
261	95	N	I-Premise
262	%	N	I-Premise
263	CI	N	I-Premise
264	39.9-54.5	N	I-Premise
265	%	N	I-Premise
266	)	N	I-Premise
267	and	N	I-Premise
268	30.9	N	I-Premise
269	%	N	I-Premise
270	for	N	I-Premise
271	carboplatin	N	I-Premise
272	group	N	I-Premise
273	(	N	I-Premise
274	95	N	I-Premise
275	%	N	I-Premise
276	CI	N	I-Premise
277	24.1-37.7	N	I-Premise
278	%	N	I-Premise
279	;	N	I-Premise
280	P	N	I-Premise
281	=	N	I-Premise
282	0.0016	N	I-Premise
283	)	N	I-Premise
284	.	N	I-Premise

285	The	N	I-Premise
286	HR	N	I-Premise
287	for	N	I-Premise
288	overall	N	I-Premise
289	survival	N	I-Premise
290	was	N	I-Premise
291	0.96	N	I-Premise
292	(	N	I-Premise
293	95	N	I-Premise
294	%	N	I-Premise
295	CI	N	I-Premise
296	0.75-1.23	N	I-Premise
297	;	N	I-Premise
298	P	N	I-Premise
299	=	N	I-Premise
300	0.7349	N	I-Premise
301	)	N	I-Premise
302	.	N	I-Premise

303	Patients	N	I-Premise
304	treated	N	I-Premise
305	with	N	I-Premise
306	gemcitabine-carboplatin	N	I-Premise
307	reported	N	I-Premise
308	significantly	N	I-Premise
309	faster	N	I-Premise
310	palliation	N	I-Premise
311	of	N	I-Premise
312	abdominal	N	I-Premise
313	symptoms	N	I-Premise
314	and	N	I-Premise
315	a	N	I-Premise
316	significantly	N	I-Premise
317	improved	N	I-Premise
318	global	N	I-Premise
319	quality	N	I-Premise
320	of	N	I-Premise
321	life	N	I-Premise
322	.	N	I-Premise

323	Gemcitabine-carboplatin	N	I-Claim
324	treatment	N	I-Claim
325	significantly	N	I-Claim
326	improves	N	I-Claim
327	the	N	I-Claim
328	PFS	N	I-Claim
329	of	N	I-Claim
330	patients	N	I-Claim
331	with	N	I-Claim
332	platinum-sensitive	N	I-Claim
333	recurrent	N	I-Claim
334	ovarian	N	I-Claim
335	cancer	N	I-Claim
336	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	investigate	N	O
9	whether	N	O
10	specialized	N	O
11	supportive	N	O
12	enteral	N	O
13	and	N	O
14	parenteral	N	O
15	feeding	N	O
16	have	N	O
17	superior	N	O
18	effects	N	O
19	compared	N	O
20	to	N	O
21	oral	N	O
22	nutrition	N	O
23	on	N	O
24	recovery	N	O
25	during	N	O
26	long-term	N	O
27	postoperative	N	O
28	treatment	N	O
29	of	N	O
30	cancer	N	O
31	patients	N	O
32	with	N	O
33	preoperative	N	O
34	weight	N	O
35	loss	N	O
36	and	N	O
37	reduced	N	O
38	maximum	N	O
39	exercise	N	O
40	capacity	N	O
41	.	N	O

42	One	N	O
43	hundred	N	O
44	twenty-six	N	O
45	patients	N	O
46	referred	N	O
47	for	N	O
48	resection	N	O
49	of	N	O
50	the	N	O
51	esophagus	N	O
52	(	N	O
53	n	N	O
54	=	N	O
55	48	N	O
56	)	N	O
57	,	N	O
58	stomach	N	O
59	(	N	O
60	n	N	O
61	=	N	O
62	28	N	O
63	)	N	O
64	,	N	O
65	or	N	O
66	pancreas	N	O
67	(	N	O
68	n	N	O
69	=	N	O
70	50	N	O
71	)	N	O
72	were	N	O
73	considered	N	O
74	to	N	O
75	be	N	O
76	included	N	O
77	before	N	O
78	operation	N	O
79	.	N	O

80	Included	N	O
81	patients	N	O
82	(	N	O
83	n	N	O
84	=	N	O
85	80	N	O
86	)	N	O
87	received	N	O
88	supportive	N	O
89	enteral	N	O
90	or	N	O
91	parenteral	N	O
92	nutrition	N	O
93	postoperatively	N	O
94	at	N	O
95	home	N	O
96	corresponding	N	O
97	to	N	O
98	1000	N	O
99	kcal/d	N	O
100	until	N	O
101	the	N	O
102	patients	N	O
103	did	N	O
104	not	N	O
105	wish	N	O
106	to	N	O
107	continue	N	O
108	with	N	O
109	artificial	N	O
110	nutrition	N	O
111	for	N	O
112	any	N	O
113	reason	N	O
114	.	N	O

115	Patients	N	O
116	randomized	N	O
117	to	N	O
118	oral	N	O
119	nutrition	N	O
120	only	N	O
121	served	N	O
122	as	N	O
123	control	N	O
124	subjects	N	O
125	.	N	O

126	Caloric	N	O
127	intake	N	O
128	,	N	O
129	body	N	O
130	composition	N	O
131	(	N	O
132	dual-energy	N	O
133	x-ray	N	O
134	absorptiometry	N	O
135	)	N	O
136	,	N	O
137	and	N	O
138	respiratory	N	O
139	gas	N	O
140	exchanges	N	O
141	at	N	O
142	rest	N	O
143	and	N	O
144	during	N	O
145	exercise	N	O
146	were	N	O
147	measured	N	O
148	including	N	O
149	health-related	N	O
150	quality	N	O
151	of	N	O
152	life	N	O
153	.	N	O

154	Survival	N	I-Premise
155	and	N	I-Premise
156	hospital	N	I-Premise
157	stay	N	I-Premise
158	did	N	I-Premise
159	not	N	I-Premise
160	differ	N	I-Premise
161	among	N	I-Premise
162	the	N	I-Premise
163	groups	N	I-Premise
164	,	N	I-Premise
165	whereas	N	I-Premise
166	overall	N	I-Premise
167	complications	N	I-Premise
168	were	N	I-Premise
169	higher	N	I-Premise
170	on	N	I-Premise
171	artificial	N	I-Premise
172	nutrition	N	I-Premise
173	(	N	I-Premise
174	P	N	I-Premise
175	<	N	I-Premise
176	.05	N	I-Premise
177	)	N	I-Premise
178	.	N	I-Premise

179	Changes	N	I-Premise
180	in	N	I-Premise
181	resting	N	I-Premise
182	energy	N	I-Premise
183	expenditure	N	I-Premise
184	and	N	I-Premise
185	biochemical	N	I-Premise
186	tests	N	I-Premise
187	did	N	I-Premise
188	not	N	I-Premise
189	differ	N	I-Premise
190	during	N	I-Premise
191	follow-up	N	I-Premise
192	among	N	I-Premise
193	the	N	I-Premise
194	groups	N	I-Premise
195	.	N	I-Premise

196	Body	N	I-Premise
197	weight	N	I-Premise
198	and	N	I-Premise
199	whole	N	I-Premise
200	body	N	I-Premise
201	fat	N	I-Premise
202	declined	N	I-Premise
203	similarly	N	I-Premise
204	over	N	I-Premise
205	time	N	I-Premise
206	in	N	I-Premise
207	all	N	I-Premise
208	groups	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	<	N	I-Premise
212	.005	N	I-Premise
213	)	N	I-Premise
214	,	N	I-Premise
215	whereas	N	O
216	lean	N	I-Premise
217	body	N	I-Premise
218	mass	N	I-Premise
219	was	N	I-Premise
220	unchanged	N	I-Premise
221	during	N	I-Premise
222	follow-up	N	I-Premise
223	compared	N	I-Premise
224	to	N	I-Premise
225	preoperative	N	I-Premise
226	values	N	I-Premise
227	.	N	I-Premise

228	Maximum	N	I-Premise
229	exercise	N	I-Premise
230	capacity	N	I-Premise
231	and	N	I-Premise
232	maximum	N	I-Premise
233	oxygen	N	I-Premise
234	consumption	N	I-Premise
235	were	N	I-Premise
236	normalized	N	I-Premise
237	within	N	I-Premise
238	6	N	I-Premise
239	months	N	I-Premise
240	postoperatively	N	I-Premise
241	in	N	I-Premise
242	all	N	I-Premise
243	groups	N	I-Premise
244	.	N	I-Premise

245	There	N	I-Premise
246	was	N	I-Premise
247	no	N	I-Premise
248	difference	N	I-Premise
249	in	N	I-Premise
250	recovery	N	I-Premise
251	of	N	I-Premise
252	food	N	I-Premise
253	intake	N	I-Premise
254	among	N	I-Premise
255	the	N	I-Premise
256	groups	N	I-Premise
257	.	N	I-Premise

258	Parenteral	N	I-Claim
259	feeding	N	I-Claim
260	was	N	I-Claim
261	associated	N	I-Claim
262	with	N	I-Claim
263	the	N	I-Claim
264	highest	N	I-Claim
265	rate	N	I-Claim
266	of	N	I-Claim
267	nutrition-related	N	I-Claim
268	complications	N	I-Claim
269	,	N	I-Claim
270	whereas	N	O
271	enteral	N	I-Claim
272	feeding	N	I-Claim
273	reduced	N	I-Claim
274	quality	N	I-Claim
275	of	N	I-Claim
276	life	N	I-Claim
277	most	N	I-Claim
278	extensively	N	I-Claim
279	.	N	I-Claim

280	After	N	I-Claim
281	major	N	I-Claim
282	surgery	N	I-Claim
283	,	N	I-Claim
284	specialized	N	I-Claim
285	supportive	N	I-Claim
286	enteral	N	I-Claim
287	and	N	I-Claim
288	parenteral	N	I-Claim
289	nutrition	N	I-Claim
290	are	N	I-Claim
291	not	N	I-Claim
292	superior	N	I-Claim
293	to	N	I-Claim
294	oral	N	I-Claim
295	nutrition	N	I-Claim
296	only	N	I-Claim
297	when	N	I-Claim
298	guided	N	I-Claim
299	by	N	I-Claim
300	a	N	I-Claim
301	dietitian	N	I-Claim
302	.	N	I-Claim

1	Facial	N	I-Claim
2	hirsutism	N	I-Claim
3	is	N	I-Claim
4	one	N	I-Claim
5	of	N	I-Claim
6	the	N	I-Claim
7	characteristic	N	I-Claim
8	features	N	I-Claim
9	of	N	I-Claim
10	polycystic	N	I-Claim
11	ovary	N	I-Claim
12	syndrome	N	I-Claim
13	(	N	I-Claim
14	PCOS	N	I-Claim
15	)	N	I-Claim
16	,	N	I-Claim
17	and	N	I-Claim
18	this	N	I-Claim
19	can	N	I-Claim
20	lead	N	I-Claim
21	to	N	I-Claim
22	high	N	I-Claim
23	levels	N	I-Claim
24	of	N	I-Claim
25	depression	N	I-Claim
26	and	N	I-Claim
27	anxiety	N	I-Claim
28	.	N	I-Claim

29	To	N	O
30	evaluate	N	O
31	the	N	O
32	impact	N	O
33	of	N	O
34	laser	N	O
35	treatment	N	O
36	on	N	O
37	the	N	O
38	severity	N	O
39	of	N	O
40	facial	N	O
41	hirsutism	N	O
42	and	N	O
43	on	N	O
44	psychological	N	O
45	morbidity	N	O
46	in	N	O
47	women	N	O
48	with	N	O
49	PCOS	N	O
50	.	N	O

51	A	N	O
52	randomized	N	O
53	controlled	N	O
54	trial	N	O
55	of	N	O
56	five	N	O
57	high-fluence	N	O
58	treatments	N	O
59	(	N	O
60	intervention	N	O
61	)	N	O
62	vs.	N	O
63	five	N	O
64	low-fluence	N	O
65	treatments	N	O
66	(	N	O
67	control	N	O
68	)	N	O
69	was	N	O
70	performed	N	O
71	over	N	O
72	6	N	O
73	months	N	O
74	in	N	O
75	a	N	O
76	National	N	O
77	Health	N	O
78	Service	N	O
79	teaching	N	O
80	hospital	N	O
81	.	N	O

82	Subjects	N	O
83	were	N	O
84	88	N	O
85	women	N	O
86	with	N	O
87	facial	N	O
88	hirsutism	N	O
89	due	N	O
90	to	N	O
91	PCOS	N	O
92	recruited	N	O
93	from	N	O
94	hospital	N	O
95	outpatient	N	O
96	clinics	N	O
97	and	N	O
98	a	N	O
99	patient	N	O
100	support	N	O
101	group	N	O
102	in	N	O
103	2001-2002	N	O
104	.	N	O

105	The	N	O
106	main	N	O
107	outcomes	N	O
108	were	N	O
109	self-reported	N	O
110	severity	N	O
111	of	N	O
112	facial	N	O
113	hair	N	O
114	(	N	O
115	measured	N	O
116	on	N	O
117	a	N	O
118	scale	N	O
119	of	N	O
120	1-10	N	O
121	)	N	O
122	,	N	O
123	depression	N	O
124	,	N	O
125	anxiety	N	O
126	(	N	O
127	measured	N	O
128	on	N	O
129	the	N	O
130	Hospital	N	O
131	Anxiety	N	O
132	and	N	O
133	Depression	N	O
134	Scale	N	O
135	)	N	O
136	and	N	O
137	quality	N	O
138	of	N	O
139	life	N	O
140	(	N	O
141	measured	N	O
142	on	N	O
143	the	N	O
144	WHOQOL-BREF	N	O
145	)	N	O
146	.	N	O

147	Self-reported	N	I-Premise
148	severity	N	I-Premise
149	of	N	I-Premise
150	facial	N	I-Premise
151	hair	N	I-Premise
152	in	N	I-Premise
153	the	N	I-Premise
154	intervention	N	I-Premise
155	group	N	I-Premise
156	(	N	I-Premise
157	n	N	I-Premise
158	=	N	I-Premise
159	51	N	I-Premise
160	)	N	I-Premise
161	fell	N	I-Premise
162	from	N	I-Premise
163	7.3	N	I-Premise
164	to	N	I-Premise
165	3.6	N	I-Premise
166	over	N	I-Premise
167	the	N	I-Premise
168	6-month	N	I-Premise
169	study	N	I-Premise
170	period	N	I-Premise
171	;	N	I-Premise
172	for	N	I-Premise
173	the	N	I-Premise
174	control	N	I-Premise
175	group	N	I-Premise
176	(	N	I-Premise
177	n	N	I-Premise
178	=	N	I-Premise
179	37	N	I-Premise
180	)	N	I-Premise
181	the	N	I-Premise
182	corresponding	N	I-Premise
183	scores	N	I-Premise
184	were	N	I-Premise
185	7.1	N	I-Premise
186	and	N	I-Premise
187	6.1	N	I-Premise
188	.	N	I-Premise

189	The	N	I-Premise
190	change	N	I-Premise
191	was	N	I-Premise
192	significantly	N	I-Premise
193	greater	N	I-Premise
194	in	N	I-Premise
195	the	N	I-Premise
196	intervention	N	I-Premise
197	group	N	I-Premise
198	[	N	I-Premise
199	ancova	N	I-Premise
200	F	N	I-Premise
201	(	N	I-Premise
202	(	N	I-Premise
203	1,83	N	I-Premise
204	)	N	I-Premise
205	)	N	I-Premise
206	=	N	I-Premise
207	24.5	N	I-Premise
208	,	N	I-Premise
209	P	N	I-Premise
210	<	N	I-Premise
211	0.05	N	I-Premise
212	]	N	I-Premise
213	.	N	I-Premise

214	Self-reported	N	I-Premise
215	time	N	I-Premise
216	spent	N	I-Premise
217	on	N	I-Premise
218	hair	N	I-Premise
219	removal	N	I-Premise
220	declined	N	I-Premise
221	from	N	I-Premise
222	112	N	I-Premise
223	to	N	I-Premise
224	21	N	I-Premise
225	min	N	I-Premise
226	per	N	I-Premise
227	week	N	I-Premise
228	in	N	I-Premise
229	the	N	I-Premise
230	intervention	N	I-Premise
231	group	N	I-Premise
232	and	N	I-Premise
233	from	N	I-Premise
234	92	N	I-Premise
235	to	N	I-Premise
236	56	N	I-Premise
237	min	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	control	N	I-Premise
241	group	N	I-Premise
242	[	N	I-Premise
243	F	N	I-Premise
244	(	N	I-Premise
245	(	N	I-Premise
246	1,80	N	I-Premise
247	)	N	I-Premise
248	)	N	I-Premise
249	=	N	I-Premise
250	10.2	N	I-Premise
251	,	N	I-Premise
252	P	N	I-Premise
253	<	N	I-Premise
254	/=	N	I-Premise
255	0.05	N	I-Premise
256	]	N	I-Premise
257	.	N	I-Premise

258	Mean	N	I-Premise
259	depression	N	I-Premise
260	scores	N	I-Premise
261	fell	N	I-Premise
262	from	N	I-Premise
263	6.7	N	I-Premise
264	to	N	I-Premise
265	3.6	N	I-Premise
266	in	N	I-Premise
267	the	N	I-Premise
268	intervention	N	I-Premise
269	group	N	I-Premise
270	,	N	I-Premise
271	compared	N	I-Premise
272	with	N	I-Premise
273	6.1	N	I-Premise
274	to	N	I-Premise
275	5.4	N	I-Premise
276	in	N	I-Premise
277	the	N	I-Premise
278	control	N	I-Premise
279	group	N	I-Premise
280	[	N	I-Premise
281	F	N	I-Premise
282	(	N	I-Premise
283	(	N	I-Premise
284	1,83	N	I-Premise
285	)	N	I-Premise
286	)	N	I-Premise
287	=	N	I-Premise
288	14.7	N	I-Premise
289	,	N	I-Premise
290	P	N	I-Premise
291	<	N	I-Premise
292	0.05	N	I-Premise
293	]	N	I-Premise
294	.	N	I-Premise

295	A	N	I-Premise
296	similar	N	I-Premise
297	change	N	I-Premise
298	was	N	I-Premise
299	seen	N	I-Premise
300	for	N	I-Premise
301	mean	N	I-Premise
302	anxiety	N	I-Premise
303	scores	N	I-Premise
304	:	N	I-Premise
305	intervention	N	I-Premise
306	11.1	N	I-Premise
307	to	N	I-Premise
308	8.2	N	I-Premise
309	,	N	I-Premise
310	control	N	I-Premise
311	9.6	N	I-Premise
312	to	N	I-Premise
313	9.3	N	I-Premise
314	[	N	I-Premise
315	F	N	I-Premise
316	(	N	I-Premise
317	(	N	I-Premise
318	1,84	N	I-Premise
319	)	N	I-Premise
320	)	N	I-Premise
321	=	N	I-Premise
322	17.8	N	I-Premise
323	,	N	I-Premise
324	P	N	I-Premise
325	<	N	I-Premise
326	0.05	N	I-Premise
327	]	N	I-Premise
328	.	N	I-Premise

329	Psychological	N	I-Premise
330	quality	N	I-Premise
331	of	N	I-Premise
332	life	N	I-Premise
333	also	N	I-Premise
334	improved	N	I-Premise
335	more	N	I-Premise
336	in	N	I-Premise
337	the	N	I-Premise
338	intervention	N	I-Premise
339	group	N	I-Premise
340	,	N	I-Premise
341	from	N	I-Premise
342	49.6	N	I-Premise
343	to	N	I-Premise
344	61.2	N	I-Premise
345	vs.	N	I-Premise
346	50.1	N	I-Premise
347	to	N	I-Premise
348	51.5	N	I-Premise
349	in	N	I-Premise
350	the	N	I-Premise
351	control	N	I-Premise
352	group	N	I-Premise
353	[	N	I-Premise
354	F	N	I-Premise
355	(	N	I-Premise
356	(	N	I-Premise
357	1,84	N	I-Premise
358	)	N	I-Premise
359	)	N	I-Premise
360	=	N	I-Premise
361	10.9	N	I-Premise
362	,	N	I-Premise
363	P	N	I-Premise
364	<	N	I-Premise
365	0.05	N	I-Premise
366	]	N	I-Premise
367	.	N	I-Premise

368	Laser	N	I-Claim
369	treatment	N	I-Claim
370	appeared	N	I-Claim
371	to	N	I-Claim
372	reduce	N	I-Claim
373	the	N	I-Claim
374	severity	N	I-Claim
375	of	N	I-Claim
376	facial	N	I-Claim
377	hair	N	I-Claim
378	and	N	I-Claim
379	time	N	I-Claim
380	spent	N	I-Claim
381	on	N	I-Claim
382	hair	N	I-Claim
383	removal	N	I-Claim
384	as	N	I-Claim
385	well	N	I-Claim
386	as	N	I-Claim
387	alleviating	N	I-Claim
388	depression	N	I-Claim
389	and	N	I-Claim
390	anxiety	N	I-Claim
391	in	N	I-Claim
392	women	N	I-Claim
393	with	N	I-Claim
394	PCOS	N	I-Claim
395	.	N	I-Claim

396	These	N	I-Claim
397	findings	N	I-Claim
398	suggest	N	I-Claim
399	that	N	I-Claim
400	ways	N	I-Claim
401	of	N	I-Claim
402	making	N	I-Claim
403	this	N	I-Claim
404	method	N	I-Claim
405	of	N	I-Claim
406	hair	N	I-Claim
407	removal	N	I-Claim
408	more	N	I-Claim
409	widely	N	I-Claim
410	available	N	I-Claim
411	to	N	I-Claim
412	women	N	I-Claim
413	with	N	I-Claim
414	facial	N	I-Claim
415	hirsutism	N	I-Claim
416	should	N	I-Claim
417	be	N	I-Claim
418	considered	N	I-Claim
419	.	N	I-Claim

1	For	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	anthracycline-pretreated	N	I-Claim
5	metastatic	N	I-Claim
6	breast	N	I-Claim
7	carcinoma	N	I-Claim
8	,	N	I-Claim
9	capecitabine	N	I-Claim
10	plus	N	I-Claim
11	docetaxel	N	I-Claim
12	significantly	N	I-Claim
13	increased	N	I-Claim
14	overall	N	I-Claim
15	survival	N	I-Claim
16	compared	N	I-Claim
17	with	N	I-Claim
18	docetaxel	N	I-Claim
19	alone	N	I-Claim
20	.	N	I-Claim

21	The	N	O
22	current	N	O
23	study	N	O
24	evaluated	N	O
25	the	N	O
26	cost-effectiveness	N	O
27	of	N	O
28	the	N	O
29	capecitabine/docetaxel	N	O
30	combination	N	O
31	versus	N	O
32	docetaxel	N	O
33	monotherapy	N	O
34	,	N	O
35	comparing	N	O
36	the	N	O
37	gain	N	O
38	in	N	O
39	quality-adjusted	N	O
40	survival	N	O
41	with	N	O
42	associated	N	O
43	health	N	O
44	care	N	O
45	costs	N	O
46	.	N	O

47	Patients	N	O
48	were	N	O
49	randomized	N	O
50	to	N	O
51	receive	N	O
52	21-day	N	O
53	cycles	N	O
54	of	N	O
55	oral	N	O
56	capecitabine	N	O
57	1250	N	O
58	mg/m2	N	O
59	twice	N	O
60	daily	N	O
61	,	N	O
62	on	N	O
63	Days	N	O
64	1-14	N	O
65	,	N	O
66	plus	N	O
67	docetaxel	N	O
68	75	N	O
69	mg/m2	N	O
70	Day	N	O
71	1	N	O
72	(	N	O
73	n	N	O
74	=	N	O
75	255	N	O
76	)	N	O
77	,	N	O
78	or	N	O
79	docetaxel	N	O
80	100	N	O
81	mg/m2	N	O
82	on	N	O
83	Day	N	O
84	1	N	O
85	(	N	O
86	n	N	O
87	=	N	O
88	256	N	O
89	)	N	O
90	.	N	O

91	Health	N	O
92	and	N	O
93	cost	N	O
94	outcomes	N	O
95	in	N	O
96	the	N	O
97	two	N	O
98	arms	N	O
99	were	N	O
100	compared	N	O
101	,	N	O
102	and	N	O
103	cost-effectiveness	N	O
104	was	N	O
105	estimated	N	O
106	.	N	O

107	Data	N	O
108	on	N	O
109	survival	N	O
110	time	N	O
111	and	N	O
112	medical	N	O
113	care	N	O
114	resource	N	O
115	use	N	O
116	were	N	O
117	prospectively	N	O
118	collected	N	O
119	in	N	O
120	the	N	O
121	trial	N	O
122	.	N	O

123	Costs	N	O
124	associated	N	O
125	with	N	O
126	medical	N	O
127	care	N	O
128	resource	N	O
129	use	N	O
130	and	N	O
131	quality-of-life	N	O
132	adjustments	N	O
133	were	N	O
134	obtained	N	O
135	from	N	O
136	the	N	O
137	published	N	O
138	literature	N	O
139	.	N	O

140	The	N	O
141	incremental	N	O
142	cost-effectiveness	N	O
143	ratio	N	O
144	was	N	O
145	calculated	N	O
146	as	N	O
147	the	N	O
148	cost	N	O
149	per	N	O
150	quality-adjusted	N	O
151	life	N	O
152	year	N	O
153	(	N	O
154	QALY	N	O
155	)	N	O
156	gained	N	O
157	.	N	O

158	Capecitabine/docetaxel	N	I-Premise
159	increased	N	I-Premise
160	the	N	I-Premise
161	median	N	I-Premise
162	overall	N	I-Premise
163	survival	N	I-Premise
164	by	N	I-Premise
165	3	N	I-Premise
166	months	N	I-Premise
167	compared	N	I-Premise
168	with	N	I-Premise
169	docetaxel	N	I-Premise
170	alone	N	I-Premise
171	(	N	I-Premise
172	14.5	N	I-Premise
173	vs.	N	I-Premise
174	11.5	N	I-Premise
175	months	N	I-Premise
176	)	N	I-Premise
177	.	N	I-Premise

178	The	N	I-Premise
179	mean	N	I-Premise
180	quality-adjusted	N	I-Premise
181	survival	N	I-Premise
182	was	N	I-Premise
183	increased	N	I-Premise
184	by	N	I-Premise
185	1.8	N	I-Premise
186	months	N	I-Premise
187	in	N	I-Premise
188	the	N	I-Premise
189	capecitabine/docetaxel	N	I-Premise
190	group	N	I-Premise
191	.	N	I-Premise

192	The	N	I-Premise
193	total	N	I-Premise
194	medical-resource	N	I-Premise
195	utilization	N	I-Premise
196	cost	N	I-Premise
197	per	N	I-Premise
198	patient	N	I-Premise
199	was	N	I-Premise
200	8.9	N	I-Premise
201	%	N	I-Premise
202	higher	N	I-Premise
203	with	N	I-Premise
204	the	N	I-Premise
205	combination	N	I-Premise
206	:	N	I-Premise
207	24,475	N	I-Premise
208	dollars	N	I-Premise
209	for	N	I-Premise
210	combination	N	I-Premise
211	therapy	N	I-Premise
212	versus	N	I-Premise
213	22,477	N	I-Premise
214	dollars	N	I-Premise
215	for	N	I-Premise
216	single-agent	N	I-Premise
217	docetaxel	N	I-Premise
218	.	N	I-Premise

219	The	N	I-Premise
220	mean	N	I-Premise
221	cost	N	I-Premise
222	per	N	I-Premise
223	QALY	N	I-Premise
224	gained	N	I-Premise
225	with	N	I-Premise
226	combination	N	I-Premise
227	therapy	N	I-Premise
228	was	N	I-Premise
229	13,558	N	I-Premise
230	dollars	N	I-Premise
231	(	N	I-Premise
232	standard	N	I-Premise
233	deviation	N	I-Premise
234	,	N	I-Premise
235	6742	N	I-Premise
236	dollars	N	I-Premise
237	)	N	I-Premise
238	.	N	I-Premise

239	Cost	N	I-Premise
240	savings	N	I-Premise
241	due	N	I-Premise
242	to	N	I-Premise
243	reduced	N	I-Premise
244	docetaxel	N	I-Premise
245	dose	N	I-Premise
246	and	N	I-Premise
247	hospital	N	I-Premise
248	use	N	I-Premise
249	were	N	I-Premise
250	the	N	I-Premise
251	major	N	I-Premise
252	cost	N	I-Premise
253	offsets	N	I-Premise
254	with	N	I-Premise
255	the	N	I-Premise
256	combination	N	I-Premise
257	.	N	I-Premise

258	Sensitivity	N	I-Premise
259	analyses	N	I-Premise
260	showed	N	I-Premise
261	that	N	I-Premise
262	varying	N	I-Premise
263	the	N	I-Premise
264	mean	N	I-Premise
265	hospital	N	I-Premise
266	cost	N	I-Premise
267	per	N	I-Premise
268	day	N	I-Premise
269	from	N	I-Premise
270	the	N	I-Premise
271	5th	N	I-Premise
272	to	N	I-Premise
273	the	N	I-Premise
274	95th	N	I-Premise
275	percentile	N	I-Premise
276	resulted	N	I-Premise
277	in	N	I-Premise
278	cost-utility	N	I-Premise
279	ratios	N	I-Premise
280	ranging	N	I-Premise
281	from	N	I-Premise
282	20,326	N	I-Premise
283	dollars	N	I-Premise
284	to	N	I-Premise
285	as	N	I-Premise
286	low	N	I-Premise
287	as	N	I-Premise
288	6360	N	I-Premise
289	dollars	N	I-Premise
290	.	N	I-Premise

291	Capecitabine/docetaxel	N	I-Claim
292	was	N	I-Claim
293	a	N	I-Claim
294	cost-effective	N	I-Claim
295	treatment	N	I-Claim
296	in	N	I-Claim
297	patients	N	I-Claim
298	with	N	I-Claim
299	anthracycline-pretreated	N	I-Claim
300	advanced	N	I-Claim
301	breast	N	I-Claim
302	carcinoma	N	I-Claim
303	,	N	I-Claim
304	and	N	I-Claim
305	had	N	I-Claim
306	an	N	I-Claim
307	incremental	N	I-Claim
308	cost-effectiveness	N	I-Claim
309	ratio	N	I-Claim
310	that	N	I-Claim
311	compares	N	I-Claim
312	very	N	I-Claim
313	favorably	N	I-Claim
314	with	N	I-Claim
315	that	N	I-Claim
316	of	N	I-Claim
317	many	N	I-Claim
318	other	N	I-Claim
319	oncology	N	I-Claim
320	therapies	N	I-Claim
321	.	N	I-Claim

1	We	N	O
2	aimed	N	O
3	to	N	O
4	determine	N	O
5	the	N	O
6	effect	N	O
7	of	N	O
8	dietary	N	O
9	counseling	N	O
10	or	N	O
11	oral	N	O
12	supplements	N	O
13	on	N	O
14	outcome	N	O
15	for	N	O
16	patients	N	O
17	with	N	O
18	cancer	N	O
19	,	N	O
20	specifically	N	O
21	,	N	O
22	nutritional	N	O
23	outcome	N	O
24	,	N	O
25	morbidity	N	O
26	,	N	O
27	and	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	(	N	O
32	QOL	N	O
33	)	N	O
34	,	N	O
35	during	N	O
36	and	N	O
37	3	N	O
38	months	N	O
39	after	N	O
40	radiotherapy	N	O
41	.	N	O

42	Seventy-five	N	O
43	patients	N	O
44	with	N	O
45	head	N	O
46	and	N	O
47	neck	N	O
48	cancer	N	O
49	who	N	O
50	were	N	O
51	referred	N	O
52	for	N	O
53	radiotherapy	N	O
54	(	N	O
55	RT	N	O
56	)	N	O
57	were	N	O
58	randomized	N	O
59	to	N	O
60	the	N	O
61	following	N	O
62	groups	N	O
63	:	N	O
64	group	N	O
65	1	N	O
66	(	N	O
67	n	N	O
68	=	N	O
69	25	N	O
70	)	N	O
71	,	N	O
72	patients	N	O
73	who	N	O
74	received	N	O
75	dietary	N	O
76	counseling	N	O
77	with	N	O
78	regular	N	O
79	foods	N	O
80	;	N	O
81	group	N	O
82	2	N	O
83	(	N	O
84	n	N	O
85	=	N	O
86	25	N	O
87	)	N	O
88	,	N	O
89	patients	N	O
90	who	N	O
91	maintained	N	O
92	usual	N	O
93	diet	N	O
94	plus	N	O
95	supplements	N	O
96	;	N	O
97	and	N	O
98	group	N	O
99	3	N	O
100	(	N	O
101	n	N	O
102	=	N	O
103	25	N	O
104	)	N	O
105	,	N	O
106	patients	N	O
107	who	N	O
108	maintained	N	O
109	intake	N	O
110	ad	N	O
111	lib	N	O
112	.	N	O

113	Nutritional	N	O
114	intake	N	O
115	(	N	O
116	determined	N	O
117	by	N	O
118	diet	N	O
119	history	N	O
120	)	N	O
121	and	N	O
122	status	N	O
123	(	N	O
124	determined	N	O
125	by	N	O
126	Ottery	N	O
127	's	N	O
128	Subjective	N	O
129	Global	N	O
130	Assessment	N	O
131	)	N	O
132	,	N	O
133	and	N	O
134	QOL	N	O
135	(	N	O
136	determined	N	O
137	by	N	O
138	the	N	O
139	European	N	O
140	Organization	N	O
141	for	N	O
142	the	N	O
143	Research	N	O
144	and	N	O
145	Treatment	N	O
146	of	N	O
147	Cancer	N	O
148	Quality	N	O
149	of	N	O
150	Life	N	O
151	Questionnaire	N	O
152	version	N	O
153	3.0	N	O
154	[	N	O
155	EORTC	N	O
156	QLQ-C30	N	O
157	]	N	O
158	)	N	O
159	were	N	O
160	evaluated	N	O
161	at	N	O
162	baseline	N	O
163	,	N	O
164	at	N	O
165	the	N	O
166	end	N	O
167	of	N	O
168	RT	N	O
169	,	N	O
170	and	N	O
171	at	N	O
172	3	N	O
173	months	N	O
174	.	N	O

175	Energy	N	I-Premise
176	intake	N	I-Premise
177	after	N	I-Premise
178	RT	N	I-Premise
179	increased	N	I-Premise
180	in	N	I-Premise
181	both	N	I-Premise
182	groups	N	I-Premise
183	1	N	I-Premise
184	and	N	I-Premise
185	2	N	I-Premise
186	(	N	I-Premise
187	p	N	I-Premise
188	<	N	I-Premise
189	or	N	I-Premise
190	=	N	I-Premise
191	.05	N	I-Premise
192	)	N	I-Premise
193	.	N	I-Premise

194	Protein	N	I-Premise
195	intake	N	I-Premise
196	also	N	I-Premise
197	increased	N	I-Premise
198	in	N	I-Premise
199	both	N	I-Premise
200	groups	N	I-Premise
201	1	N	I-Premise
202	and	N	I-Premise
203	2	N	I-Premise
204	(	N	I-Premise
205	p	N	I-Premise
206	<	N	I-Premise
207	or	N	I-Premise
208	=	N	I-Premise
209	.006	N	I-Premise
210	)	N	I-Premise
211	.	N	I-Premise

212	Both	N	I-Premise
213	energy	N	I-Premise
214	and	N	I-Premise
215	protein	N	I-Premise
216	intake	N	I-Premise
217	decreased	N	I-Premise
218	significantly	N	I-Premise
219	in	N	I-Premise
220	group	N	I-Premise
221	3	N	I-Premise
222	(	N	I-Premise
223	p	N	I-Premise
224	<	N	I-Premise
225	.01	N	I-Premise
226	)	N	I-Premise
227	.	N	I-Premise

228	At	N	I-Premise
229	3	N	I-Premise
230	months	N	I-Premise
231	,	N	I-Premise
232	group	N	I-Premise
233	1	N	I-Premise
234	maintained	N	I-Premise
235	intakes	N	I-Premise
236	,	N	I-Premise
237	whereas	N	I-Premise
238	groups	N	I-Premise
239	2	N	I-Premise
240	and	N	I-Premise
241	3	N	I-Premise
242	returned	N	I-Premise
243	to	N	I-Premise
244	or	N	I-Premise
245	below	N	I-Premise
246	baseline	N	I-Premise
247	levels	N	I-Premise
248	.	N	I-Premise

249	After	N	I-Premise
250	RT	N	I-Premise
251	,	N	I-Premise
252	>	N	I-Premise
253	90	N	I-Premise
254	%	N	I-Premise
255	of	N	I-Premise
256	patients	N	I-Premise
257	experienced	N	I-Premise
258	RT	N	I-Premise
259	toxicity	N	I-Premise
260	;	N	I-Premise
261	this	N	I-Premise
262	was	N	I-Premise
263	not	N	I-Premise
264	significantly	N	I-Premise
265	different	N	I-Premise
266	between	N	I-Premise
267	groups	N	I-Premise
268	,	N	I-Premise
269	with	N	I-Premise
270	a	N	I-Premise
271	trend	N	I-Premise
272	for	N	I-Premise
273	reduced	N	I-Premise
274	symptomatology	N	I-Premise
275	in	N	I-Premise
276	group	N	I-Premise
277	1	N	I-Premise
278	versus	N	I-Premise
279	group	N	I-Premise
280	2/group	N	I-Premise
281	3	N	I-Premise
282	(	N	I-Premise
283	p	N	I-Premise
284	<	N	I-Premise
285	.07	N	I-Premise
286	)	N	I-Premise
287	.	N	I-Premise

288	At	N	I-Premise
289	3	N	I-Premise
290	months	N	I-Premise
291	,	N	I-Premise
292	the	N	I-Premise
293	reduction	N	I-Premise
294	of	N	I-Premise
295	incidence/severity	N	I-Premise
296	of	N	I-Premise
297	grade	N	I-Premise
298	1+2	N	I-Premise
299	anorexia	N	I-Premise
300	,	N	I-Premise
301	nausea/vomiting	N	I-Premise
302	,	N	I-Premise
303	xerostomia	N	I-Premise
304	,	N	I-Premise
305	and	N	I-Premise
306	dysgeusia	N	I-Premise
307	was	N	I-Premise
308	different	N	I-Premise
309	:	N	I-Premise
310	90	N	I-Premise
311	%	N	I-Premise
312	of	N	I-Premise
313	the	N	I-Premise
314	patients	N	I-Premise
315	improved	N	I-Premise
316	in	N	I-Premise
317	group	N	I-Premise
318	1	N	I-Premise
319	versus	N	I-Premise
320	67	N	I-Premise
321	%	N	I-Premise
322	in	N	I-Premise
323	group	N	I-Premise
324	2	N	I-Premise
325	versus	N	I-Premise
326	51	N	I-Premise
327	%	N	I-Premise
328	in	N	I-Premise
329	group	N	I-Premise
330	3	N	I-Premise
331	(	N	I-Premise
332	p	N	I-Premise
333	<	N	I-Premise
334	.0001	N	I-Premise
335	)	N	I-Premise
336	.	N	I-Premise

337	After	N	I-Premise
338	RT	N	I-Premise
339	,	N	I-Premise
340	QOL	N	I-Premise
341	function	N	I-Premise
342	scores	N	I-Premise
343	improved	N	I-Premise
344	(	N	I-Premise
345	p	N	I-Premise
346	<	N	I-Premise
347	.003	N	I-Premise
348	)	N	I-Premise
349	proportionally	N	I-Premise
350	with	N	I-Premise
351	improved	N	I-Premise
352	nutritional	N	I-Premise
353	intake	N	I-Premise
354	and	N	I-Premise
355	status	N	I-Premise
356	in	N	I-Premise
357	group	N	I-Premise
358	1/group	N	I-Premise
359	2	N	I-Premise
360	(	N	I-Premise
361	p	N	I-Premise
362	<	N	I-Premise
363	.05	N	I-Premise
364	)	N	I-Premise
365	and	N	I-Premise
366	worsened	N	I-Premise
367	in	N	I-Premise
368	group	N	I-Premise
369	3	N	I-Premise
370	(	N	I-Premise
371	p	N	I-Premise
372	<	N	I-Premise
373	.05	N	I-Premise
374	)	N	I-Premise
375	;	N	I-Premise
376	at	N	I-Premise
377	3	N	I-Premise
378	months	N	I-Premise
379	,	N	I-Premise
380	patients	N	I-Premise
381	in	N	I-Premise
382	group	N	I-Premise
383	1	N	I-Premise
384	maintained	N	I-Premise
385	or	N	I-Premise
386	improved	N	I-Premise
387	overall	N	I-Premise
388	QOL	N	I-Premise
389	,	N	I-Premise
390	whereas	N	I-Premise
391	patients	N	I-Premise
392	in	N	I-Premise
393	groups	N	I-Premise
394	2	N	I-Premise
395	and	N	I-Premise
396	3	N	I-Premise
397	maintained	N	I-Premise
398	or	N	I-Premise
399	worsened	N	I-Premise
400	overall	N	I-Premise
401	QOL	N	I-Premise
402	.	N	I-Premise

403	During	N	I-Claim
404	RT	N	I-Claim
405	,	N	I-Claim
406	nutritional	N	I-Claim
407	interventions	N	I-Claim
408	positively	N	I-Claim
409	influenced	N	I-Claim
410	outcomes	N	I-Claim
411	,	N	I-Claim
412	and	N	I-Claim
413	counseling	N	I-Claim
414	was	N	I-Claim
415	of	N	I-Claim
416	similar/higher	N	I-Claim
417	benefit	N	I-Claim
418	;	N	I-Claim
419	in	N	I-Claim
420	the	N	I-Claim
421	medium	N	I-Claim
422	term	N	I-Claim
423	,	N	I-Claim
424	only	N	I-Claim
425	counseling	N	I-Claim
426	exerted	N	I-Claim
427	a	N	I-Claim
428	significant	N	I-Claim
429	impact	N	I-Claim
430	on	N	I-Claim
431	patient	N	I-Claim
432	outcomes	N	I-Claim
433	.	N	I-Claim

1	This	N	O
2	is	N	O
3	a	N	O
4	randomized	N	O
5	phase	N	O
6	II	N	O
7	study	N	O
8	designed	N	O
9	to	N	O
10	compare	N	O
11	the	N	O
12	toxicity	N	O
13	profile	N	O
14	of	N	O
15	a	N	O
16	non-platinum-based	N	O
17	with	N	O
18	a	N	O
19	platinum-based	N	O
20	regimen	N	O
21	in	N	O
22	the	N	O
23	treatment	N	O
24	of	N	O
25	advanced	N	O
26	non-small	N	O
27	cell	N	O
28	lung	N	O
29	cancer	N	O
30	.	N	O

31	Eighty-nine	N	O
32	chemotherapy-nave	N	O
33	patients	N	O
34	were	N	O
35	randomized	N	O
36	either	N	O
37	to	N	O
38	gemcitabine	N	O
39	(	N	O
40	1,000	N	O
41	mg/m2	N	O
42	,	N	O
43	30-min	N	O
44	infusion	N	O
45	on	N	O
46	days	N	O
47	1	N	O
48	,	N	O
49	8	N	O
50	and	N	O
51	15	N	O
52	)	N	O
53	and	N	O
54	oral	N	O
55	etoposide	N	O
56	(	N	O
57	50	N	O
58	mg	N	O
59	,	N	O
60	days	N	O
61	1-14	N	O
62	;	N	O
63	GE	N	O
64	group	N	O
65	)	N	O
66	or	N	O
67	gemcitabine	N	O
68	at	N	O
69	the	N	O
70	same	N	O
71	schedule	N	O
72	and	N	O
73	cisplatin	N	O
74	(	N	O
75	75	N	O
76	mg/m2	N	O
77	on	N	O
78	day	N	O
79	15	N	O
80	;	N	O
81	GP	N	O
82	group	N	O
83	)	N	O
84	.	N	O

85	The	N	O
86	primary	N	O
87	endpoint	N	O
88	is	N	O
89	toxicity	N	O
90	,	N	O
91	and	N	O
92	secondary	N	O
93	endpoints	N	O
94	include	N	O
95	response	N	O
96	rate	N	O
97	,	N	O
98	survival	N	O
99	outcome	N	O
100	and	N	O
101	quality	N	O
102	of	N	O
103	life	N	O
104	(	N	O
105	QOL	N	O
106	)	N	O
107	.	N	O

108	The	N	I-Premise
109	incidence	N	I-Premise
110	of	N	I-Premise
111	WHO	N	I-Premise
112	grade	N	I-Premise
113	3	N	I-Premise
114	or	N	I-Premise
115	4	N	I-Premise
116	anemia	N	I-Premise
117	,	N	I-Premise
118	neutropenia	N	I-Premise
119	and	N	I-Premise
120	thrombocytopenia	N	I-Premise
121	was	N	I-Premise
122	29	N	I-Premise
123	,	N	I-Premise
124	44	N	I-Premise
125	and	N	I-Premise
126	22	N	I-Premise
127	%	N	I-Premise
128	(	N	I-Premise
129	GE	N	I-Premise
130	group	N	I-Premise
131	)	N	I-Premise
132	,	N	I-Premise
133	and	N	I-Premise
134	28	N	I-Premise
135	,	N	I-Premise
136	49	N	I-Premise
137	and	N	I-Premise
138	23	N	I-Premise
139	%	N	I-Premise
140	(	N	I-Premise
141	GP	N	I-Premise
142	group	N	I-Premise
143	)	N	I-Premise
144	,	N	I-Premise
145	respectively	N	I-Premise
146	(	N	I-Premise
147	p	N	I-Premise
148	=	N	I-Premise
149	0.75	N	I-Premise
150	,	N	I-Premise
151	0.95	N	I-Premise
152	and	N	I-Premise
153	0.87	N	I-Premise
154	,	N	I-Premise
155	respectively	N	I-Premise
156	)	N	I-Premise
157	.	N	I-Premise

158	The	N	I-Premise
159	rate	N	I-Premise
160	of	N	I-Premise
161	grade	N	I-Premise
162	2	N	I-Premise
163	or	N	I-Premise
164	above	N	I-Premise
165	nausea	N	I-Premise
166	was	N	I-Premise
167	numerically	N	I-Premise
168	higher	N	I-Premise
169	in	N	I-Premise
170	the	N	I-Premise
171	GP	N	I-Premise
172	arm	N	I-Premise
173	,	N	I-Premise
174	but	N	I-Premise
175	the	N	I-Premise
176	difference	N	I-Premise
177	was	N	I-Premise
178	not	N	I-Premise
179	statistically	N	I-Premise
180	significant	N	I-Premise
181	(	N	I-Premise
182	GE	N	I-Premise
183	15.5	N	I-Premise
184	%	N	I-Premise
185	,	N	I-Premise
186	GP	N	I-Premise
187	27.7	N	I-Premise
188	%	N	I-Premise
189	,	N	I-Premise
190	p	N	I-Premise
191	=	N	I-Premise
192	0.20	N	I-Premise
193	)	N	I-Premise
194	.	N	I-Premise

195	The	N	I-Premise
196	rate	N	I-Premise
197	of	N	I-Premise
198	vomiting	N	I-Premise
199	in	N	I-Premise
200	the	N	I-Premise
201	GE	N	I-Premise
202	and	N	I-Premise
203	GP	N	I-Premise
204	arms	N	I-Premise
205	was	N	I-Premise
206	20.0	N	I-Premise
207	and	N	I-Premise
208	20.5	N	I-Premise
209	%	N	I-Premise
210	,	N	I-Premise
211	respectively	N	I-Premise
212	(	N	I-Premise
213	p	N	I-Premise
214	=	N	I-Premise
215	0.96	N	I-Premise
216	)	N	I-Premise
217	.	N	I-Premise

218	However	N	I-Premise
219	,	N	I-Premise
220	subjective	N	I-Premise
221	changes	N	I-Premise
222	in	N	I-Premise
223	QOL	N	I-Premise
224	scores	N	I-Premise
225	on	N	I-Premise
226	nausea	N	I-Premise
227	and	N	I-Premise
228	vomiting	N	I-Premise
229	were	N	I-Premise
230	significantly	N	I-Premise
231	higher	N	I-Premise
232	in	N	I-Premise
233	the	N	I-Premise
234	GP	N	I-Premise
235	arm	N	I-Premise
236	(	N	I-Premise
237	p	N	I-Premise
238	=	N	I-Premise
239	0.001	N	I-Premise
240	)	N	I-Premise
241	.	N	I-Premise

242	Other	N	I-Premise
243	symptoms	N	I-Premise
244	including	N	I-Premise
245	sore	N	I-Premise
246	mouth	N	I-Premise
247	and	N	I-Premise
248	hair	N	I-Premise
249	loss	N	I-Premise
250	were	N	I-Premise
251	significantly	N	I-Premise
252	higher	N	I-Premise
253	in	N	I-Premise
254	the	N	I-Premise
255	GE	N	I-Premise
256	arm	N	I-Premise
257	(	N	I-Premise
258	p	N	I-Premise
259	=	N	I-Premise
260	0.003	N	I-Premise
261	and	N	I-Premise
262	0.007	N	I-Premise
263	,	N	I-Premise
264	respectively	N	I-Premise
265	)	N	I-Premise
266	.	N	I-Premise

267	There	N	I-Premise
268	were	N	I-Premise
269	also	N	I-Premise
270	significant	N	I-Premise
271	differences	N	I-Premise
272	observed	N	I-Premise
273	in	N	I-Premise
274	emotional	N	I-Premise
275	(	N	I-Premise
276	p	N	I-Premise
277	=	N	I-Premise
278	0.014	N	I-Premise
279	)	N	I-Premise
280	,	N	I-Premise
281	cognitive	N	I-Premise
282	(	N	I-Premise
283	p	N	I-Premise
284	=	N	I-Premise
285	0.028	N	I-Premise
286	)	N	I-Premise
287	and	N	I-Premise
288	social	N	I-Premise
289	functioning	N	I-Premise
290	(	N	I-Premise
291	p	N	I-Premise
292	=	N	I-Premise
293	0.034	N	I-Premise
294	)	N	I-Premise
295	in	N	I-Premise
296	favor	N	I-Premise
297	of	N	I-Premise
298	GP	N	I-Premise
299	.	N	I-Premise

300	The	N	I-Premise
301	differences	N	I-Premise
302	in	N	I-Premise
303	tumor	N	I-Premise
304	response	N	I-Premise
305	(	N	I-Premise
306	35.5	N	I-Premise
307	and	N	I-Premise
308	46.5	N	I-Premise
309	%	N	I-Premise
310	for	N	I-Premise
311	GE	N	I-Premise
312	and	N	I-Premise
313	GP	N	I-Premise
314	,	N	I-Premise
315	respectively	N	I-Premise
316	)	N	I-Premise
317	were	N	I-Premise
318	not	N	I-Premise
319	significantly	N	I-Premise
320	different	N	I-Premise
321	.	N	I-Premise

322	Median	N	I-Premise
323	time	N	I-Premise
324	to	N	I-Premise
325	disease	N	I-Premise
326	progression	N	I-Premise
327	(	N	I-Premise
328	33.8	N	I-Premise
329	and	N	I-Premise
330	40.7	N	I-Premise
331	weeks	N	I-Premise
332	,	N	I-Premise
333	respectively	N	I-Premise
334	)	N	I-Premise
335	and	N	I-Premise
336	overall	N	I-Premise
337	survival	N	I-Premise
338	(	N	I-Premise
339	41.4	N	I-Premise
340	and	N	I-Premise
341	57.3	N	I-Premise
342	weeks	N	I-Premise
343	,	N	I-Premise
344	respectively	N	I-Premise
345	)	N	I-Premise
346	were	N	I-Premise
347	of	N	I-Premise
348	borderline	N	I-Premise
349	significance	N	I-Premise
350	in	N	I-Premise
351	favor	N	I-Premise
352	of	N	I-Premise
353	the	N	I-Premise
354	GP	N	I-Premise
355	arm	N	I-Premise
356	(	N	I-Premise
357	p	N	I-Premise
358	=	N	I-Premise
359	0.055	N	I-Premise
360	)	N	I-Premise
361	.	N	I-Premise

362	This	N	I-Claim
363	toxicity	N	I-Claim
364	profile	N	I-Claim
365	of	N	I-Claim
366	GE	N	I-Claim
367	is	N	I-Claim
368	similar	N	I-Claim
369	to	N	I-Claim
370	GP	N	I-Claim
371	,	N	I-Claim
372	but	N	I-Claim
373	the	N	I-Claim
374	apparent	N	I-Claim
375	inferior	N	I-Claim
376	efficacy	N	I-Claim
377	may	N	I-Claim
378	discourage	N	I-Claim
379	further	N	I-Claim
380	investigation	N	I-Claim
381	.	N	O

1	A	N	O
2	multidimensional	N	O
3	rehabilitation	N	O
4	program	N	O
5	for	N	O
6	cancer	N	O
7	survivors	N	O
8	was	N	O
9	developed	N	O
10	to	N	O
11	overcome	N	O
12	cancer-related	N	O
13	problems	N	O
14	and	N	O
15	to	N	O
16	improve	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	.	N	O

21	The	N	O
22	two	N	O
23	purposes	N	O
24	of	N	O
25	the	N	O
26	study	N	O
27	were	N	O
28	to	N	O
29	describe	N	O
30	the	N	O
31	effectiveness	N	O
32	of	N	O
33	the	N	O
34	program	N	O
35	and	N	O
36	to	N	O
37	obtain	N	O
38	information	N	O
39	about	N	O
40	patient	N	O
41	preferences	N	O
42	for	N	O
43	multi	N	O
44	or	N	O
45	mono	N	O
46	dimensional	N	O
47	rehabilitation	N	O
48	programs	N	O
49	.	N	O

50	cancer	N	O
51	survivors	N	O
52	with	N	O
53	different	N	O
54	diagnoses	N	O
55	,	N	O
56	and	N	O
57	cancer-related	N	O
58	physical	N	O
59	and	N	O
60	psychosocial	N	O
61	problems	N	O
62	.	N	O

63	a	N	O
64	15-week	N	O
65	rehabilitation	N	O
66	program	N	O
67	including	N	O
68	individual	N	O
69	exercise	N	O
70	,	N	O
71	sports	N	O
72	,	N	O
73	psycho-education	N	O
74	,	N	O
75	and	N	O
76	information	N	O
77	.	N	O

78	Group-wise	N	O
79	randomization	N	O
80	was	N	O
81	implemented	N	O
82	by	N	O
83	assigning	N	O
84	one	N	O
85	half	N	O
86	of	N	O
87	the	N	O
88	patients	N	O
89	to	N	O
90	the	N	O
91	complete	N	O
92	program	N	O
93	while	N	O
94	the	N	O
95	other	N	O
96	half	N	O
97	were	N	O
98	allowed	N	O
99	to	N	O
100	choose	N	O
101	which	N	O
102	program	N	O
103	components	N	O
104	they	N	O
105	considered	N	O
106	relevant	N	O
107	.	N	O

108	Health-Related	N	O
109	Quality	N	O
110	of	N	O
111	Life	N	O
112	[	N	O
113	RAND-36	N	O
114	and	N	O
115	Rotterdam	N	O
116	Symptom	N	O
117	Check	N	O
118	List	N	O
119	(	N	O
120	RSCL	N	O
121	)	N	O
122	]	N	O
123	,	N	O
124	exercise	N	O
125	capacity	N	O
126	(	N	O
127	symptom	N	O
128	limited	N	O
129	bicycle	N	O
130	ergometry	N	O
131	)	N	O
132	,	N	O
133	muscle	N	O
134	force	N	O
135	(	N	O
136	hand-held	N	O
137	dynamometry	N	O
138	)	N	O
139	,	N	O
140	and	N	O
141	patient	N	O
142	preferences	N	O
143	.	N	O

144	Measurements	N	O
145	were	N	O
146	performed	N	O
147	before	N	O
148	(	N	O
149	T0	N	O
150	)	N	O
151	and	N	O
152	after	N	O
153	the	N	O
154	rehabilitation	N	O
155	program	N	O
156	(	N	O
157	T1	N	O
158	)	N	O
159	,	N	O
160	and	N	O
161	at	N	O
162	a	N	O
163	3-month	N	O
164	follow-up	N	O
165	(	N	O
166	T2	N	O
167	)	N	O
168	.	N	O

169	After	N	I-Premise
170	the	N	I-Premise
171	rehabilitation	N	I-Premise
172	program	N	I-Premise
173	,	N	I-Premise
174	cancer	N	I-Premise
175	survivors	N	I-Premise
176	(	N	I-Premise
177	n=63	N	I-Premise
178	)	N	I-Premise
179	displayed	N	I-Premise
180	statistically	N	I-Premise
181	significant	N	I-Premise
182	improvements	N	I-Premise
183	on	N	I-Premise
184	health-related	N	I-Premise
185	quality	N	I-Premise
186	of	N	I-Premise
187	life	N	I-Premise
188	with	N	I-Premise
189	effect	N	I-Premise
190	sizes	N	I-Premise
191	(	N	I-Premise
192	ES	N	I-Premise
193	)	N	I-Premise
194	varying	N	I-Premise
195	from	N	I-Premise
196	0.38	N	I-Premise
197	to	N	I-Premise
198	0.99	N	I-Premise
199	(	N	I-Premise
200	RAND-36	N	I-Premise
201	)	N	I-Premise
202	and	N	I-Premise
203	from	N	I-Premise
204	-0.34	N	I-Premise
205	to	N	I-Premise
206	-0.57	N	I-Premise
207	(	N	I-Premise
208	RSCL	N	I-Premise
209	)	N	I-Premise
210	,	N	I-Premise
211	most	N	I-Premise
212	persistent	N	I-Premise
213	at	N	I-Premise
214	3-month	N	I-Premise
215	follow-up	N	I-Premise
216	.	N	I-Premise

217	Furthermore	N	I-Premise
218	,	N	I-Premise
219	statistically	N	I-Premise
220	significant	N	I-Premise
221	improvements	N	I-Premise
222	in	N	I-Premise
223	exercise	N	I-Premise
224	capacity	N	I-Premise
225	and	N	I-Premise
226	muscle	N	I-Premise
227	force	N	I-Premise
228	of	N	I-Premise
229	upper	N	I-Premise
230	and	N	I-Premise
231	lower	N	I-Premise
232	extremities	N	I-Premise
233	were	N	I-Premise
234	displayed	N	I-Premise
235	after	N	I-Premise
236	rehabilitation	N	I-Premise
237	.	N	I-Premise

238	If	N	I-Premise
239	offered	N	I-Premise
240	a	N	I-Premise
241	choice	N	I-Premise
242	,	N	I-Premise
243	80	N	I-Premise
244	%	N	I-Premise
245	of	N	I-Premise
246	the	N	I-Premise
247	patients	N	I-Premise
248	prior	N	I-Premise
249	to	N	I-Premise
250	start	N	I-Premise
251	and	N	I-Premise
252	58	N	I-Premise
253	%	N	I-Premise
254	of	N	I-Premise
255	the	N	I-Premise
256	patients	N	I-Premise
257	after	N	I-Premise
258	completion	N	I-Premise
259	of	N	I-Premise
260	the	N	I-Premise
261	program	N	I-Premise
262	indicated	N	I-Premise
263	that	N	I-Premise
264	they	N	I-Premise
265	preferred	N	I-Premise
266	the	N	I-Premise
267	entire	N	I-Premise
268	multidimensional	N	I-Premise
269	program	N	I-Premise
270	.	N	I-Premise

271	A	N	I-Claim
272	multidimensional	N	I-Claim
273	rehabilitation	N	I-Claim
274	program	N	I-Claim
275	has	N	I-Claim
276	statistically	N	I-Claim
277	and	N	I-Claim
278	clinically	N	I-Claim
279	relevant	N	I-Claim
280	beneficial	N	I-Claim
281	effects	N	I-Claim
282	on	N	I-Claim
283	health-related	N	I-Claim
284	quality	N	I-Claim
285	of	N	I-Claim
286	life	N	I-Claim
287	,	N	I-Claim
288	exercise	N	I-Claim
289	capacity	N	I-Claim
290	,	N	I-Claim
291	and	N	I-Claim
292	muscle	N	I-Claim
293	force	N	I-Claim
294	in	N	I-Claim
295	cancer	N	I-Claim
296	patients	N	I-Claim
297	with	N	I-Claim
298	different	N	I-Claim
299	diagnoses	N	I-Claim
300	.	N	I-Claim

301	Furthermore	N	O
302	,	N	O
303	if	N	I-Claim
304	offered	N	I-Claim
305	the	N	I-Claim
306	choice	N	I-Claim
307	,	N	I-Claim
308	the	N	I-Claim
309	majority	N	I-Claim
310	of	N	I-Claim
311	cancer	N	I-Claim
312	survivors	N	I-Claim
313	seem	N	I-Claim
314	to	N	I-Claim
315	prefer	N	I-Claim
316	multidimensional	N	I-Claim
317	programs	N	I-Claim
318	to	N	I-Claim
319	programs	N	I-Claim
320	with	N	I-Claim
321	only	N	I-Claim
322	one	N	I-Claim
323	component	N	I-Claim
324	.	N	I-Claim

1	Evidence	N	I-Claim
2	suggests	N	I-Claim
3	that	N	I-Claim
4	the	N	I-Claim
5	re-entry	N	I-Claim
6	phase	N	I-Claim
7	(	N	I-Claim
8	ie	N	I-Claim
9	,	N	I-Claim
10	early	N	I-Claim
11	period	N	I-Claim
12	after	N	I-Claim
13	medical	N	I-Claim
14	treatment	N	I-Claim
15	completion	N	I-Claim
16	)	N	I-Claim
17	presents	N	I-Claim
18	distinct	N	I-Claim
19	challenges	N	I-Claim
20	for	N	I-Claim
21	cancer	N	I-Claim
22	patients	N	I-Claim
23	.	N	I-Claim

24	To	N	O
25	facilitate	N	O
26	the	N	O
27	transition	N	O
28	to	N	O
29	recovery	N	O
30	,	N	O
31	we	N	O
32	conducted	N	O
33	the	N	O
34	Moving	N	O
35	Beyond	N	O
36	Cancer	N	O
37	(	N	O
38	MBC	N	O
39	)	N	O
40	trial	N	O
41	,	N	O
42	a	N	O
43	multisite	N	O
44	,	N	O
45	randomized	N	O
46	,	N	O
47	controlled	N	O
48	trial	N	O
49	of	N	O
50	psychoeducational	N	O
51	interventions	N	O
52	for	N	O
53	breast	N	O
54	cancer	N	O
55	patients	N	O
56	.	N	O

57	Breast	N	O
58	cancer	N	O
59	patients	N	O
60	were	N	O
61	registered	N	O
62	within	N	O
63	6	N	O
64	weeks	N	O
65	after	N	O
66	surgery	N	O
67	.	N	O

68	After	N	O
69	medical	N	O
70	treatment	N	O
71	,	N	O
72	they	N	O
73	completed	N	O
74	baseline	N	O
75	measures	N	O
76	and	N	O
77	were	N	O
78	randomly	N	O
79	assigned	N	O
80	to	N	O
81	standard	N	O
82	National	N	O
83	Cancer	N	O
84	Institute	N	O
85	print	N	O
86	material	N	O
87	(	N	O
88	CTL	N	O
89	)	N	O
90	;	N	O
91	standard	N	O
92	print	N	O
93	material	N	O
94	and	N	O
95	peer-modeling	N	O
96	videotape	N	O
97	(	N	O
98	VID	N	O
99	)	N	O
100	;	N	O
101	or	N	O
102	standard	N	O
103	print	N	O
104	material	N	O
105	,	N	O
106	videotape	N	O
107	,	N	O
108	two	N	O
109	sessions	N	O
110	with	N	O
111	a	N	O
112	trained	N	O
113	cancer	N	O
114	educator	N	O
115	,	N	O
116	and	N	O
117	informational	N	O
118	workbook	N	O
119	(	N	O
120	EDU	N	O
121	)	N	O
122	.	N	O

123	Two	N	O
124	primary	N	O
125	end	N	O
126	points	N	O
127	were	N	O
128	examined	N	O
129	:	N	O
130	energy/fatigue	N	O
131	and	N	O
132	cancer-specific	N	O
133	distress	N	O
134	.	N	O

135	Secondary	N	O
136	end	N	O
137	points	N	O
138	were	N	O
139	depressive	N	O
140	symptoms	N	O
141	and	N	O
142	post-traumatic	N	O
143	growth	N	O
144	.	N	O

145	Perceived	N	O
146	preparedness	N	O
147	for	N	O
148	re-entry	N	O
149	was	N	O
150	analyzed	N	O
151	as	N	O
152	a	N	O
153	moderator	N	O
154	of	N	O
155	effects	N	O
156	.	N	O

157	Of	N	O
158	558	N	O
159	women	N	O
160	randomly	N	O
161	assigned	N	O
162	to	N	O
163	treatment	N	O
164	,	N	O
165	418	N	O
166	completed	N	O
167	the	N	O
168	6-month	N	O
169	assessment	N	O
170	and	N	O
171	399	N	O
172	completed	N	O
173	the	N	O
174	12-month	N	O
175	assessment	N	O
176	.	N	O

177	In	N	I-Premise
178	analyses	N	I-Premise
179	controlling	N	I-Premise
180	for	N	I-Premise
181	study	N	I-Premise
182	site	N	I-Premise
183	and	N	I-Premise
184	baseline	N	I-Premise
185	depressive	N	I-Premise
186	symptoms	N	I-Premise
187	,	N	I-Premise
188	VID	N	I-Premise
189	produced	N	I-Premise
190	significant	N	I-Premise
191	improvement	N	I-Premise
192	in	N	I-Premise
193	energy/fatigue	N	I-Premise
194	at	N	I-Premise
195	6	N	I-Premise
196	months	N	I-Premise
197	relative	N	I-Premise
198	to	N	I-Premise
199	CTL	N	I-Premise
200	,	N	I-Premise
201	particularly	N	I-Premise
202	among	N	I-Premise
203	women	N	I-Premise
204	who	N	I-Premise
205	felt	N	I-Premise
206	less	N	I-Premise
207	prepared	N	I-Premise
208	for	N	I-Premise
209	re-entry	N	I-Premise
210	at	N	I-Premise
211	baseline	N	I-Premise
212	.	N	I-Premise

213	No	N	I-Premise
214	significant	N	I-Premise
215	main	N	I-Premise
216	effect	N	I-Premise
217	of	N	I-Premise
218	the	N	I-Premise
219	interventions	N	I-Premise
220	emerged	N	I-Premise
221	on	N	I-Premise
222	cancer-specific	N	I-Premise
223	distress	N	I-Premise
224	,	N	I-Premise
225	but	N	I-Premise
226	EDU	N	I-Premise
227	prompted	N	I-Premise
228	greater	N	I-Premise
229	reduction	N	I-Premise
230	in	N	I-Premise
231	this	N	I-Premise
232	outcome	N	I-Premise
233	relative	N	I-Premise
234	to	N	I-Premise
235	CTL	N	I-Premise
236	at	N	I-Premise
237	6	N	I-Premise
238	months	N	I-Premise
239	for	N	I-Premise
240	patients	N	I-Premise
241	who	N	I-Premise
242	felt	N	I-Premise
243	more	N	I-Premise
244	prepared	N	I-Premise
245	for	N	I-Premise
246	re-entry	N	I-Premise
247	.	N	I-Premise

248	Between-group	N	I-Premise
249	differences	N	I-Premise
250	in	N	I-Premise
251	the	N	I-Premise
252	primary	N	I-Premise
253	outcomes	N	I-Premise
254	were	N	I-Premise
255	not	N	I-Premise
256	significant	N	I-Premise
257	at	N	I-Premise
258	12	N	I-Premise
259	months	N	I-Premise
260	,	N	I-Premise
261	and	N	I-Premise
262	no	N	I-Premise
263	significant	N	I-Premise
264	effects	N	I-Premise
265	emerged	N	I-Premise
266	on	N	I-Premise
267	the	N	I-Premise
268	secondary	N	I-Premise
269	end	N	I-Premise
270	points	N	I-Premise
271	.	N	I-Premise

272	A	N	I-Claim
273	peer-modeling	N	I-Claim
274	videotape	N	I-Claim
275	can	N	I-Claim
276	accelerate	N	I-Claim
277	the	N	I-Claim
278	recovery	N	I-Claim
279	of	N	I-Claim
280	energy	N	I-Claim
281	during	N	I-Claim
282	the	N	I-Claim
283	re-entry	N	I-Claim
284	phase	N	I-Claim
285	in	N	I-Claim
286	women	N	I-Claim
287	treated	N	I-Claim
288	for	N	I-Claim
289	breast	N	I-Claim
290	cancer	N	I-Claim
291	,	N	I-Claim
292	particularly	N	I-Claim
293	among	N	I-Claim
294	those	N	I-Claim
295	who	N	I-Claim
296	feel	N	I-Claim
297	less	N	I-Claim
298	prepared	N	I-Claim
299	for	N	I-Claim
300	re-entry	N	I-Claim
301	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	a	N	O
7	psychoeducational	N	O
8	intervention	N	O
9	in	N	O
10	improving	N	O
11	cancer-related	N	O
12	fatigue	N	O
13	.	N	O

14	This	N	O
15	randomized	N	O
16	controlled	N	O
17	trial	N	O
18	involved	N	O
19	109	N	O
20	women	N	O
21	commencing	N	O
22	adjuvant	N	O
23	chemotherapy	N	O
24	for	N	O
25	stage	N	O
26	I	N	O
27	or	N	O
28	II	N	O
29	breast	N	O
30	cancer	N	O
31	in	N	O
32	five	N	O
33	chemotherapy	N	O
34	treatment	N	O
35	centers	N	O
36	.	N	O

37	Intervention	N	O
38	group	N	O
39	patients	N	O
40	received	N	O
41	an	N	O
42	individualized	N	O
43	fatigue	N	O
44	education	N	O
45	and	N	O
46	support	N	O
47	program	N	O
48	delivered	N	O
49	in	N	O
50	the	N	O
51	clinic	N	O
52	and	N	O
53	by	N	O
54	phone	N	O
55	over	N	O
56	three	N	O
57	10-	N	O
58	to	N	O
59	20-minute	N	O
60	sessions	N	O
61	1	N	O
62	week	N	O
63	apart	N	O
64	.	N	O

65	Instruments	N	O
66	included	N	O
67	a	N	O
68	numeric	N	O
69	rating	N	O
70	scale	N	O
71	assessing	N	O
72	confidence	N	O
73	with	N	O
74	managing	N	O
75	fatigue	N	O
76	;	N	O
77	11-point	N	O
78	numeric	N	O
79	rating	N	O
80	scales	N	O
81	measuring	N	O
82	fatigue	N	O
83	at	N	O
84	worst	N	O
85	,	N	O
86	average	N	O
87	,	N	O
88	and	N	O
89	best	N	O
90	;	N	O
91	the	N	O
92	Functional	N	O
93	Assessment	N	O
94	of	N	O
95	Cancer	N	O
96	Therapy-Fatigue	N	O
97	and	N	O
98	Piper	N	O
99	Fatigue	N	O
100	Scales	N	O
101	;	N	O
102	the	N	O
103	Cancer	N	O
104	Self-Efficacy	N	O
105	Scale	N	O
106	;	N	O
107	the	N	O
108	European	N	O
109	Organisation	N	O
110	for	N	O
111	Research	N	O
112	and	N	O
113	Treatment	N	O
114	of	N	O
115	Cancer	N	O
116	Quality	N	O
117	of	N	O
118	Life	N	O
119	Questionnaire	N	O
120	C30	N	O
121	;	N	O
122	and	N	O
123	the	N	O
124	Hospital	N	O
125	Anxiety	N	O
126	and	N	O
127	Depression	N	O
128	Scale	N	O
129	.	N	O

130	For	N	O
131	each	N	O
132	outcome	N	O
133	,	N	O
134	separate	N	O
135	analyses	N	O
136	of	N	O
137	covariance	N	O
138	of	N	O
139	change	N	O
140	scores	N	O
141	between	N	O
142	baseline	N	O
143	(	N	O
144	T1	N	O
145	)	N	O
146	and	N	O
147	the	N	O
148	three	N	O
149	follow-up	N	O
150	time	N	O
151	points	N	O
152	(	N	O
153	T2	N	O
154	,	N	O
155	T3	N	O
156	,	N	O
157	and	N	O
158	T4	N	O
159	)	N	O
160	were	N	O
161	conducted	N	O
162	,	N	O
163	controlling	N	O
164	for	N	O
165	the	N	O
166	variable	N	O
167	's	N	O
168	corresponding	N	O
169	baseline	N	O
170	value	N	O
171	.	N	O

172	Compared	N	I-Premise
173	with	N	I-Premise
174	the	N	I-Premise
175	intervention	N	I-Premise
176	group	N	I-Premise
177	,	N	I-Premise
178	mean	N	I-Premise
179	difference	N	I-Premise
180	scores	N	I-Premise
181	between	N	I-Premise
182	the	N	I-Premise
183	baseline	N	I-Premise
184	(	N	I-Premise
185	T1	N	I-Premise
186	)	N	I-Premise
187	and	N	I-Premise
188	immediate	N	I-Premise
189	after	N	I-Premise
190	the	N	I-Premise
191	test	N	I-Premise
192	(	N	I-Premise
193	T2	N	I-Premise
194	)	N	I-Premise
195	assessments	N	I-Premise
196	increased	N	I-Premise
197	significantly	N	I-Premise
198	more	N	I-Premise
199	for	N	I-Premise
200	the	N	I-Premise
201	control	N	I-Premise
202	group	N	I-Premise
203	for	N	I-Premise
204	worst	N	I-Premise
205	and	N	I-Premise
206	average	N	I-Premise
207	fatigue	N	I-Premise
208	,	N	I-Premise
209	Functional	N	I-Premise
210	Assessment	N	I-Premise
211	of	N	I-Premise
212	Cancer	N	I-Premise
213	Therapy-Fatigue	N	I-Premise
214	,	N	I-Premise
215	and	N	I-Premise
216	Piper	N	I-Premise
217	fatigue	N	I-Premise
218	severity	N	I-Premise
219	and	N	I-Premise
220	interference	N	I-Premise
221	measures	N	I-Premise
222	.	N	I-Premise

223	These	N	I-Premise
224	differences	N	I-Premise
225	were	N	I-Premise
226	not	N	I-Premise
227	observed	N	I-Premise
228	between	N	I-Premise
229	baseline	N	I-Premise
230	and	N	I-Premise
231	T3	N	I-Premise
232	and	N	I-Premise
233	T4	N	I-Premise
234	assessments	N	I-Premise
235	.	N	I-Premise

236	No	N	I-Premise
237	significant	N	I-Premise
238	differences	N	I-Premise
239	were	N	I-Premise
240	identified	N	I-Premise
241	for	N	I-Premise
242	any	N	I-Premise
243	pre-	N	I-Premise
244	or	N	I-Premise
245	post-test	N	I-Premise
246	change	N	I-Premise
247	scores	N	I-Premise
248	for	N	I-Premise
249	confidence	N	I-Premise
250	with	N	I-Premise
251	managing	N	I-Premise
252	fatigue	N	I-Premise
253	,	N	I-Premise
254	cancer	N	I-Premise
255	self-efficacy	N	I-Premise
256	,	N	I-Premise
257	anxiety	N	I-Premise
258	,	N	I-Premise
259	depression	N	I-Premise
260	,	N	I-Premise
261	or	N	I-Premise
262	quality	N	I-Premise
263	of	N	I-Premise
264	life	N	I-Premise
265	.	N	I-Premise

266	Preparatory	N	I-Claim
267	education	N	I-Claim
268	and	N	I-Claim
269	support	N	I-Claim
270	has	N	I-Claim
271	the	N	I-Claim
272	potential	N	I-Claim
273	to	N	I-Claim
274	assist	N	I-Claim
275	women	N	I-Claim
276	to	N	I-Claim
277	cope	N	I-Claim
278	with	N	I-Claim
279	cancer-related	N	I-Claim
280	fatigue	N	I-Claim
281	in	N	I-Claim
282	the	N	I-Claim
283	short	N	I-Claim
284	term	N	I-Claim
285	.	N	I-Claim

286	However	N	I-Claim
287	,	N	I-Claim
288	further	N	I-Claim
289	research	N	I-Claim
290	is	N	I-Claim
291	needed	N	I-Claim
292	to	N	I-Claim
293	identify	N	I-Claim
294	ways	N	I-Claim
295	to	N	I-Claim
296	improve	N	I-Claim
297	the	N	I-Claim
298	potency	N	I-Claim
299	and	N	I-Claim
300	sustainability	N	I-Claim
301	of	N	I-Claim
302	psychoeducational	N	I-Claim
303	interventions	N	I-Claim
304	for	N	I-Claim
305	managing	N	I-Claim
306	cancer-related	N	I-Claim
307	fatigue	N	I-Claim
308	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	letrozole	N	O
7	compared	N	O
8	with	N	O
9	placebo	N	O
10	after	N	O
11	adjuvant	N	O
12	tamoxifen	N	O
13	on	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	(	N	O
18	QOL	N	O
19	)	N	O
20	in	N	O
21	the	N	O
22	MA.17	N	O
23	trial	N	O
24	.	N	O

25	Patients	N	O
26	completed	N	O
27	the	N	O
28	Short	N	O
29	Form	N	O
30	36-item	N	O
31	Health	N	O
32	Survey	N	O
33	(	N	O
34	SF-36	N	O
35	)	N	O
36	and	N	O
37	the	N	O
38	Menopause	N	O
39	Specific	N	O
40	Quality	N	O
41	of	N	O
42	Life	N	O
43	Questionnaire	N	O
44	(	N	O
45	MENQOL	N	O
46	)	N	O
47	at	N	O
48	baseline	N	O
49	,	N	O
50	6	N	O
51	months	N	O
52	,	N	O
53	and	N	O
54	annually	N	O
55	.	N	O

56	Mean	N	O
57	change	N	O
58	scores	N	O
59	from	N	O
60	baseline	N	O
61	were	N	O
62	compared	N	O
63	between	N	O
64	groups	N	O
65	for	N	O
66	summary	N	O
67	measures	N	O
68	and	N	O
69	domains	N	O
70	.	N	O

71	A	N	O
72	response	N	O
73	analysis	N	O
74	compared	N	O
75	the	N	O
76	proportion	N	O
77	of	N	O
78	patients	N	O
79	who	N	O
80	demonstrated	N	O
81	an	N	O
82	important	N	O
83	change	N	O
84	in	N	O
85	QOL	N	O
86	.	N	O

87	Of	N	O
88	5,187	N	O
89	randomly	N	O
90	assigned	N	O
91	women	N	O
92	in	N	O
93	the	N	O
94	trial	N	O
95	,	N	O
96	3,612	N	O
97	(	N	O
98	69.9	N	O
99	%	N	O
100	)	N	O
101	participated	N	O
102	in	N	O
103	the	N	O
104	QOL	N	O
105	substudy	N	O
106	:	N	O
107	1,799	N	O
108	were	N	O
109	allocated	N	O
110	to	N	O
111	placebo	N	O
112	and	N	O
113	1,813	N	O
114	were	N	O
115	allocated	N	O
116	to	N	O
117	letrozole	N	O
118	.	N	O

119	No	N	I-Premise
120	differences	N	I-Premise
121	were	N	I-Premise
122	seen	N	I-Premise
123	between	N	I-Premise
124	groups	N	I-Premise
125	in	N	I-Premise
126	mean	N	I-Premise
127	change	N	I-Premise
128	scores	N	I-Premise
129	from	N	I-Premise
130	baseline	N	I-Premise
131	for	N	I-Premise
132	the	N	I-Premise
133	SF-36	N	I-Premise
134	physical	N	I-Premise
135	and	N	I-Premise
136	mental	N	I-Premise
137	component	N	I-Premise
138	summary	N	I-Premise
139	scores	N	I-Premise
140	at	N	I-Premise
141	6	N	I-Premise
142	,	N	I-Premise
143	12	N	I-Premise
144	,	N	I-Premise
145	24	N	I-Premise
146	,	N	I-Premise
147	and	N	I-Premise
148	36	N	I-Premise
149	months	N	I-Premise
150	.	N	I-Premise

151	Small	N	I-Premise
152	(	N	I-Premise
153	<	N	I-Premise
154	0.2	N	I-Premise
155	standard	N	I-Premise
156	deviations	N	I-Premise
157	)	N	I-Premise
158	but	N	I-Premise
159	statistically	N	I-Premise
160	significant	N	I-Premise
161	differences	N	I-Premise
162	in	N	I-Premise
163	mean	N	I-Premise
164	change	N	I-Premise
165	scores	N	I-Premise
166	from	N	I-Premise
167	baseline	N	I-Premise
168	were	N	I-Premise
169	seen	N	I-Premise
170	for	N	I-Premise
171	the	N	I-Premise
172	SF-36	N	I-Premise
173	domains	N	I-Premise
174	of	N	I-Premise
175	physical	N	I-Premise
176	functioning	N	I-Premise
177	(	N	I-Premise
178	12	N	I-Premise
179	months	N	I-Premise
180	)	N	I-Premise
181	,	N	I-Premise
182	bodily	N	I-Premise
183	pain	N	I-Premise
184	(	N	I-Premise
185	6	N	I-Premise
186	months	N	I-Premise
187	)	N	I-Premise
188	and	N	I-Premise
189	vitality	N	I-Premise
190	(	N	I-Premise
191	6	N	I-Premise
192	and	N	I-Premise
193	12	N	I-Premise
194	months	N	I-Premise
195	)	N	I-Premise
196	,	N	I-Premise
197	and	N	I-Premise
198	the	N	I-Premise
199	MENQOL	N	I-Premise
200	vasomotor	N	I-Premise
201	(	N	I-Premise
202	6	N	I-Premise
203	,	N	I-Premise
204	12	N	I-Premise
205	,	N	I-Premise
206	and	N	I-Premise
207	24	N	I-Premise
208	months	N	I-Premise
209	)	N	I-Premise
210	and	N	I-Premise
211	sexual	N	I-Premise
212	domains	N	I-Premise
213	(	N	I-Premise
214	12	N	I-Premise
215	and	N	I-Premise
216	24	N	I-Premise
217	months	N	I-Premise
218	)	N	I-Premise
219	.	N	I-Premise

220	On	N	I-Premise
221	the	N	I-Premise
222	response	N	I-Premise
223	analysis	N	I-Premise
224	,	N	I-Premise
225	a	N	I-Premise
226	significant	N	I-Premise
227	difference	N	I-Premise
228	was	N	I-Premise
229	seen	N	I-Premise
230	between	N	I-Premise
231	groups	N	I-Premise
232	for	N	I-Premise
233	the	N	I-Premise
234	bodily	N	I-Premise
235	pain	N	I-Premise
236	domain	N	I-Premise
237	(	N	I-Premise
238	percentage	N	I-Premise
239	of	N	I-Premise
240	patients	N	I-Premise
241	reporting	N	I-Premise
242	a	N	I-Premise
243	worsening	N	I-Premise
244	of	N	I-Premise
245	QOL	N	I-Premise
246	,	N	I-Premise
247	47	N	I-Premise
248	%	N	I-Premise
249	placebo	N	I-Premise
250	v	N	I-Premise
251	51	N	I-Premise
252	%	N	I-Premise
253	letrozole	N	I-Premise
254	;	N	I-Premise
255	P	N	I-Premise
256	=	N	I-Premise
257	.009	N	I-Premise
258	)	N	I-Premise
259	and	N	I-Premise
260	the	N	I-Premise
261	vasomotor	N	I-Premise
262	domain	N	I-Premise
263	(	N	I-Premise
264	22	N	I-Premise
265	%	N	I-Premise
266	placebo	N	I-Premise
267	v	N	I-Premise
268	29	N	I-Premise
269	%	N	I-Premise
270	letrozole	N	I-Premise
271	;	N	I-Premise
272	P	N	I-Premise
273	=	N	I-Premise
274	.001	N	I-Premise
275	)	N	I-Premise
276	.	N	I-Premise

277	Letrozole	N	I-Claim
278	did	N	I-Claim
279	not	N	I-Claim
280	have	N	I-Claim
281	an	N	I-Claim
282	adverse	N	I-Claim
283	impact	N	I-Claim
284	on	N	I-Claim
285	overall	N	I-Claim
286	QOL	N	I-Claim
287	.	N	I-Claim

288	Small	N	I-Claim
289	effects	N	I-Claim
290	were	N	I-Claim
291	seen	N	I-Claim
292	in	N	I-Claim
293	some	N	I-Claim
294	domains	N	I-Claim
295	consistent	N	I-Claim
296	with	N	I-Claim
297	a	N	I-Claim
298	minority	N	I-Claim
299	of	N	I-Claim
300	patients	N	I-Claim
301	experiencing	N	I-Claim
302	changes	N	I-Claim
303	in	N	I-Claim
304	QOL	N	I-Claim
305	compatible	N	I-Claim
306	with	N	I-Claim
307	a	N	I-Claim
308	reduction	N	I-Claim
309	in	N	I-Claim
310	estrogen	N	I-Claim
311	synthesis	N	I-Claim
312	.	N	I-Claim

1	This	N	O
2	study	N	O
3	is	N	O
4	the	N	O
5	first	N	O
6	large	N	O
7	prospective	N	O
8	RCT	N	O
9	of	N	O
10	sentinel	N	O
11	node	N	O
12	biopsy	N	O
13	(	N	O
14	SNB	N	O
15	)	N	O
16	compared	N	O
17	with	N	O
18	standard	N	O
19	axillary	N	O
20	treatment	N	O
21	(	N	O
22	level	N	O
23	I-III	N	O
24	axillary	N	O
25	lymph	N	O
26	node	N	O
27	dissection	N	O
28	or	N	O
29	four	N	O
30	node	N	O
31	sampling	N	O
32	)	N	O
33	,	N	O
34	which	N	O
35	includes	N	O
36	comprehensive	N	O
37	and	N	O
38	repeated	N	O
39	quality	N	O
40	of	N	O
41	life	N	O
42	(	N	O
43	QOL	N	O
44	)	N	O
45	assessments	N	O
46	over	N	O
47	18	N	O
48	months	N	O
49	.	N	O

50	Patients	N	O
51	(	N	O
52	n	N	O
53	=	N	O
54	829	N	O
55	)	N	O
56	completed	N	O
57	the	N	O
58	Functional	N	O
59	Assessment	N	O
60	of	N	O
61	Cancer	N	O
62	Therapy	N	O
63	-	N	O
64	Breast	N	O
65	(	N	O
66	FACT-B+4	N	O
67	)	N	O
68	and	N	O
69	the	N	O
70	Spielberger	N	O
71	State/Trait	N	O
72	Anxiety	N	O
73	Inventory	N	O
74	(	N	O
75	STAI	N	O
76	)	N	O
77	at	N	O
78	baseline	N	O
79	(	N	O
80	pre-surgery	N	O
81	)	N	O
82	and	N	O
83	at	N	O
84	1	N	O
85	,	N	O
86	3	N	O
87	,	N	O
88	6	N	O
89	,	N	O
90	12	N	O
91	,	N	O
92	and	N	O
93	18	N	O
94	months	N	O
95	post-surgery	N	O
96	.	N	O

97	There	N	I-Claim
98	were	N	I-Claim
99	significant	N	I-Claim
100	differences	N	I-Claim
101	between	N	I-Claim
102	treatment	N	I-Claim
103	groups	N	I-Claim
104	favouring	N	I-Claim
105	the	N	I-Claim
106	SNB	N	I-Claim
107	group	N	I-Claim
108	throughout	N	I-Claim
109	the	N	I-Claim
110	18	N	I-Claim
111	months	N	I-Claim
112	assessment	N	I-Claim
113	.	N	I-Claim

114	Patients	N	I-Premise
115	in	N	I-Premise
116	the	N	I-Premise
117	standard	N	I-Premise
118	treatment	N	I-Premise
119	group	N	I-Premise
120	showed	N	I-Premise
121	a	N	I-Premise
122	greater	N	I-Premise
123	decline	N	I-Premise
124	in	N	I-Premise
125	Trial	N	I-Premise
126	Outcome	N	I-Premise
127	Index	N	I-Premise
128	(	N	I-Premise
129	TOI	N	I-Premise
130	)	N	I-Premise
131	scores	N	I-Premise
132	(	N	I-Premise
133	physical	N	I-Premise
134	well-being	N	I-Premise
135	,	N	I-Premise
136	functional	N	I-Premise
137	well-being	N	I-Premise
138	and	N	I-Premise
139	breast	N	I-Premise
140	cancer	N	I-Premise
141	concerns	N	I-Premise
142	subscales	N	I-Premise
143	in	N	I-Premise
144	FACT-B+4	N	I-Premise
145	)	N	I-Premise
146	and	N	I-Premise
147	recovered	N	I-Premise
148	more	N	I-Premise
149	slowly	N	I-Premise
150	than	N	I-Premise
151	patients	N	I-Premise
152	in	N	I-Premise
153	the	N	I-Premise
154	SNB	N	I-Premise
155	group	N	I-Premise
156	(	N	I-Premise
157	p	N	I-Premise
158	<	N	I-Premise
159	0.01	N	I-Premise
160	)	N	I-Premise
161	.	N	I-Premise

162	The	N	I-Premise
163	change	N	I-Premise
164	in	N	I-Premise
165	total	N	I-Premise
166	FACT-B+4	N	I-Premise
167	scores	N	I-Premise
168	(	N	I-Premise
169	measuring	N	I-Premise
170	global	N	I-Premise
171	QOL	N	I-Premise
172	)	N	I-Premise
173	closely	N	I-Premise
174	resembled	N	I-Premise
175	the	N	I-Premise
176	TOI	N	I-Premise
177	results	N	I-Premise
178	.	N	I-Premise

179	18	N	I-Premise
180	months	N	I-Premise
181	post-surgery	N	I-Premise
182	approximately	N	I-Premise
183	twice	N	I-Premise
184	as	N	I-Premise
185	many	N	I-Premise
186	patients	N	I-Premise
187	in	N	I-Premise
188	the	N	I-Premise
189	standard	N	I-Premise
190	group	N	I-Premise
191	compared	N	I-Premise
192	with	N	I-Premise
193	the	N	I-Premise
194	SNB	N	I-Premise
195	group	N	I-Premise
196	reported	N	I-Premise
197	substantial	N	I-Premise
198	arm	N	I-Premise
199	swelling	N	I-Premise
200	(	N	I-Premise
201	14	N	I-Premise
202	%	N	I-Premise
203	versus	N	I-Premise
204	7	N	I-Premise
205	%	N	I-Premise
206	)	N	I-Premise
207	(	N	I-Premise
208	p	N	I-Premise
209	=	N	I-Premise
210	0.002	N	I-Premise
211	)	N	I-Premise
212	or	N	I-Premise
213	numbness	N	I-Premise
214	(	N	I-Premise
215	19	N	I-Premise
216	%	N	I-Premise
217	versus	N	I-Premise
218	8.7	N	I-Premise
219	%	N	I-Premise
220	)	N	I-Premise
221	(	N	I-Premise
222	p	N	I-Premise
223	<	N	I-Premise
224	0.001	N	I-Premise
225	)	N	I-Premise
226	.	N	I-Premise

227	Despite	N	O
228	the	N	O
229	uncertainty	N	O
230	about	N	O
231	undergoing	N	O
232	a	N	O
233	relatively	N	O
234	new	N	O
235	procedure	N	O
236	and	N	O
237	the	N	O
238	possible	N	O
239	need	N	O
240	for	N	O
241	further	N	O
242	surgery	N	O
243	,	N	O
244	there	N	I-Premise
245	was	N	I-Premise
246	no	N	I-Premise
247	evidence	N	I-Premise
248	of	N	I-Premise
249	increased	N	I-Premise
250	anxiety	N	I-Premise
251	amongst	N	I-Premise
252	patients	N	I-Premise
253	randomised	N	I-Premise
254	to	N	I-Premise
255	SNB	N	I-Premise
256	(	N	I-Premise
257	p	N	I-Premise
258	>	N	I-Premise
259	0.05	N	I-Premise
260	)	N	I-Premise
261	.	N	I-Premise

262	For	N	I-Premise
263	6	N	I-Premise
264	months	N	I-Premise
265	post-surgery	N	I-Premise
266	younger	N	I-Premise
267	patients	N	I-Premise
268	reported	N	I-Premise
269	less	N	I-Premise
270	favourable	N	I-Premise
271	QOL	N	I-Premise
272	scores	N	I-Premise
273	(	N	I-Premise
274	p	N	I-Premise
275	<	N	I-Premise
276	0.001	N	I-Premise
277	)	N	I-Premise
278	and	N	I-Premise
279	greater	N	I-Premise
280	levels	N	I-Premise
281	of	N	I-Premise
282	anxiety	N	I-Premise
283	(	N	I-Premise
284	p	N	I-Premise
285	<	N	I-Premise
286	0.01	N	I-Premise
287	)	N	I-Premise
288	.	N	I-Premise

289	In	N	I-Claim
290	view	N	I-Claim
291	of	N	I-Claim
292	the	N	I-Claim
293	benefits	N	I-Claim
294	regarding	N	I-Claim
295	arm	N	I-Claim
296	functioning	N	I-Claim
297	and	N	I-Claim
298	quality	N	I-Claim
299	of	N	I-Claim
300	life	N	I-Claim
301	,	N	I-Claim
302	the	N	I-Claim
303	data	N	I-Claim
304	from	N	I-Claim
305	this	N	I-Claim
306	randomised	N	I-Claim
307	study	N	I-Claim
308	support	N	I-Claim
309	the	N	I-Claim
310	use	N	I-Claim
311	of	N	I-Claim
312	SNB	N	I-Claim
313	in	N	I-Claim
314	patients	N	I-Claim
315	with	N	I-Claim
316	clinically	N	I-Claim
317	node	N	I-Claim
318	negative	N	I-Claim
319	breast	N	I-Claim
320	cancer	N	I-Claim
321	.	N	I-Claim

1	To	N	O
2	describe	N	O
3	the	N	O
4	Food	N	O
5	and	N	O
6	Drug	N	O
7	Administration	N	O
8	(	N	O
9	FDA	N	O
10	)	N	O
11	review	N	O
12	and	N	O
13	approval	N	O
14	of	N	O
15	erlotinib	N	O
16	(	N	O
17	Tarceva	N	O
18	,	N	O
19	OSI	N	O
20	Pharmaceuticals	N	O
21	,	N	O
22	Melville	N	O
23	,	N	O
24	NY	N	O
25	)	N	O
26	for	N	O
27	treatment	N	O
28	of	N	O
29	patients	N	O
30	with	N	O
31	locally	N	O
32	advanced	N	O
33	or	N	O
34	metastatic	N	O
35	non-small	N	O
36	cell	N	O
37	lung	N	O
38	cancer	N	O
39	(	N	O
40	NSCLC	N	O
41	)	N	O
42	after	N	O
43	failure	N	O
44	of	N	O
45	at	N	O
46	least	N	O
47	one	N	O
48	prior	N	O
49	chemotherapy	N	O
50	regimen	N	O
51	.	N	O

52	The	N	O
53	FDA	N	O
54	reviewed	N	O
55	raw	N	O
56	data	N	O
57	in	N	O
58	electronic	N	O
59	format	N	O
60	from	N	O
61	a	N	O
62	randomized	N	O
63	controlled	N	O
64	clinical	N	O
65	trial	N	O
66	comparing	N	O
67	erlotinib	N	O
68	with	N	O
69	placebo	N	O
70	in	N	O
71	patients	N	O
72	with	N	O
73	locally	N	O
74	advanced	N	O
75	or	N	O
76	metastatic	N	O
77	NSCLC	N	O
78	after	N	O
79	failure	N	O
80	of	N	O
81	at	N	O
82	least	N	O
83	one	N	O
84	prior	N	O
85	chemotherapy	N	O
86	regimen	N	O
87	.	N	O

88	Patients	N	O
89	were	N	O
90	randomized	N	O
91	in	N	O
92	a	N	O
93	2:1	N	O
94	ratio	N	O
95	(	N	O
96	erlotinib	N	O
97	,	N	O
98	n	N	O
99	=	N	O
100	488	N	O
101	and	N	O
102	placebo	N	O
103	,	N	O
104	n	N	O
105	=	N	O
106	243	N	O
107	)	N	O
108	.	N	O

109	Erlotinib	N	I-Claim
110	was	N	I-Claim
111	superior	N	I-Claim
112	to	N	I-Claim
113	placebo	N	I-Claim
114	for	N	I-Claim
115	survival	N	I-Claim
116	,	N	I-Claim
117	progression-free	N	I-Claim
118	survival	N	I-Claim
119	,	N	I-Claim
120	and	N	I-Claim
121	tumor	N	I-Claim
122	response	N	I-Claim
123	rate	N	I-Claim
124	.	N	I-Claim

125	Exploratory	N	I-Claim
126	analyses	N	I-Claim
127	indicate	N	I-Claim
128	that	N	I-Claim
129	epidermal	N	I-Claim
130	growth	N	I-Claim
131	factor	N	I-Claim
132	receptor	N	I-Claim
133	status	N	I-Claim
134	may	N	I-Claim
135	be	N	I-Claim
136	an	N	I-Claim
137	important	N	I-Claim
138	predictor	N	I-Claim
139	of	N	I-Claim
140	the	N	I-Claim
141	erlotinib	N	I-Claim
142	survival	N	I-Claim
143	effect	N	I-Claim
144	.	N	I-Claim

145	Rash	N	I-Premise
146	(	N	I-Premise
147	75	N	I-Premise
148	%	N	I-Premise
149	versus	N	I-Premise
150	17	N	I-Premise
151	%	N	I-Premise
152	)	N	I-Premise
153	and	N	I-Premise
154	diarrhea	N	I-Premise
155	(	N	I-Premise
156	54	N	I-Premise
157	%	N	I-Premise
158	versus	N	I-Premise
159	18	N	I-Premise
160	%	N	I-Premise
161	)	N	I-Premise
162	in	N	I-Premise
163	the	N	I-Premise
164	erlotnib	N	I-Premise
165	and	N	I-Premise
166	placebo	N	I-Premise
167	group	N	I-Premise
168	respectively	N	I-Premise
169	were	N	I-Premise
170	the	N	I-Premise
171	most	N	I-Premise
172	common	N	I-Premise
173	adverse	N	I-Premise
174	events	N	I-Premise
175	.	N	I-Premise

176	Severe	N	I-Premise
177	rash	N	I-Premise
178	occurred	N	I-Premise
179	in	N	I-Premise
180	9	N	I-Premise
181	%	N	I-Premise
182	and	N	I-Premise
183	severe	N	I-Premise
184	diarrhea	N	I-Premise
185	in	N	I-Premise
186	6	N	I-Premise
187	%	N	I-Premise
188	of	N	I-Premise
189	erlotinib-treated	N	I-Premise
190	patients	N	I-Premise
191	and	N	I-Premise
192	each	N	I-Premise
193	resulted	N	I-Premise
194	in	N	I-Premise
195	study	N	I-Premise
196	discontinuation	N	I-Premise
197	in	N	I-Premise
198	1	N	I-Premise
199	%	N	I-Premise
200	of	N	I-Premise
201	patients	N	I-Premise
202	.	N	I-Premise

203	Dose	N	I-Premise
204	reductions	N	I-Premise
205	were	N	I-Premise
206	required	N	I-Premise
207	for	N	I-Premise
208	10	N	I-Premise
209	%	N	I-Premise
210	of	N	I-Premise
211	patients	N	I-Premise
212	with	N	I-Premise
213	rash	N	I-Premise
214	and	N	I-Premise
215	4	N	I-Premise
216	%	N	I-Premise
217	of	N	I-Premise
218	patients	N	I-Premise
219	with	N	I-Premise
220	diarrhea	N	I-Premise
221	.	N	I-Premise

222	On	N	O
223	November	N	O
224	18	N	O
225	,	N	O
226	2004	N	O
227	,	N	O
228	the	N	O
229	FDA	N	O
230	granted	N	O
231	erlotinib	N	O
232	regular	N	O
233	approval	N	O
234	for	N	O
235	treatment	N	O
236	of	N	O
237	patients	N	O
238	with	N	O
239	locally	N	O
240	advanced	N	O
241	or	N	O
242	metastatic	N	O
243	NSCLC	N	O
244	after	N	O
245	failure	N	O
246	of	N	O
247	at	N	O
248	least	N	O
249	one	N	O
250	prior	N	O
251	chemotherapy	N	O
252	regimen	N	O
253	.	N	O

254	The	N	O
255	applicant	N	O
256	has	N	O
257	committed	N	O
258	to	N	O
259	conduct	N	O
260	post-marketing	N	O
261	clinical	N	O
262	trials	N	O
263	to	N	O
264	assess	N	O
265	further	N	O
266	the	N	O
267	effect	N	O
268	of	N	O
269	epidermal	N	O
270	growth	N	O
271	factor	N	O
272	receptor	N	O
273	expression	N	O
274	,	N	O
275	measured	N	O
276	with	N	O
277	immunohistochemical	N	O
278	staining	N	O
279	,	N	O
280	on	N	O
281	erlotinib	N	O
282	treatment	N	O
283	effect	N	O
284	.	N	O

1	Approximately	N	O
2	30	N	O
3	%	N	O
4	of	N	O
5	lung	N	O
6	cancer	N	O
7	cases	N	O
8	are	N	O
9	diagnosed	N	O
10	in	N	O
11	patients	N	O
12	>	N	O
13	70	N	O
14	years	N	O
15	of	N	O
16	age	N	O
17	.	N	O

18	Standard	N	I-MajorClaim
19	chemotherapy	N	I-MajorClaim
20	regimens	N	I-MajorClaim
21	are	N	I-MajorClaim
22	generally	N	I-MajorClaim
23	considered	N	I-MajorClaim
24	too	N	I-MajorClaim
25	toxic	N	I-MajorClaim
26	for	N	I-MajorClaim
27	elderly	N	I-MajorClaim
28	patients	N	I-MajorClaim
29	.	N	I-MajorClaim

30	We	N	O
31	conducted	N	O
32	a	N	O
33	multicenter	N	O
34	phase	N	O
35	II	N	O
36	trial	N	O
37	to	N	O
38	determine	N	O
39	the	N	O
40	efficacy	N	O
41	and	N	O
42	safety	N	O
43	of	N	O
44	carboplatin	N	O
45	combined	N	O
46	with	N	O
47	vinorelbine	N	O
48	every	N	O
49	4	N	O
50	weeks	N	O
51	as	N	O
52	first-line	N	O
53	treatment	N	O
54	for	N	O
55	advanced	N	O
56	non-small-cell	N	O
57	lung	N	O
58	cancer	N	O
59	(	N	O
60	NSCLC	N	O
61	)	N	O
62	in	N	O
63	elderly	N	O
64	patients	N	O
65	.	N	O

66	Patients	N	O
67	were	N	O
68	eligible	N	O
69	if	N	O
70	they	N	O
71	were	N	O
72	aged	N	O
73	>	N	O
74	OR=	N	O
75	70	N	O
76	years	N	O
77	,	N	O
78	had	N	O
79	stage	N	O
80	IIIB	N	O
81	(	N	O
82	with	N	O
83	pleural	N	O
84	effusion	N	O
85	)	N	O
86	or	N	O
87	stage	N	O
88	IV	N	O
89	NSCLC	N	O
90	,	N	O
91	had	N	O
92	a	N	O
93	performance	N	O
94	status	N	O
95	of	N	O
96	0/1	N	O
97	,	N	O
98	had	N	O
99	not	N	O
100	previously	N	O
101	received	N	O
102	chemotherapy	N	O
103	,	N	O
104	and	N	O
105	had	N	O
106	normal	N	O
107	organ	N	O
108	function	N	O
109	.	N	O

110	Forty	N	O
111	patients	N	O
112	(	N	O
113	31	N	O
114	men	N	O
115	and	N	O
116	9	N	O
117	women	N	O
118	)	N	O
119	were	N	O
120	enrolled	N	O
121	and	N	O
122	received	N	O
123	3-5	N	O
124	courses	N	O
125	of	N	O
126	treatment	N	O
127	.	N	O

128	Median	N	O
129	age	N	O
130	was	N	O
131	72	N	O
132	years	N	O
133	(	N	O
134	range	N	O
135	,	N	O
136	70-82	N	O
137	years	N	O
138	)	N	O
139	.	N	O

140	Eighty	N	O
141	percent	N	O
142	of	N	O
143	patients	N	O
144	had	N	O
145	stage	N	O
146	IV	N	O
147	NSCLC	N	O
148	,	N	O
149	with	N	O
150	squamous	N	O
151	cell	N	O
152	(	N	O
153	n=21	N	O
154	)	N	O
155	,	N	O
156	adenocarcinoma	N	O
157	(	N	O
158	n=12	N	O
159	)	N	O
160	,	N	O
161	and	N	O
162	undifferentiated	N	O
163	(	N	O
164	n=7	N	O
165	)	N	O
166	histologies	N	O
167	.	N	O

168	Forty	N	O
169	patients	N	O
170	were	N	O
171	assessable	N	O
172	for	N	O
173	toxicity	N	O
174	and	N	O
175	32	N	O
176	for	N	O
177	treatment	N	O
178	response	N	O
179	.	N	O

180	Among	N	I-Premise
181	these	N	I-Premise
182	32	N	I-Premise
183	patients	N	I-Premise
184	,	N	I-Premise
185	8	N	I-Premise
186	had	N	I-Premise
187	a	N	I-Premise
188	partial	N	I-Premise
189	response	N	I-Premise
190	(	N	I-Premise
191	intent-to-treat	N	I-Premise
192	response	N	I-Premise
193	rate	N	I-Premise
194	,	N	I-Premise
195	20	N	I-Premise
196	%	N	I-Premise
197	)	N	I-Premise
198	,	N	I-Premise
199	and	N	I-Premise
200	10	N	I-Premise
201	(	N	I-Premise
202	25	N	I-Premise
203	%	N	I-Premise
204	)	N	I-Premise
205	had	N	I-Premise
206	stable	N	I-Premise
207	disease	N	I-Premise
208	.	N	I-Premise

209	The	N	I-Premise
210	median	N	I-Premise
211	survival	N	I-Premise
212	was	N	I-Premise
213	7.8	N	I-Premise
214	months	N	I-Premise
215	(	N	I-Premise
216	range	N	I-Premise
217	,	N	I-Premise
218	4-11.6	N	I-Premise
219	months	N	I-Premise
220	)	N	I-Premise
221	.	N	I-Premise

222	The	N	I-Premise
223	1-	N	I-Premise
224	and	N	I-Premise
225	2-year	N	I-Premise
226	survival	N	I-Premise
227	rates	N	I-Premise
228	were	N	I-Premise
229	25	N	I-Premise
230	%	N	I-Premise
231	and	N	I-Premise
232	7	N	I-Premise
233	%	N	I-Premise
234	,	N	I-Premise
235	respectively	N	I-Premise
236	;	N	I-Premise
237	median	N	I-Premise
238	time	N	I-Premise
239	to	N	I-Premise
240	progression	N	I-Premise
241	was	N	I-Premise
242	4.3	N	I-Premise
243	months	N	I-Premise
244	(	N	I-Premise
245	range	N	I-Premise
246	,	N	I-Premise
247	0.2-13.8	N	I-Premise
248	months	N	I-Premise
249	)	N	I-Premise
250	.	N	I-Premise

251	Grade	N	I-Premise
252	3/4	N	I-Premise
253	neutropenia	N	I-Premise
254	was	N	I-Premise
255	seen	N	I-Premise
256	in	N	I-Premise
257	27	N	I-Premise
258	patients	N	I-Premise
259	(	N	I-Premise
260	68	N	I-Premise
261	%	N	I-Premise
262	)	N	I-Premise
263	,	N	I-Premise
264	and	N	I-Premise
265	grade	N	I-Premise
266	3/4	N	I-Premise
267	anemia	N	I-Premise
268	was	N	I-Premise
269	seen	N	I-Premise
270	in	N	I-Premise
271	5	N	I-Premise
272	patients	N	I-Premise
273	(	N	I-Premise
274	13	N	I-Premise
275	%	N	I-Premise
276	)	N	I-Premise
277	.	N	I-Premise

278	One	N	I-Premise
279	patient	N	I-Premise
280	died	N	I-Premise
281	of	N	I-Premise
282	febrile	N	I-Premise
283	neutropenia	N	I-Premise
284	during	N	I-Premise
285	treatment	N	I-Premise
286	.	N	I-Premise

287	The	N	I-Premise
288	main	N	I-Premise
289	nonhematologic	N	I-Premise
290	adverse	N	I-Premise
291	effect	N	I-Premise
292	was	N	I-Premise
293	fatigue	N	I-Premise
294	(	N	I-Premise
295	grade	N	I-Premise
296	3/4	N	I-Premise
297	in	N	I-Premise
298	18	N	I-Premise
299	%	N	I-Premise
300	of	N	I-Premise
301	patients	N	I-Premise
302	)	N	I-Premise
303	.	N	I-Premise

304	Carboplatin/vinorelbine	N	I-Claim
305	is	N	I-Claim
306	well	N	I-Claim
307	tolerated	N	I-Claim
308	by	N	I-Claim
309	elderly	N	I-Claim
310	patients	N	I-Claim
311	with	N	I-Claim
312	extensive-stage	N	I-Claim
313	NSCLC	N	I-Claim
314	.	N	I-Claim

315	Efficacy	N	I-Claim
316	is	N	I-Claim
317	low	N	I-Claim
318	but	N	I-Claim
319	similar	N	I-Claim
320	to	N	I-Claim
321	that	N	I-Claim
322	of	N	I-Claim
323	other	N	I-Claim
324	treatments	N	I-Claim
325	used	N	I-Claim
326	in	N	I-Claim
327	this	N	I-Claim
328	setting	N	I-Claim
329	.	N	I-Claim

1	On	N	O
2	March	N	O
3	15	N	O
4	,	N	O
5	2005	N	O
6	,	N	O
7	the	N	O
8	US	N	O
9	Food	N	O
10	and	N	O
11	Drug	N	O
12	Administration	N	O
13	approved	N	O
14	temozolomide	N	O
15	(	N	O
16	Temodar	N	O
17	capsules	N	O
18	,	N	O
19	Schering-Plough	N	O
20	Research	N	O
21	Institute	N	O
22	)	N	O
23	for	N	O
24	the	N	O
25	treatment	N	O
26	of	N	O
27	adult	N	O
28	patients	N	O
29	with	N	O
30	newly	N	O
31	diagnosed	N	O
32	glioblastoma	N	O
33	multiforme	N	O
34	concomitantly	N	O
35	with	N	O
36	radiotherapy	N	O
37	and	N	O
38	then	N	O
39	as	N	O
40	maintenance	N	O
41	treatment	N	O
42	.	N	O

43	Five	N	O
44	hundred	N	O
45	seventy-three	N	O
46	glioblastoma	N	O
47	multiforme	N	O
48	patients	N	O
49	were	N	O
50	randomized	N	O
51	to	N	O
52	receive	N	O
53	either	N	O
54	temozolomide	N	O
55	+	N	O
56	radiotherapy	N	O
57	(	N	O
58	n	N	O
59	=	N	O
60	287	N	O
61	)	N	O
62	or	N	O
63	radiotherapy	N	O
64	alone	N	O
65	(	N	O
66	n	N	O
67	=	N	O
68	286	N	O
69	)	N	O
70	.	N	O

71	Patients	N	O
72	in	N	O
73	the	N	O
74	temozolomide	N	O
75	+	N	O
76	radiotherapy	N	O
77	arm	N	O
78	received	N	O
79	concomitant	N	O
80	temozolomide	N	O
81	(	N	O
82	75	N	O
83	mg/m2	N	O
84	)	N	O
85	once	N	O
86	daily	N	O
87	for	N	O
88	the	N	O
89	duration	N	O
90	of	N	O
91	radiation	N	O
92	therapy	N	O
93	(	N	O
94	42-49	N	O
95	days	N	O
96	)	N	O
97	.	N	O

98	This	N	O
99	was	N	O
100	followed	N	O
101	,	N	O
102	4	N	O
103	weeks	N	O
104	later	N	O
105	,	N	O
106	by	N	O
107	six	N	O
108	cycles	N	O
109	of	N	O
110	temozolomide	N	O
111	,	N	O
112	150	N	O
113	or	N	O
114	200	N	O
115	mg/m2	N	O
116	daily	N	O
117	for	N	O
118	5	N	O
119	days	N	O
120	,	N	O
121	every	N	O
122	4	N	O
123	weeks	N	O
124	.	N	O

125	Patients	N	O
126	in	N	O
127	the	N	O
128	control	N	O
129	arm	N	O
130	received	N	O
131	radiotherapy	N	O
132	only	N	O
133	.	N	O

134	In	N	O
135	both	N	O
136	arms	N	O
137	,	N	O
138	radiotherapy	N	O
139	was	N	O
140	delivered	N	O
141	as	N	O
142	60	N	O
143	Gy/30	N	O
144	fractions	N	O
145	to	N	O
146	the	N	O
147	tumor	N	O
148	site	N	O
149	with	N	O
150	a	N	O
151	2	N	O
152	to	N	O
153	3	N	O
154	cm	N	O
155	margin	N	O
156	.	N	O

157	Pneumocystis	N	O
158	carinii	N	O
159	pneumonia	N	O
160	prophylaxis	N	O
161	was	N	O
162	required	N	O
163	during	N	O
164	temozolomide	N	O
165	+	N	O
166	radiotherapy	N	O
167	treatment	N	O
168	and	N	O
169	was	N	O
170	continued	N	O
171	until	N	O
172	recovery	N	O
173	of	N	O
174	lymphocytopenia	N	O
175	(	N	O
176	Common	N	O
177	Toxicity	N	O
178	Criteria	N	O
179	grade	N	O
180	<	N	O
181	1	N	O
182	)	N	O
183	.	N	O

184	At	N	O
185	disease	N	O
186	progression	N	O
187	,	N	O
188	temozolomide	N	O
189	salvage	N	O
190	treatment	N	O
191	was	N	O
192	given	N	O
193	to	N	O
194	161	N	O
195	of	N	O
196	282	N	O
197	patients	N	O
198	(	N	O
199	57	N	O
200	%	N	O
201	)	N	O
202	in	N	O
203	the	N	O
204	radiotherapy	N	O
205	alone	N	O
206	arm	N	O
207	,	N	O
208	and	N	O
209	to	N	O
210	62	N	O
211	of	N	O
212	277	N	O
213	patients	N	O
214	(	N	O
215	22	N	O
216	%	N	O
217	)	N	O
218	in	N	O
219	the	N	O
220	temozolomide	N	O
221	+	N	O
222	radiotherapy	N	O
223	arm	N	O
224	.	N	O

225	Patients	N	I-Claim
226	receiving	N	I-Claim
227	concomitant	N	I-Claim
228	and	N	I-Claim
229	maintenance	N	I-Claim
230	temozolomide	N	I-Claim
231	+	N	I-Claim
232	radiotherapy	N	I-Claim
233	had	N	I-Claim
234	significantly	N	I-Claim
235	improved	N	I-Claim
236	overall	N	I-Claim
237	survival	N	I-Claim
238	.	N	I-Claim

239	The	N	I-Premise
240	hazard	N	I-Premise
241	ratio	N	I-Premise
242	was	N	I-Premise
243	0.63	N	I-Premise
244	(	N	I-Premise
245	95	N	I-Premise
246	%	N	I-Premise
247	confidence	N	I-Premise
248	interval	N	I-Premise
249	,	N	I-Premise
250	0.52-0.75	N	I-Premise
251	;	N	I-Premise
252	log-rank	N	I-Premise
253	,	N	I-Premise
254	P	N	I-Premise
255	<	N	I-Premise
256	0.0001	N	I-Premise
257	)	N	I-Premise
258	.	N	I-Premise

259	Median	N	I-Premise
260	survival	N	I-Premise
261	was	N	I-Premise
262	14.6	N	I-Premise
263	months	N	I-Premise
264	(	N	I-Premise
265	temozolomide	N	I-Premise
266	+	N	I-Premise
267	radiotherapy	N	I-Premise
268	)	N	I-Premise
269	versus	N	I-Premise
270	12.1	N	I-Premise
271	months	N	I-Premise
272	(	N	I-Premise
273	radiotherapy	N	I-Premise
274	alone	N	I-Premise
275	)	N	I-Premise
276	.	N	I-Premise

277	Adverse	N	I-Claim
278	events	N	I-Claim
279	during	N	I-Claim
280	temozolomide	N	I-Claim
281	treatment	N	I-Claim
282	included	N	I-Claim
283	thrombocytopenia	N	I-Claim
284	,	N	I-Claim
285	nausea	N	I-Claim
286	,	N	I-Claim
287	vomiting	N	I-Claim
288	,	N	I-Claim
289	anorexia	N	I-Claim
290	,	N	I-Claim
291	constipation	N	I-Claim
292	,	N	I-Claim
293	alopecia	N	I-Claim
294	,	N	I-Claim
295	headache	N	I-Claim
296	,	N	I-Claim
297	fatigue	N	I-Claim
298	,	N	I-Claim
299	and	N	I-Claim
300	convulsions	N	I-Claim
301	.	N	I-Claim

1	The	N	I-Claim
2	combination	N	I-Claim
3	of	N	I-Claim
4	interferon	N	I-Claim
5	alfa	N	I-Claim
6	(	N	I-Claim
7	IFNalpha	N	I-Claim
8	)	N	I-Claim
9	and	N	I-Claim
10	isotretinoin	N	I-Claim
11	has	N	I-Claim
12	shown	N	I-Claim
13	a	N	I-Claim
14	direct	N	I-Claim
15	antiproliferative	N	I-Claim
16	effect	N	I-Claim
17	on	N	I-Claim
18	human	N	I-Claim
19	melanoma	N	I-Claim
20	cell	N	I-Claim
21	lines	N	I-Claim
22	,	N	I-Claim
23	but	N	I-Claim
24	it	N	I-Claim
25	remained	N	I-Claim
26	unclear	N	I-Claim
27	whether	N	I-Claim
28	this	N	I-Claim
29	combination	N	I-Claim
30	is	N	I-Claim
31	more	N	I-Claim
32	effective	N	I-Claim
33	than	N	I-Claim
34	IFNalpha	N	I-Claim
35	alone	N	I-Claim
36	in	N	I-Claim
37	patients	N	I-Claim
38	with	N	I-Claim
39	metastatic	N	I-Claim
40	melanoma	N	I-Claim
41	.	N	I-Claim

42	We	N	O
43	evaluated	N	O
44	safety	N	O
45	and	N	O
46	efficacy	N	O
47	of	N	O
48	IFNalpha	N	O
49	and	N	O
50	isotretinoin	N	O
51	compared	N	O
52	with	N	O
53	IFNalpha	N	O
54	alone	N	O
55	as	N	O
56	adjuvant	N	O
57	treatment	N	O
58	in	N	O
59	patients	N	O
60	with	N	O
61	primary	N	O
62	malignant	N	O
63	melanoma	N	O
64	stage	N	O
65	IIA	N	O
66	and	N	O
67	IIB	N	O
68	.	N	O

69	In	N	O
70	a	N	O
71	prospective	N	O
72	,	N	O
73	randomized	N	O
74	,	N	O
75	double-blind	N	O
76	,	N	O
77	placebo-controlled	N	O
78	trial	N	O
79	,	N	O
80	407	N	O
81	melanoma	N	O
82	patients	N	O
83	in	N	O
84	stage	N	O
85	IIA	N	O
86	(	N	O
87	301	N	O
88	patients	N	O
89	)	N	O
90	and	N	O
91	IIB	N	O
92	(	N	O
93	106	N	O
94	patients	N	O
95	)	N	O
96	were	N	O
97	randomly	N	O
98	assigned	N	O
99	to	N	O
100	either	N	O
101	IFNalpha	N	O
102	and	N	O
103	isotretinoin	N	O
104	(	N	O
105	isotretinoin	N	O
106	group	N	O
107	;	N	O
108	206	N	O
109	patients	N	O
110	)	N	O
111	or	N	O
112	IFNalpha	N	O
113	and	N	O
114	placebo	N	O
115	(	N	O
116	placebo	N	O
117	group	N	O
118	;	N	O
119	201	N	O
120	patients	N	O
121	)	N	O
122	after	N	O
123	excision	N	O
124	of	N	O
125	the	N	O
126	primary	N	O
127	tumor	N	O
128	.	N	O

129	IFNalpha	N	O
130	was	N	O
131	administered	N	O
132	three	N	O
133	times	N	O
134	a	N	O
135	week	N	O
136	at	N	O
137	a	N	O
138	dose	N	O
139	of	N	O
140	3	N	O
141	million	N	O
142	units	N	O
143	subcutaneously	N	O
144	for	N	O
145	24	N	O
146	months	N	O
147	.	N	O

148	Isotretinoin	N	O
149	at	N	O
150	a	N	O
151	dose	N	O
152	of	N	O
153	20	N	O
154	mg	N	O
155	for	N	O
156	patients	N	O
157	<	N	O
158	or	N	O
159	=	N	O
160	73	N	O
161	kg	N	O
162	,	N	O
163	30	N	O
164	mg	N	O
165	for	N	O
166	patients	N	O
167	greater	N	O
168	than	N	O
169	73	N	O
170	kg	N	O
171	,	N	O
172	or	N	O
173	placebo	N	O
174	daily	N	O
175	for	N	O
176	24	N	O
177	months	N	O
178	.	N	O

179	A	N	I-Premise
180	scheduled	N	I-Premise
181	interim	N	I-Premise
182	analysis	N	I-Premise
183	revealed	N	I-Premise
184	no	N	I-Premise
185	significant	N	I-Premise
186	differences	N	I-Premise
187	in	N	I-Premise
188	survival	N	I-Premise
189	rates	N	I-Premise
190	,	N	I-Premise
191	with	N	I-Premise
192	the	N	I-Premise
193	isotretinoin	N	I-Premise
194	group	N	I-Premise
195	and	N	I-Premise
196	the	N	I-Premise
197	placebo	N	I-Premise
198	group	N	I-Premise
199	showing	N	I-Premise
200	5-year	N	I-Premise
201	disease-free	N	I-Premise
202	survival	N	I-Premise
203	rates	N	I-Premise
204	of	N	I-Premise
205	55	N	I-Premise
206	%	N	I-Premise
207	(	N	I-Premise
208	95	N	I-Premise
209	%	N	I-Premise
210	CI	N	I-Premise
211	,	N	I-Premise
212	46	N	I-Premise
213	%	N	I-Premise
214	to	N	I-Premise
215	65	N	I-Premise
216	%	N	I-Premise
217	)	N	I-Premise
218	and	N	I-Premise
219	67	N	I-Premise
220	%	N	I-Premise
221	(	N	I-Premise
222	95	N	I-Premise
223	%	N	I-Premise
224	CI	N	I-Premise
225	,	N	I-Premise
226	59	N	I-Premise
227	%	N	I-Premise
228	to	N	I-Premise
229	75	N	I-Premise
230	%	N	I-Premise
231	)	N	I-Premise
232	,	N	I-Premise
233	respectively	N	I-Premise
234	,	N	I-Premise
235	and	N	I-Premise
236	overall	N	I-Premise
237	5-year	N	I-Premise
238	survival	N	I-Premise
239	rates	N	I-Premise
240	of	N	I-Premise
241	76	N	I-Premise
242	%	N	I-Premise
243	(	N	I-Premise
244	95	N	I-Premise
245	%	N	I-Premise
246	CI	N	I-Premise
247	,	N	I-Premise
248	67	N	I-Premise
249	%	N	I-Premise
250	to	N	I-Premise
251	84	N	I-Premise
252	%	N	I-Premise
253	)	N	I-Premise
254	and	N	I-Premise
255	81	N	I-Premise
256	%	N	I-Premise
257	(	N	I-Premise
258	95	N	I-Premise
259	%	N	I-Premise
260	CI	N	I-Premise
261	,	N	I-Premise
262	74	N	I-Premise
263	%	N	I-Premise
264	to	N	I-Premise
265	88	N	I-Premise
266	%	N	I-Premise
267	)	N	I-Premise
268	,	N	I-Premise
269	respectively	N	I-Premise
270	.	N	I-Premise

271	The	N	O
272	trial	N	O
273	was	N	O
274	stopped	N	O
275	for	N	O
276	futility	N	O
277	.	N	O

278	The	N	I-Claim
279	addition	N	I-Claim
280	of	N	I-Claim
281	isotretinoin	N	I-Claim
282	to	N	I-Claim
283	an	N	I-Claim
284	adjuvant	N	I-Claim
285	treatment	N	I-Claim
286	of	N	I-Claim
287	low-dose	N	I-Claim
288	IFNalpha	N	I-Claim
289	in	N	I-Claim
290	patients	N	I-Claim
291	with	N	I-Claim
292	stage	N	I-Claim
293	IIA	N	I-Claim
294	and	N	I-Claim
295	IIB	N	I-Claim
296	melanoma	N	I-Claim
297	had	N	I-Claim
298	no	N	I-Claim
299	significant	N	I-Claim
300	effect	N	I-Claim
301	on	N	I-Claim
302	disease-free	N	I-Claim
303	or	N	I-Claim
304	overall	N	I-Claim
305	survival	N	I-Claim
306	and	N	I-Claim
307	is	N	I-Claim
308	therefore	N	I-Claim
309	not	N	I-Claim
310	recommended	N	I-Claim
311	.	N	I-Claim

1	We	N	O
2	investigated	N	O
3	the	N	O
4	role	N	O
5	of	N	O
6	tamoxifen	N	O
7	and	N	O
8	radiotherapy	N	O
9	(	N	O
10	RT	N	O
11	)	N	O
12	for	N	O
13	the	N	O
14	prevention	N	O
15	and	N	O
16	treatment	N	O
17	of	N	O
18	gynecomastia	N	O
19	and	N	O
20	breast	N	O
21	pain	N	O
22	during	N	O
23	adjuvant	N	O
24	bicalutamide	N	O
25	monotherapy	N	O
26	after	N	O
27	radical	N	O
28	prostatectomy	N	O
29	(	N	O
30	RP	N	O
31	)	N	O
32	in	N	O
33	patients	N	O
34	with	N	O
35	prostate	N	O
36	cancer	N	O
37	.	N	O

38	Also	N	O
39	,	N	O
40	we	N	O
41	evaluated	N	O
42	their	N	O
43	effects	N	O
44	on	N	O
45	patient	N	O
46	hormonal	N	O
47	status	N	O
48	,	N	O
49	quality	N	O
50	of	N	O
51	life	N	O
52	(	N	O
53	QOL	N	O
54	)	N	O
55	,	N	O
56	sexual	N	O
57	function	N	O
58	and	N	O
59	prostate	N	O
60	specific	N	O
61	antigen	N	O
62	relapse-free	N	O
63	survival	N	O
64	.	N	O

65	This	N	O
66	was	N	O
67	a	N	O
68	multicenter	N	O
69	prospective	N	O
70	trial	N	O
71	.	N	O

72	From	N	O
73	January	N	O
74	2002	N	O
75	to	N	O
76	February	N	O
77	2004	N	O
78	,	N	O
79	102	N	O
80	patients	N	O
81	who	N	O
82	had	N	O
83	undergone	N	O
84	RP	N	O
85	for	N	O
86	localized	N	O
87	or	N	O
88	locally	N	O
89	advanced	N	O
90	prostate	N	O
91	cancer	N	O
92	were	N	O
93	recruited	N	O
94	and	N	O
95	randomized	N	O
96	into	N	O
97	3	N	O
98	groups	N	O
99	,	N	O
100	namely	N	O
101	group	N	O
102	1-those	N	O
103	receiving	N	O
104	only	N	O
105	150	N	O
106	mg	N	O
107	bicalutamide	N	O
108	as	N	O
109	adjuvant	N	O
110	hormonal	N	O
111	therapy	N	O
112	,	N	O
113	group	N	O
114	2-those	N	O
115	receiving	N	O
116	bicalutamide	N	O
117	and	N	O
118	10	N	O
119	mg	N	O
120	tamoxifen	N	O
121	,	N	O
122	and	N	O
123	group	N	O
124	3-those	N	O
125	receiving	N	O
126	bicalutamide	N	O
127	and	N	O
128	RT	N	O
129	.	N	O

130	Patients	N	O
131	in	N	O
132	group	N	O
133	1	N	O
134	in	N	O
135	whom	N	O
136	gynecomastia	N	O
137	or	N	O
138	breast	N	O
139	pain	N	O
140	developed	N	O
141	were	N	O
142	subsequently	N	O
143	randomized	N	O
144	to	N	O
145	receive	N	O
146	tamoxifen	N	O
147	or	N	O
148	RT	N	O
149	soon	N	O
150	after	N	O
151	symptoms	N	O
152	started	N	O
153	.	N	O

154	Gynecomastia	N	O
155	,	N	O
156	breast	N	O
157	pain	N	O
158	,	N	O
159	prostate	N	O
160	specific	N	O
161	antigen	N	O
162	,	N	O
163	QOL	N	O
164	,	N	O
165	sexual	N	O
166	function	N	O
167	and	N	O
168	hormonal	N	O
169	levels	N	O
170	were	N	O
171	assessed	N	O
172	.	N	O

173	Minimum	N	O
174	followup	N	O
175	was	N	O
176	12	N	O
177	months	N	O
178	.	N	O

179	Of	N	I-Premise
180	group	N	I-Premise
181	1	N	I-Premise
182	patients	N	I-Premise
183	67	N	I-Premise
184	%	N	I-Premise
185	had	N	I-Premise
186	gynecomastia	N	I-Premise
187	compared	N	I-Premise
188	with	N	I-Premise
189	8	N	I-Premise
190	%	N	I-Premise
191	in	N	I-Premise
192	group	N	I-Premise
193	2	N	I-Premise
194	and	N	I-Premise
195	34	N	I-Premise
196	%	N	I-Premise
197	in	N	I-Premise
198	group	N	I-Premise
199	3	N	I-Premise
200	.	N	I-Premise

201	Breast	N	I-Premise
202	pain	N	I-Premise
203	was	N	I-Premise
204	more	N	I-Premise
205	frequent	N	I-Premise
206	in	N	I-Premise
207	group	N	I-Premise
208	1	N	I-Premise
209	than	N	I-Premise
210	in	N	I-Premise
211	groups	N	I-Premise
212	2	N	I-Premise
213	and	N	I-Premise
214	3	N	I-Premise
215	(	N	I-Premise
216	58	N	I-Premise
217	%	N	I-Premise
218	vs	N	I-Premise
219	7	N	I-Premise
220	%	N	I-Premise
221	and	N	I-Premise
222	30	N	I-Premise
223	%	N	I-Premise
224	,	N	I-Premise
225	respectively	N	I-Premise
226	)	N	I-Premise
227	.	N	I-Premise

228	Differences	N	I-Premise
229	were	N	I-Premise
230	significant	N	I-Premise
231	between	N	I-Premise
232	groups	N	I-Premise
233	1	N	I-Premise
234	and	N	I-Premise
235	2	N	I-Premise
236	(	N	I-Premise
237	OR	N	I-Premise
238	0.12	N	I-Premise
239	p	N	I-Premise
240	<	N	I-Premise
241	0.001	N	I-Premise
242	)	N	I-Premise
243	,	N	I-Premise
244	and	N	I-Premise
245	groups	N	I-Premise
246	1	N	I-Premise
247	and	N	I-Premise
248	3	N	I-Premise
249	(	N	I-Premise
250	OR	N	I-Premise
251	0.52	N	I-Premise
252	p	N	I-Premise
253	<	N	I-Premise
254	0.01	N	I-Premise
255	)	N	I-Premise
256	.	N	I-Premise

257	In	N	I-Premise
258	patients	N	I-Premise
259	in	N	I-Premise
260	group	N	I-Premise
261	1	N	I-Premise
262	who	N	I-Premise
263	had	N	I-Premise
264	gynecomastia	N	I-Premise
265	or	N	I-Premise
266	breast	N	I-Premise
267	pain	N	I-Premise
268	a	N	I-Premise
269	significant	N	I-Premise
270	decrease	N	I-Premise
271	in	N	I-Premise
272	symptoms	N	I-Premise
273	was	N	I-Premise
274	achieved	N	I-Premise
275	in	N	I-Premise
276	those	N	I-Premise
277	receiving	N	I-Premise
278	tamoxifen	N	I-Premise
279	(	N	I-Premise
280	p	N	I-Premise
281	<	N	I-Premise
282	0.05	N	I-Premise
283	)	N	I-Premise
284	.	N	I-Premise

285	Treatments	N	I-Premise
286	were	N	I-Premise
287	well	N	I-Premise
288	tolerated	N	I-Premise
289	in	N	I-Premise
290	the	N	I-Premise
291	3	N	I-Premise
292	groups	N	I-Premise
293	.	N	I-Premise

294	No	N	I-Premise
295	differences	N	I-Premise
296	in	N	I-Premise
297	QOL	N	I-Premise
298	between	N	I-Premise
299	groups	N	I-Premise
300	2	N	I-Premise
301	and	N	I-Premise
302	3	N	I-Premise
303	were	N	I-Premise
304	found	N	I-Premise
305	.	N	I-Premise

306	At	N	I-Premise
307	a	N	I-Premise
308	median	N	I-Premise
309	followup	N	I-Premise
310	of	N	I-Premise
311	26	N	I-Premise
312	months	N	I-Premise
313	we	N	I-Premise
314	observed	N	I-Premise
315	12	N	I-Premise
316	biochemical	N	I-Premise
317	relapses	N	I-Premise
318	.	N	I-Premise

319	Gynecomastia	N	I-Claim
320	and	N	I-Claim
321	breast	N	I-Claim
322	pain	N	I-Claim
323	induced	N	I-Claim
324	by	N	I-Claim
325	bicalutamide	N	I-Claim
326	monotherapy	N	I-Claim
327	after	N	I-Claim
328	RP	N	I-Claim
329	can	N	I-Claim
330	be	N	I-Claim
331	prevented	N	I-Claim
332	and	N	I-Claim
333	treated	N	I-Claim
334	.	N	I-Claim

335	Tamoxifen	N	I-Claim
336	has	N	I-Claim
337	been	N	I-Claim
338	shown	N	I-Claim
339	to	N	I-Claim
340	be	N	I-Claim
341	more	N	I-Claim
342	effective	N	I-Claim
343	and	N	I-Claim
344	safe	N	I-Claim
345	than	N	I-Claim
346	RT	N	I-Claim
347	in	N	I-Claim
348	this	N	I-Claim
349	setting	N	I-Claim
350	.	N	I-Claim

351	QOL	N	I-Claim
352	and	N	I-Claim
353	sexual	N	I-Claim
354	function	N	I-Claim
355	are	N	I-Claim
356	not	N	I-Claim
357	negatively	N	I-Claim
358	influenced	N	I-Claim
359	by	N	I-Claim
360	these	N	I-Claim
361	2	N	I-Claim
362	treatment	N	I-Claim
363	options	N	I-Claim
364	.	N	O

1	The	N	O
2	majority	N	O
3	of	N	O
4	prostate	N	O
5	carcinoma	N	O
6	survivors	N	O
7	experience	N	O
8	enduring	N	O
9	sexual	N	O
10	difficulties	N	O
11	and	N	O
12	associated	N	O
13	distress	N	O
14	in	N	O
15	the	N	O
16	years	N	O
17	after	N	O
18	definitive	N	O
19	treatment	N	O
20	.	N	O

21	A	N	O
22	counseling	N	O
23	intervention	N	O
24	aimed	N	O
25	at	N	O
26	improving	N	O
27	levels	N	O
28	of	N	O
29	sexual	N	O
30	satisfaction	N	O
31	and	N	O
32	increasing	N	O
33	successful	N	O
34	utilization	N	O
35	of	N	O
36	medical	N	O
37	treatment	N	O
38	for	N	O
39	erectile	N	O
40	dysfunction	N	O
41	(	N	O
42	ED	N	O
43	)	N	O
44	was	N	O
45	developed	N	O
46	and	N	O
47	pilot-tested	N	O
48	for	N	O
49	both	N	O
50	the	N	O
51	survivor	N	O
52	of	N	O
53	prostate	N	O
54	carcinoma	N	O
55	and	N	O
56	his	N	O
57	partner	N	O
58	.	N	O

59	All	N	O
60	male	N	O
61	participants	N	O
62	were	N	O
63	3-month	N	O
64	to	N	O
65	5-year	N	O
66	survivors	N	O
67	of	N	O
68	localized	N	O
69	prostate	N	O
70	carcinoma	N	O
71	who	N	O
72	had	N	O
73	been	N	O
74	treated	N	O
75	with	N	O
76	radical	N	O
77	prostatectomy	N	O
78	or	N	O
79	radiation	N	O
80	therapy	N	O
81	,	N	O
82	and	N	O
83	were	N	O
84	married	N	O
85	or	N	O
86	in	N	O
87	a	N	O
88	committed	N	O
89	relationship	N	O
90	.	N	O

91	Couples	N	O
92	were	N	O
93	randomized	N	O
94	to	N	O
95	attend	N	O
96	four	N	O
97	sessions	N	O
98	of	N	O
99	counseling	N	O
100	together	N	O
101	or	N	O
102	to	N	O
103	have	N	O
104	the	N	O
105	man	N	O
106	attend	N	O
107	alone	N	O
108	.	N	O

109	In	N	O
110	both	N	O
111	groups	N	O
112	,	N	O
113	partners	N	O
114	completed	N	O
115	behavioral	N	O
116	homework	N	O
117	.	N	O

118	The	N	O
119	sessions	N	O
120	included	N	O
121	education	N	O
122	on	N	O
123	prostate	N	O
124	carcinoma	N	O
125	and	N	O
126	sexual	N	O
127	function	N	O
128	and	N	O
129	options	N	O
130	to	N	O
131	treat	N	O
132	ED	N	O
133	as	N	O
134	well	N	O
135	as	N	O
136	sexual	N	O
137	communication	N	O
138	and	N	O
139	stimulation	N	O
140	skills	N	O
141	.	N	O

142	Standardized	N	O
143	questionnaires	N	O
144	at	N	O
145	baseline	N	O
146	,	N	O
147	posttreatment	N	O
148	,	N	O
149	and	N	O
150	at	N	O
151	3-month	N	O
152	and	N	O
153	6-month	N	O
154	follow-up	N	O
155	assessed	N	O
156	sexual	N	O
157	function	N	O
158	,	N	O
159	marital	N	O
160	adjustment	N	O
161	,	N	O
162	psychologic	N	O
163	distress	N	O
164	,	N	O
165	and	N	O
166	utilization	N	O
167	of	N	O
168	treatments	N	O
169	for	N	O
170	ED	N	O
171	.	N	O

172	Fifty-one	N	O
173	of	N	O
174	84	N	O
175	couples	N	O
176	randomized	N	O
177	to	N	O
178	treatment	N	O
179	completed	N	O
180	the	N	O
181	intervention	N	O
182	(	N	O
183	61	N	O
184	%	N	O
185	)	N	O
186	.	N	O

187	Attendance	N	O
188	by	N	O
189	the	N	O
190	partner	N	O
191	did	N	O
192	not	N	O
193	affect	N	O
194	outcomes	N	O
195	.	N	O

196	Participants	N	I-Premise
197	completing	N	I-Premise
198	the	N	I-Premise
199	intervention	N	I-Premise
200	demonstrated	N	I-Premise
201	improvement	N	I-Premise
202	in	N	I-Premise
203	male	N	I-Premise
204	overall	N	I-Premise
205	distress	N	I-Premise
206	(	N	I-Premise
207	P	N	I-Premise
208	<	N	I-Premise
209	0.01	N	I-Premise
210	)	N	I-Premise
211	,	N	I-Premise
212	male	N	I-Premise
213	global	N	I-Premise
214	sexual	N	I-Premise
215	function	N	I-Premise
216	(	N	I-Premise
217	P	N	I-Premise
218	<	N	I-Premise
219	0.0001	N	I-Premise
220	)	N	I-Premise
221	,	N	I-Premise
222	and	N	I-Premise
223	female	N	I-Premise
224	global	N	I-Premise
225	sexual	N	I-Premise
226	function	N	I-Premise
227	(	N	I-Premise
228	P	N	I-Premise
229	<	N	I-Premise
230	0.05	N	I-Premise
231	)	N	I-Premise
232	at	N	I-Premise
233	3-month	N	I-Premise
234	follow-up	N	I-Premise
235	,	N	I-Premise
236	but	N	I-Premise
237	regression	N	I-Premise
238	toward	N	I-Premise
239	baseline	N	I-Premise
240	was	N	I-Premise
241	noted	N	I-Premise
242	at	N	I-Premise
243	6-month	N	I-Premise
244	follow-up	N	I-Premise
245	.	N	I-Premise

246	However	N	I-Premise
247	,	N	I-Premise
248	utilization	N	I-Premise
249	of	N	I-Premise
250	ED	N	I-Premise
251	treatments	N	I-Premise
252	increased	N	I-Premise
253	from	N	I-Premise
254	31	N	I-Premise
255	%	N	I-Premise
256	at	N	I-Premise
257	the	N	I-Premise
258	time	N	I-Premise
259	of	N	I-Premise
260	study	N	I-Premise
261	entry	N	I-Premise
262	to	N	I-Premise
263	49	N	I-Premise
264	%	N	I-Premise
265	at	N	I-Premise
266	the	N	I-Premise
267	6-month	N	I-Premise
268	follow-up	N	I-Premise
269	(	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	0.003	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	The	N	I-Claim
276	results	N	I-Claim
277	of	N	I-Claim
278	this	N	I-Claim
279	brief	N	I-Claim
280	pilot	N	I-Claim
281	counseling	N	I-Claim
282	intervention	N	I-Claim
283	demonstrated	N	I-Claim
284	significant	N	I-Claim
285	gains	N	I-Claim
286	in	N	I-Claim
287	sexual	N	I-Claim
288	function	N	I-Claim
289	and	N	I-Claim
290	satisfaction	N	I-Claim
291	and	N	I-Claim
292	increased	N	I-Claim
293	utilization	N	I-Claim
294	of	N	I-Claim
295	treatments	N	I-Claim
296	for	N	I-Claim
297	ED	N	I-Claim
298	.	N	I-Claim

299	However	N	I-Claim
300	,	N	I-Claim
301	modifications	N	I-Claim
302	are	N	I-Claim
303	needed	N	I-Claim
304	in	N	I-Claim
305	future	N	I-Claim
306	randomized	N	I-Claim
307	trials	N	I-Claim
308	to	N	I-Claim
309	reduce	N	I-Claim
310	the	N	I-Claim
311	rate	N	I-Claim
312	of	N	I-Claim
313	premature	N	I-Claim
314	termination	N	I-Claim
315	and	N	I-Claim
316	to	N	I-Claim
317	improve	N	I-Claim
318	long-term	N	I-Claim
319	maintenance	N	I-Claim
320	of	N	I-Claim
321	gains	N	I-Claim
322	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	outcomes	N	O
5	of	N	O
6	uterine	N	O
7	artery	N	O
8	embolization	N	O
9	(	N	O
10	UAE	N	O
11	)	N	O
12	for	N	O
13	leiomyomas	N	O
14	with	N	O
15	use	N	O
16	of	N	O
17	tris-acryl	N	O
18	gelatin	N	O
19	microspheres	N	O
20	(	N	O
21	TAGM	N	O
22	)	N	O
23	versus	N	O
24	spherical	N	O
25	polyvinyl	N	O
26	alcohol	N	O
27	(	N	O
28	PVA	N	O
29	)	N	O
30	particles	N	O
31	.	N	O

32	Patients	N	O
33	undergoing	N	O
34	UAE	N	O
35	were	N	O
36	randomly	N	O
37	assigned	N	O
38	to	N	O
39	receive	N	O
40	TAGMs	N	O
41	or	N	O
42	PVA	N	O
43	.	N	O

44	Embolization	N	O
45	was	N	O
46	performed	N	O
47	in	N	O
48	a	N	O
49	standardized	N	O
50	manner	N	O
51	.	N	O

52	Outcome	N	O
53	data	N	O
54	were	N	O
55	collected	N	O
56	at	N	O
57	3	N	O
58	months	N	O
59	after	N	O
60	embolization	N	O
61	,	N	O
62	including	N	O
63	assessment	N	O
64	of	N	O
65	clinical	N	O
66	symptoms	N	O
67	,	N	O
68	scores	N	O
69	from	N	O
70	a	N	O
71	fibroid	N	O
72	tumor-specific	N	O
73	symptom	N	O
74	and	N	O
75	quality	N	O
76	of	N	O
77	life	N	O
78	(	N	O
79	QOL	N	O
80	)	N	O
81	questionnaire	N	O
82	,	N	O
83	and	N	O
84	findings	N	O
85	on	N	O
86	contrast	N	O
87	material-enhanced	N	O
88	magnetic	N	O
89	resonance	N	O
90	(	N	O
91	MR	N	O
92	)	N	O
93	imaging	N	O
94	,	N	O
95	including	N	O
96	the	N	O
97	degree	N	O
98	of	N	O
99	tumor	N	O
100	infarction	N	O
101	and	N	O
102	volume	N	O
103	reduction	N	O
104	.	N	O

105	Data	N	O
106	were	N	O
107	analyzed	N	O
108	with	N	O
109	use	N	O
110	of	N	O
111	t	N	O
112	tests	N	O
113	,	N	O
114	the	N	O
115	Mann-Whitney	N	O
116	U	N	O
117	test	N	O
118	,	N	O
119	and	N	O
120	chi2	N	O
121	tests	N	O
122	as	N	O
123	appropriate	N	O
124	.	N	O

125	Thirty-six	N	O
126	patients	N	O
127	were	N	O
128	treated	N	O
129	.	N	O

130	There	N	O
131	were	N	O
132	no	N	O
133	differences	N	O
134	in	N	O
135	the	N	O
136	two	N	O
137	treatment	N	O
138	groups	N	O
139	at	N	O
140	baseline	N	O
141	.	N	O

142	Clinical	N	O
143	follow-up	N	O
144	was	N	O
145	obtained	N	O
146	in	N	O
147	35	N	O
148	patients	N	O
149	.	N	O

150	Among	N	I-Premise
151	the	N	I-Premise
152	clinical	N	I-Premise
153	outcome	N	I-Premise
154	measures	N	I-Premise
155	,	N	I-Premise
156	QOL	N	I-Premise
157	score	N	I-Premise
158	improvement	N	I-Premise
159	was	N	I-Premise
160	greater	N	I-Premise
161	for	N	I-Premise
162	UAE	N	I-Premise
163	with	N	I-Premise
164	TAGMs	N	I-Premise
165	compared	N	I-Premise
166	with	N	I-Premise
167	PVA	N	I-Premise
168	(	N	I-Premise
169	49.0	N	I-Premise
170	vs	N	I-Premise
171	27.9	N	I-Premise
172	;	N	I-Premise
173	P	N	I-Premise
174	=	N	I-Premise
175	.02	N	I-Premise
176	)	N	I-Premise
177	,	N	I-Premise
178	but	N	I-Premise
179	no	N	I-Premise
180	other	N	I-Premise
181	differences	N	I-Premise
182	were	N	I-Premise
183	noted	N	I-Premise
184	.	N	I-Premise

185	Of	N	I-Premise
186	the	N	I-Premise
187	25	N	I-Premise
188	patients	N	I-Premise
189	in	N	I-Premise
190	whom	N	I-Premise
191	3-month	N	I-Premise
192	MR	N	I-Premise
193	imaging	N	I-Premise
194	follow-up	N	I-Premise
195	was	N	I-Premise
196	completed	N	I-Premise
197	,	N	I-Premise
198	those	N	I-Premise
199	treated	N	I-Premise
200	with	N	I-Premise
201	TAGM	N	I-Premise
202	were	N	I-Premise
203	significantly	N	I-Premise
204	more	N	I-Premise
205	likely	N	I-Premise
206	to	N	I-Premise
207	have	N	I-Premise
208	complete	N	I-Premise
209	infarction	N	I-Premise
210	of	N	I-Premise
211	all	N	I-Premise
212	leiomyomas	N	I-Premise
213	(	N	I-Premise
214	six	N	I-Premise
215	patients	N	I-Premise
216	vs	N	I-Premise
217	one	N	I-Premise
218	patient	N	I-Premise
219	;	N	I-Premise
220	P	N	I-Premise
221	=	N	I-Premise
222	.02	N	I-Premise
223	)	N	I-Premise
224	,	N	I-Premise
225	were	N	I-Premise
226	more	N	I-Premise
227	likely	N	I-Premise
228	to	N	I-Premise
229	have	N	I-Premise
230	at	N	I-Premise
231	least	N	I-Premise
232	90	N	I-Premise
233	%	N	I-Premise
234	tumor	N	I-Premise
235	infarction	N	I-Premise
236	(	N	I-Premise
237	eight	N	I-Premise
238	patients	N	I-Premise
239	vs	N	I-Premise
240	four	N	I-Premise
241	patients	N	I-Premise
242	;	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	.03	N	I-Premise
246	)	N	I-Premise
247	,	N	I-Premise
248	and	N	I-Premise
249	had	N	I-Premise
250	a	N	I-Premise
251	lower	N	I-Premise
252	mean	N	I-Premise
253	percent	N	I-Premise
254	of	N	I-Premise
255	residual	N	I-Premise
256	perfused	N	I-Premise
257	fibroid	N	I-Premise
258	tumor	N	I-Premise
259	tissue	N	I-Premise
260	(	N	I-Premise
261	9.6	N	I-Premise
262	%	N	I-Premise
263	vs	N	I-Premise
264	44.3	N	I-Premise
265	%	N	I-Premise
266	;	N	I-Premise
267	P	N	I-Premise
268	=	N	I-Premise
269	.004	N	I-Premise
270	)	N	I-Premise
271	compared	N	I-Premise
272	with	N	I-Premise
273	patients	N	I-Premise
274	treated	N	I-Premise
275	with	N	I-Premise
276	PVA	N	I-Premise
277	.	N	I-Premise

278	Based	N	O
279	on	N	O
280	these	N	O
281	differences	N	O
282	between	N	O
283	the	N	O
284	embolic	N	O
285	agents	N	O
286	,	N	O
287	enrollment	N	O
288	in	N	O
289	this	N	O
290	study	N	O
291	was	N	O
292	terminated	N	O
293	.	N	O

294	The	N	I-Claim
295	use	N	I-Claim
296	of	N	I-Claim
297	spherical	N	I-Claim
298	PVA	N	I-Claim
299	particles	N	I-Claim
300	in	N	I-Claim
301	the	N	I-Claim
302	manner	N	I-Claim
303	described	N	I-Claim
304	herein	N	I-Claim
305	results	N	I-Claim
306	in	N	I-Claim
307	an	N	I-Claim
308	unacceptably	N	I-Claim
309	high	N	I-Claim
310	rate	N	I-Claim
311	of	N	I-Claim
312	failed	N	I-Claim
313	tumor	N	I-Claim
314	infarction	N	I-Claim
315	in	N	I-Claim
316	UAE	N	I-Claim
317	.	N	I-Claim

1	A	N	O
2	randomised	N	O
3	controlled	N	O
4	trial	N	O
5	of	N	O
6	radiotherapy	N	O
7	alone	N	O
8	versus	N	O
9	radiotherapy	N	O
10	with	N	O
11	concomitant	N	O
12	and	N	O
13	adjuvant	N	O
14	temozolomide	N	O
15	for	N	O
16	patients	N	O
17	with	N	O
18	glioblastoma	N	O
19	showed	N	O
20	that	N	O
21	survival	N	O
22	was	N	O
23	higher	N	O
24	for	N	O
25	patients	N	O
26	assigned	N	O
27	combination	N	O
28	treatment	N	O
29	compared	N	O
30	with	N	O
31	those	N	O
32	assigned	N	O
33	standard	N	O
34	radiotherapy	N	O
35	alone	N	O
36	.	N	O

37	This	N	O
38	paper	N	O
39	reports	N	O
40	the	N	O
41	health-related	N	O
42	quality	N	O
43	of	N	O
44	life	N	O
45	(	N	O
46	HRQOL	N	O
47	)	N	O
48	of	N	O
49	the	N	O
50	patients	N	O
51	in	N	O
52	this	N	O
53	trial	N	O
54	.	N	O

55	573	N	O
56	patients	N	O
57	with	N	O
58	newly	N	O
59	diagnosed	N	O
60	glioblastoma	N	O
61	were	N	O
62	randomly	N	O
63	allocated	N	O
64	either	N	O
65	radiotherapy	N	O
66	alone	N	O
67	or	N	O
68	radiotherapy	N	O
69	and	N	O
70	temozolomide	N	O
71	.	N	O

72	The	N	O
73	primary	N	O
74	endpoint	N	O
75	was	N	O
76	survival	N	O
77	,	N	O
78	and	N	O
79	HRQOL	N	O
80	was	N	O
81	a	N	O
82	secondary	N	O
83	endpoint	N	O
84	.	N	O

85	We	N	O
86	assessed	N	O
87	HRQOL	N	O
88	at	N	O
89	baseline	N	O
90	and	N	O
91	at	N	O
92	every	N	O
93	3	N	O
94	months	N	O
95	during	N	O
96	treatment	N	O
97	until	N	O
98	progression	N	O
99	using	N	O
100	the	N	O
101	European	N	O
102	Organisation	N	O
103	for	N	O
104	Research	N	O
105	and	N	O
106	Treatment	N	O
107	of	N	O
108	Cancer	N	O
109	(	N	O
110	EORTC	N	O
111	)	N	O
112	quality	N	O
113	of	N	O
114	life	N	O
115	questionnaire	N	O
116	core-30	N	O
117	(	N	O
118	QLQ-C30	N	O
119	)	N	O
120	and	N	O
121	the	N	O
122	EORTC	N	O
123	brain	N	O
124	cancer	N	O
125	module	N	O
126	(	N	O
127	EORTC	N	O
128	BN-20	N	O
129	)	N	O
130	.	N	O

131	We	N	O
132	calculated	N	O
133	changes	N	O
134	from	N	O
135	baseline	N	O
136	score	N	O
137	for	N	O
138	seven	N	O
139	predefined	N	O
140	HRQOL	N	O
141	measures	N	O
142	(	N	O
143	fatigue	N	O
144	,	N	O
145	overall	N	O
146	health	N	O
147	,	N	O
148	social	N	O
149	function	N	O
150	,	N	O
151	emotional	N	O
152	function	N	O
153	,	N	O
154	future	N	O
155	uncertainty	N	O
156	,	N	O
157	insomnia	N	O
158	,	N	O
159	and	N	O
160	communication	N	O
161	deficit	N	O
162	)	N	O
163	and	N	O
164	differences	N	O
165	between	N	O
166	groups	N	O
167	for	N	O
168	these	N	O
169	measures	N	O
170	at	N	O
171	every	N	O
172	time	N	O
173	point	N	O
174	.	N	O

175	The	N	O
176	significance	N	O
177	of	N	O
178	,	N	O
179	and	N	O
180	proportions	N	O
181	of	N	O
182	patients	N	O
183	with	N	O
184	,	N	O
185	improved	N	O
186	HRQOL	N	O
187	scores	N	O
188	--	N	O
189	defined	N	O
190	as	N	O
191	a	N	O
192	change	N	O
193	of	N	O
194	10	N	O
195	points	N	O
196	or	N	O
197	more	N	O
198	--	N	O
199	were	N	O
200	recorded	N	O
201	.	N	O

202	Baseline	N	O
203	questionnaires	N	O
204	were	N	O
205	available	N	O
206	for	N	O
207	490	N	O
208	(	N	O
209	86	N	O
210	%	N	O
211	)	N	O
212	patients	N	O
213	.	N	O

214	Baseline	N	O
215	HRQOL	N	O
216	scores	N	O
217	did	N	O
218	not	N	O
219	differ	N	O
220	between	N	O
221	groups	N	O
222	.	N	O

223	At	N	I-Premise
224	first	N	I-Premise
225	follow-up	N	I-Premise
226	,	N	I-Premise
227	groups	N	I-Premise
228	differed	N	I-Premise
229	only	N	I-Premise
230	in	N	I-Premise
231	social	N	I-Premise
232	functioning	N	I-Premise
233	,	N	I-Premise
234	favouring	N	I-Premise
235	the	N	I-Premise
236	radiotherapy-only	N	I-Premise
237	group	N	I-Premise
238	(	N	I-Premise
239	mean	N	I-Premise
240	score	N	I-Premise
241	79.0	N	I-Premise
242	[	N	I-Premise
243	SD	N	I-Premise
244	3.2	N	I-Premise
245	]	N	I-Premise
246	for	N	I-Premise
247	patients	N	I-Premise
248	assigned	N	I-Premise
249	radiotherapy	N	I-Premise
250	vs	N	I-Premise
251	67.4	N	I-Premise
252	[	N	I-Premise
253	2.7	N	I-Premise
254	]	N	I-Premise
255	for	N	I-Premise
256	those	N	I-Premise
257	assigned	N	I-Premise
258	radiotherapy	N	I-Premise
259	and	N	I-Premise
260	temozolomide	N	I-Premise
261	;	N	I-Premise
262	difference	N	I-Premise
263	between	N	I-Premise
264	groups	N	I-Premise
265	11.6	N	I-Premise
266	points	N	I-Premise
267	[	N	I-Premise
268	95	N	I-Premise
269	%	N	I-Premise
270	CI	N	I-Premise
271	3.5-19.7	N	I-Premise
272	]	N	I-Premise
273	,	N	I-Premise
274	p=0.0052	N	I-Premise
275	)	N	I-Premise
276	.	N	I-Premise

277	Over	N	I-Premise
278	subsequent	N	I-Premise
279	assessments	N	I-Premise
280	,	N	I-Premise
281	HRQOL	N	I-Premise
282	was	N	I-Premise
283	much	N	I-Premise
284	the	N	I-Premise
285	same	N	I-Premise
286	between	N	I-Premise
287	treatment	N	I-Premise
288	groups	N	I-Premise
289	.	N	I-Premise

290	Addition	N	I-Claim
291	of	N	I-Claim
292	temozolomide	N	I-Claim
293	during	N	I-Claim
294	and	N	I-Claim
295	after	N	I-Claim
296	radiotherapy	N	I-Claim
297	for	N	I-Claim
298	patients	N	I-Claim
299	with	N	I-Claim
300	newly	N	I-Claim
301	diagnosed	N	I-Claim
302	glioblastoma	N	I-Claim
303	significantly	N	I-Claim
304	improved	N	I-Claim
305	survival	N	I-Claim
306	without	N	I-Claim
307	a	N	I-Claim
308	negative	N	I-Claim
309	effect	N	I-Claim
310	on	N	I-Claim
311	HRQOL	N	I-Claim
312	.	N	I-Claim

1	Axillary	N	I-Claim
2	clearance	N	I-Claim
3	in	N	I-Claim
4	early	N	I-Claim
5	breast	N	I-Claim
6	cancer	N	I-Claim
7	aims	N	I-Claim
8	to	N	I-Claim
9	improve	N	I-Claim
10	locoregional	N	I-Claim
11	control	N	I-Claim
12	and	N	I-Claim
13	provide	N	I-Claim
14	staging	N	I-Claim
15	information	N	I-Claim
16	but	N	O
17	is	N	O
18	associated	N	O
19	with	N	O
20	undesirable	N	O
21	morbidity	N	O
22	.	N	O

23	We	N	O
24	therefore	N	O
25	investigated	N	O
26	whether	N	O
27	avoiding	N	O
28	axillary	N	O
29	surgery	N	O
30	in	N	O
31	older	N	O
32	women	N	O
33	would	N	O
34	result	N	O
35	in	N	O
36	improved	N	O
37	quality	N	O
38	of	N	O
39	life	N	O
40	(	N	O
41	QL	N	O
42	)	N	O
43	with	N	O
44	similar	N	O
45	disease-free	N	O
46	survival	N	O
47	(	N	O
48	DFS	N	O
49	)	N	O
50	and	N	O
51	overall	N	O
52	survival	N	O
53	(	N	O
54	OS	N	O
55	)	N	O
56	.	N	O

57	Between	N	O
58	1993	N	O
59	and	N	O
60	2002	N	O
61	,	N	O
62	women	N	O
63	>	N	O
64	or	N	O
65	=	N	O
66	60	N	O
67	years	N	O
68	old	N	O
69	with	N	O
70	clinically	N	O
71	node-negative	N	O
72	operable	N	O
73	breast	N	O
74	cancer	N	O
75	in	N	O
76	whom	N	O
77	adjuvant	N	O
78	tamoxifen	N	O
79	was	N	O
80	considered	N	O
81	indicated	N	O
82	regardless	N	O
83	of	N	O
84	pathologic	N	O
85	nodal	N	O
86	status	N	O
87	were	N	O
88	randomly	N	O
89	assigned	N	O
90	to	N	O
91	primary	N	O
92	surgery	N	O
93	plus	N	O
94	axillary	N	O
95	clearance	N	O
96	(	N	O
97	Sx	N	O
98	+	N	O
99	Ax	N	O
100	)	N	O
101	followed	N	O
102	by	N	O
103	tamoxifen	N	O
104	(	N	O
105	Tam	N	O
106	)	N	O
107	versus	N	O
108	Sx	N	O
109	without	N	O
110	Ax	N	O
111	followed	N	O
112	by	N	O
113	Tam	N	O
114	for	N	O
115	5	N	O
116	consecutive	N	O
117	years	N	O
118	.	N	O

119	The	N	O
120	primary	N	O
121	end	N	O
122	point	N	O
123	was	N	O
124	QL	N	O
125	reported	N	O
126	by	N	O
127	the	N	O
128	patient	N	O
129	and	N	O
130	by	N	O
131	physician	N	O
132	assessment	N	O
133	.	N	O

134	A	N	O
135	total	N	O
136	of	N	O
137	473	N	O
138	patients	N	O
139	(	N	O
140	234	N	O
141	to	N	O
142	Sx	N	O
143	+	N	O
144	Ax	N	O
145	,	N	O
146	239	N	O
147	to	N	O
148	Sx	N	O
149	)	N	O
150	were	N	O
151	randomly	N	O
152	assigned	N	O
153	.	N	O

154	The	N	O
155	median	N	O
156	age	N	O
157	was	N	O
158	74	N	O
159	years	N	O
160	;	N	O
161	80	N	O
162	%	N	O
163	had	N	O
164	estrogen	N	O
165	receptor-positive	N	O
166	disease	N	O
167	.	N	O

168	In	N	I-Premise
169	both	N	I-Premise
170	the	N	I-Premise
171	patients	N	I-Premise
172	'	N	I-Premise
173	subjective	N	I-Premise
174	assessment	N	I-Premise
175	of	N	I-Premise
176	their	N	I-Premise
177	QL	N	I-Premise
178	and	N	I-Premise
179	the	N	I-Premise
180	physicians	N	I-Premise
181	'	N	I-Premise
182	perception	N	I-Premise
183	of	N	I-Premise
184	the	N	I-Premise
185	patients	N	I-Premise
186	'	N	I-Premise
187	QL	N	I-Premise
188	,	N	I-Premise
189	the	N	I-Premise
190	largest	N	I-Premise
191	adverse	N	I-Premise
192	QL	N	I-Premise
193	effects	N	I-Premise
194	of	N	I-Premise
195	Ax	N	I-Premise
196	were	N	I-Premise
197	observed	N	I-Premise
198	from	N	I-Premise
199	baseline	N	I-Premise
200	to	N	I-Premise
201	the	N	I-Premise
202	first	N	I-Premise
203	postoperative	N	I-Premise
204	assessment	N	I-Premise
205	,	N	I-Premise
206	but	N	I-Premise
207	the	N	I-Premise
208	differences	N	I-Premise
209	tended	N	I-Premise
210	to	N	I-Premise
211	disappear	N	I-Premise
212	in	N	I-Premise
213	6	N	I-Premise
214	to	N	I-Premise
215	12	N	I-Premise
216	months	N	I-Premise
217	.	N	I-Premise

218	At	N	I-Premise
219	a	N	I-Premise
220	median	N	I-Premise
221	follow-up	N	I-Premise
222	of	N	I-Premise
223	6.6	N	I-Premise
224	years	N	I-Premise
225	,	N	I-Premise
226	results	N	I-Premise
227	for	N	I-Premise
228	Sx	N	I-Premise
229	+	N	I-Premise
230	Ax	N	I-Premise
231	and	N	I-Premise
232	Sx	N	I-Premise
233	yielded	N	I-Premise
234	similar	N	I-Premise
235	DFS	N	I-Premise
236	(	N	I-Premise
237	6-year	N	I-Premise
238	DFS	N	I-Premise
239	,	N	I-Premise
240	67	N	I-Premise
241	%	N	I-Premise
242	v	N	I-Premise
243	66	N	I-Premise
244	%	N	I-Premise
245	;	N	I-Premise
246	hazard	N	I-Premise
247	ratio	N	I-Premise
248	[	N	I-Premise
249	HR	N	I-Premise
250	]	N	I-Premise
251	Sx	N	I-Premise
252	+	N	I-Premise
253	Ax/Sx	N	I-Premise
254	,	N	I-Premise
255	1.06	N	I-Premise
256	;	N	I-Premise
257	95	N	I-Premise
258	%	N	I-Premise
259	CI	N	I-Premise
260	,	N	I-Premise
261	0.79	N	I-Premise
262	to	N	I-Premise
263	1.42	N	I-Premise
264	;	N	I-Premise
265	P	N	I-Premise
266	=	N	I-Premise
267	.69	N	I-Premise
268	)	N	I-Premise
269	and	N	I-Premise
270	OS	N	I-Premise
271	(	N	I-Premise
272	6-year	N	I-Premise
273	OS	N	I-Premise
274	,	N	I-Premise
275	75	N	I-Premise
276	%	N	I-Premise
277	v	N	I-Premise
278	73	N	I-Premise
279	%	N	I-Premise
280	;	N	I-Premise
281	HR	N	I-Premise
282	Sx	N	I-Premise
283	+	N	I-Premise
284	Ax/Sx	N	I-Premise
285	,	N	I-Premise
286	1.05	N	I-Premise
287	;	N	I-Premise
288	95	N	I-Premise
289	%	N	I-Premise
290	CI	N	I-Premise
291	,	N	I-Premise
292	0.76	N	I-Premise
293	to	N	I-Premise
294	1.46	N	I-Premise
295	;	N	I-Premise
296	P	N	I-Premise
297	=	N	I-Premise
298	.77	N	I-Premise
299	)	N	I-Premise
300	.	N	I-Premise

301	Avoiding	N	I-Claim
302	axillary	N	I-Claim
303	clearance	N	I-Claim
304	for	N	I-Claim
305	women	N	I-Claim
306	>	N	I-Claim
307	or	N	I-Claim
308	=	N	I-Claim
309	60	N	I-Claim
310	years	N	I-Claim
311	old	N	I-Claim
312	who	N	I-Claim
313	have	N	I-Claim
314	clinically	N	I-Claim
315	node-negative	N	I-Claim
316	disease	N	I-Claim
317	and	N	I-Claim
318	receive	N	I-Claim
319	Tam	N	I-Claim
320	for	N	I-Claim
321	endocrine-responsive	N	I-Claim
322	disease	N	I-Claim
323	yields	N	I-Claim
324	similar	N	I-Claim
325	efficacy	N	I-Claim
326	with	N	I-Claim
327	better	N	I-Claim
328	early	N	I-Claim
329	QL	N	I-Claim
330	.	N	I-Claim

1	Chemotherapy	N	I-Claim
2	can	N	I-Claim
3	profoundly	N	I-Claim
4	affect	N	I-Claim
5	patients	N	I-Claim
6	'	N	I-Claim
7	quality	N	I-Claim
8	of	N	I-Claim
9	life	N	I-Claim
10	(	N	I-Claim
11	QOL	N	I-Claim
12	)	N	I-Claim
13	,	N	I-Claim
14	yet	N	O
15	few	N	O
16	clinical	N	O
17	trials	N	O
18	in	N	O
19	advanced	N	O
20	cervical	N	O
21	cancer	N	O
22	have	N	O
23	included	N	O
24	QOL	N	O
25	outcomes	N	O
26	.	N	O

27	Our	N	O
28	purpose	N	O
29	was	N	O
30	to	N	O
31	assess	N	O
32	the	N	O
33	impact	N	O
34	of	N	O
35	cisplatin	N	O
36	(	N	O
37	C	N	O
38	)	N	O
39	versus	N	O
40	cisplatin	N	O
41	plus	N	O
42	paclitaxel	N	O
43	(	N	O
44	CP	N	O
45	)	N	O
46	on	N	O
47	overall	N	O
48	QOL	N	O
49	and	N	O
50	pain	N	O
51	in	N	O
52	cervical	N	O
53	cancer	N	O
54	patients	N	O
55	.	N	O

56	QOL	N	O
57	was	N	O
58	assessed	N	O
59	using	N	O
60	FACT-Cx	N	O
61	,	N	O
62	consisting	N	O
63	of	N	O
64	the	N	O
65	Functional	N	O
66	Assessment	N	O
67	of	N	O
68	Cancer	N	O
69	Therapy	N	O
70	(	N	O
71	FACT-G	N	O
72	)	N	O
73	plus	N	O
74	a	N	O
75	cervix	N	O
76	cancer-specific	N	O
77	subscale	N	O
78	,	N	O
79	the	N	O
80	Brief	N	O
81	Pain	N	O
82	Inventory-Short	N	O
83	Form	N	O
84	(	N	O
85	BPI-SF	N	O
86	)	N	O
87	,	N	O
88	and	N	O
89	a	N	O
90	neurotoxicity	N	O
91	subscale	N	O
92	.	N	O

93	Time	N	O
94	points	N	O
95	were	N	O
96	:	N	O
97	baseline	N	O
98	(	N	O
99	prior	N	O
100	to	N	O
101	randomization	N	O
102	)	N	O
103	and	N	O
104	prior	N	O
105	to	N	O
106	chemotherapy	N	O
107	cycles	N	O
108	2	N	O
109	,	N	O
110	3	N	O
111	,	N	O
112	and	N	O
113	4	N	O
114	.	N	O

115	Overall	N	I-Premise
116	(	N	I-Premise
117	FACT-G	N	I-Premise
118	)	N	I-Premise
119	scores	N	I-Premise
120	did	N	I-Premise
121	not	N	I-Premise
122	differ	N	I-Premise
123	significantly	N	I-Premise
124	between	N	I-Premise
125	arms	N	I-Premise
126	at	N	I-Premise
127	the	N	I-Premise
128	fourth	N	I-Premise
129	assessment	N	I-Premise
130	(	N	I-Premise
131	C	N	I-Premise
132	=	N	I-Premise
133	70.3	N	I-Premise
134	(	N	I-Premise
135	19.6	N	I-Premise
136	)	N	I-Premise
137	;	N	I-Premise
138	CP	N	I-Premise
139	=	N	I-Premise
140	72.8	N	I-Premise
141	(	N	I-Premise
142	17.4	N	I-Premise
143	)	N	I-Premise
144	)	N	I-Premise
145	.	N	I-Premise

146	Scores	N	I-Premise
147	were	N	I-Premise
148	stable	N	I-Premise
149	over	N	I-Premise
150	time	N	I-Premise
151	and	N	I-Premise
152	considerably	N	I-Premise
153	lower	N	I-Premise
154	than	N	I-Premise
155	the	N	I-Premise
156	general	N	I-Premise
157	population	N	I-Premise
158	norms	N	I-Premise
159	.	N	I-Premise

160	The	N	I-Premise
161	BPI-SF	N	I-Premise
162	revealed	N	I-Premise
163	a	N	I-Premise
164	decline	N	I-Premise
165	in	N	I-Premise
166	pain	N	I-Premise
167	scores	N	I-Premise
168	in	N	I-Premise
169	both	N	I-Premise
170	arms	N	I-Premise
171	from	N	I-Premise
172	the	N	I-Premise
173	first	N	I-Premise
174	to	N	I-Premise
175	fourth	N	I-Premise
176	assessments	N	I-Premise
177	.	N	I-Premise

178	The	N	I-Premise
179	CP	N	I-Premise
180	arm	N	I-Premise
181	produced	N	I-Premise
182	a	N	I-Premise
183	significantly	N	I-Premise
184	higher	N	I-Premise
185	response	N	I-Premise
186	rate	N	I-Premise
187	and	N	I-Premise
188	progression-free	N	I-Premise
189	survival	N	I-Premise
190	(	N	I-Premise
191	PFS	N	I-Premise
192	)	N	I-Premise
193	but	N	I-Premise
194	not	N	I-Premise
195	overall	N	I-Premise
196	survival	N	I-Premise
197	(	N	I-Premise
198	OS	N	I-Premise
199	)	N	I-Premise
200	.	N	I-Premise

201	Greater	N	I-Premise
202	myelosuppression	N	I-Premise
203	was	N	I-Premise
204	reported	N	I-Premise
205	in	N	I-Premise
206	the	N	I-Premise
207	combination	N	I-Premise
208	arm	N	I-Premise
209	.	N	I-Premise

210	The	N	I-Premise
211	rate	N	I-Premise
212	of	N	I-Premise
213	QOL	N	I-Premise
214	drop-out	N	I-Premise
215	for	N	I-Premise
216	any	N	I-Premise
217	reason	N	I-Premise
218	was	N	I-Premise
219	higher	N	I-Premise
220	for	N	I-Premise
221	C	N	I-Premise
222	(	N	I-Premise
223	53	N	I-Premise
224	%	N	I-Premise
225	)	N	I-Premise
226	compared	N	I-Premise
227	to	N	I-Premise
228	CP	N	I-Premise
229	(	N	I-Premise
230	38	N	I-Premise
231	%	N	I-Premise
232	)	N	I-Premise
233	(	N	I-Premise
234	P	N	I-Premise
235	<	N	I-Premise
236	0.05	N	I-Premise
237	)	N	I-Premise
238	.	N	I-Premise

239	At	N	O
240	the	N	O
241	fourth	N	O
242	time	N	O
243	point	N	O
244	,	N	O
245	60	N	O
246	%	N	O
247	of	N	O
248	living	N	O
249	patients	N	O
250	in	N	O
251	both	N	O
252	arms	N	O
253	completed	N	O
254	a	N	O
255	QOL	N	O
256	assessment	N	O
257	.	N	O

258	There	N	I-Claim
259	was	N	I-Claim
260	no	N	I-Claim
261	significant	N	I-Claim
262	difference	N	I-Claim
263	in	N	I-Claim
264	overall	N	I-Claim
265	QOL	N	I-Claim
266	scores	N	I-Claim
267	between	N	I-Claim
268	treatment	N	I-Claim
269	arms	N	I-Claim
270	or	N	I-Claim
271	serially	N	I-Claim
272	.	N	I-Claim

273	Combined	N	I-Claim
274	with	N	I-Claim
275	QOL	N	I-Claim
276	results	N	I-Claim
277	,	N	I-Claim
278	the	N	I-Claim
279	significant	N	I-Claim
280	increase	N	I-Claim
281	in	N	I-Claim
282	response	N	I-Claim
283	and	N	I-Claim
284	PFS	N	I-Claim
285	in	N	I-Claim
286	the	N	I-Claim
287	CP	N	I-Claim
288	arm	N	I-Claim
289	and	N	I-Claim
290	the	N	I-Claim
291	higher	N	I-Claim
292	drop-out	N	I-Claim
293	rate	N	I-Claim
294	in	N	I-Claim
295	the	N	I-Claim
296	C	N	I-Claim
297	arm	N	I-Claim
298	suggest	N	I-Claim
299	a	N	I-Claim
300	better	N	I-Claim
301	outcome	N	I-Claim
302	for	N	I-Claim
303	the	N	I-Claim
304	combination	N	I-Claim
305	regimen	N	I-Claim
306	despite	N	I-Claim
307	its	N	I-Claim
308	increased	N	I-Claim
309	myelosuppression	N	I-Claim
310	.	N	I-Claim

1	After	N	O
2	surgery	N	O
3	for	N	O
4	differentiated	N	O
5	thyroid	N	O
6	carcinoma	N	O
7	,	N	O
8	many	N	O
9	patients	N	O
10	are	N	O
11	treated	N	O
12	with	N	O
13	radioiodine	N	O
14	to	N	O
15	ablate	N	O
16	remnant	N	O
17	thyroid	N	O
18	tissue	N	O
19	.	N	O

20	This	N	I-Claim
21	procedure	N	I-Claim
22	has	N	I-Claim
23	been	N	I-Claim
24	performed	N	I-Claim
25	with	N	I-Claim
26	the	N	I-Claim
27	patient	N	I-Claim
28	in	N	I-Claim
29	the	N	I-Claim
30	hypothyroid	N	I-Claim
31	state	N	I-Claim
32	to	N	I-Claim
33	promote	N	I-Claim
34	endogenous	N	I-Claim
35	TSH	N	I-Claim
36	stimulation	N	I-Claim
37	and	N	I-Claim
38	is	N	I-Claim
39	often	N	I-Claim
40	associated	N	I-Claim
41	with	N	I-Claim
42	hypothyroid	N	I-Claim
43	symptoms	N	I-Claim
44	and	N	I-Claim
45	impaired	N	I-Claim
46	quality	N	I-Claim
47	of	N	I-Claim
48	life	N	I-Claim
49	.	N	I-Claim

50	This	N	O
51	international	N	O
52	,	N	O
53	randomized	N	O
54	,	N	O
55	controlled	N	O
56	,	N	O
57	multicenter	N	O
58	trial	N	O
59	aimed	N	O
60	to	N	O
61	compare	N	O
62	the	N	O
63	efficacy	N	O
64	and	N	O
65	safety	N	O
66	of	N	O
67	recombinant	N	O
68	human	N	O
69	TSH	N	O
70	(	N	O
71	rhTSH	N	O
72	)	N	O
73	to	N	O
74	prepare	N	O
75	euthyroid	N	O
76	patients	N	O
77	on	N	O
78	L-thyroxine	N	O
79	therapy	N	O
80	(	N	O
81	euthyroid	N	O
82	group	N	O
83	)	N	O
84	to	N	O
85	ablate	N	O
86	remnant	N	O
87	thyroid	N	O
88	tissue	N	O
89	with	N	O
90	3.7	N	O
91	GBq	N	O
92	(	N	O
93	100	N	O
94	mCi	N	O
95	)	N	O
96	131I	N	O
97	,	N	O
98	compared	N	O
99	with	N	O
100	that	N	O
101	with	N	O
102	conventional	N	O
103	remnant	N	O
104	ablation	N	O
105	performed	N	O
106	in	N	O
107	the	N	O
108	hypothyroid	N	O
109	state	N	O
110	(	N	O
111	hypothyroid	N	O
112	group	N	O
113	)	N	O
114	.	N	O

115	Quality	N	O
116	of	N	O
117	life	N	O
118	was	N	O
119	determined	N	O
120	at	N	O
121	the	N	O
122	time	N	O
123	of	N	O
124	randomization	N	O
125	and	N	O
126	ablation	N	O
127	.	N	O

128	After	N	O
129	the	N	O
130	administration	N	O
131	of	N	O
132	the	N	O
133	131-I	N	O
134	dose	N	O
135	,	N	O
136	the	N	O
137	rate	N	O
138	of	N	O
139	radiation	N	O
140	clearance	N	O
141	from	N	O
142	blood	N	O
143	,	N	O
144	thyroid	N	O
145	remnant	N	O
146	,	N	O
147	and	N	O
148	whole	N	O
149	body	N	O
150	was	N	O
151	measured	N	O
152	.	N	O

153	The	N	O
154	predefined	N	O
155	primary	N	O
156	criterion	N	O
157	for	N	O
158	successful	N	O
159	ablation	N	O
160	was	N	O
161	``	N	O
162	no	N	O
163	visible	N	O
164	uptake	N	O
165	in	N	O
166	the	N	O
167	thyroid	N	O
168	bed	N	O
169	,	N	O
170	or	N	O
171	if	N	O
172	visible	N	O
173	,	N	O
174	fractional	N	O
175	uptake	N	O
176	less	N	O
177	than	N	O
178	0.1	N	O
179	%	N	O
180	''	N	O
181	on	N	O
182	neck	N	O
183	scans	N	O
184	performed	N	O
185	8	N	O
186	months	N	O
187	after	N	O
188	therapy	N	O
189	and	N	O
190	was	N	O
191	satisfied	N	O
192	in	N	O
193	100	N	O
194	%	N	O
195	of	N	O
196	patients	N	O
197	in	N	O
198	both	N	O
199	groups	N	O
200	.	N	O

201	A	N	O
202	secondary	N	O
203	criterion	N	O
204	for	N	O
205	ablation	N	O
206	,	N	O
207	an	N	O
208	rhTSH-stimulated	N	O
209	serum	N	O
210	thyroglobulin	N	O
211	concentration	N	O
212	less	N	O
213	than	N	O
214	2	N	O
215	ng/ml	N	O
216	,	N	O
217	was	N	O
218	fulfilled	N	O
219	by	N	O
220	23	N	O
221	of	N	O
222	24	N	O
223	(	N	O
224	96	N	O
225	%	N	O
226	)	N	O
227	euthyroid	N	O
228	patients	N	O
229	and	N	O
230	18	N	O
231	of	N	O
232	21	N	O
233	(	N	O
234	86	N	O
235	%	N	O
236	)	N	O
237	hypothyroid	N	O
238	patients	N	O
239	(	N	O
240	P	N	O
241	=	N	O
242	0.2341	N	O
243	)	N	O
244	.	N	O

245	Quality	N	I-Premise
246	of	N	I-Premise
247	life	N	I-Premise
248	was	N	I-Premise
249	well	N	I-Premise
250	preserved	N	I-Premise
251	in	N	I-Premise
252	the	N	I-Premise
253	euthyroid	N	I-Premise
254	group	N	I-Premise
255	,	N	I-Premise
256	compared	N	I-Premise
257	with	N	I-Premise
258	the	N	I-Premise
259	hypothyroid	N	I-Premise
260	group	N	I-Premise
261	,	N	I-Premise
262	as	N	I-Premise
263	demonstrated	N	I-Premise
264	by	N	I-Premise
265	their	N	I-Premise
266	lower	N	I-Premise
267	pretreatment	N	I-Premise
268	scores	N	I-Premise
269	on	N	I-Premise
270	the	N	I-Premise
271	Billewicz	N	I-Premise
272	scale	N	I-Premise
273	for	N	I-Premise
274	hypothyroid	N	I-Premise
275	signs	N	I-Premise
276	and	N	I-Premise
277	symptoms	N	I-Premise
278	,	N	I-Premise
279	27	N	I-Premise
280	+/-	N	I-Premise
281	7	N	I-Premise
282	vs.	N	I-Premise
283	18	N	I-Premise
284	+/-	N	I-Premise
285	4	N	I-Premise
286	(	N	I-Premise
287	P	N	I-Premise
288	<	N	I-Premise
289	0.0001	N	I-Premise
290	)	N	I-Premise
291	and	N	I-Premise
292	their	N	I-Premise
293	significantly	N	I-Premise
294	higher	N	I-Premise
295	Short	N	I-Premise
296	Form-36	N	I-Premise
297	Health	N	I-Premise
298	Assessment	N	I-Premise
299	Scale	N	I-Premise
300	scores	N	I-Premise
301	in	N	I-Premise
302	five	N	I-Premise
303	of	N	I-Premise
304	eight	N	I-Premise
305	categories	N	I-Premise
306	.	N	I-Premise

307	Euthyroid	N	I-Premise
308	patients	N	I-Premise
309	had	N	I-Premise
310	a	N	I-Premise
311	statistically	N	I-Premise
312	significant	N	I-Premise
313	one	N	I-Premise
314	third	N	I-Premise
315	lower	N	I-Premise
316	radiation	N	I-Premise
317	dose	N	I-Premise
318	to	N	I-Premise
319	the	N	I-Premise
320	blood	N	I-Premise
321	,	N	I-Premise
322	compared	N	I-Premise
323	with	N	I-Premise
324	patients	N	I-Premise
325	in	N	I-Premise
326	the	N	I-Premise
327	hypothyroid	N	I-Premise
328	group	N	I-Premise
329	.	N	I-Premise

330	This	N	I-Claim
331	study	N	I-Claim
332	demonstrates	N	I-Claim
333	comparable	N	I-Claim
334	remnant	N	I-Claim
335	ablation	N	I-Claim
336	rates	N	I-Claim
337	in	N	I-Claim
338	patients	N	I-Claim
339	prepared	N	I-Claim
340	for	N	I-Claim
341	131I	N	I-Claim
342	remnant	N	I-Claim
343	ablation	N	I-Claim
344	with	N	I-Claim
345	3.7	N	I-Claim
346	GBq	N	I-Claim
347	by	N	I-Claim
348	either	N	I-Claim
349	administering	N	I-Claim
350	rhTSH	N	I-Claim
351	or	N	I-Claim
352	withholding	N	I-Claim
353	thyroid	N	I-Claim
354	hormone	N	I-Claim
355	.	N	I-Claim

356	rhTSH-prepared	N	I-Claim
357	patients	N	I-Claim
358	maintained	N	I-Claim
359	a	N	I-Claim
360	higher	N	I-Claim
361	quality	N	I-Claim
362	of	N	I-Claim
363	life	N	I-Claim
364	and	N	I-Claim
365	received	N	I-Claim
366	less	N	I-Claim
367	radiation	N	I-Claim
368	exposure	N	I-Claim
369	to	N	I-Claim
370	the	N	I-Claim
371	blood	N	I-Claim
372	.	N	I-Claim

1	Patients	N	O
2	with	N	O
3	cancer	N	O
4	are	N	O
5	characterized	N	O
6	by	N	O
7	a	N	O
8	profound	N	O
9	impairment	N	O
10	of	N	O
11	glucose	N	O
12	utilization	N	O
13	,	N	O
14	with	N	O
15	lipids	N	O
16	being	N	O
17	the	N	O
18	preferred	N	O
19	metabolic	N	O
20	fuel	N	O
21	.	N	O

22	In	N	O
23	contrast	N	O
24	,	N	O
25	the	N	O
26	energy	N	O
27	needs	N	O
28	of	N	O
29	malignant	N	O
30	tumors	N	O
31	are	N	O
32	almost	N	O
33	entirely	N	O
34	met	N	O
35	by	N	O
36	glucose	N	O
37	.	N	O

38	We	N	O
39	therefore	N	O
40	studied	N	O
41	the	N	O
42	effects	N	O
43	of	N	O
44	a	N	O
45	high-fat	N	O
46	diet	N	O
47	,	N	O
48	particularly	N	O
49	on	N	O
50	body	N	O
51	composition	N	O
52	.	N	O

53	Twenty-three	N	O
54	moderately	N	O
55	malnourished	N	O
56	patients	N	O
57	with	N	O
58	gastrointestinal	N	O
59	carcinomas	N	O
60	were	N	O
61	randomized	N	O
62	to	N	O
63	receive	N	O
64	either	N	O
65	a	N	O
66	conventional	N	O
67	diet	N	O
68	supplying	N	O
69	35	N	O
70	nonprotein	N	O
71	kcal	N	O
72	and	N	O
73	1.1	N	O
74	g	N	O
75	of	N	O
76	protein/kg	N	O
77	per	N	O
78	day	N	O
79	(	N	O
80	group	N	O
81	A	N	O
82	,	N	O
83	n	N	O
84	=	N	O
85	11	N	O
86	)	N	O
87	or	N	O
88	a	N	O
89	fat-enriched	N	O
90	artificial	N	O
91	liquid	N	O
92	diet	N	O
93	(	N	O
94	20	N	O
95	nonprotein	N	O
96	kcal/kg	N	O
97	per	N	O
98	day	N	O
99	)	N	O
100	plus	N	O
101	normal	N	O
102	meals	N	O
103	(	N	O
104	group	N	O
105	B	N	O
106	,	N	O
107	n	N	O
108	=	N	O
109	12	N	O
110	)	N	O
111	for	N	O
112	a	N	O
113	period	N	O
114	of	N	O
115	eight	N	O
116	weeks	N	O
117	,	N	O
118	i.e.	N	O
119	,	N	O
120	from	N	O
121	the	N	O
122	first	N	O
123	to	N	O
124	the	N	O
125	third	N	O
126	chemotherapy	N	O
127	cycle	N	O
128	.	N	O

129	The	N	O
130	fat	N	O
131	content	N	O
132	of	N	O
133	the	N	O
134	artificial	N	O
135	diet	N	O
136	was	N	O
137	66	N	O
138	%	N	O
139	of	N	O
140	the	N	O
141	nonprotein	N	O
142	calories	N	O
143	.	N	O

144	The	N	O
145	day	N	O
146	before	N	O
147	the	N	O
148	nutritional	N	O
149	interventions	N	O
150	,	N	O
151	and	N	O
152	again	N	O
153	after	N	O
154	four	N	O
155	and	N	O
156	eight	N	O
157	weeks	N	O
158	,	N	O
159	body	N	O
160	compartments	N	O
161	were	N	O
162	determined	N	O
163	using	N	O
164	bioelectrical	N	O
165	impedance	N	O
166	analysis	N	O
167	,	N	O
168	lymphocyte	N	O
169	subpopulations	N	O
170	were	N	O
171	quantified	N	O
172	using	N	O
173	flow	N	O
174	cytometry	N	O
175	,	N	O
176	and	N	O
177	some	N	O
178	aspects	N	O
179	of	N	O
180	the	N	O
181	quality	N	O
182	of	N	O
183	life	N	O
184	were	N	O
185	rated	N	O
186	using	N	O
187	four	N	O
188	linear	N	O
189	analog	N	O
190	self-assessment	N	O
191	(	N	O
192	LASA	N	O
193	)	N	O
194	scales	N	O
195	.	N	O

196	The	N	O
197	statistical	N	O
198	calculations	N	O
199	were	N	O
200	done	N	O
201	as	N	O
202	an	N	O
203	exploratory	N	O
204	data	N	O
205	analysis	N	O
206	.	N	O

207	The	N	O
208	consumption	N	O
209	of	N	O
210	non-protein	N	O
211	calories	N	O
212	did	N	O
213	not	N	O
214	differ	N	O
215	significantly	N	O
216	between	N	O
217	the	N	O
218	two	N	O
219	patient	N	O
220	groups	N	O
221	.	N	O

222	An	N	I-Premise
223	average	N	I-Premise
224	weight	N	I-Premise
225	gain	N	I-Premise
226	in	N	I-Premise
227	group	N	I-Premise
228	B	N	I-Premise
229	contrasted	N	I-Premise
230	with	N	I-Premise
231	an	N	I-Premise
232	average	N	I-Premise
233	weight	N	I-Premise
234	loss	N	I-Premise
235	in	N	I-Premise
236	group	N	I-Premise
237	A	N	I-Premise
238	after	N	I-Premise
239	four	N	I-Premise
240	(	N	I-Premise
241	P	N	I-Premise
242	<	N	I-Premise
243	0.01	N	I-Premise
244	)	N	I-Premise
245	and	N	I-Premise
246	eight	N	I-Premise
247	weeks	N	I-Premise
248	(	N	I-Premise
249	P	N	I-Premise
250	<	N	I-Premise
251	0.05	N	I-Premise
252	)	N	I-Premise
253	.	N	I-Premise

254	Fat-free	N	I-Premise
255	mass	N	I-Premise
256	showed	N	I-Premise
257	an	N	I-Premise
258	intergroup	N	I-Premise
259	difference	N	I-Premise
260	in	N	I-Premise
261	favor	N	I-Premise
262	of	N	I-Premise
263	group	N	I-Premise
264	B	N	I-Premise
265	after	N	I-Premise
266	eight	N	I-Premise
267	weeks	N	I-Premise
268	(	N	I-Premise
269	P	N	I-Premise
270	<	N	I-Premise
271	0.05	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	Body	N	I-Premise
275	cell	N	I-Premise
276	mass	N	I-Premise
277	was	N	I-Premise
278	maintained	N	I-Premise
279	throughout	N	I-Premise
280	the	N	I-Premise
281	study	N	I-Premise
282	in	N	I-Premise
283	group	N	I-Premise
284	B	N	I-Premise
285	,	N	I-Premise
286	but	N	I-Premise
287	declined	N	I-Premise
288	significantly	N	I-Premise
289	up	N	I-Premise
290	to	N	I-Premise
291	weeks	N	I-Premise
292	4	N	I-Premise
293	and	N	I-Premise
294	8	N	I-Premise
295	in	N	I-Premise
296	group	N	I-Premise
297	A	N	I-Premise
298	(	N	I-Premise
299	intergroup	N	I-Premise
300	difference	N	I-Premise
301	:	N	I-Premise
302	P	N	I-Premise
303	<	N	I-Premise
304	0.05	N	I-Premise
305	and	N	I-Premise
306	0.01	N	I-Premise
307	,	N	I-Premise
308	respectively	N	I-Premise
309	)	N	I-Premise
310	.	N	I-Premise

311	A	N	I-Premise
312	decrease	N	I-Premise
313	in	N	I-Premise
314	the	N	I-Premise
315	total	N	I-Premise
316	lymphocyte	N	I-Premise
317	count	N	I-Premise
318	by	N	I-Premise
319	559	N	I-Premise
320	cells/mul	N	I-Premise
321	occurred	N	I-Premise
322	with	N	I-Premise
323	the	N	I-Premise
324	fat-enriched	N	I-Premise
325	diet	N	I-Premise
326	(	N	I-Premise
327	P	N	I-Premise
328	<	N	I-Premise
329	0.05	N	I-Premise
330	)	N	I-Premise
331	.	N	I-Premise

332	Several	N	I-Premise
333	aspects	N	I-Premise
334	of	N	I-Premise
335	the	N	I-Premise
336	quality	N	I-Premise
337	of	N	I-Premise
338	life	N	I-Premise
339	were	N	I-Premise
340	rated	N	I-Premise
341	to	N	I-Premise
342	be	N	I-Premise
343	better	N	I-Premise
344	in	N	I-Premise
345	group	N	I-Premise
346	B	N	I-Premise
347	than	N	I-Premise
348	in	N	I-Premise
349	group	N	I-Premise
350	A	N	I-Premise
351	,	N	I-Premise
352	although	N	I-Premise
353	not	N	I-Premise
354	all	N	I-Premise
355	differences	N	I-Premise
356	reached	N	I-Premise
357	statistical	N	I-Premise
358	significance	N	I-Premise
359	.	N	I-Premise

360	In	N	I-Claim
361	patients	N	I-Claim
362	with	N	I-Claim
363	cancer	N	I-Claim
364	,	N	I-Claim
365	a	N	I-Claim
366	high-fat	N	I-Claim
367	diet	N	I-Claim
368	may	N	I-Claim
369	possibly	N	I-Claim
370	support	N	I-Claim
371	the	N	I-Claim
372	maintenance	N	I-Claim
373	of	N	I-Claim
374	both	N	I-Claim
375	body	N	I-Claim
376	weight	N	I-Claim
377	and	N	I-Claim
378	body	N	I-Claim
379	cell	N	I-Claim
380	mass	N	I-Claim
381	.	N	I-Claim

382	However	N	I-Claim
383	,	N	I-Claim
384	monitoring	N	I-Claim
385	the	N	I-Claim
386	lymphocyte	N	I-Claim
387	count	N	I-Claim
388	is	N	I-Claim
389	advisable	N	I-Claim
390	.	N	I-Claim

1	For	N	I-MajorClaim
2	malignant	N	I-MajorClaim
3	pleural	N	I-MajorClaim
4	mesothelioma	N	I-MajorClaim
5	(	N	I-MajorClaim
6	MPM	N	I-MajorClaim
7	)	N	I-MajorClaim
8	patients	N	I-MajorClaim
9	with	N	I-MajorClaim
10	a	N	I-MajorClaim
11	poor	N	I-MajorClaim
12	prognosis	N	I-MajorClaim
13	,	N	I-MajorClaim
14	maintaining	N	I-MajorClaim
15	health-related	N	I-MajorClaim
16	quality	N	I-MajorClaim
17	of	N	I-MajorClaim
18	life	N	I-MajorClaim
19	(	N	I-MajorClaim
20	HRQOL	N	I-MajorClaim
21	)	N	I-MajorClaim
22	is	N	I-MajorClaim
23	important	N	I-MajorClaim
24	.	N	I-MajorClaim

25	This	N	O
26	article	N	O
27	compares	N	O
28	the	N	O
29	impact	N	O
30	on	N	O
31	HRQOL	N	O
32	of	N	O
33	first-line	N	O
34	treatment	N	O
35	with	N	O
36	cisplatin	N	O
37	versus	N	O
38	raltitrexed	N	O
39	and	N	O
40	cisplatin	N	O
41	.	N	O

42	Patients	N	O
43	with	N	O
44	histologically-proven	N	O
45	unresectable	N	O
46	MPM	N	O
47	,	N	O
48	not	N	O
49	pretreated	N	O
50	with	N	O
51	chemotherapy	N	O
52	were	N	O
53	randomly	N	O
54	assigned	N	O
55	to	N	O
56	receive	N	O
57	cisplatin	N	O
58	80	N	O
59	mg/m2	N	O
60	intravenously	N	O
61	on	N	O
62	day	N	O
63	1	N	O
64	,	N	O
65	with	N	O
66	or	N	O
67	without	N	O
68	preceding	N	O
69	infusion	N	O
70	of	N	O
71	raltitrexed	N	O
72	3	N	O
73	mg/m2	N	O
74	.	N	O

75	HRQOL	N	O
76	was	N	O
77	assessed	N	O
78	with	N	O
79	the	N	O
80	European	N	O
81	Organisation	N	O
82	for	N	O
83	Research	N	O
84	and	N	O
85	Treatment	N	O
86	of	N	O
87	Cancer	N	O
88	Core	N	O
89	Quality	N	O
90	of	N	O
91	Life	N	O
92	Questionnaire	N	O
93	C30	N	O
94	(	N	O
95	EORTC	N	O
96	QLQ-C30	N	O
97	)	N	O
98	and	N	O
99	EORTC	N	O
100	Lung	N	O
101	Cancer	N	O
102	Module	N	O
103	(	N	O
104	QLQ-LC13	N	O
105	)	N	O
106	tools	N	O
107	.	N	O

108	Assessments	N	O
109	were	N	O
110	conducted	N	O
111	at	N	O
112	baseline	N	O
113	,	N	O
114	immediately	N	O
115	before	N	O
116	every	N	O
117	treatment	N	O
118	cycle	N	O
119	,	N	O
120	at	N	O
121	the	N	O
122	end	N	O
123	of	N	O
124	treatment	N	O
125	,	N	O
126	and	N	O
127	every	N	O
128	six	N	O
129	weeks	N	O
130	for	N	O
131	12	N	O
132	months	N	O
133	.	N	O

134	Two	N	O
135	hundred	N	O
136	fifty	N	O
137	patients	N	O
138	were	N	O
139	randomly	N	O
140	assigned	N	O
141	,	N	O
142	80	N	O
143	%	N	O
144	were	N	O
145	male	N	O
146	with	N	O
147	a	N	O
148	median	N	O
149	age	N	O
150	of	N	O
151	58	N	O
152	years	N	O
153	,	N	O
154	WHO	N	O
155	performance	N	O
156	status	N	O
157	0	N	O
158	,	N	O
159	1	N	O
160	,	N	O
161	and	N	O
162	2	N	O
163	,	N	O
164	in	N	O
165	25	N	O
166	%	N	O
167	,	N	O
168	62	N	O
169	%	N	O
170	,	N	O
171	and	N	O
172	13	N	O
173	%	N	O
174	of	N	O
175	cases	N	O
176	.	N	O

177	The	N	I-Premise
178	clinical	N	I-Premise
179	results	N	I-Premise
180	found	N	I-Premise
181	raltitrexed	N	I-Premise
182	and	N	I-Premise
183	cisplatin	N	I-Premise
184	to	N	I-Premise
185	be	N	I-Premise
186	superior	N	I-Premise
187	to	N	I-Premise
188	cisplatin	N	I-Premise
189	with	N	I-Premise
190	regard	N	I-Premise
191	to	N	I-Premise
192	overall	N	I-Premise
193	survival	N	I-Premise
194	(	N	I-Premise
195	P	N	I-Premise
196	=	N	I-Premise
197	.048	N	I-Premise
198	)	N	I-Premise
199	.	N	I-Premise

200	The	N	I-Premise
201	global	N	I-Premise
202	HRQOL	N	I-Premise
203	scale	N	I-Premise
204	was	N	I-Premise
205	comparable	N	I-Premise
206	at	N	I-Premise
207	baseline	N	I-Premise
208	on	N	I-Premise
209	both	N	I-Premise
210	treatment	N	I-Premise
211	arms	N	I-Premise
212	(	N	I-Premise
213	P	N	I-Premise
214	=	N	I-Premise
215	.848	N	I-Premise
216	)	N	I-Premise
217	;	N	I-Premise
218	at	N	I-Premise
219	no	N	I-Premise
220	point	N	I-Premise
221	was	N	I-Premise
222	any	N	I-Premise
223	significant	N	I-Premise
224	difference	N	I-Premise
225	apparent	N	I-Premise
226	on	N	I-Premise
227	this	N	I-Premise
228	end	N	I-Premise
229	point	N	I-Premise
230	.	N	I-Premise

231	Both	N	I-Premise
232	treatments	N	I-Premise
233	led	N	I-Premise
234	to	N	I-Premise
235	an	N	I-Premise
236	improvement	N	I-Premise
237	,	N	I-Premise
238	over	N	I-Premise
239	time	N	I-Premise
240	,	N	I-Premise
241	in	N	I-Premise
242	dyspnoea	N	I-Premise
243	.	N	I-Premise

244	This	N	I-Claim
245	effect	N	I-Claim
246	is	N	I-Claim
247	an	N	I-Claim
248	important	N	I-Claim
249	clinically	N	I-Claim
250	meaningful	N	I-Claim
251	reduction	N	I-Claim
252	from	N	I-Claim
253	baseline	N	I-Claim
254	in	N	I-Claim
255	the	N	I-Claim
256	cisplatin/raltitrexed	N	I-Claim
257	arm	N	I-Claim
258	.	N	I-Claim

259	However	N	I-Premise
260	,	N	I-Premise
261	the	N	I-Premise
262	majority	N	I-Premise
263	of	N	I-Premise
264	scales	N	I-Premise
265	of	N	I-Premise
266	the	N	I-Premise
267	EORTC	N	I-Premise
268	QLQ-C30	N	I-Premise
269	or	N	I-Premise
270	LC13	N	I-Premise
271	showed	N	I-Premise
272	stabilization	N	I-Premise
273	of	N	I-Premise
274	HRQOL	N	I-Premise
275	with	N	I-Premise
276	few	N	I-Premise
277	clinically	N	I-Premise
278	significant	N	I-Premise
279	differences	N	I-Premise
280	between	N	I-Premise
281	the	N	I-Premise
282	treatment	N	I-Premise
283	arms	N	I-Premise
284	.	N	I-Premise

285	This	N	I-MajorClaim
286	study	N	I-MajorClaim
287	provides	N	I-MajorClaim
288	important	N	I-MajorClaim
289	information	N	I-MajorClaim
290	about	N	I-MajorClaim
291	the	N	I-MajorClaim
292	HRQOL	N	I-MajorClaim
293	of	N	I-MajorClaim
294	chemotherapy-treated	N	I-MajorClaim
295	MPM	N	I-MajorClaim
296	patients	N	I-MajorClaim
297	.	N	I-MajorClaim

1	The	N	O
2	goal	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	impact	N	O
11	of	N	O
12	neuronavigation	N	O
13	on	N	O
14	the	N	O
15	cytoreductive	N	O
16	treatment	N	O
17	of	N	O
18	solitary	N	O
19	contrast-enhancing	N	O
20	intracerebral	N	O
21	tumors	N	O
22	and	N	O
23	outcomes	N	O
24	of	N	O
25	this	N	O
26	treatment	N	O
27	in	N	O
28	cases	N	O
29	in	N	O
30	which	N	O
31	neuronavigation	N	O
32	was	N	O
33	preoperatively	N	O
34	judged	N	O
35	to	N	O
36	be	N	O
37	redundant	N	O
38	.	N	O

39	The	N	O
40	authors	N	O
41	conducted	N	O
42	a	N	O
43	prospective	N	O
44	randomized	N	O
45	study	N	O
46	in	N	O
47	which	N	O
48	45	N	O
49	patients	N	O
50	,	N	O
51	each	N	O
52	harboring	N	O
53	a	N	O
54	solitary	N	O
55	contrast-enhancing	N	O
56	intracerebral	N	O
57	tumor	N	O
58	,	N	O
59	were	N	O
60	randomized	N	O
61	for	N	O
62	surgery	N	O
63	with	N	O
64	or	N	O
65	without	N	O
66	neuronavigation	N	O
67	.	N	O

68	Peri-	N	O
69	and	N	O
70	postoperative	N	O
71	parameters	N	O
72	under	N	O
73	investigation	N	O
74	included	N	O
75	the	N	O
76	following	N	O
77	:	N	O
78	duration	N	O
79	of	N	O
80	the	N	O
81	procedure	N	O
82	;	N	O
83	surgeon	N	O
84	's	N	O
85	estimate	N	O
86	of	N	O
87	the	N	O
88	usefulness	N	O
89	of	N	O
90	neuronavigation	N	O
91	;	N	O
92	quantification	N	O
93	of	N	O
94	the	N	O
95	extent	N	O
96	of	N	O
97	resection	N	O
98	,	N	O
99	determined	N	O
100	using	N	O
101	magnetic	N	O
102	resonance	N	O
103	imaging	N	O
104	;	N	O
105	and	N	O
106	the	N	O
107	postoperative	N	O
108	course	N	O
109	,	N	O
110	as	N	O
111	evaluated	N	O
112	by	N	O
113	neurological	N	O
114	examinations	N	O
115	,	N	O
116	the	N	O
117	patient	N	O
118	's	N	O
119	quality-of-life	N	O
120	self-assessment	N	O
121	,	N	O
122	application	N	O
123	of	N	O
124	the	N	O
125	Barthel	N	O
126	index	N	O
127	and	N	O
128	the	N	O
129	Karnofsky	N	O
130	Performance	N	O
131	Scale	N	O
132	score	N	O
133	,	N	O
134	and	N	O
135	the	N	O
136	patient	N	O
137	's	N	O
138	time	N	O
139	of	N	O
140	death	N	O
141	.	N	O

142	The	N	I-Premise
143	mean	N	I-Premise
144	amount	N	I-Premise
145	of	N	I-Premise
146	residual	N	I-Premise
147	tumor	N	I-Premise
148	tissue	N	I-Premise
149	was	N	I-Premise
150	28.9	N	I-Premise
151	%	N	I-Premise
152	for	N	I-Premise
153	standard	N	I-Premise
154	surgery	N	I-Premise
155	(	N	I-Premise
156	SS	N	I-Premise
157	)	N	I-Premise
158	and	N	I-Premise
159	13.8	N	I-Premise
160	%	N	I-Premise
161	for	N	I-Premise
162	surgery	N	I-Premise
163	involving	N	I-Premise
164	neuronavigation	N	I-Premise
165	(	N	I-Premise
166	SN	N	I-Premise
167	)	N	I-Premise
168	.	N	I-Premise

169	The	N	I-Premise
170	corresponding	N	I-Premise
171	mean	N	I-Premise
172	amounts	N	I-Premise
173	of	N	I-Premise
174	residual	N	I-Premise
175	contrast-enhancing	N	I-Premise
176	tumor	N	I-Premise
177	tissue	N	I-Premise
178	were	N	I-Premise
179	29.2	N	I-Premise
180	and	N	I-Premise
181	24.4	N	I-Premise
182	%	N	I-Premise
183	,	N	I-Premise
184	respectively	N	I-Premise
185	.	N	I-Premise

186	These	N	I-Premise
187	differences	N	I-Premise
188	were	N	I-Premise
189	not	N	I-Premise
190	significant	N	I-Premise
191	.	N	I-Premise

192	Gross-total	N	I-Premise
193	removal	N	I-Premise
194	(	N	I-Premise
195	GTR	N	I-Premise
196	)	N	I-Premise
197	was	N	I-Premise
198	achieved	N	I-Premise
199	in	N	I-Premise
200	five	N	I-Premise
201	patients	N	I-Premise
202	who	N	I-Premise
203	underwent	N	I-Premise
204	SS	N	I-Premise
205	and	N	I-Premise
206	in	N	I-Premise
207	three	N	I-Premise
208	who	N	I-Premise
209	underwent	N	I-Premise
210	SN	N	I-Premise
211	.	N	I-Premise

212	Median	N	I-Premise
213	survival	N	I-Premise
214	was	N	I-Premise
215	significantly	N	I-Premise
216	shorter	N	I-Premise
217	in	N	I-Premise
218	the	N	I-Premise
219	SN	N	I-Premise
220	group	N	I-Premise
221	(	N	I-Premise
222	5.6	N	I-Premise
223	months	N	I-Premise
224	compared	N	I-Premise
225	with	N	I-Premise
226	9	N	I-Premise
227	months	N	I-Premise
228	,	N	I-Premise
229	unadjusted	N	I-Premise
230	hazard	N	I-Premise
231	ratio	N	I-Premise
232	=	N	I-Premise
233	1.6	N	I-Premise
234	)	N	I-Premise
235	;	N	I-Premise
236	however	N	I-Premise
237	,	N	I-Premise
238	this	N	I-Premise
239	difference	N	I-Premise
240	may	N	I-Premise
241	be	N	I-Premise
242	attributable	N	I-Premise
243	to	N	I-Premise
244	the	N	I-Premise
245	coincidental	N	I-Premise
246	early	N	I-Premise
247	death	N	I-Premise
248	of	N	I-Premise
249	three	N	I-Premise
250	patients	N	I-Premise
251	in	N	I-Premise
252	the	N	I-Premise
253	SN	N	I-Premise
254	group	N	I-Premise
255	.	N	I-Premise

256	No	N	I-Premise
257	discernible	N	I-Premise
258	important	N	I-Premise
259	effect	N	I-Premise
260	on	N	I-Premise
261	the	N	I-Premise
262	patients	N	I-Premise
263	'	N	I-Premise
264	3-month	N	I-Premise
265	postoperative	N	I-Premise
266	course	N	I-Premise
267	was	N	I-Premise
268	identified	N	I-Premise
269	.	N	I-Premise

270	There	N	I-Claim
271	is	N	I-Claim
272	no	N	I-Claim
273	rationale	N	I-Claim
274	for	N	I-Claim
275	the	N	I-Claim
276	routine	N	I-Claim
277	use	N	I-Claim
278	of	N	I-Claim
279	neuronavigation	N	I-Claim
280	to	N	I-Claim
281	improve	N	I-Claim
282	the	N	I-Claim
283	extent	N	I-Claim
284	of	N	I-Claim
285	tumor	N	I-Claim
286	resection	N	I-Claim
287	and	N	I-Claim
288	prognosis	N	I-Claim
289	in	N	I-Claim
290	patients	N	I-Claim
291	harboring	N	I-Claim
292	a	N	I-Claim
293	solitary	N	I-Claim
294	enhancing	N	I-Claim
295	intracerebral	N	I-Claim
296	lesion	N	I-Claim
297	when	N	I-Claim
298	neuronavigation	N	I-Claim
299	is	N	I-Claim
300	not	N	I-Claim
301	already	N	I-Claim
302	deemed	N	I-Claim
303	advantageous	N	I-Claim
304	because	N	I-Claim
305	of	N	I-Claim
306	the	N	I-Claim
307	size	N	I-Claim
308	or	N	I-Claim
309	location	N	I-Claim
310	of	N	I-Claim
311	the	N	I-Claim
312	lesion	N	I-Claim
313	.	N	I-Claim

1	Experimental	N	I-MajorClaim
2	and	N	I-MajorClaim
3	early	N	I-MajorClaim
4	clinical	N	I-MajorClaim
5	investigations	N	I-MajorClaim
6	have	N	I-MajorClaim
7	demonstrated	N	I-MajorClaim
8	encouraging	N	I-MajorClaim
9	results	N	I-MajorClaim
10	for	N	I-MajorClaim
11	estramustine	N	I-MajorClaim
12	in	N	I-MajorClaim
13	the	N	I-MajorClaim
14	treatment	N	I-MajorClaim
15	of	N	I-MajorClaim
16	malignant	N	I-MajorClaim
17	glioma	N	I-MajorClaim
18	.	N	O

19	The	N	O
20	present	N	O
21	study	N	O
22	is	N	O
23	an	N	O
24	open	N	O
25	randomized	N	O
26	clinical	N	O
27	trial	N	O
28	comparing	N	O
29	estramustine	N	O
30	phosphate	N	O
31	(	N	O
32	Estracyt	N	O
33	)	N	O
34	in	N	O
35	addition	N	O
36	to	N	O
37	radiotherapy	N	O
38	with	N	O
39	radiotherapy	N	O
40	alone	N	O
41	as	N	O
42	first	N	O
43	line	N	O
44	treatment	N	O
45	of	N	O
46	astrocytoma	N	O
47	grade	N	O
48	III	N	O
49	and	N	O
50	IV	N	O
51	.	N	O

52	The	N	O
53	140	N	O
54	patients	N	O
55	included	N	O
56	were	N	O
57	in	N	O
58	a	N	O
59	good	N	O
60	clinical	N	O
61	condition	N	O
62	with	N	O
63	a	N	O
64	median	N	O
65	age	N	O
66	of	N	O
67	55	N	O
68	years	N	O
69	(	N	O
70	range	N	O
71	22-87	N	O
72	)	N	O
73	.	N	O

74	Estramustine	N	O
75	was	N	O
76	given	N	O
77	orally	N	O
78	,	N	O
79	280	N	O
80	mg	N	O
81	twice	N	O
82	daily	N	O
83	,	N	O
84	as	N	O
85	soon	N	O
86	as	N	O
87	the	N	O
88	diagnosis	N	O
89	was	N	O
90	established	N	O
91	,	N	O
92	during	N	O
93	and	N	O
94	after	N	O
95	the	N	O
96	radiotherapy	N	O
97	for	N	O
98	a	N	O
99	period	N	O
100	of	N	O
101	in	N	O
102	total	N	O
103	3	N	O
104	months	N	O
105	.	N	O

106	Radiotherapy	N	O
107	was	N	O
108	delivered	N	O
109	on	N	O
110	weekdays	N	O
111	2	N	O
112	Gy	N	O
113	daily	N	O
114	up	N	O
115	to	N	O
116	56	N	O
117	Gy	N	O
118	.	N	O

119	Eighteen	N	O
120	patients	N	O
121	were	N	O
122	excluded	N	O
123	due	N	O
124	to	N	O
125	misclassification	N	O
126	,	N	O
127	leaving	N	O
128	122	N	O
129	patients	N	O
130	eligible	N	O
131	for	N	O
132	evaluation	N	O
133	.	N	O

134	Overall	N	I-Premise
135	the	N	I-Premise
136	treatment	N	I-Premise
137	was	N	I-Premise
138	well	N	I-Premise
139	tolerated	N	I-Premise
140	.	N	O

141	Mild	N	I-Premise
142	or	N	I-Premise
143	moderate	N	I-Premise
144	nausea	N	I-Premise
145	was	N	I-Premise
146	the	N	I-Premise
147	most	N	I-Premise
148	common	N	I-Premise
149	side	N	I-Premise
150	effect	N	I-Premise
151	of	N	I-Premise
152	estramustine	N	I-Premise
153	.	N	I-Premise

154	The	N	O
155	minimum	N	O
156	follow-up	N	O
157	time	N	O
158	was	N	O
159	5.2	N	O
160	years	N	O
161	for	N	O
162	the	N	O
163	surviving	N	O
164	patients	N	O
165	.	N	O

166	For	N	I-Premise
167	astrocytoma	N	I-Premise
168	grade	N	I-Premise
169	III	N	I-Premise
170	the	N	I-Premise
171	median	N	I-Premise
172	survival	N	I-Premise
173	time	N	I-Premise
174	was	N	I-Premise
175	10.6	N	I-Premise
176	(	N	I-Premise
177	1.3-92.7	N	I-Premise
178	)	N	I-Premise
179	months	N	I-Premise
180	for	N	I-Premise
181	the	N	I-Premise
182	radiotherapy	N	I-Premise
183	only	N	I-Premise
184	group	N	I-Premise
185	and	N	I-Premise
186	17.3	N	I-Premise
187	(	N	I-Premise
188	0.4-96.9+	N	I-Premise
189	)	N	I-Premise
190	months	N	I-Premise
191	for	N	I-Premise
192	the	N	I-Premise
193	estramustine	N	I-Premise
194	+	N	I-Premise
195	radiotherapy	N	I-Premise
196	group	N	I-Premise
197	.	N	I-Premise

198	In	N	I-Premise
199	grade	N	I-Premise
200	IV	N	I-Premise
201	the	N	I-Premise
202	corresponding	N	I-Premise
203	median	N	I-Premise
204	survival	N	I-Premise
205	time	N	I-Premise
206	was	N	I-Premise
207	12.3	N	I-Premise
208	(	N	I-Premise
209	2.1-89.2	N	I-Premise
210	)	N	I-Premise
211	and	N	I-Premise
212	10.3	N	I-Premise
213	(	N	I-Premise
214	0.3-91.7+	N	I-Premise
215	)	N	I-Premise
216	months	N	I-Premise
217	,	N	I-Premise
218	respectively	N	I-Premise
219	.	N	I-Premise

220	Median	N	I-Premise
221	time	N	I-Premise
222	to	N	I-Premise
223	progress	N	I-Premise
224	for	N	I-Premise
225	radiotherapy	N	I-Premise
226	only	N	I-Premise
227	and	N	I-Premise
228	radiotherapy	N	I-Premise
229	and	N	I-Premise
230	estramustin	N	I-Premise
231	group	N	I-Premise
232	in	N	I-Premise
233	grade	N	I-Premise
234	III	N	I-Premise
235	tumours	N	I-Premise
236	was	N	I-Premise
237	6.5	N	I-Premise
238	and	N	I-Premise
239	10.1	N	I-Premise
240	months	N	I-Premise
241	,	N	I-Premise
242	respectively	N	I-Premise
243	.	N	I-Premise

244	In	N	I-Premise
245	grade	N	I-Premise
246	IV	N	I-Premise
247	tumours	N	I-Premise
248	the	N	I-Premise
249	corresponding	N	I-Premise
250	figures	N	I-Premise
251	were	N	I-Premise
252	5.1	N	I-Premise
253	and	N	I-Premise
254	3.3	N	I-Premise
255	months	N	I-Premise
256	,	N	I-Premise
257	respectively	N	I-Premise
258	.	N	I-Premise

259	Although	N	I-Premise
260	there	N	I-Premise
261	was	N	I-Premise
262	a	N	I-Premise
263	tendency	N	I-Premise
264	for	N	I-Premise
265	improved	N	I-Premise
266	survival	N	I-Premise
267	in	N	I-Premise
268	grade	N	I-Premise
269	III	N	I-Premise
270	,	N	I-Premise
271	no	N	I-Premise
272	statistical	N	I-Premise
273	significant	N	I-Premise
274	differences	N	I-Premise
275	were	N	I-Premise
276	found	N	I-Premise
277	between	N	I-Premise
278	the	N	I-Premise
279	treatment	N	I-Premise
280	groups	N	I-Premise
281	.	N	I-Premise

282	No	N	I-Premise
283	differences	N	I-Premise
284	between	N	I-Premise
285	the	N	I-Premise
286	two	N	I-Premise
287	treatment	N	I-Premise
288	groups	N	I-Premise
289	were	N	I-Premise
290	evident	N	I-Premise
291	with	N	I-Premise
292	respect	N	I-Premise
293	to	N	I-Premise
294	quality	N	I-Premise
295	of	N	I-Premise
296	life	N	I-Premise
297	according	N	I-Premise
298	to	N	I-Premise
299	the	N	I-Premise
300	EORTC	N	I-Premise
301	QLQ-protocol	N	I-Premise
302	.	N	I-Premise

303	In	N	I-Claim
304	conclusion	N	I-Claim
305	,	N	I-Claim
306	this	N	I-Claim
307	first	N	I-Claim
308	randomized	N	I-Claim
309	study	N	I-Claim
310	did	N	I-Claim
311	not	N	I-Claim
312	demonstrate	N	I-Claim
313	any	N	I-Claim
314	significant	N	I-Claim
315	improvement	N	I-Claim
316	of	N	I-Claim
317	using	N	I-Claim
318	estramustine	N	I-Claim
319	in	N	I-Claim
320	addition	N	I-Claim
321	to	N	I-Claim
322	conventional	N	I-Claim
323	radiotherapy	N	I-Claim
324	,	N	I-Claim
325	however	N	I-Claim
326	,	N	I-Claim
327	a	N	I-Claim
328	trend	N	I-Claim
329	for	N	I-Claim
330	a	N	I-Claim
331	positive	N	I-Claim
332	response	N	I-Claim
333	for	N	I-Claim
334	the	N	I-Claim
335	estramustine	N	I-Claim
336	group	N	I-Claim
337	was	N	I-Claim
338	found	N	I-Claim
339	in	N	I-Claim
340	patients	N	I-Claim
341	with	N	I-Claim
342	grade	N	I-Claim
343	III	N	I-Claim
344	glioma	N	I-Claim
345	.	N	I-Claim

1	Sentinel	N	I-MajorClaim
2	lymph	N	I-MajorClaim
3	node	N	I-MajorClaim
4	biopsy	N	I-MajorClaim
5	in	N	I-MajorClaim
6	women	N	I-MajorClaim
7	with	N	I-MajorClaim
8	operable	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	is	N	I-MajorClaim
12	routinely	N	I-MajorClaim
13	used	N	I-MajorClaim
14	in	N	I-MajorClaim
15	some	N	I-MajorClaim
16	countries	N	I-MajorClaim
17	for	N	I-MajorClaim
18	staging	N	I-MajorClaim
19	the	N	I-MajorClaim
20	axilla	N	I-MajorClaim
21	despite	N	I-MajorClaim
22	limited	N	I-MajorClaim
23	data	N	I-MajorClaim
24	from	N	I-MajorClaim
25	randomized	N	I-MajorClaim
26	trials	N	I-MajorClaim
27	on	N	I-MajorClaim
28	morbidity	N	I-MajorClaim
29	and	N	I-MajorClaim
30	mortality	N	I-MajorClaim
31	outcomes	N	I-MajorClaim
32	.	N	I-MajorClaim

33	We	N	O
34	conducted	N	O
35	a	N	O
36	multicenter	N	O
37	randomized	N	O
38	trial	N	O
39	to	N	O
40	compare	N	O
41	quality-of-life	N	O
42	outcomes	N	O
43	between	N	O
44	patients	N	O
45	with	N	O
46	clinically	N	O
47	node-negative	N	O
48	invasive	N	O
49	breast	N	O
50	cancer	N	O
51	who	N	O
52	received	N	O
53	sentinel	N	O
54	lymph	N	O
55	node	N	O
56	biopsy	N	O
57	and	N	O
58	patients	N	O
59	who	N	O
60	received	N	O
61	standard	N	O
62	axillary	N	O
63	treatment	N	O
64	.	N	O

65	The	N	O
66	primary	N	O
67	outcome	N	O
68	measures	N	O
69	were	N	O
70	arm	N	O
71	and	N	O
72	shoulder	N	O
73	morbidity	N	O
74	and	N	O
75	quality	N	O
76	of	N	O
77	life	N	O
78	.	N	O

79	From	N	O
80	November	N	O
81	1999	N	O
82	to	N	O
83	October	N	O
84	2003	N	O
85	,	N	O
86	1031	N	O
87	patients	N	O
88	were	N	O
89	randomly	N	O
90	assigned	N	O
91	to	N	O
92	undergo	N	O
93	sentinel	N	O
94	lymph	N	O
95	node	N	O
96	biopsy	N	O
97	(	N	O
98	n	N	O
99	=	N	O
100	515	N	O
101	)	N	O
102	or	N	O
103	standard	N	O
104	axillary	N	O
105	surgery	N	O
106	(	N	O
107	n	N	O
108	=	N	O
109	516	N	O
110	)	N	O
111	.	N	O

112	Patients	N	O
113	with	N	O
114	sentinel	N	O
115	lymph	N	O
116	node	N	O
117	metastases	N	O
118	proceeded	N	O
119	to	N	O
120	delayed	N	O
121	axillary	N	O
122	clearance	N	O
123	or	N	O
124	received	N	O
125	axillary	N	O
126	radiotherapy	N	O
127	(	N	O
128	depending	N	O
129	on	N	O
130	the	N	O
131	protocol	N	O
132	at	N	O
133	the	N	O
134	treating	N	O
135	institution	N	O
136	)	N	O
137	.	N	O

138	Intention-to-treat	N	O
139	analyses	N	O
140	of	N	O
141	data	N	O
142	at	N	O
143	1	N	O
144	,	N	O
145	3	N	O
146	,	N	O
147	6	N	O
148	,	N	O
149	and	N	O
150	12	N	O
151	months	N	O
152	after	N	O
153	surgery	N	O
154	are	N	O
155	presented	N	O
156	.	N	O

157	All	N	O
158	statistical	N	O
159	tests	N	O
160	were	N	O
161	two-sided	N	O
162	.	N	O

163	The	N	I-Premise
164	relative	N	I-Premise
165	risks	N	I-Premise
166	of	N	I-Premise
167	any	N	I-Premise
168	lymphedema	N	I-Premise
169	and	N	I-Premise
170	sensory	N	I-Premise
171	loss	N	I-Premise
172	for	N	I-Premise
173	the	N	I-Premise
174	sentinel	N	I-Premise
175	lymph	N	I-Premise
176	node	N	I-Premise
177	biopsy	N	I-Premise
178	group	N	I-Premise
179	compared	N	I-Premise
180	with	N	I-Premise
181	the	N	I-Premise
182	standard	N	I-Premise
183	axillary	N	I-Premise
184	treatment	N	I-Premise
185	group	N	I-Premise
186	at	N	I-Premise
187	12	N	I-Premise
188	months	N	I-Premise
189	were	N	I-Premise
190	0.37	N	I-Premise
191	(	N	I-Premise
192	95	N	I-Premise
193	%	N	I-Premise
194	confidence	N	I-Premise
195	interval	N	I-Premise
196	[	N	I-Premise
197	CI	N	I-Premise
198	]	N	I-Premise
199	=	N	I-Premise
200	0.23	N	I-Premise
201	to	N	I-Premise
202	0.60	N	I-Premise
203	;	N	I-Premise
204	absolute	N	I-Premise
205	rates	N	I-Premise
206	:	N	I-Premise
207	5	N	I-Premise
208	%	N	I-Premise
209	versus	N	I-Premise
210	13	N	I-Premise
211	%	N	I-Premise
212	)	N	I-Premise
213	and	N	I-Premise
214	0.37	N	I-Premise
215	(	N	I-Premise
216	95	N	I-Premise
217	%	N	I-Premise
218	CI	N	I-Premise
219	=	N	I-Premise
220	0.27	N	I-Premise
221	to	N	I-Premise
222	0.50	N	I-Premise
223	;	N	I-Premise
224	absolute	N	I-Premise
225	rates	N	I-Premise
226	:	N	I-Premise
227	11	N	I-Premise
228	%	N	I-Premise
229	versus	N	I-Premise
230	31	N	I-Premise
231	%	N	I-Premise
232	)	N	I-Premise
233	,	N	I-Premise
234	respectively	N	I-Premise
235	.	N	I-Premise

236	Drain	N	I-Premise
237	usage	N	I-Premise
238	,	N	I-Premise
239	length	N	I-Premise
240	of	N	I-Premise
241	hospital	N	I-Premise
242	stay	N	I-Premise
243	,	N	I-Premise
244	and	N	I-Premise
245	time	N	I-Premise
246	to	N	I-Premise
247	resumption	N	I-Premise
248	of	N	I-Premise
249	normal	N	I-Premise
250	day-to-day	N	I-Premise
251	activities	N	I-Premise
252	after	N	I-Premise
253	surgery	N	I-Premise
254	were	N	I-Premise
255	statistically	N	I-Premise
256	significantly	N	I-Premise
257	lower	N	I-Premise
258	in	N	I-Premise
259	the	N	I-Premise
260	sentinel	N	I-Premise
261	lymph	N	I-Premise
262	node	N	I-Premise
263	biopsy	N	I-Premise
264	group	N	I-Premise
265	(	N	I-Premise
266	all	N	I-Premise
267	P	N	I-Premise
268	<	N	I-Premise
269	.001	N	I-Premise
270	)	N	I-Premise
271	,	N	I-Premise
272	and	N	I-Premise
273	axillary	N	I-Premise
274	operative	N	I-Premise
275	time	N	I-Premise
276	was	N	I-Premise
277	reduced	N	I-Premise
278	(	N	I-Premise
279	P	N	I-Premise
280	=	N	I-Premise
281	.055	N	I-Premise
282	)	N	I-Premise
283	.	N	I-Premise

284	Overall	N	I-Premise
285	patient-recorded	N	I-Premise
286	quality	N	I-Premise
287	of	N	I-Premise
288	life	N	I-Premise
289	and	N	I-Premise
290	arm	N	I-Premise
291	functioning	N	I-Premise
292	scores	N	I-Premise
293	were	N	I-Premise
294	statistically	N	I-Premise
295	significantly	N	I-Premise
296	better	N	I-Premise
297	in	N	I-Premise
298	the	N	I-Premise
299	sentinel	N	I-Premise
300	lymph	N	I-Premise
301	node	N	I-Premise
302	biopsy	N	I-Premise
303	group	N	I-Premise
304	throughout	N	I-Premise
305	(	N	I-Premise
306	all	N	I-Premise
307	P	N	I-Premise
308	<	N	I-Premise
309	or	N	I-Premise
310	=	N	I-Premise
311	.003	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	These	N	I-Premise
315	benefits	N	I-Premise
316	were	N	I-Premise
317	seen	N	I-Premise
318	with	N	I-Premise
319	no	N	I-Premise
320	increase	N	I-Premise
321	in	N	I-Premise
322	anxiety	N	I-Premise
323	levels	N	I-Premise
324	in	N	I-Premise
325	the	N	I-Premise
326	sentinel	N	I-Premise
327	lymph	N	I-Premise
328	node	N	I-Premise
329	biopsy	N	I-Premise
330	group	N	I-Premise
331	(	N	I-Premise
332	P	N	I-Premise
333	>	N	I-Premise
334	.05	N	I-Premise
335	)	N	I-Premise
336	.	N	I-Premise

337	Sentinel	N	I-Claim
338	lymph	N	I-Claim
339	node	N	I-Claim
340	biopsy	N	I-Claim
341	is	N	I-Claim
342	associated	N	I-Claim
343	with	N	I-Claim
344	reduced	N	I-Claim
345	arm	N	I-Claim
346	morbidity	N	I-Claim
347	and	N	I-Claim
348	better	N	I-Claim
349	quality	N	I-Claim
350	of	N	I-Claim
351	life	N	I-Claim
352	than	N	I-Claim
353	standard	N	I-Claim
354	axillary	N	I-Claim
355	treatment	N	I-Claim
356	and	N	I-Claim
357	should	N	I-Claim
358	be	N	I-Claim
359	the	N	I-Claim
360	treatment	N	I-Claim
361	of	N	I-Claim
362	choice	N	I-Claim
363	for	N	I-Claim
364	patients	N	I-Claim
365	who	N	I-Claim
366	have	N	I-Claim
367	early-stage	N	I-Claim
368	breast	N	I-Claim
369	cancer	N	I-Claim
370	with	N	I-Claim
371	clinically	N	I-Claim
372	negative	N	I-Claim
373	nodes	N	I-Claim
374	.	N	I-Claim

1	Patients	N	I-Claim
2	with	N	I-Claim
3	advanced	N	I-Claim
4	non-small	N	I-Claim
5	cell	N	I-Claim
6	lung	N	I-Claim
7	cancer	N	I-Claim
8	(	N	I-Claim
9	NSCLC	N	I-Claim
10	)	N	I-Claim
11	do	N	I-Claim
12	not	N	I-Claim
13	have	N	I-Claim
14	curative	N	I-Claim
15	treatment	N	I-Claim
16	options	N	I-Claim
17	;	N	I-Claim
18	therefore	N	O
19	,	N	O
20	treatments	N	O
21	should	N	O
22	prolong	N	O
23	survival	N	O
24	and	N	O
25	improve	N	O
26	quality	N	O
27	of	N	O
28	life	N	O
29	(	N	O
30	QoL	N	O
31	)	N	O
32	.	N	O

33	We	N	O
34	compared	N	O
35	the	N	O
36	effect	N	O
37	on	N	O
38	QoL	N	O
39	of	N	O
40	two	N	O
41	docetaxel-platinum	N	O
42	regimens	N	O
43	with	N	O
44	vinorelbine-cisplatin	N	O
45	.	N	O

46	QoL	N	O
47	was	N	O
48	assessed	N	O
49	by	N	O
50	the	N	O
51	Lung	N	O
52	Cancer	N	O
53	Symptom	N	O
54	Scale	N	O
55	(	N	O
56	LCSS	N	O
57	)	N	O
58	and	N	O
59	the	N	O
60	general	N	O
61	EuroQol	N	O
62	five-dimensional	N	O
63	questionnaire	N	O
64	(	N	O
65	EQ-5D	N	O
66	)	N	O
67	in	N	O
68	926	N	O
69	chemotherapy-nave	N	O
70	patients	N	O
71	with	N	O
72	stages	N	O
73	IIIB	N	O
74	to	N	O
75	IV	N	O
76	NSCLC	N	O
77	.	N	O

78	Patients	N	O
79	were	N	O
80	randomly	N	O
81	assigned	N	O
82	to	N	O
83	receive	N	O
84	:	N	O
85	docetaxel	N	O
86	75	N	O
87	mg/m2	N	O
88	plus	N	O
89	cisplatin	N	O
90	75	N	O
91	mg/m2	N	O
92	,	N	O
93	every	N	O
94	3	N	O
95	weeks	N	O
96	(	N	O
97	DC	N	O
98	)	N	O
99	;	N	O
100	docetaxel	N	O
101	75	N	O
102	mg/m2	N	O
103	and	N	O
104	carboplatin	N	O
105	6	N	O
106	mg/ml	N	O
107	min	N	O
108	,	N	O
109	every	N	O
110	3	N	O
111	weeks	N	O
112	(	N	O
113	DCb	N	O
114	)	N	O
115	;	N	O
116	or	N	O
117	vinorelbine	N	O
118	25	N	O
119	mg/m2/week	N	O
120	plus	N	O
121	cisplatin	N	O
122	100	N	O
123	mg/m2	N	O
124	,	N	O
125	every	N	O
126	4	N	O
127	weeks	N	O
128	(	N	O
129	VC	N	O
130	)	N	O
131	.	N	O

132	Overall	N	I-Premise
133	,	N	I-Premise
134	patients	N	I-Premise
135	treated	N	I-Premise
136	with	N	I-Premise
137	either	N	I-Premise
138	docetaxel-containing	N	I-Premise
139	regimen	N	I-Premise
140	had	N	I-Premise
141	better	N	I-Premise
142	QoL	N	I-Premise
143	than	N	I-Premise
144	VC-treated	N	I-Premise
145	patients	N	I-Premise
146	(	N	I-Premise
147	LCSS	N	I-Premise
148	global	N	I-Premise
149	item	N	I-Premise
150	``	N	I-Premise
151	QoL	N	I-Premise
152	today	N	I-Premise
153	''	N	I-Premise
154	:	N	I-Premise
155	P=0.064	N	I-Premise
156	for	N	I-Premise
157	DC	N	I-Premise
158	and	N	I-Premise
159	P=0.016	N	I-Premise
160	for	N	I-Premise
161	DCb	N	I-Premise
162	versus	N	I-Premise
163	VC	N	I-Premise
164	;	N	I-Premise
165	EQ-5D	N	I-Premise
166	global	N	I-Premise
167	item	N	I-Premise
168	``	N	I-Premise
169	health	N	I-Premise
170	state	N	I-Premise
171	today	N	I-Premise
172	''	N	I-Premise
173	:	N	I-Premise
174	P=0.016	N	I-Premise
175	for	N	I-Premise
176	DC	N	I-Premise
177	and	N	I-Premise
178	P	N	I-Premise
179	<	N	I-Premise
180	0.001	N	I-Premise
181	for	N	I-Premise
182	DCb	N	I-Premise
183	versus	N	I-Premise
184	VC	N	I-Premise
185	)	N	I-Premise
186	.	N	I-Premise

187	DC-treated	N	I-Premise
188	patients	N	I-Premise
189	experienced	N	I-Premise
190	improved	N	I-Premise
191	pain	N	I-Premise
192	relief	N	I-Premise
193	compared	N	I-Premise
194	with	N	I-Premise
195	VC	N	I-Premise
196	(	N	I-Premise
197	P=0.033	N	I-Premise
198	)	N	I-Premise
199	,	N	I-Premise
200	whereas	N	O
201	pain	N	I-Premise
202	relief	N	I-Premise
203	with	N	I-Premise
204	DCb	N	I-Premise
205	and	N	I-Premise
206	VC	N	I-Premise
207	was	N	I-Premise
208	similar	N	I-Premise
209	.	N	I-Premise

210	Patients	N	I-Premise
211	treated	N	I-Premise
212	with	N	I-Premise
213	either	N	I-Premise
214	docetaxel	N	I-Premise
215	regimen	N	I-Premise
216	had	N	I-Premise
217	more	N	I-Premise
218	favorable	N	I-Premise
219	changes	N	I-Premise
220	in	N	I-Premise
221	performance	N	I-Premise
222	status	N	I-Premise
223	(	N	I-Premise
224	P=0.065	N	I-Premise
225	for	N	I-Premise
226	DC	N	I-Premise
227	and	N	I-Premise
228	P	N	I-Premise
229	<	N	I-Premise
230	0.001	N	I-Premise
231	for	N	I-Premise
232	DCb	N	I-Premise
233	versus	N	I-Premise
234	VC	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	mean	N	I-Premise
238	weight	N	I-Premise
239	loss	N	I-Premise
240	(	N	I-Premise
241	0.06	N	I-Premise
242	kg	N	I-Premise
243	,	N	I-Premise
244	gain	N	I-Premise
245	of	N	I-Premise
246	0.08	N	I-Premise
247	kg	N	I-Premise
248	,	N	I-Premise
249	and	N	I-Premise
250	2.27	N	I-Premise
251	kg	N	I-Premise
252	for	N	I-Premise
253	DC	N	I-Premise
254	,	N	I-Premise
255	DCb	N	I-Premise
256	,	N	I-Premise
257	and	N	I-Premise
258	VC	N	I-Premise
259	,	N	I-Premise
260	respectively	N	I-Premise
261	;	N	I-Premise
262	P	N	I-Premise
263	<	N	I-Premise
264	0.001	N	I-Premise
265	for	N	I-Premise
266	both	N	I-Premise
267	DC	N	I-Premise
268	versus	N	I-Premise
269	VC	N	I-Premise
270	and	N	I-Premise
271	DCb	N	I-Premise
272	versus	N	I-Premise
273	VC	N	I-Premise
274	)	N	I-Premise
275	.	N	I-Premise

276	The	N	I-Claim
277	TAX	N	I-Claim
278	326	N	I-Claim
279	study	N	I-Claim
280	shows	N	I-Claim
281	that	N	I-Claim
282	docetaxel-platinum	N	I-Claim
283	regimens	N	I-Claim
284	relieve	N	I-Claim
285	symptoms	N	I-Claim
286	and	N	I-Claim
287	improve	N	I-Claim
288	QoL	N	I-Claim
289	in	N	I-Claim
290	patients	N	I-Claim
291	with	N	I-Claim
292	advanced	N	I-Claim
293	NSCLC	N	I-Claim
294	.	N	I-Claim

295	DCb	N	I-Claim
296	and	N	I-Claim
297	DC	N	I-Claim
298	were	N	I-Claim
299	superior	N	I-Claim
300	to	N	I-Claim
301	VC	N	I-Claim
302	in	N	I-Claim
303	all	N	I-Claim
304	QoL	N	I-Claim
305	outcomes	N	I-Claim
306	assessed	N	I-Claim
307	except	N	I-Claim
308	for	N	I-Claim
309	the	N	I-Claim
310	difference	N	I-Claim
311	between	N	I-Claim
312	DC	N	I-Claim
313	and	N	I-Claim
314	VC	N	I-Claim
315	in	N	I-Claim
316	LCSS	N	I-Claim
317	``	N	I-Claim
318	QoL	N	I-Claim
319	today	N	I-Claim
320	''	N	I-Claim
321	,	N	I-Claim
322	which	N	I-Claim
323	was	N	I-Claim
324	not	N	I-Claim
325	significant	N	I-Claim
326	.	N	I-Claim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	pilot	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	examine	N	O
10	the	N	O
11	effects	N	O
12	of	N	O
13	a	N	O
14	combined	N	O
15	cardiorespiratory	N	O
16	and	N	O
17	resistance	N	O
18	exercise	N	O
19	training	N	O
20	program	N	O
21	of	N	O
22	short	N	O
23	duration	N	O
24	on	N	O
25	the	N	O
26	cardiorespiratory	N	O
27	fitness	N	O
28	,	N	O
29	strength	N	O
30	endurance	N	O
31	,	N	O
32	task	N	O
33	specific	N	O
34	functional	N	O
35	muscle	N	O
36	capacity	N	O
37	,	N	O
38	body	N	O
39	composition	N	O
40	and	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	(	N	O
45	QOL	N	O
46	)	N	O
47	in	N	O
48	women	N	O
49	breast	N	O
50	cancer	N	O
51	survivors	N	O
52	.	N	O

53	Sixteen	N	O
54	subjects	N	O
55	were	N	O
56	randomly	N	O
57	assigned	N	O
58	to	N	O
59	either	N	O
60	a	N	O
61	training	N	O
62	(	N	O
63	n	N	O
64	=	N	O
65	8	N	O
66	;	N	O
67	age	N	O
68	:	N	O
69	50	N	O
70	+/-	N	O
71	5	N	O
72	yrs	N	O
73	)	N	O
74	or	N	O
75	control	N	O
76	non-exercising	N	O
77	group	N	O
78	(	N	O
79	n	N	O
80	=	N	O
81	8	N	O
82	;	N	O
83	age	N	O
84	:	N	O
85	51	N	O
86	+/-	N	O
87	10	N	O
88	yrs	N	O
89	)	N	O
90	.	N	O

91	The	N	O
92	training	N	O
93	group	N	O
94	followed	N	O
95	an	N	O
96	8-week	N	O
97	exercise	N	O
98	program	N	O
99	consisting	N	O
100	of	N	O
101	3	N	O
102	weekly	N	O
103	sessions	N	O
104	of	N	O
105	90-min	N	O
106	duration	N	O
107	,	N	O
108	supervised	N	O
109	by	N	O
110	an	N	O
111	experienced	N	O
112	investigator	N	O
113	and	N	O
114	divided	N	O
115	into	N	O
116	resistance	N	O
117	exercises	N	O
118	and	N	O
119	aerobic	N	O
120	training	N	O
121	.	N	O

122	Before	N	O
123	and	N	O
124	after	N	O
125	the	N	O
126	intervention	N	O
127	period	N	O
128	,	N	O
129	all	N	O
130	of	N	O
131	the	N	O
132	subjects	N	O
133	performed	N	O
134	a	N	O
135	cardiorespiratory	N	O
136	test	N	O
137	to	N	O
138	measure	N	O
139	peak	N	O
140	oxygen	N	O
141	uptake	N	O
142	(	N	O
143	VO2peak	N	O
144	)	N	O
145	,	N	O
146	a	N	O
147	dynamic	N	O
148	strength	N	O
149	endurance	N	O
150	test	N	O
151	(	N	O
152	maximum	N	O
153	number	N	O
154	of	N	O
155	repetitions	N	O
156	for	N	O
157	chest	N	O
158	and	N	O
159	leg	N	O
160	press	N	O
161	exercise	N	O
162	at	N	O
163	30	N	O
164	-	N	O
165	35	N	O
166	%	N	O
167	and	N	O
168	100	N	O
169	-	N	O
170	110	N	O
171	%	N	O
172	of	N	O
173	body	N	O
174	mass	N	O
175	,	N	O
176	respectively	N	O
177	)	N	O
178	and	N	O
179	a	N	O
180	sit-stand	N	O
181	test	N	O
182	.	N	O

183	Quality	N	O
184	of	N	O
185	life	N	O
186	was	N	O
187	assessed	N	O
188	using	N	O
189	the	N	O
190	European	N	O
191	Organization	N	O
192	for	N	O
193	Research	N	O
194	and	N	O
195	Treatment	N	O
196	of	N	O
197	Cancer	N	O
198	QLQ-C30	N	O
199	(	N	O
200	EORTC-C30	N	O
201	)	N	O
202	questionnaire	N	O
203	.	N	O

204	In	N	I-Premise
205	response	N	I-Premise
206	to	N	I-Premise
207	training	N	I-Premise
208	,	N	I-Premise
209	QOL	N	I-Premise
210	,	N	I-Premise
211	VO2peak	N	I-Premise
212	(	N	I-Premise
213	mean	N	I-Premise
214	3.9	N	I-Premise
215	ml/kg/min	N	I-Premise
216	;	N	I-Premise
217	95	N	I-Premise
218	%	N	I-Premise
219	CI	N	I-Premise
220	,	N	I-Premise
221	0.93	N	I-Premise
222	,	N	I-Premise
223	6.90	N	I-Premise
224	)	N	I-Premise
225	performance	N	I-Premise
226	in	N	I-Premise
227	leg	N	I-Premise
228	press	N	I-Premise
229	(	N	I-Premise
230	17.9	N	I-Premise
231	kg	N	I-Premise
232	;	N	I-Premise
233	95	N	I-Premise
234	%	N	I-Premise
235	CI	N	I-Premise
236	,	N	I-Premise
237	12.8	N	I-Premise
238	,	N	I-Premise
239	22.4	N	I-Premise
240	)	N	I-Premise
241	and	N	I-Premise
242	sit-stand	N	I-Premise
243	test	N	I-Premise
244	(	N	I-Premise
245	-	N	I-Premise
246	0.67	N	I-Premise
247	s	N	I-Premise
248	;	N	I-Premise
249	95	N	I-Premise
250	%	N	I-Premise
251	CI	N	I-Premise
252	,	N	I-Premise
253	-	N	I-Premise
254	0.52	N	I-Premise
255	,	N	I-Premise
256	-	N	I-Premise
257	1.2	N	I-Premise
258	)	N	I-Premise
259	improved	N	I-Premise
260	(	N	I-Premise
261	p	N	I-Premise
262	<	N	I-Premise
263	or	N	I-Premise
264	=	N	I-Premise
265	0.05	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	We	N	I-Premise
269	observed	N	I-Premise
270	no	N	I-Premise
271	significant	N	I-Premise
272	changes	N	I-Premise
273	in	N	I-Premise
274	the	N	I-Premise
275	control	N	I-Premise
276	group	N	I-Premise
277	.	N	I-Premise

278	Combined	N	I-Claim
279	cardiorespiratory	N	I-Claim
280	and	N	I-Claim
281	resistance	N	I-Claim
282	training	N	I-Claim
283	,	N	I-Claim
284	even	N	I-Claim
285	of	N	I-Claim
286	very	N	I-Claim
287	brief	N	I-Claim
288	duration	N	I-Claim
289	,	N	I-Claim
290	improves	N	I-Claim
291	the	N	I-Claim
292	QOL	N	I-Claim
293	and	N	I-Claim
294	the	N	I-Claim
295	overall	N	I-Claim
296	physical	N	I-Claim
297	fitness	N	I-Claim
298	of	N	I-Claim
299	women	N	I-Claim
300	breast	N	I-Claim
301	cancer	N	I-Claim
302	survivors	N	I-Claim
303	.	N	I-Claim

1	LV5FU2	N	O
2	with	N	O
3	high-dose	N	O
4	leucovorin	N	O
5	(	N	O
6	LV	N	O
7	)	N	O
8	,	N	O
9	weekly	N	O
10	infusional	N	O
11	5-fluorouracil	N	O
12	(	N	O
13	5FU	N	O
14	)	N	O
15	(	N	O
16	AIO	N	O
17	schedule	N	O
18	)	N	O
19	and	N	O
20	raltitrexed	N	O
21	have	N	O
22	been	N	O
23	demonstrated	N	O
24	to	N	O
25	be	N	O
26	active	N	O
27	agents	N	O
28	in	N	O
29	first-line	N	O
30	treatment	N	O
31	of	N	O
32	colorectal	N	O
33	cancer	N	O
34	.	N	O

35	We	N	O
36	performed	N	O
37	a	N	O
38	4-arm	N	O
39	randomised	N	O
40	trial	N	O
41	to	N	O
42	compare	N	O
43	(	N	O
44	1	N	O
45	)	N	O
46	a	N	O
47	low-dose	N	O
48	intravenous	N	O
49	bolus	N	O
50	of	N	O
51	LV	N	O
52	(	N	O
53	20	N	O
54	mg/m2	N	O
55	)	N	O
56	,	N	O
57	followed	N	O
58	by	N	O
59	an	N	O
60	intravenous	N	O
61	bolus	N	O
62	of	N	O
63	5FU	N	O
64	(	N	O
65	400	N	O
66	mg/m2	N	O
67	)	N	O
68	,	N	O
69	followed	N	O
70	by	N	O
71	a	N	O
72	22-hour	N	O
73	continuous	N	O
74	infusion	N	O
75	of	N	O
76	5FU	N	O
77	(	N	O
78	600	N	O
79	mg/m2	N	O
80	)	N	O
81	on	N	O
82	day	N	O
83	1	N	O
84	and	N	O
85	day	N	O
86	2/2	N	O
87	weeks	N	O
88	(	N	O
89	ldLV5FU2	N	O
90	arm	N	O
91	)	N	O
92	,	N	O
93	(	N	O
94	2	N	O
95	)	N	O
96	a	N	O
97	weekly	N	O
98	continuous	N	O
99	infusion	N	O
100	of	N	O
101	high-dose	N	O
102	5FU	N	O
103	(	N	O
104	2.6	N	O
105	g/m2/week	N	O
106	)	N	O
107	for	N	O
108	6	N	O
109	weeks	N	O
110	followed	N	O
111	by	N	O
112	a	N	O
113	rest	N	O
114	week	N	O
115	(	N	O
116	HD-FU	N	O
117	arm	N	O
118	)	N	O
119	and	N	O
120	(	N	O
121	3	N	O
122	)	N	O
123	raltitrexed	N	O
124	(	N	O
125	Tomudex	N	O
126	arm	N	O
127	;	N	O
128	3	N	O
129	mg/m2/3	N	O
130	weeks	N	O
131	)	N	O
132	to	N	O
133	standard	N	O
134	LV5FU2	N	O
135	.	N	O

136	From	N	O
137	1997	N	O
138	to	N	O
139	2001	N	O
140	,	N	O
141	294	N	O
142	patients	N	O
143	were	N	O
144	included	N	O
145	.	N	O

146	The	N	O
147	4	N	O
148	arms	N	O
149	were	N	O
150	well	N	O
151	balanced	N	O
152	for	N	O
153	sex	N	O
154	ratio	N	O
155	,	N	O
156	age	N	O
157	,	N	O
158	WHO	N	O
159	performance	N	O
160	status	N	O
161	,	N	O
162	the	N	O
163	primary	N	O
164	tumour	N	O
165	site	N	O
166	and	N	O
167	prior	N	O
168	adjuvant	N	O
169	chemotherapy	N	O
170	.	N	O

171	Treatment	N	O
172	was	N	O
173	stopped	N	O
174	due	N	O
175	to	N	O
176	low	N	O
177	accrual	N	O
178	.	N	O

179	Two	N	I-Premise
180	toxicity-related	N	I-Premise
181	deaths	N	I-Premise
182	were	N	I-Premise
183	observed	N	I-Premise
184	in	N	I-Premise
185	the	N	I-Premise
186	Tomudex	N	I-Premise
187	arm	N	I-Premise
188	.	N	I-Premise

189	The	N	I-Premise
190	treatments	N	I-Premise
191	gave	N	I-Premise
192	rise	N	I-Premise
193	to	N	I-Premise
194	different	N	I-Premise
195	rates	N	I-Premise
196	of	N	I-Premise
197	grade	N	I-Premise
198	3-4	N	I-Premise
199	neutropenia	N	I-Premise
200	(	N	I-Premise
201	3	N	I-Premise
202	,	N	I-Premise
203	4	N	I-Premise
204	,	N	I-Premise
205	11	N	I-Premise
206	and	N	I-Premise
207	14	N	I-Premise
208	%	N	I-Premise
209	of	N	I-Premise
210	the	N	I-Premise
211	patients	N	I-Premise
212	in	N	I-Premise
213	the	N	I-Premise
214	LV5FU2	N	I-Premise
215	,	N	I-Premise
216	ldLV5FU2	N	I-Premise
217	,	N	I-Premise
218	HD-FU	N	I-Premise
219	and	N	I-Premise
220	Tomudex	N	I-Premise
221	arms	N	I-Premise
222	,	N	I-Premise
223	respectively	N	I-Premise
224	,	N	I-Premise
225	p	N	I-Premise
226	=	N	I-Premise
227	0.028	N	I-Premise
228	)	N	I-Premise
229	,	N	I-Premise
230	leucopenia	N	I-Premise
231	and	N	I-Premise
232	vomiting	N	I-Premise
233	.	N	I-Premise

234	At	N	I-Premise
235	least	N	I-Premise
236	one	N	I-Premise
237	episode	N	I-Premise
238	of	N	I-Premise
239	grade	N	I-Premise
240	3-4	N	I-Premise
241	toxicity	N	I-Premise
242	was	N	I-Premise
243	observed	N	I-Premise
244	in	N	I-Premise
245	27	N	I-Premise
246	,	N	I-Premise
247	25	N	I-Premise
248	,	N	I-Premise
249	38	N	I-Premise
250	and	N	I-Premise
251	47	N	I-Premise
252	%	N	I-Premise
253	of	N	I-Premise
254	the	N	I-Premise
255	patients	N	I-Premise
256	in	N	I-Premise
257	the	N	I-Premise
258	LV5FU2	N	I-Premise
259	,	N	I-Premise
260	ldLV5FU2	N	I-Premise
261	,	N	I-Premise
262	HD-FU	N	I-Premise
263	and	N	I-Premise
264	Tomudex	N	I-Premise
265	arms	N	I-Premise
266	,	N	I-Premise
267	respectively	N	I-Premise
268	(	N	I-Premise
269	p	N	I-Premise
270	=	N	I-Premise
271	0.016	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	An	N	I-Premise
275	objective	N	I-Premise
276	response	N	I-Premise
277	was	N	I-Premise
278	observed	N	I-Premise
279	in	N	I-Premise
280	28	N	I-Premise
281	,	N	I-Premise
282	21	N	I-Premise
283	,	N	I-Premise
284	22	N	I-Premise
285	and	N	I-Premise
286	10	N	I-Premise
287	%	N	I-Premise
288	of	N	I-Premise
289	the	N	I-Premise
290	patients	N	I-Premise
291	in	N	I-Premise
292	the	N	I-Premise
293	LV5FU2	N	I-Premise
294	,	N	I-Premise
295	ldLV5FU2	N	I-Premise
296	,	N	I-Premise
297	HD-FU	N	I-Premise
298	and	N	I-Premise
299	Tomudex	N	I-Premise
300	arms	N	I-Premise
301	,	N	I-Premise
302	respectively	N	I-Premise
303	(	N	I-Premise
304	p	N	I-Premise
305	=	N	I-Premise
306	0.04	N	I-Premise
307	)	N	I-Premise
308	.	N	I-Premise

309	Progression-free	N	I-Premise
310	survival	N	I-Premise
311	(	N	I-Premise
312	PFS	N	I-Premise
313	)	N	I-Premise
314	of	N	I-Premise
315	the	N	I-Premise
316	patients	N	I-Premise
317	in	N	I-Premise
318	the	N	I-Premise
319	Tomudex	N	I-Premise
320	arm	N	I-Premise
321	was	N	I-Premise
322	statistically	N	I-Premise
323	lower	N	I-Premise
324	compared	N	I-Premise
325	to	N	I-Premise
326	that	N	I-Premise
327	of	N	I-Premise
328	patients	N	I-Premise
329	treated	N	I-Premise
330	with	N	I-Premise
331	LV5FU2	N	I-Premise
332	or	N	I-Premise
333	ldLV5FU2	N	I-Premise
334	(	N	I-Premise
335	combined	N	I-Premise
336	group	N	I-Premise
337	;	N	I-Premise
338	p	N	I-Premise
339	=	N	I-Premise
340	0.013	N	I-Premise
341	,	N	I-Premise
342	log	N	I-Premise
343	rank	N	I-Premise
344	test	N	I-Premise
345	)	N	I-Premise
346	.	N	I-Premise

347	In	N	I-Claim
348	conclusion	N	I-Claim
349	,	N	I-Claim
350	Tomudex	N	I-Claim
351	is	N	I-Claim
352	more	N	I-Claim
353	toxic	N	I-Claim
354	and	N	I-Claim
355	yields	N	I-Claim
356	shorter	N	I-Claim
357	PFS	N	I-Claim
358	than	N	I-Claim
359	infusional	N	I-Claim
360	5FU	N	I-Claim
361	.	N	I-Claim

362	Despite	N	I-Claim
363	the	N	I-Claim
364	early	N	I-Claim
365	closure	N	I-Claim
366	of	N	I-Claim
367	the	N	I-Claim
368	study	N	I-Claim
369	and	N	I-Claim
370	the	N	I-Claim
371	lack	N	I-Claim
372	of	N	I-Claim
373	power	N	I-Claim
374	of	N	I-Claim
375	the	N	I-Claim
376	comparison	N	I-Claim
377	,	N	I-Claim
378	it	N	I-Claim
379	seems	N	I-Claim
380	that	N	I-Claim
381	ldLV5FU2	N	I-Claim
382	could	N	I-Claim
383	be	N	I-Claim
384	considered	N	I-Claim
385	as	N	I-Claim
386	an	N	I-Claim
387	active	N	I-Claim
388	,	N	I-Claim
389	easier	N	I-Claim
390	and	N	I-Claim
391	less	N	I-Claim
392	expensive	N	I-Claim
393	option	N	I-Claim
394	for	N	I-Claim
395	the	N	I-Claim
396	treatment	N	I-Claim
397	of	N	I-Claim
398	metastatic	N	I-Claim
399	colorectal	N	I-Claim
400	cancer	N	I-Claim
401	compared	N	I-Claim
402	to	N	I-Claim
403	classic	N	I-Claim
404	LV5FU2	N	I-Claim
405	or	N	I-Claim
406	weekly	N	I-Claim
407	HD-FU	N	I-Claim
408	.	N	I-Claim

1	DPPE	N	I-Claim
2	(	N	I-Claim
3	tesmilifene	N	I-Claim
4	)	N	I-Claim
5	plus	N	I-Claim
6	doxorubicin	N	I-Claim
7	(	N	I-Claim
8	DOX	N	I-Claim
9	)	N	I-Claim
10	demonstrated	N	I-Claim
11	a	N	I-Claim
12	significant	N	I-Claim
13	improvement	N	I-Claim
14	in	N	I-Claim
15	survival	N	I-Claim
16	versus	N	I-Claim
17	DOX	N	I-Claim
18	in	N	I-Claim
19	a	N	I-Claim
20	phase	N	I-Claim
21	III	N	I-Claim
22	clinical	N	I-Claim
23	trial	N	I-Claim
24	in	N	I-Claim
25	advanced	N	I-Claim
26	breast	N	I-Claim
27	cancer	N	I-Claim
28	.	N	I-Claim

29	However	N	I-Premise
30	,	N	I-Premise
31	DPPE	N	I-Premise
32	is	N	I-Premise
33	associated	N	I-Premise
34	with	N	I-Premise
35	unusual	N	I-Premise
36	toxicity	N	I-Premise
37	in	N	I-Premise
38	the	N	I-Premise
39	form	N	I-Premise
40	of	N	I-Premise
41	hallucinations	N	I-Premise
42	,	N	I-Premise
43	nausea	N	I-Premise
44	and	N	I-Premise
45	vomiting	N	I-Premise
46	which	N	I-Premise
47	were	N	I-Premise
48	anticipated	N	I-Premise
49	to	N	I-Premise
50	impact	N	I-Premise
51	on	N	I-Premise
52	short-term	N	I-Premise
53	quality	N	I-Premise
54	of	N	I-Premise
55	life	N	I-Premise
56	(	N	I-Premise
57	QOL	N	I-Premise
58	)	N	I-Premise
59	.	N	I-Premise

60	Standard	N	O
61	National	N	O
62	Cancer	N	O
63	Institute	N	O
64	of	N	O
65	Canada	N	O
66	Clinical	N	O
67	Trials	N	O
68	Group	N	O
69	(	N	O
70	NCIC	N	O
71	CTG	N	O
72	)	N	O
73	approaches	N	O
74	were	N	O
75	applied	N	O
76	as	N	O
77	the	N	O
78	primary	N	O
79	method	N	O
80	to	N	O
81	analyze	N	O
82	the	N	O
83	QOL	N	O
84	data	N	O
85	from	N	O
86	this	N	O
87	trial	N	O
88	.	N	O

89	This	N	O
90	includes	N	O
91	cross-sectional	N	O
92	comparisons	N	O
93	,	N	O
94	together	N	O
95	with	N	O
96	a	N	O
97	global	N	O
98	test	N	O
99	for	N	O
100	the	N	O
101	QOL	N	O
102	response	N	O
103	rate	N	O
104	.	N	O

105	Sensitivity	N	O
106	analyses	N	O
107	were	N	O
108	also	N	O
109	performed	N	O
110	for	N	O
111	selected	N	O
112	QOL	N	O
113	domains	N	O
114	and	N	O
115	items	N	O
116	,	N	O
117	using	N	O
118	other	N	O
119	types	N	O
120	of	N	O
121	summary	N	O
122	measures	N	O
123	and	N	O
124	statistics	N	O
125	.	N	O

126	Two	N	O
127	hundred	N	O
128	seventy	N	O
129	one	N	O
130	patients	N	O
131	(	N	O
132	89	N	O
133	%	N	O
134	of	N	O
135	randomized	N	O
136	)	N	O
137	submitted	N	O
138	the	N	O
139	baseline	N	O
140	QOL	N	O
141	questionnaires	N	O
142	and	N	O
143	were	N	O
144	included	N	O
145	in	N	O
146	the	N	O
147	QOL	N	O
148	analysis	N	O
149	.	N	O

150	No	N	I-Premise
151	statistically	N	I-Premise
152	significant	N	I-Premise
153	difference	N	I-Premise
154	in	N	I-Premise
155	QOL	N	I-Premise
156	response	N	I-Premise
157	between	N	I-Premise
158	treatment	N	I-Premise
159	arms	N	I-Premise
160	was	N	I-Premise
161	found	N	I-Premise
162	for	N	I-Premise
163	any	N	I-Premise
164	domain	N	I-Premise
165	or	N	I-Premise
166	item	N	I-Premise
167	except	N	I-Premise
168	nausea	N	I-Premise
169	and	N	I-Premise
170	vomiting	N	I-Premise
171	(	N	I-Premise
172	P	N	I-Premise
173	=	N	I-Premise
174	0.04	N	I-Premise
175	)	N	I-Premise
176	.	N	I-Premise

177	Cross-sectional	N	I-Premise
178	comparisons	N	I-Premise
179	showed	N	I-Premise
180	statistically	N	I-Premise
181	significant	N	I-Premise
182	differences	N	I-Premise
183	for	N	I-Premise
184	some	N	I-Premise
185	domains/items	N	I-Premise
186	at	N	I-Premise
187	specific	N	I-Premise
188	assessment	N	I-Premise
189	times	N	I-Premise
190	with	N	I-Premise
191	all	N	I-Premise
192	differences	N	I-Premise
193	favoring	N	I-Premise
194	the	N	I-Premise
195	DOX	N	I-Premise
196	alone	N	I-Premise
197	arm	N	I-Premise
198	.	N	I-Premise

199	Patients	N	I-Premise
200	on	N	I-Premise
201	DPPE/DOX	N	I-Premise
202	arm	N	I-Premise
203	were	N	I-Premise
204	significantly	N	I-Premise
205	worse	N	I-Premise
206	in	N	I-Premise
207	terms	N	I-Premise
208	of	N	I-Premise
209	average	N	I-Premise
210	and	N	I-Premise
211	median	N	I-Premise
212	pain	N	I-Premise
213	change	N	I-Premise
214	scores	N	I-Premise
215	.	N	I-Premise

216	Different	N	I-Claim
217	analyses	N	I-Claim
218	yielded	N	I-Claim
219	slightly	N	I-Claim
220	different	N	I-Claim
221	conclusions	N	I-Claim
222	but	N	O
223	,	N	O
224	in	N	I-Claim
225	general	N	I-Claim
226	,	N	I-Claim
227	the	N	I-Claim
228	QOL	N	I-Claim
229	analyses	N	I-Claim
230	were	N	I-Claim
231	concordant	N	I-Claim
232	and	N	I-Claim
233	showed	N	I-Claim
234	that	N	I-Claim
235	patients	N	I-Claim
236	on	N	I-Claim
237	DOX	N	I-Claim
238	alone	N	I-Claim
239	had	N	I-Claim
240	fewer	N	I-Claim
241	disease	N	I-Claim
242	and	N	I-Claim
243	treatment	N	I-Claim
244	related	N	I-Claim
245	adverse	N	I-Claim
246	events	N	I-Claim
247	and	N	I-Claim
248	better	N	I-Claim
249	QOL	N	I-Claim
250	.	N	I-Claim

251	Interestingly	N	I-Claim
252	,	N	I-Claim
253	the	N	I-Claim
254	QOL	N	I-Claim
255	response	N	I-Claim
256	analysis	N	I-Claim
257	also	N	I-Claim
258	showed	N	I-Claim
259	that	N	I-Claim
260	aggressive	N	I-Claim
261	premedication	N	I-Claim
262	regimens	N	I-Claim
263	appear	N	I-Claim
264	to	N	I-Claim
265	ameliorate	N	I-Claim
266	potential	N	I-Claim
267	negative	N	I-Claim
268	effects	N	I-Claim
269	of	N	I-Claim
270	DPPE	N	I-Claim
271	on	N	I-Claim
272	emesis	N	I-Claim
273	and	N	I-Claim
274	nausea	N	I-Claim
275	as	N	I-Claim
276	measured	N	I-Claim
277	by	N	I-Claim
278	patient	N	I-Claim
279	assessed	N	I-Claim
280	QOL	N	I-Claim
281	.	N	I-Claim

1	Recent	N	I-Claim
2	studies	N	I-Claim
3	have	N	I-Claim
4	shown	N	I-Claim
5	that	N	I-Claim
6	administering	N	I-Claim
7	the	N	I-Claim
8	aromatase	N	I-Claim
9	inhibitor	N	I-Claim
10	exemestane	N	I-Claim
11	after	N	I-Claim
12	2-3	N	I-Claim
13	years	N	I-Claim
14	of	N	I-Claim
15	tamoxifen	N	I-Claim
16	therapy	N	I-Claim
17	significantly	N	I-Claim
18	improves	N	I-Claim
19	disease-free	N	I-Claim
20	survival	N	I-Claim
21	in	N	I-Claim
22	postmenopausal	N	I-Claim
23	women	N	I-Claim
24	with	N	I-Claim
25	primary	N	I-Claim
26	breast	N	I-Claim
27	cancer	N	I-Claim
28	in	N	I-Claim
29	comparison	N	I-Claim
30	with	N	I-Claim
31	standard	N	I-Claim
32	5-year	N	I-Claim
33	tamoxifen	N	I-Claim
34	treatment	N	I-Claim
35	.	N	I-Claim

36	Although	N	O
37	many	N	O
38	of	N	O
39	the	N	O
40	adverse	N	O
41	effects	N	O
42	associated	N	O
43	with	N	O
44	exemestane	N	O
45	and	N	O
46	tamoxifen	N	O
47	have	N	O
48	been	N	O
49	analysed	N	O
50	,	N	O
51	there	N	O
52	are	N	O
53	no	N	O
54	comparative	N	O
55	data	N	O
56	concerning	N	O
57	body	N	O
58	weight	N	O
59	and	N	O
60	body	N	O
61	composition	N	O
62	.	N	O

63	The	N	O
64	aim	N	O
65	of	N	O
66	this	N	O
67	randomised	N	O
68	study	N	O
69	was	N	O
70	to	N	O
71	evaluate	N	O
72	the	N	O
73	longitudinal	N	O
74	changes	N	O
75	in	N	O
76	body	N	O
77	composition	N	O
78	and	N	O
79	lipid	N	O
80	profiles	N	O
81	in	N	O
82	postmenopausal	N	O
83	women	N	O
84	switched	N	O
85	from	N	O
86	tamoxifen	N	O
87	to	N	O
88	exemestane	N	O
89	.	N	O

90	In	N	O
91	total	N	O
92	,	N	O
93	60	N	O
94	overweight	N	O
95	or	N	O
96	obese	N	O
97	postmenopausal	N	O
98	patients	N	O
99	were	N	O
100	enrolled	N	O
101	.	N	O

102	Their	N	O
103	anthropometric	N	O
104	data	N	O
105	,	N	O
106	body	N	O
107	composition	N	O
108	,	N	O
109	including	N	O
110	fat	N	O
111	mass	N	O
112	(	N	O
113	FM	N	O
114	)	N	O
115	and	N	O
116	fat-free	N	O
117	mass	N	O
118	(	N	O
119	FFM	N	O
120	)	N	O
121	,	N	O
122	and	N	O
123	lipid	N	O
124	profiles	N	O
125	,	N	O
126	caloric	N	O
127	intake	N	O
128	and	N	O
129	physical	N	O
130	activity	N	O
131	were	N	O
132	assessed	N	O
133	1	N	O
134	week	N	O
135	before	N	O
136	randomisation	N	O
137	,	N	O
138	and	N	O
139	6	N	O
140	and	N	O
141	12	N	O
142	months	N	O
143	later	N	O
144	.	N	O

145	In	N	O
146	all	N	O
147	,	N	O
148	55	N	O
149	patients	N	O
150	(	N	O
151	27	N	O
152	on	N	O
153	tamoxifen	N	O
154	and	N	O
155	28	N	O
156	on	N	O
157	exemestane	N	O
158	)	N	O
159	completed	N	O
160	the	N	O
161	1-year	N	O
162	study	N	O
163	period	N	O
164	.	N	O

165	Fat	N	I-Premise
166	mass	N	I-Premise
167	had	N	I-Premise
168	significantly	N	I-Premise
169	decreased	N	I-Premise
170	by	N	I-Premise
171	month	N	I-Premise
172	12	N	I-Premise
173	in	N	I-Premise
174	the	N	I-Premise
175	exemestane	N	I-Premise
176	,	N	I-Premise
177	but	N	I-Premise
178	not	N	I-Premise
179	in	N	I-Premise
180	the	N	I-Premise
181	tamoxifen	N	I-Premise
182	group	N	I-Premise
183	;	N	I-Premise
184	the	N	I-Premise
185	between-group	N	I-Premise
186	difference	N	I-Premise
187	was	N	I-Premise
188	statistically	N	I-Premise
189	significant	N	I-Premise
190	(	N	I-Premise
191	P	N	I-Premise
192	<	N	I-Premise
193	0.01	N	I-Premise
194	)	N	I-Premise
195	.	N	I-Premise

196	The	N	I-Premise
197	FFM/FM	N	I-Premise
198	ratio	N	I-Premise
199	had	N	I-Premise
200	significantly	N	I-Premise
201	increased	N	I-Premise
202	in	N	I-Premise
203	the	N	I-Premise
204	exemestane	N	I-Premise
205	group	N	I-Premise
206	,	N	I-Premise
207	but	N	I-Premise
208	not	N	I-Premise
209	the	N	I-Premise
210	tamoxifen	N	I-Premise
211	group	N	I-Premise
212	;	N	I-Premise
213	the	N	I-Premise
214	between-group	N	I-Premise
215	difference	N	I-Premise
216	was	N	I-Premise
217	statistically	N	I-Premise
218	significant	N	I-Premise
219	(	N	I-Premise
220	P	N	I-Premise
221	<	N	I-Premise
222	0.05	N	I-Premise
223	)	N	I-Premise
224	.	N	I-Premise

225	Triglycerides	N	I-Premise
226	and	N	I-Premise
227	high-density	N	I-Premise
228	lipoprotein	N	I-Premise
229	cholesterol	N	I-Premise
230	significantly	N	I-Premise
231	decreased	N	I-Premise
232	(	N	I-Premise
233	P	N	I-Premise
234	<	N	I-Premise
235	0.01	N	I-Premise
236	;	N	I-Premise
237	P	N	I-Premise
238	<	N	I-Premise
239	0.05	N	I-Premise
240	)	N	I-Premise
241	,	N	I-Premise
242	and	N	O
243	low-density	N	I-Premise
244	lipoprotein	N	I-Premise
245	cholesterol	N	I-Premise
246	significantly	N	I-Premise
247	increased	N	I-Premise
248	(	N	I-Premise
249	P	N	I-Premise
250	<	N	I-Premise
251	0.01	N	I-Premise
252	)	N	I-Premise
253	in	N	I-Premise
254	the	N	I-Premise
255	exemestane	N	I-Premise
256	group	N	I-Premise
257	at	N	I-Premise
258	the	N	I-Premise
259	end	N	I-Premise
260	of	N	I-Premise
261	the	N	I-Premise
262	1-year	N	I-Premise
263	study	N	I-Premise
264	period	N	I-Premise
265	.	N	I-Premise

266	Our	N	I-Claim
267	findings	N	I-Claim
268	suggest	N	I-Claim
269	that	N	I-Claim
270	switching	N	I-Claim
271	patients	N	I-Claim
272	to	N	I-Claim
273	adjuvant	N	I-Claim
274	exemestane	N	I-Claim
275	treatment	N	I-Claim
276	after	N	I-Claim
277	at	N	I-Claim
278	least	N	I-Claim
279	2	N	I-Claim
280	years	N	I-Claim
281	of	N	I-Claim
282	tamoxifen	N	I-Claim
283	therapy	N	I-Claim
284	may	N	I-Claim
285	be	N	I-Claim
286	associated	N	I-Claim
287	with	N	I-Claim
288	an	N	I-Claim
289	advantage	N	I-Claim
290	over	N	I-Claim
291	continuing	N	I-Claim
292	adjuvant	N	I-Claim
293	tamoxifen	N	I-Claim
294	treatment	N	I-Claim
295	in	N	I-Claim
296	terms	N	I-Claim
297	of	N	I-Claim
298	body	N	I-Claim
299	composition	N	I-Claim
300	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	cannabis	N	O
7	extract	N	O
8	(	N	O
9	CE	N	O
10	)	N	O
11	,	N	O
12	delta-9-tetrahydrocannabinol	N	O
13	(	N	O
14	THC	N	O
15	)	N	O
16	,	N	O
17	and	N	O
18	placebo	N	O
19	(	N	O
20	PL	N	O
21	)	N	O
22	on	N	O
23	appetite	N	O
24	and	N	O
25	quality	N	O
26	of	N	O
27	life	N	O
28	(	N	O
29	QOL	N	O
30	)	N	O
31	in	N	O
32	patients	N	O
33	with	N	O
34	cancer-related	N	O
35	anorexia-cachexia	N	O
36	syndrome	N	O
37	(	N	O
38	CACS	N	O
39	)	N	O
40	.	N	O

41	Adult	N	O
42	patients	N	O
43	with	N	O
44	advanced	N	O
45	cancer	N	O
46	,	N	O
47	CACS	N	O
48	,	N	O
49	weight	N	O
50	loss	N	O
51	(	N	O
52	>	N	O
53	or	N	O
54	=	N	O
55	5	N	O
56	%	N	O
57	over	N	O
58	6	N	O
59	months	N	O
60	)	N	O
61	,	N	O
62	and	N	O
63	Eastern	N	O
64	Cooperative	N	O
65	Oncology	N	O
66	Group	N	O
67	(	N	O
68	ECOG	N	O
69	)	N	O
70	performance	N	O
71	status	N	O
72	(	N	O
73	PS	N	O
74	)	N	O
75	<	N	O
76	or	N	O
77	=	N	O
78	2	N	O
79	were	N	O
80	randomly	N	O
81	assigned	N	O
82	(	N	O
83	2:2:1	N	O
84	)	N	O
85	to	N	O
86	receive	N	O
87	CE	N	O
88	(	N	O
89	standardized	N	O
90	for	N	O
91	2.5	N	O
92	mg	N	O
93	THC	N	O
94	and	N	O
95	1	N	O
96	mg	N	O
97	cannabidiol	N	O
98	)	N	O
99	or	N	O
100	THC	N	O
101	(	N	O
102	2.5	N	O
103	mg	N	O
104	)	N	O
105	or	N	O
106	PL	N	O
107	orally	N	O
108	,	N	O
109	twice	N	O
110	daily	N	O
111	for	N	O
112	6	N	O
113	weeks	N	O
114	.	N	O

115	Appetite	N	O
116	,	N	O
117	mood	N	O
118	,	N	O
119	and	N	O
120	nausea	N	O
121	were	N	O
122	monitored	N	O
123	daily	N	O
124	with	N	O
125	a	N	O
126	visual	N	O
127	analog	N	O
128	scale	N	O
129	(	N	O
130	VAS	N	O
131	)	N	O
132	;	N	O
133	QOL	N	O
134	was	N	O
135	assessed	N	O
136	with	N	O
137	the	N	O
138	European	N	O
139	Organisation	N	O
140	for	N	O
141	Research	N	O
142	and	N	O
143	Treatment	N	O
144	of	N	O
145	Cancer	N	O
146	Quality	N	O
147	of	N	O
148	Life	N	O
149	Questionnaire	N	O
150	C30	N	O
151	(	N	O
152	composite	N	O
153	score	N	O
154	:	N	O
155	questions	N	O
156	29	N	O
157	and	N	O
158	30	N	O
159	)	N	O
160	.	N	O

161	Cannabinoid-related	N	O
162	toxicity	N	O
163	was	N	O
164	assessed	N	O
165	every	N	O
166	2	N	O
167	weeks	N	O
168	.	N	O

169	Of	N	O
170	289	N	O
171	patients	N	O
172	screened	N	O
173	,	N	O
174	243	N	O
175	were	N	O
176	randomly	N	O
177	assigned	N	O
178	and	N	O
179	164	N	O
180	(	N	O
181	CE	N	O
182	,	N	O
183	66	N	O
184	of	N	O
185	95	N	O
186	patients	N	O
187	;	N	O
188	THC	N	O
189	,	N	O
190	65	N	O
191	of	N	O
192	100	N	O
193	patients	N	O
194	;	N	O
195	and	N	O
196	PL	N	O
197	,	N	O
198	33	N	O
199	of	N	O
200	48	N	O
201	patients	N	O
202	)	N	O
203	completed	N	O
204	treatment	N	O
205	.	N	O

206	At	N	O
207	baseline	N	O
208	,	N	O
209	groups	N	O
210	were	N	O
211	comparable	N	O
212	for	N	O
213	age	N	O
214	(	N	O
215	mean	N	O
216	,	N	O
217	61	N	O
218	years	N	O
219	)	N	O
220	,	N	O
221	sex	N	O
222	(	N	O
223	54	N	O
224	%	N	O
225	men	N	O
226	)	N	O
227	,	N	O
228	weight	N	O
229	loss	N	O
230	(	N	O
231	32	N	O
232	%	N	O
233	>	N	O
234	or	N	O
235	=	N	O
236	10	N	O
237	%	N	O
238	)	N	O
239	,	N	O
240	PS	N	O
241	(	N	O
242	13	N	O
243	%	N	O
244	ECOG	N	O
245	=	N	O
246	2	N	O
247	)	N	O
248	,	N	O
249	antineoplastic	N	O
250	treatment	N	O
251	(	N	O
252	50	N	O
253	%	N	O
254	)	N	O
255	,	N	O
256	appetite	N	O
257	(	N	O
258	mean	N	O
259	VAS	N	O
260	score	N	O
261	,	N	O
262	31/100	N	O
263	mm	N	O
264	)	N	O
265	,	N	O
266	and	N	O
267	QOL	N	O
268	(	N	O
269	mean	N	O
270	score	N	O
271	,	N	O
272	30/100	N	O
273	)	N	O
274	.	N	O

275	Intent-to-treat	N	I-Premise
276	analysis	N	I-Premise
277	showed	N	I-Premise
278	no	N	I-Premise
279	significant	N	I-Premise
280	differences	N	I-Premise
281	between	N	I-Premise
282	the	N	I-Premise
283	three	N	I-Premise
284	arms	N	I-Premise
285	for	N	I-Premise
286	appetite	N	I-Premise
287	,	N	I-Premise
288	QOL	N	I-Premise
289	,	N	I-Premise
290	or	N	I-Premise
291	cannabinoid-related	N	I-Premise
292	toxicity	N	I-Premise
293	.	N	I-Premise

294	Increased	N	I-Premise
295	appetite	N	I-Premise
296	was	N	I-Premise
297	reported	N	I-Premise
298	by	N	I-Premise
299	73	N	I-Premise
300	%	N	I-Premise
301	,	N	I-Premise
302	58	N	I-Premise
303	%	N	I-Premise
304	,	N	I-Premise
305	and	N	I-Premise
306	69	N	I-Premise
307	%	N	I-Premise
308	of	N	I-Premise
309	patients	N	I-Premise
310	receiving	N	I-Premise
311	CE	N	I-Premise
312	,	N	I-Premise
313	THC	N	I-Premise
314	,	N	I-Premise
315	or	N	I-Premise
316	PL	N	I-Premise
317	,	N	I-Premise
318	respectively	N	I-Premise
319	.	N	I-Premise

320	An	N	O
321	independent	N	O
322	data	N	O
323	review	N	O
324	board	N	O
325	recommended	N	O
326	termination	N	O
327	of	N	O
328	recruitment	N	O
329	because	N	O
330	of	N	O
331	insufficient	N	O
332	differences	N	O
333	between	N	O
334	study	N	O
335	arms	N	O
336	.	N	O

337	CE	N	I-Premise
338	at	N	I-Premise
339	the	N	I-Premise
340	oral	N	I-Premise
341	dose	N	I-Premise
342	administered	N	I-Premise
343	was	N	I-Premise
344	well	N	I-Premise
345	tolerated	N	I-Premise
346	by	N	I-Premise
347	these	N	I-Premise
348	patients	N	I-Premise
349	with	N	I-Premise
350	CACS	N	I-Premise
351	.	N	I-Premise

352	No	N	I-Claim
353	differences	N	I-Claim
354	in	N	I-Claim
355	patients	N	I-Claim
356	'	N	I-Claim
357	appetite	N	I-Claim
358	or	N	I-Claim
359	QOL	N	I-Claim
360	were	N	I-Claim
361	found	N	I-Claim
362	either	N	I-Claim
363	between	N	I-Claim
364	CE	N	I-Claim
365	,	N	I-Claim
366	THC	N	I-Claim
367	,	N	I-Claim
368	and	N	I-Claim
369	PL	N	I-Claim
370	or	N	I-Claim
371	between	N	I-Claim
372	CE	N	I-Claim
373	and	N	I-Claim
374	THC	N	I-Claim
375	at	N	I-Claim
376	the	N	I-Claim
377	dosages	N	I-Claim
378	investigated	N	I-Claim
379	.	N	I-Claim

1	Docetaxel	N	I-Claim
2	has	N	I-Claim
3	shown	N	I-Claim
4	activity	N	I-Claim
5	in	N	I-Claim
6	elderly	N	I-Claim
7	patients	N	I-Claim
8	with	N	I-Claim
9	advanced	N	I-Claim
10	non-small-cell	N	I-Claim
11	lung	N	I-Claim
12	cancer	N	I-Claim
13	(	N	I-Claim
14	NSCLC	N	I-Claim
15	)	N	I-Claim
16	.	N	I-Claim

17	This	N	O
18	randomized	N	O
19	phase	N	O
20	III	N	O
21	trial	N	O
22	evaluated	N	O
23	the	N	O
24	efficacy	N	O
25	and	N	O
26	safety	N	O
27	of	N	O
28	docetaxel	N	O
29	versus	N	O
30	vinorelbine	N	O
31	(	N	O
32	the	N	O
33	current	N	O
34	standard	N	O
35	treatment	N	O
36	)	N	O
37	in	N	O
38	elderly	N	O
39	patients	N	O
40	.	N	O

41	Chemotherapy-nave	N	O
42	patients	N	O
43	age	N	O
44	70	N	O
45	years	N	O
46	or	N	O
47	older	N	O
48	with	N	O
49	stage	N	O
50	IIIB/IV	N	O
51	NSCLC	N	O
52	and	N	O
53	performance	N	O
54	status	N	O
55	2	N	O
56	or	N	O
57	lower	N	O
58	were	N	O
59	eligible	N	O
60	.	N	O

61	Patients	N	O
62	randomly	N	O
63	received	N	O
64	docetaxel	N	O
65	60	N	O
66	mg/m2	N	O
67	(	N	O
68	day	N	O
69	1	N	O
70	)	N	O
71	or	N	O
72	vinorelbine	N	O
73	25	N	O
74	mg/m2	N	O
75	(	N	O
76	days	N	O
77	1	N	O
78	and	N	O
79	8	N	O
80	)	N	O
81	every	N	O
82	21	N	O
83	days	N	O
84	for	N	O
85	four	N	O
86	cycles	N	O
87	.	N	O

88	The	N	O
89	primary	N	O
90	end	N	O
91	point	N	O
92	was	N	O
93	overall	N	O
94	survival	N	O
95	.	N	O

96	Overall	N	O
97	disease-related	N	O
98	symptom	N	O
99	improvement	N	O
100	was	N	O
101	assessed	N	O
102	using	N	O
103	an	N	O
104	eight-item	N	O
105	questionnaire	N	O
106	.	N	O

107	In	N	O
108	total	N	O
109	,	N	O
110	182	N	O
111	patients	N	O
112	were	N	O
113	enrolled	N	O
114	.	N	O

115	Median	N	O
116	age	N	O
117	was	N	O
118	76	N	O
119	years	N	O
120	(	N	O
121	range	N	O
122	,	N	O
123	70	N	O
124	years	N	O
125	to	N	O
126	86	N	O
127	years	N	O
128	)	N	O
129	.	N	O

130	There	N	I-Premise
131	was	N	I-Premise
132	no	N	I-Premise
133	statistical	N	I-Premise
134	difference	N	I-Premise
135	in	N	I-Premise
136	median	N	I-Premise
137	overall	N	I-Premise
138	survival	N	I-Premise
139	with	N	I-Premise
140	docetaxel	N	I-Premise
141	versus	N	I-Premise
142	vinorelbine	N	I-Premise
143	(	N	I-Premise
144	14.3	N	I-Premise
145	months	N	I-Premise
146	v	N	I-Premise
147	9.9	N	I-Premise
148	months	N	I-Premise
149	;	N	I-Premise
150	hazard	N	I-Premise
151	ratio	N	I-Premise
152	,	N	I-Premise
153	0.780	N	I-Premise
154	;	N	I-Premise
155	95	N	I-Premise
156	%	N	I-Premise
157	CI	N	I-Premise
158	,	N	I-Premise
159	0.561	N	I-Premise
160	to	N	I-Premise
161	1.085	N	I-Premise
162	;	N	I-Premise
163	P	N	I-Premise
164	=	N	I-Premise
165	.138	N	I-Premise
166	)	N	I-Premise
167	.	N	I-Premise

168	There	N	I-Premise
169	was	N	I-Premise
170	a	N	I-Premise
171	significant	N	I-Premise
172	difference	N	I-Premise
173	in	N	I-Premise
174	median	N	I-Premise
175	progression-free	N	I-Premise
176	survival	N	I-Premise
177	(	N	I-Premise
178	5.5	N	I-Premise
179	months	N	I-Premise
180	v	N	I-Premise
181	3.1	N	I-Premise
182	months	N	I-Premise
183	;	N	I-Premise
184	P	N	I-Premise
185	<	N	I-Premise
186	.001	N	I-Premise
187	)	N	I-Premise
188	.	N	I-Premise

189	Response	N	I-Premise
190	rates	N	I-Premise
191	were	N	I-Premise
192	also	N	I-Premise
193	significantly	N	I-Premise
194	improved	N	I-Premise
195	with	N	I-Premise
196	docetaxel	N	I-Premise
197	versus	N	I-Premise
198	vinorelbine	N	I-Premise
199	(	N	I-Premise
200	22.7	N	I-Premise
201	%	N	I-Premise
202	v	N	I-Premise
203	9.9	N	I-Premise
204	%	N	I-Premise
205	;	N	I-Premise
206	P	N	I-Premise
207	=	N	I-Premise
208	.019	N	I-Premise
209	)	N	I-Premise
210	.	N	I-Premise

211	The	N	I-Premise
212	most	N	I-Premise
213	common	N	I-Premise
214	grade	N	I-Premise
215	3	N	I-Premise
216	to	N	I-Premise
217	4	N	I-Premise
218	toxicities	N	I-Premise
219	were	N	I-Premise
220	neutropenia	N	I-Premise
221	(	N	I-Premise
222	82.9	N	I-Premise
223	%	N	I-Premise
224	for	N	I-Premise
225	docetaxel	N	I-Premise
226	;	N	I-Premise
227	69.2	N	I-Premise
228	%	N	I-Premise
229	for	N	I-Premise
230	vinorelbine	N	I-Premise
231	;	N	I-Premise
232	P	N	I-Premise
233	=	N	I-Premise
234	.031	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	leukopenia	N	I-Premise
238	(	N	I-Premise
239	58.0	N	I-Premise
240	%	N	I-Premise
241	for	N	I-Premise
242	docetaxel	N	I-Premise
243	;	N	I-Premise
244	51.7	N	I-Premise
245	%	N	I-Premise
246	for	N	I-Premise
247	vinorelbine	N	I-Premise
248	)	N	I-Premise
249	.	N	I-Premise

250	Other	N	I-Premise
251	toxicities	N	I-Premise
252	were	N	I-Premise
253	mild	N	I-Premise
254	and	N	I-Premise
255	generally	N	I-Premise
256	well	N	I-Premise
257	tolerated	N	I-Premise
258	.	N	I-Premise

259	Docetaxel	N	I-Premise
260	improved	N	I-Premise
261	overall	N	I-Premise
262	disease-related	N	I-Premise
263	symptoms	N	I-Premise
264	over	N	I-Premise
265	vinorelbine	N	I-Premise
266	(	N	I-Premise
267	odds	N	I-Premise
268	ratio	N	I-Premise
269	,	N	I-Premise
270	1.86	N	I-Premise
271	;	N	I-Premise
272	95	N	I-Premise
273	%	N	I-Premise
274	CI	N	I-Premise
275	,	N	I-Premise
276	1.09	N	I-Premise
277	to	N	I-Premise
278	3.20	N	I-Premise
279	)	N	I-Premise
280	.	N	I-Premise

281	Docetaxel	N	I-Premise
282	improved	N	I-Premise
283	progression-free	N	I-Premise
284	survival	N	I-Premise
285	,	N	I-Premise
286	response	N	I-Premise
287	rate	N	I-Premise
288	,	N	I-Premise
289	and	N	I-Premise
290	disease-related	N	I-Premise
291	symptoms	N	I-Premise
292	versus	N	I-Premise
293	vinorelbine	N	I-Premise
294	.	N	I-Premise

295	Overall	N	I-Claim
296	survival	N	I-Claim
297	was	N	I-Claim
298	not	N	I-Claim
299	statistically	N	I-Claim
300	significantly	N	I-Claim
301	improved	N	I-Claim
302	at	N	I-Claim
303	this	N	I-Claim
304	time	N	I-Claim
305	.	N	I-Claim

306	Docetaxel	N	I-Claim
307	monotherapy	N	I-Claim
308	may	N	I-Claim
309	be	N	I-Claim
310	considered	N	I-Claim
311	as	N	I-Claim
312	an	N	I-Claim
313	option	N	I-Claim
314	in	N	I-Claim
315	the	N	I-Claim
316	standard	N	I-Claim
317	treatment	N	I-Claim
318	of	N	I-Claim
319	elderly	N	I-Claim
320	patients	N	I-Claim
321	with	N	I-Claim
322	advanced	N	I-Claim
323	NSCLC	N	I-Claim
324	.	N	I-Claim

1	The	N	O
2	combination	N	O
3	of	N	O
4	carboplatin	N	O
5	and	N	O
6	paclitaxel	N	O
7	is	N	O
8	the	N	O
9	standard	N	O
10	of	N	O
11	care	N	O
12	for	N	O
13	the	N	O
14	treatment	N	O
15	of	N	O
16	ovarian	N	O
17	cancer	N	O
18	,	N	O
19	yet	N	O
20	rates	N	O
21	of	N	O
22	recurrence	N	O
23	and	N	O
24	death	N	O
25	remain	N	O
26	high	N	O
27	.	N	O

28	We	N	O
29	performed	N	O
30	a	N	O
31	prospective	N	O
32	randomized	N	O
33	phase	N	O
34	III	N	O
35	study	N	O
36	to	N	O
37	examine	N	O
38	whether	N	O
39	sequential	N	O
40	administration	N	O
41	of	N	O
42	topotecan	N	O
43	can	N	O
44	improve	N	O
45	the	N	O
46	efficacy	N	O
47	of	N	O
48	carboplatin	N	O
49	and	N	O
50	paclitaxel	N	O
51	in	N	O
52	first-line	N	O
53	treatment	N	O
54	of	N	O
55	advanced	N	O
56	epithelial	N	O
57	ovarian	N	O
58	cancer	N	O
59	.	N	O

60	A	N	O
61	total	N	O
62	of	N	O
63	1308	N	O
64	patients	N	O
65	with	N	O
66	previously	N	O
67	untreated	N	O
68	ovarian	N	O
69	cancer	N	O
70	(	N	O
71	International	N	O
72	Federation	N	O
73	of	N	O
74	Gynecology	N	O
75	and	N	O
76	Obstetrics	N	O
77	stages	N	O
78	IIB-IV	N	O
79	)	N	O
80	were	N	O
81	randomly	N	O
82	assigned	N	O
83	to	N	O
84	receive	N	O
85	six	N	O
86	cycles	N	O
87	of	N	O
88	paclitaxel	N	O
89	and	N	O
90	carboplatin	N	O
91	followed	N	O
92	by	N	O
93	either	N	O
94	four	N	O
95	cycles	N	O
96	of	N	O
97	topotecan	N	O
98	(	N	O
99	TC-Top	N	O
100	;	N	O
101	658	N	O
102	patients	N	O
103	)	N	O
104	or	N	O
105	surveillance	N	O
106	(	N	O
107	TC	N	O
108	;	N	O
109	650	N	O
110	patients	N	O
111	)	N	O
112	on	N	O
113	a	N	O
114	3-week	N	O
115	per	N	O
116	cycle	N	O
117	schedule	N	O
118	.	N	O

119	The	N	O
120	primary	N	O
121	endpoint	N	O
122	was	N	O
123	overall	N	O
124	survival	N	O
125	,	N	O
126	and	N	O
127	secondary	N	O
128	endpoints	N	O
129	were	N	O
130	progression-free	N	O
131	survival	N	O
132	,	N	O
133	response	N	O
134	rate	N	O
135	,	N	O
136	toxicity	N	O
137	,	N	O
138	and	N	O
139	quality	N	O
140	of	N	O
141	life	N	O
142	.	N	O

143	Time-to-event	N	O
144	data	N	O
145	were	N	O
146	analyzed	N	O
147	using	N	O
148	the	N	O
149	Kaplan-Meier	N	O
150	method	N	O
151	,	N	O
152	and	N	O
153	a	N	O
154	stratified	N	O
155	log-rank	N	O
156	test	N	O
157	was	N	O
158	used	N	O
159	to	N	O
160	compare	N	O
161	distributions	N	O
162	between	N	O
163	treatment	N	O
164	groups	N	O
165	.	N	O

166	Hazard	N	O
167	ratios	N	O
168	(	N	O
169	HRs	N	O
170	)	N	O
171	with	N	O
172	95	N	O
173	%	N	O
174	confidence	N	O
175	intervals	N	O
176	(	N	O
177	CIs	N	O
178	)	N	O
179	were	N	O
180	estimated	N	O
181	using	N	O
182	a	N	O
183	Cox	N	O
184	proportional	N	O
185	hazards	N	O
186	model	N	O
187	.	N	O

188	Categorical	N	O
189	data	N	O
190	were	N	O
191	compared	N	O
192	using	N	O
193	a	N	O
194	stratified	N	O
195	Cochran-Mantel-Haenszel	N	O
196	test	N	O
197	.	N	O

198	All	N	O
199	statistical	N	O
200	tests	N	O
201	were	N	O
202	two-sided	N	O
203	.	N	O

204	Median	N	I-Premise
205	progression-free	N	I-Premise
206	survival	N	I-Premise
207	was	N	I-Premise
208	18.2	N	I-Premise
209	months	N	I-Premise
210	in	N	I-Premise
211	the	N	I-Premise
212	TC-Top	N	I-Premise
213	arm	N	I-Premise
214	versus	N	I-Premise
215	18.5	N	I-Premise
216	months	N	I-Premise
217	in	N	I-Premise
218	the	N	I-Premise
219	TC	N	I-Premise
220	arm	N	I-Premise
221	(	N	I-Premise
222	stratum-adjusted	N	I-Premise
223	HR	N	I-Premise
224	=	N	I-Premise
225	0.97	N	I-Premise
226	[	N	I-Premise
227	95	N	I-Premise
228	%	N	I-Premise
229	CI	N	I-Premise
230	=	N	I-Premise
231	0.85	N	I-Premise
232	to	N	I-Premise
233	1.10	N	I-Premise
234	]	N	I-Premise
235	;	N	I-Premise
236	P	N	I-Premise
237	=	N	I-Premise
238	.688	N	I-Premise
239	)	N	I-Premise
240	.	N	I-Premise

241	Median	N	I-Premise
242	overall	N	I-Premise
243	survival	N	I-Premise
244	was	N	I-Premise
245	43.1	N	I-Premise
246	months	N	I-Premise
247	for	N	I-Premise
248	the	N	I-Premise
249	TC-Top	N	I-Premise
250	arm	N	I-Premise
251	versus	N	I-Premise
252	44.5	N	I-Premise
253	months	N	I-Premise
254	for	N	I-Premise
255	the	N	I-Premise
256	TC	N	I-Premise
257	arm	N	I-Premise
258	(	N	I-Premise
259	stratum-adjusted	N	I-Premise
260	HR	N	I-Premise
261	=	N	I-Premise
262	1.01	N	I-Premise
263	[	N	I-Premise
264	95	N	I-Premise
265	%	N	I-Premise
266	CI	N	I-Premise
267	=	N	I-Premise
268	0.86	N	I-Premise
269	to	N	I-Premise
270	1.18	N	I-Premise
271	]	N	I-Premise
272	;	N	I-Premise
273	P	N	I-Premise
274	=	N	I-Premise
275	.885	N	I-Premise
276	)	N	I-Premise
277	.	N	I-Premise

278	At	N	I-Premise
279	3	N	I-Premise
280	years	N	I-Premise
281	,	N	I-Premise
282	overall	N	I-Premise
283	survival	N	I-Premise
284	in	N	I-Premise
285	both	N	I-Premise
286	arms	N	I-Premise
287	was	N	I-Premise
288	57	N	I-Premise
289	%	N	I-Premise
290	(	N	I-Premise
291	58.5	N	I-Premise
292	%	N	I-Premise
293	in	N	I-Premise
294	the	N	I-Premise
295	TC	N	I-Premise
296	arm	N	I-Premise
297	and	N	I-Premise
298	55.7	N	I-Premise
299	%	N	I-Premise
300	in	N	I-Premise
301	the	N	I-Premise
302	TC-Top	N	I-Premise
303	arm	N	I-Premise
304	)	N	I-Premise
305	.	N	I-Premise

306	Compared	N	I-Premise
307	with	N	I-Premise
308	patients	N	I-Premise
309	in	N	I-Premise
310	the	N	I-Premise
311	TC	N	I-Premise
312	arm	N	I-Premise
313	,	N	I-Premise
314	patients	N	I-Premise
315	in	N	I-Premise
316	the	N	I-Premise
317	TC-Top	N	I-Premise
318	arm	N	I-Premise
319	had	N	I-Premise
320	more	N	I-Premise
321	grade	N	I-Premise
322	3-4	N	I-Premise
323	hematologic	N	I-Premise
324	toxic	N	I-Premise
325	effects	N	I-Premise
326	(	N	I-Premise
327	requiring	N	I-Premise
328	more	N	I-Premise
329	supportive	N	I-Premise
330	care	N	I-Premise
331	)	N	I-Premise
332	and	N	I-Premise
333	more	N	I-Premise
334	grade	N	I-Premise
335	3-4	N	I-Premise
336	infections	N	I-Premise
337	(	N	I-Premise
338	5.1	N	I-Premise
339	%	N	I-Premise
340	versus	N	I-Premise
341	2.7	N	I-Premise
342	%	N	I-Premise
343	;	N	I-Premise
344	P	N	I-Premise
345	=	N	I-Premise
346	.034	N	I-Premise
347	)	N	I-Premise
348	but	N	I-Premise
349	did	N	I-Premise
350	not	N	I-Premise
351	have	N	I-Premise
352	a	N	I-Premise
353	statistically	N	I-Premise
354	significant	N	I-Premise
355	increase	N	I-Premise
356	in	N	I-Premise
357	febrile	N	I-Premise
358	neutropenia	N	I-Premise
359	(	N	I-Premise
360	3.3	N	I-Premise
361	%	N	I-Premise
362	versus	N	I-Premise
363	3.1	N	I-Premise
364	%	N	I-Premise
365	;	N	I-Premise
366	P	N	I-Premise
367	=	N	I-Premise
368	.80	N	I-Premise
369	)	N	I-Premise
370	.	N	I-Premise

371	Among	N	I-Premise
372	patients	N	I-Premise
373	who	N	I-Premise
374	had	N	I-Premise
375	measurable	N	I-Premise
376	disease	N	I-Premise
377	(	N	I-Premise
378	TC	N	I-Premise
379	,	N	I-Premise
380	n	N	I-Premise
381	=	N	I-Premise
382	147	N	I-Premise
383	;	N	I-Premise
384	TC-Top	N	I-Premise
385	,	N	I-Premise
386	n	N	I-Premise
387	=	N	I-Premise
388	145	N	I-Premise
389	)	N	I-Premise
390	,	N	I-Premise
391	overall	N	I-Premise
392	(	N	I-Premise
393	i.e.	N	I-Premise
394	,	N	I-Premise
395	complete	N	I-Premise
396	or	N	I-Premise
397	partial	N	I-Premise
398	)	N	I-Premise
399	response	N	I-Premise
400	was	N	I-Premise
401	69.0	N	I-Premise
402	%	N	I-Premise
403	(	N	I-Premise
404	95	N	I-Premise
405	%	N	I-Premise
406	CI	N	I-Premise
407	=	N	I-Premise
408	61.4	N	I-Premise
409	%	N	I-Premise
410	to	N	I-Premise
411	76.5	N	I-Premise
412	%	N	I-Premise
413	)	N	I-Premise
414	in	N	I-Premise
415	the	N	I-Premise
416	TC-Top	N	I-Premise
417	arm	N	I-Premise
418	and	N	I-Premise
419	76.2	N	I-Premise
420	%	N	I-Premise
421	(	N	I-Premise
422	95	N	I-Premise
423	%	N	I-Premise
424	CI	N	I-Premise
425	=	N	I-Premise
426	69.3	N	I-Premise
427	%	N	I-Premise
428	to	N	I-Premise
429	83.1	N	I-Premise
430	%	N	I-Premise
431	)	N	I-Premise
432	in	N	I-Premise
433	the	N	I-Premise
434	TC	N	I-Premise
435	arm	N	I-Premise
436	(	N	I-Premise
437	P	N	I-Premise
438	=	N	I-Premise
439	.166	N	I-Premise
440	)	N	I-Premise
441	.	N	I-Premise

442	The	N	I-Claim
443	sequential	N	I-Claim
444	addition	N	I-Claim
445	of	N	I-Claim
446	topotecan	N	I-Claim
447	to	N	I-Claim
448	carboplatin-paclitaxel	N	I-Claim
449	did	N	I-Claim
450	not	N	I-Claim
451	result	N	I-Claim
452	in	N	I-Claim
453	superior	N	I-Claim
454	overall	N	I-Claim
455	response	N	I-Claim
456	or	N	I-Claim
457	progression-free	N	I-Claim
458	or	N	I-Claim
459	overall	N	I-Claim
460	survival	N	I-Claim
461	.	N	I-Claim

462	Therefore	N	I-Claim
463	,	N	I-Claim
464	this	N	I-Claim
465	regimen	N	I-Claim
466	is	N	I-Claim
467	not	N	I-Claim
468	recommended	N	I-Claim
469	as	N	I-Claim
470	standard	N	I-Claim
471	of	N	I-Claim
472	care	N	I-Claim
473	treatment	N	I-Claim
474	for	N	I-Claim
475	ovarian	N	I-Claim
476	cancer	N	I-Claim
477	.	N	I-Claim

1	This	N	O
2	report	N	O
3	describes	N	O
4	the	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	QOL	N	O
10	)	N	O
11	findings	N	O
12	of	N	O
13	a	N	O
14	randomized	N	O
15	placebo	N	O
16	controlled	N	O
17	study	N	O
18	of	N	O
19	erlotinib	N	O
20	,	N	O
21	an	N	O
22	epidermal	N	O
23	growth	N	O
24	factor	N	O
25	receptor	N	O
26	inhibitor	N	O
27	,	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	non-small-cell	N	O
32	lung	N	O
33	cancer	N	O
34	(	N	O
35	NSCLC	N	O
36	)	N	O
37	.	N	O

38	This	N	O
39	double-blind	N	O
40	phase	N	O
41	III	N	O
42	trial	N	O
43	randomly	N	O
44	assigned	N	O
45	731	N	O
46	patients	N	O
47	with	N	O
48	NSCLC	N	O
49	who	N	O
50	had	N	O
51	progressed	N	O
52	after	N	O
53	prior	N	O
54	chemotherapy	N	O
55	to	N	O
56	erlotinib	N	O
57	150	N	O
58	mg	N	O
59	daily	N	O
60	or	N	O
61	placebo	N	O
62	,	N	O
63	with	N	O
64	survival	N	O
65	as	N	O
66	the	N	O
67	primary	N	O
68	study	N	O
69	outcome	N	O
70	.	N	O

71	QOL	N	O
72	was	N	O
73	assessed	N	O
74	by	N	O
75	European	N	O
76	Organisation	N	O
77	for	N	O
78	Research	N	O
79	and	N	O
80	Treatment	N	O
81	of	N	O
82	Cancer	N	O
83	QLQ-C30	N	O
84	and	N	O
85	the	N	O
86	lung	N	O
87	cancer	N	O
88	module	N	O
89	QLQ-LC13	N	O
90	.	N	O

91	The	N	O
92	primary	N	O
93	end	N	O
94	points	N	O
95	for	N	O
96	QOL	N	O
97	analysis	N	O
98	were	N	O
99	time	N	O
100	to	N	O
101	deterioration	N	O
102	of	N	O
103	three	N	O
104	common	N	O
105	lung	N	O
106	cancer	N	O
107	symptoms	N	O
108	:	N	O
109	cough	N	O
110	,	N	O
111	dyspnea	N	O
112	,	N	O
113	and	N	O
114	pain	N	O
115	.	N	O

116	Survival	N	I-Premise
117	was	N	I-Premise
118	significantly	N	I-Premise
119	longer	N	I-Premise
120	(	N	I-Premise
121	hazard	N	I-Premise
122	ratio	N	I-Premise
123	,	N	I-Premise
124	0.70	N	I-Premise
125	;	N	I-Premise
126	P	N	I-Premise
127	<	N	I-Premise
128	.0001	N	I-Premise
129	)	N	I-Premise
130	in	N	I-Premise
131	the	N	I-Premise
132	erlotinib	N	I-Premise
133	arm	N	I-Premise
134	.	N	I-Premise

135	Compliance	N	I-Premise
136	with	N	I-Premise
137	QOL	N	I-Premise
138	was	N	I-Premise
139	87	N	I-Premise
140	%	N	I-Premise
141	at	N	I-Premise
142	baseline	N	I-Premise
143	and	N	I-Premise
144	more	N	I-Premise
145	than	N	I-Premise
146	70	N	I-Premise
147	%	N	I-Premise
148	during	N	I-Premise
149	treatment	N	I-Premise
150	.	N	I-Premise

151	Patients	N	I-Premise
152	receiving	N	I-Premise
153	erlotinib	N	I-Premise
154	had	N	I-Premise
155	significantly	N	I-Premise
156	longer	N	I-Premise
157	median	N	I-Premise
158	time	N	I-Premise
159	to	N	I-Premise
160	deterioration	N	I-Premise
161	for	N	I-Premise
162	all	N	I-Premise
163	three	N	I-Premise
164	symptoms	N	I-Premise
165	(	N	I-Premise
166	4.9	N	I-Premise
167	v	N	I-Premise
168	3.7	N	I-Premise
169	months	N	I-Premise
170	for	N	I-Premise
171	cough	N	I-Premise
172	[	N	I-Premise
173	P	N	I-Premise
174	=	N	I-Premise
175	.04	N	I-Premise
176	]	N	I-Premise
177	;	N	I-Premise
178	4.7	N	I-Premise
179	v	N	I-Premise
180	2.9	N	I-Premise
181	months	N	I-Premise
182	for	N	I-Premise
183	dyspnea	N	I-Premise
184	[	N	I-Premise
185	P	N	I-Premise
186	=	N	I-Premise
187	.04	N	I-Premise
188	]	N	I-Premise
189	,	N	I-Premise
190	and	N	I-Premise
191	2.8	N	I-Premise
192	v	N	I-Premise
193	1.9	N	I-Premise
194	months	N	I-Premise
195	for	N	I-Premise
196	pain	N	I-Premise
197	[	N	I-Premise
198	P	N	I-Premise
199	=	N	I-Premise
200	.03	N	I-Premise
201	]	N	I-Premise
202	)	N	I-Premise
203	.	N	I-Premise

204	QOL	N	I-Premise
205	response	N	I-Premise
206	analyses	N	I-Premise
207	showed	N	I-Premise
208	that	N	I-Premise
209	44	N	I-Premise
210	%	N	I-Premise
211	,	N	I-Premise
212	34	N	I-Premise
213	%	N	I-Premise
214	,	N	I-Premise
215	and	N	I-Premise
216	42	N	I-Premise
217	%	N	I-Premise
218	of	N	I-Premise
219	patients	N	I-Premise
220	receiving	N	I-Premise
221	erlotinib	N	I-Premise
222	had	N	I-Premise
223	improvement	N	I-Premise
224	in	N	I-Premise
225	these	N	I-Premise
226	three	N	I-Premise
227	symptoms	N	I-Premise
228	,	N	I-Premise
229	respectively	N	I-Premise
230	.	N	I-Premise

231	This	N	I-Premise
232	was	N	I-Premise
233	accompanied	N	I-Premise
234	by	N	I-Premise
235	a	N	I-Premise
236	significant	N	I-Premise
237	improvement	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	physical	N	I-Premise
241	function	N	I-Premise
242	(	N	I-Premise
243	31	N	I-Premise
244	%	N	I-Premise
245	erlotinib	N	I-Premise
246	v	N	I-Premise
247	19	N	I-Premise
248	%	N	I-Premise
249	placebo	N	I-Premise
250	,	N	I-Premise
251	P	N	I-Premise
252	=	N	I-Premise
253	.01	N	I-Premise
254	)	N	I-Premise
255	,	N	I-Premise
256	and	N	I-Premise
257	global	N	I-Premise
258	QOL	N	I-Premise
259	(	N	I-Premise
260	35	N	I-Premise
261	%	N	I-Premise
262	v	N	I-Premise
263	26	N	I-Premise
264	%	N	I-Premise
265	,	N	I-Premise
266	P	N	I-Premise
267	<	N	I-Premise
268	.0001	N	I-Premise
269	)	N	I-Premise
270	.	N	I-Premise

271	Patients	N	I-Premise
272	with	N	I-Premise
273	complete	N	I-Premise
274	or	N	I-Premise
275	partial	N	I-Premise
276	response	N	I-Premise
277	were	N	I-Premise
278	more	N	I-Premise
279	likely	N	I-Premise
280	to	N	I-Premise
281	have	N	I-Premise
282	improvement	N	I-Premise
283	in	N	I-Premise
284	the	N	I-Premise
285	QOL	N	I-Premise
286	response	N	I-Premise
287	than	N	I-Premise
288	patients	N	I-Premise
289	with	N	I-Premise
290	stable	N	I-Premise
291	or	N	I-Premise
292	progressive	N	I-Premise
293	disease	N	I-Premise
294	(	N	I-Premise
295	P	N	I-Premise
296	<	N	I-Premise
297	.01	N	I-Premise
298	)	N	I-Premise
299	.	N	I-Premise

300	Erlotinib	N	I-Claim
301	not	N	I-Claim
302	only	N	I-Claim
303	improves	N	I-Claim
304	survival	N	I-Claim
305	in	N	I-Claim
306	previously	N	I-Claim
307	treated	N	I-Claim
308	patients	N	I-Claim
309	with	N	I-Claim
310	NSCLC	N	I-Claim
311	,	N	I-Claim
312	but	N	I-Claim
313	also	N	I-Claim
314	improves	N	I-Claim
315	tumor-related	N	I-Claim
316	symptoms	N	I-Claim
317	and	N	I-Claim
318	important	N	I-Claim
319	aspects	N	I-Claim
320	of	N	I-Claim
321	QOL	N	I-Claim
322	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	effectiveness	N	O
5	and	N	O
6	tolerability	N	O
7	of	N	O
8	gemcitabine	N	O
9	plus	N	O
10	cisplatin	N	O
11	with	N	O
12	single-agent	N	O
13	gemcitabine	N	O
14	as	N	O
15	first-line	N	O
16	chemotherapy	N	O
17	for	N	O
18	locally	N	O
19	advanced	N	O
20	or	N	O
21	metastatic	N	O
22	pancreatic	N	O
23	cancer	N	O
24	.	N	O

25	Patients	N	O
26	with	N	O
27	advanced	N	O
28	adenocarcinoma	N	O
29	of	N	O
30	the	N	O
31	pancreas	N	O
32	were	N	O
33	randomly	N	O
34	assigned	N	O
35	to	N	O
36	receive	N	O
37	either	N	O
38	gemcitabine	N	O
39	1,000	N	O
40	mg/m2	N	O
41	and	N	O
42	cisplatin	N	O
43	50	N	O
44	mg/m2	N	O
45	given	N	O
46	on	N	O
47	days	N	O
48	1	N	O
49	and	N	O
50	15	N	O
51	of	N	O
52	a	N	O
53	4-week	N	O
54	cycle	N	O
55	(	N	O
56	GemCis	N	O
57	arm	N	O
58	)	N	O
59	or	N	O
60	gemcitabine	N	O
61	alone	N	O
62	at	N	O
63	a	N	O
64	dose	N	O
65	of	N	O
66	1,000	N	O
67	mg/m2	N	O
68	on	N	O
69	days	N	O
70	1	N	O
71	,	N	O
72	8	N	O
73	,	N	O
74	and	N	O
75	15	N	O
76	of	N	O
77	a	N	O
78	4-week	N	O
79	regimen	N	O
80	(	N	O
81	Gem	N	O
82	arm	N	O
83	)	N	O
84	.	N	O

85	The	N	O
86	primary	N	O
87	end	N	O
88	point	N	O
89	was	N	O
90	overall	N	O
91	survival	N	O
92	;	N	O
93	secondary	N	O
94	end	N	O
95	points	N	O
96	were	N	O
97	progression-free	N	O
98	survival	N	O
99	,	N	O
100	response	N	O
101	rate	N	O
102	,	N	O
103	safety	N	O
104	,	N	O
105	and	N	O
106	quality	N	O
107	of	N	O
108	life	N	O
109	.	N	O

110	One	N	O
111	hundred	N	O
112	ninety-five	N	O
113	patients	N	O
114	were	N	O
115	enrolled	N	O
116	and	N	O
117	showed	N	O
118	baseline	N	O
119	characteristics	N	O
120	well	N	O
121	balanced	N	O
122	between	N	O
123	treatment	N	O
124	arms	N	O
125	.	N	O

126	Combination	N	I-Premise
127	treatment	N	I-Premise
128	in	N	I-Premise
129	the	N	I-Premise
130	GemCis	N	I-Premise
131	arm	N	I-Premise
132	was	N	I-Premise
133	associated	N	I-Premise
134	with	N	I-Premise
135	a	N	I-Premise
136	prolonged	N	I-Premise
137	median	N	I-Premise
138	progression-free	N	I-Premise
139	survival	N	I-Premise
140	(	N	I-Premise
141	5.3	N	I-Premise
142	months	N	I-Premise
143	v	N	I-Premise
144	3.1	N	I-Premise
145	months	N	I-Premise
146	;	N	I-Premise
147	hazard	N	I-Premise
148	ratio	N	I-Premise
149	[	N	I-Premise
150	HR	N	I-Premise
151	]	N	I-Premise
152	=	N	I-Premise
153	0.75	N	I-Premise
154	;	N	I-Premise
155	P	N	I-Premise
156	=	N	I-Premise
157	.053	N	I-Premise
158	)	N	I-Premise
159	.	N	I-Premise

160	Also	N	I-Premise
161	,	N	I-Premise
162	median	N	I-Premise
163	overall	N	I-Premise
164	survival	N	I-Premise
165	was	N	I-Premise
166	superior	N	I-Premise
167	for	N	I-Premise
168	patients	N	I-Premise
169	treated	N	I-Premise
170	in	N	I-Premise
171	the	N	I-Premise
172	GemCis	N	I-Premise
173	arm	N	I-Premise
174	as	N	I-Premise
175	compared	N	I-Premise
176	with	N	I-Premise
177	the	N	I-Premise
178	Gem	N	I-Premise
179	arm	N	I-Premise
180	(	N	I-Premise
181	7.5	N	I-Premise
182	v	N	I-Premise
183	6.0	N	I-Premise
184	months	N	I-Premise
185	)	N	I-Premise
186	,	N	I-Premise
187	an	N	I-Premise
188	advantage	N	I-Premise
189	which	N	I-Premise
190	did	N	I-Premise
191	not	N	I-Premise
192	,	N	I-Premise
193	however	N	I-Premise
194	,	N	I-Premise
195	reach	N	I-Premise
196	statistical	N	I-Premise
197	significance	N	I-Premise
198	(	N	I-Premise
199	HR	N	I-Premise
200	=	N	I-Premise
201	0.80	N	I-Premise
202	;	N	I-Premise
203	P	N	I-Premise
204	=	N	I-Premise
205	.15	N	I-Premise
206	)	N	I-Premise
207	.	N	I-Premise

208	Tumor	N	I-Premise
209	response	N	I-Premise
210	rates	N	I-Premise
211	were	N	I-Premise
212	comparable	N	I-Premise
213	between	N	I-Premise
214	treatment	N	I-Premise
215	arms	N	I-Premise
216	(	N	I-Premise
217	10.2	N	I-Premise
218	%	N	I-Premise
219	v	N	I-Premise
220	8.2	N	I-Premise
221	%	N	I-Premise
222	)	N	I-Premise
223	.	N	I-Premise

224	The	N	I-Premise
225	rate	N	I-Premise
226	of	N	I-Premise
227	stable	N	I-Premise
228	disease	N	I-Premise
229	was	N	I-Premise
230	,	N	I-Premise
231	however	N	I-Premise
232	,	N	I-Premise
233	greater	N	I-Premise
234	in	N	I-Premise
235	the	N	I-Premise
236	combination	N	I-Premise
237	arm	N	I-Premise
238	(	N	I-Premise
239	60.2	N	I-Premise
240	%	N	I-Premise
241	v	N	I-Premise
242	40.2	N	I-Premise
243	%	N	I-Premise
244	;	N	I-Premise
245	P	N	I-Premise
246	<	N	I-Premise
247	.001	N	I-Premise
248	)	N	I-Premise
249	.	N	O

250	Grade	N	I-Premise
251	3	N	I-Premise
252	to	N	I-Premise
253	4	N	I-Premise
254	hematologic	N	I-Premise
255	toxicity	N	I-Premise
256	did	N	I-Premise
257	not	N	I-Premise
258	exceed	N	I-Premise
259	15	N	I-Premise
260	%	N	I-Premise
261	in	N	I-Premise
262	both	N	I-Premise
263	treatment	N	I-Premise
264	arms	N	I-Premise
265	.	N	I-Premise

266	These	N	I-Claim
267	results	N	I-Claim
268	support	N	I-Claim
269	the	N	I-Claim
270	efficacy	N	I-Claim
271	and	N	I-Claim
272	safety	N	I-Claim
273	of	N	I-Claim
274	an	N	I-Claim
275	every-2-weeks	N	I-Claim
276	treatment	N	I-Claim
277	with	N	I-Claim
278	gemcitabine	N	I-Claim
279	plus	N	I-Claim
280	cisplatin	N	I-Claim
281	.	N	I-Claim

282	Median	N	I-Claim
283	overall	N	I-Claim
284	survival	N	I-Claim
285	and	N	I-Claim
286	progression-free	N	I-Claim
287	survival	N	I-Claim
288	were	N	I-Claim
289	more	N	I-Claim
290	favorable	N	I-Claim
291	in	N	I-Claim
292	the	N	I-Claim
293	combination	N	I-Claim
294	arm	N	I-Claim
295	as	N	I-Claim
296	compared	N	I-Claim
297	with	N	I-Claim
298	gemcitabine	N	I-Claim
299	alone	N	I-Claim
300	,	N	I-Claim
301	although	N	I-Premise
302	the	N	I-Premise
303	difference	N	I-Premise
304	did	N	I-Premise
305	not	N	I-Premise
306	attain	N	I-Premise
307	statistical	N	I-Premise
308	significance	N	I-Premise
309	.	N	I-Premise

1	Chemotherapy	N	I-Claim
2	prolongs	N	I-Claim
3	survival	N	I-Claim
4	and	N	I-Claim
5	improves	N	I-Claim
6	quality	N	I-Claim
7	of	N	I-Claim
8	life	N	I-Claim
9	(	N	I-Claim
10	QOL	N	I-Claim
11	)	N	I-Claim
12	for	N	I-Claim
13	good	N	I-Claim
14	performance	N	I-Claim
15	status	N	I-Claim
16	(	N	I-Claim
17	PS	N	I-Claim
18	)	N	I-Claim
19	patients	N	I-Claim
20	with	N	I-Claim
21	advanced	N	I-Claim
22	non-small	N	I-Claim
23	cell	N	I-Claim
24	lung	N	I-Claim
25	cancer	N	I-Claim
26	(	N	I-Claim
27	NSCLC	N	I-Claim
28	)	N	I-Claim
29	.	N	I-Claim

30	Targeted	N	I-MajorClaim
31	therapies	N	I-MajorClaim
32	may	N	I-MajorClaim
33	improve	N	I-MajorClaim
34	chemotherapy	N	I-MajorClaim
35	effectiveness	N	I-MajorClaim
36	without	N	I-MajorClaim
37	worsening	N	I-MajorClaim
38	toxicity	N	I-MajorClaim
39	.	N	I-MajorClaim

40	SGN-15	N	O
41	is	N	O
42	an	N	O
43	antibody-drug	N	O
44	conjugate	N	O
45	(	N	O
46	ADC	N	O
47	)	N	O
48	,	N	O
49	consisting	N	O
50	of	N	O
51	a	N	O
52	chimeric	N	O
53	murine	N	O
54	monoclonal	N	O
55	antibody	N	O
56	recognizing	N	O
57	the	N	O
58	Lewis	N	O
59	Y	N	O
60	(	N	O
61	Le	N	O
62	(	N	O
63	y	N	O
64	)	N	O
65	)	N	O
66	antigen	N	O
67	,	N	O
68	conjugated	N	O
69	to	N	O
70	doxorubicin	N	O
71	.	N	O

72	Le	N	I-Claim
73	(	N	I-Claim
74	y	N	I-Claim
75	)	N	I-Claim
76	is	N	I-Claim
77	an	N	I-Claim
78	attractive	N	I-Claim
79	target	N	I-Claim
80	since	N	I-Claim
81	it	N	I-Claim
82	is	N	I-Claim
83	expressed	N	I-Claim
84	by	N	I-Claim
85	most	N	I-Claim
86	NSCLC	N	I-Claim
87	.	N	I-Claim

88	SGN-15	N	I-Premise
89	was	N	I-Premise
90	active	N	I-Premise
91	against	N	I-Premise
92	Le	N	I-Premise
93	(	N	I-Premise
94	y	N	I-Premise
95	)	N	I-Premise
96	-positive	N	I-Premise
97	tumors	N	I-Premise
98	in	N	I-Premise
99	early	N	I-Premise
100	phase	N	I-Premise
101	clinical	N	I-Premise
102	trials	N	I-Premise
103	and	N	I-Premise
104	was	N	I-Premise
105	synergistic	N	I-Premise
106	with	N	I-Premise
107	docetaxel	N	I-Premise
108	in	N	I-Premise
109	preclinical	N	I-Premise
110	experiments	N	I-Premise
111	.	N	I-Premise

112	This	N	O
113	Phase	N	O
114	II	N	O
115	,	N	O
116	open-label	N	O
117	study	N	O
118	was	N	O
119	conducted	N	O
120	to	N	O
121	confirm	N	O
122	the	N	O
123	activity	N	O
124	of	N	O
125	SGN-15	N	O
126	plus	N	O
127	docetaxel	N	O
128	in	N	O
129	previously	N	O
130	treated	N	O
131	NSCLC	N	O
132	patients	N	O
133	.	N	O

134	Sixty-two	N	O
135	patients	N	O
136	with	N	O
137	recurrent	N	O
138	or	N	O
139	metastatic	N	O
140	NSCLC	N	O
141	expressing	N	O
142	Le	N	O
143	(	N	O
144	y	N	O
145	)	N	O
146	,	N	O
147	one	N	O
148	or	N	O
149	two	N	O
150	prior	N	O
151	chemotherapy	N	O
152	regimens	N	O
153	,	N	O
154	and	N	O
155	PS	N	O
156	<	N	O
157	or	N	O
158	=2	N	O
159	were	N	O
160	randomized	N	O
161	2:1	N	O
162	to	N	O
163	receive	N	O
164	SGN-15	N	O
165	200	N	O
166	mg/m2/week	N	O
167	with	N	O
168	docetaxel	N	O
169	35	N	O
170	mg/m2/week	N	O
171	(	N	O
172	Arm	N	O
173	A	N	O
174	)	N	O
175	or	N	O
176	docetaxel	N	O
177	35	N	O
178	mg/m2/week	N	O
179	alone	N	O
180	(	N	O
181	Arm	N	O
182	B	N	O
183	)	N	O
184	for	N	O
185	6	N	O
186	of	N	O
187	8	N	O
188	weeks	N	O
189	.	N	O

190	Intrapatient	N	O
191	dose-escalation	N	O
192	of	N	O
193	SGN-15	N	O
194	to	N	O
195	350	N	O
196	mg/m2	N	O
197	was	N	O
198	permitted	N	O
199	in	N	O
200	the	N	O
201	second	N	O
202	half	N	O
203	of	N	O
204	the	N	O
205	study	N	O
206	.	N	O

207	Endpoints	N	O
208	were	N	O
209	survival	N	O
210	,	N	O
211	safety	N	O
212	,	N	O
213	efficacy	N	O
214	,	N	O
215	and	N	O
216	quality	N	O
217	of	N	O
218	life	N	O
219	.	N	O

220	Forty	N	O
221	patients	N	O
222	on	N	O
223	Arm	N	O
224	A	N	O
225	and	N	O
226	19	N	O
227	on	N	O
228	Arm	N	O
229	B	N	O
230	received	N	O
231	at	N	O
232	least	N	O
233	one	N	O
234	treatment	N	O
235	.	N	O

236	Patients	N	I-Premise
237	on	N	I-Premise
238	Arms	N	I-Premise
239	A	N	I-Premise
240	and	N	I-Premise
241	B	N	I-Premise
242	had	N	I-Premise
243	median	N	I-Premise
244	survivals	N	I-Premise
245	of	N	I-Premise
246	31.4	N	I-Premise
247	and	N	I-Premise
248	25.3	N	I-Premise
249	weeks	N	I-Premise
250	,	N	I-Premise
251	12-month	N	I-Premise
252	survivals	N	I-Premise
253	of	N	I-Premise
254	29	N	I-Premise
255	%	N	I-Premise
256	and	N	I-Premise
257	24	N	I-Premise
258	%	N	I-Premise
259	,	N	I-Premise
260	and	N	I-Premise
261	18-month	N	I-Premise
262	survivals	N	I-Premise
263	of	N	I-Premise
264	18	N	I-Premise
265	%	N	I-Premise
266	and	N	I-Premise
267	8	N	I-Premise
268	%	N	I-Premise
269	,	N	I-Premise
270	respectively	N	I-Premise
271	.	N	O

272	Toxicity	N	I-Premise
273	was	N	I-Premise
274	mild	N	I-Premise
275	in	N	I-Premise
276	both	N	I-Premise
277	arms	N	I-Premise
278	.	N	I-Premise

279	QOL	N	I-Premise
280	analyses	N	I-Premise
281	favored	N	I-Premise
282	Arm	N	I-Premise
283	A.	N	I-Premise
284	SGN-15	N	I-Claim
285	plus	N	I-Claim
286	docetaxel	N	I-Claim
287	is	N	I-Claim
288	a	N	I-Claim
289	well-tolerated	N	I-Claim
290	and	N	I-Claim
291	active	N	I-Claim
292	second	N	I-Claim
293	and	N	I-Claim
294	third	N	I-Claim
295	line	N	I-Claim
296	treatment	N	I-Claim
297	for	N	I-Claim
298	NSCLC	N	I-Claim
299	patients	N	I-Claim
300	.	N	O

301	Ongoing	N	O
302	studies	N	O
303	are	N	O
304	exploring	N	O
305	alternate	N	O
306	schedules	N	O
307	to	N	O
308	maximize	N	O
309	synergy	N	O
310	between	N	O
311	these	N	O
312	agents	N	O
313	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	efficacy	N	O
10	and	N	O
11	safety	N	O
12	of	N	O
13	association	N	O
14	of	N	O
15	duloxetine	N	O
16	and	N	O
17	rehabilitation	N	O
18	compared	N	O
19	with	N	O
20	rehabilitation	N	O
21	alone	N	O
22	in	N	O
23	men	N	O
24	with	N	O
25	SUI	N	O
26	after	N	O
27	radical	N	O
28	retropubic	N	O
29	prostatectomy	N	O
30	(	N	O
31	RRP	N	O
32	)	N	O
33	,	N	O
34	and	N	O
35	to	N	O
36	compare	N	O
37	continence	N	O
38	rate	N	O
39	even	N	O
40	after	N	O
41	planned	N	O
42	duloxetine	N	O
43	suspension	N	O
44	.	N	O

45	After	N	O
46	catheter	N	O
47	removal	N	O
48	,	N	O
49	112	N	O
50	patients	N	O
51	were	N	O
52	randomized	N	O
53	to	N	O
54	receive	N	O
55	rehabilitation	N	O
56	and	N	O
57	duloxetine	N	O
58	(	N	O
59	group	N	O
60	A	N	O
61	)	N	O
62	or	N	O
63	rehabilitation	N	O
64	alone	N	O
65	(	N	O
66	group	N	O
67	B	N	O
68	)	N	O
69	,	N	O
70	for	N	O
71	16	N	O
72	wk	N	O
73	.	N	O

74	postprostatectomy	N	O
75	SUI	N	O
76	with	N	O
77	daily	N	O
78	incontinent	N	O
79	episodes	N	O
80	frequency	N	O
81	(	N	O
82	IEF	N	O
83	)	N	O
84	of	N	O
85	four	N	O
86	or	N	O
87	greater	N	O
88	.	N	O

89	After	N	O
90	16	N	O
91	wk	N	O
92	both	N	O
93	groups	N	O
94	suspended	N	O
95	duloxetine/placebo	N	O
96	and	N	O
97	continued	N	O
98	rehabilitation	N	O
99	.	N	O

100	All	N	O
101	patients	N	O
102	completed	N	O
103	incontinence	N	O
104	quality	N	O
105	of	N	O
106	life	N	O
107	(	N	O
108	I-QoL	N	O
109	)	N	O
110	questionnaire	N	O
111	and	N	O
112	bladder	N	O
113	diary	N	O
114	.	N	O

115	Wilcoxon	N	O
116	test	N	O
117	was	N	O
118	used	N	O
119	to	N	O
120	analyse	N	O
121	changes	N	O
122	in	N	O
123	IEF	N	O
124	and	N	O
125	in	N	O
126	I-QoL	N	O
127	score	N	O
128	;	N	O
129	Fisher	N	O
130	exact	N	O
131	test	N	O
132	was	N	O
133	used	N	O
134	to	N	O
135	compare	N	O
136	continent	N	O
137	patients	N	O
138	between	N	O
139	the	N	O
140	groups	N	O
141	.	N	O

142	Adverse	N	O
143	events	N	O
144	for	N	O
145	duloxetine	N	O
146	was	N	O
147	15.2	N	O
148	%	N	O
149	.	N	O

150	102	N	O
151	men	N	O
152	completed	N	O
153	the	N	O
154	study	N	O
155	.	N	O

156	There	N	I-Premise
157	was	N	I-Premise
158	a	N	I-Premise
159	significant	N	I-Premise
160	decrease	N	I-Premise
161	in	N	I-Premise
162	pad	N	I-Premise
163	use	N	I-Premise
164	in	N	I-Premise
165	group	N	I-Premise
166	A	N	I-Premise
167	.	N	I-Premise

168	After	N	I-Premise
169	16	N	I-Premise
170	wk	N	I-Premise
171	,	N	I-Premise
172	39	N	I-Premise
173	patients	N	I-Premise
174	versus	N	I-Premise
175	27	N	I-Premise
176	were	N	I-Premise
177	dry	N	I-Premise
178	(	N	I-Premise
179	p=0.007	N	I-Premise
180	)	N	I-Premise
181	.	N	I-Premise

182	At	N	I-Premise
183	20	N	I-Premise
184	wk	N	I-Premise
185	,	N	I-Premise
186	4	N	I-Premise
187	wk	N	I-Premise
188	after	N	I-Premise
189	planned	N	I-Premise
190	interruption	N	I-Premise
191	of	N	I-Premise
192	duloxetine	N	I-Premise
193	,	N	I-Premise
194	we	N	I-Premise
195	observed	N	I-Premise
196	a	N	I-Premise
197	U-turn	N	I-Premise
198	,	N	I-Premise
199	23	N	I-Premise
200	patients	N	I-Premise
201	were	N	I-Premise
202	completely	N	I-Premise
203	dry	N	I-Premise
204	in	N	I-Premise
205	group	N	I-Premise
206	A	N	I-Premise
207	versus	N	I-Premise
208	38	N	I-Premise
209	in	N	I-Premise
210	group	N	I-Premise
211	B	N	I-Premise
212	(	N	I-Premise
213	p=0.008	N	I-Premise
214	)	N	I-Premise
215	.	N	I-Premise

216	Whereas	N	I-Premise
217	,	N	I-Premise
218	after	N	I-Premise
219	24	N	I-Premise
220	wk	N	I-Premise
221	,	N	I-Premise
222	31	N	I-Premise
223	in	N	I-Premise
224	group	N	I-Premise
225	A	N	I-Premise
226	versus	N	I-Premise
227	41	N	I-Premise
228	in	N	I-Premise
229	group	N	I-Premise
230	B	N	I-Premise
231	were	N	I-Premise
232	dry	N	I-Premise
233	(	N	I-Premise
234	p=0.08	N	I-Premise
235	)	N	I-Premise
236	.	N	O

237	The	N	I-Claim
238	decrease	N	I-Claim
239	in	N	I-Claim
240	IEF	N	I-Claim
241	and	N	I-Claim
242	improvements	N	I-Claim
243	in	N	I-Claim
244	I-QoL	N	I-Claim
245	scores	N	I-Claim
246	were	N	I-Claim
247	significantly	N	I-Claim
248	greater	N	I-Claim
249	in	N	I-Claim
250	group	N	I-Claim
251	A	N	I-Claim
252	for	N	I-Claim
253	the	N	I-Claim
254	first	N	I-Claim
255	16	N	I-Claim
256	wk	N	I-Claim
257	.	N	I-Claim

258	The	N	I-Claim
259	data	N	I-Claim
260	suggest	N	I-Claim
261	that	N	I-Claim
262	combination	N	I-Claim
263	therapy	N	I-Claim
264	might	N	I-Claim
265	provide	N	I-Claim
266	another	N	I-Claim
267	treatment	N	I-Claim
268	option	N	I-Claim
269	for	N	I-Claim
270	SUI	N	I-Claim
271	in	N	I-Claim
272	men	N	I-Claim
273	that	N	I-Claim
274	might	N	I-Claim
275	increase	N	I-Claim
276	the	N	I-Claim
277	percentage	N	I-Claim
278	of	N	I-Claim
279	early	N	I-Claim
280	postsurgery	N	I-Claim
281	continence	N	I-Claim
282	.	N	I-Claim

1	The	N	I-MajorClaim
2	impact	N	I-MajorClaim
3	of	N	I-MajorClaim
4	treatment	N	I-MajorClaim
5	on	N	I-MajorClaim
6	health-related	N	I-MajorClaim
7	quality	N	I-MajorClaim
8	of	N	I-MajorClaim
9	life	N	I-MajorClaim
10	(	N	I-MajorClaim
11	HRQoL	N	I-MajorClaim
12	)	N	I-MajorClaim
13	is	N	I-MajorClaim
14	an	N	I-MajorClaim
15	important	N	I-MajorClaim
16	consideration	N	I-MajorClaim
17	in	N	I-MajorClaim
18	the	N	I-MajorClaim
19	adjuvant	N	I-MajorClaim
20	treatment	N	I-MajorClaim
21	of	N	I-MajorClaim
22	operable	N	I-MajorClaim
23	breast	N	I-MajorClaim
24	cancer	N	I-MajorClaim
25	.	N	I-MajorClaim

26	Here	N	O
27	we	N	O
28	report	N	O
29	mature	N	O
30	HRQoL	N	O
31	outcomes	N	O
32	from	N	O
33	the	N	O
34	ATAC	N	O
35	trial	N	O
36	,	N	O
37	comparing	N	O
38	anastrozole	N	O
39	with	N	O
40	tamoxifen	N	O
41	as	N	O
42	primary	N	O
43	adjuvant	N	O
44	therapy	N	O
45	for	N	O
46	postmenopausal	N	O
47	women	N	O
48	with	N	O
49	localized	N	O
50	breast	N	O
51	cancer	N	O
52	.	N	O

53	Patients	N	O
54	completed	N	O
55	the	N	O
56	Functional	N	O
57	Assessment	N	O
58	of	N	O
59	Cancer	N	O
60	Therapy-Breast	N	O
61	(	N	O
62	FACT-B	N	O
63	)	N	O
64	questionnaire	N	O
65	plus	N	O
66	endocrine	N	O
67	subscale	N	O
68	(	N	O
69	ES	N	O
70	)	N	O
71	at	N	O
72	baseline	N	O
73	,	N	O
74	3	N	O
75	and	N	O
76	6	N	O
77	months	N	O
78	,	N	O
79	and	N	O
80	every	N	O
81	6	N	O
82	months	N	O
83	thereafter	N	O
84	.	N	O

85	Baseline	N	O
86	characteristics	N	O
87	in	N	O
88	the	N	O
89	HRQoL	N	O
90	sub-protocol	N	O
91	were	N	O
92	well	N	O
93	balanced	N	O
94	between	N	O
95	the	N	O
96	anastrozole	N	O
97	(	N	O
98	n	N	O
99	=	N	O
100	335	N	O
101	)	N	O
102	and	N	O
103	tamoxifen	N	O
104	(	N	O
105	n	N	O
106	=	N	O
107	347	N	O
108	)	N	O
109	groups	N	O
110	in	N	O
111	the	N	O
112	primary	N	O
113	analysis	N	O
114	population	N	O
115	.	N	O

116	As	N	I-Premise
117	with	N	I-Premise
118	previously	N	I-Premise
119	published	N	I-Premise
120	results	N	I-Premise
121	at	N	I-Premise
122	2	N	I-Premise
123	years	N	I-Premise
124	,	N	I-Premise
125	there	N	I-Premise
126	was	N	I-Premise
127	no	N	I-Premise
128	statistically	N	I-Premise
129	significant	N	I-Premise
130	difference	N	I-Premise
131	in	N	I-Premise
132	the	N	I-Premise
133	Trial	N	I-Premise
134	Outcome	N	I-Premise
135	Index	N	I-Premise
136	of	N	I-Premise
137	the	N	I-Premise
138	FACT-B	N	I-Premise
139	,	N	I-Premise
140	the	N	I-Premise
141	primary	N	I-Premise
142	endpoint	N	I-Premise
143	of	N	I-Premise
144	the	N	I-Premise
145	study	N	I-Premise
146	,	N	I-Premise
147	between	N	I-Premise
148	treatments	N	I-Premise
149	at	N	I-Premise
150	5	N	I-Premise
151	years	N	I-Premise
152	.	N	I-Premise

153	There	N	I-Premise
154	were	N	I-Premise
155	no	N	I-Premise
156	statistically	N	I-Premise
157	significant	N	I-Premise
158	differences	N	I-Premise
159	between	N	I-Premise
160	treatment	N	I-Premise
161	groups	N	I-Premise
162	in	N	I-Premise
163	ES	N	I-Premise
164	total	N	I-Premise
165	scores	N	I-Premise
166	.	N	I-Premise

167	Consistent	N	O
168	with	N	O
169	the	N	O
170	2-year	N	O
171	analysis	N	O
172	,	N	O
173	there	N	I-Claim
174	were	N	I-Claim
175	differences	N	I-Claim
176	between	N	I-Claim
177	treatment	N	I-Claim
178	groups	N	I-Claim
179	in	N	I-Claim
180	patient-reported	N	I-Claim
181	side	N	I-Claim
182	effects	N	I-Claim
183	:	N	I-Claim
184	diarrhea	N	I-Premise
185	(	N	I-Premise
186	anastrozole	N	I-Premise
187	3.1	N	I-Premise
188	%	N	I-Premise
189	vs.	N	I-Premise
190	tamoxifen	N	I-Premise
191	1.3	N	I-Premise
192	%	N	I-Premise
193	)	N	I-Premise
194	,	N	I-Premise
195	vaginal	N	I-Premise
196	dryness	N	I-Premise
197	(	N	I-Premise
198	18.5	N	I-Premise
199	%	N	I-Premise
200	vs.	N	I-Premise
201	9.1	N	I-Premise
202	%	N	I-Premise
203	)	N	I-Premise
204	,	N	I-Premise
205	diminished	N	I-Premise
206	libido	N	I-Premise
207	(	N	I-Premise
208	34.0	N	I-Premise
209	%	N	I-Premise
210	vs.	N	I-Premise
211	26.1	N	I-Premise
212	%	N	I-Premise
213	)	N	I-Premise
214	,	N	I-Premise
215	and	N	I-Premise
216	dyspareunia	N	I-Premise
217	(	N	I-Premise
218	17.3	N	I-Premise
219	%	N	I-Premise
220	vs.	N	I-Premise
221	8.1	N	I-Premise
222	%	N	I-Premise
223	)	N	I-Premise
224	were	N	I-Premise
225	significantly	N	I-Premise
226	more	N	I-Premise
227	frequent	N	I-Premise
228	with	N	I-Premise
229	anastrozole	N	I-Premise
230	compared	N	I-Premise
231	to	N	I-Premise
232	tamoxifen	N	I-Premise
233	.	N	I-Premise

234	Dizziness	N	I-Premise
235	(	N	I-Premise
236	3.1	N	I-Premise
237	%	N	I-Premise
238	vs.	N	I-Premise
239	5.4	N	I-Premise
240	%	N	I-Premise
241	)	N	I-Premise
242	and	N	I-Premise
243	vaginal	N	I-Premise
244	discharge	N	I-Premise
245	(	N	I-Premise
246	1.2	N	I-Premise
247	%	N	I-Premise
248	vs.	N	I-Premise
249	5.2	N	I-Premise
250	%	N	I-Premise
251	)	N	I-Premise
252	were	N	I-Premise
253	significantly	N	I-Premise
254	less	N	I-Premise
255	frequent	N	I-Premise
256	with	N	I-Premise
257	anastrozole	N	I-Premise
258	compared	N	I-Premise
259	to	N	I-Premise
260	tamoxifen	N	I-Premise
261	.	N	I-Premise

262	In	N	I-Claim
263	this	N	I-Claim
264	,	N	I-Claim
265	the	N	I-Claim
266	first	N	I-Claim
267	report	N	I-Claim
268	of	N	I-Claim
269	HRQoL	N	I-Claim
270	over	N	I-Claim
271	5	N	I-Claim
272	years	N	I-Claim
273	of	N	I-Claim
274	initial	N	I-Claim
275	adjuvant	N	I-Claim
276	therapy	N	I-Claim
277	with	N	I-Claim
278	an	N	I-Claim
279	aromatase	N	I-Claim
280	inhibitor	N	I-Claim
281	,	N	I-Claim
282	we	N	I-Claim
283	conclude	N	I-Claim
284	that	N	I-Claim
285	anastrozole	N	I-Claim
286	and	N	I-Claim
287	tamoxifen	N	I-Claim
288	had	N	I-Claim
289	similar	N	I-Claim
290	impacts	N	I-Claim
291	on	N	I-Claim
292	HRQoL	N	I-Claim
293	,	N	I-Claim
294	which	N	I-Claim
295	was	N	I-Claim
296	maintained	N	I-Claim
297	or	N	I-Claim
298	slightly	N	I-Claim
299	improved	N	I-Claim
300	during	N	I-Claim
301	the	N	I-Claim
302	treatment	N	I-Claim
303	period	N	I-Claim
304	for	N	I-Claim
305	both	N	I-Claim
306	groups	N	I-Claim
307	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	safety	N	O
5	and	N	O
6	health-related	N	O
7	quality	N	O
8	of	N	O
9	life	N	O
10	(	N	O
11	HRQOL	N	O
12	)	N	O
13	of	N	O
14	continuous	N	O
15	combined	N	O
16	hormone	N	O
17	replacement	N	O
18	therapy	N	O
19	(	N	O
20	ccHRT	N	O
21	)	N	O
22	with	N	O
23	estradiol	N	O
24	valerate/medroxyprogesterone	N	O
25	acetate	N	O
26	(	N	O
27	E	N	O
28	(	N	O
29	2	N	O
30	)	N	O
31	V/MPA	N	O
32	)	N	O
33	over	N	O
34	nine	N	O
35	years	N	O
36	and	N	O
37	at	N	O
38	follow-up	N	O
39	one	N	O
40	year	N	O
41	after	N	O
42	discontinuation	N	O
43	.	N	O

44	A	N	O
45	total	N	O
46	of	N	O
47	419	N	O
48	women	N	O
49	were	N	O
50	randomized	N	O
51	to	N	O
52	one	N	O
53	of	N	O
54	four	N	O
55	treatments	N	O
56	:	N	O
57	once-daily	N	O
58	1	N	O
59	mg	N	O
60	E2V/2.5	N	O
61	mg	N	O
62	MPA	N	O
63	(	N	O
64	1	N	O
65	+	N	O
66	2.5	N	O
67	group	N	O
68	)	N	O
69	;	N	O
70	1	N	O
71	mg	N	O
72	E2V/5	N	O
73	mg	N	O
74	MPA	N	O
75	daily	N	O
76	(	N	O
77	1	N	O
78	+	N	O
79	5	N	O
80	group	N	O
81	)	N	O
82	;	N	O
83	2	N	O
84	mg	N	O
85	E2V/2.5	N	O
86	mg	N	O
87	MPA	N	O
88	daily	N	O
89	(	N	O
90	2	N	O
91	+	N	O
92	2.5	N	O
93	group	N	O
94	)	N	O
95	;	N	O
96	2	N	O
97	mg	N	O
98	E2V/5	N	O
99	mg	N	O
100	MPA	N	O
101	daily	N	O
102	(	N	O
103	2	N	O
104	+	N	O
105	5	N	O
106	group	N	O
107	)	N	O
108	(	N	O
109	Indivina	N	O
110	,	N	O
111	Orion	N	O
112	Pharma	N	O
113	)	N	O
114	.	N	O

115	For	N	O
116	the	N	O
117	last	N	O
118	six	N	O
119	months	N	O
120	,	N	O
121	all	N	O
122	received	N	O
123	the	N	O
124	1	N	O
125	+	N	O
126	2.5	N	O
127	dosage	N	O
128	.	N	O

129	The	N	O
130	2	N	O
131	+	N	O
132	2.5	N	O
133	dosage	N	O
134	was	N	O
135	discontinued	N	O
136	at	N	O
137	the	N	O
138	end	N	O
139	of	N	O
140	year	N	O
141	7	N	O
142	.	N	O

143	A	N	O
144	total	N	O
145	of	N	O
146	198	N	O
147	women	N	O
148	continued	N	O
149	after	N	O
150	year	N	O
151	7	N	O
152	.	N	O

153	Annualized	N	O
154	percentage	N	O
155	rates	N	O
156	for	N	O
157	cardiovascular	N	O
158	events	N	O
159	[	N	O
160	corrected	N	O
161	]	N	O
162	and	N	O
163	endometrial	N	O
164	cancers	N	O
165	[	N	O
166	corrected	N	O
167	]	N	O
168	were	N	O
169	below	N	O
170	national	N	O
171	rates	N	O
172	for	N	O
173	Finland	N	O
174	and	N	O
175	those	N	O
176	reported	N	O
177	for	N	O
178	the	N	O
179	Women	N	O
180	's	N	O
181	Health	N	O
182	Initiative	N	O
183	.	N	O

184	There	N	I-Premise
185	were	N	I-Premise
186	no	N	I-Premise
187	serious	N	I-Premise
188	events	N	I-Premise
189	with	N	I-Premise
190	the	N	I-Premise
191	1	N	I-Premise
192	+	N	I-Premise
193	2.5	N	I-Premise
194	dosage	N	I-Premise
195	or	N	I-Premise
196	after	N	I-Premise
197	ccHRT	N	I-Premise
198	discontinuation	N	I-Premise
199	.	N	I-Premise

200	Climacteric	N	I-Premise
201	symptoms	N	I-Premise
202	remained	N	I-Premise
203	significantly	N	I-Premise
204	below	N	I-Premise
205	baseline	N	I-Premise
206	values	N	I-Premise
207	after	N	I-Premise
208	dosage	N	I-Premise
209	reduction	N	I-Premise
210	;	N	I-Premise
211	some	N	I-Premise
212	symptoms	N	I-Premise
213	recurred	N	I-Premise
214	after	N	I-Premise
215	discontinuation	N	I-Premise
216	of	N	I-Premise
217	ccHRT	N	I-Premise
218	.	N	I-Premise

219	HRQOL	N	I-Premise
220	ratings	N	I-Premise
221	improved	N	I-Premise
222	with	N	I-Premise
223	ccHRT	N	I-Premise
224	,	N	I-Premise
225	irrespective	N	I-Premise
226	of	N	I-Premise
227	dosage	N	I-Premise
228	,	N	I-Premise
229	including	N	I-Premise
230	depressed	N	I-Premise
231	mood	N	I-Premise
232	,	N	I-Premise
233	anxiety	N	I-Premise
234	,	N	I-Premise
235	health	N	I-Premise
236	perception	N	I-Premise
237	and	N	I-Premise
238	sexual	N	I-Premise
239	interest	N	I-Premise
240	.	N	I-Premise

241	Scores	N	I-Premise
242	on	N	I-Premise
243	a	N	I-Premise
244	scale	N	I-Premise
245	assessing	N	I-Premise
246	daily	N	I-Premise
247	functioning	N	I-Premise
248	and	N	I-Premise
249	enjoyment	N	I-Premise
250	(	N	I-Premise
251	Q-LES-Q	N	I-Premise
252	)	N	I-Premise
253	improved	N	I-Premise
254	from	N	I-Premise
255	year	N	I-Premise
256	7	N	I-Premise
257	to	N	I-Premise
258	year	N	I-Premise
259	9	N	I-Premise
260	.	N	I-Premise

261	They	N	I-Premise
262	deteriorated	N	I-Premise
263	during	N	I-Premise
264	follow-up	N	I-Premise
265	in	N	I-Premise
266	women	N	I-Premise
267	not	N	I-Premise
268	continuing	N	I-Premise
269	ccHRT	N	I-Premise
270	.	N	I-Premise

271	Lower	N	I-Claim
272	dosages	N	I-Claim
273	of	N	I-Claim
274	HRT	N	I-Claim
275	were	N	I-Claim
276	as	N	I-Claim
277	effective	N	I-Claim
278	as	N	I-Claim
279	higher	N	I-Claim
280	doses	N	I-Claim
281	in	N	I-Claim
282	improving	N	I-Claim
283	climacteric	N	I-Claim
284	symptoms	N	I-Claim
285	and	N	I-Claim
286	HRQOL	N	I-Claim
287	ratings	N	I-Claim
288	and	N	I-Claim
289	had	N	I-Claim
290	fewer	N	I-Claim
291	safety	N	I-Claim
292	concerns	N	I-Claim
293	.	N	I-Claim

294	Following	N	I-Premise
295	discontinuation	N	I-Premise
296	of	N	I-Premise
297	ccHRT	N	I-Premise
298	,	N	I-Premise
299	patient	N	I-Premise
300	satisfaction	N	I-Premise
301	was	N	I-Premise
302	variable	N	I-Premise
303	,	N	I-Premise
304	with	N	I-Premise
305	15	N	I-Premise
306	%	N	I-Premise
307	electing	N	I-Premise
308	to	N	I-Premise
309	continue	N	I-Premise
310	or	N	I-Premise
311	restart	N	I-Premise
312	HRT	N	I-Premise
313	and	N	I-Premise
314	7	N	I-Premise
315	%	N	I-Premise
316	resuming	N	I-Premise
317	at	N	I-Premise
318	follow-up	N	I-Premise
319	.	N	I-Premise

320	This	N	I-Claim
321	supports	N	I-Claim
322	the	N	I-Claim
323	need	N	I-Claim
324	for	N	I-Claim
325	an	N	I-Claim
326	individualized	N	I-Claim
327	approach	N	I-Claim
328	to	N	I-Claim
329	therapy	N	I-Claim
330	recommendations	N	I-Claim
331	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	toxicity	N	O
11	and	N	O
12	efficacy	N	O
13	of	N	O
14	radiation	N	O
15	therapy	N	O
16	(	N	O
17	RT	N	O
18	)	N	O
19	for	N	O
20	localized	N	O
21	carcinoma	N	O
22	of	N	O
23	the	N	O
24	prostate	N	O
25	,	N	O
26	using	N	O
27	a	N	O
28	hypofractionated	N	O
29	(	N	O
30	55	N	O
31	Gy/20	N	O
32	fractions/4	N	O
33	weeks	N	O
34	)	N	O
35	vs.	N	O
36	a	N	O
37	conventionally	N	O
38	fractionated	N	O
39	(	N	O
40	64	N	O
41	Gy/32	N	O
42	fractions/6.5	N	O
43	weeks	N	O
44	)	N	O
45	dose	N	O
46	schedule	N	O
47	.	N	O

48	A	N	O
49	total	N	O
50	of	N	O
51	217	N	O
52	patients	N	O
53	were	N	O
54	randomized	N	O
55	to	N	O
56	either	N	O
57	the	N	O
58	hypofractionated	N	O
59	(	N	O
60	108	N	O
61	patients	N	O
62	)	N	O
63	or	N	O
64	the	N	O
65	conventional	N	O
66	(	N	O
67	109	N	O
68	patients	N	O
69	)	N	O
70	dose	N	O
71	schedule	N	O
72	,	N	O
73	with	N	O
74	planning	N	O
75	with	N	O
76	two-dimensional	N	O
77	(	N	O
78	2D	N	O
79	)	N	O
80	CT	N	O
81	scan	N	O
82	planning	N	O
83	methodology	N	O
84	in	N	O
85	the	N	O
86	majority	N	O
87	of	N	O
88	cases	N	O
89	.	N	O

90	All	N	O
91	patients	N	O
92	were	N	O
93	followed	N	O
94	for	N	O
95	a	N	O
96	median	N	O
97	of	N	O
98	48	N	O
99	(	N	O
100	6-108	N	O
101	)	N	O
102	months	N	O
103	.	N	O

104	Gastrointestinal	N	O
105	(	N	O
106	GI	N	O
107	)	N	O
108	and	N	O
109	genitourinary	N	O
110	(	N	O
111	GU	N	O
112	)	N	O
113	toxicity	N	O
114	was	N	O
115	evaluated	N	O
116	before	N	O
117	RT	N	O
118	and	N	O
119	after	N	O
120	its	N	O
121	completion	N	O
122	using	N	O
123	modified	N	O
124	late	N	O
125	effects	N	O
126	of	N	O
127	normal	N	O
128	tissue-subjective	N	O
129	,	N	O
130	objective	N	O
131	,	N	O
132	management	N	O
133	,	N	O
134	analytic	N	O
135	(	N	O
136	LENT-SOMA	N	O
137	)	N	O
138	scales	N	O
139	and	N	O
140	the	N	O
141	European	N	O
142	Organization	N	O
143	for	N	O
144	Research	N	O
145	and	N	O
146	Treatment	N	O
147	of	N	O
148	Cancer	N	O
149	sexual	N	O
150	function	N	O
151	questionnaire	N	O
152	.	N	O

153	Efficacy	N	O
154	of	N	O
155	RT	N	O
156	based	N	O
157	on	N	O
158	clinical	N	O
159	,	N	O
160	radiologic	N	O
161	,	N	O
162	and	N	O
163	prostate-specific	N	O
164	antigen	N	O
165	data	N	O
166	were	N	O
167	also	N	O
168	evaluated	N	O
169	at	N	O
170	baseline	N	O
171	and	N	O
172	after	N	O
173	RT	N	O
174	.	N	O

175	Gastrointestinal	N	I-Premise
176	and	N	I-Premise
177	GU	N	I-Premise
178	toxicity	N	I-Premise
179	persisted	N	I-Premise
180	5	N	I-Premise
181	years	N	I-Premise
182	after	N	I-Premise
183	RT	N	I-Premise
184	and	N	I-Premise
185	did	N	I-Premise
186	not	N	I-Premise
187	differ	N	I-Premise
188	between	N	I-Premise
189	the	N	I-Premise
190	two	N	I-Premise
191	dose	N	I-Premise
192	schedules	N	I-Premise
193	other	N	I-Premise
194	than	N	I-Premise
195	in	N	I-Premise
196	regard	N	I-Premise
197	to	N	I-Premise
198	urgency	N	I-Premise
199	of	N	I-Premise
200	defecation	N	I-Premise
201	.	N	I-Premise

202	However	N	I-Premise
203	,	N	I-Premise
204	1-month	N	I-Premise
205	GI	N	I-Premise
206	toxicity	N	I-Premise
207	was	N	I-Premise
208	not	N	I-Premise
209	only	N	I-Premise
210	worse	N	I-Premise
211	in	N	I-Premise
212	patients	N	I-Premise
213	with	N	I-Premise
214	the	N	I-Premise
215	hypofractionated	N	I-Premise
216	RT	N	I-Premise
217	schedule	N	I-Premise
218	but	N	I-Premise
219	also	N	I-Premise
220	adversely	N	I-Premise
221	affected	N	I-Premise
222	daily	N	I-Premise
223	activities	N	I-Premise
224	.	N	I-Premise

225	Nadir	N	I-Premise
226	prostate-specific	N	I-Premise
227	antigen	N	I-Premise
228	values	N	I-Premise
229	occurred	N	I-Premise
230	at	N	I-Premise
231	a	N	I-Premise
232	median	N	I-Premise
233	of	N	I-Premise
234	18.0	N	I-Premise
235	(	N	I-Premise
236	3.0-54.0	N	I-Premise
237	)	N	I-Premise
238	months	N	I-Premise
239	after	N	I-Premise
240	RT	N	I-Premise
241	.	N	I-Premise

242	A	N	I-Premise
243	total	N	I-Premise
244	of	N	I-Premise
245	76	N	I-Premise
246	biochemical	N	I-Premise
247	relapses	N	I-Premise
248	,	N	I-Premise
249	with	N	I-Premise
250	or	N	I-Premise
251	without	N	I-Premise
252	clinical	N	I-Premise
253	relapses	N	I-Premise
254	,	N	I-Premise
255	have	N	I-Premise
256	occurred	N	I-Premise
257	since	N	I-Premise
258	;	N	I-Premise
259	of	N	I-Premise
260	these	N	I-Premise
261	,	N	I-Premise
262	37	N	I-Premise
263	were	N	I-Premise
264	in	N	I-Premise
265	the	N	I-Premise
266	hypofractionated	N	I-Premise
267	and	N	I-Premise
268	39	N	I-Premise
269	in	N	I-Premise
270	the	N	I-Premise
271	conventional	N	I-Premise
272	schedule	N	I-Premise
273	.	N	I-Premise

274	The	N	I-Premise
275	5-year	N	I-Premise
276	biochemical	N	I-Premise
277	+/-	N	I-Premise
278	clinical	N	I-Premise
279	relapse-free	N	I-Premise
280	and	N	I-Premise
281	overall	N	I-Premise
282	survival	N	I-Premise
283	was	N	I-Premise
284	55.9	N	I-Premise
285	%	N	I-Premise
286	and	N	I-Premise
287	85.3	N	I-Premise
288	%	N	I-Premise
289	respectively	N	I-Premise
290	for	N	I-Premise
291	all	N	I-Premise
292	patients	N	I-Premise
293	,	N	I-Premise
294	and	N	I-Premise
295	did	N	I-Premise
296	not	N	I-Premise
297	differ	N	I-Premise
298	between	N	I-Premise
299	the	N	I-Premise
300	two	N	I-Premise
301	schedules	N	I-Premise
302	.	N	I-Premise

303	Radiation	N	I-Claim
304	therapy	N	I-Claim
305	for	N	I-Claim
306	prostate	N	I-Claim
307	carcinoma	N	I-Claim
308	causes	N	I-Claim
309	persistent	N	I-Claim
310	GI	N	I-Claim
311	toxicity	N	I-Claim
312	that	N	I-Claim
313	is	N	I-Claim
314	largely	N	I-Claim
315	independent	N	I-Claim
316	of	N	I-Claim
317	the	N	I-Claim
318	two	N	I-Claim
319	dose	N	I-Claim
320	schedules	N	I-Claim
321	.	N	I-Claim

322	The	N	I-Claim
323	hypofractionated	N	I-Claim
324	schedule	N	I-Claim
325	is	N	I-Claim
326	equivalent	N	I-Claim
327	in	N	I-Claim
328	efficacy	N	I-Claim
329	to	N	I-Claim
330	the	N	I-Claim
331	conventional	N	I-Claim
332	schedule	N	I-Claim
333	.	N	I-Claim

1	Most	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	advanced	N	I-Claim
5	ovarian	N	I-Claim
6	cancer	N	I-Claim
7	develop	N	I-Claim
8	recurrent	N	I-Claim
9	disease	N	I-Claim
10	.	N	I-Claim

11	For	N	I-Claim
12	those	N	I-Claim
13	patients	N	I-Claim
14	who	N	I-Claim
15	recur	N	I-Claim
16	at	N	I-Claim
17	least	N	I-Claim
18	6	N	I-Claim
19	months	N	I-Claim
20	after	N	I-Claim
21	initial	N	I-Claim
22	therapy	N	I-Claim
23	,	N	I-Claim
24	paclitaxel	N	I-Claim
25	platinum	N	I-Claim
26	has	N	I-Claim
27	shown	N	I-Claim
28	a	N	I-Claim
29	modest	N	I-Claim
30	survival	N	I-Claim
31	advantage	N	I-Claim
32	over	N	I-Claim
33	platinum	N	I-Claim
34	without	N	I-Claim
35	paclitaxel	N	I-Claim
36	;	N	I-Claim
37	however	N	I-Premise
38	,	N	I-Premise
39	many	N	I-Premise
40	patients	N	I-Premise
41	develop	N	I-Premise
42	clinically	N	I-Premise
43	relevant	N	I-Premise
44	neurotoxicity	N	I-Premise
45	,	N	I-Premise
46	frequently	N	I-Premise
47	resulting	N	I-Premise
48	in	N	I-Premise
49	treatment	N	I-Premise
50	discontinuation	N	I-Premise
51	.	N	O

52	Thus	N	O
53	,	N	O
54	an	N	O
55	alternative	N	O
56	regimen	N	O
57	without	N	O
58	significant	N	O
59	neurotoxicity	N	O
60	was	N	O
61	evaluated	N	O
62	by	N	O
63	comparing	N	O
64	gemcitabine	N	O
65	plus	N	O
66	carboplatin	N	O
67	with	N	O
68	single-agent	N	O
69	carboplatin	N	O
70	in	N	O
71	platinum-sensitive	N	O
72	recurrent	N	O
73	ovarian	N	O
74	cancer	N	O
75	patients	N	O
76	.	N	O

77	Patients	N	O
78	with	N	O
79	platinum-sensitive	N	O
80	recurrent	N	O
81	ovarian	N	O
82	cancer	N	O
83	were	N	O
84	randomly	N	O
85	assigned	N	O
86	to	N	O
87	receive	N	O
88	either	N	O
89	gemcitabine	N	O
90	plus	N	O
91	carboplatin	N	O
92	or	N	O
93	carboplatin	N	O
94	alone	N	O
95	,	N	O
96	every	N	O
97	21	N	O
98	days	N	O
99	.	N	O

100	The	N	O
101	primary	N	O
102	objective	N	O
103	was	N	O
104	to	N	O
105	compare	N	O
106	progression-free	N	O
107	survival	N	O
108	(	N	O
109	PFS	N	O
110	)	N	O
111	.	N	O

112	Three	N	O
113	hundred	N	O
114	fifty-six	N	O
115	patients	N	O
116	(	N	O
117	178	N	O
118	gemcitabine	N	O
119	plus	N	O
120	carboplatin	N	O
121	;	N	O
122	178	N	O
123	carboplatin	N	O
124	)	N	O
125	were	N	O
126	randomly	N	O
127	assigned	N	O
128	.	N	O

129	Patients	N	O
130	received	N	O
131	a	N	O
132	median	N	O
133	of	N	O
134	six	N	O
135	cycles	N	O
136	in	N	O
137	both	N	O
138	arms	N	O
139	.	N	O

140	With	N	I-Premise
141	a	N	I-Premise
142	median	N	I-Premise
143	follow-up	N	I-Premise
144	of	N	I-Premise
145	17	N	I-Premise
146	months	N	I-Premise
147	,	N	I-Premise
148	median	N	I-Premise
149	PFS	N	I-Premise
150	was	N	I-Premise
151	8.6	N	I-Premise
152	months	N	I-Premise
153	(	N	I-Premise
154	95	N	I-Premise
155	%	N	I-Premise
156	CI	N	I-Premise
157	,	N	I-Premise
158	7.9	N	I-Premise
159	to	N	I-Premise
160	9.7	N	I-Premise
161	months	N	I-Premise
162	)	N	I-Premise
163	for	N	I-Premise
164	gemcitabine	N	I-Premise
165	plus	N	I-Premise
166	carboplatin	N	I-Premise
167	and	N	I-Premise
168	5.8	N	I-Premise
169	months	N	I-Premise
170	(	N	I-Premise
171	95	N	I-Premise
172	%	N	I-Premise
173	CI	N	I-Premise
174	,	N	I-Premise
175	5.2	N	I-Premise
176	to	N	I-Premise
177	7.1	N	I-Premise
178	months	N	I-Premise
179	)	N	I-Premise
180	for	N	I-Premise
181	carboplatin	N	I-Premise
182	.	N	I-Premise

183	The	N	I-Premise
184	hazard	N	I-Premise
185	ration	N	I-Premise
186	(	N	I-Premise
187	HR	N	I-Premise
188	)	N	I-Premise
189	for	N	I-Premise
190	PFS	N	I-Premise
191	was	N	I-Premise
192	0.72	N	I-Premise
193	(	N	I-Premise
194	95	N	I-Premise
195	%	N	I-Premise
196	CI	N	I-Premise
197	,	N	I-Premise
198	0.58	N	I-Premise
199	to	N	I-Premise
200	0.90	N	I-Premise
201	;	N	I-Premise
202	P	N	I-Premise
203	=	N	I-Premise
204	.0031	N	I-Premise
205	)	N	I-Premise
206	.	N	I-Premise

207	Response	N	I-Premise
208	rate	N	I-Premise
209	was	N	I-Premise
210	47.2	N	I-Premise
211	%	N	I-Premise
212	(	N	I-Premise
213	95	N	I-Premise
214	%	N	I-Premise
215	CI	N	I-Premise
216	,	N	I-Premise
217	39.9	N	I-Premise
218	%	N	I-Premise
219	to	N	I-Premise
220	54.5	N	I-Premise
221	%	N	I-Premise
222	)	N	I-Premise
223	for	N	I-Premise
224	gemcitabine	N	I-Premise
225	plus	N	I-Premise
226	carboplatin	N	I-Premise
227	and	N	I-Premise
228	30.9	N	I-Premise
229	%	N	I-Premise
230	(	N	I-Premise
231	95	N	I-Premise
232	%	N	I-Premise
233	CI	N	I-Premise
234	,	N	I-Premise
235	24.1	N	I-Premise
236	%	N	I-Premise
237	to	N	I-Premise
238	37.7	N	I-Premise
239	%	N	I-Premise
240	)	N	I-Premise
241	for	N	I-Premise
242	carboplatin	N	I-Premise
243	(	N	I-Premise
244	P	N	I-Premise
245	=	N	I-Premise
246	.0016	N	I-Premise
247	)	N	I-Premise
248	.	N	I-Premise

249	The	N	I-Premise
250	HR	N	I-Premise
251	for	N	I-Premise
252	overall	N	I-Premise
253	survival	N	I-Premise
254	was	N	I-Premise
255	0.96	N	I-Premise
256	(	N	I-Premise
257	95	N	I-Premise
258	%	N	I-Premise
259	CI	N	I-Premise
260	,	N	I-Premise
261	0.75	N	I-Premise
262	to1.23	N	I-Premise
263	;	N	I-Premise
264	P	N	I-Premise
265	=	N	I-Premise
266	.7349	N	I-Premise
267	)	N	I-Premise
268	.	N	I-Premise

269	While	N	I-Premise
270	myelosuppression	N	I-Premise
271	was	N	I-Premise
272	significantly	N	I-Premise
273	more	N	I-Premise
274	common	N	I-Premise
275	in	N	I-Premise
276	the	N	I-Premise
277	combination	N	I-Premise
278	,	N	I-Premise
279	sequelae	N	I-Premise
280	such	N	I-Premise
281	as	N	I-Premise
282	febrile	N	I-Premise
283	neutropenia	N	I-Premise
284	or	N	I-Premise
285	infections	N	I-Premise
286	were	N	I-Premise
287	uncommon	N	I-Premise
288	.	N	I-Premise

289	No	N	I-Premise
290	statistically	N	I-Premise
291	significant	N	I-Premise
292	differences	N	I-Premise
293	in	N	I-Premise
294	quality	N	I-Premise
295	of	N	I-Premise
296	life	N	I-Premise
297	scores	N	I-Premise
298	between	N	I-Premise
299	arms	N	I-Premise
300	were	N	I-Premise
301	noted	N	I-Premise
302	.	N	I-Premise

303	Gemcitabine	N	I-Claim
304	plus	N	I-Claim
305	carboplatin	N	I-Claim
306	significantly	N	I-Claim
307	improves	N	I-Claim
308	PFS	N	I-Claim
309	and	N	I-Claim
310	response	N	I-Claim
311	rate	N	I-Claim
312	without	N	I-Claim
313	worsening	N	I-Claim
314	quality	N	I-Claim
315	of	N	I-Claim
316	life	N	I-Claim
317	for	N	I-Claim
318	patients	N	I-Claim
319	with	N	I-Claim
320	platinum-sensitive	N	I-Claim
321	recurrent	N	I-Claim
322	ovarian	N	I-Claim
323	cancer	N	I-Claim
324	.	N	I-Claim

1	Radiation-induced	N	O
2	mucositis	N	O
3	is	N	O
4	an	N	O
5	acute	N	O
6	reaction	N	O
7	of	N	O
8	the	N	O
9	mucosa	N	O
10	of	N	O
11	patients	N	O
12	undergoing	N	O
13	head	N	O
14	and	N	O
15	neck	N	O
16	radiotherapy	N	O
17	.	N	O

18	It	N	O
19	can	N	O
20	have	N	O
21	debilitating	N	O
22	and	N	O
23	dose-limiting	N	O
24	consequences	N	O
25	.	N	O

26	There	N	I-MajorClaim
27	is	N	I-MajorClaim
28	no	N	I-MajorClaim
29	consensus	N	I-MajorClaim
30	on	N	I-MajorClaim
31	an	N	I-MajorClaim
32	accepted	N	I-MajorClaim
33	intervention	N	I-MajorClaim
34	that	N	I-MajorClaim
35	significantly	N	I-MajorClaim
36	reduces	N	I-MajorClaim
37	its	N	I-MajorClaim
38	severity	N	I-MajorClaim
39	.	N	I-MajorClaim

40	Misoprostol	N	O
41	is	N	O
42	a	N	O
43	synthetic	N	O
44	prostaglandin	N	O
45	E1	N	O
46	analogue	N	O
47	,	N	O
48	with	N	O
49	properties	N	O
50	of	N	O
51	a	N	O
52	mucosal	N	O
53	cytoprotectant	N	O
54	.	N	O

55	We	N	O
56	designed	N	O
57	a	N	O
58	randomized	N	O
59	,	N	O
60	double-blind	N	O
61	,	N	O
62	placebo-controlled	N	O
63	trial	N	O
64	of	N	O
65	misoprostol	N	O
66	in	N	O
67	patients	N	O
68	with	N	O
69	head	N	O
70	and	N	O
71	neck	N	O
72	cancer	N	O
73	.	N	O

74	The	N	O
75	aim	N	O
76	of	N	O
77	this	N	O
78	study	N	O
79	was	N	O
80	to	N	O
81	determine	N	O
82	if	N	O
83	topical	N	O
84	misoprostol	N	O
85	was	N	O
86	effective	N	O
87	in	N	O
88	reducing	N	O
89	the	N	O
90	severity	N	O
91	of	N	O
92	radiation-induced	N	O
93	mucositis	N	O
94	in	N	O
95	patients	N	O
96	receiving	N	O
97	radical	N	O
98	dose	N	O
99	radiotherapy	N	O
100	.	N	O

101	The	N	O
102	effect	N	O
103	of	N	O
104	this	N	O
105	intervention	N	O
106	on	N	O
107	a	N	O
108	patient	N	O
109	's	N	O
110	general	N	O
111	well-being	N	O
112	was	N	O
113	also	N	O
114	investigated	N	O
115	.	N	O

116	The	N	O
117	primary	N	O
118	end-point	N	O
119	of	N	O
120	the	N	O
121	study	N	O
122	was	N	O
123	the	N	O
124	incidence	N	O
125	of	N	O
126	Radiation	N	O
127	Therapy	N	O
128	Oncology	N	O
129	Group	N	O
130	grade	N	O
131	3	N	O
132	mucositis	N	O
133	.	N	O

134	Between	N	O
135	1999	N	O
136	and	N	O
137	2002	N	O
138	,	N	O
139	83	N	O
140	patients	N	O
141	were	N	O
142	recruited	N	O
143	into	N	O
144	the	N	O
145	study	N	O
146	at	N	O
147	Westmead	N	O
148	and	N	O
149	Nepean	N	O
150	Hospitals	N	O
151	,	N	O
152	Sydney	N	O
153	.	N	O

154	Forty-two	N	O
155	patients	N	O
156	were	N	O
157	randomized	N	O
158	to	N	O
159	receive	N	O
160	misoprostol	N	O
161	and	N	O
162	41	N	O
163	to	N	O
164	receive	N	O
165	a	N	O
166	placebo	N	O
167	.	N	O

168	Most	N	O
169	patients	N	O
170	received	N	O
171	radiotherapy	N	O
172	in	N	O
173	the	N	O
174	adjuvant	N	O
175	setting	N	O
176	(	N	O
177	52	N	O
178	of	N	O
179	the	N	O
180	83	N	O
181	)	N	O
182	and	N	O
183	had	N	O
184	either	N	O
185	an	N	O
186	oral	N	O
187	cavity	N	O
188	(	N	O
189	42	N	O
190	of	N	O
191	the	N	O
192	83	N	O
193	)	N	O
194	or	N	O
195	an	N	O
196	oropharyngeal	N	O
197	(	N	O
198	16	N	O
199	of	N	O
200	the	N	O
201	83	N	O
202	)	N	O
203	cancer	N	O
204	.	N	O

205	We	N	I-Claim
206	could	N	I-Claim
207	not	N	I-Claim
208	identify	N	I-Claim
209	any	N	I-Claim
210	significant	N	I-Claim
211	difference	N	I-Claim
212	in	N	I-Claim
213	the	N	I-Claim
214	incidence	N	I-Claim
215	of	N	I-Claim
216	severe	N	I-Claim
217	mucositis	N	I-Claim
218	based	N	I-Claim
219	on	N	I-Claim
220	whether	N	I-Claim
221	patients	N	I-Claim
222	were	N	I-Claim
223	allocated	N	I-Claim
224	to	N	I-Claim
225	receive	N	I-Claim
226	misoprostol	N	I-Claim
227	or	N	I-Claim
228	placebo	N	I-Claim
229	.	N	I-Claim

230	There	N	I-Premise
231	was	N	I-Premise
232	no	N	I-Premise
233	significant	N	I-Premise
234	difference	N	I-Premise
235	in	N	I-Premise
236	the	N	I-Premise
237	mean	N	I-Premise
238	area	N	I-Premise
239	under	N	I-Premise
240	the	N	I-Premise
241	mucositis	N	I-Premise
242	curve	N	I-Premise
243	(	N	I-Premise
244	13.2	N	I-Premise
245	vs	N	I-Premise
246	16.6	N	I-Premise
247	;	N	I-Premise
248	P	N	I-Premise
249	=	N	I-Premise
250	0.1	N	I-Premise
251	)	N	I-Premise
252	.	N	I-Premise

253	Patients	N	I-Premise
254	allocated	N	I-Premise
255	to	N	I-Premise
256	misoprostol	N	I-Premise
257	did	N	I-Premise
258	report	N	I-Premise
259	slightly	N	I-Premise
260	increased	N	I-Premise
261	soreness	N	I-Premise
262	(	N	I-Premise
263	7.6	N	I-Premise
264	vs	N	I-Premise
265	6.9	N	I-Premise
266	;	N	I-Premise
267	P	N	I-Premise
268	=	N	I-Premise
269	0.04	N	I-Premise
270	)	N	I-Premise
271	and	N	I-Premise
272	a	N	I-Premise
273	greater	N	I-Premise
274	use	N	I-Premise
275	of	N	I-Premise
276	analgesics	N	I-Premise
277	.	N	I-Premise

278	However	N	I-Premise
279	,	N	I-Premise
280	this	N	I-Premise
281	difference	N	I-Premise
282	did	N	I-Premise
283	not	N	I-Premise
284	translate	N	I-Premise
285	into	N	I-Premise
286	a	N	I-Premise
287	worse	N	I-Premise
288	feeling	N	I-Premise
289	of	N	I-Premise
290	general	N	I-Premise
291	well-being	N	I-Premise
292	as	N	I-Premise
293	measured	N	I-Premise
294	by	N	I-Premise
295	a	N	I-Premise
296	simple	N	I-Premise
297	visual	N	I-Premise
298	analogue	N	I-Premise
299	scale	N	I-Premise
300	(	N	I-Premise
301	5.8	N	I-Premise
302	vs	N	I-Premise
303	5.2	N	I-Premise
304	;	N	I-Premise
305	P	N	I-Premise
306	=	N	I-Premise
307	0.3	N	I-Premise
308	)	N	I-Premise
309	.	N	I-Premise

310	In	N	I-Claim
311	conclusion	N	I-Claim
312	,	N	I-Claim
313	we	N	I-Claim
314	were	N	I-Claim
315	unable	N	I-Claim
316	to	N	I-Claim
317	identify	N	I-Claim
318	a	N	I-Claim
319	reduction	N	I-Claim
320	in	N	I-Claim
321	radiation-induced	N	I-Claim
322	mucositis	N	I-Claim
323	in	N	I-Claim
324	patients	N	I-Claim
325	receiving	N	I-Claim
326	misoprostol	N	I-Claim
327	.	N	I-Claim

328	There	N	I-MajorClaim
329	is	N	I-MajorClaim
330	a	N	I-MajorClaim
331	paucity	N	I-MajorClaim
332	of	N	I-MajorClaim
333	high-level	N	I-MajorClaim
334	evidence	N	I-MajorClaim
335	on	N	I-MajorClaim
336	potentially	N	I-MajorClaim
337	useful	N	I-MajorClaim
338	interventions	N	I-MajorClaim
339	and	N	I-MajorClaim
340	a	N	I-MajorClaim
341	continued	N	I-MajorClaim
342	need	N	I-MajorClaim
343	for	N	I-MajorClaim
344	new	N	I-MajorClaim
345	and	N	I-MajorClaim
346	innovative	N	I-MajorClaim
347	research	N	I-MajorClaim
348	,	N	I-MajorClaim
349	incorporating	N	I-MajorClaim
350	quality-of-life	N	I-MajorClaim
351	measurements	N	I-MajorClaim
352	,	N	I-MajorClaim
353	in	N	I-MajorClaim
354	patients	N	I-MajorClaim
355	experiencing	N	I-MajorClaim
356	radiation-induced	N	I-MajorClaim
357	mucositis	N	I-MajorClaim
358	.	N	I-MajorClaim

1	In	N	I-Claim
2	vivo	N	I-Claim
3	data	N	I-Claim
4	have	N	I-Claim
5	shown	N	I-Claim
6	a	N	I-Claim
7	more	N	I-Claim
8	potent	N	I-Claim
9	antiangiogenic	N	I-Claim
10	effect	N	I-Claim
11	and	N	I-Claim
12	a	N	I-Claim
13	higher	N	I-Claim
14	antitumor	N	I-Claim
15	activity	N	I-Claim
16	of	N	I-Claim
17	low-dose	N	I-Claim
18	interferon	N	I-Claim
19	(	N	I-Claim
20	IFN	N	I-Claim
21	)	N	I-Claim
22	given	N	I-Claim
23	twice	N	I-Claim
24	daily	N	I-Claim
25	.	N	I-Claim

26	In	N	O
27	a	N	O
28	randomized	N	O
29	Phase	N	O
30	II	N	O
31	trial	N	O
32	,	N	O
33	the	N	O
34	authors	N	O
35	tested	N	O
36	the	N	O
37	hypothesis	N	O
38	that	N	O
39	twice-daily	N	O
40	low-dose	N	O
41	IFN	N	O
42	is	N	O
43	more	N	O
44	effective	N	O
45	than	N	O
46	daily	N	O
47	intermediate-dose	N	O
48	IFN	N	O
49	in	N	O
50	patients	N	O
51	with	N	O
52	metastatic	N	O
53	renal	N	O
54	cell	N	O
55	cancer	N	O
56	(	N	O
57	MRCC	N	O
58	)	N	O
59	.	N	O

60	A	N	O
61	total	N	O
62	of	N	O
63	118	N	O
64	patients	N	O
65	(	N	O
66	59	N	O
67	per	N	O
68	arm	N	O
69	)	N	O
70	were	N	O
71	randomly	N	O
72	assigned	N	O
73	to	N	O
74	receive	N	O
75	IFN	N	O
76	at	N	O
77	a	N	O
78	dose	N	O
79	of	N	O
80	0.5	N	O
81	million	N	O
82	units	N	O
83	(	N	O
84	MU	N	O
85	)	N	O
86	given	N	O
87	subcutaneously	N	O
88	twice	N	O
89	daily	N	O
90	(	N	O
91	IFN1	N	O
92	)	N	O
93	or	N	O
94	IFN	N	O
95	at	N	O
96	a	N	O
97	dose	N	O
98	of	N	O
99	5	N	O
100	MU	N	O
101	given	N	O
102	subcutaneously	N	O
103	daily	N	O
104	(	N	O
105	IFN5	N	O
106	)	N	O
107	.	N	O

108	The	N	O
109	primary	N	O
110	endpoint	N	O
111	was	N	O
112	progression-free	N	O
113	survival	N	O
114	(	N	O
115	PFS	N	O
116	)	N	O
117	.	N	O

118	Secondary	N	O
119	endpoints	N	O
120	included	N	O
121	response	N	O
122	rate	N	O
123	(	N	O
124	RR	N	O
125	)	N	O
126	,	N	O
127	overall	N	O
128	survival	N	O
129	(	N	O
130	OS	N	O
131	)	N	O
132	,	N	O
133	toxicity	N	O
134	,	N	O
135	and	N	O
136	quality	N	O
137	of	N	O
138	life	N	O
139	(	N	O
140	QOL	N	O
141	)	N	O
142	.	N	O

143	There	N	I-Premise
144	were	N	I-Premise
145	no	N	I-Premise
146	significant	N	I-Premise
147	differences	N	I-Premise
148	in	N	I-Premise
149	either	N	I-Premise
150	PFS	N	I-Premise
151	or	N	I-Premise
152	OS	N	I-Premise
153	between	N	I-Premise
154	IFN1	N	I-Premise
155	and	N	I-Premise
156	IFN5	N	I-Premise
157	(	N	I-Premise
158	median	N	I-Premise
159	of	N	I-Premise
160	3.7	N	I-Premise
161	months	N	I-Premise
162	and	N	I-Premise
163	median	N	I-Premise
164	of	N	I-Premise
165	3.4	N	I-Premise
166	months	N	I-Premise
167	PFS	N	I-Premise
168	,	N	I-Premise
169	respectively	N	I-Premise
170	;	N	I-Premise
171	median	N	I-Premise
172	of	N	I-Premise
173	25.5	N	I-Premise
174	months	N	I-Premise
175	and	N	I-Premise
176	median	N	I-Premise
177	of	N	I-Premise
178	17.5	N	I-Premise
179	months	N	I-Premise
180	OS	N	I-Premise
181	,	N	I-Premise
182	respectively	N	I-Premise
183	)	N	I-Premise
184	.	N	I-Premise

185	The	N	I-Premise
186	RRs	N	I-Premise
187	were	N	I-Premise
188	identical	N	I-Premise
189	in	N	I-Premise
190	the	N	I-Premise
191	2	N	I-Premise
192	arms	N	I-Premise
193	(	N	I-Premise
194	6.7	N	I-Premise
195	%	N	I-Premise
196	;	N	I-Premise
197	95	N	I-Premise
198	%	N	I-Premise
199	confidence	N	I-Premise
200	interval	N	I-Premise
201	[	N	I-Premise
202	95	N	I-Premise
203	%	N	I-Premise
204	CI	N	I-Premise
205	]	N	I-Premise
206	,	N	I-Premise
207	1.8-16.5	N	I-Premise
208	%	N	I-Premise
209	)	N	I-Premise
210	.	N	I-Premise

211	Two	N	I-Premise
212	patients	N	I-Premise
213	,	N	I-Premise
214	1	N	I-Premise
215	in	N	I-Premise
216	each	N	I-Premise
217	arm	N	I-Premise
218	,	N	I-Premise
219	remained	N	I-Premise
220	in	N	I-Premise
221	complete	N	I-Premise
222	remission	N	I-Premise
223	at	N	I-Premise
224	the	N	I-Premise
225	time	N	I-Premise
226	of	N	I-Premise
227	last	N	I-Premise
228	follow-up	N	I-Premise
229	,	N	I-Premise
230	at	N	I-Premise
231	45+	N	I-Premise
232	and	N	I-Premise
233	38+	N	I-Premise
234	months	N	I-Premise
235	from	N	I-Premise
236	treatment	N	I-Premise
237	.	N	I-Premise

238	Thirty-two	N	I-Premise
239	patients	N	I-Premise
240	receiving	N	I-Premise
241	IFN5	N	I-Premise
242	and	N	I-Premise
243	19	N	I-Premise
244	patients	N	I-Premise
245	receiving	N	I-Premise
246	IFN1	N	I-Premise
247	experienced	N	I-Premise
248	Grade	N	I-Premise
249	3	N	I-Premise
250	or	N	I-Premise
251	higher	N	I-Premise
252	adverse	N	I-Premise
253	events	N	I-Premise
254	(	N	I-Premise
255	graded	N	I-Premise
256	using	N	I-Premise
257	the	N	I-Premise
258	National	N	I-Premise
259	Cancer	N	I-Premise
260	Institute	N	I-Premise
261	Common	N	I-Premise
262	Toxicity	N	I-Premise
263	Criteria	N	I-Premise
264	[	N	I-Premise
265	version	N	I-Premise
266	2.0	N	I-Premise
267	]	N	I-Premise
268	)	N	I-Premise
269	(	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.025	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	Eighteen	N	I-Premise
276	patients	N	I-Premise
277	receiving	N	I-Premise
278	IFN5	N	I-Premise
279	and	N	I-Premise
280	4	N	I-Premise
281	patients	N	I-Premise
282	receiving	N	I-Premise
283	IFN1	N	I-Premise
284	had	N	I-Premise
285	dose	N	I-Premise
286	reductions	N	I-Premise
287	(	N	I-Premise
288	P	N	I-Premise
289	=	N	I-Premise
290	.002	N	I-Premise
291	)	N	I-Premise
292	.	N	I-Premise

293	There	N	I-Premise
294	was	N	I-Premise
295	a	N	I-Premise
296	significant	N	I-Premise
297	deterioration	N	I-Premise
298	in	N	I-Premise
299	QOL	N	I-Premise
300	and	N	I-Premise
301	an	N	I-Premise
302	increase	N	I-Premise
303	in	N	I-Premise
304	depression	N	I-Premise
305	associated	N	I-Premise
306	with	N	I-Premise
307	IFN5	N	I-Premise
308	but	N	I-Premise
309	no	N	I-Premise
310	change	N	I-Premise
311	was	N	I-Premise
312	noted	N	I-Premise
313	with	N	I-Premise
314	IFN1	N	I-Premise
315	.	N	I-Premise

316	Compared	N	I-Claim
317	with	N	I-Claim
318	IFN5	N	I-Claim
319	,	N	I-Claim
320	IFN1	N	I-Claim
321	is	N	I-Claim
322	neither	N	I-Claim
323	more	N	I-Claim
324	nor	N	I-Claim
325	less	N	I-Claim
326	effective	N	I-Claim
327	but	N	I-Claim
328	is	N	I-Claim
329	less	N	I-Claim
330	toxic	N	I-Claim
331	,	N	I-Claim
332	with	N	I-Claim
333	a	N	I-Claim
334	better	N	I-Claim
335	reported	N	I-Claim
336	QOL	N	I-Claim
337	.	N	I-Claim

338	These	N	I-Claim
339	results	N	I-Claim
340	may	N	I-Claim
341	have	N	I-Claim
342	implications	N	I-Claim
343	for	N	I-Claim
344	the	N	I-Claim
345	design	N	I-Claim
346	of	N	I-Claim
347	combination	N	I-Claim
348	regimens	N	I-Claim
349	incorporating	N	I-Claim
350	IFN	N	I-Claim
351	with	N	I-Claim
352	targeted	N	I-Claim
353	agents	N	I-Claim
354	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	the	N	O
5	impact	N	O
6	of	N	O
7	``	N	O
8	laying	N	O
9	on	N	O
10	of	N	O
11	hands	N	O
12	''	N	O
13	on	N	O
14	the	N	O
15	well-being	N	O
16	of	N	O
17	patients	N	O
18	with	N	O
19	advanced	N	O
20	cancer	N	O
21	is	N	O
22	more	N	O
23	efficient	N	O
24	when	N	O
25	performed	N	O
26	by	N	O
27	a	N	O
28	person	N	O
29	with	N	O
30	self-declared	N	O
31	``	N	O
32	healing	N	O
33	powers	N	O
34	''	N	O
35	as	N	O
36	compared	N	O
37	to	N	O
38	an	N	O
39	actor	N	O
40	mimicking	N	O
41	the	N	O
42	healer	N	O
43	in	N	O
44	close	N	O
45	detail	N	O
46	.	N	O

47	A	N	O
48	total	N	O
49	of	N	O
50	80	N	O
51	patients	N	O
52	were	N	O
53	registered	N	O
54	to	N	O
55	participate	N	O
56	in	N	O
57	a	N	O
58	randomized	N	O
59	,	N	O
60	single-blind	N	O
61	phase	N	O
62	III	N	O
63	trial	N	O
64	to	N	O
65	evaluate	N	O
66	the	N	O
67	difference	N	O
68	in	N	O
69	efficacy	N	O
70	of	N	O
71	``	N	O
72	laying	N	O
73	on	N	O
74	of	N	O
75	hands	N	O
76	''	N	O
77	by	N	O
78	either	N	O
79	a	N	O
80	``	N	O
81	healer	N	O
82	''	N	O
83	or	N	O
84	an	N	O
85	actor	N	O
86	.	N	O

87	Each	N	O
88	group	N	O
89	consisted	N	O
90	of	N	O
91	40	N	O
92	patients	N	O
93	,	N	O
94	scheduled	N	O
95	to	N	O
96	receive	N	O
97	treatment	N	O
98	for	N	O
99	5	N	O
100	min	N	O
101	,	N	O
102	three	N	O
103	times	N	O
104	a	N	O
105	week	N	O
106	.	N	O

107	The	N	O
108	effect	N	O
109	of	N	O
110	treatment	N	O
111	was	N	O
112	measured	N	O
113	using	N	O
114	a	N	O
115	``	N	O
116	Well-Being	N	O
117	scale	N	O
118	''	N	O
119	,	N	O
120	with	N	O
121	the	N	O
122	difference	N	O
123	of	N	O
124	the	N	O
125	average	N	O
126	score	N	O
127	of	N	O
128	the	N	O
129	``	N	O
130	Well-Being	N	O
131	scale	N	O
132	''	N	O
133	on	N	O
134	day	N	O
135	10	N	O
136	being	N	O
137	defined	N	O
138	as	N	O
139	primary	N	O
140	and	N	O
141	that	N	O
142	on	N	O
143	day	N	O
144	5	N	O
145	as	N	O
146	secondary	N	O
147	endpoint	N	O
148	.	N	O

149	There	N	I-Premise
150	was	N	I-Premise
151	no	N	I-Premise
152	significant	N	I-Premise
153	difference	N	I-Premise
154	in	N	I-Premise
155	average	N	I-Premise
156	score	N	I-Premise
157	values	N	I-Premise
158	between	N	I-Premise
159	the	N	I-Premise
160	``	N	I-Premise
161	healer	N	I-Premise
162	''	N	I-Premise
163	and	N	I-Premise
164	the	N	I-Premise
165	actor	N	I-Premise
166	with	N	I-Premise
167	regard	N	I-Premise
168	to	N	I-Premise
169	the	N	I-Premise
170	primary	N	I-Premise
171	(	N	I-Premise
172	p	N	I-Premise
173	=	N	I-Premise
174	0.34	N	I-Premise
175	)	N	I-Premise
176	or	N	I-Premise
177	the	N	I-Premise
178	secondary	N	I-Premise
179	endpoint	N	I-Premise
180	(	N	I-Premise
181	p	N	I-Premise
182	=	N	I-Premise
183	0.94	N	I-Premise
184	)	N	I-Premise
185	,	N	I-Premise
186	but	N	I-Premise
187	the	N	I-Premise
188	comparison	N	I-Premise
189	was	N	I-Premise
190	limited	N	I-Premise
191	due	N	I-Premise
192	to	N	I-Premise
193	major	N	I-Premise
194	protocol	N	I-Premise
195	violations	N	I-Premise
196	by	N	I-Premise
197	the	N	I-Premise
198	``	N	I-Premise
199	healer	N	I-Premise
200	''	N	I-Premise
201	who	N	I-Premise
202	unblinded	N	I-Premise
203	his	N	I-Premise
204	status	N	I-Premise
205	after	N	I-Premise
206	the	N	I-Premise
207	first	N	I-Premise
208	run	N	I-Premise
209	and	N	I-Premise
210	quit	N	I-Premise
211	the	N	I-Premise
212	study	N	I-Premise
213	.	N	I-Premise

214	The	N	O
215	study	N	O
216	was	N	O
217	completed	N	O
218	by	N	O
219	the	N	O
220	actor	N	O
221	as	N	O
222	a	N	O
223	descriptive	N	O
224	,	N	O
225	explorative	N	O
226	study	N	O
227	on	N	O
228	the	N	O
229	impact	N	O
230	of	N	O
231	``	N	O
232	laying	N	O
233	on	N	O
234	of	N	O
235	hands	N	O
236	''	N	O
237	.	N	I-Premise

238	A	N	I-Premise
239	significant	N	I-Premise
240	improvement	N	I-Premise
241	in	N	I-Premise
242	symptoms	N	I-Premise
243	after	N	I-Premise
244	treatment	N	I-Premise
245	was	N	I-Premise
246	found	N	I-Premise
247	on	N	I-Premise
248	day	N	I-Premise
249	5	N	I-Premise
250	(	N	I-Premise
251	p	N	I-Premise
252	<	N	I-Premise
253	0.001	N	I-Premise
254	)	N	I-Premise
255	and	N	I-Premise
256	on	N	I-Premise
257	day	N	I-Premise
258	10	N	I-Premise
259	(	N	I-Premise
260	p	N	I-Premise
261	=	N	I-Premise
262	0.0002	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	``	N	I-Claim
266	Laying	N	I-Claim
267	on	N	I-Claim
268	of	N	I-Claim
269	hands	N	I-Claim
270	''	N	I-Claim
271	resulted	N	I-Claim
272	in	N	I-Claim
273	a	N	I-Claim
274	significant	N	I-Claim
275	improvement	N	I-Claim
276	of	N	I-Claim
277	cancer-	N	I-Claim
278	or	N	I-Claim
279	cancer-therapy-associated	N	I-Claim
280	symptoms	N	I-Claim
281	.	N	I-Claim

282	The	N	I-Claim
283	magnitude	N	I-Claim
284	of	N	I-Claim
285	improvement	N	I-Claim
286	obtained	N	I-Claim
287	was	N	I-Claim
288	similar	N	I-Claim
289	whether	N	I-Claim
290	on	N	I-Claim
291	a	N	I-Claim
292	self-declared-healer-	N	I-Claim
293	or	N	I-Claim
294	an	N	I-Claim
295	actor-provided	N	I-Claim
296	``	N	I-Claim
297	treatment	N	I-Claim
298	''	N	O
299	.	N	O

1	This	N	O
2	randomised	N	O
3	multicentre	N	O
4	trial	N	O
5	was	N	O
6	conducted	N	O
7	to	N	O
8	establish	N	O
9	the	N	O
10	optimal	N	O
11	duration	N	O
12	of	N	O
13	palliative	N	O
14	chemotherapy	N	O
15	in	N	O
16	advanced	N	O
17	non-small-cell	N	O
18	lung	N	O
19	cancer	N	O
20	(	N	O
21	NSCLC	N	O
22	)	N	O
23	.	N	O

24	We	N	O
25	compared	N	O
26	a	N	O
27	policy	N	O
28	of	N	O
29	three	N	O
30	vs	N	O
31	six	N	O
32	courses	N	O
33	of	N	O
34	new-generation	N	O
35	platinum-based	N	O
36	combination	N	O
37	chemotherapy	N	O
38	with	N	O
39	regard	N	O
40	to	N	O
41	effects	N	O
42	on	N	O
43	quality	N	O
44	of	N	O
45	life	N	O
46	(	N	O
47	QoL	N	O
48	)	N	O
49	and	N	O
50	survival	N	O
51	.	N	O

52	Patients	N	O
53	with	N	O
54	stage	N	O
55	IIIB	N	O
56	or	N	O
57	IV	N	O
58	NSCLC	N	O
59	and	N	O
60	WHO	N	O
61	performance	N	O
62	status	N	O
63	(	N	O
64	PS	N	O
65	)	N	O
66	0-2	N	O
67	were	N	O
68	randomised	N	O
69	to	N	O
70	receive	N	O
71	three	N	O
72	(	N	O
73	C3	N	O
74	)	N	O
75	or	N	O
76	six	N	O
77	(	N	O
78	C6	N	O
79	)	N	O
80	courses	N	O
81	of	N	O
82	carboplatin	N	O
83	(	N	O
84	area	N	O
85	under	N	O
86	the	N	O
87	curve	N	O
88	(	N	O
89	AUC	N	O
90	)	N	O
91	4	N	O
92	,	N	O
93	Chatelut	N	O
94	's	N	O
95	formula	N	O
96	,	N	O
97	equivalent	N	O
98	to	N	O
99	Calvert	N	O
100	's	N	O
101	AUC	N	O
102	5	N	O
103	)	N	O
104	on	N	O
105	day	N	O
106	1	N	O
107	and	N	O
108	vinorelbine	N	O
109	25	N	O
110	mg	N	O
111	m	N	O
112	(	N	O
113	-2	N	O
114	)	N	O
115	on	N	O
116	days	N	O
117	1	N	O
118	and	N	O
119	8	N	O
120	of	N	O
121	a	N	O
122	3-week	N	O
123	cycle	N	O
124	.	N	O

125	Key	N	O
126	end	N	O
127	points	N	O
128	were	N	O
129	QoL	N	O
130	at	N	O
131	18	N	O
132	weeks	N	O
133	,	N	O
134	measured	N	O
135	with	N	O
136	EORTC	N	O
137	Quality	N	O
138	of	N	O
139	Life	N	O
140	Questionnaire	N	O
141	(	N	O
142	QLQ	N	O
143	)	N	O
144	-C30	N	O
145	and	N	O
146	QLQ-LC13	N	O
147	,	N	O
148	and	N	O
149	overall	N	O
150	survival	N	O
151	.	N	O

152	Secondary	N	O
153	end	N	O
154	points	N	O
155	were	N	O
156	progression-free	N	O
157	survival	N	O
158	and	N	O
159	need	N	O
160	of	N	O
161	palliative	N	O
162	radiotherapy	N	O
163	.	N	O

164	Two	N	O
165	hundred	N	O
166	and	N	O
167	ninety-seven	N	O
168	patients	N	O
169	were	N	O
170	randomised	N	O
171	(	N	O
172	C3	N	O
173	150	N	O
174	,	N	O
175	C6	N	O
176	147	N	O
177	)	N	O
178	.	N	O

179	Their	N	O
180	median	N	O
181	age	N	O
182	was	N	O
183	65	N	O
184	years	N	O
185	,	N	O
186	30	N	O
187	%	N	O
188	had	N	O
189	PS	N	O
190	2	N	O
191	and	N	O
192	76	N	O
193	%	N	O
194	stage	N	O
195	IV	N	O
196	disease	N	O
197	.	N	O

198	Seventy-eight	N	O
199	and	N	O
200	54	N	O
201	%	N	O
202	of	N	O
203	C3	N	O
204	and	N	O
205	C6	N	O
206	patients	N	O
207	,	N	O
208	respectively	N	O
209	,	N	O
210	completed	N	O
211	all	N	O
212	scheduled	N	O
213	chemotherapy	N	O
214	courses	N	O
215	.	N	O

216	Compliance	N	O
217	with	N	O
218	QoL	N	O
219	questionnaires	N	O
220	was	N	O
221	88	N	O
222	%	N	O
223	.	N	O

224	There	N	I-Premise
225	were	N	I-Premise
226	no	N	I-Premise
227	significant	N	I-Premise
228	group	N	I-Premise
229	differences	N	I-Premise
230	in	N	I-Premise
231	global	N	I-Premise
232	QoL	N	I-Premise
233	,	N	I-Premise
234	pain	N	I-Premise
235	or	N	I-Premise
236	fatigue	N	I-Premise
237	up	N	I-Premise
238	to	N	I-Premise
239	26	N	I-Premise
240	weeks	N	I-Premise
241	.	N	I-Premise

242	The	N	I-Premise
243	dyspnoea	N	I-Premise
244	palliation	N	I-Premise
245	rate	N	I-Premise
246	was	N	I-Premise
247	lower	N	I-Premise
248	in	N	I-Premise
249	the	N	I-Premise
250	C3	N	I-Premise
251	arm	N	I-Premise
252	at	N	I-Premise
253	18	N	I-Premise
254	and	N	I-Premise
255	26	N	I-Premise
256	weeks	N	I-Premise
257	(	N	I-Premise
258	P	N	I-Premise
259	<	N	I-Premise
260	0.05	N	I-Premise
261	)	N	I-Premise
262	,	N	I-Premise
263	but	N	I-Premise
264	this	N	I-Premise
265	finding	N	I-Premise
266	was	N	I-Premise
267	inconsistent	N	I-Premise
268	across	N	I-Premise
269	different	N	I-Premise
270	methods	N	I-Premise
271	of	N	I-Premise
272	analysis	N	I-Premise
273	.	N	I-Premise

274	Median	N	I-Premise
275	survival	N	I-Premise
276	in	N	I-Premise
277	the	N	I-Premise
278	C3	N	I-Premise
279	group	N	I-Premise
280	was	N	I-Premise
281	28	N	I-Premise
282	vs	N	I-Premise
283	32	N	I-Premise
284	weeks	N	I-Premise
285	in	N	I-Premise
286	the	N	I-Premise
287	C6	N	I-Premise
288	group	N	I-Premise
289	(	N	I-Premise
290	P=0.75	N	I-Premise
291	,	N	I-Premise
292	HR	N	I-Premise
293	1.04	N	I-Premise
294	,	N	I-Premise
295	95	N	I-Premise
296	%	N	I-Premise
297	CI	N	I-Premise
298	0.82-1.31	N	I-Premise
299	)	N	I-Premise
300	.	N	I-Premise

301	One-	N	I-Premise
302	and	N	I-Premise
303	2-year	N	I-Premise
304	survival	N	I-Premise
305	rates	N	I-Premise
306	were	N	I-Premise
307	25	N	I-Premise
308	and	N	I-Premise
309	9	N	I-Premise
310	%	N	I-Premise
311	vs	N	I-Premise
312	25	N	I-Premise
313	and	N	I-Premise
314	5	N	I-Premise
315	%	N	I-Premise
316	in	N	I-Premise
317	the	N	I-Premise
318	C3	N	I-Premise
319	and	N	I-Premise
320	C6	N	I-Premise
321	arm	N	I-Premise
322	,	N	I-Premise
323	respectively	N	I-Premise
324	.	N	I-Premise

325	Median	N	I-Premise
326	progression-free	N	I-Premise
327	survival	N	I-Premise
328	was	N	I-Premise
329	16	N	I-Premise
330	and	N	I-Premise
331	21	N	I-Premise
332	weeks	N	I-Premise
333	in	N	I-Premise
334	the	N	I-Premise
335	C3	N	I-Premise
336	and	N	I-Premise
337	C6	N	I-Premise
338	groups	N	I-Premise
339	,	N	I-Premise
340	respectively	N	I-Premise
341	(	N	I-Premise
342	P=0.21	N	I-Premise
343	,	N	I-Premise
344	HR	N	I-Premise
345	0.86	N	I-Premise
346	,	N	I-Premise
347	95	N	I-Premise
348	%	N	I-Premise
349	CI	N	I-Premise
350	0.68-1.08	N	I-Premise
351	)	N	I-Premise
352	.	N	I-Premise

353	In	N	I-Claim
354	conclusion	N	I-Claim
355	,	N	I-Claim
356	palliative	N	I-Claim
357	chemotherapy	N	I-Claim
358	with	N	I-Claim
359	carboplatin	N	I-Claim
360	and	N	I-Claim
361	vinorelbine	N	I-Claim
362	beyond	N	I-Claim
363	three	N	I-Claim
364	courses	N	I-Claim
365	conveys	N	I-Claim
366	no	N	I-Claim
367	survival	N	I-Claim
368	or	N	I-Claim
369	consistent	N	I-Claim
370	QoL	N	I-Claim
371	benefits	N	I-Claim
372	in	N	I-Claim
373	advanced	N	I-Claim
374	NSCLC	N	I-Claim
375	.	N	I-Claim

1	In	N	O
2	the	N	O
3	randomized	N	O
4	,	N	O
5	multinational	N	O
6	phase	N	O
7	II/III	N	O
8	trial	N	O
9	(	N	O
10	V325	N	O
11	)	N	O
12	of	N	O
13	untreated	N	O
14	advanced	N	O
15	gastric	N	O
16	cancer	N	O
17	patients	N	O
18	,	N	O
19	the	N	O
20	phase	N	O
21	II	N	O
22	part	N	O
23	selected	N	O
24	docetaxel	N	O
25	,	N	O
26	cisplatin	N	O
27	,	N	O
28	and	N	O
29	fluorouracil	N	O
30	(	N	O
31	DCF	N	O
32	)	N	O
33	over	N	O
34	docetaxel	N	O
35	and	N	O
36	cisplatin	N	O
37	for	N	O
38	comparison	N	O
39	against	N	O
40	cisplatin	N	O
41	and	N	O
42	fluorouracil	N	O
43	(	N	O
44	CF	N	O
45	;	N	O
46	reference	N	O
47	regimen	N	O
48	)	N	O
49	in	N	O
50	the	N	O
51	phase	N	O
52	III	N	O
53	part	N	O
54	.	N	O

55	Advanced	N	O
56	gastric	N	O
57	cancer	N	O
58	patients	N	O
59	were	N	O
60	randomly	N	O
61	assigned	N	O
62	to	N	O
63	docetaxel	N	O
64	75	N	O
65	mg/m2	N	O
66	and	N	O
67	cisplatin	N	O
68	75	N	O
69	mg/m2	N	O
70	(	N	O
71	day	N	O
72	1	N	O
73	)	N	O
74	plus	N	O
75	fluorouracil	N	O
76	750	N	O
77	mg/m2/d	N	O
78	(	N	O
79	days	N	O
80	1	N	O
81	to	N	O
82	5	N	O
83	)	N	O
84	every	N	O
85	3	N	O
86	weeks	N	O
87	or	N	O
88	cisplatin	N	O
89	100	N	O
90	mg/m2	N	O
91	(	N	O
92	day	N	O
93	1	N	O
94	)	N	O
95	plus	N	O
96	fluorouracil	N	O
97	1,000	N	O
98	mg/m2/d	N	O
99	(	N	O
100	days	N	O
101	1	N	O
102	to	N	O
103	5	N	O
104	)	N	O
105	every	N	O
106	4	N	O
107	weeks	N	O
108	.	N	O

109	The	N	O
110	primary	N	O
111	end	N	O
112	point	N	O
113	was	N	O
114	time-to-progression	N	O
115	(	N	O
116	TTP	N	O
117	)	N	O
118	.	N	O

119	In	N	O
120	445	N	O
121	randomly	N	O
122	assigned	N	O
123	and	N	O
124	treated	N	O
125	patients	N	O
126	(	N	O
127	DCF	N	O
128	=	N	O
129	221	N	O
130	;	N	O
131	CF	N	O
132	=	N	O
133	224	N	O
134	)	N	O
135	,	N	O
136	TTP	N	O
137	was	N	O
138	longer	N	O
139	with	N	O
140	DCF	N	O
141	versus	N	O
142	CF	N	O
143	(	N	O
144	32	N	O
145	%	N	O
146	risk	N	O
147	reduction	N	O
148	;	N	O
149	log-rank	N	O
150	P	N	O
151	<	N	O
152	.001	N	O
153	)	N	O
154	.	N	O

155	Overall	N	I-Premise
156	survival	N	I-Premise
157	was	N	I-Premise
158	longer	N	I-Premise
159	with	N	I-Premise
160	DCF	N	I-Premise
161	versus	N	I-Premise
162	CF	N	I-Premise
163	(	N	I-Premise
164	23	N	I-Premise
165	%	N	I-Premise
166	risk	N	I-Premise
167	reduction	N	I-Premise
168	;	N	I-Premise
169	log-rank	N	I-Premise
170	P	N	I-Premise
171	=	N	I-Premise
172	.02	N	I-Premise
173	)	N	I-Premise
174	.	N	I-Premise

175	Two-year	N	I-Premise
176	survival	N	I-Premise
177	rate	N	I-Premise
178	was	N	I-Premise
179	18	N	I-Premise
180	%	N	I-Premise
181	with	N	I-Premise
182	DCF	N	I-Premise
183	and	N	I-Premise
184	9	N	I-Premise
185	%	N	I-Premise
186	with	N	I-Premise
187	CF	N	I-Premise
188	.	N	I-Premise

189	Overall	N	I-Premise
190	response	N	I-Premise
191	rate	N	I-Premise
192	was	N	I-Premise
193	higher	N	I-Premise
194	with	N	I-Premise
195	DCF	N	I-Premise
196	(	N	I-Premise
197	chi2	N	I-Premise
198	P	N	I-Premise
199	=	N	I-Premise
200	.01	N	I-Premise
201	)	N	I-Premise
202	.	N	I-Premise

203	Grade	N	I-Premise
204	3	N	I-Premise
205	to	N	I-Premise
206	4	N	I-Premise
207	treatment-related	N	I-Premise
208	adverse	N	I-Premise
209	events	N	I-Premise
210	occurred	N	I-Premise
211	in	N	I-Premise
212	69	N	I-Premise
213	%	N	I-Premise
214	(	N	I-Premise
215	DCF	N	I-Premise
216	)	N	I-Premise
217	v	N	I-Premise
218	59	N	I-Premise
219	%	N	I-Premise
220	(	N	I-Premise
221	CF	N	I-Premise
222	)	N	I-Premise
223	of	N	I-Premise
224	patients	N	I-Premise
225	.	N	I-Premise

226	Frequent	N	I-Premise
227	grade	N	I-Premise
228	3	N	I-Premise
229	to	N	I-Premise
230	4	N	I-Premise
231	toxicities	N	I-Premise
232	for	N	I-Premise
233	DCF	N	I-Premise
234	v	N	I-Premise
235	CF	N	I-Premise
236	were	N	I-Premise
237	:	N	I-Premise
238	neutropenia	N	I-Premise
239	(	N	I-Premise
240	82	N	I-Premise
241	%	N	I-Premise
242	v	N	I-Premise
243	57	N	I-Premise
244	%	N	I-Premise
245	)	N	I-Premise
246	,	N	I-Premise
247	stomatitis	N	I-Premise
248	(	N	I-Premise
249	21	N	I-Premise
250	%	N	I-Premise
251	v	N	I-Premise
252	27	N	I-Premise
253	%	N	I-Premise
254	)	N	I-Premise
255	,	N	I-Premise
256	diarrhea	N	I-Premise
257	(	N	I-Premise
258	19	N	I-Premise
259	%	N	I-Premise
260	v	N	I-Premise
261	8	N	I-Premise
262	%	N	I-Premise
263	)	N	I-Premise
264	,	N	I-Premise
265	lethargy	N	I-Premise
266	(	N	I-Premise
267	19	N	I-Premise
268	%	N	I-Premise
269	v	N	I-Premise
270	14	N	I-Premise
271	%	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	Complicated	N	I-Premise
275	neutropenia	N	I-Premise
276	was	N	I-Premise
277	more	N	I-Premise
278	frequent	N	I-Premise
279	with	N	I-Premise
280	DCF	N	I-Premise
281	than	N	I-Premise
282	CF	N	I-Premise
283	(	N	I-Premise
284	29	N	I-Premise
285	%	N	I-Premise
286	v	N	I-Premise
287	12	N	I-Premise
288	%	N	I-Premise
289	)	N	I-Premise
290	.	N	I-Premise

291	Adding	N	I-Claim
292	docetaxel	N	I-Claim
293	to	N	I-Claim
294	CF	N	I-Claim
295	significantly	N	I-Claim
296	improved	N	I-Claim
297	TTP	N	I-Claim
298	,	N	I-Claim
299	survival	N	I-Claim
300	,	N	I-Claim
301	and	N	I-Claim
302	response	N	I-Claim
303	rate	N	I-Claim
304	in	N	I-Claim
305	gastric	N	I-Claim
306	cancer	N	I-Claim
307	patients	N	I-Claim
308	,	N	I-Claim
309	but	N	I-Claim
310	resulted	N	I-Claim
311	in	N	I-Claim
312	some	N	I-Claim
313	increase	N	I-Claim
314	in	N	I-Claim
315	toxicity	N	I-Claim
316	.	N	I-Claim

317	Incorporation	N	I-Claim
318	of	N	I-Claim
319	docetaxel	N	I-Claim
320	,	N	I-Claim
321	as	N	I-Claim
322	in	N	I-Claim
323	DCF	N	I-Claim
324	or	N	I-Claim
325	with	N	I-Claim
326	other	N	I-Claim
327	active	N	I-Claim
328	drug	N	I-Claim
329	(	N	I-Claim
330	s	N	I-Claim
331	)	N	I-Claim
332	,	N	I-Claim
333	is	N	I-Claim
334	a	N	I-Claim
335	new	N	I-Claim
336	therapy	N	I-Claim
337	option	N	I-Claim
338	for	N	I-Claim
339	patients	N	I-Claim
340	with	N	I-Claim
341	untreated	N	I-Claim
342	advanced	N	I-Claim
343	gastric	N	I-Claim
344	cancer	N	I-Claim
345	.	N	I-Claim

1	In	N	O
2	Lithuania	N	O
3	,	N	O
4	about	N	O
5	400	N	O
6	cases	N	O
7	of	N	O
8	pancreatic	N	O
9	cancer	N	O
10	are	N	O
11	diagnosed	N	O
12	each	N	O
13	year	N	O
14	,	N	O
15	and	N	O
16	more	N	O
17	than	N	O
18	50	N	O
19	%	N	O
20	of	N	O
21	patients	N	O
22	are	N	O
23	diagnosed	N	O
24	with	N	O
25	stage	N	O
26	IV	N	O
27	disease	N	O
28	.	N	O

29	Quality	N	I-MajorClaim
30	of	N	I-MajorClaim
31	life	N	I-MajorClaim
32	is	N	I-MajorClaim
33	an	N	I-MajorClaim
34	important	N	I-MajorClaim
35	issue	N	I-MajorClaim
36	in	N	I-MajorClaim
37	pancreatic	N	I-MajorClaim
38	cancer	N	I-MajorClaim
39	patients	N	I-MajorClaim
40	.	N	I-MajorClaim

41	A	N	O
42	prospective	N	O
43	randomized	N	O
44	clinical	N	O
45	study	N	O
46	on	N	O
47	the	N	O
48	treatment	N	O
49	of	N	O
50	patients	N	O
51	with	N	O
52	resectable	N	O
53	and	N	O
54	unresectable	N	O
55	pancreatic	N	O
56	cancer	N	O
57	was	N	O
58	conducted	N	O
59	at	N	O
60	the	N	O
61	Department	N	O
62	of	N	O
63	Oncology	N	O
64	of	N	O
65	Kaunas	N	O
66	University	N	O
67	of	N	O
68	Medicine	N	O
69	Hospital	N	O
70	,	N	O
71	and	N	O
72	in	N	O
73	this	N	O
74	study	N	O
75	,	N	O
76	quality	N	O
77	of	N	O
78	life	N	O
79	was	N	O
80	analyzed	N	O
81	.	N	O

82	The	N	O
83	aim	N	O
84	of	N	O
85	the	N	O
86	study	N	O
87	was	N	O
88	to	N	O
89	analyze	N	O
90	the	N	O
91	effect	N	O
92	of	N	O
93	combined	N	O
94	treatment	N	O
95	methods	N	O
96	on	N	O
97	quality	N	O
98	of	N	O
99	life	N	O
100	in	N	O
101	patients	N	O
102	diagnosed	N	O
103	with	N	O
104	pancreatic	N	O
105	cancer	N	O
106	.	N	O

107	During	N	O
108	2000-2005	N	O
109	,	N	O
110	two	N	O
111	concomitant	N	O
112	chemoradiation	N	O
113	treatment	N	O
114	methods	N	O
115	(	N	O
116	radiotherapy	N	O
117	with	N	O
118	5-fluorouracil	N	O
119	and	N	O
120	radiotherapy	N	O
121	with	N	O
122	gemcitabine	N	O
123	)	N	O
124	were	N	O
125	analyzed	N	O
126	in	N	O
127	the	N	O
128	study	N	O
129	.	N	O

130	A	N	O
131	total	N	O
132	of	N	O
133	60	N	O
134	patients	N	O
135	were	N	O
136	enrolled	N	O
137	:	N	O
138	41	N	O
139	patients	N	O
140	diagnosed	N	O
141	with	N	O
142	resectable	N	O
143	and	N	O
144	19	N	O
145	patients	N	O
146	diagnosed	N	O
147	with	N	O
148	unresectable	N	O
149	pancreatic	N	O
150	cancer	N	O
151	.	N	O

152	Quality	N	O
153	of	N	O
154	life	N	O
155	was	N	O
156	assessed	N	O
157	using	N	O
158	European	N	O
159	Organization	N	O
160	for	N	O
161	Research	N	O
162	and	N	O
163	Treatment	N	O
164	of	N	O
165	Cancer	N	O
166	Quality	N	O
167	of	N	O
168	Life	N	O
169	Core	N	O
170	30	N	O
171	(	N	O
172	EORTC	N	O
173	QLQ-C30	N	O
174	)	N	O
175	questionnaire	N	O
176	.	N	O

177	Three	N	O
178	main	N	O
179	quality	N	O
180	of	N	O
181	life	N	O
182	scales	N	O
183	(	N	O
184	general	N	O
185	health	N	O
186	status	N	O
187	,	N	O
188	functional	N	O
189	,	N	O
190	and	N	O
191	symptom	N	O
192	scales	N	O
193	)	N	O
194	were	N	O
195	assessed	N	O
196	and	N	O
197	compared	N	O
198	between	N	O
199	two	N	O
200	treatment	N	O
201	groups	N	O
202	.	N	O

203	The	N	I-Premise
204	analysis	N	I-Premise
205	of	N	I-Premise
206	quality	N	I-Premise
207	of	N	I-Premise
208	live	N	I-Premise
209	assessment	N	I-Premise
210	showed	N	I-Premise
211	a	N	I-Premise
212	statistically	N	I-Premise
213	significant	N	I-Premise
214	decrease	N	I-Premise
215	in	N	I-Premise
216	quality	N	I-Premise
217	of	N	I-Premise
218	life	N	I-Premise
219	after	N	I-Premise
220	treatment	N	I-Premise
221	in	N	I-Premise
222	patients	N	I-Premise
223	with	N	I-Premise
224	resectable	N	I-Premise
225	pancreatic	N	I-Premise
226	cancer	N	I-Premise
227	and	N	I-Premise
228	treated	N	I-Premise
229	with	N	I-Premise
230	radiotherapy	N	I-Premise
231	and	N	I-Premise
232	gemcitabine	N	I-Premise
233	.	N	I-Premise

234	Decreased	N	I-Premise
235	quality	N	I-Premise
236	of	N	I-Premise
237	life	N	I-Premise
238	later	N	I-Premise
239	after	N	I-Premise
240	treatment	N	I-Premise
241	was	N	I-Premise
242	also	N	I-Premise
243	observed	N	I-Premise
244	in	N	I-Premise
245	patients	N	I-Premise
246	diagnosed	N	I-Premise
247	with	N	I-Premise
248	unresectable	N	I-Premise
249	pancreatic	N	I-Premise
250	cancer	N	I-Premise
251	and	N	I-Premise
252	treated	N	I-Premise
253	with	N	I-Premise
254	the	N	I-Premise
255	same	N	I-Premise
256	regimen	N	I-Premise
257	.	N	I-Premise

258	Treatment	N	I-Claim
259	with	N	I-Claim
260	radiotherapy	N	I-Claim
261	and	N	I-Claim
262	5-fluorouracil	N	I-Claim
263	changed	N	I-Claim
264	only	N	I-Claim
265	some	N	I-Claim
266	aspects	N	I-Claim
267	of	N	I-Claim
268	quality	N	I-Claim
269	of	N	I-Claim
270	life	N	I-Claim
271	and	N	I-Claim
272	did	N	I-Claim
273	not	N	I-Claim
274	have	N	I-Claim
275	a	N	I-Claim
276	significant	N	I-Claim
277	impact	N	I-Claim
278	on	N	I-Claim
279	quality	N	I-Claim
280	of	N	I-Claim
281	life	N	I-Claim
282	.	N	I-Claim

1	Surgery	N	O
2	and	N	O
3	radiotherapy	N	O
4	commonly	N	O
5	cause	N	O
6	adverse	N	O
7	musculoskeletal	N	O
8	problems	N	O
9	,	N	O
10	particularly	N	O
11	loss	N	O
12	of	N	O
13	strength	N	O
14	and	N	O
15	range	N	O
16	of	N	O
17	motion	N	O
18	,	N	O
19	in	N	O
20	the	N	O
21	upper	N	O
22	quadrant	N	O
23	of	N	O
24	breast	N	O
25	cancer	N	O
26	patients	N	O
27	.	N	O

28	Few	N	O
29	well-designed	N	O
30	studies	N	O
31	have	N	O
32	investigated	N	O
33	whether	N	O
34	these	N	O
35	impairments	N	O
36	can	N	O
37	be	N	O
38	prevented	N	O
39	.	N	O

40	Stretching	N	I-Claim
41	is	N	I-Claim
42	an	N	I-Claim
43	effective	N	I-Claim
44	technique	N	I-Claim
45	for	N	I-Claim
46	increasing	N	I-Claim
47	range	N	I-Claim
48	of	N	I-Claim
49	motion	N	I-Claim
50	,	N	I-Claim
51	hence	N	O
52	the	N	O
53	aim	N	O
54	of	N	O
55	this	N	O
56	study	N	O
57	was	N	O
58	to	N	O
59	investigate	N	O
60	whether	N	O
61	a	N	O
62	stretching	N	O
63	program	N	O
64	reduced	N	O
65	acute	N	O
66	musculoskeletal	N	O
67	impairments	N	O
68	in	N	O
69	patients	N	O
70	undergoing	N	O
71	radiotherapy	N	O
72	for	N	O
73	breast	N	O
74	cancer	N	O
75	.	N	O

76	Sixty-four	N	O
77	women	N	O
78	were	N	O
79	recruited	N	O
80	prior	N	O
81	to	N	O
82	commencement	N	O
83	of	N	O
84	radiotherapy	N	O
85	following	N	O
86	breast	N	O
87	cancer	N	O
88	surgery	N	O
89	.	N	O

90	Participants	N	O
91	were	N	O
92	randomised	N	O
93	to	N	O
94	either	N	O
95	a	N	O
96	control	N	O
97	or	N	O
98	stretch	N	O
99	group	N	O
100	.	N	O

101	Participants	N	O
102	in	N	O
103	both	N	O
104	groups	N	O
105	were	N	O
106	reviewed	N	O
107	by	N	O
108	the	N	O
109	physical	N	O
110	therapist	N	O
111	on	N	O
112	a	N	O
113	weekly	N	O
114	basis	N	O
115	for	N	O
116	approximately	N	O
117	6	N	O
118	weeks	N	O
119	,	N	O
120	and	N	O
121	were	N	O
122	given	N	O
123	general	N	O
124	information	N	O
125	about	N	O
126	skin	N	O
127	care	N	O
128	and	N	O
129	lymphedema	N	O
130	.	N	O

131	The	N	O
132	control	N	O
133	group	N	O
134	received	N	O
135	no	N	O
136	advice	N	O
137	about	N	O
138	exercise	N	O
139	.	N	O

140	The	N	O
141	stretch	N	O
142	group	N	O
143	received	N	O
144	instruction	N	O
145	on	N	O
146	low-load	N	O
147	,	N	O
148	prolonged	N	O
149	pectoral	N	O
150	stretches	N	O
151	,	N	O
152	which	N	O
153	were	N	O
154	to	N	O
155	be	N	O
156	performed	N	O
157	daily	N	O
158	and	N	O
159	were	N	O
160	checked	N	O
161	at	N	O
162	weekly	N	O
163	visits	N	O
164	.	N	O

165	Shoulder	N	O
166	range	N	O
167	of	N	O
168	motion	N	O
169	,	N	O
170	strength	N	O
171	,	N	O
172	arm	N	O
173	circumference	N	O
174	,	N	O
175	and	N	O
176	quality	N	O
177	of	N	O
178	life	N	O
179	measurements	N	O
180	were	N	O
181	taken	N	O
182	prior	N	O
183	to	N	O
184	,	N	O
185	and	N	O
186	at	N	O
187	completion	N	O
188	of	N	O
189	radiotherapy	N	O
190	,	N	O
191	and	N	O
192	at	N	O
193	7	N	O
194	months	N	O
195	after	N	O
196	radiotherapy	N	O
197	.	N	O

198	There	N	I-Premise
199	was	N	I-Premise
200	no	N	I-Premise
201	difference	N	I-Premise
202	in	N	I-Premise
203	any	N	I-Premise
204	outcome	N	I-Premise
205	between	N	I-Premise
206	groups	N	I-Premise
207	.	N	I-Premise

208	Breast	N	I-Premise
209	symptoms	N	I-Premise
210	increased	N	I-Premise
211	for	N	I-Premise
212	both	N	I-Premise
213	groups	N	I-Premise
214	during	N	I-Premise
215	radiotherapy	N	I-Premise
216	,	N	I-Premise
217	without	N	I-Premise
218	loss	N	I-Premise
219	of	N	I-Premise
220	strength	N	I-Premise
221	or	N	I-Premise
222	range	N	I-Premise
223	of	N	I-Premise
224	movement	N	I-Premise
225	.	N	I-Premise

226	The	N	I-Premise
227	incidence	N	I-Premise
228	of	N	I-Premise
229	lymphedema	N	I-Premise
230	during	N	I-Premise
231	the	N	I-Premise
232	study	N	I-Premise
233	was	N	I-Premise
234	low	N	I-Premise
235	for	N	I-Premise
236	both	N	I-Premise
237	groups	N	I-Premise
238	and	N	I-Premise
239	did	N	I-Premise
240	not	N	I-Premise
241	differ	N	I-Premise
242	between	N	I-Premise
243	groups	N	I-Premise
244	.	N	I-Premise

245	The	N	I-Premise
246	pectoral	N	I-Premise
247	stretching	N	I-Premise
248	program	N	I-Premise
249	did	N	I-Premise
250	not	N	I-Premise
251	influence	N	I-Premise
252	the	N	I-Premise
253	outcomes	N	I-Premise
254	measured	N	I-Premise
255	because	N	I-Premise
256	the	N	I-Premise
257	symptoms	N	I-Premise
258	reported	N	I-Premise
259	by	N	I-Premise
260	patients	N	I-Premise
261	were	N	I-Premise
262	not	N	I-Premise
263	a	N	I-Premise
264	consequence	N	I-Premise
265	of	N	I-Premise
266	contracture	N	I-Premise
267	.	N	I-Premise

1	To	N	O
2	compare	N	O
3	directly	N	O
4	the	N	O
5	effect	N	O
6	of	N	O
7	intensity-modulated	N	O
8	radiotherapy	N	O
9	(	N	O
10	IMRT	N	O
11	)	N	O
12	vs.	N	O
13	conventional	N	O
14	radiotherapy	N	O
15	(	N	O
16	CRT	N	O
17	)	N	O
18	on	N	O
19	salivary	N	O
20	flow	N	O
21	and	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	(	N	O
26	QoL	N	O
27	)	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	early-stage	N	O
32	nasopharyngeal	N	O
33	carcinoma	N	O
34	(	N	O
35	NPC	N	O
36	)	N	O
37	.	N	O

38	Fifty-one	N	O
39	patients	N	O
40	with	N	O
41	T2	N	O
42	,	N	O
43	N0/N1	N	O
44	,	N	O
45	M0	N	O
46	NPC	N	O
47	took	N	O
48	part	N	O
49	in	N	O
50	a	N	O
51	randomized	N	O
52	controlled	N	O
53	clinical	N	O
54	study	N	O
55	and	N	O
56	received	N	O
57	IMRT	N	O
58	or	N	O
59	CRT	N	O
60	.	N	O

61	Stimulated	N	O
62	whole	N	O
63	(	N	O
64	SWS	N	O
65	)	N	O
66	and	N	O
67	parotid	N	O
68	(	N	O
69	SPS	N	O
70	)	N	O
71	saliva	N	O
72	flow	N	O
73	were	N	O
74	measured	N	O
75	and	N	O
76	Medical	N	O
77	Outcomes	N	O
78	Short	N	O
79	Form	N	O
80	36	N	O
81	(	N	O
82	SF-36	N	O
83	)	N	O
84	,	N	O
85	European	N	O
86	Organization	N	O
87	for	N	O
88	Research	N	O
89	and	N	O
90	Treatment	N	O
91	of	N	O
92	Cancer	N	O
93	(	N	O
94	EORTC	N	O
95	)	N	O
96	core	N	O
97	quetionnaire	N	O
98	,	N	O
99	and	N	O
100	EORTC	N	O
101	head-and-neck	N	O
102	module	N	O
103	(	N	O
104	QLQ-H	N	O
105	&	N	O
106	amp	N	O
107	;	N	O
108	N35	N	O
109	)	N	O
110	were	N	O
111	completed	N	O
112	at	N	O
113	baseline	N	O
114	and	N	O
115	2	N	O
116	,	N	O
117	6	N	O
118	,	N	O
119	and	N	O
120	12	N	O
121	months	N	O
122	after	N	O
123	radiotherapy	N	O
124	.	N	O

125	Forty-six	N	I-Premise
126	patients	N	I-Premise
127	(	N	I-Premise
128	88	N	I-Premise
129	%	N	I-Premise
130	)	N	I-Premise
131	were	N	I-Premise
132	in	N	I-Premise
133	disease	N	I-Premise
134	remission	N	I-Premise
135	12	N	I-Premise
136	months	N	I-Premise
137	after	N	I-Premise
138	radiotherapy	N	I-Premise
139	.	N	I-Premise

140	At	N	I-Premise
141	12	N	I-Premise
142	months	N	I-Premise
143	postradiotherapy	N	I-Premise
144	,	N	I-Premise
145	12	N	I-Premise
146	(	N	I-Premise
147	50.0	N	I-Premise
148	%	N	I-Premise
149	)	N	I-Premise
150	and	N	I-Premise
151	20	N	I-Premise
152	patients	N	I-Premise
153	(	N	I-Premise
154	83.3	N	I-Premise
155	%	N	I-Premise
156	)	N	I-Premise
157	in	N	I-Premise
158	the	N	I-Premise
159	IMRT	N	I-Premise
160	group	N	I-Premise
161	had	N	I-Premise
162	recovered	N	I-Premise
163	at	N	I-Premise
164	least	N	I-Premise
165	25	N	I-Premise
166	%	N	I-Premise
167	of	N	I-Premise
168	preradiotherapy	N	I-Premise
169	SWS	N	I-Premise
170	and	N	I-Premise
171	SPS	N	I-Premise
172	flow	N	I-Premise
173	respectively	N	I-Premise
174	,	N	I-Premise
175	compared	N	I-Premise
176	with	N	I-Premise
177	1	N	I-Premise
178	(	N	I-Premise
179	4.8	N	I-Premise
180	%	N	I-Premise
181	)	N	I-Premise
182	and	N	I-Premise
183	2	N	I-Premise
184	patients	N	I-Premise
185	(	N	I-Premise
186	9.5	N	I-Premise
187	%	N	I-Premise
188	)	N	I-Premise
189	,	N	I-Premise
190	respectively	N	I-Premise
191	,	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	CRT	N	I-Premise
195	group	N	I-Premise
196	.	N	I-Premise

197	Global	N	I-Premise
198	health	N	I-Premise
199	scores	N	I-Premise
200	showed	N	I-Premise
201	continuous	N	I-Premise
202	improvement	N	I-Premise
203	in	N	I-Premise
204	QoL	N	I-Premise
205	after	N	I-Premise
206	both	N	I-Premise
207	treatments	N	I-Premise
208	(	N	I-Premise
209	p	N	I-Premise
210	<	N	I-Premise
211	0.001	N	I-Premise
212	)	N	I-Premise
213	.	N	I-Premise

214	However	N	I-Premise
215	,	N	I-Premise
216	after	N	I-Premise
217	12	N	I-Premise
218	months	N	I-Premise
219	subscale	N	I-Premise
220	scores	N	I-Premise
221	for	N	I-Premise
222	role-physical	N	I-Premise
223	,	N	I-Premise
224	bodily	N	I-Premise
225	pain	N	I-Premise
226	,	N	I-Premise
227	and	N	I-Premise
228	physical	N	I-Premise
229	function	N	I-Premise
230	were	N	I-Premise
231	significantly	N	I-Premise
232	higher	N	I-Premise
233	in	N	I-Premise
234	the	N	I-Premise
235	IMRT	N	I-Premise
236	group	N	I-Premise
237	,	N	I-Premise
238	indicating	N	I-Premise
239	a	N	I-Premise
240	better	N	I-Premise
241	condition	N	I-Premise
242	(	N	I-Premise
243	p	N	I-Premise
244	<	N	I-Premise
245	0.05	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	Dry	N	I-Premise
249	mouth	N	I-Premise
250	and	N	I-Premise
251	sticky	N	I-Premise
252	saliva	N	I-Premise
253	were	N	I-Premise
254	problems	N	I-Premise
255	in	N	I-Premise
256	both	N	I-Premise
257	groups	N	I-Premise
258	2	N	I-Premise
259	months	N	I-Premise
260	after	N	I-Premise
261	treatment	N	I-Premise
262	.	N	I-Premise

263	In	N	I-Premise
264	the	N	I-Premise
265	IMRT	N	I-Premise
266	group	N	I-Premise
267	,	N	I-Premise
268	there	N	I-Premise
269	was	N	I-Premise
270	consistent	N	I-Premise
271	improvement	N	I-Premise
272	over	N	I-Premise
273	time	N	I-Premise
274	with	N	I-Premise
275	xerostomia-related	N	I-Premise
276	symptoms	N	I-Premise
277	significantly	N	I-Premise
278	less	N	I-Premise
279	common	N	I-Premise
280	than	N	I-Premise
281	in	N	I-Premise
282	the	N	I-Premise
283	CRT	N	I-Premise
284	group	N	I-Premise
285	at	N	I-Premise
286	12	N	I-Premise
287	months	N	I-Premise
288	postradiotherapy	N	I-Premise
289	.	N	I-Premise

290	IMRT	N	I-Claim
291	was	N	I-Claim
292	significantly	N	I-Claim
293	better	N	I-Claim
294	than	N	I-Claim
295	CRT	N	I-Claim
296	in	N	I-Claim
297	terms	N	I-Claim
298	of	N	I-Claim
299	parotid	N	I-Claim
300	sparing	N	I-Claim
301	and	N	I-Claim
302	improved	N	I-Claim
303	QoL	N	I-Claim
304	for	N	I-Claim
305	early-stage	N	I-Claim
306	disease	N	I-Claim
307	.	N	I-Claim

308	The	N	I-Claim
309	findings	N	I-Claim
310	support	N	I-Claim
311	the	N	I-Claim
312	case	N	I-Claim
313	for	N	I-Claim
314	assessment	N	I-Claim
315	of	N	I-Claim
316	health-related	N	I-Claim
317	QoL	N	I-Claim
318	in	N	I-Claim
319	relation	N	I-Claim
320	to	N	I-Claim
321	head-and-neck	N	I-Claim
322	cancer	N	I-Claim
323	using	N	I-Claim
324	a	N	I-Claim
325	site-specific	N	I-Claim
326	approach	N	I-Claim
327	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	article	N	O
6	is	N	O
7	to	N	O
8	compare	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	QOL	N	O
14	)	N	O
15	and	N	O
16	menopausal	N	O
17	symptoms	N	O
18	among	N	O
19	premenopausal	N	O
20	patients	N	O
21	with	N	O
22	lymph	N	O
23	node-negative	N	O
24	breast	N	O
25	cancer	N	O
26	receiving	N	O
27	chemotherapy	N	O
28	,	N	O
29	goserelin	N	O
30	,	N	O
31	or	N	O
32	their	N	O
33	sequential	N	O
34	combination	N	O
35	,	N	O
36	and	N	O
37	to	N	O
38	investigate	N	O
39	differential	N	O
40	effects	N	O
41	by	N	O
42	age	N	O
43	.	N	O

44	We	N	O
45	evaluated	N	O
46	QOL	N	O
47	data	N	O
48	from	N	O
49	874	N	O
50	pre-	N	O
51	and	N	O
52	perimenopausal	N	O
53	women	N	O
54	with	N	O
55	lymph	N	O
56	node-negative	N	O
57	breast	N	O
58	cancer	N	O
59	who	N	O
60	were	N	O
61	randomly	N	O
62	assigned	N	O
63	to	N	O
64	receive	N	O
65	six	N	O
66	courses	N	O
67	of	N	O
68	classical	N	O
69	cyclophosphamide	N	O
70	,	N	O
71	methotrexate	N	O
72	,	N	O
73	and	N	O
74	fluorouracil	N	O
75	(	N	O
76	CMF	N	O
77	)	N	O
78	chemotherapy	N	O
79	,	N	O
80	ovarian	N	O
81	suppression	N	O
82	with	N	O
83	goserelin	N	O
84	for	N	O
85	24	N	O
86	months	N	O
87	,	N	O
88	or	N	O
89	six	N	O
90	courses	N	O
91	of	N	O
92	classical	N	O
93	CMF	N	O
94	followed	N	O
95	by	N	O
96	18	N	O
97	months	N	O
98	of	N	O
99	goserelin	N	O
100	.	N	O

101	We	N	O
102	report	N	O
103	QOL	N	O
104	data	N	O
105	collected	N	O
106	during	N	O
107	3	N	O
108	years	N	O
109	after	N	O
110	random	N	O
111	assignment	N	O
112	in	N	O
113	patients	N	O
114	without	N	O
115	disease	N	O
116	recurrence	N	O
117	.	N	O

118	Overall	N	I-Premise
119	,	N	I-Premise
120	patients	N	I-Premise
121	receiving	N	I-Premise
122	goserelin	N	I-Premise
123	alone	N	I-Premise
124	showed	N	I-Premise
125	a	N	I-Premise
126	marked	N	I-Premise
127	improvement	N	I-Premise
128	or	N	I-Premise
129	less	N	I-Premise
130	deterioration	N	I-Premise
131	in	N	I-Premise
132	QOL	N	I-Premise
133	measures	N	I-Premise
134	over	N	I-Premise
135	the	N	I-Premise
136	first	N	I-Premise
137	6	N	I-Premise
138	months	N	I-Premise
139	than	N	I-Premise
140	those	N	I-Premise
141	patients	N	I-Premise
142	treated	N	I-Premise
143	with	N	I-Premise
144	CMF	N	I-Premise
145	.	N	I-Premise

146	There	N	I-Premise
147	were	N	I-Premise
148	no	N	I-Premise
149	differences	N	I-Premise
150	at	N	I-Premise
151	3	N	I-Premise
152	years	N	I-Premise
153	after	N	I-Premise
154	random	N	I-Premise
155	assignment	N	I-Premise
156	according	N	I-Premise
157	to	N	I-Premise
158	treatment	N	I-Premise
159	except	N	I-Premise
160	for	N	I-Premise
161	hot	N	I-Premise
162	flashes	N	I-Premise
163	.	N	I-Premise

164	As	N	I-Premise
165	reflected	N	I-Premise
166	in	N	I-Premise
167	the	N	I-Premise
168	hot	N	I-Premise
169	flashes	N	I-Premise
170	scores	N	I-Premise
171	,	N	I-Premise
172	patients	N	I-Premise
173	in	N	I-Premise
174	all	N	I-Premise
175	three	N	I-Premise
176	treatment	N	I-Premise
177	groups	N	I-Premise
178	experienced	N	I-Premise
179	induced	N	I-Premise
180	amenorrhea	N	I-Premise
181	,	N	I-Premise
182	but	N	I-Premise
183	the	N	I-Premise
184	onset	N	I-Premise
185	of	N	I-Premise
186	ovarian	N	I-Premise
187	function	N	I-Premise
188	suppression	N	I-Premise
189	was	N	I-Premise
190	slightly	N	I-Premise
191	delayed	N	I-Premise
192	for	N	I-Premise
193	patients	N	I-Premise
194	receiving	N	I-Premise
195	chemotherapy	N	I-Premise
196	.	N	I-Premise

197	Younger	N	I-Premise
198	patients	N	I-Premise
199	(	N	I-Premise
200	<	N	I-Premise
201	40	N	I-Premise
202	years	N	I-Premise
203	)	N	I-Premise
204	who	N	I-Premise
205	received	N	I-Premise
206	goserelin	N	I-Premise
207	alone	N	I-Premise
208	returned	N	I-Premise
209	to	N	I-Premise
210	their	N	I-Premise
211	premenopausal	N	I-Premise
212	status	N	I-Premise
213	at	N	I-Premise
214	6	N	I-Premise
215	months	N	I-Premise
216	after	N	I-Premise
217	the	N	I-Premise
218	cessation	N	I-Premise
219	of	N	I-Premise
220	therapy	N	I-Premise
221	,	N	I-Premise
222	while	N	I-Premise
223	those	N	I-Premise
224	who	N	I-Premise
225	received	N	I-Premise
226	CMF	N	I-Premise
227	showed	N	I-Premise
228	marginal	N	I-Premise
229	changes	N	I-Premise
230	from	N	I-Premise
231	their	N	I-Premise
232	baseline	N	I-Premise
233	hot	N	I-Premise
234	flashes	N	I-Premise
235	scores	N	I-Premise
236	.	N	I-Premise

237	Age-adjusted	N	I-Claim
238	risk	N	I-Claim
239	profiles	N	I-Claim
240	that	N	I-Claim
241	consider	N	I-Claim
242	patient-reported	N	I-Claim
243	outcomes	N	I-Claim
244	enable	N	I-Claim
245	patients	N	I-Claim
246	to	N	I-Claim
247	adapt	N	I-Claim
248	to	N	I-Claim
249	their	N	I-Claim
250	disease	N	I-Claim
251	and	N	I-Claim
252	treatment	N	I-Claim
253	,	N	I-Claim
254	such	N	I-Claim
255	as	N	I-Claim
256	considering	N	I-Claim
257	the	N	I-Claim
258	trade-offs	N	I-Claim
259	between	N	I-Claim
260	delayed	N	I-Claim
261	endocrine	N	I-Claim
262	symptoms	N	I-Claim
263	,	N	I-Claim
264	but	N	I-Claim
265	higher	N	I-Claim
266	risk	N	I-Claim
267	of	N	I-Claim
268	permanent	N	I-Claim
269	menopause	N	I-Claim
270	with	N	I-Claim
271	chemotherapy	N	I-Claim
272	,	N	I-Claim
273	and	N	I-Claim
274	immediate	N	I-Claim
275	but	N	I-Claim
276	reversible	N	I-Claim
277	endocrine	N	I-Claim
278	symptoms	N	I-Claim
279	with	N	I-Claim
280	goserelin	N	I-Claim
281	,	N	I-Claim
282	in	N	I-Claim
283	younger	N	I-Claim
284	premenopausal	N	I-Claim
285	patients	N	I-Claim
286	.	N	I-Claim

1	Although	N	O
2	numerous	N	O
3	treatment	N	O
4	modalities	N	O
5	have	N	O
6	been	N	O
7	explored	N	O
8	in	N	O
9	patients	N	O
10	with	N	O
11	advanced	N	O
12	HCC	N	O
13	,	N	O
14	the	N	O
15	therapeutic	N	O
16	options	N	O
17	are	N	O
18	still	N	O
19	limited	N	O
20	.	N	O

21	Somatostatin	N	I-Claim
22	has	N	I-Claim
23	been	N	I-Claim
24	shown	N	I-Claim
25	to	N	I-Claim
26	have	N	I-Claim
27	antimitotic	N	I-Claim
28	activity	N	I-Claim
29	in	N	I-Claim
30	endocrine	N	I-Claim
31	as	N	I-Claim
32	well	N	I-Claim
33	as	N	I-Claim
34	in	N	I-Claim
35	a	N	I-Claim
36	variety	N	I-Claim
37	of	N	I-Claim
38	nonendocrine	N	I-Claim
39	tumors	N	I-Claim
40	.	N	I-Claim

41	Expression	N	I-Premise
42	of	N	I-Premise
43	somatostatin	N	I-Premise
44	receptors	N	I-Premise
45	is	N	I-Premise
46	found	N	I-Premise
47	in	N	I-Premise
48	HCCs	N	I-Premise
49	,	N	I-Premise
50	but	N	O
51	the	N	I-Claim
52	efficacy	N	I-Claim
53	of	N	I-Claim
54	the	N	I-Claim
55	somatostatin	N	I-Claim
56	analogue	N	I-Claim
57	octreotide	N	I-Claim
58	remains	N	I-Claim
59	controversial	N	I-Claim
60	.	N	I-Claim

61	Therefore	N	O
62	,	N	O
63	a	N	O
64	randomized	N	O
65	double-blind	N	O
66	placebo-controlled	N	O
67	multicenter	N	O
68	trial	N	O
69	was	N	O
70	performed	N	O
71	to	N	O
72	assess	N	O
73	the	N	O
74	efficacy	N	O
75	of	N	O
76	long-acting	N	O
77	octreotide	N	O
78	for	N	O
79	the	N	O
80	treatment	N	O
81	of	N	O
82	advanced	N	O
83	HCC	N	O
84	.	N	O

85	One	N	O
86	hundred	N	O
87	twenty	N	O
88	untreated	N	O
89	patients	N	O
90	with	N	O
91	histologically	N	O
92	confirmed	N	O
93	HCC	N	O
94	were	N	O
95	randomized	N	O
96	to	N	O
97	receive	N	O
98	either	N	O
99	long-acting	N	O
100	octreotide	N	O
101	(	N	O
102	Sandostation	N	O
103	LAR	N	O
104	30	N	O
105	mg	N	O
106	)	N	O
107	intramuscularly	N	O
108	every	N	O
109	4	N	O
110	weeks	N	O
111	or	N	O
112	placebo	N	O
113	.	N	O

114	The	N	O
115	study	N	O
116	groups	N	O
117	were	N	O
118	comparable	N	O
119	with	N	O
120	respect	N	O
121	to	N	O
122	clinical	N	O
123	characteristics	N	O
124	.	N	O

125	There	N	I-Premise
126	was	N	I-Premise
127	no	N	I-Premise
128	difference	N	I-Premise
129	in	N	I-Premise
130	the	N	I-Premise
131	cumulative	N	I-Premise
132	survival	N	I-Premise
133	.	N	I-Premise

134	The	N	I-Premise
135	median	N	I-Premise
136	survival	N	I-Premise
137	time	N	I-Premise
138	was	N	I-Premise
139	4.7	N	I-Premise
140	months	N	I-Premise
141	in	N	I-Premise
142	the	N	I-Premise
143	octreotide	N	I-Premise
144	group	N	I-Premise
145	compared	N	I-Premise
146	with	N	I-Premise
147	5.3	N	I-Premise
148	months	N	I-Premise
149	in	N	I-Premise
150	the	N	I-Premise
151	control	N	I-Premise
152	group	N	I-Premise
153	.	N	I-Premise

154	Six-month	N	I-Premise
155	survival	N	I-Premise
156	rates	N	I-Premise
157	were	N	I-Premise
158	41	N	I-Premise
159	%	N	I-Premise
160	for	N	I-Premise
161	octreotide	N	I-Premise
162	patients	N	I-Premise
163	and	N	I-Premise
164	42	N	I-Premise
165	%	N	I-Premise
166	for	N	I-Premise
167	control	N	I-Premise
168	patients	N	I-Premise
169	,	N	I-Premise
170	respectively	N	I-Premise
171	.	N	I-Premise

172	The	N	I-Premise
173	unadjusted	N	I-Premise
174	relative	N	I-Premise
175	risk	N	I-Premise
176	for	N	I-Premise
177	mortality	N	I-Premise
178	in	N	I-Premise
179	the	N	I-Premise
180	octreotide	N	I-Premise
181	group	N	I-Premise
182	compared	N	I-Premise
183	with	N	I-Premise
184	patients	N	I-Premise
185	in	N	I-Premise
186	the	N	I-Premise
187	control	N	I-Premise
188	group	N	I-Premise
189	was	N	I-Premise
190	1.11	N	I-Premise
191	(	N	I-Premise
192	95	N	I-Premise
193	%	N	I-Premise
194	CI	N	I-Premise
195	0.76-1.63	N	I-Premise
196	;	N	I-Premise
197	P	N	I-Premise
198	=	N	I-Premise
199	0.59	N	I-Premise
200	)	N	I-Premise
201	.	N	I-Premise

202	When	N	I-Premise
203	adjusted	N	I-Premise
204	for	N	I-Premise
205	Okuda	N	I-Premise
206	,	N	I-Premise
207	CTP	N	I-Premise
208	,	N	I-Premise
209	and	N	I-Premise
210	Cancer	N	I-Premise
211	of	N	I-Premise
212	the	N	I-Premise
213	Liver	N	I-Premise
214	Italian	N	I-Premise
215	Program	N	I-Premise
216	(	N	I-Premise
217	CLIP	N	I-Premise
218	)	N	I-Premise
219	scores	N	I-Premise
220	,	N	I-Premise
221	the	N	I-Premise
222	relative	N	I-Premise
223	risk	N	I-Premise
224	for	N	I-Premise
225	octreotide	N	I-Premise
226	did	N	I-Premise
227	not	N	I-Premise
228	change	N	I-Premise
229	markedly	N	I-Premise
230	and	N	I-Premise
231	was	N	I-Premise
232	1.05	N	I-Premise
233	(	N	I-Premise
234	95	N	I-Premise
235	%	N	I-Premise
236	CI	N	I-Premise
237	0.71-1.55	N	I-Premise
238	;	N	I-Premise
239	P	N	I-Premise
240	=	N	I-Premise
241	0.83	N	I-Premise
242	)	N	I-Premise
243	.	N	I-Premise

244	The	N	I-Claim
245	CLIP	N	I-Claim
246	score	N	I-Claim
247	seems	N	I-Claim
248	to	N	I-Claim
249	predict	N	I-Claim
250	survival	N	I-Claim
251	better	N	I-Claim
252	than	N	I-Claim
253	both	N	I-Claim
254	Okuda	N	I-Claim
255	and	N	I-Claim
256	CTP	N	I-Claim
257	score	N	I-Claim
258	.	N	I-Claim

259	The	N	I-Claim
260	randomized	N	I-Claim
261	controlled	N	I-Claim
262	double-blind	N	I-Claim
263	HECTOR	N	I-Claim
264	trial	N	I-Claim
265	showed	N	I-Claim
266	no	N	I-Claim
267	survival	N	I-Claim
268	benefit	N	I-Claim
269	for	N	I-Claim
270	HCC	N	I-Claim
271	patients	N	I-Claim
272	treated	N	I-Claim
273	with	N	I-Claim
274	long-acting	N	I-Claim
275	octreotide	N	I-Claim
276	compared	N	I-Claim
277	with	N	I-Claim
278	placebo	N	I-Claim
279	.	N	I-Claim

1	This	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	evaluate	N	O
7	the	N	O
8	impact	N	O
9	of	N	O
10	laparoscopic	N	O
11	rectal	N	O
12	resection	N	O
13	on	N	O
14	short-term	N	O
15	postoperative	N	O
16	morbidity	N	O
17	and	N	O
18	costs	N	O
19	.	N	O

20	A	N	O
21	total	N	O
22	of	N	O
23	168	N	O
24	patients	N	O
25	with	N	O
26	rectal	N	O
27	cancer	N	O
28	were	N	O
29	randomly	N	O
30	assigned	N	O
31	to	N	O
32	laparoscopic	N	O
33	(	N	O
34	n	N	O
35	=	N	O
36	83	N	O
37	)	N	O
38	or	N	O
39	open	N	O
40	(	N	O
41	n	N	O
42	=	N	O
43	85	N	O
44	)	N	O
45	resection	N	O
46	.	N	O

47	Outcome	N	O
48	parameters	N	O
49	were	N	O
50	:	N	O
51	postoperative	N	O
52	morbidity	N	O
53	,	N	O
54	length	N	O
55	of	N	O
56	hospital	N	O
57	stay	N	O
58	,	N	O
59	quality	N	O
60	of	N	O
61	life	N	O
62	,	N	O
63	long-term	N	O
64	survival	N	O
65	,	N	O
66	and	N	O
67	local	N	O
68	recurrences	N	O
69	.	N	O

70	The	N	O
71	mean	N	O
72	follow-up	N	O
73	period	N	O
74	was	N	O
75	53.6	N	O
76	months	N	O
77	.	N	O

78	Cost-benefit	N	O
79	analysis	N	O
80	was	N	O
81	based	N	O
82	on	N	O
83	hospital	N	O
84	costs	N	O
85	.	N	O

86	Operative	N	I-Premise
87	time	N	I-Premise
88	was	N	I-Premise
89	53	N	I-Premise
90	minutes	N	I-Premise
91	longer	N	I-Premise
92	in	N	I-Premise
93	the	N	I-Premise
94	laparoscopic	N	I-Premise
95	group	N	I-Premise
96	(	N	I-Premise
97	P	N	I-Premise
98	<	N	I-Premise
99	0.0001	N	I-Premise
100	)	N	I-Premise
101	.	N	I-Premise

102	Postoperative	N	I-Premise
103	morbidity	N	I-Premise
104	rate	N	I-Premise
105	was	N	I-Premise
106	28.9	N	I-Premise
107	percent	N	I-Premise
108	in	N	I-Premise
109	the	N	I-Premise
110	laparoscopic	N	I-Premise
111	vs.	N	I-Premise
112	40	N	I-Premise
113	percent	N	I-Premise
114	in	N	I-Premise
115	the	N	I-Premise
116	open	N	I-Premise
117	group	N	I-Premise
118	(	N	I-Premise
119	P	N	I-Premise
120	=	N	I-Premise
121	0.18	N	I-Premise
122	)	N	I-Premise
123	.	N	I-Premise

124	The	N	I-Premise
125	mean	N	I-Premise
126	length	N	I-Premise
127	of	N	I-Premise
128	hospital	N	I-Premise
129	stay	N	I-Premise
130	was	N	I-Premise
131	10	N	I-Premise
132	(	N	I-Premise
133	4.9	N	I-Premise
134	)	N	I-Premise
135	days	N	I-Premise
136	in	N	I-Premise
137	the	N	I-Premise
138	laparoscopic	N	I-Premise
139	group	N	I-Premise
140	and	N	I-Premise
141	13.6	N	I-Premise
142	(	N	I-Premise
143	10	N	I-Premise
144	)	N	I-Premise
145	days	N	I-Premise
146	in	N	I-Premise
147	the	N	I-Premise
148	open	N	I-Premise
149	group	N	I-Premise
150	(	N	I-Premise
151	P	N	I-Premise
152	=	N	I-Premise
153	0.004	N	I-Premise
154	)	N	I-Premise
155	.	N	I-Premise

156	Local	N	I-Premise
157	recurrence	N	I-Premise
158	rate	N	I-Premise
159	and	N	I-Premise
160	five-year	N	I-Premise
161	survival	N	I-Premise
162	were	N	I-Premise
163	similar	N	I-Premise
164	in	N	I-Premise
165	both	N	I-Premise
166	groups	N	I-Premise
167	;	N	I-Premise
168	however	N	I-Claim
169	,	N	I-Claim
170	the	N	I-Claim
171	limited	N	I-Claim
172	number	N	I-Claim
173	of	N	I-Claim
174	patients	N	I-Claim
175	does	N	I-Claim
176	not	N	I-Claim
177	allow	N	I-Claim
178	firm	N	I-Claim
179	conclusions	N	I-Claim
180	.	N	I-Claim

181	Quality	N	I-Premise
182	of	N	I-Premise
183	life	N	I-Premise
184	was	N	I-Premise
185	better	N	I-Premise
186	in	N	I-Premise
187	the	N	I-Premise
188	laparoscopic	N	I-Premise
189	group	N	I-Premise
190	only	N	I-Premise
191	in	N	I-Premise
192	the	N	I-Premise
193	first	N	I-Premise
194	year	N	I-Premise
195	after	N	I-Premise
196	surgery	N	I-Premise
197	(	N	I-Premise
198	P	N	I-Premise
199	<	N	I-Premise
200	0.0001	N	I-Premise
201	)	N	I-Premise
202	.	N	I-Premise

203	The	N	I-Premise
204	additional	N	I-Premise
205	charge	N	I-Premise
206	in	N	I-Premise
207	the	N	I-Premise
208	laparoscopic	N	I-Premise
209	group	N	I-Premise
210	was	N	I-Premise
211	$	N	I-Premise
212	1,748	N	I-Premise
213	per	N	I-Premise
214	patient	N	I-Premise
215	randomized	N	I-Premise
216	(	N	I-Premise
217	$	N	I-Premise
218	1,194	N	I-Premise
219	the	N	I-Premise
220	result	N	I-Premise
221	of	N	I-Premise
222	surgical	N	I-Premise
223	instruments	N	I-Premise
224	and	N	I-Premise
225	$	N	I-Premise
226	554	N	I-Premise
227	the	N	I-Premise
228	result	N	I-Premise
229	of	N	I-Premise
230	longer	N	I-Premise
231	operative	N	I-Premise
232	time	N	I-Premise
233	)	N	I-Premise
234	.	N	I-Premise

235	The	N	I-Premise
236	saving	N	I-Premise
237	in	N	I-Premise
238	the	N	I-Premise
239	laparoscopic	N	I-Premise
240	group	N	I-Premise
241	was	N	I-Premise
242	$	N	I-Premise
243	1,396	N	I-Premise
244	per	N	I-Premise
245	patient	N	I-Premise
246	randomized	N	I-Premise
247	(	N	I-Premise
248	$	N	I-Premise
249	647	N	I-Premise
250	the	N	I-Premise
251	result	N	I-Premise
252	of	N	I-Premise
253	shorter	N	I-Premise
254	length	N	I-Premise
255	of	N	I-Premise
256	hospital	N	I-Premise
257	stay	N	I-Premise
258	and	N	I-Premise
259	$	N	I-Premise
260	749	N	I-Premise
261	the	N	I-Premise
262	result	N	I-Premise
263	of	N	I-Premise
264	the	N	I-Premise
265	lower	N	I-Premise
266	cost	N	I-Premise
267	of	N	I-Premise
268	postoperative	N	I-Premise
269	complications	N	I-Premise
270	)	N	I-Premise
271	.	N	I-Premise

272	The	N	I-Premise
273	net	N	I-Premise
274	balance	N	I-Premise
275	resulted	N	I-Premise
276	in	N	I-Premise
277	$	N	I-Premise
278	351	N	I-Premise
279	extra	N	I-Premise
280	cost	N	I-Premise
281	per	N	I-Premise
282	patient	N	I-Premise
283	randomly	N	I-Premise
284	allocated	N	I-Premise
285	to	N	I-Premise
286	the	N	I-Premise
287	laparoscopic	N	I-Premise
288	group	N	I-Premise
289	.	N	I-Premise

290	Short-term	N	I-Claim
291	postoperative	N	I-Claim
292	morbidity	N	I-Claim
293	was	N	I-Claim
294	similar	N	I-Claim
295	in	N	I-Claim
296	the	N	I-Claim
297	two	N	I-Claim
298	groups	N	I-Claim
299	.	N	I-Claim

300	Laparoscopic	N	I-Claim
301	resection	N	I-Claim
302	reduced	N	I-Claim
303	length	N	I-Claim
304	of	N	I-Claim
305	hospital	N	I-Claim
306	stay	N	I-Claim
307	,	N	I-Claim
308	improved	N	I-Claim
309	first-year	N	I-Claim
310	quality	N	I-Claim
311	of	N	I-Claim
312	life	N	I-Claim
313	,	N	I-Claim
314	and	N	I-Claim
315	slightly	N	I-Claim
316	increased	N	I-Claim
317	hospital	N	I-Claim
318	costs	N	I-Claim
319	.	N	I-Claim

1	The	N	I-MajorClaim
2	efficacy	N	I-MajorClaim
3	and	N	I-MajorClaim
4	safety	N	I-MajorClaim
5	of	N	I-MajorClaim
6	uterine-artery	N	I-MajorClaim
7	embolization	N	I-MajorClaim
8	,	N	I-MajorClaim
9	as	N	I-MajorClaim
10	compared	N	I-MajorClaim
11	with	N	I-MajorClaim
12	standard	N	I-MajorClaim
13	surgical	N	I-MajorClaim
14	methods	N	I-MajorClaim
15	,	N	I-MajorClaim
16	for	N	I-MajorClaim
17	the	N	I-MajorClaim
18	treatment	N	I-MajorClaim
19	of	N	I-MajorClaim
20	symptomatic	N	I-MajorClaim
21	uterine	N	I-MajorClaim
22	fibroids	N	I-MajorClaim
23	remain	N	I-MajorClaim
24	uncertain	N	I-MajorClaim
25	.	N	I-MajorClaim

26	We	N	O
27	conducted	N	O
28	a	N	O
29	randomized	N	O
30	trial	N	O
31	comparing	N	O
32	uterine-artery	N	O
33	embolization	N	O
34	and	N	O
35	surgery	N	O
36	in	N	O
37	women	N	O
38	with	N	O
39	symptomatic	N	O
40	uterine	N	O
41	fibroids	N	O
42	.	N	O

43	The	N	O
44	primary	N	O
45	outcome	N	O
46	was	N	O
47	quality	N	O
48	of	N	O
49	life	N	O
50	at	N	O
51	1	N	O
52	year	N	O
53	of	N	O
54	follow-up	N	O
55	,	N	O
56	as	N	O
57	measured	N	O
58	by	N	O
59	the	N	O
60	Medical	N	O
61	Outcomes	N	O
62	Study	N	O
63	36-Item	N	O
64	Short-Form	N	O
65	General	N	O
66	Health	N	O
67	Survey	N	O
68	(	N	O
69	SF-36	N	O
70	)	N	O
71	.	N	O

72	Patients	N	O
73	were	N	O
74	randomly	N	O
75	assigned	N	O
76	in	N	O
77	a	N	O
78	2:1	N	O
79	ratio	N	O
80	to	N	O
81	undergo	N	O
82	either	N	O
83	uterine-artery	N	O
84	embolization	N	O
85	or	N	O
86	surgery	N	O
87	,	N	O
88	with	N	O
89	106	N	O
90	patients	N	O
91	undergoing	N	O
92	embolization	N	O
93	and	N	O
94	51	N	O
95	undergoing	N	O
96	surgery	N	O
97	(	N	O
98	43	N	O
99	hysterectomies	N	O
100	and	N	O
101	8	N	O
102	myomectomies	N	O
103	)	N	O
104	.	N	O

105	There	N	I-Premise
106	were	N	I-Premise
107	no	N	I-Premise
108	significant	N	I-Premise
109	differences	N	I-Premise
110	between	N	I-Premise
111	groups	N	I-Premise
112	in	N	I-Premise
113	any	N	I-Premise
114	of	N	I-Premise
115	the	N	I-Premise
116	eight	N	I-Premise
117	components	N	I-Premise
118	of	N	I-Premise
119	the	N	I-Premise
120	SF-36	N	I-Premise
121	scores	N	I-Premise
122	at	N	I-Premise
123	1	N	I-Premise
124	year	N	I-Premise
125	.	N	I-Premise

126	The	N	I-Premise
127	embolization	N	I-Premise
128	group	N	I-Premise
129	had	N	I-Premise
130	a	N	I-Premise
131	shorter	N	I-Premise
132	median	N	I-Premise
133	duration	N	I-Premise
134	of	N	I-Premise
135	hospitalization	N	I-Premise
136	than	N	I-Premise
137	the	N	I-Premise
138	surgical	N	I-Premise
139	group	N	I-Premise
140	(	N	I-Premise
141	1	N	I-Premise
142	day	N	I-Premise
143	vs.	N	I-Premise
144	5	N	I-Premise
145	days	N	I-Premise
146	,	N	I-Premise
147	P	N	I-Premise
148	<	N	I-Premise
149	0.001	N	I-Premise
150	)	N	I-Premise
151	and	N	I-Premise
152	a	N	I-Premise
153	shorter	N	I-Premise
154	time	N	I-Premise
155	before	N	I-Premise
156	returning	N	I-Premise
157	to	N	I-Premise
158	work	N	I-Premise
159	(	N	I-Premise
160	P	N	I-Premise
161	<	N	I-Premise
162	0.001	N	I-Premise
163	)	N	I-Premise
164	.	N	I-Premise

165	At	N	I-Premise
166	1	N	I-Premise
167	year	N	I-Premise
168	,	N	I-Premise
169	symptom	N	I-Premise
170	scores	N	I-Premise
171	were	N	I-Premise
172	better	N	I-Premise
173	in	N	I-Premise
174	the	N	I-Premise
175	surgical	N	I-Premise
176	group	N	I-Premise
177	(	N	I-Premise
178	P=0.03	N	I-Premise
179	)	N	I-Premise
180	.	N	I-Premise

181	During	N	I-Premise
182	the	N	I-Premise
183	first	N	I-Premise
184	year	N	I-Premise
185	of	N	I-Premise
186	follow-up	N	I-Premise
187	,	N	I-Premise
188	there	N	I-Premise
189	were	N	I-Premise
190	13	N	I-Premise
191	major	N	I-Premise
192	adverse	N	I-Premise
193	events	N	I-Premise
194	in	N	I-Premise
195	the	N	I-Premise
196	embolization	N	I-Premise
197	group	N	I-Premise
198	(	N	I-Premise
199	12	N	I-Premise
200	%	N	I-Premise
201	)	N	I-Premise
202	and	N	I-Premise
203	10	N	I-Premise
204	in	N	I-Premise
205	the	N	I-Premise
206	surgical	N	I-Premise
207	group	N	I-Premise
208	(	N	I-Premise
209	20	N	I-Premise
210	%	N	I-Premise
211	)	N	I-Premise
212	(	N	I-Premise
213	P=0.22	N	I-Premise
214	)	N	I-Premise
215	,	N	I-Premise
216	mostly	N	I-Premise
217	related	N	I-Premise
218	to	N	I-Premise
219	the	N	I-Premise
220	intervention	N	I-Premise
221	.	N	I-Premise

222	Ten	N	I-Premise
223	patients	N	I-Premise
224	in	N	I-Premise
225	the	N	I-Premise
226	embolization	N	I-Premise
227	group	N	I-Premise
228	(	N	I-Premise
229	9	N	I-Premise
230	%	N	I-Premise
231	)	N	I-Premise
232	required	N	I-Premise
233	repeated	N	I-Premise
234	embolization	N	I-Premise
235	or	N	I-Premise
236	hysterectomy	N	I-Premise
237	for	N	I-Premise
238	inadequate	N	I-Premise
239	symptom	N	I-Premise
240	control	N	I-Premise
241	.	N	I-Premise

242	After	N	I-Premise
243	the	N	I-Premise
244	first	N	I-Premise
245	year	N	I-Premise
246	of	N	I-Premise
247	follow-up	N	I-Premise
248	,	N	I-Premise
249	14	N	I-Premise
250	women	N	I-Premise
251	in	N	I-Premise
252	the	N	I-Premise
253	embolization	N	I-Premise
254	group	N	I-Premise
255	(	N	I-Premise
256	13	N	I-Premise
257	%	N	I-Premise
258	)	N	I-Premise
259	required	N	I-Premise
260	hospitalization	N	I-Premise
261	,	N	I-Premise
262	3	N	I-Premise
263	of	N	I-Premise
264	them	N	I-Premise
265	for	N	I-Premise
266	major	N	I-Premise
267	adverse	N	I-Premise
268	events	N	I-Premise
269	and	N	I-Premise
270	11	N	I-Premise
271	for	N	I-Premise
272	reintervention	N	I-Premise
273	for	N	I-Premise
274	treatment	N	I-Premise
275	failure	N	I-Premise
276	.	N	I-Premise

277	In	N	I-Claim
278	women	N	I-Claim
279	with	N	I-Claim
280	symptomatic	N	I-Claim
281	fibroids	N	I-Claim
282	,	N	I-Claim
283	the	N	I-Claim
284	faster	N	I-Claim
285	recovery	N	I-Claim
286	after	N	I-Claim
287	embolization	N	I-Claim
288	must	N	I-Claim
289	be	N	I-Claim
290	weighed	N	I-Claim
291	against	N	I-Claim
292	the	N	I-Claim
293	need	N	I-Claim
294	for	N	I-Claim
295	further	N	I-Claim
296	treatment	N	I-Claim
297	in	N	I-Claim
298	a	N	I-Claim
299	minority	N	I-Claim
300	of	N	I-Claim
301	patients	N	I-Claim
302	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	functional	N	O
4	and	N	O
5	psychological	N	O
6	benefits	N	O
7	of	N	O
8	a	N	O
9	12	N	O
10	week	N	O
11	supervised	N	O
12	group	N	O
13	exercise	N	O
14	programme	N	O
15	during	N	O
16	treatment	N	O
17	for	N	O
18	early	N	O
19	stage	N	O
20	breast	N	O
21	cancer	N	O
22	,	N	O
23	with	N	O
24	six	N	O
25	month	N	O
26	follow-up	N	O
27	.	N	O

28	Pragmatic	N	O
29	randomised	N	O
30	controlled	N	O
31	prospective	N	O
32	open	N	O
33	trial	N	O
34	.	N	O

35	Three	N	O
36	National	N	O
37	Health	N	O
38	Service	N	O
39	oncology	N	O
40	clinics	N	O
41	in	N	O
42	Scotland	N	O
43	and	N	O
44	community	N	O
45	exercise	N	O
46	facilities	N	O
47	.	N	O

48	203	N	O
49	women	N	O
50	entered	N	O
51	the	N	O
52	study	N	O
53	;	N	O
54	177	N	O
55	completed	N	O
56	the	N	O
57	six	N	O
58	month	N	O
59	follow-up	N	O
60	.	N	O

61	Supervised	N	O
62	12	N	O
63	week	N	O
64	group	N	O
65	exercise	N	O
66	programme	N	O
67	in	N	O
68	addition	N	O
69	to	N	O
70	usual	N	O
71	care	N	O
72	,	N	O
73	compared	N	O
74	with	N	O
75	usual	N	O
76	care	N	O
77	.	N	O

78	Functional	N	O
79	assessment	N	O
80	of	N	O
81	cancer	N	O
82	therapy	N	O
83	(	N	O
84	FACT	N	O
85	)	N	O
86	questionnaire	N	O
87	,	N	O
88	Beck	N	O
89	depression	N	O
90	inventory	N	O
91	,	N	O
92	positive	N	O
93	and	N	O
94	negative	N	O
95	affect	N	O
96	scale	N	O
97	,	N	O
98	body	N	O
99	mass	N	O
100	index	N	O
101	,	N	O
102	seven	N	O
103	day	N	O
104	recall	N	O
105	of	N	O
106	physical	N	O
107	activity	N	O
108	,	N	O
109	12	N	O
110	minute	N	O
111	walk	N	O
112	test	N	O
113	,	N	O
114	and	N	O
115	assessment	N	O
116	of	N	O
117	shoulder	N	O
118	mobility	N	O
119	.	N	O

120	Mixed	N	I-Premise
121	effects	N	I-Premise
122	models	N	I-Premise
123	with	N	I-Premise
124	adjustment	N	I-Premise
125	for	N	I-Premise
126	baseline	N	I-Premise
127	values	N	I-Premise
128	,	N	I-Premise
129	study	N	I-Premise
130	site	N	I-Premise
131	,	N	I-Premise
132	treatment	N	I-Premise
133	at	N	I-Premise
134	baseline	N	I-Premise
135	,	N	I-Premise
136	and	N	I-Premise
137	age	N	I-Premise
138	gave	N	I-Premise
139	intervention	N	I-Premise
140	effect	N	I-Premise
141	estimates	N	I-Premise
142	(	N	I-Premise
143	intervention	N	I-Premise
144	minus	N	I-Premise
145	control	N	I-Premise
146	)	N	I-Premise
147	at	N	I-Premise
148	12	N	I-Premise
149	weeks	N	I-Premise
150	of	N	I-Premise
151	129	N	I-Premise
152	(	N	I-Premise
153	95	N	I-Premise
154	%	N	I-Premise
155	confidence	N	I-Premise
156	interval	N	I-Premise
157	83	N	I-Premise
158	to	N	I-Premise
159	176	N	I-Premise
160	)	N	I-Premise
161	for	N	I-Premise
162	metres	N	I-Premise
163	walked	N	I-Premise
164	in	N	I-Premise
165	12	N	I-Premise
166	minutes	N	I-Premise
167	,	N	I-Premise
168	182	N	I-Premise
169	(	N	I-Premise
170	75	N	I-Premise
171	to	N	I-Premise
172	289	N	I-Premise
173	)	N	I-Premise
174	for	N	I-Premise
175	minutes	N	I-Premise
176	of	N	I-Premise
177	moderate	N	I-Premise
178	intensity	N	I-Premise
179	activity	N	I-Premise
180	reported	N	I-Premise
181	in	N	I-Premise
182	a	N	I-Premise
183	week	N	I-Premise
184	,	N	I-Premise
185	2.6	N	I-Premise
186	(	N	I-Premise
187	1.6	N	I-Premise
188	to	N	I-Premise
189	3.7	N	I-Premise
190	)	N	I-Premise
191	for	N	I-Premise
192	shoulder	N	I-Premise
193	mobility	N	I-Premise
194	,	N	I-Premise
195	2.5	N	I-Premise
196	(	N	I-Premise
197	1.0	N	I-Premise
198	to	N	I-Premise
199	3.9	N	I-Premise
200	)	N	I-Premise
201	for	N	I-Premise
202	breast	N	I-Premise
203	cancer	N	I-Premise
204	specific	N	I-Premise
205	subscale	N	I-Premise
206	of	N	I-Premise
207	quality	N	I-Premise
208	of	N	I-Premise
209	life	N	I-Premise
210	,	N	I-Premise
211	and	N	I-Premise
212	4.0	N	I-Premise
213	(	N	I-Premise
214	1.8	N	I-Premise
215	to	N	I-Premise
216	6.3	N	I-Premise
217	)	N	I-Premise
218	for	N	I-Premise
219	positive	N	I-Premise
220	mood	N	I-Premise
221	.	N	I-Premise

222	No	N	I-Premise
223	significant	N	I-Premise
224	effect	N	I-Premise
225	was	N	I-Premise
226	seen	N	I-Premise
227	for	N	I-Premise
228	general	N	I-Premise
229	quality	N	I-Premise
230	of	N	I-Premise
231	life	N	I-Premise
232	(	N	I-Premise
233	FACT-G	N	I-Premise
234	)	N	I-Premise
235	,	N	I-Premise
236	which	N	I-Premise
237	was	N	I-Premise
238	the	N	I-Premise
239	primary	N	I-Premise
240	outcome	N	I-Premise
241	.	N	I-Premise

242	At	N	I-Premise
243	the	N	I-Premise
244	six	N	I-Premise
245	month	N	I-Premise
246	follow-up	N	I-Premise
247	,	N	I-Premise
248	most	N	I-Premise
249	of	N	I-Premise
250	these	N	I-Premise
251	effects	N	I-Premise
252	were	N	I-Premise
253	maintained	N	I-Premise
254	and	N	I-Premise
255	an	N	I-Premise
256	intervention	N	I-Premise
257	effect	N	I-Premise
258	for	N	I-Premise
259	breast	N	I-Premise
260	cancer	N	I-Premise
261	specific	N	I-Premise
262	quality	N	I-Premise
263	of	N	I-Premise
264	life	N	I-Premise
265	emerged	N	I-Premise
266	.	N	I-Premise

267	No	N	I-Premise
268	adverse	N	I-Premise
269	effects	N	I-Premise
270	were	N	I-Premise
271	noted	N	I-Premise
272	.	N	I-Premise

273	Supervised	N	I-Claim
274	group	N	I-Claim
275	exercise	N	I-Claim
276	provided	N	I-Claim
277	functional	N	I-Claim
278	and	N	I-Claim
279	psychological	N	I-Claim
280	benefit	N	I-Claim
281	after	N	I-Claim
282	a	N	I-Claim
283	12	N	I-Claim
284	week	N	I-Claim
285	intervention	N	I-Claim
286	and	N	I-Claim
287	six	N	I-Claim
288	months	N	I-Claim
289	later	N	I-Claim
290	.	N	I-Claim

291	Clinicians	N	I-Claim
292	should	N	I-Claim
293	encourage	N	I-Claim
294	activity	N	I-Claim
295	for	N	I-Claim
296	their	N	I-Claim
297	patients	N	I-Claim
298	.	N	I-Claim

299	Policy	N	I-Claim
300	makers	N	I-Claim
301	should	N	I-Claim
302	consider	N	I-Claim
303	the	N	I-Claim
304	inclusion	N	I-Claim
305	of	N	I-Claim
306	exercise	N	I-Claim
307	opportunities	N	I-Claim
308	in	N	I-Claim
309	cancer	N	I-Claim
310	rehabilitation	N	I-Claim
311	services	N	I-Claim
312	.	N	I-Claim

1	Previous	N	I-Claim
2	trials	N	I-Claim
3	have	N	I-Claim
4	suggested	N	I-Claim
5	a	N	I-Claim
6	quality-of-life	N	I-Claim
7	(	N	I-Claim
8	QOL	N	I-Claim
9	)	N	I-Claim
10	improvement	N	I-Claim
11	for	N	I-Claim
12	anemic	N	I-Claim
13	cancer	N	I-Claim
14	patients	N	I-Claim
15	treated	N	I-Claim
16	with	N	I-Claim
17	erythropoietin	N	I-Claim
18	,	N	I-Claim
19	but	N	I-Claim
20	few	N	I-Claim
21	used	N	I-Claim
22	QOL	N	I-Claim
23	as	N	I-Claim
24	the	N	I-Claim
25	primary	N	I-Claim
26	outcome	N	I-Claim
27	.	N	I-Claim

28	We	N	O
29	designed	N	O
30	a	N	O
31	trial	N	O
32	to	N	O
33	investigate	N	O
34	the	N	O
35	effects	N	O
36	of	N	O
37	epoetin	N	O
38	alfa	N	O
39	therapy	N	O
40	on	N	O
41	the	N	O
42	QOL	N	O
43	of	N	O
44	anemic	N	O
45	patients	N	O
46	with	N	O
47	advanced	N	O
48	non-small-cell	N	O
49	carcinoma	N	O
50	of	N	O
51	the	N	O
52	lung	N	O
53	(	N	O
54	NSCLC	N	O
55	)	N	O
56	.	N	O

57	A	N	O
58	multicenter	N	O
59	,	N	O
60	randomized	N	O
61	,	N	O
62	double-blind	N	O
63	,	N	O
64	placebo-controlled	N	O
65	trial	N	O
66	was	N	O
67	conducted	N	O
68	.	N	O

69	The	N	O
70	proposed	N	O
71	sample	N	O
72	size	N	O
73	was	N	O
74	300	N	O
75	patients	N	O
76	.	N	O

77	Eligible	N	O
78	patients	N	O
79	were	N	O
80	required	N	O
81	to	N	O
82	have	N	O
83	NSCLC	N	O
84	unsuitable	N	O
85	for	N	O
86	curative	N	O
87	therapy	N	O
88	and	N	O
89	baseline	N	O
90	hemoglobin	N	O
91	(	N	O
92	Hgb	N	O
93	)	N	O
94	levels	N	O
95	less	N	O
96	than	N	O
97	121	N	O
98	g/L	N	O
99	.	N	O

100	Patients	N	O
101	were	N	O
102	assigned	N	O
103	to	N	O
104	12	N	O
105	weekly	N	O
106	injections	N	O
107	of	N	O
108	subcutaneous	N	O
109	epoetin	N	O
110	alpha	N	O
111	or	N	O
112	placebo	N	O
113	,	N	O
114	targeting	N	O
115	Hgb	N	O
116	levels	N	O
117	between	N	O
118	120	N	O
119	and	N	O
120	140	N	O
121	g/L	N	O
122	.	N	O

123	The	N	O
124	primary	N	O
125	outcome	N	O
126	was	N	O
127	the	N	O
128	difference	N	O
129	in	N	O
130	the	N	O
131	change	N	O
132	in	N	O
133	Functional	N	O
134	Assessment	N	O
135	of	N	O
136	Cancer	N	O
137	Therapy-Anemia	N	O
138	scores	N	O
139	between	N	O
140	baseline	N	O
141	and	N	O
142	12	N	O
143	weeks	N	O
144	.	N	O

145	Reports	N	O
146	of	N	O
147	thrombotic	N	O
148	events	N	O
149	in	N	O
150	other	N	O
151	epoetin	N	O
152	trials	N	O
153	prompted	N	O
154	an	N	O
155	unplanned	N	O
156	safety	N	O
157	analysis	N	O
158	after	N	O
159	70	N	O
160	patients	N	O
161	had	N	O
162	been	N	O
163	randomly	N	O
164	assigned	N	O
165	(	N	O
166	33	N	O
167	to	N	O
168	the	N	O
169	active	N	O
170	arm	N	O
171	and	N	O
172	37	N	O
173	to	N	O
174	the	N	O
175	placebo	N	O
176	arm	N	O
177	)	N	O
178	.	N	O

179	This	N	I-Premise
180	revealed	N	I-Premise
181	a	N	I-Premise
182	significant	N	I-Premise
183	difference	N	I-Premise
184	in	N	I-Premise
185	the	N	I-Premise
186	median	N	I-Premise
187	survival	N	I-Premise
188	in	N	I-Premise
189	favor	N	I-Premise
190	of	N	I-Premise
191	the	N	I-Premise
192	patients	N	I-Premise
193	on	N	I-Premise
194	the	N	I-Premise
195	placebo	N	I-Premise
196	arm	N	I-Premise
197	of	N	I-Premise
198	the	N	I-Premise
199	trial	N	I-Premise
200	(	N	I-Premise
201	63	N	I-Premise
202	v	N	I-Premise
203	129	N	I-Premise
204	days	N	I-Premise
205	;	N	I-Premise
206	hazard	N	I-Premise
207	ratio	N	I-Premise
208	,	N	I-Premise
209	1.84	N	I-Premise
210	;	N	I-Premise
211	P	N	I-Premise
212	=	N	I-Premise
213	.04	N	I-Premise
214	)	N	I-Premise
215	.	N	I-Premise

216	The	N	O
217	Steering	N	O
218	Committee	N	O
219	closed	N	O
220	the	N	O
221	trial	N	O
222	.	N	O

223	Patient	N	I-Premise
224	numbers	N	I-Premise
225	compromised	N	I-Premise
226	the	N	I-Premise
227	interpretation	N	I-Premise
228	of	N	I-Premise
229	the	N	I-Premise
230	QOL	N	I-Premise
231	analysis	N	I-Premise
232	,	N	I-Premise
233	but	N	O
234	a	N	I-Premise
235	positive	N	I-Premise
236	Hgb	N	I-Premise
237	response	N	I-Premise
238	was	N	I-Premise
239	noted	N	I-Premise
240	with	N	I-Premise
241	epoetin	N	I-Premise
242	alfa	N	I-Premise
243	treatment	N	I-Premise
244	.	N	I-Premise

245	An	N	I-Claim
246	unplanned	N	I-Claim
247	safety	N	I-Claim
248	analysis	N	I-Claim
249	suggested	N	I-Claim
250	decreased	N	I-Claim
251	overall	N	I-Claim
252	survival	N	I-Claim
253	in	N	I-Claim
254	patients	N	I-Claim
255	with	N	I-Claim
256	advanced	N	I-Claim
257	NSCLC	N	I-Claim
258	treated	N	I-Claim
259	with	N	I-Claim
260	epoetin	N	I-Claim
261	alfa	N	I-Claim
262	.	N	I-Claim

263	Although	N	O
264	infrequent	N	O
265	,	N	O
266	other	N	O
267	similar	N	O
268	reports	N	O
269	highlight	N	O
270	the	N	O
271	need	N	O
272	for	N	O
273	ongoing	N	O
274	trials	N	O
275	evaluating	N	O
276	erythropoietin	N	O
277	receptor	N	O
278	agonists	N	O
279	to	N	O
280	ensure	N	O
281	that	N	O
282	overall	N	O
283	survival	N	O
284	is	N	O
285	monitored	N	O
286	closely	N	O
287	.	N	O

1	A	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	previously	N	O
6	conducted	N	O
7	in	N	O
8	radiation	N	O
9	oncology	N	O
10	patients	N	O
11	demonstrated	N	O
12	that	N	O
13	nutrition	N	O
14	intervention	N	O
15	had	N	O
16	a	N	O
17	beneficial	N	O
18	impact	N	O
19	on	N	O
20	body	N	O
21	weight	N	O
22	,	N	O
23	nutritional	N	O
24	status	N	O
25	,	N	O
26	and	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	compared	N	O
31	with	N	O
32	standard	N	O
33	practice	N	O
34	,	N	O
35	but	N	O
36	it	N	O
37	did	N	O
38	not	N	O
39	report	N	O
40	on	N	O
41	dietary	N	O
42	intake	N	O
43	data	N	O
44	.	N	O

45	To	N	O
46	determine	N	O
47	the	N	O
48	impact	N	O
49	of	N	O
50	nutrition	N	O
51	intervention	N	O
52	compared	N	O
53	with	N	O
54	standard	N	O
55	practice	N	O
56	on	N	O
57	dietary	N	O
58	intake	N	O
59	in	N	O
60	outpatients	N	O
61	receiving	N	O
62	radiotherapy	N	O
63	.	N	O

64	Prospective	N	O
65	,	N	O
66	randomized	N	O
67	,	N	O
68	controlled	N	O
69	trial	N	O
70	.	N	O

71	Sixty	N	O
72	consecutive	N	O
73	radiation	N	O
74	oncology	N	O
75	outpatients	N	O
76	(	N	O
77	51	N	O
78	men	N	O
79	and	N	O
80	nine	N	O
81	women	N	O
82	;	N	O
83	age	N	O
84	61.9+/-14	N	O
85	years	N	O
86	[	N	O
87	mean+/-standard	N	O
88	deviation	N	O
89	]	N	O
90	)	N	O
91	.	N	O

92	Australian	N	O
93	private	N	O
94	radiotherapy	N	O
95	facility	N	O
96	.	N	O

97	Patients	N	O
98	were	N	O
99	randomly	N	O
100	assigned	N	O
101	to	N	O
102	receive	N	O
103	either	N	O
104	nutrition	N	O
105	intervention	N	O
106	(	N	O
107	n=29	N	O
108	)	N	O
109	(	N	O
110	nutrition	N	O
111	counseling	N	O
112	following	N	O
113	the	N	O
114	American	N	O
115	Dietetic	N	O
116	Association	N	O
117	[	N	O
118	ADA	N	O
119	]	N	O
120	medical	N	O
121	nutrition	N	O
122	therapy	N	O
123	[	N	O
124	MNT	N	O
125	]	N	O
126	protocol	N	O
127	for	N	O
128	radiation	N	O
129	oncology	N	O
130	)	N	O
131	or	N	O
132	standard	N	O
133	practice	N	O
134	(	N	O
135	n=31	N	O
136	)	N	O
137	(	N	O
138	general	N	O
139	nutrition	N	O
140	talk	N	O
141	and	N	O
142	booklet	N	O
143	)	N	O
144	.	N	O

145	Dietary	N	O
146	intake	N	O
147	(	N	O
148	protein	N	O
149	,	N	O
150	energy	N	O
151	,	N	O
152	fiber	N	O
153	)	N	O
154	assessed	N	O
155	at	N	O
156	baseline	N	O
157	and	N	O
158	at	N	O
159	4	N	O
160	,	N	O
161	8	N	O
162	,	N	O
163	and	N	O
164	12	N	O
165	weeks	N	O
166	after	N	O
167	starting	N	O
168	radiotherapy	N	O
169	.	N	O

170	Repeated-measures	N	O
171	analysis	N	O
172	of	N	O
173	variance	N	O
174	done	N	O
175	on	N	O
176	an	N	O
177	intention	N	O
178	to	N	O
179	treat	N	O
180	basis	N	O
181	.	N	O

182	The	N	I-Premise
183	nutrition	N	I-Premise
184	intervention	N	I-Premise
185	group	N	I-Premise
186	had	N	I-Premise
187	a	N	I-Premise
188	higher	N	I-Premise
189	mean	N	I-Premise
190	total	N	I-Premise
191	energy	N	I-Premise
192	(	N	I-Premise
193	P=0.029	N	I-Premise
194	)	N	I-Premise
195	and	N	I-Premise
196	protein	N	I-Premise
197	intake	N	I-Premise
198	(	N	I-Premise
199	P	N	I-Premise
200	<	N	I-Premise
201	0.001	N	I-Premise
202	)	N	I-Premise
203	compared	N	I-Premise
204	with	N	I-Premise
205	the	N	I-Premise
206	standard	N	I-Premise
207	practice	N	I-Premise
208	group	N	I-Premise
209	.	N	I-Premise

210	Mean	N	I-Premise
211	intake	N	I-Premise
212	per	N	I-Premise
213	kilogram	N	I-Premise
214	of	N	I-Premise
215	body	N	I-Premise
216	weight	N	I-Premise
217	for	N	I-Premise
218	the	N	I-Premise
219	nutrition	N	I-Premise
220	intervention	N	I-Premise
221	group	N	I-Premise
222	ranged	N	I-Premise
223	from	N	I-Premise
224	28	N	I-Premise
225	to	N	I-Premise
226	31	N	I-Premise
227	kcal/kg/day	N	I-Premise
228	compared	N	I-Premise
229	with	N	I-Premise
230	25	N	I-Premise
231	to	N	I-Premise
232	29	N	I-Premise
233	kcal/kg/day	N	I-Premise
234	for	N	I-Premise
235	the	N	I-Premise
236	standard	N	I-Premise
237	practice	N	I-Premise
238	group	N	I-Premise
239	(	N	I-Premise
240	P=0.022	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	The	N	I-Premise
244	nutrition	N	I-Premise
245	intervention	N	I-Premise
246	group	N	I-Premise
247	had	N	I-Premise
248	a	N	I-Premise
249	higher	N	I-Premise
250	mean	N	I-Premise
251	protein	N	I-Premise
252	intake	N	I-Premise
253	(	N	I-Premise
254	1.1	N	I-Premise
255	to	N	I-Premise
256	1.3	N	I-Premise
257	g/kg/day	N	I-Premise
258	)	N	I-Premise
259	compared	N	I-Premise
260	with	N	I-Premise
261	the	N	I-Premise
262	standard	N	I-Premise
263	practice	N	I-Premise
264	group	N	I-Premise
265	(	N	I-Premise
266	1.0	N	I-Premise
267	to	N	I-Premise
268	1.1	N	I-Premise
269	g/kg/day	N	I-Premise
270	)	N	I-Premise
271	(	N	I-Premise
272	P=0.001	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	Although	N	I-Premise
276	the	N	I-Premise
277	change	N	I-Premise
278	in	N	I-Premise
279	fiber	N	I-Premise
280	intake	N	I-Premise
281	between	N	I-Premise
282	the	N	I-Premise
283	groups	N	I-Premise
284	was	N	I-Premise
285	not	N	I-Premise
286	significant	N	I-Premise
287	,	N	I-Premise
288	there	N	I-Premise
289	was	N	I-Premise
290	a	N	I-Premise
291	trend	N	I-Premise
292	in	N	I-Premise
293	the	N	I-Premise
294	anticipated	N	I-Premise
295	direction	N	I-Premise
296	(	N	I-Premise
297	P=0.083	N	I-Premise
298	)	N	I-Premise
299	.	N	I-Premise

300	Intensive	N	I-Claim
301	nutrition	N	I-Claim
302	intervention	N	I-Claim
303	following	N	I-Claim
304	the	N	I-Claim
305	ADA	N	I-Claim
306	MNT	N	I-Claim
307	protocol	N	I-Claim
308	results	N	I-Claim
309	in	N	I-Claim
310	improved	N	I-Claim
311	dietary	N	I-Claim
312	intake	N	I-Claim
313	compared	N	I-Claim
314	with	N	I-Claim
315	standard	N	I-Claim
316	practice	N	I-Claim
317	and	N	I-Claim
318	seems	N	I-Claim
319	to	N	I-Claim
320	beneficially	N	I-Claim
321	impact	N	I-Claim
322	nutrition-related	N	I-Claim
323	outcomes	N	I-Claim
324	previously	N	I-Claim
325	observed	N	I-Claim
326	in	N	I-Claim
327	oncology	N	I-Claim
328	outpatients	N	I-Claim
329	receiving	N	I-Claim
330	radiotherapy	N	I-Claim
331	.	N	I-Claim

332	The	N	I-MajorClaim
333	ADA	N	I-MajorClaim
334	MNT	N	I-MajorClaim
335	protocol	N	I-MajorClaim
336	for	N	I-MajorClaim
337	radiation	N	I-MajorClaim
338	oncology	N	I-MajorClaim
339	is	N	I-MajorClaim
340	a	N	I-MajorClaim
341	useful	N	I-MajorClaim
342	guide	N	I-MajorClaim
343	to	N	I-MajorClaim
344	the	N	I-MajorClaim
345	level	N	I-MajorClaim
346	of	N	I-MajorClaim
347	nutrition	N	I-MajorClaim
348	support	N	I-MajorClaim
349	required	N	I-MajorClaim
350	.	N	I-MajorClaim

1	Imatinib	N	O
2	is	N	O
3	the	N	O
4	standard	N	O
5	treatment	N	O
6	of	N	O
7	advanced	N	O
8	GI	N	O
9	stromal	N	O
10	tumors	N	O
11	(	N	O
12	GISTs	N	O
13	)	N	O
14	.	N	O

15	It	N	I-Claim
16	is	N	I-Claim
17	not	N	I-Claim
18	known	N	I-Claim
19	whether	N	I-Claim
20	imatinib	N	I-Claim
21	may	N	I-Claim
22	be	N	I-Claim
23	stopped	N	I-Claim
24	in	N	I-Claim
25	patients	N	I-Claim
26	in	N	I-Claim
27	whom	N	I-Claim
28	disease	N	I-Claim
29	is	N	I-Claim
30	controlled	N	I-Claim
31	.	N	I-Claim

32	This	N	O
33	prospective	N	O
34	,	N	O
35	randomized	N	O
36	,	N	O
37	multicentric	N	O
38	phase	N	O
39	III	N	O
40	study	N	O
41	was	N	O
42	designed	N	O
43	to	N	O
44	compare	N	O
45	continuous	N	O
46	(	N	O
47	CONT	N	O
48	)	N	O
49	compared	N	O
50	with	N	O
51	interrupted	N	O
52	(	N	O
53	INT	N	O
54	)	N	O
55	imatinib	N	O
56	beyond	N	O
57	1	N	O
58	year	N	O
59	of	N	O
60	treatment	N	O
61	in	N	O
62	patients	N	O
63	with	N	O
64	advanced	N	O
65	GIST	N	O
66	.	N	O

67	The	N	O
68	primary	N	O
69	end	N	O
70	point	N	O
71	was	N	O
72	progression-free	N	O
73	survival	N	O
74	.	N	O

75	Secondary	N	O
76	end	N	O
77	points	N	O
78	included	N	O
79	overall	N	O
80	survival	N	O
81	,	N	O
82	response	N	O
83	rate	N	O
84	after	N	O
85	reinitiation	N	O
86	of	N	O
87	imatinib	N	O
88	,	N	O
89	and	N	O
90	quality	N	O
91	of	N	O
92	life	N	O
93	.	N	O

94	Early	N	O
95	stopping	N	O
96	rules	N	O
97	in	N	O
98	cases	N	O
99	of	N	O
100	rapid	N	O
101	progression	N	O
102	of	N	O
103	disease	N	O
104	were	N	O
105	defined	N	O
106	,	N	O
107	with	N	O
108	preplanned	N	O
109	interim	N	O
110	analyses	N	O
111	.	N	O

112	Between	N	O
113	May	N	O
114	2002	N	O
115	and	N	O
116	April	N	O
117	2004	N	O
118	,	N	O
119	182	N	O
120	patients	N	O
121	with	N	O
122	advanced	N	O
123	GIST	N	O
124	were	N	O
125	enrolled	N	O
126	.	N	O

127	Between	N	O
128	May	N	O
129	2003	N	O
130	and	N	O
131	April	N	O
132	2004	N	O
133	,	N	O
134	98	N	O
135	patients	N	O
136	in	N	O
137	response	N	O
138	or	N	O
139	stable	N	O
140	disease	N	O
141	under	N	O
142	imatinib	N	O
143	reached	N	O
144	more	N	O
145	than	N	O
146	1	N	O
147	year	N	O
148	of	N	O
149	follow-up	N	O
150	.	N	O

151	Forty	N	O
152	were	N	O
153	not	N	O
154	eligible	N	O
155	for	N	O
156	randomization	N	O
157	,	N	O
158	and	N	O
159	58	N	O
160	patients	N	O
161	were	N	O
162	randomly	N	O
163	assigned	N	O
164	,	N	O
165	32	N	O
166	and	N	O
167	26	N	O
168	patients	N	O
169	in	N	O
170	the	N	O
171	INT	N	O
172	and	N	O
173	CONT	N	O
174	arms	N	O
175	,	N	O
176	respectively	N	O
177	.	N	O

178	As	N	I-Premise
179	of	N	I-Premise
180	October	N	I-Premise
181	15	N	I-Premise
182	,	N	I-Premise
183	2005	N	I-Premise
184	,	N	I-Premise
185	eight	N	I-Premise
186	of	N	I-Premise
187	26	N	I-Premise
188	patients	N	I-Premise
189	in	N	I-Premise
190	the	N	I-Premise
191	CONT	N	I-Premise
192	group	N	I-Premise
193	and	N	I-Premise
194	26	N	I-Premise
195	of	N	I-Premise
196	32	N	I-Premise
197	patients	N	I-Premise
198	in	N	I-Premise
199	the	N	I-Premise
200	INT	N	I-Premise
201	group	N	I-Premise
202	had	N	I-Premise
203	documented	N	I-Premise
204	disease	N	I-Premise
205	progression	N	I-Premise
206	(	N	I-Premise
207	P	N	I-Premise
208	<	N	I-Premise
209	.0001	N	I-Premise
210	)	N	I-Premise
211	.	N	I-Premise

212	Twenty-four	N	I-Premise
213	of	N	I-Premise
214	26	N	I-Premise
215	patients	N	I-Premise
216	with	N	I-Premise
217	documented	N	I-Premise
218	progression	N	I-Premise
219	in	N	I-Premise
220	the	N	I-Premise
221	INT	N	I-Premise
222	arm	N	I-Premise
223	responded	N	I-Premise
224	to	N	I-Premise
225	imatinib	N	I-Premise
226	reintroduction	N	I-Premise
227	.	N	I-Premise

228	No	N	I-Premise
229	differences	N	I-Premise
230	in	N	I-Premise
231	overall	N	I-Premise
232	survival	N	I-Premise
233	or	N	I-Premise
234	imatinib	N	I-Premise
235	resistance	N	I-Premise
236	were	N	I-Premise
237	observed	N	I-Premise
238	between	N	I-Premise
239	the	N	I-Premise
240	two	N	I-Premise
241	arms	N	I-Premise
242	.	N	I-Premise

243	Quality	N	I-Premise
244	of	N	I-Premise
245	life	N	I-Premise
246	evaluated	N	I-Premise
247	6	N	I-Premise
248	months	N	I-Premise
249	after	N	I-Premise
250	random	N	I-Premise
251	assignment	N	I-Premise
252	using	N	I-Premise
253	the	N	I-Premise
254	30-item	N	I-Premise
255	Quality	N	I-Premise
256	of	N	I-Premise
257	Life	N	I-Premise
258	Questionnaire	N	I-Premise
259	was	N	I-Premise
260	not	N	I-Premise
261	significantly	N	I-Premise
262	different	N	I-Premise
263	between	N	I-Premise
264	the	N	I-Premise
265	two	N	I-Premise
266	groups	N	I-Premise
267	of	N	I-Premise
268	randomly	N	I-Premise
269	assigned	N	I-Premise
270	patients	N	I-Premise
271	.	N	I-Premise

272	Imatinib	N	I-Claim
273	interruption	N	I-Claim
274	results	N	I-Claim
275	in	N	I-Claim
276	rapid	N	I-Claim
277	progression	N	I-Claim
278	in	N	I-Claim
279	most	N	I-Claim
280	patients	N	I-Claim
281	with	N	I-Claim
282	advanced	N	I-Claim
283	GIST	N	I-Claim
284	,	N	I-Claim
285	and	N	I-Claim
286	can	N	I-Claim
287	not	N	I-Claim
288	be	N	I-Claim
289	recommended	N	I-Claim
290	in	N	I-Claim
291	routine	N	I-Claim
292	practice	N	I-Claim
293	unless	N	I-Claim
294	patient	N	I-Claim
295	experience	N	I-Claim
296	significant	N	I-Claim
297	toxicity	N	I-Claim
298	.	N	I-Claim

1	Psychological	N	I-Claim
2	interventions	N	I-Claim
3	are	N	I-Claim
4	efficacious	N	I-Claim
5	in	N	I-Claim
6	reducing	N	I-Claim
7	emotional	N	I-Claim
8	distress	N	I-Claim
9	for	N	I-Claim
10	cancer	N	I-Claim
11	patients	N	I-Claim
12	.	N	I-Claim

13	However	N	I-Claim
14	,	N	I-Claim
15	it	N	I-Claim
16	is	N	I-Claim
17	not	N	I-Claim
18	clear	N	I-Claim
19	whether	N	I-Claim
20	psychological	N	I-Claim
21	improvements	N	I-Claim
22	are	N	I-Claim
23	,	N	I-Claim
24	in	N	I-Claim
25	turn	N	I-Claim
26	,	N	I-Claim
27	related	N	I-Claim
28	to	N	I-Claim
29	improved	N	I-Claim
30	health	N	I-Claim
31	.	N	I-Claim

32	A	N	O
33	clinical	N	O
34	trial	N	O
35	tests	N	O
36	whether	N	O
37	a	N	O
38	psychological	N	O
39	intervention	N	O
40	for	N	O
41	cancer	N	O
42	patients	N	O
43	can	N	O
44	do	N	O
45	so	N	O
46	,	N	O
47	and	N	O
48	also	N	O
49	tests	N	O
50	two	N	O
51	routes	N	O
52	to	N	O
53	achieve	N	O
54	better	N	O
55	health	N	O
56	:	N	O
57	(	N	O
58	a	N	O
59	)	N	O
60	reducing	N	O
61	patients	N	O
62	'	N	O
63	Emotional	N	O
64	Distress	N	O
65	,	N	O
66	and/or	N	O
67	(	N	O
68	b	N	O
69	)	N	O
70	enhancing	N	O
71	their	N	O
72	functional	N	O
73	immunity	N	O
74	.	N	O

75	Post-surgery	N	O
76	,	N	O
77	227	N	O
78	breast	N	O
79	cancer	N	O
80	patients	N	O
81	were	N	O
82	randomized	N	O
83	to	N	O
84	intervention	N	O
85	or	N	O
86	assessment	N	O
87	only	N	O
88	Study	N	O
89	Arms	N	O
90	.	N	O

91	Conducted	N	O
92	in	N	O
93	small	N	O
94	groups	N	O
95	,	N	O
96	intervention	N	O
97	sessions	N	O
98	were	N	O
99	offered	N	O
100	weekly	N	O
101	for	N	O
102	4	N	O
103	months	N	O
104	and	N	O
105	followed	N	O
106	by	N	O
107	monthly	N	O
108	sessions	N	O
109	for	N	O
110	8	N	O
111	months	N	O
112	.	N	O

113	Measures	N	O
114	included	N	O
115	psychological	N	O
116	(	N	O
117	distress	N	O
118	)	N	O
119	,	N	O
120	biological	N	O
121	(	N	O
122	immune	N	O
123	)	N	O
124	,	N	O
125	and	N	O
126	health	N	O
127	outcomes	N	O
128	(	N	O
129	performance	N	O
130	status	N	O
131	and	N	O
132	evaluations	N	O
133	of	N	O
134	patient	N	O
135	's	N	O
136	symptomatology	N	O
137	,	N	O
138	including	N	O
139	toxicity	N	O
140	from	N	O
141	cancer	N	O
142	treatment	N	O
143	,	N	O
144	lab	N	O
145	values	N	O
146	)	N	O
147	collected	N	O
148	at	N	O
149	baseline	N	O
150	,	N	O
151	4	N	O
152	months	N	O
153	,	N	O
154	and	N	O
155	12	N	O
156	months	N	O
157	.	N	O

158	A	N	I-Premise
159	path	N	I-Premise
160	model	N	I-Premise
161	revealed	N	I-Premise
162	that	N	I-Premise
163	intervention	N	I-Premise
164	participation	N	I-Premise
165	directly	N	I-Premise
166	improved	N	I-Premise
167	health	N	I-Premise
168	(	N	I-Premise
169	p	N	I-Premise
170	<	N	I-Premise
171	.05	N	I-Premise
172	)	N	I-Premise
173	at	N	I-Premise
174	12	N	I-Premise
175	months	N	I-Premise
176	.	N	I-Premise

177	These	N	I-Premise
178	effects	N	I-Premise
179	remained	N	I-Premise
180	when	N	I-Premise
181	statistically	N	I-Premise
182	controlling	N	I-Premise
183	for	N	I-Premise
184	baseline	N	I-Premise
185	levels	N	I-Premise
186	of	N	I-Premise
187	distress	N	I-Premise
188	,	N	I-Premise
189	immunity	N	I-Premise
190	,	N	I-Premise
191	and	N	I-Premise
192	health	N	I-Premise
193	as	N	I-Premise
194	well	N	I-Premise
195	as	N	I-Premise
196	sociodemographic	N	I-Premise
197	,	N	I-Premise
198	disease	N	I-Premise
199	,	N	I-Premise
200	and	N	I-Premise
201	cancer	N	I-Premise
202	treatment	N	I-Premise
203	variables	N	I-Premise
204	.	N	I-Premise

205	Regarding	N	I-Premise
206	the	N	I-Premise
207	mechanisms	N	I-Premise
208	for	N	I-Premise
209	achieving	N	I-Premise
210	better	N	I-Premise
211	health	N	I-Premise
212	,	N	I-Premise
213	support	N	I-Premise
214	was	N	I-Premise
215	found	N	I-Premise
216	for	N	I-Premise
217	an	N	I-Premise
218	indirect	N	I-Premise
219	effect	N	I-Premise
220	of	N	I-Premise
221	distress	N	I-Premise
222	reduction	N	I-Premise
223	.	N	I-Premise

224	That	N	I-Premise
225	is	N	I-Premise
226	,	N	I-Premise
227	by	N	I-Premise
228	specifically	N	I-Premise
229	lowering	N	I-Premise
230	intervention	N	I-Premise
231	patients	N	I-Premise
232	'	N	I-Premise
233	distress	N	I-Premise
234	at	N	I-Premise
235	4	N	I-Premise
236	months	N	I-Premise
237	,	N	I-Premise
238	their	N	I-Premise
239	health	N	I-Premise
240	was	N	I-Premise
241	improved	N	I-Premise
242	at	N	I-Premise
243	12	N	I-Premise
244	months	N	I-Premise
245	(	N	I-Premise
246	p	N	I-Premise
247	<	N	I-Premise
248	.05	N	I-Premise
249	)	N	I-Premise
250	.	N	I-Premise

251	Although	N	I-Premise
252	the	N	I-Premise
253	intervention	N	I-Premise
254	simultaneously	N	I-Premise
255	improved	N	I-Premise
256	patients	N	I-Premise
257	'	N	I-Premise
258	T-cell	N	I-Premise
259	blastogenesis	N	I-Premise
260	in	N	I-Premise
261	response	N	I-Premise
262	to	N	I-Premise
263	phytohemagglutinin	N	I-Premise
264	(	N	I-Premise
265	PHA	N	I-Premise
266	)	N	I-Premise
267	,	N	I-Premise
268	the	N	I-Premise
269	latter	N	I-Premise
270	increases	N	I-Premise
271	were	N	I-Premise
272	unrelated	N	I-Premise
273	to	N	I-Premise
274	improved	N	I-Premise
275	health	N	I-Premise
276	.	N	I-Premise

277	A	N	I-Premise
278	convergence	N	I-Premise
279	of	N	I-Premise
280	biobehavioral	N	I-Premise
281	effects	N	I-Premise
282	and	N	I-Premise
283	health	N	I-Premise
284	improvements	N	I-Premise
285	were	N	I-Premise
286	observed	N	I-Premise
287	.	N	I-Premise

288	Behavioral	N	I-Claim
289	change	N	I-Claim
290	,	N	I-Claim
291	rather	N	I-Claim
292	than	N	I-Claim
293	immunity	N	I-Claim
294	change	N	I-Claim
295	,	N	I-Claim
296	was	N	I-Claim
297	influential	N	I-Claim
298	in	N	I-Claim
299	achieving	N	I-Claim
300	lower	N	I-Claim
301	levels	N	I-Claim
302	of	N	I-Claim
303	symptomatology	N	I-Claim
304	and	N	I-Claim
305	higher	N	I-Claim
306	functional	N	I-Claim
307	status	N	I-Claim
308	.	N	I-Claim

309	Distress	N	I-Claim
310	reduction	N	I-Claim
311	is	N	I-Claim
312	highlighted	N	I-Claim
313	as	N	I-Claim
314	an	N	I-Claim
315	important	N	I-Claim
316	mechanism	N	I-Claim
317	by	N	I-Claim
318	which	N	I-Claim
319	health	N	I-Claim
320	can	N	I-Claim
321	be	N	I-Claim
322	improved	N	I-Claim
323	.	N	I-Claim

1	This	N	O
2	study	N	O
3	aimed	N	O
4	to	N	O
5	compare	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	(	N	O
10	QOL	N	O
11	)	N	O
12	,	N	O
13	functional	N	O
14	outcome	N	O
15	,	N	O
16	body	N	O
17	image	N	O
18	,	N	O
19	and	N	O
20	cosmesis	N	O
21	after	N	O
22	hand-assisted	N	O
23	laparoscopic	N	O
24	(	N	O
25	LRP	N	O
26	)	N	O
27	versus	N	O
28	open	N	O
29	restorative	N	O
30	proctocolectomy	N	O
31	(	N	O
32	ORP	N	O
33	)	N	O
34	.	N	O

35	The	N	O
36	potential	N	O
37	long-term	N	O
38	advantages	N	O
39	of	N	O
40	LRP	N	O
41	over	N	O
42	ORP	N	O
43	remain	N	O
44	to	N	O
45	be	N	O
46	determined	N	O
47	.	N	O

48	The	N	O
49	most	N	O
50	likely	N	O
51	advantage	N	O
52	of	N	O
53	LRP	N	O
54	is	N	O
55	the	N	O
56	superior	N	O
57	cosmetic	N	O
58	result	N	O
59	.	N	O

60	It	N	O
61	is	N	O
62	,	N	O
63	however	N	O
64	,	N	O
65	unclear	N	O
66	whether	N	O
67	the	N	O
68	size	N	O
69	and	N	O
70	location	N	O
71	of	N	O
72	incisions	N	O
73	affect	N	O
74	body	N	O
75	image	N	O
76	and	N	O
77	QOL	N	O
78	.	N	O

79	In	N	O
80	a	N	O
81	previously	N	O
82	conducted	N	O
83	randomized	N	O
84	trial	N	O
85	comparing	N	O
86	LRP	N	O
87	with	N	O
88	ORP	N	O
89	,	N	O
90	60	N	O
91	patients	N	O
92	were	N	O
93	prospectively	N	O
94	evaluated	N	O
95	.	N	O

96	The	N	O
97	primary	N	O
98	end	N	O
99	points	N	O
100	were	N	O
101	body	N	O
102	image	N	O
103	and	N	O
104	cosmesis	N	O
105	.	N	O

106	The	N	O
107	secondary	N	O
108	end	N	O
109	points	N	O
110	were	N	O
111	morbidity	N	O
112	,	N	O
113	QOL	N	O
114	,	N	O
115	and	N	O
116	functional	N	O
117	outcome	N	O
118	.	N	O

119	A	N	O
120	body	N	O
121	image	N	O
122	questionnaire	N	O
123	was	N	O
124	used	N	O
125	to	N	O
126	evaluate	N	O
127	body	N	O
128	image	N	O
129	and	N	O
130	cosmesis	N	O
131	.	N	O

132	The	N	O
133	Short	N	O
134	Form-36	N	O
135	Health	N	O
136	Survey	N	O
137	and	N	O
138	the	N	O
139	Gastrointestinal	N	O
140	Quality	N	O
141	of	N	O
142	Life	N	O
143	Inventory	N	O
144	were	N	O
145	used	N	O
146	to	N	O
147	assess	N	O
148	QOL	N	O
149	.	N	O

150	Body	N	O
151	image	N	O
152	and	N	O
153	QOL	N	O
154	also	N	O
155	were	N	O
156	assessed	N	O
157	preoperatively	N	O
158	.	N	O

159	A	N	O
160	total	N	O
161	of	N	O
162	53	N	O
163	patients	N	O
164	completed	N	O
165	the	N	O
166	QOL	N	O
167	and	N	O
168	functional	N	O
169	outcome	N	O
170	questionnaires	N	O
171	.	N	O

172	There	N	I-Premise
173	were	N	I-Premise
174	no	N	I-Premise
175	differences	N	I-Premise
176	in	N	I-Premise
177	functional	N	I-Premise
178	outcome	N	I-Premise
179	,	N	I-Premise
180	morbidity	N	I-Premise
181	,	N	I-Premise
182	or	N	I-Premise
183	QOL	N	I-Premise
184	between	N	I-Premise
185	LRP	N	I-Premise
186	and	N	I-Premise
187	ORP	N	I-Premise
188	.	N	I-Premise

189	At	N	O
190	a	N	O
191	median	N	O
192	of	N	O
193	2.7	N	O
194	years	N	O
195	after	N	O
196	surgery	N	O
197	,	N	O
198	46	N	O
199	patients	N	O
200	returned	N	O
201	the	N	O
202	questionnaires	N	O
203	regarding	N	O
204	body	N	O
205	image	N	O
206	,	N	O
207	cosmesis	N	O
208	,	N	O
209	and	N	O
210	morbidity	N	O
211	.	N	O

212	The	N	I-Premise
213	body	N	I-Premise
214	image	N	I-Premise
215	and	N	I-Premise
216	cosmesis	N	I-Premise
217	scores	N	I-Premise
218	of	N	I-Premise
219	female	N	I-Premise
220	patients	N	I-Premise
221	were	N	I-Premise
222	significantly	N	I-Premise
223	higher	N	I-Premise
224	in	N	I-Premise
225	the	N	I-Premise
226	LRP	N	I-Premise
227	group	N	I-Premise
228	than	N	I-Premise
229	in	N	I-Premise
230	the	N	I-Premise
231	ORP	N	I-Premise
232	group	N	I-Premise
233	(	N	I-Premise
234	body	N	I-Premise
235	image	N	I-Premise
236	,	N	I-Premise
237	17.4	N	I-Premise
238	vs	N	I-Premise
239	14.9	N	I-Premise
240	;	N	I-Premise
241	cosmesis	N	I-Premise
242	,	N	I-Premise
243	19.1	N	I-Premise
244	vs	N	I-Premise
245	13.0	N	I-Premise
246	,	N	I-Premise
247	respectively	N	I-Premise
248	)	N	I-Premise
249	.	N	I-Premise

250	The	N	I-Premise
251	female	N	I-Premise
252	patients	N	I-Premise
253	in	N	I-Premise
254	the	N	I-Premise
255	ORP	N	I-Premise
256	group	N	I-Premise
257	had	N	I-Premise
258	significantly	N	I-Premise
259	lower	N	I-Premise
260	body	N	I-Premise
261	image	N	I-Premise
262	scores	N	I-Premise
263	than	N	I-Premise
264	the	N	I-Premise
265	male	N	I-Premise
266	patients	N	I-Premise
267	(	N	I-Premise
268	14.9	N	I-Premise
269	vs	N	I-Premise
270	18.3	N	I-Premise
271	)	N	I-Premise
272	.	N	I-Premise

273	This	N	I-Claim
274	study	N	I-Claim
275	is	N	I-Claim
276	the	N	I-Claim
277	first	N	I-Claim
278	to	N	I-Claim
279	show	N	I-Claim
280	that	N	I-Claim
281	ORP	N	I-Claim
282	has	N	I-Claim
283	a	N	I-Claim
284	negative	N	I-Claim
285	impact	N	I-Claim
286	on	N	I-Claim
287	body	N	I-Claim
288	image	N	I-Claim
289	and	N	I-Claim
290	cosmesis	N	I-Claim
291	as	N	I-Claim
292	compared	N	I-Claim
293	with	N	I-Claim
294	LRP	N	I-Claim
295	.	N	I-Claim

296	Functional	N	I-Claim
297	outcome	N	I-Claim
298	,	N	I-Claim
299	QOL	N	I-Claim
300	,	N	I-Claim
301	and	N	I-Claim
302	morbidity	N	I-Claim
303	are	N	I-Claim
304	similar	N	I-Claim
305	for	N	I-Claim
306	the	N	I-Claim
307	two	N	I-Claim
308	approaches	N	I-Claim
309	.	N	I-Claim

310	The	N	I-Claim
311	advantages	N	I-Claim
312	of	N	I-Claim
313	a	N	I-Claim
314	long-lasting	N	I-Claim
315	improved	N	I-Claim
316	body	N	I-Claim
317	image	N	I-Claim
318	and	N	I-Claim
319	cosmesis	N	I-Claim
320	for	N	I-Claim
321	this	N	I-Claim
322	relatively	N	I-Claim
323	young	N	I-Claim
324	patient	N	I-Claim
325	population	N	I-Claim
326	may	N	I-Claim
327	compensate	N	I-Claim
328	for	N	I-Claim
329	the	N	I-Claim
330	longer	N	I-Claim
331	operating	N	I-Claim
332	times	N	I-Claim
333	and	N	I-Claim
334	higher	N	I-Claim
335	costs	N	I-Claim
336	,	N	I-Claim
337	particularly	N	I-Claim
338	for	N	I-Claim
339	women	N	I-Claim
340	.	N	I-Claim

1	Depression	N	I-Claim
2	,	N	I-Claim
3	anxiety	N	I-Claim
4	,	N	I-Claim
5	fatigue	N	I-Claim
6	,	N	I-Claim
7	and	N	I-Claim
8	impaired	N	I-Claim
9	wellbeing	N	I-Claim
10	are	N	I-Claim
11	common	N	I-Claim
12	,	N	I-Claim
13	important	N	I-Claim
14	,	N	I-Claim
15	and	N	I-Claim
16	closely	N	I-Claim
17	related	N	I-Claim
18	in	N	I-Claim
19	advanced	N	I-Claim
20	cancer	N	I-Claim
21	.	N	I-Claim

22	We	N	O
23	aimed	N	O
24	to	N	O
25	identify	N	O
26	the	N	O
27	effects	N	O
28	of	N	O
29	an	N	O
30	established	N	O
31	antidepressant	N	O
32	on	N	O
33	these	N	O
34	symptoms	N	O
35	and	N	O
36	survival	N	O
37	in	N	O
38	patients	N	O
39	with	N	O
40	advanced	N	O
41	cancer	N	O
42	who	N	O
43	did	N	O
44	not	N	O
45	have	N	O
46	major	N	O
47	depression	N	O
48	as	N	O
49	assessed	N	O
50	by	N	O
51	clinicians	N	O
52	.	N	O

53	Between	N	O
54	July	N	O
55	,	N	O
56	2001	N	O
57	,	N	O
58	and	N	O
59	February	N	O
60	,	N	O
61	2006	N	O
62	,	N	O
63	189	N	O
64	patients	N	O
65	with	N	O
66	advanced	N	O
67	cancer	N	O
68	were	N	O
69	randomly	N	O
70	assigned	N	O
71	sertraline	N	O
72	50	N	O
73	mg	N	O
74	(	N	O
75	n=95	N	O
76	)	N	O
77	,	N	O
78	or	N	O
79	placebo	N	O
80	(	N	O
81	n=94	N	O
82	)	N	O
83	,	N	O
84	once	N	O
85	per	N	O
86	day	N	O
87	.	N	O

88	The	N	O
89	primary	N	O
90	outcome	N	O
91	was	N	O
92	depression	N	O
93	as	N	O
94	assessed	N	O
95	by	N	O
96	the	N	O
97	Centre	N	O
98	for	N	O
99	Epidemiologic	N	O
100	Studies	N	O
101	Depression	N	O
102	scale	N	O
103	(	N	O
104	CES-D	N	O
105	)	N	O
106	;	N	O
107	the	N	O
108	main	N	O
109	secondary	N	O
110	outcomes	N	O
111	were	N	O
112	:	N	O
113	anxiety	N	O
114	as	N	O
115	assessed	N	O
116	by	N	O
117	Hospital	N	O
118	Anxiety	N	O
119	and	N	O
120	Depression	N	O
121	Scales	N	O
122	(	N	O
123	HADS-A	N	O
124	)	N	O
125	;	N	O
126	overall	N	O
127	quality	N	O
128	of	N	O
129	life	N	O
130	and	N	O
131	fatigue	N	O
132	as	N	O
133	assessed	N	O
134	by	N	O
135	Functional	N	O
136	Assessment	N	O
137	of	N	O
138	Cancer	N	O
139	Therapy	N	O
140	General	N	O
141	and	N	O
142	Fatigue	N	O
143	scales	N	O
144	(	N	O
145	FACT-G	N	O
146	and	N	O
147	FACT-F	N	O
148	,	N	O
149	respectively	N	O
150	)	N	O
151	;	N	O
152	and	N	O
153	clinicians	N	O
154	'	N	O
155	ratings	N	O
156	of	N	O
157	quality	N	O
158	of	N	O
159	life	N	O
160	by	N	O
161	use	N	O
162	of	N	O
163	Spizter	N	O
164	's	N	O
165	Quality	N	O
166	of	N	O
167	Life	N	O
168	Index	N	O
169	(	N	O
170	SQLI	N	O
171	)	N	O
172	.	N	O

173	Multiple	N	O
174	measures	N	O
175	were	N	O
176	used	N	O
177	for	N	O
178	corroboration	N	O
179	of	N	O
180	the	N	O
181	most	N	O
182	important	N	O
183	outcomes	N	O
184	.	N	O

185	Primary	N	O
186	analyses	N	O
187	were	N	O
188	done	N	O
189	by	N	O
190	intention	N	O
191	to	N	O
192	treat	N	O
193	and	N	O
194	were	N	O
195	based	N	O
196	on	N	O
197	scale	N	O
198	scores	N	O
199	at	N	O
200	4	N	O
201	weeks	N	O
202	and	N	O
203	8	N	O
204	weeks	N	O
205	.	N	O

206	The	N	O
207	benefits	N	O
208	of	N	O
209	sertraline	N	O
210	compared	N	O
211	with	N	O
212	placebo	N	O
213	are	N	O
214	expressed	N	O
215	on	N	O
216	a	N	O
217	range	N	O
218	from	N	O
219	+100	N	O
220	(	N	O
221	ie	N	O
222	,	N	O
223	maximum	N	O
224	benefit	N	O
225	)	N	O
226	to	N	O
227	-100	N	O
228	(	N	O
229	ie	N	O
230	,	N	O
231	maximum	N	O
232	harm	N	O
233	)	N	O
234	;	N	O
235	a	N	O
236	difference	N	O
237	of	N	O
238	10	N	O
239	was	N	O
240	deemed	N	O
241	clinically	N	O
242	significant	N	O
243	.	N	O

244	This	N	O
245	clinical	N	O
246	trial	N	O
247	is	N	O
248	registered	N	O
249	at	N	O
250	Current	N	O
251	Controlled	N	O
252	Trials	N	O
253	website	N	O
254	http	N	O
255	:	N	O
256	//www.controlled-trials.com/ISRCTN72466475	N	O
257	.	N	O

258	Sertraline	N	I-Premise
259	had	N	I-Premise
260	no	N	I-Premise
261	significant	N	I-Premise
262	effect	N	I-Premise
263	(	N	I-Premise
264	scale	N	I-Premise
265	,	N	I-Premise
266	benefit	N	I-Premise
267	over	N	I-Premise
268	placebo	N	I-Premise
269	[	N	I-Premise
270	95	N	I-Premise
271	%	N	I-Premise
272	CI	N	I-Premise
273	]	N	I-Premise
274	)	N	I-Premise
275	on	N	I-Premise
276	depression	N	I-Premise
277	(	N	I-Premise
278	CES-D	N	I-Premise
279	0.4	N	I-Premise
280	[	N	I-Premise
281	-2.6	N	I-Premise
282	to	N	I-Premise
283	3.4	N	I-Premise
284	]	N	I-Premise
285	)	N	I-Premise
286	,	N	I-Premise
287	anxiety	N	I-Premise
288	(	N	I-Premise
289	HADS-A	N	I-Premise
290	2.0	N	I-Premise
291	[	N	I-Premise
292	-1.5	N	I-Premise
293	to	N	I-Premise
294	5.5	N	I-Premise
295	]	N	I-Premise
296	)	N	I-Premise
297	,	N	I-Premise
298	fatigue	N	I-Premise
299	(	N	I-Premise
300	FACT-F	N	I-Premise
301	0.3	N	I-Premise
302	[	N	I-Premise
303	-4.3	N	I-Premise
304	to	N	I-Premise
305	4.9	N	I-Premise
306	]	N	I-Premise
307	)	N	I-Premise
308	,	N	I-Premise
309	overall	N	I-Premise
310	quality	N	I-Premise
311	of	N	I-Premise
312	life	N	I-Premise
313	(	N	I-Premise
314	FACT-G	N	I-Premise
315	1.7	N	I-Premise
316	[	N	I-Premise
317	-1.3	N	I-Premise
318	to	N	I-Premise
319	4.7	N	I-Premise
320	]	N	I-Premise
321	)	N	I-Premise
322	,	N	I-Premise
323	or	N	I-Premise
324	clinicians	N	I-Premise
325	'	N	I-Premise
326	ratings	N	I-Premise
327	(	N	I-Premise
328	SQLI	N	I-Premise
329	2.0	N	I-Premise
330	[	N	I-Premise
331	-2.5	N	I-Premise
332	to	N	I-Premise
333	6.5	N	I-Premise
334	]	N	I-Premise
335	)	N	I-Premise
336	,	N	I-Premise
337	and	N	I-Premise
338	the	N	I-Premise
339	95	N	I-Premise
340	%	N	I-Premise
341	CI	N	I-Premise
342	ruled	N	I-Premise
343	out	N	I-Premise
344	a	N	I-Premise
345	clinically	N	I-Premise
346	significant	N	I-Premise
347	benefit	N	I-Premise
348	for	N	I-Premise
349	all	N	I-Premise
350	main	N	I-Premise
351	outcomes	N	I-Premise
352	.	N	I-Premise

353	Sertraline	N	I-Premise
354	was	N	I-Premise
355	discontinued	N	I-Premise
356	more	N	I-Premise
357	often	N	I-Premise
358	and	N	I-Premise
359	earlier	N	I-Premise
360	than	N	I-Premise
361	was	N	I-Premise
362	placebo	N	I-Premise
363	(	N	I-Premise
364	hazard	N	I-Premise
365	ratio	N	I-Premise
366	1.46	N	I-Premise
367	[	N	I-Premise
368	1.03-2.06	N	I-Premise
369	]	N	I-Premise
370	,	N	I-Premise
371	p=0.03	N	I-Premise
372	)	N	I-Premise
373	.	N	I-Premise

374	Recruitment	N	O
375	was	N	O
376	stopped	N	O
377	after	N	O
378	the	N	I-Premise
379	first	N	I-Premise
380	planned	N	I-Premise
381	interim	N	I-Premise
382	analysis	N	I-Premise
383	in	N	I-Premise
384	February	N	I-Premise
385	2006	N	I-Premise
386	(	N	I-Premise
387	n=150	N	I-Premise
388	)	N	I-Premise
389	showed	N	I-Premise
390	that	N	I-Premise
391	survival	N	I-Premise
392	was	N	I-Premise
393	longer	N	I-Premise
394	in	N	I-Premise
395	patients	N	I-Premise
396	assigned	N	I-Premise
397	placebo	N	I-Premise
398	than	N	I-Premise
399	in	N	I-Premise
400	patients	N	I-Premise
401	assigned	N	I-Premise
402	sertraline	N	I-Premise
403	(	N	I-Premise
404	unadjusted	N	I-Premise
405	hazard	N	I-Premise
406	ratio	N	I-Premise
407	1.60	N	I-Premise
408	[	N	I-Premise
409	95	N	I-Premise
410	%	N	I-Premise
411	CI	N	I-Premise
412	1.04-2.45	N	I-Premise
413	]	N	I-Premise
414	,	N	I-Premise
415	log-rank	N	I-Premise
416	p=0.04	N	I-Premise
417	;	N	I-Premise
418	adjusted	N	I-Premise
419	hazard	N	I-Premise
420	ratio	N	I-Premise
421	1.62	N	I-Premise
422	[	N	I-Premise
423	1.06-2.41	N	I-Premise
424	]	N	I-Premise
425	,	N	I-Premise
426	Cox	N	I-Premise
427	model	N	I-Premise
428	p=0.02	N	I-Premise
429	)	N	I-Premise
430	.	N	I-Premise

431	However	N	I-Premise
432	,	N	I-Premise
433	at	N	I-Premise
434	the	N	I-Premise
435	final	N	I-Premise
436	analysis	N	I-Premise
437	in	N	I-Premise
438	July	N	I-Premise
439	2006	N	I-Premise
440	of	N	I-Premise
441	all	N	I-Premise
442	patients	N	I-Premise
443	(	N	I-Premise
444	n=189	N	I-Premise
445	)	N	I-Premise
446	and	N	I-Premise
447	with	N	I-Premise
448	longer	N	I-Premise
449	follow-up	N	I-Premise
450	,	N	I-Premise
451	survival	N	I-Premise
452	did	N	I-Premise
453	not	N	I-Premise
454	differ	N	I-Premise
455	significantly	N	I-Premise
456	between	N	I-Premise
457	the	N	I-Premise
458	treatment	N	I-Premise
459	groups	N	I-Premise
460	(	N	I-Premise
461	unadjusted	N	I-Premise
462	hazard	N	I-Premise
463	ratio	N	I-Premise
464	1.35	N	I-Premise
465	[	N	I-Premise
466	0.95-1.91	N	I-Premise
467	]	N	I-Premise
468	,	N	I-Premise
469	log-rank	N	I-Premise
470	p=0.09	N	I-Premise
471	;	N	I-Premise
472	adjusted	N	I-Premise
473	hazard	N	I-Premise
474	ratio	N	I-Premise
475	1.27	N	I-Premise
476	[	N	I-Premise
477	0.87-1.84	N	I-Premise
478	]	N	I-Premise
479	,	N	I-Premise
480	Cox	N	I-Premise
481	model	N	I-Premise
482	p=0.20	N	I-Premise
483	)	N	I-Premise
484	.	N	I-Premise

485	The	N	O
486	trial	N	O
487	was	N	O
488	closed	N	O
489	because	N	O
490	it	N	O
491	had	N	O
492	ruled	N	O
493	out	N	O
494	a	N	O
495	significant	N	O
496	benefit	N	O
497	of	N	O
498	sertraline	N	O
499	.	N	O

500	Sertraline	N	I-Claim
501	did	N	I-Claim
502	not	N	I-Claim
503	improve	N	I-Claim
504	symptoms	N	I-Claim
505	,	N	I-Claim
506	wellbeing	N	I-Claim
507	,	N	I-Claim
508	or	N	I-Claim
509	survival	N	I-Claim
510	in	N	I-Claim
511	patients	N	I-Claim
512	with	N	I-Claim
513	advanced	N	I-Claim
514	cancer	N	I-Claim
515	who	N	I-Claim
516	do	N	I-Claim
517	not	N	I-Claim
518	have	N	I-Claim
519	major	N	I-Claim
520	depression	N	I-Claim
521	,	N	I-Claim
522	and	N	I-Claim
523	should	N	I-Claim
524	be	N	I-Claim
525	reserved	N	I-Claim
526	for	N	I-Claim
527	those	N	I-Claim
528	with	N	I-Claim
529	a	N	I-Claim
530	proven	N	I-Claim
531	indication	N	I-Claim
532	.	N	I-Claim

1	Recently	N	I-Claim
2	,	N	I-Claim
3	the	N	I-Claim
4	treatment	N	I-Claim
5	of	N	I-Claim
6	advanced	N	I-Claim
7	gastric	N	I-Claim
8	cancer	N	I-Claim
9	by	N	I-Claim
10	continuous	N	I-Claim
11	infusion	N	I-Claim
12	of	N	I-Claim
13	5-fluorouracil	N	I-Claim
14	(	N	I-Claim
15	5-FU	N	I-Claim
16	)	N	I-Claim
17	with	N	I-Claim
18	low-dose	N	I-Claim
19	cisplatin	N	I-Claim
20	(	N	I-Claim
21	CDDP	N	I-Claim
22	)	N	I-Claim
23	has	N	I-Claim
24	improved	N	I-Claim
25	efficacy	N	I-Claim
26	without	N	I-Claim
27	severe	N	I-Claim
28	toxicities	N	I-Claim
29	.	N	I-Claim

30	The	N	I-Claim
31	possible	N	I-Claim
32	effectiveness	N	I-Claim
33	of	N	I-Claim
34	5-FU+low-dose	N	I-Claim
35	CDDP	N	I-Claim
36	for	N	I-Claim
37	colorectal	N	I-Claim
38	cancer	N	I-Claim
39	(	N	I-Claim
40	CRC	N	I-Claim
41	)	N	I-Claim
42	is	N	I-Claim
43	intriguing	N	I-Claim
44	.	N	I-Claim

45	One	N	O
46	hundred	N	O
47	fifty-five	N	O
48	patients	N	O
49	with	N	O
50	far-advanced	N	O
51	CRC	N	O
52	including	N	O
53	at	N	O
54	least	N	O
55	one	N	O
56	measurable	N	O
57	lesion	N	O
58	were	N	O
59	enrolled	N	O
60	in	N	O
61	a	N	O
62	prospective	N	O
63	randomized	N	O
64	clinical	N	O
65	trial	N	O
66	funded	N	O
67	by	N	O
68	the	N	O
69	Japanese	N	O
70	Foundation	N	O
71	for	N	O
72	Multidisciplinary	N	O
73	Treatment	N	O
74	of	N	O
75	Cancer	N	O
76	.	N	O

77	These	N	O
78	patients	N	O
79	were	N	O
80	assigned	N	O
81	to	N	O
82	the	N	O
83	two	N	O
84	arms	N	O
85	to	N	O
86	assess	N	O
87	the	N	O
88	value	N	O
89	of	N	O
90	low-dose	N	O
91	CDDP	N	O
92	when	N	O
93	added	N	O
94	to	N	O
95	a	N	O
96	continuous	N	O
97	intravenous	N	O
98	infusion	N	O
99	of	N	O
100	5-FU	N	O
101	at	N	O
102	a	N	O
103	dose	N	O
104	of	N	O
105	300	N	O
106	mg/m	N	O
107	(	N	O
108	2	N	O
109	)	N	O
110	/24	N	O
111	hrs	N	O
112	in	N	O
113	a	N	O
114	one-week	N	O
115	cycle	N	O
116	consisting	N	O
117	of	N	O
118	5	N	O
119	days	N	O
120	of	N	O
121	treatment	N	O
122	and	N	O
123	2	N	O
124	days	N	O
125	of	N	O
126	rest	N	O
127	for	N	O
128	at	N	O
129	least	N	O
130	12	N	O
131	weeks	N	O
132	.	N	O

133	CD-DP	N	O
134	was	N	O
135	given	N	O
136	intravenously	N	O
137	at	N	O
138	a	N	O
139	dose	N	O
140	of	N	O
141	3	N	O
142	mg/m	N	O
143	(	N	O
144	2	N	O
145	)	N	O
146	on	N	O
147	days	N	O
148	1-5	N	O
149	and	N	O
150	days	N	O
151	8-12	N	O
152	,	N	O
153	and	N	O
154	then	N	O
155	at	N	O
156	a	N	O
157	dose	N	O
158	of	N	O
159	7	N	O
160	mg/m	N	O
161	(	N	O
162	2	N	O
163	)	N	O
164	twice	N	O
165	a	N	O
166	week	N	O
167	.	N	O

168	Three	N	O
169	patients	N	O
170	were	N	O
171	excluded	N	O
172	from	N	O
173	the	N	O
174	trial	N	O
175	.	N	O

176	The	N	I-Premise
177	response	N	I-Premise
178	rate	N	I-Premise
179	in	N	I-Premise
180	the	N	I-Premise
181	5-FU+low-dose	N	I-Premise
182	CDDP	N	I-Premise
183	arm	N	I-Premise
184	(	N	I-Premise
185	n=75	N	I-Premise
186	)	N	I-Premise
187	was	N	I-Premise
188	significantly	N	I-Premise
189	higher	N	I-Premise
190	than	N	I-Premise
191	that	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	5-FU	N	I-Premise
195	arm	N	I-Premise
196	(	N	I-Premise
197	n=77	N	I-Premise
198	)	N	I-Premise
199	(	N	I-Premise
200	25.3	N	I-Premise
201	%	N	I-Premise
202	vs.	N	I-Premise
203	11.7	N	I-Premise
204	%	N	I-Premise
205	;	N	I-Premise
206	P	N	I-Premise
207	=	N	I-Premise
208	0.037	N	I-Premise
209	)	N	I-Premise
210	.	N	I-Premise

211	There	N	I-Premise
212	was	N	I-Premise
213	no	N	I-Premise
214	significant	N	I-Premise
215	difference	N	I-Premise
216	in	N	I-Premise
217	the	N	I-Premise
218	median	N	I-Premise
219	overall	N	I-Premise
220	survival	N	I-Premise
221	time	N	I-Premise
222	between	N	I-Premise
223	the	N	I-Premise
224	5-FU+low-dose	N	I-Premise
225	CDDP	N	I-Premise
226	arm	N	I-Premise
227	and	N	I-Premise
228	the	N	I-Premise
229	5-FU	N	I-Premise
230	arm	N	I-Premise
231	(	N	I-Premise
232	479	N	I-Premise
233	and	N	I-Premise
234	491	N	I-Premise
235	days	N	I-Premise
236	,	N	I-Premise
237	respectively	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	Grades	N	I-Premise
241	3/4	N	I-Premise
242	toxicities	N	I-Premise
243	occurred	N	I-Premise
244	infrequently	N	I-Premise
245	in	N	I-Premise
246	both	N	I-Premise
247	arms	N	I-Premise
248	.	N	I-Premise

249	The	N	I-Premise
250	quality	N	I-Premise
251	of	N	I-Premise
252	life	N	I-Premise
253	was	N	I-Premise
254	almost	N	I-Premise
255	the	N	I-Premise
256	same	N	I-Premise
257	between	N	I-Premise
258	the	N	I-Premise
259	arms	N	I-Premise
260	.	N	O

261	Low-dose	N	I-Claim
262	CDDP	N	I-Claim
263	improved	N	I-Claim
264	the	N	I-Claim
265	response	N	I-Claim
266	rate	N	I-Claim
267	while	N	I-Claim
268	keeping	N	I-Claim
269	toxicities	N	I-Claim
270	within	N	I-Claim
271	clinically	N	I-Claim
272	acceptable	N	I-Claim
273	limits	N	I-Claim
274	.	N	I-Claim

275	However	N	I-Claim
276	,	N	I-Claim
277	this	N	I-Claim
278	combined	N	I-Claim
279	treatment	N	I-Claim
280	did	N	I-Claim
281	not	N	I-Claim
282	confer	N	I-Claim
283	a	N	I-Claim
284	survival	N	I-Claim
285	advantage	N	I-Claim
286	over	N	I-Claim
287	treatment	N	I-Claim
288	with	N	I-Claim
289	continuous	N	I-Claim
290	infusion	N	I-Claim
291	of	N	I-Claim
292	5-FU	N	I-Claim
293	alone	N	I-Claim
294	for	N	I-Claim
295	patients	N	I-Claim
296	with	N	I-Claim
297	far-advanced	N	I-Claim
298	CRC	N	I-Claim
299	;	N	I-Claim
300	that	N	I-Claim
301	might	N	I-Claim
302	be	N	I-Claim
303	attributable	N	I-Claim
304	to	N	I-Claim
305	the	N	I-Claim
306	short	N	I-Claim
307	CDDP	N	I-Claim
308	administration	N	I-Claim
309	setting	N	I-Claim
310	of	N	I-Claim
311	12	N	I-Claim
312	weeks	N	I-Claim
313	.	N	I-Claim

1	The	N	O
2	impact	N	O
3	of	N	O
4	psychotherapeutic	N	O
5	support	N	O
6	on	N	O
7	survival	N	O
8	for	N	O
9	patients	N	O
10	with	N	O
11	gastrointestinal	N	O
12	cancer	N	O
13	undergoing	N	O
14	surgery	N	O
15	was	N	O
16	studied	N	O
17	.	N	O

18	A	N	O
19	randomized	N	O
20	controlled	N	O
21	trial	N	O
22	was	N	O
23	conducted	N	O
24	in	N	O
25	cooperation	N	O
26	with	N	O
27	the	N	O
28	Departments	N	O
29	of	N	O
30	General	N	O
31	Surgery	N	O
32	and	N	O
33	Medical	N	O
34	Psychology	N	O
35	,	N	O
36	University	N	O
37	Hospital	N	O
38	of	N	O
39	Hamburg	N	O
40	,	N	O
41	Germany	N	O
42	,	N	O
43	from	N	O
44	January	N	O
45	1991	N	O
46	to	N	O
47	January	N	O
48	1993	N	O
49	.	N	O

50	Consenting	N	O
51	patients	N	O
52	(	N	O
53	N	N	O
54	=	N	O
55	271	N	O
56	)	N	O
57	with	N	O
58	a	N	O
59	preliminary	N	O
60	diagnosis	N	O
61	of	N	O
62	cancer	N	O
63	of	N	O
64	the	N	O
65	esophagus	N	O
66	,	N	O
67	stomach	N	O
68	,	N	O
69	liver/gallbladder	N	O
70	,	N	O
71	pancreas	N	O
72	,	N	O
73	or	N	O
74	colon/rectum	N	O
75	were	N	O
76	stratified	N	O
77	by	N	O
78	sex	N	O
79	and	N	O
80	randomly	N	O
81	assigned	N	O
82	to	N	O
83	a	N	O
84	control	N	O
85	group	N	O
86	that	N	O
87	received	N	O
88	standard	N	O
89	care	N	O
90	as	N	O
91	provided	N	O
92	on	N	O
93	the	N	O
94	surgical	N	O
95	wards	N	O
96	,	N	O
97	or	N	O
98	to	N	O
99	an	N	O
100	experimental	N	O
101	group	N	O
102	that	N	O
103	received	N	O
104	formal	N	O
105	psychotherapeutic	N	O
106	support	N	O
107	in	N	O
108	addition	N	O
109	to	N	O
110	routine	N	O
111	care	N	O
112	during	N	O
113	the	N	O
114	hospital	N	O
115	stay	N	O
116	.	N	O

117	From	N	O
118	June	N	O
119	2003	N	O
120	to	N	O
121	December	N	O
122	2003	N	O
123	,	N	O
124	the	N	O
125	10-year	N	O
126	follow-up	N	O
127	was	N	O
128	conducted	N	O
129	.	N	O

130	Survival	N	O
131	status	N	O
132	for	N	O
133	all	N	O
134	patients	N	O
135	was	N	O
136	determined	N	O
137	from	N	O
138	our	N	O
139	own	N	O
140	records	N	O
141	and	N	O
142	from	N	O
143	three	N	O
144	external	N	O
145	sources	N	O
146	:	N	O
147	the	N	O
148	Hamburg	N	O
149	cancer	N	O
150	registry	N	O
151	,	N	O
152	family	N	O
153	doctors	N	O
154	,	N	O
155	and	N	O
156	the	N	O
157	general	N	O
158	citizen	N	O
159	registration	N	O
160	offices	N	O
161	.	N	O

162	Kaplan-Meier	N	I-Premise
163	survival	N	I-Premise
164	curves	N	I-Premise
165	demonstrated	N	I-Premise
166	better	N	I-Premise
167	survival	N	I-Premise
168	for	N	I-Premise
169	the	N	I-Premise
170	experimental	N	I-Premise
171	group	N	I-Premise
172	than	N	I-Premise
173	the	N	I-Premise
174	control	N	I-Premise
175	group	N	I-Premise
176	.	N	I-Premise

177	The	N	I-Premise
178	unadjusted	N	I-Premise
179	significance	N	I-Premise
180	level	N	I-Premise
181	for	N	I-Premise
182	group	N	I-Premise
183	differences	N	I-Premise
184	was	N	I-Premise
185	P	N	I-Premise
186	=	N	I-Premise
187	.0006	N	I-Premise
188	for	N	I-Premise
189	survival	N	I-Premise
190	to	N	I-Premise
191	10	N	I-Premise
192	years	N	I-Premise
193	.	N	I-Premise

194	Cox	N	I-Premise
195	regression	N	I-Premise
196	models	N	I-Premise
197	that	N	I-Premise
198	took	N	I-Premise
199	TNM	N	I-Premise
200	staging	N	I-Premise
201	or	N	I-Premise
202	the	N	I-Premise
203	residual	N	I-Premise
204	tumor	N	I-Premise
205	classification	N	I-Premise
206	and	N	I-Premise
207	tumor	N	I-Premise
208	site	N	I-Premise
209	into	N	I-Premise
210	account	N	I-Premise
211	also	N	I-Premise
212	found	N	I-Premise
213	significant	N	I-Premise
214	differences	N	I-Premise
215	at	N	I-Premise
216	10	N	I-Premise
217	years	N	I-Premise
218	.	N	I-Premise

219	Secondary	N	I-Premise
220	analyses	N	I-Premise
221	found	N	I-Premise
222	that	N	I-Premise
223	differences	N	I-Premise
224	in	N	I-Premise
225	favor	N	I-Premise
226	of	N	I-Premise
227	the	N	I-Premise
228	experimental	N	I-Premise
229	group	N	I-Premise
230	occurred	N	I-Premise
231	in	N	I-Premise
232	patients	N	I-Premise
233	with	N	I-Premise
234	stomach	N	I-Premise
235	,	N	I-Premise
236	pancreatic	N	I-Premise
237	,	N	I-Premise
238	primary	N	I-Premise
239	liver	N	I-Premise
240	,	N	I-Premise
241	or	N	I-Premise
242	colorectal	N	I-Premise
243	cancer	N	I-Premise
244	.	N	I-Premise

245	The	N	I-Claim
246	results	N	I-Claim
247	of	N	I-Claim
248	this	N	I-Claim
249	study	N	I-Claim
250	indicate	N	I-Claim
251	that	N	I-Claim
252	patients	N	I-Claim
253	with	N	I-Claim
254	gastrointestinal	N	I-Claim
255	cancer	N	I-Claim
256	,	N	I-Claim
257	who	N	I-Claim
258	undergo	N	I-Claim
259	surgery	N	I-Claim
260	for	N	I-Claim
261	stomach	N	I-Claim
262	,	N	I-Claim
263	pancreatic	N	I-Claim
264	,	N	I-Claim
265	primary	N	I-Claim
266	liver	N	I-Claim
267	,	N	I-Claim
268	or	N	I-Claim
269	colorectal	N	I-Claim
270	cancer	N	I-Claim
271	,	N	I-Claim
272	benefit	N	I-Claim
273	from	N	I-Claim
274	a	N	I-Claim
275	formal	N	I-Claim
276	program	N	I-Claim
277	of	N	I-Claim
278	psychotherapeutic	N	I-Claim
279	support	N	I-Claim
280	during	N	I-Claim
281	the	N	I-Claim
282	inpatient	N	I-Claim
283	hospital	N	I-Claim
284	stay	N	I-Claim
285	in	N	I-Claim
286	terms	N	I-Claim
287	of	N	I-Claim
288	long-term	N	I-Claim
289	survival	N	I-Claim
290	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	long	N	O
5	term	N	O
6	risks	N	O
7	and	N	O
8	benefits	N	O
9	of	N	O
10	hormone	N	O
11	replacement	N	O
12	therapy	N	O
13	(	N	O
14	combined	N	O
15	hormone	N	O
16	therapy	N	O
17	versus	N	O
18	placebo	N	O
19	,	N	O
20	and	N	O
21	oestrogen	N	O
22	alone	N	O
23	versus	N	O
24	combined	N	O
25	hormone	N	O
26	therapy	N	O
27	)	N	O
28	.	N	O

29	Multicentre	N	O
30	,	N	O
31	randomised	N	O
32	,	N	O
33	placebo	N	O
34	controlled	N	O
35	,	N	O
36	double	N	O
37	blind	N	O
38	trial	N	O
39	.	N	O

40	General	N	O
41	practices	N	O
42	in	N	O
43	UK	N	O
44	(	N	O
45	384	N	O
46	)	N	O
47	,	N	O
48	Australia	N	O
49	(	N	O
50	91	N	O
51	)	N	O
52	,	N	O
53	and	N	O
54	New	N	O
55	Zealand	N	O
56	(	N	O
57	24	N	O
58	)	N	O
59	.	N	O

60	Postmenopausal	N	O
61	women	N	O
62	aged	N	O
63	50-69	N	O
64	years	N	O
65	at	N	O
66	randomisation	N	O
67	.	N	O

68	At	N	O
69	early	N	O
70	closure	N	O
71	of	N	O
72	the	N	O
73	trial	N	O
74	,	N	O
75	56,583	N	O
76	had	N	O
77	been	N	O
78	screened	N	O
79	,	N	O
80	8980	N	O
81	entered	N	O
82	run-in	N	O
83	,	N	O
84	and	N	O
85	5692	N	O
86	(	N	O
87	26	N	O
88	%	N	O
89	of	N	O
90	target	N	O
91	of	N	O
92	22,300	N	O
93	)	N	O
94	started	N	O
95	treatment	N	O
96	.	N	O

97	Oestrogen	N	O
98	only	N	O
99	therapy	N	O
100	(	N	O
101	conjugated	N	O
102	equine	N	O
103	oestrogens	N	O
104	0.625	N	O
105	mg	N	O
106	orally	N	O
107	daily	N	O
108	)	N	O
109	or	N	O
110	combined	N	O
111	hormone	N	O
112	therapy	N	O
113	(	N	O
114	conjugated	N	O
115	equine	N	O
116	oestrogens	N	O
117	plus	N	O
118	medroxyprogesterone	N	O
119	acetate	N	O
120	2.5/5.0	N	O
121	mg	N	O
122	orally	N	O
123	daily	N	O
124	)	N	O
125	.	N	O

126	Ten	N	O
127	years	N	O
128	of	N	O
129	treatment	N	O
130	planned	N	O
131	.	N	O

132	major	N	O
133	cardiovascular	N	O
134	disease	N	O
135	,	N	O
136	osteoporotic	N	O
137	fractures	N	O
138	,	N	O
139	and	N	O
140	breast	N	O
141	cancer	N	O
142	.	N	O

143	other	N	O
144	cancers	N	O
145	,	N	O
146	death	N	O
147	from	N	O
148	all	N	O
149	causes	N	O
150	,	N	O
151	venous	N	O
152	thromboembolism	N	O
153	,	N	O
154	cerebrovascular	N	O
155	disease	N	O
156	,	N	O
157	dementia	N	O
158	,	N	O
159	and	N	O
160	quality	N	O
161	of	N	O
162	life	N	O
163	.	N	O

164	The	N	O
165	trial	N	O
166	was	N	O
167	prematurely	N	O
168	closed	N	O
169	during	N	O
170	recruitment	N	O
171	,	N	O
172	after	N	O
173	a	N	O
174	median	N	O
175	follow-up	N	O
176	of	N	O
177	11.9	N	O
178	months	N	O
179	(	N	O
180	interquartile	N	O
181	range	N	O
182	7.1-19.6	N	O
183	,	N	O
184	total	N	O
185	6498	N	O
186	women	N	O
187	years	N	O
188	)	N	O
189	in	N	O
190	those	N	O
191	enrolled	N	O
192	,	N	O
193	after	N	O
194	the	N	O
195	publication	N	O
196	of	N	O
197	early	N	O
198	results	N	O
199	from	N	O
200	the	N	O
201	women	N	O
202	's	N	O
203	health	N	O
204	initiative	N	O
205	study	N	O
206	.	N	O

207	The	N	O
208	mean	N	O
209	age	N	O
210	of	N	O
211	randomised	N	O
212	women	N	O
213	was	N	O
214	62.8	N	O
215	(	N	O
216	SD	N	O
217	4.8	N	O
218	)	N	O
219	years	N	O
220	.	N	O

221	When	N	I-Premise
222	combined	N	I-Premise
223	hormone	N	I-Premise
224	therapy	N	I-Premise
225	(	N	I-Premise
226	n=2196	N	I-Premise
227	)	N	I-Premise
228	was	N	I-Premise
229	compared	N	I-Premise
230	with	N	I-Premise
231	placebo	N	I-Premise
232	(	N	I-Premise
233	n=2189	N	I-Premise
234	)	N	I-Premise
235	,	N	I-Premise
236	there	N	I-Premise
237	was	N	I-Premise
238	a	N	I-Premise
239	significant	N	I-Premise
240	increase	N	I-Premise
241	in	N	I-Premise
242	the	N	I-Premise
243	number	N	I-Premise
244	of	N	I-Premise
245	major	N	I-Premise
246	cardiovascular	N	I-Premise
247	events	N	I-Premise
248	(	N	I-Premise
249	7	N	I-Premise
250	v	N	I-Premise
251	0	N	I-Premise
252	,	N	I-Premise
253	P=0.016	N	I-Premise
254	)	N	I-Premise
255	and	N	I-Premise
256	venous	N	I-Premise
257	thromboembolisms	N	I-Premise
258	(	N	I-Premise
259	22	N	I-Premise
260	v	N	I-Premise
261	3	N	I-Premise
262	,	N	I-Premise
263	hazard	N	I-Premise
264	ratio	N	I-Premise
265	7.36	N	I-Premise
266	(	N	I-Premise
267	95	N	I-Premise
268	%	N	I-Premise
269	CI	N	I-Premise
270	2.20	N	I-Premise
271	to	N	I-Premise
272	24.60	N	I-Premise
273	)	N	I-Premise
274	)	N	I-Premise
275	.	N	I-Premise

276	There	N	I-Premise
277	were	N	I-Premise
278	no	N	I-Premise
279	statistically	N	I-Premise
280	significant	N	I-Premise
281	differences	N	I-Premise
282	in	N	I-Premise
283	numbers	N	I-Premise
284	of	N	I-Premise
285	breast	N	I-Premise
286	or	N	I-Premise
287	other	N	I-Premise
288	cancers	N	I-Premise
289	(	N	I-Premise
290	22	N	I-Premise
291	v	N	I-Premise
292	25	N	I-Premise
293	,	N	I-Premise
294	hazard	N	I-Premise
295	ratio	N	I-Premise
296	0.88	N	I-Premise
297	(	N	I-Premise
298	0.49	N	I-Premise
299	to	N	I-Premise
300	1.56	N	I-Premise
301	)	N	I-Premise
302	)	N	I-Premise
303	,	N	I-Premise
304	cerebrovascular	N	I-Premise
305	events	N	I-Premise
306	(	N	I-Premise
307	14	N	I-Premise
308	v	N	I-Premise
309	19	N	I-Premise
310	,	N	I-Premise
311	0.73	N	I-Premise
312	(	N	I-Premise
313	0.37	N	I-Premise
314	to	N	I-Premise
315	1.46	N	I-Premise
316	)	N	I-Premise
317	)	N	I-Premise
318	,	N	I-Premise
319	fractures	N	I-Premise
320	(	N	I-Premise
321	40	N	I-Premise
322	v	N	I-Premise
323	58	N	I-Premise
324	,	N	I-Premise
325	0.69	N	I-Premise
326	(	N	I-Premise
327	0.46	N	I-Premise
328	to	N	I-Premise
329	1.03	N	I-Premise
330	)	N	I-Premise
331	)	N	I-Premise
332	,	N	I-Premise
333	and	N	I-Premise
334	overall	N	I-Premise
335	deaths	N	I-Premise
336	(	N	I-Premise
337	8	N	I-Premise
338	v	N	I-Premise
339	5	N	I-Premise
340	,	N	I-Premise
341	1.60	N	I-Premise
342	(	N	I-Premise
343	0.52	N	I-Premise
344	to	N	I-Premise
345	4.89	N	I-Premise
346	)	N	I-Premise
347	)	N	I-Premise
348	.	N	I-Premise

349	Comparison	N	I-Premise
350	of	N	I-Premise
351	combined	N	I-Premise
352	hormone	N	I-Premise
353	therapy	N	I-Premise
354	(	N	I-Premise
355	n=815	N	I-Premise
356	)	N	I-Premise
357	versus	N	I-Premise
358	oestrogen	N	I-Premise
359	therapy	N	I-Premise
360	(	N	I-Premise
361	n=826	N	I-Premise
362	)	N	I-Premise
363	outcomes	N	I-Premise
364	revealed	N	I-Premise
365	no	N	I-Premise
366	significant	N	I-Premise
367	differences	N	I-Premise
368	.	N	I-Premise

369	Hormone	N	I-Claim
370	replacement	N	I-Claim
371	therapy	N	I-Claim
372	increases	N	I-Claim
373	cardiovascular	N	I-Claim
374	and	N	I-Claim
375	thromboembolic	N	I-Claim
376	risk	N	I-Claim
377	when	N	I-Claim
378	started	N	I-Claim
379	many	N	I-Claim
380	years	N	I-Claim
381	after	N	I-Claim
382	the	N	I-Claim
383	menopause	N	I-Claim
384	.	N	I-Claim

385	The	N	I-Claim
386	results	N	I-Claim
387	are	N	I-Claim
388	consistent	N	I-Claim
389	with	N	I-Claim
390	the	N	I-Claim
391	findings	N	I-Claim
392	of	N	I-Claim
393	the	N	I-Claim
394	women	N	I-Claim
395	's	N	I-Claim
396	health	N	I-Claim
397	initiative	N	I-Claim
398	study	N	I-Claim
399	and	N	I-Claim
400	secondary	N	I-Claim
401	prevention	N	I-Claim
402	studies	N	I-Claim
403	.	N	I-Claim

404	Research	N	I-Claim
405	is	N	I-Claim
406	needed	N	I-Claim
407	to	N	I-Claim
408	assess	N	I-Claim
409	the	N	I-Claim
410	long	N	I-Claim
411	term	N	I-Claim
412	risks	N	I-Claim
413	and	N	I-Claim
414	benefits	N	I-Claim
415	of	N	I-Claim
416	starting	N	I-Claim
417	hormone	N	I-Claim
418	replacement	N	I-Claim
419	therapy	N	I-Claim
420	near	N	I-Claim
421	the	N	I-Claim
422	menopause	N	I-Claim
423	,	N	I-Claim
424	when	N	I-Claim
425	the	N	I-Claim
426	effect	N	I-Claim
427	may	N	I-Claim
428	be	N	I-Claim
429	different	N	I-Claim
430	.	N	I-Claim

1	It	N	I-Claim
2	has	N	I-Claim
3	been	N	I-Claim
4	shown	N	I-Claim
5	that	N	I-Claim
6	nonpharmacologic	N	I-Claim
7	interventions	N	I-Claim
8	are	N	I-Claim
9	effective	N	I-Claim
10	management	N	I-Claim
11	techniques	N	I-Claim
12	for	N	I-Claim
13	cancer-related	N	I-Claim
14	fatigue	N	I-Claim
15	(	N	I-Claim
16	CRF	N	I-Claim
17	)	N	I-Claim
18	in	N	I-Claim
19	cancer	N	I-Claim
20	survivors	N	I-Claim
21	.	N	I-Claim

22	However	N	O
23	,	N	O
24	few	N	O
25	studies	N	O
26	have	N	O
27	investigated	N	O
28	their	N	O
29	effectiveness	N	O
30	in	N	O
31	patients	N	O
32	who	N	O
33	are	N	O
34	receiving	N	O
35	chemotherapy	N	O
36	.	N	O

37	In	N	O
38	this	N	O
39	study	N	O
40	,	N	O
41	the	N	O
42	authors	N	O
43	tested	N	O
44	the	N	O
45	effectiveness	N	O
46	of	N	O
47	a	N	O
48	brief	N	O
49	behaviorally	N	O
50	oriented	N	O
51	intervention	N	O
52	in	N	O
53	reducing	N	O
54	CRF	N	O
55	and	N	O
56	improving	N	O
57	physical	N	O
58	function	N	O
59	and	N	O
60	associated	N	O
61	distress	N	O
62	in	N	O
63	individuals	N	O
64	who	N	O
65	were	N	O
66	receiving	N	O
67	chemotherapy	N	O
68	.	N	O

69	For	N	O
70	this	N	O
71	randomized	N	O
72	controlled	N	O
73	trial	N	O
74	,	N	O
75	60	N	O
76	patients	N	O
77	with	N	O
78	cancer	N	O
79	were	N	O
80	recruited	N	O
81	and	N	O
82	received	N	O
83	either	N	O
84	usual	N	O
85	care	N	O
86	or	N	O
87	the	N	O
88	intervention	N	O
89	.	N	O

90	The	N	O
91	intervention	N	O
92	was	N	O
93	delivered	N	O
94	on	N	O
95	an	N	O
96	individual	N	O
97	basis	N	O
98	on	N	O
99	3	N	O
100	occasions	N	O
101	over	N	O
102	a	N	O
103	period	N	O
104	from	N	O
105	9	N	O
106	weeks	N	O
107	to	N	O
108	12	N	O
109	weeks	N	O
110	,	N	O
111	and	N	O
112	the	N	O
113	objective	N	O
114	of	N	O
115	the	N	O
116	intervention	N	O
117	was	N	O
118	to	N	O
119	alter	N	O
120	fatigue-related	N	O
121	thoughts	N	O
122	and	N	O
123	behavior	N	O
124	.	N	O

125	Primary	N	O
126	outcomes	N	O
127	were	N	O
128	assessed	N	O
129	as	N	O
130	follows	N	O
131	:	N	O
132	CRF	N	O
133	using	N	O
134	the	N	O
135	Visual	N	O
136	Analogue	N	O
137	Scale-Global	N	O
138	Fatigue	N	O
139	;	N	O
140	physical	N	O
141	functioning	N	O
142	using	N	O
143	the	N	O
144	European	N	O
145	Organization	N	O
146	for	N	O
147	Research	N	O
148	and	N	O
149	Treatment	N	O
150	of	N	O
151	Cancer	N	O
152	Quality-of-Life	N	O
153	Core	N	O
154	30	N	O
155	Questionnaire	N	O
156	,	N	O
157	and	N	O
158	CRF-associated	N	O
159	distress	N	O
160	using	N	O
161	the	N	O
162	Fatigue	N	O
163	Outcome	N	O
164	Measure	N	O
165	.	N	O

166	Assessments	N	O
167	were	N	O
168	made	N	O
169	on	N	O
170	4	N	O
171	occasions	N	O
172	:	N	O
173	at	N	O
174	baseline	N	O
175	(	N	O
176	T0	N	O
177	)	N	O
178	,	N	O
179	at	N	O
180	the	N	O
181	end	N	O
182	of	N	O
183	chemotherapy	N	O
184	(	N	O
185	T1	N	O
186	)	N	O
187	,	N	O
188	1	N	O
189	month	N	O
190	after	N	O
191	chemotherapy	N	O
192	(	N	O
193	T2	N	O
194	)	N	O
195	,	N	O
196	and	N	O
197	9	N	O
198	months	N	O
199	after	N	O
200	recruitment	N	O
201	(	N	O
202	T3	N	O
203	)	N	O
204	.	N	O

205	Normally	N	O
206	distributed	N	O
207	data	N	O
208	were	N	O
209	analyzed	N	O
210	using	N	O
211	t	N	O
212	tests	N	O
213	and	N	O
214	random-slope/random-intercept	N	O
215	mixed	N	O
216	models	N	O
217	.	N	O

218	The	N	I-Premise
219	intervention	N	I-Premise
220	demonstrated	N	I-Premise
221	a	N	I-Premise
222	trend	N	I-Premise
223	toward	N	I-Premise
224	improved	N	I-Premise
225	CRF	N	I-Premise
226	,	N	I-Premise
227	although	N	I-Premise
228	this	N	I-Premise
229	effect	N	I-Premise
230	was	N	I-Premise
231	reduced	N	I-Premise
232	once	N	I-Premise
233	confounders	N	I-Premise
234	had	N	I-Premise
235	been	N	I-Premise
236	controlled	N	I-Premise
237	statistically	N	I-Premise
238	.	N	I-Premise

239	There	N	I-Premise
240	was	N	I-Premise
241	a	N	I-Premise
242	significant	N	I-Premise
243	improvement	N	I-Premise
244	in	N	I-Premise
245	physical	N	I-Premise
246	functioning	N	I-Premise
247	(	N	I-Premise
248	coefficient	N	I-Premise
249	,	N	I-Premise
250	10.0	N	I-Premise
251	;	N	I-Premise
252	95	N	I-Premise
253	%	N	I-Premise
254	confidence	N	I-Premise
255	interval	N	I-Premise
256	,	N	I-Premise
257	2.5-17.5	N	I-Premise
258	;	N	I-Premise
259	P	N	I-Premise
260	=	N	I-Premise
261	.009	N	I-Premise
262	)	N	I-Premise
263	,	N	I-Premise
264	and	N	I-Premise
265	this	N	I-Premise
266	effect	N	I-Premise
267	remained	N	I-Premise
268	once	N	I-Premise
269	the	N	I-Premise
270	confounding	N	I-Premise
271	effects	N	I-Premise
272	of	N	I-Premise
273	mood	N	I-Premise
274	disturbance	N	I-Premise
275	and	N	I-Premise
276	comorbid	N	I-Premise
277	disorders	N	I-Premise
278	were	N	I-Premise
279	controlled	N	I-Premise
280	statistically	N	I-Premise
281	.	N	I-Premise

282	No	N	I-Premise
283	decrease	N	I-Premise
284	in	N	I-Premise
285	fatigue-related	N	I-Premise
286	distress	N	I-Premise
287	was	N	I-Premise
288	detected	N	I-Premise
289	.	N	I-Premise

290	The	N	I-Claim
291	behaviorally	N	I-Claim
292	oriented	N	I-Claim
293	intervention	N	I-Claim
294	brought	N	I-Claim
295	about	N	I-Claim
296	significant	N	I-Claim
297	improvements	N	I-Claim
298	in	N	I-Claim
299	physical	N	I-Claim
300	functioning	N	I-Claim
301	,	N	I-Claim
302	indicated	N	I-Claim
303	a	N	I-Claim
304	trend	N	I-Claim
305	toward	N	I-Claim
306	improved	N	I-Claim
307	CRF	N	I-Claim
308	,	N	I-Claim
309	but	N	I-Claim
310	detected	N	I-Claim
311	no	N	I-Claim
312	effect	N	I-Claim
313	for	N	I-Claim
314	fatigue-related	N	I-Claim
315	distress	N	I-Claim
316	.	N	I-Claim

1	Therapy	N	I-MajorClaim
2	of	N	I-MajorClaim
3	patients	N	I-MajorClaim
4	with	N	I-MajorClaim
5	advanced	N	I-MajorClaim
6	gastric	N	I-MajorClaim
7	or	N	I-MajorClaim
8	gastroesophageal	N	I-MajorClaim
9	junction	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	should	N	I-MajorClaim
12	provide	N	I-MajorClaim
13	symptom	N	I-MajorClaim
14	relief	N	I-MajorClaim
15	and	N	I-MajorClaim
16	improve	N	I-MajorClaim
17	quality	N	I-MajorClaim
18	of	N	I-MajorClaim
19	life	N	I-MajorClaim
20	(	N	I-MajorClaim
21	QOL	N	I-MajorClaim
22	)	N	I-MajorClaim
23	because	N	I-MajorClaim
24	most	N	I-MajorClaim
25	patients	N	I-MajorClaim
26	are	N	I-MajorClaim
27	symptomatic	N	I-MajorClaim
28	at	N	I-MajorClaim
29	baseline	N	I-MajorClaim
30	.	N	I-MajorClaim

31	Using	N	O
32	validated	N	O
33	instruments	N	O
34	,	N	O
35	we	N	O
36	prospectively	N	O
37	assessed	N	O
38	QOL	N	O
39	(	N	O
40	even	N	O
41	after	N	O
42	completion	N	O
43	of	N	O
44	protocol	N	O
45	treatment	N	O
46	)	N	O
47	as	N	O
48	one	N	O
49	of	N	O
50	the	N	O
51	secondary	N	O
52	end	N	O
53	points	N	O
54	of	N	O
55	the	N	O
56	V325	N	O
57	phase	N	O
58	III	N	O
59	trial	N	O
60	.	N	O

61	Four	N	O
62	hundred	N	O
63	forty-five	N	O
64	patients	N	O
65	randomly	N	O
66	received	N	O
67	either	N	O
68	docetaxel	N	O
69	75	N	O
70	mg/m	N	O
71	(	N	O
72	2	N	O
73	)	N	O
74	and	N	O
75	cisplatin	N	O
76	75	N	O
77	mg/m	N	O
78	(	N	O
79	2	N	O
80	)	N	O
81	each	N	O
82	on	N	O
83	day	N	O
84	1	N	O
85	plus	N	O
86	fluorouracil	N	O
87	750	N	O
88	mg/m	N	O
89	(	N	O
90	2	N	O
91	)	N	O
92	/d	N	O
93	continuous	N	O
94	infusion	N	O
95	on	N	O
96	days	N	O
97	1	N	O
98	to	N	O
99	5	N	O
100	every	N	O
101	3	N	O
102	weeks	N	O
103	(	N	O
104	DCF	N	O
105	)	N	O
106	or	N	O
107	cisplatin	N	O
108	100	N	O
109	mg/m	N	O
110	(	N	O
111	2	N	O
112	)	N	O
113	on	N	O
114	day	N	O
115	1	N	O
116	plus	N	O
117	fluorouracil	N	O
118	1,000	N	O
119	mg/m	N	O
120	(	N	O
121	2	N	O
122	)	N	O
123	/d	N	O
124	continuous	N	O
125	infusion	N	O
126	on	N	O
127	days	N	O
128	1	N	O
129	to	N	O
130	5	N	O
131	every	N	O
132	4	N	O
133	weeks	N	O
134	(	N	O
135	CF	N	O
136	)	N	O
137	.	N	O

138	The	N	O
139	European	N	O
140	Organisation	N	O
141	for	N	O
142	Research	N	O
143	and	N	O
144	Treatment	N	O
145	of	N	O
146	Cancer	N	O
147	Quality	N	O
148	of	N	O
149	Life	N	O
150	Questionnaire	N	O
151	C30	N	O
152	(	N	O
153	EORTC	N	O
154	QLQ-C30	N	O
155	)	N	O
156	and	N	O
157	,	N	O
158	where	N	O
159	available	N	O
160	,	N	O
161	the	N	O
162	EuroQOL	N	O
163	EQ-5D	N	O
164	questionnaire	N	O
165	were	N	O
166	administered	N	O
167	every	N	O
168	8	N	O
169	weeks	N	O
170	from	N	O
171	baseline	N	O
172	until	N	O
173	progression	N	O
174	and	N	O
175	then	N	O
176	every	N	O
177	3	N	O
178	months	N	O
179	.	N	O

180	Time	N	O
181	to	N	O
182	definitive	N	O
183	deterioration	N	O
184	of	N	O
185	QOL	N	O
186	parameters	N	O
187	was	N	O
188	analyzed	N	O
189	.	N	O

190	The	N	O
191	proportions	N	O
192	of	N	O
193	patients	N	O
194	having	N	O
195	assessable	N	O
196	EORTC	N	O
197	QLQ-C30	N	O
198	and	N	O
199	EQ-5D	N	O
200	questionnaires	N	O
201	at	N	O
202	baseline	N	O
203	were	N	O
204	86.0	N	O
205	%	N	O
206	and	N	O
207	78.7	N	O
208	%	N	O
209	with	N	O
210	DCF	N	O
211	,	N	O
212	respectively	N	O
213	,	N	O
214	and	N	O
215	89.7	N	O
216	%	N	O
217	and	N	O
218	92.8	N	O
219	%	N	O
220	with	N	O
221	CF	N	O
222	,	N	O
223	respectively	N	O
224	.	N	O

225	Time	N	I-Premise
226	to	N	I-Premise
227	5	N	I-Premise
228	%	N	I-Premise
229	deterioration	N	I-Premise
230	of	N	I-Premise
231	global	N	I-Premise
232	health	N	I-Premise
233	status	N	I-Premise
234	(	N	I-Premise
235	primary	N	I-Premise
236	end	N	I-Premise
237	point	N	I-Premise
238	)	N	I-Premise
239	significantly	N	I-Premise
240	favored	N	I-Premise
241	DCF	N	I-Premise
242	over	N	I-Premise
243	CF	N	I-Premise
244	(	N	I-Premise
245	log-rank	N	I-Premise
246	test	N	I-Premise
247	,	N	I-Premise
248	P	N	I-Premise
249	=	N	I-Premise
250	.01	N	I-Premise
251	)	N	I-Premise
252	.	N	I-Premise

253	QOL	N	I-Premise
254	was	N	I-Premise
255	preserved	N	I-Premise
256	longer	N	I-Premise
257	for	N	I-Premise
258	patients	N	I-Premise
259	on	N	I-Premise
260	DCF	N	I-Premise
261	than	N	I-Premise
262	those	N	I-Premise
263	on	N	I-Premise
264	CF	N	I-Premise
265	for	N	I-Premise
266	all	N	I-Premise
267	time	N	I-Premise
268	to	N	I-Premise
269	deterioration	N	I-Premise
270	analyses	N	I-Premise
271	,	N	I-Premise
272	demonstrating	N	I-Premise
273	the	N	I-Premise
274	statistical	N	I-Premise
275	superiority	N	I-Premise
276	of	N	I-Premise
277	DCF	N	I-Premise
278	compared	N	I-Premise
279	with	N	I-Premise
280	CF	N	I-Premise
281	.	N	I-Premise

282	V325	N	O
283	represents	N	O
284	the	N	O
285	largest	N	O
286	trial	N	O
287	with	N	O
288	the	N	O
289	longest	N	O
290	prospectively	N	O
291	controlled	N	O
292	evaluations	N	O
293	of	N	O
294	QOL	N	O
295	during	N	O
296	protocol	N	O
297	chemotherapy	N	O
298	and	N	O
299	follow-up	N	O
300	in	N	O
301	patients	N	O
302	with	N	O
303	advanced	N	O
304	gastric	N	O
305	or	N	O
306	gastroesophageal	N	O
307	junction	N	O
308	cancer	N	O
309	.	N	O

310	In	N	I-Claim
311	V325	N	I-Claim
312	,	N	I-Claim
313	advanced	N	I-Claim
314	gastric	N	I-Claim
315	or	N	I-Claim
316	gastroesophageal	N	I-Claim
317	junction	N	I-Claim
318	cancer	N	I-Claim
319	patients	N	I-Claim
320	receiving	N	I-Claim
321	DCF	N	I-Claim
322	not	N	I-Claim
323	only	N	I-Claim
324	had	N	I-Claim
325	statistically	N	I-Claim
326	improved	N	I-Claim
327	overall	N	I-Claim
328	survival	N	I-Claim
329	and	N	I-Claim
330	time	N	I-Claim
331	to	N	I-Claim
332	tumor-progression	N	I-Claim
333	,	N	I-Claim
334	but	N	I-Claim
335	they	N	I-Claim
336	also	N	I-Claim
337	had	N	I-Claim
338	better	N	I-Claim
339	preservation	N	I-Claim
340	of	N	I-Claim
341	QOL	N	I-Claim
342	compared	N	I-Claim
343	with	N	I-Claim
344	patients	N	I-Claim
345	receiving	N	I-Claim
346	CF	N	I-Claim
347	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	phase	N	O
4	II	N	O
5	trial	N	O
6	evaluated	N	O
7	two	N	O
8	docetaxel-based	N	O
9	regimens	N	O
10	to	N	O
11	see	N	O
12	which	N	O
13	would	N	O
14	be	N	O
15	most	N	O
16	promising	N	O
17	according	N	O
18	to	N	O
19	overall	N	O
20	response	N	O
21	rate	N	O
22	(	N	O
23	ORR	N	O
24	)	N	O
25	for	N	O
26	comparison	N	O
27	in	N	O
28	a	N	O
29	phase	N	O
30	III	N	O
31	trial	N	O
32	with	N	O
33	epirubicin-cisplatin-fluorouracil	N	O
34	(	N	O
35	ECF	N	O
36	)	N	O
37	as	N	O
38	first-line	N	O
39	advanced	N	O
40	gastric	N	O
41	cancer	N	O
42	therapy	N	O
43	.	N	O

44	Chemotherapy-nave	N	O
45	patients	N	O
46	with	N	O
47	measurable	N	O
48	unresectable	N	O
49	and/or	N	O
50	metastatic	N	O
51	gastric	N	O
52	carcinoma	N	O
53	,	N	O
54	a	N	O
55	performance	N	O
56	status	N	O
57	<	N	O
58	or=	N	O
59	1	N	O
60	,	N	O
61	and	N	O
62	adequate	N	O
63	hematologic	N	O
64	,	N	O
65	hepatic	N	O
66	,	N	O
67	and	N	O
68	renal	N	O
69	function	N	O
70	randomly	N	O
71	received	N	O
72	<	N	O
73	or=	N	O
74	eight	N	O
75	3-weekly	N	O
76	cycles	N	O
77	of	N	O
78	ECF	N	O
79	(	N	O
80	epirubicin	N	O
81	50	N	O
82	mg/m	N	O
83	(	N	O
84	2	N	O
85	)	N	O
86	on	N	O
87	day	N	O
88	1	N	O
89	,	N	O
90	cisplatin	N	O
91	60	N	O
92	mg/m	N	O
93	(	N	O
94	2	N	O
95	)	N	O
96	on	N	O
97	day	N	O
98	1	N	O
99	,	N	O
100	and	N	O
101	fluorouracil	N	O
102	[	N	O
103	FU	N	O
104	]	N	O
105	200	N	O
106	mg/m	N	O
107	(	N	O
108	2	N	O
109	)	N	O
110	/d	N	O
111	on	N	O
112	days	N	O
113	1	N	O
114	to	N	O
115	21	N	O
116	)	N	O
117	,	N	O
118	TC	N	O
119	(	N	O
120	docetaxel	N	O
121	initially	N	O
122	85	N	O
123	mg/m	N	O
124	(	N	O
125	2	N	O
126	)	N	O
127	on	N	O
128	day	N	O
129	1	N	O
130	[	N	O
131	later	N	O
132	reduced	N	O
133	to	N	O
134	75	N	O
135	mg/m	N	O
136	(	N	O
137	2	N	O
138	)	N	O
139	as	N	O
140	a	N	O
141	result	N	O
142	of	N	O
143	toxicity	N	O
144	]	N	O
145	and	N	O
146	cisplatin	N	O
147	75	N	O
148	mg/m	N	O
149	(	N	O
150	2	N	O
151	)	N	O
152	on	N	O
153	day	N	O
154	1	N	O
155	)	N	O
156	,	N	O
157	or	N	O
158	TCF	N	O
159	(	N	O
160	TC	N	O
161	plus	N	O
162	FU	N	O
163	300	N	O
164	mg/m	N	O
165	(	N	O
166	2	N	O
167	)	N	O
168	/d	N	O
169	on	N	O
170	days	N	O
171	1	N	O
172	to	N	O
173	14	N	O
174	)	N	O
175	.	N	O

176	Study	N	O
177	objectives	N	O
178	included	N	O
179	response	N	O
180	(	N	O
181	primary	N	O
182	)	N	O
183	,	N	O
184	survival	N	O
185	,	N	O
186	toxicity	N	O
187	,	N	O
188	and	N	O
189	quality	N	O
190	of	N	O
191	life	N	O
192	(	N	O
193	QOL	N	O
194	)	N	O
195	.	N	O

196	ORR	N	I-Premise
197	was	N	I-Premise
198	25.0	N	I-Premise
199	%	N	I-Premise
200	(	N	I-Premise
201	95	N	I-Premise
202	%	N	I-Premise
203	CI	N	I-Premise
204	,	N	I-Premise
205	13	N	I-Premise
206	%	N	I-Premise
207	to	N	I-Premise
208	41	N	I-Premise
209	%	N	I-Premise
210	)	N	I-Premise
211	for	N	I-Premise
212	ECF	N	I-Premise
213	,	N	I-Premise
214	18.5	N	I-Premise
215	%	N	I-Premise
216	(	N	I-Premise
217	95	N	I-Premise
218	%	N	I-Premise
219	CI	N	I-Premise
220	,	N	I-Premise
221	9	N	I-Premise
222	%	N	I-Premise
223	to	N	I-Premise
224	34	N	I-Premise
225	%	N	I-Premise
226	)	N	I-Premise
227	for	N	I-Premise
228	TC	N	I-Premise
229	,	N	I-Premise
230	and	N	I-Premise
231	36.6	N	I-Premise
232	%	N	I-Premise
233	(	N	I-Premise
234	95	N	I-Premise
235	%	N	I-Premise
236	CI	N	I-Premise
237	,	N	I-Premise
238	23	N	I-Premise
239	%	N	I-Premise
240	to	N	I-Premise
241	53	N	I-Premise
242	%	N	I-Premise
243	)	N	I-Premise
244	for	N	I-Premise
245	TCF	N	I-Premise
246	(	N	I-Premise
247	n	N	I-Premise
248	=	N	I-Premise
249	119	N	I-Premise
250	)	N	I-Premise
251	.	N	I-Premise

252	Median	N	I-Premise
253	overall	N	I-Premise
254	survival	N	I-Premise
255	times	N	I-Premise
256	were	N	I-Premise
257	8.3	N	I-Premise
258	,	N	I-Premise
259	11.0	N	I-Premise
260	,	N	I-Premise
261	and	N	I-Premise
262	10.4	N	I-Premise
263	months	N	I-Premise
264	for	N	I-Premise
265	ECF	N	I-Premise
266	,	N	I-Premise
267	TC	N	I-Premise
268	,	N	I-Premise
269	and	N	I-Premise
270	TCF	N	I-Premise
271	,	N	I-Premise
272	respectively	N	I-Premise
273	.	N	I-Premise

274	Toxicity	N	I-Premise
275	was	N	I-Premise
276	acceptable	N	I-Premise
277	,	N	I-Premise
278	with	N	I-Premise
279	one	N	I-Premise
280	toxic	N	I-Premise
281	death	N	I-Premise
282	(	N	I-Premise
283	TC	N	I-Premise
284	arm	N	I-Premise
285	)	N	I-Premise
286	.	N	I-Premise

287	Grade	N	I-Premise
288	3	N	I-Premise
289	or	N	I-Premise
290	4	N	I-Premise
291	neutropenia	N	I-Premise
292	occurred	N	I-Premise
293	in	N	I-Premise
294	more	N	I-Premise
295	treatment	N	I-Premise
296	cycles	N	I-Premise
297	with	N	I-Premise
298	docetaxel	N	I-Premise
299	(	N	I-Premise
300	TC	N	I-Premise
301	,	N	I-Premise
302	49	N	I-Premise
303	%	N	I-Premise
304	;	N	I-Premise
305	TCF	N	I-Premise
306	,	N	I-Premise
307	57	N	I-Premise
308	%	N	I-Premise
309	;	N	I-Premise
310	ECF	N	I-Premise
311	,	N	I-Premise
312	34	N	I-Premise
313	%	N	I-Premise
314	)	N	I-Premise
315	.	N	I-Premise

316	Global	N	I-Claim
317	health	N	I-Claim
318	status/QOL	N	I-Claim
319	substantially	N	I-Claim
320	improved	N	I-Claim
321	with	N	I-Claim
322	ECF	N	I-Claim
323	and	N	I-Claim
324	remained	N	I-Claim
325	similar	N	I-Claim
326	to	N	I-Claim
327	baseline	N	I-Claim
328	with	N	I-Claim
329	both	N	I-Claim
330	docetaxel	N	I-Claim
331	regimens	N	I-Claim
332	.	N	I-Claim

333	Time	N	I-Premise
334	to	N	I-Premise
335	response	N	I-Premise
336	and	N	I-Premise
337	ORR	N	I-Premise
338	favor	N	I-Premise
339	TCF	N	I-Premise
340	over	N	I-Premise
341	TC	N	I-Premise
342	for	N	I-Premise
343	further	N	I-Premise
344	evaluation	N	I-Premise
345	,	N	I-Premise
346	particularly	N	I-Premise
347	in	N	I-Premise
348	the	N	I-Premise
349	neoadjuvant	N	I-Premise
350	setting	N	I-Premise
351	.	N	I-Premise

352	A	N	I-Premise
353	trend	N	I-Premise
354	towards	N	I-Premise
355	increased	N	I-Premise
356	myelosuppression	N	I-Premise
357	and	N	I-Premise
358	infectious	N	I-Premise
359	complications	N	I-Premise
360	with	N	I-Premise
361	TCF	N	I-Premise
362	versus	N	I-Premise
363	TC	N	I-Premise
364	or	N	I-Premise
365	ECF	N	I-Premise
366	was	N	I-Premise
367	observed	N	I-Premise
368	.	N	I-Premise

1	To	N	O
2	assess	N	O
3	whether	N	O
4	omission	N	O
5	of	N	O
6	postoperative	N	O
7	radiotherapy	N	O
8	in	N	O
9	women	N	O
10	with	N	O
11	'low-risk	N	O
12	'	N	O
13	axillary	N	O
14	node	N	O
15	negative	N	O
16	breast	N	O
17	cancer	N	O
18	(	N	O
19	T0-2	N	O
20	)	N	O
21	treated	N	O
22	by	N	O
23	breast-conserving	N	O
24	surgery	N	O
25	and	N	O
26	endocrine	N	O
27	therapy	N	O
28	improves	N	O
29	quality	N	O
30	of	N	O
31	life	N	O
32	and	N	O
33	is	N	O
34	more	N	O
35	cost-effective	N	O
36	.	N	O

37	A	N	O
38	randomised	N	O
39	controlled	N	O
40	clinical	N	O
41	trial	N	O
42	,	N	O
43	using	N	O
44	a	N	O
45	method	N	O
46	of	N	O
47	minimisation	N	O
48	balanced	N	O
49	by	N	O
50	centre	N	O
51	,	N	O
52	grade	N	O
53	of	N	O
54	cancer	N	O
55	,	N	O
56	age	N	O
57	,	N	O
58	lymphatic/vascular	N	O
59	invasion	N	O
60	and	N	O
61	preoperative	N	O
62	endocrine	N	O
63	therapy	N	O
64	,	N	O
65	was	N	O
66	performed	N	O
67	.	N	O

68	A	N	O
69	non-randomised	N	O
70	cohort	N	O
71	was	N	O
72	also	N	O
73	recruited	N	O
74	,	N	O
75	in	N	O
76	order	N	O
77	to	N	O
78	complete	N	O
79	a	N	O
80	comprehensive	N	O
81	cohort	N	O
82	study	N	O
83	.	N	O

84	The	N	O
85	setting	N	O
86	was	N	O
87	breast	N	O
88	cancer	N	O
89	clinics	N	O
90	in	N	O
91	cancer	N	O
92	centres	N	O
93	in	N	O
94	the	N	O
95	UK	N	O
96	.	N	O

97	Patients	N	O
98	aged	N	O
99	65	N	O
100	years	N	O
101	or	N	O
102	more	N	O
103	were	N	O
104	eligible	N	O
105	provided	N	O
106	that	N	O
107	their	N	O
108	cancers	N	O
109	were	N	O
110	considered	N	O
111	to	N	O
112	be	N	O
113	at	N	O
114	low	N	O
115	risk	N	O
116	of	N	O
117	local	N	O
118	recurrence	N	O
119	,	N	O
120	were	N	O
121	suitable	N	O
122	for	N	O
123	breast-conservation	N	O
124	surgery	N	O
125	,	N	O
126	were	N	O
127	receiving	N	O
128	endocrine	N	O
129	therapy	N	O
130	and	N	O
131	were	N	O
132	able	N	O
133	and	N	O
134	willing	N	O
135	to	N	O
136	give	N	O
137	informed	N	O
138	consent	N	O
139	.	N	O

140	The	N	O
141	standard	N	O
142	treatment	N	O
143	of	N	O
144	postoperative	N	O
145	breast	N	O
146	irradiation	N	O
147	or	N	O
148	the	N	O
149	omission	N	O
150	of	N	O
151	radiotherapy	N	O
152	.	N	O

153	Quality	N	O
154	of	N	O
155	life	N	O
156	was	N	O
157	the	N	O
158	primary	N	O
159	outcome	N	O
160	measure	N	O
161	,	N	O
162	together	N	O
163	with	N	O
164	anxiety	N	O
165	and	N	O
166	depression	N	O
167	and	N	O
168	cost-effectiveness	N	O
169	.	N	O

170	Secondary	N	O
171	outcome	N	O
172	measures	N	O
173	were	N	O
174	recurrence	N	O
175	rates	N	O
176	,	N	O
177	functional	N	O
178	status	N	O
179	,	N	O
180	treatment-related	N	O
181	morbidity	N	O
182	and	N	O
183	cosmesis	N	O
184	.	N	O

185	The	N	O
186	principal	N	O
187	method	N	O
188	of	N	O
189	data	N	O
190	collection	N	O
191	was	N	O
192	by	N	O
193	questionnaire	N	O
194	,	N	O
195	completed	N	O
196	at	N	O
197	home	N	O
198	with	N	O
199	a	N	O
200	research	N	O
201	nurse	N	O
202	at	N	O
203	four	N	O
204	times	N	O
205	over	N	O
206	15	N	O
207	months	N	O
208	.	N	O

209	The	N	I-Claim
210	hypothesised	N	I-Claim
211	improvement	N	I-Claim
212	in	N	I-Claim
213	overall	N	I-Claim
214	quality	N	I-Claim
215	of	N	I-Claim
216	life	N	I-Claim
217	with	N	I-Claim
218	the	N	I-Claim
219	omission	N	I-Claim
220	of	N	I-Claim
221	radiotherapy	N	I-Claim
222	was	N	I-Claim
223	not	N	I-Claim
224	seen	N	I-Claim
225	in	N	I-Claim
226	the	N	I-Claim
227	EuroQol	N	I-Claim
228	assessment	N	I-Claim
229	or	N	I-Claim
230	in	N	I-Claim
231	the	N	I-Claim
232	functionality	N	I-Claim
233	and	N	I-Claim
234	symptoms	N	I-Claim
235	summary	N	I-Claim
236	domains	N	I-Claim
237	of	N	I-Claim
238	the	N	I-Claim
239	European	N	I-Claim
240	Organisation	N	I-Claim
241	for	N	I-Claim
242	Research	N	I-Claim
243	in	N	I-Claim
244	the	N	I-Claim
245	Treatment	N	I-Claim
246	of	N	I-Claim
247	Cancer	N	I-Claim
248	(	N	I-Claim
249	EORTC	N	I-Claim
250	)	N	I-Claim
251	scales	N	I-Claim
252	.	N	I-Claim

253	Some	N	O
254	differences	N	O
255	were	N	O
256	apparent	N	O
257	within	N	O
258	subscales	N	O
259	of	N	O
260	the	N	O
261	EORTC	N	O
262	questionnaires	N	O
263	,	N	O
264	and	N	O
265	insights	N	O
266	into	N	O
267	the	N	O
268	impact	N	O
269	of	N	O
270	treatment	N	O
271	were	N	O
272	also	N	O
273	provided	N	O
274	by	N	O
275	the	N	O
276	qualitative	N	O
277	data	N	O
278	obtained	N	O
279	by	N	O
280	open-ended	N	O
281	questions	N	O
282	.	N	O

283	Differences	N	I-Premise
284	were	N	I-Premise
285	most	N	I-Premise
286	apparent	N	I-Premise
287	shortly	N	I-Premise
288	after	N	I-Premise
289	the	N	I-Premise
290	time	N	I-Premise
291	of	N	I-Premise
292	completion	N	I-Premise
293	of	N	I-Premise
294	radiotherapy	N	I-Premise
295	.	N	I-Premise

296	Radiotherapy	N	I-Claim
297	was	N	I-Claim
298	then	N	I-Claim
299	associated	N	I-Claim
300	with	N	I-Claim
301	increased	N	I-Claim
302	breast	N	I-Claim
303	symptoms	N	I-Claim
304	and	N	I-Claim
305	with	N	I-Claim
306	greater	N	I-Claim
307	fatigue	N	I-Claim
308	but	N	I-Claim
309	with	N	I-Claim
310	less	N	I-Claim
311	insomnia	N	I-Claim
312	and	N	I-Claim
313	endocrine	N	I-Claim
314	side-effects	N	I-Claim
315	.	N	I-Claim

316	Patients	N	I-Premise
317	had	N	I-Premise
318	significant	N	I-Premise
319	concerns	N	I-Premise
320	about	N	I-Premise
321	the	N	I-Premise
322	delivery	N	I-Premise
323	of	N	I-Premise
324	radiotherapy	N	I-Premise
325	services	N	I-Premise
326	,	N	I-Premise
327	such	N	I-Premise
328	as	N	I-Premise
329	transport	N	I-Premise
330	,	N	I-Premise
331	accommodation	N	I-Premise
332	and	N	I-Premise
333	travel	N	I-Premise
334	costs	N	I-Premise
335	associated	N	I-Premise
336	with	N	I-Premise
337	receiving	N	I-Premise
338	radiotherapy	N	I-Premise
339	.	N	I-Premise

340	By	N	I-Premise
341	the	N	I-Premise
342	end	N	I-Premise
343	of	N	I-Premise
344	follow-up	N	I-Premise
345	,	N	I-Premise
346	patients	N	I-Premise
347	receiving	N	I-Premise
348	radiotherapy	N	I-Premise
349	were	N	I-Premise
350	expressing	N	I-Premise
351	less	N	I-Premise
352	anxiety	N	I-Premise
353	about	N	I-Premise
354	recurrence	N	I-Premise
355	than	N	I-Premise
356	those	N	I-Premise
357	who	N	I-Premise
358	had	N	I-Premise
359	not	N	I-Premise
360	received	N	I-Premise
361	radiotherapy	N	I-Premise
362	.	N	I-Premise

363	Functionality	N	I-Premise
364	was	N	I-Premise
365	not	N	I-Premise
366	greatly	N	I-Premise
367	affected	N	I-Premise
368	by	N	I-Premise
369	treatment	N	I-Premise
370	.	N	I-Premise

371	Within	N	I-Premise
372	the	N	I-Premise
373	randomised	N	I-Premise
374	controlled	N	I-Premise
375	trial	N	I-Premise
376	,	N	I-Premise
377	the	N	I-Premise
378	Barthel	N	I-Premise
379	Index	N	I-Premise
380	demonstrated	N	I-Premise
381	a	N	I-Premise
382	small	N	I-Premise
383	but	N	I-Premise
384	significant	N	I-Premise
385	fall	N	I-Premise
386	in	N	I-Premise
387	functionality	N	I-Premise
388	with	N	I-Premise
389	radiotherapy	N	I-Premise
390	compared	N	I-Premise
391	with	N	I-Premise
392	the	N	I-Premise
393	no	N	I-Premise
394	radiotherapy	N	I-Premise
395	arm	N	I-Premise
396	of	N	I-Premise
397	the	N	I-Premise
398	trial	N	I-Premise
399	.	N	I-Premise

400	Results	N	I-Premise
401	from	N	I-Premise
402	the	N	I-Premise
403	non-randomised	N	I-Premise
404	patients	N	I-Premise
405	did	N	I-Premise
406	not	N	I-Premise
407	confirm	N	I-Premise
408	this	N	I-Premise
409	effect	N	I-Premise
410	,	N	I-Premise
411	however	N	I-Premise
412	.	N	I-Premise

413	Cosmetic	N	I-Premise
414	results	N	I-Premise
415	were	N	I-Premise
416	better	N	I-Premise
417	in	N	I-Premise
418	those	N	I-Premise
419	not	N	I-Premise
420	receiving	N	I-Premise
421	radiotherapy	N	I-Premise
422	but	N	I-Premise
423	this	N	I-Premise
424	did	N	I-Premise
425	not	N	I-Premise
426	appear	N	I-Premise
427	to	N	I-Premise
428	be	N	I-Premise
429	an	N	I-Premise
430	important	N	I-Premise
431	issue	N	I-Premise
432	to	N	I-Premise
433	the	N	I-Premise
434	patients	N	I-Premise
435	.	N	I-Premise

436	The	N	I-Claim
437	use	N	I-Claim
438	of	N	I-Claim
439	home-based	N	I-Claim
440	assessments	N	I-Claim
441	by	N	I-Claim
442	a	N	I-Claim
443	research	N	I-Claim
444	nurse	N	I-Claim
445	proved	N	I-Claim
446	to	N	I-Claim
447	be	N	I-Claim
448	an	N	I-Claim
449	effective	N	I-Claim
450	way	N	I-Claim
451	of	N	I-Claim
452	obtaining	N	I-Claim
453	high-quality	N	I-Claim
454	data	N	I-Claim
455	.	N	I-Claim

456	Costs	N	O
457	to	N	O
458	the	N	O
459	NHS	N	O
460	associated	N	O
461	with	N	O
462	postoperative	N	O
463	radiotherapy	N	O
464	were	N	O
465	calculated	N	O
466	to	N	O
467	be	N	O
468	of	N	O
469	the	N	O
470	order	N	O
471	of	N	O
472	2000	N	O
473	pounds	N	O
474	per	N	O
475	patient	N	O
476	.	N	O

477	In	N	I-Premise
478	the	N	I-Premise
479	follow-up	N	I-Premise
480	in	N	I-Premise
481	this	N	I-Premise
482	study	N	I-Premise
483	,	N	I-Premise
484	there	N	I-Premise
485	were	N	I-Premise
486	no	N	I-Premise
487	recurrences	N	I-Premise
488	,	N	I-Premise
489	and	N	I-Premise
490	the	N	I-Premise
491	quality	N	I-Premise
492	of	N	I-Premise
493	life	N	I-Premise
494	utilities	N	I-Premise
495	from	N	I-Premise
496	EuroQol	N	I-Premise
497	were	N	I-Premise
498	almost	N	I-Premise
499	identical	N	I-Premise
500	.	N	I-Premise

501	Although	N	I-Premise
502	there	N	I-Premise
503	are	N	I-Premise
504	no	N	I-Premise
505	differences	N	I-Premise
506	in	N	I-Premise
507	overall	N	I-Premise
508	quality	N	I-Premise
509	of	N	I-Premise
510	life	N	I-Premise
511	scores	N	I-Premise
512	between	N	I-Premise
513	the	N	I-Premise
514	patients	N	I-Premise
515	treated	N	I-Premise
516	with	N	I-Premise
517	and	N	I-Premise
518	without	N	I-Premise
519	radiotherapy	N	I-Premise
520	,	N	I-Premise
521	there	N	I-Premise
522	are	N	I-Premise
523	several	N	I-Premise
524	dimensions	N	I-Premise
525	that	N	I-Premise
526	exhibit	N	I-Premise
527	significant	N	I-Premise
528	advantage	N	I-Premise
529	to	N	I-Premise
530	the	N	I-Premise
531	omission	N	I-Premise
532	of	N	I-Premise
533	irradiation	N	I-Premise
534	.	N	I-Premise

535	Over	N	I-Premise
536	the	N	I-Premise
537	first	N	I-Premise
538	15	N	I-Premise
539	months	N	I-Premise
540	,	N	I-Premise
541	radiotherapy	N	I-Premise
542	for	N	I-Premise
543	this	N	I-Premise
544	population	N	I-Premise
545	is	N	I-Premise
546	not	N	I-Premise
547	a	N	I-Premise
548	cost-effective	N	I-Premise
549	treatment	N	I-Premise
550	.	N	I-Premise

551	However	N	O
552	,	N	O
553	the	N	O
554	early	N	I-Claim
555	postoperative	N	I-Claim
556	outcome	N	I-Claim
557	does	N	I-Claim
558	not	N	I-Claim
559	give	N	I-Claim
560	a	N	I-Claim
561	complete	N	I-Claim
562	answer	N	I-Claim
563	and	N	O
564	the	N	I-Claim
565	eventual	N	I-Claim
566	cost-effectiveness	N	I-Claim
567	will	N	I-Claim
568	only	N	I-Claim
569	become	N	I-Claim
570	clear	N	I-Claim
571	after	N	I-Claim
572	long-term	N	I-Claim
573	follow-up	N	I-Claim
574	.	N	I-Claim

575	Extrapolations	N	I-Claim
576	from	N	I-Claim
577	these	N	I-Claim
578	data	N	I-Claim
579	suggest	N	I-Claim
580	that	N	I-Claim
581	radiotherapy	N	I-Claim
582	may	N	I-Claim
583	not	N	I-Claim
584	be	N	I-Claim
585	a	N	I-Claim
586	cost-effective	N	I-Claim
587	treatment	N	I-Claim
588	unless	N	I-Claim
589	it	N	I-Claim
590	results	N	I-Claim
591	in	N	I-Claim
592	a	N	I-Claim
593	recurrence	N	I-Claim
594	rate	N	I-Claim
595	that	N	I-Claim
596	is	N	I-Claim
597	at	N	I-Claim
598	least	N	I-Claim
599	5	N	I-Claim
600	%	N	I-Claim
601	lower	N	I-Claim
602	in	N	I-Claim
603	absolute	N	I-Claim
604	terms	N	I-Claim
605	than	N	I-Claim
606	those	N	I-Claim
607	treated	N	I-Claim
608	without	N	I-Claim
609	radiotherapy	N	I-Claim
610	.	N	I-Claim

611	Further	N	I-Claim
612	research	N	I-Claim
613	is	N	I-Claim
614	needed	N	I-Claim
615	into	N	I-Claim
616	a	N	I-Claim
617	number	N	I-Claim
618	of	N	I-Claim
619	areas	N	I-Claim
620	including	N	I-Claim
621	the	N	I-Claim
622	long-term	N	I-Claim
623	aspects	N	I-Claim
624	of	N	I-Claim
625	quality	N	I-Claim
626	of	N	I-Claim
627	life	N	I-Claim
628	,	N	I-Claim
629	clinical	N	I-Claim
630	outcomes	N	I-Claim
631	,	N	I-Claim
632	costs	N	I-Claim
633	and	N	I-Claim
634	consequences	N	I-Claim
635	of	N	I-Claim
636	omitting	N	I-Claim
637	radiotherapy	N	I-Claim
638	.	N	I-Claim

1	This	N	O
2	double-blind	N	O
3	randomized	N	O
4	phase	N	O
5	II	N	O
6	trial	N	O
7	examined	N	O
8	whether	N	O
9	vandetanib	N	O
10	,	N	O
11	an	N	O
12	inhibitor	N	O
13	of	N	O
14	vascular	N	O
15	endothelial	N	O
16	and	N	O
17	epidermal	N	O
18	growth	N	O
19	factor	N	O
20	receptors	N	O
21	,	N	O
22	could	N	O
23	prolong	N	O
24	progression-free	N	O
25	survival	N	O
26	in	N	O
27	responding	N	O
28	patients	N	O
29	with	N	O
30	small-cell	N	O
31	lung	N	O
32	cancer	N	O
33	.	N	O

34	Eligible	N	O
35	patients	N	O
36	with	N	O
37	complete	N	O
38	response	N	O
39	(	N	O
40	CR	N	O
41	)	N	O
42	or	N	O
43	partial	N	O
44	response	N	O
45	(	N	O
46	PR	N	O
47	)	N	O
48	to	N	O
49	combination	N	O
50	chemotherapy	N	O
51	(	N	O
52	+/-	N	O
53	thoracic	N	O
54	or	N	O
55	prophylactic	N	O
56	cranial	N	O
57	radiation	N	O
58	)	N	O
59	received	N	O
60	oral	N	O
61	vandetanib	N	O
62	300	N	O
63	mg/d	N	O
64	or	N	O
65	matched	N	O
66	placebo	N	O
67	.	N	O

68	With	N	O
69	100	N	O
70	patients	N	O
71	and	N	O
72	77	N	O
73	events	N	O
74	,	N	O
75	the	N	O
76	study	N	O
77	had	N	O
78	80	N	O
79	%	N	O
80	power	N	O
81	to	N	O
82	detect	N	O
83	an	N	O
84	improvement	N	O
85	in	N	O
86	median	N	O
87	progression-free	N	O
88	survival	N	O
89	from	N	O
90	4	N	O
91	to	N	O
92	6.5	N	O
93	months	N	O
94	(	N	O
95	one-sided	N	O
96	,	N	O
97	10	N	O
98	%	N	O
99	-level	N	O
100	test	N	O
101	)	N	O
102	.	N	O

103	Between	N	O
104	May	N	O
105	2003	N	O
106	and	N	O
107	March	N	O
108	2006	N	O
109	,	N	O
110	107	N	O
111	patients	N	O
112	were	N	O
113	accrued	N	O
114	;	N	O
115	46	N	O
116	had	N	O
117	limited	N	O
118	disease	N	O
119	and	N	O
120	61	N	O
121	extensive	N	O
122	disease	N	O
123	.	N	O

124	There	N	O
125	were	N	O
126	fewer	N	O
127	patients	N	O
128	with	N	O
129	a	N	O
130	performance	N	O
131	status	N	O
132	of	N	O
133	0	N	O
134	(	N	O
135	n	N	O
136	=	N	O
137	11	N	O
138	v	N	O
139	20	N	O
140	)	N	O
141	,	N	O
142	and	N	O
143	fewer	N	O
144	had	N	O
145	CR	N	O
146	to	N	O
147	initial	N	O
148	therapy	N	O
149	(	N	O
150	n	N	O
151	=	N	O
152	4	N	O
153	v	N	O
154	8	N	O
155	)	N	O
156	in	N	O
157	the	N	O
158	vandetanib	N	O
159	arm	N	O
160	.	N	O

161	Vandetanib	N	I-Premise
162	patients	N	I-Premise
163	had	N	I-Premise
164	more	N	I-Premise
165	toxicity	N	I-Premise
166	and	N	I-Premise
167	required	N	I-Premise
168	more	N	I-Premise
169	dose	N	I-Premise
170	modifications	N	I-Premise
171	for	N	I-Premise
172	gastrointestinal	N	I-Premise
173	toxicity	N	I-Premise
174	and	N	I-Premise
175	rash	N	I-Premise
176	.	N	I-Premise

177	Asymptomatic	N	I-Premise
178	Corrected	N	I-Premise
179	QT	N	I-Premise
180	interval	N	I-Premise
181	(	N	I-Premise
182	QTC	N	I-Premise
183	)	N	I-Premise
184	prolongation	N	I-Premise
185	was	N	I-Premise
186	observed	N	I-Premise
187	in	N	I-Premise
188	eight	N	I-Premise
189	vandetanib	N	I-Premise
190	patients	N	I-Premise
191	.	N	I-Premise

192	Median	N	I-Premise
193	progression-free	N	I-Premise
194	survival	N	I-Premise
195	for	N	I-Premise
196	vandetanib	N	I-Premise
197	and	N	I-Premise
198	placebo	N	I-Premise
199	was	N	I-Premise
200	2.7	N	I-Premise
201	and	N	I-Premise
202	2.8	N	I-Premise
203	months	N	I-Premise
204	,	N	I-Premise
205	respectively	N	I-Premise
206	(	N	I-Premise
207	hazard	N	I-Premise
208	ratio	N	I-Premise
209	[	N	I-Premise
210	HR	N	I-Premise
211	]	N	I-Premise
212	,	N	I-Premise
213	1.01	N	I-Premise
214	;	N	I-Premise
215	80	N	I-Premise
216	%	N	I-Premise
217	CI	N	I-Premise
218	,	N	I-Premise
219	0.75	N	I-Premise
220	to	N	I-Premise
221	1.36	N	I-Premise
222	;	N	I-Premise
223	one-sided	N	I-Premise
224	P	N	I-Premise
225	=	N	I-Premise
226	.51	N	I-Premise
227	)	N	I-Premise
228	.	N	I-Premise

229	Overall	N	I-Premise
230	survival	N	I-Premise
231	for	N	I-Premise
232	vandetanib	N	I-Premise
233	was	N	I-Premise
234	10.6	N	I-Premise
235	versus	N	I-Premise
236	11.9	N	I-Premise
237	months	N	I-Premise
238	for	N	I-Premise
239	placebo	N	I-Premise
240	(	N	I-Premise
241	HR	N	I-Premise
242	,	N	I-Premise
243	1.43	N	I-Premise
244	;	N	I-Premise
245	80	N	I-Premise
246	%	N	I-Premise
247	CI	N	I-Premise
248	,	N	I-Premise
249	1.00	N	I-Premise
250	to	N	I-Premise
251	2.05	N	I-Premise
252	;	N	I-Premise
253	one-sided	N	I-Premise
254	P	N	I-Premise
255	=	N	I-Premise
256	0.9	N	I-Premise
257	)	N	I-Premise
258	.	N	I-Premise

259	In	N	I-Premise
260	planned	N	I-Premise
261	subgroup	N	I-Premise
262	analyses	N	I-Premise
263	,	N	I-Premise
264	a	N	I-Premise
265	significant	N	I-Premise
266	interaction	N	I-Premise
267	was	N	I-Premise
268	noted	N	I-Premise
269	(	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.01	N	I-Premise
273	)	N	I-Premise
274	:	N	I-Premise
275	limited-stage	N	I-Premise
276	vandetanib	N	I-Premise
277	patients	N	I-Premise
278	had	N	I-Premise
279	longer	N	I-Premise
280	overall	N	I-Premise
281	survival	N	I-Premise
282	(	N	I-Premise
283	HR	N	I-Premise
284	,	N	I-Premise
285	0.45	N	I-Premise
286	;	N	I-Premise
287	one-sided	N	I-Premise
288	P	N	I-Premise
289	=	N	I-Premise
290	.07	N	I-Premise
291	)	N	I-Premise
292	and	N	I-Premise
293	extensive-stage	N	I-Premise
294	vandetanib	N	I-Premise
295	patients	N	I-Premise
296	shorter	N	I-Premise
297	survival	N	I-Premise
298	compared	N	I-Premise
299	with	N	I-Premise
300	placebo	N	I-Premise
301	(	N	I-Premise
302	HR	N	I-Premise
303	,	N	I-Premise
304	2.27	N	I-Premise
305	;	N	I-Premise
306	one-sided	N	I-Premise
307	P	N	I-Premise
308	=	N	I-Premise
309	.996	N	I-Premise
310	)	N	I-Premise
311	.	N	I-Premise

312	Vandetanib	N	I-Claim
313	failed	N	I-Claim
314	to	N	I-Claim
315	demonstrate	N	I-Claim
316	efficacy	N	I-Claim
317	as	N	I-Claim
318	maintenance	N	I-Claim
319	therapy	N	I-Claim
320	for	N	I-Claim
321	small-cell	N	I-Claim
322	lung	N	I-Claim
323	cancer	N	I-Claim
324	.	N	I-Claim

1	To	N	O
2	analyze	N	O
3	the	N	O
4	prospectively	N	O
5	collected	N	O
6	health-related	N	O
7	quality-of-life	N	O
8	(	N	O
9	HRQOL	N	O
10	)	N	O
11	data	N	O
12	from	N	O
13	patients	N	O
14	enrolled	N	O
15	in	N	O
16	two	N	O
17	Radiation	N	O
18	Therapy	N	O
19	Oncology	N	O
20	Group	N	O
21	randomized	N	O
22	Phase	N	O
23	III	N	O
24	head	N	O
25	and	N	O
26	neck	N	O
27	cancer	N	O
28	trials	N	O
29	(	N	O
30	90-03	N	O
31	and	N	O
32	91-11	N	O
33	)	N	O
34	to	N	O
35	assess	N	O
36	their	N	O
37	value	N	O
38	as	N	O
39	an	N	O
40	independent	N	O
41	prognostic	N	O
42	factor	N	O
43	for	N	O
44	locoregional	N	O
45	control	N	O
46	(	N	O
47	LRC	N	O
48	)	N	O
49	and/or	N	O
50	overall	N	O
51	survival	N	O
52	(	N	O
53	OS	N	O
54	)	N	O
55	.	N	O

56	HRQOL	N	O
57	questionnaires	N	O
58	,	N	O
59	using	N	O
60	a	N	O
61	validated	N	O
62	instrument	N	O
63	,	N	O
64	the	N	O
65	Functional	N	O
66	Assessment	N	O
67	of	N	O
68	Cancer	N	O
69	Therapy-Head	N	O
70	and	N	O
71	Neck	N	O
72	(	N	O
73	FACT-H	N	O
74	&	N	O
75	amp	N	O
76	;	N	O
77	N	N	O
78	)	N	O
79	,	N	O
80	version	N	O
81	2	N	O
82	,	N	O
83	were	N	O
84	completed	N	O
85	by	N	O
86	patients	N	O
87	before	N	O
88	the	N	O
89	start	N	O
90	of	N	O
91	treatment	N	O
92	.	N	O

93	OS	N	O
94	and	N	O
95	LRC	N	O
96	were	N	O
97	the	N	O
98	outcome	N	O
99	measures	N	O
100	analyzed	N	O
101	using	N	O
102	a	N	O
103	multivariate	N	O
104	Cox	N	O
105	proportional	N	O
106	hazard	N	O
107	model	N	O
108	.	N	O

109	Baseline	N	O
110	FACT-H	N	O
111	&	N	O
112	amp	N	O
113	;	N	O
114	N	N	O
115	data	N	O
116	were	N	O
117	available	N	O
118	for	N	O
119	1,093	N	O
120	patients	N	O
121	and	N	O
122	missing	N	O
123	for	N	O
124	417	N	O
125	patients	N	O
126	.	N	O

127	No	N	O
128	significant	N	O
129	difference	N	O
130	in	N	O
131	outcome	N	O
132	was	N	O
133	found	N	O
134	between	N	O
135	the	N	O
136	patients	N	O
137	with	N	O
138	and	N	O
139	without	N	O
140	baseline	N	O
141	FACT-H	N	O
142	&	N	O
143	amp	N	O
144	;	N	O
145	N	N	O
146	data	N	O
147	(	N	O
148	p	N	O
149	=	N	O
150	0.58	N	O
151	)	N	O
152	.	N	O

153	The	N	O
154	median	N	O
155	follow-up	N	O
156	time	N	O
157	was	N	O
158	27.2	N	O
159	months	N	O
160	for	N	O
161	all	N	O
162	patients	N	O
163	and	N	O
164	49	N	O
165	months	N	O
166	for	N	O
167	surviving	N	O
168	patients	N	O
169	.	N	O

170	Multivariate	N	O
171	analyses	N	O
172	were	N	O
173	performed	N	O
174	for	N	O
175	both	N	O
176	OS	N	O
177	and	N	O
178	LRC	N	O
179	.	N	O

180	Beyond	N	I-Premise
181	tumor	N	I-Premise
182	and	N	I-Premise
183	nodal	N	I-Premise
184	stage	N	I-Premise
185	,	N	I-Premise
186	Karnofsky	N	I-Premise
187	performance	N	I-Premise
188	status	N	I-Premise
189	,	N	I-Premise
190	primary	N	I-Premise
191	site	N	I-Premise
192	,	N	I-Premise
193	cigarette	N	I-Premise
194	use	N	I-Premise
195	,	N	I-Premise
196	use	N	I-Premise
197	of	N	I-Premise
198	concurrent	N	I-Premise
199	chemotherapy	N	I-Premise
200	,	N	I-Premise
201	and	N	I-Premise
202	altered	N	I-Premise
203	fractionation	N	I-Premise
204	schedules	N	I-Premise
205	,	N	I-Premise
206	the	N	I-Premise
207	FACT-H	N	I-Premise
208	&	N	I-Premise
209	amp	N	I-Premise
210	;	N	I-Premise
211	N	N	I-Premise
212	score	N	I-Premise
213	was	N	I-Premise
214	independently	N	I-Premise
215	predictive	N	I-Premise
216	of	N	I-Premise
217	LRC	N	I-Premise
218	(	N	I-Premise
219	but	N	I-Premise
220	not	N	I-Premise
221	OS	N	I-Premise
222	)	N	I-Premise
223	,	N	I-Premise
224	with	N	I-Premise
225	p	N	I-Premise
226	=	N	I-Premise
227	0.0038	N	I-Premise
228	.	N	I-Premise

229	The	N	I-Premise
230	functional	N	I-Premise
231	well-being	N	I-Premise
232	component	N	I-Premise
233	of	N	I-Premise
234	the	N	I-Premise
235	FACT-H	N	I-Premise
236	&	N	I-Premise
237	amp	N	I-Premise
238	;	N	I-Premise
239	N	N	I-Premise
240	predicted	N	I-Premise
241	most	N	I-Premise
242	significantly	N	I-Premise
243	for	N	I-Premise
244	LRC	N	I-Premise
245	(	N	I-Premise
246	p	N	I-Premise
247	=	N	I-Premise
248	0.0004	N	I-Premise
249	)	N	I-Premise
250	.	N	I-Premise

251	This	N	I-Claim
252	study	N	I-Claim
253	represents	N	I-Claim
254	,	N	I-Claim
255	to	N	I-Claim
256	our	N	I-Claim
257	knowledge	N	I-Claim
258	,	N	I-Claim
259	the	N	I-Claim
260	largest	N	I-Claim
261	analysis	N	I-Claim
262	of	N	I-Claim
263	HRQOL	N	I-Claim
264	as	N	I-Claim
265	a	N	I-Claim
266	prognostic	N	I-Claim
267	factor	N	I-Claim
268	in	N	I-Claim
269	locally	N	I-Claim
270	advanced	N	I-Claim
271	head	N	I-Claim
272	and	N	I-Claim
273	neck	N	I-Claim
274	cancer	N	I-Claim
275	patients	N	I-Claim
276	.	N	I-Claim

277	The	N	I-Claim
278	results	N	I-Claim
279	of	N	I-Claim
280	this	N	I-Claim
281	study	N	I-Claim
282	have	N	I-Claim
283	demonstrated	N	I-Claim
284	the	N	I-Claim
285	importance	N	I-Claim
286	of	N	I-Claim
287	baseline	N	I-Claim
288	HRQOL	N	I-Claim
289	as	N	I-Claim
290	a	N	I-Claim
291	significant	N	I-Claim
292	and	N	I-Claim
293	independent	N	I-Claim
294	predictor	N	I-Claim
295	of	N	I-Claim
296	LRC	N	I-Claim
297	in	N	I-Claim
298	patients	N	I-Claim
299	with	N	I-Claim
300	locally	N	I-Claim
301	advanced	N	I-Claim
302	head	N	I-Claim
303	and	N	I-Claim
304	neck	N	I-Claim
305	cancer	N	I-Claim
306	.	N	I-Claim

1	Relapse	N	I-MajorClaim
2	after	N	I-MajorClaim
3	completing	N	I-MajorClaim
4	adjuvant	N	I-MajorClaim
5	tamoxifen	N	I-MajorClaim
6	therapy	N	I-MajorClaim
7	is	N	I-MajorClaim
8	a	N	I-MajorClaim
9	persistent	N	I-MajorClaim
10	threat	N	I-MajorClaim
11	for	N	I-MajorClaim
12	women	N	I-MajorClaim
13	with	N	I-MajorClaim
14	hormone-responsive	N	I-MajorClaim
15	breast	N	I-MajorClaim
16	cancer	N	I-MajorClaim
17	.	N	I-MajorClaim

18	Third-generation	N	O
19	aromatase	N	O
20	inhibitors	N	O
21	,	N	O
22	such	N	O
23	as	N	O
24	letrozole	N	O
25	,	N	O
26	provide	N	O
27	a	N	O
28	new	N	O
29	option	N	O
30	for	N	O
31	extended	N	O
32	adjuvant	N	O
33	hormonal	N	O
34	therapy	N	O
35	after	N	O
36	5	N	O
37	years	N	O
38	of	N	O
39	tamoxifen	N	O
40	.	N	O

41	MA.17	N	O
42	was	N	O
43	conducted	N	O
44	to	N	O
45	determine	N	O
46	whether	N	O
47	letrozole	N	O
48	improves	N	O
49	outcome	N	O
50	after	N	O
51	discontinuation	N	O
52	of	N	O
53	tamoxifen	N	O
54	.	N	O

55	Postmenopausal	N	O
56	women	N	O
57	with	N	O
58	hormone	N	O
59	receptor-positive	N	O
60	breast	N	O
61	cancer	N	O
62	(	N	O
63	N=5,187	N	O
64	)	N	O
65	were	N	O
66	randomized	N	O
67	to	N	O
68	letrozole	N	O
69	2.5	N	O
70	mg	N	O
71	or	N	O
72	placebo	N	O
73	once	N	O
74	daily	N	O
75	for	N	O
76	5	N	O
77	years	N	O
78	.	N	O

79	At	N	I-Premise
80	a	N	I-Premise
81	median	N	I-Premise
82	follow-up	N	I-Premise
83	of	N	I-Premise
84	30	N	I-Premise
85	months	N	I-Premise
86	,	N	I-Premise
87	letrozole	N	I-Premise
88	significantly	N	I-Premise
89	improved	N	I-Premise
90	disease-free	N	I-Premise
91	survival	N	I-Premise
92	(	N	I-Premise
93	DFS	N	I-Premise
94	;	N	I-Premise
95	P	N	I-Premise
96	<	N	I-Premise
97	0.001	N	I-Premise
98	)	N	I-Premise
99	,	N	I-Premise
100	the	N	I-Premise
101	primary	N	I-Premise
102	end	N	I-Premise
103	point	N	I-Premise
104	,	N	I-Premise
105	compared	N	I-Premise
106	with	N	I-Premise
107	placebo	N	I-Premise
108	(	N	I-Premise
109	hazard	N	I-Premise
110	ratio	N	I-Premise
111	[	N	I-Premise
112	HR	N	I-Premise
113	]	N	I-Premise
114	for	N	I-Premise
115	recurrence	N	I-Premise
116	or	N	I-Premise
117	contralateral	N	I-Premise
118	breast	N	I-Premise
119	cancer	N	I-Premise
120	0.58	N	I-Premise
121	;	N	I-Premise
122	95	N	I-Premise
123	%	N	I-Premise
124	confidence	N	I-Premise
125	interval	N	I-Premise
126	[	N	I-Premise
127	CI	N	I-Premise
128	]	N	I-Premise
129	0.45	N	I-Premise
130	,	N	I-Premise
131	0.76	N	I-Premise
132	]	N	I-Premise
133	P	N	I-Premise
134	<	N	I-Premise
135	0.001	N	I-Premise
136	)	N	I-Premise
137	.	N	I-Premise

138	Furthermore	N	I-Premise
139	,	N	I-Premise
140	letrozole	N	I-Premise
141	significantly	N	I-Premise
142	improved	N	I-Premise
143	distant	N	I-Premise
144	DFS	N	I-Premise
145	(	N	I-Premise
146	HR=0.60	N	I-Premise
147	;	N	I-Premise
148	95	N	I-Premise
149	%	N	I-Premise
150	CI	N	I-Premise
151	0.43	N	I-Premise
152	,	N	I-Premise
153	0.84	N	I-Premise
154	;	N	I-Premise
155	P=0.002	N	I-Premise
156	)	N	I-Premise
157	and	N	I-Premise
158	,	N	I-Premise
159	in	N	I-Premise
160	women	N	I-Premise
161	with	N	I-Premise
162	node-positive	N	I-Premise
163	tumors	N	I-Premise
164	,	N	I-Premise
165	overall	N	I-Premise
166	survival	N	I-Premise
167	(	N	I-Premise
168	HR=0.61	N	I-Premise
169	;	N	I-Premise
170	95	N	I-Premise
171	%	N	I-Premise
172	CI	N	I-Premise
173	0.38	N	I-Premise
174	,	N	I-Premise
175	0.98	N	I-Premise
176	;	N	I-Premise
177	P=0.04	N	I-Premise
178	)	N	I-Premise
179	.	N	I-Premise

180	Clinical	N	I-Premise
181	benefits	N	I-Premise
182	,	N	I-Premise
183	including	N	I-Premise
184	an	N	I-Premise
185	overall	N	I-Premise
186	survival	N	I-Premise
187	advantage	N	I-Premise
188	,	N	I-Premise
189	were	N	I-Premise
190	also	N	I-Premise
191	seen	N	I-Premise
192	in	N	I-Premise
193	women	N	I-Premise
194	who	N	I-Premise
195	crossed	N	I-Premise
196	over	N	I-Premise
197	from	N	I-Premise
198	placebo	N	I-Premise
199	to	N	I-Premise
200	letrozole	N	I-Premise
201	after	N	I-Premise
202	unblinding	N	I-Premise
203	,	N	I-Premise
204	indicating	N	I-Premise
205	that	N	I-Premise
206	tumors	N	I-Premise
207	remain	N	I-Premise
208	sensitive	N	I-Premise
209	to	N	I-Premise
210	hormone	N	I-Premise
211	therapy	N	I-Premise
212	despite	N	I-Premise
213	a	N	I-Premise
214	prolonged	N	I-Premise
215	period	N	I-Premise
216	since	N	I-Premise
217	discontinuation	N	I-Premise
218	of	N	I-Premise
219	tamoxifen	N	I-Premise
220	.	N	I-Premise

221	The	N	O
222	efficacy	N	O
223	and	N	O
224	safety	N	O
225	of	N	O
226	letrozole	N	O
227	therapy	N	O
228	beyond	N	O
229	5	N	O
230	years	N	O
231	is	N	O
232	being	N	O
233	assessed	N	O
234	in	N	O
235	a	N	O
236	re-randomization	N	O
237	study	N	O
238	,	N	O
239	following	N	O
240	the	N	O
241	emergence	N	O
242	of	N	O
243	new	N	O
244	data	N	O
245	suggesting	N	O
246	that	N	O
247	clinical	N	O
248	benefit	N	O
249	correlates	N	O
250	with	N	O
251	the	N	O
252	duration	N	O
253	of	N	O
254	letrozole	N	O
255	.	N	O

256	MA.17	N	I-Claim
257	showed	N	I-Claim
258	that	N	I-Claim
259	letrozole	N	I-Claim
260	is	N	I-Claim
261	extremely	N	I-Claim
262	well-tolerated	N	I-Claim
263	relative	N	I-Claim
264	to	N	I-Claim
265	placebo	N	I-Claim
266	.	N	I-Claim

267	Letrozole	N	I-Claim
268	should	N	I-Claim
269	be	N	I-Claim
270	considered	N	I-Claim
271	for	N	I-Claim
272	all	N	I-Claim
273	women	N	I-Claim
274	completing	N	I-Claim
275	tamoxifen	N	I-Claim
276	;	N	I-Claim
277	new	N	I-Claim
278	results	N	I-Claim
279	from	N	I-Claim
280	the	N	I-Claim
281	post-unblinding	N	I-Claim
282	analysis	N	I-Claim
283	suggest	N	I-Claim
284	that	N	I-Claim
285	letrozole	N	I-Claim
286	treatment	N	I-Claim
287	should	N	I-Claim
288	also	N	I-Claim
289	be	N	I-Claim
290	considered	N	I-Claim
291	for	N	I-Claim
292	all	N	I-Claim
293	disease-free	N	I-Claim
294	women	N	I-Claim
295	for	N	I-Claim
296	periods	N	I-Claim
297	up	N	I-Claim
298	to	N	I-Claim
299	5	N	I-Claim
300	years	N	I-Claim
301	following	N	I-Claim
302	completion	N	I-Claim
303	of	N	I-Claim
304	adjuvant	N	I-Claim
305	tamoxifen	N	I-Claim
306	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	safety	N	O
5	and	N	O
6	efficacy	N	O
7	of	N	O
8	abatacept	N	O
9	during	N	O
10	2	N	O
11	years	N	O
12	of	N	O
13	the	N	O
14	ATTAIN	N	O
15	(	N	O
16	Abatacept	N	O
17	Trial	N	O
18	in	N	O
19	Treatment	N	O
20	of	N	O
21	Anti-TNF	N	O
22	INadequate	N	O
23	responders	N	O
24	)	N	O
25	trial	N	O
26	in	N	O
27	patients	N	O
28	with	N	O
29	rheumatoid	N	O
30	arthritis	N	O
31	.	N	O

32	Patients	N	O
33	completing	N	O
34	the	N	O
35	6-month	N	O
36	,	N	O
37	double-blind	N	O
38	period	N	O
39	were	N	O
40	eligible	N	O
41	to	N	O
42	enter	N	O
43	the	N	O
44	long-term	N	O
45	extension	N	O
46	;	N	O
47	patients	N	O
48	received	N	O
49	abatacept	N	O
50	approximately	N	O
51	10	N	O
52	mg/kg	N	O
53	,	N	O
54	plus	N	O
55	disease-modifying	N	O
56	antirheumatic	N	O
57	drugs	N	O
58	.	N	O

59	Safety	N	O
60	and	N	O
61	efficacy	N	O
62	(	N	O
63	American	N	O
64	College	N	O
65	of	N	O
66	Rheumatology	N	O
67	(	N	O
68	ACR	N	O
69	)	N	O
70	criteria	N	O
71	responses	N	O
72	,	N	O
73	DAS28	N	O
74	(	N	O
75	C-reactive	N	O
76	protein	N	O
77	)	N	O
78	,	N	O
79	HAQ-DI	N	O
80	,	N	O
81	SF-36	N	O
82	,	N	O
83	Medical	N	O
84	Outcomes	N	O
85	Study	N	O
86	Sleep	N	O
87	Problems	N	O
88	Index	N	O
89	,	N	O
90	fatigue	N	O
91	VAS	N	O
92	)	N	O
93	were	N	O
94	assessed	N	O
95	through	N	O
96	2	N	O
97	years	N	O
98	.	N	O

99	317	N	O
100	patients	N	O
101	(	N	O
102	218	N	O
103	from	N	O
104	the	N	O
105	abatacept	N	O
106	and	N	O
107	99	N	O
108	from	N	O
109	the	N	O
110	placebo	N	O
111	group	N	O
112	)	N	O
113	entered	N	O
114	and	N	O
115	222	N	O
116	(	N	O
117	70	N	O
118	%	N	O
119	)	N	O
120	completed	N	O
121	18	N	O
122	months	N	O
123	of	N	O
124	long-term	N	O
125	extension	N	O
126	treatment	N	O
127	.	N	O

128	The	N	I-Premise
129	incidence	N	I-Premise
130	and	N	I-Premise
131	type	N	I-Premise
132	of	N	I-Premise
133	adverse	N	I-Premise
134	events	N	I-Premise
135	were	N	I-Premise
136	consistent	N	I-Premise
137	between	N	I-Premise
138	the	N	I-Premise
139	double-blind	N	I-Premise
140	and	N	I-Premise
141	cumulative	N	I-Premise
142	(	N	I-Premise
143	double-blind	N	I-Premise
144	plus	N	I-Premise
145	long-term	N	I-Premise
146	extension	N	I-Premise
147	)	N	I-Premise
148	periods	N	I-Premise
149	.	N	I-Premise

150	Rates	N	I-Premise
151	of	N	I-Premise
152	serious	N	I-Premise
153	adverse	N	I-Premise
154	events	N	I-Premise
155	were	N	I-Premise
156	25.6	N	I-Premise
157	and	N	I-Premise
158	23.4	N	I-Premise
159	per	N	I-Premise
160	100	N	I-Premise
161	patient-years	N	I-Premise
162	in	N	I-Premise
163	the	N	I-Premise
164	double-blind	N	I-Premise
165	versus	N	I-Premise
166	cumulative	N	I-Premise
167	period	N	I-Premise
168	.	N	I-Premise

169	At	N	I-Premise
170	6	N	I-Premise
171	months	N	I-Premise
172	and	N	I-Premise
173	2	N	I-Premise
174	years	N	I-Premise
175	,	N	I-Premise
176	using	N	I-Premise
177	non-responder	N	I-Premise
178	analyses	N	I-Premise
179	,	N	I-Premise
180	ACR	N	I-Premise
181	responses	N	I-Premise
182	in	N	I-Premise
183	abatacept-treated	N	I-Premise
184	patients	N	I-Premise
185	were	N	I-Premise
186	:	N	I-Premise
187	ACR	N	I-Premise
188	20	N	I-Premise
189	,	N	I-Premise
190	59.4	N	I-Premise
191	%	N	I-Premise
192	and	N	I-Premise
193	56.2	N	I-Premise
194	%	N	I-Premise
195	;	N	I-Premise
196	ACR	N	I-Premise
197	50	N	I-Premise
198	,	N	I-Premise
199	23.5	N	I-Premise
200	%	N	I-Premise
201	and	N	I-Premise
202	33.2	N	I-Premise
203	%	N	I-Premise
204	;	N	I-Premise
205	ACR	N	I-Premise
206	70	N	I-Premise
207	,	N	I-Premise
208	11.5	N	I-Premise
209	%	N	I-Premise
210	and	N	I-Premise
211	16.1	N	I-Premise
212	%	N	I-Premise
213	;	N	I-Premise
214	HAQ-DI	N	I-Premise
215	responses	N	I-Premise
216	were	N	I-Premise
217	54.4	N	I-Premise
218	%	N	I-Premise
219	and	N	I-Premise
220	47.9	N	I-Premise
221	%	N	I-Premise
222	.	N	I-Premise

223	At	N	I-Premise
224	6	N	I-Premise
225	months	N	I-Premise
226	and	N	I-Premise
227	2	N	I-Premise
228	years	N	I-Premise
229	,	N	I-Premise
230	using	N	I-Premise
231	post-hoc	N	I-Premise
232	as-observed	N	I-Premise
233	analyses	N	I-Premise
234	,	N	I-Premise
235	the	N	I-Premise
236	percentage	N	I-Premise
237	of	N	I-Premise
238	patients	N	I-Premise
239	(	N	I-Premise
240	95	N	I-Premise
241	%	N	I-Premise
242	confidence	N	I-Premise
243	interval	N	I-Premise
244	)	N	I-Premise
245	achieving	N	I-Premise
246	DAS28	N	I-Premise
247	(	N	I-Premise
248	C-reactive	N	I-Premise
249	protein	N	I-Premise
250	)	N	I-Premise
251	low	N	I-Premise
252	disease	N	I-Premise
253	activity	N	I-Premise
254	score	N	I-Premise
255	(	N	I-Premise
256	<	N	I-Premise
257	or	N	I-Premise
258	=	N	I-Premise
259	3.2	N	I-Premise
260	)	N	I-Premise
261	and	N	I-Premise
262	DAS28	N	I-Premise
263	(	N	I-Premise
264	C-reactive	N	I-Premise
265	protein	N	I-Premise
266	)	N	I-Premise
267	-defined	N	I-Premise
268	remission	N	I-Premise
269	(	N	I-Premise
270	<	N	I-Premise
271	2.6	N	I-Premise
272	)	N	I-Premise
273	increased	N	I-Premise
274	from	N	I-Premise
275	18.3	N	I-Premise
276	%	N	I-Premise
277	(	N	I-Premise
278	13.0	N	I-Premise
279	,	N	I-Premise
280	23.5	N	I-Premise
281	)	N	I-Premise
282	to	N	I-Premise
283	32.0	N	I-Premise
284	%	N	I-Premise
285	(	N	I-Premise
286	24.6	N	I-Premise
287	,	N	I-Premise
288	39.4	N	I-Premise
289	)	N	I-Premise
290	and	N	I-Premise
291	11.1	N	I-Premise
292	%	N	I-Premise
293	(	N	I-Premise
294	6.8	N	I-Premise
295	,	N	I-Premise
296	15.3	N	I-Premise
297	)	N	I-Premise
298	to	N	I-Premise
299	20.3	N	I-Premise
300	%	N	I-Premise
301	(	N	I-Premise
302	13.9	N	I-Premise
303	,	N	I-Premise
304	26.6	N	I-Premise
305	)	N	I-Premise
306	.	N	I-Premise

307	Clinically	N	I-Premise
308	meaningful	N	I-Premise
309	improvements	N	I-Premise
310	in	N	I-Premise
311	SF-36	N	I-Premise
312	,	N	I-Premise
313	pain	N	I-Premise
314	,	N	I-Premise
315	fatigue	N	I-Premise
316	and	N	I-Premise
317	sleep	N	I-Premise
318	problems	N	I-Premise
319	were	N	I-Premise
320	also	N	I-Premise
321	maintained	N	I-Premise
322	throughout	N	I-Premise
323	the	N	I-Premise
324	2	N	I-Premise
325	years	N	I-Premise
326	of	N	I-Premise
327	abatacept	N	I-Premise
328	treatment	N	I-Premise
329	.	N	I-Premise

330	No	N	I-Premise
331	unique	N	I-Premise
332	safety	N	I-Premise
333	observations	N	I-Premise
334	were	N	I-Premise
335	reported	N	I-Premise
336	during	N	I-Premise
337	open-label	N	I-Premise
338	exposure	N	I-Premise
339	.	N	I-Premise

340	Improvements	N	I-Premise
341	in	N	I-Premise
342	the	N	I-Premise
343	signs	N	I-Premise
344	and	N	I-Premise
345	symptoms	N	I-Premise
346	of	N	I-Premise
347	rheumatoid	N	I-Premise
348	arthritis	N	I-Premise
349	,	N	I-Premise
350	physical	N	I-Premise
351	function	N	I-Premise
352	and	N	I-Premise
353	health-related	N	I-Premise
354	quality	N	I-Premise
355	of	N	I-Premise
356	life	N	I-Premise
357	observed	N	I-Premise
358	after	N	I-Premise
359	6	N	I-Premise
360	months	N	I-Premise
361	,	N	I-Premise
362	were	N	I-Premise
363	maintained	N	I-Premise
364	throughout	N	I-Premise
365	the	N	I-Premise
366	2	N	I-Premise
367	years	N	I-Premise
368	in	N	I-Premise
369	this	N	I-Premise
370	population	N	I-Premise
371	with	N	I-Premise
372	difficult-to-treat	N	I-Premise
373	disease	N	I-Premise
374	.	N	I-Premise

1	Few	N	O
2	randomized	N	O
3	trials	N	O
4	have	N	O
5	compared	N	O
6	the	N	O
7	survival	N	O
8	benefit	N	O
9	of	N	O
10	interferon-alfa	N	O
11	over	N	O
12	controls	N	O
13	in	N	O
14	metastatic	N	O
15	renal	N	O
16	cell	N	O
17	carcinoma	N	O
18	,	N	O
19	and	N	O
20	none	N	O
21	has	N	O
22	been	N	O
23	performed	N	O
24	using	N	O
25	interleukin-2	N	O
26	.	N	O

27	The	N	O
28	Programme	N	O
29	Etude	N	O
30	Rein	N	O
31	Cytokines	N	O
32	(	N	O
33	PERCY	N	O
34	)	N	O
35	Quattro	N	O
36	trial	N	O
37	was	N	O
38	designed	N	O
39	to	N	O
40	evaluate	N	O
41	both	N	O
42	cytokines	N	O
43	for	N	O
44	their	N	O
45	survival	N	O
46	benefit	N	O
47	to	N	O
48	intermediate	N	O
49	prognosis	N	O
50	patients	N	O
51	,	N	O
52	who	N	O
53	represent	N	O
54	the	N	O
55	majority	N	O
56	of	N	O
57	candidates	N	O
58	for	N	O
59	these	N	O
60	treatments	N	O
61	.	N	O

62	Patients	N	O
63	were	N	O
64	randomized	N	O
65	in	N	O
66	a	N	O
67	2-by-2	N	O
68	factorial	N	O
69	design	N	O
70	to	N	O
71	medroxyprogesterone	N	O
72	acetate	N	O
73	200	N	O
74	mg	N	O
75	daily	N	O
76	,	N	O
77	interferon-alfa	N	O
78	9	N	O
79	million	N	O
80	IU	N	O
81	3	N	O
82	times	N	O
83	a	N	O
84	week	N	O
85	,	N	O
86	subcutaneous	N	O
87	interleukin-2	N	O
88	9	N	O
89	million	N	O
90	IU	N	O
91	daily	N	O
92	,	N	O
93	or	N	O
94	a	N	O
95	combination	N	O
96	of	N	O
97	both	N	O
98	cytokines	N	O
99	.	N	O

100	Tumor	N	O
101	response	N	O
102	was	N	O
103	evaluated	N	O
104	at	N	O
105	Week	N	O
106	12	N	O
107	and	N	O
108	Month	N	O
109	6	N	O
110	;	N	O
111	progression-free	N	O
112	patients	N	O
113	received	N	O
114	further	N	O
115	identical	N	O
116	treatment	N	O
117	for	N	O
118	a	N	O
119	maximum	N	O
120	of	N	O
121	3	N	O
122	additional	N	O
123	months	N	O
124	.	N	O

125	Primary	N	O
126	endpoint	N	O
127	was	N	O
128	overall	N	O
129	survival	N	O
130	;	N	O
131	secondary	N	O
132	endpoints	N	O
133	were	N	O
134	disease-free	N	O
135	survival	N	O
136	,	N	O
137	response	N	O
138	rate	N	O
139	,	N	O
140	toxicity	N	O
141	,	N	O
142	and	N	O
143	quality	N	O
144	of	N	O
145	life	N	O
146	.	N	O

147	Survival	N	O
148	was	N	O
149	analyzed	N	O
150	on	N	O
151	an	N	O
152	intent-to-treat	N	O
153	basis	N	O
154	.	N	O

155	From	N	O
156	January	N	O
157	2000	N	O
158	to	N	O
159	July	N	O
160	2004	N	O
161	,	N	O
162	492	N	O
163	patients	N	O
164	were	N	O
165	enrolled	N	O
166	.	N	O

167	Analysis	N	O
168	was	N	O
169	performed	N	O
170	after	N	O
171	a	N	O
172	29.2-month	N	O
173	median	N	O
174	follow-up	N	O
175	(	N	O
176	range	N	O
177	,	N	O
178	0	N	O
179	months	N	O
180	to	N	O
181	54.6	N	O
182	months	N	O
183	)	N	O
184	.	N	O

185	There	N	I-Premise
186	were	N	I-Premise
187	no	N	I-Premise
188	significant	N	I-Premise
189	survival	N	I-Premise
190	differences	N	I-Premise
191	between	N	I-Premise
192	the	N	I-Premise
193	244	N	I-Premise
194	interferon-alfa-treated	N	I-Premise
195	patients	N	I-Premise
196	and	N	I-Premise
197	248	N	I-Premise
198	noninterferon-alfa	N	I-Premise
199	patients	N	I-Premise
200	(	N	I-Premise
201	hazard	N	I-Premise
202	ratio	N	I-Premise
203	,	N	I-Premise
204	1.00	N	I-Premise
205	;	N	I-Premise
206	95	N	I-Premise
207	%	N	I-Premise
208	CI	N	I-Premise
209	,	N	I-Premise
210	0.81-1.24	N	I-Premise
211	)	N	I-Premise
212	or	N	I-Premise
213	between	N	I-Premise
214	the	N	I-Premise
215	247	N	I-Premise
216	interleukin-2	N	I-Premise
217	and	N	I-Premise
218	245	N	I-Premise
219	noninterleukin-2-treated	N	I-Premise
220	patients	N	I-Premise
221	(	N	I-Premise
222	hazard	N	I-Premise
223	ratio	N	I-Premise
224	,	N	I-Premise
225	1.07	N	I-Premise
226	;	N	I-Premise
227	95	N	I-Premise
228	%	N	I-Premise
229	CI	N	I-Premise
230	,	N	I-Premise
231	0.87-1.33	N	I-Premise
232	;	N	I-Premise
233	log	N	I-Premise
234	rank	N	I-Premise
235	,	N	I-Premise
236	0.99	N	I-Premise
237	and	N	I-Premise
238	0.52	N	I-Premise
239	,	N	I-Premise
240	respectively	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	Grade	N	I-Premise
244	3-4	N	I-Premise
245	toxicities	N	I-Premise
246	were	N	I-Premise
247	significantly	N	I-Premise
248	more	N	I-Premise
249	frequent	N	I-Premise
250	in	N	I-Premise
251	cytokine-treated	N	I-Premise
252	patients	N	I-Premise
253	than	N	I-Premise
254	in	N	I-Premise
255	medroxyprogesterone-treated	N	I-Premise
256	patients	N	I-Premise
257	.	N	I-Premise

258	Subcutaneous	N	I-Claim
259	interleukin-2	N	I-Claim
260	and/or	N	I-Claim
261	interferon-alfa	N	I-Claim
262	provide	N	I-Claim
263	no	N	I-Claim
264	survival	N	I-Claim
265	benefit	N	I-Claim
266	in	N	I-Claim
267	metastatic	N	I-Claim
268	renal	N	I-Claim
269	cancers	N	I-Claim
270	of	N	I-Claim
271	intermediate	N	I-Claim
272	prognosis	N	I-Claim
273	,	N	I-Claim
274	and	N	I-Claim
275	they	N	I-Claim
276	induce	N	I-Claim
277	a	N	I-Claim
278	significant	N	I-Claim
279	risk	N	I-Claim
280	of	N	I-Claim
281	toxicity	N	I-Claim
282	.	N	I-Claim

283	Newly	N	I-Claim
284	available	N	I-Claim
285	angiogenesis	N	I-Claim
286	inhibitors	N	I-Claim
287	should	N	I-Claim
288	be	N	I-Claim
289	preferred	N	I-Claim
290	for	N	I-Claim
291	these	N	I-Claim
292	patients	N	I-Claim
293	.	N	I-Claim

1	Hormonal	N	I-Claim
2	breast	N	I-Claim
3	cancer	N	I-Claim
4	treatment	N	I-Claim
5	increases	N	I-Claim
6	menopausal	N	I-Claim
7	symptoms	N	I-Claim
8	in	N	I-Claim
9	women	N	I-Claim
10	.	N	I-Claim

11	This	N	O
12	study	N	O
13	investigated	N	O
14	differences	N	O
15	between	N	O
16	the	N	O
17	symptoms	N	O
18	associated	N	O
19	with	N	O
20	either	N	O
21	adjuvant	N	O
22	tamoxifen	N	O
23	or	N	O
24	exemestane	N	O
25	.	N	O

26	Ten	N	O
27	common	N	O
28	symptoms	N	O
29	were	N	O
30	assessed	N	O
31	by	N	O
32	self-report	N	O
33	questionnaire	N	O
34	administered	N	O
35	to	N	O
36	1,614	N	O
37	consecutive	N	O
38	patients	N	O
39	at	N	O
40	baseline	N	O
41	and	N	O
42	every	N	O
43	3	N	O
44	months	N	O
45	during	N	O
46	the	N	O
47	first	N	O
48	year	N	O
49	of	N	O
50	a	N	O
51	double-blind	N	O
52	,	N	O
53	randomized	N	O
54	trial	N	O
55	of	N	O
56	postmenopausal	N	O
57	women	N	O
58	with	N	O
59	early	N	O
60	hormone	N	O
61	receptor-positive	N	O
62	breast	N	O
63	cancer	N	O
64	.	N	O

65	Symptoms	N	O
66	were	N	O
67	categorized	N	O
68	as	N	O
69	none	N	O
70	,	N	O
71	mild	N	O
72	,	N	O
73	moderate	N	O
74	,	N	O
75	or	N	O
76	severe	N	O
77	.	N	O

78	A	N	O
79	hot	N	O
80	flash	N	O
81	score	N	O
82	was	N	O
83	calculated	N	O
84	at	N	O
85	each	N	O
86	time	N	O
87	point	N	O
88	.	N	O

89	Symptoms	N	O
90	were	N	O
91	analyzed	N	O
92	by	N	O
93	repeated-measures	N	O
94	analysis	N	O
95	of	N	O
96	variance	N	O
97	.	N	O

98	Each	N	O
99	time	N	O
100	period	N	O
101	was	N	O
102	tested	N	O
103	repeatedly	N	O
104	against	N	O
105	the	N	O
106	baseline	N	O
107	;	N	O
108	an	N	O
109	overall	N	O
110	P	N	O
111	value	N	O
112	was	N	O
113	assigned	N	O
114	for	N	O
115	each	N	O
116	reported	N	O
117	symptom	N	O
118	.	N	O

119	Compliance	N	O
120	was	N	O
121	excellent	N	O
122	,	N	O
123	with	N	O
124	7,286	N	O
125	questionnaires	N	O
126	analyzed	N	O
127	.	N	O

128	Baseline	N	O
129	symptom	N	O
130	prevalence	N	O
131	ranged	N	O
132	from	N	O
133	2	N	O
134	%	N	O
135	(	N	O
136	vaginal	N	O
137	bleeding	N	O
138	)	N	O
139	to	N	O
140	60	N	O
141	%	N	O
142	to	N	O
143	70	N	O
144	%	N	O
145	(	N	O
146	bone/muscle	N	O
147	aches	N	O
148	and	N	O
149	low	N	O
150	energy	N	O
151	)	N	O
152	.	N	O

153	There	N	I-Premise
154	were	N	I-Premise
155	no	N	I-Premise
156	significant	N	I-Premise
157	differences	N	I-Premise
158	in	N	I-Premise
159	vaginal	N	I-Premise
160	bleeding	N	I-Premise
161	,	N	I-Premise
162	mood	N	I-Premise
163	alteration	N	I-Premise
164	,	N	I-Premise
165	or	N	I-Premise
166	low	N	I-Premise
167	energy	N	I-Premise
168	.	N	I-Premise

169	Patients	N	I-Premise
170	receiving	N	I-Premise
171	tamoxifen	N	I-Premise
172	had	N	I-Premise
173	significantly	N	I-Premise
174	more	N	I-Premise
175	vaginal	N	I-Premise
176	discharge	N	I-Premise
177	(	N	I-Premise
178	P	N	I-Premise
179	<	N	I-Premise
180	.0001	N	I-Premise
181	)	N	I-Premise
182	.	N	I-Premise

183	Exemestane	N	I-Premise
184	patients	N	I-Premise
185	reported	N	I-Premise
186	more	N	I-Premise
187	bone/muscle	N	I-Premise
188	aches	N	I-Premise
189	(	N	I-Premise
190	P	N	I-Premise
191	<	N	I-Premise
192	.0001	N	I-Premise
193	)	N	I-Premise
194	,	N	I-Premise
195	vaginal	N	I-Premise
196	dryness	N	I-Premise
197	(	N	I-Premise
198	P	N	I-Premise
199	=	N	I-Premise
200	.0004	N	I-Premise
201	)	N	I-Premise
202	,	N	I-Premise
203	and	N	I-Premise
204	difficulty	N	I-Premise
205	sleeping	N	I-Premise
206	(	N	I-Premise
207	P	N	I-Premise
208	=	N	I-Premise
209	.03	N	I-Premise
210	)	N	I-Premise
211	.	N	I-Premise

212	In	N	I-Premise
213	both	N	I-Premise
214	groups	N	I-Premise
215	,	N	I-Premise
216	the	N	I-Premise
217	hot	N	I-Premise
218	flash	N	I-Premise
219	score	N	I-Premise
220	peaked	N	I-Premise
221	at	N	I-Premise
222	3	N	I-Premise
223	months	N	I-Premise
224	and	N	I-Premise
225	decreased	N	I-Premise
226	thereafter	N	I-Premise
227	.	N	I-Premise

228	At	N	I-Premise
229	12	N	I-Premise
230	months	N	I-Premise
231	,	N	I-Premise
232	patients	N	I-Premise
233	receiving	N	I-Premise
234	tamoxifen	N	I-Premise
235	had	N	I-Premise
236	a	N	I-Premise
237	significantly	N	I-Premise
238	higher	N	I-Premise
239	mean	N	I-Premise
240	hot	N	I-Premise
241	flash	N	I-Premise
242	score	N	I-Premise
243	(	N	I-Premise
244	P	N	I-Premise
245	=	N	I-Premise
246	.03	N	I-Premise
247	)	N	I-Premise
248	,	N	I-Premise
249	with	N	I-Premise
250	daily	N	I-Premise
251	hot	N	I-Premise
252	flashes	N	I-Premise
253	increasing	N	I-Premise
254	from	N	I-Premise
255	baseline	N	I-Premise
256	by	N	I-Premise
257	33	N	I-Premise
258	%	N	I-Premise
259	compared	N	I-Premise
260	with	N	I-Premise
261	a	N	I-Premise
262	7	N	I-Premise
263	%	N	I-Premise
264	increase	N	I-Premise
265	from	N	I-Premise
266	baseline	N	I-Premise
267	with	N	I-Premise
268	exemestane	N	I-Premise
269	.	N	I-Premise

270	At	N	I-Premise
271	12	N	I-Premise
272	months	N	I-Premise
273	,	N	I-Premise
274	exemestane	N	I-Premise
275	was	N	I-Premise
276	associated	N	I-Premise
277	with	N	I-Premise
278	fewer	N	I-Premise
279	hot	N	I-Premise
280	flashes	N	I-Premise
281	and	N	I-Premise
282	less	N	I-Premise
283	vaginal	N	I-Premise
284	discharge	N	I-Premise
285	than	N	I-Premise
286	tamoxifen	N	I-Premise
287	,	N	I-Premise
288	but	N	I-Premise
289	with	N	I-Premise
290	more	N	I-Premise
291	vaginal	N	I-Premise
292	dryness	N	I-Premise
293	,	N	I-Premise
294	bone/muscle	N	I-Premise
295	aches	N	I-Premise
296	,	N	I-Premise
297	and	N	I-Premise
298	difficulty	N	I-Premise
299	sleeping	N	I-Premise
300	.	N	I-Premise

301	Symptoms	N	I-Claim
302	were	N	I-Claim
303	common	N	I-Claim
304	in	N	I-Claim
305	both	N	I-Claim
306	groups	N	I-Claim
307	.	N	I-Claim

1	Few	N	O
2	intervention	N	O
3	studies	N	O
4	have	N	O
5	been	N	O
6	conducted	N	O
7	to	N	O
8	help	N	O
9	couples	N	O
10	manage	N	O
11	the	N	O
12	effects	N	O
13	of	N	O
14	prostate	N	O
15	cancer	N	O
16	and	N	O
17	maintain	N	O
18	their	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	.	N	O

23	The	N	O
24	objective	N	O
25	of	N	O
26	this	N	O
27	study	N	O
28	was	N	O
29	to	N	O
30	determine	N	O
31	whether	N	O
32	a	N	O
33	family-based	N	O
34	intervention	N	O
35	could	N	O
36	improve	N	O
37	appraisal	N	O
38	variables	N	O
39	(	N	O
40	appraisal	N	O
41	of	N	O
42	illness	N	O
43	or	N	O
44	caregiving	N	O
45	,	N	O
46	uncertainty	N	O
47	,	N	O
48	hopelessness	N	O
49	)	N	O
50	,	N	O
51	coping	N	O
52	resources	N	O
53	(	N	O
54	coping	N	O
55	strategies	N	O
56	,	N	O
57	self-efficacy	N	O
58	,	N	O
59	communication	N	O
60	)	N	O
61	,	N	O
62	symptom	N	O
63	distress	N	O
64	,	N	O
65	and	N	O
66	quality	N	O
67	of	N	O
68	life	N	O
69	in	N	O
70	men	N	O
71	with	N	O
72	prostate	N	O
73	cancer	N	O
74	and	N	O
75	their	N	O
76	spouses	N	O
77	.	N	O

78	For	N	O
79	this	N	O
80	clinical	N	O
81	trial	N	O
82	,	N	O
83	263	N	O
84	patient-spouse	N	O
85	dyads	N	O
86	were	N	O
87	stratified	N	O
88	by	N	O
89	research	N	O
90	site	N	O
91	,	N	O
92	phase	N	O
93	of	N	O
94	illness	N	O
95	,	N	O
96	and	N	O
97	treatment	N	O
98	;	N	O
99	then	N	O
100	,	N	O
101	they	N	O
102	were	N	O
103	randomized	N	O
104	to	N	O
105	the	N	O
106	control	N	O
107	group	N	O
108	(	N	O
109	standard	N	O
110	care	N	O
111	)	N	O
112	or	N	O
113	the	N	O
114	experimental	N	O
115	group	N	O
116	(	N	O
117	standard	N	O
118	care	N	O
119	plus	N	O
120	a	N	O
121	5-session	N	O
122	family	N	O
123	intervention	N	O
124	)	N	O
125	.	N	O

126	The	N	O
127	intervention	N	O
128	targeted	N	O
129	couples	N	O
130	'	N	O
131	communication	N	O
132	,	N	O
133	hope	N	O
134	,	N	O
135	coping	N	O
136	,	N	O
137	uncertainty	N	O
138	,	N	O
139	and	N	O
140	symptom	N	O
141	management	N	O
142	.	N	O

143	The	N	O
144	final	N	O
145	sample	N	O
146	consisted	N	O
147	of	N	O
148	235	N	O
149	couples	N	O
150	:	N	O
151	123	N	O
152	couples	N	O
153	in	N	O
154	the	N	O
155	control	N	O
156	group	N	O
157	and	N	O
158	112	N	O
159	couples	N	O
160	in	N	O
161	the	N	O
162	experimental	N	O
163	group	N	O
164	.	N	O

165	Data	N	O
166	collection	N	O
167	occurred	N	O
168	at	N	O
169	baseline	N	O
170	before	N	O
171	randomization	N	O
172	and	N	O
173	at	N	O
174	4	N	O
175	months	N	O
176	,	N	O
177	8	N	O
178	months	N	O
179	,	N	O
180	and	N	O
181	12	N	O
182	months	N	O
183	.	N	O

184	At	N	I-Premise
185	4-month	N	I-Premise
186	follow-up	N	I-Premise
187	,	N	I-Premise
188	intervention	N	I-Premise
189	patients	N	I-Premise
190	reported	N	I-Premise
191	less	N	I-Premise
192	uncertainty	N	I-Premise
193	and	N	I-Premise
194	better	N	I-Premise
195	communication	N	I-Premise
196	with	N	I-Premise
197	spouses	N	I-Premise
198	than	N	I-Premise
199	control	N	I-Premise
200	patients	N	I-Premise
201	,	N	I-Premise
202	but	N	I-Premise
203	they	N	I-Premise
204	reported	N	I-Premise
205	no	N	I-Premise
206	other	N	I-Premise
207	effects	N	I-Premise
208	.	N	I-Premise

209	Intervention	N	I-Premise
210	spouses	N	I-Premise
211	reported	N	I-Premise
212	higher	N	I-Premise
213	quality	N	I-Premise
214	of	N	I-Premise
215	life	N	I-Premise
216	,	N	I-Premise
217	more	N	I-Premise
218	self-efficacy	N	I-Premise
219	,	N	I-Premise
220	better	N	I-Premise
221	communication	N	I-Premise
222	,	N	I-Premise
223	and	N	I-Premise
224	less	N	I-Premise
225	negative	N	I-Premise
226	appraisal	N	I-Premise
227	of	N	I-Premise
228	caregiving	N	I-Premise
229	,	N	I-Premise
230	uncertainty	N	I-Premise
231	,	N	I-Premise
232	hopelessness	N	I-Premise
233	,	N	I-Premise
234	and	N	I-Premise
235	symptom	N	I-Premise
236	distress	N	I-Premise
237	at	N	I-Premise
238	4	N	I-Premise
239	months	N	I-Premise
240	compared	N	I-Premise
241	with	N	I-Premise
242	controls	N	I-Premise
243	,	N	I-Premise
244	and	N	I-Premise
245	some	N	I-Premise
246	effects	N	I-Premise
247	were	N	I-Premise
248	sustained	N	I-Premise
249	to	N	I-Premise
250	8	N	I-Premise
251	months	N	I-Premise
252	and	N	I-Premise
253	12	N	I-Premise
254	months	N	I-Premise
255	.	N	I-Premise

256	Men	N	I-Premise
257	with	N	I-Premise
258	prostate	N	I-Premise
259	cancer	N	I-Premise
260	and	N	I-Premise
261	their	N	I-Premise
262	spouses	N	I-Premise
263	reported	N	I-Premise
264	positive	N	I-Premise
265	outcomes	N	I-Premise
266	from	N	I-Premise
267	a	N	I-Premise
268	family	N	I-Premise
269	intervention	N	I-Premise
270	that	N	I-Premise
271	offered	N	I-Premise
272	them	N	I-Premise
273	information	N	I-Premise
274	and	N	I-Premise
275	support	N	I-Premise
276	.	N	I-Premise

277	Programs	N	I-Claim
278	of	N	I-Claim
279	care	N	I-Claim
280	need	N	I-Claim
281	to	N	I-Claim
282	be	N	I-Claim
283	extended	N	I-Claim
284	to	N	I-Claim
285	spouses	N	I-Claim
286	who	N	I-Claim
287	likely	N	I-Claim
288	will	N	I-Claim
289	experience	N	I-Claim
290	multiple	N	I-Claim
291	benefits	N	I-Claim
292	from	N	I-Claim
293	intervention	N	I-Claim
294	.	N	I-Claim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	multicenter	N	O
5	,	N	O
6	randomized	N	O
7	trial	N	O
8	to	N	O
9	compare	N	O
10	progression-free	N	O
11	survival	N	O
12	(	N	O
13	PFS	N	O
14	)	N	O
15	,	N	O
16	overall	N	O
17	survival	N	O
18	(	N	O
19	OS	N	O
20	)	N	O
21	,	N	O
22	and	N	O
23	quality	N	O
24	of	N	O
25	life	N	O
26	in	N	O
27	women	N	O
28	with	N	O
29	metastatic	N	O
30	breast	N	O
31	cancer	N	O
32	(	N	O
33	MBC	N	O
34	)	N	O
35	receiving	N	O
36	high-dose	N	O
37	chemotherapy	N	O
38	plus	N	O
39	autologous	N	O
40	stem-cell	N	O
41	transplantation	N	O
42	(	N	O
43	ASCT	N	O
44	;	N	O
45	HDCT	N	O
46	)	N	O
47	compared	N	O
48	with	N	O
49	standard-dose	N	O
50	therapy	N	O
51	.	N	O

52	Between	N	O
53	April	N	O
54	1997	N	O
55	and	N	O
56	December	N	O
57	2000	N	O
58	,	N	O
59	386	N	O
60	women	N	O
61	with	N	O
62	MBC	N	O
63	and	N	O
64	no	N	O
65	prior	N	O
66	chemotherapy	N	O
67	for	N	O
68	metastatic	N	O
69	disease	N	O
70	were	N	O
71	registered	N	O
72	.	N	O

73	After	N	O
74	initial	N	O
75	response	N	O
76	to	N	O
77	anthracycline-	N	O
78	or	N	O
79	taxane-based	N	O
80	induction	N	O
81	chemotherapy	N	O
82	,	N	O
83	224	N	O
84	patients	N	O
85	were	N	O
86	randomly	N	O
87	assigned	N	O
88	:	N	O
89	112	N	O
90	to	N	O
91	high-dose	N	O
92	cyclophosphamide	N	O
93	,	N	O
94	mitoxantrone	N	O
95	,	N	O
96	and	N	O
97	carboplatin	N	O
98	chemotherapy	N	O
99	and	N	O
100	ASCT	N	O
101	(	N	O
102	HDCT	N	O
103	)	N	O
104	,	N	O
105	and	N	O
106	112	N	O
107	to	N	O
108	standard	N	O
109	therapy	N	O
110	(	N	O
111	ST	N	O
112	)	N	O
113	.	N	O

114	Median	N	O
115	age	N	O
116	was	N	O
117	47	N	O
118	years	N	O
119	(	N	O
120	range	N	O
121	,	N	O
122	25	N	O
123	to	N	O
124	67	N	O
125	years	N	O
126	)	N	O
127	.	N	O

128	Thirty	N	O
129	two	N	O
130	percent	N	O
131	of	N	O
132	women	N	O
133	randomly	N	O
134	assigned	N	O
135	had	N	O
136	estrogen	N	O
137	and	N	O
138	progesterone	N	O
139	receptor-negative	N	O
140	breast	N	O
141	cancer	N	O
142	,	N	O
143	42	N	O
144	%	N	O
145	had	N	O
146	visceral	N	O
147	metastases	N	O
148	,	N	O
149	and	N	O
150	58	N	O
151	%	N	O
152	had	N	O
153	bone	N	O
154	metastases	N	O
155	.	N	O

156	Complete	N	O
157	remission	N	O
158	rates	N	O
159	before	N	O
160	random	N	O
161	assignment	N	O
162	were	N	O
163	11	N	O
164	%	N	O
165	for	N	O
166	those	N	O
167	receiving	N	O
168	HDCT	N	O
169	and	N	O
170	12	N	O
171	%	N	O
172	for	N	O
173	those	N	O
174	receiving	N	O
175	ST.	N	O
176	After	N	I-Premise
177	a	N	I-Premise
178	median	N	I-Premise
179	follow-up	N	I-Premise
180	of	N	I-Premise
181	48	N	I-Premise
182	months	N	I-Premise
183	,	N	I-Premise
184	79	N	I-Premise
185	deaths	N	I-Premise
186	were	N	I-Premise
187	observed	N	I-Premise
188	in	N	I-Premise
189	the	N	I-Premise
190	HDCT	N	I-Premise
191	arm	N	I-Premise
192	and	N	I-Premise
193	77	N	I-Premise
194	deaths	N	I-Premise
195	were	N	I-Premise
196	observed	N	I-Premise
197	in	N	I-Premise
198	the	N	I-Premise
199	ST	N	I-Premise
200	arm	N	I-Premise
201	;	N	I-Premise
202	seven	N	I-Premise
203	patients	N	I-Premise
204	(	N	I-Premise
205	6	N	I-Premise
206	%	N	I-Premise
207	)	N	I-Premise
208	in	N	I-Premise
209	the	N	I-Premise
210	HDCT	N	I-Premise
211	arm	N	I-Premise
212	died	N	I-Premise
213	as	N	I-Premise
214	a	N	I-Premise
215	result	N	I-Premise
216	of	N	I-Premise
217	toxicity	N	I-Premise
218	.	N	I-Premise

219	The	N	I-Premise
220	median	N	I-Premise
221	OS	N	I-Premise
222	was	N	I-Premise
223	24	N	I-Premise
224	months	N	I-Premise
225	for	N	I-Premise
226	the	N	I-Premise
227	HDCT	N	I-Premise
228	arm	N	I-Premise
229	(	N	I-Premise
230	95	N	I-Premise
231	%	N	I-Premise
232	CI	N	I-Premise
233	,	N	I-Premise
234	21	N	I-Premise
235	to	N	I-Premise
236	35	N	I-Premise
237	months	N	I-Premise
238	)	N	I-Premise
239	and	N	I-Premise
240	28	N	I-Premise
241	months	N	I-Premise
242	for	N	I-Premise
243	ST	N	I-Premise
244	(	N	I-Premise
245	95	N	I-Premise
246	%	N	I-Premise
247	CI	N	I-Premise
248	,	N	I-Premise
249	22	N	I-Premise
250	to	N	I-Premise
251	33	N	I-Premise
252	months	N	I-Premise
253	;	N	I-Premise
254	hazard	N	I-Premise
255	ratio	N	I-Premise
256	[	N	I-Premise
257	HR	N	I-Premise
258	]	N	I-Premise
259	,	N	I-Premise
260	0.9	N	I-Premise
261	;	N	I-Premise
262	95	N	I-Premise
263	%	N	I-Premise
264	CI	N	I-Premise
265	,	N	I-Premise
266	0.6	N	I-Premise
267	to	N	I-Premise
268	1.2	N	I-Premise
269	;	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.43	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	PFS	N	I-Premise
276	was	N	I-Premise
277	11	N	I-Premise
278	months	N	I-Premise
279	for	N	I-Premise
280	HDCT	N	I-Premise
281	and	N	I-Premise
282	9	N	I-Premise
283	months	N	I-Premise
284	for	N	I-Premise
285	ST	N	I-Premise
286	(	N	I-Premise
287	HR	N	I-Premise
288	,	N	I-Premise
289	0.6	N	I-Premise
290	in	N	I-Premise
291	favor	N	I-Premise
292	of	N	I-Premise
293	HDCT	N	I-Premise
294	;	N	I-Premise
295	95	N	I-Premise
296	%	N	I-Premise
297	CI	N	I-Premise
298	,	N	I-Premise
299	0.5	N	I-Premise
300	to	N	I-Premise
301	0.9	N	I-Premise
302	;	N	I-Premise
303	P	N	I-Premise
304	=	N	I-Premise
305	.006	N	I-Premise
306	)	N	I-Premise
307	.	N	I-Premise

308	HDCT	N	I-Claim
309	did	N	I-Claim
310	not	N	I-Claim
311	improve	N	I-Claim
312	OS	N	I-Claim
313	in	N	I-Claim
314	women	N	I-Claim
315	with	N	I-Claim
316	MBC	N	I-Claim
317	when	N	I-Claim
318	used	N	I-Claim
319	as	N	I-Claim
320	consolidation	N	I-Claim
321	after	N	I-Claim
322	response	N	I-Claim
323	to	N	I-Claim
324	induction	N	I-Claim
325	chemotherapy	N	I-Claim
326	.	N	I-Claim

1	Studies	N	O
2	have	N	O
3	shown	N	O
4	that	N	O
5	there	N	O
6	is	N	O
7	a	N	O
8	high	N	O
9	prevalence	N	O
10	of	N	O
11	depression	N	O
12	in	N	O
13	cancer	N	O
14	patients	N	O
15	.	N	O

16	Women	N	I-MajorClaim
17	with	N	I-MajorClaim
18	breast	N	I-MajorClaim
19	cancer	N	I-MajorClaim
20	may	N	I-MajorClaim
21	have	N	I-MajorClaim
22	an	N	I-MajorClaim
23	even	N	I-MajorClaim
24	higher	N	I-MajorClaim
25	risk	N	I-MajorClaim
26	of	N	I-MajorClaim
27	depression	N	I-MajorClaim
28	particularly	N	I-MajorClaim
29	in	N	I-MajorClaim
30	a	N	I-MajorClaim
31	postmenopausal	N	I-MajorClaim
32	or	N	I-MajorClaim
33	estrogen	N	I-MajorClaim
34	deficiency	N	I-MajorClaim
35	state	N	I-MajorClaim
36	.	N	I-MajorClaim

37	A	N	O
38	small	N	O
39	number	N	O
40	of	N	O
41	randomized	N	O
42	controlled	N	O
43	trials	N	O
44	have	N	O
45	examined	N	O
46	the	N	O
47	efficacy	N	O
48	of	N	O
49	antidepressants	N	O
50	compared	N	O
51	to	N	O
52	that	N	O
53	of	N	O
54	a	N	O
55	placebo	N	O
56	in	N	O
57	cancer	N	O
58	patients	N	O
59	,	N	O
60	but	N	O
61	some	N	O
62	results	N	O
63	have	N	O
64	been	N	O
65	difficult	N	O
66	to	N	O
67	interpret	N	O
68	due	N	O
69	to	N	O
70	a	N	O
71	heterogeneous	N	O
72	patient	N	O
73	group	N	O
74	.	N	O

75	In	N	O
76	the	N	O
77	current	N	O
78	investigation	N	O
79	,	N	O
80	we	N	O
81	screened	N	O
82	newly	N	O
83	diagnosed	N	O
84	early	N	O
85	stage	N	O
86	breast	N	O
87	cancer	N	O
88	patients	N	O
89	for	N	O
90	depressive	N	O
91	symptoms	N	O
92	prior	N	O
93	to	N	O
94	the	N	O
95	initiation	N	O
96	of	N	O
97	adjuvant	N	O
98	therapy	N	O
99	and	N	O
100	investigated	N	O
101	whether	N	O
102	the	N	O
103	oral	N	O
104	antidepressant	N	O
105	fluoxetine	N	O
106	affected	N	O
107	depressive	N	O
108	symptoms	N	O
109	,	N	O
110	completion	N	O
111	of	N	O
112	adjuvant	N	O
113	treatment	N	O
114	,	N	O
115	and	N	O
116	quality	N	O
117	of	N	O
118	life	N	O
119	.	N	O

120	Patients	N	O
121	with	N	O
122	newly	N	O
123	diagnosed	N	O
124	early	N	O
125	stage	N	O
126	breast	N	O
127	cancer	N	O
128	were	N	O
129	screened	N	O
130	for	N	O
131	depressive	N	O
132	symptoms	N	O
133	prior	N	O
134	to	N	O
135	the	N	O
136	initiation	N	O
137	of	N	O
138	adjuvant	N	O
139	therapy	N	O
140	.	N	O

141	Patients	N	O
142	with	N	O
143	depressive	N	O
144	symptoms	N	O
145	were	N	O
146	randomized	N	O
147	to	N	O
148	a	N	O
149	daily	N	O
150	oral	N	O
151	fluoxetine	N	O
152	or	N	O
153	a	N	O
154	placebo	N	O
155	.	N	O

156	Patients	N	O
157	were	N	O
158	then	N	O
159	followed	N	O
160	for	N	O
161	6	N	O
162	months	N	O
163	and	N	O
164	evaluated	N	O
165	for	N	O
166	quality	N	O
167	of	N	O
168	life	N	O
169	,	N	O
170	completion	N	O
171	of	N	O
172	adjuvant	N	O
173	treatment	N	O
174	,	N	O
175	and	N	O
176	depressive	N	O
177	symptoms	N	O
178	.	N	O

179	A	N	O
180	high	N	O
181	percentage	N	O
182	of	N	O
183	patients	N	O
184	with	N	O
185	newly	N	O
186	diagnosed	N	O
187	early	N	O
188	stage	N	O
189	breast	N	O
190	cancer	N	O
191	were	N	O
192	found	N	O
193	to	N	O
194	have	N	O
195	depressive	N	O
196	symptoms	N	O
197	prior	N	O
198	to	N	O
199	the	N	O
200	initiation	N	O
201	of	N	O
202	adjuvant	N	O
203	therapy	N	O
204	.	N	O

205	The	N	I-Premise
206	use	N	I-Premise
207	of	N	I-Premise
208	fluoxetine	N	I-Premise
209	for	N	I-Premise
210	6	N	I-Premise
211	months	N	I-Premise
212	resulted	N	I-Premise
213	in	N	I-Premise
214	an	N	I-Premise
215	improvement	N	I-Premise
216	in	N	I-Premise
217	quality	N	I-Premise
218	of	N	I-Premise
219	life	N	I-Premise
220	,	N	I-Premise
221	a	N	I-Premise
222	higher	N	I-Premise
223	completion	N	I-Premise
224	of	N	I-Premise
225	adjuvant	N	I-Premise
226	treatment	N	I-Premise
227	(	N	I-Premise
228	chemotherapy	N	I-Premise
229	,	N	I-Premise
230	hormonal	N	I-Premise
231	therapy	N	I-Premise
232	,	N	I-Premise
233	chemotherapy	N	I-Premise
234	plus	N	I-Premise
235	hormonal	N	I-Premise
236	therapy	N	I-Premise
237	)	N	I-Premise
238	,	N	I-Premise
239	and	N	I-Premise
240	a	N	I-Premise
241	reduction	N	I-Premise
242	in	N	I-Premise
243	depressive	N	I-Premise
244	symptoms	N	I-Premise
245	compared	N	I-Premise
246	to	N	I-Premise
247	patients	N	I-Premise
248	who	N	I-Premise
249	received	N	I-Premise
250	placebo	N	I-Premise
251	.	N	I-Premise

252	An	N	I-Claim
253	antidepressant	N	I-Claim
254	should	N	I-Claim
255	be	N	I-Claim
256	considered	N	I-Claim
257	for	N	I-Claim
258	early	N	I-Claim
259	stage	N	I-Claim
260	breast	N	I-Claim
261	cancer	N	I-Claim
262	patients	N	I-Claim
263	with	N	I-Claim
264	depressive	N	I-Claim
265	symptoms	N	I-Claim
266	who	N	I-Claim
267	are	N	I-Claim
268	receiving	N	I-Claim
269	adjuvant	N	I-Claim
270	treatment	N	I-Claim
271	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	immediate	N	O
5	and	N	O
6	long-term	N	O
7	effects	N	O
8	of	N	O
9	true	N	O
10	acupuncture	N	O
11	versus	N	O
12	sham	N	O
13	acupuncture	N	O
14	on	N	O
15	hot	N	O
16	flash	N	O
17	frequency	N	O
18	in	N	O
19	women	N	O
20	with	N	O
21	breast	N	O
22	cancer	N	O
23	.	N	O

24	Seventy-two	N	O
25	women	N	O
26	with	N	O
27	breast	N	O
28	cancer	N	O
29	experiencing	N	O
30	three	N	O
31	or	N	O
32	more	N	O
33	hot	N	O
34	flashes	N	O
35	per	N	O
36	day	N	O
37	were	N	O
38	randomly	N	O
39	assigned	N	O
40	to	N	O
41	receive	N	O
42	either	N	O
43	true	N	O
44	or	N	O
45	sham	N	O
46	acupuncture	N	O
47	.	N	O

48	Interventions	N	O
49	were	N	O
50	given	N	O
51	twice	N	O
52	weekly	N	O
53	for	N	O
54	4	N	O
55	consecutive	N	O
56	weeks	N	O
57	.	N	O

58	Hot	N	O
59	flash	N	O
60	frequency	N	O
61	was	N	O
62	evaluated	N	O
63	at	N	O
64	baseline	N	O
65	,	N	O
66	at	N	O
67	6	N	O
68	weeks	N	O
69	,	N	O
70	and	N	O
71	at	N	O
72	6	N	O
73	months	N	O
74	after	N	O
75	initiation	N	O
76	of	N	O
77	treatment	N	O
78	.	N	O

79	Patients	N	O
80	initially	N	O
81	randomly	N	O
82	assigned	N	O
83	to	N	O
84	the	N	O
85	sham	N	O
86	group	N	O
87	were	N	O
88	crossed	N	O
89	over	N	O
90	to	N	O
91	true	N	O
92	acupuncture	N	O
93	starting	N	O
94	at	N	O
95	week	N	O
96	7	N	O
97	.	N	O

98	The	N	O
99	mean	N	O
100	number	N	O
101	of	N	O
102	hot	N	O
103	flashes	N	O
104	per	N	O
105	day	N	O
106	was	N	O
107	reduced	N	O
108	from	N	O
109	8.7	N	O
110	(	N	O
111	standard	N	O
112	deviation	N	O
113	[	N	O
114	SD	N	O
115	]	N	O
116	,	N	O
117	3.9	N	O
118	)	N	O
119	to	N	O
120	6.2	N	O
121	(	N	O
122	SD	N	O
123	,	N	O
124	4.2	N	O
125	)	N	O
126	in	N	O
127	the	N	O
128	true	N	O
129	acupuncture	N	O
130	group	N	O
131	and	N	O
132	from	N	O
133	10.0	N	O
134	(	N	O
135	SD	N	O
136	,	N	O
137	6.1	N	O
138	)	N	O
139	to	N	O
140	7.6	N	O
141	(	N	O
142	SD	N	O
143	,	N	O
144	5.7	N	O
145	)	N	O
146	in	N	O
147	the	N	O
148	sham	N	O
149	group	N	O
150	.	N	O

151	True	N	I-Premise
152	acupuncture	N	I-Premise
153	was	N	I-Premise
154	associated	N	I-Premise
155	with	N	I-Premise
156	0.8	N	I-Premise
157	fewer	N	I-Premise
158	hot	N	I-Premise
159	flashes	N	I-Premise
160	per	N	I-Premise
161	day	N	I-Premise
162	than	N	I-Premise
163	sham	N	I-Premise
164	at	N	I-Premise
165	6	N	I-Premise
166	weeks	N	I-Premise
167	,	N	O
168	but	N	I-Premise
169	the	N	I-Premise
170	difference	N	I-Premise
171	did	N	I-Premise
172	not	N	I-Premise
173	reach	N	I-Premise
174	statistical	N	I-Premise
175	significance	N	I-Premise
176	(	N	I-Premise
177	95	N	I-Premise
178	%	N	I-Premise
179	CI	N	I-Premise
180	,	N	I-Premise
181	-0.7	N	I-Premise
182	to	N	I-Premise
183	2.4	N	I-Premise
184	;	N	I-Premise
185	P	N	I-Premise
186	=	N	I-Premise
187	.3	N	I-Premise
188	)	N	I-Premise
189	.	N	I-Premise

190	When	N	I-Premise
191	participants	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	sham	N	I-Premise
195	acupuncture	N	I-Premise
196	group	N	I-Premise
197	were	N	I-Premise
198	crossed	N	I-Premise
199	over	N	I-Premise
200	to	N	I-Premise
201	true	N	I-Premise
202	acupuncture	N	I-Premise
203	,	N	I-Premise
204	a	N	I-Premise
205	further	N	I-Premise
206	reduction	N	I-Premise
207	in	N	I-Premise
208	the	N	I-Premise
209	frequency	N	I-Premise
210	of	N	I-Premise
211	hot	N	I-Premise
212	flashes	N	I-Premise
213	was	N	I-Premise
214	seen	N	I-Premise
215	.	N	I-Premise

216	This	N	O
217	reduction	N	O
218	in	N	O
219	hot	N	O
220	flash	N	O
221	frequency	N	O
222	persisted	N	O
223	for	N	O
224	up	N	O
225	to	N	O
226	6	N	O
227	months	N	O
228	after	N	O
229	the	N	O
230	completion	N	O
231	of	N	O
232	treatment	N	O
233	.	N	O

234	Hot	N	I-Claim
235	flash	N	I-Claim
236	frequency	N	I-Claim
237	in	N	I-Claim
238	breast	N	I-Claim
239	cancer	N	I-Claim
240	patients	N	I-Claim
241	was	N	I-Claim
242	reduced	N	I-Claim
243	following	N	I-Claim
244	acupuncture	N	I-Claim
245	.	N	I-Claim

246	However	N	O
247	,	N	O
248	when	N	I-Premise
249	compared	N	I-Premise
250	with	N	I-Premise
251	sham	N	I-Premise
252	acupuncture	N	I-Premise
253	,	N	I-Premise
254	the	N	I-Premise
255	reduction	N	I-Premise
256	by	N	I-Premise
257	the	N	I-Premise
258	acupuncture	N	I-Premise
259	regimen	N	I-Premise
260	as	N	I-Premise
261	provided	N	I-Premise
262	in	N	I-Premise
263	the	N	I-Premise
264	current	N	I-Premise
265	study	N	I-Premise
266	did	N	I-Premise
267	not	N	I-Premise
268	reach	N	I-Premise
269	statistical	N	I-Premise
270	significance	N	I-Premise
271	.	N	I-Premise

272	We	N	I-Claim
273	can	N	I-Claim
274	not	N	I-Claim
275	exclude	N	I-Claim
276	the	N	I-Claim
277	possibility	N	I-Claim
278	that	N	I-Claim
279	a	N	I-Claim
280	longer	N	I-Claim
281	and	N	I-Claim
282	more	N	I-Claim
283	intense	N	I-Claim
284	acupuncture	N	I-Claim
285	intervention	N	I-Claim
286	could	N	I-Claim
287	produce	N	I-Claim
288	a	N	I-Claim
289	larger	N	I-Claim
290	reduction	N	I-Claim
291	of	N	I-Claim
292	these	N	I-Claim
293	symptoms	N	I-Claim
294	.	N	I-Claim

1	Few	N	O
2	exercise	N	O
3	trials	N	O
4	in	N	O
5	cancer	N	O
6	patients	N	O
7	have	N	O
8	reported	N	O
9	longer-term	N	O
10	follow-up	N	O
11	.	N	O

12	Here	N	O
13	,	N	O
14	we	N	O
15	report	N	O
16	a	N	O
17	6-month	N	O
18	follow-up	N	O
19	of	N	O
20	exercise	N	O
21	behavior	N	O
22	and	N	O
23	patient-rated	N	O
24	outcomes	N	O
25	from	N	O
26	an	N	O
27	exercise	N	O
28	trial	N	O
29	in	N	O
30	breast	N	O
31	cancer	N	O
32	patients	N	O
33	.	N	O

34	Breast	N	O
35	cancer	N	O
36	patients	N	O
37	initiating	N	O
38	adjuvant	N	O
39	chemotherapy	N	O
40	(	N	O
41	n	N	O
42	=	N	O
43	242	N	O
44	)	N	O
45	were	N	O
46	randomly	N	O
47	assigned	N	O
48	to	N	O
49	usual	N	O
50	care	N	O
51	(	N	O
52	n	N	O
53	=	N	O
54	82	N	O
55	)	N	O
56	,	N	O
57	resistance	N	O
58	exercise	N	O
59	training	N	O
60	(	N	O
61	RET	N	O
62	;	N	O
63	n	N	O
64	=	N	O
65	82	N	O
66	)	N	O
67	,	N	O
68	or	N	O
69	aerobic	N	O
70	exercise	N	O
71	training	N	O
72	(	N	O
73	AET	N	O
74	;	N	O
75	n	N	O
76	=	N	O
77	78	N	O
78	)	N	O
79	for	N	O
80	the	N	O
81	duration	N	O
82	of	N	O
83	their	N	O
84	chemotherapy	N	O
85	.	N	O

86	At	N	O
87	6-month	N	O
88	follow-up	N	O
89	,	N	O
90	participants	N	O
91	were	N	O
92	mailed	N	O
93	a	N	O
94	questionnaire	N	O
95	that	N	O
96	assessed	N	O
97	quality	N	O
98	of	N	O
99	life	N	O
100	,	N	O
101	self-esteem	N	O
102	,	N	O
103	fatigue	N	O
104	,	N	O
105	anxiety	N	O
106	,	N	O
107	depression	N	O
108	,	N	O
109	and	N	O
110	exercise	N	O
111	behavior	N	O
112	.	N	O

113	Two	N	O
114	hundred	N	O
115	one	N	O
116	(	N	O
117	83.1	N	O
118	%	N	O
119	)	N	O
120	participants	N	O
121	provided	N	O
122	6-month	N	O
123	follow-up	N	O
124	data	N	O
125	.	N	O

126	Adjusted	N	I-Premise
127	linear	N	I-Premise
128	mixed-model	N	I-Premise
129	analyses	N	I-Premise
130	showed	N	I-Premise
131	that	N	I-Premise
132	,	N	I-Premise
133	at	N	I-Premise
134	6-month	N	I-Premise
135	follow-up	N	I-Premise
136	,	N	I-Premise
137	the	N	I-Premise
138	RET	N	I-Premise
139	group	N	I-Premise
140	reported	N	I-Premise
141	higher	N	I-Premise
142	self-esteem	N	I-Premise
143	[	N	I-Premise
144	adjusted	N	I-Premise
145	mean	N	I-Premise
146	difference	N	I-Premise
147	,	N	I-Premise
148	1.6	N	I-Premise
149	;	N	I-Premise
150	95	N	I-Premise
151	%	N	I-Premise
152	confidence	N	I-Premise
153	interval	N	I-Premise
154	(	N	I-Premise
155	95	N	I-Premise
156	%	N	I-Premise
157	CI	N	I-Premise
158	)	N	I-Premise
159	,	N	I-Premise
160	0.1-3.2	N	I-Premise
161	;	N	I-Premise
162	P	N	I-Premise
163	=	N	I-Premise
164	0.032	N	I-Premise
165	]	N	I-Premise
166	and	N	I-Premise
167	the	N	I-Premise
168	AET	N	I-Premise
169	group	N	I-Premise
170	reported	N	I-Premise
171	lower	N	I-Premise
172	anxiety	N	I-Premise
173	(	N	I-Premise
174	adjusted	N	I-Premise
175	mean	N	I-Premise
176	difference	N	I-Premise
177	,	N	I-Premise
178	-4.7	N	I-Premise
179	;	N	I-Premise
180	95	N	I-Premise
181	%	N	I-Premise
182	CI	N	I-Premise
183	,	N	I-Premise
184	-0.0	N	I-Premise
185	to	N	I-Premise
186	-9.3	N	I-Premise
187	;	N	I-Premise
188	P	N	I-Premise
189	=	N	I-Premise
190	0.049	N	I-Premise
191	)	N	I-Premise
192	compared	N	I-Premise
193	with	N	I-Premise
194	the	N	I-Premise
195	usual	N	I-Premise
196	care	N	I-Premise
197	group	N	I-Premise
198	.	N	I-Premise

199	Moreover	N	O
200	,	N	O
201	compared	N	I-Premise
202	with	N	I-Premise
203	participants	N	I-Premise
204	reporting	N	I-Premise
205	no	N	I-Premise
206	regular	N	I-Premise
207	exercise	N	I-Premise
208	during	N	I-Premise
209	the	N	I-Premise
210	follow-up	N	I-Premise
211	period	N	I-Premise
212	,	N	I-Premise
213	those	N	I-Premise
214	reporting	N	I-Premise
215	regular	N	I-Premise
216	aerobic	N	I-Premise
217	and	N	I-Premise
218	resistance	N	I-Premise
219	exercise	N	I-Premise
220	also	N	I-Premise
221	reported	N	I-Premise
222	better	N	I-Premise
223	patient-rated	N	I-Premise
224	outcomes	N	I-Premise
225	,	N	I-Premise
226	including	N	I-Premise
227	quality	N	I-Premise
228	of	N	I-Premise
229	life	N	I-Premise
230	(	N	I-Premise
231	adjusted	N	I-Premise
232	mean	N	I-Premise
233	difference	N	I-Premise
234	,	N	I-Premise
235	9.5	N	I-Premise
236	;	N	I-Premise
237	95	N	I-Premise
238	%	N	I-Premise
239	CI	N	I-Premise
240	,	N	I-Premise
241	1.2-17.8	N	I-Premise
242	;	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	0.025	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	Improvements	N	I-Premise
249	in	N	I-Premise
250	self-esteem	N	I-Premise
251	observed	N	I-Premise
252	with	N	I-Premise
253	RET	N	I-Premise
254	during	N	I-Premise
255	breast	N	I-Premise
256	cancer	N	I-Premise
257	chemotherapy	N	I-Premise
258	were	N	I-Premise
259	maintained	N	I-Premise
260	at	N	I-Premise
261	6-month	N	I-Premise
262	follow-up	N	I-Premise
263	whereas	N	O
264	reductions	N	I-Premise
265	in	N	I-Premise
266	anxiety	N	I-Premise
267	not	N	I-Premise
268	observed	N	I-Premise
269	with	N	I-Premise
270	AET	N	I-Premise
271	during	N	I-Premise
272	breast	N	I-Premise
273	cancer	N	I-Premise
274	chemotherapy	N	I-Premise
275	emerged	N	I-Premise
276	at	N	I-Premise
277	6-month	N	I-Premise
278	follow-up	N	I-Premise
279	.	N	I-Premise

280	Moreover	N	O
281	,	N	O
282	adopting	N	I-Premise
283	a	N	I-Premise
284	combined	N	I-Premise
285	aerobic	N	I-Premise
286	and	N	I-Premise
287	resistance	N	I-Premise
288	exercise	N	I-Premise
289	program	N	I-Premise
290	after	N	I-Premise
291	breast	N	I-Premise
292	cancer	N	I-Premise
293	chemotherapy	N	I-Premise
294	was	N	I-Premise
295	associated	N	I-Premise
296	with	N	I-Premise
297	further	N	I-Premise
298	improvements	N	I-Premise
299	in	N	I-Premise
300	patient-rated	N	I-Premise
301	outcomes	N	I-Premise
302	.	N	I-Premise

303	Exercise	N	I-Claim
304	training	N	I-Claim
305	during	N	I-Claim
306	breast	N	I-Claim
307	cancer	N	I-Claim
308	chemotherapy	N	I-Claim
309	may	N	I-Claim
310	result	N	I-Claim
311	in	N	I-Claim
312	some	N	I-Claim
313	longer-term	N	I-Claim
314	and	N	I-Claim
315	late	N	I-Claim
316	effects	N	I-Claim
317	for	N	I-Claim
318	selected	N	I-Claim
319	patient-rated	N	I-Claim
320	outcomes	N	I-Claim
321	.	N	I-Claim

1	Standard	N	O
2	guidelines	N	O
3	for	N	O
4	cancer	N	O
5	pain	N	O
6	treatment	N	O
7	routinely	N	O
8	recommend	N	O
9	training	N	O
10	patients	N	O
11	to	N	O
12	reduce	N	O
13	barriers	N	O
14	to	N	O
15	pain	N	O
16	relief	N	O
17	,	N	O
18	use	N	O
19	medications	N	O
20	appropriately	N	O
21	,	N	O
22	and	N	O
23	communicate	N	O
24	their	N	O
25	pain-related	N	O
26	needs	N	O
27	.	N	O

28	Methods	N	I-MajorClaim
29	are	N	I-MajorClaim
30	needed	N	I-MajorClaim
31	to	N	I-MajorClaim
32	reduce	N	I-MajorClaim
33	professional	N	I-MajorClaim
34	time	N	I-MajorClaim
35	required	N	I-MajorClaim
36	while	N	I-MajorClaim
37	achieving	N	I-MajorClaim
38	sustained	N	I-MajorClaim
39	intervention	N	I-MajorClaim
40	effectiveness	N	I-MajorClaim
41	.	N	I-MajorClaim

42	In	N	O
43	a	N	O
44	multisite	N	O
45	,	N	O
46	randomized	N	O
47	controlled	N	O
48	trial	N	O
49	,	N	O
50	this	N	O
51	study	N	O
52	tested	N	O
53	a	N	O
54	pain	N	O
55	training	N	O
56	method	N	O
57	versus	N	O
58	a	N	O
59	nutrition	N	O
60	control	N	O
61	.	N	O

62	At	N	O
63	six	N	O
64	oncology	N	O
65	clinics	N	O
66	,	N	O
67	physicians	N	O
68	(	N	O
69	N=22	N	O
70	)	N	O
71	and	N	O
72	nurses	N	O
73	(	N	O
74	N=23	N	O
75	)	N	O
76	enrolled	N	O
77	patients	N	O
78	(	N	O
79	N=93	N	O
80	)	N	O
81	who	N	O
82	were	N	O
83	over	N	O
84	18	N	O
85	years	N	O
86	of	N	O
87	age	N	O
88	,	N	O
89	with	N	O
90	cancer	N	O
91	diagnoses	N	O
92	,	N	O
93	pain	N	O
94	,	N	O
95	and	N	O
96	a	N	O
97	life	N	O
98	expectancy	N	O
99	of	N	O
100	at	N	O
101	least	N	O
102	6	N	O
103	months	N	O
104	.	N	O

105	Pain	N	O
106	training	N	O
107	and	N	O
108	control	N	O
109	interventions	N	O
110	were	N	O
111	matched	N	O
112	for	N	O
113	materials	N	O
114	and	N	O
115	method	N	O
116	.	N	O

117	Patients	N	O
118	watched	N	O
119	a	N	O
120	video	N	O
121	followed	N	O
122	by	N	O
123	about	N	O
124	20	N	O
125	min	N	O
126	of	N	O
127	manual-standardized	N	O
128	training	N	O
129	with	N	O
130	an	N	O
131	oncology	N	O
132	nurse	N	O
133	focused	N	O
134	on	N	O
135	reviewing	N	O
136	the	N	O
137	printed	N	O
138	material	N	O
139	and	N	O
140	adapted	N	O
141	to	N	O
142	individual	N	O
143	concerns	N	O
144	of	N	O
145	patients	N	O
146	.	N	O

147	A	N	O
148	follow-up	N	O
149	phone	N	O
150	call	N	O
151	after	N	O
152	72	N	O
153	h	N	O
154	addressed	N	O
155	individualized	N	O
156	treatment	N	O
157	content	N	O
158	and	N	O
159	pain	N	O
160	communication	N	O
161	.	N	O

162	Assessments	N	O
163	at	N	O
164	baseline	N	O
165	,	N	O
166	one	N	O
167	,	N	O
168	three	N	O
169	,	N	O
170	and	N	O
171	6	N	O
172	months	N	O
173	included	N	O
174	barriers	N	O
175	,	N	O
176	the	N	O
177	Brief	N	O
178	Pain	N	O
179	Inventory	N	O
180	,	N	O
181	opioid	N	O
182	use	N	O
183	,	N	O
184	and	N	O
185	physician	N	O
186	and	N	O
187	nurse	N	O
188	ratings	N	O
189	of	N	O
190	their	N	O
191	patients	N	O
192	'	N	O
193	pain	N	O
194	.	N	O

195	Trained	N	I-Premise
196	versus	N	I-Premise
197	control	N	I-Premise
198	patients	N	I-Premise
199	reported	N	I-Premise
200	reduced	N	I-Premise
201	barriers	N	I-Premise
202	to	N	I-Premise
203	pain	N	I-Premise
204	relief	N	I-Premise
205	(	N	I-Premise
206	P	N	I-Premise
207	<	N	I-Premise
208	.001	N	I-Premise
209	)	N	I-Premise
210	,	N	I-Premise
211	lower	N	I-Premise
212	usual	N	I-Premise
213	pain	N	I-Premise
214	(	N	I-Premise
215	P=.03	N	I-Premise
216	)	N	I-Premise
217	,	N	I-Premise
218	and	N	I-Premise
219	greater	N	I-Premise
220	opioid	N	I-Premise
221	use	N	I-Premise
222	(	N	I-Premise
223	P	N	I-Premise
224	<	N	I-Premise
225	.001	N	I-Premise
226	)	N	I-Premise
227	.	N	I-Premise

228	No	N	I-Premise
229	pain	N	I-Premise
230	training	N	I-Premise
231	patients	N	I-Premise
232	reported	N	I-Premise
233	severe	N	I-Premise
234	pain	N	I-Premise
235	(	N	I-Premise
236	>	N	I-Premise
237	6	N	I-Premise
238	on	N	I-Premise
239	a	N	I-Premise
240	0-10	N	I-Premise
241	scale	N	I-Premise
242	)	N	I-Premise
243	at	N	I-Premise
244	1-month	N	I-Premise
245	outcomes	N	I-Premise
246	(	N	I-Premise
247	P=.03	N	I-Premise
248	)	N	I-Premise
249	.	N	I-Premise

250	Physician	N	O
251	and	N	O
252	nurse	N	O
253	ratings	N	O
254	were	N	O
255	closer	N	O
256	to	N	O
257	patients	N	O
258	'	N	O
259	ratings	N	O
260	of	N	O
261	pain	N	O
262	for	N	O
263	trained	N	O
264	versus	N	O
265	nutrition	N	O
266	groups	N	O
267	(	N	O
268	P=.04	N	O
269	and	N	O
270	<	N	O
271	.001	N	O
272	,	N	O
273	respectively	N	O
274	)	N	O
275	.	N	O

276	Training	N	O
277	efficacy	N	O
278	was	N	O
279	not	N	O
280	modified	N	O
281	by	N	O
282	patient	N	O
283	characteristics	N	O
284	.	N	O

285	Using	N	I-Claim
286	video	N	I-Claim
287	and	N	I-Claim
288	print	N	I-Claim
289	materials	N	I-Claim
290	,	N	I-Claim
291	with	N	I-Claim
292	brief	N	I-Claim
293	individualized	N	I-Claim
294	training	N	I-Claim
295	,	N	I-Claim
296	effectively	N	I-Claim
297	improved	N	I-Claim
298	pain	N	I-Claim
299	management	N	I-Claim
300	over	N	I-Claim
301	time	N	I-Claim
302	for	N	I-Claim
303	cancer	N	I-Claim
304	patients	N	I-Claim
305	of	N	I-Claim
306	varying	N	I-Claim
307	diagnostic	N	I-Claim
308	and	N	I-Claim
309	demographic	N	I-Claim
310	groups	N	I-Claim
311	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	short-	N	O
4	and	N	O
5	long-term	N	O
6	effects	N	O
7	of	N	O
8	adjuvant	N	O
9	treatment	N	O
10	versus	N	O
11	observation	N	O
12	after	N	O
13	surgery	N	O
14	on	N	O
15	health-related	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	HRQL	N	O
21	)	N	O
22	of	N	O
23	prostate	N	O
24	cancer	N	O
25	patients	N	O
26	.	N	O

27	The	N	O
28	Southwest	N	O
29	Oncology	N	O
30	Group	N	O
31	(	N	O
32	SWOG	N	O
33	)	N	O
34	intergroup	N	O
35	trial	N	O
36	compared	N	O
37	radical	N	O
38	prostatectomy	N	O
39	(	N	O
40	RP	N	O
41	)	N	O
42	plus	N	O
43	observation	N	O
44	versus	N	O
45	RP	N	O
46	plus	N	O
47	adjuvant	N	O
48	radiation	N	O
49	therapy	N	O
50	(	N	O
51	RT	N	O
52	)	N	O
53	.	N	O

54	Two-hundred	N	O
55	seventeen	N	O
56	of	N	O
57	425	N	O
58	therapeutic	N	O
59	trial	N	O
60	patients	N	O
61	were	N	O
62	eligible	N	O
63	and	N	O
64	registered	N	O
65	to	N	O
66	the	N	O
67	HRQL	N	O
68	study	N	O
69	.	N	O

70	Patients	N	O
71	completed	N	O
72	the	N	O
73	SWOG	N	O
74	Quality	N	O
75	of	N	O
76	Life	N	O
77	Questionnaire	N	O
78	(	N	O
79	emotional	N	O
80	,	N	O
81	physical	N	O
82	,	N	O
83	social	N	O
84	,	N	O
85	and	N	O
86	role	N	O
87	function	N	O
88	;	N	O
89	general	N	O
90	symptom	N	O
91	status	N	O
92	;	N	O
93	treatment/disease-specific	N	O
94	symptoms	N	O
95	;	N	O
96	and	N	O
97	global	N	O
98	HRQL	N	O
99	[	N	O
100	GHRQL	N	O
101	]	N	O
102	)	N	O
103	at	N	O
104	baseline	N	O
105	,	N	O
106	6	N	O
107	weeks	N	O
108	,	N	O
109	6	N	O
110	months	N	O
111	,	N	O
112	and	N	O
113	annually	N	O
114	for	N	O
115	5	N	O
116	years	N	O
117	.	N	O

118	Prespecified	N	O
119	outcomes	N	O
120	were	N	O
121	three	N	O
122	genitourinary	N	O
123	symptoms	N	O
124	(	N	O
125	bowel	N	O
126	function	N	O
127	tenderness	N	O
128	,	N	O
129	frequent	N	O
130	urination	N	O
131	,	N	O
132	and	N	O
133	erectile	N	O
134	dysfunction	N	O
135	[	N	O
136	ED	N	O
137	]	N	O
138	)	N	O
139	and	N	O
140	measures	N	O
141	of	N	O
142	physical	N	O
143	and	N	O
144	emotional	N	O
145	function	N	O
146	.	N	O

147	Adjustments	N	O
148	were	N	O
149	made	N	O
150	for	N	O
151	the	N	O
152	baseline	N	O
153	score	N	O
154	.	N	O

155	Patients	N	O
156	receiving	N	O
157	adjuvant	N	O
158	RT	N	O
159	reported	N	O
160	worse	N	O
161	bowel	N	O
162	function	N	O
163	(	N	O
164	through	N	O
165	approximately	N	O
166	2	N	O
167	years	N	O
168	)	N	O
169	and	N	O
170	worse	N	O
171	urinary	N	O
172	function	N	O
173	.	N	O

174	There	N	O
175	were	N	O
176	no	N	O
177	statistically	N	O
178	significant	N	O
179	differences	N	O
180	for	N	O
181	ED	N	O
182	.	N	O

183	GHRQL	N	I-Premise
184	was	N	I-Premise
185	initially	N	I-Premise
186	worse	N	I-Premise
187	for	N	I-Premise
188	the	N	I-Premise
189	RP+RT	N	I-Premise
190	arm	N	I-Premise
191	but	N	I-Premise
192	improved	N	I-Premise
193	over	N	I-Premise
194	time	N	I-Premise
195	and	N	I-Premise
196	was	N	I-Premise
197	better	N	I-Premise
198	at	N	I-Premise
199	the	N	I-Premise
200	end	N	I-Premise
201	of	N	I-Premise
202	the	N	I-Premise
203	period	N	I-Premise
204	than	N	I-Premise
205	the	N	I-Premise
206	GHRQL	N	I-Premise
207	reported	N	I-Premise
208	for	N	I-Premise
209	RP	N	I-Premise
210	alone	N	I-Premise
211	(	N	I-Premise
212	treatment	N	I-Premise
213	arm	N	I-Premise
214	x	N	I-Premise
215	time	N	I-Premise
216	interaction	N	I-Premise
217	,	N	I-Premise
218	P	N	I-Premise
219	=	N	I-Premise
220	.0004	N	I-Premise
221	)	N	I-Premise
222	.	N	I-Premise

223	Symptom	N	I-Premise
224	distress	N	I-Premise
225	was	N	I-Premise
226	significantly	N	I-Premise
227	worse	N	I-Premise
228	for	N	I-Premise
229	the	N	I-Premise
230	RP+RT	N	I-Premise
231	arm	N	I-Premise
232	compared	N	I-Premise
233	with	N	I-Premise
234	the	N	I-Premise
235	RP	N	I-Premise
236	alone	N	I-Premise
237	arm	N	I-Premise
238	,	N	O
239	but	N	I-Premise
240	the	N	I-Premise
241	treatment	N	I-Premise
242	arms	N	I-Premise
243	did	N	I-Premise
244	not	N	I-Premise
245	differ	N	I-Premise
246	with	N	I-Premise
247	respect	N	I-Premise
248	to	N	I-Premise
249	other	N	I-Premise
250	general	N	I-Premise
251	measures	N	I-Premise
252	of	N	I-Premise
253	HRQL	N	I-Premise
254	.	N	I-Premise

255	The	N	I-Premise
256	addition	N	I-Premise
257	of	N	I-Premise
258	RT	N	I-Premise
259	to	N	I-Premise
260	surgery	N	I-Premise
261	resulted	N	I-Premise
262	in	N	I-Premise
263	more	N	I-Premise
264	frequent	N	I-Premise
265	urination	N	I-Premise
266	,	N	I-Premise
267	as	N	I-Premise
268	well	N	I-Premise
269	as	N	I-Premise
270	early	N	I-Premise
271	report	N	I-Premise
272	of	N	I-Premise
273	more	N	I-Premise
274	bowel	N	I-Premise
275	dysfunction	N	I-Premise
276	,	N	O
277	although	N	I-Premise
278	bowel	N	I-Premise
279	function	N	I-Premise
280	differences	N	I-Premise
281	disappeared	N	I-Premise
282	over	N	I-Premise
283	the	N	I-Premise
284	5-year	N	I-Premise
285	period	N	I-Premise
286	.	N	I-Premise

287	The	N	I-Claim
288	addition	N	I-Claim
289	of	N	I-Claim
290	RT	N	I-Claim
291	did	N	I-Claim
292	not	N	I-Claim
293	negatively	N	I-Claim
294	impact	N	I-Claim
295	ED	N	I-Claim
296	.	N	I-Claim

1	The	N	O
2	TAX	N	O
3	327	N	O
4	study	N	O
5	compared	N	O
6	docetaxel	N	O
7	administered	N	O
8	every	N	O
9	3	N	O
10	weeks	N	O
11	(	N	O
12	D3	N	O
13	)	N	O
14	,	N	O
15	weekly	N	O
16	docetaxel	N	O
17	(	N	O
18	D1	N	O
19	)	N	O
20	,	N	O
21	and	N	O
22	mitoxantrone	N	O
23	(	N	O
24	M	N	O
25	)	N	O
26	,	N	O
27	each	N	O
28	with	N	O
29	prednisone	N	O
30	(	N	O
31	P	N	O
32	)	N	O
33	,	N	O
34	in	N	O
35	1,006	N	O
36	men	N	O
37	with	N	O
38	metastatic	N	O
39	hormone-resistant	N	O
40	prostate	N	O
41	cancer	N	O
42	(	N	O
43	HRPC	N	O
44	)	N	O
45	.	N	O

46	The	N	O
47	original	N	O
48	analysis	N	O
49	,	N	O
50	undertaken	N	O
51	in	N	O
52	August	N	O
53	2003	N	O
54	when	N	O
55	557	N	O
56	deaths	N	O
57	had	N	O
58	occurred	N	O
59	,	N	O
60	showed	N	O
61	significantly	N	O
62	better	N	O
63	survival	N	O
64	and	N	O
65	response	N	O
66	rates	N	O
67	for	N	O
68	pain	N	O
69	,	N	O
70	prostate-specific	N	O
71	antigen	N	O
72	(	N	O
73	PSA	N	O
74	)	N	O
75	,	N	O
76	and	N	O
77	quality	N	O
78	of	N	O
79	life	N	O
80	for	N	O
81	D3P	N	O
82	when	N	O
83	compared	N	O
84	with	N	O
85	MP	N	O
86	.	N	O

87	Here	N	O
88	,	N	O
89	we	N	O
90	report	N	O
91	an	N	O
92	updated	N	O
93	analysis	N	O
94	of	N	O
95	survival	N	O
96	.	N	O

97	Investigators	N	O
98	were	N	O
99	asked	N	O
100	to	N	O
101	provide	N	O
102	the	N	O
103	date	N	O
104	of	N	O
105	death	N	O
106	or	N	O
107	last	N	O
108	follow-up	N	O
109	for	N	O
110	all	N	O
111	participants	N	O
112	who	N	O
113	were	N	O
114	alive	N	O
115	in	N	O
116	August	N	O
117	2003	N	O
118	.	N	O

119	By	N	O
120	March	N	O
121	2007	N	O
122	,	N	O
123	data	N	O
124	on	N	O
125	310	N	O
126	additional	N	O
127	deaths	N	O
128	were	N	O
129	obtained	N	O
130	(	N	O
131	total	N	O
132	=	N	O
133	867	N	O
134	deaths	N	O
135	)	N	O
136	.	N	O

137	The	N	I-Premise
138	survival	N	I-Premise
139	benefit	N	I-Premise
140	of	N	I-Premise
141	D3P	N	I-Premise
142	compared	N	I-Premise
143	with	N	I-Premise
144	MP	N	I-Premise
145	has	N	I-Premise
146	persisted	N	I-Premise
147	with	N	I-Premise
148	extended	N	I-Premise
149	follow-up	N	I-Premise
150	(	N	I-Premise
151	P	N	I-Premise
152	=	N	I-Premise
153	.004	N	I-Premise
154	)	N	I-Premise
155	.	N	I-Premise

156	Median	N	O
157	survival	N	O
158	time	N	O
159	was	N	O
160	19.2	N	O
161	months	N	O
162	(	N	O
163	95	N	O
164	%	N	O
165	CI	N	O
166	,	N	O
167	17.5	N	O
168	to	N	O
169	21.3	N	O
170	months	N	O
171	)	N	O
172	in	N	O
173	the	N	O
174	D3P	N	O
175	arm	N	O
176	,	N	O
177	17.8	N	O
178	months	N	O
179	(	N	O
180	95	N	O
181	%	N	O
182	CI	N	O
183	,	N	O
184	16.2	N	O
185	to	N	O
186	19.2	N	O
187	months	N	O
188	)	N	O
189	in	N	O
190	the	N	O
191	D1P	N	O
192	arm	N	O
193	,	N	O
194	and	N	O
195	16.3	N	O
196	months	N	O
197	(	N	O
198	95	N	O
199	%	N	O
200	CI	N	O
201	,	N	O
202	14.3	N	O
203	to	N	O
204	17.9	N	O
205	months	N	O
206	)	N	O
207	in	N	O
208	the	N	O
209	MP	N	O
210	arm	N	O
211	.	N	O

212	More	N	I-Premise
213	patients	N	I-Premise
214	survived	N	I-Premise
215	>	N	I-Premise
216	/=	N	I-Premise
217	3	N	I-Premise
218	years	N	I-Premise
219	in	N	I-Premise
220	the	N	I-Premise
221	D3P	N	I-Premise
222	and	N	I-Premise
223	D1P	N	I-Premise
224	arms	N	I-Premise
225	(	N	I-Premise
226	18.6	N	I-Premise
227	%	N	I-Premise
228	and	N	I-Premise
229	16.6	N	I-Premise
230	%	N	I-Premise
231	,	N	I-Premise
232	respectively	N	I-Premise
233	)	N	I-Premise
234	compared	N	I-Premise
235	with	N	I-Premise
236	the	N	I-Premise
237	MP	N	I-Premise
238	arm	N	I-Premise
239	(	N	I-Premise
240	13.5	N	I-Premise
241	%	N	I-Premise
242	)	N	I-Premise
243	.	N	I-Premise

244	Similar	N	I-Premise
245	trends	N	I-Premise
246	in	N	I-Premise
247	survival	N	I-Premise
248	between	N	I-Premise
249	treatment	N	I-Premise
250	arms	N	I-Premise
251	were	N	I-Premise
252	seen	N	I-Premise
253	for	N	I-Premise
254	men	N	I-Premise
255	greater	N	I-Premise
256	than	N	I-Premise
257	and	N	I-Premise
258	less	N	I-Premise
259	than	N	I-Premise
260	65	N	I-Premise
261	years	N	I-Premise
262	of	N	I-Premise
263	age	N	I-Premise
264	,	N	I-Premise
265	for	N	I-Premise
266	those	N	I-Premise
267	with	N	I-Premise
268	and	N	I-Premise
269	without	N	I-Premise
270	pain	N	I-Premise
271	at	N	I-Premise
272	baseline	N	I-Premise
273	,	N	I-Premise
274	and	N	I-Premise
275	for	N	I-Premise
276	those	N	I-Premise
277	with	N	I-Premise
278	baseline	N	I-Premise
279	PSA	N	I-Premise
280	greater	N	I-Premise
281	than	N	I-Premise
282	and	N	I-Premise
283	less	N	I-Premise
284	than	N	I-Premise
285	the	N	I-Premise
286	median	N	I-Premise
287	value	N	I-Premise
288	of	N	I-Premise
289	115	N	I-Premise
290	ng/mL	N	I-Premise
291	.	N	I-Premise

292	The	N	I-Claim
293	present	N	I-Claim
294	analysis	N	I-Claim
295	confirms	N	I-Claim
296	that	N	I-Claim
297	survival	N	I-Claim
298	of	N	I-Claim
299	men	N	I-Claim
300	with	N	I-Claim
301	metastatic	N	I-Claim
302	HRPC	N	I-Claim
303	is	N	I-Claim
304	significantly	N	I-Claim
305	longer	N	I-Claim
306	after	N	I-Claim
307	treatment	N	I-Claim
308	with	N	I-Claim
309	D3P	N	I-Claim
310	than	N	I-Claim
311	with	N	I-Claim
312	MP	N	I-Claim
313	.	N	I-Claim

314	Consistent	N	O
315	results	N	O
316	are	N	O
317	observed	N	O
318	across	N	O
319	subgroups	N	O
320	of	N	O
321	patients	N	O
322	.	N	O

1	To	N	O
2	prospectively	N	O
3	evaluate	N	O
4	health-related	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	HRQOL	N	O
10	)	N	O
11	outcomes	N	O
12	for	N	O
13	uterine	N	O
14	artery	N	O
15	embolization	N	O
16	(	N	O
17	UAE	N	O
18	)	N	O
19	and	N	O
20	hysterectomy	N	O
21	up	N	O
22	to	N	O
23	24	N	O
24	months	N	O
25	after	N	O
26	the	N	O
27	intervention	N	O
28	in	N	O
29	terms	N	O
30	of	N	O
31	mental	N	O
32	and	N	O
33	physical	N	O
34	health	N	O
35	,	N	O
36	urinary	N	O
37	and	N	O
38	defecatory	N	O
39	function	N	O
40	,	N	O
41	and	N	O
42	overall	N	O
43	patient	N	O
44	satisfaction	N	O
45	.	N	O

46	Ethics	N	O
47	committee	N	O
48	approval	N	O
49	and	N	O
50	informed	N	O
51	consent	N	O
52	were	N	O
53	obtained	N	O
54	for	N	O
55	the	N	O
56	Embolisation	N	O
57	versus	N	O
58	Hysterectomy	N	O
59	Trial	N	O
60	.	N	O

61	Women	N	O
62	(	N	O
63	n	N	O
64	=	N	O
65	177	N	O
66	)	N	O
67	with	N	O
68	uterine	N	O
69	fibroids	N	O
70	and	N	O
71	heavy	N	O
72	menstrual	N	O
73	bleeding	N	O
74	who	N	O
75	were	N	O
76	scheduled	N	O
77	to	N	O
78	undergo	N	O
79	hysterectomy	N	O
80	were	N	O
81	randomly	N	O
82	assigned	N	O
83	to	N	O
84	undergo	N	O
85	UAE	N	O
86	(	N	O
87	n	N	O
88	=	N	O
89	88	N	O
90	)	N	O
91	or	N	O
92	hysterectomy	N	O
93	(	N	O
94	n	N	O
95	=	N	O
96	89	N	O
97	)	N	O
98	.	N	O

99	HRQOL	N	O
100	was	N	O
101	measured	N	O
102	six	N	O
103	times	N	O
104	during	N	O
105	a	N	O
106	24-month	N	O
107	follow-up	N	O
108	period	N	O
109	with	N	O
110	the	N	O
111	following	N	O
112	validated	N	O
113	questionnaires	N	O
114	:	N	O
115	Medical	N	O
116	Outcome	N	O
117	Study	N	O
118	Short	N	O
119	Form	N	O
120	36	N	O
121	(	N	O
122	SF-36	N	O
123	)	N	O
124	mental	N	O
125	component	N	O
126	summary	N	O
127	(	N	O
128	MCS	N	O
129	)	N	O
130	and	N	O
131	physical	N	O
132	component	N	O
133	summary	N	O
134	(	N	O
135	PCS	N	O
136	)	N	O
137	,	N	O
138	Health	N	O
139	Utilities	N	O
140	Index	N	O
141	Mark	N	O
142	3	N	O
143	,	N	O
144	EuroQol	N	O
145	5D	N	O
146	,	N	O
147	urogenital	N	O
148	distress	N	O
149	inventory	N	O
150	(	N	O
151	UDI	N	O
152	)	N	O
153	,	N	O
154	incontinence	N	O
155	impact	N	O
156	questionnaire	N	O
157	,	N	O
158	and	N	O
159	defecation	N	O
160	distress	N	O
161	inventory	N	O
162	(	N	O
163	DDI	N	O
164	)	N	O
165	.	N	O

166	Satisfaction	N	O
167	was	N	O
168	assessed	N	O
169	with	N	O
170	a	N	O
171	seven-point	N	O
172	Likert	N	O
173	scale	N	O
174	.	N	O

175	Repeated	N	O
176	measurement	N	O
177	analysis	N	O
178	was	N	O
179	performed	N	O
180	for	N	O
181	between-group	N	O
182	analysis	N	O
183	.	N	O

184	Paired	N	O
185	t	N	O
186	tests	N	O
187	were	N	O
188	performed	N	O
189	for	N	O
190	within-group	N	O
191	analysis	N	O
192	.	N	O

193	Satisfaction	N	O
194	was	N	O
195	analyzed	N	O
196	with	N	O
197	the	N	O
198	Fisher	N	O
199	exact	N	O
200	test	N	O
201	.	N	O

202	The	N	I-Premise
203	SF-36	N	I-Premise
204	MCS	N	I-Premise
205	and	N	I-Premise
206	PCS	N	I-Premise
207	,	N	I-Premise
208	Health	N	I-Premise
209	Utilities	N	I-Premise
210	Index	N	I-Premise
211	Mark	N	I-Premise
212	3	N	I-Premise
213	,	N	I-Premise
214	EuroQol	N	I-Premise
215	5D	N	I-Premise
216	,	N	I-Premise
217	and	N	I-Premise
218	UDI	N	I-Premise
219	scores	N	I-Premise
220	were	N	I-Premise
221	improved	N	I-Premise
222	significantly	N	I-Premise
223	in	N	I-Premise
224	both	N	I-Premise
225	groups	N	I-Premise
226	at	N	I-Premise
227	6	N	I-Premise
228	months	N	I-Premise
229	and	N	I-Premise
230	afterward	N	I-Premise
231	(	N	I-Premise
232	P	N	I-Premise
233	<	N	I-Premise
234	.05	N	I-Premise
235	)	N	I-Premise
236	.	N	I-Premise

237	The	N	O
238	DDI	N	O
239	score	N	O
240	was	N	O
241	improved	N	O
242	significantly	N	O
243	in	N	O
244	only	N	O
245	the	N	O
246	UAE	N	O
247	group	N	O
248	at	N	O
249	6	N	O
250	months	N	O
251	and	N	O
252	afterward	N	O
253	(	N	O
254	P	N	O
255	<	N	O
256	.05	N	O
257	)	N	O
258	.	N	O

259	No	N	O
260	differences	N	O
261	between	N	O
262	groups	N	O
263	were	N	O
264	observed	N	O
265	,	N	O
266	with	N	O
267	the	N	O
268	exception	N	O
269	of	N	O
270	PCS	N	O
271	scores	N	O
272	at	N	O
273	6-week	N	O
274	follow-up	N	O
275	:	N	O
276	Patients	N	O
277	in	N	O
278	the	N	O
279	UAE	N	O
280	group	N	O
281	had	N	O
282	significantly	N	O
283	better	N	O
284	scores	N	O
285	than	N	O
286	did	N	O
287	patients	N	O
288	in	N	O
289	the	N	O
290	hysterectomy	N	O
291	group	N	O
292	(	N	O
293	P	N	O
294	<	N	O
295	.001	N	O
296	)	N	O
297	.	N	O

298	Improvement	N	O
299	in	N	O
300	PCS	N	O
301	score	N	O
302	at	N	O
303	24-month	N	O
304	follow-up	N	O
305	was	N	O
306	significantly	N	O
307	higher	N	O
308	for	N	O
309	patients	N	O
310	who	N	O
311	were	N	O
312	employed	N	O
313	at	N	O
314	baseline	N	O
315	(	N	O
316	P	N	O
317	=	N	O
318	.035	N	O
319	)	N	O
320	.	N	O

321	At	N	I-Premise
322	24-month	N	I-Premise
323	follow-up	N	I-Premise
324	,	N	I-Premise
325	patients	N	I-Premise
326	in	N	I-Premise
327	the	N	I-Premise
328	hysterectomy	N	I-Premise
329	group	N	I-Premise
330	were	N	I-Premise
331	significantly	N	I-Premise
332	more	N	I-Premise
333	satisfied	N	I-Premise
334	than	N	I-Premise
335	those	N	I-Premise
336	in	N	I-Premise
337	the	N	I-Premise
338	UAE	N	I-Premise
339	group	N	I-Premise
340	(	N	I-Premise
341	P	N	I-Premise
342	=	N	I-Premise
343	.02	N	I-Premise
344	)	N	I-Premise
345	.	N	I-Premise

346	Both	N	I-Claim
347	UAE	N	I-Claim
348	and	N	I-Claim
349	hysterectomy	N	I-Claim
350	improved	N	I-Claim
351	HRQOL	N	I-Claim
352	.	N	I-Claim

353	No	N	I-Claim
354	differences	N	I-Claim
355	were	N	I-Claim
356	observed	N	I-Claim
357	between	N	I-Claim
358	groups	N	I-Claim
359	regarding	N	I-Claim
360	HRQOL	N	I-Claim
361	at	N	I-Claim
362	24-month	N	I-Claim
363	follow-up	N	I-Claim
364	.	N	I-Claim

365	On	N	I-Claim
366	the	N	I-Claim
367	basis	N	I-Claim
368	of	N	I-Claim
369	HRQOL	N	I-Claim
370	results	N	I-Claim
371	,	N	I-Claim
372	the	N	I-Claim
373	authors	N	I-Claim
374	determined	N	I-Claim
375	that	N	I-Claim
376	UAE	N	I-Claim
377	is	N	I-Claim
378	a	N	I-Claim
379	good	N	I-Claim
380	alternative	N	I-Claim
381	to	N	I-Claim
382	hysterectomy	N	I-Claim
383	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	(	N	O
14	QOL	N	O
15	)	N	O
16	of	N	O
17	high-risk	N	O
18	breast	N	O
19	cancer	N	O
20	patients	N	O
21	included	N	O
22	in	N	O
23	a	N	O
24	randomized	N	O
25	clinical	N	O
26	trial	N	O
27	(	N	O
28	PEGASE	N	O
29	01	N	O
30	)	N	O
31	comparing	N	O
32	conventional	N	O
33	chemotherapy	N	O
34	versus	N	O
35	adding	N	O
36	an	N	O
37	additional	N	O
38	high-dose	N	O
39	chemotherapy	N	O
40	(	N	O
41	HDC	N	O
42	)	N	O
43	cycle	N	O
44	with	N	O
45	blood	N	O
46	stem	N	O
47	cell	N	O
48	support	N	O
49	.	N	O

50	A	N	O
51	total	N	O
52	of	N	O
53	314	N	O
54	patients	N	O
55	were	N	O
56	included	N	O
57	in	N	O
58	the	N	O
59	clinical	N	O
60	trial	N	O
61	.	N	O

62	QOL	N	O
63	evaluations	N	O
64	were	N	O
65	available	N	O
66	for	N	O
67	199	N	O
68	patients	N	O
69	.	N	O

70	QOL	N	O
71	was	N	O
72	assessed	N	O
73	over	N	O
74	a	N	O
75	1-year	N	O
76	follow-up	N	O
77	period	N	O
78	,	N	O
79	using	N	O
80	the	N	O
81	European	N	O
82	Organization	N	O
83	for	N	O
84	Research	N	O
85	and	N	O
86	Treatment	N	O
87	of	N	O
88	Cancer	N	O
89	Quality	N	O
90	of	N	O
91	Life	N	O
92	Questionnaire	N	O
93	C-30	N	O
94	.	N	O

95	The	N	O
96	results	N	O
97	were	N	O
98	analyzed	N	O
99	using	N	O
100	a	N	O
101	linear	N	O
102	mixed-effects	N	O
103	model	N	O
104	.	N	O

105	Toxicity	N	I-Premise
106	of	N	I-Premise
107	HDC	N	I-Premise
108	has	N	I-Premise
109	a	N	I-Premise
110	strong	N	I-Premise
111	negative	N	I-Premise
112	impact	N	I-Premise
113	on	N	I-Premise
114	patients	N	I-Premise
115	'	N	I-Premise
116	QOL	N	I-Premise
117	during	N	I-Premise
118	the	N	I-Premise
119	treatment	N	I-Premise
120	phase	N	I-Premise
121	.	N	I-Premise

122	This	N	I-Premise
123	negative	N	I-Premise
124	impact	N	I-Premise
125	tended	N	I-Premise
126	to	N	I-Premise
127	last	N	I-Premise
128	longer	N	I-Premise
129	in	N	I-Premise
130	the	N	I-Premise
131	HDC	N	I-Premise
132	group	N	I-Premise
133	,	N	I-Premise
134	as	N	I-Premise
135	for	N	I-Premise
136	most	N	I-Premise
137	of	N	I-Premise
138	the	N	I-Premise
139	QLQ-C30	N	I-Premise
140	scales	N	I-Premise
141	,	N	I-Premise
142	the	N	I-Premise
143	QOL	N	I-Premise
144	scores	N	I-Premise
145	of	N	I-Premise
146	HDC	N	I-Premise
147	patients	N	I-Premise
148	tend	N	I-Premise
149	to	N	I-Premise
150	improve	N	I-Premise
151	at	N	I-Premise
152	a	N	I-Premise
153	slower	N	I-Premise
154	rate	N	I-Premise
155	than	N	I-Premise
156	that	N	I-Premise
157	of	N	I-Premise
158	patients	N	I-Premise
159	receiving	N	I-Premise
160	standard	N	I-Premise
161	chemotherapy	N	I-Premise
162	.	N	I-Premise

163	In	N	O
164	particular	N	O
165	,	N	O
166	physical	N	I-Premise
167	functioning	N	I-Premise
168	remains	N	I-Premise
169	deteriorated	N	I-Premise
170	1	N	I-Premise
171	year	N	I-Premise
172	after	N	I-Premise
173	inclusion	N	I-Premise
174	for	N	I-Premise
175	HDC	N	I-Premise
176	patients	N	I-Premise
177	comparatively	N	I-Premise
178	to	N	I-Premise
179	conventional	N	I-Premise
180	chemotherapy	N	I-Premise
181	patients	N	I-Premise
182	(	N	I-Premise
183	85.99	N	I-Premise
184	vs.	N	I-Premise
185	76.65	N	I-Premise
186	,	N	I-Premise
187	P	N	I-Premise
188	=	N	I-Premise
189	0.021	N	I-Premise
190	)	N	I-Premise
191	,	N	O
192	and	N	I-Premise
193	the	N	I-Premise
194	pain	N	I-Premise
195	score	N	I-Premise
196	was	N	I-Premise
197	still	N	I-Premise
198	higher	N	I-Premise
199	in	N	I-Premise
200	the	N	I-Premise
201	HDC	N	I-Premise
202	group	N	I-Premise
203	at	N	I-Premise
204	that	N	I-Premise
205	time	N	I-Premise
206	(	N	I-Premise
207	28.32	N	I-Premise
208	vs.	N	I-Premise
209	15.97	N	I-Premise
210	,	N	I-Premise
211	P	N	I-Premise
212	=	N	I-Premise
213	0.004	N	I-Premise
214	)	N	I-Premise
215	.	N	I-Premise

216	HDC	N	I-Claim
217	has	N	I-Claim
218	a	N	I-Claim
219	negative	N	I-Claim
220	impact	N	I-Claim
221	on	N	I-Claim
222	QOL	N	I-Claim
223	even	N	I-Claim
224	after	N	I-Claim
225	treatment	N	I-Claim
226	phase	N	I-Claim
227	.	N	I-Claim

228	In	N	O
229	the	N	O
230	absence	N	O
231	of	N	O
232	an	N	O
233	overall	N	O
234	survival	N	O
235	benefit	N	O
236	of	N	O
237	using	N	O
238	HDC	N	O
239	for	N	O
240	high-risk	N	O
241	breast	N	O
242	cancer	N	O
243	patients	N	O
244	,	N	O
245	QOL	N	O
246	studies	N	O
247	with	N	O
248	a	N	O
249	longer	N	O
250	follow-up	N	O
251	play	N	O
252	an	N	O
253	important	N	O
254	role	N	O
255	in	N	O
256	informing	N	O
257	the	N	O
258	complex	N	O
259	trade-off	N	O
260	implied	N	O
261	by	N	O
262	HDC	N	O
263	between	N	O
264	higher	N	O
265	toxicity	N	O
266	,	N	O
267	reduced	N	O
268	risk	N	O
269	of	N	O
270	relapse	N	O
271	,	N	O
272	and	N	O
273	QOL	N	O
274	decrease	N	O
275	after	N	O
276	the	N	O
277	active	N	O
278	phase	N	O
279	of	N	O
280	treatment	N	O
281	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	multicenter	N	O
6	randomized	N	O
7	trial	N	O
8	was	N	O
9	to	N	O
10	assess	N	O
11	the	N	O
12	efficacy	N	O
13	and	N	O
14	safety	N	O
15	of	N	O
16	sentinel	N	O
17	lymph	N	O
18	node	N	O
19	(	N	O
20	SLN	N	O
21	)	N	O
22	biopsy	N	O
23	compared	N	O
24	with	N	O
25	axillary	N	O
26	lymph	N	O
27	node	N	O
28	dissection	N	O
29	(	N	O
30	ALND	N	O
31	)	N	O
32	.	N	O

33	All	N	O
34	studies	N	O
35	on	N	O
36	SLN	N	O
37	biopsy	N	O
38	in	N	O
39	breast	N	O
40	cancer	N	O
41	report	N	O
42	a	N	O
43	variable	N	O
44	false	N	O
45	negative	N	O
46	rate	N	O
47	,	N	O
48	whose	N	O
49	prognostic	N	O
50	consequences	N	O
51	are	N	O
52	still	N	O
53	unclear	N	O
54	.	N	O

55	From	N	O
56	May	N	O
57	1999	N	O
58	to	N	O
59	December	N	O
60	2004	N	O
61	,	N	O
62	patients	N	O
63	with	N	O
64	breast	N	O
65	cancer	N	O
66	<	N	O
67	or	N	O
68	=3	N	O
69	cm	N	O
70	were	N	O
71	randomly	N	O
72	assigned	N	O
73	to	N	O
74	receive	N	O
75	SLN	N	O
76	biopsy	N	O
77	associated	N	O
78	with	N	O
79	ALND	N	O
80	(	N	O
81	ALND	N	O
82	arm	N	O
83	)	N	O
84	or	N	O
85	SLN	N	O
86	biopsy	N	O
87	followed	N	O
88	by	N	O
89	ALND	N	O
90	only	N	O
91	if	N	O
92	the	N	O
93	SLN	N	O
94	was	N	O
95	metastatic	N	O
96	(	N	O
97	SLN	N	O
98	arm	N	O
99	)	N	O
100	.	N	O

101	The	N	O
102	main	N	O
103	aim	N	O
104	was	N	O
105	the	N	O
106	comparison	N	O
107	of	N	O
108	disease-free	N	O
109	survival	N	O
110	in	N	O
111	the	N	O
112	2	N	O
113	arms	N	O
114	.	N	O

115	A	N	O
116	total	N	O
117	of	N	O
118	749	N	O
119	patients	N	O
120	were	N	O
121	randomized	N	O
122	and	N	O
123	697	N	O
124	were	N	O
125	available	N	O
126	for	N	O
127	analysis	N	O
128	.	N	O

129	SLNs	N	O
130	were	N	O
131	identified	N	O
132	in	N	O
133	662	N	O
134	of	N	O
135	697	N	O
136	patients	N	O
137	(	N	O
138	95	N	O
139	%	N	O
140	)	N	O
141	and	N	O
142	positive	N	O
143	SLNs	N	O
144	were	N	O
145	found	N	O
146	in	N	O
147	189	N	O
148	of	N	O
149	662	N	O
150	patients	N	O
151	(	N	O
152	28.5	N	O
153	%	N	O
154	)	N	O
155	.	N	O

156	In	N	O
157	the	N	O
158	ALND	N	O
159	group	N	O
160	,	N	O
161	positive	N	O
162	non-SLNs	N	O
163	were	N	O
164	found	N	O
165	in	N	O
166	18	N	O
167	patients	N	O
168	with	N	O
169	negative	N	O
170	SLN	N	O
171	,	N	O
172	giving	N	O
173	a	N	O
174	false	N	O
175	negative	N	O
176	rate	N	O
177	of	N	O
178	16.7	N	O
179	%	N	O
180	(	N	O
181	18	N	O
182	of	N	O
183	108	N	O
184	)	N	O
185	.	N	O

186	Postoperative	N	I-Premise
187	side	N	I-Premise
188	effects	N	I-Premise
189	were	N	I-Premise
190	significantly	N	I-Premise
191	less	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	SLN	N	I-Premise
195	group	N	I-Premise
196	and	N	I-Premise
197	there	N	I-Premise
198	was	N	I-Premise
199	no	N	I-Premise
200	negative	N	I-Premise
201	impact	N	I-Premise
202	of	N	I-Premise
203	the	N	I-Premise
204	SLN	N	I-Premise
205	procedure	N	I-Premise
206	on	N	I-Premise
207	psychologic	N	I-Premise
208	well	N	I-Premise
209	being	N	I-Premise
210	.	N	I-Premise

211	At	N	O
212	a	N	O
213	median	N	O
214	follow-up	N	O
215	of	N	O
216	56	N	O
217	months	N	O
218	,	N	O
219	there	N	O
220	were	N	O
221	more	N	O
222	locoregional	N	O
223	recurrences	N	O
224	in	N	O
225	the	N	O
226	SLN	N	O
227	arm	N	O
228	,	N	O
229	and	N	O
230	the	N	O
231	5-year	N	O
232	disease-free	N	O
233	survival	N	O
234	was	N	O
235	89.9	N	O
236	%	N	O
237	in	N	O
238	the	N	O
239	ALND	N	O
240	arm	N	O
241	and	N	O
242	87.6	N	O
243	%	N	O
244	in	N	O
245	the	N	O
246	SLN	N	O
247	arm	N	O
248	,	N	O
249	with	N	O
250	a	N	O
251	difference	N	O
252	of	N	O
253	2.3	N	O
254	%	N	O
255	(	N	O
256	95	N	O
257	%	N	O
258	confidence	N	O
259	interval	N	O
260	:	N	O
261	-3.1	N	O
262	%	N	O
263	to	N	O
264	7.6	N	O
265	%	N	O
266	)	N	O
267	.	N	O

268	However	N	I-Premise
269	,	N	I-Premise
270	the	N	I-Premise
271	number	N	I-Premise
272	of	N	I-Premise
273	enrolled	N	I-Premise
274	patients	N	I-Premise
275	was	N	I-Premise
276	not	N	I-Premise
277	sufficient	N	I-Premise
278	to	N	I-Premise
279	draw	N	I-Premise
280	definitive	N	I-Premise
281	conclusions	N	I-Premise
282	.	N	I-Premise

283	SLN	N	I-Claim
284	biopsy	N	I-Claim
285	is	N	I-Claim
286	an	N	I-Claim
287	effective	N	I-Claim
288	and	N	I-Claim
289	well-tolerated	N	I-Claim
290	procedure	N	I-Claim
291	.	N	I-Claim

292	However	N	I-Claim
293	,	N	I-Claim
294	its	N	I-Claim
295	safety	N	I-Claim
296	should	N	I-Claim
297	be	N	I-Claim
298	confirmed	N	I-Claim
299	by	N	I-Claim
300	the	N	I-Claim
301	results	N	I-Claim
302	of	N	I-Claim
303	larger	N	I-Claim
304	randomized	N	I-Claim
305	trials	N	I-Claim
306	and	N	I-Claim
307	meta-analyses	N	I-Claim
308	.	N	I-Claim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	analysis	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	impact	N	O
11	of	N	O
12	pretreatment	N	O
13	factors	N	O
14	on	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QOL	N	O
20	)	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	locally	N	O
25	advanced	N	O
26	nonsmall	N	O
27	cell	N	O
28	lung	N	O
29	cancer	N	O
30	(	N	O
31	NSCLC	N	O
32	)	N	O
33	.	N	O

34	In	N	O
35	particular	N	O
36	,	N	O
37	this	N	O
38	study	N	O
39	focused	N	O
40	on	N	O
41	the	N	O
42	possible	N	O
43	interaction	N	O
44	between	N	O
45	gender-specific	N	O
46	baseline	N	O
47	health-related	N	O
48	QOL	N	O
49	and	N	O
50	Karnofsky	N	O
51	performance	N	O
52	score	N	O
53	(	N	O
54	KPS	N	O
55	)	N	O
56	in	N	O
57	a	N	O
58	prospective	N	O
59	randomized	N	O
60	lung	N	O
61	cancer	N	O
62	trial	N	O
63	.	N	O

64	QOL	N	O
65	information	N	O
66	,	N	O
67	using	N	O
68	validated	N	O
69	instruments	N	O
70	(	N	O
71	Functional	N	O
72	Assessment	N	O
73	of	N	O
74	Cancer	N	O
75	Therapy-Lung	N	O
76	[	N	O
77	FACT-L	N	O
78	]	N	O
79	,	N	O
80	version	N	O
81	2	N	O
82	,	N	O
83	and	N	O
84	Functional	N	O
85	Living	N	O
86	Index-Cancer	N	O
87	[	N	O
88	FLIC	N	O
89	]	N	O
90	)	N	O
91	,	N	O
92	was	N	O
93	prospectively	N	O
94	collected	N	O
95	in	N	O
96	patients	N	O
97	with	N	O
98	locally	N	O
99	advanced	N	O
100	NSCLC	N	O
101	treated	N	O
102	on	N	O
103	Radiation	N	O
104	Therapy	N	O
105	Oncology	N	O
106	Group	N	O
107	(	N	O
108	RTOG	N	O
109	)	N	O
110	trial	N	O
111	89-01	N	O
112	.	N	O

113	Between	N	O
114	April	N	O
115	1990	N	O
116	and	N	O
117	April	N	O
118	1994	N	O
119	,	N	O
120	70	N	O
121	eligible	N	O
122	patients	N	O
123	participated	N	O
124	in	N	O
125	a	N	O
126	phase	N	O
127	III	N	O
128	trial	N	O
129	comparing	N	O
130	a	N	O
131	regimen	N	O
132	containing	N	O
133	sequential	N	O
134	chemotherapy	N	O
135	and	N	O
136	radiation	N	O
137	therapy	N	O
138	versus	N	O
139	sequential	N	O
140	chemotherapy	N	O
141	plus	N	O
142	surgery	N	O
143	.	N	O

144	Of	N	O
145	these	N	O
146	70	N	O
147	patients	N	O
148	,	N	O
149	46	N	O
150	underwent	N	O
151	pretreatment	N	O
152	FLIC	N	O
153	and	N	O
154	49	N	O
155	underwent	N	O
156	pretreatment	N	O
157	FACT-L	N	O
158	.	N	O

159	There	N	I-Premise
160	was	N	I-Premise
161	a	N	I-Premise
162	significant	N	I-Premise
163	interaction	N	I-Premise
164	between	N	I-Premise
165	gender	N	I-Premise
166	and	N	I-Premise
167	KPS	N	I-Premise
168	using	N	I-Premise
169	FLIC	N	I-Premise
170	(	N	I-Premise
171	P	N	I-Premise
172	=	N	I-Premise
173	0.009	N	I-Premise
174	)	N	I-Premise
175	,	N	I-Premise
176	which	N	I-Premise
177	also	N	I-Premise
178	showed	N	I-Premise
179	a	N	I-Premise
180	trend	N	I-Premise
181	toward	N	I-Premise
182	significance	N	I-Premise
183	with	N	I-Premise
184	FACT	N	I-Premise
185	(	N	I-Premise
186	P	N	I-Premise
187	=	N	I-Premise
188	0.09	N	I-Premise
189	)	N	I-Premise
190	.	N	I-Premise

191	Significant	N	I-Premise
192	KPS-by-gender	N	I-Premise
193	interactions	N	I-Premise
194	were	N	I-Premise
195	noted	N	I-Premise
196	for	N	I-Premise
197	FACT-L	N	I-Premise
198	in	N	I-Premise
199	the	N	I-Premise
200	physical	N	I-Premise
201	well-being	N	I-Premise
202	and	N	I-Premise
203	additional	N	I-Premise
204	concerns-lung	N	I-Premise
205	subscales	N	I-Premise
206	(	N	I-Premise
207	P	N	I-Premise
208	=	N	I-Premise
209	0.012	N	I-Premise
210	and	N	I-Premise
211	P	N	I-Premise
212	=	N	I-Premise
213	0.0003	N	I-Premise
214	,	N	I-Premise
215	respectively	N	I-Premise
216	)	N	I-Premise
217	.	N	I-Premise

218	The	N	I-Premise
219	results	N	I-Premise
220	of	N	I-Premise
221	both	N	I-Premise
222	the	N	I-Premise
223	FLIC	N	I-Premise
224	and	N	I-Premise
225	FACT-L	N	I-Premise
226	demonstrated	N	I-Premise
227	significantly	N	I-Premise
228	lower	N	I-Premise
229	scores	N	I-Premise
230	corresponding	N	I-Premise
231	to	N	I-Premise
232	lower	N	I-Premise
233	KPS	N	I-Premise
234	values	N	I-Premise
235	(	N	I-Premise
236	P	N	I-Premise
237	=	N	I-Premise
238	0.009	N	I-Premise
239	and	N	I-Premise
240	P	N	I-Premise
241	=	N	I-Premise
242	0.016	N	I-Premise
243	,	N	I-Premise
244	respectively	N	I-Premise
245	)	N	I-Premise
246	.	N	I-Premise

247	Results	N	I-Claim
248	of	N	I-Claim
249	this	N	I-Claim
250	randomized	N	I-Claim
251	study	N	I-Claim
252	incorporating	N	I-Claim
253	prospective	N	I-Claim
254	QOL	N	I-Claim
255	measurements	N	I-Claim
256	suggested	N	I-Claim
257	that	N	I-Claim
258	in	N	I-Claim
259	patients	N	I-Claim
260	with	N	I-Claim
261	locally	N	I-Claim
262	advanced	N	I-Claim
263	NSCLC	N	I-Claim
264	,	N	I-Claim
265	analyzing	N	I-Claim
266	QOL	N	I-Claim
267	data	N	I-Claim
268	by	N	I-Claim
269	either	N	I-Claim
270	gender	N	I-Claim
271	or	N	I-Claim
272	performance	N	I-Claim
273	status	N	I-Claim
274	alone	N	I-Claim
275	may	N	I-Claim
276	not	N	I-Claim
277	accurately	N	I-Claim
278	reflect	N	I-Claim
279	how	N	I-Claim
280	these	N	I-Claim
281	factors	N	I-Claim
282	depend	N	I-Claim
283	upon	N	I-Claim
284	each	N	I-Claim
285	another	N	I-Claim
286	.	N	I-Claim

287	Understanding	N	O
288	the	N	O
289	interaction	N	O
290	between	N	O
291	gender	N	O
292	and	N	O
293	performance	N	O
294	status	N	O
295	could	N	O
296	lead	N	O
297	to	N	O
298	better	N	O
299	prognosticators	N	O
300	and	N	O
301	potentially	N	O
302	could	N	O
303	tailor	N	O
304	interventions	N	O
305	for	N	O
306	specific	N	O
307	groups	N	O
308	of	N	O
309	patients	N	O
310	with	N	O
311	lung	N	O
312	cancer	N	O
313	.	N	O

1	We	N	O
2	aimed	N	O
3	at	N	O
4	investigating	N	O
5	the	N	O
6	efficacy	N	O
7	,	N	O
8	tolerability	N	O
9	,	N	O
10	and	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	(	N	O
15	QOL	N	O
16	)	N	O
17	of	N	O
18	gemcitabine	N	O
19	(	N	O
20	GEM	N	O
21	)	N	O
22	compared	N	O
23	with	N	O
24	pegylated	N	O
25	liposomal	N	O
26	doxorubicin	N	O
27	(	N	O
28	PLD	N	O
29	)	N	O
30	in	N	O
31	the	N	O
32	salvage	N	O
33	treatment	N	O
34	of	N	O
35	recurrent	N	O
36	ovarian	N	O
37	cancer	N	O
38	.	N	O

39	A	N	O
40	phase	N	O
41	III	N	O
42	randomized	N	O
43	multicenter	N	O
44	trial	N	O
45	was	N	O
46	planned	N	O
47	to	N	O
48	compare	N	O
49	GEM	N	O
50	(	N	O
51	1,000	N	O
52	mg/m	N	O
53	(	N	O
54	2	N	O
55	)	N	O
56	on	N	O
57	days	N	O
58	1	N	O
59	,	N	O
60	8	N	O
61	,	N	O
62	and	N	O
63	15	N	O
64	every	N	O
65	28	N	O
66	days	N	O
67	)	N	O
68	with	N	O
69	PLD	N	O
70	(	N	O
71	40	N	O
72	mg/m	N	O
73	(	N	O
74	2	N	O
75	)	N	O
76	every	N	O
77	28	N	O
78	days	N	O
79	)	N	O
80	in	N	O
81	ovarian	N	O
82	cancer	N	O
83	patients	N	O
84	who	N	O
85	experienced	N	O
86	treatment	N	O
87	failure	N	O
88	with	N	O
89	only	N	O
90	one	N	O
91	platinum/paclitaxel	N	O
92	regimen	N	O
93	and	N	O
94	who	N	O
95	experienced	N	O
96	recurrence	N	O
97	or	N	O
98	progression	N	O
99	within	N	O
100	12	N	O
101	months	N	O
102	after	N	O
103	completion	N	O
104	of	N	O
105	primary	N	O
106	treatment	N	O
107	.	N	O

108	One	N	O
109	hundred	N	O
110	fifty-three	N	O
111	patients	N	O
112	were	N	O
113	randomly	N	O
114	assigned	N	O
115	to	N	O
116	PLD	N	O
117	(	N	O
118	n	N	O
119	=	N	O
120	76	N	O
121	)	N	O
122	or	N	O
123	GEM	N	O
124	(	N	O
125	n	N	O
126	=	N	O
127	77	N	O
128	)	N	O
129	.	N	O

130	Treatment	N	O
131	arms	N	O
132	were	N	O
133	well	N	O
134	balanced	N	O
135	for	N	O
136	clinicopathologic	N	O
137	characteristics	N	O
138	.	N	O

139	Grade	N	O
140	3	N	O
141	or	N	O
142	4	N	O
143	neutropenia	N	O
144	was	N	O
145	more	N	O
146	frequent	N	O
147	in	N	O
148	GEM-treated	N	O
149	patients	N	O
150	versus	N	O
151	PLD-treated	N	O
152	patients	N	O
153	(	N	O
154	P	N	O
155	=	N	O
156	.007	N	O
157	)	N	O
158	.	N	O

159	Grade	N	O
160	3	N	O
161	or	N	O
162	4	N	O
163	palmar-plantar	N	O
164	erythrodysesthesia	N	O
165	was	N	O
166	documented	N	O
167	in	N	O
168	a	N	O
169	higher	N	O
170	proportion	N	O
171	of	N	O
172	PLD	N	O
173	patients	N	O
174	(	N	O
175	6	N	O
176	%	N	O
177	)	N	O
178	versus	N	O
179	GEM	N	O
180	patients	N	O
181	(	N	O
182	0	N	O
183	%	N	O
184	;	N	O
185	P	N	O
186	=	N	O
187	.061	N	O
188	)	N	O
189	.	N	O

190	The	N	I-Premise
191	overall	N	I-Premise
192	response	N	I-Premise
193	rate	N	I-Premise
194	was	N	I-Premise
195	16	N	I-Premise
196	%	N	I-Premise
197	in	N	I-Premise
198	the	N	I-Premise
199	PLD	N	I-Premise
200	arm	N	I-Premise
201	compared	N	I-Premise
202	with	N	I-Premise
203	29	N	I-Premise
204	%	N	I-Premise
205	in	N	I-Premise
206	the	N	I-Premise
207	GEM	N	I-Premise
208	arm	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	=	N	I-Premise
212	.056	N	I-Premise
213	)	N	I-Premise
214	.	N	I-Premise

215	No	N	I-Premise
216	statistically	N	I-Premise
217	significant	N	I-Premise
218	difference	N	I-Premise
219	in	N	I-Premise
220	time	N	I-Premise
221	to	N	I-Premise
222	progression	N	I-Premise
223	(	N	I-Premise
224	TTP	N	I-Premise
225	)	N	I-Premise
226	curves	N	I-Premise
227	according	N	I-Premise
228	to	N	I-Premise
229	treatment	N	I-Premise
230	allocation	N	I-Premise
231	was	N	I-Premise
232	documented	N	I-Premise
233	(	N	I-Premise
234	P	N	I-Premise
235	=	N	I-Premise
236	.411	N	I-Premise
237	)	N	I-Premise
238	.	N	I-Premise

239	However	N	I-Premise
240	,	N	I-Premise
241	a	N	I-Premise
242	trend	N	I-Premise
243	for	N	I-Premise
244	more	N	I-Premise
245	favorable	N	I-Premise
246	overall	N	I-Premise
247	survival	N	I-Premise
248	was	N	I-Premise
249	documented	N	I-Premise
250	in	N	I-Premise
251	the	N	I-Premise
252	PLD	N	I-Premise
253	arm	N	I-Premise
254	compared	N	I-Premise
255	with	N	I-Premise
256	the	N	I-Premise
257	GEM	N	I-Premise
258	arm	N	I-Premise
259	,	N	I-Premise
260	although	N	I-Premise
261	the	N	I-Premise
262	P	N	I-Premise
263	value	N	I-Premise
264	was	N	I-Premise
265	of	N	I-Premise
266	borderline	N	I-Premise
267	statistical	N	I-Premise
268	significance	N	I-Premise
269	(	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.048	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	Statistically	N	I-Premise
276	significantly	N	I-Premise
277	higher	N	I-Premise
278	global	N	I-Premise
279	QOL	N	I-Premise
280	scores	N	I-Premise
281	were	N	I-Premise
282	found	N	I-Premise
283	in	N	I-Premise
284	PLD-treated	N	I-Premise
285	patients	N	I-Premise
286	at	N	I-Premise
287	the	N	I-Premise
288	first	N	I-Premise
289	and	N	I-Premise
290	second	N	I-Premise
291	postbaseline	N	I-Premise
292	QOL	N	I-Premise
293	assessments	N	I-Premise
294	.	N	I-Premise

295	GEM	N	I-Claim
296	does	N	I-Claim
297	not	N	I-Claim
298	provide	N	I-Claim
299	an	N	I-Claim
300	advantage	N	I-Claim
301	compared	N	I-Claim
302	with	N	I-Claim
303	PLD	N	I-Claim
304	in	N	I-Claim
305	terms	N	I-Claim
306	of	N	I-Claim
307	TTP	N	I-Claim
308	in	N	I-Claim
309	ovarian	N	I-Claim
310	cancer	N	I-Claim
311	patients	N	I-Claim
312	who	N	I-Claim
313	experience	N	I-Claim
314	recurrence	N	I-Claim
315	within	N	I-Claim
316	12	N	I-Claim
317	months	N	I-Claim
318	after	N	I-Claim
319	primary	N	I-Claim
320	treatment	N	I-Claim
321	but	N	I-Claim
322	should	N	I-Claim
323	be	N	I-Claim
324	considered	N	I-Claim
325	in	N	I-Claim
326	the	N	I-Claim
327	spectrum	N	I-Claim
328	of	N	I-Claim
329	drugs	N	I-Claim
330	to	N	I-Claim
331	be	N	I-Claim
332	possibly	N	I-Claim
333	used	N	I-Claim
334	in	N	I-Claim
335	the	N	I-Claim
336	salvage	N	I-Claim
337	setting	N	I-Claim
338	.	N	I-Claim

1	Dermatitis	N	I-MajorClaim
2	is	N	I-MajorClaim
3	a	N	I-MajorClaim
4	frequent	N	I-MajorClaim
5	adverse	N	I-MajorClaim
6	effect	N	I-MajorClaim
7	of	N	I-MajorClaim
8	adjuvant	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	radiotherapy	N	I-MajorClaim
11	.	N	I-MajorClaim

12	It	N	I-MajorClaim
13	is	N	I-MajorClaim
14	more	N	I-MajorClaim
15	likely	N	I-MajorClaim
16	in	N	I-MajorClaim
17	full-breasted	N	I-MajorClaim
18	women	N	I-MajorClaim
19	and	N	I-MajorClaim
20	when	N	I-MajorClaim
21	the	N	I-MajorClaim
22	radiation	N	I-MajorClaim
23	is	N	I-MajorClaim
24	distributed	N	I-MajorClaim
25	nonhomogeneously	N	I-MajorClaim
26	in	N	I-MajorClaim
27	the	N	I-MajorClaim
28	breast	N	I-MajorClaim
29	.	N	I-MajorClaim

30	Breast	N	O
31	intensity-modulated	N	O
32	radiation	N	O
33	therapy	N	O
34	(	N	O
35	IMRT	N	O
36	)	N	O
37	is	N	O
38	a	N	O
39	technique	N	O
40	that	N	O
41	ensures	N	O
42	a	N	O
43	more	N	O
44	homogeneous	N	O
45	dose	N	O
46	distribution	N	O
47	.	N	O

48	A	N	O
49	multicenter	N	O
50	,	N	O
51	double-blind	N	O
52	,	N	O
53	randomized	N	O
54	clinical	N	O
55	trial	N	O
56	was	N	O
57	performed	N	O
58	to	N	O
59	test	N	O
60	if	N	O
61	breast	N	O
62	IMRT	N	O
63	would	N	O
64	reduce	N	O
65	the	N	O
66	rate	N	O
67	of	N	O
68	acute	N	O
69	skin	N	O
70	reaction	N	O
71	(	N	O
72	notably	N	O
73	moist	N	O
74	desquamation	N	O
75	)	N	O
76	,	N	O
77	decrease	N	O
78	pain	N	O
79	,	N	O
80	and	N	O
81	improve	N	O
82	quality	N	O
83	of	N	O
84	life	N	O
85	compared	N	O
86	with	N	O
87	standard	N	O
88	radiotherapy	N	O
89	using	N	O
90	wedges	N	O
91	.	N	O

92	Patients	N	O
93	were	N	O
94	assessed	N	O
95	each	N	O
96	week	N	O
97	during	N	O
98	and	N	O
99	up	N	O
100	to	N	O
101	6	N	O
102	weeks	N	O
103	after	N	O
104	radiotherapy	N	O
105	.	N	O

106	A	N	O
107	total	N	O
108	of	N	O
109	358	N	O
110	patients	N	O
111	were	N	O
112	randomly	N	O
113	assigned	N	O
114	between	N	O
115	July	N	O
116	2003	N	O
117	and	N	O
118	March	N	O
119	2005	N	O
120	in	N	O
121	two	N	O
122	Canadian	N	O
123	centers	N	O
124	,	N	O
125	and	N	O
126	331	N	O
127	were	N	O
128	included	N	O
129	in	N	O
130	the	N	O
131	analysis	N	O
132	.	N	O

133	Breast	N	I-Premise
134	IMRT	N	I-Premise
135	significantly	N	I-Premise
136	improved	N	I-Premise
137	the	N	I-Premise
138	dose	N	I-Premise
139	distribution	N	I-Premise
140	compared	N	I-Premise
141	with	N	I-Premise
142	standard	N	I-Premise
143	radiation	N	I-Premise
144	.	N	I-Premise

145	This	N	I-Premise
146	translated	N	I-Premise
147	into	N	I-Premise
148	a	N	I-Premise
149	lower	N	I-Premise
150	proportion	N	I-Premise
151	of	N	I-Premise
152	patients	N	I-Premise
153	experiencing	N	I-Premise
154	moist	N	I-Premise
155	desquamation	N	I-Premise
156	during	N	I-Premise
157	or	N	I-Premise
158	up	N	I-Premise
159	to	N	I-Premise
160	6	N	I-Premise
161	weeks	N	I-Premise
162	after	N	I-Premise
163	their	N	I-Premise
164	radiation	N	I-Premise
165	treatment	N	I-Premise
166	;	N	I-Premise
167	31.2	N	I-Premise
168	%	N	I-Premise
169	with	N	I-Premise
170	IMRT	N	I-Premise
171	compared	N	I-Premise
172	with	N	I-Premise
173	47.8	N	I-Premise
174	%	N	I-Premise
175	with	N	I-Premise
176	standard	N	I-Premise
177	treatment	N	I-Premise
178	(	N	I-Premise
179	P	N	I-Premise
180	=	N	I-Premise
181	.002	N	I-Premise
182	)	N	I-Premise
183	.	N	I-Premise

184	A	N	I-Premise
185	multivariate	N	I-Premise
186	analysis	N	I-Premise
187	found	N	I-Premise
188	the	N	I-Premise
189	use	N	I-Premise
190	of	N	I-Premise
191	breast	N	I-Premise
192	IMRT	N	I-Premise
193	(	N	I-Premise
194	P	N	I-Premise
195	=	N	I-Premise
196	.003	N	I-Premise
197	)	N	I-Premise
198	and	N	I-Premise
199	smaller	N	I-Premise
200	breast	N	I-Premise
201	size	N	I-Premise
202	(	N	I-Premise
203	P	N	I-Premise
204	<	N	I-Premise
205	.001	N	I-Premise
206	)	N	I-Premise
207	were	N	I-Premise
208	significantly	N	I-Premise
209	associated	N	I-Premise
210	with	N	I-Premise
211	a	N	I-Premise
212	decreased	N	I-Premise
213	risk	N	I-Premise
214	of	N	I-Premise
215	moist	N	I-Premise
216	desquamation	N	I-Premise
217	.	N	I-Premise

218	The	N	I-Premise
219	use	N	I-Premise
220	of	N	I-Premise
221	IMRT	N	I-Premise
222	did	N	I-Premise
223	not	N	I-Premise
224	correlate	N	I-Premise
225	with	N	I-Premise
226	pain	N	I-Premise
227	and	N	I-Premise
228	quality	N	I-Premise
229	of	N	I-Premise
230	life	N	I-Premise
231	,	N	O
232	but	N	O
233	the	N	I-Premise
234	presence	N	I-Premise
235	of	N	I-Premise
236	moist	N	I-Premise
237	desquamation	N	I-Premise
238	did	N	I-Premise
239	significantly	N	I-Premise
240	correlate	N	I-Premise
241	with	N	I-Premise
242	pain	N	I-Premise
243	(	N	I-Premise
244	P	N	I-Premise
245	=	N	I-Premise
246	.002	N	I-Premise
247	)	N	I-Premise
248	and	N	I-Premise
249	a	N	I-Premise
250	reduced	N	I-Premise
251	quality	N	I-Premise
252	of	N	I-Premise
253	life	N	I-Premise
254	(	N	I-Premise
255	P	N	I-Premise
256	=	N	I-Premise
257	.003	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	Breast	N	I-Claim
261	IMRT	N	I-Claim
262	significantly	N	I-Claim
263	reduced	N	I-Claim
264	the	N	I-Claim
265	occurrence	N	I-Claim
266	of	N	I-Claim
267	moist	N	I-Claim
268	desquamation	N	I-Claim
269	compared	N	I-Claim
270	with	N	I-Claim
271	a	N	I-Claim
272	standard	N	I-Claim
273	wedged	N	I-Claim
274	technique	N	I-Claim
275	.	N	I-Claim

276	Moist	N	I-Claim
277	desquamation	N	I-Claim
278	was	N	I-Claim
279	correlated	N	I-Claim
280	with	N	I-Claim
281	increased	N	I-Claim
282	pain	N	I-Claim
283	and	N	I-Claim
284	reduction	N	I-Claim
285	in	N	I-Claim
286	the	N	I-Claim
287	quality	N	I-Claim
288	of	N	I-Claim
289	life	N	I-Claim
290	.	N	I-Claim

1	Cancer	N	O
2	cachexia	N	O
3	is	N	O
4	a	N	O
5	common	N	O
6	problem	N	O
7	among	N	O
8	advanced	N	O
9	cancer	N	O
10	patients	N	O
11	.	N	O

12	A	N	O
13	mixture	N	O
14	of	N	O
15	beta-hydroxyl	N	O
16	beta-methyl	N	O
17	butyrate	N	O
18	,	N	O
19	glutamine	N	O
20	,	N	O
21	and	N	O
22	arginine	N	O
23	(	N	O
24	HMB/Arg/Gln	N	O
25	)	N	O
26	previously	N	O
27	showed	N	O
28	activity	N	O
29	for	N	O
30	increasing	N	O
31	lean	N	O
32	body	N	O
33	mass	N	O
34	(	N	O
35	LBM	N	O
36	)	N	O
37	among	N	O
38	patients	N	O
39	with	N	O
40	cancer	N	O
41	cachexia	N	O
42	.	N	O

43	Therefore	N	O
44	a	N	O
45	phase	N	O
46	III	N	O
47	trial	N	O
48	was	N	O
49	implemented	N	O
50	to	N	O
51	confirm	N	O
52	this	N	O
53	activity	N	O
54	.	N	O

55	Four	N	O
56	hundred	N	O
57	seventy-two	N	O
58	advanced	N	O
59	cancer	N	O
60	patients	N	O
61	with	N	O
62	between	N	O
63	2	N	O
64	%	N	O
65	and	N	O
66	10	N	O
67	%	N	O
68	weight	N	O
69	loss	N	O
70	were	N	O
71	randomized	N	O
72	to	N	O
73	a	N	O
74	mixture	N	O
75	of	N	O
76	beta-hydroxyl	N	O
77	beta-methyl	N	O
78	butyrate	N	O
79	,	N	O
80	glutamine	N	O
81	,	N	O
82	and	N	O
83	arginine	N	O
84	or	N	O
85	an	N	O
86	isonitrogenous	N	O
87	,	N	O
88	isocaloric	N	O
89	control	N	O
90	mixture	N	O
91	taken	N	O
92	twice	N	O
93	a	N	O
94	day	N	O
95	for	N	O
96	8	N	O
97	weeks	N	O
98	.	N	O

99	Lean	N	O
100	body	N	O
101	mass	N	O
102	was	N	O
103	estimated	N	O
104	by	N	O
105	bioimpedance	N	O
106	and	N	O
107	skin-fold	N	O
108	measurements	N	O
109	.	N	O

110	Body	N	O
111	plethysmography	N	O
112	was	N	O
113	used	N	O
114	when	N	O
115	available	N	O
116	.	N	O

117	Weight	N	O
118	,	N	O
119	the	N	O
120	Schwartz	N	O
121	Fatigue	N	O
122	Scale	N	O
123	,	N	O
124	and	N	O
125	the	N	O
126	Spitzer	N	O
127	Quality	N	O
128	of	N	O
129	Life	N	O
130	Scale	N	O
131	were	N	O
132	also	N	O
133	measured	N	O
134	.	N	O

135	Only	N	O
136	37	N	O
137	%	N	O
138	of	N	O
139	the	N	O
140	patients	N	O
141	completed	N	O
142	protocol	N	O
143	treatment	N	O
144	.	N	O

145	The	N	O
146	majority	N	O
147	of	N	O
148	the	N	O
149	patient	N	O
150	loss	N	O
151	was	N	O
152	because	N	O
153	of	N	O
154	patient	N	O
155	preference	N	O
156	(	N	O
157	45	N	O
158	%	N	O
159	of	N	O
160	enrolled	N	O
161	patients	N	O
162	)	N	O
163	.	N	O

164	However	N	O
165	,	N	O
166	loss	N	O
167	of	N	O
168	power	N	O
169	was	N	O
170	not	N	O
171	an	N	O
172	issue	N	O
173	because	N	O
174	of	N	O
175	the	N	O
176	planned	N	O
177	large	N	O
178	target	N	O
179	sample	N	O
180	size	N	O
181	.	N	O

182	Based	N	O
183	on	N	O
184	an	N	O
185	intention	N	O
186	to	N	O
187	treat	N	O
188	analysis	N	O
189	,	N	O
190	there	N	O
191	was	N	O
192	no	N	O
193	statistically	N	O
194	significant	N	O
195	difference	N	O
196	in	N	O
197	the	N	O
198	8-week	N	O
199	lean	N	O
200	body	N	O
201	mass	N	O
202	between	N	O
203	the	N	O
204	two	N	O
205	arms	N	O
206	.	N	O

207	The	N	O
208	secondary	N	O
209	endpoints	N	O
210	were	N	O
211	also	N	O
212	not	N	O
213	significantly	N	O
214	different	N	O
215	between	N	O
216	the	N	O
217	arms	N	O
218	.	N	O

219	Based	N	I-Premise
220	on	N	I-Premise
221	the	N	I-Premise
222	results	N	I-Premise
223	of	N	I-Premise
224	the	N	I-Premise
225	area	N	I-Premise
226	under	N	I-Premise
227	the	N	I-Premise
228	curve	N	I-Premise
229	(	N	I-Premise
230	AUC	N	I-Premise
231	)	N	I-Premise
232	analysis	N	I-Premise
233	,	N	I-Premise
234	patients	N	I-Premise
235	receiving	N	I-Premise
236	HMB/Arg/Gln	N	I-Premise
237	had	N	I-Premise
238	a	N	I-Premise
239	strong	N	I-Premise
240	trend	N	I-Premise
241	higher	N	I-Premise
242	LBM	N	I-Premise
243	throughout	N	I-Premise
244	the	N	I-Premise
245	study	N	I-Premise
246	as	N	I-Premise
247	measured	N	I-Premise
248	by	N	I-Premise
249	both	N	I-Premise
250	bioimpedance	N	I-Premise
251	(	N	I-Premise
252	p	N	I-Premise
253	=	N	I-Premise
254	0.08	N	I-Premise
255	)	N	I-Premise
256	and	N	I-Premise
257	skin-fold	N	I-Premise
258	measurements	N	I-Premise
259	(	N	I-Premise
260	p	N	I-Premise
261	=	N	I-Premise
262	0.08	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	Among	N	I-Premise
266	the	N	I-Premise
267	subset	N	I-Premise
268	of	N	I-Premise
269	patients	N	I-Premise
270	receiving	N	I-Premise
271	concurrent	N	I-Premise
272	chemotherapy	N	I-Premise
273	,	N	I-Premise
274	there	N	I-Premise
275	were	N	I-Premise
276	again	N	I-Premise
277	no	N	I-Premise
278	significant	N	I-Premise
279	differences	N	I-Premise
280	in	N	I-Premise
281	the	N	I-Premise
282	endpoints	N	I-Premise
283	.	N	I-Premise

284	The	N	I-Premise
285	secondary	N	I-Premise
286	endpoints	N	I-Premise
287	were	N	I-Premise
288	also	N	I-Premise
289	not	N	I-Premise
290	significantly	N	I-Premise
291	different	N	I-Premise
292	between	N	I-Premise
293	the	N	I-Premise
294	arms	N	I-Premise
295	.	N	I-Premise

296	This	N	I-Claim
297	trial	N	I-Claim
298	was	N	I-Claim
299	unable	N	I-Claim
300	to	N	I-Claim
301	adequately	N	I-Claim
302	test	N	I-Claim
303	the	N	I-Claim
304	ability	N	I-Claim
305	of	N	I-Claim
306	beta-hydroxy	N	I-Claim
307	beta-methylbutyrate	N	I-Claim
308	,	N	I-Claim
309	glutamine	N	I-Claim
310	,	N	I-Claim
311	and	N	I-Claim
312	arginine	N	I-Claim
313	to	N	I-Claim
314	reverse	N	I-Claim
315	or	N	I-Claim
316	prevent	N	I-Claim
317	lean	N	I-Claim
318	body	N	I-Claim
319	mass	N	I-Claim
320	wasting	N	I-Claim
321	among	N	I-Claim
322	cancer	N	I-Claim
323	patients	N	I-Claim
324	.	N	I-Claim

325	Possible	N	O
326	contributing	N	O
327	factors	N	O
328	beyond	N	O
329	the	N	O
330	efficacy	N	O
331	of	N	O
332	the	N	O
333	intervention	N	O
334	were	N	O
335	the	N	O
336	inability	N	O
337	of	N	O
338	patients	N	O
339	to	N	O
340	complete	N	O
341	an	N	O
342	8-week	N	O
343	course	N	O
344	of	N	O
345	treatment	N	O
346	and	N	O
347	return	N	O
348	in	N	O
349	a	N	O
350	timely	N	O
351	fashion	N	O
352	for	N	O
353	follow-up	N	O
354	assessment	N	O
355	,	N	O
356	and	N	O
357	because	N	O
358	the	N	O
359	patients	N	O
360	may	N	O
361	have	N	O
362	only	N	O
363	had	N	O
364	weight	N	O
365	loss	N	O
366	possible	N	O
367	not	N	O
368	related	N	O
369	to	N	O
370	cachexia	N	O
371	,	N	O
372	but	N	O
373	other	N	O
374	causes	N	O
375	of	N	O
376	weight	N	O
377	loss	N	O
378	,	N	O
379	such	N	O
380	as	N	O
381	decreased	N	O
382	appetite	N	O
383	.	N	O

384	However	N	O
385	,	N	O
386	there	N	O
387	was	N	O
388	a	N	O
389	strong	N	O
390	trend	N	O
391	towards	N	O
392	an	N	O
393	increased	N	O
394	body	N	O
395	mass	N	O
396	among	N	O
397	patients	N	O
398	taking	N	O
399	the	N	O
400	Juven	N	O
401	compound	N	O
402	using	N	O
403	the	N	O
404	secondary	N	O
405	endpoint	N	O
406	of	N	O
407	AUC	N	O
408	.	N	O

1	Exercise	N	O
2	training	N	O
3	improves	N	O
4	supportive	N	O
5	care	N	O
6	outcomes	N	O
7	in	N	O
8	patients	N	O
9	with	N	O
10	breast	N	O
11	cancer	N	O
12	who	N	O
13	are	N	O
14	receiving	N	O
15	adjuvant	N	O
16	therapy	N	O
17	,	N	O
18	but	N	O
19	the	N	O
20	responses	N	O
21	are	N	O
22	heterogeneous	N	O
23	.	N	O

24	In	N	O
25	this	N	O
26	study	N	O
27	,	N	O
28	the	N	O
29	authors	N	O
30	examined	N	O
31	personal	N	O
32	and	N	O
33	clinical	N	O
34	factors	N	O
35	that	N	O
36	may	N	O
37	predict	N	O
38	exercise	N	O
39	training	N	O
40	responses	N	O
41	.	N	O

42	Breast	N	O
43	cancer	N	O
44	patients	N	O
45	who	N	O
46	were	N	O
47	initiating	N	O
48	adjuvant	N	O
49	chemotherapy	N	O
50	(	N	O
51	N=242	N	O
52	)	N	O
53	were	N	O
54	assigned	N	O
55	randomly	N	O
56	to	N	O
57	receive	N	O
58	usual	N	O
59	care	N	O
60	(	N	O
61	UC	N	O
62	)	N	O
63	(	N	O
64	n=82	N	O
65	)	N	O
66	,	N	O
67	resistance	N	O
68	exercise	N	O
69	training	N	O
70	(	N	O
71	RET	N	O
72	)	N	O
73	(	N	O
74	n=82	N	O
75	)	N	O
76	,	N	O
77	or	N	O
78	aerobic	N	O
79	exercise	N	O
80	training	N	O
81	(	N	O
82	AET	N	O
83	)	N	O
84	(	N	O
85	n=78	N	O
86	)	N	O
87	for	N	O
88	the	N	O
89	duration	N	O
90	of	N	O
91	chemotherapy	N	O
92	.	N	O

93	Endpoints	N	O
94	were	N	O
95	quality	N	O
96	of	N	O
97	life	N	O
98	(	N	O
99	QoL	N	O
100	)	N	O
101	,	N	O
102	aerobic	N	O
103	fitness	N	O
104	,	N	O
105	muscular	N	O
106	strength	N	O
107	,	N	O
108	lean	N	O
109	body	N	O
110	mass	N	O
111	,	N	O
112	and	N	O
113	body	N	O
114	fat	N	O
115	.	N	O

116	Moderators	N	O
117	were	N	O
118	patient	N	O
119	preference	N	O
120	for	N	O
121	group	N	O
122	assignment	N	O
123	,	N	O
124	marital	N	O
125	status	N	O
126	,	N	O
127	age	N	O
128	,	N	O
129	disease	N	O
130	stage	N	O
131	,	N	O
132	and	N	O
133	chemotherapy	N	O
134	regimen	N	O
135	.	N	O

136	Adjusted	N	O
137	linear	N	O
138	mixed-model	N	O
139	analyses	N	O
140	demonstrated	N	O
141	that	N	O
142	patient	N	O
143	preference	N	O
144	moderated	N	O
145	QoL	N	O
146	response	N	O
147	(	N	O
148	P=	N	O
149	.005	N	O
150	)	N	O
151	.	N	O

152	Patients	N	I-Premise
153	who	N	I-Premise
154	preferred	N	I-Premise
155	RET	N	I-Premise
156	improved	N	I-Premise
157	QoL	N	I-Premise
158	when	N	I-Premise
159	they	N	I-Premise
160	were	N	I-Premise
161	assigned	N	I-Premise
162	to	N	I-Premise
163	receive	N	I-Premise
164	RET	N	I-Premise
165	compared	N	I-Premise
166	with	N	I-Premise
167	UC	N	I-Premise
168	(	N	I-Premise
169	mean	N	I-Premise
170	difference	N	I-Premise
171	,	N	I-Premise
172	16.5	N	I-Premise
173	;	N	I-Premise
174	95	N	I-Premise
175	%	N	I-Premise
176	confidence	N	I-Premise
177	interval	N	I-Premise
178	[	N	I-Premise
179	95	N	I-Premise
180	%	N	I-Premise
181	CI	N	I-Premise
182	]	N	I-Premise
183	,	N	I-Premise
184	4.3-28.7	N	I-Premise
185	;	N	I-Premise
186	P=	N	I-Premise
187	.008	N	I-Premise
188	)	N	I-Premise
189	or	N	I-Premise
190	AET	N	I-Premise
191	(	N	I-Premise
192	mean	N	I-Premise
193	difference	N	I-Premise
194	,	N	I-Premise
195	11	N	I-Premise
196	;	N	I-Premise
197	95	N	I-Premise
198	%	N	I-Premise
199	CI	N	I-Premise
200	,	N	I-Premise
201	-1.1-23.4	N	I-Premise
202	;	N	I-Premise
203	P=	N	I-Premise
204	.076	N	I-Premise
205	)	N	I-Premise
206	.	N	I-Premise

207	Patients	N	I-Premise
208	who	N	I-Premise
209	had	N	I-Premise
210	no	N	I-Premise
211	preference	N	I-Premise
212	had	N	I-Premise
213	improved	N	I-Premise
214	QoL	N	I-Premise
215	when	N	I-Premise
216	they	N	I-Premise
217	were	N	I-Premise
218	assigned	N	I-Premise
219	to	N	I-Premise
220	receive	N	I-Premise
221	AET	N	I-Premise
222	compared	N	I-Premise
223	with	N	I-Premise
224	RET	N	I-Premise
225	(	N	I-Premise
226	mean	N	I-Premise
227	difference	N	I-Premise
228	,	N	I-Premise
229	23	N	I-Premise
230	;	N	I-Premise
231	95	N	I-Premise
232	%	N	I-Premise
233	CI	N	I-Premise
234	,	N	I-Premise
235	4.9-41	N	I-Premise
236	;	N	I-Premise
237	P=	N	I-Premise
238	.014	N	I-Premise
239	)	N	I-Premise
240	.	N	I-Premise

241	Marital	N	I-Premise
242	status	N	I-Premise
243	also	N	I-Premise
244	moderated	N	I-Premise
245	QoL	N	I-Premise
246	response	N	I-Premise
247	(	N	I-Premise
248	P=	N	I-Premise
249	.026	N	I-Premise
250	)	N	I-Premise
251	,	N	I-Premise
252	age	N	I-Premise
253	moderated	N	I-Premise
254	aerobic	N	I-Premise
255	fitness	N	I-Premise
256	response	N	I-Premise
257	(	N	I-Premise
258	P=	N	I-Premise
259	.029	N	I-Premise
260	)	N	I-Premise
261	,	N	I-Premise
262	chemotherapy	N	I-Premise
263	regimen	N	I-Premise
264	moderated	N	I-Premise
265	strength	N	I-Premise
266	gain	N	I-Premise
267	(	N	I-Premise
268	P=	N	I-Premise
269	.009	N	I-Premise
270	)	N	I-Premise
271	,	N	I-Premise
272	and	N	I-Premise
273	disease	N	I-Premise
274	stage	N	I-Premise
275	moderated	N	I-Premise
276	both	N	I-Premise
277	lean	N	I-Premise
278	body	N	I-Premise
279	mass	N	I-Premise
280	gain	N	I-Premise
281	(	N	I-Premise
282	P	N	I-Premise
283	<	N	I-Premise
284	.001	N	I-Premise
285	)	N	I-Premise
286	and	N	I-Premise
287	fat	N	I-Premise
288	loss	N	I-Premise
289	(	N	I-Premise
290	P=	N	I-Premise
291	.059	N	I-Premise
292	)	N	I-Premise
293	.	N	I-Premise

294	Unmarried	N	I-Premise
295	,	N	I-Premise
296	younger	N	I-Premise
297	patients	N	I-Premise
298	who	N	I-Premise
299	were	N	I-Premise
300	receiving	N	I-Premise
301	nontaxane-based	N	I-Premise
302	therapies	N	I-Premise
303	and	N	I-Premise
304	had	N	I-Premise
305	more	N	I-Premise
306	advanced	N	I-Premise
307	disease	N	I-Premise
308	stage	N	I-Premise
309	experienced	N	I-Premise
310	better	N	I-Premise
311	outcomes	N	I-Premise
312	.	N	I-Premise

313	The	N	O
314	findings	N	O
315	were	N	O
316	not	N	O
317	explained	N	O
318	by	N	O
319	differences	N	O
320	in	N	O
321	adherence	N	O
322	.	N	O

323	Patient	N	I-Claim
324	preference	N	I-Claim
325	,	N	I-Claim
326	demographic	N	I-Claim
327	variables	N	I-Claim
328	,	N	I-Claim
329	and	N	I-Claim
330	medical	N	I-Claim
331	variables	N	I-Claim
332	moderated	N	I-Claim
333	the	N	I-Claim
334	effects	N	I-Claim
335	of	N	I-Claim
336	exercise	N	I-Claim
337	training	N	I-Claim
338	in	N	I-Claim
339	breast	N	I-Claim
340	cancer	N	I-Claim
341	patients	N	I-Claim
342	who	N	I-Claim
343	were	N	I-Claim
344	receiving	N	I-Claim
345	chemotherapy	N	I-Claim
346	.	N	I-Claim

347	If	N	O
348	replicated	N	O
349	,	N	O
350	these	N	O
351	results	N	O
352	may	N	O
353	inform	N	O
354	clinical	N	O
355	practice	N	O
356	.	N	O

1	A	N	O
2	phase	N	O
3	III	N	O
4	randomized	N	O
5	trial	N	O
6	was	N	O
7	carried	N	O
8	out	N	O
9	to	N	O
10	compare	N	O
11	two	N	O
12	schedules	N	O
13	of	N	O
14	the	N	O
15	vinorelbine	N	O
16	(	N	O
17	VNR	N	O
18	)	N	O
19	-cisplatin	N	O
20	(	N	O
21	CDDP	N	O
22	)	N	O
23	regimen	N	O
24	in	N	O
25	patients	N	O
26	with	N	O
27	locally	N	O
28	advanced	N	O
29	unresectable	N	O
30	poor	N	O
31	prognosis	N	O
32	stage	N	O
33	IIIB	N	O
34	or	N	O
35	metastatic	N	O
36	stage	N	O
37	IV	N	O
38	non-small	N	O
39	cell	N	O
40	lung	N	O
41	cancer	N	O
42	.	N	O

43	The	N	O
44	primary	N	O
45	endpoints	N	O
46	were	N	O
47	overall	N	O
48	survival	N	O
49	(	N	O
50	OS	N	O
51	)	N	O
52	and	N	O
53	analysis	N	O
54	of	N	O
55	toxicity	N	O
56	,	N	O
57	while	N	O
58	secondary	N	O
59	endpoints	N	O
60	included	N	O
61	response	N	O
62	rates	N	O
63	,	N	O
64	time-to-progression	N	O
65	(	N	O
66	TTP	N	O
67	)	N	O
68	and	N	O
69	quality	N	O
70	of	N	O
71	life	N	O
72	(	N	O
73	QoL	N	O
74	)	N	O
75	.	N	O

76	Eligible	N	O
77	patients	N	O
78	were	N	O
79	randomized	N	O
80	to	N	O
81	receive	N	O
82	:	N	O
83	(	N	O
84	a	N	O
85	)	N	O
86	VNR	N	O
87	25mg/m	N	O
88	(	N	O
89	2	N	O
90	)	N	O
91	on	N	O
92	day	N	O
93	1	N	O
94	,	N	O
95	8	N	O
96	and	N	O
97	15	N	O
98	plus	N	O
99	CDDP	N	O
100	100mg/m	N	O
101	(	N	O
102	2	N	O
103	)	N	O
104	on	N	O
105	day	N	O
106	1	N	O
107	every	N	O
108	4	N	O
109	weeks	N	O
110	or	N	O
111	(	N	O
112	b	N	O
113	)	N	O
114	VNR	N	O
115	30	N	O
116	mg/m	N	O
117	(	N	O
118	2	N	O
119	)	N	O
120	on	N	O
121	day	N	O
122	1	N	O
123	and	N	O
124	8	N	O
125	plus	N	O
126	CDDP	N	O
127	80	N	O
128	mg/m	N	O
129	(	N	O
130	2	N	O
131	)	N	O
132	on	N	O
133	day	N	O
134	1	N	O
135	every	N	O
136	3	N	O
137	weeks	N	O
138	.	N	O

139	All	N	O
140	patients	N	O
141	were	N	O
142	chemotherapy-nave	N	O
143	and	N	O
144	had	N	O
145	an	N	O
146	ECOG	N	O
147	performance	N	O
148	status	N	O
149	(	N	O
150	PS	N	O
151	)	N	O
152	of	N	O
153	0-1	N	O
154	.	N	O

155	Overall	N	O
156	278	N	O
157	patients	N	O
158	were	N	O
159	enrolled	N	O
160	into	N	O
161	the	N	O
162	trial	N	O
163	.	N	O

164	Overall	N	O
165	response	N	O
166	rate	N	O
167	was	N	O
168	34	N	O
169	%	N	O
170	(	N	O
171	95	N	O
172	%	N	O
173	CL	N	O
174	26-42	N	O
175	%	N	O
176	)	N	O
177	in	N	O
178	the	N	O
179	weekly	N	O
180	VNR/CDDP	N	O
181	arm	N	O
182	,	N	O
183	and	N	O
184	32	N	O
185	%	N	O
186	(	N	O
187	95	N	O
188	%	N	O
189	CL	N	O
190	24-40	N	O
191	%	N	O
192	)	N	O
193	in	N	O
194	patients	N	O
195	treated	N	O
196	with	N	O
197	day	N	O
198	1-8	N	O
199	VNR/CDDP	N	O
200	without	N	O
201	any	N	O
202	statistically	N	O
203	significant	N	O
204	difference	N	O
205	.	N	O

206	Median	N	I-Premise
207	TTP	N	I-Premise
208	was	N	I-Premise
209	4.5	N	I-Premise
210	and	N	I-Premise
211	4.6	N	I-Premise
212	months	N	I-Premise
213	respectively	N	I-Premise
214	for	N	I-Premise
215	weekly	N	I-Premise
216	VNR/CDDP	N	I-Premise
217	arm	N	I-Premise
218	and	N	I-Premise
219	the	N	I-Premise
220	day	N	I-Premise
221	1-8	N	I-Premise
222	VNR/CDDP	N	I-Premise
223	one	N	I-Premise
224	.	N	I-Premise

225	This	N	I-Premise
226	difference	N	I-Premise
227	was	N	I-Premise
228	not	N	I-Premise
229	statistically	N	I-Premise
230	significant	N	I-Premise
231	(	N	I-Premise
232	log-rank	N	I-Premise
233	test	N	I-Premise
234	,	N	I-Premise
235	p=0.818	N	I-Premise
236	)	N	I-Premise
237	.	N	I-Premise

238	Median	N	I-Premise
239	OS	N	I-Premise
240	was	N	I-Premise
241	9.45	N	I-Premise
242	and	N	I-Premise
243	10	N	I-Premise
244	months	N	I-Premise
245	respectively	N	I-Premise
246	for	N	I-Premise
247	weekly	N	I-Premise
248	VNR/CDDP	N	I-Premise
249	arm	N	I-Premise
250	and	N	I-Premise
251	the	N	I-Premise
252	day	N	I-Premise
253	1-8	N	I-Premise
254	VNR/CDDP	N	I-Premise
255	one	N	I-Premise
256	without	N	I-Premise
257	statistically	N	I-Premise
258	a	N	I-Premise
259	significant	N	I-Premise
260	difference	N	I-Premise
261	(	N	I-Premise
262	log-rank	N	I-Premise
263	test	N	I-Premise
264	,	N	I-Premise
265	p=0.259	N	I-Premise
266	)	N	I-Premise
267	.	N	I-Premise

268	The	N	I-Premise
269	1-	N	I-Premise
270	and	N	I-Premise
271	2-year	N	I-Premise
272	survival	N	I-Premise
273	rates	N	I-Premise
274	were	N	I-Premise
275	31	N	I-Premise
276	and	N	I-Premise
277	36	N	I-Premise
278	%	N	I-Premise
279	,	N	I-Premise
280	and	N	I-Premise
281	10	N	I-Premise
282	and	N	I-Premise
283	11	N	I-Premise
284	%	N	I-Premise
285	respectively	N	I-Premise
286	.	N	I-Premise

287	The	N	I-Premise
288	incidence	N	I-Premise
289	of	N	I-Premise
290	severe	N	I-Premise
291	neutropenia	N	I-Premise
292	(	N	I-Premise
293	34	N	I-Premise
294	%	N	I-Premise
295	versus	N	I-Premise
296	68	N	I-Premise
297	%	N	I-Premise
298	;	N	I-Premise
299	p=0.0001	N	I-Premise
300	)	N	I-Premise
301	and	N	I-Premise
302	of	N	I-Premise
303	febrile	N	I-Premise
304	neutropenia	N	I-Premise
305	(	N	I-Premise
306	5	N	I-Premise
307	%	N	I-Premise
308	versus	N	I-Premise
309	12	N	I-Premise
310	%	N	I-Premise
311	;	N	I-Premise
312	p=0.026	N	I-Premise
313	)	N	I-Premise
314	,	N	I-Premise
315	as	N	I-Premise
316	well	N	I-Premise
317	as	N	I-Premise
318	the	N	I-Premise
319	rate	N	I-Premise
320	of	N	I-Premise
321	therapy	N	I-Premise
322	omissions	N	I-Premise
323	(	N	I-Premise
324	10	N	I-Premise
325	%	N	I-Premise
326	versus	N	I-Premise
327	24	N	I-Premise
328	%	N	I-Premise
329	;	N	I-Premise
330	p=0.0037	N	I-Premise
331	)	N	I-Premise
332	were	N	I-Premise
333	higher	N	I-Premise
334	in	N	I-Premise
335	the	N	I-Premise
336	weekly	N	I-Premise
337	VNR/CDDP	N	I-Premise
338	arm	N	I-Premise
339	than	N	I-Premise
340	in	N	I-Premise
341	the	N	I-Premise
342	day	N	I-Premise
343	1-8	N	I-Premise
344	VNR/CDDP	N	I-Premise
345	one	N	I-Premise
346	.	N	I-Premise

347	The	N	I-Premise
348	weekly	N	I-Premise
349	VNR/CDDP	N	I-Premise
350	regimen	N	I-Premise
351	was	N	I-Premise
352	associated	N	I-Premise
353	with	N	I-Premise
354	a	N	I-Premise
355	lower	N	I-Premise
356	received	N	I-Premise
357	dose	N	I-Premise
358	intensity	N	I-Premise
359	in	N	I-Premise
360	a	N	I-Premise
361	statistically	N	I-Premise
362	significant	N	I-Premise
363	fashion	N	I-Premise
364	(	N	I-Premise
365	9	N	I-Premise
366	%	N	I-Premise
367	versus	N	I-Premise
368	22	N	I-Premise
369	%	N	I-Premise
370	;	N	I-Premise
371	p=0.0001	N	I-Premise
372	)	N	I-Premise
373	and	N	I-Premise
374	with	N	I-Premise
375	a	N	I-Premise
376	lower	N	I-Premise
377	non-statistically	N	I-Premise
378	significant	N	I-Premise
379	quality	N	I-Premise
380	of	N	I-Premise
381	life	N	I-Premise
382	score	N	I-Premise
383	as	N	I-Premise
384	compared	N	I-Premise
385	to	N	I-Premise
386	the	N	I-Premise
387	day	N	I-Premise
388	1-8	N	I-Premise
389	VNR/CDDP	N	I-Premise
390	schedule	N	I-Premise
391	.	N	I-Premise

392	The	N	I-Claim
393	combination	N	I-Claim
394	of	N	I-Claim
395	day	N	I-Claim
396	1-8	N	I-Claim
397	VNR	N	I-Claim
398	plus	N	I-Claim
399	CDDP	N	I-Claim
400	every	N	I-Claim
401	3	N	I-Claim
402	weeks	N	I-Claim
403	is	N	I-Claim
404	less	N	I-Claim
405	toxic	N	I-Claim
406	and	N	I-Claim
407	better	N	I-Claim
408	tolerated	N	I-Claim
409	than	N	I-Claim
410	the	N	I-Claim
411	regimen	N	I-Claim
412	of	N	I-Claim
413	weekly	N	I-Claim
414	VNR	N	I-Claim
415	plus	N	I-Claim
416	CDDP	N	I-Claim
417	every	N	I-Claim
418	4	N	I-Claim
419	weeks	N	I-Claim
420	.	N	I-Claim

421	The	N	I-Claim
422	two	N	I-Claim
423	schedules	N	I-Claim
424	are	N	I-Claim
425	equivalent	N	I-Claim
426	in	N	I-Claim
427	terms	N	I-Claim
428	of	N	I-Claim
429	overall	N	I-Claim
430	response	N	I-Claim
431	rate	N	I-Claim
432	,	N	I-Claim
433	median	N	I-Claim
434	time-to-progression	N	I-Claim
435	and	N	I-Claim
436	overall	N	I-Claim
437	survival	N	I-Claim
438	.	N	I-Claim

439	The	N	I-Claim
440	combination	N	I-Claim
441	of	N	I-Claim
442	VNR	N	I-Claim
443	on	N	I-Claim
444	day	N	I-Claim
445	1-8	N	I-Claim
446	plus	N	I-Claim
447	CDDP	N	I-Claim
448	every	N	I-Claim
449	3	N	I-Claim
450	weeks	N	I-Claim
451	may	N	I-Claim
452	be	N	I-Claim
453	considered	N	I-Claim
454	as	N	I-Claim
455	a	N	I-Claim
456	reference	N	I-Claim
457	regimen	N	I-Claim
458	for	N	I-Claim
459	the	N	I-Claim
460	treatment	N	I-Claim
461	of	N	I-Claim
462	patients	N	I-Claim
463	with	N	I-Claim
464	advanced	N	I-Claim
465	disease	N	I-Claim
466	and	N	I-Claim
467	those	N	I-Claim
468	who	N	I-Claim
469	deserve	N	I-Claim
470	a	N	I-Claim
471	postoperative	N	I-Claim
472	therapy	N	I-Claim
473	,	N	I-Claim
474	and	N	I-Claim
475	for	N	I-Claim
476	future	N	I-Claim
477	studies	N	I-Claim
478	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	analgesic	N	O
11	and	N	O
12	adverse	N	O
13	effects	N	O
14	,	N	O
15	doses	N	O
16	,	N	O
17	as	N	O
18	well	N	O
19	as	N	O
20	cost	N	O
21	of	N	O
22	opioid	N	O
23	drugs	N	O
24	,	N	O
25	supportive	N	O
26	drug	N	O
27	therapy	N	O
28	and	N	O
29	other	N	O
30	analgesic	N	O
31	drugs	N	O
32	in	N	O
33	patients	N	O
34	treated	N	O
35	with	N	O
36	oral	N	O
37	sustained-release	N	O
38	morphine	N	O
39	,	N	O
40	transdermal	N	O
41	fentanyl	N	O
42	,	N	O
43	and	N	O
44	oral	N	O
45	methadone	N	O
46	.	N	O

47	One	N	O
48	hundred	N	O
49	and	N	O
50	eight	N	O
51	cancer	N	O
52	patients	N	O
53	,	N	O
54	no	N	O
55	longer	N	O
56	responsive	N	O
57	to	N	O
58	opioids	N	O
59	for	N	O
60	moderate	N	O
61	pain	N	O
62	,	N	O
63	were	N	O
64	selected	N	O
65	to	N	O
66	randomly	N	O
67	receive	N	O
68	initial	N	O
69	daily	N	O
70	doses	N	O
71	of	N	O
72	60	N	O
73	mg	N	O
74	of	N	O
75	oral	N	O
76	sustained-release	N	O
77	morphine	N	O
78	,	N	O
79	15	N	O
80	mg	N	O
81	of	N	O
82	oral	N	O
83	methadone	N	O
84	,	N	O
85	or	N	O
86	0.6	N	O
87	mg	N	O
88	(	N	O
89	25	N	O
90	microg/h	N	O
91	)	N	O
92	of	N	O
93	transdermal	N	O
94	fentanyl	N	O
95	.	N	O

96	Oral	N	O
97	morphine	N	O
98	was	N	O
99	used	N	O
100	as	N	O
101	breakthrough	N	O
102	pain	N	O
103	medication	N	O
104	during	N	O
105	opioid	N	O
106	titration	N	O
107	.	N	O

108	Opioid	N	O
109	doses	N	O
110	,	N	O
111	pain	N	O
112	intensity	N	O
113	,	N	O
114	adverse	N	O
115	effects	N	O
116	,	N	O
117	symptomatic	N	O
118	drugs	N	O
119	,	N	O
120	were	N	O
121	recorded	N	O
122	at	N	O
123	week	N	O
124	intervals	N	O
125	for	N	O
126	4	N	O
127	weeks	N	O
128	.	N	O

129	Costs	N	O
130	of	N	O
131	opioid	N	O
132	therapy	N	O
133	,	N	O
134	supportive	N	O
135	drugs	N	O
136	,	N	O
137	and	N	O
138	other	N	O
139	analgesic	N	O
140	drugs	N	O
141	were	N	O
142	also	N	O
143	evaluated	N	O
144	.	N	O

145	Seventy	N	O
146	patients	N	O
147	completed	N	O
148	the	N	O
149	4	N	O
150	weeks	N	O
151	period	N	O
152	of	N	O
153	study	N	O
154	.	N	O

155	Five	N	O
156	,	N	O
157	five	N	O
158	,	N	O
159	and	N	O
160	four	N	O
161	patients	N	O
162	,	N	O
163	treated	N	O
164	with	N	O
165	oral	N	O
166	morphine	N	O
167	,	N	O
168	transdermal	N	O
169	fentanyl	N	O
170	,	N	O
171	and	N	O
172	oral	N	O
173	methadone	N	O
174	,	N	O
175	respectively	N	O
176	,	N	O
177	required	N	O
178	opioid	N	O
179	switching	N	O
180	.	N	O

181	No	N	I-Premise
182	differences	N	I-Premise
183	in	N	I-Premise
184	pain	N	I-Premise
185	and	N	I-Premise
186	symptom	N	I-Premise
187	intensity	N	I-Premise
188	were	N	I-Premise
189	observed	N	I-Premise
190	.	N	I-Premise

191	Opioid	N	I-Premise
192	escalation	N	I-Premise
193	index	N	I-Premise
194	was	N	I-Premise
195	significantly	N	I-Premise
196	lower	N	I-Premise
197	in	N	I-Premise
198	patients	N	I-Premise
199	receiving	N	I-Premise
200	methadone	N	I-Premise
201	(	N	I-Premise
202	p	N	I-Premise
203	<	N	I-Premise
204	0.0001	N	I-Premise
205	)	N	I-Premise
206	,	N	I-Premise
207	although	N	I-Premise
208	requiring	N	I-Premise
209	up	N	I-Premise
210	and	N	I-Premise
211	down	N	I-Premise
212	changes	N	I-Premise
213	in	N	I-Premise
214	doses	N	I-Premise
215	.	N	I-Premise

216	At	N	I-Premise
217	the	N	I-Premise
218	doses	N	I-Premise
219	used	N	I-Premise
220	,	N	I-Premise
221	methadone	N	I-Premise
222	was	N	I-Premise
223	significantly	N	I-Premise
224	less	N	I-Premise
225	expensive	N	I-Premise
226	(	N	I-Premise
227	p	N	I-Premise
228	<	N	I-Premise
229	0.0001	N	I-Premise
230	)	N	I-Premise
231	,	N	I-Premise
232	while	N	I-Premise
233	the	N	I-Premise
234	use	N	I-Premise
235	and	N	I-Premise
236	costs	N	I-Premise
237	of	N	I-Premise
238	supportive	N	I-Premise
239	drugs	N	I-Premise
240	and	N	I-Premise
241	other	N	I-Premise
242	analgesics	N	I-Premise
243	were	N	I-Premise
244	similar	N	I-Premise
245	in	N	I-Premise
246	the	N	I-Premise
247	three	N	I-Premise
248	groups	N	I-Premise
249	.	N	I-Premise

250	No	N	I-Premise
251	relevant	N	I-Premise
252	differences	N	I-Premise
253	in	N	I-Premise
254	adverse	N	I-Premise
255	effects	N	I-Premise
256	were	N	I-Premise
257	observed	N	I-Premise
258	among	N	I-Premise
259	the	N	I-Premise
260	groups	N	I-Premise
261	during	N	I-Premise
262	either	N	I-Premise
263	the	N	I-Premise
264	titration	N	I-Premise
265	phase	N	I-Premise
266	and	N	I-Premise
267	chronic	N	I-Premise
268	treatment	N	I-Premise
269	.	N	I-Premise

270	All	N	I-Claim
271	the	N	I-Claim
272	three	N	I-Claim
273	opioids	N	I-Claim
274	used	N	I-Claim
275	as	N	I-Claim
276	first-line	N	I-Claim
277	therapy	N	I-Claim
278	were	N	I-Claim
279	effective	N	I-Claim
280	,	N	I-Claim
281	well	N	I-Claim
282	tolerated	N	I-Claim
283	,	N	I-Claim
284	and	N	I-Claim
285	required	N	I-Claim
286	similar	N	I-Claim
287	amounts	N	I-Claim
288	of	N	I-Claim
289	symptomatic	N	I-Claim
290	drugs	N	I-Claim
291	or	N	I-Claim
292	co-analgesics	N	I-Claim
293	.	N	I-Claim

294	Methadone	N	I-Claim
295	was	N	I-Claim
296	significantly	N	I-Claim
297	less	N	I-Claim
298	expensive	N	I-Claim
299	,	N	I-Claim
300	but	N	I-Claim
301	required	N	I-Claim
302	more	N	I-Claim
303	changes	N	I-Claim
304	,	N	I-Claim
305	up	N	I-Claim
306	and	N	I-Claim
307	down	N	I-Claim
308	,	N	I-Claim
309	of	N	I-Claim
310	the	N	I-Claim
311	doses	N	I-Claim
312	,	N	I-Claim
313	suggesting	N	I-Claim
314	that	N	I-Claim
315	dose	N	I-Claim
316	titration	N	I-Claim
317	of	N	I-Claim
318	this	N	I-Claim
319	drug	N	I-Claim
320	requires	N	I-Claim
321	major	N	I-Claim
322	clinical	N	I-Claim
323	expertise	N	I-Claim
324	.	N	I-Claim

1	To	N	O
2	observe	N	O
3	the	N	O
4	clinical	N	O
5	efficacy	N	O
6	of	N	O
7	Shenqi	N	O
8	Fuzheng	N	O
9	Injection	N	O
10	(	N	O
11	SFI	N	O
12	)	N	O
13	combined	N	O
14	with	N	O
15	chemotherapy	N	O
16	in	N	O
17	treating	N	O
18	patients	N	O
19	with	N	O
20	advanced	N	O
21	breast	N	O
22	cancer	N	O
23	.	N	O

24	Sixty	N	O
25	patients	N	O
26	were	N	O
27	randomly	N	O
28	assigned	N	O
29	to	N	O
30	two	N	O
31	groups	N	O
32	by	N	O
33	digital	N	O
34	table	N	O
35	,	N	O
36	the	N	O
37	control	N	O
38	group	N	O
39	and	N	O
40	the	N	O
41	treatment	N	O
42	group	N	O
43	,	N	O
44	30	N	O
45	in	N	O
46	each	N	O
47	group	N	O
48	.	N	O

49	All	N	O
50	patients	N	O
51	were	N	O
52	treated	N	O
53	with	N	O
54	the	N	O
55	same	N	O
56	CTF	N	O
57	regimen	N	O
58	of	N	O
59	chemotherapy	N	O
60	for	N	O
61	21	N	O
62	days	N	O
63	as	N	O
64	one	N	O
65	therapeutic	N	O
66	cycle	N	O
67	,	N	O
68	while	N	O
69	those	N	O
70	in	N	O
71	the	N	O
72	treatment	N	O
73	group	N	O
74	were	N	O
75	given	N	O
76	SFI	N	O
77	additionally	N	O
78	in	N	O
79	the	N	O
80	meanwhite	N	O
81	.	N	O

82	The	N	O
83	therapeutic	N	O
84	efficacy	N	O
85	was	N	O
86	evaluated	N	O
87	after	N	O
88	2	N	O
89	cycles	N	O
90	of	N	O
91	treatment	N	O
92	by	N	O
93	observing	N	O
94	the	N	O
95	changes	N	O
96	of	N	O
97	short-term	N	O
98	efficacy	N	O
99	,	N	O
100	TCM	N	O
101	syndrome	N	O
102	,	N	O
103	quality	N	O
104	of	N	O
105	life	N	O
106	and	N	O
107	immune	N	O
108	function	N	O
109	,	N	O
110	as	N	O
111	well	N	O
112	as	N	O
113	the	N	O
114	adverse	N	O
115	reaction	N	O
116	.	N	O

117	The	N	I-Premise
118	total	N	I-Premise
119	short-term	N	I-Premise
120	remission	N	I-Premise
121	rate	N	I-Premise
122	,	N	I-Premise
123	the	N	I-Premise
124	improvement	N	I-Premise
125	rate	N	I-Premise
126	of	N	I-Premise
127	clinical	N	I-Premise
128	syndrome	N	I-Premise
129	and	N	I-Premise
130	quality	N	I-Premise
131	of	N	I-Premise
132	life	N	I-Premise
133	was	N	I-Premise
134	50.0	N	I-Premise
135	%	N	I-Premise
136	,	N	I-Premise
137	70.0	N	I-Premise
138	%	N	I-Premise
139	and	N	I-Premise
140	76.7	N	I-Premise
141	%	N	I-Premise
142	in	N	I-Premise
143	the	N	I-Premise
144	treatment	N	I-Premise
145	group	N	I-Premise
146	,	N	I-Premise
147	and	N	I-Premise
148	43.3	N	I-Premise
149	%	N	I-Premise
150	,	N	I-Premise
151	46.7	N	I-Premise
152	%	N	I-Premise
153	and	N	I-Premise
154	50.0	N	I-Premise
155	%	N	I-Premise
156	in	N	I-Premise
157	the	N	I-Premise
158	control	N	I-Premise
159	group	N	I-Premise
160	,	N	I-Premise
161	respectively	N	I-Premise
162	,	N	I-Premise
163	showing	N	I-Premise
164	significant	N	I-Premise
165	difference	N	I-Premise
166	between	N	I-Premise
167	the	N	I-Premise
168	two	N	I-Premise
169	groups	N	I-Premise
170	(	N	I-Premise
171	all	N	I-Premise
172	P	N	I-Premise
173	<	N	I-Premise
174	0.05	N	I-Premise
175	)	N	I-Premise
176	.	N	I-Premise

177	The	N	I-Premise
178	occurrence	N	I-Premise
179	of	N	I-Premise
180	adverse	N	I-Premise
181	reaction	N	I-Premise
182	in	N	I-Premise
183	the	N	I-Premise
184	treatment	N	I-Premise
185	group	N	I-Premise
186	was	N	I-Premise
187	lower	N	I-Premise
188	than	N	I-Premise
189	that	N	I-Premise
190	in	N	I-Premise
191	the	N	I-Premise
192	control	N	I-Premise
193	group	N	I-Premise
194	(	N	I-Premise
195	P	N	I-Premise
196	<	N	I-Premise
197	0.05	N	I-Premise
198	)	N	I-Premise
199	.	N	I-Premise

200	The	N	I-Premise
201	level	N	I-Premise
202	of	N	I-Premise
203	CD3+	N	I-Premise
204	CD4+	N	I-Premise
205	and	N	I-Premise
206	CD4+/CD8+	N	I-Premise
207	ratio	N	I-Premise
208	increased	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	<	N	I-Premise
212	0.05	N	I-Premise
213	)	N	I-Premise
214	and	N	I-Premise
215	CD8+	N	I-Premise
216	decreased	N	I-Premise
217	in	N	I-Premise
218	the	N	I-Premise
219	treatment	N	I-Premise
220	group	N	I-Premise
221	(	N	I-Premise
222	P	N	I-Premise
223	<	N	I-Premise
224	0.01	N	I-Premise
225	)	N	I-Premise
226	,	N	I-Premise
227	while	N	I-Premise
228	they	N	I-Premise
229	showed	N	I-Premise
230	insignificant	N	I-Premise
231	change	N	I-Premise
232	in	N	I-Premise
233	the	N	I-Premise
234	control	N	I-Premise
235	group	N	I-Premise
236	.	N	I-Premise

237	For	N	I-Claim
238	treatment	N	I-Claim
239	of	N	I-Claim
240	advanced	N	I-Claim
241	breast	N	I-Claim
242	cancer	N	I-Claim
243	,	N	I-Claim
244	SFI	N	I-Claim
245	can	N	I-Claim
246	alleviate	N	I-Claim
247	the	N	I-Claim
248	bone	N	I-Claim
249	marrow	N	I-Claim
250	inhibition	N	I-Claim
251	caused	N	I-Claim
252	by	N	I-Claim
253	chemotherapy	N	I-Claim
254	,	N	I-Claim
255	improve	N	I-Claim
256	clinical	N	I-Claim
257	symptoms	N	I-Claim
258	and	N	I-Claim
259	quality	N	I-Claim
260	of	N	I-Claim
261	life	N	I-Claim
262	and	N	I-Claim
263	prolong	N	I-Claim
264	the	N	I-Claim
265	survival	N	I-Claim
266	period	N	I-Claim
267	by	N	I-Claim
268	regulating	N	I-Claim
269	cellular	N	I-Claim
270	immune	N	I-Claim
271	function	N	I-Claim
272	of	N	I-Claim
273	patients	N	I-Claim
274	,	N	I-Claim
275	so	N	I-Claim
276	as	N	I-Claim
277	to	N	I-Claim
278	enhance	N	I-Claim
279	the	N	I-Claim
280	therapeutic	N	I-Claim
281	effect	N	I-Claim
282	of	N	I-Claim
283	chemotherapy	N	I-Claim
284	.	N	I-Claim

1	To	N	O
2	observe	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	TCM	N	O
7	therapy	N	O
8	for	N	O
9	removing	N	O
10	toxic	N	O
11	substance	N	O
12	and	N	O
13	unblocking	N	O
14	meridians	N	O
15	on	N	O
16	post-radiation	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QOF	N	O
22	)	N	O
23	in	N	O
24	55	N	O
25	patients	N	O
26	with	N	O
27	lung	N	O
28	cancer	N	O
29	.	N	O

30	All	N	O
31	patients	N	O
32	were	N	O
33	randomly	N	O
34	assigned	N	O
35	to	N	O
36	two	N	O
37	groups	N	O
38	,	N	O
39	the	N	O
40	55	N	O
41	patients	N	O
42	in	N	O
43	the	N	O
44	treated	N	O
45	group	N	O
46	were	N	O
47	treated	N	O
48	with	N	O
49	radiotherapy	N	O
50	combined	N	O
51	with	N	O
52	the	N	O
53	TCM	N	O
54	therapy	N	O
55	,	N	O
56	and	N	O
57	the	N	O
58	53	N	O
59	in	N	O
60	the	N	O
61	control	N	O
62	group	N	O
63	were	N	O
64	given	N	O
65	radiotherapy	N	O
66	alone	N	O
67	.	N	O

68	The	N	O
69	clinical	N	O
70	efficacy	N	O
71	was	N	O
72	evaluated	N	O
73	by	N	O
74	indexes	N	O
75	including	N	O
76	KPS	N	O
77	scores	N	O
78	,	N	O
79	QLQ-C30	N	O
80	questionnaire	N	O
81	,	N	O
82	LC13	N	O
83	specific	N	O
84	scale	N	O
85	for	N	O
86	lung	N	O
87	cancer	N	O
88	,	N	O
89	evaluation	N	O
90	criteria	N	O
91	for	N	O
92	TCM	N	O
93	efficacy	N	O
94	,	N	O
95	the	N	O
96	6-min	N	O
97	walking	N	O
98	distance	N	O
99	,	N	O
100	and	N	O
101	body	N	O
102	weight	N	O
103	,	N	O
104	etc	N	O
105	.	N	O

106	The	N	I-Premise
107	KPS	N	I-Premise
108	score	N	I-Premise
109	in	N	I-Premise
110	the	N	I-Premise
111	treated	N	I-Premise
112	group	N	I-Premise
113	after	N	I-Premise
114	treatment	N	I-Premise
115	was	N	I-Premise
116	improved	N	I-Premise
117	in	N	I-Premise
118	13	N	I-Premise
119	patients	N	I-Premise
120	(	N	I-Premise
121	23.6	N	I-Premise
122	%	N	I-Premise
123	)	N	I-Premise
124	,	N	I-Premise
125	stabilized	N	I-Premise
126	in	N	I-Premise
127	27	N	I-Premise
128	(	N	I-Premise
129	49.6	N	I-Premise
130	%	N	I-Premise
131	)	N	I-Premise
132	and	N	I-Premise
133	declined	N	I-Premise
134	in	N	I-Premise
135	15	N	I-Premise
136	(	N	I-Premise
137	27.3	N	I-Premise
138	%	N	I-Premise
139	)	N	I-Premise
140	,	N	I-Premise
141	while	N	I-Premise
142	in	N	I-Premise
143	the	N	I-Premise
144	control	N	I-Premise
145	group	N	I-Premise
146	,	N	I-Premise
147	it	N	I-Premise
148	was	N	I-Premise
149	improved	N	I-Premise
150	in	N	I-Premise
151	7	N	I-Premise
152	(	N	I-Premise
153	13.2	N	I-Premise
154	%	N	I-Premise
155	)	N	I-Premise
156	,	N	I-Premise
157	stabilized	N	I-Premise
158	in	N	I-Premise
159	21	N	I-Premise
160	(	N	I-Premise
161	39.6	N	I-Premise
162	%	N	I-Premise
163	)	N	I-Premise
164	and	N	I-Premise
165	declined	N	I-Premise
166	in	N	I-Premise
167	25	N	I-Premise
168	(	N	I-Premise
169	47.2	N	I-Premise
170	%	N	I-Premise
171	)	N	I-Premise
172	,	N	I-Premise
173	the	N	I-Premise
174	difference	N	I-Premise
175	between	N	I-Premise
176	the	N	I-Premise
177	two	N	I-Premise
178	groups	N	I-Premise
179	was	N	I-Premise
180	significant	N	I-Premise
181	(	N	I-Premise
182	P	N	I-Premise
183	<	N	I-Premise
184	0.05	N	I-Premise
185	)	N	I-Premise
186	.	N	I-Premise

187	The	N	I-Premise
188	results	N	I-Premise
189	from	N	I-Premise
190	evaluation	N	I-Premise
191	with	N	I-Premise
192	QLQ-C30	N	I-Premise
193	questionnaire	N	I-Premise
194	and	N	I-Premise
195	LC30	N	I-Premise
196	scale	N	I-Premise
197	in	N	I-Premise
198	the	N	I-Premise
199	treated	N	I-Premise
200	group	N	I-Premise
201	was	N	I-Premise
202	also	N	I-Premise
203	superior	N	I-Premise
204	to	N	I-Premise
205	those	N	I-Premise
206	in	N	I-Premise
207	the	N	I-Premise
208	control	N	I-Premise
209	group	N	I-Premise
210	(	N	I-Premise
211	P	N	I-Premise
212	<	N	I-Premise
213	0.05	N	I-Premise
214	)	N	I-Premise
215	,	N	I-Premise
216	respectively	N	I-Premise
217	.	N	I-Premise

218	The	N	I-Premise
219	scores	N	I-Premise
220	of	N	I-Premise
221	TCM	N	I-Premise
222	efficacy	N	I-Premise
223	(	N	I-Premise
224	24.52	N	I-Premise
225	+/-	N	I-Premise
226	8.98	N	I-Premise
227	vs	N	I-Premise
228	29.76	N	I-Premise
229	+/-	N	I-Premise
230	7.09	N	I-Premise
231	,	N	I-Premise
232	P	N	I-Premise
233	<	N	I-Premise
234	0.05	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	the	N	I-Premise
238	6-min	N	I-Premise
239	walking	N	I-Premise
240	distance	N	I-Premise
241	(	N	I-Premise
242	233.4	N	I-Premise
243	+/-	N	I-Premise
244	29.2	N	I-Premise
245	m	N	I-Premise
246	vs	N	I-Premise
247	205.8	N	I-Premise
248	+/-	N	I-Premise
249	31.9	N	I-Premise
250	m	N	I-Premise
251	,	N	I-Premise
252	P	N	I-Premise
253	<	N	I-Premise
254	0.05	N	I-Premise
255	)	N	I-Premise
256	were	N	I-Premise
257	better	N	I-Premise
258	in	N	I-Premise
259	the	N	I-Premise
260	treated	N	I-Premise
261	group	N	I-Premise
262	.	N	I-Premise

263	After	N	I-Premise
264	treatment	N	I-Premise
265	in	N	I-Premise
266	the	N	I-Premise
267	treated	N	I-Premise
268	group	N	I-Premise
269	,	N	I-Premise
270	the	N	I-Premise
271	body	N	I-Premise
272	weight	N	I-Premise
273	was	N	I-Premise
274	increased	N	I-Premise
275	in	N	I-Premise
276	11	N	I-Premise
277	patients	N	I-Premise
278	(	N	I-Premise
279	20.0	N	I-Premise
280	%	N	I-Premise
281	)	N	I-Premise
282	,	N	I-Premise
283	stabilized	N	I-Premise
284	in	N	I-Premise
285	28	N	I-Premise
286	(	N	I-Premise
287	50.9	N	I-Premise
288	%	N	I-Premise
289	)	N	I-Premise
290	and	N	I-Premise
291	decreased	N	I-Premise
292	in	N	I-Premise
293	16	N	I-Premise
294	(	N	I-Premise
295	29.1	N	I-Premise
296	%	N	I-Premise
297	)	N	I-Premise
298	,	N	I-Premise
299	while	N	I-Premise
300	in	N	I-Premise
301	the	N	I-Premise
302	control	N	I-Premise
303	group	N	I-Premise
304	it	N	I-Premise
305	was	N	I-Premise
306	increased	N	I-Premise
307	in	N	I-Premise
308	5	N	I-Premise
309	(	N	I-Premise
310	9.4	N	I-Premise
311	%	N	I-Premise
312	)	N	I-Premise
313	,	N	I-Premise
314	stabilized	N	I-Premise
315	in	N	I-Premise
316	26	N	I-Premise
317	(	N	I-Premise
318	49.1	N	I-Premise
319	%	N	I-Premise
320	)	N	I-Premise
321	and	N	I-Premise
322	decreased	N	I-Premise
323	in	N	I-Premise
324	22	N	I-Premise
325	(	N	I-Premise
326	41.5	N	I-Premise
327	%	N	I-Premise
328	)	N	I-Premise
329	,	N	I-Premise
330	difference	N	I-Premise
331	between	N	I-Premise
332	the	N	I-Premise
333	two	N	I-Premise
334	groups	N	I-Premise
335	was	N	I-Premise
336	significant	N	I-Premise
337	,	N	I-Premise
338	too	N	I-Premise
339	(	N	I-Premise
340	P	N	I-Premise
341	<	N	I-Premise
342	0.05	N	I-Premise
343	)	N	I-Premise
344	.	N	I-Premise

345	TCM	N	I-Claim
346	therapy	N	I-Claim
347	for	N	I-Claim
348	removing	N	I-Claim
349	toxic	N	I-Claim
350	substance	N	I-Claim
351	and	N	I-Claim
352	unblocking	N	I-Claim
353	meridians	N	I-Claim
354	can	N	I-Claim
355	improve	N	I-Claim
356	the	N	I-Claim
357	post-radiation	N	I-Claim
358	QOL	N	I-Claim
359	of	N	I-Claim
360	patients	N	I-Claim
361	with	N	I-Claim
362	lung	N	I-Claim
363	cancer	N	I-Claim
364	to	N	I-Claim
365	some	N	I-Claim
366	extent	N	I-Claim
367	.	N	I-Claim

1	Anaemia	N	O
2	is	N	O
3	common	N	O
4	in	N	O
5	patients	N	O
6	receiving	N	O
7	chemotherapy	N	O
8	,	N	O
9	causing	N	O
10	symptoms	N	O
11	that	N	O
12	have	N	O
13	a	N	O
14	major	N	O
15	impact	N	O
16	on	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QoL	N	O
22	)	N	O
23	.	N	O

24	Epoetin	N	O
25	beta	N	O
26	rapidly	N	O
27	increases	N	O
28	haemoglobin	N	O
29	(	N	O
30	Hb	N	O
31	)	N	O
32	levels	N	O
33	and	N	O
34	improves	N	O
35	QoL	N	O
36	in	N	O
37	anaemic	N	O
38	patients	N	O
39	with	N	O
40	a	N	O
41	variety	N	O
42	of	N	O
43	tumours	N	O
44	.	N	O

45	This	N	O
46	was	N	O
47	a	N	O
48	randomized	N	O
49	,	N	O
50	double-blind	N	O
51	,	N	O
52	parallel-group	N	O
53	,	N	O
54	dose-finding	N	O
55	study	N	O
56	assessing	N	O
57	the	N	O
58	efficacy	N	O
59	and	N	O
60	safety	N	O
61	of	N	O
62	once-weekly	N	O
63	epoetin	N	O
64	beta	N	O
65	in	N	O
66	patients	N	O
67	with	N	O
68	solid	N	O
69	tumours	N	O
70	receiving	N	O
71	chemotherapy	N	O
72	.	N	O

73	Adult	N	O
74	patients	N	O
75	with	N	O
76	anaemia	N	O
77	(	N	O
78	Hb	N	O
79	<	N	O
80	11	N	O
81	g/dL	N	O
82	)	N	O
83	were	N	O
84	randomized	N	O
85	to	N	O
86	receive	N	O
87	epoetin	N	O
88	beta	N	O
89	30,000	N	O
90	IU	N	O
91	or	N	O
92	20,000	N	O
93	IU	N	O
94	once	N	O
95	weekly	N	O
96	for	N	O
97	12	N	O
98	weeks	N	O
99	.	N	O

100	All	N	O
101	patients	N	O
102	received	N	O
103	oral	N	O
104	iron	N	O
105	supplementation	N	O
106	.	N	O

107	Haemoglobin	N	O
108	levels	N	O
109	,	N	O
110	transfusion	N	O
111	need	N	O
112	and	N	O
113	QoL	N	O
114	[	N	O
115	Functional	N	O
116	Assessment	N	O
117	of	N	O
118	Cancer	N	O
119	Therapy-fatigue	N	O
120	(	N	O
121	FACT-F	N	O
122	)	N	O
123	subscale	N	O
124	score	N	O
125	]	N	O
126	were	N	O
127	assessed	N	O
128	at	N	O
129	regular	N	O
130	intervals	N	O
131	.	N	O

132	Fifty	N	O
133	patients	N	O
134	were	N	O
135	randomized	N	O
136	;	N	O
137	30	N	O
138	patients	N	O
139	received	N	O
140	epoetin	N	O
141	beta	N	O
142	30,000	N	O
143	IU	N	O
144	once	N	O
145	weekly	N	O
146	and	N	O
147	20	N	O
148	received	N	O
149	20,000	N	O
150	IU	N	O
151	once	N	O
152	weekly	N	O
153	.	N	O

154	Mean	N	I-Premise
155	(	N	I-Premise
156	+/-	N	I-Premise
157	SD	N	I-Premise
158	)	N	I-Premise
159	increase	N	I-Premise
160	in	N	I-Premise
161	Hb	N	I-Premise
162	from	N	I-Premise
163	baseline	N	I-Premise
164	to	N	I-Premise
165	week	N	I-Premise
166	12	N	I-Premise
167	was	N	I-Premise
168	1.75	N	I-Premise
169	+/-	N	I-Premise
170	2.15	N	I-Premise
171	g/dL	N	I-Premise
172	in	N	I-Premise
173	the	N	I-Premise
174	30,000	N	I-Premise
175	IU	N	I-Premise
176	group	N	I-Premise
177	(	N	I-Premise
178	P	N	I-Premise
179	=	N	I-Premise
180	0.008	N	I-Premise
181	vs.	N	I-Premise
182	baseline	N	I-Premise
183	)	N	I-Premise
184	and	N	I-Premise
185	1.04	N	I-Premise
186	+/-	N	I-Premise
187	1.75	N	I-Premise
188	g/dL	N	I-Premise
189	in	N	I-Premise
190	the	N	I-Premise
191	20,000	N	I-Premise
192	IU	N	I-Premise
193	group	N	I-Premise
194	(	N	I-Premise
195	non-significant	N	I-Premise
196	)	N	I-Premise
197	.	N	I-Premise

198	Haemoglobin	N	I-Premise
199	response	N	I-Premise
200	(	N	I-Premise
201	increase	N	I-Premise
202	in	N	I-Premise
203	Hb	N	I-Premise
204	>	N	I-Premise
205	or=2	N	I-Premise
206	g/dL	N	I-Premise
207	from	N	I-Premise
208	baseline	N	I-Premise
209	)	N	I-Premise
210	was	N	I-Premise
211	observed	N	I-Premise
212	in	N	I-Premise
213	78.3	N	I-Premise
214	%	N	I-Premise
215	of	N	I-Premise
216	patients	N	I-Premise
217	receiving	N	I-Premise
218	epoetin	N	I-Premise
219	beta	N	I-Premise
220	30,000	N	I-Premise
221	IU	N	I-Premise
222	and	N	I-Premise
223	66.7	N	I-Premise
224	%	N	I-Premise
225	receiving	N	I-Premise
226	epoetin	N	I-Premise
227	beta	N	I-Premise
228	20,000	N	I-Premise
229	IU	N	I-Premise
230	.	N	I-Premise

231	Improvements	N	O
232	in	N	O
233	FACT-F	N	O
234	subscale	N	O
235	score	N	O
236	were	N	O
237	significantly	N	O
238	(	N	O
239	P	N	O
240	<	N	O
241	0.001	N	O
242	)	N	O
243	correlated	N	O
244	with	N	O
245	increases	N	O
246	in	N	O
247	Hb	N	O
248	level	N	O
249	.	N	O

250	Transfusion	N	O
251	use	N	O
252	was	N	O
253	low	N	O
254	during	N	O
255	the	N	O
256	study	N	O
257	in	N	O
258	both	N	O
259	groups	N	O
260	.	N	O

261	Both	N	I-Premise
262	epoetin	N	I-Premise
263	beta	N	I-Premise
264	regiments	N	I-Premise
265	were	N	I-Premise
266	well	N	I-Premise
267	tolerated	N	I-Premise
268	and	N	I-Premise
269	there	N	I-Premise
270	were	N	I-Premise
271	no	N	I-Premise
272	dose-dependent	N	I-Premise
273	adverse	N	I-Premise
274	events	N	I-Premise
275	.	N	I-Premise

276	Epoetin	N	I-Claim
277	beta	N	I-Claim
278	30,000	N	I-Claim
279	IU	N	I-Claim
280	once	N	I-Claim
281	weekly	N	I-Claim
282	is	N	I-Claim
283	an	N	I-Claim
284	effective	N	I-Claim
285	and	N	I-Claim
286	well-tolerated	N	I-Claim
287	treatment	N	I-Claim
288	of	N	I-Claim
289	anaemia	N	I-Claim
290	in	N	I-Claim
291	patients	N	I-Claim
292	with	N	I-Claim
293	solid	N	I-Claim
294	tumours	N	I-Claim
295	.	N	I-Claim

1	The	N	O
2	combination	N	O
3	of	N	O
4	cisplatin	N	O
5	and	N	O
6	etoposide	N	O
7	(	N	O
8	PE	N	O
9	)	N	O
10	has	N	O
11	been	N	O
12	a	N	O
13	standard	N	O
14	treatment	N	O
15	for	N	O
16	patients	N	O
17	with	N	O
18	poor-prognosis	N	O
19	small	N	O
20	cell	N	O
21	lung	N	O
22	cancer	N	O
23	(	N	O
24	SCLC	N	O
25	)	N	O
26	.	N	O

27	This	N	O
28	non-inferiority	N	O
29	design	N	O
30	trial	N	O
31	aimed	N	O
32	to	N	O
33	determine	N	O
34	whether	N	O
35	the	N	O
36	combination	N	O
37	of	N	O
38	gemcitabine	N	O
39	and	N	O
40	carboplatin	N	O
41	(	N	O
42	GC	N	O
43	)	N	O
44	results	N	O
45	in	N	O
46	similar	N	O
47	survival	N	O
48	but	N	O
49	is	N	O
50	less	N	O
51	toxic	N	O
52	with	N	O
53	better	N	O
54	quality	N	O
55	of	N	O
56	life	N	O
57	.	N	O

58	Previously	N	O
59	untreated	N	O
60	patients	N	O
61	with	N	O
62	SCLC	N	O
63	with	N	O
64	extensive	N	O
65	disease	N	O
66	or	N	O
67	limited	N	O
68	stage	N	O
69	with	N	O
70	poor	N	O
71	prognostic	N	O
72	factors	N	O
73	were	N	O
74	randomly	N	O
75	assigned	N	O
76	to	N	O
77	six	N	O
78	3-weekly	N	O
79	cycles	N	O
80	of	N	O
81	GC	N	O
82	or	N	O
83	PE	N	O
84	.	N	O

85	241	N	O
86	patients	N	O
87	(	N	O
88	121	N	O
89	GC	N	O
90	,	N	O
91	120	N	O
92	PE	N	O
93	)	N	O
94	were	N	O
95	recruited	N	O
96	,	N	O
97	of	N	O
98	which	N	O
99	216	N	O
100	(	N	O
101	90	N	O
102	%	N	O
103	)	N	O
104	had	N	O
105	died	N	O
106	.	N	O

107	There	N	I-Premise
108	was	N	I-Premise
109	no	N	I-Premise
110	difference	N	I-Premise
111	in	N	I-Premise
112	overall	N	I-Premise
113	survival	N	I-Premise
114	(	N	I-Premise
115	HR	N	I-Premise
116	1.01	N	I-Premise
117	,	N	I-Premise
118	95	N	I-Premise
119	%	N	I-Premise
120	CI	N	I-Premise
121	0.77	N	I-Premise
122	to	N	I-Premise
123	1.32	N	I-Premise
124	)	N	I-Premise
125	.	N	I-Premise

126	Median	N	I-Premise
127	survival	N	I-Premise
128	with	N	I-Premise
129	GC	N	I-Premise
130	and	N	I-Premise
131	PE	N	I-Premise
132	was	N	I-Premise
133	8.0	N	I-Premise
134	and	N	I-Premise
135	8.1	N	I-Premise
136	months	N	I-Premise
137	,	N	I-Premise
138	respectively	N	I-Premise
139	.	N	I-Premise

140	Median	N	I-Premise
141	progression-free	N	I-Premise
142	survival	N	I-Premise
143	was	N	I-Premise
144	5.9	N	I-Premise
145	months	N	I-Premise
146	with	N	I-Premise
147	GC	N	I-Premise
148	and	N	I-Premise
149	6.3	N	I-Premise
150	months	N	I-Premise
151	with	N	I-Premise
152	PE	N	I-Premise
153	.	N	I-Premise

154	Grade	N	I-Premise
155	3	N	I-Premise
156	or	N	I-Premise
157	4	N	I-Premise
158	myelosuppressions	N	I-Premise
159	were	N	I-Premise
160	more	N	I-Premise
161	frequent	N	I-Premise
162	with	N	I-Premise
163	GC	N	I-Premise
164	(	N	I-Premise
165	anaemia	N	I-Premise
166	:	N	I-Premise
167	14	N	I-Premise
168	%	N	I-Premise
169	GC	N	I-Premise
170	vs	N	I-Premise
171	2	N	I-Premise
172	%	N	I-Premise
173	PE	N	I-Premise
174	;	N	I-Premise
175	leucopenia	N	I-Premise
176	:	N	I-Premise
177	32	N	I-Premise
178	%	N	I-Premise
179	GC	N	I-Premise
180	vs	N	I-Premise
181	13	N	I-Premise
182	%	N	I-Premise
183	PE	N	I-Premise
184	;	N	I-Premise
185	thrombocytopenia	N	I-Premise
186	:	N	I-Premise
187	22	N	I-Premise
188	%	N	I-Premise
189	GC	N	I-Premise
190	vs	N	I-Premise
191	4	N	I-Premise
192	%	N	I-Premise
193	PE	N	I-Premise
194	)	N	I-Premise
195	,	N	I-Premise
196	but	N	I-Premise
197	these	N	I-Premise
198	were	N	I-Premise
199	not	N	I-Premise
200	associated	N	I-Premise
201	with	N	I-Premise
202	increased	N	I-Premise
203	hospital	N	I-Premise
204	admissions	N	I-Premise
205	,	N	I-Premise
206	infections	N	I-Premise
207	or	N	I-Premise
208	fatalities	N	I-Premise
209	.	N	I-Premise

210	Grade	N	I-Premise
211	2-3	N	I-Premise
212	alopecia	N	I-Premise
213	(	N	I-Premise
214	68	N	I-Premise
215	%	N	I-Premise
216	PE	N	I-Premise
217	vs	N	I-Premise
218	17	N	I-Premise
219	%	N	I-Premise
220	GC	N	I-Premise
221	)	N	I-Premise
222	and	N	I-Premise
223	nausea	N	I-Premise
224	(	N	I-Premise
225	43	N	I-Premise
226	%	N	I-Premise
227	PE	N	I-Premise
228	vs	N	I-Premise
229	26	N	I-Premise
230	%	N	I-Premise
231	GC	N	I-Premise
232	)	N	I-Premise
233	were	N	I-Premise
234	more	N	I-Premise
235	frequent	N	I-Premise
236	with	N	I-Premise
237	PE	N	I-Premise
238	.	N	I-Premise

239	Patients	N	O
240	given	N	O
241	GC	N	O
242	received	N	O
243	more	N	O
244	chemotherapy	N	O
245	as	N	O
246	outpatients	N	O
247	(	N	O
248	89	N	O
249	%	N	O
250	GC	N	O
251	vs	N	O
252	66	N	O
253	%	N	O
254	PE	N	O
255	of	N	O
256	treatment	N	O
257	cycles	N	O
258	)	N	O
259	.	N	O

260	In	N	I-Premise
261	QoL	N	I-Premise
262	questionnaires	N	I-Premise
263	,	N	I-Premise
264	more	N	I-Premise
265	patients	N	I-Premise
266	receiving	N	I-Premise
267	PE	N	I-Premise
268	reported	N	I-Premise
269	being	N	I-Premise
270	upset	N	I-Premise
271	by	N	I-Premise
272	hair	N	I-Premise
273	loss	N	I-Premise
274	(	N	I-Premise
275	p	N	I-Premise
276	=	N	I-Premise
277	0.004	N	I-Premise
278	)	N	I-Premise
279	and	N	I-Premise
280	impaired	N	I-Premise
281	cognitive	N	I-Premise
282	functioning	N	I-Premise
283	(	N	I-Premise
284	p	N	I-Premise
285	=	N	I-Premise
286	0.04	N	I-Premise
287	)	N	I-Premise
288	.	N	I-Premise

289	GC	N	I-Claim
290	is	N	I-Claim
291	as	N	I-Claim
292	effective	N	I-Claim
293	as	N	I-Claim
294	PE	N	I-Claim
295	in	N	I-Claim
296	terms	N	I-Claim
297	of	N	I-Claim
298	overall	N	I-Claim
299	survival	N	I-Claim
300	and	N	I-Claim
301	progression-free	N	I-Claim
302	survival	N	I-Claim
303	and	N	I-Claim
304	has	N	I-Claim
305	a	N	I-Claim
306	toxicity	N	I-Claim
307	profile	N	I-Claim
308	more	N	I-Claim
309	acceptable	N	I-Claim
310	to	N	I-Claim
311	patients	N	I-Claim
312	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	effectiveness	N	O
5	of	N	O
6	the	N	O
7	Alleviating	N	O
8	Depression	N	O
9	Among	N	O
10	Patients	N	O
11	With	N	O
12	Cancer	N	O
13	(	N	O
14	ADAPt-C	N	O
15	)	N	O
16	collaborative	N	O
17	care	N	O
18	management	N	O
19	for	N	O
20	major	N	O
21	depression	N	O
22	or	N	O
23	dysthymia	N	O
24	.	N	O

25	Study	N	O
26	patients	N	O
27	included	N	O
28	472	N	O
29	low-income	N	O
30	,	N	O
31	predominantly	N	O
32	female	N	O
33	Hispanic	N	O
34	patients	N	O
35	with	N	O
36	cancer	N	O
37	age	N	O
38	>	N	O
39	or=	N	O
40	18	N	O
41	years	N	O
42	with	N	O
43	major	N	O
44	depression	N	O
45	(	N	O
46	49	N	O
47	%	N	O
48	)	N	O
49	,	N	O
50	dysthymia	N	O
51	(	N	O
52	5	N	O
53	%	N	O
54	)	N	O
55	,	N	O
56	or	N	O
57	both	N	O
58	(	N	O
59	46	N	O
60	%	N	O
61	)	N	O
62	.	N	O

63	Patients	N	O
64	were	N	O
65	randomly	N	O
66	assigned	N	O
67	to	N	O
68	intervention	N	O
69	(	N	O
70	n	N	O
71	=	N	O
72	242	N	O
73	)	N	O
74	or	N	O
75	enhanced	N	O
76	usual	N	O
77	care	N	O
78	(	N	O
79	EUC	N	O
80	;	N	O
81	n	N	O
82	=	N	O
83	230	N	O
84	)	N	O
85	.	N	O

86	Intervention	N	O
87	patients	N	O
88	had	N	O
89	access	N	O
90	for	N	O
91	up	N	O
92	to	N	O
93	12	N	O
94	months	N	O
95	to	N	O
96	a	N	O
97	depression	N	O
98	clinical	N	O
99	specialist	N	O
100	(	N	O
101	supervised	N	O
102	by	N	O
103	a	N	O
104	psychiatrist	N	O
105	)	N	O
106	who	N	O
107	offered	N	O
108	education	N	O
109	,	N	O
110	structured	N	O
111	psychotherapy	N	O
112	,	N	O
113	and	N	O
114	maintenance/relapse	N	O
115	prevention	N	O
116	support	N	O
117	.	N	O

118	The	N	O
119	psychiatrist	N	O
120	prescribed	N	O
121	antidepressant	N	O
122	medications	N	O
123	for	N	O
124	patients	N	O
125	preferring	N	O
126	or	N	O
127	assessed	N	O
128	to	N	O
129	require	N	O
130	medication	N	O
131	.	N	O

132	At	N	I-Premise
133	12	N	I-Premise
134	months	N	I-Premise
135	,	N	I-Premise
136	63	N	I-Premise
137	%	N	I-Premise
138	of	N	I-Premise
139	intervention	N	I-Premise
140	patients	N	I-Premise
141	had	N	I-Premise
142	a	N	I-Premise
143	50	N	I-Premise
144	%	N	I-Premise
145	or	N	I-Premise
146	greater	N	I-Premise
147	reduction	N	I-Premise
148	in	N	I-Premise
149	depressive	N	I-Premise
150	symptoms	N	I-Premise
151	from	N	I-Premise
152	baseline	N	I-Premise
153	as	N	I-Premise
154	assessed	N	I-Premise
155	by	N	I-Premise
156	the	N	I-Premise
157	Patient	N	I-Premise
158	Health	N	I-Premise
159	Questionnaire-9	N	I-Premise
160	(	N	I-Premise
161	PHQ-9	N	I-Premise
162	)	N	I-Premise
163	depression	N	I-Premise
164	scale	N	I-Premise
165	compared	N	I-Premise
166	with	N	I-Premise
167	50	N	I-Premise
168	%	N	I-Premise
169	of	N	I-Premise
170	EUC	N	I-Premise
171	patients	N	I-Premise
172	(	N	I-Premise
173	odds	N	I-Premise
174	ratio	N	I-Premise
175	[	N	I-Premise
176	OR	N	I-Premise
177	]	N	I-Premise
178	=	N	I-Premise
179	1.98	N	I-Premise
180	;	N	I-Premise
181	95	N	I-Premise
182	%	N	I-Premise
183	CI	N	I-Premise
184	,	N	I-Premise
185	1.16	N	I-Premise
186	to	N	I-Premise
187	3.38	N	I-Premise
188	;	N	I-Premise
189	P	N	I-Premise
190	=	N	I-Premise
191	.01	N	I-Premise
192	)	N	I-Premise
193	.	N	I-Premise

194	Improvement	N	I-Premise
195	was	N	I-Premise
196	also	N	I-Premise
197	found	N	I-Premise
198	for	N	I-Premise
199	5-point	N	I-Premise
200	decrease	N	I-Premise
201	in	N	I-Premise
202	PHQ-9	N	I-Premise
203	score	N	I-Premise
204	among	N	I-Premise
205	72.2	N	I-Premise
206	%	N	I-Premise
207	of	N	I-Premise
208	intervention	N	I-Premise
209	patients	N	I-Premise
210	compared	N	I-Premise
211	with	N	I-Premise
212	59.7	N	I-Premise
213	%	N	I-Premise
214	of	N	I-Premise
215	EUC	N	I-Premise
216	patients	N	I-Premise
217	(	N	I-Premise
218	OR	N	I-Premise
219	=	N	I-Premise
220	1.99	N	I-Premise
221	;	N	I-Premise
222	95	N	I-Premise
223	%	N	I-Premise
224	CI	N	I-Premise
225	,	N	I-Premise
226	1.14	N	I-Premise
227	to	N	I-Premise
228	3.50	N	I-Premise
229	;	N	I-Premise
230	P	N	I-Premise
231	=	N	I-Premise
232	.02	N	I-Premise
233	)	N	I-Premise
234	.	N	I-Premise

235	Intervention	N	I-Premise
236	patients	N	I-Premise
237	also	N	I-Premise
238	experienced	N	I-Premise
239	greater	N	I-Premise
240	rates	N	I-Premise
241	of	N	I-Premise
242	depression	N	I-Premise
243	treatment	N	I-Premise
244	(	N	I-Premise
245	72.3	N	I-Premise
246	%	N	I-Premise
247	v	N	I-Premise
248	10.4	N	I-Premise
249	%	N	I-Premise
250	of	N	I-Premise
251	EUC	N	I-Premise
252	patients	N	I-Premise
253	;	N	I-Premise
254	P	N	I-Premise
255	<	N	I-Premise
256	.0001	N	I-Premise
257	)	N	I-Premise
258	and	N	I-Premise
259	significantly	N	I-Premise
260	better	N	I-Premise
261	quality-of-life	N	I-Premise
262	outcomes	N	I-Premise
263	,	N	I-Premise
264	including	N	I-Premise
265	social/family	N	I-Premise
266	(	N	I-Premise
267	adjusted	N	I-Premise
268	mean	N	I-Premise
269	difference	N	I-Premise
270	between	N	I-Premise
271	groups	N	I-Premise
272	,	N	I-Premise
273	2.7	N	I-Premise
274	;	N	I-Premise
275	95	N	I-Premise
276	%	N	I-Premise
277	CI	N	I-Premise
278	,	N	I-Premise
279	1.22	N	I-Premise
280	to	N	I-Premise
281	4.17	N	I-Premise
282	;	N	I-Premise
283	P	N	I-Premise
284	<	N	I-Premise
285	.001	N	I-Premise
286	)	N	I-Premise
287	,	N	I-Premise
288	emotional	N	I-Premise
289	(	N	I-Premise
290	adjusted	N	I-Premise
291	mean	N	I-Premise
292	difference	N	I-Premise
293	,	N	I-Premise
294	1.29	N	I-Premise
295	;	N	I-Premise
296	95	N	I-Premise
297	%	N	I-Premise
298	CI	N	I-Premise
299	,	N	I-Premise
300	0.26	N	I-Premise
301	to	N	I-Premise
302	2.22	N	I-Premise
303	;	N	I-Premise
304	P	N	I-Premise
305	=	N	I-Premise
306	.01	N	I-Premise
307	)	N	I-Premise
308	,	N	I-Premise
309	functional	N	I-Premise
310	(	N	I-Premise
311	adjusted	N	I-Premise
312	mean	N	I-Premise
313	difference	N	I-Premise
314	,	N	I-Premise
315	1.34	N	I-Premise
316	;	N	I-Premise
317	95	N	I-Premise
318	%	N	I-Premise
319	CI	N	I-Premise
320	,	N	I-Premise
321	0.08	N	I-Premise
322	to	N	I-Premise
323	2.59	N	I-Premise
324	;	N	I-Premise
325	P	N	I-Premise
326	=	N	I-Premise
327	.04	N	I-Premise
328	)	N	I-Premise
329	,	N	I-Premise
330	and	N	I-Premise
331	physical	N	I-Premise
332	well-being	N	I-Premise
333	(	N	I-Premise
334	adjusted	N	I-Premise
335	mean	N	I-Premise
336	difference	N	I-Premise
337	,	N	I-Premise
338	2.79	N	I-Premise
339	;	N	I-Premise
340	95	N	I-Premise
341	%	N	I-Premise
342	CI	N	I-Premise
343	,	N	I-Premise
344	0.49	N	I-Premise
345	to	N	I-Premise
346	5.1	N	I-Premise
347	;	N	I-Premise
348	P	N	I-Premise
349	=	N	I-Premise
350	.02	N	I-Premise
351	)	N	I-Premise
352	.	N	I-Premise

353	ADAPt-C	N	I-Claim
354	collaborative	N	I-Claim
355	care	N	I-Claim
356	is	N	I-Claim
357	feasible	N	I-Claim
358	and	N	I-Claim
359	results	N	I-Claim
360	in	N	I-Claim
361	significant	N	I-Claim
362	reduction	N	I-Claim
363	in	N	I-Claim
364	depressive	N	I-Claim
365	symptoms	N	I-Claim
366	,	N	I-Claim
367	improvement	N	I-Claim
368	in	N	I-Claim
369	quality	N	I-Claim
370	of	N	I-Claim
371	life	N	I-Claim
372	,	N	I-Claim
373	and	N	I-Claim
374	lower	N	I-Claim
375	pain	N	I-Claim
376	levels	N	I-Claim
377	compared	N	I-Claim
378	with	N	I-Claim
379	EUC	N	I-Claim
380	for	N	I-Claim
381	patients	N	I-Claim
382	with	N	I-Claim
383	depressive	N	I-Claim
384	disorders	N	I-Claim
385	in	N	I-Claim
386	a	N	I-Claim
387	low-income	N	I-Claim
388	,	N	I-Claim
389	predominantly	N	I-Claim
390	Hispanic	N	I-Claim
391	population	N	I-Claim
392	in	N	I-Claim
393	public	N	I-Claim
394	sector	N	I-Claim
395	oncology	N	I-Claim
396	clinics	N	I-Claim
397	.	N	I-Claim

1	Recombinant	N	O
2	human	N	O
3	TSH	N	O
4	(	N	O
5	rhTSH	N	O
6	)	N	O
7	has	N	O
8	become	N	O
9	the	N	O
10	modality	N	O
11	of	N	O
12	choice	N	O
13	for	N	O
14	radioiodine	N	O
15	remnant	N	O
16	ablation	N	O
17	(	N	O
18	RRA	N	O
19	)	N	O
20	in	N	O
21	low-risk	N	O
22	thyroid	N	O
23	cancer	N	O
24	patients	N	O
25	.	N	O

26	The	N	O
27	aims	N	O
28	of	N	O
29	the	N	O
30	present	N	O
31	prospective	N	O
32	randomized	N	O
33	study	N	O
34	were	N	O
35	to	N	O
36	evaluate	N	O
37	the	N	O
38	impact	N	O
39	of	N	O
40	TSH	N	O
41	stimulation	N	O
42	procedure	N	O
43	(	N	O
44	hypothyroidism	N	O
45	vs.	N	O
46	rhTSH	N	O
47	)	N	O
48	on	N	O
49	quality	N	O
50	of	N	O
51	life	N	O
52	(	N	O
53	QoL	N	O
54	)	N	O
55	of	N	O
56	thyroid	N	O
57	cancer	N	O
58	patients	N	O
59	undergoing	N	O
60	RRA	N	O
61	and	N	O
62	to	N	O
63	evaluate	N	O
64	efficacy	N	O
65	of	N	O
66	both	N	O
67	procedures	N	O
68	.	N	O

69	L-T4	N	O
70	was	N	O
71	initiated	N	O
72	in	N	O
73	both	N	O
74	groups	N	O
75	after	N	O
76	thyroidectomy	N	O
77	.	N	O

78	After	N	O
79	randomization	N	O
80	,	N	O
81	L-T4	N	O
82	was	N	O
83	discontinued	N	O
84	in	N	O
85	hypothyroid	N	O
86	(	N	O
87	hypo	N	O
88	)	N	O
89	group	N	O
90	and	N	O
91	continued	N	O
92	in	N	O
93	rhTSH	N	O
94	group	N	O
95	.	N	O

96	A	N	O
97	measure	N	O
98	of	N	O
99	3.7	N	O
100	GBq	N	O
101	of	N	O
102	radioiodine	N	O
103	was	N	O
104	given	N	O
105	to	N	O
106	both	N	O
107	groups	N	O
108	.	N	O

109	The	N	O
110	functional	N	O
111	assessment	N	O
112	of	N	O
113	chronic	N	O
114	illness	N	O
115	therapy-fatigue	N	O
116	(	N	O
117	FACIT-F	N	O
118	)	N	O
119	was	N	O
120	administered	N	O
121	from	N	O
122	the	N	O
123	early	N	O
124	postoperative	N	O
125	period	N	O
126	to	N	O
127	9	N	O
128	months	N	O
129	.	N	O

130	Socio-demographic	N	O
131	parameters	N	O
132	,	N	O
133	anxiety	N	O
134	and	N	O
135	depression	N	O
136	scales	N	O
137	were	N	O
138	also	N	O
139	evaluated	N	O
140	(	N	O
141	CES-D	N	O
142	,	N	O
143	BDI	N	O
144	and	N	O
145	Spielberger	N	O
146	state-trait	N	O
147	questionnaires	N	O
148	)	N	O
149	.	N	O

150	At	N	O
151	9	N	O
152	months	N	O
153	,	N	O
154	patients	N	O
155	underwent	N	O
156	an	N	O
157	rhTSH	N	O
158	stimulation	N	O
159	test	N	O
160	,	N	O
161	diagnostic	N	O
162	(	N	O
163	131	N	O
164	)	N	O
165	I	N	O
166	whole	N	O
167	body	N	O
168	scan	N	O
169	(	N	O
170	dxWBS	N	O
171	)	N	O
172	and	N	O
173	neck	N	O
174	ultrasonography	N	O
175	.	N	O

176	A	N	O
177	total	N	O
178	of	N	O
179	74	N	O
180	patients	N	O
181	were	N	O
182	enrolled	N	O
183	for	N	O
184	the	N	O
185	study	N	O
186	.	N	O

187	There	N	I-Premise
188	was	N	I-Premise
189	a	N	I-Premise
190	significant	N	I-Premise
191	decrease	N	I-Premise
192	in	N	I-Premise
193	QoL	N	I-Premise
194	from	N	I-Premise
195	baseline	N	I-Premise
196	(	N	I-Premise
197	t0	N	I-Premise
198	)	N	I-Premise
199	to	N	I-Premise
200	t1	N	I-Premise
201	(	N	I-Premise
202	RRA	N	I-Premise
203	period	N	I-Premise
204	)	N	I-Premise
205	in	N	I-Premise
206	the	N	I-Premise
207	hypothyroid	N	I-Premise
208	group	N	I-Premise
209	with	N	I-Premise
210	significant	N	I-Premise
211	differences	N	I-Premise
212	in	N	I-Premise
213	FACIT-F	N	I-Premise
214	TOI	N	I-Premise
215	(	N	I-Premise
216	P	N	I-Premise
217	<	N	I-Premise
218	10	N	I-Premise
219	(	N	I-Premise
220	-3	N	I-Premise
221	)	N	I-Premise
222	)	N	I-Premise
223	,	N	I-Premise
224	FACT-G	N	I-Premise
225	total	N	I-Premise
226	score	N	I-Premise
227	(	N	I-Premise
228	P	N	I-Premise
229	=	N	I-Premise
230	0.005	N	I-Premise
231	)	N	I-Premise
232	and	N	I-Premise
233	FACIT-F	N	I-Premise
234	total	N	I-Premise
235	score	N	I-Premise
236	(	N	I-Premise
237	P	N	I-Premise
238	=	N	I-Premise
239	0.003	N	I-Premise
240	)	N	I-Premise
241	.	N	I-Premise

242	By	N	I-Premise
243	contrast	N	I-Premise
244	,	N	I-Premise
245	QoL	N	I-Premise
246	was	N	I-Premise
247	preserved	N	I-Premise
248	in	N	I-Premise
249	the	N	I-Premise
250	rhTSH	N	I-Premise
251	group	N	I-Premise
252	.	N	I-Premise

253	In	N	O
254	the	N	O
255	multivariate	N	O
256	analysis	N	O
257	,	N	O
258	FACIT-TOI	N	O
259	changes	N	O
260	were	N	O
261	only	N	O
262	affected	N	O
263	by	N	O
264	the	N	O
265	modality	N	O
266	of	N	O
267	TSH	N	O
268	stimulation	N	O
269	performed	N	O
270	for	N	O
271	RRA	N	O
272	.	N	O

273	From	N	I-Premise
274	3	N	I-Premise
275	to	N	I-Premise
276	9	N	I-Premise
277	months	N	I-Premise
278	,	N	I-Premise
279	changes	N	I-Premise
280	of	N	I-Premise
281	QoL	N	I-Premise
282	scales	N	I-Premise
283	and	N	I-Premise
284	subscales	N	I-Premise
285	were	N	I-Premise
286	no	N	I-Premise
287	longer	N	I-Premise
288	statistically	N	I-Premise
289	different	N	I-Premise
290	in	N	I-Premise
291	both	N	I-Premise
292	groups	N	I-Premise
293	of	N	I-Premise
294	patients	N	I-Premise
295	.	N	I-Premise

296	Based	N	I-Premise
297	on	N	I-Premise
298	serum	N	I-Premise
299	rhTSH-stimulated	N	I-Premise
300	Tg	N	I-Premise
301	alone	N	I-Premise
302	(	N	I-Premise
303	Tg	N	I-Premise
304	<	N	I-Premise
305	0.8	N	I-Premise
306	microg/l	N	I-Premise
307	,	N	I-Premise
308	BRAHMS	N	I-Premise
309	Tg	N	I-Premise
310	Kryptor	N	I-Premise
311	)	N	I-Premise
312	,	N	I-Premise
313	no	N	I-Premise
314	difference	N	I-Premise
315	in	N	I-Premise
316	ablation	N	I-Premise
317	success	N	I-Premise
318	was	N	I-Premise
319	observed	N	I-Premise
320	between	N	I-Premise
321	rhTSH	N	I-Premise
322	and	N	I-Premise
323	hypothyroidism	N	I-Premise
324	groups	N	I-Premise
325	,	N	I-Premise
326	91.7	N	I-Premise
327	%	N	I-Premise
328	and	N	I-Premise
329	97.1	N	I-Premise
330	%	N	I-Premise
331	,	N	I-Premise
332	respectively	N	I-Premise
333	.	N	I-Premise

334	A	N	I-Premise
335	higher	N	I-Premise
336	rate	N	I-Premise
337	of	N	I-Premise
338	persistent	N	I-Premise
339	thyroid	N	I-Premise
340	remnants	N	I-Premise
341	was	N	I-Premise
342	observed	N	I-Premise
343	in	N	I-Premise
344	the	N	I-Premise
345	rhTSH	N	I-Premise
346	arm	N	I-Premise
347	,	N	I-Premise
348	although	N	I-Premise
349	in	N	I-Premise
350	most	N	I-Premise
351	cases	N	I-Premise
352	uptake	N	I-Premise
353	was	N	I-Premise
354	<	N	I-Premise
355	0.1	N	I-Premise
356	%	N	I-Premise
357	and	N	I-Premise
358	of	N	I-Premise
359	no	N	I-Premise
360	clinical	N	I-Premise
361	significance	N	I-Premise
362	.	N	I-Premise

363	rhTSH	N	I-Claim
364	preserves	N	I-Claim
365	QoL	N	I-Claim
366	of	N	I-Claim
367	patients	N	I-Claim
368	undergoing	N	I-Claim
369	RRA	N	I-Claim
370	with	N	I-Claim
371	similar	N	I-Claim
372	rates	N	I-Claim
373	of	N	I-Claim
374	ablation	N	I-Claim
375	success	N	I-Claim
376	compared	N	I-Claim
377	to	N	I-Claim
378	hypothyrodism	N	I-Claim
379	.	N	I-Claim

380	However	N	O
381	,	N	O
382	there	N	O
383	is	N	O
384	a	N	O
385	wide	N	O
386	heterogeneity	N	O
387	in	N	O
388	the	N	O
389	clinical	N	O
390	impact	N	O
391	of	N	O
392	hypothyroidism	N	O
393	.	N	O

1	Hot	N	I-MajorClaim
2	flashes	N	I-MajorClaim
3	are	N	I-MajorClaim
4	a	N	I-MajorClaim
5	significant	N	I-MajorClaim
6	problem	N	I-MajorClaim
7	for	N	I-MajorClaim
8	many	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	survivors	N	I-MajorClaim
12	.	N	I-MajorClaim

13	Hot	N	I-MajorClaim
14	flashes	N	I-MajorClaim
15	can	N	I-MajorClaim
16	cause	N	I-MajorClaim
17	discomfort	N	I-MajorClaim
18	,	N	I-MajorClaim
19	disrupted	N	I-MajorClaim
20	sleep	N	I-MajorClaim
21	,	N	I-MajorClaim
22	anxiety	N	I-MajorClaim
23	,	N	I-MajorClaim
24	and	N	I-MajorClaim
25	decreased	N	I-MajorClaim
26	quality	N	I-MajorClaim
27	of	N	I-MajorClaim
28	life	N	I-MajorClaim
29	.	N	I-MajorClaim

30	A	N	O
31	well-tolerated	N	O
32	and	N	O
33	effective	N	O
34	mind-body	N	O
35	treatment	N	O
36	for	N	O
37	hot	N	O
38	flashes	N	O
39	would	N	O
40	be	N	O
41	of	N	O
42	great	N	O
43	value	N	O
44	.	N	O

45	On	N	O
46	the	N	O
47	basis	N	O
48	of	N	O
49	previous	N	O
50	case	N	O
51	studies	N	O
52	,	N	O
53	this	N	O
54	study	N	O
55	was	N	O
56	developed	N	O
57	to	N	O
58	evaluate	N	O
59	the	N	O
60	effect	N	O
61	of	N	O
62	a	N	O
63	hypnosis	N	O
64	intervention	N	O
65	for	N	O
66	hot	N	O
67	flashes	N	O
68	.	N	O

69	Sixty	N	O
70	female	N	O
71	breast	N	O
72	cancer	N	O
73	survivors	N	O
74	with	N	O
75	hot	N	O
76	flashes	N	O
77	were	N	O
78	randomly	N	O
79	assigned	N	O
80	to	N	O
81	receive	N	O
82	hypnosis	N	O
83	intervention	N	O
84	(	N	O
85	five	N	O
86	weekly	N	O
87	sessions	N	O
88	)	N	O
89	or	N	O
90	no	N	O
91	treatment	N	O
92	.	N	O

93	Eligible	N	O
94	patients	N	O
95	had	N	O
96	to	N	O
97	have	N	O
98	a	N	O
99	history	N	O
100	of	N	O
101	primary	N	O
102	breast	N	O
103	cancer	N	O
104	without	N	O
105	evidence	N	O
106	of	N	O
107	detectable	N	O
108	disease	N	O
109	and	N	O
110	14	N	O
111	or	N	O
112	more	N	O
113	weekly	N	O
114	hot	N	O
115	flashes	N	O
116	for	N	O
117	at	N	O
118	least	N	O
119	1	N	O
120	month	N	O
121	.	N	O

122	The	N	O
123	major	N	O
124	outcome	N	O
125	measure	N	O
126	was	N	O
127	a	N	O
128	bivariate	N	O
129	construct	N	O
130	that	N	O
131	represented	N	O
132	hot	N	O
133	flash	N	O
134	frequency	N	O
135	and	N	O
136	hot	N	O
137	flash	N	O
138	score	N	O
139	,	N	O
140	which	N	O
141	was	N	O
142	analyzed	N	O
143	by	N	O
144	a	N	O
145	classic	N	O
146	sums	N	O
147	and	N	O
148	differences	N	O
149	comparison	N	O
150	.	N	O

151	Secondary	N	O
152	outcome	N	O
153	measures	N	O
154	were	N	O
155	self-reports	N	O
156	of	N	O
157	interference	N	O
158	of	N	O
159	hot	N	O
160	flashes	N	O
161	on	N	O
162	daily	N	O
163	activities	N	O
164	.	N	O

165	Fifty-one	N	O
166	randomly	N	O
167	assigned	N	O
168	women	N	O
169	completed	N	O
170	the	N	O
171	study	N	O
172	.	N	O

173	By	N	I-Premise
174	the	N	I-Premise
175	end	N	I-Premise
176	of	N	I-Premise
177	the	N	I-Premise
178	treatment	N	I-Premise
179	period	N	I-Premise
180	,	N	I-Premise
181	hot	N	I-Premise
182	flash	N	I-Premise
183	scores	N	I-Premise
184	(	N	I-Premise
185	frequency	N	I-Premise
186	x	N	I-Premise
187	average	N	I-Premise
188	severity	N	I-Premise
189	)	N	I-Premise
190	decreased	N	I-Premise
191	68	N	I-Premise
192	%	N	I-Premise
193	from	N	I-Premise
194	baseline	N	I-Premise
195	to	N	I-Premise
196	end	N	I-Premise
197	point	N	I-Premise
198	in	N	I-Premise
199	the	N	I-Premise
200	hypnosis	N	I-Premise
201	arm	N	I-Premise
202	(	N	I-Premise
203	P	N	I-Premise
204	<	N	I-Premise
205	.001	N	I-Premise
206	)	N	I-Premise
207	.	N	I-Premise

208	Significant	N	I-Premise
209	improvements	N	I-Premise
210	in	N	I-Premise
211	self-reported	N	I-Premise
212	anxiety	N	I-Premise
213	,	N	I-Premise
214	depression	N	I-Premise
215	,	N	I-Premise
216	interference	N	I-Premise
217	of	N	I-Premise
218	hot	N	I-Premise
219	flashes	N	I-Premise
220	on	N	I-Premise
221	daily	N	I-Premise
222	activities	N	I-Premise
223	,	N	I-Premise
224	and	N	I-Premise
225	sleep	N	I-Premise
226	were	N	I-Premise
227	observed	N	I-Premise
228	for	N	I-Premise
229	patients	N	I-Premise
230	who	N	I-Premise
231	received	N	I-Premise
232	the	N	I-Premise
233	hypnosis	N	I-Premise
234	intervention	N	I-Premise
235	(	N	I-Premise
236	P	N	I-Premise
237	<	N	I-Premise
238	.005	N	I-Premise
239	)	N	I-Premise
240	in	N	I-Premise
241	comparison	N	I-Premise
242	to	N	I-Premise
243	the	N	I-Premise
244	no	N	I-Premise
245	treatment	N	I-Premise
246	control	N	I-Premise
247	group	N	I-Premise
248	.	N	I-Premise

249	Hypnosis	N	I-Claim
250	appears	N	I-Claim
251	to	N	I-Claim
252	reduce	N	I-Claim
253	perceived	N	I-Claim
254	hot	N	I-Claim
255	flashes	N	I-Claim
256	in	N	I-Claim
257	breast	N	I-Claim
258	cancer	N	I-Claim
259	survivors	N	I-Claim
260	and	N	I-Claim
261	may	N	I-Claim
262	have	N	I-Claim
263	additional	N	I-Claim
264	benefits	N	I-Claim
265	such	N	I-Claim
266	as	N	I-Claim
267	reduced	N	I-Claim
268	anxiety	N	I-Claim
269	and	N	I-Claim
270	depression	N	I-Claim
271	,	N	I-Claim
272	and	N	I-Claim
273	improved	N	I-Claim
274	sleep	N	I-Claim
275	.	N	I-Claim

1	Adjuvant	N	O
2	chemotherapy	N	O
3	for	N	O
4	early	N	O
5	stage	N	O
6	non-small-cell	N	O
7	lung	N	O
8	cancer	N	O
9	(	N	O
10	NSCLC	N	O
11	)	N	O
12	is	N	O
13	now	N	O
14	the	N	O
15	standard	N	O
16	of	N	O
17	care	N	O
18	,	N	O
19	but	N	O
20	there	N	O
21	is	N	O
22	little	N	O
23	information	N	O
24	regarding	N	O
25	its	N	O
26	impact	N	O
27	on	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	(	N	O
32	QOL	N	O
33	)	N	O
34	.	N	O

35	We	N	O
36	report	N	O
37	the	N	O
38	QOL	N	O
39	results	N	O
40	of	N	O
41	JBR.10	N	O
42	,	N	O
43	a	N	O
44	North	N	O
45	American	N	O
46	,	N	O
47	intergroup	N	O
48	,	N	O
49	randomized	N	O
50	trial	N	O
51	of	N	O
52	adjuvant	N	O
53	cisplatin	N	O
54	and	N	O
55	vinorelbine	N	O
56	compared	N	O
57	with	N	O
58	observation	N	O
59	in	N	O
60	patients	N	O
61	who	N	O
62	have	N	O
63	completely	N	O
64	resected	N	O
65	,	N	O
66	stages	N	O
67	IB	N	O
68	to	N	O
69	II	N	O
70	NSCLC	N	O
71	.	N	O

72	QOL	N	O
73	was	N	O
74	assessed	N	O
75	with	N	O
76	the	N	O
77	European	N	O
78	Organisation	N	O
79	for	N	O
80	Research	N	O
81	and	N	O
82	Treatment	N	O
83	of	N	O
84	Cancer	N	O
85	Quality	N	O
86	of	N	O
87	Life	N	O
88	Questionnaire	N	O
89	C30	N	O
90	and	N	O
91	a	N	O
92	trial-specific	N	O
93	checklist	N	O
94	at	N	O
95	baseline	N	O
96	and	N	O
97	at	N	O
98	weeks	N	O
99	5	N	O
100	and	N	O
101	9	N	O
102	for	N	O
103	those	N	O
104	who	N	O
105	received	N	O
106	chemotherapy	N	O
107	and	N	O
108	at	N	O
109	follow-up	N	O
110	months	N	O
111	3	N	O
112	,	N	O
113	6	N	O
114	,	N	O
115	9	N	O
116	,	N	O
117	12	N	O
118	,	N	O
119	18	N	O
120	,	N	O
121	24	N	O
122	,	N	O
123	30	N	O
124	and	N	O
125	36	N	O
126	.	N	O

127	A	N	O
128	10-point	N	O
129	change	N	O
130	in	N	O
131	QOL	N	O
132	scores	N	O
133	from	N	O
134	baseline	N	O
135	was	N	O
136	considered	N	O
137	clinically	N	O
138	significant	N	O
139	.	N	O

140	Four	N	O
141	hundred	N	O
142	eighty-two	N	O
143	patients	N	O
144	were	N	O
145	randomly	N	O
146	assigned	N	O
147	on	N	O
148	JBR.10	N	O
149	.	N	O

150	A	N	O
151	total	N	O
152	of	N	O
153	173	N	O
154	patients	N	O
155	(	N	O
156	82	N	O
157	%	N	O
158	of	N	O
159	the	N	O
160	expected	N	O
161	)	N	O
162	in	N	O
163	the	N	O
164	observation	N	O
165	arm	N	O
166	and	N	O
167	186	N	O
168	(	N	O
169	85	N	O
170	%	N	O
171	of	N	O
172	expected	N	O
173	)	N	O
174	in	N	O
175	the	N	O
176	chemotherapy	N	O
177	arm	N	O
178	completed	N	O
179	baseline	N	O
180	QOL	N	O
181	assessments	N	O
182	.	N	O

183	The	N	I-Premise
184	two	N	I-Premise
185	groups	N	I-Premise
186	were	N	I-Premise
187	comparable	N	I-Premise
188	,	N	I-Premise
189	with	N	I-Premise
190	low	N	I-Premise
191	global	N	I-Premise
192	QOL	N	I-Premise
193	scores	N	I-Premise
194	and	N	I-Premise
195	significant	N	I-Premise
196	symptom	N	I-Premise
197	burden	N	I-Premise
198	,	N	I-Premise
199	especially	N	I-Premise
200	pain	N	I-Premise
201	and	N	I-Premise
202	fatigue	N	I-Premise
203	,	N	I-Premise
204	after	N	I-Premise
205	thoracotomy	N	I-Premise
206	.	N	I-Premise

207	Changes	N	O
208	in	N	O
209	QOL	N	O
210	during	N	O
211	chemotherapy	N	O
212	were	N	O
213	relatively	N	O
214	modest	N	O
215	;	N	O
216	fatigue	N	I-Premise
217	,	N	I-Premise
218	nausea	N	I-Premise
219	,	N	I-Premise
220	and	N	I-Premise
221	vomiting	N	I-Premise
222	worsened	N	I-Premise
223	,	N	I-Premise
224	but	N	I-Premise
225	there	N	I-Premise
226	was	N	I-Premise
227	a	N	I-Premise
228	reduction	N	I-Premise
229	in	N	I-Premise
230	pain	N	I-Premise
231	and	N	I-Premise
232	no	N	I-Premise
233	change	N	I-Premise
234	in	N	I-Premise
235	global	N	I-Premise
236	QOL	N	I-Premise
237	.	N	I-Premise

238	Patients	N	I-Premise
239	in	N	I-Premise
240	the	N	I-Premise
241	observation	N	I-Premise
242	arm	N	I-Premise
243	showed	N	I-Premise
244	considerable	N	I-Premise
245	improvements	N	I-Premise
246	in	N	I-Premise
247	QOL	N	I-Premise
248	by	N	I-Premise
249	3	N	I-Premise
250	months	N	I-Premise
251	.	N	I-Premise

252	QOL	N	I-Premise
253	,	N	I-Premise
254	except	N	I-Premise
255	for	N	I-Premise
256	symptoms	N	I-Premise
257	of	N	I-Premise
258	sensory	N	I-Premise
259	neuropathy	N	I-Premise
260	and	N	I-Premise
261	hearing	N	I-Premise
262	loss	N	I-Premise
263	,	N	I-Premise
264	in	N	I-Premise
265	those	N	I-Premise
266	treated	N	I-Premise
267	with	N	I-Premise
268	chemotherapy	N	I-Premise
269	returned	N	I-Premise
270	to	N	I-Premise
271	baseline	N	I-Premise
272	by	N	I-Premise
273	9	N	I-Premise
274	months	N	I-Premise
275	.	N	I-Premise

276	The	N	I-Claim
277	findings	N	I-Claim
278	of	N	I-Claim
279	this	N	I-Claim
280	trial	N	I-Claim
281	indicate	N	I-Claim
282	that	N	I-Claim
283	the	N	I-Claim
284	negative	N	I-Claim
285	effects	N	I-Claim
286	of	N	I-Claim
287	adjuvant	N	I-Claim
288	chemotherapy	N	I-Claim
289	on	N	I-Claim
290	QOL	N	I-Claim
291	appear	N	I-Claim
292	to	N	I-Claim
293	be	N	I-Claim
294	temporary	N	I-Claim
295	,	N	I-Claim
296	and	N	I-Claim
297	that	N	I-Claim
298	improvements	N	I-Claim
299	(	N	I-Claim
300	with	N	I-Claim
301	a	N	I-Claim
302	return	N	I-Claim
303	to	N	I-Claim
304	baseline	N	I-Claim
305	function	N	I-Claim
306	)	N	I-Claim
307	are	N	I-Claim
308	likely	N	I-Claim
309	in	N	I-Claim
310	most	N	I-Claim
311	patients	N	I-Claim
312	.	N	I-Claim

1	The	N	O
2	physiological	N	O
3	and	N	O
4	psychological	N	O
5	stress	N	O
6	that	N	O
7	brain	N	O
8	tumor	N	O
9	patients	N	O
10	undergo	N	O
11	during	N	O
12	the	N	O
13	entire	N	O
14	surgical	N	O
15	experience	N	O
16	can	N	O
17	considerably	N	O
18	affect	N	O
19	several	N	O
20	aspects	N	O
21	of	N	O
22	their	N	O
23	hospitalization	N	O
24	.	N	O

25	The	N	O
26	purpose	N	O
27	of	N	O
28	this	N	O
29	study	N	O
30	was	N	O
31	to	N	O
32	examine	N	O
33	the	N	O
34	effects	N	O
35	of	N	O
36	live	N	O
37	music	N	O
38	therapy	N	O
39	on	N	O
40	quality	N	O
41	of	N	O
42	life	N	O
43	indicators	N	O
44	,	N	O
45	amount	N	O
46	of	N	O
47	medications	N	O
48	administered	N	O
49	and	N	O
50	length	N	O
51	of	N	O
52	stay	N	O
53	for	N	O
54	persons	N	O
55	receiving	N	O
56	elective	N	O
57	surgical	N	O
58	procedures	N	O
59	of	N	O
60	the	N	O
61	brain	N	O
62	.	N	O

63	Subjects	N	O
64	(	N	O
65	N	N	O
66	=	N	O
67	27	N	O
68	)	N	O
69	were	N	O
70	patients	N	O
71	admitted	N	O
72	for	N	O
73	some	N	O
74	type	N	O
75	of	N	O
76	surgical	N	O
77	procedure	N	O
78	of	N	O
79	the	N	O
80	brain	N	O
81	.	N	O

82	Subjects	N	O
83	were	N	O
84	randomly	N	O
85	assigned	N	O
86	to	N	O
87	either	N	O
88	the	N	O
89	control	N	O
90	group	N	O
91	receiving	N	O
92	no	N	O
93	music	N	O
94	intervention	N	O
95	(	N	O
96	n	N	O
97	=	N	O
98	13	N	O
99	)	N	O
100	or	N	O
101	the	N	O
102	experimental	N	O
103	group	N	O
104	receiving	N	O
105	pre	N	O
106	and	N	O
107	postoperative	N	O
108	live	N	O
109	music	N	O
110	therapy	N	O
111	sessions	N	O
112	(	N	O
113	n	N	O
114	=	N	O
115	14	N	O
116	)	N	O
117	.	N	O

118	Anxiety	N	O
119	,	N	O
120	mood	N	O
121	,	N	O
122	pain	N	O
123	,	N	O
124	perception	N	O
125	of	N	O
126	hospitalization	N	O
127	or	N	O
128	procedure	N	O
129	,	N	O
130	relaxation	N	O
131	,	N	O
132	and	N	O
133	stress	N	O
134	were	N	O
135	measured	N	O
136	using	N	O
137	a	N	O
138	self-report	N	O
139	Visual	N	O
140	Analog	N	O
141	Scale	N	O
142	(	N	O
143	VAS	N	O
144	)	N	O
145	for	N	O
146	each	N	O
147	of	N	O
148	the	N	O
149	variables	N	O
150	.	N	O

151	The	N	O
152	documented	N	O
153	administration	N	O
154	of	N	O
155	postoperative	N	O
156	pain	N	O
157	medications	N	O
158	;	N	O
159	the	N	O
160	frequency	N	O
161	,	N	O
162	dosage	N	O
163	,	N	O
164	type	N	O
165	,	N	O
166	and	N	O
167	how	N	O
168	it	N	O
169	was	N	O
170	given	N	O
171	was	N	O
172	also	N	O
173	compared	N	O
174	between	N	O
175	groups	N	O
176	.	N	O

177	Experimental	N	O
178	subjects	N	O
179	live	N	O
180	and	N	O
181	interactive	N	O
182	music	N	O
183	therapy	N	O
184	sessions	N	O
185	,	N	O
186	including	N	O
187	a	N	O
188	pre-operative	N	O
189	session	N	O
190	and	N	O
191	continuing	N	O
192	with	N	O
193	daily	N	O
194	sessions	N	O
195	until	N	O
196	the	N	O
197	patient	N	O
198	was	N	O
199	discharged	N	O
200	home	N	O
201	.	N	O

202	Control	N	O
203	subjects	N	O
204	received	N	O
205	routine	N	O
206	hospital	N	O
207	care	N	O
208	without	N	O
209	any	N	O
210	music	N	O
211	therapy	N	O
212	intervention	N	O
213	.	N	O

214	Differences	N	O
215	in	N	O
216	experimental	N	O
217	pretest	N	O
218	and	N	O
219	posttest	N	O
220	scores	N	O
221	were	N	O
222	analyzed	N	O
223	using	N	O
224	a	N	O
225	Wilcoxon	N	O
226	Matched-Pairs	N	O
227	Signed-Rank	N	O
228	test	N	O
229	.	N	O

230	Results	N	I-Premise
231	indicated	N	I-Premise
232	statistically	N	I-Premise
233	significant	N	I-Premise
234	differences	N	I-Premise
235	for	N	I-Premise
236	4	N	I-Premise
237	of	N	I-Premise
238	the	N	I-Premise
239	6	N	I-Premise
240	quality	N	I-Premise
241	of	N	I-Premise
242	life	N	I-Premise
243	measures	N	I-Premise
244	:	N	I-Premise
245	anxiety	N	I-Premise
246	(	N	I-Premise
247	p	N	I-Premise
248	=	N	I-Premise
249	.03	N	I-Premise
250	)	N	I-Premise
251	,	N	I-Premise
252	perception	N	I-Premise
253	of	N	I-Premise
254	hospitalization	N	I-Premise
255	(	N	I-Premise
256	p	N	I-Premise
257	=	N	I-Premise
258	.03	N	I-Premise
259	)	N	I-Premise
260	,	N	I-Premise
261	relaxation	N	I-Premise
262	(	N	I-Premise
263	p	N	I-Premise
264	=	N	I-Premise
265	.001	N	I-Premise
266	)	N	I-Premise
267	,	N	I-Premise
268	and	N	I-Premise
269	stress	N	I-Premise
270	(	N	I-Premise
271	p	N	I-Premise
272	=	N	I-Premise
273	.001	N	I-Premise
274	)	N	I-Premise
275	.	N	I-Premise

276	No	N	I-Premise
277	statistically	N	I-Premise
278	significant	N	I-Premise
279	differences	N	I-Premise
280	were	N	I-Premise
281	found	N	I-Premise
282	for	N	I-Premise
283	mood	N	I-Premise
284	(	N	I-Premise
285	p	N	I-Premise
286	>	N	I-Premise
287	.05	N	I-Premise
288	)	N	I-Premise
289	or	N	I-Premise
290	pain	N	I-Premise
291	(	N	I-Premise
292	p	N	I-Premise
293	>	N	I-Premise
294	.05	N	I-Premise
295	)	N	I-Premise
296	levels	N	I-Premise
297	.	N	I-Premise

298	Administration	N	O
299	amounts	N	O
300	of	N	O
301	nausea	N	O
302	and	N	O
303	pain	N	O
304	medications	N	O
305	were	N	O
306	compared	N	O
307	with	N	O
308	a	N	O
309	Two-Way	N	O
310	ANOVA	N	O
311	with	N	O
312	One	N	O
313	Repeated	N	O
314	Measure	N	O
315	resulting	N	O
316	in	N	O
317	no	N	O
318	significant	N	O
319	differences	N	O
320	between	N	O
321	groups	N	O
322	and	N	O
323	medications	N	O
324	,	N	O
325	F	N	O
326	(	N	O
327	1	N	O
328	,	N	O
329	51	N	O
330	)	N	O
331	=	N	O
332	0.03	N	O
333	;	N	O
334	p	N	O
335	>	N	O
336	.05	N	O
337	.	N	O

338	Results	N	O
339	indicate	N	O
340	no	N	O
341	significant	N	O
342	differences	N	O
343	between	N	O
344	groups	N	O
345	for	N	O
346	length	N	O
347	of	N	O
348	stay	N	O
349	(	N	O
350	t	N	O
351	=	N	O
352	.97	N	O
353	,	N	O
354	df	N	O
355	=	N	O
356	25	N	O
357	,	N	O
358	p	N	O
359	>	N	O
360	.05	N	O
361	)	N	O
362	.	N	O

363	This	N	I-Claim
364	research	N	I-Claim
365	study	N	I-Claim
366	indicates	N	I-Claim
367	that	N	I-Claim
368	live	N	I-Claim
369	music	N	I-Claim
370	therapy	N	I-Claim
371	using	N	I-Claim
372	patient-preferred	N	I-Claim
373	music	N	I-Claim
374	can	N	I-Claim
375	be	N	I-Claim
376	beneficial	N	I-Claim
377	in	N	I-Claim
378	improving	N	I-Claim
379	quality	N	I-Claim
380	of	N	I-Claim
381	life	N	I-Claim
382	indicators	N	I-Claim
383	such	N	I-Claim
384	as	N	I-Claim
385	anxiety	N	I-Claim
386	,	N	I-Claim
387	perception	N	I-Claim
388	of	N	I-Claim
389	the	N	I-Claim
390	hospitalization	N	I-Claim
391	or	N	I-Claim
392	procedure	N	I-Claim
393	,	N	I-Claim
394	relaxation	N	I-Claim
395	,	N	I-Claim
396	and	N	I-Claim
397	stress	N	I-Claim
398	in	N	I-Claim
399	patients	N	I-Claim
400	undergoing	N	I-Claim
401	surgical	N	I-Claim
402	procedures	N	I-Claim
403	of	N	I-Claim
404	the	N	I-Claim
405	brain	N	I-Claim
406	.	N	I-Claim

1	Many	N	O
2	women	N	O
3	with	N	O
4	breast	N	O
5	cancer	N	O
6	need	N	O
7	psychological	N	O
8	help	N	O
9	to	N	O
10	cope	N	O
11	more	N	O
12	effectively	N	O
13	after	N	O
14	treatment	N	O
15	.	N	O

16	Cognitive	N	O
17	and	N	O
18	behavioural	N	O
19	techniques	N	O
20	are	N	O
21	not	N	O
22	yet	N	O
23	well	N	O
24	established	N	O
25	in	N	O
26	France	N	O
27	.	N	O

28	A	N	O
29	multi-site	N	O
30	randomized	N	O
31	study	N	O
32	was	N	O
33	conducted	N	O
34	to	N	O
35	evaluate	N	O
36	the	N	O
37	effects	N	O
38	of	N	O
39	a	N	O
40	psycho-educational	N	O
41	group	N	O
42	intervention	N	O
43	in	N	O
44	this	N	O
45	population	N	O
46	.	N	O

47	Two	N	O
48	hundred	N	O
49	and	N	O
50	three	N	O
51	patients	N	O
52	,	N	O
53	recruited	N	O
54	after	N	O
55	primary	N	O
56	treatment	N	O
57	,	N	O
58	were	N	O
59	randomly	N	O
60	assigned	N	O
61	either	N	O
62	to	N	O
63	a	N	O
64	treatment	N	O
65	group	N	O
66	(	N	O
67	psycho-educational	N	O
68	intervention	N	O
69	)	N	O
70	or	N	O
71	to	N	O
72	a	N	O
73	waiting-list	N	O
74	control	N	O
75	group	N	O
76	.	N	O

77	The	N	O
78	8-week	N	O
79	programme	N	O
80	of	N	O
81	2	N	O
82	h	N	O
83	sessions	N	O
84	comprised	N	O
85	of	N	O
86	thematic	N	O
87	discussions	N	O
88	,	N	O
89	information	N	O
90	and	N	O
91	training	N	O
92	in	N	O
93	stress	N	O
94	management	N	O
95	techniques	N	O
96	.	N	O

97	Evaluation	N	O
98	at	N	O
99	baseline	N	O
100	,	N	O
101	after	N	O
102	8	N	O
103	sessions	N	O
104	,	N	O
105	and	N	O
106	1	N	O
107	month	N	O
108	after	N	O
109	programme	N	O
110	completion	N	O
111	,	N	O
112	included	N	O
113	evaluations	N	O
114	using	N	O
115	the	N	O
116	STAI	N	O
117	,	N	O
118	POMS	N	O
119	,	N	O
120	MAC	N	O
121	,	N	O
122	EORTC	N	O
123	QLQ-C30	N	O
124	and	N	O
125	EORTC	N	O
126	QLQ-BR23	N	O
127	breast	N	O
128	module	N	O
129	scales	N	O
130	.	N	O

131	We	N	I-Premise
132	observed	N	I-Premise
133	a	N	I-Premise
134	significant	N	I-Premise
135	reduction	N	I-Premise
136	in	N	I-Premise
137	anxiety	N	I-Premise
138	(	N	I-Premise
139	STAI	N	I-Premise
140	,	N	I-Premise
141	POMS	N	I-Premise
142	)	N	I-Premise
143	among	N	I-Premise
144	group	N	I-Premise
145	participants	N	I-Premise
146	,	N	I-Premise
147	a	N	I-Premise
148	reduction	N	I-Premise
149	in	N	I-Premise
150	anger	N	I-Premise
151	,	N	I-Premise
152	depression	N	I-Premise
153	and	N	I-Premise
154	fatigue	N	I-Premise
155	(	N	I-Premise
156	POMS	N	I-Premise
157	)	N	I-Premise
158	,	N	I-Premise
159	a	N	I-Premise
160	significant	N	I-Premise
161	improvement	N	I-Premise
162	in	N	I-Premise
163	vigor	N	I-Premise
164	and	N	I-Premise
165	interpersonal	N	I-Premise
166	relationships	N	I-Premise
167	(	N	I-Premise
168	POMS	N	I-Premise
169	)	N	I-Premise
170	,	N	I-Premise
171	in	N	I-Premise
172	emotional	N	I-Premise
173	and	N	I-Premise
174	role	N	I-Premise
175	functioning	N	I-Premise
176	,	N	I-Premise
177	in	N	I-Premise
178	health	N	I-Premise
179	status	N	I-Premise
180	and	N	I-Premise
181	fatigue	N	I-Premise
182	level	N	I-Premise
183	(	N	I-Premise
184	EORTC	N	I-Premise
185	QLQ-C30	N	I-Premise
186	)	N	I-Premise
187	.	N	I-Premise

188	In	N	O
189	contrast	N	O
190	,	N	O
191	coping	N	I-Premise
192	strategies	N	I-Premise
193	(	N	I-Premise
194	MAC	N	I-Premise
195	)	N	I-Premise
196	were	N	I-Premise
197	not	N	I-Premise
198	significantly	N	I-Premise
199	different	N	I-Premise
200	between	N	I-Premise
201	groups	N	I-Premise
202	.	N	I-Premise

203	No	N	I-Premise
204	group-related	N	I-Premise
205	negative	N	I-Premise
206	effects	N	I-Premise
207	were	N	I-Premise
208	observed	N	I-Premise
209	and	N	I-Premise
210	the	N	I-Premise
211	global	N	I-Premise
212	satisfaction	N	I-Premise
213	levels	N	I-Premise
214	were	N	I-Premise
215	very	N	I-Premise
216	high	N	I-Premise
217	.	N	I-Premise

218	This	N	I-Claim
219	study	N	I-Claim
220	demonstrates	N	I-Claim
221	the	N	I-Claim
222	feasibility	N	I-Claim
223	and	N	I-Claim
224	effectiveness	N	I-Claim
225	of	N	I-Claim
226	a	N	I-Claim
227	psycho-educational	N	I-Claim
228	intervention	N	I-Claim
229	,	N	I-Claim
230	which	N	I-Claim
231	can	N	I-Claim
232	accelerate	N	I-Claim
233	the	N	I-Claim
234	reduction	N	I-Claim
235	of	N	I-Claim
236	those	N	I-Claim
237	negative	N	I-Claim
238	affects	N	I-Claim
239	which	N	I-Claim
240	are	N	I-Claim
241	present	N	I-Claim
242	at	N	I-Claim
243	the	N	I-Claim
244	end	N	I-Claim
245	of	N	I-Claim
246	treatment	N	I-Claim
247	.	N	I-Claim

248	It	N	I-Claim
249	represents	N	I-Claim
250	an	N	I-Claim
251	excellent	N	I-Claim
252	complement	N	I-Claim
253	or	N	I-Claim
254	an	N	I-Claim
255	alternative	N	I-Claim
256	to	N	I-Claim
257	individual	N	I-Claim
258	psycho-oncologic	N	I-Claim
259	therapeutic	N	I-Claim
260	support	N	I-Claim
261	,	N	I-Claim
262	widely	N	O
263	proposed	N	O
264	in	N	O
265	France	N	O
266	,	N	O
267	and	N	O
268	should	N	O
269	now	N	O
270	be	N	O
271	tested	N	O
272	in	N	O
273	groups	N	O
274	with	N	O
275	other	N	O
276	types	N	O
277	of	N	O
278	cancer	N	O
279	and	N	O
280	at	N	O
281	other	N	O
282	disease	N	O
283	phases	N	O
284	.	N	O

1	We	N	O
2	sought	N	O
3	the	N	O
4	extent	N	O
5	to	N	O
6	which	N	O
7	arm	N	O
8	morbidity	N	O
9	could	N	O
10	be	N	O
11	reduced	N	O
12	by	N	O
13	using	N	O
14	sentinel-lymph-node-based	N	O
15	management	N	O
16	in	N	O
17	women	N	O
18	with	N	O
19	clinically	N	O
20	node-negative	N	O
21	early	N	O
22	breast	N	O
23	cancer	N	O
24	.	N	O

25	One	N	O
26	thousand	N	O
27	eighty-eight	N	O
28	women	N	O
29	were	N	O
30	randomly	N	O
31	allocated	N	O
32	to	N	O
33	sentinel-lymph-node	N	O
34	biopsy	N	O
35	followed	N	O
36	by	N	O
37	axillary	N	O
38	clearance	N	O
39	if	N	O
40	the	N	O
41	sentinel	N	O
42	node	N	O
43	was	N	O
44	positive	N	O
45	or	N	O
46	not	N	O
47	detected	N	O
48	(	N	O
49	SNBM	N	O
50	)	N	O
51	or	N	O
52	routine	N	O
53	axillary	N	O
54	clearance	N	O
55	(	N	O
56	RAC	N	O
57	,	N	O
58	sentinel-lymph-node	N	O
59	biopsy	N	O
60	followed	N	O
61	immediately	N	O
62	by	N	O
63	axillary	N	O
64	clearance	N	O
65	)	N	O
66	.	N	O

67	Sentinel	N	O
68	nodes	N	O
69	were	N	O
70	located	N	O
71	using	N	O
72	blue	N	O
73	dye	N	O
74	,	N	O
75	alone	N	O
76	or	N	O
77	with	N	O
78	technetium-labeled	N	O
79	antimony	N	O
80	sulfide	N	O
81	colloid	N	O
82	.	N	O

83	The	N	O
84	primary	N	O
85	endpoint	N	O
86	was	N	O
87	increase	N	O
88	in	N	O
89	arm	N	O
90	volume	N	O
91	from	N	O
92	baseline	N	O
93	to	N	O
94	the	N	O
95	average	N	O
96	of	N	O
97	measurements	N	O
98	at	N	O
99	6	N	O
100	and	N	O
101	12	N	O
102	months	N	O
103	.	N	O

104	Secondary	N	O
105	endpoints	N	O
106	were	N	O
107	the	N	O
108	proportions	N	O
109	of	N	O
110	women	N	O
111	with	N	O
112	at	N	O
113	least	N	O
114	15	N	O
115	%	N	O
116	increase	N	O
117	in	N	O
118	arm	N	O
119	volume	N	O
120	or	N	O
121	early	N	O
122	axillary	N	O
123	morbidity	N	O
124	,	N	O
125	and	N	O
126	average	N	O
127	scores	N	O
128	for	N	O
129	arm	N	O
130	symptoms	N	O
131	,	N	O
132	dysfunctions	N	O
133	,	N	O
134	and	N	O
135	disabilities	N	O
136	assessed	N	O
137	at	N	O
138	6	N	O
139	and	N	O
140	12	N	O
141	months	N	O
142	by	N	O
143	patients	N	O
144	with	N	O
145	the	N	O
146	SNAC	N	O
147	Study-Specific	N	O
148	Scales	N	O
149	and	N	O
150	other	N	O
151	quality-of-life	N	O
152	instruments	N	O
153	.	N	O

154	Sensitivity	N	O
155	,	N	O
156	false-negative	N	O
157	rates	N	O
158	,	N	O
159	and	N	O
160	negative	N	O
161	predictive	N	O
162	values	N	O
163	for	N	O
164	sentinel-lymph-node	N	O
165	biopsy	N	O
166	were	N	O
167	estimated	N	O
168	in	N	O
169	the	N	O
170	RAC	N	O
171	group	N	O
172	.	N	O

173	The	N	I-Premise
174	average	N	I-Premise
175	increase	N	I-Premise
176	in	N	I-Premise
177	arm	N	I-Premise
178	volume	N	I-Premise
179	was	N	I-Premise
180	2.8	N	I-Premise
181	%	N	I-Premise
182	in	N	I-Premise
183	the	N	I-Premise
184	SNBM	N	I-Premise
185	group	N	I-Premise
186	and	N	I-Premise
187	4.2	N	I-Premise
188	%	N	I-Premise
189	in	N	I-Premise
190	the	N	I-Premise
191	RAC	N	I-Premise
192	group	N	I-Premise
193	(	N	I-Premise
194	P	N	I-Premise
195	=	N	I-Premise
196	0.002	N	I-Premise
197	)	N	I-Premise
198	.	N	I-Premise

199	Patients	N	I-Premise
200	in	N	I-Premise
201	the	N	I-Premise
202	SNBM	N	I-Premise
203	group	N	I-Premise
204	gave	N	I-Premise
205	lower	N	I-Premise
206	ratings	N	I-Premise
207	for	N	I-Premise
208	arm	N	I-Premise
209	swelling	N	I-Premise
210	(	N	I-Premise
211	P	N	I-Premise
212	<	N	I-Premise
213	0.001	N	I-Premise
214	)	N	I-Premise
215	,	N	I-Premise
216	symptoms	N	I-Premise
217	(	N	I-Premise
218	P	N	I-Premise
219	<	N	I-Premise
220	0.001	N	I-Premise
221	)	N	I-Premise
222	,	N	I-Premise
223	and	N	I-Premise
224	dysfunctions	N	I-Premise
225	(	N	I-Premise
226	P	N	I-Premise
227	=	N	I-Premise
228	0.02	N	I-Premise
229	)	N	I-Premise
230	,	N	I-Premise
231	but	N	I-Premise
232	not	N	I-Premise
233	disabilities	N	I-Premise
234	(	N	I-Premise
235	P	N	I-Premise
236	=	N	I-Premise
237	0.5	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	Sentinel	N	I-Premise
241	nodes	N	I-Premise
242	were	N	I-Premise
243	found	N	I-Premise
244	in	N	I-Premise
245	95	N	I-Premise
246	%	N	I-Premise
247	of	N	I-Premise
248	the	N	I-Premise
249	SNBM	N	I-Premise
250	group	N	I-Premise
251	(	N	I-Premise
252	29	N	I-Premise
253	%	N	I-Premise
254	positive	N	I-Premise
255	)	N	I-Premise
256	and	N	I-Premise
257	93	N	I-Premise
258	%	N	I-Premise
259	of	N	I-Premise
260	the	N	I-Premise
261	RAC	N	I-Premise
262	group	N	I-Premise
263	(	N	I-Premise
264	25	N	I-Premise
265	%	N	I-Premise
266	positive	N	I-Premise
267	)	N	I-Premise
268	.	N	I-Premise

269	SNB	N	O
270	had	N	O
271	sensitivity	N	O
272	94.5	N	O
273	%	N	O
274	,	N	O
275	false-negative	N	O
276	rate	N	O
277	5.5	N	O
278	%	N	O
279	,	N	O
280	and	N	O
281	negative	N	O
282	predictive	N	O
283	value	N	O
284	98	N	O
285	%	N	O
286	.	N	O

287	SNBM	N	I-Claim
288	was	N	I-Claim
289	successfully	N	I-Claim
290	undertaken	N	I-Claim
291	in	N	I-Claim
292	a	N	I-Claim
293	wide	N	I-Claim
294	range	N	I-Claim
295	of	N	I-Claim
296	surgical	N	I-Claim
297	centers	N	I-Claim
298	and	N	I-Claim
299	caused	N	I-Claim
300	significantly	N	I-Claim
301	less	N	I-Claim
302	morbidity	N	I-Claim
303	than	N	I-Claim
304	RAC	N	I-Claim
305	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	toxicities	N	O
5	,	N	O
6	tumor	N	O
7	control	N	O
8	,	N	O
9	survival	N	O
10	,	N	O
11	and	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	of	N	O
16	nasopharyngeal	N	O
17	cancer	N	O
18	(	N	O
19	NPC	N	O
20	)	N	O
21	patients	N	O
22	treated	N	O
23	with	N	O
24	sequential	N	O
25	neoadjuvant	N	O
26	chemotherapy	N	O
27	followed	N	O
28	by	N	O
29	concurrent	N	O
30	cisplatin-radiotherapy	N	O
31	(	N	O
32	CRT	N	O
33	)	N	O
34	or	N	O
35	CRT	N	O
36	alone	N	O
37	.	N	O

38	Previously	N	O
39	untreated	N	O
40	stage	N	O
41	III	N	O
42	to	N	O
43	IVB	N	O
44	NPC	N	O
45	were	N	O
46	randomly	N	O
47	assigned	N	O
48	to	N	O
49	(	N	O
50	1	N	O
51	)	N	O
52	neoadjuvant	N	O
53	docetaxel	N	O
54	75	N	O
55	mg/m	N	O
56	(	N	O
57	2	N	O
58	)	N	O
59	and	N	O
60	cisplatin	N	O
61	75	N	O
62	mg/m	N	O
63	(	N	O
64	2	N	O
65	)	N	O
66	every	N	O
67	3	N	O
68	weeks	N	O
69	for	N	O
70	two	N	O
71	cycles	N	O
72	,	N	O
73	followed	N	O
74	by	N	O
75	cisplatin	N	O
76	40	N	O
77	mg/m	N	O
78	(	N	O
79	2	N	O
80	)	N	O
81	/wk	N	O
82	concurrent	N	O
83	with	N	O
84	radiotherapy	N	O
85	,	N	O
86	or	N	O
87	(	N	O
88	2	N	O
89	)	N	O
90	CRT	N	O
91	alone	N	O
92	.	N	O

93	Planned	N	O
94	accrual	N	O
95	was	N	O
96	30	N	O
97	patients	N	O
98	per	N	O
99	arm	N	O
100	to	N	O
101	detect	N	O
102	20	N	O
103	%	N	O
104	difference	N	O
105	of	N	O
106	toxicities	N	O
107	based	N	O
108	on	N	O
109	95	N	O
110	%	N	O
111	CIs	N	O
112	.	N	O

113	From	N	O
114	November	N	O
115	2002	N	O
116	to	N	O
117	November	N	O
118	2004	N	O
119	,	N	O
120	65	N	O
121	eligible	N	O
122	patients	N	O
123	were	N	O
124	randomly	N	O
125	assigned	N	O
126	to	N	O
127	neoadjuvant	N	O
128	chemotherapy	N	O
129	followed	N	O
130	by	N	O
131	CRT	N	O
132	(	N	O
133	n	N	O
134	=	N	O
135	34	N	O
136	)	N	O
137	or	N	O
138	CRT	N	O
139	alone	N	O
140	(	N	O
141	n	N	O
142	=	N	O
143	31	N	O
144	)	N	O
145	.	N	O

146	There	N	I-Premise
147	was	N	I-Premise
148	a	N	I-Premise
149	high	N	I-Premise
150	rate	N	I-Premise
151	of	N	I-Premise
152	grade	N	I-Premise
153	3/4	N	I-Premise
154	neutropenia	N	I-Premise
155	(	N	I-Premise
156	97	N	I-Premise
157	%	N	I-Premise
158	)	N	I-Premise
159	but	N	I-Premise
160	not	N	I-Premise
161	neutropenic	N	I-Premise
162	fever	N	I-Premise
163	(	N	I-Premise
164	12	N	I-Premise
165	%	N	I-Premise
166	)	N	I-Premise
167	during	N	I-Premise
168	neoadjuvant	N	I-Premise
169	chemotherapy	N	I-Premise
170	.	N	I-Premise

171	No	N	I-Premise
172	significant	N	I-Premise
173	differences	N	I-Premise
174	in	N	I-Premise
175	rates	N	I-Premise
176	of	N	I-Premise
177	acute	N	I-Premise
178	toxicities	N	I-Premise
179	were	N	I-Premise
180	observed	N	I-Premise
181	between	N	I-Premise
182	the	N	I-Premise
183	two	N	I-Premise
184	arms	N	I-Premise
185	during	N	I-Premise
186	CRT	N	I-Premise
187	.	N	I-Premise

188	Dose	N	I-Premise
189	intensities	N	I-Premise
190	of	N	I-Premise
191	concurrent	N	I-Premise
192	cisplatin	N	I-Premise
193	,	N	I-Premise
194	late	N	I-Premise
195	RT	N	I-Premise
196	toxicities	N	I-Premise
197	and	N	I-Premise
198	quality	N	I-Premise
199	of	N	I-Premise
200	life	N	I-Premise
201	scores	N	I-Premise
202	were	N	I-Premise
203	comparable	N	I-Premise
204	in	N	I-Premise
205	both	N	I-Premise
206	arms	N	I-Premise
207	.	N	I-Premise

208	The	N	I-Premise
209	3-year	N	I-Premise
210	progression-free	N	I-Premise
211	survival	N	I-Premise
212	for	N	I-Premise
213	neoadjuvant	N	I-Premise
214	versus	N	I-Premise
215	control	N	I-Premise
216	arm	N	I-Premise
217	was	N	I-Premise
218	88.2	N	I-Premise
219	%	N	I-Premise
220	and	N	I-Premise
221	59.5	N	I-Premise
222	%	N	I-Premise
223	(	N	I-Premise
224	hazard	N	I-Premise
225	ratio	N	I-Premise
226	=	N	I-Premise
227	0.49	N	I-Premise
228	;	N	I-Premise
229	95	N	I-Premise
230	%	N	I-Premise
231	CI	N	I-Premise
232	,	N	I-Premise
233	0.20	N	I-Premise
234	to	N	I-Premise
235	1.19	N	I-Premise
236	;	N	I-Premise
237	P	N	I-Premise
238	=	N	I-Premise
239	.12	N	I-Premise
240	)	N	I-Premise
241	.	N	I-Premise

242	The	N	I-Premise
243	3-year	N	I-Premise
244	overall	N	I-Premise
245	survival	N	I-Premise
246	for	N	I-Premise
247	neoadjuvant	N	I-Premise
248	versus	N	I-Premise
249	control	N	I-Premise
250	arm	N	I-Premise
251	was	N	I-Premise
252	94.1	N	I-Premise
253	%	N	I-Premise
254	and	N	I-Premise
255	67.7	N	I-Premise
256	%	N	I-Premise
257	(	N	I-Premise
258	hazard	N	I-Premise
259	ratio	N	I-Premise
260	=	N	I-Premise
261	0.24	N	I-Premise
262	;	N	I-Premise
263	95	N	I-Premise
264	%	N	I-Premise
265	CI	N	I-Premise
266	,	N	I-Premise
267	0.078	N	I-Premise
268	to	N	I-Premise
269	0.73	N	I-Premise
270	;	N	I-Premise
271	P	N	I-Premise
272	=	N	I-Premise
273	.012	N	I-Premise
274	)	N	I-Premise
275	.	N	I-Premise

276	Neoadjuvant	N	I-Claim
277	docetaxel-cisplatin	N	I-Claim
278	followed	N	I-Claim
279	by	N	I-Claim
280	CRT	N	I-Claim
281	was	N	I-Claim
282	well	N	I-Claim
283	tolerated	N	I-Claim
284	with	N	I-Claim
285	a	N	I-Claim
286	manageable	N	I-Claim
287	toxicity	N	I-Claim
288	profile	N	I-Claim
289	that	N	I-Claim
290	allowed	N	I-Claim
291	subsequent	N	I-Claim
292	delivery	N	I-Claim
293	of	N	I-Claim
294	full-dose	N	I-Claim
295	CRT	N	I-Claim
296	.	N	I-Claim

297	Preliminary	N	I-Claim
298	results	N	I-Claim
299	suggested	N	I-Claim
300	a	N	I-Claim
301	positive	N	I-Claim
302	impact	N	I-Claim
303	on	N	I-Claim
304	survival	N	I-Claim
305	.	N	I-Claim

306	A	N	O
307	phase	N	O
308	III	N	O
309	study	N	O
310	to	N	O
311	definitively	N	O
312	test	N	O
313	this	N	O
314	neoadjuvant-concurrent	N	O
315	strategy	N	O
316	is	N	O
317	warranted	N	O
318	.	N	O

1	To	N	O
2	assess	N	O
3	the	N	O
4	safety	N	O
5	,	N	O
6	tolerability	N	O
7	and	N	O
8	efficacy	N	O
9	of	N	O
10	abatacept	N	O
11	in	N	O
12	patients	N	O
13	with	N	O
14	rheumatoid	N	O
15	arthritis	N	O
16	(	N	O
17	RA	N	O
18	)	N	O
19	who	N	O
20	had	N	O
21	failed	N	O
22	anti-tumour	N	O
23	necrosis	N	O
24	factor	N	O
25	(	N	O
26	TNF	N	O
27	)	N	O
28	therapy	N	O
29	and	N	O
30	were	N	O
31	switched	N	O
32	to	N	O
33	abatacept	N	O
34	directly	N	O
35	or	N	O
36	after	N	O
37	completing	N	O
38	washout	N	O
39	.	N	O

40	In	N	O
41	this	N	O
42	international	N	O
43	,	N	O
44	6-month	N	O
45	,	N	O
46	open-label	N	O
47	trial	N	O
48	,	N	O
49	patients	N	O
50	had	N	O
51	active	N	O
52	RA	N	O
53	,	N	O
54	an	N	O
55	inadequate	N	O
56	response	N	O
57	to	N	O
58	anti-TNF	N	O
59	therapy	N	O
60	for	N	O
61	3	N	O
62	months	N	O
63	or	N	O
64	longer	N	O
65	and	N	O
66	a	N	O
67	disease	N	O
68	activity	N	O
69	score	N	O
70	in	N	O
71	28	N	O
72	joints	N	O
73	(	N	O
74	DAS28	N	O
75	(	N	O
76	C-reactive	N	O
77	protein	N	O
78	;	N	O
79	CRP	N	O
80	)	N	O
81	of	N	O
82	5.1	N	O
83	or	N	O
84	greater	N	O
85	.	N	O

86	``	N	O
87	Washout	N	O
88	''	N	O
89	patients	N	O
90	discontinued	N	O
91	anti-TNF	N	O
92	therapy	N	O
93	2	N	O
94	months	N	O
95	or	N	O
96	longer	N	O
97	pre-screening	N	O
98	;	N	O
99	``	N	O
100	direct-switch	N	O
101	''	N	O
102	patients	N	O
103	began	N	O
104	abatacept	N	O
105	(	N	O
106	approximately	N	O
107	10	N	O
108	mg/kg	N	O
109	)	N	O
110	at	N	O
111	their	N	O
112	next	N	O
113	scheduled	N	O
114	anti-TNF	N	O
115	therapy	N	O
116	dose	N	O
117	.	N	O

118	1046	N	O
119	patients	N	O
120	were	N	O
121	treated	N	O
122	(	N	O
123	449	N	O
124	washout	N	O
125	,	N	O
126	597	N	O
127	direct-switch	N	O
128	;	N	O
129	baseline	N	O
130	characteristics	N	O
131	were	N	O
132	similar	N	O
133	between	N	O
134	groups	N	O
135	)	N	O
136	.	N	O

137	At	N	I-Premise
138	6	N	I-Premise
139	months	N	I-Premise
140	,	N	I-Premise
141	adverse	N	I-Premise
142	events	N	I-Premise
143	(	N	I-Premise
144	AE	N	I-Premise
145	;	N	I-Premise
146	78.0	N	I-Premise
147	%	N	I-Premise
148	vs	N	I-Premise
149	79.2	N	I-Premise
150	%	N	I-Premise
151	)	N	I-Premise
152	,	N	I-Premise
153	serious	N	I-Premise
154	AE	N	I-Premise
155	(	N	I-Premise
156	11.1	N	I-Premise
157	%	N	I-Premise
158	vs	N	I-Premise
159	9.9	N	I-Premise
160	%	N	I-Premise
161	)	N	I-Premise
162	and	N	I-Premise
163	discontinuations	N	I-Premise
164	due	N	I-Premise
165	to	N	I-Premise
166	AE	N	I-Premise
167	(	N	I-Premise
168	3.8	N	I-Premise
169	%	N	I-Premise
170	vs	N	I-Premise
171	4.0	N	I-Premise
172	%	N	I-Premise
173	)	N	I-Premise
174	and	N	I-Premise
175	serious	N	I-Premise
176	AE	N	I-Premise
177	(	N	I-Premise
178	2.0	N	I-Premise
179	%	N	I-Premise
180	vs	N	I-Premise
181	1.3	N	I-Premise
182	%	N	I-Premise
183	)	N	I-Premise
184	were	N	I-Premise
185	comparable	N	I-Premise
186	in	N	I-Premise
187	washout	N	I-Premise
188	versus	N	I-Premise
189	direct-switch	N	I-Premise
190	patients	N	I-Premise
191	.	N	I-Premise

192	There	N	I-Premise
193	were	N	I-Premise
194	no	N	I-Premise
195	opportunistic	N	I-Premise
196	infections	N	I-Premise
197	.	N	I-Premise

198	At	N	I-Premise
199	6	N	I-Premise
200	months	N	I-Premise
201	,	N	I-Premise
202	in	N	I-Premise
203	washout	N	I-Premise
204	versus	N	I-Premise
205	direct-switch	N	I-Premise
206	patients	N	I-Premise
207	,	N	I-Premise
208	similar	N	I-Premise
209	clinically	N	I-Premise
210	meaningful	N	I-Premise
211	improvements	N	I-Premise
212	were	N	I-Premise
213	seen	N	I-Premise
214	in	N	I-Premise
215	DAS28	N	I-Premise
216	(	N	I-Premise
217	CRP	N	I-Premise
218	)	N	I-Premise
219	(	N	I-Premise
220	>	N	I-Premise
221	or	N	I-Premise
222	=1.2	N	I-Premise
223	unit	N	I-Premise
224	improvement	N	I-Premise
225	,	N	I-Premise
226	59.5	N	I-Premise
227	%	N	I-Premise
228	vs	N	I-Premise
229	53.6	N	I-Premise
230	%	N	I-Premise
231	,	N	I-Premise
232	respectively	N	I-Premise
233	;	N	I-Premise
234	low	N	I-Premise
235	disease	N	I-Premise
236	activity	N	I-Premise
237	state	N	I-Premise
238	,	N	I-Premise
239	22.5	N	I-Premise
240	%	N	I-Premise
241	vs	N	I-Premise
242	22.3	N	I-Premise
243	%	N	I-Premise
244	;	N	I-Premise
245	DAS28-defined	N	I-Premise
246	remission	N	I-Premise
247	,	N	I-Premise
248	12.0	N	I-Premise
249	%	N	I-Premise
250	vs	N	I-Premise
251	13.7	N	I-Premise
252	%	N	I-Premise
253	)	N	I-Premise
254	,	N	I-Premise
255	physical	N	I-Premise
256	function	N	I-Premise
257	(	N	I-Premise
258	health	N	I-Premise
259	assessment	N	I-Premise
260	questionnaire	N	I-Premise
261	disability	N	I-Premise
262	index	N	I-Premise
263	>	N	I-Premise
264	or	N	I-Premise
265	=0.22	N	I-Premise
266	improvement	N	I-Premise
267	;	N	I-Premise
268	46.3	N	I-Premise
269	%	N	I-Premise
270	vs	N	I-Premise
271	47.1	N	I-Premise
272	%	N	I-Premise
273	)	N	I-Premise
274	and	N	I-Premise
275	health-related	N	I-Premise
276	quality	N	I-Premise
277	of	N	I-Premise
278	life	N	I-Premise
279	(	N	I-Premise
280	mean	N	I-Premise
281	change	N	I-Premise
282	in	N	I-Premise
283	short-form	N	I-Premise
284	36	N	I-Premise
285	scores	N	I-Premise
286	:	N	I-Premise
287	physical	N	I-Premise
288	component	N	I-Premise
289	summary	N	I-Premise
290	,	N	I-Premise
291	5.5	N	I-Premise
292	vs	N	I-Premise
293	6.1	N	I-Premise
294	;	N	I-Premise
295	mental	N	I-Premise
296	component	N	I-Premise
297	summary	N	I-Premise
298	,	N	I-Premise
299	4.8	N	I-Premise
300	vs	N	I-Premise
301	5.4	N	I-Premise
302	)	N	I-Premise
303	.	N	I-Premise

304	Abatacept	N	I-Claim
305	demonstrated	N	I-Claim
306	acceptable	N	I-Claim
307	safety	N	I-Claim
308	and	N	I-Claim
309	tolerability	N	I-Claim
310	and	N	I-Claim
311	clinically	N	I-Claim
312	meaningful	N	I-Claim
313	efficacy	N	I-Claim
314	over	N	I-Claim
315	6	N	I-Claim
316	months	N	I-Claim
317	in	N	I-Claim
318	patients	N	I-Claim
319	with	N	I-Claim
320	inadequate	N	I-Claim
321	response	N	I-Claim
322	to	N	I-Claim
323	anti-TNF	N	I-Claim
324	therapy	N	I-Claim
325	.	N	I-Claim

326	Results	N	I-Claim
327	were	N	I-Claim
328	comparable	N	I-Claim
329	with	N	I-Claim
330	or	N	I-Claim
331	without	N	I-Claim
332	a	N	I-Claim
333	washout	N	I-Claim
334	,	N	I-Claim
335	supporting	N	I-Claim
336	direct	N	I-Claim
337	switching	N	I-Claim
338	from	N	I-Claim
339	anti-TNF	N	I-Claim
340	therapy	N	I-Claim
341	to	N	I-Claim
342	abatacept	N	I-Claim
343	as	N	I-Claim
344	an	N	I-Claim
345	option	N	I-Claim
346	in	N	I-Claim
347	clinical	N	I-Claim
348	practice	N	I-Claim
349	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	an	N	O
7	expressive	N	O
8	writing	N	O
9	(	N	O
10	EW	N	O
11	)	N	O
12	intervention	N	O
13	on	N	O
14	perceptions	N	O
15	of	N	O
16	emotional	N	O
17	support	N	O
18	in	N	O
19	women	N	O
20	completing	N	O
21	treatment	N	O
22	for	N	O
23	early	N	O
24	stage	N	O
25	breast	N	O
26	cancer	N	O
27	.	N	O

28	Women	N	O
29	were	N	O
30	recruited	N	O
31	to	N	O
32	the	N	O
33	study	N	O
34	during	N	O
35	their	N	O
36	final	N	O
37	week	N	O
38	of	N	O
39	treatment	N	O
40	.	N	O

41	Of	N	O
42	260	N	O
43	eligible	N	O
44	patients	N	O
45	,	N	O
46	104	N	O
47	(	N	O
48	40	N	O
49	%	N	O
50	)	N	O
51	agreed	N	O
52	to	N	O
53	participate	N	O
54	,	N	O
55	and	N	O
56	93	N	O
57	were	N	O
58	randomised	N	O
59	.	N	O

60	Women	N	O
61	in	N	O
62	the	N	O
63	writing	N	O
64	group	N	O
65	wrote	N	O
66	for	N	O
67	20	N	O
68	min	N	O
69	on	N	O
70	four	N	O
71	consecutive	N	O
72	days	N	O
73	.	N	O

74	The	N	O
75	control	N	O
76	group	N	O
77	received	N	O
78	normal	N	O
79	care	N	O
80	.	N	O

81	Women	N	O
82	's	N	O
83	perceptions	N	O
84	of	N	O
85	emotional	N	O
86	support	N	O
87	,	N	O
88	quality	N	O
89	of	N	O
90	life	N	O
91	(	N	O
92	QOL	N	O
93	)	N	O
94	,	N	O
95	mood	N	O
96	,	N	O
97	and	N	O
98	healthcare	N	O
99	utilisation	N	O
100	were	N	O
101	assessed	N	O
102	at	N	O
103	baseline	N	O
104	,	N	O
105	1	N	O
106	month	N	O
107	,	N	O
108	3	N	O
109	months	N	O
110	and	N	O
111	6	N	O
112	months	N	O
113	.	N	O

114	Interviews	N	O
115	were	N	O
116	conducted	N	O
117	to	N	O
118	explore	N	O
119	women	N	O
120	's	N	O
121	experience	N	O
122	of	N	O
123	writing	N	O
124	.	N	O

125	Eighty	N	O
126	participants	N	O
127	completed	N	O
128	all	N	O
129	follow-ups	N	O
130	.	N	O

131	There	N	I-Premise
132	was	N	I-Premise
133	a	N	I-Premise
134	significant	N	I-Premise
135	effect	N	I-Premise
136	of	N	I-Premise
137	group	N	I-Premise
138	on	N	I-Premise
139	women	N	I-Premise
140	's	N	I-Premise
141	perceptions	N	I-Premise
142	of	N	I-Premise
143	social	N	I-Premise
144	support	N	I-Premise
145	with	N	I-Premise
146	those	N	I-Premise
147	in	N	I-Premise
148	the	N	I-Premise
149	intervention	N	I-Premise
150	group	N	I-Premise
151	being	N	I-Premise
152	more	N	I-Premise
153	satisfied	N	I-Premise
154	with	N	I-Premise
155	the	N	I-Premise
156	emotional	N	I-Premise
157	support	N	I-Premise
158	they	N	I-Premise
159	received	N	I-Premise
160	(	N	I-Premise
161	p	N	I-Premise
162	<	N	I-Premise
163	0.05	N	I-Premise
164	)	N	I-Premise
165	.	N	I-Premise

166	Satisfaction	N	I-Premise
167	with	N	I-Premise
168	emotional	N	I-Premise
169	support	N	I-Premise
170	was	N	I-Premise
171	negatively	N	I-Premise
172	correlated	N	I-Premise
173	with	N	I-Premise
174	depression/dejection	N	I-Premise
175	(	N	I-Premise
176	p	N	I-Premise
177	<	N	I-Premise
178	0.05	N	I-Premise
179	)	N	I-Premise
180	and	N	I-Premise
181	anger/hostility	N	I-Premise
182	(	N	I-Premise
183	p	N	I-Premise
184	<	N	I-Premise
185	0.05	N	I-Premise
186	)	N	I-Premise
187	and	N	I-Premise
188	positively	N	I-Premise
189	correlated	N	I-Premise
190	with	N	I-Premise
191	social	N	I-Premise
192	and	N	I-Premise
193	family	N	I-Premise
194	well-being	N	I-Premise
195	(	N	I-Premise
196	p	N	I-Premise
197	<	N	I-Premise
198	0.001	N	I-Premise
199	)	N	I-Premise
200	6	N	I-Premise
201	months	N	I-Premise
202	post	N	I-Premise
203	intervention	N	I-Premise
204	.	N	I-Premise

205	There	N	I-Premise
206	were	N	I-Premise
207	no	N	I-Premise
208	significant	N	I-Premise
209	effects	N	I-Premise
210	of	N	I-Premise
211	the	N	I-Premise
212	intervention	N	I-Premise
213	on	N	I-Premise
214	mood	N	I-Premise
215	,	N	I-Premise
216	QOL	N	I-Premise
217	or	N	I-Premise
218	healthcare	N	I-Premise
219	utilisation	N	I-Premise
220	.	N	I-Premise

221	Most	N	I-Premise
222	participants	N	I-Premise
223	found	N	I-Premise
224	writing	N	I-Premise
225	valuable	N	I-Premise
226	and	N	I-Premise
227	did	N	I-Premise
228	not	N	I-Premise
229	report	N	I-Premise
230	any	N	I-Premise
231	long-term	N	I-Premise
232	negative	N	I-Premise
233	effects	N	I-Premise
234	.	N	I-Premise

235	EW	N	I-Claim
236	was	N	I-Claim
237	associated	N	I-Claim
238	with	N	I-Claim
239	a	N	I-Claim
240	higher	N	I-Claim
241	level	N	I-Claim
242	of	N	I-Claim
243	satisfaction	N	I-Claim
244	with	N	I-Claim
245	emotional	N	I-Claim
246	support	N	I-Claim
247	compared	N	I-Claim
248	with	N	I-Claim
249	controls	N	I-Claim
250	.	N	I-Claim

251	Given	N	O
252	the	N	O
253	existing	N	O
254	evidence	N	O
255	supporting	N	O
256	the	N	O
257	importance	N	O
258	of	N	O
259	social	N	O
260	support	N	O
261	in	N	O
262	adjustment	N	O
263	to	N	O
264	breast	N	O
265	cancer	N	O
266	,	N	O
267	it	N	I-MajorClaim
268	seems	N	I-MajorClaim
269	feasible	N	I-MajorClaim
270	to	N	I-MajorClaim
271	suggest	N	I-MajorClaim
272	that	N	I-MajorClaim
273	EW	N	I-MajorClaim
274	may	N	I-MajorClaim
275	be	N	I-MajorClaim
276	a	N	I-MajorClaim
277	cost	N	I-MajorClaim
278	effective	N	I-MajorClaim
279	accessible	N	I-MajorClaim
280	treatment	N	I-MajorClaim
281	that	N	I-MajorClaim
282	could	N	I-MajorClaim
283	be	N	I-MajorClaim
284	incorporated	N	I-MajorClaim
285	into	N	I-MajorClaim
286	the	N	I-MajorClaim
287	ongoing	N	I-MajorClaim
288	care	N	I-MajorClaim
289	of	N	I-MajorClaim
290	women	N	I-MajorClaim
291	.	N	I-MajorClaim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	treatment	N	O
11	and	N	O
12	retention	N	O
13	effects	N	O
14	between	N	O
15	standard	N	O
16	decongestive	N	O
17	lymphatic	N	O
18	therapy	N	O
19	(	N	O
20	DLT	N	O
21	)	N	O
22	combined	N	O
23	with	N	O
24	pneumatic	N	O
25	compression	N	O
26	(	N	O
27	PC	N	O
28	)	N	O
29	and	N	O
30	modified	N	O
31	DLT	N	O
32	,	N	O
33	in	N	O
34	which	N	O
35	the	N	O
36	use	N	O
37	of	N	O
38	a	N	O
39	short-stretch	N	O
40	bandage	N	O
41	is	N	O
42	replaced	N	O
43	with	N	O
44	the	N	O
45	use	N	O
46	of	N	O
47	Kinesio	N	O
48	tape	N	O
49	(	N	O
50	K-tape	N	O
51	)	N	O
52	combined	N	O
53	with	N	O
54	PC	N	O
55	.	N	O

56	Forty-one	N	O
57	patients	N	O
58	with	N	O
59	unilateral	N	O
60	breast-cancer-related	N	O
61	lymphedema	N	O
62	for	N	O
63	at	N	O
64	least	N	O
65	3	N	O
66	months	N	O
67	were	N	O
68	randomly	N	O
69	grouped	N	O
70	into	N	O
71	the	N	O
72	DLT	N	O
73	group	N	O
74	(	N	O
75	bandage	N	O
76	group	N	O
77	,	N	O
78	N	N	O
79	=	N	O
80	21	N	O
81	)	N	O
82	or	N	O
83	the	N	O
84	modified	N	O
85	DLT	N	O
86	group	N	O
87	(	N	O
88	K-tape	N	O
89	group	N	O
90	,	N	O
91	N	N	O
92	=	N	O
93	20	N	O
94	)	N	O
95	.	N	O

96	Skin	N	O
97	care	N	O
98	,	N	O
99	30-min	N	O
100	manual	N	O
101	lymphatic	N	O
102	drainage	N	O
103	,	N	O
104	1-h	N	O
105	pneumatic	N	O
106	compression	N	O
107	therapy	N	O
108	,	N	O
109	application	N	O
110	of	N	O
111	a	N	O
112	short-stretch	N	O
113	bandage	N	O
114	or	N	O
115	K-tape	N	O
116	for	N	O
117	each	N	O
118	group	N	O
119	,	N	O
120	and	N	O
121	a	N	O
122	20-min	N	O
123	physical	N	O
124	therapy	N	O
125	exercise	N	O
126	were	N	O
127	given	N	O
128	during	N	O
129	every	N	O
130	treatment	N	O
131	session	N	O
132	.	N	O

133	Patient	N	O
134	evaluation	N	O
135	items	N	O
136	included	N	O
137	physical	N	O
138	therapy	N	O
139	assessment	N	O
140	,	N	O
141	limb	N	O
142	size	N	O
143	,	N	O
144	water	N	O
145	composition	N	O
146	of	N	O
147	the	N	O
148	upper	N	O
149	extremity	N	O
150	,	N	O
151	lymphedema-related	N	O
152	symptoms	N	O
153	,	N	O
154	quality	N	O
155	of	N	O
156	life	N	O
157	,	N	O
158	and	N	O
159	patients	N	O
160	'	N	O
161	acceptance	N	O
162	to	N	O
163	the	N	O
164	bandage	N	O
165	or	N	O
166	tape	N	O
167	.	N	O

168	There	N	I-Premise
169	was	N	I-Premise
170	no	N	I-Premise
171	significant	N	I-Premise
172	difference	N	I-Premise
173	between	N	I-Premise
174	groups	N	I-Premise
175	in	N	I-Premise
176	all	N	I-Premise
177	outcome	N	I-Premise
178	variables	N	I-Premise
179	(	N	I-Premise
180	P	N	I-Premise
181	>	N	I-Premise
182	0.05	N	I-Premise
183	)	N	I-Premise
184	through	N	I-Premise
185	the	N	I-Premise
186	whole	N	I-Premise
187	study	N	I-Premise
188	period	N	I-Premise
189	.	N	I-Premise

190	Excess	N	I-Premise
191	limb	N	I-Premise
192	size	N	I-Premise
193	(	N	I-Premise
194	circumference	N	I-Premise
195	and	N	I-Premise
196	water	N	I-Premise
197	displacement	N	I-Premise
198	)	N	I-Premise
199	and	N	I-Premise
200	excess	N	I-Premise
201	water	N	I-Premise
202	composition	N	I-Premise
203	were	N	I-Premise
204	reduced	N	I-Premise
205	significantly	N	I-Premise
206	in	N	I-Premise
207	the	N	I-Premise
208	bandage	N	I-Premise
209	group	N	I-Premise
210	;	N	I-Premise
211	excess	N	I-Premise
212	circumference	N	I-Premise
213	and	N	I-Premise
214	excess	N	I-Premise
215	water	N	I-Premise
216	composition	N	I-Premise
217	were	N	I-Premise
218	reduced	N	I-Premise
219	significantly	N	I-Premise
220	in	N	I-Premise
221	the	N	I-Premise
222	tape	N	I-Premise
223	group	N	I-Premise
224	.	N	I-Premise

225	The	N	I-Premise
226	acceptance	N	I-Premise
227	of	N	I-Premise
228	K-tape	N	I-Premise
229	was	N	I-Premise
230	better	N	I-Premise
231	than	N	I-Premise
232	the	N	I-Premise
233	bandage	N	I-Premise
234	,	N	I-Premise
235	and	N	I-Premise
236	benefits	N	I-Premise
237	included	N	I-Premise
238	longer	N	I-Premise
239	wearing	N	I-Premise
240	time	N	I-Premise
241	,	N	I-Premise
242	less	N	I-Premise
243	difficulty	N	I-Premise
244	in	N	I-Premise
245	usage	N	I-Premise
246	,	N	I-Premise
247	and	N	I-Premise
248	increased	N	I-Premise
249	comfort	N	I-Premise
250	and	N	I-Premise
251	convenience	N	I-Premise
252	(	N	I-Premise
253	P	N	I-Premise
254	<	N	I-Premise
255	0.05	N	I-Premise
256	)	N	I-Premise
257	.	N	I-Premise

258	The	N	I-Claim
259	study	N	I-Claim
260	results	N	I-Claim
261	suggest	N	I-Claim
262	that	N	I-Claim
263	K-tape	N	I-Claim
264	could	N	I-Claim
265	replace	N	I-Claim
266	the	N	I-Claim
267	bandage	N	I-Claim
268	in	N	I-Claim
269	DLT	N	I-Claim
270	,	N	I-Claim
271	and	N	I-Claim
272	it	N	I-Claim
273	could	N	I-Claim
274	be	N	I-Claim
275	an	N	I-Claim
276	alternative	N	I-Claim
277	choice	N	I-Claim
278	for	N	I-Claim
279	the	N	I-Claim
280	breast-cancer-related	N	I-Claim
281	lymphedema	N	I-Claim
282	patient	N	I-Claim
283	with	N	I-Claim
284	poor	N	I-Claim
285	short-stretch	N	I-Claim
286	bandage	N	I-Claim
287	compliance	N	I-Claim
288	after	N	I-Claim
289	1-month	N	I-Claim
290	intervention	N	I-Claim
291	.	N	I-Claim

292	If	N	O
293	the	N	O
294	intervention	N	O
295	period	N	O
296	was	N	O
297	prolonged	N	O
298	,	N	O
299	we	N	O
300	might	N	O
301	get	N	O
302	different	N	O
303	conclusion	N	O
304	.	N	O

305	Moreover	N	O
306	,	N	O
307	these	N	I-Claim
308	two	N	I-Claim
309	treatment	N	I-Claim
310	protocols	N	I-Claim
311	are	N	I-Claim
312	inefficient	N	I-Claim
313	and	N	I-Claim
314	cost	N	I-Claim
315	time	N	I-Claim
316	in	N	I-Claim
317	application	N	I-Claim
318	.	N	I-Claim

319	More	N	I-MajorClaim
320	efficient	N	I-MajorClaim
321	treatment	N	I-MajorClaim
322	protocol	N	I-MajorClaim
323	is	N	I-MajorClaim
324	needed	N	I-MajorClaim
325	for	N	I-MajorClaim
326	clinical	N	I-MajorClaim
327	practice	N	I-MajorClaim
328	.	N	I-MajorClaim

1	National	N	O
2	Cancer	N	O
3	Institute	N	O
4	of	N	O
5	Canada	N	O
6	Clinical	N	O
7	Trials	N	O
8	Group	N	O
9	CO.17	N	O
10	demonstrated	N	O
11	the	N	O
12	antiepidermal	N	O
13	growth	N	O
14	factor	N	O
15	receptor	N	O
16	(	N	O
17	anti-EGFR	N	O
18	)	N	O
19	monoclonal	N	O
20	antibody	N	O
21	cetuximab	N	O
22	improves	N	O
23	overall	N	O
24	and	N	O
25	progression-free	N	O
26	survival	N	O
27	in	N	O
28	patients	N	O
29	with	N	O
30	advanced	N	O
31	,	N	O
32	chemotherapy-refractory	N	O
33	colorectal	N	O
34	cancer	N	O
35	(	N	O
36	CRC	N	O
37	)	N	O
38	,	N	O
39	particularly	N	O
40	in	N	O
41	patients	N	O
42	with	N	O
43	wild-type	N	O
44	KRAS	N	O
45	tumors	N	O
46	.	N	O

47	This	N	O
48	article	N	O
49	reports	N	O
50	the	N	O
51	health-related	N	O
52	quality-of-life	N	O
53	(	N	O
54	HRQL	N	O
55	)	N	O
56	outcomes	N	O
57	from	N	O
58	CO.17	N	O
59	.	N	O

60	Patients	N	O
61	(	N	O
62	N	N	O
63	=	N	O
64	572	N	O
65	)	N	O
66	with	N	O
67	pretreated	N	O
68	EGFR-detectable	N	O
69	advanced	N	O
70	CRC	N	O
71	were	N	O
72	randomly	N	O
73	assigned	N	O
74	to	N	O
75	cetuximab	N	O
76	and	N	O
77	best	N	O
78	supportive	N	O
79	care	N	O
80	(	N	O
81	BSC	N	O
82	)	N	O
83	or	N	O
84	to	N	O
85	BSC	N	O
86	alone	N	O
87	.	N	O

88	HRQL	N	O
89	primary	N	O
90	end	N	O
91	points	N	O
92	assessed	N	O
93	by	N	O
94	the	N	O
95	EORTC	N	O
96	QLQ-C30	N	O
97	were	N	O
98	physical	N	O
99	function	N	O
100	(	N	O
101	PF	N	O
102	)	N	O
103	and	N	O
104	global	N	O
105	health	N	O
106	status	N	O
107	(	N	O
108	GHS	N	O
109	)	N	O
110	;	N	O
111	mean	N	O
112	changes	N	O
113	from	N	O
114	baseline	N	O
115	to	N	O
116	8	N	O
117	and	N	O
118	16	N	O
119	weeks	N	O
120	were	N	O
121	assessed	N	O
122	.	N	O

123	Post	N	O
124	hoc	N	O
125	analysis	N	O
126	by	N	O
127	KRAS	N	O
128	mutation	N	O
129	status	N	O
130	was	N	O
131	performed	N	O
132	.	N	O

133	Questionnaire	N	O
134	compliance	N	O
135	was	N	O
136	94	N	O
137	%	N	O
138	at	N	O
139	baseline	N	O
140	,	N	O
141	but	N	O
142	it	N	O
143	declined	N	O
144	differentially	N	O
145	(	N	O
146	67	N	O
147	%	N	O
148	v	N	O
149	47	N	O
150	%	N	O
151	for	N	O
152	cetuximab	N	O
153	v	N	O
154	BSC	N	O
155	at	N	O
156	16	N	O
157	weeks	N	O
158	)	N	O
159	.	N	O

160	PF	N	I-Premise
161	change	N	I-Premise
162	scores	N	I-Premise
163	were	N	I-Premise
164	-3.9	N	I-Premise
165	for	N	I-Premise
166	cetuximab	N	I-Premise
167	and	N	I-Premise
168	-8.6	N	I-Premise
169	for	N	I-Premise
170	BSC	N	I-Premise
171	(	N	I-Premise
172	P	N	I-Premise
173	=	N	I-Premise
174	.046	N	I-Premise
175	)	N	I-Premise
176	at	N	I-Premise
177	8	N	I-Premise
178	weeks	N	I-Premise
179	and	N	I-Premise
180	were	N	I-Premise
181	-5.9	N	I-Premise
182	and	N	I-Premise
183	-12.5	N	I-Premise
184	for	N	I-Premise
185	cetuximab	N	I-Premise
186	and	N	I-Premise
187	BSC	N	I-Premise
188	,	N	I-Premise
189	respectively	N	I-Premise
190	,	N	I-Premise
191	(	N	I-Premise
192	P	N	I-Premise
193	=	N	I-Premise
194	.027	N	I-Premise
195	)	N	I-Premise
196	at	N	I-Premise
197	16	N	I-Premise
198	weeks	N	I-Premise
199	.	N	I-Premise

200	GHS	N	I-Premise
201	change	N	I-Premise
202	scores	N	I-Premise
203	were	N	I-Premise
204	-0.5	N	I-Premise
205	and	N	I-Premise
206	-7.1	N	I-Premise
207	(	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	.008	N	I-Premise
211	)	N	I-Premise
212	at	N	I-Premise
213	8	N	I-Premise
214	weeks	N	I-Premise
215	and	N	I-Premise
216	were	N	I-Premise
217	-3.6	N	I-Premise
218	and	N	I-Premise
219	-15.2	N	I-Premise
220	(	N	I-Premise
221	P	N	I-Premise
222	=	N	I-Premise
223	.008	N	I-Premise
224	)	N	I-Premise
225	at	N	I-Premise
226	16	N	I-Premise
227	weeks	N	I-Premise
228	for	N	I-Premise
229	cetuximab	N	I-Premise
230	and	N	I-Premise
231	BSC	N	I-Premise
232	,	N	I-Premise
233	respectively	N	I-Premise
234	.	N	I-Premise

235	In	N	I-Premise
236	patients	N	I-Premise
237	who	N	I-Premise
238	had	N	I-Premise
239	tumors	N	I-Premise
240	with	N	I-Premise
241	wild-type	N	I-Premise
242	KRAS	N	I-Premise
243	status	N	I-Premise
244	,	N	I-Premise
245	cetuximab	N	I-Premise
246	resulted	N	I-Premise
247	in	N	I-Premise
248	less	N	I-Premise
249	PF	N	I-Premise
250	deterioration	N	I-Premise
251	at	N	I-Premise
252	8	N	I-Premise
253	weeks	N	I-Premise
254	(	N	I-Premise
255	-0.7	N	I-Premise
256	v	N	I-Premise
257	-7.2	N	I-Premise
258	;	N	I-Premise
259	P	N	I-Premise
260	=	N	I-Premise
261	.11	N	I-Premise
262	)	N	I-Premise
263	and	N	I-Premise
264	16	N	I-Premise
265	weeks	N	I-Premise
266	(	N	I-Premise
267	-3.4	N	I-Premise
268	v	N	I-Premise
269	-13.8	N	I-Premise
270	;	N	I-Premise
271	P	N	I-Premise
272	=	N	I-Premise
273	.008	N	I-Premise
274	)	N	I-Premise
275	compared	N	I-Premise
276	with	N	I-Premise
277	BSC	N	I-Premise
278	.	N	I-Premise

279	Patients	N	I-Premise
280	with	N	I-Premise
281	wild-type	N	I-Premise
282	status	N	I-Premise
283	who	N	I-Premise
284	received	N	I-Premise
285	cetuximab	N	I-Premise
286	experienced	N	I-Premise
287	improved	N	I-Premise
288	GHS	N	I-Premise
289	at	N	I-Premise
290	8	N	I-Premise
291	weeks	N	I-Premise
292	,	N	I-Premise
293	whereas	N	I-Premise
294	patients	N	I-Premise
295	who	N	I-Premise
296	received	N	I-Premise
297	BSC	N	I-Premise
298	alone	N	I-Premise
299	deteriorated	N	I-Premise
300	(	N	I-Premise
301	3.2	N	I-Premise
302	v	N	I-Premise
303	-7.7	N	I-Premise
304	;	N	I-Premise
305	P	N	I-Premise
306	=	N	I-Premise
307	.002	N	I-Premise
308	)	N	I-Premise
309	.	N	I-Premise

310	Cetuximab	N	I-Premise
311	preserved	N	I-Premise
312	GHS	N	I-Premise
313	at	N	I-Premise
314	16	N	I-Premise
315	weeks	N	I-Premise
316	(	N	I-Premise
317	-0.2	N	I-Premise
318	v	N	I-Premise
319	-18.1	N	I-Premise
320	;	N	I-Premise
321	P	N	I-Premise
322	<	N	I-Premise
323	.001	N	I-Premise
324	)	N	I-Premise
325	.	N	I-Premise

326	No	N	I-Premise
327	significant	N	I-Premise
328	differences	N	I-Premise
329	were	N	I-Premise
330	noted	N	I-Premise
331	between	N	I-Premise
332	study	N	I-Premise
333	arms	N	I-Premise
334	for	N	I-Premise
335	patients	N	I-Premise
336	with	N	I-Premise
337	mutated	N	I-Premise
338	KRAS	N	I-Premise
339	tumors	N	I-Premise
340	.	N	I-Premise

341	Cetuximab	N	I-Claim
342	offers	N	I-Claim
343	important	N	I-Claim
344	HRQL	N	I-Claim
345	and	N	I-Claim
346	survival	N	I-Claim
347	benefits	N	I-Claim
348	for	N	I-Claim
349	pretreated	N	I-Claim
350	patients	N	I-Claim
351	with	N	I-Claim
352	advanced	N	I-Claim
353	,	N	I-Claim
354	wild-type	N	I-Claim
355	KRAS	N	I-Claim
356	CRC	N	I-Claim
357	.	N	I-Claim

1	Androgen	N	O
2	treatment	N	O
3	for	N	O
4	prostate	N	O
5	cancer	N	O
6	can	N	O
7	adversely	N	O
8	affect	N	O
9	functional	N	O
10	domains	N	O
11	of	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	.	N	O

16	We	N	O
17	aimed	N	O
18	to	N	O
19	assess	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	in	N	O
24	men	N	O
25	with	N	O
26	locally	N	O
27	advanced	N	O
28	prostate	N	O
29	cancer	N	O
30	in	N	O
31	an	N	O
32	open-label	N	O
33	phase	N	O
34	III	N	O
35	randomised	N	O
36	comparison	N	O
37	between	N	O
38	lifelong	N	O
39	endocrine	N	O
40	treatment	N	O
41	with	N	O
42	and	N	O
43	without	N	O
44	radiotherapy	N	O
45	.	N	O

46	We	N	O
47	obtained	N	O
48	quality-of-life	N	O
49	information	N	O
50	from	N	O
51	872	N	O
52	(	N	O
53	99	N	O
54	%	N	O
55	)	N	O
56	of	N	O
57	875	N	O
58	eligible	N	O
59	men	N	O
60	with	N	O
61	locally	N	O
62	advanced	N	O
63	prostate	N	O
64	cancer	N	O
65	(	N	O
66	T3	N	O
67	;	N	O
68	78	N	O
69	%	N	O
70	)	N	O
71	who	N	O
72	were	N	O
73	randomly	N	O
74	assigned	N	O
75	,	N	O
76	between	N	O
77	1996	N	O
78	and	N	O
79	2002	N	O
80	,	N	O
81	to	N	O
82	3	N	O
83	months	N	O
84	of	N	O
85	total	N	O
86	androgen	N	O
87	blockade	N	O
88	followed	N	O
89	by	N	O
90	continuous	N	O
91	endocrine	N	O
92	treatment	N	O
93	(	N	O
94	439	N	O
95	patients	N	O
96	)	N	O
97	or	N	O
98	the	N	O
99	same	N	O
100	hormonal	N	O
101	treatment	N	O
102	with	N	O
103	radiotherapy	N	O
104	3	N	O
105	months	N	O
106	after	N	O
107	randomisation	N	O
108	(	N	O
109	436	N	O
110	patients	N	O
111	)	N	O
112	.	N	O

113	Prospective	N	O
114	outcomes	N	O
115	included	N	O
116	patient-reported	N	O
117	symptoms	N	O
118	and	N	O
119	quality	N	O
120	of	N	O
121	life	N	O
122	assessed	N	O
123	with	N	O
124	questionnaires	N	O
125	from	N	O
126	baseline	N	O
127	to	N	O
128	4	N	O
129	years	N	O
130	after	N	O
131	randomisation	N	O
132	.	N	O

133	Analysis	N	O
134	was	N	O
135	by	N	O
136	intention	N	O
137	to	N	O
138	treat	N	O
139	.	N	O

140	This	N	O
141	study	N	O
142	is	N	O
143	registered	N	O
144	as	N	O
145	an	N	O
146	international	N	O
147	standard	N	O
148	randomised	N	O
149	controlled	N	O
150	trial	N	O
151	,	N	O
152	number	N	O
153	ISRCTN01534787	N	O
154	.	N	O

155	438	N	O
156	of	N	O
157	439	N	O
158	men	N	O
159	assigned	N	O
160	endocrine	N	O
161	treatment	N	O
162	and	N	O
163	434	N	O
164	of	N	O
165	436	N	O
166	assigned	N	O
167	endocrine	N	O
168	plus	N	O
169	radiotherapy	N	O
170	completed	N	O
171	at	N	O
172	least	N	O
173	one	N	O
174	questionnaire	N	O
175	.	N	O

176	Missing	N	O
177	data	N	O
178	at	N	O
179	baseline	N	O
180	and	N	O
181	during	N	O
182	follow-up	N	O
183	was	N	O
184	equally	N	O
185	distributed	N	O
186	between	N	O
187	groups	N	O
188	.	N	O

189	At	N	I-Premise
190	4	N	I-Premise
191	years	N	I-Premise
192	,	N	I-Premise
193	64	N	I-Premise
194	(	N	I-Premise
195	18	N	I-Premise
196	%	N	I-Premise
197	)	N	I-Premise
198	of	N	I-Premise
199	353	N	I-Premise
200	patients	N	I-Premise
201	on	N	I-Premise
202	combined	N	I-Premise
203	therapy	N	I-Premise
204	and	N	I-Premise
205	39	N	I-Premise
206	(	N	I-Premise
207	12	N	I-Premise
208	%	N	I-Premise
209	)	N	I-Premise
210	of	N	I-Premise
211	337	N	I-Premise
212	on	N	I-Premise
213	endocrine-alone	N	I-Premise
214	therapy	N	I-Premise
215	had	N	I-Premise
216	moderate	N	I-Premise
217	to	N	I-Premise
218	severe	N	I-Premise
219	urinary	N	I-Premise
220	bother	N	I-Premise
221	(	N	I-Premise
222	p=0.005	N	I-Premise
223	)	N	I-Premise
224	,	N	I-Premise
225	and	N	I-Premise
226	16	N	I-Premise
227	(	N	I-Premise
228	4	N	I-Premise
229	%	N	I-Premise
230	)	N	I-Premise
231	of	N	I-Premise
232	355	N	I-Premise
233	on	N	I-Premise
234	combined	N	I-Premise
235	therapy	N	I-Premise
236	and	N	I-Premise
237	five	N	I-Premise
238	(	N	I-Premise
239	2	N	I-Premise
240	%	N	I-Premise
241	)	N	I-Premise
242	of	N	I-Premise
243	338	N	I-Premise
244	on	N	I-Premise
245	endocrine	N	I-Premise
246	treatment	N	I-Premise
247	alone	N	I-Premise
248	had	N	I-Premise
249	pain	N	I-Premise
250	while	N	I-Premise
251	urinating	N	I-Premise
252	(	N	I-Premise
253	p=0.024	N	I-Premise
254	)	N	I-Premise
255	.	N	I-Premise

256	37	N	I-Premise
257	(	N	I-Premise
258	11	N	I-Premise
259	%	N	I-Premise
260	)	N	I-Premise
261	of	N	I-Premise
262	350	N	I-Premise
263	in	N	I-Premise
264	the	N	I-Premise
265	combined	N	I-Premise
266	group	N	I-Premise
267	and	N	I-Premise
268	23	N	I-Premise
269	(	N	I-Premise
270	7	N	I-Premise
271	%	N	I-Premise
272	)	N	I-Premise
273	of	N	I-Premise
274	35	N	I-Premise
275	in	N	I-Premise
276	the	N	I-Premise
277	endocrine-only	N	I-Premise
278	group	N	I-Premise
279	had	N	I-Premise
280	overall	N	I-Premise
281	bother	N	I-Premise
282	from	N	I-Premise
283	all	N	I-Premise
284	bowel	N	I-Premise
285	symptoms	N	I-Premise
286	(	N	I-Premise
287	p=0.022	N	I-Premise
288	)	N	I-Premise
289	.	N	I-Premise

290	281	N	I-Premise
291	(	N	I-Premise
292	85	N	I-Premise
293	%	N	I-Premise
294	)	N	I-Premise
295	of	N	I-Premise
296	332	N	I-Premise
297	in	N	I-Premise
298	the	N	I-Premise
299	combined-treatment	N	I-Premise
300	group	N	I-Premise
301	and	N	I-Premise
302	227	N	I-Premise
303	(	N	I-Premise
304	72	N	I-Premise
305	%	N	I-Premise
306	)	N	I-Premise
307	of	N	I-Premise
308	313	N	I-Premise
309	in	N	I-Premise
310	the	N	I-Premise
311	endocrine-only	N	I-Premise
312	group	N	I-Premise
313	had	N	I-Premise
314	erectile	N	I-Premise
315	dysfunction	N	I-Premise
316	(	N	I-Premise
317	p=0.0002	N	I-Premise
318	)	N	I-Premise
319	.	N	I-Premise

320	Quality	N	I-Premise
321	of	N	I-Premise
322	life	N	I-Premise
323	at	N	I-Premise
324	4	N	I-Premise
325	years	N	I-Premise
326	was	N	I-Premise
327	similar	N	I-Premise
328	,	N	I-Premise
329	with	N	I-Premise
330	the	N	I-Premise
331	exception	N	I-Premise
332	of	N	I-Premise
333	decreased	N	I-Premise
334	social	N	I-Premise
335	function	N	I-Premise
336	in	N	I-Premise
337	patients	N	I-Premise
338	receiving	N	I-Premise
339	endocrine	N	I-Premise
340	treatment	N	I-Premise
341	plus	N	I-Premise
342	radiotherapy	N	I-Premise
343	.	N	I-Premise

344	Although	N	I-Claim
345	addition	N	I-Claim
346	of	N	I-Claim
347	radiotherapy	N	I-Claim
348	to	N	I-Claim
349	endocrine	N	I-Claim
350	treatment	N	I-Claim
351	significantly	N	I-Claim
352	increased	N	I-Claim
353	some	N	I-Claim
354	treatment-related	N	I-Claim
355	symptoms	N	I-Claim
356	,	N	I-Claim
357	none	N	I-Claim
358	were	N	I-Claim
359	serious	N	I-Claim
360	.	N	I-Claim

361	Given	N	O
362	the	N	O
363	substantial	N	O
364	survival	N	O
365	benefit	N	O
366	of	N	O
367	combined	N	O
368	treatment	N	O
369	,	N	O
370	the	N	I-Claim
371	increase	N	I-Claim
372	of	N	I-Claim
373	symptoms	N	I-Claim
374	seems	N	I-Claim
375	acceptable	N	I-Claim
376	and	N	I-Claim
377	has	N	I-Claim
378	little	N	I-Claim
379	extra	N	I-Claim
380	effect	N	I-Claim
381	on	N	I-Claim
382	quality	N	I-Claim
383	of	N	I-Claim
384	life	N	I-Claim
385	after	N	I-Claim
386	4	N	I-Claim
387	years	N	I-Claim
388	compared	N	I-Claim
389	with	N	I-Claim
390	endocrine	N	I-Claim
391	treatment	N	I-Claim
392	alone	N	I-Claim
393	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	survival	N	O
4	in	N	O
5	patients	N	O
6	with	N	O
7	recurrent	N	O
8	or	N	O
9	metastatic	N	O
10	squamous	N	O
11	cell	N	O
12	carcinoma	N	O
13	of	N	O
14	the	N	O
15	head	N	O
16	and	N	O
17	neck	N	O
18	(	N	O
19	SCCHN	N	O
20	)	N	O
21	treated	N	O
22	with	N	O
23	gefitinib	N	O
24	250	N	O
25	or	N	O
26	500	N	O
27	mg/day	N	O
28	or	N	O
29	standard	N	O
30	methotrexate	N	O
31	.	N	O

32	Four	N	O
33	hundred	N	O
34	eighty-six	N	O
35	patients	N	O
36	with	N	O
37	recurrent	N	O
38	SCCHN	N	O
39	were	N	O
40	randomly	N	O
41	assigned	N	O
42	to	N	O
43	oral	N	O
44	gefitinib	N	O
45	250	N	O
46	mg/day	N	O
47	,	N	O
48	gefitinib	N	O
49	500	N	O
50	mg/day	N	O
51	,	N	O
52	or	N	O
53	methotrexate	N	O
54	40	N	O
55	mg/m	N	O
56	(	N	O
57	2	N	O
58	)	N	O
59	intravenously	N	O
60	weekly	N	O
61	.	N	O

62	Primary	N	O
63	end	N	O
64	point	N	O
65	was	N	O
66	overall	N	O
67	survival	N	O
68	,	N	O
69	secondary	N	O
70	end	N	O
71	points	N	O
72	were	N	O
73	objective	N	O
74	response	N	O
75	rate	N	O
76	(	N	O
77	ORR	N	O
78	)	N	O
79	,	N	O
80	safety	N	O
81	,	N	O
82	symptom	N	O
83	improvement	N	O
84	,	N	O
85	and	N	O
86	quality	N	O
87	of	N	O
88	life	N	O
89	(	N	O
90	QOL	N	O
91	)	N	O
92	.	N	O

93	Exploratory	N	O
94	end	N	O
95	points	N	O
96	included	N	O
97	association	N	O
98	of	N	O
99	efficacy	N	O
100	with	N	O
101	epidermal	N	O
102	growth	N	O
103	factor	N	O
104	receptor	N	O
105	gene	N	O
106	copy	N	O
107	number	N	O
108	and	N	O
109	other	N	O
110	biomarkers	N	O
111	.	N	O

112	Neither	N	I-Premise
113	gefitinib	N	I-Premise
114	250	N	I-Premise
115	nor	N	I-Premise
116	500	N	I-Premise
117	mg/day	N	I-Premise
118	improved	N	I-Premise
119	overall	N	I-Premise
120	survival	N	I-Premise
121	compared	N	I-Premise
122	with	N	I-Premise
123	methotrexate	N	I-Premise
124	(	N	I-Premise
125	hazard	N	I-Premise
126	ratio	N	I-Premise
127	[	N	I-Premise
128	HR	N	I-Premise
129	]	N	I-Premise
130	,	N	I-Premise
131	1.22	N	I-Premise
132	;	N	I-Premise
133	95	N	I-Premise
134	%	N	I-Premise
135	CI	N	I-Premise
136	,	N	I-Premise
137	0.95	N	I-Premise
138	to	N	I-Premise
139	1.57	N	I-Premise
140	;	N	I-Premise
141	P	N	I-Premise
142	=	N	I-Premise
143	.12	N	I-Premise
144	;	N	I-Premise
145	and	N	I-Premise
146	HR	N	I-Premise
147	,	N	I-Premise
148	1.12	N	I-Premise
149	;	N	I-Premise
150	95	N	I-Premise
151	%	N	I-Premise
152	CI	N	I-Premise
153	,	N	I-Premise
154	0.87	N	I-Premise
155	to	N	I-Premise
156	1.43	N	I-Premise
157	;	N	I-Premise
158	P	N	I-Premise
159	=	N	I-Premise
160	.39	N	I-Premise
161	,	N	I-Premise
162	respectively	N	I-Premise
163	)	N	I-Premise
164	.	N	I-Premise

165	In	N	I-Premise
166	the	N	I-Premise
167	gefitinib	N	I-Premise
168	250	N	I-Premise
169	mg/day	N	I-Premise
170	,	N	I-Premise
171	500	N	I-Premise
172	mg/day	N	I-Premise
173	,	N	I-Premise
174	and	N	I-Premise
175	methotrexate	N	I-Premise
176	groups	N	I-Premise
177	,	N	I-Premise
178	respectively	N	I-Premise
179	,	N	I-Premise
180	median	N	I-Premise
181	overall	N	I-Premise
182	survival	N	I-Premise
183	was	N	I-Premise
184	5.6	N	I-Premise
185	,	N	I-Premise
186	6.0	N	I-Premise
187	,	N	I-Premise
188	and	N	I-Premise
189	6.7	N	I-Premise
190	months	N	I-Premise
191	;	N	I-Premise
192	ORRs	N	I-Premise
193	(	N	I-Premise
194	Response	N	I-Premise
195	Evaluation	N	I-Premise
196	Criteria	N	I-Premise
197	in	N	I-Premise
198	Solid	N	I-Premise
199	Tumors	N	I-Premise
200	)	N	I-Premise
201	were	N	I-Premise
202	2.7	N	I-Premise
203	%	N	I-Premise
204	,	N	I-Premise
205	7.6	N	I-Premise
206	%	N	I-Premise
207	and	N	I-Premise
208	3.9	N	I-Premise
209	%	N	I-Premise
210	,	N	I-Premise
211	with	N	I-Premise
212	no	N	I-Premise
213	statistically	N	I-Premise
214	significant	N	I-Premise
215	difference	N	I-Premise
216	between	N	I-Premise
217	either	N	I-Premise
218	gefitinib	N	I-Premise
219	arm	N	I-Premise
220	and	N	I-Premise
221	methotrexate	N	I-Premise
222	.	N	I-Premise

223	No	N	I-Premise
224	unexpected	N	I-Premise
225	adverse	N	I-Premise
226	events	N	I-Premise
227	were	N	I-Premise
228	observed	N	I-Premise
229	,	N	I-Premise
230	except	N	I-Premise
231	for	N	I-Premise
232	tumor	N	I-Premise
233	hemorrhage-type	N	I-Premise
234	events	N	I-Premise
235	with	N	I-Premise
236	gefitinib	N	I-Premise
237	(	N	I-Premise
238	8.9	N	I-Premise
239	%	N	I-Premise
240	,	N	I-Premise
241	gefitinib	N	I-Premise
242	250	N	I-Premise
243	mg/day	N	I-Premise
244	;	N	I-Premise
245	11.4	N	I-Premise
246	%	N	I-Premise
247	,	N	I-Premise
248	gefitinib	N	I-Premise
249	500	N	I-Premise
250	mg/day	N	I-Premise
251	;	N	I-Premise
252	1.9	N	I-Premise
253	%	N	I-Premise
254	,	N	I-Premise
255	methotrexate	N	I-Premise
256	)	N	I-Premise
257	.	N	I-Premise

258	QOL	N	I-Premise
259	improvement	N	I-Premise
260	rates	N	I-Premise
261	(	N	I-Premise
262	Functional	N	I-Premise
263	Assessment	N	I-Premise
264	of	N	I-Premise
265	Cancer	N	I-Premise
266	Therapy-Head	N	I-Premise
267	&	N	I-Premise
268	amp	N	I-Premise
269	;	N	I-Premise
270	Neck	N	I-Premise
271	total	N	I-Premise
272	score	N	I-Premise
273	)	N	I-Premise
274	were	N	I-Premise
275	13.4	N	I-Premise
276	%	N	I-Premise
277	,	N	I-Premise
278	18.0	N	I-Premise
279	%	N	I-Premise
280	,	N	I-Premise
281	and	N	I-Premise
282	6.0	N	I-Premise
283	%	N	I-Premise
284	for	N	I-Premise
285	gefitinib	N	I-Premise
286	250	N	I-Premise
287	mg/day	N	I-Premise
288	,	N	I-Premise
289	500	N	I-Premise
290	mg/day	N	I-Premise
291	,	N	I-Premise
292	and	N	I-Premise
293	methotrexate	N	I-Premise
294	,	N	I-Premise
295	respectively	N	I-Premise
296	.	N	I-Premise

297	In	N	I-Claim
298	patients	N	I-Claim
299	with	N	I-Claim
300	recurrent	N	I-Claim
301	or	N	I-Claim
302	metastatic	N	I-Claim
303	SCCHN	N	I-Claim
304	,	N	I-Claim
305	while	N	I-Claim
306	responses	N	I-Claim
307	with	N	I-Claim
308	gefitinib	N	I-Claim
309	were	N	I-Claim
310	seen	N	I-Claim
311	,	N	I-Claim
312	neither	N	I-Claim
313	gefitinib	N	I-Claim
314	250	N	I-Claim
315	nor	N	I-Claim
316	500	N	I-Claim
317	mg/day	N	I-Claim
318	improved	N	I-Claim
319	overall	N	I-Claim
320	survival	N	I-Claim
321	compared	N	I-Claim
322	with	N	I-Claim
323	methotrexate	N	I-Claim
324	.	N	I-Claim

325	With	N	I-Claim
326	the	N	I-Claim
327	exception	N	I-Claim
328	of	N	I-Claim
329	tumor	N	I-Claim
330	hemorrhage-type	N	I-Claim
331	events	N	I-Claim
332	with	N	I-Claim
333	gefitinib	N	I-Claim
334	,	N	I-Claim
335	the	N	I-Claim
336	adverse	N	I-Claim
337	event	N	I-Claim
338	profiles	N	I-Claim
339	were	N	I-Claim
340	generally	N	I-Claim
341	consistent	N	I-Claim
342	with	N	I-Claim
343	those	N	I-Claim
344	previously	N	I-Claim
345	observed	N	I-Claim
346	.	N	I-Claim

1	The	N	O
2	European	N	O
3	Study	N	O
4	Group	N	O
5	for	N	O
6	Pancreatic	N	O
7	Cancer	N	O
8	(	N	O
9	ESPAC-1	N	O
10	)	N	O
11	study	N	O
12	is	N	O
13	the	N	O
14	largest	N	O
15	study	N	O
16	of	N	O
17	adjuvant	N	O
18	treatment	N	O
19	for	N	O
20	pancreatic	N	O
21	ductal	N	O
22	adenocarcinoma	N	O
23	to	N	O
24	date	N	O
25	and	N	O
26	confirmed	N	O
27	a	N	O
28	survival	N	O
29	advantage	N	O
30	for	N	O
31	adjuvant	N	O
32	chemotherapy	N	O
33	but	N	O
34	not	N	O
35	for	N	O
36	chemoradiation	N	O
37	.	N	O

38	The	N	O
39	importance	N	O
40	of	N	O
41	parallel	N	O
42	evaluation	N	O
43	of	N	O
44	survival	N	O
45	and	N	O
46	quality	N	O
47	of	N	O
48	life	N	O
49	(	N	O
50	QoL	N	O
51	)	N	O
52	has	N	O
53	been	N	O
54	recognized	N	O
55	as	N	O
56	fundamental	N	O
57	and	N	O
58	the	N	O
59	aim	N	O
60	was	N	O
61	to	N	O
62	assess	N	O
63	QoL	N	O
64	and	N	O
65	quality	N	O
66	adjusted	N	O
67	survival	N	O
68	.	N	O

69	A	N	O
70	longitudinal	N	O
71	QoL	N	O
72	study	N	O
73	on	N	O
74	a	N	O
75	subset	N	O
76	of	N	O
77	ESPAC-1	N	O
78	patients	N	O
79	who	N	O
80	prospectively	N	O
81	completed	N	O
82	the	N	O
83	EORTC	N	O
84	QLQ	N	O
85	C-30	N	O
86	questionnaire	N	O
87	during	N	O
88	treatment	N	O
89	and	N	O
90	follow-up	N	O
91	.	N	O

92	An	N	O
93	integrated	N	O
94	quality-survival	N	O
95	product	N	O
96	method	N	O
97	was	N	O
98	used	N	O
99	to	N	O
100	adjust	N	O
101	any	N	O
102	treatment	N	O
103	effect	N	O
104	on	N	O
105	survival	N	O
106	by	N	O
107	a	N	O
108	function	N	O
109	of	N	O
110	measured	N	O
111	QoL	N	O
112	,	N	O
113	calculated	N	O
114	over	N	O
115	a	N	O
116	restricted	N	O
117	24-month-period	N	O
118	(	N	O
119	QALM-24	N	O
120	)	N	O
121	.	N	O

122	Three	N	O
123	hundred	N	O
124	and	N	O
125	sixteen	N	O
126	patients	N	O
127	completed	N	O
128	1,201	N	O
129	questionnaires	N	O
130	.	N	O

131	There	N	O
132	were	N	O
133	no	N	O
134	differences	N	O
135	between	N	O
136	treatment	N	O
137	groups	N	O
138	in	N	O
139	dimension	N	O
140	scores	N	O
141	at	N	O
142	baseline	N	O
143	(	N	O
144	randomization	N	O
145	)	N	O
146	.	N	O

147	For	N	I-Premise
148	the	N	I-Premise
149	chemotherapy	N	I-Premise
150	group	N	I-Premise
151	,	N	I-Premise
152	the	N	I-Premise
153	mean	N	I-Premise
154	Quality	N	I-Premise
155	Adjusted	N	I-Premise
156	Life	N	I-Premise
157	Months	N	I-Premise
158	over	N	I-Premise
159	24	N	I-Premise
160	months	N	I-Premise
161	(	N	I-Premise
162	QALM-24	N	I-Premise
163	)	N	I-Premise
164	was	N	I-Premise
165	9.6	N	I-Premise
166	(	N	I-Premise
167	95	N	I-Premise
168	%	N	I-Premise
169	CI	N	I-Premise
170	:	N	I-Premise
171	8.7	N	I-Premise
172	,	N	I-Premise
173	11.2	N	I-Premise
174	)	N	I-Premise
175	months	N	I-Premise
176	compared	N	I-Premise
177	with	N	I-Premise
178	the	N	I-Premise
179	mean	N	I-Premise
180	QALM-24	N	I-Premise
181	of	N	I-Premise
182	8.6	N	I-Premise
183	(	N	I-Premise
184	95	N	I-Premise
185	%	N	I-Premise
186	CI	N	I-Premise
187	:	N	I-Premise
188	7.6	N	I-Premise
189	,	N	I-Premise
190	10.5	N	I-Premise
191	)	N	I-Premise
192	months	N	I-Premise
193	for	N	I-Premise
194	the	N	I-Premise
195	no	N	I-Premise
196	chemotherapy	N	I-Premise
197	group	N	I-Premise
198	.	N	I-Premise

199	For	N	I-Premise
200	the	N	I-Premise
201	chemoradiation	N	I-Premise
202	group	N	I-Premise
203	,	N	I-Premise
204	the	N	I-Premise
205	mean	N	I-Premise
206	QALM-24	N	I-Premise
207	was	N	I-Premise
208	7.1	N	I-Premise
209	(	N	I-Premise
210	95	N	I-Premise
211	%	N	I-Premise
212	CI	N	I-Premise
213	:	N	I-Premise
214	6.0	N	I-Premise
215	,	N	I-Premise
216	9.0	N	I-Premise
217	)	N	I-Premise
218	months	N	I-Premise
219	compared	N	I-Premise
220	with	N	I-Premise
221	the	N	I-Premise
222	mean	N	I-Premise
223	QALM-24	N	I-Premise
224	of	N	I-Premise
225	8.1	N	I-Premise
226	(	N	I-Premise
227	95	N	I-Premise
228	%	N	I-Premise
229	CI	N	I-Premise
230	:	N	I-Premise
231	7.0	N	I-Premise
232	,	N	I-Premise
233	10.0	N	I-Premise
234	)	N	I-Premise
235	months	N	I-Premise
236	for	N	I-Premise
237	the	N	I-Premise
238	no	N	I-Premise
239	chemoradiation	N	I-Premise
240	group	N	I-Premise
241	.	N	I-Premise

242	The	N	I-Claim
243	previously	N	I-Claim
244	reported	N	I-Claim
245	survival	N	I-Claim
246	advantage	N	I-Claim
247	supporting	N	I-Claim
248	the	N	I-Claim
249	use	N	I-Claim
250	of	N	I-Claim
251	adjuvant	N	I-Claim
252	chemotherapy	N	I-Claim
253	is	N	I-Claim
254	maintained	N	I-Claim
255	when	N	I-Claim
256	adjusted	N	I-Claim
257	using	N	I-Claim
258	quality	N	I-Claim
259	adjusted	N	I-Claim
260	survival	N	I-Claim
261	methodology	N	I-Claim
262	.	N	I-Claim

263	Chemotherapy	N	I-Claim
264	provided	N	I-Claim
265	on	N	I-Claim
266	average	N	I-Claim
267	an	N	I-Claim
268	additional	N	I-Claim
269	1.0	N	I-Claim
270	quality-adjusted	N	I-Claim
271	life	N	I-Claim
272	months	N	I-Claim
273	within	N	I-Claim
274	a	N	I-Claim
275	restricted	N	I-Claim
276	2-year	N	I-Claim
277	time	N	I-Claim
278	period	N	I-Claim
279	from	N	I-Claim
280	the	N	I-Claim
281	time	N	I-Claim
282	of	N	I-Claim
283	resection	N	I-Claim
284	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	clinical	N	O
10	outcomes	N	O
11	and	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	in	N	O
16	patients	N	O
17	undergoing	N	O
18	surgery	N	O
19	for	N	O
20	pilonidal	N	O
21	disease	N	O
22	with	N	O
23	unroofing	N	O
24	and	N	O
25	marsupialization	N	O
26	(	N	O
27	UM	N	O
28	)	N	O
29	or	N	O
30	rhomboid	N	O
31	excision	N	O
32	and	N	O
33	Limberg	N	O
34	flap	N	O
35	(	N	O
36	RELP	N	O
37	)	N	O
38	procedures	N	O
39	.	N	O

40	One	N	O
41	hundred	N	O
42	forty	N	O
43	consecutive	N	O
44	patients	N	O
45	with	N	O
46	pilonidal	N	O
47	sinus	N	O
48	were	N	O
49	randomly	N	O
50	assigned	N	O
51	to	N	O
52	receive	N	O
53	either	N	O
54	UM	N	O
55	or	N	O
56	RELP	N	O
57	procedures	N	O
58	.	N	O

59	A	N	O
60	specifically	N	O
61	designed	N	O
62	questionnaire	N	O
63	was	N	O
64	administered	N	O
65	at	N	O
66	three	N	O
67	months	N	O
68	to	N	O
69	assess	N	O
70	time	N	O
71	from	N	O
72	the	N	O
73	operation	N	O
74	until	N	O
75	the	N	O
76	patient	N	O
77	was	N	O
78	able	N	O
79	to	N	O
80	walk	N	O
81	,	N	O
82	return	N	O
83	to	N	O
84	daily	N	O
85	activities	N	O
86	,	N	O
87	or	N	O
88	sit	N	O
89	without	N	O
90	pain	N	O
91	,	N	O
92	time	N	O
93	to	N	O
94	return	N	O
95	to	N	O
96	work	N	O
97	or	N	O
98	school	N	O
99	,	N	O
100	and	N	O
101	time	N	O
102	to	N	O
103	healing	N	O
104	.	N	O

105	Postoperative	N	O
106	pain	N	O
107	was	N	O
108	assessed	N	O
109	with	N	O
110	a	N	O
111	visual	N	O
112	analog	N	O
113	scale	N	O
114	and	N	O
115	the	N	O
116	McGill	N	O
117	Pain	N	O
118	Questionnaire	N	O
119	.	N	O

120	Patients	N	O
121	'	N	O
122	quality	N	O
123	of	N	O
124	life	N	O
125	was	N	O
126	evaluated	N	O
127	with	N	O
128	the	N	O
129	Cardiff	N	O
130	Wound	N	O
131	Impact	N	O
132	Schedule	N	O
133	(	N	O
134	CWIS	N	O
135	)	N	O
136	.	N	O

137	Questionnaires	N	O
138	were	N	O
139	administered	N	O
140	by	N	O
141	a	N	O
142	clinician	N	O
143	blinded	N	O
144	to	N	O
145	treatment	N	O
146	.	N	O

147	Compared	N	I-Premise
148	with	N	I-Premise
149	RELP	N	I-Premise
150	,	N	I-Premise
151	patients	N	I-Premise
152	receiving	N	I-Premise
153	UM	N	I-Premise
154	had	N	I-Premise
155	significantly	N	I-Premise
156	shorter	N	I-Premise
157	duration	N	I-Premise
158	of	N	I-Premise
159	operation	N	I-Premise
160	and	N	I-Premise
161	hospital	N	I-Premise
162	stay	N	I-Premise
163	,	N	I-Premise
164	shorter	N	I-Premise
165	time	N	I-Premise
166	periods	N	I-Premise
167	to	N	I-Premise
168	walk	N	I-Premise
169	,	N	I-Premise
170	return	N	I-Premise
171	to	N	I-Premise
172	daily	N	I-Premise
173	activities	N	I-Premise
174	,	N	I-Premise
175	or	N	I-Premise
176	sit	N	I-Premise
177	without	N	I-Premise
178	pain	N	I-Premise
179	and	N	I-Premise
180	to	N	I-Premise
181	return	N	I-Premise
182	to	N	I-Premise
183	work	N	I-Premise
184	or	N	I-Premise
185	school	N	I-Premise
186	,	N	I-Premise
187	and	N	I-Premise
188	fewer	N	I-Premise
189	complications	N	I-Premise
190	.	N	I-Premise

191	Time	N	I-Premise
192	to	N	I-Premise
193	final	N	I-Premise
194	healing	N	I-Premise
195	was	N	I-Premise
196	significantly	N	I-Premise
197	shorter	N	I-Premise
198	and	N	I-Premise
199	quality	N	I-Premise
200	of	N	I-Premise
201	life	N	I-Premise
202	scores	N	I-Premise
203	on	N	I-Premise
204	the	N	I-Premise
205	CWIS	N	I-Premise
206	were	N	I-Premise
207	higher	N	I-Premise
208	in	N	I-Premise
209	patients	N	I-Premise
210	receiving	N	I-Premise
211	RELP	N	I-Premise
212	than	N	I-Premise
213	in	N	I-Premise
214	those	N	I-Premise
215	receiving	N	I-Premise
216	UM	N	I-Premise
217	.	N	I-Premise

218	Patients	N	I-Premise
219	with	N	I-Premise
220	UM	N	I-Premise
221	had	N	I-Premise
222	lower	N	I-Premise
223	levels	N	I-Premise
224	of	N	I-Premise
225	pain	N	I-Premise
226	one	N	I-Premise
227	week	N	I-Premise
228	after	N	I-Premise
229	surgery	N	I-Premise
230	.	N	I-Premise

231	The	N	I-Claim
232	unroofing	N	I-Claim
233	and	N	I-Claim
234	marsupialization	N	I-Claim
235	procedure	N	I-Claim
236	provides	N	I-Claim
237	more	N	I-Claim
238	clinical	N	I-Claim
239	benefits	N	I-Claim
240	in	N	I-Claim
241	the	N	I-Claim
242	treatment	N	I-Claim
243	of	N	I-Claim
244	pilonidal	N	I-Claim
245	disease	N	I-Claim
246	than	N	I-Claim
247	rhomboid	N	I-Claim
248	excision	N	I-Claim
249	and	N	I-Claim
250	Limberg	N	I-Claim
251	flap	N	I-Claim
252	and	N	I-Claim
253	should	N	I-Claim
254	be	N	I-Claim
255	considered	N	I-Claim
256	the	N	I-Claim
257	procedure	N	I-Claim
258	of	N	I-Claim
259	choice	N	I-Claim
260	.	N	I-Claim

261	However	N	I-Claim
262	,	N	I-Claim
263	it	N	I-Claim
264	may	N	I-Claim
265	be	N	I-Claim
266	associated	N	I-Claim
267	with	N	I-Claim
268	more	N	I-Claim
269	inconvenience	N	I-Claim
270	in	N	I-Claim
271	wound	N	I-Claim
272	care	N	I-Claim
273	and	N	I-Claim
274	longer	N	I-Claim
275	healing	N	I-Claim
276	time	N	I-Claim
277	than	N	I-Claim
278	rhomboid	N	I-Claim
279	excision	N	I-Claim
280	and	N	I-Claim
281	Lindberg	N	I-Claim
282	flap	N	I-Claim
283	.	N	I-Claim

1	We	N	O
2	evaluated	N	O
3	the	N	O
4	role	N	O
5	of	N	O
6	glutathione-related	N	O
7	genotypes	N	O
8	on	N	O
9	overall	N	O
10	survival	N	O
11	,	N	O
12	time	N	O
13	to	N	O
14	progression	N	O
15	,	N	O
16	adverse	N	O
17	events	N	O
18	,	N	O
19	and	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QOL	N	O
25	)	N	O
26	in	N	O
27	stage	N	O
28	IIIB/IV	N	O
29	non-small	N	O
30	cell	N	O
31	lung	N	O
32	cancer	N	O
33	patients	N	O
34	who	N	O
35	were	N	O
36	stable	N	O
37	or	N	O
38	responding	N	O
39	from	N	O
40	initial	N	O
41	treatment	N	O
42	with	N	O
43	platinum-based	N	O
44	chemotherapy	N	O
45	and	N	O
46	subsequently	N	O
47	randomized	N	O
48	to	N	O
49	receive	N	O
50	daily	N	O
51	oral	N	O
52	carboxyaminoimidazole	N	O
53	or	N	O
54	a	N	O
55	placebo	N	O
56	.	N	O

57	Of	N	O
58	the	N	O
59	186	N	O
60	total	N	O
61	patients	N	O
62	,	N	O
63	113	N	O
64	had	N	O
65	initial	N	O
66	treatment	N	O
67	with	N	O
68	platinum	N	O
69	therapy	N	O
70	and	N	O
71	DNA	N	O
72	samples	N	O
73	of	N	O
74	whom	N	O
75	46	N	O
76	also	N	O
77	had	N	O
78	QOL	N	O
79	data	N	O
80	.	N	O

81	These	N	O
82	samples	N	O
83	were	N	O
84	analyzed	N	O
85	using	N	O
86	six	N	O
87	polymorphic	N	O
88	DNA	N	O
89	markers	N	O
90	that	N	O
91	encode	N	O
92	five	N	O
93	important	N	O
94	enzymes	N	O
95	in	N	O
96	the	N	O
97	glutathione	N	O
98	metabolic	N	O
99	pathway	N	O
100	.	N	O

101	Patient	N	O
102	QOL	N	O
103	was	N	O
104	assessed	N	O
105	using	N	O
106	the	N	O
107	Functional	N	O
108	Assessment	N	O
109	of	N	O
110	Cancer	N	O
111	Therapy-Lung	N	O
112	and	N	O
113	the	N	O
114	UNISCALE	N	O
115	QOL	N	O
116	questionnaires	N	O
117	.	N	O

118	A	N	O
119	clinically	N	O
120	significant	N	O
121	decline	N	O
122	in	N	O
123	QOL	N	O
124	was	N	O
125	defined	N	O
126	as	N	O
127	a	N	O
128	10	N	O
129	%	N	O
130	decrease	N	O
131	from	N	O
132	baseline	N	O
133	to	N	O
134	week-8	N	O
135	.	N	O

136	Multivariate	N	O
137	analyses	N	O
138	were	N	O
139	used	N	O
140	to	N	O
141	evaluate	N	O
142	the	N	O
143	association	N	O
144	of	N	O
145	the	N	O
146	genotypes	N	O
147	on	N	O
148	the	N	O
149	four	N	O
150	endpoints	N	O
151	.	N	O

152	Patients	N	I-Premise
153	carrying	N	I-Premise
154	a	N	I-Premise
155	GCLC	N	I-Premise
156	77	N	I-Premise
157	genotype	N	I-Premise
158	had	N	I-Premise
159	a	N	I-Premise
160	worse	N	I-Premise
161	overall	N	I-Premise
162	survival	N	I-Premise
163	(	N	I-Premise
164	hazard	N	I-Premise
165	ratio	N	I-Premise
166	(	N	I-Premise
167	HR	N	I-Premise
168	)	N	I-Premise
169	=	N	I-Premise
170	1.5	N	I-Premise
171	,	N	I-Premise
172	p	N	I-Premise
173	=	N	I-Premise
174	0.05	N	I-Premise
175	)	N	I-Premise
176	.	N	I-Premise

177	Patients	N	I-Premise
178	carrying	N	I-Premise
179	the	N	I-Premise
180	GPX1-CC	N	I-Premise
181	genotype	N	I-Premise
182	had	N	I-Premise
183	a	N	I-Premise
184	clinically	N	I-Premise
185	significant	N	I-Premise
186	decline	N	I-Premise
187	in	N	I-Premise
188	the	N	I-Premise
189	UNISCALE	N	I-Premise
190	(	N	I-Premise
191	odds	N	I-Premise
192	ratio	N	I-Premise
193	(	N	I-Premise
194	OR	N	I-Premise
195	)	N	I-Premise
196	:	N	I-Premise
197	7.5	N	I-Premise
198	;	N	I-Premise
199	p	N	I-Premise
200	=	N	I-Premise
201	0.04	N	I-Premise
202	)	N	I-Premise
203	,	N	I-Premise
204	total	N	I-Premise
205	Functional	N	I-Premise
206	Assessment	N	I-Premise
207	of	N	I-Premise
208	Cancer	N	I-Premise
209	Therapy-Lung	N	I-Premise
210	score	N	I-Premise
211	(	N	I-Premise
212	OR	N	I-Premise
213	:	N	I-Premise
214	11.0	N	I-Premise
215	;	N	I-Premise
216	p	N	I-Premise
217	=	N	I-Premise
218	0.04	N	I-Premise
219	)	N	I-Premise
220	,	N	I-Premise
221	physical	N	I-Premise
222	(	N	I-Premise
223	OR	N	I-Premise
224	:	N	I-Premise
225	7.1	N	I-Premise
226	;	N	I-Premise
227	p	N	I-Premise
228	=	N	I-Premise
229	0.03	N	I-Premise
230	)	N	I-Premise
231	,	N	I-Premise
232	functional	N	I-Premise
233	(	N	I-Premise
234	OR	N	I-Premise
235	:	N	I-Premise
236	5.2	N	I-Premise
237	;	N	I-Premise
238	p	N	I-Premise
239	=	N	I-Premise
240	0.04	N	I-Premise
241	)	N	I-Premise
242	,	N	I-Premise
243	and	N	I-Premise
244	emotional	N	I-Premise
245	well-being	N	I-Premise
246	constructs	N	I-Premise
247	(	N	I-Premise
248	OR	N	I-Premise
249	:	N	I-Premise
250	23.8	N	I-Premise
251	;	N	I-Premise
252	p	N	I-Premise
253	=	N	I-Premise
254	0.01	N	I-Premise
255	)	N	I-Premise
256	.	N	I-Premise

257	Genotypes	N	I-Claim
258	of	N	I-Claim
259	glutathione-related	N	I-Claim
260	enzymes	N	I-Claim
261	,	N	I-Claim
262	especially	N	I-Claim
263	GCLC	N	I-Claim
264	,	N	I-Claim
265	may	N	I-Claim
266	be	N	I-Claim
267	used	N	I-Claim
268	as	N	I-Claim
269	host	N	I-Claim
270	factors	N	I-Claim
271	in	N	I-Claim
272	predicting	N	I-Claim
273	patients	N	I-Claim
274	'	N	I-Claim
275	survival	N	I-Claim
276	after	N	I-Claim
277	platinum-based	N	I-Claim
278	chemotherapy	N	I-Claim
279	.	N	I-Claim

280	GPX1	N	I-Claim
281	may	N	I-Claim
282	be	N	I-Claim
283	an	N	I-Claim
284	inherited	N	I-Claim
285	factor	N	I-Claim
286	in	N	I-Claim
287	predicting	N	I-Claim
288	patients	N	I-Claim
289	'	N	I-Claim
290	QOL	N	I-Claim
291	.	N	I-Claim

292	Further	N	I-Claim
293	investigation	N	I-Claim
294	to	N	I-Claim
295	define	N	I-Claim
296	and	N	I-Claim
297	measure	N	I-Claim
298	the	N	I-Claim
299	effects	N	I-Claim
300	of	N	I-Claim
301	these	N	I-Claim
302	genes	N	I-Claim
303	in	N	I-Claim
304	chemotherapeutic	N	I-Claim
305	regimens	N	I-Claim
306	,	N	I-Claim
307	drug	N	I-Claim
308	toxicities	N	I-Claim
309	,	N	I-Claim
310	disease	N	I-Claim
311	progression	N	I-Claim
312	,	N	I-Claim
313	and	N	I-Claim
314	QOL	N	I-Claim
315	are	N	I-Claim
316	critical	N	I-Claim
317	.	N	I-Claim

1	To	N	O
2	analyze	N	O
3	and	N	O
4	compare	N	O
5	radiologic	N	O
6	lung	N	O
7	expansion	N	O
8	after	N	O
9	talc	N	O
10	pleurodesis	N	O
11	performed	N	O
12	either	N	O
13	by	N	O
14	videothoracoscopy	N	O
15	or	N	O
16	chest	N	O
17	tube	N	O
18	and	N	O
19	correlate	N	O
20	it	N	O
21	with	N	O
22	clinical	N	O
23	outcome	N	O
24	.	N	O

25	Secondary	N	O
26	end	N	O
27	points	N	O
28	evaluated	N	O
29	were	N	O
30	as	N	O
31	follows	N	O
32	:	N	O
33	clinical	N	O
34	efficacy	N	O
35	;	N	O
36	quality	N	O
37	of	N	O
38	life	N	O
39	;	N	O
40	safety	N	O
41	;	N	O
42	and	N	O
43	survival	N	O
44	.	N	O

45	Prospective	N	O
46	randomized	N	O
47	study	N	O
48	that	N	O
49	included	N	O
50	60	N	O
51	patients	N	O
52	(	N	O
53	45	N	O
54	women	N	O
55	,	N	O
56	15	N	O
57	men	N	O
58	;	N	O
59	mean	N	O
60	age	N	O
61	,	N	O
62	55.2	N	O
63	years	N	O
64	)	N	O
65	with	N	O
66	recurrent	N	O
67	malignant	N	O
68	pleural	N	O
69	effusion	N	O
70	between	N	O
71	January	N	O
72	2005	N	O
73	and	N	O
74	January	N	O
75	2008	N	O
76	.	N	O

77	They	N	O
78	were	N	O
79	randomized	N	O
80	into	N	O
81	the	N	O
82	following	N	O
83	two	N	O
84	groups	N	O
85	:	N	O
86	video-assisted	N	O
87	thoracic	N	O
88	surgery	N	O
89	(	N	O
90	VATS	N	O
91	)	N	O
92	talc	N	O
93	poudrage	N	O
94	;	N	O
95	and	N	O
96	talc	N	O
97	slurry	N	O
98	(	N	O
99	TS	N	O
100	)	N	O
101	administered	N	O
102	through	N	O
103	a	N	O
104	chest	N	O
105	tube	N	O
106	.	N	O

107	Lung	N	O
108	expansion	N	O
109	was	N	O
110	evaluated	N	O
111	through	N	O
112	chest	N	O
113	CT	N	O
114	scans	N	O
115	obtained	N	O
116	0	N	O
117	,	N	O
118	1	N	O
119	,	N	O
120	3	N	O
121	and	N	O
122	6	N	O
123	months	N	O
124	after	N	O
125	pleurodesis	N	O
126	.	N	O

127	Complications	N	O
128	,	N	O
129	drainage	N	O
130	time	N	O
131	,	N	O
132	hospital	N	O
133	stay	N	O
134	,	N	O
135	and	N	O
136	quality	N	O
137	of	N	O
138	life	N	O
139	(	N	O
140	Medical	N	O
141	Outcomes	N	O
142	Study	N	O
143	36-item	N	O
144	short	N	O
145	form	N	O
146	and	N	O
147	World	N	O
148	Health	N	O
149	Organization	N	O
150	quality-of-life	N	O
151	questionnaires	N	O
152	)	N	O
153	were	N	O
154	also	N	O
155	analyzed	N	O
156	.	N	O

157	There	N	O
158	were	N	O
159	no	N	O
160	significant	N	O
161	differences	N	O
162	in	N	O
163	preprocedure	N	O
164	clinical	N	O
165	and	N	O
166	pathologic	N	O
167	variables	N	O
168	between	N	O
169	groups	N	O
170	.	N	O

171	The	N	O
172	immediate	N	O
173	total	N	O
174	(	N	O
175	ie	N	O
176	,	N	O
177	>	N	O
178	90	N	O
179	%	N	O
180	)	N	O
181	lung	N	O
182	expansion	N	O
183	was	N	O
184	observed	N	O
185	in	N	O
186	27	N	O
187	patients	N	O
188	(	N	O
189	45	N	O
190	%	N	O
191	)	N	O
192	and	N	O
193	was	N	O
194	more	N	O
195	frequent	N	O
196	in	N	O
197	the	N	O
198	VATS	N	O
199	group	N	O
200	(	N	O
201	60	N	O
202	%	N	O
203	vs	N	O
204	30	N	O
205	%	N	O
206	,	N	O
207	respectively	N	O
208	;	N	O
209	p	N	O
210	=	N	O
211	0.027	N	O
212	)	N	O
213	.	N	O

214	During	N	I-Premise
215	follow-up	N	I-Premise
216	,	N	I-Premise
217	71	N	I-Premise
218	%	N	I-Premise
219	of	N	I-Premise
220	the	N	I-Premise
221	patients	N	I-Premise
222	showed	N	I-Premise
223	unaltered	N	I-Premise
224	or	N	I-Premise
225	improved	N	I-Premise
226	lung	N	I-Premise
227	expansion	N	I-Premise
228	and	N	I-Premise
229	9	N	I-Premise
230	patients	N	I-Premise
231	(	N	I-Premise
232	15	N	I-Premise
233	%	N	I-Premise
234	)	N	I-Premise
235	needed	N	I-Premise
236	new	N	I-Premise
237	pleural	N	I-Premise
238	procedures	N	I-Premise
239	(	N	I-Premise
240	VATS	N	I-Premise
241	group	N	I-Premise
242	,	N	I-Premise
243	5	N	I-Premise
244	recurrences	N	I-Premise
245	;	N	I-Premise
246	TS	N	I-Premise
247	group	N	I-Premise
248	,	N	I-Premise
249	4	N	I-Premise
250	recurrences	N	I-Premise
251	;	N	I-Premise
252	p	N	I-Premise
253	=	N	I-Premise
254	0.999	N	I-Premise
255	)	N	I-Premise
256	.	N	I-Premise

257	No	N	I-Premise
258	differences	N	I-Premise
259	were	N	I-Premise
260	found	N	I-Premise
261	between	N	I-Premise
262	groups	N	I-Premise
263	regarding	N	I-Premise
264	quality	N	I-Premise
265	of	N	I-Premise
266	life	N	I-Premise
267	,	N	I-Premise
268	complications	N	I-Premise
269	,	N	I-Premise
270	drainage	N	I-Premise
271	time	N	I-Premise
272	,	N	I-Premise
273	hospital	N	I-Premise
274	stay	N	I-Premise
275	,	N	I-Premise
276	and	N	I-Premise
277	survival	N	I-Premise
278	.	N	I-Premise

279	Immediate	N	I-Premise
280	lung	N	I-Premise
281	expansion	N	I-Premise
282	did	N	I-Premise
283	not	N	I-Premise
284	correlate	N	I-Premise
285	with	N	I-Premise
286	radiologic	N	I-Premise
287	recurrence	N	I-Premise
288	,	N	I-Premise
289	clinical	N	I-Premise
290	recurrence	N	I-Premise
291	,	N	I-Premise
292	or	N	I-Premise
293	complications	N	I-Premise
294	(	N	I-Premise
295	p	N	I-Premise
296	=	N	I-Premise
297	0.60	N	I-Premise
298	,	N	I-Premise
299	0.15	N	I-Premise
300	,	N	I-Premise
301	and	N	I-Premise
302	0.20	N	I-Premise
303	,	N	I-Premise
304	respectively	N	I-Premise
305	)	N	I-Premise
306	.	N	I-Premise

307	Immediate	N	I-Premise
308	partial	N	I-Premise
309	lung	N	I-Premise
310	expansion	N	I-Premise
311	was	N	I-Premise
312	a	N	I-Premise
313	frequent	N	I-Premise
314	finding	N	I-Premise
315	and	N	I-Premise
316	was	N	I-Premise
317	more	N	I-Premise
318	frequent	N	I-Premise
319	after	N	I-Premise
320	TS	N	I-Premise
321	.	N	I-Premise

322	Nonetheless	N	O
323	,	N	O
324	no	N	I-Claim
325	correlation	N	I-Claim
326	between	N	I-Claim
327	immediate	N	I-Claim
328	lung	N	I-Claim
329	expansion	N	I-Claim
330	and	N	I-Claim
331	clinical	N	I-Claim
332	outcome	N	I-Claim
333	was	N	I-Claim
334	found	N	I-Claim
335	in	N	I-Claim
336	this	N	I-Claim
337	study	N	I-Claim
338	.	N	I-Claim

1	A	N	O
2	dramatic	N	O
3	rise	N	O
4	in	N	O
5	incidence	N	O
6	,	N	O
7	an	N	O
8	aging	N	O
9	population	N	O
10	,	N	O
11	and	N	O
12	expensive	N	O
13	palliative	N	O
14	treatments	N	O
15	have	N	O
16	led	N	O
17	to	N	O
18	an	N	O
19	escalating	N	O
20	burden	N	O
21	on	N	O
22	clinicians	N	O
23	managing	N	O
24	inoperable	N	O
25	esophageal	N	O
26	cancer	N	O
27	with	N	O
28	only	N	O
29	limited	N	O
30	evidence	N	O
31	of	N	O
32	effectiveness	N	O
33	.	N	O

34	This	N	O
35	study	N	O
36	compares	N	O
37	the	N	O
38	clinical	N	O
39	effectiveness	N	O
40	and	N	O
41	cost-effectiveness	N	O
42	of	N	O
43	self-expanding	N	O
44	metal	N	O
45	stents	N	O
46	(	N	O
47	SEMSs	N	O
48	)	N	O
49	with	N	O
50	other	N	O
51	palliative	N	O
52	therapies	N	O
53	to	N	O
54	aid	N	O
55	clinicians	N	O
56	in	N	O
57	making	N	O
58	an	N	O
59	evidence-based	N	O
60	treatment	N	O
61	choice	N	O
62	.	N	O

63	We	N	O
64	conducted	N	O
65	a	N	O
66	prospective	N	O
67	,	N	O
68	multicenter	N	O
69	,	N	O
70	randomized	N	O
71	,	N	O
72	controlled	N	O
73	,	N	O
74	clinical	N	O
75	trial	N	O
76	with	N	O
77	215	N	O
78	patients	N	O
79	followed	N	O
80	until	N	O
81	death	N	O
82	or	N	O
83	study	N	O
84	closure	N	O
85	.	N	O

86	The	N	O
87	primary	N	O
88	outcome	N	O
89	measures	N	O
90	were	N	O
91	dysphagia	N	O
92	,	N	O
93	quality	N	O
94	of	N	O
95	life	N	O
96	(	N	O
97	QL	N	O
98	)	N	O
99	6	N	O
100	weeks	N	O
101	following	N	O
102	treatment	N	O
103	,	N	O
104	and	N	O
105	total	N	O
106	cost	N	O
107	of	N	O
108	treatment	N	O
109	.	N	O

110	Secondary	N	O
111	outcome	N	O
112	measures	N	O
113	included	N	O
114	treatment-associated	N	O
115	morbidity	N	O
116	,	N	O
117	mortality	N	O
118	,	N	O
119	survival	N	O
120	,	N	O
121	and	N	O
122	cost-effectiveness	N	O
123	.	N	O

124	An	N	O
125	intention-to-treat	N	O
126	analysis	N	O
127	was	N	O
128	carried	N	O
129	out	N	O
130	.	N	O

131	There	N	I-Premise
132	was	N	I-Premise
133	a	N	I-Premise
134	significant	N	I-Premise
135	difference	N	I-Premise
136	in	N	I-Premise
137	mean	N	I-Premise
138	dysphagia	N	I-Premise
139	grade	N	I-Premise
140	between	N	I-Premise
141	treatment	N	I-Premise
142	arms	N	I-Premise
143	6	N	I-Premise
144	weeks	N	I-Premise
145	following	N	I-Premise
146	treatment	N	I-Premise
147	(	N	I-Premise
148	P=0.046	N	I-Premise
149	)	N	I-Premise
150	,	N	I-Premise
151	with	N	I-Premise
152	worse	N	I-Premise
153	swallowing	N	I-Premise
154	reported	N	I-Premise
155	by	N	I-Premise
156	rigid	N	I-Premise
157	stent-treated	N	I-Premise
158	patients	N	I-Premise
159	(	N	I-Premise
160	mean	N	I-Premise
161	dysphagia	N	I-Premise
162	score	N	I-Premise
163	difference=-0.49	N	I-Premise
164	;	N	I-Premise
165	95	N	I-Premise
166	%	N	I-Premise
167	confidence	N	I-Premise
168	interval	N	I-Premise
169	(	N	I-Premise
170	CI	N	I-Premise
171	)	N	I-Premise
172	-0.10	N	I-Premise
173	to	N	I-Premise
174	-0.89	N	I-Premise
175	,	N	I-Premise
176	P=0.014	N	I-Premise
177	)	N	I-Premise
178	.	N	I-Premise

179	Global	N	I-Premise
180	QL	N	I-Premise
181	scores	N	I-Premise
182	were	N	I-Premise
183	lower	N	I-Premise
184	at	N	I-Premise
185	both	N	I-Premise
186	1	N	I-Premise
187	and	N	I-Premise
188	6	N	I-Premise
189	weeks	N	I-Premise
190	following	N	I-Premise
191	treatment	N	I-Premise
192	for	N	I-Premise
193	patients	N	I-Premise
194	treated	N	I-Premise
195	by	N	I-Premise
196	SEMSs	N	I-Premise
197	(	N	I-Premise
198	mean	N	I-Premise
199	difference	N	I-Premise
200	QL	N	I-Premise
201	index	N	I-Premise
202	week	N	I-Premise
203	1=-0.66	N	I-Premise
204	;	N	I-Premise
205	95	N	I-Premise
206	%	N	I-Premise
207	CI	N	I-Premise
208	:	N	I-Premise
209	-0.02	N	I-Premise
210	to	N	I-Premise
211	-1.30	N	I-Premise
212	,	N	I-Premise
213	P=0.04	N	I-Premise
214	;	N	I-Premise
215	mean	N	I-Premise
216	difference	N	I-Premise
217	QL	N	I-Premise
218	index	N	I-Premise
219	week	N	I-Premise
220	6=-1.01	N	I-Premise
221	;	N	I-Premise
222	95	N	I-Premise
223	%	N	I-Premise
224	CI	N	I-Premise
225	-0.30	N	I-Premise
226	to	N	I-Premise
227	-1.72	N	I-Premise
228	,	N	I-Premise
229	P=0.006	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	These	N	I-Premise
233	findings	N	I-Premise
234	were	N	I-Premise
235	associated	N	I-Premise
236	with	N	I-Premise
237	higher	N	I-Premise
238	post-procedure	N	I-Premise
239	pain	N	I-Premise
240	scores	N	I-Premise
241	in	N	I-Premise
242	the	N	I-Premise
243	SEMS	N	I-Premise
244	patient	N	I-Premise
245	group	N	I-Premise
246	(	N	I-Premise
247	mean	N	I-Premise
248	difference	N	I-Premise
249	of	N	I-Premise
250	the	N	I-Premise
251	European	N	I-Premise
252	Organisation	N	I-Premise
253	for	N	I-Premise
254	Research	N	I-Premise
255	and	N	I-Premise
256	Treatment	N	I-Premise
257	of	N	I-Premise
258	Cancer	N	I-Premise
259	QLQ	N	I-Premise
260	C-30	N	I-Premise
261	pain	N	I-Premise
262	symptom	N	I-Premise
263	score	N	I-Premise
264	at	N	I-Premise
265	week	N	I-Premise
266	1=11.13	N	I-Premise
267	;	N	I-Premise
268	95	N	I-Premise
269	%	N	I-Premise
270	CI	N	I-Premise
271	:	N	I-Premise
272	2.89-19.4	N	I-Premise
273	;	N	I-Premise
274	P=0.01	N	I-Premise
275	)	N	I-Premise
276	.	N	I-Premise

277	Although	N	I-Premise
278	mean	N	I-Premise
279	EQ-5D	N	I-Premise
280	QL	N	I-Premise
281	values	N	I-Premise
282	differed	N	I-Premise
283	between	N	I-Premise
284	the	N	I-Premise
285	treatments	N	I-Premise
286	(	N	I-Premise
287	P	N	I-Premise
288	<	N	I-Premise
289	0.001	N	I-Premise
290	)	N	I-Premise
291	,	N	I-Premise
292	this	N	I-Premise
293	difference	N	I-Premise
294	dissipated	N	I-Premise
295	following	N	I-Premise
296	generation	N	I-Premise
297	of	N	I-Premise
298	quality-adjusted	N	I-Premise
299	life	N	I-Premise
300	year	N	I-Premise
301	values	N	I-Premise
302	.	N	I-Premise

303	Total	N	O
304	costs	N	O
305	varied	N	O
306	between	N	O
307	treatment	N	O
308	arms	N	O
309	but	N	O
310	these	N	O
311	findings	N	O
312	canceled	N	O
313	out	N	O
314	when	N	O
315	SEMSs	N	O
316	were	N	O
317	compared	N	O
318	with	N	O
319	non-SEMS	N	O
320	therapies	N	O
321	(	N	O
322	95	N	O
323	%	N	O
324	CI	N	O
325	-845.15-1,332.62	N	O
326	)	N	O
327	.	N	O

328	These	N	O
329	results	N	O
330	were	N	O
331	robust	N	O
332	to	N	O
333	sensitivity	N	O
334	analysis	N	O
335	.	N	O

336	There	N	I-Premise
337	were	N	I-Premise
338	no	N	I-Premise
339	differences	N	I-Premise
340	in	N	I-Premise
341	the	N	I-Premise
342	in-hospital	N	I-Premise
343	mortality	N	I-Premise
344	or	N	I-Premise
345	early	N	I-Premise
346	complication	N	I-Premise
347	rates	N	I-Premise
348	,	N	I-Premise
349	but	N	I-Premise
350	late	N	I-Premise
351	complications	N	I-Premise
352	were	N	I-Premise
353	more	N	I-Premise
354	frequent	N	I-Premise
355	after	N	I-Premise
356	rigid	N	I-Premise
357	stenting	N	I-Premise
358	(	N	I-Premise
359	risk	N	I-Premise
360	ratio=2.47	N	I-Premise
361	;	N	I-Premise
362	95	N	I-Premise
363	%	N	I-Premise
364	CI	N	I-Premise
365	1.88-3.04	N	I-Premise
366	)	N	I-Premise
367	.	N	I-Premise

368	There	N	I-Premise
369	was	N	I-Premise
370	a	N	I-Premise
371	survival	N	I-Premise
372	advantage	N	I-Premise
373	for	N	I-Premise
374	non-stent-treated	N	I-Premise
375	patients	N	I-Premise
376	(	N	I-Premise
377	log-rank	N	I-Premise
378	statistic=4.21	N	I-Premise
379	,	N	I-Premise
380	P=0.04	N	I-Premise
381	)	N	I-Premise
382	.	N	I-Premise

383	The	N	I-Claim
384	treatment	N	I-Claim
385	choice	N	I-Claim
386	for	N	I-Claim
387	patients	N	I-Claim
388	with	N	I-Claim
389	inoperable	N	I-Claim
390	esophageal	N	I-Claim
391	cancer	N	I-Claim
392	should	N	I-Claim
393	be	N	I-Claim
394	between	N	I-Claim
395	a	N	I-Claim
396	SEMS	N	I-Claim
397	or	N	I-Claim
398	a	N	I-Claim
399	non-stent	N	I-Claim
400	treatment	N	I-Claim
401	after	N	I-Claim
402	consideration	N	I-Claim
403	has	N	I-Claim
404	been	N	I-Claim
405	given	N	I-Claim
406	to	N	I-Claim
407	both	N	I-Claim
408	patient	N	I-Claim
409	and	N	I-Claim
410	tumor	N	I-Claim
411	characteristics	N	I-Claim
412	and	N	I-Claim
413	clinician	N	I-Claim
414	and	N	I-Claim
415	patient	N	I-Claim
416	preferences	N	I-Claim
417	.	N	I-Claim

1	Lymphedema	N	O
2	is	N	O
3	an	N	O
4	adverse	N	O
5	effect	N	O
6	of	N	O
7	breast	N	O
8	cancer	N	O
9	surgery	N	O
10	.	N	O

11	Aqua	N	O
12	lymphatic	N	O
13	therapy	N	O
14	(	N	O
15	ALT	N	O
16	)	N	O
17	is	N	O
18	a	N	O
19	novel	N	O
20	treatment	N	O
21	for	N	O
22	limb	N	O
23	volume	N	O
24	reduction	N	O
25	.	N	O

26	The	N	O
27	aim	N	O
28	of	N	O
29	this	N	O
30	study	N	O
31	was	N	O
32	to	N	O
33	examine	N	O
34	whether	N	O
35	ALT	N	O
36	is	N	O
37	a	N	O
38	safe	N	O
39	method	N	O
40	and	N	O
41	whether	N	O
42	there	N	O
43	are	N	O
44	differences	N	O
45	in	N	O
46	adherence	N	O
47	,	N	O
48	limb	N	O
49	volume	N	O
50	,	N	O
51	and	N	O
52	quality	N	O
53	of	N	O
54	life	N	O
55	between	N	O
56	women	N	O
57	who	N	O
58	perform	N	O
59	only	N	O
60	self-management	N	O
61	treatment	N	O
62	and	N	O
63	women	N	O
64	who	N	O
65	participate	N	O
66	as	N	O
67	well	N	O
68	in	N	O
69	ALT	N	O
70	.	N	O

71	Design	N	O
72	of	N	O
73	the	N	O
74	study	N	O
75	was	N	O
76	single-blind	N	O
77	randomized	N	O
78	clinical	N	O
79	trial	N	O
80	.	N	O

81	The	N	O
82	setting	N	O
83	was	N	O
84	in	N	O
85	a	N	O
86	hydrotherapy	N	O
87	pool	N	O
88	,	N	O
89	1.2	N	O
90	m	N	O
91	depth	N	O
92	,	N	O
93	and	N	O
94	a	N	O
95	temperature	N	O
96	of	N	O
97	32-33	N	O
98	degrees	N	O
99	capital	N	O
100	ES	N	O
101	,	N	O
102	Cyrillic	N	O
103	.	N	O

104	Forty-eight	N	O
105	women	N	O
106	(	N	O
107	56	N	O
108	+/-	N	O
109	10	N	O
110	years	N	O
111	)	N	O
112	,	N	O
113	with	N	O
114	a	N	O
115	12.8	N	O
116	%	N	O
117	lymphedema	N	O
118	relative	N	O
119	volume	N	O
120	,	N	O
121	participated	N	O
122	in	N	O
123	the	N	O
124	study	N	O
125	.	N	O

126	The	N	O
127	control	N	O
128	group	N	O
129	was	N	O
130	instructed	N	O
131	to	N	O
132	perform	N	O
133	the	N	O
134	self-management	N	O
135	treatment	N	O
136	.	N	O

137	The	N	O
138	study	N	O
139	group	N	O
140	joined	N	O
141	a	N	O
142	weekly	N	O
143	session	N	O
144	of	N	O
145	ALT	N	O
146	for	N	O
147	3	N	O
148	months	N	O
149	in	N	O
150	addition	N	O
151	to	N	O
152	the	N	O
153	self-management	N	O
154	therapy	N	O
155	.	N	O

156	Adherence	N	O
157	was	N	O
158	assessed	N	O
159	by	N	O
160	a	N	O
161	self-reported	N	O
162	diary	N	O
163	,	N	O
164	limb	N	O
165	volume	N	O
166	by	N	O
167	a	N	O
168	water	N	O
169	displacement	N	O
170	device	N	O
171	,	N	O
172	quality	N	O
173	of	N	O
174	life	N	O
175	by	N	O
176	the	N	O
177	Upper	N	O
178	Limb	N	O
179	Lymphedema	N	O
180	Questionnaire	N	O
181	(	N	O
182	ULL27	N	O
183	)	N	O
184	,	N	O
185	prior	N	O
186	to	N	O
187	,	N	O
188	and	N	O
189	after	N	O
190	the	N	O
191	intervention	N	O
192	period	N	O
193	.	N	O

194	There	N	I-Premise
195	was	N	I-Premise
196	no	N	I-Premise
197	episode	N	I-Premise
198	of	N	I-Premise
199	arm	N	I-Premise
200	infection	N	I-Premise
201	or	N	I-Premise
202	aggravation	N	I-Premise
203	in	N	I-Premise
204	limb	N	I-Premise
205	volume	N	I-Premise
206	during	N	I-Premise
207	the	N	I-Premise
208	study	N	I-Premise
209	period	N	I-Premise
210	.	N	I-Premise

211	ALT	N	I-Premise
212	had	N	I-Premise
213	a	N	I-Premise
214	positive	N	I-Premise
215	,	N	I-Premise
216	statistically	N	I-Premise
217	and	N	I-Premise
218	clinically	N	I-Premise
219	significant	N	I-Premise
220	immediate	N	I-Premise
221	effect	N	I-Premise
222	on	N	I-Premise
223	limb	N	I-Premise
224	volume	N	I-Premise
225	but	N	I-Premise
226	no	N	I-Premise
227	long-term	N	I-Premise
228	effect	N	I-Premise
229	was	N	I-Premise
230	noted	N	I-Premise
231	.	N	I-Premise

232	The	N	I-Premise
233	adherence	N	I-Premise
234	rate	N	I-Premise
235	to	N	I-Premise
236	ALT	N	I-Premise
237	was	N	I-Premise
238	significantly	N	I-Premise
239	higher	N	I-Premise
240	than	N	I-Premise
241	the	N	I-Premise
242	adherence	N	I-Premise
243	to	N	I-Premise
244	self-management	N	I-Premise
245	therapy	N	I-Premise
246	.	N	I-Premise

247	QOL	N	I-Premise
248	improved	N	I-Premise
249	in	N	I-Premise
250	the	N	I-Premise
251	study	N	I-Premise
252	group	N	I-Premise
253	.	N	I-Premise

254	ALT	N	I-Claim
255	was	N	I-Claim
256	found	N	I-Claim
257	to	N	I-Claim
258	be	N	I-Claim
259	a	N	I-Claim
260	safe	N	I-Claim
261	method	N	I-Claim
262	,	N	I-Claim
263	with	N	I-Claim
264	high	N	I-Claim
265	adherence	N	I-Claim
266	,	N	I-Claim
267	in	N	I-Claim
268	treating	N	I-Claim
269	women	N	I-Claim
270	who	N	I-Claim
271	suffer	N	I-Claim
272	from	N	I-Claim
273	mild	N	I-Claim
274	to	N	I-Claim
275	moderate	N	I-Claim
276	lymphedema	N	I-Claim
277	.	N	I-Claim

278	A	N	I-Claim
279	significant	N	I-Claim
280	immediate	N	I-Claim
281	and	N	I-Claim
282	insignificant	N	I-Claim
283	long-term	N	I-Claim
284	effect	N	I-Claim
285	on	N	I-Claim
286	limb	N	I-Claim
287	volume	N	I-Claim
288	was	N	I-Claim
289	noted	N	I-Claim
290	.	N	I-Claim

1	The	N	O
2	combination	N	O
3	of	N	O
4	radiotherapy	N	O
5	plus	N	O
6	long-term	N	O
7	medical	N	O
8	suppression	N	O
9	of	N	O
10	androgens	N	O
11	(	N	O
12	>	N	O
13	or	N	O
14	=	N	O
15	2	N	O
16	years	N	O
17	)	N	O
18	improves	N	O
19	overall	N	O
20	survival	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	locally	N	O
25	advanced	N	O
26	prostate	N	O
27	cancer	N	O
28	.	N	O

29	We	N	O
30	compared	N	O
31	the	N	O
32	use	N	O
33	of	N	O
34	radiotherapy	N	O
35	plus	N	O
36	short-term	N	O
37	androgen	N	O
38	suppression	N	O
39	with	N	O
40	the	N	O
41	use	N	O
42	of	N	O
43	radiotherapy	N	O
44	plus	N	O
45	long-term	N	O
46	androgen	N	O
47	suppression	N	O
48	in	N	O
49	the	N	O
50	treatment	N	O
51	of	N	O
52	locally	N	O
53	advanced	N	O
54	prostate	N	O
55	cancer	N	O
56	.	N	O

57	We	N	O
58	randomly	N	O
59	assigned	N	O
60	patients	N	O
61	with	N	O
62	locally	N	O
63	advanced	N	O
64	prostate	N	O
65	cancer	N	O
66	who	N	O
67	had	N	O
68	received	N	O
69	external-beam	N	O
70	radiotherapy	N	O
71	plus	N	O
72	6	N	O
73	months	N	O
74	of	N	O
75	androgen	N	O
76	suppression	N	O
77	to	N	O
78	two	N	O
79	groups	N	O
80	,	N	O
81	one	N	O
82	to	N	O
83	receive	N	O
84	no	N	O
85	further	N	O
86	treatment	N	O
87	(	N	O
88	short-term	N	O
89	suppression	N	O
90	)	N	O
91	and	N	O
92	the	N	O
93	other	N	O
94	to	N	O
95	receive	N	O
96	2.5	N	O
97	years	N	O
98	of	N	O
99	further	N	O
100	treatment	N	O
101	with	N	O
102	a	N	O
103	luteinizing	N	O
104	hormone-releasing	N	O
105	hormone	N	O
106	agonist	N	O
107	(	N	O
108	long-term	N	O
109	suppression	N	O
110	)	N	O
111	.	N	O

112	An	N	O
113	outcome	N	O
114	of	N	O
115	noninferiority	N	O
116	of	N	O
117	short-term	N	O
118	androgen	N	O
119	suppression	N	O
120	as	N	O
121	compared	N	O
122	with	N	O
123	long-term	N	O
124	suppression	N	O
125	required	N	O
126	a	N	O
127	hazard	N	O
128	ratio	N	O
129	of	N	O
130	more	N	O
131	than	N	O
132	1.35	N	O
133	for	N	O
134	overall	N	O
135	survival	N	O
136	,	N	O
137	with	N	O
138	a	N	O
139	one-sided	N	O
140	alpha	N	O
141	level	N	O
142	of	N	O
143	0.05	N	O
144	.	N	O

145	An	N	O
146	interim	N	O
147	analysis	N	O
148	showed	N	O
149	futility	N	O
150	,	N	O
151	and	N	O
152	the	N	O
153	results	N	O
154	are	N	O
155	presented	N	O
156	with	N	O
157	an	N	O
158	adjusted	N	O
159	one-sided	N	O
160	alpha	N	O
161	level	N	O
162	of	N	O
163	0.0429	N	O
164	.	N	O

165	A	N	O
166	total	N	O
167	of	N	O
168	1113	N	O
169	men	N	O
170	were	N	O
171	registered	N	O
172	,	N	O
173	of	N	O
174	whom	N	O
175	970	N	O
176	were	N	O
177	randomly	N	O
178	assigned	N	O
179	,	N	O
180	483	N	O
181	to	N	O
182	short-term	N	O
183	suppression	N	O
184	and	N	O
185	487	N	O
186	to	N	O
187	long-term	N	O
188	suppression	N	O
189	.	N	O

190	After	N	I-Premise
191	a	N	I-Premise
192	median	N	I-Premise
193	follow-up	N	I-Premise
194	of	N	I-Premise
195	6.4	N	I-Premise
196	years	N	I-Premise
197	,	N	I-Premise
198	132	N	I-Premise
199	patients	N	I-Premise
200	in	N	I-Premise
201	the	N	I-Premise
202	short-term	N	I-Premise
203	group	N	I-Premise
204	and	N	I-Premise
205	98	N	I-Premise
206	in	N	I-Premise
207	the	N	I-Premise
208	long-term	N	I-Premise
209	group	N	I-Premise
210	had	N	I-Premise
211	died	N	I-Premise
212	;	N	I-Premise
213	the	N	I-Premise
214	number	N	I-Premise
215	of	N	I-Premise
216	deaths	N	I-Premise
217	due	N	I-Premise
218	to	N	I-Premise
219	prostate	N	I-Premise
220	cancer	N	I-Premise
221	was	N	I-Premise
222	47	N	I-Premise
223	in	N	I-Premise
224	the	N	I-Premise
225	short-term	N	I-Premise
226	group	N	I-Premise
227	and	N	I-Premise
228	29	N	I-Premise
229	in	N	I-Premise
230	the	N	I-Premise
231	long-term	N	I-Premise
232	group	N	I-Premise
233	.	N	I-Premise

234	The	N	I-Premise
235	5-year	N	I-Premise
236	overall	N	I-Premise
237	mortality	N	I-Premise
238	for	N	I-Premise
239	short-term	N	I-Premise
240	and	N	I-Premise
241	long-term	N	I-Premise
242	suppression	N	I-Premise
243	was	N	I-Premise
244	19.0	N	I-Premise
245	%	N	I-Premise
246	and	N	I-Premise
247	15.2	N	I-Premise
248	%	N	I-Premise
249	,	N	I-Premise
250	respectively	N	I-Premise
251	;	N	I-Premise
252	the	N	O
253	observed	N	O
254	hazard	N	O
255	ratio	N	O
256	was	N	O
257	1.42	N	O
258	(	N	O
259	upper	N	O
260	95.71	N	O
261	%	N	O
262	confidence	N	O
263	limit	N	O
264	,	N	O
265	1.79	N	O
266	;	N	O
267	P=0.65	N	O
268	for	N	O
269	noninferiority	N	O
270	)	N	O
271	.	N	O

272	Adverse	N	I-Premise
273	events	N	I-Premise
274	in	N	I-Premise
275	both	N	I-Premise
276	groups	N	I-Premise
277	included	N	I-Premise
278	fatigue	N	I-Premise
279	,	N	I-Premise
280	diminished	N	I-Premise
281	sexual	N	I-Premise
282	function	N	I-Premise
283	,	N	I-Premise
284	and	N	I-Premise
285	hot	N	I-Premise
286	flushes	N	I-Premise
287	.	N	I-Premise

288	The	N	I-Claim
289	combination	N	I-Claim
290	of	N	I-Claim
291	radiotherapy	N	I-Claim
292	plus	N	I-Claim
293	6	N	I-Claim
294	months	N	I-Claim
295	of	N	I-Claim
296	androgen	N	I-Claim
297	suppression	N	I-Claim
298	provides	N	I-Claim
299	inferior	N	I-Claim
300	survival	N	I-Claim
301	as	N	I-Claim
302	compared	N	I-Claim
303	with	N	I-Claim
304	radiotherapy	N	I-Claim
305	plus	N	I-Claim
306	3	N	I-Claim
307	years	N	I-Claim
308	of	N	I-Claim
309	androgen	N	I-Claim
310	suppression	N	I-Claim
311	in	N	I-Claim
312	the	N	I-Claim
313	treatment	N	I-Claim
314	of	N	I-Claim
315	locally	N	I-Claim
316	advanced	N	I-Claim
317	prostate	N	I-Claim
318	cancer	N	I-Claim
319	.	N	I-Claim

1	Studies	N	O
2	on	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	(	N	O
7	QOL	N	O
8	)	N	O
9	among	N	O
10	women	N	O
11	with	N	O
12	endometrial	N	O
13	cancer	N	O
14	have	N	O
15	shown	N	O
16	that	N	O
17	patients	N	O
18	who	N	O
19	undergo	N	O
20	pelvic	N	O
21	radiotherapy	N	O
22	report	N	O
23	lower	N	O
24	role	N	O
25	functioning	N	O
26	and	N	O
27	more	N	O
28	diarrhea	N	O
29	and	N	O
30	fatigue	N	O
31	.	N	O

32	In	N	O
33	the	N	O
34	Post	N	O
35	Operative	N	O
36	Radiation	N	O
37	Therapy	N	O
38	in	N	O
39	Endometrial	N	O
40	Cancer	N	O
41	(	N	O
42	PORTEC	N	O
43	)	N	O
44	trial	N	O
45	,	N	O
46	patients	N	O
47	with	N	O
48	endometrial	N	O
49	carcinoma	N	O
50	were	N	O
51	randomly	N	O
52	assigned	N	O
53	to	N	O
54	receive	N	O
55	external-beam	N	O
56	radiotherapy	N	O
57	(	N	O
58	EBRT	N	O
59	)	N	O
60	or	N	O
61	vaginal	N	O
62	brachytherapy	N	O
63	(	N	O
64	VBT	N	O
65	)	N	O
66	.	N	O

67	QOL	N	O
68	was	N	O
69	evaluated	N	O
70	by	N	O
71	using	N	O
72	the	N	O
73	European	N	O
74	Organisation	N	O
75	for	N	O
76	Research	N	O
77	and	N	O
78	Treatment	N	O
79	of	N	O
80	Cancer	N	O
81	Quality	N	O
82	of	N	O
83	Life	N	O
84	Questionnaire	N	O
85	C30	N	O
86	and	N	O
87	subscales	N	O
88	from	N	O
89	the	N	O
90	prostate	N	O
91	cancer	N	O
92	module	N	O
93	,	N	O
94	PR-25	N	O
95	,	N	O
96	and	N	O
97	the	N	O
98	ovarian	N	O
99	cancer	N	O
100	module	N	O
101	,	N	O
102	OV-28	N	O
103	.	N	O

104	PORTEC-2	N	O
105	accrued	N	O
106	427	N	O
107	patients	N	O
108	between	N	O
109	2002	N	O
110	and	N	O
111	2006	N	O
112	,	N	O
113	of	N	O
114	whom	N	O
115	214	N	O
116	were	N	O
117	randomly	N	O
118	assigned	N	O
119	to	N	O
120	EBRT	N	O
121	,	N	O
122	and	N	O
123	213	N	O
124	were	N	O
125	randomly	N	O
126	assigned	N	O
127	to	N	O
128	VBT	N	O
129	.	N	O

130	Three-hundred	N	O
131	forty-eight	N	O
132	patients	N	O
133	(	N	O
134	81	N	O
135	%	N	O
136	)	N	O
137	were	N	O
138	evaluable	N	O
139	for	N	O
140	QOL	N	O
141	.	N	O

142	QOL	N	O
143	outcomes	N	O
144	were	N	O
145	analyzed	N	O
146	at	N	O
147	a	N	O
148	median	N	O
149	follow-up	N	O
150	of	N	O
151	2	N	O
152	years	N	O
153	.	N	O

154	At	N	O
155	baseline	N	O
156	after	N	O
157	surgery	N	O
158	,	N	O
159	patient	N	O
160	functioning	N	O
161	was	N	O
162	at	N	O
163	the	N	O
164	lowest	N	O
165	level	N	O
166	,	N	O
167	and	N	O
168	it	N	O
169	increased	N	O
170	during	N	O
171	and	N	O
172	after	N	O
173	radiotherapy	N	O
174	to	N	O
175	reach	N	O
176	a	N	O
177	plateau	N	O
178	after	N	O
179	12	N	O
180	months	N	O
181	.	N	O

182	Patients	N	I-Premise
183	in	N	I-Premise
184	the	N	I-Premise
185	VBT	N	I-Premise
186	group	N	I-Premise
187	reported	N	I-Premise
188	better	N	I-Premise
189	social	N	I-Premise
190	functioning	N	I-Premise
191	(	N	I-Premise
192	P	N	I-Premise
193	<	N	I-Premise
194	.002	N	I-Premise
195	)	N	I-Premise
196	and	N	I-Premise
197	lower	N	I-Premise
198	symptom	N	I-Premise
199	scores	N	I-Premise
200	for	N	I-Premise
201	diarrhea	N	I-Premise
202	,	N	I-Premise
203	fecal	N	I-Premise
204	leakage	N	I-Premise
205	,	N	I-Premise
206	the	N	I-Premise
207	need	N	I-Premise
208	to	N	I-Premise
209	stay	N	I-Premise
210	close	N	I-Premise
211	to	N	I-Premise
212	the	N	I-Premise
213	toilet	N	I-Premise
214	,	N	I-Premise
215	and	N	I-Premise
216	limitation	N	I-Premise
217	in	N	I-Premise
218	daily	N	I-Premise
219	activities	N	I-Premise
220	because	N	I-Premise
221	of	N	I-Premise
222	bowel	N	I-Premise
223	symptoms	N	I-Premise
224	(	N	I-Premise
225	P	N	I-Premise
226	<	N	I-Premise
227	.001	N	I-Premise
228	)	N	I-Premise
229	.	N	I-Premise

230	At	N	O
231	baseline	N	O
232	,	N	O
233	15	N	O
234	%	N	O
235	of	N	O
236	patients	N	O
237	were	N	O
238	sexually	N	O
239	active	N	O
240	;	N	O
241	this	N	O
242	increased	N	O
243	significantly	N	O
244	to	N	O
245	39	N	O
246	%	N	O
247	during	N	O
248	the	N	O
249	first	N	O
250	year	N	O
251	(	N	O
252	P	N	O
253	<	N	O
254	.001	N	O
255	)	N	O
256	.	N	O

257	Sexual	N	I-Premise
258	functioning	N	I-Premise
259	and	N	I-Premise
260	symptoms	N	I-Premise
261	did	N	I-Premise
262	not	N	I-Premise
263	differ	N	I-Premise
264	between	N	I-Premise
265	the	N	I-Premise
266	treatment	N	I-Premise
267	groups	N	I-Premise
268	.	N	I-Premise

269	Patients	N	I-Premise
270	who	N	I-Premise
271	received	N	I-Premise
272	EBRT	N	I-Premise
273	reported	N	I-Premise
274	significantly	N	I-Premise
275	higher	N	I-Premise
276	levels	N	I-Premise
277	of	N	I-Premise
278	diarrhea	N	I-Premise
279	and	N	I-Premise
280	bowel	N	I-Premise
281	symptoms	N	I-Premise
282	.	N	I-Premise

283	This	N	O
284	resulted	N	O
285	in	N	O
286	a	N	O
287	higher	N	O
288	need	N	O
289	to	N	O
290	remain	N	O
291	close	N	O
292	to	N	O
293	a	N	O
294	toilet	N	O
295	and	N	O
296	,	N	O
297	as	N	O
298	a	N	O
299	consequence	N	O
300	,	N	O
301	more	N	O
302	limitation	N	O
303	of	N	O
304	daily	N	O
305	activities	N	O
306	because	N	O
307	of	N	O
308	bowel	N	O
309	symptoms	N	O
310	and	N	O
311	decreased	N	O
312	social	N	O
313	functioning	N	O
314	.	N	O

315	Vaginal	N	I-Claim
316	brachytherapy	N	I-Claim
317	provides	N	I-Claim
318	a	N	I-Claim
319	better	N	I-Claim
320	QOL	N	I-Claim
321	,	N	I-Claim
322	and	N	I-Claim
323	should	N	I-Claim
324	be	N	I-Claim
325	the	N	I-Claim
326	preferred	N	I-Claim
327	treatment	N	I-Claim
328	from	N	I-Claim
329	a	N	I-Claim
330	QOL	N	I-Claim
331	perspective	N	I-Claim
332	.	N	I-Claim

1	Cancer	N	O
2	cells	N	O
3	rely	N	O
4	on	N	O
5	angiogenesis	N	O
6	for	N	O
7	growth	N	O
8	and	N	O
9	dissemination	N	O
10	,	N	O
11	and	N	O
12	small	N	O
13	cell	N	O
14	lung	N	O
15	cancer	N	O
16	(	N	O
17	SCLC	N	O
18	)	N	O
19	is	N	O
20	a	N	O
21	highly	N	O
22	angiogenic	N	O
23	tumor	N	O
24	.	N	O

25	We	N	O
26	evaluated	N	O
27	thalidomide	N	O
28	,	N	O
29	an	N	O
30	anti-angiogenic	N	O
31	agent	N	O
32	,	N	O
33	when	N	O
34	combined	N	O
35	with	N	O
36	chemotherapy	N	O
37	and	N	O
38	as	N	O
39	maintenance	N	O
40	treatment	N	O
41	.	N	O

42	A	N	O
43	total	N	O
44	of	N	O
45	724	N	O
46	patients	N	O
47	(	N	O
48	51	N	O
49	%	N	O
50	with	N	O
51	limited	N	O
52	and	N	O
53	49	N	O
54	%	N	O
55	with	N	O
56	extensive	N	O
57	disease	N	O
58	)	N	O
59	were	N	O
60	randomly	N	O
61	assigned	N	O
62	to	N	O
63	receive	N	O
64	placebo	N	O
65	or	N	O
66	thalidomide	N	O
67	capsules	N	O
68	,	N	O
69	100-200	N	O
70	mg	N	O
71	daily	N	O
72	for	N	O
73	up	N	O
74	to	N	O
75	2	N	O
76	years	N	O
77	.	N	O

78	All	N	O
79	patients	N	O
80	received	N	O
81	etoposide	N	O
82	and	N	O
83	carboplatin	N	O
84	every	N	O
85	3	N	O
86	weeks	N	O
87	for	N	O
88	up	N	O
89	to	N	O
90	six	N	O
91	cycles	N	O
92	.	N	O

93	Endpoints	N	O
94	were	N	O
95	overall	N	O
96	survival	N	O
97	,	N	O
98	progression-free	N	O
99	survival	N	O
100	,	N	O
101	tumor	N	O
102	response	N	O
103	rate	N	O
104	,	N	O
105	toxicity	N	O
106	,	N	O
107	and	N	O
108	quality	N	O
109	of	N	O
110	life	N	O
111	(	N	O
112	QoL	N	O
113	)	N	O
114	.	N	O

115	Hazard	N	O
116	ratios	N	O
117	(	N	O
118	HRs	N	O
119	)	N	O
120	for	N	O
121	comparing	N	O
122	thalidomide	N	O
123	against	N	O
124	placebo	N	O
125	were	N	O
126	estimated	N	O
127	using	N	O
128	Cox	N	O
129	regression	N	O
130	modeling	N	O
131	.	N	O

132	Statistical	N	O
133	tests	N	O
134	were	N	O
135	two-sided	N	O
136	.	N	O

137	The	N	I-Premise
138	median	N	I-Premise
139	overall	N	I-Premise
140	survival	N	I-Premise
141	was	N	I-Premise
142	10.5	N	I-Premise
143	months	N	I-Premise
144	(	N	I-Premise
145	placebo	N	I-Premise
146	)	N	I-Premise
147	and	N	I-Premise
148	10.1	N	I-Premise
149	months	N	I-Premise
150	(	N	I-Premise
151	thalidomide	N	I-Premise
152	)	N	I-Premise
153	(	N	I-Premise
154	HR	N	I-Premise
155	for	N	I-Premise
156	death	N	I-Premise
157	=	N	I-Premise
158	1.09	N	I-Premise
159	,	N	I-Premise
160	95	N	I-Premise
161	%	N	I-Premise
162	confidence	N	I-Premise
163	interval	N	I-Premise
164	[	N	I-Premise
165	CI	N	I-Premise
166	]	N	I-Premise
167	=	N	I-Premise
168	0.93	N	I-Premise
169	to	N	I-Premise
170	1.27	N	I-Premise
171	;	N	I-Premise
172	P	N	I-Premise
173	=	N	I-Premise
174	.28	N	I-Premise
175	)	N	I-Premise
176	.	N	I-Premise

177	Among	N	I-Premise
178	patients	N	I-Premise
179	with	N	I-Premise
180	limited-stage	N	I-Premise
181	disease	N	I-Premise
182	,	N	I-Premise
183	there	N	I-Premise
184	was	N	I-Premise
185	no	N	I-Premise
186	evidence	N	I-Premise
187	of	N	I-Premise
188	a	N	I-Premise
189	survival	N	I-Premise
190	difference	N	I-Premise
191	(	N	I-Premise
192	HR	N	I-Premise
193	for	N	I-Premise
194	death	N	I-Premise
195	=	N	I-Premise
196	0.91	N	I-Premise
197	,	N	I-Premise
198	95	N	I-Premise
199	%	N	I-Premise
200	CI	N	I-Premise
201	=	N	I-Premise
202	0.73	N	I-Premise
203	to	N	I-Premise
204	1.15	N	I-Premise
205	)	N	I-Premise
206	,	N	I-Premise
207	but	N	I-Premise
208	among	N	I-Premise
209	patients	N	I-Premise
210	with	N	I-Premise
211	extensive	N	I-Premise
212	disease	N	I-Premise
213	,	N	I-Premise
214	survival	N	I-Premise
215	was	N	I-Premise
216	worse	N	I-Premise
217	in	N	I-Premise
218	the	N	I-Premise
219	thalidomide	N	I-Premise
220	group	N	I-Premise
221	(	N	I-Premise
222	HR	N	I-Premise
223	for	N	I-Premise
224	death	N	I-Premise
225	=	N	I-Premise
226	1.36	N	I-Premise
227	,	N	I-Premise
228	95	N	I-Premise
229	%	N	I-Premise
230	CI	N	I-Premise
231	=	N	I-Premise
232	1.10	N	I-Premise
233	to	N	I-Premise
234	1.68	N	I-Premise
235	)	N	I-Premise
236	.	N	I-Premise

237	Progression-free	N	I-Premise
238	survival	N	I-Premise
239	rates	N	I-Premise
240	were	N	I-Premise
241	also	N	I-Premise
242	similar	N	I-Premise
243	in	N	I-Premise
244	the	N	I-Premise
245	two	N	I-Premise
246	groups	N	I-Premise
247	(	N	I-Premise
248	HR	N	I-Premise
249	=	N	I-Premise
250	1.07	N	I-Premise
251	,	N	I-Premise
252	95	N	I-Premise
253	%	N	I-Premise
254	CI	N	I-Premise
255	=	N	I-Premise
256	0.92	N	I-Premise
257	to	N	I-Premise
258	1.24	N	I-Premise
259	)	N	I-Premise
260	.	N	I-Premise

261	Thalidomide	N	I-Premise
262	was	N	I-Premise
263	associated	N	I-Premise
264	with	N	I-Premise
265	an	N	I-Premise
266	increased	N	I-Premise
267	risk	N	I-Premise
268	of	N	I-Premise
269	having	N	I-Premise
270	a	N	I-Premise
271	thrombotic	N	I-Premise
272	event	N	I-Premise
273	,	N	I-Premise
274	mainly	N	I-Premise
275	pulmonary	N	I-Premise
276	embolus	N	I-Premise
277	and	N	I-Premise
278	deep	N	I-Premise
279	vein	N	I-Premise
280	thrombosis	N	I-Premise
281	(	N	I-Premise
282	19	N	I-Premise
283	%	N	I-Premise
284	thalidomide	N	I-Premise
285	vs	N	I-Premise
286	10	N	I-Premise
287	%	N	I-Premise
288	placebo	N	I-Premise
289	;	N	I-Premise
290	HR	N	I-Premise
291	=	N	I-Premise
292	2.13	N	I-Premise
293	,	N	I-Premise
294	95	N	I-Premise
295	%	N	I-Premise
296	CI	N	I-Premise
297	=	N	I-Premise
298	1.41	N	I-Premise
299	to	N	I-Premise
300	3.20	N	I-Premise
301	;	N	I-Premise
302	P	N	I-Premise
303	<	N	I-Premise
304	.001	N	I-Premise
305	)	N	I-Premise
306	.	N	I-Premise

307	There	N	I-Premise
308	were	N	I-Premise
309	no	N	I-Premise
310	statistically	N	I-Premise
311	significant	N	I-Premise
312	differences	N	I-Premise
313	between	N	I-Premise
314	treatments	N	I-Premise
315	in	N	I-Premise
316	hematological	N	I-Premise
317	and	N	I-Premise
318	nonhematological	N	I-Premise
319	toxic	N	I-Premise
320	effects	N	I-Premise
321	,	N	I-Premise
322	except	N	I-Premise
323	more	N	I-Premise
324	patients	N	I-Premise
325	in	N	I-Premise
326	the	N	I-Premise
327	thalidomide	N	I-Premise
328	group	N	I-Premise
329	had	N	I-Premise
330	rash	N	I-Premise
331	,	N	I-Premise
332	constipation	N	I-Premise
333	,	N	I-Premise
334	or	N	I-Premise
335	neuropathy	N	I-Premise
336	.	N	I-Premise

337	Overall	N	O
338	,	N	O
339	QoL	N	I-Claim
340	scores	N	I-Claim
341	were	N	I-Claim
342	similar	N	I-Claim
343	in	N	I-Claim
344	the	N	I-Claim
345	two	N	I-Claim
346	treatment	N	I-Claim
347	groups	N	I-Claim
348	,	N	I-Claim
349	but	N	I-Claim
350	thalidomide	N	I-Claim
351	was	N	I-Claim
352	associated	N	I-Claim
353	with	N	I-Claim
354	less	N	I-Claim
355	insomnia	N	I-Claim
356	and	N	I-Claim
357	diarrhea	N	I-Claim
358	and	N	I-Claim
359	more	N	I-Claim
360	constipation	N	I-Claim
361	and	N	I-Claim
362	peripheral	N	I-Claim
363	neuropathy	N	I-Claim
364	.	N	I-Claim

365	In	N	O
366	this	N	O
367	large	N	O
368	randomized	N	O
369	trial	N	O
370	,	N	O
371	thalidomide	N	I-Claim
372	in	N	I-Claim
373	combination	N	I-Claim
374	with	N	I-Claim
375	chemotherapy	N	I-Claim
376	did	N	I-Claim
377	not	N	I-Claim
378	improve	N	I-Claim
379	survival	N	I-Claim
380	of	N	I-Claim
381	patients	N	I-Claim
382	with	N	I-Claim
383	SCLC	N	I-Claim
384	but	N	I-Claim
385	was	N	I-Claim
386	associated	N	I-Claim
387	with	N	I-Claim
388	an	N	I-Claim
389	increased	N	I-Claim
390	risk	N	I-Claim
391	of	N	I-Claim
392	thrombotic	N	I-Claim
393	events	N	I-Claim
394	.	N	I-Claim

1	Transthoracic	N	O
2	and	N	O
3	transhiatal	N	O
4	esophagectomy	N	O
5	are	N	O
6	two	N	O
7	common	N	O
8	procedures	N	O
9	for	N	O
10	esophageal	N	O
11	cancer	N	O
12	resection	N	O
13	.	N	O

14	Prospective	N	O
15	studies	N	O
16	comparing	N	O
17	the	N	O
18	two	N	O
19	methods	N	O
20	in	N	O
21	Asian	N	O
22	people	N	O
23	are	N	O
24	few	N	O
25	.	N	O

26	In	N	O
27	addition	N	O
28	,	N	O
29	the	N	O
30	data	N	O
31	comparing	N	O
32	their	N	O
33	effects	N	O
34	on	N	O
35	the	N	O
36	quality	N	O
37	of	N	O
38	life	N	O
39	are	N	O
40	lacking	N	O
41	.	N	O

42	A	N	O
43	prospective	N	O
44	randomized	N	O
45	study	N	O
46	was	N	O
47	conducted	N	O
48	from	N	O
49	January	N	O
50	2003	N	O
51	.	N	O

52	Patients	N	O
53	of	N	O
54	resectable	N	O
55	esophageal	N	O
56	cancer	N	O
57	of	N	O
58	comparable	N	O
59	stage	N	O
60	were	N	O
61	allocated	N	O
62	to	N	O
63	undergo	N	O
64	the	N	O
65	transthoracic	N	O
66	or	N	O
67	transhiatal	N	O
68	procedure	N	O
69	in	N	O
70	turn	N	O
71	.	N	O

72	They	N	O
73	were	N	O
74	all	N	O
75	reconstructed	N	O
76	with	N	O
77	stomach	N	O
78	interposition	N	O
79	through	N	O
80	the	N	O
81	retrosternal	N	O
82	route	N	O
83	.	N	O

84	Discharged	N	O
85	patients	N	O
86	were	N	O
87	followed-up	N	O
88	in	N	O
89	the	N	O
90	outpatient	N	O
91	clinic	N	O
92	.	N	O

93	They	N	O
94	were	N	O
95	questioned	N	O
96	on	N	O
97	the	N	O
98	topics	N	O
99	of	N	O
100	(	N	O
101	i	N	O
102	)	N	O
103	severity	N	O
104	of	N	O
105	pain	N	O
106	,	N	O
107	(	N	O
108	ii	N	O
109	)	N	O
110	ease	N	O
111	of	N	O
112	swallowing	N	O
113	,	N	O
114	(	N	O
115	iii	N	O
116	)	N	O
117	satisfaction	N	O
118	of	N	O
119	daily	N	O
120	activities	N	O
121	,	N	O
122	(	N	O
123	iv	N	O
124	)	N	O
125	dependence	N	O
126	on	N	O
127	medications	N	O
128	,	N	O
129	(	N	O
130	v	N	O
131	)	N	O
132	working	N	O
133	ability	N	O
134	,	N	O
135	(	N	O
136	vi	N	O
137	)	N	O
138	fatigue	N	O
139	,	N	O
140	(	N	O
141	vii	N	O
142	)	N	O
143	appetite	N	O
144	,	N	O
145	(	N	O
146	viii	N	O
147	)	N	O
148	sociality	N	O
149	,	N	O
150	(	N	O
151	ix	N	O
152	)	N	O
153	happiness	N	O
154	and	N	O
155	(	N	O
156	x	N	O
157	)	N	O
158	self	N	O
159	respect	N	O
160	,	N	O
161	in	N	O
162	the	N	O
163	third	N	O
164	,	N	O
165	sixth	N	O
166	and	N	O
167	twelfth	N	O
168	month	N	O
169	.	N	O

170	Also	N	O
171	the	N	O
172	demographic	N	O
173	data	N	O
174	,	N	O
175	operative	N	O
176	results	N	O
177	and	N	O
178	survival	N	O
179	were	N	O
180	recorded	N	O
181	.	N	O

182	Up	N	O
183	to	N	O
184	December	N	O
185	2006	N	O
186	,	N	O
187	eighty-seven	N	O
188	patients	N	O
189	of	N	O
190	stage	N	O
191	II	N	O
192	and	N	O
193	III	N	O
194	,	N	O
195	including	N	O
196	71	N	O
197	patients	N	O
198	of	N	O
199	middle	N	O
200	third	N	O
201	lesions	N	O
202	and	N	O
203	16	N	O
204	lower	N	O
205	third	N	O
206	lesions	N	O
207	were	N	O
208	enrolled	N	O
209	.	N	O

210	The	N	I-Premise
211	operation	N	I-Premise
212	time	N	I-Premise
213	was	N	I-Premise
214	significantly	N	I-Premise
215	longer	N	I-Premise
216	,	N	I-Premise
217	and	N	I-Premise
218	the	N	I-Premise
219	leakage	N	I-Premise
220	rate	N	I-Premise
221	was	N	I-Premise
222	higher	N	I-Premise
223	in	N	I-Premise
224	the	N	I-Premise
225	transthoracic	N	I-Premise
226	group	N	I-Premise
227	(	N	I-Premise
228	Student	N	I-Premise
229	's	N	I-Premise
230	t-test	N	I-Premise
231	and	N	I-Premise
232	Fischer	N	I-Premise
233	's	N	I-Premise
234	exact	N	I-Premise
235	test	N	I-Premise
236	,	N	I-Premise
237	respectively	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	However	N	O
241	,	N	O
242	intraoperative	N	I-Premise
243	blood	N	I-Premise
244	loss	N	I-Premise
245	and	N	I-Premise
246	postoperative	N	I-Premise
247	hospital	N	I-Premise
248	stay	N	I-Premise
249	were	N	I-Premise
250	not	N	I-Premise
251	significantly	N	I-Premise
252	different	N	I-Premise
253	(	N	I-Premise
254	Student	N	I-Premise
255	t-test	N	I-Premise
256	)	N	I-Premise
257	.	N	I-Premise

258	Also	N	O
259	,	N	O
260	the	N	I-Premise
261	Kaplan-Meier	N	I-Premise
262	survival	N	I-Premise
263	curves	N	I-Premise
264	of	N	I-Premise
265	these	N	I-Premise
266	two	N	I-Premise
267	groups	N	I-Premise
268	were	N	I-Premise
269	not	N	I-Premise
270	significantly	N	I-Premise
271	different	N	I-Premise
272	by	N	I-Premise
273	log-rank	N	I-Premise
274	test	N	I-Premise
275	(	N	I-Premise
276	p=0.286	N	I-Premise
277	)	N	I-Premise
278	.	N	I-Premise

279	The	N	I-Premise
280	score	N	I-Premise
281	on	N	I-Premise
282	the	N	I-Premise
283	quality	N	I-Premise
284	of	N	I-Premise
285	life	N	I-Premise
286	of	N	I-Premise
287	transhiatal	N	I-Premise
288	patients	N	I-Premise
289	was	N	I-Premise
290	significantly	N	I-Premise
291	higher	N	I-Premise
292	than	N	I-Premise
293	that	N	I-Premise
294	of	N	I-Premise
295	transthoracic	N	I-Premise
296	patients	N	I-Premise
297	in	N	I-Premise
298	the	N	I-Premise
299	third	N	I-Premise
300	,	N	I-Premise
301	sixth	N	I-Premise
302	and	N	I-Premise
303	twelfth	N	I-Premise
304	month	N	I-Premise
305	.	N	I-Premise

306	Transhiatal	N	I-Claim
307	esophagectomy	N	I-Claim
308	is	N	I-Claim
309	a	N	I-Claim
310	safe	N	I-Claim
311	and	N	I-Claim
312	fast	N	I-Claim
313	procedure	N	I-Claim
314	.	N	I-Claim

315	The	N	I-Claim
316	survival	N	I-Claim
317	was	N	I-Claim
318	similar	N	I-Claim
319	to	N	I-Claim
320	that	N	I-Claim
321	of	N	I-Claim
322	transthoracic	N	I-Claim
323	approach	N	I-Claim
324	.	N	I-Claim

325	Its	N	I-Claim
326	leakage	N	I-Claim
327	rate	N	I-Claim
328	was	N	I-Claim
329	lower	N	I-Claim
330	and	N	I-Claim
331	quality	N	I-Claim
332	of	N	I-Claim
333	life	N	I-Claim
334	was	N	I-Claim
335	better	N	I-Claim
336	.	N	I-Claim

1	Therapy	N	O
2	for	N	O
3	polycystic	N	O
4	liver	N	O
5	is	N	O
6	invasive	N	O
7	,	N	O
8	expensive	N	O
9	,	N	O
10	and	N	O
11	has	N	O
12	disappointing	N	O
13	long-term	N	O
14	results	N	O
15	.	N	O

16	Treatment	N	O
17	with	N	O
18	somatostatin	N	O
19	analogues	N	O
20	slowed	N	O
21	kidney	N	O
22	growth	N	O
23	in	N	O
24	patients	N	O
25	with	N	O
26	polycystic	N	O
27	kidney	N	O
28	disease	N	O
29	(	N	O
30	PKD	N	O
31	)	N	O
32	and	N	O
33	reduced	N	O
34	liver	N	O
35	and	N	O
36	kidney	N	O
37	volume	N	O
38	in	N	O
39	a	N	O
40	PKD	N	O
41	rodent	N	O
42	model	N	O
43	.	N	O

44	We	N	O
45	evaluated	N	O
46	the	N	O
47	effects	N	O
48	of	N	O
49	lanreotide	N	O
50	,	N	O
51	a	N	O
52	somatostatin	N	O
53	analogue	N	O
54	,	N	O
55	in	N	O
56	patients	N	O
57	with	N	O
58	polycystic	N	O
59	liver	N	O
60	because	N	O
61	of	N	O
62	autosomal-dominant	N	O
63	(	N	O
64	AD	N	O
65	)	N	O
66	PKD	N	O
67	or	N	O
68	autosomal-dominant	N	O
69	polycystic	N	O
70	liver	N	O
71	disease	N	O
72	(	N	O
73	PCLD	N	O
74	)	N	O
75	.	N	O

76	We	N	O
77	performed	N	O
78	a	N	O
79	randomized	N	O
80	,	N	O
81	double-blind	N	O
82	,	N	O
83	placebo-controlled	N	O
84	trial	N	O
85	in	N	O
86	2	N	O
87	tertiary	N	O
88	referral	N	O
89	centers	N	O
90	.	N	O

91	Patients	N	O
92	with	N	O
93	polycystic	N	O
94	liver	N	O
95	(	N	O
96	n	N	O
97	=	N	O
98	54	N	O
99	)	N	O
100	were	N	O
101	randomly	N	O
102	assigned	N	O
103	to	N	O
104	groups	N	O
105	given	N	O
106	lanreotide	N	O
107	(	N	O
108	120	N	O
109	mg	N	O
110	)	N	O
111	or	N	O
112	placebo	N	O
113	,	N	O
114	administered	N	O
115	every	N	O
116	28	N	O
117	days	N	O
118	for	N	O
119	24	N	O
120	weeks	N	O
121	.	N	O

122	The	N	O
123	primary	N	O
124	end	N	O
125	point	N	O
126	was	N	O
127	the	N	O
128	difference	N	O
129	in	N	O
130	total	N	O
131	liver	N	O
132	volume	N	O
133	,	N	O
134	measured	N	O
135	by	N	O
136	computerized	N	O
137	tomography	N	O
138	at	N	O
139	weeks	N	O
140	0	N	O
141	and	N	O
142	24	N	O
143	.	N	O

144	Analyses	N	O
145	were	N	O
146	performed	N	O
147	on	N	O
148	an	N	O
149	intention-to-treat	N	O
150	basis	N	O
151	.	N	O

152	Baseline	N	I-Premise
153	characteristics	N	I-Premise
154	were	N	I-Premise
155	comparable	N	I-Premise
156	for	N	I-Premise
157	both	N	I-Premise
158	groups	N	I-Premise
159	,	N	I-Premise
160	except	N	I-Premise
161	that	N	I-Premise
162	more	N	I-Premise
163	patients	N	I-Premise
164	with	N	I-Premise
165	ADPKD	N	I-Premise
166	were	N	I-Premise
167	assigned	N	I-Premise
168	to	N	I-Premise
169	the	N	I-Premise
170	placebo	N	I-Premise
171	group	N	I-Premise
172	(	N	I-Premise
173	P	N	I-Premise
174	=	N	I-Premise
175	.03	N	I-Premise
176	)	N	I-Premise
177	.	N	I-Premise

178	The	N	I-Premise
179	mean	N	I-Premise
180	liver	N	I-Premise
181	volume	N	I-Premise
182	decreased	N	I-Premise
183	2.9	N	I-Premise
184	%	N	I-Premise
185	,	N	I-Premise
186	from	N	I-Premise
187	4606	N	I-Premise
188	mL	N	I-Premise
189	(	N	I-Premise
190	95	N	I-Premise
191	%	N	I-Premise
192	confidence	N	I-Premise
193	interval	N	I-Premise
194	(	N	I-Premise
195	CI	N	I-Premise
196	)	N	I-Premise
197	:	N	I-Premise
198	547-8665	N	I-Premise
199	)	N	I-Premise
200	to	N	I-Premise
201	4471	N	I-Premise
202	mL	N	I-Premise
203	(	N	I-Premise
204	95	N	I-Premise
205	%	N	I-Premise
206	CI	N	I-Premise
207	:	N	I-Premise
208	542-8401	N	I-Premise
209	mL	N	I-Premise
210	)	N	I-Premise
211	,	N	I-Premise
212	in	N	I-Premise
213	patients	N	I-Premise
214	given	N	I-Premise
215	lanreotide	N	I-Premise
216	.	N	I-Premise

217	In	N	I-Premise
218	the	N	I-Premise
219	placebo	N	I-Premise
220	group	N	I-Premise
221	,	N	I-Premise
222	the	N	I-Premise
223	mean	N	I-Premise
224	liver	N	I-Premise
225	volume	N	I-Premise
226	increased	N	I-Premise
227	1.6	N	I-Premise
228	%	N	I-Premise
229	,	N	I-Premise
230	from	N	I-Premise
231	4689	N	I-Premise
232	mL	N	I-Premise
233	(	N	I-Premise
234	95	N	I-Premise
235	%	N	I-Premise
236	CI	N	I-Premise
237	:	N	I-Premise
238	613-8765	N	I-Premise
239	mL	N	I-Premise
240	)	N	I-Premise
241	to	N	I-Premise
242	4895	N	I-Premise
243	mL	N	I-Premise
244	(	N	I-Premise
245	95	N	I-Premise
246	%	N	I-Premise
247	CI	N	I-Premise
248	:	N	I-Premise
249	739-9053	N	I-Premise
250	mL	N	I-Premise
251	)	N	I-Premise
252	(	N	I-Premise
253	P	N	I-Premise
254	<	N	I-Premise
255	.01	N	I-Premise
256	)	N	I-Premise
257	.	N	I-Premise

258	Post	N	I-Premise
259	hoc	N	I-Premise
260	stratification	N	I-Premise
261	for	N	I-Premise
262	patients	N	I-Premise
263	with	N	I-Premise
264	ADPKD	N	I-Premise
265	or	N	I-Premise
266	PCLD	N	I-Premise
267	revealed	N	I-Premise
268	similar	N	I-Premise
269	changes	N	I-Premise
270	in	N	I-Premise
271	liver	N	I-Premise
272	volume	N	I-Premise
273	,	N	I-Premise
274	with	N	I-Premise
275	statistically	N	I-Premise
276	significant	N	I-Premise
277	differences	N	I-Premise
278	in	N	I-Premise
279	patients	N	I-Premise
280	given	N	I-Premise
281	lanreotide	N	I-Premise
282	(	N	I-Premise
283	P	N	I-Premise
284	<	N	I-Premise
285	.01	N	I-Premise
286	for	N	I-Premise
287	both	N	I-Premise
288	diseases	N	I-Premise
289	)	N	I-Premise
290	.	N	I-Premise

291	In	N	I-Claim
292	patients	N	I-Claim
293	with	N	I-Claim
294	polycystic	N	I-Claim
295	liver	N	I-Claim
296	,	N	I-Claim
297	6	N	I-Claim
298	months	N	I-Claim
299	of	N	I-Claim
300	treatment	N	I-Claim
301	with	N	I-Claim
302	lanreotide	N	I-Claim
303	reduces	N	I-Claim
304	liver	N	I-Claim
305	volume	N	I-Claim
306	.	N	I-Claim

1	Sunitinib	N	O
2	has	N	O
3	demonstrated	N	O
4	antitumor	N	O
5	activity	N	O
6	in	N	O
7	metastatic	N	O
8	renal	N	O
9	cell	N	O
10	carcinoma	N	O
11	(	N	O
12	mRCC	N	O
13	)	N	O
14	when	N	O
15	given	N	O
16	at	N	O
17	50	N	O
18	mg/d	N	O
19	on	N	O
20	a	N	O
21	4-weeks-on	N	O
22	2-weeks-off	N	O
23	regimen	N	O
24	.	N	O

25	Herein	N	O
26	,	N	O
27	we	N	O
28	report	N	O
29	results	N	O
30	of	N	O
31	an	N	O
32	open-label	N	O
33	,	N	O
34	multicenter	N	O
35	phase	N	O
36	II	N	O
37	mRCC	N	O
38	study	N	O
39	of	N	O
40	sunitinib	N	O
41	administered	N	O
42	on	N	O
43	a	N	O
44	continuous	N	O
45	once-daily	N	O
46	dosing	N	O
47	regimen	N	O
48	.	N	O

49	Eligibility	N	O
50	criteria	N	O
51	included	N	O
52	histologically	N	O
53	proven	N	O
54	mRCC	N	O
55	with	N	O
56	measurable	N	O
57	disease	N	O
58	,	N	O
59	failure	N	O
60	of	N	O
61	one	N	O
62	prior	N	O
63	cytokine	N	O
64	regimen	N	O
65	,	N	O
66	and	N	O
67	good	N	O
68	performance	N	O
69	status	N	O
70	.	N	O

71	Patients	N	O
72	were	N	O
73	randomly	N	O
74	assigned	N	O
75	to	N	O
76	a	N	O
77	sunitinib	N	O
78	starting	N	O
79	dose	N	O
80	of	N	O
81	37.5	N	O
82	mg/d	N	O
83	in	N	O
84	the	N	O
85	morning	N	O
86	(	N	O
87	AM	N	O
88	)	N	O
89	or	N	O
90	evening	N	O
91	(	N	O
92	PM	N	O
93	)	N	O
94	.	N	O

95	RECIST-defined	N	O
96	objective	N	O
97	response	N	O
98	rate	N	O
99	(	N	O
100	ORR	N	O
101	)	N	O
102	was	N	O
103	the	N	O
104	primary	N	O
105	end	N	O
106	point	N	O
107	.	N	O

108	Secondary	N	O
109	end	N	O
110	points	N	O
111	included	N	O
112	progression-free	N	O
113	survival	N	O
114	(	N	O
115	PFS	N	O
116	)	N	O
117	,	N	O
118	overall	N	O
119	survival	N	O
120	(	N	O
121	OS	N	O
122	)	N	O
123	,	N	O
124	adverse	N	O
125	events	N	O
126	(	N	O
127	AEs	N	O
128	)	N	O
129	,	N	O
130	and	N	O
131	quality-of-life	N	O
132	measures	N	O
133	.	N	O

134	One	N	O
135	hundred	N	O
136	seven	N	O
137	patients	N	O
138	were	N	O
139	randomly	N	O
140	assigned	N	O
141	to	N	O
142	AM	N	O
143	(	N	O
144	n	N	O
145	=	N	O
146	54	N	O
147	)	N	O
148	or	N	O
149	PM	N	O
150	(	N	O
151	n	N	O
152	=	N	O
153	53	N	O
154	)	N	O
155	dosing	N	O
156	and	N	O
157	on	N	O
158	study	N	O
159	for	N	O
160	a	N	O
161	median	N	O
162	8.3	N	O
163	months	N	O
164	.	N	O

165	Eighty-three	N	O
166	patients	N	O
167	discontinued	N	O
168	,	N	O
169	65	N	O
170	due	N	O
171	to	N	O
172	disease	N	O
173	progression	N	O
174	and	N	O
175	16	N	O
176	because	N	O
177	of	N	O
178	AEs	N	O
179	;	N	O
180	two	N	O
181	patients	N	O
182	withdrew	N	O
183	consent	N	O
184	.	N	O

185	Dosing	N	O
186	was	N	O
187	reduced	N	O
188	to	N	O
189	25	N	O
190	mg/d	N	O
191	in	N	O
192	46	N	O
193	patients	N	O
194	(	N	O
195	43	N	O
196	%	N	O
197	)	N	O
198	due	N	O
199	to	N	O
200	grade	N	O
201	3/4	N	O
202	AEs	N	O
203	.	N	O

204	The	N	I-Premise
205	most	N	I-Premise
206	common	N	I-Premise
207	grade	N	I-Premise
208	3	N	I-Premise
209	treatment-related	N	I-Premise
210	AEs	N	I-Premise
211	were	N	I-Premise
212	asthenia/fatigue	N	I-Premise
213	(	N	I-Premise
214	16	N	I-Premise
215	%	N	I-Premise
216	)	N	I-Premise
217	,	N	I-Premise
218	diarrhea	N	I-Premise
219	(	N	I-Premise
220	11	N	I-Premise
221	%	N	I-Premise
222	)	N	I-Premise
223	,	N	I-Premise
224	hypertension	N	I-Premise
225	(	N	I-Premise
226	11	N	I-Premise
227	%	N	I-Premise
228	)	N	I-Premise
229	,	N	I-Premise
230	hand-foot	N	I-Premise
231	syndrome	N	I-Premise
232	(	N	I-Premise
233	9	N	I-Premise
234	%	N	I-Premise
235	)	N	I-Premise
236	,	N	I-Premise
237	and	N	I-Premise
238	anorexia	N	I-Premise
239	(	N	I-Premise
240	8	N	I-Premise
241	%	N	I-Premise
242	)	N	I-Premise
243	.	N	I-Premise

244	ORR	N	O
245	was	N	O
246	20	N	O
247	%	N	O
248	with	N	O
249	a	N	O
250	7.2-month	N	O
251	median	N	O
252	response	N	O
253	duration	N	O
254	.	N	O

255	Median	N	I-Premise
256	PFS	N	I-Premise
257	and	N	I-Premise
258	OS	N	I-Premise
259	were	N	I-Premise
260	8.2	N	I-Premise
261	and	N	I-Premise
262	19.8	N	I-Premise
263	months	N	I-Premise
264	,	N	I-Premise
265	respectively	N	I-Premise
266	,	N	I-Premise
267	at	N	I-Premise
268	median	N	I-Premise
269	follow-up	N	I-Premise
270	of	N	I-Premise
271	26.4	N	I-Premise
272	months	N	I-Premise
273	.	N	I-Premise

274	Efficacy	N	I-Premise
275	,	N	I-Premise
276	tolerability	N	I-Premise
277	,	N	I-Premise
278	and	N	I-Premise
279	quality-of-life	N	I-Premise
280	results	N	I-Premise
281	were	N	I-Premise
282	similar	N	I-Premise
283	between	N	I-Premise
284	patients	N	I-Premise
285	dosed	N	I-Premise
286	in	N	I-Premise
287	the	N	I-Premise
288	AM	N	I-Premise
289	or	N	I-Premise
290	PM	N	I-Premise
291	.	N	I-Premise

292	Sunitinib	N	I-Claim
293	37.5	N	I-Claim
294	mg	N	I-Claim
295	,	N	I-Claim
296	administered	N	I-Claim
297	on	N	I-Claim
298	a	N	I-Claim
299	continuous	N	I-Claim
300	once-daily	N	I-Claim
301	dosing	N	I-Claim
302	regimen	N	I-Claim
303	,	N	I-Claim
304	has	N	I-Claim
305	a	N	I-Claim
306	manageable	N	I-Claim
307	safety	N	I-Claim
308	profile	N	I-Claim
309	as	N	I-Claim
310	second-line	N	I-Claim
311	mRCC	N	I-Claim
312	therapy	N	I-Claim
313	,	N	I-Claim
314	providing	N	I-Claim
315	flexible	N	I-Claim
316	dosing	N	I-Claim
317	,	N	I-Claim
318	which	N	I-Claim
319	can	N	I-Claim
320	be	N	I-Claim
321	explored	N	I-Claim
322	in	N	I-Claim
323	combination	N	I-Claim
324	studies	N	I-Claim
325	.	N	I-Claim

1	Lymphoma	N	O
2	patients	N	O
3	commonly	N	O
4	experience	N	O
5	declines	N	O
6	in	N	O
7	physical	N	O
8	functioning	N	O
9	and	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	(	N	O
14	QoL	N	O
15	)	N	O
16	that	N	O
17	may	N	O
18	be	N	O
19	reversed	N	O
20	with	N	O
21	exercise	N	O
22	training	N	O
23	.	N	O

24	We	N	O
25	conducted	N	O
26	a	N	O
27	randomized	N	O
28	controlled	N	O
29	trial	N	O
30	in	N	O
31	Edmonton	N	O
32	,	N	O
33	Alberta	N	O
34	,	N	O
35	Canada	N	O
36	,	N	O
37	between	N	O
38	2005	N	O
39	and	N	O
40	2008	N	O
41	that	N	O
42	stratified	N	O
43	122	N	O
44	lymphoma	N	O
45	patients	N	O
46	by	N	O
47	major	N	O
48	disease	N	O
49	type	N	O
50	and	N	O
51	current	N	O
52	treatment	N	O
53	status	N	O
54	and	N	O
55	randomly	N	O
56	assigned	N	O
57	them	N	O
58	to	N	O
59	usual	N	O
60	care	N	O
61	(	N	O
62	UC	N	O
63	;	N	O
64	n	N	O
65	=	N	O
66	62	N	O
67	)	N	O
68	or	N	O
69	12	N	O
70	weeks	N	O
71	of	N	O
72	supervised	N	O
73	aerobic	N	O
74	exercise	N	O
75	training	N	O
76	(	N	O
77	AET	N	O
78	;	N	O
79	n	N	O
80	=	N	O
81	60	N	O
82	)	N	O
83	.	N	O

84	Our	N	O
85	primary	N	O
86	end	N	O
87	point	N	O
88	was	N	O
89	patient-rated	N	O
90	physical	N	O
91	functioning	N	O
92	assessed	N	O
93	by	N	O
94	the	N	O
95	Trial	N	O
96	Outcome	N	O
97	Index-Anemia	N	O
98	.	N	O

99	Secondary	N	O
100	end	N	O
101	points	N	O
102	were	N	O
103	overall	N	O
104	QoL	N	O
105	,	N	O
106	psychosocial	N	O
107	functioning	N	O
108	,	N	O
109	cardiovascular	N	O
110	fitness	N	O
111	,	N	O
112	and	N	O
113	body	N	O
114	composition	N	O
115	.	N	O

116	Follow-up	N	O
117	assessment	N	O
118	for	N	O
119	our	N	O
120	primary	N	O
121	end	N	O
122	point	N	O
123	was	N	O
124	96	N	O
125	%	N	O
126	(	N	O
127	117	N	O
128	of	N	O
129	122	N	O
130	)	N	O
131	at	N	O
132	postintervention	N	O
133	and	N	O
134	90	N	O
135	%	N	O
136	(	N	O
137	110	N	O
138	of	N	O
139	122	N	O
140	)	N	O
141	at	N	O
142	6-month	N	O
143	follow-up	N	O
144	.	N	O

145	Median	N	O
146	adherence	N	O
147	to	N	O
148	the	N	O
149	supervised	N	O
150	exercise	N	O
151	program	N	O
152	was	N	O
153	92	N	O
154	%	N	O
155	.	N	O

156	At	N	I-Premise
157	postintervention	N	I-Premise
158	,	N	I-Premise
159	AET	N	I-Premise
160	was	N	I-Premise
161	superior	N	I-Premise
162	to	N	I-Premise
163	UC	N	I-Premise
164	for	N	I-Premise
165	patient-rated	N	I-Premise
166	physical	N	I-Premise
167	functioning	N	I-Premise
168	(	N	I-Premise
169	mean	N	I-Premise
170	group	N	I-Premise
171	difference	N	I-Premise
172	,	N	I-Premise
173	+9.0	N	I-Premise
174	;	N	I-Premise
175	95	N	I-Premise
176	%	N	I-Premise
177	CI	N	I-Premise
178	,	N	I-Premise
179	2.0	N	I-Premise
180	to	N	I-Premise
181	16.0	N	I-Premise
182	;	N	I-Premise
183	P	N	I-Premise
184	=	N	I-Premise
185	.012	N	I-Premise
186	)	N	I-Premise
187	,	N	I-Premise
188	overall	N	I-Premise
189	QoL	N	I-Premise
190	(	N	I-Premise
191	P	N	I-Premise
192	=	N	I-Premise
193	.021	N	I-Premise
194	)	N	I-Premise
195	,	N	I-Premise
196	fatigue	N	I-Premise
197	(	N	I-Premise
198	P	N	I-Premise
199	=	N	I-Premise
200	.013	N	I-Premise
201	)	N	I-Premise
202	,	N	I-Premise
203	happiness	N	I-Premise
204	(	N	I-Premise
205	P	N	I-Premise
206	=	N	I-Premise
207	.004	N	I-Premise
208	)	N	I-Premise
209	,	N	I-Premise
210	depression	N	I-Premise
211	(	N	I-Premise
212	P	N	I-Premise
213	=	N	I-Premise
214	.005	N	I-Premise
215	)	N	I-Premise
216	,	N	I-Premise
217	general	N	I-Premise
218	health	N	I-Premise
219	(	N	I-Premise
220	P	N	I-Premise
221	<	N	I-Premise
222	.001	N	I-Premise
223	)	N	I-Premise
224	,	N	I-Premise
225	cardiovascular	N	I-Premise
226	fitness	N	I-Premise
227	(	N	I-Premise
228	P	N	I-Premise
229	<	N	I-Premise
230	.001	N	I-Premise
231	)	N	I-Premise
232	,	N	I-Premise
233	and	N	I-Premise
234	lean	N	I-Premise
235	body	N	I-Premise
236	mass	N	I-Premise
237	(	N	I-Premise
238	P	N	I-Premise
239	=	N	I-Premise
240	.008	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	Change	N	O
244	in	N	O
245	peak	N	O
246	cardiovascular	N	O
247	fitness	N	O
248	mediated	N	O
249	the	N	O
250	change	N	O
251	in	N	O
252	patient-rated	N	O
253	physical	N	O
254	functioning	N	O
255	.	N	O

256	AET	N	I-Premise
257	did	N	I-Premise
258	not	N	I-Premise
259	interfere	N	I-Premise
260	with	N	I-Premise
261	chemotherapy	N	I-Premise
262	completion	N	I-Premise
263	rate	N	I-Premise
264	or	N	I-Premise
265	treatment	N	I-Premise
266	response	N	I-Premise
267	.	N	I-Premise

268	At	N	I-Premise
269	6-month	N	I-Premise
270	follow-up	N	I-Premise
271	,	N	I-Premise
272	AET	N	I-Premise
273	was	N	I-Premise
274	still	N	I-Premise
275	borderline	N	I-Premise
276	or	N	I-Premise
277	significantly	N	I-Premise
278	superior	N	I-Premise
279	to	N	I-Premise
280	UC	N	I-Premise
281	for	N	I-Premise
282	overall	N	I-Premise
283	QoL	N	I-Premise
284	(	N	I-Premise
285	P	N	I-Premise
286	=	N	I-Premise
287	.054	N	I-Premise
288	)	N	I-Premise
289	,	N	I-Premise
290	happiness	N	I-Premise
291	(	N	I-Premise
292	P	N	I-Premise
293	=	N	I-Premise
294	.034	N	I-Premise
295	)	N	I-Premise
296	,	N	I-Premise
297	and	N	I-Premise
298	depression	N	I-Premise
299	(	N	I-Premise
300	P	N	I-Premise
301	=	N	I-Premise
302	.009	N	I-Premise
303	)	N	I-Premise
304	without	N	I-Premise
305	an	N	I-Premise
306	increased	N	I-Premise
307	risk	N	I-Premise
308	of	N	I-Premise
309	disease	N	I-Premise
310	recurrence/progression	N	I-Premise
311	.	N	I-Premise

312	AET	N	I-Claim
313	significantly	N	I-Claim
314	improved	N	I-Claim
315	important	N	I-Claim
316	patient-rated	N	I-Claim
317	outcomes	N	I-Claim
318	and	N	I-Claim
319	objective	N	I-Claim
320	physical	N	I-Claim
321	functioning	N	I-Claim
322	in	N	I-Claim
323	lymphoma	N	I-Claim
324	patients	N	I-Claim
325	without	N	I-Claim
326	interfering	N	I-Claim
327	with	N	I-Claim
328	medical	N	I-Claim
329	treatments	N	I-Claim
330	or	N	I-Claim
331	response	N	I-Claim
332	.	N	I-Claim

333	Exercise	N	I-MajorClaim
334	training	N	I-MajorClaim
335	to	N	I-MajorClaim
336	improve	N	I-MajorClaim
337	cardiovascular	N	I-MajorClaim
338	fitness	N	I-MajorClaim
339	should	N	I-MajorClaim
340	be	N	I-MajorClaim
341	considered	N	I-MajorClaim
342	in	N	I-MajorClaim
343	the	N	I-MajorClaim
344	management	N	I-MajorClaim
345	of	N	I-MajorClaim
346	lymphoma	N	I-MajorClaim
347	patients	N	I-MajorClaim
348	.	N	I-MajorClaim

1	There	N	O
2	are	N	O
3	few	N	O
4	randomized	N	O
5	controlled	N	O
6	trials	N	O
7	on	N	O
8	the	N	O
9	effectiveness	N	O
10	of	N	O
11	palliative	N	O
12	care	N	O
13	interventions	N	O
14	to	N	O
15	improve	N	O
16	the	N	O
17	care	N	O
18	of	N	O
19	patients	N	O
20	with	N	O
21	advanced	N	O
22	cancer	N	O
23	.	N	O

24	To	N	O
25	determine	N	O
26	the	N	O
27	effect	N	O
28	of	N	O
29	a	N	O
30	nursing-led	N	O
31	intervention	N	O
32	on	N	O
33	quality	N	O
34	of	N	O
35	life	N	O
36	,	N	O
37	symptom	N	O
38	intensity	N	O
39	,	N	O
40	mood	N	O
41	,	N	O
42	and	N	O
43	resource	N	O
44	use	N	O
45	in	N	O
46	patients	N	O
47	with	N	O
48	advanced	N	O
49	cancer	N	O
50	.	N	O

51	Randomized	N	O
52	controlled	N	O
53	trial	N	O
54	conducted	N	O
55	from	N	O
56	November	N	O
57	2003	N	O
58	through	N	O
59	May	N	O
60	2008	N	O
61	of	N	O
62	322	N	O
63	patients	N	O
64	with	N	O
65	advanced	N	O
66	cancer	N	O
67	in	N	O
68	a	N	O
69	rural	N	O
70	,	N	O
71	National	N	O
72	Cancer	N	O
73	Institute-designated	N	O
74	comprehensive	N	O
75	cancer	N	O
76	center	N	O
77	in	N	O
78	New	N	O
79	Hampshire	N	O
80	and	N	O
81	affiliated	N	O
82	outreach	N	O
83	clinics	N	O
84	and	N	O
85	a	N	O
86	VA	N	O
87	medical	N	O
88	center	N	O
89	in	N	O
90	Vermont	N	O
91	.	N	O

92	A	N	O
93	multicomponent	N	O
94	,	N	O
95	psychoeducational	N	O
96	intervention	N	O
97	(	N	O
98	Project	N	O
99	ENABLE	N	O
100	[	N	O
101	Educate	N	O
102	,	N	O
103	Nurture	N	O
104	,	N	O
105	Advise	N	O
106	,	N	O
107	Before	N	O
108	Life	N	O
109	Ends	N	O
110	]	N	O
111	)	N	O
112	conducted	N	O
113	by	N	O
114	advanced	N	O
115	practice	N	O
116	nurses	N	O
117	consisting	N	O
118	of	N	O
119	4	N	O
120	weekly	N	O
121	educational	N	O
122	sessions	N	O
123	and	N	O
124	monthly	N	O
125	follow-up	N	O
126	sessions	N	O
127	until	N	O
128	death	N	O
129	or	N	O
130	study	N	O
131	completion	N	O
132	(	N	O
133	n	N	O
134	=	N	O
135	161	N	O
136	)	N	O
137	vs	N	O
138	usual	N	O
139	care	N	O
140	(	N	O
141	n	N	O
142	=	N	O
143	161	N	O
144	)	N	O
145	.	N	O

146	Quality	N	O
147	of	N	O
148	life	N	O
149	was	N	O
150	measured	N	O
151	by	N	O
152	the	N	O
153	Functional	N	O
154	Assessment	N	O
155	of	N	O
156	Chronic	N	O
157	Illness	N	O
158	Therapy	N	O
159	for	N	O
160	Palliative	N	O
161	Care	N	O
162	(	N	O
163	score	N	O
164	range	N	O
165	,	N	O
166	0-184	N	O
167	)	N	O
168	.	N	O

169	Symptom	N	O
170	intensity	N	O
171	was	N	O
172	measured	N	O
173	by	N	O
174	the	N	O
175	Edmonton	N	O
176	Symptom	N	O
177	Assessment	N	O
178	Scale	N	O
179	(	N	O
180	score	N	O
181	range	N	O
182	,	N	O
183	0-900	N	O
184	)	N	O
185	.	N	O

186	Mood	N	O
187	was	N	O
188	measured	N	O
189	by	N	O
190	the	N	O
191	Center	N	O
192	for	N	O
193	Epidemiological	N	O
194	Studies	N	O
195	Depression	N	O
196	Scale	N	O
197	(	N	O
198	range	N	O
199	,	N	O
200	0-60	N	O
201	)	N	O
202	.	N	O

203	These	N	O
204	measures	N	O
205	were	N	O
206	assessed	N	O
207	at	N	O
208	baseline	N	O
209	,	N	O
210	1	N	O
211	month	N	O
212	,	N	O
213	and	N	O
214	every	N	O
215	3	N	O
216	months	N	O
217	until	N	O
218	death	N	O
219	or	N	O
220	study	N	O
221	completion	N	O
222	.	N	O

223	Intensity	N	O
224	of	N	O
225	service	N	O
226	was	N	O
227	measured	N	O
228	as	N	O
229	the	N	O
230	number	N	O
231	of	N	O
232	days	N	O
233	in	N	O
234	the	N	O
235	hospital	N	O
236	and	N	O
237	in	N	O
238	the	N	O
239	intensive	N	O
240	care	N	O
241	unit	N	O
242	(	N	O
243	ICU	N	O
244	)	N	O
245	and	N	O
246	the	N	O
247	number	N	O
248	of	N	O
249	emergency	N	O
250	department	N	O
251	visits	N	O
252	recorded	N	O
253	in	N	O
254	the	N	O
255	electronic	N	O
256	medical	N	O
257	record	N	O
258	.	N	O

259	A	N	O
260	total	N	O
261	of	N	O
262	322	N	O
263	participants	N	O
264	with	N	O
265	cancer	N	O
266	of	N	O
267	the	N	O
268	gastrointestinal	N	O
269	tract	N	O
270	(	N	O
271	41	N	O
272	%	N	O
273	;	N	O
274	67	N	O
275	in	N	O
276	the	N	O
277	usual	N	O
278	care	N	O
279	group	N	O
280	vs	N	O
281	66	N	O
282	in	N	O
283	the	N	O
284	intervention	N	O
285	group	N	O
286	)	N	O
287	,	N	O
288	lung	N	O
289	(	N	O
290	36	N	O
291	%	N	O
292	;	N	O
293	58	N	O
294	vs	N	O
295	59	N	O
296	)	N	O
297	,	N	O
298	genitourinary	N	O
299	tract	N	O
300	(	N	O
301	12	N	O
302	%	N	O
303	;	N	O
304	20	N	O
305	vs	N	O
306	19	N	O
307	)	N	O
308	,	N	O
309	and	N	O
310	breast	N	O
311	(	N	O
312	10	N	O
313	%	N	O
314	;	N	O
315	16	N	O
316	vs	N	O
317	17	N	O
318	)	N	O
319	were	N	O
320	randomized	N	O
321	.	N	O

322	The	N	I-Premise
323	estimated	N	I-Premise
324	treatment	N	I-Premise
325	effects	N	I-Premise
326	(	N	I-Premise
327	intervention	N	I-Premise
328	minus	N	I-Premise
329	usual	N	I-Premise
330	care	N	I-Premise
331	)	N	I-Premise
332	for	N	I-Premise
333	all	N	I-Premise
334	participants	N	I-Premise
335	were	N	I-Premise
336	a	N	I-Premise
337	mean	N	I-Premise
338	(	N	I-Premise
339	SE	N	I-Premise
340	)	N	I-Premise
341	of	N	I-Premise
342	4.6	N	I-Premise
343	(	N	I-Premise
344	2	N	I-Premise
345	)	N	I-Premise
346	for	N	I-Premise
347	quality	N	I-Premise
348	of	N	I-Premise
349	life	N	I-Premise
350	(	N	I-Premise
351	P	N	I-Premise
352	=	N	I-Premise
353	.02	N	I-Premise
354	)	N	I-Premise
355	,	N	I-Premise
356	-27.8	N	I-Premise
357	(	N	I-Premise
358	15	N	I-Premise
359	)	N	I-Premise
360	for	N	I-Premise
361	symptom	N	I-Premise
362	intensity	N	I-Premise
363	(	N	I-Premise
364	P	N	I-Premise
365	=	N	I-Premise
366	.06	N	I-Premise
367	)	N	I-Premise
368	,	N	I-Premise
369	and	N	I-Premise
370	-1.8	N	I-Premise
371	(	N	I-Premise
372	0.81	N	I-Premise
373	)	N	I-Premise
374	for	N	I-Premise
375	depressed	N	I-Premise
376	mood	N	I-Premise
377	(	N	I-Premise
378	P	N	I-Premise
379	=	N	I-Premise
380	.02	N	I-Premise
381	)	N	I-Premise
382	.	N	I-Premise

383	The	N	I-Premise
384	estimated	N	I-Premise
385	treatment	N	I-Premise
386	effects	N	I-Premise
387	in	N	I-Premise
388	participants	N	I-Premise
389	who	N	I-Premise
390	died	N	I-Premise
391	during	N	I-Premise
392	the	N	I-Premise
393	study	N	I-Premise
394	were	N	I-Premise
395	a	N	I-Premise
396	mean	N	I-Premise
397	(	N	I-Premise
398	SE	N	I-Premise
399	)	N	I-Premise
400	of	N	I-Premise
401	8.6	N	I-Premise
402	(	N	I-Premise
403	3.6	N	I-Premise
404	)	N	I-Premise
405	for	N	I-Premise
406	quality	N	I-Premise
407	of	N	I-Premise
408	life	N	I-Premise
409	(	N	I-Premise
410	P	N	I-Premise
411	=	N	I-Premise
412	.02	N	I-Premise
413	)	N	I-Premise
414	,	N	I-Premise
415	-24.2	N	I-Premise
416	(	N	I-Premise
417	20.5	N	I-Premise
418	)	N	I-Premise
419	for	N	I-Premise
420	symptom	N	I-Premise
421	intensity	N	I-Premise
422	(	N	I-Premise
423	P	N	I-Premise
424	=	N	I-Premise
425	.24	N	I-Premise
426	)	N	I-Premise
427	,	N	I-Premise
428	and	N	I-Premise
429	-2.7	N	I-Premise
430	(	N	I-Premise
431	1.2	N	I-Premise
432	)	N	I-Premise
433	for	N	I-Premise
434	depressed	N	I-Premise
435	mood	N	I-Premise
436	(	N	I-Premise
437	P	N	I-Premise
438	=	N	I-Premise
439	.03	N	I-Premise
440	)	N	I-Premise
441	.	N	I-Premise

442	Intensity	N	O
443	of	N	O
444	service	N	O
445	did	N	O
446	not	N	O
447	differ	N	O
448	between	N	O
449	the	N	O
450	2	N	O
451	groups	N	O
452	.	N	O

453	Compared	N	I-Claim
454	with	N	I-Claim
455	participants	N	I-Claim
456	receiving	N	I-Claim
457	usual	N	I-Claim
458	oncology	N	I-Claim
459	care	N	I-Claim
460	,	N	I-Claim
461	those	N	I-Claim
462	receiving	N	I-Claim
463	a	N	I-Claim
464	nurse-led	N	I-Claim
465	,	N	I-Claim
466	palliative	N	I-Claim
467	care-focused	N	I-Claim
468	intervention	N	I-Claim
469	addressing	N	I-Claim
470	physical	N	I-Claim
471	,	N	I-Claim
472	psychosocial	N	I-Claim
473	,	N	I-Claim
474	and	N	I-Claim
475	care	N	I-Claim
476	coordination	N	I-Claim
477	provided	N	I-Claim
478	concurrently	N	I-Claim
479	with	N	I-Claim
480	oncology	N	I-Claim
481	care	N	I-Claim
482	had	N	I-Claim
483	higher	N	I-Claim
484	scores	N	I-Claim
485	for	N	I-Claim
486	quality	N	I-Claim
487	of	N	I-Claim
488	life	N	I-Claim
489	and	N	I-Claim
490	mood	N	I-Claim
491	,	N	I-Claim
492	but	N	I-Claim
493	did	N	I-Claim
494	not	N	I-Claim
495	have	N	I-Claim
496	improvements	N	I-Claim
497	in	N	I-Claim
498	symptom	N	I-Claim
499	intensity	N	I-Claim
500	scores	N	I-Claim
501	or	N	I-Claim
502	reduced	N	I-Claim
503	days	N	I-Claim
504	in	N	I-Claim
505	the	N	I-Claim
506	hospital	N	I-Claim
507	or	N	I-Claim
508	ICU	N	I-Claim
509	or	N	I-Claim
510	emergency	N	I-Claim
511	department	N	I-Claim
512	visits	N	I-Claim
513	.	N	I-Claim

1	A	N	O
2	recent	N	O
3	randomized	N	O
4	trial	N	O
5	to	N	O
6	compare	N	O
7	external	N	O
8	beam	N	O
9	radiation	N	O
10	therapy	N	O
11	(	N	O
12	EBRT	N	O
13	)	N	O
14	to	N	O
15	cryoablation	N	O
16	for	N	O
17	localized	N	O
18	disease	N	O
19	showed	N	O
20	cryoablation	N	O
21	to	N	O
22	be	N	O
23	noninferior	N	O
24	to	N	O
25	external	N	O
26	beam	N	O
27	EBRT	N	O
28	in	N	O
29	disease	N	O
30	progression	N	O
31	and	N	O
32	overall	N	O
33	and	N	O
34	disease-specific	N	O
35	survival	N	O
36	.	N	O

37	We	N	O
38	report	N	O
39	on	N	O
40	the	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	(	N	O
45	QOL	N	O
46	)	N	O
47	outcomes	N	O
48	for	N	O
49	this	N	O
50	trial	N	O
51	.	N	O

52	From	N	O
53	December	N	O
54	1997	N	O
55	through	N	O
56	February	N	O
57	2003	N	O
58	,	N	O
59	244	N	O
60	men	N	O
61	with	N	O
62	newly	N	O
63	diagnosed	N	O
64	localized	N	O
65	prostate	N	O
66	cancer	N	O
67	were	N	O
68	randomly	N	O
69	assigned	N	O
70	to	N	O
71	cryoablation	N	O
72	or	N	O
73	EBRT	N	O
74	(	N	O
75	median	N	O
76	dose	N	O
77	68	N	O
78	Gy	N	O
79	)	N	O
80	.	N	O

81	All	N	O
82	patients	N	O
83	received	N	O
84	neoadjuvant	N	O
85	antiandrogen	N	O
86	therapy	N	O
87	.	N	O

88	Patients	N	O
89	completed	N	O
90	the	N	O
91	EORTC	N	O
92	QLQ	N	O
93	C30	N	O
94	and	N	O
95	the	N	O
96	Prostate	N	O
97	Cancer	N	O
98	Index	N	O
99	(	N	O
100	PCI	N	O
101	)	N	O
102	before	N	O
103	treatment	N	O
104	and	N	O
105	at	N	O
106	1.5	N	O
107	,	N	O
108	3	N	O
109	,	N	O
110	6	N	O
111	,	N	O
112	12	N	O
113	,	N	O
114	18	N	O
115	,	N	O
116	24	N	O
117	,	N	O
118	and	N	O
119	36	N	O
120	months	N	O
121	post-treatment	N	O
122	.	N	O

123	Regardless	N	I-Premise
124	of	N	I-Premise
125	treatment	N	I-Premise
126	arm	N	I-Premise
127	,	N	I-Premise
128	participants	N	I-Premise
129	reported	N	I-Premise
130	high	N	I-Premise
131	levels	N	I-Premise
132	of	N	I-Premise
133	QOL	N	I-Premise
134	with	N	I-Premise
135	few	N	I-Premise
136	exceptions	N	I-Premise
137	.	N	I-Premise

138	cryoablation	N	I-Premise
139	was	N	I-Premise
140	associated	N	I-Premise
141	with	N	I-Premise
142	more	N	I-Premise
143	acute	N	I-Premise
144	urinary	N	I-Premise
145	dysfunction	N	I-Premise
146	(	N	I-Premise
147	mean	N	I-Premise
148	PCI	N	I-Premise
149	urinary	N	I-Premise
150	function	N	I-Premise
151	cryoablation=69.4	N	I-Premise
152	;	N	I-Premise
153	mean	N	I-Premise
154	EBRT=90.7	N	I-Premise
155	;	N	I-Premise
156	P	N	I-Premise
157	<	N	I-Premise
158	.001	N	I-Premise
159	)	N	I-Premise
160	,	N	I-Premise
161	which	N	I-Premise
162	resolved	N	I-Premise
163	over	N	I-Premise
164	time	N	I-Premise
165	.	N	I-Premise

166	No	N	I-Premise
167	late	N	I-Premise
168	arising	N	I-Premise
169	QOL	N	I-Premise
170	issues	N	I-Premise
171	were	N	I-Premise
172	observed	N	I-Premise
173	.	N	I-Premise

174	Both	N	I-Premise
175	EBRT	N	I-Premise
176	and	N	I-Premise
177	cryoablation	N	I-Premise
178	participants	N	I-Premise
179	reported	N	I-Premise
180	decreases	N	I-Premise
181	in	N	I-Premise
182	sexual	N	I-Premise
183	function	N	I-Premise
184	at	N	I-Premise
185	3	N	I-Premise
186	months	N	I-Premise
187	with	N	I-Premise
188	the	N	I-Premise
189	cryoablation	N	I-Premise
190	patients	N	I-Premise
191	reporting	N	I-Premise
192	poorer	N	I-Premise
193	functioning	N	I-Premise
194	(	N	I-Premise
195	mean	N	I-Premise
196	cryoablation=7.2	N	I-Premise
197	:	N	I-Premise
198	mean	N	I-Premise
199	EBRT=32.9	N	I-Premise
200	;	N	I-Premise
201	P	N	I-Premise
202	<	N	I-Premise
203	.001	N	I-Premise
204	)	N	I-Premise
205	.	N	I-Premise

206	Mean	N	I-Premise
207	sexual	N	I-Premise
208	function	N	I-Premise
209	score	N	I-Premise
210	was	N	I-Premise
211	15	N	I-Premise
212	points	N	I-Premise
213	lower	N	I-Premise
214	at	N	I-Premise
215	3	N	I-Premise
216	years	N	I-Premise
217	for	N	I-Premise
218	the	N	I-Premise
219	cryoablation	N	I-Premise
220	group	N	I-Premise
221	and	N	I-Premise
222	13	N	I-Premise
223	%	N	I-Premise
224	more	N	I-Premise
225	of	N	I-Premise
226	the	N	I-Premise
227	cryoablation	N	I-Premise
228	men	N	I-Premise
229	said	N	I-Premise
230	that	N	I-Premise
231	sexuality	N	I-Premise
232	was	N	I-Premise
233	a	N	I-Premise
234	moderate	N	I-Premise
235	or	N	I-Premise
236	big	N	I-Premise
237	problem	N	I-Premise
238	.	N	I-Premise

239	In	N	I-Claim
240	this	N	I-Claim
241	randomized	N	I-Claim
242	trial	N	I-Claim
243	,	N	I-Claim
244	no	N	I-Claim
245	long-term	N	I-Claim
246	QOL	N	I-Claim
247	advantage	N	I-Claim
248	for	N	I-Claim
249	either	N	I-Claim
250	treatment	N	I-Claim
251	was	N	I-Claim
252	apparent	N	I-Claim
253	with	N	I-Claim
254	the	N	I-Claim
255	exception	N	I-Claim
256	of	N	I-Claim
257	poorer	N	I-Claim
258	sexual	N	I-Claim
259	function	N	I-Claim
260	reported	N	I-Claim
261	by	N	I-Claim
262	those	N	I-Claim
263	treated	N	I-Claim
264	with	N	I-Claim
265	cryoablation	N	I-Claim
266	.	N	I-Claim

267	Men	N	O
268	who	N	O
269	wish	N	O
270	to	N	O
271	increase	N	O
272	their	N	O
273	odds	N	O
274	of	N	O
275	retaining	N	O
276	sexual	N	O
277	function	N	O
278	might	N	O
279	be	N	O
280	counseled	N	O
281	to	N	O
282	choose	N	O
283	EBRT	N	O
284	over	N	O
285	cryoablation	N	O
286	.	N	O

1	Gemcitabine	N	O
2	(	N	O
3	G	N	O
4	)	N	O
5	is	N	O
6	standard	N	O
7	therapy	N	O
8	for	N	O
9	pancreatic	N	O
10	cancer	N	O
11	.	N	O

12	Enzastaurin	N	O
13	(	N	O
14	E	N	O
15	)	N	O
16	inhibits	N	O
17	PKC	N	O
18	and	N	O
19	PI3K/AKT	N	O
20	signaling	N	O
21	pathways	N	O
22	with	N	O
23	a	N	O
24	dose-dependent	N	O
25	effect	N	O
26	on	N	O
27	growth	N	O
28	of	N	O
29	pancreatic	N	O
30	carcinoma	N	O
31	xenografts	N	O
32	.	N	O

33	Data	N	I-Claim
34	suggest	N	I-Claim
35	that	N	I-Claim
36	the	N	I-Claim
37	GE	N	I-Claim
38	combination	N	I-Claim
39	may	N	I-Claim
40	improve	N	I-Claim
41	clinical	N	I-Claim
42	outcomes	N	I-Claim
43	.	N	I-Claim

44	Primary	N	O
45	objective	N	O
46	was	N	O
47	overall	N	O
48	survival	N	O
49	(	N	O
50	OS	N	O
51	)	N	O
52	;	N	O
53	secondary	N	O
54	objectives	N	O
55	assessed	N	O
56	progression-free	N	O
57	survival	N	O
58	(	N	O
59	PFS	N	O
60	)	N	O
61	,	N	O
62	response	N	O
63	rate	N	O
64	(	N	O
65	RR	N	O
66	)	N	O
67	,	N	O
68	quality	N	O
69	of	N	O
70	life	N	O
71	(	N	O
72	QOL	N	O
73	)	N	O
74	,	N	O
75	toxicity	N	O
76	,	N	O
77	and	N	O
78	relationships	N	O
79	between	N	O
80	biomarker	N	O
81	expression	N	O
82	and	N	O
83	clinical	N	O
84	outcomes	N	O
85	.	N	O

86	Patients	N	O
87	were	N	O
88	randomly	N	O
89	assigned	N	O
90	(	N	O
91	2:1	N	O
92	)	N	O
93	to	N	O
94	GE	N	O
95	or	N	O
96	G	N	O
97	treatment	N	O
98	;	N	O
99	GE	N	O
100	arm	N	O
101	:	N	O
102	E	N	O
103	500	N	O
104	mg	N	O
105	p.o	N	O
106	.	N	O

107	daily	N	O
108	;	N	O
109	loading-dose	N	O
110	(	N	O
111	1200	N	O
112	mg	N	O
113	;	N	O
114	Day	N	O
115	1	N	O
116	Cycle	N	O
117	1	N	O
118	only	N	O
119	)	N	O
120	and	N	O
121	G	N	O
122	1000	N	O
123	mg/m	N	O
124	(	N	O
125	2	N	O
126	)	N	O
127	i.v	N	O
128	.	N	O

129	Days	N	O
130	1	N	O
131	,	N	O
132	8	N	O
133	,	N	O
134	and	N	O
135	15	N	O
136	in	N	O
137	28-day	N	O
138	cycles	N	O
139	;	N	O
140	G	N	O
141	arm	N	O
142	:	N	O
143	G	N	O
144	as	N	O
145	in	N	O
146	GE	N	O
147	.	N	O

148	Biomarker	N	O
149	expression	N	O
150	was	N	O
151	assessed	N	O
152	by	N	O
153	immunohistochemistry	N	O
154	.	N	O

155	Randomization	N	O
156	totaled	N	O
157	130	N	O
158	patients	N	O
159	(	N	O
160	GE	N	O
161	=	N	O
162	86	N	O
163	,	N	O
164	G	N	O
165	=	N	O
166	44	N	O
167	)	N	O
168	;	N	O
169	121	N	O
170	patients	N	O
171	were	N	O
172	treated	N	O
173	(	N	O
174	GE	N	O
175	=	N	O
176	82	N	O
177	,	N	O
178	G	N	O
179	=	N	O
180	39	N	O
181	)	N	O
182	.	N	O

183	GE/G	N	O
184	median	N	O
185	OS	N	O
186	was	N	O
187	5.6/5.1	N	O
188	months	N	O
189	;	N	O
190	median	N	O
191	PFS	N	O
192	was	N	O
193	3.4/3.0	N	O
194	months	N	O
195	.	N	O

196	GE	N	O
197	responses	N	O
198	:	N	O
199	1	N	O
200	complete	N	O
201	response	N	O
202	(	N	O
203	CR	N	O
204	,	N	O
205	1.2	N	O
206	%	N	O
207	)	N	O
208	,	N	O
209	6	N	O
210	partial	N	O
211	response	N	O
212	(	N	O
213	PR	N	O
214	,	N	O
215	7.4	N	O
216	%	N	O
217	)	N	O
218	,	N	O
219	and	N	O
220	33	N	O
221	stable	N	O
222	disease	N	O
223	(	N	O
224	SD	N	O
225	,	N	O
226	40.7	N	O
227	%	N	O
228	)	N	O
229	;	N	O
230	disease	N	O
231	control	N	O
232	rate	N	O
233	(	N	O
234	DCR=CR+PR+SD	N	O
235	,	N	O
236	49.4	N	O
237	%	N	O
238	)	N	O
239	.	N	O

240	G	N	O
241	responses	N	O
242	:	N	O
243	2	N	O
244	PR	N	O
245	(	N	O
246	5.3	N	O
247	%	N	O
248	)	N	O
249	and	N	O
250	16	N	O
251	SD	N	O
252	(	N	O
253	42.1	N	O
254	%	N	O
255	)	N	O
256	;	N	O
257	DCR	N	O
258	(	N	O
259	47.4	N	O
260	%	N	O
261	)	N	O
262	.	N	O

263	No	N	I-Premise
264	QOL	N	I-Premise
265	differences	N	I-Premise
266	were	N	I-Premise
267	noted	N	I-Premise
268	between	N	I-Premise
269	arms	N	I-Premise
270	.	N	I-Premise

271	GE/G	N	I-Premise
272	Grade	N	I-Premise
273	3-4	N	I-Premise
274	toxicities	N	I-Premise
275	included	N	I-Premise
276	:	N	I-Premise
277	neutropenia	N	I-Premise
278	(	N	I-Premise
279	18.3	N	I-Premise
280	%	N	I-Premise
281	/28.2	N	I-Premise
282	%	N	I-Premise
283	)	N	I-Premise
284	;	N	I-Premise
285	thrombocytopenia	N	I-Premise
286	(	N	I-Premise
287	14.6	N	I-Premise
288	%	N	I-Premise
289	/25.6	N	I-Premise
290	%	N	I-Premise
291	)	N	I-Premise
292	;	N	I-Premise
293	and	N	I-Premise
294	fatigue	N	I-Premise
295	(	N	I-Premise
296	11.0	N	I-Premise
297	%	N	I-Premise
298	/7.7	N	I-Premise
299	%	N	I-Premise
300	)	N	I-Premise
301	.	N	I-Premise

302	No	N	I-Premise
303	statistically	N	I-Premise
304	significant	N	I-Premise
305	relationships	N	I-Premise
306	between	N	I-Premise
307	biomarker	N	I-Premise
308	expression	N	I-Premise
309	and	N	I-Premise
310	outcomes	N	I-Premise
311	were	N	I-Premise
312	observed	N	I-Premise
313	.	N	I-Premise

314	However	N	O
315	,	N	O
316	patients	N	I-Premise
317	with	N	I-Premise
318	low	N	I-Premise
319	expression	N	I-Premise
320	of	N	I-Premise
321	cytoplasmic	N	I-Premise
322	pGSK-3	N	I-Premise
323	trended	N	I-Premise
324	toward	N	I-Premise
325	greater	N	I-Premise
326	OS	N	I-Premise
327	with	N	I-Premise
328	GE	N	I-Premise
329	treatment	N	I-Premise
330	.	N	I-Premise

331	OS	N	I-Premise
332	,	N	I-Premise
333	PFS	N	I-Premise
334	,	N	I-Premise
335	QOL	N	I-Premise
336	,	N	I-Premise
337	and	N	I-Premise
338	RR	N	I-Premise
339	were	N	I-Premise
340	comparable	N	I-Premise
341	between	N	I-Premise
342	arms	N	I-Premise
343	.	N	I-Premise

344	Adding	N	I-Claim
345	E	N	I-Claim
346	to	N	I-Claim
347	G	N	I-Claim
348	did	N	I-Claim
349	not	N	I-Claim
350	increase	N	I-Claim
351	hematologic	N	I-Claim
352	toxicities	N	I-Claim
353	.	N	I-Claim

354	GE	N	O
355	does	N	O
356	not	N	O
357	warrant	N	O
358	further	N	O
359	investigation	N	O
360	in	N	O
361	unselected	N	O
362	pancreatic	N	O
363	cancer	N	O
364	patients	N	O
365	.	N	O

1	Assess	N	O
2	toxicity	N	O
3	and	N	O
4	efficacy	N	O
5	of	N	O
6	cisplatin	N	O
7	(	N	O
8	Cis	N	O
9	)	N	O
10	doublet	N	O
11	combinations	N	O
12	in	N	O
13	advanced	N	O
14	and	N	O
15	recurrent	N	O
16	cervical	N	O
17	carcinoma	N	O
18	.	N	O

19	Patients	N	O
20	were	N	O
21	randomly	N	O
22	assigned	N	O
23	to	N	O
24	paclitaxel	N	O
25	135	N	O
26	mg/m	N	O
27	(	N	O
28	2	N	O
29	)	N	O
30	over	N	O
31	24	N	O
32	hours	N	O
33	plus	N	O
34	Cis	N	O
35	50	N	O
36	mg/m	N	O
37	(	N	O
38	2	N	O
39	)	N	O
40	day	N	O
41	2	N	O
42	every	N	O
43	3	N	O
44	weeks	N	O
45	(	N	O
46	PC	N	O
47	,	N	O
48	reference	N	O
49	arm	N	O
50	)	N	O
51	;	N	O
52	vinorelbine	N	O
53	30	N	O
54	mg/m	N	O
55	(	N	O
56	2	N	O
57	)	N	O
58	days	N	O
59	1	N	O
60	and	N	O
61	8	N	O
62	plus	N	O
63	Cis	N	O
64	50	N	O
65	mg/m	N	O
66	(	N	O
67	2	N	O
68	)	N	O
69	day	N	O
70	1	N	O
71	every	N	O
72	3	N	O
73	weeks	N	O
74	(	N	O
75	VC	N	O
76	)	N	O
77	;	N	O
78	gemcitabine	N	O
79	1,000	N	O
80	mg/m	N	O
81	(	N	O
82	2	N	O
83	)	N	O
84	day	N	O
85	1	N	O
86	and	N	O
87	8	N	O
88	plus	N	O
89	Cis	N	O
90	50	N	O
91	mg/m	N	O
92	(	N	O
93	2	N	O
94	)	N	O
95	day	N	O
96	1	N	O
97	every	N	O
98	3	N	O
99	weeks	N	O
100	(	N	O
101	GC	N	O
102	)	N	O
103	;	N	O
104	or	N	O
105	topotecan	N	O
106	0.75	N	O
107	mg/m	N	O
108	(	N	O
109	2	N	O
110	)	N	O
111	days	N	O
112	1	N	O
113	,	N	O
114	2	N	O
115	,	N	O
116	and	N	O
117	3	N	O
118	plus	N	O
119	Cis	N	O
120	50	N	O
121	mg/m	N	O
122	(	N	O
123	2	N	O
124	)	N	O
125	day	N	O
126	1	N	O
127	every	N	O
128	3	N	O
129	weeks	N	O
130	(	N	O
131	TC	N	O
132	)	N	O
133	.	N	O

134	Survival	N	O
135	was	N	O
136	the	N	O
137	primary	N	O
138	end	N	O
139	point	N	O
140	with	N	O
141	a	N	O
142	33	N	O
143	%	N	O
144	improvement	N	O
145	relative	N	O
146	to	N	O
147	PC	N	O
148	considered	N	O
149	important	N	O
150	(	N	O
151	85	N	O
152	%	N	O
153	power	N	O
154	,	N	O
155	alpha	N	O
156	=	N	O
157	5	N	O
158	%	N	O
159	)	N	O
160	.	N	O

161	Quality-of-life	N	O
162	data	N	O
163	were	N	O
164	prospectively	N	O
165	collected	N	O
166	.	N	O

167	A	N	O
168	total	N	O
169	of	N	O
170	513	N	O
171	patients	N	O
172	were	N	O
173	enrolled	N	O
174	when	N	O
175	a	N	O
176	planned	N	O
177	interim	N	O
178	analysis	N	O
179	recommended	N	O
180	early	N	O
181	closure	N	O
182	for	N	O
183	futility	N	O
184	.	N	O

185	The	N	I-Premise
186	experimental-to-PC	N	I-Premise
187	hazard	N	I-Premise
188	ratios	N	I-Premise
189	of	N	I-Premise
190	death	N	I-Premise
191	were	N	I-Premise
192	1.15	N	I-Premise
193	(	N	I-Premise
194	95	N	I-Premise
195	%	N	I-Premise
196	CI	N	I-Premise
197	,	N	I-Premise
198	0.79	N	I-Premise
199	to	N	I-Premise
200	1.67	N	I-Premise
201	)	N	I-Premise
202	for	N	I-Premise
203	VC	N	I-Premise
204	,	N	I-Premise
205	1.32	N	I-Premise
206	(	N	I-Premise
207	95	N	I-Premise
208	%	N	I-Premise
209	CI	N	I-Premise
210	,	N	I-Premise
211	0.91	N	I-Premise
212	to	N	I-Premise
213	1.92	N	I-Premise
214	)	N	I-Premise
215	for	N	I-Premise
216	GC	N	I-Premise
217	,	N	I-Premise
218	and	N	I-Premise
219	1.26	N	I-Premise
220	(	N	I-Premise
221	95	N	I-Premise
222	%	N	I-Premise
223	CI	N	I-Premise
224	,	N	I-Premise
225	0.86	N	I-Premise
226	to	N	I-Premise
227	1.82	N	I-Premise
228	)	N	I-Premise
229	for	N	I-Premise
230	TC	N	I-Premise
231	.	N	I-Premise

232	The	N	I-Premise
233	hazard	N	I-Premise
234	ratios	N	I-Premise
235	for	N	I-Premise
236	progression-free	N	I-Premise
237	survival	N	I-Premise
238	(	N	I-Premise
239	PFS	N	I-Premise
240	)	N	I-Premise
241	were	N	I-Premise
242	1.36	N	I-Premise
243	(	N	I-Premise
244	95	N	I-Premise
245	%	N	I-Premise
246	CI	N	I-Premise
247	,	N	I-Premise
248	0.97	N	I-Premise
249	to	N	I-Premise
250	1.90	N	I-Premise
251	)	N	I-Premise
252	for	N	I-Premise
253	VC	N	I-Premise
254	,	N	I-Premise
255	1.39	N	I-Premise
256	(	N	I-Premise
257	95	N	I-Premise
258	%	N	I-Premise
259	CI	N	I-Premise
260	,	N	I-Premise
261	0.99	N	I-Premise
262	to	N	I-Premise
263	1.96	N	I-Premise
264	)	N	I-Premise
265	for	N	I-Premise
266	GC	N	I-Premise
267	,	N	I-Premise
268	and	N	I-Premise
269	1.27	N	I-Premise
270	(	N	I-Premise
271	95	N	I-Premise
272	%	N	I-Premise
273	CI	N	I-Premise
274	,	N	I-Premise
275	0.90	N	I-Premise
276	to	N	I-Premise
277	1.78	N	I-Premise
278	)	N	I-Premise
279	for	N	I-Premise
280	TC	N	I-Premise
281	.	N	I-Premise

282	Response	N	I-Premise
283	rates	N	I-Premise
284	(	N	I-Premise
285	RRs	N	I-Premise
286	)	N	I-Premise
287	for	N	I-Premise
288	PC	N	I-Premise
289	,	N	I-Premise
290	VC	N	I-Premise
291	,	N	I-Premise
292	GC	N	I-Premise
293	,	N	I-Premise
294	and	N	I-Premise
295	TC	N	I-Premise
296	were	N	I-Premise
297	29.1	N	I-Premise
298	%	N	I-Premise
299	,	N	I-Premise
300	25.9	N	I-Premise
301	%	N	I-Premise
302	,	N	I-Premise
303	22.3	N	I-Premise
304	%	N	I-Premise
305	,	N	I-Premise
306	and	N	I-Premise
307	23.4	N	I-Premise
308	%	N	I-Premise
309	,	N	I-Premise
310	respectively	N	I-Premise
311	.	N	I-Premise

312	The	N	I-Premise
313	arms	N	I-Premise
314	were	N	I-Premise
315	comparable	N	I-Premise
316	with	N	I-Premise
317	respect	N	I-Premise
318	to	N	I-Premise
319	toxicity	N	I-Premise
320	except	N	I-Premise
321	for	N	I-Premise
322	leucopenia	N	I-Premise
323	,	N	I-Premise
324	neutropenia	N	I-Premise
325	,	N	I-Premise
326	infection	N	I-Premise
327	,	N	I-Premise
328	and	N	I-Premise
329	alopecia	N	I-Premise
330	.	N	I-Premise

331	VC	N	I-Claim
332	,	N	I-Claim
333	GC	N	I-Claim
334	,	N	I-Claim
335	and	N	I-Claim
336	TC	N	I-Claim
337	are	N	I-Claim
338	not	N	I-Claim
339	superior	N	I-Claim
340	to	N	I-Claim
341	PC	N	I-Claim
342	in	N	I-Claim
343	terms	N	I-Claim
344	of	N	I-Claim
345	overall	N	I-Claim
346	survival	N	I-Claim
347	(	N	I-Claim
348	OS	N	I-Claim
349	)	N	I-Claim
350	.	N	I-Claim

351	However	N	I-Claim
352	,	N	I-Claim
353	the	N	I-Claim
354	trend	N	I-Claim
355	in	N	I-Claim
356	RR	N	I-Claim
357	,	N	I-Claim
358	PFS	N	I-Claim
359	,	N	I-Claim
360	and	N	I-Claim
361	OS	N	I-Claim
362	favors	N	I-Claim
363	PC	N	I-Claim
364	.	N	I-Claim

365	Differences	N	I-MajorClaim
366	in	N	I-MajorClaim
367	chemotherapy	N	I-MajorClaim
368	scheduling	N	I-MajorClaim
369	,	N	I-MajorClaim
370	pre-existing	N	I-MajorClaim
371	morbidity	N	I-MajorClaim
372	,	N	I-MajorClaim
373	and	N	I-MajorClaim
374	toxicity	N	I-MajorClaim
375	are	N	I-MajorClaim
376	important	N	I-MajorClaim
377	in	N	I-MajorClaim
378	individualizing	N	I-MajorClaim
379	therapy	N	I-MajorClaim
380	.	N	I-MajorClaim

1	A	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	was	N	O
6	performed	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	outcome	N	O
11	of	N	O
12	early	N	O
13	oral	N	O
14	postoperative	N	O
15	feeding	N	O
16	(	N	O
17	EOF	N	O
18	)	N	O
19	compared	N	O
20	with	N	O
21	traditional	N	O
22	oral	N	O
23	feeding	N	O
24	(	N	O
25	TOF	N	O
26	)	N	O
27	in	N	O
28	gynecologic	N	O
29	oncology	N	O
30	patients	N	O
31	undergoing	N	O
32	a	N	O
33	complex	N	O
34	laparotomy	N	O
35	,	N	O
36	including	N	O
37	upper	N	O
38	abdominal	N	O
39	surgery	N	O
40	.	N	O

41	Patients	N	O
42	aged	N	O
43	18-75	N	O
44	years	N	O
45	,	N	O
46	undergoing	N	O
47	an	N	O
48	elective	N	O
49	laparotomy	N	O
50	and	N	O
51	with	N	O
52	a	N	O
53	preoperative	N	O
54	suspicion	N	O
55	of	N	O
56	gynecologic	N	O
57	malignancy	N	O
58	,	N	O
59	were	N	O
60	eligible	N	O
61	.	N	O

62	Exclusion	N	O
63	criteria	N	O
64	included	N	O
65	infectious	N	O
66	conditions	N	O
67	,	N	O
68	intestinal	N	O
69	obstruction	N	O
70	,	N	O
71	severe	N	O
72	malnutrition	N	O
73	,	N	O
74	American	N	O
75	Society	N	O
76	of	N	O
77	Anesthesiologists	N	O
78	score	N	O
79	C4	N	O
80	,	N	O
81	intestinal	N	O
82	resection	N	O
83	,	N	O
84	and	N	O
85	postoperative	N	O
86	stay	N	O
87	in	N	O
88	the	N	O
89	intensive	N	O
90	care	N	O
91	unit	N	O
92	lasting	N	O
93	24	N	O
94	h.	N	O
95	Patients	N	O
96	allocated	N	O
97	to	N	O
98	EOF	N	O
99	received	N	O
100	liquid	N	O
101	diet	N	O
102	in	N	O
103	the	N	O
104	first	N	O
105	postoperative	N	O
106	day	N	O
107	and	N	O
108	then	N	O
109	regular	N	O
110	diet	N	O
111	.	N	O

112	Patients	N	O
113	received	N	O
114	traditional	N	O
115	feeding	N	O
116	scheme	N	O
117	until	N	O
118	resolution	N	O
119	of	N	O
120	postoperative	N	O
121	ileus	N	O
122	to	N	O
123	start	N	O
124	liquid	N	O
125	diet	N	O
126	.	N	O

127	The	N	O
128	primary	N	O
129	end-point	N	O
130	of	N	O
131	the	N	O
132	trial	N	O
133	was	N	O
134	length	N	O
135	of	N	O
136	hospital	N	O
137	stay	N	O
138	.	N	O

139	Between	N	O
140	January	N	O
141	1	N	O
142	,	N	O
143	2007	N	O
144	,	N	O
145	and	N	O
146	November	N	O
147	17	N	O
148	,	N	O
149	2007	N	O
150	,	N	O
151	a	N	O
152	total	N	O
153	of	N	O
154	143	N	O
155	patients	N	O
156	were	N	O
157	randomized	N	O
158	to	N	O
159	receive	N	O
160	either	N	O
161	EOF	N	O
162	or	N	O
163	TOF	N	O
164	.	N	O

165	Hospital	N	I-Premise
166	stay	N	I-Premise
167	for	N	I-Premise
168	patients	N	I-Premise
169	who	N	I-Premise
170	received	N	I-Premise
171	EOF	N	I-Premise
172	(	N	I-Premise
173	n=71	N	I-Premise
174	)	N	I-Premise
175	was	N	I-Premise
176	4.7	N	I-Premise
177	vs.	N	I-Premise
178	5.8	N	I-Premise
179	days	N	I-Premise
180	for	N	I-Premise
181	the	N	I-Premise
182	TOF	N	I-Premise
183	group	N	I-Premise
184	(	N	I-Premise
185	n=72	N	I-Premise
186	)	N	I-Premise
187	(	N	I-Premise
188	P=0.006	N	I-Premise
189	)	N	I-Premise
190	.	N	I-Premise

191	The	N	I-Premise
192	mean	N	I-Premise
193	level	N	I-Premise
194	of	N	I-Premise
195	postoperative	N	I-Premise
196	satisfaction	N	I-Premise
197	was	N	I-Premise
198	significantly	N	I-Premise
199	higher	N	I-Premise
200	in	N	I-Premise
201	the	N	I-Premise
202	EOF	N	I-Premise
203	group	N	I-Premise
204	(	N	I-Premise
205	82.8	N	I-Premise
206	vs.	N	I-Premise
207	71.7	N	I-Premise
208	mm	N	I-Premise
209	,	N	I-Premise
210	P	N	I-Premise
211	B	N	I-Premise
212	0.001	N	I-Premise
213	)	N	I-Premise
214	.	N	I-Premise

215	Patients	N	I-Premise
216	who	N	I-Premise
217	received	N	I-Premise
218	the	N	I-Premise
219	TOF	N	I-Premise
220	scheme	N	I-Premise
221	had	N	I-Premise
222	significantly	N	I-Premise
223	higher	N	I-Premise
224	overall	N	I-Premise
225	postoperative	N	I-Premise
226	complications	N	I-Premise
227	(	N	I-Premise
228	39	N	I-Premise
229	vs.	N	I-Premise
230	17	N	I-Premise
231	%	N	I-Premise
232	in	N	I-Premise
233	EOF	N	I-Premise
234	group	N	I-Premise
235	,	N	I-Premise
236	P=0.003	N	I-Premise
237	)	N	I-Premise
238	and	N	I-Premise
239	infective	N	I-Premise
240	complications	N	I-Premise
241	(	N	I-Premise
242	14	N	I-Premise
243	%	N	I-Premise
244	in	N	I-Premise
245	TOF	N	I-Premise
246	group	N	I-Premise
247	vs.	N	I-Premise
248	3	N	I-Premise
249	%	N	I-Premise
250	in	N	I-Premise
251	EOF	N	I-Premise
252	group	N	I-Premise
253	,	N	I-Premise
254	P=0.017	N	I-Premise
255	)	N	I-Premise
256	.	N	I-Premise

257	Variables	N	I-Premise
258	such	N	I-Premise
259	as	N	I-Premise
260	nausea	N	I-Premise
261	and	N	I-Premise
262	vomiting	N	I-Premise
263	,	N	I-Premise
264	analgesic	N	I-Premise
265	and	N	I-Premise
266	antiemetic	N	I-Premise
267	requirement	N	I-Premise
268	as	N	I-Premise
269	well	N	I-Premise
270	as	N	I-Premise
271	level	N	I-Premise
272	of	N	I-Premise
273	pain	N	I-Premise
274	and	N	I-Premise
275	quality	N	I-Premise
276	of	N	I-Premise
277	life	N	I-Premise
278	were	N	I-Premise
279	not	N	I-Premise
280	different	N	I-Premise
281	between	N	I-Premise
282	groups	N	I-Premise
283	.	N	I-Premise

284	On	N	I-Claim
285	the	N	I-Claim
286	basis	N	I-Claim
287	of	N	I-Claim
288	these	N	I-Claim
289	findings	N	I-Claim
290	,	N	I-Claim
291	the	N	I-Claim
292	policy	N	I-Claim
293	of	N	I-Claim
294	EOF	N	I-Claim
295	should	N	I-Claim
296	be	N	I-Claim
297	used	N	I-Claim
298	after	N	I-Claim
299	a	N	I-Claim
300	complex	N	I-Claim
301	gynecologic	N	I-Claim
302	oncologic	N	I-Claim
303	laparotomy	N	I-Claim
304	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	a	N	O
7	multimodal	N	O
8	group	N	O
9	exercise	N	O
10	intervention	N	O
11	,	N	O
12	as	N	O
13	an	N	O
14	adjunct	N	O
15	to	N	O
16	conventional	N	O
17	care	N	O
18	,	N	O
19	on	N	O
20	fatigue	N	O
21	,	N	O
22	physical	N	O
23	capacity	N	O
24	,	N	O
25	general	N	O
26	wellbeing	N	O
27	,	N	O
28	physical	N	O
29	activity	N	O
30	,	N	O
31	and	N	O
32	quality	N	O
33	of	N	O
34	life	N	O
35	in	N	O
36	patients	N	O
37	with	N	O
38	cancer	N	O
39	who	N	O
40	were	N	O
41	undergoing	N	O
42	adjuvant	N	O
43	chemotherapy	N	O
44	or	N	O
45	treatment	N	O
46	for	N	O
47	advanced	N	O
48	disease	N	O
49	.	N	O

50	Randomised	N	O
51	controlled	N	O
52	trial	N	O
53	.	N	O

54	Two	N	O
55	university	N	O
56	hospitals	N	O
57	in	N	O
58	Copenhagen	N	O
59	,	N	O
60	Denmark	N	O
61	.	N	O

62	269	N	O
63	patients	N	O
64	with	N	O
65	cancer	N	O
66	;	N	O
67	73	N	O
68	men	N	O
69	,	N	O
70	196	N	O
71	women	N	O
72	,	N	O
73	mean	N	O
74	age	N	O
75	47	N	O
76	years	N	O
77	(	N	O
78	range	N	O
79	20-65	N	O
80	)	N	O
81	representing	N	O
82	21	N	O
83	diagnoses	N	O
84	.	N	O

85	Main	N	O
86	exclusion	N	O
87	criteria	N	O
88	were	N	O
89	brain	N	O
90	or	N	O
91	bone	N	O
92	metastases	N	O
93	.	N	O

94	235	N	O
95	patients	N	O
96	completed	N	O
97	follow-up	N	O
98	.	N	O

99	Supervised	N	O
100	exercise	N	O
101	comprising	N	O
102	high	N	O
103	intensity	N	O
104	cardiovascular	N	O
105	and	N	O
106	resistance	N	O
107	training	N	O
108	,	N	O
109	relaxation	N	O
110	and	N	O
111	body	N	O
112	awareness	N	O
113	training	N	O
114	,	N	O
115	massage	N	O
116	,	N	O
117	nine	N	O
118	hours	N	O
119	weekly	N	O
120	for	N	O
121	six	N	O
122	weeks	N	O
123	in	N	O
124	addition	N	O
125	to	N	O
126	conventional	N	O
127	care	N	O
128	,	N	O
129	compared	N	O
130	with	N	O
131	conventional	N	O
132	care	N	O
133	.	N	O

134	The	N	O
135	general	N	O
136	linear	N	O
137	model	N	O
138	was	N	O
139	used	N	O
140	for	N	O
141	continuous	N	O
142	outcome	N	O
143	while	N	O
144	analysis	N	O
145	of	N	O
146	associates	N	O
147	between	N	O
148	categorical	N	O
149	outcomes	N	O
150	was	N	O
151	performed	N	O
152	as	N	O
153	analysis	N	O
154	of	N	O
155	marginal	N	O
156	homogeneity	N	O
157	in	N	O
158	contingency	N	O
159	tables	N	O
160	.	N	O

161	Adjusted	N	I-Premise
162	for	N	I-Premise
163	baseline	N	I-Premise
164	score	N	I-Premise
165	,	N	I-Premise
166	disease	N	I-Premise
167	,	N	I-Premise
168	and	N	I-Premise
169	demographic	N	I-Premise
170	covariates	N	I-Premise
171	,	N	I-Premise
172	the	N	I-Premise
173	intervention	N	I-Premise
174	group	N	I-Premise
175	showed	N	I-Premise
176	an	N	I-Premise
177	estimated	N	I-Premise
178	improvement	N	I-Premise
179	at	N	I-Premise
180	six	N	I-Premise
181	weeks	N	I-Premise
182	for	N	I-Premise
183	the	N	I-Premise
184	primary	N	I-Premise
185	outcome	N	I-Premise
186	,	N	I-Premise
187	fatigue	N	I-Premise
188	,	N	I-Premise
189	of	N	I-Premise
190	-6.6	N	I-Premise
191	points	N	I-Premise
192	(	N	I-Premise
193	95	N	I-Premise
194	%	N	I-Premise
195	confidence	N	I-Premise
196	interval	N	I-Premise
197	-12.3	N	I-Premise
198	to	N	I-Premise
199	-0.9	N	I-Premise
200	,	N	I-Premise
201	P=0.02	N	I-Premise
202	;	N	I-Premise
203	effect	N	I-Premise
204	size=0.33	N	I-Premise
205	,	N	I-Premise
206	0.04	N	I-Premise
207	to	N	I-Premise
208	0.61	N	I-Premise
209	)	N	I-Premise
210	.	N	I-Premise

211	Significant	N	I-Premise
212	effects	N	I-Premise
213	were	N	I-Premise
214	seen	N	I-Premise
215	on	N	I-Premise
216	vitality	N	I-Premise
217	(	N	I-Premise
218	effect	N	I-Premise
219	size	N	I-Premise
220	0.55	N	I-Premise
221	,	N	I-Premise
222	95	N	I-Premise
223	%	N	I-Premise
224	CI	N	I-Premise
225	0.27	N	I-Premise
226	to	N	I-Premise
227	0.82	N	I-Premise
228	)	N	I-Premise
229	,	N	I-Premise
230	physical	N	I-Premise
231	functioning	N	I-Premise
232	(	N	I-Premise
233	0.37	N	I-Premise
234	,	N	I-Premise
235	0.09	N	I-Premise
236	to	N	I-Premise
237	0.65	N	I-Premise
238	)	N	I-Premise
239	,	N	I-Premise
240	role	N	I-Premise
241	physical	N	I-Premise
242	(	N	I-Premise
243	0.37	N	I-Premise
244	,	N	I-Premise
245	0.10	N	I-Premise
246	to	N	I-Premise
247	0.64	N	I-Premise
248	)	N	I-Premise
249	,	N	I-Premise
250	role	N	I-Premise
251	emotional	N	I-Premise
252	(	N	I-Premise
253	0.32	N	I-Premise
254	,	N	I-Premise
255	0.05	N	I-Premise
256	to	N	I-Premise
257	0.59	N	I-Premise
258	)	N	I-Premise
259	,	N	I-Premise
260	and	N	I-Premise
261	mental	N	I-Premise
262	health	N	I-Premise
263	(	N	I-Premise
264	0.28	N	I-Premise
265	,	N	I-Premise
266	0.02	N	I-Premise
267	to	N	I-Premise
268	0.56	N	I-Premise
269	)	N	I-Premise
270	scores	N	I-Premise
271	.	N	I-Premise

272	Improvement	N	I-Premise
273	was	N	I-Premise
274	noted	N	I-Premise
275	in	N	I-Premise
276	physical	N	I-Premise
277	capacity	N	I-Premise
278	:	N	I-Premise
279	estimated	N	I-Premise
280	mean	N	I-Premise
281	difference	N	I-Premise
282	between	N	I-Premise
283	groups	N	I-Premise
284	for	N	I-Premise
285	maximum	N	I-Premise
286	oxygen	N	I-Premise
287	consumption	N	I-Premise
288	was	N	I-Premise
289	0.16	N	I-Premise
290	l/min	N	I-Premise
291	(	N	I-Premise
292	95	N	I-Premise
293	%	N	I-Premise
294	CI	N	I-Premise
295	0.1	N	I-Premise
296	to	N	I-Premise
297	0.2	N	I-Premise
298	,	N	I-Premise
299	P	N	I-Premise
300	<	N	I-Premise
301	0.0001	N	I-Premise
302	)	N	I-Premise
303	and	N	I-Premise
304	for	N	I-Premise
305	muscular	N	I-Premise
306	strength	N	I-Premise
307	(	N	I-Premise
308	leg	N	I-Premise
309	press	N	I-Premise
310	)	N	I-Premise
311	was	N	I-Premise
312	29.7	N	I-Premise
313	kg	N	I-Premise
314	(	N	I-Premise
315	23.4	N	I-Premise
316	to	N	I-Premise
317	34.9	N	I-Premise
318	,	N	I-Premise
319	P	N	I-Premise
320	<	N	I-Premise
321	0.0001	N	I-Premise
322	)	N	I-Premise
323	.	N	I-Premise

324	No	N	I-Premise
325	significant	N	I-Premise
326	effect	N	I-Premise
327	was	N	I-Premise
328	seen	N	I-Premise
329	on	N	I-Premise
330	global	N	I-Premise
331	health	N	I-Premise
332	status/quality	N	I-Premise
333	of	N	I-Premise
334	life	N	I-Premise
335	.	N	I-Premise

336	A	N	I-Claim
337	supervised	N	I-Claim
338	multimodal	N	I-Claim
339	exercise	N	I-Claim
340	intervention	N	I-Claim
341	including	N	I-Claim
342	high	N	I-Claim
343	and	N	I-Claim
344	low	N	I-Claim
345	intensity	N	I-Claim
346	components	N	I-Claim
347	was	N	I-Claim
348	feasible	N	I-Claim
349	and	N	I-Claim
350	could	N	I-Claim
351	safely	N	I-Claim
352	be	N	I-Claim
353	used	N	I-Claim
354	in	N	I-Claim
355	patients	N	I-Claim
356	with	N	I-Claim
357	various	N	I-Claim
358	cancers	N	I-Claim
359	who	N	I-Claim
360	were	N	I-Claim
361	receiving	N	I-Claim
362	adjuvant	N	I-Claim
363	chemotherapy	N	I-Claim
364	or	N	I-Claim
365	treatment	N	I-Claim
366	for	N	I-Claim
367	advanced	N	I-Claim
368	disease	N	I-Claim
369	.	N	I-Claim

370	The	N	I-Claim
371	intervention	N	I-Claim
372	reduced	N	I-Claim
373	fatigue	N	I-Claim
374	and	N	I-Claim
375	improved	N	I-Claim
376	vitality	N	I-Claim
377	,	N	I-Claim
378	aerobic	N	I-Claim
379	capacity	N	I-Claim
380	,	N	I-Claim
381	muscular	N	I-Claim
382	strength	N	I-Claim
383	,	N	I-Claim
384	and	N	I-Claim
385	physical	N	I-Claim
386	and	N	I-Claim
387	functional	N	I-Claim
388	activity	N	I-Claim
389	,	N	I-Claim
390	and	N	I-Claim
391	emotional	N	I-Claim
392	wellbeing	N	I-Claim
393	,	N	I-Claim
394	but	N	I-Claim
395	not	N	I-Claim
396	quality	N	I-Claim
397	of	N	I-Claim
398	life	N	I-Claim
399	.	N	I-Claim

1	Depression	N	O
2	is	N	O
3	common	N	O
4	among	N	O
5	older	N	O
6	cancer	N	O
7	patients	N	O
8	,	N	O
9	but	N	O
10	little	N	O
11	is	N	O
12	known	N	O
13	about	N	O
14	the	N	O
15	optimal	N	O
16	approach	N	O
17	to	N	O
18	caring	N	O
19	for	N	O
20	this	N	O
21	population	N	O
22	.	N	O

23	This	N	O
24	analysis	N	O
25	evaluates	N	O
26	the	N	O
27	effectiveness	N	O
28	of	N	O
29	the	N	O
30	Improving	N	O
31	Mood-Promoting	N	O
32	Access	N	O
33	to	N	O
34	Collaborative	N	O
35	Treatment	N	O
36	(	N	O
37	IMPACT	N	O
38	)	N	O
39	program	N	O
40	,	N	O
41	a	N	O
42	stepped	N	O
43	care	N	O
44	management	N	O
45	program	N	O
46	for	N	O
47	depression	N	O
48	in	N	O
49	primary	N	O
50	care	N	O
51	patients	N	O
52	who	N	O
53	had	N	O
54	an	N	O
55	ICD-9	N	O
56	cancer	N	O
57	diagnosis	N	O
58	.	N	O

59	Two	N	O
60	hundred	N	O
61	fifteen	N	O
62	cancer	N	O
63	patients	N	O
64	were	N	O
65	identified	N	O
66	from	N	O
67	the	N	O
68	1,801	N	O
69	participants	N	O
70	in	N	O
71	the	N	O
72	parent	N	O
73	study	N	O
74	.	N	O

75	Subjects	N	O
76	were	N	O
77	60	N	O
78	years	N	O
79	or	N	O
80	older	N	O
81	with	N	O
82	major	N	O
83	depression	N	O
84	(	N	O
85	18	N	O
86	%	N	O
87	)	N	O
88	,	N	O
89	dysthymic	N	O
90	disorder	N	O
91	(	N	O
92	33	N	O
93	%	N	O
94	)	N	O
95	,	N	O
96	or	N	O
97	both	N	O
98	(	N	O
99	49	N	O
100	%	N	O
101	)	N	O
102	,	N	O
103	recruited	N	O
104	from	N	O
105	18	N	O
106	primary	N	O
107	care	N	O
108	clinics	N	O
109	belonging	N	O
110	to	N	O
111	8	N	O
112	health-care	N	O
113	organizations	N	O
114	in	N	O
115	5	N	O
116	states	N	O
117	.	N	O

118	Patients	N	O
119	were	N	O
120	randomly	N	O
121	assigned	N	O
122	to	N	O
123	the	N	O
124	IMPACT	N	O
125	intervention	N	O
126	(	N	O
127	n	N	O
128	=	N	O
129	112	N	O
130	)	N	O
131	or	N	O
132	usual	N	O
133	care	N	O
134	(	N	O
135	n	N	O
136	=	N	O
137	103	N	O
138	)	N	O
139	.	N	O

140	Intervention	N	O
141	patients	N	O
142	had	N	O
143	access	N	O
144	for	N	O
145	up	N	O
146	to	N	O
147	12	N	O
148	months	N	O
149	to	N	O
150	a	N	O
151	depression	N	O
152	care	N	O
153	manager	N	O
154	who	N	O
155	was	N	O
156	supervised	N	O
157	by	N	O
158	a	N	O
159	psychiatrist	N	O
160	and	N	O
161	a	N	O
162	primary	N	O
163	care	N	O
164	provider	N	O
165	and	N	O
166	who	N	O
167	offered	N	O
168	education	N	O
169	,	N	O
170	care	N	O
171	management	N	O
172	,	N	O
173	support	N	O
174	of	N	O
175	antidepressant	N	O
176	management	N	O
177	,	N	O
178	and	N	O
179	brief	N	O
180	,	N	O
181	structured	N	O
182	psychosocial	N	O
183	interventions	N	O
184	including	N	O
185	behavioral	N	O
186	activation	N	O
187	and	N	O
188	problem-solving	N	O
189	treatment	N	O
190	.	N	O

191	At	N	I-Premise
192	6	N	I-Premise
193	and	N	I-Premise
194	12	N	I-Premise
195	months	N	I-Premise
196	,	N	I-Premise
197	55	N	I-Premise
198	%	N	I-Premise
199	and	N	I-Premise
200	39	N	I-Premise
201	%	N	I-Premise
202	of	N	I-Premise
203	intervention	N	I-Premise
204	patients	N	I-Premise
205	had	N	I-Premise
206	a	N	I-Premise
207	50	N	I-Premise
208	%	N	I-Premise
209	or	N	I-Premise
210	greater	N	I-Premise
211	reduction	N	I-Premise
212	in	N	I-Premise
213	depressive	N	I-Premise
214	symptoms	N	I-Premise
215	(	N	I-Premise
216	SCL-20	N	I-Premise
217	)	N	I-Premise
218	from	N	I-Premise
219	baseline	N	I-Premise
220	compared	N	I-Premise
221	to	N	I-Premise
222	34	N	I-Premise
223	%	N	I-Premise
224	and	N	I-Premise
225	20	N	I-Premise
226	%	N	I-Premise
227	of	N	I-Premise
228	usual	N	I-Premise
229	care	N	I-Premise
230	participants	N	I-Premise
231	(	N	I-Premise
232	P	N	I-Premise
233	=	N	I-Premise
234	0.003	N	I-Premise
235	and	N	I-Premise
236	P	N	I-Premise
237	=	N	I-Premise
238	0.029	N	I-Premise
239	)	N	I-Premise
240	.	N	I-Premise

241	Intervention	N	I-Premise
242	patients	N	I-Premise
243	also	N	I-Premise
244	experienced	N	I-Premise
245	greater	N	I-Premise
246	remission	N	I-Premise
247	rates	N	I-Premise
248	(	N	I-Premise
249	P	N	I-Premise
250	=	N	I-Premise
251	0.031	N	I-Premise
252	)	N	I-Premise
253	,	N	I-Premise
254	more	N	I-Premise
255	depression-free	N	I-Premise
256	days	N	I-Premise
257	(	N	I-Premise
258	P	N	I-Premise
259	<	N	I-Premise
260	0.001	N	I-Premise
261	)	N	I-Premise
262	,	N	I-Premise
263	less	N	I-Premise
264	functional	N	I-Premise
265	impairment	N	I-Premise
266	(	N	I-Premise
267	P	N	I-Premise
268	=	N	I-Premise
269	0.011	N	I-Premise
270	)	N	I-Premise
271	,	N	I-Premise
272	and	N	I-Premise
273	greater	N	I-Premise
274	quality	N	I-Premise
275	of	N	I-Premise
276	life	N	I-Premise
277	(	N	I-Premise
278	P	N	I-Premise
279	=	N	I-Premise
280	0.039	N	I-Premise
281	)	N	I-Premise
282	at	N	I-Premise
283	12	N	I-Premise
284	months	N	I-Premise
285	than	N	I-Premise
286	usual	N	I-Premise
287	care	N	I-Premise
288	participants	N	I-Premise
289	.	N	I-Premise

290	The	N	I-Claim
291	IMPACT	N	I-Claim
292	collaborative	N	I-Claim
293	care	N	I-Claim
294	program	N	I-Claim
295	appears	N	I-Claim
296	to	N	I-Claim
297	be	N	I-Claim
298	feasible	N	I-Claim
299	and	N	I-Claim
300	effective	N	I-Claim
301	for	N	I-Claim
302	depression	N	I-Claim
303	among	N	I-Claim
304	older	N	I-Claim
305	cancer	N	I-Claim
306	patients	N	I-Claim
307	in	N	I-Claim
308	diverse	N	I-Claim
309	primary	N	I-Claim
310	care	N	I-Claim
311	settings	N	I-Claim
312	.	N	I-Claim

1	Both	N	O
2	gemcitabine	N	O
3	(	N	O
4	GEM	N	O
5	)	N	O
6	and	N	O
7	fluoropyrimidines	N	O
8	are	N	O
9	valuable	N	O
10	treatment	N	O
11	for	N	O
12	advanced	N	O
13	pancreatic	N	O
14	cancer	N	O
15	.	N	O

16	This	N	O
17	open-label	N	O
18	study	N	O
19	was	N	O
20	designed	N	O
21	to	N	O
22	compare	N	O
23	the	N	O
24	overall	N	O
25	survival	N	O
26	(	N	O
27	OS	N	O
28	)	N	O
29	of	N	O
30	patients	N	O
31	randomly	N	O
32	assigned	N	O
33	to	N	O
34	GEM	N	O
35	alone	N	O
36	or	N	O
37	GEM	N	O
38	plus	N	O
39	capecitabine	N	O
40	(	N	O
41	GEM-CAP	N	O
42	)	N	O
43	.	N	O

44	Patients	N	O
45	with	N	O
46	previously	N	O
47	untreated	N	O
48	histologically	N	O
49	or	N	O
50	cytologically	N	O
51	proven	N	O
52	locally	N	O
53	advanced	N	O
54	or	N	O
55	metastatic	N	O
56	carcinoma	N	O
57	of	N	O
58	the	N	O
59	pancreas	N	O
60	with	N	O
61	a	N	O
62	performance	N	O
63	status	N	O
64	<	N	O
65	or=	N	O
66	2	N	O
67	were	N	O
68	recruited	N	O
69	.	N	O

70	Patients	N	O
71	were	N	O
72	randomly	N	O
73	assigned	N	O
74	to	N	O
75	GEM	N	O
76	or	N	O
77	GEM-CAP	N	O
78	.	N	O

79	The	N	O
80	primary	N	O
81	outcome	N	O
82	measure	N	O
83	was	N	O
84	survival	N	O
85	.	N	O

86	Meta-analysis	N	O
87	of	N	O
88	published	N	O
89	studies	N	O
90	was	N	O
91	also	N	O
92	conducted	N	O
93	.	N	O

94	Between	N	O
95	May	N	O
96	2002	N	O
97	and	N	O
98	January	N	O
99	2005	N	O
100	,	N	O
101	533	N	O
102	patients	N	O
103	were	N	O
104	randomly	N	O
105	assigned	N	O
106	to	N	O
107	GEM	N	O
108	(	N	O
109	n	N	O
110	=	N	O
111	266	N	O
112	)	N	O
113	and	N	O
114	GEM-CAP	N	O
115	(	N	O
116	n	N	O
117	=	N	O
118	267	N	O
119	)	N	O
120	arms	N	O
121	.	N	O

122	GEM-CAP	N	I-Premise
123	significantly	N	I-Premise
124	improved	N	I-Premise
125	objective	N	I-Premise
126	response	N	I-Premise
127	rate	N	I-Premise
128	(	N	I-Premise
129	19.1	N	I-Premise
130	%	N	I-Premise
131	v	N	I-Premise
132	12.4	N	I-Premise
133	%	N	I-Premise
134	;	N	I-Premise
135	P	N	I-Premise
136	=	N	I-Premise
137	.034	N	I-Premise
138	)	N	I-Premise
139	and	N	I-Premise
140	progression-free	N	I-Premise
141	survival	N	I-Premise
142	(	N	I-Premise
143	hazard	N	I-Premise
144	ratio	N	I-Premise
145	[	N	I-Premise
146	HR	N	I-Premise
147	]	N	I-Premise
148	,	N	I-Premise
149	0.78	N	I-Premise
150	;	N	I-Premise
151	95	N	I-Premise
152	%	N	I-Premise
153	CI	N	I-Premise
154	,	N	I-Premise
155	0.66	N	I-Premise
156	to	N	I-Premise
157	0.93	N	I-Premise
158	;	N	I-Premise
159	P	N	I-Premise
160	=	N	I-Premise
161	.004	N	I-Premise
162	)	N	I-Premise
163	and	N	I-Premise
164	was	N	I-Premise
165	associated	N	I-Premise
166	with	N	I-Premise
167	a	N	I-Premise
168	trend	N	I-Premise
169	toward	N	I-Premise
170	improved	N	I-Premise
171	OS	N	I-Premise
172	(	N	I-Premise
173	HR	N	I-Premise
174	,	N	I-Premise
175	0.86	N	I-Premise
176	;	N	I-Premise
177	95	N	I-Premise
178	%	N	I-Premise
179	CI	N	I-Premise
180	,	N	I-Premise
181	0.72	N	I-Premise
182	to	N	I-Premise
183	1.02	N	I-Premise
184	;	N	I-Premise
185	P	N	I-Premise
186	=	N	I-Premise
187	.08	N	I-Premise
188	)	N	I-Premise
189	compared	N	I-Premise
190	with	N	I-Premise
191	GEM	N	I-Premise
192	alone	N	I-Premise
193	.	N	I-Premise

194	This	N	I-Premise
195	trend	N	I-Premise
196	for	N	I-Premise
197	OS	N	I-Premise
198	benefit	N	I-Premise
199	for	N	I-Premise
200	GEM-CAP	N	I-Premise
201	was	N	I-Premise
202	consistent	N	I-Premise
203	across	N	I-Premise
204	different	N	I-Premise
205	prognostic	N	I-Premise
206	subgroups	N	I-Premise
207	according	N	I-Premise
208	to	N	I-Premise
209	baseline	N	I-Premise
210	stratification	N	I-Premise
211	factors	N	I-Premise
212	(	N	I-Premise
213	stage	N	I-Premise
214	and	N	I-Premise
215	performance	N	I-Premise
216	status	N	I-Premise
217	)	N	I-Premise
218	and	N	I-Premise
219	remained	N	I-Premise
220	after	N	I-Premise
221	adjusting	N	I-Premise
222	for	N	I-Premise
223	these	N	I-Premise
224	stratification	N	I-Premise
225	factors	N	I-Premise
226	(	N	I-Premise
227	P	N	I-Premise
228	=	N	I-Premise
229	.077	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	Moreover	N	O
233	,	N	O
234	the	N	I-Premise
235	meta-analysis	N	I-Premise
236	of	N	I-Premise
237	two	N	I-Premise
238	additional	N	I-Premise
239	studies	N	I-Premise
240	involving	N	I-Premise
241	935	N	I-Premise
242	patients	N	I-Premise
243	showed	N	I-Premise
244	a	N	I-Premise
245	significant	N	I-Premise
246	survival	N	I-Premise
247	benefit	N	I-Premise
248	in	N	I-Premise
249	favor	N	I-Premise
250	of	N	I-Premise
251	GEM-CAP	N	I-Premise
252	(	N	I-Premise
253	HR	N	I-Premise
254	,	N	I-Premise
255	0.86	N	I-Premise
256	;	N	I-Premise
257	95	N	I-Premise
258	%	N	I-Premise
259	CI	N	I-Premise
260	,	N	I-Premise
261	0.75	N	I-Premise
262	to	N	I-Premise
263	0.98	N	I-Premise
264	;	N	I-Premise
265	P	N	I-Premise
266	=	N	I-Premise
267	.02	N	I-Premise
268	)	N	I-Premise
269	with	N	I-Premise
270	no	N	I-Premise
271	intertrial	N	I-Premise
272	heterogeneity	N	I-Premise
273	.	N	I-Premise

274	On	N	I-MajorClaim
275	the	N	I-MajorClaim
276	basis	N	I-MajorClaim
277	of	N	I-MajorClaim
278	our	N	I-MajorClaim
279	trial	N	I-MajorClaim
280	and	N	I-MajorClaim
281	the	N	I-MajorClaim
282	meta-analysis	N	I-MajorClaim
283	,	N	I-MajorClaim
284	GEM-CAP	N	I-MajorClaim
285	should	N	I-MajorClaim
286	be	N	I-MajorClaim
287	considered	N	I-MajorClaim
288	as	N	I-MajorClaim
289	one	N	I-MajorClaim
290	of	N	I-MajorClaim
291	the	N	I-MajorClaim
292	standard	N	I-MajorClaim
293	first-line	N	I-MajorClaim
294	options	N	I-MajorClaim
295	in	N	I-MajorClaim
296	locally	N	I-MajorClaim
297	advanced	N	I-MajorClaim
298	and	N	I-MajorClaim
299	metastatic	N	I-MajorClaim
300	pancreatic	N	I-MajorClaim
301	cancer	N	I-MajorClaim
302	.	N	I-MajorClaim

1	To	N	O
2	determine	N	O
3	1-year	N	O
4	outcomes	N	O
5	of	N	O
6	a	N	O
7	four-component	N	O
8	behavioral	N	O
9	therapy	N	O
10	(	N	O
11	BT	N	O
12	)	N	O
13	sleep	N	O
14	intervention	N	O
15	(	N	O
16	Individualized	N	O
17	Sleep	N	O
18	Promotion	N	O
19	Plan	N	O
20	[	N	O
21	ISPP	N	O
22	]	N	O
23	)	N	O
24	versus	N	O
25	a	N	O
26	healthy	N	O
27	eating	N	O
28	control	N	O
29	(	N	O
30	HEC	N	O
31	)	N	O
32	on	N	O
33	cancer-related	N	O
34	fatigue	N	O
35	in	N	O
36	women	N	O
37	receiving	N	O
38	breast	N	O
39	cancer	N	O
40	adjuvant	N	O
41	chemotherapy	N	O
42	treatment	N	O
43	(	N	O
44	CTX	N	O
45	)	N	O
46	.	N	O

47	A	N	O
48	total	N	O
49	of	N	O
50	219	N	O
51	participants	N	O
52	from	N	O
53	12	N	O
54	oncology	N	O
55	clinics	N	O
56	were	N	O
57	randomly	N	O
58	assigned	N	O
59	in	N	O
60	a	N	O
61	clinical	N	O
62	trial	N	O
63	.	N	O

64	Before	N	O
65	CTX	N	O
66	,	N	O
67	research	N	O
68	nurses	N	O
69	coached	N	O
70	intervention	N	O
71	participants	N	O
72	to	N	O
73	develop	N	O
74	a	N	O
75	BT	N	O
76	plan	N	O
77	including	N	O
78	stimulus	N	O
79	control	N	O
80	,	N	O
81	modified	N	O
82	sleep	N	O
83	restriction	N	O
84	,	N	O
85	relaxation	N	O
86	therapy	N	O
87	,	N	O
88	and	N	O
89	sleep	N	O
90	hygiene	N	O
91	.	N	O

92	BT	N	O
93	plans	N	O
94	were	N	O
95	revised	N	O
96	before	N	O
97	each	N	O
98	CTX	N	O
99	and	N	O
100	30	N	O
101	,	N	O
102	60	N	O
103	,	N	O
104	and	N	O
105	90	N	O
106	days	N	O
107	after	N	O
108	the	N	O
109	last	N	O
110	CTX	N	O
111	and	N	O
112	reinforced	N	O
113	7	N	O
114	to	N	O
115	9	N	O
116	days	N	O
117	later	N	O
118	.	N	O

119	HEC	N	O
120	participants	N	O
121	received	N	O
122	nutritional	N	O
123	information	N	O
124	and	N	O
125	equal	N	O
126	attention	N	O
127	.	N	O

128	Pittsburgh	N	O
129	Sleep	N	O
130	Quality	N	O
131	Index	N	O
132	(	N	O
133	PSQI	N	O
134	)	N	O
135	,	N	O
136	Daily	N	O
137	Diary	N	O
138	,	N	O
139	Wrist	N	O
140	Actigraph	N	O
141	,	N	O
142	and	N	O
143	Piper	N	O
144	Fatigue	N	O
145	Scale	N	O
146	measures	N	O
147	and	N	O
148	Repeated	N	O
149	Linear	N	O
150	Mixed	N	O
151	Model	N	O
152	analysis	N	O
153	following	N	O
154	the	N	O
155	Intent	N	O
156	to	N	O
157	Treat	N	O
158	paradigm	N	O
159	were	N	O
160	used	N	O
161	.	N	O

162	Sleep	N	I-Premise
163	quality	N	I-Premise
164	differed	N	I-Premise
165	over	N	I-Premise
166	1	N	I-Premise
167	years	N	I-Premise
168	time	N	I-Premise
169	(	N	I-Premise
170	F	N	I-Premise
171	[	N	I-Premise
172	4,162	N	I-Premise
173	]	N	I-Premise
174	=	N	I-Premise
175	7.7	N	I-Premise
176	,	N	I-Premise
177	P	N	I-Premise
178	<	N	I-Premise
179	.001	N	I-Premise
180	;	N	I-Premise
181	by	N	I-Premise
182	group	N	I-Premise
183	,	N	I-Premise
184	F	N	I-Premise
185	[	N	I-Premise
186	1,173	N	I-Premise
187	]	N	I-Premise
188	=	N	I-Premise
189	4.8	N	I-Premise
190	,	N	I-Premise
191	P	N	I-Premise
192	=	N	I-Premise
193	.029	N	I-Premise
194	;	N	I-Premise
195	and	N	I-Premise
196	over	N	I-Premise
197	time	N	I-Premise
198	by	N	I-Premise
199	group	N	I-Premise
200	,	N	I-Premise
201	F	N	I-Premise
202	[	N	I-Premise
203	4,162	N	I-Premise
204	]	N	I-Premise
205	=	N	I-Premise
206	3.3	N	I-Premise
207	,	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	.013	N	I-Premise
211	)	N	I-Premise
212	.	N	I-Premise

213	Pairwise	N	I-Premise
214	comparisons	N	I-Premise
215	revealed	N	I-Premise
216	significant	N	I-Premise
217	differences	N	I-Premise
218	between	N	I-Premise
219	groups	N	I-Premise
220	at	N	I-Premise
221	90	N	I-Premise
222	days	N	I-Premise
223	(	N	I-Premise
224	P	N	I-Premise
225	=	N	I-Premise
226	.002	N	I-Premise
227	)	N	I-Premise
228	but	N	I-Premise
229	not	N	I-Premise
230	at	N	I-Premise
231	1	N	I-Premise
232	year	N	I-Premise
233	(	N	I-Premise
234	P	N	I-Premise
235	=	N	I-Premise
236	.052	N	I-Premise
237	)	N	I-Premise
238	.	N	I-Premise

239	Seven	N	O
240	days	N	O
241	of	N	O
242	diary	N	O
243	and	N	O
244	actigraphy	N	O
245	data	N	O
246	did	N	O
247	not	N	O
248	corroborate	N	O
249	with	N	O
250	monthly	N	O
251	reflections	N	O
252	(	N	O
253	PSQI	N	O
254	)	N	O
255	.	N	O

256	The	N	I-Premise
257	night	N	I-Premise
258	awakenings	N	I-Premise
259	(	N	I-Premise
260	Actigraph	N	I-Premise
261	)	N	I-Premise
262	pattern	N	I-Premise
263	was	N	I-Premise
264	significantly	N	I-Premise
265	different	N	I-Premise
266	by	N	I-Premise
267	group	N	I-Premise
268	over	N	I-Premise
269	time	N	I-Premise
270	(	N	I-Premise
271	P	N	I-Premise
272	=	N	I-Premise
273	.046	N	I-Premise
274	)	N	I-Premise
275	,	N	I-Premise
276	with	N	I-Premise
277	no	N	I-Premise
278	differences	N	I-Premise
279	between	N	I-Premise
280	groups	N	I-Premise
281	at	N	I-Premise
282	90	N	I-Premise
283	days	N	I-Premise
284	or	N	I-Premise
285	at	N	I-Premise
286	1	N	I-Premise
287	year	N	I-Premise
288	.	N	I-Premise

289	Fatigue	N	I-Premise
290	was	N	I-Premise
291	lower	N	I-Premise
292	at	N	I-Premise
293	1	N	I-Premise
294	year	N	I-Premise
295	than	N	I-Premise
296	before	N	I-Premise
297	CTX	N	I-Premise
298	;	N	I-Premise
299	no	N	I-Premise
300	group	N	I-Premise
301	effects	N	I-Premise
302	were	N	I-Premise
303	found	N	I-Premise
304	.	N	I-Premise

305	The	N	I-Claim
306	BT	N	I-Claim
307	group	N	I-Claim
308	,	N	I-Claim
309	on	N	I-Claim
310	average	N	I-Claim
311	,	N	I-Claim
312	experienced	N	I-Claim
313	significant	N	I-Claim
314	improvement	N	I-Claim
315	on	N	I-Claim
316	global	N	I-Claim
317	sleep	N	I-Claim
318	quality	N	I-Claim
319	compared	N	I-Claim
320	with	N	I-Claim
321	the	N	I-Claim
322	HEC	N	I-Claim
323	group	N	I-Claim
324	,	N	I-Claim
325	but	N	I-Claim
326	not	N	I-Claim
327	on	N	I-Claim
328	objective	N	I-Claim
329	sleep	N	I-Claim
330	or	N	I-Claim
331	fatigue	N	I-Claim
332	outcomes	N	I-Claim
333	.	N	I-Claim

1	Both	N	O
2	gastrojejunostomy	N	O
3	(	N	O
4	GJJ	N	O
5	)	N	O
6	and	N	O
7	stent	N	O
8	placement	N	O
9	are	N	O
10	commonly	N	O
11	used	N	O
12	palliative	N	O
13	treatments	N	O
14	of	N	O
15	obstructive	N	O
16	symptoms	N	O
17	caused	N	O
18	by	N	O
19	malignant	N	O
20	gastric	N	O
21	outlet	N	O
22	obstruction	N	O
23	(	N	O
24	GOO	N	O
25	)	N	O
26	.	N	O

27	Compare	N	O
28	GJJ	N	O
29	and	N	O
30	stent	N	O
31	placement	N	O
32	.	N	O

33	Multicenter	N	O
34	,	N	O
35	randomized	N	O
36	trial	N	O
37	.	N	O

38	Twenty-one	N	O
39	centers	N	O
40	in	N	O
41	The	N	O
42	Netherlands	N	O
43	.	N	O

44	Patients	N	O
45	with	N	O
46	GOO	N	O
47	.	N	O

48	GJJ	N	O
49	and	N	O
50	stent	N	O
51	placement	N	O
52	.	N	O

53	Outcomes	N	O
54	were	N	O
55	medical	N	O
56	effects	N	O
57	,	N	O
58	quality	N	O
59	of	N	O
60	life	N	O
61	,	N	O
62	and	N	O
63	costs	N	O
64	.	N	O

65	Analysis	N	O
66	was	N	O
67	by	N	O
68	intent	N	O
69	to	N	O
70	treat	N	O
71	.	N	O

72	Eighteen	N	O
73	patients	N	O
74	were	N	O
75	randomized	N	O
76	to	N	O
77	GJJ	N	O
78	and	N	O
79	21	N	O
80	to	N	O
81	stent	N	O
82	placement	N	O
83	.	N	O

84	Food	N	I-Premise
85	intake	N	I-Premise
86	improved	N	I-Premise
87	more	N	I-Premise
88	rapidly	N	I-Premise
89	after	N	I-Premise
90	stent	N	I-Premise
91	placement	N	I-Premise
92	than	N	I-Premise
93	after	N	I-Premise
94	GJJ	N	I-Premise
95	(	N	I-Premise
96	GOO	N	I-Premise
97	Scoring	N	I-Premise
98	System	N	I-Premise
99	score	N	I-Premise
100	>	N	I-Premise
101	or	N	I-Premise
102	=	N	I-Premise
103	2	N	I-Premise
104	:	N	I-Premise
105	median	N	I-Premise
106	5	N	I-Premise
107	vs	N	I-Premise
108	8	N	I-Premise
109	days	N	I-Premise
110	,	N	I-Premise
111	respectively	N	I-Premise
112	;	N	I-Premise
113	P	N	I-Premise
114	<	N	I-Premise
115	.01	N	I-Premise
116	)	N	I-Premise
117	but	N	I-Premise
118	long-term	N	I-Premise
119	relief	N	I-Premise
120	was	N	I-Premise
121	better	N	I-Premise
122	after	N	I-Premise
123	GJJ	N	I-Premise
124	,	N	I-Premise
125	with	N	I-Premise
126	more	N	I-Premise
127	patients	N	I-Premise
128	living	N	I-Premise
129	more	N	I-Premise
130	days	N	I-Premise
131	with	N	I-Premise
132	a	N	I-Premise
133	GOO	N	I-Premise
134	Scoring	N	I-Premise
135	System	N	I-Premise
136	score	N	I-Premise
137	of	N	I-Premise
138	2	N	I-Premise
139	or	N	I-Premise
140	more	N	I-Premise
141	than	N	I-Premise
142	after	N	I-Premise
143	stent	N	I-Premise
144	placement	N	I-Premise
145	(	N	I-Premise
146	72	N	I-Premise
147	vs	N	I-Premise
148	50	N	I-Premise
149	days	N	I-Premise
150	,	N	I-Premise
151	respectively	N	I-Premise
152	;	N	I-Premise
153	P	N	I-Premise
154	=	N	I-Premise
155	.05	N	I-Premise
156	)	N	I-Premise
157	.	N	I-Premise

158	More	N	I-Premise
159	major	N	I-Premise
160	complications	N	I-Premise
161	(	N	I-Premise
162	stent	N	I-Premise
163	:	N	I-Premise
164	6	N	I-Premise
165	in	N	I-Premise
166	4	N	I-Premise
167	patients	N	I-Premise
168	vs	N	I-Premise
169	GJJ	N	I-Premise
170	:	N	I-Premise
171	0	N	I-Premise
172	;	N	I-Premise
173	P	N	I-Premise
174	=	N	I-Premise
175	.02	N	I-Premise
176	)	N	I-Premise
177	,	N	I-Premise
178	recurrent	N	I-Premise
179	obstructive	N	I-Premise
180	symptoms	N	I-Premise
181	(	N	I-Premise
182	stent	N	I-Premise
183	:	N	I-Premise
184	8	N	I-Premise
185	in	N	I-Premise
186	5	N	I-Premise
187	patients	N	I-Premise
188	vs	N	I-Premise
189	GJJ	N	I-Premise
190	:	N	I-Premise
191	1	N	I-Premise
192	in	N	I-Premise
193	1	N	I-Premise
194	patient	N	I-Premise
195	;	N	I-Premise
196	P	N	I-Premise
197	=	N	I-Premise
198	.02	N	I-Premise
199	)	N	I-Premise
200	,	N	I-Premise
201	and	N	I-Premise
202	reinterventions	N	I-Premise
203	(	N	I-Premise
204	stent	N	I-Premise
205	:	N	I-Premise
206	10	N	I-Premise
207	in	N	I-Premise
208	7	N	I-Premise
209	patients	N	I-Premise
210	vs	N	I-Premise
211	GJJ	N	I-Premise
212	:	N	I-Premise
213	2	N	I-Premise
214	in	N	I-Premise
215	2	N	I-Premise
216	patients	N	I-Premise
217	;	N	I-Premise
218	P	N	I-Premise
219	<	N	I-Premise
220	.01	N	I-Premise
221	)	N	I-Premise
222	were	N	I-Premise
223	observed	N	I-Premise
224	after	N	I-Premise
225	stent	N	I-Premise
226	placement	N	I-Premise
227	compared	N	I-Premise
228	with	N	I-Premise
229	GJJ	N	I-Premise
230	.	N	I-Premise

231	When	N	I-Premise
232	stent	N	I-Premise
233	obstruction	N	I-Premise
234	was	N	I-Premise
235	not	N	I-Premise
236	regarded	N	I-Premise
237	as	N	I-Premise
238	a	N	I-Premise
239	major	N	I-Premise
240	complication	N	I-Premise
241	,	N	I-Premise
242	no	N	I-Premise
243	differences	N	I-Premise
244	in	N	I-Premise
245	complications	N	I-Premise
246	were	N	I-Premise
247	found	N	I-Premise
248	(	N	I-Premise
249	P	N	I-Premise
250	=	N	I-Premise
251	.4	N	I-Premise
252	)	N	I-Premise
253	.	N	I-Premise

254	There	N	I-Premise
255	were	N	I-Premise
256	also	N	I-Premise
257	no	N	I-Premise
258	differences	N	I-Premise
259	in	N	I-Premise
260	median	N	I-Premise
261	survival	N	I-Premise
262	(	N	I-Premise
263	stent	N	I-Premise
264	:	N	I-Premise
265	56	N	I-Premise
266	days	N	I-Premise
267	vs	N	I-Premise
268	GJJ	N	I-Premise
269	:	N	I-Premise
270	78	N	I-Premise
271	days	N	I-Premise
272	)	N	I-Premise
273	and	N	I-Premise
274	quality	N	I-Premise
275	of	N	I-Premise
276	life	N	I-Premise
277	.	N	I-Premise

278	Mean	N	I-Premise
279	total	N	I-Premise
280	costs	N	I-Premise
281	of	N	I-Premise
282	GJJ	N	I-Premise
283	were	N	I-Premise
284	higher	N	I-Premise
285	compared	N	I-Premise
286	with	N	I-Premise
287	stent	N	I-Premise
288	placement	N	I-Premise
289	(	N	I-Premise
290	$	N	I-Premise
291	16,535	N	I-Premise
292	vs	N	I-Premise
293	$	N	I-Premise
294	11,720	N	I-Premise
295	,	N	I-Premise
296	respectively	N	I-Premise
297	;	N	I-Premise
298	P	N	I-Premise
299	=	N	I-Premise
300	.049	N	I-Premise
301	[	N	I-Premise
302	comparing	N	I-Premise
303	medians	N	I-Premise
304	]	N	I-Premise
305	)	N	I-Premise
306	.	N	I-Premise

307	Because	N	O
308	of	N	O
309	the	N	O
310	small	N	O
311	study	N	O
312	population	N	O
313	,	N	O
314	only	N	O
315	initial	N	O
316	hospital	N	O
317	costs	N	O
318	would	N	O
319	have	N	O
320	been	N	O
321	statistically	N	O
322	significant	N	O
323	if	N	O
324	the	N	O
325	Bonferroni	N	O
326	correction	N	O
327	for	N	O
328	multiple	N	O
329	testing	N	O
330	had	N	O
331	been	N	O
332	applied	N	O
333	.	N	O

334	Relatively	N	O
335	small	N	O
336	patient	N	O
337	population	N	O
338	.	N	O

339	Despite	N	I-Premise
340	slow	N	I-Premise
341	initial	N	I-Premise
342	symptom	N	I-Premise
343	improvement	N	I-Premise
344	,	N	I-Premise
345	GJJ	N	I-Claim
346	was	N	I-Claim
347	associated	N	I-Claim
348	with	N	I-Claim
349	better	N	I-Claim
350	long-term	N	I-Claim
351	results	N	I-Claim
352	and	N	I-Claim
353	is	N	I-Claim
354	therefore	N	I-Claim
355	the	N	I-Claim
356	treatment	N	I-Claim
357	of	N	I-Claim
358	choice	N	I-Claim
359	in	N	I-Claim
360	patients	N	I-Claim
361	with	N	I-Claim
362	a	N	I-Claim
363	life	N	I-Claim
364	expectancy	N	I-Claim
365	of	N	I-Claim
366	2	N	I-Claim
367	months	N	I-Claim
368	or	N	I-Claim
369	longer	N	I-Claim
370	.	N	I-Claim

371	Because	N	I-Claim
372	stent	N	I-Claim
373	placement	N	I-Claim
374	was	N	I-Claim
375	associated	N	I-Claim
376	with	N	I-Claim
377	better	N	I-Claim
378	short-term	N	I-Claim
379	outcomes	N	I-Claim
380	,	N	I-Claim
381	this	N	I-Claim
382	treatment	N	I-Claim
383	is	N	I-Claim
384	preferable	N	I-Claim
385	for	N	I-Claim
386	patients	N	I-Claim
387	expected	N	I-Claim
388	to	N	I-Claim
389	live	N	I-Claim
390	less	N	I-Claim
391	than	N	I-Claim
392	2	N	I-Claim
393	months	N	I-Claim
394	.	N	I-Claim

1	Gastrojejunostomy	N	O
2	(	N	O
3	GJJ	N	O
4	)	N	O
5	and	N	O
6	stent	N	O
7	placement	N	O
8	are	N	O
9	the	N	O
10	most	N	O
11	commonly	N	O
12	used	N	O
13	palliative	N	O
14	treatments	N	O
15	for	N	O
16	malignant	N	O
17	gastric	N	O
18	outlet	N	O
19	obstruction	N	O
20	(	N	O
21	GOO	N	O
22	)	N	O
23	.	N	O

24	In	N	O
25	a	N	O
26	recent	N	O
27	randomized	N	O
28	trial	N	O
29	,	N	O
30	stent	N	O
31	placement	N	O
32	was	N	O
33	preferred	N	O
34	in	N	O
35	patients	N	O
36	with	N	O
37	a	N	O
38	relatively	N	O
39	short	N	O
40	survival	N	O
41	and	N	O
42	GJJ	N	O
43	in	N	O
44	patients	N	O
45	with	N	O
46	a	N	O
47	longer	N	O
48	survival	N	O
49	.	N	O

50	As	N	O
51	health	N	O
52	economic	N	O
53	aspects	N	O
54	have	N	O
55	only	N	O
56	been	N	O
57	studied	N	O
58	in	N	O
59	general	N	O
60	terms	N	O
61	,	N	O
62	we	N	O
63	estimated	N	O
64	the	N	O
65	cost	N	O
66	of	N	O
67	GJJ	N	O
68	and	N	O
69	that	N	O
70	of	N	O
71	stent	N	O
72	placement	N	O
73	in	N	O
74	such	N	O
75	patients	N	O
76	.	N	O

77	In	N	O
78	the	N	O
79	SUSTENT	N	O
80	study	N	O
81	,	N	O
82	patients	N	O
83	were	N	O
84	randomized	N	O
85	to	N	O
86	GJJ	N	O
87	(	N	O
88	n	N	O
89	=	N	O
90	18	N	O
91	)	N	O
92	or	N	O
93	stent	N	O
94	placement	N	O
95	(	N	O
96	n	N	O
97	=	N	O
98	21	N	O
99	)	N	O
100	.	N	O

101	Pancreatic	N	O
102	cancer	N	O
103	was	N	O
104	the	N	O
105	most	N	O
106	common	N	O
107	cause	N	O
108	of	N	O
109	GOO	N	O
110	.	N	O

111	We	N	O
112	compared	N	O
113	initial	N	O
114	costs	N	O
115	and	N	O
116	costs	N	O
117	during	N	O
118	follow-up	N	O
119	.	N	O

120	For	N	O
121	cost-effectiveness	N	O
122	,	N	O
123	the	N	O
124	incremental	N	O
125	cost-effectiveness	N	O
126	ratio	N	O
127	was	N	O
128	calculated	N	O
129	.	N	O

130	Food	N	I-Premise
131	intake	N	I-Premise
132	improved	N	I-Premise
133	more	N	I-Premise
134	rapidly	N	I-Premise
135	after	N	I-Premise
136	stent	N	I-Premise
137	placement	N	I-Premise
138	than	N	I-Premise
139	after	N	I-Premise
140	GJJ	N	I-Premise
141	,	N	I-Premise
142	but	N	I-Premise
143	long-term	N	I-Premise
144	relief	N	I-Premise
145	of	N	I-Premise
146	obstructive	N	I-Premise
147	symptoms	N	I-Premise
148	was	N	I-Premise
149	better	N	I-Premise
150	after	N	I-Premise
151	GJJ	N	I-Premise
152	.	N	I-Premise

153	More	N	I-Premise
154	major	N	I-Premise
155	complications	N	I-Premise
156	(	N	I-Premise
157	P	N	I-Premise
158	=	N	I-Premise
159	0.02	N	I-Premise
160	)	N	I-Premise
161	occurred	N	I-Premise
162	and	N	I-Premise
163	more	N	I-Premise
164	reinterventions	N	I-Premise
165	were	N	I-Premise
166	performed	N	I-Premise
167	(	N	I-Premise
168	P	N	I-Premise
169	<	N	I-Premise
170	0.01	N	I-Premise
171	)	N	I-Premise
172	after	N	I-Premise
173	stent	N	I-Premise
174	placement	N	I-Premise
175	than	N	I-Premise
176	after	N	I-Premise
177	GJJ	N	I-Premise
178	.	N	I-Premise

179	Initial	N	I-Premise
180	costs	N	I-Premise
181	were	N	I-Premise
182	higher	N	I-Premise
183	for	N	I-Premise
184	GJJ	N	I-Premise
185	compared	N	I-Premise
186	to	N	I-Premise
187	stent	N	I-Premise
188	placement	N	I-Premise
189	(	N	I-Premise
190	euro8315	N	I-Premise
191	vs.	N	I-Premise
192	euro4820	N	I-Premise
193	,	N	I-Premise
194	P	N	I-Premise
195	<	N	I-Premise
196	0.001	N	I-Premise
197	)	N	I-Premise
198	.	N	I-Premise

199	We	N	I-Premise
200	found	N	I-Premise
201	no	N	I-Premise
202	difference	N	I-Premise
203	in	N	I-Premise
204	follow-up	N	I-Premise
205	costs	N	I-Premise
206	.	N	I-Premise

207	Total	N	I-Premise
208	costs	N	I-Premise
209	per	N	I-Premise
210	patient	N	I-Premise
211	were	N	I-Premise
212	higher	N	I-Premise
213	for	N	I-Premise
214	GJJ	N	I-Premise
215	compared	N	I-Premise
216	to	N	I-Premise
217	stent	N	I-Premise
218	placement	N	I-Premise
219	(	N	I-Premise
220	euro12433	N	I-Premise
221	vs.	N	I-Premise
222	euro8819	N	I-Premise
223	,	N	I-Premise
224	P	N	I-Premise
225	=	N	I-Premise
226	0.049	N	I-Premise
227	)	N	I-Premise
228	.	N	I-Premise

229	The	N	I-Premise
230	incremental	N	I-Premise
231	cost-effectiveness	N	I-Premise
232	ratio	N	I-Premise
233	of	N	I-Premise
234	GJJ	N	I-Premise
235	compared	N	I-Premise
236	to	N	I-Premise
237	stent	N	I-Premise
238	placement	N	I-Premise
239	was	N	I-Premise
240	euro164	N	I-Premise
241	per	N	I-Premise
242	extra	N	I-Premise
243	day	N	I-Premise
244	with	N	I-Premise
245	a	N	I-Premise
246	gastric	N	I-Premise
247	outlet	N	I-Premise
248	obstruction	N	I-Premise
249	scoring	N	I-Premise
250	system	N	I-Premise
251	(	N	I-Premise
252	GOOSS	N	I-Premise
253	)	N	I-Premise
254	>	N	I-Premise
255	or=2	N	I-Premise
256	adjusted	N	I-Premise
257	for	N	I-Premise
258	survival	N	I-Premise
259	.	N	I-Premise

260	Medical	N	I-Claim
261	effects	N	I-Claim
262	were	N	I-Claim
263	better	N	I-Claim
264	after	N	I-Claim
265	GJJ	N	I-Claim
266	,	N	O
267	although	N	I-Claim
268	GJJ	N	I-Claim
269	had	N	I-Claim
270	higher	N	I-Claim
271	total	N	I-Claim
272	costs	N	I-Claim
273	.	N	I-Claim

274	Since	N	I-Claim
275	the	N	I-Claim
276	cost	N	I-Claim
277	difference	N	I-Claim
278	between	N	I-Claim
279	the	N	I-Claim
280	two	N	I-Claim
281	treatments	N	I-Claim
282	was	N	I-Claim
283	only	N	I-Claim
284	small	N	I-Claim
285	,	N	I-Claim
286	cost	N	I-Claim
287	should	N	I-Claim
288	not	N	I-Claim
289	play	N	I-Claim
290	a	N	I-Claim
291	predominant	N	I-Claim
292	role	N	I-Claim
293	when	N	I-Claim
294	deciding	N	I-Claim
295	on	N	I-Claim
296	the	N	I-Claim
297	type	N	I-Claim
298	of	N	I-Claim
299	treatment	N	I-Claim
300	assigned	N	I-Claim
301	to	N	I-Claim
302	patients	N	I-Claim
303	with	N	I-Claim
304	malignant	N	I-Claim
305	GOO	N	I-Claim
306	.	N	I-Claim

1	Vasomotor	N	O
2	symptoms	N	O
3	are	N	O
4	common	N	O
5	adverse	N	O
6	effects	N	O
7	of	N	O
8	antiestrogen	N	O
9	hormone	N	O
10	treatment	N	O
11	in	N	O
12	conventional	N	O
13	breast	N	O
14	cancer	N	O
15	care	N	O
16	.	N	O

17	Hormone	N	O
18	replacement	N	O
19	therapy	N	O
20	is	N	O
21	contraindicated	N	O
22	in	N	O
23	patients	N	O
24	with	N	O
25	breast	N	O
26	cancer	N	O
27	.	N	O

28	Venlafaxine	N	O
29	(	N	O
30	Effexor	N	O
31	)	N	O
32	,	N	O
33	the	N	O
34	therapy	N	O
35	of	N	O
36	choice	N	O
37	for	N	O
38	these	N	O
39	symptoms	N	O
40	,	N	O
41	has	N	O
42	numerous	N	O
43	adverse	N	O
44	effects	N	O
45	.	N	O

46	Recent	N	O
47	studies	N	O
48	suggest	N	O
49	acupuncture	N	O
50	may	N	O
51	be	N	O
52	effective	N	O
53	in	N	O
54	reducing	N	O
55	vasomotor	N	O
56	symptoms	N	O
57	in	N	O
58	menopausal	N	O
59	women	N	O
60	.	N	O

61	This	N	O
62	randomized	N	O
63	controlled	N	O
64	trial	N	O
65	tested	N	O
66	whether	N	O
67	acupuncture	N	O
68	reduces	N	O
69	vasomotor	N	O
70	symptoms	N	O
71	and	N	O
72	produces	N	O
73	fewer	N	O
74	adverse	N	O
75	effects	N	O
76	than	N	O
77	venlafaxine	N	O
78	.	N	O

79	Fifty	N	O
80	patients	N	O
81	were	N	O
82	randomly	N	O
83	assigned	N	O
84	to	N	O
85	receive	N	O
86	12	N	O
87	weeks	N	O
88	of	N	O
89	acupuncture	N	O
90	(	N	O
91	n	N	O
92	=	N	O
93	25	N	O
94	)	N	O
95	or	N	O
96	venlafaxine	N	O
97	(	N	O
98	n	N	O
99	=	N	O
100	25	N	O
101	)	N	O
102	treatment	N	O
103	.	N	O

104	Health	N	O
105	outcomes	N	O
106	were	N	O
107	measured	N	O
108	for	N	O
109	up	N	O
110	to	N	O
111	1	N	O
112	year	N	O
113	post-treatment	N	O
114	.	N	O

115	Both	N	I-Premise
116	groups	N	I-Premise
117	exhibited	N	I-Premise
118	significant	N	I-Premise
119	decreases	N	I-Premise
120	in	N	I-Premise
121	hot	N	I-Premise
122	flashes	N	I-Premise
123	,	N	I-Premise
124	depressive	N	I-Premise
125	symptoms	N	I-Premise
126	,	N	I-Premise
127	and	N	I-Premise
128	other	N	I-Premise
129	quality-of-life	N	I-Premise
130	symptoms	N	I-Premise
131	,	N	I-Premise
132	including	N	I-Premise
133	significant	N	I-Premise
134	improvements	N	I-Premise
135	in	N	I-Premise
136	mental	N	I-Premise
137	health	N	I-Premise
138	from	N	I-Premise
139	pre-	N	I-Premise
140	to	N	I-Premise
141	post-treatment	N	I-Premise
142	.	N	I-Premise

143	These	N	I-Premise
144	changes	N	I-Premise
145	were	N	I-Premise
146	similar	N	I-Premise
147	in	N	I-Premise
148	both	N	I-Premise
149	groups	N	I-Premise
150	,	N	I-Premise
151	indicating	N	I-Premise
152	that	N	I-Premise
153	acupuncture	N	I-Premise
154	was	N	I-Premise
155	as	N	I-Premise
156	effective	N	I-Premise
157	as	N	I-Premise
158	venlafaxine	N	I-Premise
159	.	N	I-Premise

160	By	N	I-Premise
161	2	N	I-Premise
162	weeks	N	I-Premise
163	post-treatment	N	I-Premise
164	,	N	I-Premise
165	the	N	I-Premise
166	venlafaxine	N	I-Premise
167	group	N	I-Premise
168	experienced	N	I-Premise
169	significant	N	I-Premise
170	increases	N	I-Premise
171	in	N	I-Premise
172	hot	N	I-Premise
173	flashes	N	I-Premise
174	,	N	I-Premise
175	whereas	N	I-Premise
176	hot	N	I-Premise
177	flashes	N	I-Premise
178	in	N	I-Premise
179	the	N	I-Premise
180	acupuncture	N	I-Premise
181	group	N	I-Premise
182	remained	N	I-Premise
183	at	N	I-Premise
184	low	N	I-Premise
185	levels	N	I-Premise
186	.	N	I-Premise

187	The	N	I-Premise
188	venlafaxine	N	I-Premise
189	group	N	I-Premise
190	experienced	N	I-Premise
191	18	N	I-Premise
192	incidences	N	I-Premise
193	of	N	I-Premise
194	adverse	N	I-Premise
195	effects	N	I-Premise
196	(	N	I-Premise
197	eg	N	I-Premise
198	,	N	I-Premise
199	nausea	N	I-Premise
200	,	N	I-Premise
201	dry	N	I-Premise
202	mouth	N	I-Premise
203	,	N	I-Premise
204	dizziness	N	I-Premise
205	,	N	I-Premise
206	anxiety	N	I-Premise
207	)	N	I-Premise
208	,	N	I-Premise
209	whereas	N	I-Premise
210	the	N	I-Premise
211	acupuncture	N	I-Premise
212	group	N	I-Premise
213	experienced	N	I-Premise
214	no	N	I-Premise
215	negative	N	I-Premise
216	adverse	N	I-Premise
217	effects	N	I-Premise
218	.	N	I-Premise

219	Acupuncture	N	I-Premise
220	had	N	I-Premise
221	the	N	I-Premise
222	additional	N	I-Premise
223	benefit	N	I-Premise
224	of	N	I-Premise
225	increased	N	I-Premise
226	sex	N	I-Premise
227	drive	N	I-Premise
228	in	N	I-Premise
229	some	N	I-Premise
230	women	N	I-Premise
231	,	N	I-Premise
232	and	N	I-Premise
233	most	N	I-Premise
234	reported	N	I-Premise
235	an	N	I-Premise
236	improvement	N	I-Premise
237	in	N	I-Premise
238	their	N	I-Premise
239	energy	N	I-Premise
240	,	N	I-Premise
241	clarity	N	I-Premise
242	of	N	I-Premise
243	thought	N	I-Premise
244	,	N	I-Premise
245	and	N	I-Premise
246	sense	N	I-Premise
247	of	N	I-Premise
248	well-being	N	I-Premise
249	.	N	I-Premise

250	Acupuncture	N	I-Claim
251	appears	N	I-Claim
252	to	N	I-Claim
253	be	N	I-Claim
254	equivalent	N	I-Claim
255	to	N	I-Claim
256	drug	N	I-Claim
257	therapy	N	I-Claim
258	in	N	I-Claim
259	these	N	I-Claim
260	patients	N	I-Claim
261	.	N	I-Claim

262	It	N	I-Claim
263	is	N	I-Claim
264	a	N	I-Claim
265	safe	N	I-Claim
266	,	N	I-Claim
267	effective	N	I-Claim
268	and	N	I-Claim
269	durable	N	I-Claim
270	treatment	N	I-Claim
271	for	N	I-Claim
272	vasomotor	N	I-Claim
273	symptoms	N	I-Claim
274	secondary	N	I-Claim
275	to	N	I-Claim
276	long-term	N	I-Claim
277	antiestrogen	N	I-Claim
278	hormone	N	I-Claim
279	use	N	I-Claim
280	in	N	I-Claim
281	patients	N	I-Claim
282	with	N	I-Claim
283	breast	N	I-Claim
284	cancer	N	I-Claim
285	.	N	I-Claim

1	Few	N	O
2	reports	N	O
3	have	N	O
4	examined	N	O
5	the	N	O
6	use	N	O
7	of	N	O
8	recombinant	N	O
9	human	N	O
10	thyroid-stimulating	N	O
11	hormone	N	O
12	(	N	O
13	rhTSH	N	O
14	)	N	O
15	for	N	O
16	ablation	N	O
17	of	N	O
18	postsurgical	N	O
19	thyroid	N	O
20	remnants	N	O
21	after	N	O
22	low-dose	N	O
23	radioactive	N	O
24	iodine	N	O
25	(	N	O
26	RI	N	O
27	)	N	O
28	therapy	N	O
29	,	N	O
30	compared	N	O
31	with	N	O
32	conventional	N	O
33	thyroid	N	O
34	hormone	N	O
35	withdrawal	N	O
36	.	N	O

37	We	N	O
38	investigated	N	O
39	whether	N	O
40	patient	N	O
41	preparation	N	O
42	using	N	O
43	rhTSH	N	O
44	was	N	O
45	comparable	N	O
46	to	N	O
47	conventional	N	O
48	thyroid	N	O
49	hormone	N	O
50	withdrawal	N	O
51	with	N	O
52	respect	N	O
53	to	N	O
54	efficacy	N	O
55	of	N	O
56	postsurgical	N	O
57	remnant	N	O
58	ablation	N	O
59	in	N	O
60	low-risk	N	O
61	patients	N	O
62	receiving	N	O
63	a	N	O
64	30	N	O
65	mCi	N	O
66	RI	N	O
67	.	N	O

68	In	N	O
69	addition	N	O
70	,	N	O
71	we	N	O
72	also	N	O
73	evaluated	N	O
74	the	N	O
75	impact	N	O
76	of	N	O
77	rhTSH	N	O
78	(	N	O
79	rhTSH	N	O
80	vs.	N	O
81	conventional	N	O
82	thyroid	N	O
83	hormone	N	O
84	withdrawal	N	O
85	)	N	O
86	on	N	O
87	quality	N	O
88	of	N	O
89	life	N	O
90	(	N	O
91	QoL	N	O
92	)	N	O
93	of	N	O
94	thyroid	N	O
95	cancer	N	O
96	patients	N	O
97	undergoing	N	O
98	RI	N	O
99	ablation	N	O
100	.	N	O

101	This	N	O
102	study	N	O
103	included	N	O
104	three	N	O
105	groups	N	O
106	of	N	O
107	patients	N	O
108	,	N	O
109	enrolled	N	O
110	consecutively	N	O
111	.	N	O

112	From	N	O
113	February	N	O
114	2006	N	O
115	to	N	O
116	March	N	O
117	2007	N	O
118	,	N	O
119	291	N	O
120	patients	N	O
121	were	N	O
122	enrolled	N	O
123	and	N	O
124	randomized	N	O
125	,	N	O
126	after	N	O
127	total	N	O
128	thyroidectomy	N	O
129	:	N	O
130	(	N	O
131	1	N	O
132	)	N	O
133	withdrawal	N	O
134	of	N	O
135	levothyroxine	N	O
136	(	N	O
137	LT4	N	O
138	)	N	O
139	for	N	O
140	4	N	O
141	weeks	N	O
142	(	N	O
143	T4-WD	N	O
144	Group	N	O
145	,	N	O
146	n	N	O
147	=	N	O
148	89	N	O
149	)	N	O
150	,	N	O
151	(	N	O
152	2	N	O
153	)	N	O
154	withdrawal	N	O
155	of	N	O
156	LT4	N	O
157	for	N	O
158	4	N	O
159	weeks	N	O
160	plus	N	O
161	2	N	O
162	weeks	N	O
163	on	N	O
164	and	N	O
165	then	N	O
166	2	N	O
167	weeks	N	O
168	off	N	O
169	liothyronine	N	O
170	(	N	O
171	LT3	N	O
172	)	N	O
173	(	N	O
174	T3-WD	N	O
175	Group	N	O
176	,	N	O
177	n	N	O
178	=	N	O
179	133	N	O
180	)	N	O
181	,	N	O
182	and	N	O
183	(	N	O
184	3	N	O
185	)	N	O
186	rhTSH	N	O
187	administration	N	O
188	(	N	O
189	rhTSH	N	O
190	Group	N	O
191	,	N	O
192	n	N	O
193	=	N	O
194	69	N	O
195	)	N	O
196	.	N	O

197	QoL	N	O
198	was	N	O
199	determined	N	O
200	at	N	O
201	the	N	O
202	time	N	O
203	of	N	O
204	ablation	N	O
205	.	N	O

206	Patients	N	O
207	in	N	O
208	the	N	O
209	three	N	O
210	groups	N	O
211	did	N	O
212	not	N	O
213	differ	N	O
214	significantly	N	O
215	in	N	O
216	baseline	N	O
217	characteristics	N	O
218	or	N	O
219	tumor	N	O
220	,	N	O
221	node	N	O
222	and	N	O
223	metastasis	N	O
224	(	N	O
225	TNM	N	O
226	)	N	O
227	staging	N	O
228	.	N	O

229	In	N	I-Premise
230	all	N	I-Premise
231	study	N	I-Premise
232	groups	N	I-Premise
233	,	N	I-Premise
234	serum	N	I-Premise
235	TSH	N	I-Premise
236	levels	N	I-Premise
237	showed	N	I-Premise
238	very	N	I-Premise
239	good	N	I-Premise
240	stimulation	N	I-Premise
241	(	N	I-Premise
242	mean	N	I-Premise
243	,	N	I-Premise
244	82.24	N	I-Premise
245	+/-	N	I-Premise
246	18.21	N	I-Premise
247	mU/L	N	I-Premise
248	)	N	I-Premise
249	,	N	I-Premise
250	without	N	I-Premise
251	significant	N	I-Premise
252	between-group	N	I-Premise
253	differences	N	I-Premise
254	(	N	I-Premise
255	p	N	I-Premise
256	=	N	I-Premise
257	0.5213	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	Follow-up	N	O
261	examinations	N	O
262	were	N	O
263	performed	N	O
264	12	N	O
265	months	N	O
266	after	N	O
267	ablation	N	O
268	to	N	O
269	assess	N	O
270	ablation	N	O
271	outcome	N	O
272	in	N	O
273	each	N	O
274	group	N	O
275	by	N	O
276	131	N	O
277	whole	N	O
278	body	N	O
279	scans	N	O
280	(	N	O
281	WBSs	N	O
282	)	N	O
283	,	N	O
284	serum	N	O
285	thyroglobulin	N	O
286	measurement	N	O
287	after	N	O
288	TSH	N	O
289	stimulation	N	O
290	,	N	O
291	and	N	O
292	neck	N	O
293	ultrasonography	N	O
294	.	N	O

295	The	N	I-Premise
296	successful	N	I-Premise
297	ablation	N	I-Premise
298	rate	N	I-Premise
299	was	N	I-Premise
300	91.0	N	I-Premise
301	%	N	I-Premise
302	in	N	I-Premise
303	T4-WD	N	I-Premise
304	Group	N	I-Premise
305	,	N	I-Premise
306	91.7	N	I-Premise
307	%	N	I-Premise
308	in	N	I-Premise
309	T3-WD	N	I-Premise
310	Group	N	I-Premise
311	,	N	I-Premise
312	and	N	I-Premise
313	91.3	N	I-Premise
314	%	N	I-Premise
315	in	N	I-Premise
316	rhTSH	N	I-Premise
317	Group	N	I-Premise
318	,	N	I-Premise
319	without	N	I-Premise
320	significant	N	I-Premise
321	between-preparation	N	I-Premise
322	differences	N	I-Premise
323	(	N	I-Premise
324	p	N	I-Premise
325	=	N	I-Premise
326	0.2061	N	I-Premise
327	)	N	I-Premise
328	.	N	I-Premise

329	QoL	N	I-Premise
330	was	N	I-Premise
331	better	N	I-Premise
332	preserved	N	I-Premise
333	in	N	I-Premise
334	rhTSH	N	I-Premise
335	Group	N	I-Premise
336	than	N	I-Premise
337	in	N	I-Premise
338	T4-WD	N	I-Premise
339	and	N	I-Premise
340	T3-WD	N	I-Premise
341	Groups	N	I-Premise
342	(	N	I-Premise
343	p	N	I-Premise
344	<	N	I-Premise
345	0.0001	N	I-Premise
346	)	N	I-Premise
347	.	N	I-Premise

348	However	N	I-Premise
349	,	N	I-Premise
350	there	N	I-Premise
351	was	N	I-Premise
352	no	N	I-Premise
353	QoL	N	I-Premise
354	difference	N	I-Premise
355	at	N	I-Premise
356	the	N	I-Premise
357	time	N	I-Premise
358	of	N	I-Premise
359	ablation	N	I-Premise
360	between	N	I-Premise
361	T4-WD	N	I-Premise
362	and	N	I-Premise
363	T3-WD	N	I-Premise
364	Groups	N	I-Premise
365	.	N	I-Premise

366	Our	N	I-Claim
367	study	N	I-Claim
368	indicates	N	I-Claim
369	that	N	I-Claim
370	use	N	I-Claim
371	of	N	I-Claim
372	rhTSH	N	I-Claim
373	preserves	N	I-Claim
374	QoL	N	I-Claim
375	in	N	I-Claim
376	patients	N	I-Claim
377	undergoing	N	I-Claim
378	RI	N	I-Claim
379	ablation	N	I-Claim
380	and	N	I-Claim
381	affords	N	I-Claim
382	an	N	I-Claim
383	ablation	N	I-Claim
384	success	N	I-Claim
385	rate	N	I-Claim
386	comparable	N	I-Claim
387	to	N	I-Claim
388	that	N	I-Claim
389	seen	N	I-Claim
390	after	N	I-Claim
391	thyroid	N	I-Claim
392	hormone	N	I-Claim
393	withdrawal	N	I-Claim
394	.	N	I-Claim

395	Notably	N	O
396	,	N	O
397	ablation	N	O
398	preparation	N	O
399	using	N	O
400	withdrawal	N	O
401	of	N	O
402	LT3	N	O
403	for	N	O
404	2	N	O
405	weeks	N	O
406	did	N	O
407	not	N	O
408	prevent	N	O
409	development	N	O
410	of	N	O
411	profound	N	O
412	hypothyroidism	N	O
413	,	N	O
414	as	N	O
415	also	N	O
416	occurred	N	O
417	when	N	O
418	LT4	N	O
419	alone	N	O
420	was	N	O
421	withdrawn	N	O
422	for	N	O
423	4	N	O
424	weeks	N	O
425	.	N	O

1	To	N	O
2	test	N	O
3	the	N	O
4	hypothesis	N	O
5	that	N	O
6	modulation	N	O
7	of	N	O
8	Bcl-2	N	O
9	with	N	O
10	13-cis	N	O
11	retinoic	N	O
12	acid	N	O
13	(	N	O
14	CRA	N	O
15	)	N	O
16	/interferon-alpha2b	N	O
17	(	N	O
18	IFN	N	O
19	)	N	O
20	with	N	O
21	paclitaxel	N	O
22	(	N	O
23	TAX	N	O
24	)	N	O
25	,	N	O
26	or	N	O
27	mitoxantrone	N	O
28	,	N	O
29	estramustine	N	O
30	and	N	O
31	vinorelbine	N	O
32	(	N	O
33	MEV	N	O
34	)	N	O
35	will	N	O
36	have	N	O
37	clinical	N	O
38	activity	N	O
39	in	N	O
40	men	N	O
41	with	N	O
42	metastatic	N	O
43	castrate-resistant	N	O
44	prostate	N	O
45	cancer	N	O
46	(	N	O
47	CRPC	N	O
48	)	N	O
49	.	N	O

50	70	N	O
51	patients	N	O
52	were	N	O
53	treated	N	O
54	with	N	O
55	either	N	O
56	MEV	N	O
57	(	N	O
58	Arm	N	O
59	A	N	O
60	)	N	O
61	in	N	O
62	a	N	O
63	3-week	N	O
64	cycle	N	O
65	or	N	O
66	CRA/IFN/TAX	N	O
67	with	N	O
68	an	N	O
69	8-week	N	O
70	cycle	N	O
71	(	N	O
72	Arm	N	O
73	B	N	O
74	)	N	O
75	.	N	O

76	Patients	N	O
77	were	N	O
78	assessed	N	O
79	for	N	O
80	response	N	O
81	,	N	O
82	toxicity	N	O
83	,	N	O
84	quality	N	O
85	of	N	O
86	life	N	O
87	(	N	O
88	QOL	N	O
89	)	N	O
90	,	N	O
91	and	N	O
92	the	N	O
93	effect	N	O
94	of	N	O
95	treatment	N	O
96	on	N	O
97	Bcl-2	N	O
98	levels	N	O
99	in	N	O
100	peripheral	N	O
101	blood	N	O
102	mononuclear	N	O
103	cells	N	O
104	(	N	O
105	PBMC	N	O
106	)	N	O
107	.	N	O

108	The	N	I-Premise
109	PSA	N	I-Premise
110	response	N	I-Premise
111	rates	N	I-Premise
112	were	N	I-Premise
113	50	N	I-Premise
114	%	N	I-Premise
115	and	N	I-Premise
116	23	N	I-Premise
117	%	N	I-Premise
118	,	N	I-Premise
119	measurable	N	I-Premise
120	disease	N	I-Premise
121	response	N	I-Premise
122	rates	N	I-Premise
123	(	N	I-Premise
124	CR+PR	N	I-Premise
125	)	N	I-Premise
126	14	N	I-Premise
127	%	N	I-Premise
128	and	N	I-Premise
129	15	N	I-Premise
130	%	N	I-Premise
131	,	N	I-Premise
132	and	N	I-Premise
133	median	N	I-Premise
134	overall	N	I-Premise
135	survival	N	I-Premise
136	19.4	N	I-Premise
137	months	N	I-Premise
138	and	N	I-Premise
139	13.9	N	I-Premise
140	months	N	I-Premise
141	on	N	I-Premise
142	Arm	N	I-Premise
143	A	N	I-Premise
144	and	N	I-Premise
145	Arm	N	I-Premise
146	B	N	I-Premise
147	respectively	N	I-Premise
148	.	N	I-Premise

149	Transient	N	I-Premise
150	grade	N	I-Premise
151	4	N	I-Premise
152	neutropenia	N	I-Premise
153	occurred	N	I-Premise
154	in	N	I-Premise
155	18	N	I-Premise
156	and	N	I-Premise
157	2	N	I-Premise
158	patients	N	I-Premise
159	,	N	I-Premise
160	and	N	I-Premise
161	grade	N	I-Premise
162	3	N	I-Premise
163	to	N	I-Premise
164	4	N	I-Premise
165	thrombosis	N	I-Premise
166	in	N	I-Premise
167	7	N	I-Premise
168	patients	N	I-Premise
169	and	N	I-Premise
170	1	N	I-Premise
171	patient	N	I-Premise
172	in	N	I-Premise
173	Arm	N	I-Premise
174	A	N	I-Premise
175	and	N	I-Premise
176	Arm	N	I-Premise
177	B	N	I-Premise
178	respectively	N	I-Premise
179	.	N	I-Premise

180	Patients	N	I-Premise
181	on	N	I-Premise
182	Arm	N	I-Premise
183	B	N	I-Premise
184	reported	N	I-Premise
185	a	N	I-Premise
186	clinically	N	I-Premise
187	significant	N	I-Premise
188	decline	N	I-Premise
189	in	N	I-Premise
190	QOL	N	I-Premise
191	between	N	I-Premise
192	baseline	N	I-Premise
193	and	N	I-Premise
194	week	N	I-Premise
195	9/10	N	I-Premise
196	(	N	I-Premise
197	.71	N	I-Premise
198	s.d	N	I-Premise
199	.	N	I-Premise

200	)	N	I-Premise
201	,	N	I-Premise
202	and	N	I-Premise
203	a	N	I-Premise
204	significantly	N	I-Premise
205	lower	N	I-Premise
206	level	N	I-Premise
207	of	N	I-Premise
208	QOL	N	I-Premise
209	than	N	I-Premise
210	Arm	N	I-Premise
211	A	N	I-Premise
212	(	N	I-Premise
213	p	N	I-Premise
214	=	N	I-Premise
215	0.01	N	I-Premise
216	)	N	I-Premise
217	.	N	I-Premise

218	As	N	I-Premise
219	hypothesized	N	I-Premise
220	,	N	I-Premise
221	Bcl-2	N	I-Premise
222	levels	N	I-Premise
223	decreased	N	I-Premise
224	with	N	I-Premise
225	CRA/IFN	N	I-Premise
226	therapy	N	I-Premise
227	only	N	I-Premise
228	in	N	I-Premise
229	Arm	N	I-Premise
230	B	N	I-Premise
231	(	N	I-Premise
232	p	N	I-Premise
233	=	N	I-Premise
234	0.03	N	I-Premise
235	)	N	I-Premise
236	.	N	I-Premise

237	Treatment	N	I-Claim
238	with	N	I-Claim
239	MEV	N	I-Claim
240	was	N	I-Claim
241	well	N	I-Claim
242	tolerated	N	I-Claim
243	and	N	I-Claim
244	demonstrated	N	I-Claim
245	clinical	N	I-Claim
246	activity	N	I-Claim
247	in	N	I-Claim
248	patients	N	I-Claim
249	with	N	I-Claim
250	CRPC	N	I-Claim
251	.	N	I-Claim

252	Given	N	I-Claim
253	the	N	I-Claim
254	adverse	N	I-Claim
255	effect	N	I-Claim
256	of	N	I-Claim
257	CRA/IFN/TAX	N	I-Claim
258	on	N	I-Claim
259	QOL	N	I-Claim
260	,	N	I-Claim
261	the	N	I-Claim
262	study	N	I-Claim
263	of	N	I-Claim
264	other	N	I-Claim
265	novel	N	I-Claim
266	agents	N	I-Claim
267	that	N	I-Claim
268	target	N	I-Claim
269	Bcl-2	N	I-Claim
270	family	N	I-Claim
271	proteins	N	I-Claim
272	is	N	I-Claim
273	warranted	N	I-Claim
274	.	N	I-Claim

275	The	N	O
276	feasibility	N	O
277	of	N	O
278	measuring	N	O
279	Bcl-2	N	O
280	protein	N	O
281	in	N	O
282	a	N	O
283	cooperative	N	O
284	group	N	O
285	setting	N	O
286	is	N	O
287	hypothesis	N	O
288	generating	N	O
289	and	N	O
290	supports	N	O
291	further	N	O
292	study	N	O
293	as	N	O
294	a	N	O
295	marker	N	O
296	for	N	O
297	Bcl-2	N	O
298	targeted	N	O
299	therapy	N	O
300	.	N	O

1	To	N	O
2	determine	N	O
3	the	N	O
4	feasibility	N	O
5	of	N	O
6	administering	N	O
7	a	N	O
8	flavonoid-rich	N	O
9	adjunctive	N	O
10	treatment	N	O
11	(	N	O
12	Concord	N	O
13	grape	N	O
14	juice	N	O
15	)	N	O
16	for	N	O
17	the	N	O
18	management	N	O
19	of	N	O
20	chemotherapy-induced	N	O
21	nausea	N	O
22	and	N	O
23	vomiting	N	O
24	(	N	O
25	CINV	N	O
26	)	N	O
27	;	N	O
28	to	N	O
29	evaluate	N	O
30	the	N	O
31	usefulness	N	O
32	of	N	O
33	existing	N	O
34	measures	N	O
35	for	N	O
36	assessing	N	O
37	CINV	N	O
38	frequency	N	O
39	and	N	O
40	severity	N	O
41	,	N	O
42	quality	N	O
43	of	N	O
44	life	N	O
45	,	N	O
46	control	N	O
47	over	N	O
48	life	N	O
49	events	N	O
50	,	N	O
51	and	N	O
52	psychological	N	O
53	state	N	O
54	;	N	O
55	to	N	O
56	identify	N	O
57	any	N	O
58	actual	N	O
59	or	N	O
60	potential	N	O
61	adverse	N	O
62	events	N	O
63	associated	N	O
64	with	N	O
65	frequent	N	O
66	grape	N	O
67	juice	N	O
68	intake	N	O
69	;	N	O
70	and	N	O
71	to	N	O
72	provide	N	O
73	preliminary	N	O
74	data	N	O
75	concerning	N	O
76	the	N	O
77	effect	N	O
78	of	N	O
79	Concord	N	O
80	grape	N	O
81	juice	N	O
82	on	N	O
83	CINV	N	O
84	,	N	O
85	quality	N	O
86	of	N	O
87	life	N	O
88	,	N	O
89	perceived	N	O
90	control	N	O
91	over	N	O
92	life	N	O
93	events	N	O
94	,	N	O
95	and	N	O
96	psychological	N	O
97	state	N	O
98	.	N	O

99	Double-blind	N	O
100	,	N	O
101	randomized	N	O
102	clinical	N	O
103	trial	N	O
104	.	N	O

105	A	N	O
106	cancer	N	O
107	center	N	O
108	in	N	O
109	an	N	O
110	academic	N	O
111	health	N	O
112	science	N	O
113	center	N	O
114	in	N	O
115	the	N	O
116	northeastern	N	O
117	United	N	O
118	States	N	O
119	.	N	O

120	77	N	O
121	adult	N	O
122	patients	N	O
123	with	N	O
124	cancer	N	O
125	receiving	N	O
126	moderately	N	O
127	or	N	O
128	highly	N	O
129	emetogenic	N	O
130	chemotherapy	N	O
131	agents	N	O
132	.	N	O

133	Participants	N	O
134	drank	N	O
135	4	N	O
136	oz	N	O
137	.	N	O

138	of	N	O
139	grape	N	O
140	juice	N	O
141	or	N	O
142	placebo	N	O
143	prior	N	O
144	to	N	O
145	meals	N	O
146	for	N	O
147	one	N	O
148	week	N	O
149	following	N	O
150	each	N	O
151	of	N	O
152	four	N	O
153	chemotherapy	N	O
154	treatment	N	O
155	cycles	N	O
156	.	N	O

157	They	N	O
158	recorded	N	O
159	frequency	N	O
160	,	N	O
161	duration	N	O
162	,	N	O
163	and	N	O
164	distress	N	O
165	of	N	O
166	nausea	N	O
167	,	N	O
168	vomiting	N	O
169	,	N	O
170	and	N	O
171	retching	N	O
172	daily	N	O
173	,	N	O
174	beginning	N	O
175	the	N	O
176	evening	N	O
177	of	N	O
178	chemotherapy	N	O
179	administration	N	O
180	and	N	O
181	continuing	N	O
182	for	N	O
183	seven	N	O
184	days	N	O
185	.	N	O

186	Data	N	O
187	were	N	O
188	analyzed	N	O
189	with	N	O
190	generalized	N	O
191	estimating	N	O
192	equations	N	O
193	methodology	N	O
194	to	N	O
195	model	N	O
196	differences	N	O
197	between	N	O
198	groups	N	O
199	over	N	O
200	time	N	O
201	.	N	O

202	Nausea	N	I-Premise
203	and	N	I-Premise
204	vomiting	N	I-Premise
205	frequency	N	I-Premise
206	,	N	I-Premise
207	duration	N	I-Premise
208	,	N	I-Premise
209	and	N	I-Premise
210	distress	N	I-Premise
211	were	N	I-Premise
212	lower	N	I-Premise
213	for	N	I-Premise
214	experimental	N	I-Premise
215	group	N	I-Premise
216	members	N	I-Premise
217	,	N	I-Premise
218	although	N	I-Premise
219	a	N	I-Premise
220	high	N	I-Premise
221	attrition	N	I-Premise
222	rate	N	I-Premise
223	(	N	I-Premise
224	50	N	I-Premise
225	%	N	I-Premise
226	)	N	I-Premise
227	resulted	N	I-Premise
228	in	N	I-Premise
229	insufficient	N	I-Premise
230	power	N	I-Premise
231	to	N	I-Premise
232	detect	N	I-Premise
233	statistically	N	I-Premise
234	significant	N	I-Premise
235	differences	N	I-Premise
236	over	N	I-Premise
237	time	N	I-Premise
238	.	N	I-Premise

239	Greater	N	O
240	levels	N	O
241	of	N	O
242	anxiety	N	O
243	,	N	O
244	depression	N	O
245	,	N	O
246	and	N	O
247	hostility	N	O
248	at	N	O
249	baseline	N	O
250	were	N	O
251	related	N	O
252	to	N	O
253	nausea	N	O
254	and	N	O
255	vomiting	N	O
256	,	N	O
257	quality	N	O
258	of	N	O
259	life	N	O
260	,	N	O
261	and	N	O
262	perceived	N	O
263	control	N	O
264	over	N	O
265	decision	N	O
266	making	N	O
267	.	N	O

268	The	N	I-Claim
269	effect	N	I-Claim
270	of	N	I-Claim
271	grape	N	I-Claim
272	juice	N	I-Claim
273	flavonoids	N	I-Claim
274	on	N	I-Claim
275	CINV	N	I-Claim
276	should	N	I-Claim
277	be	N	I-Claim
278	investigated	N	I-Claim
279	further	N	I-Claim
280	with	N	I-Claim
281	a	N	I-Claim
282	larger	N	I-Claim
283	sample	N	I-Claim
284	to	N	I-Claim
285	determine	N	I-Claim
286	whether	N	I-Claim
287	preliminary	N	I-Claim
288	findings	N	I-Claim
289	are	N	I-Claim
290	supported	N	I-Claim
291	.	N	I-Claim

292	Alterations	N	O
293	to	N	O
294	the	N	O
295	study	N	O
296	protocol	N	O
297	will	N	O
298	be	N	O
299	necessary	N	O
300	to	N	O
301	decrease	N	O
302	attrition	N	O
303	.	N	O

304	Flavonoid-rich	N	I-Claim
305	fruits	N	I-Claim
306	and	N	I-Claim
307	vegetables	N	I-Claim
308	may	N	I-Claim
309	provide	N	I-Claim
310	additional	N	I-Claim
311	protection	N	I-Claim
312	against	N	I-Claim
313	CINV	N	I-Claim
314	.	N	I-Claim

315	If	N	O
316	the	N	O
317	compounds	N	O
318	work	N	O
319	,	N	O
320	they	N	O
321	would	N	O
322	offer	N	O
323	a	N	O
324	low-cost	N	O
325	,	N	O
326	readily	N	O
327	available	N	O
328	adjunctive	N	O
329	treatment	N	O
330	for	N	O
331	the	N	O
332	management	N	O
333	of	N	O
334	CINV	N	O
335	.	N	O

1	Promising	N	O
2	results	N	O
3	in	N	O
4	a	N	O
5	randomized	N	O
6	phase	N	O
7	II	N	O
8	trial	N	O
9	with	N	O
10	the	N	O
11	hypoxic	N	O
12	cytotoxin	N	O
13	tirapazamine	N	O
14	(	N	O
15	TPZ	N	O
16	)	N	O
17	combined	N	O
18	with	N	O
19	cisplatin	N	O
20	(	N	O
21	CIS	N	O
22	)	N	O
23	and	N	O
24	radiation	N	O
25	led	N	O
26	to	N	O
27	this	N	O
28	phase	N	O
29	III	N	O
30	trial	N	O
31	.	N	O

32	Patients	N	O
33	with	N	O
34	previously	N	O
35	untreated	N	O
36	stage	N	O
37	III	N	O
38	or	N	O
39	IV	N	O
40	(	N	O
41	excluding	N	O
42	T1-2N1	N	O
43	and	N	O
44	M1	N	O
45	)	N	O
46	squamous	N	O
47	cell	N	O
48	carcinoma	N	O
49	of	N	O
50	the	N	O
51	oral	N	O
52	cavity	N	O
53	,	N	O
54	oropharynx	N	O
55	,	N	O
56	hypopharynx	N	O
57	,	N	O
58	or	N	O
59	larynx	N	O
60	were	N	O
61	randomly	N	O
62	assigned	N	O
63	to	N	O
64	receive	N	O
65	definitive	N	O
66	radiotherapy	N	O
67	(	N	O
68	70	N	O
69	Gy	N	O
70	in	N	O
71	7	N	O
72	weeks	N	O
73	)	N	O
74	concurrently	N	O
75	with	N	O
76	either	N	O
77	CIS	N	O
78	(	N	O
79	100	N	O
80	mg/m	N	O
81	(	N	O
82	2	N	O
83	)	N	O
84	)	N	O
85	on	N	O
86	day	N	O
87	1	N	O
88	of	N	O
89	weeks	N	O
90	1	N	O
91	,	N	O
92	4	N	O
93	,	N	O
94	and	N	O
95	7	N	O
96	or	N	O
97	CIS	N	O
98	(	N	O
99	75	N	O
100	mg/m	N	O
101	(	N	O
102	2	N	O
103	)	N	O
104	)	N	O
105	plus	N	O
106	TPZ	N	O
107	(	N	O
108	290	N	O
109	mg/m	N	O
110	(	N	O
111	2	N	O
112	)	N	O
113	/d	N	O
114	)	N	O
115	on	N	O
116	day	N	O
117	1	N	O
118	of	N	O
119	weeks	N	O
120	1	N	O
121	,	N	O
122	4	N	O
123	,	N	O
124	and	N	O
125	7	N	O
126	and	N	O
127	TPZ	N	O
128	alone	N	O
129	(	N	O
130	160	N	O
131	mg/m	N	O
132	(	N	O
133	2	N	O
134	)	N	O
135	/d	N	O
136	)	N	O
137	on	N	O
138	days	N	O
139	1	N	O
140	,	N	O
141	3	N	O
142	,	N	O
143	and	N	O
144	5	N	O
145	of	N	O
146	weeks	N	O
147	2	N	O
148	and	N	O
149	3	N	O
150	(	N	O
151	TPZ/CIS	N	O
152	)	N	O
153	.	N	O

154	The	N	O
155	primary	N	O
156	end	N	O
157	point	N	O
158	was	N	O
159	overall	N	O
160	survival	N	O
161	(	N	O
162	OS	N	O
163	)	N	O
164	.	N	O

165	The	N	O
166	planned	N	O
167	sample	N	O
168	size	N	O
169	was	N	O
170	850	N	O
171	,	N	O
172	estimated	N	O
173	to	N	O
174	result	N	O
175	in	N	O
176	334	N	O
177	deaths	N	O
178	,	N	O
179	which	N	O
180	would	N	O
181	provide	N	O
182	90	N	O
183	%	N	O
184	power	N	O
185	to	N	O
186	detect	N	O
187	a	N	O
188	difference	N	O
189	in	N	O
190	2-year	N	O
191	survival	N	O
192	rates	N	O
193	of	N	O
194	60	N	O
195	%	N	O
196	v	N	O
197	70	N	O
198	%	N	O
199	for	N	O
200	CIS	N	O
201	versus	N	O
202	TPZ/CIS	N	O
203	,	N	O
204	respectively	N	O
205	(	N	O
206	hazard	N	O
207	ratio	N	O
208	=	N	O
209	0.69	N	O
210	)	N	O
211	.	N	O

212	Eight	N	O
213	hundred	N	O
214	sixty-one	N	O
215	patients	N	O
216	were	N	O
217	accrued	N	O
218	from	N	O
219	89	N	O
220	sites	N	O
221	in	N	O
222	16	N	O
223	countries	N	O
224	.	N	O

225	In	N	I-Premise
226	an	N	I-Premise
227	intent-to-treat	N	I-Premise
228	analysis	N	I-Premise
229	,	N	I-Premise
230	the	N	I-Premise
231	2-year	N	I-Premise
232	OS	N	I-Premise
233	rates	N	I-Premise
234	were	N	I-Premise
235	65.7	N	I-Premise
236	%	N	I-Premise
237	for	N	I-Premise
238	CIS	N	I-Premise
239	and	N	I-Premise
240	66.2	N	I-Premise
241	%	N	I-Premise
242	for	N	I-Premise
243	TPZ/CIS	N	I-Premise
244	(	N	I-Premise
245	TPZ/CIS	N	I-Premise
246	--	N	I-Premise
247	CIS	N	I-Premise
248	:	N	I-Premise
249	95	N	I-Premise
250	%	N	I-Premise
251	CI	N	I-Premise
252	,	N	I-Premise
253	-5.9	N	I-Premise
254	%	N	I-Premise
255	to	N	I-Premise
256	6.9	N	I-Premise
257	%	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	There	N	I-Premise
261	were	N	I-Premise
262	no	N	I-Premise
263	significant	N	I-Premise
264	differences	N	I-Premise
265	in	N	I-Premise
266	failure-free	N	I-Premise
267	survival	N	I-Premise
268	,	N	I-Premise
269	time	N	I-Premise
270	to	N	I-Premise
271	locoregional	N	I-Premise
272	failure	N	I-Premise
273	,	N	I-Premise
274	or	N	I-Premise
275	quality	N	I-Premise
276	of	N	I-Premise
277	life	N	I-Premise
278	as	N	I-Premise
279	measured	N	I-Premise
280	by	N	I-Premise
281	Functional	N	I-Premise
282	Assessment	N	I-Premise
283	of	N	I-Premise
284	Cancer	N	I-Premise
285	Therapy-Head	N	I-Premise
286	and	N	I-Premise
287	Neck	N	I-Premise
288	.	N	I-Premise

289	We	N	I-Claim
290	found	N	I-Claim
291	no	N	I-Claim
292	evidence	N	I-Claim
293	that	N	I-Claim
294	the	N	I-Claim
295	addition	N	I-Claim
296	of	N	I-Claim
297	TPZ	N	I-Claim
298	to	N	I-Claim
299	chemoradiotherapy	N	I-Claim
300	,	N	I-Claim
301	in	N	I-Claim
302	patients	N	I-Claim
303	with	N	I-Claim
304	advanced	N	I-Claim
305	head	N	I-Claim
306	and	N	I-Claim
307	neck	N	I-Claim
308	cancer	N	I-Claim
309	not	N	I-Claim
310	selected	N	I-Claim
311	for	N	I-Claim
312	the	N	I-Claim
313	presence	N	I-Claim
314	of	N	I-Claim
315	hypoxia	N	I-Claim
316	,	N	I-Claim
317	improves	N	I-Claim
318	OS	N	I-Claim
319	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	a	N	O
7	scapula-oriented	N	O
8	exercise	N	O
9	on	N	O
10	upper	N	O
11	limb	N	O
12	dysfunction	N	O
13	in	N	O
14	breast	N	O
15	cancer	N	O
16	survivors	N	O
17	.	N	O

18	A	N	O
19	prospective	N	O
20	randomized	N	O
21	,	N	O
22	controlled	N	O
23	pilot	N	O
24	trial	N	O
25	with	N	O
26	historical	N	O
27	control	N	O
28	.	N	O

29	Rehabilitation	N	O
30	department	N	O
31	at	N	O
32	a	N	O
33	university	N	O
34	hospital	N	O
35	.	N	O

36	Thirty-two	N	O
37	women	N	O
38	with	N	O
39	breast	N	O
40	cancer	N	O
41	were	N	O
42	randomly	N	O
43	assigned	N	O
44	to	N	O
45	scapula-oriented	N	O
46	exercise	N	O
47	group	N	O
48	(	N	O
49	n	N	O
50	=	N	O
51	16	N	O
52	)	N	O
53	and	N	O
54	general	N	O
55	exercise	N	O
56	group	N	O
57	(	N	O
58	n	N	O
59	=	N	O
60	16	N	O
61	)	N	O
62	.	N	O

63	An	N	O
64	historical	N	O
65	control	N	O
66	group	N	O
67	(	N	O
68	n	N	O
69	=	N	O
70	18	N	O
71	)	N	O
72	without	N	O
73	exercise	N	O
74	was	N	O
75	enrolled	N	O
76	from	N	O
77	breast	N	O
78	cancer	N	O
79	survivors	N	O
80	.	N	O

81	The	N	O
82	scapula-oriented	N	O
83	exercises	N	O
84	were	N	O
85	designed	N	O
86	focusing	N	O
87	on	N	O
88	scapulothoracic	N	O
89	movement	N	O
90	.	N	O

91	The	N	O
92	general	N	O
93	exercise	N	O
94	group	N	O
95	performed	N	O
96	body	N	O
97	conditioning	N	O
98	exercise	N	O
99	.	N	O

100	Exercise	N	O
101	therapies	N	O
102	were	N	O
103	performed	N	O
104	for	N	O
105	one	N	O
106	session	N	O
107	per	N	O
108	week	N	O
109	for	N	O
110	eight	N	O
111	weeks	N	O
112	.	N	O

113	Pain	N	O
114	and	N	O
115	physical	N	O
116	disabilities	N	O
117	related	N	O
118	to	N	O
119	upper	N	O
120	limb	N	O
121	dysfunction	N	O
122	,	N	O
123	quality	N	O
124	of	N	O
125	life	N	O
126	and	N	O
127	depression	N	O
128	were	N	O
129	used	N	O
130	as	N	O
131	subjective	N	O
132	outcomes	N	O
133	.	N	O

134	Objective	N	O
135	outcome	N	O
136	measures	N	O
137	included	N	O
138	shoulder	N	O
139	range	N	O
140	of	N	O
141	motion	N	O
142	and	N	O
143	strength	N	O
144	.	N	O

145	Outcomes	N	O
146	were	N	O
147	assessed	N	O
148	at	N	O
149	baseline	N	O
150	and	N	O
151	post	N	O
152	exercise	N	O
153	.	N	O

154	At	N	O
155	baseline	N	O
156	,	N	O
157	no	N	O
158	significant	N	O
159	difference	N	O
160	was	N	O
161	observed	N	O
162	among	N	O
163	the	N	O
164	three	N	O
165	groups	N	O
166	.	N	O

167	The	N	I-Premise
168	scapula-oriented	N	I-Premise
169	exercise	N	I-Premise
170	group	N	I-Premise
171	showed	N	I-Premise
172	improvements	N	I-Premise
173	in	N	I-Premise
174	pain	N	I-Premise
175	,	N	I-Premise
176	physical	N	I-Premise
177	function	N	I-Premise
178	,	N	I-Premise
179	social	N	I-Premise
180	function	N	I-Premise
181	,	N	I-Premise
182	and	N	I-Premise
183	global	N	I-Premise
184	quality	N	I-Premise
185	of	N	I-Premise
186	life	N	I-Premise
187	compared	N	I-Premise
188	with	N	I-Premise
189	baseline	N	I-Premise
190	,	N	I-Premise
191	whereas	N	I-Premise
192	the	N	I-Premise
193	general	N	I-Premise
194	exercise	N	I-Premise
195	group	N	I-Premise
196	showed	N	I-Premise
197	improved	N	I-Premise
198	fatigue	N	I-Premise
199	and	N	I-Premise
200	range	N	I-Premise
201	of	N	I-Premise
202	motion	N	I-Premise
203	.	N	I-Premise

204	The	N	I-Premise
205	change	N	I-Premise
206	in	N	I-Premise
207	global	N	I-Premise
208	quality	N	I-Premise
209	of	N	I-Premise
210	life	N	I-Premise
211	(	N	I-Premise
212	P	N	I-Premise
213	=	N	I-Premise
214	0.067	N	I-Premise
215	;	N	I-Premise
216	effect	N	I-Premise
217	size	N	I-Premise
218	,	N	I-Premise
219	0.33	N	I-Premise
220	)	N	I-Premise
221	and	N	I-Premise
222	strength	N	I-Premise
223	of	N	I-Premise
224	external	N	I-Premise
225	rotation	N	I-Premise
226	(	N	I-Premise
227	P	N	I-Premise
228	=	N	I-Premise
229	0.001	N	I-Premise
230	;	N	I-Premise
231	effect	N	I-Premise
232	size	N	I-Premise
233	,	N	I-Premise
234	0.55	N	I-Premise
235	)	N	I-Premise
236	were	N	I-Premise
237	significantly	N	I-Premise
238	greater	N	I-Premise
239	in	N	I-Premise
240	the	N	I-Premise
241	scapula-oriented	N	I-Premise
242	exercise	N	I-Premise
243	group	N	I-Premise
244	than	N	I-Premise
245	in	N	I-Premise
246	the	N	I-Premise
247	general	N	I-Premise
248	exercise	N	I-Premise
249	and	N	I-Premise
250	control	N	I-Premise
251	group	N	I-Premise
252	.	N	I-Premise

253	Scapula-oriented	N	I-Claim
254	exercise	N	I-Claim
255	had	N	I-Claim
256	beneficial	N	I-Claim
257	effects	N	I-Claim
258	on	N	I-Claim
259	pain	N	I-Claim
260	,	N	I-Claim
261	quality	N	I-Claim
262	of	N	I-Claim
263	life	N	I-Claim
264	and	N	I-Claim
265	aspects	N	I-Claim
266	of	N	I-Claim
267	strength	N	I-Claim
268	.	N	I-Claim

269	The	N	O
270	sample	N	O
271	size	N	O
272	required	N	O
273	in	N	O
274	a	N	O
275	larger	N	O
276	definitive	N	O
277	study	N	O
278	is	N	O
279	32	N	O
280	subjects	N	O
281	per	N	O
282	group	N	O
283	.	N	O

1	For	N	O
2	patients	N	O
3	undergoing	N	O
4	oncologic	N	O
5	surgery	N	O
6	,	N	O
7	the	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	(	N	O
12	QoL	N	O
13	)	N	O
14	is	N	O
15	generally	N	O
16	accepted	N	O
17	as	N	O
18	an	N	O
19	important	N	O
20	outcome	N	O
21	parameter	N	O
22	in	N	O
23	addition	N	O
24	to	N	O
25	long-term	N	O
26	survival	N	O
27	,	N	O
28	mortality	N	O
29	and	N	O
30	complication	N	O
31	rates	N	O
32	.	N	O

33	This	N	O
34	study	N	O
35	focussed	N	O
36	on	N	O
37	the	N	O
38	QoL	N	O
39	in	N	O
40	patients	N	O
41	after	N	O
42	oesophagectomy	N	O
43	for	N	O
44	cancer	N	O
45	,	N	O
46	comparing	N	O
47	the	N	O
48	method	N	O
49	of	N	O
50	reconstruction	N	O
51	(	N	O
52	narrow	N	O
53	gastric	N	O
54	tube	N	O
55	vs	N	O
56	whole	N	O
57	stomach	N	O
58	)	N	O
59	.	N	O

60	In	N	O
61	a	N	O
62	prospective	N	O
63	randomised	N	O
64	single-centre	N	O
65	study	N	O
66	from	N	O
67	2007	N	O
68	to	N	O
69	2008	N	O
70	,	N	O
71	104	N	O
72	patients	N	O
73	underwent	N	O
74	oesophagectomy	N	O
75	for	N	O
76	cancer	N	O
77	.	N	O

78	To	N	O
79	assess	N	O
80	the	N	O
81	QoL	N	O
82	,	N	O
83	a	N	O
84	questionnaire	N	O
85	in	N	O
86	reference	N	O
87	to	N	O
88	the	N	O
89	EORTC-QLQ-C30	N	O
90	and	N	O
91	the	N	O
92	QLQ-OES24	N	O
93	was	N	O
94	administered	N	O
95	at	N	O
96	3	N	O
97	weeks	N	O
98	,	N	O
99	6	N	O
100	months	N	O
101	and	N	O
102	1	N	O
103	year	N	O
104	after	N	O
105	surgery	N	O
106	.	N	O

107	Clinical	N	O
108	data	N	O
109	were	N	O
110	collected	N	O
111	prospectively	N	O
112	,	N	O
113	and	N	O
114	follow-up	N	O
115	was	N	O
116	performed	N	O
117	regularly	N	O
118	.	N	O

119	There	N	I-Premise
120	were	N	I-Premise
121	no	N	I-Premise
122	significant	N	I-Premise
123	differences	N	I-Premise
124	between	N	I-Premise
125	the	N	I-Premise
126	narrow	N	I-Premise
127	gastric	N	I-Premise
128	tube	N	I-Premise
129	group	N	I-Premise
130	(	N	I-Premise
131	NGT	N	I-Premise
132	group	N	I-Premise
133	,	N	I-Premise
134	n=52	N	I-Premise
135	)	N	I-Premise
136	and	N	I-Premise
137	the	N	I-Premise
138	whole-stomach	N	I-Premise
139	group	N	I-Premise
140	(	N	I-Premise
141	WS	N	I-Premise
142	group	N	I-Premise
143	,	N	I-Premise
144	n=52	N	I-Premise
145	)	N	I-Premise
146	with	N	I-Premise
147	regard	N	I-Premise
148	to	N	I-Premise
149	patient	N	I-Premise
150	and	N	I-Premise
151	cancer	N	I-Premise
152	characteristics	N	I-Premise
153	,	N	I-Premise
154	operative	N	I-Premise
155	procedure	N	I-Premise
156	,	N	I-Premise
157	postoperative	N	I-Premise
158	intensive	N	I-Premise
159	care	N	I-Premise
160	unit	N	I-Premise
161	(	N	I-Premise
162	ICU	N	I-Premise
163	)	N	I-Premise
164	hospitalisation	N	I-Premise
165	,	N	I-Premise
166	and	N	I-Premise
167	overall	N	I-Premise
168	survival	N	I-Premise
169	at	N	I-Premise
170	1	N	I-Premise
171	year	N	I-Premise
172	.	N	I-Premise

173	Regarding	N	I-Premise
174	the	N	I-Premise
175	postoperative	N	I-Premise
176	complication	N	I-Premise
177	,	N	I-Premise
178	there	N	I-Premise
179	were	N	I-Premise
180	more	N	I-Premise
181	cases	N	I-Premise
182	of	N	I-Premise
183	postoperative	N	I-Premise
184	reflux	N	I-Premise
185	oesophagitis	N	I-Premise
186	and	N	I-Premise
187	impairment	N	I-Premise
188	of	N	I-Premise
189	pulmonary	N	I-Premise
190	function	N	I-Premise
191	in	N	I-Premise
192	the	N	I-Premise
193	WS	N	I-Premise
194	group	N	I-Premise
195	(	N	I-Premise
196	P	N	I-Premise
197	<	N	I-Premise
198	0.05	N	I-Premise
199	)	N	I-Premise
200	.	N	I-Premise

201	Regarding	N	I-Premise
202	the	N	I-Premise
203	QoL	N	I-Premise
204	investigation	N	I-Premise
205	,	N	I-Premise
206	the	N	I-Premise
207	scores	N	I-Premise
208	of	N	I-Premise
209	QoL	N	I-Premise
210	dropped	N	I-Premise
211	for	N	I-Premise
212	all	N	I-Premise
213	patients	N	I-Premise
214	at	N	I-Premise
215	3	N	I-Premise
216	weeks	N	I-Premise
217	after	N	I-Premise
218	surgery	N	I-Premise
219	.	N	I-Premise

220	Slowly	N	O
221	,	N	O
222	recovery	N	I-Premise
223	was	N	I-Premise
224	found	N	I-Premise
225	at	N	I-Premise
226	both	N	I-Premise
227	6	N	I-Premise
228	months	N	I-Premise
229	and	N	I-Premise
230	1	N	I-Premise
231	year	N	I-Premise
232	in	N	I-Premise
233	both	N	I-Premise
234	groups	N	I-Premise
235	.	N	I-Premise

236	Patients	N	I-Premise
237	in	N	I-Premise
238	the	N	I-Premise
239	NGT	N	I-Premise
240	group	N	I-Premise
241	reported	N	I-Premise
242	significantly	N	I-Premise
243	(	N	I-Premise
244	P	N	I-Premise
245	<	N	I-Premise
246	0.05	N	I-Premise
247	)	N	I-Premise
248	better	N	I-Premise
249	scores	N	I-Premise
250	of	N	I-Premise
251	QoL	N	I-Premise
252	at	N	I-Premise
253	both	N	I-Premise
254	6	N	I-Premise
255	months	N	I-Premise
256	and	N	I-Premise
257	1	N	I-Premise
258	year	N	I-Premise
259	.	N	I-Premise

260	Patients	N	I-Claim
261	who	N	I-Claim
262	underwent	N	I-Claim
263	gastric	N	I-Claim
264	tube	N	I-Claim
265	reconstruction	N	I-Claim
266	develop	N	I-Claim
267	less	N	I-Claim
268	postoperative	N	I-Claim
269	digestive	N	I-Claim
270	tract	N	I-Claim
271	complications	N	I-Claim
272	,	N	I-Claim
273	and	N	I-Claim
274	have	N	I-Claim
275	a	N	I-Claim
276	quicker	N	I-Claim
277	recovery	N	I-Claim
278	and	N	I-Claim
279	a	N	I-Claim
280	better	N	I-Claim
281	QoL	N	I-Claim
282	during	N	I-Claim
283	the	N	I-Claim
284	follow-up	N	I-Claim
285	period	N	I-Claim
286	.	N	I-Claim

287	Further	N	O
288	investigation	N	O
289	and	N	O
290	data	N	O
291	collection	N	O
292	will	N	O
293	allow	N	O
294	the	N	O
295	assessment	N	O
296	of	N	O
297	this	N	O
298	procedure	N	O
299	beyond	N	O
300	1	N	O
301	year	N	O
302	after	N	O
303	operation	N	O
304	.	N	O

1	Paclitaxel	N	O
2	and	N	O
3	pegylated	N	O
4	liposomal	N	O
5	doxorubicin	N	O
6	(	N	O
7	PLD	N	O
8	)	N	O
9	are	N	O
10	active	N	O
11	cytotoxic	N	O
12	agents	N	O
13	for	N	O
14	the	N	O
15	treatment	N	O
16	of	N	O
17	human	N	O
18	immunodeficiency	N	O
19	virus	N	O
20	(	N	O
21	HIV	N	O
22	)	N	O
23	-associated	N	O
24	Kaposi	N	O
25	sarcoma	N	O
26	(	N	O
27	KS	N	O
28	)	N	O
29	.	N	O

30	A	N	O
31	randomized	N	O
32	trial	N	O
33	comparing	N	O
34	the	N	O
35	efficacy	N	O
36	and	N	O
37	toxicity	N	O
38	of	N	O
39	paclitaxel	N	O
40	and	N	O
41	PLD	N	O
42	was	N	O
43	performed	N	O
44	,	N	O
45	and	N	O
46	the	N	O
47	effects	N	O
48	of	N	O
49	therapy	N	O
50	on	N	O
51	symptom	N	O
52	palliation	N	O
53	and	N	O
54	quality	N	O
55	of	N	O
56	life	N	O
57	were	N	O
58	determined	N	O
59	.	N	O

60	Patients	N	O
61	with	N	O
62	advanced	N	O
63	HIV-associated	N	O
64	KS	N	O
65	were	N	O
66	randomly	N	O
67	assigned	N	O
68	to	N	O
69	receive	N	O
70	paclitaxel	N	O
71	at	N	O
72	a	N	O
73	dose	N	O
74	of	N	O
75	100	N	O
76	mg/m2	N	O
77	intravenously	N	O
78	(	N	O
79	iv	N	O
80	)	N	O
81	every	N	O
82	2	N	O
83	weeks	N	O
84	or	N	O
85	PLD	N	O
86	at	N	O
87	a	N	O
88	dose	N	O
89	of	N	O
90	20	N	O
91	mg/m2	N	O
92	iv	N	O
93	every	N	O
94	3	N	O
95	weeks	N	O
96	.	N	O

97	The	N	O
98	KS	N	O
99	Functional	N	O
100	Assessment	N	O
101	of	N	O
102	HIV	N	O
103	(	N	O
104	FAHI	N	O
105	)	N	O
106	quality	N	O
107	of	N	O
108	life	N	O
109	instrument	N	O
110	was	N	O
111	used	N	O
112	before	N	O
113	and	N	O
114	after	N	O
115	every	N	O
116	other	N	O
117	treatment	N	O
118	cycle	N	O
119	.	N	O

120	The	N	O
121	study	N	O
122	included	N	O
123	73	N	O
124	analyzable	N	O
125	patients	N	O
126	enrolled	N	O
127	between	N	O
128	1998	N	O
129	and	N	O
130	2002	N	O
131	,	N	O
132	including	N	O
133	36	N	O
134	in	N	O
135	the	N	O
136	paclitaxel	N	O
137	arm	N	O
138	and	N	O
139	37	N	O
140	in	N	O
141	the	N	O
142	PLD	N	O
143	arm	N	O
144	;	N	O
145	73	N	O
146	%	N	O
147	of	N	O
148	patients	N	O
149	received	N	O
150	highly	N	O
151	active	N	O
152	antiretroviral	N	O
153	therapy	N	O
154	(	N	O
155	HAART	N	O
156	)	N	O
157	and	N	O
158	32	N	O
159	%	N	O
160	had	N	O
161	an	N	O
162	undetectable	N	O
163	viral	N	O
164	load	N	O
165	(	N	O
166	<	N	O
167	400	N	O
168	copies/mL	N	O
169	)	N	O
170	.	N	O

171	Treatment	N	I-Premise
172	was	N	I-Premise
173	associated	N	I-Premise
174	with	N	I-Premise
175	significant	N	I-Premise
176	improvements	N	I-Premise
177	in	N	I-Premise
178	pain	N	I-Premise
179	(	N	I-Premise
180	P=.024	N	I-Premise
181	)	N	I-Premise
182	and	N	I-Premise
183	swelling	N	I-Premise
184	(	N	I-Premise
185	P	N	I-Premise
186	<	N	I-Premise
187	.001	N	I-Premise
188	)	N	I-Premise
189	.	N	I-Premise

190	Of	N	I-Premise
191	the	N	I-Premise
192	36	N	I-Premise
193	patients	N	I-Premise
194	who	N	I-Premise
195	reported	N	I-Premise
196	that	N	I-Premise
197	pain	N	I-Premise
198	interfered	N	I-Premise
199	with	N	I-Premise
200	their	N	I-Premise
201	normal	N	I-Premise
202	work	N	I-Premise
203	or	N	I-Premise
204	activities	N	I-Premise
205	at	N	I-Premise
206	baseline	N	I-Premise
207	,	N	I-Premise
208	25	N	I-Premise
209	(	N	I-Premise
210	69	N	I-Premise
211	%	N	I-Premise
212	)	N	I-Premise
213	improved	N	I-Premise
214	.	N	I-Premise

215	Of	N	I-Premise
216	the	N	I-Premise
217	41	N	I-Premise
218	patients	N	I-Premise
219	who	N	I-Premise
220	reported	N	I-Premise
221	swelling	N	I-Premise
222	at	N	I-Premise
223	baseline	N	I-Premise
224	,	N	I-Premise
225	38	N	I-Premise
226	(	N	I-Premise
227	93	N	I-Premise
228	%	N	I-Premise
229	)	N	I-Premise
230	improved	N	I-Premise
231	.	N	I-Premise

232	Comparing	N	I-Premise
233	the	N	I-Premise
234	paclitaxel	N	I-Premise
235	and	N	I-Premise
236	PLD	N	I-Premise
237	arms	N	I-Premise
238	revealed	N	I-Premise
239	comparable	N	I-Premise
240	response	N	I-Premise
241	rates	N	I-Premise
242	(	N	I-Premise
243	56	N	I-Premise
244	%	N	I-Premise
245	vs	N	I-Premise
246	46	N	I-Premise
247	%	N	I-Premise
248	;	N	I-Premise
249	P=.49	N	I-Premise
250	)	N	I-Premise
251	,	N	I-Premise
252	median	N	I-Premise
253	progression-free	N	I-Premise
254	survival	N	I-Premise
255	(	N	I-Premise
256	17.5	N	I-Premise
257	months	N	I-Premise
258	vs	N	I-Premise
259	12.2	N	I-Premise
260	months	N	I-Premise
261	;	N	I-Premise
262	P=.66	N	I-Premise
263	)	N	I-Premise
264	,	N	I-Premise
265	and	N	I-Premise
266	2-year	N	I-Premise
267	survival	N	I-Premise
268	rates	N	I-Premise
269	(	N	I-Premise
270	79	N	I-Premise
271	%	N	I-Premise
272	vs	N	I-Premise
273	78	N	I-Premise
274	%	N	I-Premise
275	;	N	I-Premise
276	P=.75	N	I-Premise
277	)	N	I-Premise
278	,	N	I-Premise
279	but	N	I-Premise
280	somewhat	N	I-Premise
281	more	N	I-Premise
282	grade	N	I-Premise
283	3	N	I-Premise
284	to	N	I-Premise
285	5	N	I-Premise
286	toxicity	N	I-Premise
287	for	N	I-Premise
288	paclitaxel	N	I-Premise
289	(	N	I-Premise
290	84	N	I-Premise
291	%	N	I-Premise
292	vs	N	I-Premise
293	66	N	I-Premise
294	%	N	I-Premise
295	;	N	I-Premise
296	P=.077	N	I-Premise
297	)	N	I-Premise
298	.	N	I-Premise

299	Treatment	N	I-Claim
300	with	N	I-Claim
301	either	N	I-Claim
302	paclitaxel	N	I-Claim
303	or	N	I-Claim
304	PLD	N	I-Claim
305	appears	N	I-Claim
306	to	N	I-Claim
307	produce	N	I-Claim
308	significant	N	I-Claim
309	improvements	N	I-Claim
310	in	N	I-Claim
311	pain	N	I-Claim
312	and	N	I-Claim
313	swelling	N	I-Claim
314	in	N	I-Claim
315	patients	N	I-Claim
316	with	N	I-Claim
317	advanced	N	I-Claim
318	,	N	I-Claim
319	symptomatic	N	I-Claim
320	,	N	I-Claim
321	HIV-associated	N	I-Claim
322	KS	N	I-Claim
323	treated	N	I-Claim
324	in	N	I-Claim
325	the	N	I-Claim
326	HAART	N	I-Claim
327	era	N	I-Claim
328	.	N	I-Claim

1	Lung	N	O
2	cancer	N	O
3	is	N	O
4	one	N	O
5	of	N	O
6	the	N	O
7	most	N	O
8	common	N	O
9	cancers	N	O
10	in	N	O
11	the	N	O
12	United	N	O
13	States	N	O
14	and	N	O
15	is	N	O
16	associated	N	O
17	with	N	O
18	high	N	O
19	levels	N	O
20	of	N	O
21	symptoms	N	O
22	,	N	O
23	including	N	O
24	pain	N	O
25	,	N	O
26	fatigue	N	O
27	,	N	O
28	shortness	N	O
29	of	N	O
30	breath	N	O
31	,	N	O
32	and	N	O
33	psychological	N	O
34	distress	N	O
35	.	N	O

36	Caregivers	N	O
37	and	N	O
38	patients	N	O
39	are	N	O
40	adversely	N	O
41	affected	N	O
42	.	N	O

43	However	N	O
44	,	N	O
45	previous	N	O
46	studies	N	O
47	of	N	O
48	coping	N	O
49	skills	N	O
50	training	N	O
51	(	N	O
52	CST	N	O
53	)	N	O
54	interventions	N	O
55	have	N	O
56	not	N	O
57	been	N	O
58	tested	N	O
59	in	N	O
60	patients	N	O
61	with	N	O
62	lung	N	O
63	cancer	N	O
64	nor	N	O
65	have	N	O
66	systematically	N	O
67	included	N	O
68	caregivers	N	O
69	.	N	O

70	This	N	O
71	study	N	O
72	tested	N	O
73	the	N	O
74	efficacy	N	O
75	of	N	O
76	a	N	O
77	caregiver-assisted	N	O
78	CST	N	O
79	protocol	N	O
80	in	N	O
81	a	N	O
82	sample	N	O
83	of	N	O
84	patients	N	O
85	with	N	O
86	lung	N	O
87	cancer	N	O
88	.	N	O

89	Two	N	O
90	hundred	N	O
91	thirty-three	N	O
92	lung	N	O
93	cancer	N	O
94	patients	N	O
95	and	N	O
96	their	N	O
97	caregivers	N	O
98	were	N	O
99	randomly	N	O
100	assigned	N	O
101	to	N	O
102	receive	N	O
103	14	N	O
104	telephone-based	N	O
105	sessions	N	O
106	of	N	O
107	either	N	O
108	caregiver-assisted	N	O
109	CST	N	O
110	or	N	O
111	education/support	N	O
112	involving	N	O
113	the	N	O
114	caregiver	N	O
115	.	N	O

116	Patients	N	O
117	completed	N	O
118	measures	N	O
119	assessing	N	O
120	pain	N	O
121	,	N	O
122	psychological	N	O
123	distress	N	O
124	,	N	O
125	quality	N	O
126	of	N	O
127	life	N	O
128	(	N	O
129	QOL	N	O
130	)	N	O
131	,	N	O
132	and	N	O
133	self-efficacy	N	O
134	for	N	O
135	symptom	N	O
136	management	N	O
137	;	N	O
138	caregivers	N	O
139	completed	N	O
140	measures	N	O
141	assessing	N	O
142	psychological	N	O
143	distress	N	O
144	,	N	O
145	caregiver	N	O
146	strain	N	O
147	,	N	O
148	and	N	O
149	self-efficacy	N	O
150	for	N	O
151	helping	N	O
152	the	N	O
153	patient	N	O
154	manage	N	O
155	symptoms	N	O
156	.	N	O

157	Patients	N	I-Premise
158	in	N	I-Premise
159	both	N	I-Premise
160	treatment	N	I-Premise
161	conditions	N	I-Premise
162	showed	N	I-Premise
163	improvements	N	I-Premise
164	in	N	I-Premise
165	pain	N	I-Premise
166	,	N	I-Premise
167	depression	N	I-Premise
168	,	N	I-Premise
169	QOL	N	I-Premise
170	,	N	I-Premise
171	and	N	I-Premise
172	self-efficacy	N	I-Premise
173	,	N	I-Premise
174	and	N	I-Premise
175	caregivers	N	I-Premise
176	in	N	I-Premise
177	both	N	I-Premise
178	conditions	N	I-Premise
179	showed	N	I-Premise
180	improvements	N	I-Premise
181	in	N	I-Premise
182	anxiety	N	I-Premise
183	and	N	I-Premise
184	self-efficacy	N	I-Premise
185	from	N	I-Premise
186	baseline	N	I-Premise
187	to	N	I-Premise
188	four-month	N	I-Premise
189	follow-up	N	I-Premise
190	.	N	I-Premise

191	Results	N	I-Premise
192	of	N	I-Premise
193	exploratory	N	I-Premise
194	analyses	N	I-Premise
195	suggested	N	I-Premise
196	that	N	I-Premise
197	the	N	I-Premise
198	CST	N	I-Premise
199	intervention	N	I-Premise
200	was	N	I-Premise
201	more	N	I-Premise
202	beneficial	N	I-Premise
203	to	N	I-Premise
204	patients/caregivers	N	I-Premise
205	with	N	I-Premise
206	Stage	N	I-Premise
207	II	N	I-Premise
208	and	N	I-Premise
209	III	N	I-Premise
210	cancers	N	I-Premise
211	,	N	I-Premise
212	whereas	N	O
213	the	N	I-Premise
214	education/support	N	I-Premise
215	intervention	N	I-Premise
216	was	N	I-Premise
217	more	N	I-Premise
218	beneficial	N	I-Premise
219	to	N	I-Premise
220	patients/caregivers	N	I-Premise
221	with	N	I-Premise
222	Stage	N	I-Premise
223	I	N	I-Premise
224	cancer	N	I-Premise
225	.	N	I-Premise

226	Taken	N	I-Premise
227	together	N	I-Premise
228	with	N	I-Premise
229	the	N	I-Premise
230	broader	N	I-Premise
231	literature	N	I-Premise
232	in	N	I-Premise
233	this	N	I-Premise
234	area	N	I-Premise
235	,	N	I-Premise
236	results	N	I-Claim
237	from	N	I-Claim
238	this	N	I-Claim
239	study	N	I-Claim
240	suggest	N	I-Claim
241	that	N	I-Claim
242	psychosocial	N	I-Claim
243	interventions	N	I-Claim
244	can	N	I-Claim
245	lead	N	I-Claim
246	to	N	I-Claim
247	improvements	N	I-Claim
248	in	N	I-Claim
249	a	N	I-Claim
250	range	N	I-Claim
251	of	N	I-Claim
252	outcomes	N	I-Claim
253	for	N	I-Claim
254	cancer	N	I-Claim
255	patients	N	I-Claim
256	.	N	I-Claim

257	Suggestions	N	O
258	for	N	O
259	future	N	O
260	studies	N	O
261	include	N	O
262	the	N	O
263	use	N	O
264	of	N	O
265	three-group	N	O
266	designs	N	O
267	(	N	O
268	e.g.	N	O
269	,	N	O
270	comparing	N	O
271	two	N	O
272	active	N	O
273	interventions	N	O
274	with	N	O
275	a	N	O
276	standard-care	N	O
277	control	N	O
278	)	N	O
279	and	N	O
280	examining	N	O
281	mechanisms	N	O
282	of	N	O
283	change	N	O
284	.	N	O

1	The	N	O
2	EORTC	N	O
3	24971/TAX	N	O
4	323	N	O
5	,	N	O
6	a	N	O
7	phase	N	O
8	III	N	O
9	study	N	O
10	of	N	O
11	358	N	O
12	patients	N	O
13	with	N	O
14	unresectable	N	O
15	locoregionally	N	O
16	advanced	N	O
17	squamous	N	O
18	cell	N	O
19	carcinoma	N	O
20	of	N	O
21	the	N	O
22	head	N	O
23	and	N	O
24	neck	N	O
25	,	N	O
26	showed	N	O
27	an	N	O
28	improved	N	O
29	progression-free	N	O
30	and	N	O
31	overall	N	O
32	survival	N	O
33	(	N	O
34	OS	N	O
35	)	N	O
36	with	N	O
37	less	N	O
38	toxicity	N	O
39	when	N	O
40	docetaxel	N	O
41	(	N	O
42	T	N	O
43	)	N	O
44	was	N	O
45	added	N	O
46	to	N	O
47	cisplatin	N	O
48	and	N	O
49	5-fluorouracil	N	O
50	(	N	O
51	PF	N	O
52	)	N	O
53	for	N	O
54	induction	N	O
55	and	N	O
56	given	N	O
57	before	N	O
58	radiotherapy	N	O
59	(	N	O
60	RT	N	O
61	)	N	O
62	.	N	O

63	The	N	O
64	impact	N	O
65	of	N	O
66	the	N	O
67	addition	N	O
68	of	N	O
69	docetaxel	N	O
70	on	N	O
71	patients	N	O
72	'	N	O
73	health-related	N	O
74	quality	N	O
75	of	N	O
76	life	N	O
77	(	N	O
78	HRQOL	N	O
79	)	N	O
80	and	N	O
81	symptoms	N	O
82	was	N	O
83	investigated	N	O
84	.	N	O

85	HRQOL	N	O
86	was	N	O
87	assessed	N	O
88	at	N	O
89	baseline	N	O
90	,	N	O
91	at	N	O
92	end	N	O
93	of	N	O
94	cycle	N	O
95	2	N	O
96	,	N	O
97	and	N	O
98	4	N	O
99	,	N	O
100	6	N	O
101	,	N	O
102	and	N	O
103	9	N	O
104	months	N	O
105	after	N	O
106	completion	N	O
107	of	N	O
108	RT	N	O
109	using	N	O
110	the	N	O
111	European	N	O
112	Organisation	N	O
113	for	N	O
114	Research	N	O
115	and	N	O
116	Treatment	N	O
117	of	N	O
118	Cancer	N	O
119	(	N	O
120	EORTC	N	O
121	)	N	O
122	Quality	N	O
123	of	N	O
124	Life	N	O
125	Questionnaire	N	O
126	C30	N	O
127	(	N	O
128	QLQ-C30	N	O
129	)	N	O
130	and	N	O
131	the	N	O
132	EORTC	N	O
133	QLQ	N	O
134	Head	N	O
135	and	N	O
136	Neck	N	O
137	Cancer-Specific	N	O
138	Module	N	O
139	(	N	O
140	EORTC	N	O
141	QLQ-H	N	O
142	&	N	O
143	amp	N	O
144	;	N	O
145	N35	N	O
146	)	N	O
147	.	N	O

148	The	N	O
149	primary	N	O
150	HRQOL	N	O
151	scale	N	O
152	was	N	O
153	global	N	O
154	HRQOL	N	O
155	per	N	O
156	protocol	N	O
157	.	N	O

158	Compliance	N	O
159	to	N	O
160	HRQOL	N	O
161	assessments	N	O
162	was	N	O
163	97	N	O
164	%	N	O
165	at	N	O
166	baseline	N	O
167	,	N	O
168	but	N	O
169	dropped	N	O
170	to	N	O
171	54	N	O
172	%	N	O
173	by	N	O
174	6	N	O
175	months	N	O
176	.	N	O

177	Data	N	O
178	were	N	O
179	analysed	N	O
180	up	N	O
181	to	N	O
182	6	N	O
183	months	N	O
184	.	N	O

185	There	N	I-Premise
186	was	N	I-Premise
187	a	N	I-Premise
188	trend	N	I-Premise
189	towards	N	I-Premise
190	improved	N	I-Premise
191	global	N	I-Premise
192	HRQOL	N	I-Premise
193	during	N	I-Premise
194	the	N	I-Premise
195	treatment	N	I-Premise
196	period	N	I-Premise
197	.	N	I-Premise

198	At	N	I-Premise
199	6	N	I-Premise
200	months	N	I-Premise
201	after	N	I-Premise
202	the	N	I-Premise
203	end	N	I-Premise
204	of	N	I-Premise
205	RT	N	I-Premise
206	,	N	I-Premise
207	global	N	I-Premise
208	HRQOL	N	I-Premise
209	was	N	I-Premise
210	higher	N	I-Premise
211	in	N	I-Premise
212	the	N	I-Premise
213	TPF	N	I-Premise
214	arm	N	I-Premise
215	than	N	I-Premise
216	in	N	I-Premise
217	the	N	I-Premise
218	PF	N	I-Premise
219	arm	N	I-Premise
220	,	N	I-Premise
221	but	N	I-Premise
222	the	N	I-Premise
223	low	N	I-Premise
224	compliance	N	I-Premise
225	does	N	I-Premise
226	not	N	I-Premise
227	allow	N	I-Premise
228	to	N	I-Premise
229	draw	N	I-Premise
230	definitive	N	I-Premise
231	conclusions	N	I-Premise
232	.	N	I-Premise

233	Swallowing	N	I-Premise
234	and	N	I-Premise
235	coughing	N	I-Premise
236	problems	N	I-Premise
237	decreased	N	I-Premise
238	more	N	I-Premise
239	in	N	I-Premise
240	the	N	I-Premise
241	TPF	N	I-Premise
242	arm	N	I-Premise
243	than	N	I-Premise
244	in	N	I-Premise
245	the	N	I-Premise
246	PF	N	I-Premise
247	arm	N	I-Premise
248	at	N	I-Premise
249	the	N	I-Premise
250	end	N	I-Premise
251	of	N	I-Premise
252	cycle	N	I-Premise
253	2	N	I-Premise
254	,	N	I-Premise
255	but	N	I-Premise
256	to	N	I-Premise
257	a	N	I-Premise
258	limited	N	I-Premise
259	extent	N	I-Premise
260	.	N	I-Premise

261	Induction	N	I-Claim
262	chemotherapy	N	I-Claim
263	with	N	I-Claim
264	TPF	N	I-Claim
265	before	N	I-Claim
266	RT	N	I-Claim
267	not	N	I-Claim
268	only	N	I-Claim
269	improves	N	I-Claim
270	survival	N	I-Claim
271	and	N	I-Claim
272	reduces	N	I-Claim
273	toxicity	N	I-Claim
274	compared	N	I-Claim
275	with	N	I-Claim
276	PF	N	I-Claim
277	but	N	I-Claim
278	also	N	I-Claim
279	seems	N	I-Claim
280	to	N	I-Claim
281	improve	N	I-Claim
282	global	N	I-Claim
283	HRQOL	N	I-Claim
284	in	N	I-Claim
285	a	N	I-Claim
286	more	N	I-Claim
287	sustainable	N	I-Claim
288	manner	N	I-Claim
289	.	N	I-Claim

1	We	N	O
2	compared	N	O
3	fulvestrant	N	O
4	500	N	O
5	mg	N	O
6	regimen	N	O
7	with	N	O
8	the	N	O
9	approved	N	O
10	dose	N	O
11	of	N	O
12	fulvestrant	N	O
13	250	N	O
14	mg	N	O
15	per	N	O
16	month	N	O
17	for	N	O
18	treatment	N	O
19	of	N	O
20	postmenopausal	N	O
21	women	N	O
22	with	N	O
23	estrogen	N	O
24	receptor-positive	N	O
25	advanced	N	O
26	breast	N	O
27	cancer	N	O
28	who	N	O
29	experienced	N	O
30	progression	N	O
31	after	N	O
32	prior	N	O
33	endocrine	N	O
34	therapy	N	O
35	.	N	O

36	Comparison	N	O
37	of	N	O
38	Faslodex	N	O
39	in	N	O
40	Recurrent	N	O
41	or	N	O
42	Metastatic	N	O
43	Breast	N	O
44	Cancer	N	O
45	(	N	O
46	CONFIRM	N	O
47	)	N	O
48	is	N	O
49	a	N	O
50	double-blind	N	O
51	,	N	O
52	parallel-group	N	O
53	,	N	O
54	multicenter	N	O
55	,	N	O
56	phase	N	O
57	III	N	O
58	study	N	O
59	.	N	O

60	Patients	N	O
61	were	N	O
62	randomly	N	O
63	assigned	N	O
64	to	N	O
65	fulvestrant	N	O
66	500	N	O
67	mg	N	O
68	(	N	O
69	500	N	O
70	mg	N	O
71	intramuscularly	N	O
72	[	N	O
73	IM	N	O
74	]	N	O
75	on	N	O
76	day	N	O
77	0	N	O
78	,	N	O
79	then	N	O
80	500	N	O
81	mg	N	O
82	IM	N	O
83	on	N	O
84	days	N	O
85	14	N	O
86	and	N	O
87	28	N	O
88	and	N	O
89	every	N	O
90	28	N	O
91	days	N	O
92	thereafter	N	O
93	)	N	O
94	or	N	O
95	250	N	O
96	mg	N	O
97	every	N	O
98	28	N	O
99	days	N	O
100	.	N	O

101	Primary	N	O
102	end	N	O
103	point	N	O
104	was	N	O
105	progression-free	N	O
106	survival	N	O
107	(	N	O
108	PFS	N	O
109	)	N	O
110	.	N	O

111	Secondary	N	O
112	end	N	O
113	points	N	O
114	included	N	O
115	objective	N	O
116	response	N	O
117	rate	N	O
118	,	N	O
119	clinical	N	O
120	benefit	N	O
121	rate	N	O
122	(	N	O
123	CBR	N	O
124	)	N	O
125	,	N	O
126	duration	N	O
127	of	N	O
128	clinical	N	O
129	benefit	N	O
130	(	N	O
131	DoCB	N	O
132	)	N	O
133	,	N	O
134	overall	N	O
135	survival	N	O
136	(	N	O
137	OS	N	O
138	)	N	O
139	,	N	O
140	and	N	O
141	quality	N	O
142	of	N	O
143	life	N	O
144	(	N	O
145	QOL	N	O
146	)	N	O
147	.	N	O

148	PFS	N	I-Premise
149	was	N	I-Premise
150	significantly	N	I-Premise
151	longer	N	I-Premise
152	for	N	I-Premise
153	fulvestrant	N	I-Premise
154	500	N	I-Premise
155	mg	N	I-Premise
156	(	N	I-Premise
157	n	N	I-Premise
158	=	N	I-Premise
159	362	N	I-Premise
160	)	N	I-Premise
161	than	N	I-Premise
162	250	N	I-Premise
163	mg	N	I-Premise
164	(	N	I-Premise
165	n	N	I-Premise
166	=	N	I-Premise
167	374	N	I-Premise
168	)	N	I-Premise
169	(	N	I-Premise
170	hazard	N	I-Premise
171	ratio	N	I-Premise
172	[	N	I-Premise
173	HR	N	I-Premise
174	]	N	I-Premise
175	=	N	I-Premise
176	0.80	N	I-Premise
177	;	N	I-Premise
178	95	N	I-Premise
179	%	N	I-Premise
180	CI	N	I-Premise
181	,	N	I-Premise
182	0.68	N	I-Premise
183	to	N	I-Premise
184	0.94	N	I-Premise
185	;	N	I-Premise
186	P	N	I-Premise
187	=	N	I-Premise
188	.006	N	I-Premise
189	)	N	I-Premise
190	,	N	I-Premise
191	corresponding	N	I-Premise
192	to	N	I-Premise
193	a	N	I-Premise
194	20	N	I-Premise
195	%	N	I-Premise
196	reduction	N	I-Premise
197	in	N	I-Premise
198	risk	N	I-Premise
199	of	N	I-Premise
200	progression	N	I-Premise
201	.	N	I-Premise

202	Objective	N	I-Premise
203	response	N	I-Premise
204	rate	N	I-Premise
205	was	N	I-Premise
206	similar	N	I-Premise
207	for	N	I-Premise
208	fulvestrant	N	I-Premise
209	500	N	I-Premise
210	mg	N	I-Premise
211	and	N	I-Premise
212	250	N	I-Premise
213	mg	N	I-Premise
214	(	N	I-Premise
215	9.1	N	I-Premise
216	%	N	I-Premise
217	v	N	I-Premise
218	10.2	N	I-Premise
219	%	N	I-Premise
220	,	N	I-Premise
221	respectively	N	I-Premise
222	)	N	I-Premise
223	.	N	I-Premise

224	CBR	N	I-Premise
225	was	N	I-Premise
226	45.6	N	I-Premise
227	%	N	I-Premise
228	for	N	I-Premise
229	fulvestrant	N	I-Premise
230	500	N	I-Premise
231	mg	N	I-Premise
232	and	N	I-Premise
233	39.6	N	I-Premise
234	%	N	I-Premise
235	for	N	I-Premise
236	fulvestrant	N	I-Premise
237	250	N	I-Premise
238	mg.	N	I-Premise
239	DoCB	N	I-Premise
240	and	N	I-Premise
241	OS	N	I-Premise
242	were	N	I-Premise
243	16.6	N	I-Premise
244	and	N	I-Premise
245	25.1	N	I-Premise
246	months	N	I-Premise
247	,	N	I-Premise
248	respectively	N	I-Premise
249	,	N	I-Premise
250	for	N	I-Premise
251	the	N	I-Premise
252	500-mg	N	I-Premise
253	group	N	I-Premise
254	,	N	I-Premise
255	whereas	N	I-Premise
256	DoCB	N	I-Premise
257	and	N	I-Premise
258	OS	N	I-Premise
259	were	N	I-Premise
260	13.9	N	I-Premise
261	and	N	I-Premise
262	22.8	N	I-Premise
263	months	N	I-Premise
264	,	N	I-Premise
265	respectively	N	I-Premise
266	,	N	I-Premise
267	in	N	I-Premise
268	the	N	I-Premise
269	250-mg	N	I-Premise
270	group	N	I-Premise
271	.	N	I-Premise

272	Fulvestrant	N	I-Claim
273	500	N	I-Claim
274	mg	N	I-Claim
275	was	N	I-Claim
276	well	N	I-Claim
277	tolerated	N	I-Claim
278	with	N	I-Claim
279	no	N	I-Claim
280	dose-dependent	N	I-Claim
281	adverse	N	I-Claim
282	events	N	I-Claim
283	.	N	I-Claim

284	QOL	N	I-Claim
285	was	N	I-Claim
286	similar	N	I-Claim
287	for	N	I-Claim
288	both	N	I-Claim
289	arms	N	I-Claim
290	.	N	I-Claim

291	Fulvestrant	N	I-Claim
292	500	N	I-Claim
293	mg	N	I-Claim
294	was	N	I-Claim
295	associated	N	I-Claim
296	with	N	I-Claim
297	a	N	I-Claim
298	statistically	N	I-Claim
299	significant	N	I-Claim
300	increase	N	I-Claim
301	in	N	I-Claim
302	PFS	N	I-Claim
303	and	N	I-Claim
304	not	N	I-Claim
305	associated	N	I-Claim
306	with	N	I-Claim
307	increased	N	I-Claim
308	toxicity	N	I-Claim
309	,	N	I-Claim
310	corresponding	N	O
311	to	N	O
312	a	N	O
313	clinically	N	O
314	meaningful	N	O
315	improvement	N	O
316	in	N	O
317	benefit	N	O
318	versus	N	O
319	risk	N	O
320	compared	N	O
321	with	N	O
322	fulvestrant	N	O
323	250	N	O
324	mg	N	O
325	.	N	O

1	Temozolomide	N	O
2	(	N	O
3	TMZ	N	O
4	)	N	O
5	is	N	O
6	an	N	O
7	alkylating	N	O
8	agent	N	O
9	licensed	N	O
10	for	N	O
11	treatment	N	O
12	of	N	O
13	high-grade	N	O
14	glioma	N	O
15	(	N	O
16	HGG	N	O
17	)	N	O
18	.	N	O

19	No	N	O
20	prospective	N	O
21	comparison	N	O
22	with	N	O
23	nitrosourea-based	N	O
24	chemotherapy	N	O
25	exists	N	O
26	.	N	O

27	We	N	O
28	report	N	O
29	,	N	O
30	to	N	O
31	our	N	O
32	knowledge	N	O
33	,	N	O
34	the	N	O
35	first	N	O
36	randomized	N	O
37	trial	N	O
38	of	N	O
39	procarbazine	N	O
40	,	N	O
41	lomustine	N	O
42	,	N	O
43	and	N	O
44	vincristine	N	O
45	(	N	O
46	PCV	N	O
47	)	N	O
48	versus	N	O
49	TMZ	N	O
50	in	N	O
51	chemotherapy-naive	N	O
52	patients	N	O
53	with	N	O
54	recurrent	N	O
55	HGG	N	O
56	.	N	O

57	Four	N	O
58	hundred	N	O
59	forty-seven	N	O
60	patients	N	O
61	were	N	O
62	randomly	N	O
63	assigned	N	O
64	to	N	O
65	PCV	N	O
66	(	N	O
67	224	N	O
68	patients	N	O
69	)	N	O
70	or	N	O
71	TMZ	N	O
72	(	N	O
73	sub-random	N	O
74	assignment	N	O
75	:	N	O
76	TMZ-5	N	O
77	[	N	O
78	200	N	O
79	mg/m	N	O
80	(	N	O
81	2	N	O
82	)	N	O
83	for	N	O
84	5	N	O
85	days	N	O
86	,	N	O
87	112	N	O
88	patients	N	O
89	]	N	O
90	or	N	O
91	TMZ-21	N	O
92	[	N	O
93	100	N	O
94	mg/m	N	O
95	(	N	O
96	2	N	O
97	)	N	O
98	for	N	O
99	21	N	O
100	days	N	O
101	,	N	O
102	111	N	O
103	patients	N	O
104	]	N	O
105	)	N	O
106	for	N	O
107	up	N	O
108	to	N	O
109	9	N	O
110	months	N	O
111	or	N	O
112	until	N	O
113	progression	N	O
114	.	N	O

115	The	N	O
116	primary	N	O
117	outcomes	N	O
118	were	N	O
119	survival	N	O
120	(	N	O
121	PCV	N	O
122	v	N	O
123	TMZ	N	O
124	)	N	O
125	and	N	O
126	12-week	N	O
127	progression-free	N	O
128	survival	N	O
129	(	N	O
130	PFS	N	O
131	;	N	O
132	TMZ-5	N	O
133	v	N	O
134	TMZ-21	N	O
135	)	N	O
136	.	N	O

137	This	N	O
138	study	N	O
139	is	N	O
140	registered	N	O
141	as	N	O
142	ISRCTN83176944	N	O
143	.	N	O

144	Percentages	N	O
145	of	N	O
146	patients	N	O
147	completing	N	O
148	9	N	O
149	months	N	O
150	of	N	O
151	treatment	N	O
152	in	N	O
153	the	N	O
154	PCV	N	O
155	,	N	O
156	TMZ-5	N	O
157	,	N	O
158	and	N	O
159	TMZ-21	N	O
160	arms	N	O
161	were	N	O
162	17	N	O
163	%	N	O
164	,	N	O
165	26	N	O
166	%	N	O
167	,	N	O
168	and	N	O
169	13	N	O
170	%	N	O
171	,	N	O
172	respectively	N	O
173	.	N	O

174	Major	N	I-Premise
175	toxicity	N	I-Premise
176	was	N	I-Premise
177	similar	N	I-Premise
178	across	N	I-Premise
179	all	N	I-Premise
180	three	N	I-Premise
181	groups	N	I-Premise
182	.	N	I-Premise

183	With	N	I-Premise
184	a	N	I-Premise
185	median	N	I-Premise
186	follow-up	N	I-Premise
187	time	N	I-Premise
188	of	N	I-Premise
189	12	N	I-Premise
190	months	N	I-Premise
191	and	N	I-Premise
192	382	N	I-Premise
193	deaths	N	I-Premise
194	,	N	I-Premise
195	there	N	I-Premise
196	was	N	I-Premise
197	no	N	I-Premise
198	clear	N	I-Premise
199	survival	N	I-Premise
200	benefit	N	I-Premise
201	when	N	I-Premise
202	comparing	N	I-Premise
203	PCV	N	I-Premise
204	with	N	I-Premise
205	TMZ	N	I-Premise
206	(	N	I-Premise
207	hazard	N	I-Premise
208	ratio	N	I-Premise
209	[	N	I-Premise
210	HR	N	I-Premise
211	]	N	I-Premise
212	,	N	I-Premise
213	0.91	N	I-Premise
214	;	N	I-Premise
215	95	N	I-Premise
216	%	N	I-Premise
217	CI	N	I-Premise
218	,	N	I-Premise
219	0.74	N	I-Premise
220	to	N	I-Premise
221	1.11	N	I-Premise
222	;	N	I-Premise
223	P	N	I-Premise
224	=	N	I-Premise
225	.350	N	I-Premise
226	)	N	I-Premise
227	.	N	I-Premise

228	For	N	I-Premise
229	TMZ-5	N	I-Premise
230	versus	N	I-Premise
231	TMZ-21	N	I-Premise
232	,	N	I-Premise
233	12-week	N	I-Premise
234	PFS	N	I-Premise
235	rates	N	I-Premise
236	were	N	I-Premise
237	similar	N	I-Premise
238	(	N	I-Premise
239	63.6	N	I-Premise
240	%	N	I-Premise
241	and	N	I-Premise
242	65.7	N	I-Premise
243	%	N	I-Premise
244	,	N	I-Premise
245	respectively	N	I-Premise
246	;	N	I-Premise
247	P	N	I-Premise
248	=	N	I-Premise
249	.745	N	I-Premise
250	)	N	I-Premise
251	,	N	I-Premise
252	but	N	I-Premise
253	TMZ-5	N	I-Premise
254	improved	N	I-Premise
255	overall	N	I-Premise
256	PFS	N	I-Premise
257	(	N	I-Premise
258	HR	N	I-Premise
259	,	N	I-Premise
260	1.38	N	I-Premise
261	;	N	I-Premise
262	95	N	I-Premise
263	%	N	I-Premise
264	CI	N	I-Premise
265	,	N	I-Premise
266	1.05	N	I-Premise
267	to	N	I-Premise
268	1.82	N	I-Premise
269	;	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.023	N	I-Premise
273	)	N	I-Premise
274	,	N	I-Premise
275	survival	N	I-Premise
276	(	N	I-Premise
277	HR	N	I-Premise
278	,	N	I-Premise
279	1.32	N	I-Premise
280	;	N	I-Premise
281	95	N	I-Premise
282	%	N	I-Premise
283	CI	N	I-Premise
284	,	N	I-Premise
285	0.99	N	I-Premise
286	to	N	I-Premise
287	1.75	N	I-Premise
288	;	N	I-Premise
289	P	N	I-Premise
290	=	N	I-Premise
291	.056	N	I-Premise
292	)	N	I-Premise
293	,	N	I-Premise
294	and	N	I-Premise
295	global	N	I-Premise
296	quality	N	I-Premise
297	of	N	I-Premise
298	life	N	I-Premise
299	(	N	I-Premise
300	49	N	I-Premise
301	%	N	I-Premise
302	v	N	I-Premise
303	19	N	I-Premise
304	%	N	I-Premise
305	improved	N	I-Premise
306	>	N	I-Premise
307	10	N	I-Premise
308	points	N	I-Premise
309	at	N	I-Premise
310	6	N	I-Premise
311	months	N	I-Premise
312	,	N	I-Premise
313	respectively	N	I-Premise
314	;	N	I-Premise
315	P	N	I-Premise
316	=	N	I-Premise
317	.005	N	I-Premise
318	)	N	I-Premise
319	.	N	I-Premise

320	Although	N	I-Claim
321	TMZ	N	I-Claim
322	(	N	I-Claim
323	both	N	I-Claim
324	arms	N	I-Claim
325	combined	N	I-Claim
326	)	N	I-Claim
327	did	N	I-Claim
328	not	N	I-Claim
329	show	N	I-Claim
330	a	N	I-Claim
331	clear	N	I-Claim
332	benefit	N	I-Claim
333	compared	N	I-Claim
334	with	N	I-Claim
335	PCV	N	I-Claim
336	,	N	I-Claim
337	comparison	N	I-Claim
338	of	N	I-Claim
339	the	N	I-Claim
340	TMZ	N	I-Claim
341	schedules	N	I-Claim
342	demonstrated	N	I-Claim
343	that	N	I-Claim
344	the	N	I-Claim
345	21-day	N	I-Claim
346	schedule	N	I-Claim
347	was	N	I-Claim
348	inferior	N	I-Claim
349	to	N	I-Claim
350	the	N	I-Claim
351	5-day	N	I-Claim
352	schedule	N	I-Claim
353	in	N	I-Claim
354	this	N	I-Claim
355	setting	N	I-Claim
356	.	N	I-Claim

357	This	N	I-Claim
358	challenges	N	I-Claim
359	the	N	I-Claim
360	current	N	I-Claim
361	understanding	N	I-Claim
362	of	N	I-Claim
363	increasing	N	I-Claim
364	TMZ	N	I-Claim
365	dose-intensity	N	I-Claim
366	by	N	I-Claim
367	prolonged	N	I-Claim
368	scheduling	N	I-Claim
369	.	N	I-Claim

1	Compared	N	O
2	with	N	O
3	placebo	N	O
4	,	N	O
5	prophylactic	N	O
6	treatment	N	O
7	with	N	O
8	bisphosphonates	N	O
9	reduces	N	O
10	risk	N	O
11	of	N	O
12	skeletal	N	O
13	events	N	O
14	in	N	O
15	patients	N	O
16	with	N	O
17	multiple	N	O
18	myeloma	N	O
19	.	N	O

20	However	N	O
21	,	N	O
22	because	N	O
23	of	N	O
24	toxicity	N	O
25	associated	N	O
26	with	N	O
27	long-term	N	O
28	bisphosphonate	N	O
29	treatment	N	O
30	,	N	O
31	establishing	N	O
32	the	N	O
33	lowest	N	O
34	effective	N	O
35	dose	N	O
36	is	N	O
37	important	N	O
38	.	N	O

39	This	N	O
40	study	N	O
41	compared	N	O
42	the	N	O
43	effect	N	O
44	of	N	O
45	two	N	O
46	doses	N	O
47	of	N	O
48	pamidronate	N	O
49	on	N	O
50	health-related	N	O
51	quality	N	O
52	of	N	O
53	life	N	O
54	and	N	O
55	skeletal	N	O
56	morbidity	N	O
57	in	N	O
58	patients	N	O
59	with	N	O
60	newly	N	O
61	diagnosed	N	O
62	multiple	N	O
63	myeloma	N	O
64	.	N	O

65	This	N	O
66	double-blind	N	O
67	,	N	O
68	randomised	N	O
69	,	N	O
70	phase	N	O
71	3	N	O
72	trial	N	O
73	was	N	O
74	undertaken	N	O
75	at	N	O
76	37	N	O
77	clinics	N	O
78	in	N	O
79	Denmark	N	O
80	,	N	O
81	Norway	N	O
82	,	N	O
83	and	N	O
84	Sweden	N	O
85	.	N	O

86	Patients	N	O
87	with	N	O
88	multiple	N	O
89	myeloma	N	O
90	who	N	O
91	were	N	O
92	starting	N	O
93	antimyeloma	N	O
94	treatment	N	O
95	were	N	O
96	randomly	N	O
97	assigned	N	O
98	in	N	O
99	a	N	O
100	1:1	N	O
101	ratio	N	O
102	to	N	O
103	receive	N	O
104	one	N	O
105	of	N	O
106	two	N	O
107	doses	N	O
108	of	N	O
109	pamidronate	N	O
110	(	N	O
111	30	N	O
112	mg	N	O
113	or	N	O
114	90	N	O
115	mg	N	O
116	)	N	O
117	given	N	O
118	by	N	O
119	intravenous	N	O
120	infusion	N	O
121	once	N	O
122	a	N	O
123	month	N	O
124	for	N	O
125	at	N	O
126	least	N	O
127	3	N	O
128	years	N	O
129	.	N	O

130	Randomisation	N	O
131	was	N	O
132	done	N	O
133	by	N	O
134	use	N	O
135	of	N	O
136	a	N	O
137	central	N	O
138	,	N	O
139	computerised	N	O
140	minimisation	N	O
141	system	N	O
142	.	N	O

143	Primary	N	O
144	outcome	N	O
145	was	N	O
146	physical	N	O
147	function	N	O
148	after	N	O
149	12	N	O
150	months	N	O
151	estimated	N	O
152	by	N	O
153	the	N	O
154	European	N	O
155	Organisation	N	O
156	for	N	O
157	Research	N	O
158	and	N	O
159	Treatment	N	O
160	of	N	O
161	Cancer	N	O
162	(	N	O
163	EORTC	N	O
164	)	N	O
165	QLQ-C30	N	O
166	questionnaire	N	O
167	(	N	O
168	scale	N	O
169	0-100	N	O
170	)	N	O
171	.	N	O

172	All	N	O
173	patients	N	O
174	who	N	O
175	returned	N	O
176	questionnaires	N	O
177	at	N	O
178	12	N	O
179	months	N	O
180	and	N	O
181	were	N	O
182	still	N	O
183	on	N	O
184	study	N	O
185	treatment	N	O
186	were	N	O
187	included	N	O
188	in	N	O
189	the	N	O
190	analysis	N	O
191	of	N	O
192	the	N	O
193	primary	N	O
194	endpoint	N	O
195	.	N	O

196	From	N	O
197	January	N	O
198	,	N	O
199	2001	N	O
200	,	N	O
201	until	N	O
202	August	N	O
203	,	N	O
204	2005	N	O
205	,	N	O
206	504	N	O
207	patients	N	O
208	were	N	O
209	randomly	N	O
210	assigned	N	O
211	to	N	O
212	pamidronate	N	O
213	30	N	O
214	mg	N	O
215	or	N	O
216	90	N	O
217	mg	N	O
218	(	N	O
219	252	N	O
220	in	N	O
221	each	N	O
222	group	N	O
223	)	N	O
224	.	N	O

225	157	N	O
226	patients	N	O
227	in	N	O
228	the	N	O
229	90	N	O
230	mg	N	O
231	group	N	O
232	and	N	O
233	156	N	O
234	in	N	O
235	the	N	O
236	30	N	O
237	mg	N	O
238	group	N	O
239	were	N	O
240	included	N	O
241	in	N	O
242	the	N	O
243	primary	N	O
244	analysis	N	O
245	.	N	O

246	Mean	N	I-Premise
247	physical	N	I-Premise
248	function	N	I-Premise
249	at	N	I-Premise
250	12	N	I-Premise
251	months	N	I-Premise
252	was	N	I-Premise
253	66	N	I-Premise
254	points	N	I-Premise
255	(	N	I-Premise
256	95	N	I-Premise
257	%	N	I-Premise
258	CI	N	I-Premise
259	629-700	N	I-Premise
260	)	N	I-Premise
261	in	N	I-Premise
262	the	N	I-Premise
263	90	N	I-Premise
264	mg	N	I-Premise
265	group	N	I-Premise
266	and	N	I-Premise
267	68	N	I-Premise
268	points	N	I-Premise
269	(	N	I-Premise
270	646-714	N	I-Premise
271	)	N	I-Premise
272	in	N	I-Premise
273	the	N	I-Premise
274	30	N	I-Premise
275	mg	N	I-Premise
276	group	N	I-Premise
277	(	N	I-Premise
278	95	N	I-Premise
279	%	N	I-Premise
280	CI	N	I-Premise
281	of	N	I-Premise
282	difference	N	I-Premise
283	-66	N	I-Premise
284	to	N	I-Premise
285	33	N	I-Premise
286	;	N	I-Premise
287	p=052	N	I-Premise
288	)	N	I-Premise
289	.	N	I-Premise

290	Median	N	I-Premise
291	time	N	I-Premise
292	to	N	I-Premise
293	first	N	I-Premise
294	skeletal-related	N	I-Premise
295	event	N	I-Premise
296	in	N	I-Premise
297	patients	N	I-Premise
298	who	N	I-Premise
299	had	N	I-Premise
300	such	N	I-Premise
301	an	N	I-Premise
302	event	N	I-Premise
303	was	N	I-Premise
304	92	N	I-Premise
305	months	N	I-Premise
306	(	N	I-Premise
307	81-107	N	I-Premise
308	)	N	I-Premise
309	in	N	I-Premise
310	the	N	I-Premise
311	90	N	I-Premise
312	mg	N	I-Premise
313	group	N	I-Premise
314	and	N	I-Premise
315	102	N	I-Premise
316	months	N	I-Premise
317	(	N	I-Premise
318	73-140	N	I-Premise
319	)	N	I-Premise
320	in	N	I-Premise
321	the	N	I-Premise
322	30	N	I-Premise
323	mg	N	I-Premise
324	group	N	I-Premise
325	(	N	I-Premise
326	p=063	N	I-Premise
327	)	N	I-Premise
328	.	N	I-Premise

329	In	N	O
330	a	N	O
331	retrospective	N	O
332	analysis	N	O
333	,	N	O
334	eight	N	I-Premise
335	patients	N	I-Premise
336	in	N	I-Premise
337	the	N	I-Premise
338	pamidronate	N	I-Premise
339	90	N	I-Premise
340	mg	N	I-Premise
341	group	N	I-Premise
342	developed	N	I-Premise
343	osteonecrosis	N	I-Premise
344	of	N	I-Premise
345	the	N	I-Premise
346	jaw	N	I-Premise
347	compared	N	I-Premise
348	with	N	I-Premise
349	two	N	I-Premise
350	patients	N	I-Premise
351	in	N	I-Premise
352	the	N	I-Premise
353	30	N	I-Premise
354	mg	N	I-Premise
355	group	N	I-Premise
356	.	N	I-Premise

357	Monthly	N	I-Claim
358	infusion	N	I-Claim
359	of	N	I-Claim
360	pamidronate	N	I-Claim
361	30	N	I-Claim
362	mg	N	I-Claim
363	should	N	I-Claim
364	be	N	I-Claim
365	the	N	I-Claim
366	recommended	N	I-Claim
367	dose	N	I-Claim
368	for	N	I-Claim
369	prevention	N	I-Claim
370	of	N	I-Claim
371	bone	N	I-Claim
372	disease	N	I-Claim
373	in	N	I-Claim
374	patients	N	I-Claim
375	with	N	I-Claim
376	multiple	N	I-Claim
377	myeloma	N	I-Claim
378	.	N	I-Claim

1	Before	N	O
2	the	N	O
3	knowledge	N	O
4	that	N	O
5	5	N	O
6	years	N	O
7	of	N	O
8	adjuvant	N	O
9	tamoxifen	N	O
10	is	N	O
11	less	N	O
12	efficacious	N	O
13	than	N	O
14	2	N	O
15	to	N	O
16	3	N	O
17	years	N	O
18	of	N	O
19	tamoxifen	N	O
20	followed	N	O
21	by	N	O
22	2	N	O
23	to	N	O
24	3	N	O
25	years	N	O
26	of	N	O
27	anastrozole/exemestane	N	O
28	,	N	O
29	we	N	O
30	designed	N	O
31	a	N	O
32	multicenter	N	O
33	double-blind	N	O
34	randomized	N	O
35	controlled	N	O
36	trial	N	O
37	in	N	O
38	women	N	O
39	taking	N	O
40	tamoxifen	N	O
41	with	N	O
42	a	N	O
43	thickened	N	O
44	endometrium	N	O
45	to	N	O
46	compare	N	O
47	uterine	N	O
48	and	N	O
49	quality-of-life	N	O
50	parameters	N	O
51	between	N	O
52	those	N	O
53	switching	N	O
54	to	N	O
55	anastrozole	N	O
56	and	N	O
57	those	N	O
58	continuing	N	O
59	tamoxifen	N	O
60	.	N	O

61	Asymptomatic	N	O
62	postmenopausal	N	O
63	women	N	O
64	who	N	O
65	took	N	O
66	adjuvant	N	O
67	tamoxifen	N	O
68	for	N	O
69	2	N	O
70	to	N	O
71	3	N	O
72	years	N	O
73	for	N	O
74	operable	N	O
75	breast	N	O
76	cancer	N	O
77	with	N	O
78	a	N	O
79	double	N	O
80	endometrial	N	O
81	thickness	N	O
82	greater	N	O
83	than	N	O
84	7	N	O
85	mm	N	O
86	were	N	O
87	randomized	N	O
88	to	N	O
89	20	N	O
90	mg	N	O
91	tamoxifen	N	O
92	or	N	O
93	1	N	O
94	mg	N	O
95	anastrozole	N	O
96	for	N	O
97	the	N	O
98	remaining	N	O
99	duration	N	O
100	,	N	O
101	totaling	N	O
102	5	N	O
103	years	N	O
104	.	N	O

105	Tablets	N	O
106	were	N	O
107	unrecognizable	N	O
108	for	N	O
109	drug	N	O
110	assignment	N	O
111	.	N	O

112	The	N	O
113	primary	N	O
114	endpoints	N	O
115	were	N	O
116	the	N	O
117	differences	N	O
118	in	N	O
119	double	N	O
120	endometrial	N	O
121	thickness	N	O
122	and	N	O
123	uterine	N	O
124	volume	N	O
125	after	N	O
126	1	N	O
127	year	N	O
128	.	N	O

129	Uterine	N	O
130	and	N	O
131	quality-of-life	N	O
132	data	N	O
133	were	N	O
134	analyzed	N	O
135	using	N	O
136	regression	N	O
137	methods	N	O
138	,	N	O
139	and	N	O
140	missing	N	O
141	values	N	O
142	were	N	O
143	handled	N	O
144	using	N	O
145	multiple	N	O
146	imputation	N	O
147	.	N	O

148	Seventy-two	N	O
149	women	N	O
150	(	N	O
151	median	N	O
152	age	N	O
153	,	N	O
154	60	N	O
155	y	N	O
156	)	N	O
157	were	N	O
158	randomized	N	O
159	in	N	O
160	five	N	O
161	hospitals	N	O
162	.	N	O

163	Relative	N	I-Premise
164	to	N	I-Premise
165	women	N	I-Premise
166	continuing	N	I-Premise
167	tamoxifen	N	I-Premise
168	,	N	I-Premise
169	women	N	I-Premise
170	switching	N	I-Premise
171	to	N	I-Premise
172	anastrozole	N	I-Premise
173	experienced	N	I-Premise
174	a	N	I-Premise
175	decrease	N	I-Premise
176	of	N	I-Premise
177	53	N	I-Premise
178	%	N	I-Premise
179	(	N	I-Premise
180	95	N	I-Premise
181	%	N	I-Premise
182	CI	N	I-Premise
183	,	N	I-Premise
184	41	N	I-Premise
185	%	N	I-Premise
186	-63	N	I-Premise
187	%	N	I-Premise
188	)	N	I-Premise
189	in	N	I-Premise
190	double	N	I-Premise
191	endometrial	N	I-Premise
192	thickness	N	I-Premise
193	and	N	I-Premise
194	a	N	I-Premise
195	decrease	N	I-Premise
196	of	N	I-Premise
197	51	N	I-Premise
198	%	N	I-Premise
199	(	N	I-Premise
200	95	N	I-Premise
201	%	N	I-Premise
202	CI	N	I-Premise
203	,	N	I-Premise
204	39	N	I-Premise
205	%	N	I-Premise
206	-60	N	I-Premise
207	%	N	I-Premise
208	)	N	I-Premise
209	in	N	I-Premise
210	uterine	N	I-Premise
211	volume	N	I-Premise
212	.	N	I-Premise

213	Vaginal	N	I-Premise
214	dryness	N	I-Premise
215	(	N	I-Premise
216	b	N	I-Premise
217	=	N	I-Premise
218	0.064	N	I-Premise
219	;	N	I-Premise
220	95	N	I-Premise
221	%	N	I-Premise
222	CI	N	I-Premise
223	,	N	I-Premise
224	0.016-0.112	N	I-Premise
225	)	N	I-Premise
226	and	N	I-Premise
227	sexual	N	I-Premise
228	problems	N	I-Premise
229	(	N	I-Premise
230	b	N	I-Premise
231	=	N	I-Premise
232	0.054	N	I-Premise
233	;	N	I-Premise
234	95	N	I-Premise
235	%	N	I-Premise
236	CI	N	I-Premise
237	,	N	I-Premise
238	0.007-0.102	N	I-Premise
239	)	N	I-Premise
240	increased	N	I-Premise
241	in	N	I-Premise
242	women	N	I-Premise
243	taking	N	I-Premise
244	anastrozole	N	I-Premise
245	compared	N	I-Premise
246	with	N	I-Premise
247	women	N	I-Premise
248	taking	N	I-Premise
249	tamoxifen	N	I-Premise
250	.	N	I-Premise

251	Treatment	N	I-Premise
252	arms	N	I-Premise
253	did	N	I-Premise
254	not	N	I-Premise
255	differ	N	I-Premise
256	regarding	N	I-Premise
257	withdrawal	N	I-Premise
258	rate	N	I-Premise
259	and	N	I-Premise
260	the	N	I-Premise
261	experience	N	I-Premise
262	of	N	I-Premise
263	(	N	I-Premise
264	serious	N	I-Premise
265	)	N	I-Premise
266	adverse	N	I-Premise
267	events	N	I-Premise
268	.	N	I-Premise

269	Despite	N	O
270	premature	N	O
271	trial	N	O
272	closure	N	O
273	,	N	O
274	our	N	O
275	data	N	O
276	provided	N	O
277	valuable	N	O
278	insights	N	O
279	.	N	O

280	Switching	N	I-Claim
281	to	N	I-Claim
282	anastrozole	N	I-Claim
283	strongly	N	I-Claim
284	decreased	N	I-Claim
285	the	N	I-Claim
286	endometrial	N	I-Claim
287	thickness	N	I-Claim
288	and	N	I-Claim
289	uterine	N	I-Claim
290	volume	N	I-Claim
291	but	N	I-Claim
292	increased	N	I-Claim
293	sexual	N	I-Claim
294	disturbances	N	I-Claim
295	.	N	I-Claim

296	Safe	N	I-MajorClaim
297	and	N	I-MajorClaim
298	effective	N	I-MajorClaim
299	interventions	N	I-MajorClaim
300	are	N	I-MajorClaim
301	needed	N	I-MajorClaim
302	to	N	I-MajorClaim
303	alleviate	N	I-MajorClaim
304	sexual	N	I-MajorClaim
305	dysfunction	N	I-MajorClaim
306	.	N	I-MajorClaim

1	Systematic	N	I-MajorClaim
2	assessment	N	I-MajorClaim
3	is	N	I-MajorClaim
4	vital	N	I-MajorClaim
5	to	N	I-MajorClaim
6	palliative	N	I-MajorClaim
7	care	N	I-MajorClaim
8	,	N	O
9	but	N	O
10	documentation	N	O
11	confirming	N	O
12	completion	N	O
13	of	N	O
14	systematic	N	O
15	assessment	N	O
16	in	N	O
17	hospice	N	O
18	settings	N	O
19	is	N	O
20	often	N	O
21	inadequate	N	O
22	or	N	O
23	absent	N	O
24	.	N	O

25	The	N	O
26	objective	N	O
27	of	N	O
28	the	N	O
29	study	N	O
30	was	N	O
31	to	N	O
32	determine	N	O
33	the	N	O
34	efficacy	N	O
35	of	N	O
36	systematic	N	O
37	feedback	N	O
38	from	N	O
39	standardized	N	O
40	assessment	N	O
41	tools	N	O
42	for	N	O
43	hospice	N	O
44	patient-caregiver	N	O
45	dyads	N	O
46	in	N	O
47	improving	N	O
48	hospice	N	O
49	outcomes	N	O
50	compared	N	O
51	with	N	O
52	the	N	O
53	usual	N	O
54	clinical	N	O
55	practice	N	O
56	.	N	O

57	The	N	O
58	sample	N	O
59	of	N	O
60	patients	N	O
61	(	N	O
62	n	N	O
63	=	N	O
64	709	N	O
65	)	N	O
66	newly	N	O
67	admitted	N	O
68	to	N	O
69	hospice	N	O
70	home	N	O
71	care	N	O
72	in	N	O
73	2	N	O
74	hospices	N	O
75	had	N	O
76	designated	N	O
77	family	N	O
78	caregivers	N	O
79	.	N	O

80	The	N	O
81	interdisciplinary	N	O
82	teams	N	O
83	(	N	O
84	IDTs	N	O
85	)	N	O
86	caring	N	O
87	for	N	O
88	these	N	O
89	dyads	N	O
90	were	N	O
91	randomly	N	O
92	assigned	N	O
93	to	N	O
94	either	N	O
95	experimental	N	O
96	(	N	O
97	n	N	O
98	=	N	O
99	338	N	O
100	)	N	O
101	or	N	O
102	control	N	O
103	(	N	O
104	n	N	O
105	=	N	O
106	371	N	O
107	)	N	O
108	conditions	N	O
109	.	N	O

110	Data	N	O
111	were	N	O
112	collected	N	O
113	from	N	O
114	both	N	O
115	groups	N	O
116	of	N	O
117	dyads	N	O
118	using	N	O
119	standardized	N	O
120	assessments	N	O
121	on	N	O
122	admission	N	O
123	and	N	O
124	1	N	O
125	week	N	O
126	after	N	O
127	each	N	O
128	of	N	O
129	the	N	O
130	first	N	O
131	2	N	O
132	IDT	N	O
133	meetings	N	O
134	in	N	O
135	which	N	O
136	these	N	O
137	dyads	N	O
138	were	N	O
139	discussed	N	O
140	.	N	O

141	The	N	O
142	experimental	N	O
143	intervention	N	O
144	consisted	N	O
145	of	N	O
146	reporting	N	O
147	data	N	O
148	from	N	O
149	the	N	O
150	standardized	N	O
151	assessments	N	O
152	to	N	O
153	the	N	O
154	IDTs	N	O
155	.	N	O

156	Results	N	I-Premise
157	showed	N	I-Premise
158	improved	N	I-Premise
159	patient	N	I-Premise
160	depression	N	I-Premise
161	(	N	I-Premise
162	P	N	I-Premise
163	<	N	I-Premise
164	.001	N	I-Premise
165	)	N	I-Premise
166	as	N	I-Premise
167	a	N	I-Premise
168	result	N	I-Premise
169	of	N	I-Premise
170	the	N	I-Premise
171	intervention	N	I-Premise
172	and	N	I-Premise
173	improvement	N	I-Premise
174	in	N	I-Premise
175	both	N	I-Premise
176	groups	N	I-Premise
177	in	N	I-Premise
178	patients	N	I-Premise
179	'	N	I-Premise
180	quality	N	I-Premise
181	of	N	I-Premise
182	life	N	I-Premise
183	(	N	I-Premise
184	P	N	I-Premise
185	<	N	I-Premise
186	.001	N	I-Premise
187	)	N	I-Premise
188	.	N	I-Premise

189	No	N	I-Premise
190	other	N	I-Premise
191	patient	N	I-Premise
192	outcomes	N	I-Premise
193	(	N	I-Premise
194	symptom	N	I-Premise
195	distress	N	I-Premise
196	,	N	I-Premise
197	spiritual	N	I-Premise
198	needs	N	I-Premise
199	)	N	I-Premise
200	or	N	I-Premise
201	caregiver	N	I-Premise
202	outcomes	N	I-Premise
203	(	N	I-Premise
204	depression	N	I-Premise
205	,	N	I-Premise
206	support	N	I-Premise
207	,	N	I-Premise
208	spiritual	N	I-Premise
209	needs	N	I-Premise
210	)	N	I-Premise
211	were	N	I-Premise
212	significantly	N	I-Premise
213	different	N	I-Premise
214	.	N	I-Premise

215	Assessment	N	O
216	of	N	O
217	depression	N	O
218	added	N	O
219	to	N	O
220	usual	N	O
221	care	N	O
222	probably	N	O
223	had	N	O
224	an	N	O
225	effect	N	O
226	because	N	O
227	it	N	O
228	is	N	O
229	not	N	O
230	normally	N	O
231	a	N	O
232	focus	N	O
233	of	N	O
234	hospice	N	O
235	staff	N	O
236	.	N	O

237	Hospice	N	I-Premise
238	care	N	I-Premise
239	was	N	I-Premise
240	so	N	I-Premise
241	good	N	I-Premise
242	during	N	I-Premise
243	the	N	I-Premise
244	study	N	I-Premise
245	that	N	I-Premise
246	overall	N	I-Premise
247	quality	N	I-Premise
248	of	N	I-Premise
249	life	N	I-Premise
250	improved	N	I-Premise
251	as	N	I-Premise
252	a	N	I-Premise
253	result	N	I-Premise
254	of	N	I-Premise
255	standard	N	I-Premise
256	care	N	I-Premise
257	and	N	I-Premise
258	left	N	I-Premise
259	little	N	I-Premise
260	room	N	I-Premise
261	for	N	I-Premise
262	improvement	N	I-Premise
263	in	N	I-Premise
264	other	N	I-Premise
265	variables	N	I-Premise
266	.	N	I-Premise

267	Systematic	N	I-Claim
268	assessment	N	I-Claim
269	of	N	I-Claim
270	depression	N	I-Claim
271	is	N	I-Claim
272	needed	N	I-Claim
273	in	N	I-Claim
274	hospice	N	I-Claim
275	patients	N	I-Claim
276	.	N	I-Claim

277	No	N	O
278	caregiver	N	O
279	variables	N	O
280	changed	N	O
281	,	N	O
282	which	N	O
283	may	N	O
284	indicate	N	O
285	a	N	O
286	need	N	O
287	for	N	O
288	a	N	O
289	focus	N	O
290	on	N	O
291	caregivers	N	O
292	.	N	O

1	Serum	N	O
2	CA125	N	O
3	concentration	N	O
4	often	N	O
5	rises	N	O
6	several	N	O
7	months	N	O
8	before	N	O
9	clinical	N	O
10	or	N	O
11	symptomatic	N	O
12	relapse	N	O
13	in	N	O
14	women	N	O
15	with	N	O
16	ovarian	N	O
17	cancer	N	O
18	.	N	O

19	In	N	O
20	the	N	O
21	MRC	N	O
22	OV05/EORTC	N	O
23	55955	N	O
24	collaborative	N	O
25	trial	N	O
26	,	N	O
27	we	N	O
28	aimed	N	O
29	to	N	O
30	establish	N	O
31	the	N	O
32	benefits	N	O
33	of	N	O
34	early	N	O
35	treatment	N	O
36	on	N	O
37	the	N	O
38	basis	N	O
39	of	N	O
40	increased	N	O
41	CA125	N	O
42	concentrations	N	O
43	compared	N	O
44	with	N	O
45	delayed	N	O
46	treatment	N	O
47	on	N	O
48	the	N	O
49	basis	N	O
50	of	N	O
51	clinical	N	O
52	recurrence	N	O
53	.	N	O

54	Women	N	O
55	with	N	O
56	ovarian	N	O
57	cancer	N	O
58	in	N	O
59	complete	N	O
60	remission	N	O
61	after	N	O
62	first-line	N	O
63	platinum-based	N	O
64	chemotherapy	N	O
65	and	N	O
66	a	N	O
67	normal	N	O
68	CA125	N	O
69	concentration	N	O
70	were	N	O
71	registered	N	O
72	for	N	O
73	this	N	O
74	randomised	N	O
75	controlled	N	O
76	trial	N	O
77	.	N	O

78	Clinical	N	O
79	examination	N	O
80	and	N	O
81	CA125	N	O
82	measurement	N	O
83	were	N	O
84	done	N	O
85	every	N	O
86	3	N	O
87	months	N	O
88	.	N	O

89	Patients	N	O
90	and	N	O
91	investigators	N	O
92	were	N	O
93	masked	N	O
94	to	N	O
95	CA125	N	O
96	results	N	O
97	,	N	O
98	which	N	O
99	were	N	O
100	monitored	N	O
101	by	N	O
102	coordinating	N	O
103	centres	N	O
104	.	N	O

105	If	N	O
106	CA125	N	O
107	concentration	N	O
108	exceeded	N	O
109	twice	N	O
110	the	N	O
111	upper	N	O
112	limit	N	O
113	of	N	O
114	normal	N	O
115	,	N	O
116	patients	N	O
117	were	N	O
118	randomly	N	O
119	assigned	N	O
120	(	N	O
121	1:1	N	O
122	)	N	O
123	by	N	O
124	minimisation	N	O
125	to	N	O
126	early	N	O
127	or	N	O
128	delayed	N	O
129	chemotherapy	N	O
130	.	N	O

131	Patients	N	O
132	and	N	O
133	clinical	N	O
134	sites	N	O
135	were	N	O
136	informed	N	O
137	of	N	O
138	allocation	N	O
139	to	N	O
140	early	N	O
141	treatment	N	O
142	,	N	O
143	and	N	O
144	treatment	N	O
145	was	N	O
146	started	N	O
147	as	N	O
148	soon	N	O
149	as	N	O
150	possible	N	O
151	within	N	O
152	28	N	O
153	days	N	O
154	of	N	O
155	the	N	O
156	increased	N	O
157	CA125	N	O
158	measurement	N	O
159	.	N	O

160	Patients	N	O
161	assigned	N	O
162	to	N	O
163	delayed	N	O
164	treatment	N	O
165	continued	N	O
166	masked	N	O
167	CA125	N	O
168	measurements	N	O
169	,	N	O
170	with	N	O
171	treatment	N	O
172	commencing	N	O
173	at	N	O
174	clinical	N	O
175	or	N	O
176	symptomatic	N	O
177	relapse	N	O
178	.	N	O

179	All	N	O
180	patients	N	O
181	were	N	O
182	treated	N	O
183	according	N	O
184	to	N	O
185	standard	N	O
186	local	N	O
187	practice	N	O
188	.	N	O

189	The	N	O
190	primary	N	O
191	outcome	N	O
192	was	N	O
193	overall	N	O
194	survival	N	O
195	.	N	O

196	Analysis	N	O
197	was	N	O
198	by	N	O
199	intention	N	O
200	to	N	O
201	treat	N	O
202	.	N	O

203	This	N	O
204	study	N	O
205	is	N	O
206	registered	N	O
207	,	N	O
208	ISRCTN87786644	N	O
209	.	N	O

210	1442	N	O
211	patients	N	O
212	were	N	O
213	registered	N	O
214	for	N	O
215	the	N	O
216	trial	N	O
217	,	N	O
218	of	N	O
219	whom	N	O
220	529	N	O
221	were	N	O
222	randomly	N	O
223	assigned	N	O
224	to	N	O
225	treatment	N	O
226	groups	N	O
227	and	N	O
228	were	N	O
229	included	N	O
230	in	N	O
231	our	N	O
232	analysis	N	O
233	(	N	O
234	265	N	O
235	early	N	O
236	,	N	O
237	264	N	O
238	delayed	N	O
239	)	N	O
240	.	N	O

241	With	N	I-Premise
242	a	N	I-Premise
243	median	N	I-Premise
244	follow-up	N	I-Premise
245	of	N	I-Premise
246	569	N	I-Premise
247	months	N	I-Premise
248	(	N	I-Premise
249	IQR	N	I-Premise
250	374-818	N	I-Premise
251	)	N	I-Premise
252	from	N	I-Premise
253	randomisation	N	I-Premise
254	and	N	I-Premise
255	370	N	I-Premise
256	deaths	N	I-Premise
257	(	N	I-Premise
258	186	N	I-Premise
259	early	N	I-Premise
260	,	N	I-Premise
261	184	N	I-Premise
262	delayed	N	I-Premise
263	)	N	I-Premise
264	,	N	I-Premise
265	there	N	I-Premise
266	was	N	I-Premise
267	no	N	I-Premise
268	evidence	N	I-Premise
269	of	N	I-Premise
270	a	N	I-Premise
271	difference	N	I-Premise
272	in	N	I-Premise
273	overall	N	I-Premise
274	survival	N	I-Premise
275	between	N	I-Premise
276	early	N	I-Premise
277	and	N	I-Premise
278	delayed	N	I-Premise
279	treatment	N	I-Premise
280	(	N	I-Premise
281	HR	N	I-Premise
282	098	N	I-Premise
283	,	N	I-Premise
284	95	N	I-Premise
285	%	N	I-Premise
286	CI	N	I-Premise
287	080-120	N	I-Premise
288	,	N	I-Premise
289	p=085	N	I-Premise
290	)	N	I-Premise
291	.	N	I-Premise

292	Median	N	I-Premise
293	survival	N	I-Premise
294	from	N	I-Premise
295	randomisation	N	I-Premise
296	was	N	I-Premise
297	257	N	I-Premise
298	months	N	I-Premise
299	(	N	I-Premise
300	95	N	I-Premise
301	%	N	I-Premise
302	CI	N	I-Premise
303	230-279	N	I-Premise
304	)	N	I-Premise
305	for	N	I-Premise
306	patients	N	I-Premise
307	on	N	I-Premise
308	early	N	I-Premise
309	treatment	N	I-Premise
310	and	N	I-Premise
311	271	N	I-Premise
312	months	N	I-Premise
313	(	N	I-Premise
314	228-309	N	I-Premise
315	)	N	I-Premise
316	for	N	I-Premise
317	those	N	I-Premise
318	on	N	I-Premise
319	delayed	N	I-Premise
320	treatment	N	I-Premise
321	.	N	I-Premise

322	Our	N	I-Claim
323	findings	N	I-Claim
324	showed	N	I-Claim
325	no	N	I-Claim
326	evidence	N	I-Claim
327	of	N	I-Claim
328	a	N	I-Claim
329	survival	N	I-Claim
330	benefit	N	I-Claim
331	with	N	I-Claim
332	early	N	I-Claim
333	treatment	N	I-Claim
334	of	N	I-Claim
335	relapse	N	I-Claim
336	on	N	I-Claim
337	the	N	I-Claim
338	basis	N	I-Claim
339	of	N	I-Claim
340	a	N	I-Claim
341	raised	N	I-Claim
342	CA125	N	I-Claim
343	concentration	N	I-Claim
344	alone	N	I-Claim
345	,	N	I-Claim
346	and	N	I-Claim
347	therefore	N	I-Claim
348	the	N	I-Claim
349	value	N	I-Claim
350	of	N	I-Claim
351	routine	N	I-Claim
352	measurement	N	I-Claim
353	of	N	I-Claim
354	CA125	N	I-Claim
355	in	N	I-Claim
356	the	N	I-Claim
357	follow-up	N	I-Claim
358	of	N	I-Claim
359	patients	N	I-Claim
360	with	N	I-Claim
361	ovarian	N	I-Claim
362	cancer	N	I-Claim
363	who	N	I-Claim
364	attain	N	I-Claim
365	a	N	I-Claim
366	complete	N	I-Claim
367	response	N	I-Claim
368	after	N	I-Claim
369	first-line	N	I-Claim
370	treatment	N	I-Claim
371	is	N	I-Claim
372	not	N	I-Claim
373	proven	N	I-Claim
374	.	N	I-Claim

1	Chemotherapy-induced	N	O
2	anemia	N	O
3	(	N	O
4	CIA	N	O
5	)	N	O
6	is	N	O
7	responsive	N	O
8	to	N	O
9	treatment	N	O
10	with	N	O
11	erythropoiesis-stimulating	N	O
12	agents	N	O
13	(	N	O
14	ESAs	N	O
15	)	N	O
16	such	N	O
17	as	N	O
18	darbepoetin	N	O
19	alfa	N	O
20	.	N	O

21	Administration	N	O
22	of	N	O
23	ESAs	N	O
24	on	N	O
25	a	N	O
26	synchronous	N	O
27	schedule	N	O
28	with	N	O
29	chemotherapy	N	O
30	administration	N	O
31	could	N	O
32	benefit	N	O
33	patients	N	O
34	by	N	O
35	reducing	N	O
36	clinic	N	O
37	visits	N	O
38	and	N	O
39	potentially	N	O
40	enhancing	N	O
41	on-time	N	O
42	chemotherapy	N	O
43	delivery	N	O
44	.	N	O

45	This	N	O
46	phase	N	O
47	2	N	O
48	,	N	O
49	25-week	N	O
50	,	N	O
51	open-label	N	O
52	study	N	O
53	evaluated	N	O
54	the	N	O
55	noninferiority	N	O
56	of	N	O
57	darbepoetin	N	O
58	alfa	N	O
59	administered	N	O
60	weekly	N	O
61	vs.	N	O
62	as	N	O
63	an	N	O
64	extended	N	O
65	dosing	N	O
66	schedule	N	O
67	(	N	O
68	every	N	O
69	2	N	O
70	or	N	O
71	3	N	O
72	weeks	N	O
73	)	N	O
74	in	N	O
75	patients	N	O
76	with	N	O
77	CIA	N	O
78	.	N	O

79	Patients	N	O
80	were	N	O
81	randomized	N	O
82	1:1	N	O
83	to	N	O
84	an	N	O
85	extended	N	O
86	dosing	N	O
87	schedule	N	O
88	(	N	O
89	EDS	N	O
90	:	N	O
91	darbepoetin	N	O
92	alfa	N	O
93	300	N	O
94	g	N	O
95	Q2W	N	O
96	if	N	O
97	chemotherapy	N	O
98	was	N	O
99	QW	N	O
100	,	N	O
101	Q2W	N	O
102	,	N	O
103	or	N	O
104	Q4W	N	O
105	or	N	O
106	darbepoetin	N	O
107	alfa	N	O
108	500	N	O
109	g	N	O
110	Q3W	N	O
111	if	N	O
112	chemotherapy	N	O
113	was	N	O
114	Q3W	N	O
115	)	N	O
116	or	N	O
117	weekly	N	O
118	(	N	O
119	150	N	O
120	g	N	O
121	QW	N	O
122	regardless	N	O
123	of	N	O
124	chemotherapy	N	O
125	schedule	N	O
126	)	N	O
127	.	N	O

128	Stratification	N	O
129	factors	N	O
130	included	N	O
131	chemotherapy	N	O
132	cycle	N	O
133	length	N	O
134	,	N	O
135	screening	N	O
136	hemoglobin	N	O
137	(	N	O
138	<	N	O
139	10	N	O
140	g/dL	N	O
141	vs.	N	O
142	10	N	O
143	g/dL	N	O
144	)	N	O
145	,	N	O
146	and	N	O
147	tumor	N	O
148	type	N	O
149	(	N	O
150	lung/gynecological	N	O
151	vs.	N	O
152	other	N	O
153	nonmyeloid	N	O
154	malignancies	N	O
155	)	N	O
156	.	N	O

157	The	N	O
158	primary	N	O
159	endpoint	N	O
160	was	N	O
161	change	N	O
162	in	N	O
163	hemoglobin	N	O
164	from	N	O
165	baseline	N	O
166	to	N	O
167	Week	N	O
168	13	N	O
169	.	N	O

170	Seven	N	O
171	hundred	N	O
172	fifty-two	N	O
173	patients	N	O
174	(	N	O
175	374	N	O
176	QW	N	O
177	patients	N	O
178	;	N	O
179	378	N	O
180	EDS	N	O
181	patients	N	O
182	)	N	O
183	received	N	O
184	1	N	O
185	dose	N	O
186	of	N	O
187	darbepoetin	N	O
188	alfa	N	O
189	and	N	O
190	were	N	O
191	included	N	O
192	in	N	O
193	the	N	O
194	analysis	N	O
195	.	N	O

196	Demographics	N	O
197	and	N	O
198	disease	N	O
199	state	N	O
200	were	N	O
201	similar	N	O
202	between	N	O
203	groups	N	O
204	.	N	O

205	Seventy-one	N	I-Premise
206	percent	N	I-Premise
207	of	N	I-Premise
208	patients	N	I-Premise
209	in	N	I-Premise
210	the	N	I-Premise
211	EDS	N	I-Premise
212	group	N	I-Premise
213	and	N	I-Premise
214	76	N	I-Premise
215	%	N	I-Premise
216	in	N	I-Premise
217	the	N	I-Premise
218	QW	N	I-Premise
219	group	N	I-Premise
220	achieved	N	I-Premise
221	the	N	I-Premise
222	target	N	I-Premise
223	hemoglobin	N	I-Premise
224	of	N	I-Premise
225	11.0	N	I-Premise
226	g/dL	N	I-Premise
227	.	N	I-Premise

228	There	N	O
229	was	N	O
230	a	N	O
231	minimal	N	O
232	difference	N	O
233	in	N	O
234	the	N	O
235	primary	N	O
236	endpoint	N	O
237	of	N	O
238	mean	N	O
239	change	N	O
240	in	N	O
241	hemoglobin	N	O
242	(	N	O
243	baseline	N	O
244	to	N	O
245	Week	N	O
246	13	N	O
247	)	N	O
248	between	N	O
249	the	N	O
250	QW	N	O
251	and	N	O
252	the	N	O
253	EDS	N	O
254	groups	N	O
255	(	N	O
256	-0.04	N	O
257	g/dL	N	O
258	;	N	O
259	95	N	O
260	%	N	O
261	confidence	N	O
262	interval	N	O
263	:	N	O
264	-0.26	N	O
265	,	N	O
266	0.17	N	O
267	g/dL	N	O
268	)	N	O
269	.	N	O

270	The	N	O
271	upper	N	O
272	limit	N	O
273	of	N	O
274	the	N	O
275	95	N	O
276	%	N	O
277	confidence	N	O
278	interval	N	O
279	was	N	O
280	less	N	O
281	than	N	O
282	the	N	O
283	prespecified	N	O
284	limit	N	O
285	of	N	O
286	<	N	O
287	0.75	N	O
288	g/dL	N	O
289	,	N	O
290	supporting	N	O
291	noninferiority	N	O
292	of	N	O
293	the	N	O
294	EDS	N	O
295	dosing	N	O
296	schedule	N	O
297	.	N	O

298	Reported	N	I-Premise
299	adverse	N	I-Premise
300	events	N	I-Premise
301	were	N	I-Premise
302	similar	N	I-Premise
303	between	N	I-Premise
304	groups	N	I-Premise
305	.	N	I-Premise

306	A	N	I-Premise
307	slight	N	I-Premise
308	increase	N	I-Premise
309	in	N	I-Premise
310	transfusions	N	I-Premise
311	was	N	I-Premise
312	reported	N	I-Premise
313	in	N	I-Premise
314	the	N	I-Premise
315	QW	N	I-Premise
316	group	N	I-Premise
317	.	N	I-Premise

318	Darbepoetin	N	I-Claim
319	alfa	N	I-Claim
320	,	N	I-Claim
321	when	N	I-Claim
322	administered	N	I-Claim
323	synchronously	N	I-Claim
324	with	N	I-Claim
325	chemotherapy	N	I-Claim
326	,	N	I-Claim
327	on	N	I-Claim
328	an	N	I-Claim
329	EDS	N	I-Claim
330	appears	N	I-Claim
331	to	N	I-Claim
332	be	N	I-Claim
333	similarly	N	I-Claim
334	efficacious	N	I-Claim
335	to	N	I-Claim
336	darbepoetin	N	I-Claim
337	alfa	N	I-Claim
338	weekly	N	I-Claim
339	dosing	N	I-Claim
340	with	N	I-Claim
341	no	N	I-Claim
342	unexpected	N	I-Claim
343	adverse	N	I-Claim
344	events	N	I-Claim
345	.	N	I-Claim

346	This	N	O
347	study	N	O
348	provides	N	O
349	prospective	N	O
350	data	N	O
351	on	N	O
352	how	N	O
353	multiple	N	O
354	dosing	N	O
355	regimens	N	O
356	available	N	O
357	with	N	O
358	darbepoetin	N	O
359	alfa	N	O
360	can	N	O
361	be	N	O
362	synchronized	N	O
363	with	N	O
364	chemotherapy	N	O
365	administered	N	O
366	across	N	O
367	a	N	O
368	range	N	O
369	of	N	O
370	dosing	N	O
371	schedules	N	O
372	.	N	O

1	To	N	O
2	perform	N	O
3	a	N	O
4	randomized	N	O
5	trial	N	O
6	comparing	N	O
7	70	N	O
8	and	N	O
9	80	N	O
10	Gy	N	O
11	radiotherapy	N	O
12	for	N	O
13	prostate	N	O
14	cancer	N	O
15	.	N	O

16	A	N	O
17	total	N	O
18	of	N	O
19	306	N	O
20	patients	N	O
21	with	N	O
22	localized	N	O
23	prostate	N	O
24	cancer	N	O
25	were	N	O
26	randomized	N	O
27	.	N	O

28	No	N	O
29	androgen	N	O
30	deprivation	N	O
31	was	N	O
32	allowed	N	O
33	.	N	O

34	The	N	O
35	primary	N	O
36	endpoint	N	O
37	was	N	O
38	biochemical	N	O
39	relapse	N	O
40	according	N	O
41	to	N	O
42	the	N	O
43	modified	N	O
44	1997-American	N	O
45	Society	N	O
46	for	N	O
47	Therapeutic	N	O
48	Radiology	N	O
49	and	N	O
50	Oncology	N	O
51	and	N	O
52	Phoenix	N	O
53	definitions	N	O
54	.	N	O

55	Toxicity	N	O
56	was	N	O
57	graded	N	O
58	using	N	O
59	the	N	O
60	Radiation	N	O
61	Therapy	N	O
62	Oncology	N	O
63	Group	N	O
64	1991	N	O
65	criteria	N	O
66	and	N	O
67	the	N	O
68	late	N	O
69	effects	N	O
70	on	N	O
71	normal	N	O
72	tissues-subjective	N	O
73	,	N	O
74	objective	N	O
75	,	N	O
76	management	N	O
77	,	N	O
78	analytic	N	O
79	scales	N	O
80	(	N	O
81	LENT-SOMA	N	O
82	)	N	O
83	scales	N	O
84	.	N	O

85	The	N	O
86	patients	N	O
87	'	N	O
88	quality	N	O
89	of	N	O
90	life	N	O
91	was	N	O
92	scored	N	O
93	using	N	O
94	the	N	O
95	European	N	O
96	Organization	N	O
97	for	N	O
98	Research	N	O
99	and	N	O
100	Treatment	N	O
101	of	N	O
102	Cancer	N	O
103	Quality	N	O
104	of	N	O
105	Life	N	O
106	Questionnaire	N	O
107	30-item	N	O
108	cancer-specific	N	O
109	and	N	O
110	25-item	N	O
111	prostate-specific	N	O
112	modules	N	O
113	.	N	O

114	The	N	O
115	median	N	O
116	follow-up	N	O
117	was	N	O
118	61	N	O
119	months	N	O
120	.	N	O

121	According	N	O
122	to	N	O
123	the	N	O
124	1997-American	N	O
125	Society	N	O
126	for	N	O
127	Therapeutic	N	O
128	Radiology	N	O
129	and	N	O
130	Oncology	N	O
131	definition	N	O
132	,	N	O
133	the	N	O
134	5-year	N	O
135	biochemical	N	O
136	relapse	N	O
137	rate	N	O
138	was	N	O
139	39	N	O
140	%	N	O
141	and	N	O
142	28	N	O
143	%	N	O
144	in	N	O
145	the	N	O
146	70-	N	O
147	and	N	O
148	80-Gy	N	O
149	arms	N	O
150	,	N	O
151	respectively	N	O
152	(	N	O
153	p	N	O
154	=	N	O
155	.036	N	O
156	)	N	O
157	.	N	O

158	Using	N	O
159	the	N	O
160	Phoenix	N	O
161	definition	N	O
162	,	N	O
163	the	N	O
164	5-year	N	O
165	biochemical	N	O
166	relapse	N	O
167	rate	N	O
168	was	N	O
169	32	N	O
170	%	N	O
171	and	N	O
172	23.5	N	O
173	%	N	O
174	,	N	O
175	respectively	N	O
176	(	N	O
177	p	N	O
178	=	N	O
179	.09	N	O
180	)	N	O
181	.	N	O

182	The	N	O
183	subgroup	N	O
184	analysis	N	O
185	showed	N	O
186	a	N	O
187	better	N	O
188	biochemical	N	O
189	outcome	N	O
190	for	N	O
191	the	N	O
192	higher	N	O
193	dose	N	O
194	group	N	O
195	with	N	O
196	an	N	O
197	initial	N	O
198	prostate-specific	N	O
199	antigen	N	O
200	level	N	O
201	>	N	O
202	15	N	O
203	ng/mL	N	O
204	.	N	O

205	At	N	O
206	the	N	O
207	last	N	O
208	follow-up	N	O
209	date	N	O
210	,	N	O
211	26	N	O
212	patients	N	O
213	had	N	O
214	died	N	O
215	,	N	O
216	10	N	O
217	of	N	O
218	their	N	O
219	disease	N	O
220	and	N	O
221	none	N	O
222	of	N	O
223	toxicity	N	O
224	,	N	O
225	with	N	O
226	no	N	O
227	differences	N	O
228	between	N	O
229	the	N	O
230	two	N	O
231	arms	N	O
232	.	N	O

233	According	N	I-Premise
234	to	N	I-Premise
235	the	N	I-Premise
236	Radiation	N	I-Premise
237	Therapy	N	I-Premise
238	Oncology	N	I-Premise
239	Group	N	I-Premise
240	scale	N	I-Premise
241	,	N	I-Premise
242	the	N	I-Premise
243	Grade	N	I-Premise
244	2	N	I-Premise
245	or	N	I-Premise
246	greater	N	I-Premise
247	rectal	N	I-Premise
248	toxicity	N	I-Premise
249	rate	N	I-Premise
250	was	N	I-Premise
251	14	N	I-Premise
252	%	N	I-Premise
253	and	N	I-Premise
254	19.5	N	I-Premise
255	%	N	I-Premise
256	for	N	I-Premise
257	the	N	I-Premise
258	70-	N	I-Premise
259	and	N	I-Premise
260	80-Gy	N	I-Premise
261	arms	N	I-Premise
262	(	N	I-Premise
263	p	N	I-Premise
264	=	N	I-Premise
265	.22	N	I-Premise
266	)	N	I-Premise
267	,	N	I-Premise
268	respectively	N	I-Premise
269	.	N	I-Premise

270	The	N	I-Premise
271	Grade	N	I-Premise
272	2	N	I-Premise
273	or	N	I-Premise
274	greater	N	I-Premise
275	urinary	N	I-Premise
276	toxicity	N	I-Premise
277	was	N	I-Premise
278	10	N	I-Premise
279	%	N	I-Premise
280	at	N	I-Premise
281	70	N	I-Premise
282	Gy	N	I-Premise
283	and	N	I-Premise
284	17.5	N	I-Premise
285	%	N	I-Premise
286	at	N	I-Premise
287	80	N	I-Premise
288	Gy	N	I-Premise
289	(	N	I-Premise
290	p	N	I-Premise
291	=	N	I-Premise
292	.046	N	I-Premise
293	)	N	I-Premise
294	.	N	I-Premise

295	Similar	N	I-Premise
296	results	N	I-Premise
297	were	N	I-Premise
298	observed	N	I-Premise
299	using	N	I-Premise
300	the	N	I-Premise
301	LENT-SOMA	N	I-Premise
302	scale	N	I-Premise
303	.	N	I-Premise

304	Bladder	N	I-Premise
305	toxicity	N	I-Premise
306	was	N	I-Premise
307	more	N	I-Premise
308	frequent	N	I-Premise
309	at	N	I-Premise
310	80	N	I-Premise
311	Gy	N	I-Premise
312	than	N	I-Premise
313	at	N	I-Premise
314	70	N	I-Premise
315	Gy	N	I-Premise
316	(	N	I-Premise
317	p	N	I-Premise
318	=	N	I-Premise
319	.039	N	I-Premise
320	)	N	I-Premise
321	.	N	I-Premise

322	The	N	I-Premise
323	quality-of-life	N	I-Premise
324	questionnaire	N	I-Premise
325	results	N	I-Premise
326	before	N	I-Premise
327	and	N	I-Premise
328	5	N	I-Premise
329	years	N	I-Premise
330	after	N	I-Premise
331	treatment	N	I-Premise
332	were	N	I-Premise
333	available	N	I-Premise
334	for	N	I-Premise
335	103	N	I-Premise
336	patients	N	I-Premise
337	with	N	I-Premise
338	no	N	I-Premise
339	differences	N	I-Premise
340	found	N	I-Premise
341	between	N	I-Premise
342	the	N	I-Premise
343	70-	N	I-Premise
344	and	N	I-Premise
345	80-Gy	N	I-Premise
346	arms	N	I-Premise
347	.	N	I-Premise

348	High-dose	N	I-Claim
349	radiotherapy	N	I-Claim
350	provided	N	I-Claim
351	a	N	I-Claim
352	better	N	I-Claim
353	5-year	N	I-Claim
354	biochemical	N	I-Claim
355	outcome	N	I-Claim
356	with	N	I-Claim
357	slightly	N	I-Claim
358	greater	N	I-Claim
359	toxicity	N	I-Claim
360	.	N	I-Claim

1	Numerous	N	O
2	studies	N	O
3	have	N	O
4	examined	N	O
5	the	N	O
6	comorbidity	N	O
7	of	N	O
8	depression	N	O
9	with	N	O
10	cancer	N	O
11	,	N	O
12	and	N	O
13	some	N	O
14	have	N	O
15	indicated	N	O
16	that	N	O
17	depression	N	O
18	may	N	O
19	be	N	O
20	associated	N	O
21	with	N	O
22	cancer	N	O
23	progression	N	O
24	or	N	O
25	survival	N	O
26	.	N	O

27	However	N	O
28	,	N	O
29	few	N	O
30	studies	N	O
31	have	N	O
32	assessed	N	O
33	whether	N	O
34	changes	N	O
35	in	N	O
36	depression	N	O
37	symptoms	N	O
38	are	N	O
39	associated	N	O
40	with	N	O
41	survival	N	O
42	.	N	O

43	In	N	O
44	a	N	O
45	secondary	N	O
46	analysis	N	O
47	of	N	O
48	a	N	O
49	randomized	N	O
50	trial	N	O
51	of	N	O
52	supportive-expressive	N	O
53	group	N	O
54	therapy	N	O
55	,	N	O
56	125	N	O
57	women	N	O
58	with	N	O
59	metastatic	N	O
60	breast	N	O
61	cancer	N	O
62	(	N	O
63	MBC	N	O
64	)	N	O
65	completed	N	O
66	a	N	O
67	depression	N	O
68	symptom	N	O
69	measure	N	O
70	(	N	O
71	Center	N	O
72	for	N	O
73	Epidemiologic	N	O
74	Studies-Depression	N	O
75	Scale	N	O
76	[	N	O
77	CES-D	N	O
78	]	N	O
79	)	N	O
80	at	N	O
81	baseline	N	O
82	and	N	O
83	were	N	O
84	randomly	N	O
85	assigned	N	O
86	to	N	O
87	a	N	O
88	treatment	N	O
89	group	N	O
90	or	N	O
91	to	N	O
92	a	N	O
93	control	N	O
94	group	N	O
95	that	N	O
96	received	N	O
97	educational	N	O
98	materials	N	O
99	.	N	O

100	At	N	O
101	baseline	N	O
102	and	N	O
103	three	N	O
104	follow-up	N	O
105	points	N	O
106	,	N	O
107	101	N	O
108	of	N	O
109	125	N	O
110	women	N	O
111	completed	N	O
112	a	N	O
113	depression	N	O
114	symptom	N	O
115	measure	N	O
116	.	N	O

117	We	N	O
118	used	N	O
119	these	N	O
120	data	N	O
121	in	N	O
122	a	N	O
123	Cox	N	O
124	proportional	N	O
125	hazards	N	O
126	analysis	N	O
127	to	N	O
128	examine	N	O
129	whether	N	O
130	decreasing	N	O
131	depression	N	O
132	symptoms	N	O
133	over	N	O
134	the	N	O
135	first	N	O
136	year	N	O
137	of	N	O
138	the	N	O
139	study	N	O
140	(	N	O
141	the	N	O
142	length	N	O
143	of	N	O
144	the	N	O
145	intervention	N	O
146	)	N	O
147	would	N	O
148	be	N	O
149	associated	N	O
150	with	N	O
151	longer	N	O
152	survival	N	O
153	.	N	O

154	Median	N	I-Premise
155	survival	N	I-Premise
156	time	N	I-Premise
157	was	N	I-Premise
158	53.6	N	I-Premise
159	months	N	I-Premise
160	for	N	I-Premise
161	women	N	I-Premise
162	with	N	I-Premise
163	decreasing	N	I-Premise
164	CES-D	N	I-Premise
165	scores	N	I-Premise
166	over	N	I-Premise
167	1	N	I-Premise
168	year	N	I-Premise
169	and	N	I-Premise
170	25.1	N	I-Premise
171	months	N	I-Premise
172	for	N	I-Premise
173	women	N	I-Premise
174	with	N	I-Premise
175	increasing	N	I-Premise
176	CES-D	N	I-Premise
177	scores	N	I-Premise
178	.	N	I-Premise

179	There	N	I-Premise
180	was	N	I-Premise
181	a	N	I-Premise
182	significant	N	I-Premise
183	effect	N	I-Premise
184	of	N	I-Premise
185	change	N	I-Premise
186	in	N	I-Premise
187	CES-D	N	I-Premise
188	over	N	I-Premise
189	the	N	I-Premise
190	first	N	I-Premise
191	year	N	I-Premise
192	on	N	I-Premise
193	survival	N	I-Premise
194	out	N	I-Premise
195	to	N	I-Premise
196	14	N	I-Premise
197	years	N	I-Premise
198	(	N	I-Premise
199	P	N	I-Premise
200	=	N	I-Premise
201	.007	N	I-Premise
202	)	N	I-Premise
203	but	N	I-Premise
204	no	N	I-Premise
205	significant	N	I-Premise
206	interaction	N	I-Premise
207	between	N	I-Premise
208	treatment	N	I-Premise
209	condition	N	I-Premise
210	and	N	I-Premise
211	CES-D	N	I-Premise
212	change	N	I-Premise
213	on	N	I-Premise
214	survival	N	I-Premise
215	.	N	I-Premise

216	Neither	N	O
217	demographic	N	O
218	nor	N	O
219	medical	N	O
220	variables	N	O
221	explained	N	O
222	this	N	O
223	association	N	O
224	.	N	O

225	Decreasing	N	I-Claim
226	depression	N	I-Claim
227	symptoms	N	I-Claim
228	over	N	I-Claim
229	the	N	I-Claim
230	first	N	I-Claim
231	year	N	I-Claim
232	were	N	I-Claim
233	associated	N	I-Claim
234	with	N	I-Claim
235	longer	N	I-Claim
236	subsequent	N	I-Claim
237	survival	N	I-Claim
238	for	N	I-Claim
239	women	N	I-Claim
240	with	N	I-Claim
241	MBC	N	I-Claim
242	in	N	I-Claim
243	this	N	I-Claim
244	sample	N	I-Claim
245	.	N	I-Claim

246	Further	N	I-Claim
247	research	N	I-Claim
248	is	N	I-Claim
249	necessary	N	I-Claim
250	to	N	I-Claim
251	confirm	N	I-Claim
252	this	N	I-Claim
253	hypothesis	N	I-Claim
254	in	N	I-Claim
255	other	N	I-Claim
256	samples	N	I-Claim
257	,	N	I-Claim
258	and	N	I-Claim
259	causation	N	I-Claim
260	can	N	I-Claim
261	not	N	I-Claim
262	be	N	I-Claim
263	assumed	N	I-Claim
264	based	N	I-Claim
265	on	N	I-Claim
266	this	N	I-Claim
267	analysis	N	I-Claim
268	.	N	I-Claim

1	The	N	O
2	American	N	O
3	College	N	O
4	of	N	O
5	Surgeons	N	O
6	Oncology	N	O
7	Group	N	O
8	phase	N	O
9	III	N	O
10	Surgical	N	O
11	Prostatectomy	N	O
12	Versus	N	O
13	Interstitial	N	O
14	Radiation	N	O
15	Intervention	N	O
16	Trial	N	O
17	comparing	N	O
18	radical	N	O
19	prostatectomy	N	O
20	(	N	O
21	RP	N	O
22	)	N	O
23	and	N	O
24	brachytherapy	N	O
25	(	N	O
26	BT	N	O
27	)	N	O
28	closed	N	O
29	after	N	O
30	2	N	O
31	years	N	O
32	due	N	O
33	to	N	O
34	poor	N	O
35	accrual	N	O
36	.	N	O

37	We	N	O
38	report	N	O
39	health-related	N	O
40	quality	N	O
41	of	N	O
42	life	N	O
43	(	N	O
44	HRQOL	N	O
45	)	N	O
46	at	N	O
47	a	N	O
48	mean	N	O
49	of	N	O
50	5.3	N	O
51	years	N	O
52	for	N	O
53	168	N	O
54	trial-eligible	N	O
55	men	N	O
56	who	N	O
57	either	N	O
58	chose	N	O
59	or	N	O
60	were	N	O
61	randomly	N	O
62	assigned	N	O
63	to	N	O
64	RP	N	O
65	or	N	O
66	BT	N	O
67	following	N	O
68	a	N	O
69	multidisciplinary	N	O
70	educational	N	O
71	session	N	O
72	.	N	O

73	After	N	O
74	initial	N	O
75	lack	N	O
76	of	N	O
77	accrual	N	O
78	,	N	O
79	a	N	O
80	multidisciplinary	N	O
81	educational	N	O
82	session	N	O
83	was	N	O
84	introduced	N	O
85	for	N	O
86	eligible	N	O
87	patients	N	O
88	.	N	O

89	In	N	O
90	all	N	O
91	,	N	O
92	263	N	O
93	men	N	O
94	attended	N	O
95	47	N	O
96	sessions	N	O
97	.	N	O

98	Of	N	O
99	those	N	O
100	,	N	O
101	34	N	O
102	consented	N	O
103	to	N	O
104	random	N	O
105	assignment	N	O
106	,	N	O
107	62	N	O
108	chose	N	O
109	RP	N	O
110	,	N	O
111	and	N	O
112	94	N	O
113	chose	N	O
114	BT	N	O
115	.	N	O

116	Five	N	O
117	years	N	O
118	later	N	O
119	,	N	O
120	these	N	O
121	190	N	O
122	men	N	O
123	underwent	N	O
124	HRQOL	N	O
125	evaluation	N	O
126	by	N	O
127	using	N	O
128	the	N	O
129	cancer-specific	N	O
130	50-item	N	O
131	Expanded	N	O
132	Prostate	N	O
133	Cancer	N	O
134	Index	N	O
135	Composite	N	O
136	,	N	O
137	the	N	O
138	Short	N	O
139	Form	N	O
140	12	N	O
141	Physical	N	O
142	Component	N	O
143	Score	N	O
144	,	N	O
145	and	N	O
146	Short	N	O
147	Form	N	O
148	12	N	O
149	Mental	N	O
150	Component	N	O
151	Score	N	O
152	.	N	O

153	Response	N	O
154	rate	N	O
155	was	N	O
156	88.4	N	O
157	%	N	O
158	.	N	O

159	The	N	O
160	Wilcoxon	N	O
161	rank	N	O
162	sum	N	O
163	test	N	O
164	was	N	O
165	used	N	O
166	to	N	O
167	compare	N	O
168	summary	N	O
169	scores	N	O
170	between	N	O
171	the	N	O
172	two	N	O
173	interventions	N	O
174	.	N	O

175	Of	N	O
176	168	N	O
177	survey	N	O
178	responders	N	O
179	,	N	O
180	60.7	N	O
181	%	N	O
182	had	N	O
183	BT	N	O
184	(	N	O
185	9.5	N	O
186	%	N	O
187	randomly	N	O
188	assigned	N	O
189	)	N	O
190	and	N	O
191	39.3	N	O
192	%	N	O
193	had	N	O
194	RP	N	O
195	(	N	O
196	9.5	N	O
197	%	N	O
198	randomly	N	O
199	assigned	N	O
200	)	N	O
201	.	N	O

202	Median	N	O
203	age	N	O
204	was	N	O
205	61.4	N	O
206	years	N	O
207	for	N	O
208	BT	N	O
209	and	N	O
210	59.4	N	O
211	for	N	O
212	RP	N	O
213	(	N	O
214	P	N	O
215	=	N	O
216	.05	N	O
217	)	N	O
218	.	N	O

219	Median	N	O
220	follow-up	N	O
221	was	N	O
222	5.2	N	O
223	years	N	O
224	(	N	O
225	range	N	O
226	,	N	O
227	3.2	N	O
228	to	N	O
229	6.5	N	O
230	years	N	O
231	)	N	O
232	.	N	O

233	For	N	I-Premise
234	BT	N	I-Premise
235	versus	N	I-Premise
236	RP	N	I-Premise
237	,	N	I-Premise
238	there	N	I-Premise
239	was	N	I-Premise
240	no	N	I-Premise
241	difference	N	I-Premise
242	in	N	I-Premise
243	bowel	N	I-Premise
244	or	N	I-Premise
245	hormonal	N	I-Premise
246	domains	N	I-Premise
247	,	N	I-Premise
248	but	N	O
249	men	N	I-Premise
250	treated	N	I-Premise
251	with	N	I-Premise
252	BT	N	I-Premise
253	scored	N	I-Premise
254	better	N	I-Premise
255	in	N	I-Premise
256	urinary	N	I-Premise
257	(	N	I-Premise
258	91.8	N	I-Premise
259	v	N	I-Premise
260	88.1	N	I-Premise
261	;	N	I-Premise
262	P	N	I-Premise
263	=	N	I-Premise
264	.02	N	I-Premise
265	)	N	I-Premise
266	and	N	I-Premise
267	sexual	N	I-Premise
268	(	N	I-Premise
269	52.5	N	I-Premise
270	v	N	I-Premise
271	39.2	N	I-Premise
272	;	N	I-Premise
273	P	N	I-Premise
274	=	N	I-Premise
275	.001	N	I-Premise
276	)	N	I-Premise
277	domains	N	I-Premise
278	,	N	I-Premise
279	and	N	I-Premise
280	in	N	I-Premise
281	patient	N	I-Premise
282	satisfaction	N	I-Premise
283	(	N	I-Premise
284	93.6	N	I-Premise
285	v	N	I-Premise
286	76.9	N	I-Premise
287	;	N	I-Premise
288	P	N	I-Premise
289	<	N	I-Premise
290	.001	N	I-Premise
291	)	N	I-Premise
292	.	N	I-Premise

293	Although	N	O
294	treatment	N	O
295	allocation	N	O
296	was	N	O
297	random	N	O
298	in	N	O
299	only	N	O
300	19	N	O
301	%	N	O
302	,	N	O
303	all	N	O
304	patients	N	O
305	received	N	O
306	identical	N	O
307	information	N	O
308	in	N	O
309	a	N	O
310	multidisciplinary	N	O
311	setting	N	O
312	before	N	O
313	selecting	N	O
314	RP	N	O
315	,	N	O
316	BT	N	O
317	,	N	O
318	or	N	O
319	random	N	O
320	assignment	N	O
321	.	N	O

322	HRQOL	N	I-Claim
323	evaluated	N	I-Claim
324	3.2	N	I-Claim
325	to	N	I-Claim
326	6.5	N	I-Claim
327	years	N	I-Claim
328	after	N	I-Claim
329	treatment	N	I-Claim
330	showed	N	I-Claim
331	an	N	I-Claim
332	advantage	N	I-Claim
333	for	N	I-Claim
334	BT	N	I-Claim
335	in	N	I-Claim
336	urinary	N	I-Claim
337	and	N	I-Claim
338	sexual	N	I-Claim
339	domains	N	I-Claim
340	and	N	I-Claim
341	in	N	I-Claim
342	patient	N	I-Claim
343	satisfaction	N	I-Claim
344	.	N	I-Claim

1	Bone-cancer	N	O
2	pain	N	O
3	is	N	O
4	a	N	O
5	common	N	O
6	and	N	O
7	refractory	N	O
8	cancer	N	O
9	pain	N	O
10	.	N	O

11	Opioids	N	O
12	,	N	O
13	on	N	O
14	their	N	O
15	own	N	O
16	,	N	O
17	do	N	O
18	not	N	O
19	control	N	O
20	this	N	O
21	type	N	O
22	of	N	O
23	pain	N	O
24	well	N	O
25	enough	N	O
26	,	N	O
27	and	N	O
28	co-analgesics	N	O
29	are	N	O
30	necessary	N	O
31	.	N	O

32	Patients	N	O
33	with	N	O
34	bone	N	O
35	metastasis-related	N	O
36	pain	N	O
37	at	N	O
38	Numeric	N	O
39	Rating	N	O
40	Scale	N	O
41	4	N	O
42	were	N	O
43	enrolled	N	O
44	to	N	O
45	this	N	O
46	randomized	N	O
47	placebo-controlled	N	O
48	trial	N	O
49	.	N	O

50	They	N	O
51	had	N	O
52	also	N	O
53	received	N	O
54	morphine	N	O
55	or	N	O
56	transdermal	N	O
57	fentanyl	N	O
58	patches	N	O
59	for	N	O
60	at	N	O
61	least	N	O
62	1	N	O
63	week	N	O
64	.	N	O

65	During	N	O
66	the	N	O
67	3-day	N	O
68	efficacy	N	O
69	phase	N	O
70	,	N	O
71	patients	N	O
72	received	N	O
73	placebo	N	O
74	or	N	O
75	1-3	N	O
76	tablets	N	O
77	of	N	O
78	oxycodone/paracetamol	N	O
79	(	N	O
80	5/325	N	O
81	mg	N	O
82	)	N	O
83	,	N	O
84	four	N	O
85	times	N	O
86	daily	N	O
87	for	N	O
88	3	N	O
89	days	N	O
90	.	N	O

91	All	N	O
92	patients	N	O
93	kept	N	O
94	a	N	O
95	daily	N	O
96	pain	N	O
97	diary	N	O
98	.	N	O

99	The	N	O
100	primary	N	O
101	endpoint	N	O
102	was	N	O
103	the	N	O
104	Pain	N	O
105	Intensity	N	O
106	Difference	N	O
107	(	N	O
108	PID	N	O
109	)	N	O
110	.	N	O

111	Secondary	N	O
112	endpoints	N	O
113	were	N	O
114	cases	N	O
115	of	N	O
116	breakthrough	N	O
117	pain	N	O
118	and	N	O
119	rescue	N	O
120	morphine	N	O
121	consumption	N	O
122	.	N	O

123	Additional	N	O
124	analyses	N	O
125	included	N	O
126	the	N	O
127	Short	N	O
128	Form-6	N	O
129	Dimensions	N	O
130	(	N	O
131	SF-6D	N	O
132	)	N	O
133	quality-of-life	N	O
134	scale	N	O
135	and	N	O
136	a	N	O
137	general	N	O
138	impression	N	O
139	(	N	O
140	GI	N	O
141	)	N	O
142	of	N	O
143	patient	N	O
144	satisfaction	N	O
145	with	N	O
146	treatment	N	O
147	at	N	O
148	the	N	O
149	end	N	O
150	of	N	O
151	the	N	O
152	phase	N	O
153	.	N	O

154	Of	N	O
155	the	N	O
156	246	N	O
157	patients	N	O
158	in	N	O
159	the	N	O
160	intent-to-treat	N	O
161	set	N	O
162	,	N	O
163	894	N	O
164	%	N	O
165	completed	N	O
166	the	N	O
167	3-day	N	O
168	efficacy	N	O
169	phase	N	O
170	.	N	O

171	PIDs	N	I-Premise
172	were	N	I-Premise
173	09	N	I-Premise
174	and	N	I-Premise
175	03	N	I-Premise
176	in	N	I-Premise
177	the	N	I-Premise
178	oxycodone/paracetamol	N	I-Premise
179	and	N	I-Premise
180	placebo	N	I-Premise
181	groups	N	I-Premise
182	respectively	N	I-Premise
183	,	N	I-Premise
184	on	N	I-Premise
185	day	N	I-Premise
186	1	N	I-Premise
187	(	N	I-Premise
188	P	N	I-Premise
189	<	N	I-Premise
190	0001	N	I-Premise
191	)	N	I-Premise
192	,	N	I-Premise
193	and	N	I-Premise
194	15	N	I-Premise
195	and	N	I-Premise
196	03	N	I-Premise
197	respectively	N	I-Premise
198	on	N	I-Premise
199	day	N	I-Premise
200	3	N	I-Premise
201	(	N	I-Premise
202	P	N	I-Premise
203	<	N	I-Premise
204	0001	N	I-Premise
205	)	N	I-Premise
206	.	N	I-Premise

207	Thirty-eight	N	I-Premise
208	patients	N	I-Premise
209	in	N	I-Premise
210	the	N	I-Premise
211	treatment	N	I-Premise
212	group	N	I-Premise
213	,	N	I-Premise
214	and	N	I-Premise
215	58	N	I-Premise
216	in	N	I-Premise
217	the	N	I-Premise
218	placebo	N	I-Premise
219	group	N	I-Premise
220	,	N	I-Premise
221	suffered	N	I-Premise
222	breakthrough	N	I-Premise
223	pain	N	I-Premise
224	on	N	I-Premise
225	day	N	I-Premise
226	3	N	I-Premise
227	(	N	I-Premise
228	P	N	I-Premise
229	<	N	I-Premise
230	0001	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	The	N	I-Premise
234	SF-6D	N	I-Premise
235	score	N	I-Premise
236	decreased	N	I-Premise
237	to	N	I-Premise
238	212	N	I-Premise
239		N	I-Premise
240	25	N	I-Premise
241	in	N	I-Premise
242	the	N	I-Premise
243	oxycodone/paracetamol	N	I-Premise
244	group	N	I-Premise
245	at	N	I-Premise
246	the	N	I-Premise
247	end	N	I-Premise
248	of	N	I-Premise
249	the	N	I-Premise
250	phase	N	I-Premise
251	(	N	I-Premise
252	P	N	I-Premise
253	=	N	I-Premise
254	0001	N	I-Premise
255	)	N	I-Premise
256	.	N	I-Premise

257	In	N	I-Premise
258	the	N	I-Premise
259	oxycodone/paracetamol	N	I-Premise
260	group	N	I-Premise
261	,	N	I-Premise
262	67	N	I-Premise
263	%	N	I-Premise
264	rated	N	I-Premise
265	GI	N	I-Premise
266	as	N	I-Premise
267	good	N	I-Premise
268	,	N	I-Premise
269	very	N	I-Premise
270	good	N	I-Premise
271	,	N	I-Premise
272	or	N	I-Premise
273	excellent	N	I-Premise
274	.	N	I-Premise

275	Patients	N	I-Claim
276	with	N	I-Claim
277	bone-cancer	N	I-Claim
278	pain	N	I-Claim
279	,	N	I-Claim
280	already	N	I-Claim
281	on	N	I-Claim
282	opioids	N	I-Claim
283	,	N	I-Claim
284	obtain	N	I-Claim
285	clinically	N	I-Claim
286	important	N	I-Claim
287	,	N	I-Claim
288	additional	N	I-Claim
289	pain-control	N	I-Claim
290	,	N	I-Claim
291	with	N	I-Claim
292	regular	N	I-Claim
293	oxycodone/paracetamol	N	I-Claim
294	dosing	N	I-Claim
295	.	N	I-Claim

1	There	N	O
2	are	N	O
3	very	N	O
4	few	N	O
5	randomized	N	O
6	controlled	N	O
7	studies	N	O
8	on	N	O
9	exercise	N	O
10	in	N	O
11	cancer	N	O
12	patients	N	O
13	.	N	O

14	Consequently	N	O
15	,	N	O
16	there	N	O
17	are	N	O
18	no	N	O
19	guidelines	N	O
20	available	N	O
21	with	N	O
22	regard	N	O
23	to	N	O
24	the	N	O
25	exercises	N	O
26	that	N	O
27	can	N	O
28	be	N	O
29	recommended	N	O
30	and	N	O
31	difficulties	N	O
32	are	N	O
33	encountered	N	O
34	in	N	O
35	the	N	O
36	clinical	N	O
37	practice	N	O
38	as	N	O
39	to	N	O
40	which	N	O
41	exercise	N	O
42	is	N	O
43	more	N	O
44	suitable	N	O
45	to	N	O
46	the	N	O
47	patients	N	O
48	.	N	O

49	The	N	O
50	purpose	N	O
51	of	N	O
52	this	N	O
53	study	N	O
54	was	N	O
55	to	N	O
56	investigate	N	O
57	the	N	O
58	impact	N	O
59	of	N	O
60	pilates	N	O
61	exercises	N	O
62	on	N	O
63	physical	N	O
64	performance	N	O
65	,	N	O
66	flexibility	N	O
67	,	N	O
68	fatigue	N	O
69	,	N	O
70	depression	N	O
71	and	N	O
72	quality	N	O
73	of	N	O
74	life	N	O
75	in	N	O
76	women	N	O
77	who	N	O
78	had	N	O
79	been	N	O
80	treated	N	O
81	for	N	O
82	breast	N	O
83	cancer	N	O
84	.	N	O

85	Randomized	N	O
86	controlled	N	O
87	trial	N	O
88	.	N	O

89	Out	N	O
90	patient	N	O
91	group	N	O
92	,	N	O
93	Department	N	O
94	of	N	O
95	Physical	N	O
96	Medicine	N	O
97	and	N	O
98	Rehabilitation	N	O
99	and	N	O
100	Medical	N	O
101	Oncology	N	O
102	Department	N	O
103	,	N	O
104	University	N	O
105	Hospital	N	O
106	.	N	O

107	Fifty-two	N	O
108	patients	N	O
109	with	N	O
110	breast	N	O
111	cancer	N	O
112	were	N	O
113	divided	N	O
114	into	N	O
115	either	N	O
116	pilates	N	O
117	exercise	N	O
118	(	N	O
119	group	N	O
120	1	N	O
121	)	N	O
122	and	N	O
123	control	N	O
124	group	N	O
125	(	N	O
126	group	N	O
127	2	N	O
128	)	N	O
129	.	N	O

130	Patients	N	O
131	in	N	O
132	Group	N	O
133	1	N	O
134	performed	N	O
135	pilates	N	O
136	and	N	O
137	home	N	O
138	exercises	N	O
139	and	N	O
140	patients	N	O
141	in	N	O
142	group	N	O
143	2	N	O
144	performed	N	O
145	only	N	O
146	home	N	O
147	exercises	N	O
148	.	N	O

149	Pilates	N	O
150	exercise	N	O
151	sessions	N	O
152	were	N	O
153	performed	N	O
154	three	N	O
155	times	N	O
156	a	N	O
157	week	N	O
158	for	N	O
159	a	N	O
160	period	N	O
161	of	N	O
162	eight	N	O
163	weeks	N	O
164	in	N	O
165	the	N	O
166	rehabilitation	N	O
167	unit	N	O
168	.	N	O

169	Subjects	N	O
170	were	N	O
171	assessed	N	O
172	before	N	O
173	and	N	O
174	after	N	O
175	rehabilitation	N	O
176	program	N	O
177	,	N	O
178	with	N	O
179	respect	N	O
180	to	N	O
181	,	N	O
182	6-min	N	O
183	walk	N	O
184	test	N	O
185	(	N	O
186	6MWT	N	O
187	)	N	O
188	,	N	O
189	modified	N	O
190	sit	N	O
191	and	N	O
192	reach	N	O
193	test	N	O
194	,	N	O
195	Brief	N	O
196	Fatigue	N	O
197	Inventory	N	O
198	(	N	O
199	BFI	N	O
200	)	N	O
201	,	N	O
202	Beck	N	O
203	Depression	N	O
204	Index	N	O
205	(	N	O
206	BDI	N	O
207	)	N	O
208	and	N	O
209	the	N	O
210	European	N	O
211	Organisation	N	O
212	for	N	O
213	Research	N	O
214	and	N	O
215	Treatment	N	O
216	of	N	O
217	Cancer	N	O
218	Quality	N	O
219	of	N	O
220	Life	N	O
221	C30	N	O
222	(	N	O
223	EORTC	N	O
224	QLQ-C30	N	O
225	)	N	O
226	and	N	O
227	EORTC	N	O
228	QLQ	N	O
229	BR23	N	O
230	.	N	O

231	After	N	I-Premise
232	the	N	I-Premise
233	exercise	N	I-Premise
234	program	N	I-Premise
235	,	N	I-Premise
236	improvements	N	I-Premise
237	were	N	I-Premise
238	observed	N	I-Premise
239	in	N	I-Premise
240	Group	N	I-Premise
241	1	N	I-Premise
242	in	N	I-Premise
243	6-minute	N	I-Premise
244	walk	N	I-Premise
245	test	N	I-Premise
246	,	N	I-Premise
247	BDI	N	I-Premise
248	,	N	I-Premise
249	EORTC	N	I-Premise
250	QLQ-C30	N	I-Premise
251	functional	N	I-Premise
252	,	N	I-Premise
253	and	N	I-Premise
254	EORTC	N	I-Premise
255	QLQ-C30	N	I-Premise
256	BR23	N	I-Premise
257	functional	N	I-Premise
258	scores	N	I-Premise
259	(	N	I-Premise
260	P	N	I-Premise
261	<	N	I-Premise
262	0.05	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	In	N	O
266	contrast	N	O
267	,	N	O
268	no	N	I-Premise
269	significant	N	I-Premise
270	improvement	N	I-Premise
271	was	N	I-Premise
272	observed	N	I-Premise
273	in	N	I-Premise
274	Group	N	I-Premise
275	2	N	I-Premise
276	after	N	I-Premise
277	the	N	I-Premise
278	exercise	N	I-Premise
279	program	N	I-Premise
280	in	N	I-Premise
281	any	N	I-Premise
282	of	N	I-Premise
283	parameters	N	I-Premise
284	in	N	I-Premise
285	comparison	N	I-Premise
286	to	N	I-Premise
287	the	N	I-Premise
288	pre-exercise	N	I-Premise
289	period	N	I-Premise
290	(	N	I-Premise
291	P	N	I-Premise
292	>	N	I-Premise
293	0.05	N	I-Premise
294	)	N	I-Premise
295	.	N	I-Premise

296	When	N	I-Premise
297	the	N	I-Premise
298	two	N	I-Premise
299	exercise	N	I-Premise
300	groups	N	I-Premise
301	were	N	I-Premise
302	compared	N	I-Premise
303	,	N	I-Premise
304	there	N	I-Premise
305	were	N	I-Premise
306	significant	N	I-Premise
307	differences	N	I-Premise
308	in	N	I-Premise
309	6MWT	N	I-Premise
310	in	N	I-Premise
311	pilates-exercise	N	I-Premise
312	group	N	I-Premise
313	(	N	I-Premise
314	P	N	I-Premise
315	<	N	I-Premise
316	0.05	N	I-Premise
317	)	N	I-Premise
318	.	N	I-Premise

319	Pilates	N	I-Claim
320	exercises	N	I-Claim
321	are	N	I-Claim
322	effective	N	I-Claim
323	and	N	I-Claim
324	safe	N	I-Claim
325	in	N	I-Claim
326	female	N	I-Claim
327	breast	N	I-Claim
328	cancer	N	I-Claim
329	patients	N	I-Claim
330	.	N	I-Claim

331	There	N	I-Claim
332	is	N	I-Claim
333	a	N	I-Claim
334	need	N	I-Claim
335	for	N	I-Claim
336	further	N	I-Claim
337	studies	N	I-Claim
338	so	N	I-Claim
339	that	N	I-Claim
340	its	N	I-Claim
341	effect	N	I-Claim
342	can	N	I-Claim
343	be	N	I-Claim
344	confirmed	N	I-Claim
345	.	N	I-Claim

346	This	N	O
347	study	N	O
348	addressed	N	O
349	the	N	O
350	effects	N	O
351	of	N	O
352	pilates	N	O
353	exercise	N	O
354	,	N	O
355	as	N	O
356	a	N	O
357	new	N	O
358	approach	N	O
359	,	N	O
360	on	N	O
361	functional	N	O
362	capacity	N	O
363	,	N	O
364	fatigue	N	O
365	,	N	O
366	depression	N	O
367	and	N	O
368	quality	N	O
369	of	N	O
370	life	N	O
371	in	N	O
372	breast	N	O
373	cancer	N	O
374	patients	N	O
375	in	N	O
376	whom	N	O
377	there	N	O
378	are	N	O
379	doubts	N	O
380	regarding	N	O
381	the	N	O
382	efficacy	N	O
383	and	N	O
384	usefulness	N	O
385	of	N	O
386	the	N	O
387	exercise	N	O
388	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	2-year	N	O
11	functional	N	O
12	performance	N	O
13	and	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	in	N	O
18	patients	N	O
19	with	N	O
20	operable	N	O
21	squamous	N	O
22	cell	N	O
23	carcinoma	N	O
24	of	N	O
25	the	N	O
26	esophagus	N	O
27	,	N	O
28	who	N	O
29	have	N	O
30	received	N	O
31	either	N	O
32	surgery	N	O
33	or	N	O
34	definitive	N	O
35	chemoradiation	N	O
36	(	N	O
37	CRT	N	O
38	)	N	O
39	.	N	O

40	The	N	O
41	functional	N	O
42	outcomes	N	O
43	and	N	O
44	quality	N	O
45	of	N	O
46	life	N	O
47	in	N	O
48	patients	N	O
49	receiving	N	O
50	esophagectomy	N	O
51	or	N	O
52	definitive	N	O
53	CRT	N	O
54	is	N	O
55	uncertain	N	O
56	.	N	O

57	Data	N	O
58	were	N	O
59	extracted	N	O
60	from	N	O
61	the	N	O
62	database	N	O
63	of	N	O
64	a	N	O
65	prospective	N	O
66	randomized	N	O
67	controlled	N	O
68	trial	N	O
69	that	N	O
70	included	N	O
71	patients	N	O
72	with	N	O
73	resectable	N	O
74	mid	N	O
75	or	N	O
76	lower	N	O
77	thoracic	N	O
78	esophageal	N	O
79	cancers	N	O
80	.	N	O

81	The	N	O
82	patients	N	O
83	were	N	O
84	randomized	N	O
85	to	N	O
86	either	N	O
87	standard	N	O
88	esophagectomy	N	O
89	or	N	O
90	definitive	N	O
91	CRT	N	O
92	.	N	O

93	Quality	N	O
94	of	N	O
95	life	N	O
96	assessments	N	O
97	were	N	O
98	performed	N	O
99	using	N	O
100	the	N	O
101	EORTC	N	O
102	QLQ-C30	N	O
103	and	N	O
104	QLQ-OES24	N	O
105	modules	N	O
106	.	N	O

107	Other	N	O
108	functional	N	O
109	assessments	N	O
110	included	N	O
111	pulmonary	N	O
112	and	N	O
113	eating	N	O
114	functions	N	O
115	.	N	O

116	From	N	O
117	July	N	O
118	2000	N	O
119	to	N	O
120	December	N	O
121	2004	N	O
122	,	N	O
123	a	N	O
124	total	N	O
125	of	N	O
126	81	N	O
127	patients	N	O
128	were	N	O
129	enrolled	N	O
130	into	N	O
131	the	N	O
132	study	N	O
133	.	N	O

134	No	N	I-Premise
135	significant	N	I-Premise
136	longitudinal	N	I-Premise
137	changes	N	I-Premise
138	were	N	I-Premise
139	detected	N	I-Premise
140	in	N	I-Premise
141	the	N	I-Premise
142	global	N	I-Premise
143	health	N	I-Premise
144	status	N	I-Premise
145	in	N	I-Premise
146	both	N	I-Premise
147	groups	N	I-Premise
148	upon	N	I-Premise
149	available	N	I-Premise
150	follow-up	N	I-Premise
151	.	N	I-Premise

152	Surgery	N	I-Premise
153	was	N	I-Premise
154	associated	N	I-Premise
155	with	N	I-Premise
156	worsened	N	I-Premise
157	physical	N	I-Premise
158	functioning	N	I-Premise
159	and	N	I-Premise
160	fatigue	N	I-Premise
161	symptoms	N	I-Premise
162	up	N	I-Premise
163	to	N	I-Premise
164	6	N	I-Premise
165	months	N	I-Premise
166	after	N	I-Premise
167	treatment	N	I-Premise
168	(	N	I-Premise
169	P	N	I-Premise
170	<	N	I-Premise
171	0.001	N	I-Premise
172	and	N	I-Premise
173	P	N	I-Premise
174	=	N	I-Premise
175	0.021	N	I-Premise
176	,	N	I-Premise
177	respectively	N	I-Premise
178	)	N	I-Premise
179	and	N	I-Premise
180	these	N	I-Premise
181	scales	N	I-Premise
182	improved	N	I-Premise
183	at	N	I-Premise
184	2	N	I-Premise
185	years	N	I-Premise
186	.	N	I-Premise

187	In	N	I-Premise
188	terms	N	I-Premise
189	of	N	I-Premise
190	pulmonary	N	I-Premise
191	function	N	I-Premise
192	,	N	I-Premise
193	dyspnoic	N	I-Premise
194	and	N	I-Premise
195	coughing	N	I-Premise
196	symptoms	N	I-Premise
197	were	N	I-Premise
198	significantly	N	I-Premise
199	worsened	N	I-Premise
200	3	N	I-Premise
201	months	N	I-Premise
202	after	N	I-Premise
203	surgery	N	I-Premise
204	(	N	I-Premise
205	P	N	I-Premise
206	=	N	I-Premise
207	0.024	N	I-Premise
208	and	N	I-Premise
209	P	N	I-Premise
210	=	N	I-Premise
211	0.036	N	I-Premise
212	,	N	I-Premise
213	respectively	N	I-Premise
214	)	N	I-Premise
215	whereas	N	I-Premise
216	symptoms	N	I-Premise
217	in	N	I-Premise
218	the	N	I-Premise
219	CRT	N	I-Premise
220	group	N	I-Premise
221	progressively	N	I-Premise
222	deteriorated	N	I-Premise
223	over	N	I-Premise
224	time	N	I-Premise
225	.	N	I-Premise

226	Concerning	N	I-Premise
227	the	N	I-Premise
228	eating	N	I-Premise
229	function	N	I-Premise
230	,	N	I-Premise
231	both	N	I-Premise
232	groups	N	I-Premise
233	had	N	I-Premise
234	improvements	N	I-Premise
235	in	N	I-Premise
236	dysphagia	N	I-Premise
237	but	N	I-Premise
238	there	N	I-Premise
239	were	N	I-Premise
240	frequent	N	I-Premise
241	need	N	I-Premise
242	for	N	I-Premise
243	endoscopic	N	I-Premise
244	intervention	N	I-Premise
245	.	N	I-Premise

246	Neither	N	I-Premise
247	surgery	N	I-Premise
248	nor	N	I-Premise
249	definitive	N	I-Premise
250	CRT	N	I-Premise
251	significantly	N	I-Premise
252	impaired	N	I-Premise
253	the	N	I-Premise
254	global	N	I-Premise
255	health	N	I-Premise
256	status	N	I-Premise
257	of	N	I-Premise
258	patients	N	I-Premise
259	.	N	I-Premise

260	Surgery	N	I-Claim
261	was	N	I-Claim
262	associated	N	I-Claim
263	with	N	I-Claim
264	a	N	I-Claim
265	short-term	N	I-Claim
266	negative	N	I-Claim
267	impact	N	I-Claim
268	in	N	I-Claim
269	some	N	I-Claim
270	aspects	N	I-Claim
271	of	N	I-Claim
272	health	N	I-Claim
273	related	N	I-Claim
274	quality	N	I-Claim
275	of	N	I-Claim
276	life	N	I-Claim
277	assessments	N	I-Claim
278	but	N	I-Claim
279	these	N	I-Claim
280	changes	N	I-Claim
281	became	N	I-Claim
282	insignificant	N	I-Claim
283	2	N	I-Claim
284	years	N	I-Claim
285	after	N	I-Claim
286	treatment	N	I-Claim
287	.	N	I-Claim

288	However	N	O
289	,	N	O
290	CRT	N	I-Claim
291	was	N	I-Claim
292	associated	N	I-Claim
293	with	N	I-Claim
294	progressive	N	I-Claim
295	deteriorations	N	I-Claim
296	in	N	I-Claim
297	pulmonary	N	I-Claim
298	function	N	I-Claim
299	in	N	I-Claim
300	the	N	I-Claim
301	longer	N	I-Claim
302	term	N	I-Claim
303	.	N	I-Claim

1	Anti-aromatase	N	I-MajorClaim
2	therapy	N	I-MajorClaim
3	is	N	I-MajorClaim
4	important	N	I-MajorClaim
5	in	N	I-MajorClaim
6	the	N	I-MajorClaim
7	treatment	N	I-MajorClaim
8	of	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	in	N	I-MajorClaim
12	postmenopausal	N	I-MajorClaim
13	women	N	I-MajorClaim
14	but	N	O
15	they	N	O
16	have	N	O
17	effects	N	O
18	on	N	O
19	the	N	O
20	bone	N	O
21	mineral	N	O
22	density	N	O
23	(	N	O
24	BMD	N	O
25	)	N	O
26	and	N	O
27	osteoporosis	N	O
28	.	N	O

29	Cyclooxygenase-2	N	I-Claim
30	(	N	I-Claim
31	COX-2	N	I-Claim
32	)	N	I-Claim
33	inhibitors	N	I-Claim
34	have	N	I-Claim
35	been	N	I-Claim
36	shown	N	I-Claim
37	to	N	I-Claim
38	be	N	I-Claim
39	effective	N	I-Claim
40	in	N	I-Claim
41	chemoprevention	N	I-Claim
42	in	N	I-Claim
43	animal	N	I-Claim
44	and	N	I-Claim
45	clinical	N	I-Claim
46	studies	N	I-Claim
47	.	N	I-Claim

48	A	N	O
49	proof	N	O
50	of	N	O
51	principle	N	O
52	study	N	O
53	was	N	O
54	performed	N	O
55	to	N	O
56	investigate	N	O
57	the	N	O
58	efficacy	N	O
59	of	N	O
60	combing	N	O
61	anti-aromatase	N	O
62	therapy	N	O
63	(	N	O
64	exemestane	N	O
65	)	N	O
66	and	N	O
67	COX-2	N	O
68	inhibitors	N	O
69	neoadjuvantly	N	O
70	.	N	O

71	The	N	O
72	changes	N	O
73	in	N	O
74	the	N	O
75	BMD	N	O
76	,	N	O
77	bone	N	O
78	turnover	N	O
79	proteins	N	O
80	and	N	O
81	quality-of-life	N	O
82	(	N	O
83	QoL	N	O
84	)	N	O
85	were	N	O
86	analyzed	N	O
87	and	N	O
88	presented	N	O
89	here	N	O
90	.	N	O

91	82	N	O
92	postmenopausal	N	O
93	patients	N	O
94	with	N	O
95	histologically	N	O
96	confirmed	N	O
97	invasive	N	O
98	hormone-sensitive	N	O
99	breast	N	O
100	cancers	N	O
101	were	N	O
102	included	N	O
103	for	N	O
104	the	N	O
105	neoadjuvant	N	O
106	therapy	N	O
107	(	N	O
108	NHT	N	O
109	)	N	O
110	.	N	O

111	30	N	O
112	patients	N	O
113	received	N	O
114	exemestane	N	O
115	(	N	O
116	EXE	N	O
117	)	N	O
118	25	N	O
119	mg	N	O
120	daily	N	O
121	and	N	O
122	celecoxib	N	O
123	(	N	O
124	CXB	N	O
125	)	N	O
126	400	N	O
127	mg	N	O
128	twice	N	O
129	daily	N	O
130	(	N	O
131	group	N	O
132	A	N	O
133	)	N	O
134	,	N	O
135	24	N	O
136	patients	N	O
137	received	N	O
138	EXE	N	O
139	25	N	O
140	mg	N	O
141	daily	N	O
142	(	N	O
143	group	N	O
144	B	N	O
145	)	N	O
146	and	N	O
147	28	N	O
148	patients	N	O
149	received	N	O
150	letrozole	N	O
151	(	N	O
152	LET	N	O
153	)	N	O
154	2.5	N	O
155	mg	N	O
156	daily	N	O
157	(	N	O
158	group	N	O
159	C	N	O
160	)	N	O
161	.	N	O

162	The	N	O
163	same	N	O
164	assigned	N	O
165	treatment	N	O
166	was	N	O
167	intended	N	O
168	to	N	O
169	continue	N	O
170	for	N	O
171	2	N	O
172	years	N	O
173	to	N	O
174	study	N	O
175	the	N	O
176	changes	N	O
177	in	N	O
178	the	N	O
179	bone	N	O
180	metabolism	N	O
181	.	N	O

182	BMD	N	O
183	of	N	O
184	48	N	O
185	patients	N	O
186	were	N	O
187	analyzed	N	O
188	;	N	O
189	23	N	O
190	belongs	N	O
191	to	N	O
192	group	N	O
193	A	N	O
194	,	N	O
195	10	N	O
196	to	N	O
197	group	N	O
198	B	N	O
199	and	N	O
200	15	N	O
201	to	N	O
202	group	N	O
203	C.	N	O
204	The	N	O
205	serum	N	O
206	bone	N	O
207	turnover	N	O
208	proteins	N	O
209	bone-specific	N	O
210	alkaline	N	O
211	phosphatase	N	O
212	(	N	O
213	BAP	N	O
214	)	N	O
215	and	N	O
216	carboxyterminal	N	O
217	crosslinked	N	O
218	telopeptide	N	O
219	of	N	O
220	type	N	O
221	I	N	O
222	collagen	N	O
223	(	N	O
224	ICTP	N	O
225	)	N	O
226	,	N	O
227	were	N	O
228	measured	N	O
229	with	N	O
230	commercially	N	O
231	available	N	O
232	test	N	O
233	kits	N	O
234	before	N	O
235	treatment	N	O
236	,	N	O
237	3	N	O
238	months	N	O
239	and	N	O
240	15	N	O
241	months	N	O
242	after	N	O
243	treatment	N	O
244	.	N	O

245	Functional	N	O
246	Assessment	N	O
247	of	N	O
248	Cancer	N	O
249	Therapy	N	O
250	core	N	O
251	questionnaire	N	O
252	(	N	O
253	FACT-G	N	O
254	)	N	O
255	with	N	O
256	its	N	O
257	additional	N	O
258	breast	N	O
259	cancer	N	O
260	subscale	N	O
261	were	N	O
262	performed	N	O
263	at	N	O
264	baseline	N	O
265	,	N	O
266	4	N	O
267	,	N	O
268	8	N	O
269	,	N	O
270	and	N	O
271	12	N	O
272	weeks	N	O
273	after	N	O
274	NHT	N	O
275	.	N	O

276	Difference	N	I-Premise
277	between	N	I-Premise
278	groups	N	I-Premise
279	(	N	I-Premise
280	p=0.007	N	I-Premise
281	)	N	I-Premise
282	for	N	I-Premise
283	BMD	N	I-Premise
284	at	N	I-Premise
285	femur	N	I-Premise
286	was	N	I-Premise
287	significant	N	I-Premise
288	.	N	I-Premise

289	The	N	I-Premise
290	changes	N	I-Premise
291	of	N	I-Premise
292	BMD	N	I-Premise
293	in	N	I-Premise
294	group	N	I-Premise
295	B	N	I-Premise
296	patients	N	I-Premise
297	were	N	I-Premise
298	significantly	N	I-Premise
299	greater	N	I-Premise
300	than	N	I-Premise
301	patients	N	I-Premise
302	in	N	I-Premise
303	group	N	I-Premise
304	A	N	I-Premise
305	(	N	I-Premise
306	p=0.011	N	I-Premise
307	,	N	I-Premise
308	CI=0.063-0.437	N	I-Premise
309	)	N	I-Premise
310	,	N	I-Premise
311	and	N	I-Premise
312	group	N	I-Premise
313	C	N	I-Premise
314	(	N	I-Premise
315	p=0.003	N	I-Premise
316	,	N	I-Premise
317	CI=0.146-0.620	N	I-Premise
318	)	N	I-Premise
319	.	N	I-Premise

320	The	N	I-Premise
321	mean	N	I-Premise
322	BAP	N	I-Premise
323	increased	N	I-Premise
324	from	N	I-Premise
325	baseline	N	I-Premise
326	in	N	I-Premise
327	group	N	I-Premise
328	B	N	I-Premise
329	patients	N	I-Premise
330	but	N	I-Premise
331	decreased	N	I-Premise
332	from	N	I-Premise
333	baseline	N	I-Premise
334	in	N	I-Premise
335	group	N	I-Premise
336	C	N	I-Premise
337	patients	N	I-Premise
338	at	N	I-Premise
339	3	N	I-Premise
340	months	N	I-Premise
341	and	N	I-Premise
342	15	N	I-Premise
343	months	N	I-Premise
344	.	N	I-Premise

345	No	N	I-Premise
346	statistical	N	I-Premise
347	significance	N	I-Premise
348	was	N	I-Premise
349	found	N	I-Premise
350	in	N	I-Premise
351	the	N	I-Premise
352	FACT-G	N	I-Premise
353	scores	N	I-Premise
354	and	N	I-Premise
355	FACT-B	N	I-Premise
356	scores	N	I-Premise
357	among	N	I-Premise
358	different	N	I-Premise
359	groups	N	I-Premise
360	at	N	I-Premise
361	baseline	N	I-Premise
362	,	N	I-Premise
363	week	N	I-Premise
364	4	N	I-Premise
365	,	N	I-Premise
366	week	N	I-Premise
367	8	N	I-Premise
368	and	N	I-Premise
369	week	N	I-Premise
370	12	N	I-Premise
371	after	N	I-Premise
372	NHT	N	I-Premise
373	.	N	I-Premise

374	The	N	I-Premise
375	Breast	N	I-Premise
376	Cancer	N	I-Premise
377	Subscale	N	I-Premise
378	scores	N	I-Premise
379	in	N	I-Premise
380	group	N	I-Premise
381	A	N	I-Premise
382	patients	N	I-Premise
383	were	N	I-Premise
384	significantly	N	I-Premise
385	higher	N	I-Premise
386	than	N	I-Premise
387	that	N	I-Premise
388	of	N	I-Premise
389	group	N	I-Premise
390	C	N	I-Premise
391	patients	N	I-Premise
392	(	N	I-Premise
393	p=0.021	N	I-Premise
394	)	N	I-Premise
395	.	N	I-Premise

396	After	N	I-Premise
397	4	N	I-Premise
398	weeks	N	I-Premise
399	of	N	I-Premise
400	NHT	N	I-Premise
401	,	N	I-Premise
402	negative	N	I-Premise
403	changes	N	I-Premise
404	of	N	I-Premise
405	FACT-B	N	I-Premise
406	and	N	I-Premise
407	FACT-G	N	I-Premise
408	scores	N	I-Premise
409	were	N	I-Premise
410	found	N	I-Premise
411	in	N	I-Premise
412	group	N	I-Premise
413	B	N	I-Premise
414	and	N	I-Premise
415	C	N	I-Premise
416	patients	N	I-Premise
417	,	N	I-Premise
418	but	N	I-Premise
419	there	N	I-Premise
420	were	N	I-Premise
421	positive	N	I-Premise
422	changes	N	I-Premise
423	in	N	I-Premise
424	group	N	I-Premise
425	A	N	I-Premise
426	patients	N	I-Premise
427	.	N	I-Premise

428	Significant	N	I-Premise
429	differences	N	I-Premise
430	of	N	I-Premise
431	FACT-B	N	I-Premise
432	score	N	I-Premise
433	(	N	I-Premise
434	p=0.008	N	I-Premise
435	)	N	I-Premise
436	and	N	I-Premise
437	FACT-G	N	I-Premise
438	score	N	I-Premise
439	(	N	I-Premise
440	p=0.019	N	I-Premise
441	)	N	I-Premise
442	were	N	I-Premise
443	observed	N	I-Premise
444	at	N	I-Premise
445	that	N	I-Premise
446	time	N	I-Premise
447	point	N	I-Premise
448	.	N	I-Premise

449	Article	N	O
450	from	N	O
451	the	N	O
452	Special	N	O
453	issue	N	O
454	on	N	O
455	Targeted	N	O
456	Inhibitors	N	O
457	.	N	O

1	To	N	O
2	investigate	N	O
3	whether	N	O
4	frequent	N	O
5	hospital	N	O
6	follow-up	N	O
7	in	N	O
8	the	N	O
9	first	N	O
10	year	N	O
11	after	N	O
12	breast	N	O
13	cancer	N	O
14	treatment	N	O
15	might	N	O
16	partly	N	O
17	be	N	O
18	replaced	N	O
19	by	N	O
20	nurse-led	N	O
21	telephone	N	O
22	follow-up	N	O
23	without	N	O
24	deteriorating	N	O
25	health-related	N	O
26	quality	N	O
27	of	N	O
28	life	N	O
29	(	N	O
30	HRQoL	N	O
31	)	N	O
32	,	N	O
33	and	N	O
34	whether	N	O
35	a	N	O
36	short	N	O
37	educational	N	O
38	group	N	O
39	programme	N	O
40	(	N	O
41	EGP	N	O
42	)	N	O
43	would	N	O
44	enhance	N	O
45	HRQoL	N	O
46	.	N	O

47	A	N	O
48	multicentre	N	O
49	pragmatic	N	O
50	randomised	N	O
51	controlled	N	O
52	trial	N	O
53	(	N	O
54	RCT	N	O
55	)	N	O
56	with	N	O
57	a	N	O
58	22	N	O
59	factorial	N	O
60	design	N	O
61	was	N	O
62	performed	N	O
63	among	N	O
64	320	N	O
65	breast	N	O
66	cancer	N	O
67	patients	N	O
68	who	N	O
69	were	N	O
70	treated	N	O
71	with	N	O
72	curative	N	O
73	intent	N	O
74	.	N	O

75	Participants	N	O
76	were	N	O
77	randomised	N	O
78	to	N	O
79	follow-up	N	O
80	care	N	O
81	as	N	O
82	usual	N	O
83	(	N	O
84	3-monthly	N	O
85	outpatient	N	O
86	clinic	N	O
87	visits	N	O
88	)	N	O
89	,	N	O
90	nurse-led	N	O
91	telephone	N	O
92	follow-up	N	O
93	,	N	O
94	or	N	O
95	the	N	O
96	former	N	O
97	strategies	N	O
98	combined	N	O
99	with	N	O
100	an	N	O
101	educational	N	O
102	group	N	O
103	programme	N	O
104	.	N	O

105	The	N	O
106	primary	N	O
107	outcome	N	O
108	for	N	O
109	both	N	O
110	interventions	N	O
111	was	N	O
112	HRQoL	N	O
113	,	N	O
114	measured	N	O
115	by	N	O
116	EORTC	N	O
117	QLQ-C30	N	O
118	.	N	O

119	Secondary	N	O
120	outcomes	N	O
121	were	N	O
122	role	N	O
123	and	N	O
124	emotional	N	O
125	functioning	N	O
126	and	N	O
127	feelings	N	O
128	of	N	O
129	control	N	O
130	and	N	O
131	anxiety	N	O
132	.	N	O

133	Data	N	O
134	of	N	O
135	299	N	O
136	patients	N	O
137	were	N	O
138	available	N	O
139	for	N	O
140	evaluation	N	O
141	.	N	O

142	There	N	I-Premise
143	was	N	I-Premise
144	no	N	I-Premise
145	significant	N	I-Premise
146	difference	N	I-Premise
147	in	N	I-Premise
148	HRQoL	N	I-Premise
149	between	N	I-Premise
150	nurse-led	N	I-Premise
151	telephone	N	I-Premise
152	and	N	I-Premise
153	hospital	N	I-Premise
154	follow-up	N	I-Premise
155	at	N	I-Premise
156	12	N	I-Premise
157	months	N	I-Premise
158	after	N	I-Premise
159	treatment	N	I-Premise
160	(	N	I-Premise
161	p	N	I-Premise
162	=	N	I-Premise
163	0.42	N	I-Premise
164	;	N	I-Premise
165	95	N	I-Premise
166	%	N	I-Premise
167	confidence	N	I-Premise
168	interval	N	I-Premise
169	(	N	I-Premise
170	CI	N	I-Premise
171	)	N	I-Premise
172	for	N	I-Premise
173	difference	N	I-Premise
174	:	N	I-Premise
175	-1.93-4.64	N	I-Premise
176	)	N	I-Premise
177	and	N	I-Premise
178	neither	N	I-Premise
179	between	N	I-Premise
180	follow-up	N	I-Premise
181	with	N	I-Premise
182	or	N	I-Premise
183	without	N	I-Premise
184	EGP	N	I-Premise
185	(	N	I-Premise
186	p	N	I-Premise
187	=	N	I-Premise
188	0.86	N	I-Premise
189	;	N	I-Premise
190	95	N	I-Premise
191	%	N	I-Premise
192	CI	N	I-Premise
193	for	N	I-Premise
194	difference	N	I-Premise
195	:	N	I-Premise
196	-3.59-3.00	N	I-Premise
197	)	N	I-Premise
198	.	N	I-Premise

199	Furthermore	N	O
200	,	N	O
201	no	N	I-Premise
202	differences	N	I-Premise
203	between	N	I-Premise
204	the	N	I-Premise
205	intervention	N	I-Premise
206	groups	N	I-Premise
207	and	N	I-Premise
208	their	N	I-Premise
209	corresponding	N	I-Premise
210	control	N	I-Premise
211	groups	N	I-Premise
212	were	N	I-Premise
213	found	N	I-Premise
214	in	N	I-Premise
215	role	N	I-Premise
216	and	N	I-Premise
217	emotional	N	I-Premise
218	functioning	N	I-Premise
219	,	N	I-Premise
220	and	N	I-Premise
221	feelings	N	I-Premise
222	of	N	I-Premise
223	control	N	I-Premise
224	and	N	I-Premise
225	anxiety	N	I-Premise
226	(	N	I-Premise
227	all	N	I-Premise
228	p-values	N	I-Premise
229	>	N	I-Premise
230	0.05	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	Replacement	N	I-Claim
234	of	N	I-Claim
235	most	N	I-Claim
236	hospital	N	I-Claim
237	follow-up	N	I-Claim
238	visits	N	I-Claim
239	in	N	I-Claim
240	the	N	I-Claim
241	first	N	I-Claim
242	year	N	I-Claim
243	after	N	I-Claim
244	breast	N	I-Claim
245	cancer	N	I-Claim
246	treatment	N	I-Claim
247	by	N	I-Claim
248	nurse-led	N	I-Claim
249	telephone	N	I-Claim
250	follow-up	N	I-Claim
251	does	N	I-Claim
252	not	N	I-Claim
253	impede	N	I-Claim
254	patient	N	I-Claim
255	outcomes	N	I-Claim
256	.	N	I-Claim

257	Hence	N	O
258	,	N	O
259	nurse-led	N	I-MajorClaim
260	telephone	N	I-MajorClaim
261	follow-up	N	I-MajorClaim
262	seems	N	I-MajorClaim
263	an	N	I-MajorClaim
264	appropriate	N	I-MajorClaim
265	way	N	I-MajorClaim
266	to	N	I-MajorClaim
267	reduce	N	I-MajorClaim
268	clinic	N	I-MajorClaim
269	visits	N	I-MajorClaim
270	and	N	I-MajorClaim
271	represents	N	I-MajorClaim
272	an	N	I-MajorClaim
273	accepted	N	I-MajorClaim
274	alternative	N	I-MajorClaim
275	strategy	N	I-MajorClaim
276	.	N	I-MajorClaim

277	An	N	O
278	EGP	N	O
279	does	N	O
280	not	N	O
281	unequivocally	N	O
282	affect	N	O
283	positive	N	O
284	HRQoL	N	O
285	outcomes	N	O
286	.	N	O

1	A	N	O
2	phase	N	O
3	III	N	O
4	trial	N	O
5	(	N	O
6	Cancer	N	O
7	and	N	O
8	Leukemia	N	O
9	Group	N	O
10	B	N	O
11	CALGB-49907	N	O
12	)	N	O
13	was	N	O
14	conducted	N	O
15	to	N	O
16	test	N	O
17	whether	N	O
18	older	N	O
19	patients	N	O
20	with	N	O
21	early-stage	N	O
22	breast	N	O
23	cancer	N	O
24	would	N	O
25	have	N	O
26	equivalent	N	O
27	relapse-free	N	O
28	and	N	O
29	overall	N	O
30	survival	N	O
31	with	N	O
32	capecitabine	N	O
33	compared	N	O
34	with	N	O
35	standard	N	O
36	chemotherapy	N	O
37	.	N	O

38	The	N	O
39	quality	N	O
40	of	N	O
41	life	N	O
42	(	N	O
43	QoL	N	O
44	)	N	O
45	substudy	N	O
46	tested	N	O
47	whether	N	O
48	capecitabine	N	O
49	treatment	N	O
50	would	N	O
51	be	N	O
52	associated	N	O
53	with	N	O
54	a	N	O
55	better	N	O
56	QoL	N	O
57	than	N	O
58	standard	N	O
59	chemotherapy	N	O
60	.	N	O

61	QoL	N	O
62	was	N	O
63	assessed	N	O
64	in	N	O
65	350	N	O
66	patients	N	O
67	randomly	N	O
68	assigned	N	O
69	to	N	O
70	either	N	O
71	standard	N	O
72	chemotherapy	N	O
73	(	N	O
74	cyclophosphamide	N	O
75	,	N	O
76	methotrexate	N	O
77	,	N	O
78	and	N	O
79	fluorouracil	N	O
80	[	N	O
81	CMF	N	O
82	]	N	O
83	or	N	O
84	doxorubicin	N	O
85	and	N	O
86	cyclophosphamide	N	O
87	[	N	O
88	AC	N	O
89	]	N	O
90	;	N	O
91	n	N	O
92	=	N	O
93	182	N	O
94	)	N	O
95	or	N	O
96	capecitabine	N	O
97	(	N	O
98	n	N	O
99	=	N	O
100	168	N	O
101	)	N	O
102	.	N	O

103	Patients	N	O
104	were	N	O
105	interviewed	N	O
106	by	N	O
107	telephone	N	O
108	before	N	O
109	treatment	N	O
110	(	N	O
111	baseline	N	O
112	)	N	O
113	,	N	O
114	midtreatment	N	O
115	,	N	O
116	within	N	O
117	1	N	O
118	month	N	O
119	post-treatment	N	O
120	,	N	O
121	and	N	O
122	at	N	O
123	12	N	O
124	,	N	O
125	18	N	O
126	,	N	O
127	and	N	O
128	24	N	O
129	months	N	O
130	postbaseline	N	O
131	by	N	O
132	using	N	O
133	questionnaires	N	O
134	from	N	O
135	the	N	O
136	European	N	O
137	Organisation	N	O
138	for	N	O
139	Research	N	O
140	and	N	O
141	Treatment	N	O
142	of	N	O
143	Cancer	N	O
144	Quality	N	O
145	of	N	O
146	Life	N	O
147	Questionnaire	N	O
148	C30	N	O
149	(	N	O
150	EORTC	N	O
151	QLQ-C30	N	O
152	)	N	O
153	,	N	O
154	a	N	O
155	breast	N	O
156	systemic	N	O
157	adverse	N	O
158	effects	N	O
159	scale	N	O
160	(	N	O
161	EORTC	N	O
162	BR23	N	O
163	)	N	O
164	,	N	O
165	and	N	O
166	the	N	O
167	Hospital	N	O
168	Anxiety	N	O
169	and	N	O
170	Depression	N	O
171	Scale	N	O
172	(	N	O
173	HADS	N	O
174	)	N	O
175	.	N	O

176	Compared	N	I-Premise
177	with	N	I-Premise
178	patients	N	I-Premise
179	who	N	I-Premise
180	were	N	I-Premise
181	treated	N	I-Premise
182	with	N	I-Premise
183	standard	N	I-Premise
184	chemotherapy	N	I-Premise
185	,	N	I-Premise
186	patients	N	I-Premise
187	who	N	I-Premise
188	were	N	I-Premise
189	treated	N	I-Premise
190	with	N	I-Premise
191	capecitabine	N	I-Premise
192	had	N	I-Premise
193	significantly	N	I-Premise
194	better	N	I-Premise
195	QoL	N	I-Premise
196	,	N	I-Premise
197	role	N	I-Premise
198	function	N	I-Premise
199	,	N	I-Premise
200	and	N	I-Premise
201	social	N	I-Premise
202	function	N	I-Premise
203	,	N	I-Premise
204	fewer	N	I-Premise
205	systemic	N	I-Premise
206	adverse	N	I-Premise
207	effects	N	I-Premise
208	,	N	I-Premise
209	less	N	I-Premise
210	psychological	N	I-Premise
211	distress	N	I-Premise
212	,	N	I-Premise
213	and	N	I-Premise
214	less	N	I-Premise
215	fatigue	N	I-Premise
216	during	N	I-Premise
217	and	N	I-Premise
218	at	N	I-Premise
219	the	N	I-Premise
220	completion	N	I-Premise
221	of	N	I-Premise
222	treatment	N	I-Premise
223	(	N	I-Premise
224	P	N	I-Premise
225		N	I-Premise
226	.005	N	I-Premise
227	)	N	I-Premise
228	.	N	I-Premise

229	Capecitabine	N	I-Premise
230	treatment	N	I-Premise
231	was	N	I-Premise
232	associated	N	I-Premise
233	with	N	I-Premise
234	less	N	I-Premise
235	nausea	N	I-Premise
236	,	N	I-Premise
237	vomiting	N	I-Premise
238	,	N	I-Premise
239	and	N	I-Premise
240	constipation	N	I-Premise
241	and	N	I-Premise
242	with	N	I-Premise
243	better	N	I-Premise
244	appetite	N	I-Premise
245	than	N	I-Premise
246	standard	N	I-Premise
247	treatment	N	I-Premise
248	(	N	I-Premise
249	P	N	I-Premise
250		N	I-Premise
251	.004	N	I-Premise
252	)	N	I-Premise
253	,	N	I-Premise
254	but	N	I-Premise
255	worse	N	I-Premise
256	hand-foot	N	I-Premise
257	syndrome	N	I-Premise
258	and	N	I-Premise
259	diarrhea	N	I-Premise
260	(	N	I-Premise
261	P	N	I-Premise
262	<	N	I-Premise
263	.005	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	These	N	O
267	differences	N	O
268	all	N	O
269	resolved	N	O
270	by	N	O
271	12	N	O
272	months	N	O
273	.	N	O

274	Standard	N	I-Claim
275	chemotherapy	N	I-Claim
276	was	N	I-Claim
277	superior	N	I-Claim
278	to	N	I-Claim
279	capecitabine	N	I-Claim
280	in	N	I-Claim
281	improving	N	I-Claim
282	relapse-free	N	I-Claim
283	and	N	I-Claim
284	overall	N	I-Claim
285	survival	N	I-Claim
286	for	N	I-Claim
287	older	N	I-Claim
288	women	N	I-Claim
289	with	N	I-Claim
290	early-stage	N	I-Claim
291	breast	N	I-Claim
292	cancer	N	I-Claim
293	.	N	I-Claim

294	Although	N	O
295	capecitabine	N	I-Claim
296	was	N	I-Claim
297	associated	N	I-Claim
298	with	N	I-Claim
299	better	N	I-Claim
300	QoL	N	I-Claim
301	during	N	I-Claim
302	treatment	N	I-Claim
303	,	N	O
304	QoL	N	I-Premise
305	was	N	I-Premise
306	similar	N	I-Premise
307	for	N	I-Premise
308	both	N	I-Premise
309	groups	N	I-Premise
310	at	N	I-Premise
311	1	N	I-Premise
312	year	N	I-Premise
313	.	N	I-Premise

314	The	N	O
315	brief	N	O
316	period	N	O
317	of	N	O
318	poorer	N	O
319	QoL	N	O
320	with	N	O
321	standard	N	O
322	treatment	N	O
323	is	N	O
324	a	N	O
325	modest	N	O
326	price	N	O
327	to	N	O
328	pay	N	O
329	for	N	O
330	a	N	O
331	chance	N	O
332	at	N	O
333	improved	N	O
334	survival	N	O
335	.	N	O

1	Premenopausal	N	O
2	women	N	O
3	with	N	O
4	breast	N	O
5	cancer	N	O
6	receiving	N	O
7	adjuvant	N	O
8	chemotherapy	N	O
9	are	N	O
10	at	N	O
11	risk	N	O
12	for	N	O
13	amenorrhea	N	O
14	.	N	O

15	The	N	O
16	National	N	O
17	Surgical	N	O
18	Adjuvant	N	O
19	Breast	N	O
20	and	N	O
21	Bowel	N	O
22	Project	N	O
23	B-30	N	O
24	trial	N	O
25	included	N	O
26	menstrual	N	O
27	history	N	O
28	(	N	O
29	MH	N	O
30	)	N	O
31	and	N	O
32	quality-of-life	N	O
33	(	N	O
34	QOL	N	O
35	)	N	O
36	studies	N	O
37	to	N	O
38	compare	N	O
39	treatments	N	O
40	on	N	O
41	these	N	O
42	outcomes	N	O
43	.	N	O

44	Patients	N	O
45	were	N	O
46	randomly	N	O
47	assigned	N	O
48	to	N	O
49	sequential	N	O
50	doxorubicin	N	O
51	(	N	O
52	A	N	O
53	)	N	O
54	and	N	O
55	cyclophosphamide	N	O
56	(	N	O
57	C	N	O
58	)	N	O
59	followed	N	O
60	by	N	O
61	docetaxel	N	O
62	(	N	O
63	T	N	O
64	;	N	O
65	ACT	N	O
66	)	N	O
67	,	N	O
68	concurrent	N	O
69	TAC	N	O
70	,	N	O
71	or	N	O
72	AT	N	O
73	,	N	O
74	which	N	O
75	varied	N	O
76	in	N	O
77	duration	N	O
78	(	N	O
79	24	N	O
80	,	N	O
81	12	N	O
82	,	N	O
83	12	N	O
84	weeks	N	O
85	,	N	O
86	respectively	N	O
87	)	N	O
88	,	N	O
89	and	N	O
90	use	N	O
91	of	N	O
92	C.	N	O
93	Endocrine	N	O
94	therapy	N	O
95	was	N	O
96	prescribed	N	O
97	for	N	O
98	women	N	O
99	with	N	O
100	hormone	N	O
101	receptor-positive	N	O
102	tumors	N	O
103	.	N	O

104	MH	N	O
105	and	N	O
106	QOL	N	O
107	were	N	O
108	assessed	N	O
109	with	N	O
110	standardized	N	O
111	questionnaires	N	O
112	at	N	O
113	baseline	N	O
114	;	N	O
115	cycle	N	O
116	4	N	O
117	,	N	O
118	day	N	O
119	1	N	O
120	;	N	O
121	and	N	O
122	every	N	O
123	6	N	O
124	months	N	O
125	through	N	O
126	24	N	O
127	months	N	O
128	.	N	O

129	Prespecified	N	O
130	analyses	N	O
131	examined	N	O
132	rates	N	O
133	of	N	O
134	amenorrhea	N	O
135	by	N	O
136	treatment	N	O
137	arm	N	O
138	,	N	O
139	the	N	O
140	relationship	N	O
141	between	N	O
142	amenorrhea	N	O
143	and	N	O
144	QOL	N	O
145	,	N	O
146	and	N	O
147	QOL	N	O
148	by	N	O
149	treatment	N	O
150	arm	N	O
151	.	N	O

152	Amenorrhea	N	I-Premise
153	12	N	I-Premise
154	months	N	I-Premise
155	after	N	I-Premise
156	random	N	I-Premise
157	assignment	N	I-Premise
158	was	N	I-Premise
159	significantly	N	I-Premise
160	different	N	I-Premise
161	between	N	I-Premise
162	treatment	N	I-Premise
163	groups	N	I-Premise
164	:	N	I-Premise
165	69.8	N	I-Premise
166	%	N	I-Premise
167	for	N	I-Premise
168	ACT	N	I-Premise
169	,	N	I-Premise
170	57.7	N	I-Premise
171	%	N	I-Premise
172	for	N	I-Premise
173	TAC	N	I-Premise
174	,	N	I-Premise
175	and	N	I-Premise
176	37.9	N	I-Premise
177	%	N	I-Premise
178	for	N	I-Premise
179	AT	N	I-Premise
180	(	N	I-Premise
181	P	N	I-Premise
182	<	N	I-Premise
183	.001	N	I-Premise
184	)	N	I-Premise
185	.	N	I-Premise

186	The	N	I-Premise
187	AT	N	I-Premise
188	group	N	I-Premise
189	without	N	I-Premise
190	tamoxifen	N	I-Premise
191	had	N	I-Premise
192	the	N	I-Premise
193	lowest	N	I-Premise
194	rate	N	I-Premise
195	of	N	I-Premise
196	amenorrhea	N	I-Premise
197	.	N	I-Premise

198	QOL	N	I-Premise
199	was	N	I-Premise
200	poorer	N	I-Premise
201	for	N	I-Premise
202	patients	N	I-Premise
203	receiving	N	I-Premise
204	ACT	N	I-Premise
205	at	N	I-Premise
206	6	N	I-Premise
207	months	N	I-Premise
208	but	N	I-Premise
209	similar	N	I-Premise
210	to	N	I-Premise
211	others	N	I-Premise
212	by	N	I-Premise
213	12	N	I-Premise
214	months	N	I-Premise
215	.	N	I-Premise

216	Post-treatment	N	I-Premise
217	symptoms	N	I-Premise
218	were	N	I-Premise
219	increased	N	I-Premise
220	above	N	I-Premise
221	baseline	N	I-Premise
222	for	N	I-Premise
223	all	N	I-Premise
224	treatments	N	I-Premise
225	.	N	I-Premise

226	Multivariable	N	I-Premise
227	repeated	N	I-Premise
228	measures	N	I-Premise
229	modeling	N	I-Premise
230	demonstrated	N	I-Premise
231	that	N	I-Premise
232	treatment	N	I-Premise
233	arm	N	I-Premise
234	,	N	I-Premise
235	time	N	I-Premise
236	point	N	I-Premise
237	,	N	I-Premise
238	age	N	I-Premise
239	,	N	I-Premise
240	and	N	I-Premise
241	tamoxifen	N	I-Premise
242	use	N	I-Premise
243	were	N	I-Premise
244	significantly	N	I-Premise
245	associated	N	I-Premise
246	with	N	I-Premise
247	symptom	N	I-Premise
248	severity	N	I-Premise
249	(	N	I-Premise
250	all	N	I-Premise
251	P	N	I-Premise
252	values	N	I-Premise
253	<	N	I-Premise
254	.002	N	I-Premise
255	)	N	I-Premise
256	.	N	I-Premise

257	Amenorrhea	N	I-Claim
258	rates	N	I-Claim
259	differed	N	I-Claim
260	significantly	N	I-Claim
261	by	N	I-Claim
262	treatment	N	I-Claim
263	arm	N	I-Claim
264	,	N	I-Claim
265	with	N	I-Claim
266	the	N	I-Claim
267	AT	N	I-Claim
268	arm	N	I-Claim
269	having	N	I-Claim
270	the	N	I-Claim
271	lowest	N	I-Claim
272	rate	N	I-Claim
273	.	N	I-Claim

274	Patients	N	I-Claim
275	treated	N	I-Claim
276	with	N	I-Claim
277	longer	N	I-Claim
278	duration	N	I-Claim
279	therapy	N	I-Claim
280	(	N	I-Claim
281	ACT	N	I-Claim
282	)	N	I-Claim
283	had	N	I-Claim
284	greater	N	I-Claim
285	symptom	N	I-Claim
286	severity	N	I-Claim
287	and	N	I-Claim
288	poorer	N	I-Claim
289	QOL	N	I-Claim
290	at	N	I-Claim
291	6	N	I-Claim
292	months	N	I-Claim
293	,	N	I-Claim
294	but	N	I-Claim
295	did	N	I-Claim
296	not	N	I-Claim
297	differ	N	I-Claim
298	from	N	I-Claim
299	shorter	N	I-Claim
300	duration	N	I-Claim
301	treatments	N	I-Claim
302	at	N	I-Claim
303	12	N	I-Claim
304	months	N	I-Claim
305	.	N	I-Claim

1	The	N	O
2	objective	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	explore	N	O
9	the	N	O
10	inflammatory	N	O
11	modulation	N	O
12	effect	N	O
13	of	N	O
14	glutamine-enriched	N	O
15	total	N	O
16	parenteral	N	O
17	nutrition	N	O
18	(	N	O
19	TPN	N	O
20	)	N	O
21	by	N	O
22	investigating	N	O
23	the	N	O
24	alterations	N	O
25	of	N	O
26	inflammation-related	N	O
27	cytokines	N	O
28	in	N	O
29	gastrointestinal	N	O
30	(	N	O
31	GI	N	O
32	)	N	O
33	cancer	N	O
34	patients	N	O
35	postoperatively	N	O
36	.	N	O

37	Fifty	N	O
38	GI	N	O
39	cancer	N	O
40	patients	N	O
41	received	N	O
42	postoperative	N	O
43	7	N	O
44	days	N	O
45	of	N	O
46	isocaloric	N	O
47	and	N	O
48	isonitrogenous	N	O
49	TPN	N	O
50	after	N	O
51	operation	N	O
52	.	N	O

53	They	N	O
54	were	N	O
55	randomly	N	O
56	divided	N	O
57	to	N	O
58	receive	N	O
59	either	N	O
60	glutamine-enriched	N	O
61	TPN	N	O
62	or	N	O
63	standard	N	O
64	TPN	N	O
65	.	N	O

66	The	N	O
67	inflammation-related	N	O
68	cytokines	N	O
69	including	N	O
70	interleukin-6	N	O
71	,	N	O
72	interleukin-10	N	O
73	,	N	O
74	and	N	O
75	tumor	N	O
76	necrosis	N	O
77	factor-	N	O
78	were	N	O
79	also	N	O
80	determined	N	O
81	.	N	O

82	Records	N	O
83	of	N	O
84	nutritional	N	O
85	assessments	N	O
86	,	N	O
87	inflammatory	N	O
88	status	N	O
89	,	N	O
90	and	N	O
91	postoperative	N	O
92	complications	N	O
93	were	N	O
94	compared	N	O
95	between	N	O
96	the	N	O
97	two	N	O
98	groups	N	O
99	.	N	O

100	Of	N	O
101	50	N	O
102	enrolled	N	O
103	patients	N	O
104	,	N	O
105	25	N	O
106	patients	N	O
107	were	N	O
108	classified	N	O
109	as	N	O
110	the	N	O
111	intervention	N	O
112	group	N	O
113	,	N	O
114	and	N	O
115	the	N	O
116	control	N	O
117	group	N	O
118	also	N	O
119	comprised	N	O
120	25	N	O
121	patients	N	O
122	.	N	O

123	The	N	O
124	differences	N	O
125	of	N	O
126	gender	N	O
127	,	N	O
128	age	N	O
129	,	N	O
130	primary	N	O
131	GI	N	O
132	malignancies	N	O
133	,	N	O
134	and	N	O
135	hematological	N	O
136	and	N	O
137	biochemical	N	O
138	data	N	O
139	between	N	O
140	the	N	O
141	two	N	O
142	compared	N	O
143	groups	N	O
144	were	N	O
145	not	N	O
146	statistically	N	O
147	significant	N	O
148	(	N	O
149	all	N	O
150	P	N	O
151	>	N	O
152	0.05	N	O
153	)	N	O
154	.	N	O

155	Compared	N	I-Premise
156	with	N	I-Premise
157	standard	N	I-Premise
158	TPN	N	I-Premise
159	,	N	I-Premise
160	a	N	I-Premise
161	higher	N	I-Premise
162	serum	N	I-Premise
163	prealbumin	N	I-Premise
164	level	N	I-Premise
165	and	N	I-Premise
166	better	N	I-Premise
167	nitrogen	N	I-Premise
168	balance	N	I-Premise
169	were	N	I-Premise
170	observed	N	I-Premise
171	in	N	I-Premise
172	glutamine-enriched	N	I-Premise
173	TPN	N	I-Premise
174	(	N	I-Premise
175	P	N	I-Premise
176	=	N	I-Premise
177	0.039	N	I-Premise
178	and	N	I-Premise
179	0.048	N	I-Premise
180	respectively	N	I-Premise
181	)	N	I-Premise
182	.	N	I-Premise

183	A	N	I-Premise
184	significantly	N	I-Premise
185	lower	N	I-Premise
186	serum	N	I-Premise
187	interleukin-6	N	I-Premise
188	level	N	I-Premise
189	was	N	I-Premise
190	found	N	I-Premise
191	in	N	I-Premise
192	comparing	N	I-Premise
193	glutamine-enriched	N	I-Premise
194	with	N	I-Premise
195	standard	N	I-Premise
196	TPN	N	I-Premise
197	(	N	I-Premise
198	P	N	I-Premise
199	=	N	I-Premise
200	0.01	N	I-Premise
201	)	N	I-Premise
202	,	N	I-Premise
203	but	N	I-Premise
204	not	N	I-Premise
205	in	N	I-Premise
206	interleukin-10	N	I-Premise
207	(	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	0.374	N	I-Premise
211	)	N	I-Premise
212	and	N	I-Premise
213	tumor	N	I-Premise
214	necrosis	N	I-Premise
215	factor-	N	I-Premise
216	levels	N	I-Premise
217	(	N	I-Premise
218	P	N	I-Premise
219	=	N	I-Premise
220	0.653	N	I-Premise
221	)	N	I-Premise
222	.	N	I-Premise

223	Moreover	N	O
224	,	N	O
225	a	N	I-Premise
226	significant	N	I-Premise
227	lower	N	I-Premise
228	serum	N	I-Premise
229	C-reactive	N	I-Premise
230	protein	N	I-Premise
231	level	N	I-Premise
232	was	N	I-Premise
233	detected	N	I-Premise
234	in	N	I-Premise
235	glutamine-enriched	N	I-Premise
236	TPN	N	I-Premise
237	compared	N	I-Premise
238	with	N	I-Premise
239	standard	N	I-Premise
240	TPN	N	I-Premise
241	(	N	I-Premise
242	P	N	I-Premise
243	=	N	I-Premise
244	0.013	N	I-Premise
245	)	N	I-Premise
246	.	N	I-Premise

247	Indeed	N	O
248	,	N	O
249	four	N	I-Premise
250	cases	N	I-Premise
251	of	N	I-Premise
252	postoperative	N	I-Premise
253	infectious	N	I-Premise
254	complications	N	I-Premise
255	were	N	I-Premise
256	noted	N	I-Premise
257	in	N	I-Premise
258	the	N	I-Premise
259	control	N	I-Premise
260	group	N	I-Premise
261	,	N	I-Premise
262	but	N	I-Premise
263	no	N	I-Premise
264	postoperative	N	I-Premise
265	infectious	N	I-Premise
266	complications	N	I-Premise
267	were	N	I-Premise
268	observed	N	I-Premise
269	in	N	I-Premise
270	the	N	I-Premise
271	interventional	N	I-Premise
272	group	N	I-Premise
273	(	N	I-Premise
274	P	N	I-Premise
275	=	N	I-Premise
276	0.037	N	I-Premise
277	)	N	I-Premise
278	.	N	I-Premise

279	Our	N	I-Claim
280	present	N	I-Claim
281	study	N	I-Claim
282	shows	N	I-Claim
283	that	N	I-Claim
284	glutamine-enriched	N	I-Claim
285	TPN	N	I-Claim
286	may	N	I-Claim
287	be	N	I-Claim
288	beneficial	N	I-Claim
289	in	N	I-Claim
290	improving	N	I-Claim
291	the	N	I-Claim
292	inflammatory	N	I-Claim
293	status	N	I-Claim
294	and	N	I-Claim
295	decreasing	N	I-Claim
296	the	N	I-Claim
297	infectious	N	I-Claim
298	morbidity	N	I-Claim
299	in	N	I-Claim
300	postoperative	N	I-Claim
301	GI	N	I-Claim
302	cancer	N	I-Claim
303	patients	N	I-Claim
304	.	N	I-Claim

1	We	N	O
2	aimed	N	O
3	to	N	O
4	determine	N	O
5	the	N	O
6	effectiveness	N	O
7	of	N	O
8	a	N	O
9	lay-administered	N	O
10	tailored	N	O
11	education	N	O
12	and	N	O
13	coaching	N	O
14	(	N	O
15	TEC	N	O
16	)	N	O
17	intervention	N	O
18	(	N	O
19	aimed	N	O
20	at	N	O
21	reducing	N	O
22	pain	N	O
23	misconceptions	N	O
24	and	N	O
25	enhancing	N	O
26	self-efficacy	N	O
27	for	N	O
28	communicating	N	O
29	with	N	O
30	physicians	N	O
31	)	N	O
32	on	N	O
33	cancer	N	O
34	pain	N	O
35	severity	N	O
36	,	N	O
37	pain-related	N	O
38	impairment	N	O
39	,	N	O
40	and	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	.	N	O

45	Cancer	N	O
46	patients	N	O
47	with	N	O
48	baseline	N	O
49	``	N	O
50	worst	N	O
51	pain	N	O
52	''	N	O
53	of	N	O
54	4	N	O
55	on	N	O
56	a	N	O
57	0-10	N	O
58	scale	N	O
59	or	N	O
60	at	N	O
61	least	N	O
62	moderate	N	O
63	functional	N	O
64	impairment	N	O
65	due	N	O
66	to	N	O
67	pain	N	O
68	were	N	O
69	randomly	N	O
70	assigned	N	O
71	to	N	O
72	TEC	N	O
73	or	N	O
74	enhanced	N	O
75	usual	N	O
76	care	N	O
77	(	N	O
78	EUC	N	O
79	)	N	O
80	during	N	O
81	a	N	O
82	telephone	N	O
83	interview	N	O
84	conducted	N	O
85	in	N	O
86	advance	N	O
87	of	N	O
88	a	N	O
89	planned	N	O
90	oncology	N	O
91	office	N	O
92	visit	N	O
93	(	N	O
94	265	N	O
95	patients	N	O
96	randomized	N	O
97	to	N	O
98	TEC	N	O
99	or	N	O
100	EUC	N	O
101	;	N	O
102	258	N	O
103	completed	N	O
104	at	N	O
105	least	N	O
106	one	N	O
107	follow-up	N	O
108	)	N	O
109	.	N	O

110	Patients	N	O
111	completed	N	O
112	questionnaires	N	O
113	before	N	O
114	and	N	O
115	after	N	O
116	the	N	O
117	visit	N	O
118	and	N	O
119	were	N	O
120	interviewed	N	O
121	by	N	O
122	telephone	N	O
123	at	N	O
124	2	N	O
125	,	N	O
126	6	N	O
127	,	N	O
128	and	N	O
129	12	N	O
130	weeks	N	O
131	.	N	O

132	Mixed	N	O
133	effects	N	O
134	regressions	N	O
135	were	N	O
136	used	N	O
137	to	N	O
138	evaluate	N	O
139	the	N	O
140	intervention	N	O
141	adjusting	N	O
142	for	N	O
143	patient	N	O
144	,	N	O
145	practice	N	O
146	,	N	O
147	and	N	O
148	site	N	O
149	characteristics	N	O
150	.	N	O

151	Compared	N	I-Premise
152	to	N	I-Premise
153	EUC	N	I-Premise
154	,	N	I-Premise
155	TEC	N	I-Premise
156	was	N	I-Premise
157	associated	N	I-Premise
158	with	N	I-Premise
159	increased	N	I-Premise
160	pain	N	I-Premise
161	communication	N	I-Premise
162	self-efficacy	N	I-Premise
163	after	N	I-Premise
164	the	N	I-Premise
165	intervention	N	I-Premise
166	(	N	I-Premise
167	P	N	I-Premise
168	<	N	I-Premise
169	.001	N	I-Premise
170	)	N	I-Premise
171	;	N	I-Premise
172	both	N	I-Premise
173	groups	N	I-Premise
174	showed	N	I-Premise
175	significant	N	I-Premise
176	(	N	I-Premise
177	P	N	I-Premise
178	<	N	I-Premise
179	.0001	N	I-Premise
180	)	N	I-Premise
181	,	N	I-Premise
182	similar	N	I-Premise
183	,	N	I-Premise
184	reductions	N	I-Premise
185	in	N	I-Premise
186	pain	N	I-Premise
187	misconceptions	N	I-Premise
188	.	N	I-Premise

189	At	N	I-Premise
190	2	N	I-Premise
191	weeks	N	I-Premise
192	,	N	I-Premise
193	assignment	N	I-Premise
194	to	N	I-Premise
195	TEC	N	I-Premise
196	was	N	I-Premise
197	associated	N	I-Premise
198	with	N	I-Premise
199	improvement	N	I-Premise
200	in	N	I-Premise
201	pain-related	N	I-Premise
202	impairment	N	I-Premise
203	(	N	I-Premise
204	-0.25	N	I-Premise
205	points	N	I-Premise
206	on	N	I-Premise
207	a	N	I-Premise
208	5-point	N	I-Premise
209	scale	N	I-Premise
210	,	N	I-Premise
211	95	N	I-Premise
212	%	N	I-Premise
213	confidence	N	I-Premise
214	interval	N	I-Premise
215	-0.43	N	I-Premise
216	to	N	I-Premise
217	-0.06	N	I-Premise
218	,	N	I-Premise
219	P=.01	N	I-Premise
220	)	N	I-Premise
221	but	N	I-Premise
222	not	N	I-Premise
223	in	N	I-Premise
224	pain	N	I-Premise
225	severity	N	I-Premise
226	(	N	I-Premise
227	-0.21	N	I-Premise
228	points	N	I-Premise
229	on	N	I-Premise
230	an	N	I-Premise
231	11-point	N	I-Premise
232	scale	N	I-Premise
233	,	N	I-Premise
234	-0.60	N	I-Premise
235	to	N	I-Premise
236	0.17	N	I-Premise
237	,	N	I-Premise
238	P=.27	N	I-Premise
239	)	N	I-Premise
240	.	N	I-Premise

241	The	N	I-Premise
242	improvement	N	I-Premise
243	in	N	I-Premise
244	pain-related	N	I-Premise
245	impairment	N	I-Premise
246	was	N	I-Premise
247	not	N	I-Premise
248	sustained	N	I-Premise
249	at	N	I-Premise
250	6	N	I-Premise
251	and	N	I-Premise
252	12	N	I-Premise
253	weeks	N	I-Premise
254	.	N	I-Premise

255	There	N	I-Premise
256	were	N	I-Premise
257	no	N	I-Premise
258	significant	N	I-Premise
259	intervention	N	I-Premise
260	by	N	I-Premise
261	subgroup	N	I-Premise
262	interactions	N	I-Premise
263	(	N	I-Premise
264	P	N	I-Premise
265	>	N	I-Premise
266	.10	N	I-Premise
267	)	N	I-Premise
268	.	N	I-Premise

269	We	N	I-Claim
270	conclude	N	I-Claim
271	that	N	I-Claim
272	TEC	N	I-Claim
273	,	N	I-Claim
274	compared	N	I-Claim
275	with	N	I-Claim
276	EUC	N	I-Claim
277	,	N	I-Claim
278	resulted	N	I-Claim
279	in	N	I-Claim
280	improved	N	I-Claim
281	pain	N	I-Claim
282	communication	N	I-Claim
283	self-efficacy	N	I-Claim
284	and	N	I-Claim
285	temporary	N	I-Claim
286	improvement	N	I-Claim
287	in	N	I-Claim
288	pain-related	N	I-Claim
289	impairment	N	I-Claim
290	,	N	I-Claim
291	but	N	I-Claim
292	no	N	I-Claim
293	improvement	N	I-Claim
294	in	N	I-Claim
295	pain	N	I-Claim
296	severity	N	I-Claim
297	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	long-term	N	O
5	outcome	N	O
6	and	N	O
7	health-related	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	(	N	O
12	HRQL	N	O
13	)	N	O
14	of	N	O
15	patients	N	O
16	with	N	O
17	endometrial	N	O
18	carcinoma	N	O
19	(	N	O
20	EC	N	O
21	)	N	O
22	treated	N	O
23	with	N	O
24	or	N	O
25	without	N	O
26	pelvic	N	O
27	radiotherapy	N	O
28	in	N	O
29	the	N	O
30	Post	N	O
31	Operative	N	O
32	Radiation	N	O
33	Therapy	N	O
34	in	N	O
35	Endometrial	N	O
36	Carcinoma	N	O
37	1	N	O
38	(	N	O
39	PORTEC-1	N	O
40	)	N	O
41	trial	N	O
42	.	N	O

43	Between	N	O
44	1990	N	O
45	and	N	O
46	1997	N	O
47	,	N	O
48	714	N	O
49	patients	N	O
50	with	N	O
51	stage	N	O
52	IC	N	O
53	grade	N	O
54	1	N	O
55	to	N	O
56	2	N	O
57	or	N	O
58	IB	N	O
59	grade	N	O
60	2	N	O
61	to	N	O
62	3	N	O
63	EC	N	O
64	were	N	O
65	randomly	N	O
66	allocated	N	O
67	to	N	O
68	pelvic	N	O
69	external-beam	N	O
70	radiotherapy	N	O
71	(	N	O
72	EBRT	N	O
73	)	N	O
74	or	N	O
75	no	N	O
76	additional	N	O
77	treatment	N	O
78	(	N	O
79	NAT	N	O
80	)	N	O
81	.	N	O

82	HRQL	N	O
83	was	N	O
84	evaluated	N	O
85	with	N	O
86	the	N	O
87	Short	N	O
88	Form	N	O
89	36-Item	N	O
90	(	N	O
91	SF-36	N	O
92	)	N	O
93	questionnaire	N	O
94	;	N	O
95	subscales	N	O
96	from	N	O
97	the	N	O
98	European	N	O
99	Organisation	N	O
100	for	N	O
101	Research	N	O
102	and	N	O
103	Treatment	N	O
104	of	N	O
105	Cancer	N	O
106	(	N	O
107	EORTC	N	O
108	)	N	O
109	PR25	N	O
110	module	N	O
111	for	N	O
112	bowel	N	O
113	and	N	O
114	bladder	N	O
115	symptoms	N	O
116	and	N	O
117	the	N	O
118	OV28	N	O
119	and	N	O
120	CX24	N	O
121	modules	N	O
122	for	N	O
123	sexual	N	O
124	symptoms	N	O
125	;	N	O
126	and	N	O
127	demographic	N	O
128	questions	N	O
129	.	N	O

130	Analysis	N	O
131	was	N	O
132	by	N	O
133	intention-to-treat	N	O
134	.	N	O

135	Median	N	O
136	follow-up	N	O
137	was	N	O
138	13.3	N	O
139	years	N	O
140	.	N	O

141	The	N	I-Premise
142	15-year	N	I-Premise
143	actuarial	N	I-Premise
144	locoregional	N	I-Premise
145	recurrence	N	I-Premise
146	rates	N	I-Premise
147	were	N	I-Premise
148	5.8	N	I-Premise
149	%	N	I-Premise
150	for	N	I-Premise
151	EBRT	N	I-Premise
152	versus	N	I-Premise
153	15.5	N	I-Premise
154	%	N	I-Premise
155	for	N	I-Premise
156	NAT	N	I-Premise
157	(	N	I-Premise
158	P	N	I-Premise
159	<	N	I-Premise
160	.001	N	I-Premise
161	)	N	I-Premise
162	,	N	I-Premise
163	and	N	I-Premise
164	15-year	N	I-Premise
165	overall	N	I-Premise
166	survival	N	I-Premise
167	was	N	I-Premise
168	52	N	I-Premise
169	%	N	I-Premise
170	versus	N	I-Premise
171	60	N	I-Premise
172	%	N	I-Premise
173	(	N	I-Premise
174	P	N	I-Premise
175	=	N	I-Premise
176	.14	N	I-Premise
177	)	N	I-Premise
178	.	N	I-Premise

179	Of	N	O
180	the	N	O
181	351	N	O
182	patients	N	O
183	confirmed	N	O
184	to	N	O
185	be	N	O
186	alive	N	O
187	with	N	O
188	correct	N	O
189	address	N	O
190	,	N	O
191	246	N	O
192	(	N	O
193	70	N	O
194	%	N	O
195	)	N	O
196	returned	N	O
197	the	N	O
198	questionnaire	N	O
199	.	N	O

200	Patients	N	I-Premise
201	treated	N	I-Premise
202	with	N	I-Premise
203	EBRT	N	I-Premise
204	reported	N	I-Premise
205	significant	N	I-Premise
206	(	N	I-Premise
207	P	N	I-Premise
208	<	N	I-Premise
209	.01	N	I-Premise
210	)	N	I-Premise
211	and	N	I-Premise
212	clinically	N	I-Premise
213	relevant	N	I-Premise
214	higher	N	I-Premise
215	rates	N	I-Premise
216	of	N	I-Premise
217	urinary	N	I-Premise
218	incontinence	N	I-Premise
219	,	N	I-Premise
220	diarrhea	N	I-Premise
221	,	N	I-Premise
222	and	N	I-Premise
223	fecal	N	I-Premise
224	leakage	N	I-Premise
225	leading	N	I-Premise
226	to	N	I-Premise
227	more	N	I-Premise
228	limitations	N	I-Premise
229	in	N	I-Premise
230	daily	N	I-Premise
231	activities	N	I-Premise
232	.	N	I-Premise

233	Increased	N	I-Premise
234	symptoms	N	I-Premise
235	were	N	I-Premise
236	reflected	N	I-Premise
237	by	N	I-Premise
238	the	N	I-Premise
239	frequent	N	I-Premise
240	use	N	I-Premise
241	of	N	I-Premise
242	incontinence	N	I-Premise
243	materials	N	I-Premise
244	after	N	I-Premise
245	EBRT	N	I-Premise
246	(	N	I-Premise
247	day	N	I-Premise
248	and	N	I-Premise
249	night	N	I-Premise
250	use	N	I-Premise
251	,	N	I-Premise
252	42.9	N	I-Premise
253	%	N	I-Premise
254	v	N	I-Premise
255	15.2	N	I-Premise
256	%	N	I-Premise
257	for	N	I-Premise
258	NAT	N	I-Premise
259	;	N	I-Premise
260	P	N	I-Premise
261	<	N	I-Premise
262	.001	N	I-Premise
263	)	N	I-Premise
264	.	N	I-Premise

265	Patients	N	I-Premise
266	treated	N	I-Premise
267	with	N	I-Premise
268	EBRT	N	I-Premise
269	reported	N	I-Premise
270	lower	N	I-Premise
271	scores	N	I-Premise
272	on	N	I-Premise
273	the	N	I-Premise
274	SF-36	N	I-Premise
275	scales	N	I-Premise
276	``	N	I-Premise
277	physical	N	I-Premise
278	functioning	N	I-Premise
279	''	N	I-Premise
280	(	N	I-Premise
281	P	N	I-Premise
282	=	N	I-Premise
283	.004	N	I-Premise
284	)	N	I-Premise
285	and	N	I-Premise
286	``	N	I-Premise
287	role-physical	N	I-Premise
288	''	N	I-Premise
289	(	N	I-Premise
290	P	N	I-Premise
291	=	N	I-Premise
292	.003	N	I-Premise
293	)	N	I-Claim
294	.	N	I-Claim

295	EBRT	N	I-Claim
296	for	N	I-Claim
297	endometrial	N	I-Claim
298	cancer	N	I-Claim
299	is	N	I-Claim
300	associated	N	I-Claim
301	with	N	I-Claim
302	long-term	N	I-Claim
303	urinary	N	I-Claim
304	and	N	I-Claim
305	bowel	N	I-Claim
306	symptoms	N	I-Claim
307	and	N	I-Claim
308	lower	N	I-Claim
309	physical	N	I-Claim
310	and	N	I-Claim
311	role-physical	N	I-Claim
312	functioning	N	I-Claim
313	,	N	I-Claim
314	even	N	I-Claim
315	15	N	I-Claim
316	years	N	I-Claim
317	after	N	I-Claim
318	treatment	N	I-Claim
319	.	N	I-Claim

320	Despite	N	I-MajorClaim
321	its	N	I-MajorClaim
322	efficacy	N	I-MajorClaim
323	in	N	I-MajorClaim
324	reducing	N	I-MajorClaim
325	locoregional	N	I-MajorClaim
326	recurrence	N	I-MajorClaim
327	,	N	I-MajorClaim
328	EBRT	N	I-MajorClaim
329	should	N	I-MajorClaim
330	be	N	I-MajorClaim
331	avoided	N	I-MajorClaim
332	in	N	I-MajorClaim
333	patients	N	I-MajorClaim
334	with	N	I-MajorClaim
335	low-	N	I-MajorClaim
336	and	N	I-MajorClaim
337	intermediate-risk	N	I-MajorClaim
338	EC	N	I-MajorClaim
339	.	N	I-MajorClaim

1	Postoperative	N	I-Claim
2	outcomes	N	I-Claim
3	of	N	I-Claim
4	patients	N	I-Claim
5	undergoing	N	I-Claim
6	laparoscopic-assisted	N	I-Claim
7	colectomy	N	I-Claim
8	(	N	I-Claim
9	LAC	N	I-Claim
10	)	N	I-Claim
11	have	N	I-Claim
12	shown	N	I-Claim
13	modest	N	I-Claim
14	improvements	N	I-Claim
15	in	N	I-Claim
16	recovery	N	I-Claim
17	but	N	I-Claim
18	only	N	I-Claim
19	minimal	N	I-Claim
20	differences	N	I-Claim
21	in	N	I-Claim
22	quality	N	I-Claim
23	of	N	I-Claim
24	life	N	I-Claim
25	(	N	I-Claim
26	QOL	N	I-Claim
27	)	N	I-Claim
28	compared	N	I-Claim
29	with	N	I-Claim
30	open	N	I-Claim
31	colectomy	N	I-Claim
32	.	N	I-Claim

33	We	N	O
34	therefore	N	O
35	sought	N	O
36	to	N	O
37	assess	N	O
38	the	N	O
39	effect	N	O
40	of	N	O
41	LAC	N	O
42	on	N	O
43	QOL	N	O
44	in	N	O
45	the	N	O
46	short	N	O
47	and	N	O
48	long	N	O
49	term	N	O
50	,	N	O
51	using	N	O
52	individual	N	O
53	item	N	O
54	analysis	N	O
55	of	N	O
56	multi-item	N	O
57	QOL	N	O
58	assessments	N	O
59	.	N	O

60	QOL	N	O
61	variables	N	O
62	were	N	O
63	analyzed	N	O
64	in	N	O
65	449	N	O
66	randomized	N	O
67	patients	N	O
68	from	N	O
69	the	N	O
70	COST	N	O
71	trial	N	O
72	93-46-53	N	O
73	(	N	O
74	INT	N	O
75	0146	N	O
76	)	N	O
77	.	N	O

78	Both	N	O
79	cross-sectional	N	O
80	single-time	N	O
81	and	N	O
82	change	N	O
83	from	N	O
84	baseline	N	O
85	assessments	N	O
86	were	N	O
87	run	N	O
88	at	N	O
89	day	N	O
90	2	N	O
91	,	N	O
92	week	N	O
93	2	N	O
94	,	N	O
95	month	N	O
96	2	N	O
97	,	N	O
98	and	N	O
99	month	N	O
100	18	N	O
101	postoperatively	N	O
102	in	N	O
103	an	N	O
104	intention-to-treat	N	O
105	analysis	N	O
106	using	N	O
107	Wilcoxon	N	O
108	rank-sum	N	O
109	tests	N	O
110	.	N	O

111	Stepwise	N	O
112	regression	N	O
113	models	N	O
114	were	N	O
115	used	N	O
116	to	N	O
117	determine	N	O
118	predictors	N	O
119	of	N	O
120	QOL	N	O
121	.	N	O

122	Of	N	O
123	449	N	O
124	colon	N	O
125	cancer	N	O
126	patients	N	O
127	,	N	O
128	230	N	O
129	underwent	N	O
130	LAC	N	O
131	and	N	O
132	219	N	O
133	underwent	N	O
134	open	N	O
135	colectomy	N	O
136	.	N	O

137	Subdomain	N	I-Premise
138	analysis	N	I-Premise
139	revealed	N	I-Premise
140	a	N	I-Premise
141	clinically	N	I-Premise
142	moderate	N	I-Premise
143	improvement	N	I-Premise
144	from	N	I-Premise
145	baseline	N	I-Premise
146	for	N	I-Premise
147	LAC	N	I-Premise
148	in	N	I-Premise
149	total	N	I-Premise
150	QOL	N	I-Premise
151	index	N	I-Premise
152	at	N	I-Premise
153	18	N	I-Premise
154	months	N	I-Premise
155	(	N	I-Premise
156	P	N	I-Premise
157	=	N	I-Premise
158	0.02	N	I-Premise
159	)	N	I-Premise
160	as	N	I-Premise
161	well	N	I-Premise
162	as	N	I-Premise
163	other	N	I-Premise
164	small	N	I-Premise
165	symptomatic	N	I-Premise
166	improvements	N	I-Premise
167	.	N	I-Premise

168	Poor	N	O
169	preoperative	N	O
170	QOL	N	O
171	as	N	O
172	indicated	N	O
173	by	N	O
174	a	N	O
175	rating	N	O
176	scale	N	O
177	of	N	O
178		N	O
179	50	N	O
180	was	N	O
181	an	N	O
182	independent	N	O
183	predictor	N	O
184	of	N	O
185	poor	N	O
186	QOL	N	O
187	at	N	O
188	2	N	O
189	months	N	O
190	postoperatively	N	O
191	.	N	O

192	QOL	N	O
193	variables	N	O
194	related	N	O
195	to	N	O
196	survival	N	O
197	were	N	O
198	baseline	N	O
199	support	N	O
200	(	N	O
201	P	N	O
202	=	N	O
203	0.001	N	O
204	)	N	O
205	and	N	O
206	baseline	N	O
207	outlook	N	O
208	(	N	O
209	P	N	O
210	=	N	O
211	0.01	N	O
212	)	N	O
213	.	N	O

214	Eighteen	N	I-Premise
215	months	N	I-Premise
216	after	N	I-Premise
217	surgery	N	I-Premise
218	,	N	I-Premise
219	any	N	I-Premise
220	differences	N	I-Premise
221	in	N	I-Premise
222	quality	N	I-Premise
223	of	N	I-Premise
224	life	N	I-Premise
225	between	N	I-Premise
226	patients	N	I-Premise
227	randomized	N	I-Premise
228	to	N	I-Premise
229	LAC	N	I-Premise
230	or	N	I-Premise
231	open	N	I-Premise
232	colectomy	N	I-Premise
233	favored	N	I-Premise
234	LAC	N	I-Premise
235	.	N	I-Premise

236	However	N	I-Premise
237	,	N	I-Premise
238	the	N	I-Premise
239	magnitude	N	I-Premise
240	of	N	I-Premise
241	the	N	I-Premise
242	benefits	N	I-Premise
243	was	N	I-Premise
244	small	N	I-Premise
245	.	N	I-Premise

246	Patients	N	I-Claim
247	with	N	I-Claim
248	poor	N	I-Claim
249	preoperative	N	I-Claim
250	QOL	N	I-Claim
251	appear	N	I-Claim
252	to	N	I-Claim
253	be	N	I-Claim
254	at	N	I-Claim
255	higher	N	I-Claim
256	risk	N	I-Claim
257	for	N	I-Claim
258	difficult	N	I-Claim
259	postoperative	N	I-Claim
260	courses	N	I-Claim
261	,	N	I-Claim
262	and	N	I-Claim
263	may	N	I-Claim
264	be	N	I-Claim
265	candidates	N	I-Claim
266	for	N	I-Claim
267	enhanced	N	I-Claim
268	ancillary	N	I-Claim
269	services	N	I-Claim
270	to	N	I-Claim
271	address	N	I-Claim
272	their	N	I-Claim
273	particular	N	I-Claim
274	needs	N	I-Claim
275	.	N	I-Claim

1	Improvements	N	O
2	can	N	O
3	be	N	O
4	made	N	O
5	in	N	O
6	the	N	O
7	quality	N	O
8	of	N	O
9	cancer	N	O
10	care	N	O
11	if	N	O
12	supportive	N	O
13	care	N	O
14	needs	N	O
15	are	N	O
16	addressed	N	O
17	;	N	O
18	however	N	O
19	,	N	O
20	there	N	O
21	are	N	O
22	few	N	O
23	trials	N	O
24	of	N	O
25	supportive	N	O
26	care	N	O
27	interventions	N	O
28	to	N	O
29	guide	N	O
30	policy	N	O
31	and	N	O
32	practice	N	O
33	.	N	O

34	This	N	O
35	study	N	O
36	aimed	N	O
37	to	N	O
38	determine	N	O
39	the	N	O
40	effectiveness	N	O
41	of	N	O
42	a	N	O
43	nurse-delivered	N	O
44	telephone	N	O
45	supportive	N	O
46	intervention	N	O
47	(	N	O
48	the	N	O
49	``	N	O
50	CONNECT	N	O
51	''	N	O
52	intervention	N	O
53	)	N	O
54	.	N	O

55	This	N	O
56	study	N	O
57	was	N	O
58	a	N	O
59	pilot	N	O
60	randomized	N	O
61	controlled	N	O
62	trial	N	O
63	.	N	O

64	Intervention	N	O
65	group	N	O
66	patients	N	O
67	received	N	O
68	5	N	O
69	calls	N	O
70	from	N	O
71	a	N	O
72	specialist	N	O
73	colorectal	N	O
74	nurse	N	O
75	in	N	O
76	the	N	O
77	6	N	O
78	months	N	O
79	after	N	O
80	hospital	N	O
81	discharge	N	O
82	.	N	O

83	Each	N	O
84	call	N	O
85	was	N	O
86	standardized	N	O
87	,	N	O
88	comprising	N	O
89	the	N	O
90	assessment	N	O
91	of	N	O
92	unmet	N	O
93	need	N	O
94	and	N	O
95	the	N	O
96	provision	N	O
97	of	N	O
98	information	N	O
99	and	N	O
100	emotional	N	O
101	support	N	O
102	.	N	O

103	CONNECT	N	O
104	was	N	O
105	in	N	O
106	addition	N	O
107	to	N	O
108	standard	N	O
109	clinical	N	O
110	follow-up	N	O
111	.	N	O

112	Patients	N	O
113	allocated	N	O
114	to	N	O
115	the	N	O
116	control	N	O
117	group	N	O
118	received	N	O
119	standard	N	O
120	follow-up	N	O
121	only	N	O
122	.	N	O

123	This	N	O
124	study	N	O
125	took	N	O
126	place	N	O
127	at	N	O
128	the	N	O
129	Royal	N	O
130	Prince	N	O
131	Alfred	N	O
132	Hospital	N	O
133	,	N	O
134	Sydney	N	O
135	,	N	O
136	Australia	N	O
137	.	N	O

138	Patients	N	O
139	(	N	O
140	n	N	O
141	=	N	O
142	75	N	O
143	)	N	O
144	were	N	O
145	included	N	O
146	who	N	O
147	had	N	O
148	been	N	O
149	surgically	N	O
150	treated	N	O
151	for	N	O
152	colorectal	N	O
153	cancer	N	O
154	(	N	O
155	any	N	O
156	stage	N	O
157	)	N	O
158	.	N	O

159	The	N	O
160	main	N	O
161	outcome	N	O
162	measures	N	O
163	were	N	O
164	the	N	O
165	unmet	N	O
166	supportive	N	O
167	care	N	O
168	needs	N	O
169	,	N	O
170	health	N	O
171	service	N	O
172	utilization	N	O
173	,	N	O
174	and	N	O
175	quality	N	O
176	of	N	O
177	life	N	O
178	at	N	O
179	1	N	O
180	,	N	O
181	3	N	O
182	,	N	O
183	and	N	O
184	6	N	O
185	months	N	O
186	postdischarge	N	O
187	.	N	O

188	Of	N	O
189	87	N	O
190	eligible	N	O
191	patients	N	O
192	,	N	O
193	75	N	O
194	consented	N	O
195	(	N	O
196	86	N	O
197	%	N	O
198	consent	N	O
199	rate	N	O
200	)	N	O
201	.	N	O

202	Thirty-nine	N	O
203	patients	N	O
204	were	N	O
205	randomly	N	O
206	assigned	N	O
207	to	N	O
208	CONNECT	N	O
209	and	N	O
210	36	N	O
211	to	N	O
212	usual	N	O
213	care	N	O
214	.	N	O

215	At	N	I-Premise
216	6	N	I-Premise
217	months	N	I-Premise
218	,	N	I-Premise
219	there	N	I-Premise
220	was	N	I-Premise
221	a	N	I-Premise
222	clinically	N	I-Premise
223	relevant	N	I-Premise
224	,	N	I-Premise
225	but	N	I-Premise
226	nonsignificant	N	I-Premise
227	reduction	N	I-Premise
228	in	N	I-Premise
229	presentations	N	I-Premise
230	to	N	I-Premise
231	emergency	N	I-Premise
232	departments	N	I-Premise
233	(	N	I-Premise
234	21	N	I-Premise
235	%	N	I-Premise
236	vs	N	I-Premise
237	33	N	I-Premise
238	%	N	I-Premise
239	;	N	I-Premise
240	1	N	I-Premise
241	=	N	I-Premise
242	1.41	N	I-Premise
243	,	N	I-Premise
244	P	N	I-Premise
245	=	N	I-Premise
246	.23	N	I-Premise
247	)	N	I-Premise
248	and	N	I-Premise
249	readmission	N	I-Premise
250	to	N	I-Premise
251	the	N	I-Premise
252	hospital	N	I-Premise
253	(	N	I-Premise
254	37	N	I-Premise
255	%	N	I-Premise
256	vs	N	I-Premise
257	47	N	I-Premise
258	%	N	I-Premise
259	;	N	I-Premise
260	1	N	I-Premise
261	=	N	I-Premise
262	0.82	N	I-Premise
263	,	N	I-Premise
264	P	N	I-Premise
265	=	N	I-Premise
266	.37	N	I-Premise
267	)	N	I-Premise
268	among	N	I-Premise
269	intervention	N	I-Premise
270	compared	N	I-Premise
271	with	N	I-Premise
272	control	N	I-Premise
273	group	N	I-Premise
274	participants	N	I-Premise
275	.	N	I-Premise

276	Nonsignificant	N	I-Premise
277	differences	N	I-Premise
278	between	N	I-Premise
279	groups	N	I-Premise
280	were	N	I-Premise
281	found	N	I-Premise
282	for	N	I-Premise
283	all	N	I-Premise
284	unmet	N	I-Premise
285	supportive	N	I-Premise
286	care	N	I-Premise
287	need	N	I-Premise
288	and	N	I-Premise
289	quality-of-life	N	I-Premise
290	scores	N	I-Premise
291	,	N	I-Premise
292	change	N	I-Premise
293	scores	N	I-Premise
294	,	N	I-Premise
295	and	N	I-Premise
296	trends	N	I-Premise
297	.	N	I-Premise

298	However	N	I-Premise
299	,	N	I-Premise
300	at	N	I-Premise
301	6	N	I-Premise
302	months	N	I-Premise
303	,	N	I-Premise
304	total	N	I-Premise
305	quality-of-life	N	I-Premise
306	scores	N	I-Premise
307	were	N	I-Premise
308	higher	N	I-Premise
309	for	N	I-Premise
310	intervention	N	I-Premise
311	group	N	I-Premise
312	patients	N	I-Premise
313	than	N	I-Premise
314	controls	N	I-Premise
315	(	N	I-Premise
316	106.0	N	I-Premise
317	vs	N	I-Premise
318	98.6	N	I-Premise
319	)	N	I-Premise
320	.	N	I-Premise

321	This	N	O
322	difference	N	O
323	(	N	O
324	7.4	N	O
325	)	N	O
326	was	N	O
327	clinically	N	O
328	relevant	N	O
329	.	N	O

330	Improvements	N	I-Claim
331	in	N	I-Claim
332	total	N	I-Claim
333	quality-of-life	N	I-Claim
334	change	N	I-Claim
335	scores	N	I-Claim
336	demonstrated	N	I-Claim
337	that	N	I-Claim
338	at	N	I-Claim
339	6	N	I-Claim
340	months	N	I-Claim
341	,	N	I-Claim
342	improvements	N	I-Claim
343	were	N	I-Claim
344	more	N	I-Claim
345	than	N	I-Claim
346	twice	N	I-Claim
347	as	N	I-Claim
348	large	N	I-Claim
349	and	N	I-Claim
350	clinically	N	I-Claim
351	significant	N	I-Claim
352	in	N	I-Claim
353	the	N	I-Claim
354	intervention	N	I-Claim
355	compared	N	I-Claim
356	with	N	I-Claim
357	the	N	I-Claim
358	control	N	I-Claim
359	group	N	I-Claim
360	.	N	I-Claim

361	CONNECT	N	I-Claim
362	has	N	I-Claim
363	shown	N	I-Claim
364	promising	N	I-Claim
365	indications	N	I-Claim
366	on	N	I-Claim
367	health	N	I-Claim
368	system	N	I-Claim
369	and	N	I-Claim
370	patient	N	I-Claim
371	outcomes	N	I-Claim
372	that	N	I-Claim
373	warrant	N	I-Claim
374	a	N	I-Claim
375	larger	N	I-Claim
376	study	N	I-Claim
377	to	N	I-Claim
378	further	N	I-Claim
379	investigate	N	I-Claim
380	the	N	I-Claim
381	potential	N	I-Claim
382	of	N	I-Claim
383	this	N	I-Claim
384	intervention	N	I-Claim
385	.	N	I-Claim

1	Thalidomide	N	O
2	with	N	O
3	melphalan/prednisone	N	O
4	(	N	O
5	MPT	N	O
6	)	N	O
7	was	N	O
8	defined	N	O
9	as	N	O
10	standard	N	O
11	treatment	N	O
12	in	N	O
13	elderly	N	O
14	patients	N	O
15	with	N	O
16	multiple	N	O
17	myeloma	N	O
18	(	N	O
19	MM	N	O
20	)	N	O
21	based	N	O
22	on	N	O
23	five	N	O
24	randomized	N	O
25	trials	N	O
26	.	N	O

27	In	N	O
28	one	N	O
29	of	N	O
30	these	N	O
31	trials	N	O
32	,	N	O
33	HOVON49	N	O
34	,	N	O
35	a	N	O
36	prospective	N	O
37	health-related	N	O
38	quality-of-life	N	O
39	(	N	O
40	HRQoL	N	O
41	)	N	O
42	study	N	O
43	was	N	O
44	initiated	N	O
45	in	N	O
46	order	N	O
47	to	N	O
48	assess	N	O
49	the	N	O
50	impact	N	O
51	of	N	O
52	thalidomide	N	O
53	on	N	O
54	QoL	N	O
55	.	N	O

56	Patients	N	O
57	aged	N	O
58	>	N	O
59	65	N	O
60	years	N	O
61	with	N	O
62	newly	N	O
63	diagnosed	N	O
64	MM	N	O
65	were	N	O
66	randomized	N	O
67	to	N	O
68	receive	N	O
69	melphalan	N	O
70	plus	N	O
71	prednisone	N	O
72	(	N	O
73	MP	N	O
74	)	N	O
75	or	N	O
76	MPT	N	O
77	,	N	O
78	followed	N	O
79	by	N	O
80	thalidomide	N	O
81	maintenance	N	O
82	in	N	O
83	the	N	O
84	MPT	N	O
85	arm	N	O
86	.	N	O

87	Two	N	O
88	hundred	N	O
89	eighty-four	N	O
90	patients	N	O
91	were	N	O
92	included	N	O
93	in	N	O
94	this	N	O
95	side	N	O
96	study	N	O
97	(	N	O
98	MP	N	O
99	,	N	O
100	n=149	N	O
101	;	N	O
102	MPT	N	O
103	n=135	N	O
104	)	N	O
105	.	N	O

106	HRQoL	N	O
107	was	N	O
108	assessed	N	O
109	with	N	O
110	the	N	O
111	EORTC	N	O
112	Core	N	O
113	QoL	N	O
114	Questionnaire	N	O
115	(	N	O
116	QLQ-C30	N	O
117	)	N	O
118	and	N	O
119	the	N	O
120	myeloma-specific	N	O
121	module	N	O
122	(	N	O
123	QLQ-MY24	N	O
124	)	N	O
125	at	N	O
126	baseline	N	O
127	and	N	O
128	at	N	O
129	predetermined	N	O
130	intervals	N	O
131	during	N	O
132	treatment	N	O
133	.	N	O

134	The	N	I-Premise
135	QLQ-C30	N	I-Premise
136	subscales	N	I-Premise
137	physical	N	I-Premise
138	function	N	I-Premise
139	(	N	I-Premise
140	P=0.044	N	I-Premise
141	)	N	I-Premise
142	and	N	I-Premise
143	constipation	N	I-Premise
144	(	N	I-Premise
145	P	N	I-Premise
146	<	N	I-Premise
147	0.001	N	I-Premise
148	)	N	I-Premise
149	showed	N	I-Premise
150	an	N	I-Premise
151	improvement	N	I-Premise
152	during	N	I-Premise
153	induction	N	I-Premise
154	in	N	I-Premise
155	favour	N	I-Premise
156	of	N	I-Premise
157	the	N	I-Premise
158	MP	N	I-Premise
159	arm	N	I-Premise
160	.	N	I-Premise

161	During	N	I-Premise
162	thalidomide	N	I-Premise
163	maintenance	N	I-Premise
164	,	N	I-Premise
165	the	N	I-Premise
166	scores	N	I-Premise
167	for	N	I-Premise
168	the	N	I-Premise
169	QLQ-MY24	N	I-Premise
170	paraesthesia	N	I-Premise
171	became	N	I-Premise
172	significantly	N	I-Premise
173	higher	N	I-Premise
174	in	N	I-Premise
175	the	N	I-Premise
176	MPT	N	I-Premise
177	arm	N	I-Premise
178	(	N	I-Premise
179	P	N	I-Premise
180	<	N	I-Premise
181	0.001	N	I-Premise
182	)	N	I-Premise
183	.	N	I-Premise

184	The	N	I-Premise
185	QLQ-C30	N	I-Premise
186	subscales	N	I-Premise
187	pain	N	I-Premise
188	(	N	I-Premise
189	P=0.12	N	I-Premise
190	)	N	I-Premise
191	,	N	I-Premise
192	insomnia	N	I-Premise
193	(	N	I-Premise
194	P=0.068	N	I-Premise
195	)	N	I-Premise
196	,	N	I-Premise
197	appetite	N	I-Premise
198	loss	N	I-Premise
199	(	N	I-Premise
200	P=0.074	N	I-Premise
201	)	N	I-Premise
202	and	N	I-Premise
203	the	N	I-Premise
204	QLQ-MY24	N	I-Premise
205	item	N	I-Premise
206	sick	N	I-Premise
207	(	N	I-Premise
208	P=0.086	N	I-Premise
209	)	N	I-Premise
210	scored	N	I-Premise
211	marginally	N	I-Premise
212	better	N	I-Premise
213	during	N	I-Premise
214	thalidomide	N	I-Premise
215	maintenance	N	I-Premise
216	.	N	I-Premise

217	The	N	I-Premise
218	overall	N	I-Premise
219	QoL-scale	N	I-Premise
220	QLQ-C30-HRQoL	N	I-Premise
221	showed	N	I-Premise
222	a	N	I-Premise
223	significant	N	I-Premise
224	time	N	I-Premise
225	trend	N	I-Premise
226	towards	N	I-Premise
227	more	N	I-Premise
228	favourable	N	I-Premise
229	mean	N	I-Premise
230	values	N	I-Premise
231	during	N	I-Premise
232	protocol	N	I-Premise
233	treatment	N	I-Premise
234	without	N	I-Premise
235	differences	N	I-Premise
236	between	N	I-Premise
237	MP	N	I-Premise
238	and	N	I-Premise
239	MPT	N	I-Premise
240	.	N	I-Premise

241	For	N	I-Premise
242	the	N	I-Premise
243	QLQ-C30	N	I-Premise
244	subscales	N	I-Premise
245	emotional	N	I-Premise
246	function	N	I-Premise
247	and	N	I-Premise
248	future	N	I-Premise
249	perspectives	N	I-Premise
250	,	N	I-Premise
251	difference	N	I-Premise
252	in	N	I-Premise
253	favour	N	I-Premise
254	of	N	I-Premise
255	the	N	I-Premise
256	MPT	N	I-Premise
257	arm	N	I-Premise
258	from	N	I-Premise
259	the	N	I-Premise
260	start	N	I-Premise
261	of	N	I-Premise
262	treatment	N	I-Premise
263	was	N	I-Premise
264	observed	N	I-Premise
265	(	N	I-Premise
266	P=0.018	N	I-Premise
267	and	N	I-Premise
268	P=0.045	N	I-Premise
269	,	N	I-Premise
270	respectively	N	I-Premise
271	)	N	I-Premise
272	with	N	I-Premise
273	no	N	I-Premise
274	significant	N	I-Premise
275	'time	N	I-Premise
276		N	I-Premise
277	arm	N	I-Premise
278	'	N	I-Premise
279	interaction	N	I-Premise
280	,	N	I-Premise
281	indicating	N	I-Premise
282	a	N	I-Premise
283	persistent	N	I-Premise
284	better	N	I-Premise
285	patient	N	I-Premise
286	perspective	N	I-Premise
287	with	N	I-Premise
288	MPT	N	I-Premise
289	treatment	N	I-Premise
290	.	N	I-Premise

291	This	N	I-Claim
292	study	N	I-Claim
293	shows	N	I-Claim
294	that	N	I-Claim
295	the	N	I-Claim
296	higher	N	I-Claim
297	frequency	N	I-Claim
298	of	N	I-Claim
299	toxicity	N	I-Claim
300	associated	N	I-Claim
301	with	N	I-Claim
302	MPT	N	I-Claim
303	does	N	I-Claim
304	not	N	I-Claim
305	translate	N	I-Claim
306	into	N	I-Claim
307	a	N	I-Claim
308	negative	N	I-Claim
309	effect	N	I-Claim
310	on	N	I-Claim
311	HRQoL	N	I-Claim
312	and	N	I-Claim
313	that	N	I-Claim
314	MPT	N	I-Claim
315	holds	N	I-Claim
316	a	N	I-Claim
317	better	N	I-Claim
318	patient	N	I-Claim
319	perspective	N	I-Claim
320	.	N	I-Claim

1	Insomnia	N	I-MajorClaim
2	is	N	I-MajorClaim
3	a	N	I-MajorClaim
4	common	N	I-MajorClaim
5	complaint	N	I-MajorClaim
6	among	N	I-MajorClaim
7	cancer	N	I-MajorClaim
8	survivors	N	I-MajorClaim
9	.	N	I-MajorClaim

10	Fortunately	N	O
11	,	N	O
12	cognitive-behavioral	N	O
13	therapy	N	O
14	for	N	O
15	insomnia	N	O
16	(	N	O
17	CBT-I	N	O
18	)	N	O
19	has	N	O
20	been	N	O
21	shown	N	O
22	to	N	O
23	be	N	O
24	an	N	O
25	effective	N	O
26	treatment	N	O
27	in	N	O
28	this	N	O
29	population	N	O
30	.	N	O

31	However	N	O
32	,	N	O
33	it	N	O
34	is	N	O
35	rarely	N	O
36	implemented	N	O
37	given	N	O
38	its	N	O
39	limited	N	O
40	availability	N	O
41	.	N	O

42	To	N	O
43	address	N	O
44	this	N	O
45	barrier	N	O
46	,	N	O
47	we	N	O
48	examined	N	O
49	the	N	O
50	ability	N	O
51	of	N	O
52	an	N	O
53	easily	N	O
54	accessible	N	O
55	online	N	O
56	CBT-I	N	O
57	program	N	O
58	to	N	O
59	improve	N	O
60	insomnia	N	O
61	symptoms	N	O
62	in	N	O
63	cancer	N	O
64	survivors	N	O
65	.	N	O

66	Twenty-eight	N	O
67	cancer	N	O
68	survivors	N	O
69	with	N	O
70	insomnia	N	O
71	were	N	O
72	randomly	N	O
73	assigned	N	O
74	to	N	O
75	either	N	O
76	an	N	O
77	Internet	N	O
78	insomnia	N	O
79	intervention	N	O
80	(	N	O
81	n	N	O
82	=	N	O
83	14	N	O
84	)	N	O
85	or	N	O
86	to	N	O
87	a	N	O
88	waitlist	N	O
89	control	N	O
90	group	N	O
91	(	N	O
92	n	N	O
93	=	N	O
94	14	N	O
95	)	N	O
96	.	N	O

97	The	N	O
98	online	N	O
99	program	N	O
100	,	N	O
101	Sleep	N	O
102	Healthy	N	O
103	Using	N	O
104	The	N	O
105	Internet	N	O
106	,	N	O
107	delivers	N	O
108	the	N	O
109	primary	N	O
110	components	N	O
111	of	N	O
112	CBT-I	N	O
113	(	N	O
114	sleep	N	O
115	restriction	N	O
116	,	N	O
117	stimulus	N	O
118	control	N	O
119	,	N	O
120	cognitive	N	O
121	restructuring	N	O
122	,	N	O
123	sleep	N	O
124	hygiene	N	O
125	,	N	O
126	and	N	O
127	relapse	N	O
128	prevention	N	O
129	)	N	O
130	.	N	O

131	Pre-	N	O
132	and	N	O
133	post-assessment	N	O
134	data	N	O
135	were	N	O
136	collected	N	O
137	via	N	O
138	online	N	O
139	questionnaires	N	O
140	and	N	O
141	daily	N	O
142	sleep	N	O
143	diaries	N	O
144	.	N	O

145	Participants	N	I-Premise
146	in	N	I-Premise
147	the	N	I-Premise
148	Internet	N	I-Premise
149	group	N	I-Premise
150	showed	N	I-Premise
151	significant	N	I-Premise
152	improvements	N	I-Premise
153	at	N	I-Premise
154	post-assessment	N	I-Premise
155	compared	N	I-Premise
156	with	N	I-Premise
157	those	N	I-Premise
158	in	N	I-Premise
159	the	N	I-Premise
160	control	N	I-Premise
161	group	N	I-Premise
162	in	N	I-Premise
163	overall	N	I-Premise
164	insomnia	N	I-Premise
165	severity	N	I-Premise
166	(	N	I-Premise
167	F	N	I-Premise
168	(	N	I-Premise
169	1,26	N	I-Premise
170	)	N	I-Premise
171	=	N	I-Premise
172	22.8	N	I-Premise
173	;	N	I-Premise
174	p	N	I-Premise
175	<	N	I-Premise
176	0.001	N	I-Premise
177	)	N	I-Premise
178	,	N	I-Premise
179	sleep	N	I-Premise
180	efficiency	N	I-Premise
181	(	N	I-Premise
182	F	N	I-Premise
183	(	N	I-Premise
184	1,24	N	I-Premise
185	)	N	I-Premise
186	=	N	I-Premise
187	11.45	N	I-Premise
188	;	N	I-Premise
189	P	N	I-Premise
190	=	N	I-Premise
191	0.002	N	I-Premise
192	)	N	I-Premise
193	,	N	I-Premise
194	sleep	N	I-Premise
195	onset	N	I-Premise
196	latency	N	I-Premise
197	(	N	I-Premise
198	F	N	I-Premise
199	(	N	I-Premise
200	1,24	N	I-Premise
201	)	N	I-Premise
202	=	N	I-Premise
203	5.18	N	I-Premise
204	;	N	I-Premise
205	P	N	I-Premise
206	=	N	I-Premise
207	0.03	N	I-Premise
208	)	N	I-Premise
209	,	N	I-Premise
210	soundness	N	I-Premise
211	of	N	I-Premise
212	sleep	N	I-Premise
213	(	N	I-Premise
214	F	N	I-Premise
215	(	N	I-Premise
216	1,24	N	I-Premise
217	)	N	I-Premise
218	=	N	I-Premise
219	9.34	N	I-Premise
220	;	N	I-Premise
221	P	N	I-Premise
222	=	N	I-Premise
223	0.005	N	I-Premise
224	)	N	I-Premise
225	,	N	I-Premise
226	restored	N	I-Premise
227	feeling	N	I-Premise
228	upon	N	I-Premise
229	awakening	N	I-Premise
230	(	N	I-Premise
231	F	N	I-Premise
232	(	N	I-Premise
233	1,24	N	I-Premise
234	)	N	I-Premise
235	=	N	I-Premise
236	11.95	N	I-Premise
237	;	N	I-Premise
238	P	N	I-Premise
239	=	N	I-Premise
240	0.002	N	I-Premise
241	)	N	I-Premise
242	,	N	I-Premise
243	and	N	I-Premise
244	general	N	I-Premise
245	fatigue	N	I-Premise
246	(	N	I-Premise
247	F	N	I-Premise
248	(	N	I-Premise
249	1,26	N	I-Premise
250	)	N	I-Premise
251	=	N	I-Premise
252	13.88	N	I-Premise
253	;	N	I-Premise
254	P	N	I-Premise
255	=	N	I-Premise
256	0.001	N	I-Premise
257	)	N	I-Premise
258	.	N	I-Premise

259	Although	N	I-Premise
260	other	N	I-Premise
261	group	N	I-Premise
262		N	I-Premise
263	time	N	I-Premise
264	interactions	N	I-Premise
265	were	N	I-Premise
266	not	N	I-Premise
267	significant	N	I-Premise
268	,	N	I-Premise
269	overall	N	I-Premise
270	adjusted	N	I-Premise
271	effect	N	I-Premise
272	sizes	N	I-Premise
273	for	N	I-Premise
274	all	N	I-Premise
275	sleep	N	I-Premise
276	variables	N	I-Premise
277	as	N	I-Premise
278	well	N	I-Premise
279	as	N	I-Premise
280	for	N	I-Premise
281	fatigue	N	I-Premise
282	,	N	I-Premise
283	depression	N	I-Premise
284	,	N	I-Premise
285	anxiety	N	I-Premise
286	,	N	I-Premise
287	and	N	I-Premise
288	quality	N	I-Premise
289	of	N	I-Premise
290	life	N	I-Premise
291	ranged	N	I-Premise
292	from	N	I-Premise
293	small	N	I-Premise
294	to	N	I-Premise
295	large	N	I-Premise
296	.	N	I-Premise

297	CBT-I	N	I-Claim
298	delivered	N	I-Claim
299	through	N	I-Claim
300	an	N	I-Claim
301	interactive	N	I-Claim
302	,	N	I-Claim
303	individually	N	I-Claim
304	tailored	N	I-Claim
305	Internet	N	I-Claim
306	intervention	N	I-Claim
307	may	N	I-Claim
308	be	N	I-Claim
309	a	N	I-Claim
310	viable	N	I-Claim
311	treatment	N	I-Claim
312	option	N	I-Claim
313	for	N	I-Claim
314	cancer	N	I-Claim
315	survivors	N	I-Claim
316	experiencing	N	I-Claim
317	insomnia	N	I-Claim
318	.	N	I-Claim

1	A	N	O
2	randomised	N	O
3	controlled	N	O
4	trial	N	O
5	(	N	O
6	RCT	N	O
7	)	N	O
8	demonstrated	N	O
9	that	N	O
10	cognitive	N	O
11	behaviour	N	O
12	therapy	N	O
13	(	N	O
14	CBT	N	O
15	)	N	O
16	for	N	O
17	fatigue	N	O
18	during	N	O
19	curative	N	O
20	cancer	N	O
21	treatment	N	O
22	was	N	O
23	effective	N	O
24	shortly	N	O
25	after	N	O
26	cancer	N	O
27	treatment	N	O
28	.	N	O

29	This	N	O
30	study	N	O
31	aimed	N	O
32	to	N	O
33	identify	N	O
34	which	N	O
35	patient	N	O
36	characteristics	N	O
37	predict	N	O
38	fatigue	N	O
39	improvement	N	O
40	after	N	O
41	CBT	N	O
42	.	N	O

43	In	N	O
44	addition	N	O
45	,	N	O
46	the	N	O
47	long-term	N	O
48	effectiveness	N	O
49	was	N	O
50	investigated	N	O
51	.	N	O

52	Patients	N	O
53	with	N	O
54	various	N	O
55	malignancies	N	O
56	participated	N	O
57	in	N	O
58	the	N	O
59	RCT	N	O
60	(	N	O
61	n	N	O
62	=	N	O
63	210	N	O
64	)	N	O
65	.	N	O

66	Participants	N	O
67	were	N	O
68	assessed	N	O
69	before	N	O
70	cancer	N	O
71	treatment	N	O
72	(	N	O
73	T1	N	O
74	)	N	O
75	,	N	O
76	postintervention	N	O
77	(	N	O
78	T2	N	O
79	)	N	O
80	,	N	O
81	which	N	O
82	was	N	O
83	at	N	O
84	least	N	O
85	2	N	O
86	months	N	O
87	after	N	O
88	cancer	N	O
89	treatment	N	O
90	,	N	O
91	and	N	O
92	after	N	O
93	1-year	N	O
94	follow-up	N	O
95	(	N	O
96	T3	N	O
97	)	N	O
98	.	N	O

99	Monthly	N	O
100	fatigue	N	O
101	assessments	N	O
102	were	N	O
103	completed	N	O
104	between	N	O
105	T2	N	O
106	and	N	O
107	T3	N	O
108	.	N	O

109	A	N	O
110	regression	N	O
111	analysis	N	O
112	with	N	O
113	interactions	N	O
114	was	N	O
115	performed	N	O
116	to	N	O
117	determine	N	O
118	if	N	O
119	domains	N	O
120	of	N	O
121	quality	N	O
122	of	N	O
123	life	N	O
124	(	N	O
125	EORTC-QLQ-C30	N	O
126	)	N	O
127	functioning	N	O
128	(	N	O
129	Health	N	O
130	Survey	N	O
131	Short	N	O
132	Form-36	N	O
133	)	N	O
134	or	N	O
135	psychological	N	O
136	distress	N	O
137	(	N	O
138	Symptom	N	O
139	Checklist-90	N	O
140	)	N	O
141	moderated	N	O
142	the	N	O
143	effect	N	O
144	of	N	O
145	CBT	N	O
146	on	N	O
147	fatigue	N	O
148	.	N	O

149	Analyses	N	O
150	of	N	O
151	covariance	N	O
152	were	N	O
153	used	N	O
154	to	N	O
155	study	N	O
156	the	N	O
157	long-term	N	O
158	effectiveness	N	O
159	of	N	O
160	CBT	N	O
161	.	N	O

162	Fatigue	N	I-Premise
163	at	N	I-Premise
164	T2	N	I-Premise
165	was	N	I-Premise
166	predicted	N	I-Premise
167	by	N	I-Premise
168	a	N	I-Premise
169	significant	N	I-Premise
170	interaction	N	I-Premise
171	between	N	I-Premise
172	self-reported	N	I-Premise
173	cognitive	N	I-Premise
174	functioning	N	I-Premise
175	and	N	I-Premise
176	CBT	N	I-Premise
177	.	N	I-Premise

178	No	N	I-Premise
179	interactions	N	I-Premise
180	were	N	I-Premise
181	found	N	I-Premise
182	between	N	I-Premise
183	other	N	I-Premise
184	domains	N	I-Premise
185	of	N	I-Premise
186	quality	N	I-Premise
187	of	N	I-Premise
188	life	N	I-Premise
189	,	N	I-Premise
190	functioning	N	I-Premise
191	,	N	I-Premise
192	psychological	N	I-Premise
193	distress	N	I-Premise
194	and	N	I-Premise
195	CBT	N	I-Premise
196	.	N	I-Premise

197	At	N	I-Premise
198	T3	N	I-Premise
199	,	N	I-Premise
200	no	N	I-Premise
201	significant	N	I-Premise
202	difference	N	I-Premise
203	on	N	I-Premise
204	fatigue	N	I-Premise
205	was	N	I-Premise
206	found	N	I-Premise
207	between	N	I-Premise
208	CBT	N	I-Premise
209	and	N	I-Premise
210	usual	N	I-Premise
211	care	N	I-Premise
212	.	N	I-Premise

213	Exploratory	N	I-Premise
214	analyses	N	I-Premise
215	showed	N	I-Premise
216	that	N	I-Premise
217	the	N	I-Premise
218	difference	N	I-Premise
219	nearly	N	I-Premise
220	reached	N	I-Premise
221	significance	N	I-Premise
222	until	N	I-Premise
223	7	N	I-Premise
224	months	N	I-Premise
225	postintervention	N	I-Premise
226	.	N	I-Premise

227	Patients	N	I-Premise
228	who	N	I-Premise
229	experienced	N	I-Premise
230	more	N	I-Premise
231	concentration	N	I-Premise
232	and	N	I-Premise
233	memory	N	I-Premise
234	problems	N	I-Premise
235	at	N	I-Premise
236	T1	N	I-Premise
237	benefited	N	I-Premise
238	more	N	I-Premise
239	from	N	I-Premise
240	CBT	N	I-Premise
241	for	N	I-Premise
242	fatigue	N	I-Premise
243	and	N	I-Premise
244	are	N	I-Premise
245	indicators	N	I-Premise
246	.	N	I-Premise

247	After	N	I-Premise
248	a	N	I-Premise
249	year	N	I-Premise
250	of	N	I-Premise
251	follow-up	N	I-Premise
252	,	N	I-Premise
253	the	N	I-Premise
254	effect	N	I-Premise
255	of	N	I-Premise
256	CBT	N	I-Premise
257	for	N	I-Premise
258	fatigue	N	I-Premise
259	was	N	I-Premise
260	no	N	I-Premise
261	longer	N	I-Premise
262	observed	N	I-Premise
263	,	N	I-Premise
264	and	N	I-Premise
265	the	N	I-Premise
266	effect	N	I-Premise
267	on	N	I-Premise
268	fatigue	N	I-Premise
269	seemed	N	I-Premise
270	to	N	I-Premise
271	be	N	I-Premise
272	diminished	N	I-Premise
273	7	N	I-Premise
274	months	N	I-Premise
275	postintervention	N	I-Premise
276	.	N	I-Premise

277	The	N	I-Claim
278	implication	N	I-Claim
279	is	N	I-Claim
280	that	N	I-Claim
281	CBT	N	I-Claim
282	for	N	I-Claim
283	fatigue	N	I-Claim
284	should	N	I-Claim
285	be	N	I-Claim
286	offered	N	I-Claim
287	to	N	I-Claim
288	patients	N	I-Claim
289	with	N	I-Claim
290	cancer	N	I-Claim
291	with	N	I-Claim
292	the	N	I-Claim
293	highest	N	I-Claim
294	chance	N	I-Claim
295	to	N	I-Claim
296	benefit	N	I-Claim
297	.	N	I-Claim

1	To	N	O
2	analyze	N	O
3	the	N	O
4	predictive	N	O
5	value	N	O
6	of	N	O
7	PSA	N	O
8	for	N	O
9	progression	N	O
10	and	N	O
11	the	N	O
12	role	N	O
13	of	N	O
14	testosterone	N	O
15	for	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	QOL	N	O
21	)	N	O
22	in	N	O
23	patients	N	O
24	with	N	O
25	androgen	N	O
26	deprivation	N	O
27	therapy	N	O
28	(	N	O
29	ADT	N	O
30	)	N	O
31	for	N	O
32	metastatic	N	O
33	prostate	N	O
34	cancer	N	O
35	.	N	O

36	PSA	N	O
37	and	N	O
38	testosterone	N	O
39	data	N	O
40	were	N	O
41	used	N	O
42	from	N	O
43	a	N	O
44	phase	N	O
45	III	N	O
46	trial	N	O
47	randomizing	N	O
48	patients	N	O
49	without	N	O
50	progression	N	O
51	and	N	O
52	PSA	N	O
53	<	N	O
54	4	N	O
55	ng/ml	N	O
56	(	N	O
57	n	N	O
58	=	N	O
59	193	N	O
60	)	N	O
61	,	N	O
62	after	N	O
63	6	N	O
64	months	N	O
65	induction	N	O
66	course	N	O
67	,	N	O
68	between	N	O
69	continuous	N	O
70	(	N	O
71	CAD	N	O
72	)	N	O
73	(	N	O
74	n	N	O
75	=	N	O
76	96	N	O
77	)	N	O
78	and	N	O
79	intermittent	N	O
80	(	N	O
81	IAD	N	O
82	)	N	O
83	(	N	O
84	n	N	O
85	=	N	O
86	97	N	O
87	)	N	O
88	ADT	N	O
89	.	N	O

90	The	N	O
91	2-year	N	O
92	risk	N	O
93	of	N	O
94	progression	N	O
95	was	N	O
96	calculated	N	O
97	for	N	O
98	baseline	N	O
99	PSA	N	O
100	,	N	O
101	'fast	N	O
102	'	N	O
103	and	N	O
104	'slow	N	O
105	'	N	O
106	PSA	N	O
107	decline	N	O
108	to	N	O
109	<	N	O
110	4	N	O
111	ng/ml	N	O
112	(	N	O
113	60	N	O
114	days	N	O
115	cut-off	N	O
116	)	N	O
117	,	N	O
118	PSA	N	O
119	nadir	N	O
120	,	N	O
121	performance	N	O
122	status	N	O
123	and	N	O
124	pain	N	O
125	.	N	O

126	Testosterone	N	O
127	kinetics	N	O
128	and	N	O
129	QOL	N	O
130	were	N	O
131	also	N	O
132	evaluated	N	O
133	.	N	O

134	Univariate	N	O
135	Kaplan	N	O
136	Meier	N	O
137	survival	N	O
138	analysis	N	O
139	and	N	O
140	log	N	O
141	rank	N	O
142	tests	N	O
143	were	N	O
144	used	N	O
145	to	N	O
146	compare	N	O
147	the	N	O
148	risk	N	O
149	of	N	O
150	progression	N	O
151	.	N	O

152	For	N	O
153	progression	N	O
154	analysis	N	O
155	,	N	O
156	173	N	O
157	patients	N	O
158	'	N	O
159	data	N	O
160	were	N	O
161	available	N	O
162	.	N	O

163	The	N	O
164	2-year	N	O
165	risk	N	O
166	of	N	O
167	progression	N	O
168	for	N	O
169	baseline	N	O
170	PSA	N	O
171	<	N	O
172	50	N	O
173	ng/ml	N	O
174	,	N	O
175	50	N	O
176	to	N	O
177	<	N	O
178	500	N	O
179	ng/ml	N	O
180	,	N	O
181	and	N	O
182		N	O
183	500	N	O
184	ng/ml	N	O
185	was	N	O
186	25	N	O
187	%	N	O
188	,	N	O
189	55	N	O
190	%	N	O
191	,	N	O
192	and	N	O
193	76	N	O
194	%	N	O
195	(	N	O
196	P	N	O
197	=	N	O
198	0.03	N	O
199	)	N	O
200	in	N	O
201	CAD	N	O
202	,	N	O
203	and	N	O
204	38	N	O
205	%	N	O
206	,	N	O
207	64	N	O
208	%	N	O
209	,	N	O
210	and	N	O
211	85	N	O
212	%	N	O
213	(	N	O
214	P	N	O
215	=	N	O
216	0.006	N	O
217	)	N	O
218	in	N	O
219	IAD	N	O
220	,	N	O
221	respectively	N	O
222	.	N	O

223	The	N	I-Premise
224	2-year	N	I-Premise
225	risk	N	I-Premise
226	of	N	I-Premise
227	progression	N	I-Premise
228	for	N	I-Premise
229	PSA	N	I-Premise
230	nadir	N	I-Premise
231		N	I-Premise
232	0.2	N	I-Premise
233	ng/ml	N	I-Premise
234	,	N	I-Premise
235	and	N	I-Premise
236	>	N	I-Premise
237	0.2	N	I-Premise
238	to	N	I-Premise
239	4	N	I-Premise
240	ng/ml	N	I-Premise
241	in	N	I-Premise
242	CAD	N	I-Premise
243	was	N	I-Premise
244	31	N	I-Premise
245	%	N	I-Premise
246	and	N	I-Premise
247	70	N	I-Premise
248	%	N	I-Premise
249	(	N	I-Premise
250	P	N	I-Premise
251	<	N	I-Premise
252	0.001	N	I-Premise
253	)	N	I-Premise
254	,	N	I-Premise
255	respectively	N	I-Premise
256	.	N	I-Premise

257	In	N	I-Premise
258	the	N	I-Premise
259	IAD	N	I-Premise
260	group	N	I-Premise
261	,	N	I-Premise
262	a	N	I-Premise
263	similar	N	I-Premise
264	trend	N	I-Premise
265	was	N	I-Premise
266	seen	N	I-Premise
267	.	N	I-Premise

268	Patients	N	I-Premise
269	with	N	I-Premise
270	PSA	N	I-Premise
271	nadir	N	I-Premise
272		N	I-Premise
273	0.2	N	I-Premise
274	ng/ml	N	I-Premise
275	,	N	I-Premise
276	though	N	I-Premise
277	had	N	I-Premise
278	significantly	N	I-Premise
279	higher	N	I-Premise
280	2-year	N	I-Premise
281	risk	N	I-Premise
282	of	N	I-Premise
283	progression	N	I-Premise
284	compared	N	I-Premise
285	to	N	I-Premise
286	CAD	N	I-Premise
287	(	N	I-Premise
288	53	N	I-Premise
289	%	N	I-Premise
290	vs.	N	I-Premise
291	31	N	I-Premise
292	%	N	I-Premise
293	(	N	I-Premise
294	P	N	I-Premise
295	=	N	I-Premise
296	0.03	N	I-Premise
297	)	N	I-Premise
298	,	N	I-Premise
299	respectively	N	I-Premise
300	.	N	I-Premise

301	PSA	N	O
302	decline	N	O
303	showed	N	O
304	no	N	O
305	predictive	N	O
306	value	N	O
307	.	N	O

308	Patients	N	I-Premise
309	without	N	I-Premise
310	pain	N	I-Premise
311	had	N	I-Premise
312	a	N	I-Premise
313	significantly	N	I-Premise
314	lower	N	I-Premise
315	2-year	N	I-Premise
316	risk	N	I-Premise
317	of	N	I-Premise
318	progression	N	I-Premise
319	in	N	I-Premise
320	both	N	I-Premise
321	groups	N	I-Premise
322	.	N	I-Premise

323	Without	N	I-Premise
324	ADT	N	I-Premise
325	testosterone	N	I-Premise
326	remained	N	I-Premise
327	at	N	I-Premise
328	castrate	N	I-Premise
329	level	N	I-Premise
330	for	N	I-Premise
331	4	N	I-Premise
332	months	N	I-Premise
333	.	N	I-Premise

334	After	N	O
335	the	N	O
336	first	N	O
337	and	N	O
338	second	N	O
339	IAD	N	O
340	cycle	N	O
341	92	N	O
342	%	N	O
343	and	N	O
344	46	N	O
345	%	N	O
346	,	N	O
347	respectively	N	O
348	,	N	O
349	had	N	O
350	a	N	O
351	normalized	N	O
352	testosterone	N	O
353	.	N	O

354	No	N	I-Premise
355	QOL	N	I-Premise
356	difference	N	I-Premise
357	was	N	I-Premise
358	found	N	I-Premise
359	,	N	I-Premise
360	although	N	I-Premise
361	more	N	I-Premise
362	side	N	I-Premise
363	effects	N	I-Premise
364	occurred	N	I-Premise
365	in	N	I-Premise
366	CAD	N	I-Premise
367	.	N	I-Premise

368	Metastatic	N	I-Claim
369	prostate	N	I-Claim
370	cancer	N	I-Claim
371	patients	N	I-Claim
372	with	N	I-Claim
373	high	N	I-Claim
374	baseline	N	I-Claim
375	PSA	N	I-Claim
376	,	N	I-Claim
377	pain	N	I-Claim
378	,	N	I-Claim
379	and	N	I-Claim
380	high	N	I-Claim
381	PSA	N	I-Claim
382	nadir	N	I-Claim
383	have	N	I-Claim
384	a	N	I-Claim
385	poor	N	I-Claim
386	prognosis	N	I-Claim
387	with	N	I-Claim
388	ADT	N	I-Claim
389	.	N	I-Claim

390	Patients	N	I-Claim
391	with	N	I-Claim
392	low	N	I-Claim
393	PSA	N	I-Claim
394	nadir	N	I-Claim
395	do	N	I-Claim
396	significantly	N	I-Claim
397	worse	N	I-Claim
398	with	N	I-Claim
399	IAD	N	I-Claim
400	compared	N	I-Claim
401	with	N	I-Claim
402	CAD	N	I-Claim
403	.	N	I-Claim

404	Low	N	O
405	testosterone	N	O
406	after	N	O
407	ADT	N	O
408	and	N	O
409	incomplete	N	O
410	testosterone	N	O
411	recovery	N	O
412	may	N	O
413	explain	N	O
414	similar	N	O
415	QOL	N	O
416	.	N	O

417	Therefore	N	O
418	,	N	O
419	IAD	N	I-Claim
420	is	N	I-Claim
421	not	N	I-Claim
422	a	N	I-Claim
423	good	N	I-Claim
424	treatment	N	I-Claim
425	option	N	I-Claim
426	for	N	I-Claim
427	many	N	I-Claim
428	metastatic	N	I-Claim
429	prostate	N	I-Claim
430	cancer	N	I-Claim
431	patients	N	I-Claim
432	.	N	I-Claim

1	This	N	O
2	randomised	N	O
3	non-inferiority	N	O
4	trial	N	O
5	was	N	O
6	designed	N	O
7	to	N	O
8	assess	N	O
9	whether	N	O
10	radiosurgery	N	O
11	plus	N	O
12	adjuvant	N	O
13	whole	N	O
14	brain	N	O
15	radiotherapy	N	O
16	(	N	O
17	RS	N	O
18	+	N	O
19	WBRT	N	O
20	)	N	O
21	is	N	O
22	as	N	O
23	effective	N	O
24	as	N	O
25	surgery	N	O
26	plus	N	O
27	whole	N	O
28	brain	N	O
29	radiotherapy	N	O
30	(	N	O
31	S	N	O
32	+	N	O
33	WBRT	N	O
34	)	N	O
35	for	N	O
36	cancer	N	O
37	patients	N	O
38	with	N	O
39	a	N	O
40	solitary	N	O
41	brain	N	O
42	metastasis	N	O
43	,	N	O
44	with	N	O
45	respect	N	O
46	to	N	O
47	overall	N	O
48	survival	N	O
49	and	N	O
50	quality	N	O
51	of	N	O
52	life	N	O
53	.	N	O

54	Major	N	O
55	inclusion	N	O
56	criteria	N	O
57	were	N	O
58	a	N	O
59	history	N	O
60	of	N	O
61	systemic	N	O
62	cancer	N	O
63	within	N	O
64	5	N	O
65	years	N	O
66	and	N	O
67	enhanced	N	O
68	magnetic	N	O
69	resonance	N	O
70	imaging-confirmed	N	O
71	solitary	N	O
72	brain	N	O
73	metastasis	N	O
74	suitable	N	O
75	for	N	O
76	both	N	O
77	radiosurgery	N	O
78	and	N	O
79	surgery	N	O
80	.	N	O

81	All	N	O
82	patients	N	O
83	were	N	O
84	to	N	O
85	receive	N	O
86	WBRT	N	O
87	(	N	O
88	30	N	O
89	Gy	N	O
90	in	N	O
91	10	N	O
92	fractions	N	O
93	)	N	O
94	.	N	O

95	Between	N	O
96	February	N	O
97	2003	N	O
98	and	N	O
99	April	N	O
100	2009	N	O
101	,	N	O
102	40	N	O
103	patients	N	O
104	were	N	O
105	considered	N	O
106	eligible	N	O
107	,	N	O
108	22	N	O
109	consented	N	O
110	to	N	O
111	randomisation	N	O
112	and	N	O
113	21	N	O
114	were	N	O
115	analysed	N	O
116	(	N	O
117	11	N	O
118	RS	N	O
119	+	N	O
120	WBRT	N	O
121	,	N	O
122	10	N	O
123	S	N	O
124	+	N	O
125	WBRT	N	O
126	)	N	O
127	.	N	O

128	The	N	O
129	trial	N	O
130	was	N	O
131	closed	N	O
132	early	N	O
133	due	N	O
134	to	N	O
135	slow	N	O
136	accrual	N	O
137	.	N	O

138	The	N	I-Premise
139	estimated	N	I-Premise
140	median	N	I-Premise
141	overall	N	I-Premise
142	survival	N	I-Premise
143	times	N	I-Premise
144	for	N	I-Premise
145	RS	N	I-Premise
146	+	N	I-Premise
147	WBRT	N	I-Premise
148	and	N	I-Premise
149	S	N	I-Premise
150	+	N	I-Premise
151	WBRT	N	I-Premise
152	patients	N	I-Premise
153	were	N	I-Premise
154	6.2	N	I-Premise
155	and	N	I-Premise
156	2.8	N	I-Premise
157	months	N	I-Premise
158	,	N	I-Premise
159	respectively	N	I-Premise
160	(	N	I-Premise
161	hazard	N	I-Premise
162	ratio	N	I-Premise
163	0.53	N	I-Premise
164	,	N	I-Premise
165	95	N	I-Premise
166	%	N	I-Premise
167	confidence	N	I-Premise
168	interval	N	I-Premise
169	0.20-1.43	N	I-Premise
170	,	N	I-Premise
171	P	N	I-Premise
172	=	N	I-Premise
173	0.20	N	I-Premise
174	)	N	I-Premise
175	.	N	I-Premise

176	Corresponding	N	I-Premise
177	median	N	I-Premise
178	failure-free	N	I-Premise
179	survival	N	I-Premise
180	times	N	I-Premise
181	were	N	I-Premise
182	3.1	N	I-Premise
183	and	N	I-Premise
184	1.7	N	I-Premise
185	months	N	I-Premise
186	(	N	I-Premise
187	P	N	I-Premise
188	=	N	I-Premise
189	0.20	N	I-Premise
190	)	N	I-Premise
191	.	N	I-Premise

192	For	N	I-Premise
193	19	N	I-Premise
194	'per	N	I-Premise
195	protocol	N	I-Premise
196	'	N	I-Premise
197	patients	N	I-Premise
198	,	N	I-Premise
199	2/10	N	I-Premise
200	in	N	I-Premise
201	the	N	I-Premise
202	RS	N	I-Premise
203	+	N	I-Premise
204	WBRT	N	I-Premise
205	arm	N	I-Premise
206	had	N	I-Premise
207	distant	N	I-Premise
208	intracranial	N	I-Premise
209	failure	N	I-Premise
210	(	N	I-Premise
211	one	N	I-Premise
212	also	N	I-Premise
213	had	N	I-Premise
214	local	N	I-Premise
215	failure	N	I-Premise
216	)	N	I-Premise
217	and	N	I-Premise
218	3/9	N	I-Premise
219	S	N	I-Premise
220	+	N	I-Premise
221	WBRT	N	I-Premise
222	patients	N	I-Premise
223	had	N	I-Premise
224	distant	N	I-Premise
225	intracranial	N	I-Premise
226	failure	N	I-Premise
227	(	N	I-Premise
228	no	N	I-Premise
229	local	N	I-Premise
230	failures	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	There	N	I-Premise
234	were	N	I-Premise
235	no	N	I-Premise
236	grade	N	I-Premise
237	3-4	N	I-Premise
238	late	N	I-Premise
239	radiation	N	I-Premise
240	toxicities	N	I-Premise
241	.	N	I-Premise

242	Two	N	I-Claim
243	months	N	I-Claim
244	after	N	I-Claim
245	starting	N	I-Claim
246	treatment	N	I-Claim
247	there	N	I-Claim
248	were	N	I-Claim
249	no	N	I-Claim
250	significant	N	I-Claim
251	differences	N	I-Claim
252	in	N	I-Claim
253	quality	N	I-Claim
254	of	N	I-Claim
255	life	N	I-Claim
256	between	N	I-Claim
257	the	N	I-Claim
258	arms	N	I-Claim
259	.	N	I-Claim

260	This	N	I-Claim
261	randomised	N	I-Claim
262	trial	N	I-Claim
263	encountered	N	I-Claim
264	the	N	I-Claim
265	accrual	N	I-Claim
266	difficulties	N	I-Claim
267	and	N	I-Claim
268	consequent	N	I-Claim
269	low	N	I-Claim
270	statistical	N	I-Claim
271	power	N	I-Claim
272	commonly	N	I-Claim
273	associated	N	I-Claim
274	with	N	I-Claim
275	interdisciplinary	N	I-Claim
276	studies	N	I-Claim
277	drawing	N	I-Claim
278	from	N	I-Claim
279	a	N	I-Claim
280	small	N	I-Claim
281	eligible	N	I-Claim
282	population	N	I-Claim
283	,	N	I-Claim
284	but	N	O
285	can	N	O
286	contribute	N	O
287	to	N	O
288	future	N	O
289	overviews	N	O
290	on	N	O
291	the	N	O
292	management	N	O
293	of	N	O
294	solitary	N	O
295	brain	N	O
296	metastases	N	O
297	.	N	O

1	Regularly	N	O
2	collecting	N	O
3	patient-reported	N	O
4	outcomes	N	O
5	(	N	O
6	PROs	N	O
7	)	N	O
8	of	N	O
9	health-related	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	with	N	O
14	feedback	N	O
15	to	N	O
16	oncologists	N	O
17	may	N	O
18	assist	N	O
19	in	N	O
20	eliciting	N	O
21	and	N	O
22	monitoring	N	O
23	patients	N	O
24	'	N	O
25	problems	N	O
26	during	N	O
27	cancer	N	O
28	treatment	N	O
29	.	N	O

30	This	N	O
31	study	N	O
32	examined	N	O
33	how	N	O
34	PRO	N	O
35	feedback	N	O
36	had	N	O
37	an	N	O
38	impact	N	O
39	on	N	O
40	patient-physician	N	O
41	communication	N	O
42	over	N	O
43	time	N	O
44	to	N	O
45	gain	N	O
46	a	N	O
47	better	N	O
48	understanding	N	O
49	of	N	O
50	how	N	O
51	it	N	O
52	may	N	O
53	influence	N	O
54	patient	N	O
55	care	N	O
56	.	N	O

57	Exploratory	N	O
58	analyses	N	O
59	were	N	O
60	performed	N	O
61	on	N	O
62	a	N	O
63	data	N	O
64	set	N	O
65	from	N	O
66	a	N	O
67	previous	N	O
68	study	N	O
69	.	N	O

70	Patients	N	O
71	were	N	O
72	randomly	N	O
73	assigned	N	O
74	to	N	O
75	intervention	N	O
76	(	N	O
77	regular	N	O
78	completion	N	O
79	of	N	O
80	European	N	O
81	Organisation	N	O
82	for	N	O
83	Research	N	O
84	and	N	O
85	Treatment	N	O
86	of	N	O
87	Cancer	N	O
88	Quality	N	O
89	of	N	O
90	Life	N	O
91	Questionnaire-Core	N	O
92	30	N	O
93	and	N	O
94	Hospital	N	O
95	Anxiety	N	O
96	and	N	O
97	Depression	N	O
98	Scale	N	O
99	with	N	O
100	feedback	N	O
101	to	N	O
102	oncologists	N	O
103	)	N	O
104	,	N	O
105	attention-control	N	O
106	(	N	O
107	completion	N	O
108	of	N	O
109	same	N	O
110	questionnaires	N	O
111	without	N	O
112	feedback	N	O
113	)	N	O
114	,	N	O
115	and	N	O
116	control	N	O
117	(	N	O
118	standard	N	O
119	care	N	O
120	)	N	O
121	arms	N	O
122	.	N	O

123	The	N	O
124	content	N	O
125	of	N	O
126	consultation	N	O
127	audio	N	O
128	recordings	N	O
129	between	N	O
130	28	N	O
131	oncologists	N	O
132	and	N	O
133	198	N	O
134	patients	N	O
135	over	N	O
136	four	N	O
137	consecutive	N	O
138	visits	N	O
139	(	N	O
140	792	N	O
141	consultations	N	O
142	)	N	O
143	was	N	O
144	analyzed	N	O
145	.	N	O

146	Mixed-effects	N	O
147	models	N	O
148	and	N	O
149	multivariate	N	O
150	regressions	N	O
151	were	N	O
152	used	N	O
153	to	N	O
154	examine	N	O
155	the	N	O
156	longitudinal	N	O
157	impact	N	O
158	of	N	O
159	the	N	O
160	intervention	N	O
161	on	N	O
162	patient-physician	N	O
163	communication	N	O
164	,	N	O
165	dynamics	N	O
166	of	N	O
167	patient-physician	N	O
168	interaction	N	O
169	,	N	O
170	and	N	O
171	the	N	O
172	association	N	O
173	between	N	O
174	PROs	N	O
175	and	N	O
176	the	N	O
177	content	N	O
178	of	N	O
179	clinic	N	O
180	discussion	N	O
181	.	N	O

182	Patients	N	I-Premise
183	in	N	I-Premise
184	the	N	I-Premise
185	intervention	N	I-Premise
186	arm	N	I-Premise
187	discussed	N	I-Premise
188	more	N	I-Premise
189	symptoms	N	I-Premise
190	over	N	I-Premise
191	time	N	I-Premise
192	compared	N	I-Premise
193	with	N	I-Premise
194	patients	N	I-Premise
195	in	N	I-Premise
196	the	N	I-Premise
197	attention-control	N	I-Premise
198	(	N	I-Premise
199	P	N	I-Premise
200	=	N	I-Premise
201	.008	N	I-Premise
202	)	N	I-Premise
203	and	N	I-Premise
204	control	N	I-Premise
205	(	N	I-Premise
206	P	N	I-Premise
207	=	N	I-Premise
208	.04	N	I-Premise
209	)	N	I-Premise
210	arms	N	I-Premise
211	.	N	I-Premise

212	No	N	I-Premise
213	study	N	I-Premise
214	arm	N	I-Premise
215	effect	N	I-Premise
216	was	N	I-Premise
217	observed	N	I-Premise
218	for	N	I-Premise
219	function	N	I-Premise
220	discussions	N	I-Premise
221	.	N	I-Premise

222	Discussion	N	O
223	topics	N	O
224	were	N	O
225	predominantly	N	O
226	raised	N	O
227	by	N	O
228	patients/relatives	N	O
229	,	N	O
230	regardless	N	O
231	of	N	O
232	arm	N	O
233	allocation	N	O
234	.	N	O

235	Clinic	N	I-Premise
236	discussions	N	I-Premise
237	were	N	I-Premise
238	associated	N	I-Premise
239	with	N	I-Premise
240	severity	N	I-Premise
241	of	N	I-Premise
242	patient-reported	N	I-Premise
243	symptoms	N	I-Premise
244	but	N	I-Premise
245	not	N	I-Premise
246	with	N	I-Premise
247	patient-reported	N	I-Premise
248	functional	N	I-Premise
249	concerns	N	I-Premise
250	.	N	I-Premise

251	A	N	I-Premise
252	positive	N	I-Premise
253	longitudinal	N	I-Premise
254	impact	N	I-Premise
255	of	N	I-Premise
256	the	N	I-Premise
257	intervention	N	I-Premise
258	on	N	I-Premise
259	symptom	N	I-Premise
260	discussion	N	I-Premise
261	was	N	I-Premise
262	observed	N	I-Premise
263	,	N	I-Premise
264	but	N	I-Premise
265	not	N	I-Premise
266	for	N	I-Premise
267	function	N	I-Premise
268	discussion	N	I-Premise
269	,	N	I-Premise
270	suggesting	N	I-Premise
271	that	N	I-Premise
272	potentially	N	I-Premise
273	serious	N	I-Premise
274	problems	N	I-Premise
275	may	N	I-Premise
276	remain	N	I-Premise
277	unaddressed	N	I-Premise
278	.	N	I-Premise

279	Training	N	I-Claim
280	oncologists	N	I-Claim
281	in	N	I-Claim
282	responding	N	I-Claim
283	to	N	I-Claim
284	patient-reported	N	I-Claim
285	functional	N	I-Claim
286	concerns	N	I-Claim
287	may	N	I-Claim
288	increase	N	I-Claim
289	the	N	I-Claim
290	impact	N	I-Claim
291	of	N	I-Claim
292	this	N	I-Claim
293	intervention	N	I-Claim
294	.	N	I-Claim

1	This	N	O
2	phase	N	O
3	III	N	O
4	trial	N	O
5	was	N	O
6	conducted	N	O
7	to	N	O
8	test	N	O
9	whether	N	O
10	the	N	O
11	novel	N	O
12	vascular	N	O
13	disrupting	N	O
14	agent	N	O
15	ASA404	N	O
16	(	N	O
17	vadimezan	N	O
18	)	N	O
19	,	N	O
20	when	N	O
21	combined	N	O
22	with	N	O
23	first-line	N	O
24	platinum-based	N	O
25	chemotherapy	N	O
26	,	N	O
27	improves	N	O
28	survival	N	O
29	in	N	O
30	patients	N	O
31	with	N	O
32	advanced	N	O
33	non-small-cell	N	O
34	lung	N	O
35	cancer	N	O
36	(	N	O
37	NSCLC	N	O
38	)	N	O
39	versus	N	O
40	chemotherapy	N	O
41	alone	N	O
42	.	N	O

43	Patients	N	O
44	with	N	O
45	advanced	N	O
46	stage	N	O
47	IIIB	N	O
48	or	N	O
49	IV	N	O
50	NSCLC	N	O
51	,	N	O
52	stratified	N	O
53	by	N	O
54	sex	N	O
55	and	N	O
56	tumor	N	O
57	histology	N	O
58	,	N	O
59	were	N	O
60	randomly	N	O
61	assigned	N	O
62	1:1	N	O
63	to	N	O
64	paclitaxel	N	O
65	(	N	O
66	200	N	O
67	mg/m	N	O
68	(	N	O
69	2	N	O
70	)	N	O
71	)	N	O
72	and	N	O
73	carboplatin	N	O
74	(	N	O
75	area	N	O
76	under	N	O
77	the	N	O
78	curve	N	O
79	,	N	O
80	6.0	N	O
81	)	N	O
82	with	N	O
83	or	N	O
84	without	N	O
85	ASA404	N	O
86	(	N	O
87	1,800	N	O
88	mg	N	O
89	m	N	O
90	(	N	O
91	2	N	O
92	)	N	O
93	)	N	O
94	,	N	O
95	given	N	O
96	intravenously	N	O
97	once	N	O
98	every	N	O
99	3	N	O
100	weeks	N	O
101	for	N	O
102	six	N	O
103	cycles	N	O
104	followed	N	O
105	by	N	O
106	maintenance	N	O
107	ASA404	N	O
108	or	N	O
109	placebo	N	O
110	.	N	O

111	Primary	N	O
112	end	N	O
113	point	N	O
114	was	N	O
115	overall	N	O
116	survival	N	O
117	(	N	O
118	OS	N	O
119	)	N	O
120	;	N	O
121	secondary	N	O
122	end	N	O
123	points	N	O
124	included	N	O
125	overall	N	O
126	response	N	O
127	rate	N	O
128	(	N	O
129	ORR	N	O
130	)	N	O
131	and	N	O
132	progression-free	N	O
133	survival	N	O
134	(	N	O
135	PFS	N	O
136	)	N	O
137	.	N	O

138	One	N	O
139	thousand	N	O
140	two	N	O
141	hundred	N	O
142	ninety-nine	N	O
143	patients	N	O
144	were	N	O
145	randomly	N	O
146	assigned	N	O
147	.	N	O

148	The	N	O
149	trial	N	O
150	was	N	O
151	stopped	N	O
152	for	N	O
153	futility	N	O
154	at	N	O
155	interim	N	O
156	analysis	N	O
157	.	N	O

158	At	N	O
159	final	N	O
160	analysis	N	O
161	,	N	O
162	there	N	I-Premise
163	was	N	I-Premise
164	no	N	I-Premise
165	difference	N	I-Premise
166	in	N	I-Premise
167	OS	N	I-Premise
168	seen	N	I-Premise
169	between	N	I-Premise
170	ASA404	N	I-Premise
171	(	N	I-Premise
172	n	N	I-Premise
173	=	N	I-Premise
174	649	N	I-Premise
175	)	N	I-Premise
176	and	N	I-Premise
177	placebo	N	I-Premise
178	(	N	I-Premise
179	n	N	I-Premise
180	=	N	I-Premise
181	650	N	I-Premise
182	)	N	I-Premise
183	arms	N	I-Premise
184	:	N	I-Premise
185	median	N	I-Premise
186	OS	N	I-Premise
187	was	N	I-Premise
188	13.4	N	I-Premise
189	and	N	I-Premise
190	12.7	N	I-Premise
191	months	N	I-Premise
192	respectively	N	I-Premise
193	(	N	I-Premise
194	hazard	N	I-Premise
195	ratio	N	I-Premise
196	[	N	I-Premise
197	HR	N	I-Premise
198	]	N	I-Premise
199	,	N	I-Premise
200	1.01	N	I-Premise
201	;	N	I-Premise
202	95	N	I-Premise
203	%	N	I-Premise
204	CI	N	I-Premise
205	,	N	I-Premise
206	0.85	N	I-Premise
207	to	N	I-Premise
208	1.19	N	I-Premise
209	;	N	I-Premise
210	P	N	I-Premise
211	=	N	I-Premise
212	.535	N	I-Premise
213	)	N	I-Premise
214	.	N	I-Premise

215	Similarly	N	O
216	,	N	O
217	no	N	I-Premise
218	OS	N	I-Premise
219	difference	N	I-Premise
220	was	N	I-Premise
221	seen	N	I-Premise
222	in	N	I-Premise
223	the	N	I-Premise
224	histologic	N	I-Premise
225	(	N	I-Premise
226	squamous	N	I-Premise
227	or	N	I-Premise
228	nonsquamous	N	I-Premise
229	)	N	I-Premise
230	and	N	I-Premise
231	sex	N	I-Premise
232	(	N	I-Premise
233	male	N	I-Premise
234	or	N	I-Premise
235	female	N	I-Premise
236	)	N	I-Premise
237	strata	N	I-Premise
238	.	N	I-Premise

239	Median	N	I-Premise
240	PFS	N	I-Premise
241	was	N	I-Premise
242	5.5	N	I-Premise
243	months	N	I-Premise
244	in	N	I-Premise
245	both	N	I-Premise
246	arms	N	I-Premise
247	(	N	I-Premise
248	HR	N	I-Premise
249	,	N	I-Premise
250	1.04	N	I-Premise
251	;	N	I-Premise
252	P	N	I-Premise
253	=	N	I-Premise
254	.727	N	I-Premise
255	)	N	I-Premise
256	,	N	I-Premise
257	while	N	I-Premise
258	ORR	N	I-Premise
259	was	N	I-Premise
260	25	N	I-Premise
261	%	N	I-Premise
262	in	N	I-Premise
263	both	N	I-Premise
264	arms	N	I-Premise
265	(	N	I-Premise
266	P	N	I-Premise
267	=	N	I-Premise
268	1.0	N	I-Premise
269	)	N	I-Premise
270	.	N	I-Premise

271	Overall	N	I-Premise
272	rate	N	I-Premise
273	of	N	I-Premise
274	adverse	N	I-Premise
275	events	N	I-Premise
276	(	N	I-Premise
277	AEs	N	I-Premise
278	)	N	I-Premise
279	was	N	I-Premise
280	comparable	N	I-Premise
281	between	N	I-Premise
282	the	N	I-Premise
283	ASA404	N	I-Premise
284	and	N	I-Premise
285	placebo	N	I-Premise
286	arms	N	I-Premise
287	.	N	I-Premise

288	Grade	N	I-Premise
289	4	N	I-Premise
290	neutropenia	N	I-Premise
291	(	N	I-Premise
292	27	N	I-Premise
293	%	N	I-Premise
294	v	N	I-Premise
295	19	N	I-Premise
296	%	N	I-Premise
297	)	N	I-Premise
298	and	N	I-Premise
299	infusion	N	I-Premise
300	site	N	I-Premise
301	pain	N	I-Premise
302	(	N	I-Premise
303	10	N	I-Premise
304	%	N	I-Premise
305	v	N	I-Premise
306	0.5	N	I-Premise
307	%	N	I-Premise
308	)	N	I-Premise
309	were	N	I-Premise
310	reported	N	I-Premise
311	more	N	I-Premise
312	frequently	N	I-Premise
313	in	N	I-Premise
314	the	N	I-Premise
315	ASA404	N	I-Premise
316	arm	N	I-Premise
317	.	N	I-Premise

318	The	N	I-Claim
319	addition	N	I-Claim
320	of	N	I-Claim
321	ASA404	N	I-Claim
322	to	N	I-Claim
323	carboplatin	N	I-Claim
324	and	N	I-Claim
325	paclitaxel	N	I-Claim
326	,	N	I-Claim
327	although	N	I-Claim
328	generally	N	I-Claim
329	well	N	I-Claim
330	tolerated	N	I-Claim
331	,	N	I-Claim
332	failed	N	I-Claim
333	to	N	I-Claim
334	improve	N	I-Claim
335	frontline	N	I-Claim
336	efficacy	N	I-Claim
337	in	N	I-Claim
338	advanced	N	I-Claim
339	NSCLC	N	I-Claim
340	.	N	I-Claim

1	The	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	bevacizumab	N	I-Claim
5	to	N	I-Claim
6	paclitaxel	N	I-Claim
7	improved	N	I-Claim
8	progression-free	N	I-Claim
9	survival	N	I-Claim
10	(	N	I-Claim
11	PFS	N	I-Claim
12	)	N	I-Claim
13	of	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	metastatic	N	I-Claim
17	breast	N	I-Claim
18	cancer	N	I-Claim
19	(	N	I-Claim
20	MBC	N	I-Claim
21	)	N	I-Claim
22	.	N	I-Claim

23	We	N	O
24	examined	N	O
25	the	N	O
26	efficacy	N	O
27	and	N	O
28	safety	N	O
29	of	N	O
30	adding	N	O
31	gemcitabine	N	O
32	to	N	O
33	paclitaxel/bevacizumab	N	O
34	(	N	O
35	PB	N	O
36	)	N	O
37	.	N	O

38	In	N	O
39	this	N	O
40	multicenter	N	O
41	,	N	O
42	open-label	N	O
43	,	N	O
44	randomized	N	O
45	phase	N	O
46	II	N	O
47	trial	N	O
48	,	N	O
49	women	N	O
50	with	N	O
51	locally	N	O
52	advanced	N	O
53	or	N	O
54	MBC	N	O
55	were	N	O
56	randomly	N	O
57	assigned	N	O
58	to	N	O
59	receive	N	O
60	paclitaxel	N	O
61	90	N	O
62	mg/m	N	O
63	(	N	O
64	2	N	O
65	)	N	O
66	(	N	O
67	days	N	O
68	1	N	O
69	,	N	O
70	8	N	O
71	,	N	O
72	15	N	O
73	)	N	O
74	and	N	O
75	bevacizumab	N	O
76	10	N	O
77	mg/kg	N	O
78	(	N	O
79	days	N	O
80	1	N	O
81	,	N	O
82	15	N	O
83	)	N	O
84	with	N	O
85	or	N	O
86	without	N	O
87	gemcitabine	N	O
88	1500	N	O
89	mg/m	N	O
90	(	N	O
91	2	N	O
92	)	N	O
93	(	N	O
94	days	N	O
95	1	N	O
96	,	N	O
97	15	N	O
98	)	N	O
99	in	N	O
100	28-day	N	O
101	cycles	N	O
102	.	N	O

103	Patients	N	O
104	with	N	O
105	prior	N	O
106	cytotoxic	N	O
107	therapy	N	O
108	for	N	O
109	MBC	N	O
110	were	N	O
111	ineligible	N	O
112	.	N	O

113	The	N	O
114	primary	N	O
115	endpoint	N	O
116	was	N	O
117	investigator-assessed	N	O
118	overall	N	O
119	response	N	O
120	rate	N	O
121	(	N	O
122	ORR	N	O
123	)	N	O
124	;	N	O
125	secondary	N	O
126	endpoints	N	O
127	were	N	O
128	PFS	N	O
129	,	N	O
130	overall	N	O
131	survival	N	O
132	(	N	O
133	OS	N	O
134	)	N	O
135	,	N	O
136	safety	N	O
137	,	N	O
138	and	N	O
139	quality	N	O
140	of	N	O
141	life	N	O
142	.	N	O

143	Ninety-four	N	O
144	patients	N	O
145	received	N	O
146	PB	N	O
147	,	N	O
148	and	N	O
149	93	N	O
150	received	N	O
151	paclitaxel/bevacizumab/gemcitabine	N	O
152	(	N	O
153	PB+G	N	O
154	)	N	O
155	.	N	O

156	The	N	I-Premise
157	ORRs	N	I-Premise
158	were	N	I-Premise
159	48.9	N	I-Premise
160	%	N	I-Premise
161	(	N	I-Premise
162	95	N	I-Premise
163	%	N	I-Premise
164	confidence	N	I-Premise
165	interval	N	I-Premise
166	[	N	I-Premise
167	CI	N	I-Premise
168	]	N	I-Premise
169	,	N	I-Premise
170	38.5	N	I-Premise
171	%	N	I-Premise
172	-59.5	N	I-Premise
173	%	N	I-Premise
174	)	N	I-Premise
175	and	N	I-Premise
176	58.7	N	I-Premise
177	%	N	I-Premise
178	(	N	I-Premise
179	95	N	I-Premise
180	%	N	I-Premise
181	CI	N	I-Premise
182	,	N	I-Premise
183	47.9	N	I-Premise
184	%	N	I-Premise
185	-68.9	N	I-Premise
186	%	N	I-Premise
187	;	N	I-Premise
188	P	N	I-Premise
189	=	N	I-Premise
190	.117	N	I-Premise
191	)	N	I-Premise
192	with	N	I-Premise
193	PB	N	I-Premise
194	and	N	I-Premise
195	PB+G	N	I-Premise
196	,	N	I-Premise
197	respectively	N	I-Premise
198	.	N	I-Premise

199	The	N	I-Premise
200	median	N	I-Premise
201	PFS	N	I-Premise
202	was	N	I-Premise
203	8.8	N	I-Premise
204	months	N	I-Premise
205	(	N	I-Premise
206	95	N	I-Premise
207	%	N	I-Premise
208	CI	N	I-Premise
209	,	N	I-Premise
210	8.1-10.4	N	I-Premise
211	months	N	I-Premise
212	)	N	I-Premise
213	and	N	I-Premise
214	11.3	N	I-Premise
215	months	N	I-Premise
216	(	N	I-Premise
217	95	N	I-Premise
218	%	N	I-Premise
219	CI	N	I-Premise
220	,	N	I-Premise
221	9.7-12.7	N	I-Premise
222	months	N	I-Premise
223	;	N	I-Premise
224	P	N	I-Premise
225	=	N	I-Premise
226	.247	N	I-Premise
227	;	N	I-Premise
228	hazard	N	I-Premise
229	ratio	N	I-Premise
230	,	N	I-Premise
231	0.82	N	I-Premise
232	)	N	I-Premise
233	;	N	I-Premise
234	the	N	I-Premise
235	median	N	I-Premise
236	OS	N	I-Premise
237	was	N	I-Premise
238	25.0	N	I-Premise
239	months	N	I-Premise
240	(	N	I-Premise
241	95	N	I-Premise
242	%	N	I-Premise
243	CI	N	I-Premise
244	,	N	I-Premise
245	18.8-not	N	I-Premise
246	assessable	N	I-Premise
247	[	N	I-Premise
248	N/A	N	I-Premise
249	]	N	I-Premise
250	months	N	I-Premise
251	)	N	I-Premise
252	and	N	I-Premise
253	24.3	N	I-Premise
254	months	N	I-Premise
255	(	N	I-Premise
256	95	N	I-Premise
257	%	N	I-Premise
258	CI	N	I-Premise
259	,	N	I-Premise
260	20.3-N/A	N	I-Premise
261	months	N	I-Premise
262	;	N	I-Premise
263	P	N	I-Premise
264	=	N	I-Premise
265	.475	N	I-Premise
266	;	N	I-Premise
267	hazard	N	I-Premise
268	ratio	N	I-Premise
269	,	N	I-Premise
270	0.84	N	I-Premise
271	)	N	I-Premise
272	,	N	I-Premise
273	with	N	I-Premise
274	PB	N	I-Premise
275	and	N	I-Premise
276	PB+G	N	I-Premise
277	,	N	I-Premise
278	respectively	N	I-Premise
279	.	N	I-Premise

280	There	N	I-Premise
281	was	N	I-Premise
282	significantly	N	I-Premise
283	more	N	I-Premise
284	grade	N	I-Premise
285	3-4	N	I-Premise
286	neutropenia	N	I-Premise
287	(	N	I-Premise
288	P	N	I-Premise
289	=	N	I-Premise
290	.001	N	I-Premise
291	)	N	I-Premise
292	and	N	I-Premise
293	dyspnea	N	I-Premise
294	(	N	I-Premise
295	P	N	I-Premise
296	=	N	I-Premise
297	.014	N	I-Premise
298	)	N	I-Premise
299	with	N	I-Premise
300	PB+G	N	I-Premise
301	.	N	I-Premise

302	Patients	N	I-Premise
303	treated	N	I-Premise
304	with	N	I-Premise
305	PB	N	I-Premise
306	experienced	N	I-Premise
307	more	N	I-Premise
308	improvement	N	I-Premise
309	in	N	I-Premise
310	total	N	I-Premise
311	FACT-B	N	I-Premise
312	(	N	I-Premise
313	Functional	N	I-Premise
314	Assessment	N	I-Premise
315	of	N	I-Premise
316	Cancer	N	I-Premise
317	Therapy-Breast	N	I-Premise
318	)	N	I-Premise
319	(	N	I-Premise
320	P	N	I-Premise
321	=	N	I-Premise
322	.021	N	I-Premise
323	)	N	I-Premise
324	,	N	I-Premise
325	FACT-B	N	I-Premise
326	Social/Family	N	I-Premise
327	Well-being	N	I-Premise
328	(	N	I-Premise
329	P	N	I-Premise
330	=	N	I-Premise
331	.041	N	I-Premise
332	)	N	I-Premise
333	,	N	I-Premise
334	and	N	I-Premise
335	Breast	N	I-Premise
336	Cancer-Additional	N	I-Premise
337	Concerns	N	I-Premise
338	(	N	I-Premise
339	P	N	I-Premise
340	=	N	I-Premise
341	.008	N	I-Premise
342	)	N	I-Premise
343	scores	N	I-Premise
344	than	N	I-Premise
345	patients	N	I-Premise
346	treated	N	I-Premise
347	with	N	I-Premise
348	PB+G	N	I-Premise
349	.	N	I-Premise

350	The	N	I-Claim
351	addition	N	I-Claim
352	of	N	I-Claim
353	gemcitabine	N	I-Claim
354	to	N	I-Claim
355	PB	N	I-Claim
356	was	N	I-Claim
357	not	N	I-Claim
358	associated	N	I-Claim
359	with	N	I-Claim
360	a	N	I-Claim
361	statistically	N	I-Claim
362	significant	N	I-Claim
363	improvement	N	I-Claim
364	in	N	I-Claim
365	ORR	N	I-Claim
366	.	N	I-Claim

367	Treatment	N	I-Claim
368	with	N	I-Claim
369	PB+G	N	I-Claim
370	increased	N	I-Claim
371	the	N	I-Claim
372	incidence	N	I-Claim
373	of	N	I-Claim
374	severe	N	I-Claim
375	neutropenia	N	I-Claim
376	and	N	I-Claim
377	dyspnea	N	I-Claim
378	,	N	I-Claim
379	although	N	I-Claim
380	the	N	I-Claim
381	regimen	N	I-Claim
382	generally	N	I-Claim
383	was	N	I-Claim
384	well	N	I-Claim
385	tolerated	N	I-Claim
386	.	N	I-Claim

1	Dignity	N	O
2	therapy	N	O
3	is	N	O
4	a	N	O
5	unique	N	O
6	,	N	O
7	individualised	N	O
8	,	N	O
9	short-term	N	O
10	psychotherapy	N	O
11	that	N	O
12	was	N	O
13	developed	N	O
14	for	N	O
15	patients	N	O
16	(	N	O
17	and	N	O
18	their	N	O
19	families	N	O
20	)	N	O
21	living	N	O
22	with	N	O
23	life-threatening	N	O
24	or	N	O
25	life-limiting	N	O
26	illness	N	O
27	.	N	O

28	We	N	O
29	investigated	N	O
30	whether	N	O
31	dignity	N	O
32	therapy	N	O
33	could	N	O
34	mitigate	N	O
35	distress	N	O
36	or	N	O
37	bolster	N	O
38	the	N	O
39	experience	N	O
40	in	N	O
41	patients	N	O
42	nearing	N	O
43	the	N	O
44	end	N	O
45	of	N	O
46	their	N	O
47	lives	N	O
48	.	N	O

49	Patients	N	O
50	(	N	O
51	aged	N	O
52	18	N	O
53	years	N	O
54	)	N	O
55	with	N	O
56	a	N	O
57	terminal	N	O
58	prognosis	N	O
59	(	N	O
60	life	N	O
61	expectancy	N	O
62	6	N	O
63	months	N	O
64	)	N	O
65	who	N	O
66	were	N	O
67	receiving	N	O
68	palliative	N	O
69	care	N	O
70	in	N	O
71	a	N	O
72	hospital	N	O
73	or	N	O
74	community	N	O
75	setting	N	O
76	(	N	O
77	hospice	N	O
78	or	N	O
79	home	N	O
80	)	N	O
81	in	N	O
82	Canada	N	O
83	,	N	O
84	USA	N	O
85	,	N	O
86	and	N	O
87	Australia	N	O
88	were	N	O
89	randomly	N	O
90	assigned	N	O
91	to	N	O
92	dignity	N	O
93	therapy	N	O
94	,	N	O
95	client-centred	N	O
96	care	N	O
97	,	N	O
98	or	N	O
99	standard	N	O
100	palliative	N	O
101	care	N	O
102	in	N	O
103	a	N	O
104	1:1:1	N	O
105	ratio	N	O
106	.	N	O

107	Randomisation	N	O
108	was	N	O
109	by	N	O
110	use	N	O
111	of	N	O
112	a	N	O
113	computer-generated	N	O
114	table	N	O
115	of	N	O
116	random	N	O
117	numbers	N	O
118	in	N	O
119	blocks	N	O
120	of	N	O
121	30	N	O
122	.	N	O

123	Allocation	N	O
124	concealment	N	O
125	was	N	O
126	by	N	O
127	use	N	O
128	of	N	O
129	opaque	N	O
130	sealed	N	O
131	envelopes	N	O
132	.	N	O

133	The	N	O
134	primary	N	O
135	outcomes	N	O
136	--	N	O
137	reductions	N	O
138	in	N	O
139	various	N	O
140	dimensions	N	O
141	of	N	O
142	distress	N	O
143	before	N	O
144	and	N	O
145	after	N	O
146	completion	N	O
147	of	N	O
148	the	N	O
149	study	N	O
150	--	N	O
151	were	N	O
152	measured	N	O
153	with	N	O
154	the	N	O
155	Functional	N	O
156	Assessment	N	O
157	of	N	O
158	Chronic	N	O
159	Illness	N	O
160	Therapy	N	O
161	Spiritual	N	O
162	Well-Being	N	O
163	Scale	N	O
164	,	N	O
165	Patient	N	O
166	Dignity	N	O
167	Inventory	N	O
168	,	N	O
169	Hospital	N	O
170	Anxiety	N	O
171	and	N	O
172	Depression	N	O
173	Scale	N	O
174	,	N	O
175	items	N	O
176	from	N	O
177	the	N	O
178	Structured	N	O
179	Interview	N	O
180	for	N	O
181	Symptoms	N	O
182	and	N	O
183	Concerns	N	O
184	,	N	O
185	Quality	N	O
186	of	N	O
187	Life	N	O
188	Scale	N	O
189	,	N	O
190	and	N	O
191	modified	N	O
192	Edmonton	N	O
193	Symptom	N	O
194	Assessment	N	O
195	Scale	N	O
196	.	N	O

197	Secondary	N	O
198	outcomes	N	O
199	of	N	O
200	self-reported	N	O
201	end-of-life	N	O
202	experiences	N	O
203	were	N	O
204	assessed	N	O
205	in	N	O
206	a	N	O
207	survey	N	O
208	that	N	O
209	was	N	O
210	undertaken	N	O
211	after	N	O
212	the	N	O
213	completion	N	O
214	of	N	O
215	the	N	O
216	study	N	O
217	.	N	O

218	Outcomes	N	O
219	were	N	O
220	assessed	N	O
221	by	N	O
222	research	N	O
223	staff	N	O
224	with	N	O
225	whom	N	O
226	the	N	O
227	participant	N	O
228	had	N	O
229	no	N	O
230	previous	N	O
231	contact	N	O
232	to	N	O
233	avoid	N	O
234	any	N	O
235	possible	N	O
236	response	N	O
237	bias	N	O
238	or	N	O
239	contamination	N	O
240	.	N	O

241	Analyses	N	O
242	were	N	O
243	done	N	O
244	on	N	O
245	all	N	O
246	patients	N	O
247	with	N	O
248	available	N	O
249	data	N	O
250	at	N	O
251	baseline	N	O
252	and	N	O
253	at	N	O
254	the	N	O
255	end	N	O
256	of	N	O
257	the	N	O
258	study	N	O
259	intervention	N	O
260	.	N	O

261	165	N	O
262	of	N	O
263	441	N	O
264	patients	N	O
265	were	N	O
266	assigned	N	O
267	to	N	O
268	dignity	N	O
269	therapy	N	O
270	,	N	O
271	140	N	O
272	standard	N	O
273	palliative	N	O
274	care	N	O
275	,	N	O
276	and	N	O
277	136	N	O
278	client-centred	N	O
279	care	N	O
280	.	N	O

281	108	N	O
282	,	N	O
283	111	N	O
284	,	N	O
285	and	N	O
286	107	N	O
287	patients	N	O
288	,	N	O
289	respectively	N	O
290	,	N	O
291	were	N	O
292	analysed	N	O
293	.	N	O

294	No	N	I-Premise
295	significant	N	I-Premise
296	differences	N	I-Premise
297	were	N	I-Premise
298	noted	N	I-Premise
299	in	N	I-Premise
300	the	N	I-Premise
301	distress	N	I-Premise
302	levels	N	I-Premise
303	before	N	I-Premise
304	and	N	I-Premise
305	after	N	I-Premise
306	completion	N	I-Premise
307	of	N	I-Premise
308	the	N	I-Premise
309	study	N	I-Premise
310	in	N	I-Premise
311	the	N	I-Premise
312	three	N	I-Premise
313	groups	N	I-Premise
314	.	N	I-Premise

315	For	N	I-Premise
316	the	N	I-Premise
317	secondary	N	I-Premise
318	outcomes	N	I-Premise
319	,	N	I-Premise
320	patients	N	I-Premise
321	reported	N	I-Premise
322	that	N	I-Premise
323	dignity	N	I-Premise
324	therapy	N	I-Premise
325	was	N	I-Premise
326	significantly	N	I-Premise
327	more	N	I-Premise
328	likely	N	I-Premise
329	than	N	I-Premise
330	the	N	I-Premise
331	other	N	I-Premise
332	two	N	I-Premise
333	interventions	N	I-Premise
334	to	N	I-Premise
335	have	N	I-Premise
336	been	N	I-Premise
337	helpful	N	I-Premise
338	(	N	I-Premise
339		N	I-Premise
340	(	N	I-Premise
341	2	N	I-Premise
342	)	N	I-Premise
343	=3550	N	I-Premise
344	,	N	I-Premise
345	df=2	N	I-Premise
346	;	N	I-Premise
347	p	N	I-Premise
348	<	N	I-Premise
349	00001	N	I-Premise
350	)	N	I-Premise
351	,	N	I-Premise
352	improve	N	I-Premise
353	quality	N	I-Premise
354	of	N	I-Premise
355	life	N	I-Premise
356	(	N	I-Premise
357		N	I-Premise
358	(	N	I-Premise
359	2	N	I-Premise
360	)	N	I-Premise
361	=1452	N	I-Premise
362	;	N	I-Premise
363	p=0001	N	I-Premise
364	)	N	I-Premise
365	,	N	I-Premise
366	increase	N	I-Premise
367	sense	N	I-Premise
368	of	N	I-Premise
369	dignity	N	I-Premise
370	(	N	I-Premise
371		N	I-Premise
372	(	N	I-Premise
373	2	N	I-Premise
374	)	N	I-Premise
375	=1266	N	I-Premise
376	;	N	I-Premise
377	p=0002	N	I-Premise
378	)	N	I-Premise
379	,	N	I-Premise
380	change	N	I-Premise
381	how	N	I-Premise
382	their	N	I-Premise
383	family	N	I-Premise
384	saw	N	I-Premise
385	and	N	I-Premise
386	appreciated	N	I-Premise
387	them	N	I-Premise
388	(	N	I-Premise
389		N	I-Premise
390	(	N	I-Premise
391	2	N	I-Premise
392	)	N	I-Premise
393	=3381	N	I-Premise
394	;	N	I-Premise
395	p	N	I-Premise
396	<	N	I-Premise
397	00001	N	I-Premise
398	)	N	I-Premise
399	,	N	I-Premise
400	and	N	I-Premise
401	be	N	I-Premise
402	helpful	N	I-Premise
403	to	N	I-Premise
404	their	N	I-Premise
405	family	N	I-Premise
406	(	N	I-Premise
407		N	I-Premise
408	(	N	I-Premise
409	2	N	I-Premise
410	)	N	I-Premise
411	=3386	N	I-Premise
412	;	N	I-Premise
413	p	N	I-Premise
414	<	N	I-Premise
415	00001	N	I-Premise
416	)	N	I-Premise
417	.	N	I-Premise

418	Dignity	N	I-Premise
419	therapy	N	I-Premise
420	was	N	I-Premise
421	significantly	N	I-Premise
422	better	N	I-Premise
423	than	N	I-Premise
424	client-centred	N	I-Premise
425	care	N	I-Premise
426	in	N	I-Premise
427	improving	N	I-Premise
428	spiritual	N	I-Premise
429	wellbeing	N	I-Premise
430	(	N	I-Premise
431		N	I-Premise
432	(	N	I-Premise
433	2	N	I-Premise
434	)	N	I-Premise
435	=1035	N	I-Premise
436	;	N	I-Premise
437	p=0006	N	I-Premise
438	)	N	I-Premise
439	,	N	I-Premise
440	and	N	I-Premise
441	was	N	I-Premise
442	significantly	N	I-Premise
443	better	N	I-Premise
444	than	N	I-Premise
445	standard	N	I-Premise
446	palliative	N	I-Premise
447	care	N	I-Premise
448	in	N	I-Premise
449	terms	N	I-Premise
450	of	N	I-Premise
451	lessening	N	I-Premise
452	sadness	N	I-Premise
453	or	N	I-Premise
454	depression	N	I-Premise
455	(	N	I-Premise
456		N	I-Premise
457	(	N	I-Premise
458	2	N	I-Premise
459	)	N	I-Premise
460	=938	N	I-Premise
461	;	N	I-Premise
462	p=0009	N	I-Premise
463	)	N	I-Premise
464	;	N	I-Premise
465	significantly	N	I-Premise
466	more	N	I-Premise
467	patients	N	I-Premise
468	who	N	I-Premise
469	had	N	I-Premise
470	received	N	I-Premise
471	dignity	N	I-Premise
472	therapy	N	I-Premise
473	reported	N	I-Premise
474	that	N	I-Premise
475	the	N	I-Premise
476	study	N	I-Premise
477	group	N	I-Premise
478	had	N	I-Premise
479	been	N	I-Premise
480	satisfactory	N	I-Premise
481	,	N	I-Premise
482	compared	N	I-Premise
483	with	N	I-Premise
484	those	N	I-Premise
485	who	N	I-Premise
486	received	N	I-Premise
487	standard	N	I-Premise
488	palliative	N	I-Premise
489	care	N	I-Premise
490	(	N	I-Premise
491		N	I-Premise
492	(	N	I-Premise
493	2	N	I-Premise
494	)	N	I-Premise
495	=2958	N	I-Premise
496	;	N	I-Premise
497	p	N	I-Premise
498	<	N	I-Premise
499	00001	N	I-Premise
500	)	N	I-Premise
501	.	N	I-Premise

502	Although	N	I-Claim
503	the	N	I-Claim
504	ability	N	I-Claim
505	of	N	I-Claim
506	dignity	N	I-Claim
507	therapy	N	I-Claim
508	to	N	I-Claim
509	mitigate	N	I-Claim
510	outright	N	I-Claim
511	distress	N	I-Claim
512	,	N	I-Claim
513	such	N	I-Claim
514	as	N	I-Claim
515	depression	N	I-Claim
516	,	N	I-Claim
517	desire	N	I-Claim
518	for	N	I-Claim
519	death	N	I-Claim
520	or	N	I-Claim
521	suicidality	N	I-Claim
522	,	N	I-Claim
523	has	N	I-Claim
524	yet	N	I-Claim
525	to	N	I-Claim
526	be	N	I-Claim
527	proven	N	I-Claim
528	,	N	I-Claim
529	its	N	I-Claim
530	benefits	N	I-Claim
531	in	N	I-Claim
532	terms	N	I-Claim
533	of	N	I-Claim
534	self-reported	N	I-Claim
535	end-of-life	N	I-Claim
536	experiences	N	I-Claim
537	support	N	I-Claim
538	its	N	I-Claim
539	clinical	N	I-Claim
540	application	N	I-Claim
541	for	N	I-Claim
542	patients	N	I-Claim
543	nearing	N	I-Claim
544	death	N	I-Claim
545	.	N	I-Claim

1	Anemia	N	I-MajorClaim
2	is	N	I-MajorClaim
3	an	N	I-MajorClaim
4	expected	N	I-MajorClaim
5	consequence	N	I-MajorClaim
6	of	N	I-MajorClaim
7	intensive	N	I-MajorClaim
8	chemotherapy	N	I-MajorClaim
9	regimens	N	I-MajorClaim
10	administered	N	I-MajorClaim
11	to	N	I-MajorClaim
12	patients	N	I-MajorClaim
13	with	N	I-MajorClaim
14	acute	N	I-MajorClaim
15	leukemia	N	I-MajorClaim
16	.	N	I-MajorClaim

17	This	N	O
18	study	N	O
19	was	N	O
20	designed	N	O
21	to	N	O
22	determine	N	O
23	whether	N	O
24	epoetin	N	O
25	alpha	N	O
26	would	N	O
27	decrease	N	O
28	the	N	O
29	number	N	O
30	of	N	O
31	transfusion	N	O
32	events	N	O
33	and	N	O
34	units	N	O
35	of	N	O
36	packed	N	O
37	erythrocytes	N	O
38	(	N	O
39	PRBCs	N	O
40	)	N	O
41	transfused	N	O
42	,	N	O
43	and	N	O
44	the	N	O
45	secondary	N	O
46	objective	N	O
47	was	N	O
48	to	N	O
49	study	N	O
50	the	N	O
51	effects	N	O
52	of	N	O
53	epoetin	N	O
54	alpha	N	O
55	on	N	O
56	quality	N	O
57	of	N	O
58	life	N	O
59	(	N	O
60	QOL	N	O
61	)	N	O
62	and	N	O
63	complete	N	O
64	remission	N	O
65	(	N	O
66	CR	N	O
67	)	N	O
68	rates	N	O
69	.	N	O

70	Patients	N	O
71	with	N	O
72	acute	N	O
73	lymphoblastic	N	O
74	leukemia	N	O
75	(	N	O
76	ALL	N	O
77	)	N	O
78	,	N	O
79	lymphoblastic	N	O
80	lymphoma	N	O
81	(	N	O
82	LL	N	O
83	)	N	O
84	,	N	O
85	or	N	O
86	Burkitt	N	O
87	lymphoma	N	O
88	(	N	O
89	BL	N	O
90	)	N	O
91	who	N	O
92	were	N	O
93	receiving	N	O
94	frontline	N	O
95	myelosuppressive	N	O
96	chemotherapy	N	O
97	were	N	O
98	randomized	N	O
99	to	N	O
100	receive	N	O
101	epoetin	N	O
102	alpha	N	O
103	or	N	O
104	no	N	O
105	epoetin	N	O
106	during	N	O
107	the	N	O
108	first	N	O
109	6	N	O
110	cycles	N	O
111	of	N	O
112	their	N	O
113	planned	N	O
114	chemotherapy	N	O
115	.	N	O

116	QOL	N	O
117	was	N	O
118	assessed	N	O
119	by	N	O
120	using	N	O
121	the	N	O
122	Edmonton	N	O
123	Symptom	N	O
124	Assessment	N	O
125	Scale	N	O
126	(	N	O
127	ESAS	N	O
128	)	N	O
129	and	N	O
130	the	N	O
131	Functional	N	O
132	Assessment	N	O
133	of	N	O
134	Cancer	N	O
135	Therapy	N	O
136	(	N	O
137	FACT	N	O
138	)	N	O
139	-Anemia	N	O
140	questionnaires	N	O
141	.	N	O

142	Fifty-five	N	O
143	patients	N	O
144	were	N	O
145	randomized	N	O
146	to	N	O
147	receive	N	O
148	epoetin	N	O
149	alpha	N	O
150	,	N	O
151	and	N	O
152	54	N	O
153	patients	N	O
154	received	N	O
155	no	N	O
156	epoetin	N	O
157	.	N	O

158	Transfusion	N	O
159	data	N	O
160	were	N	O
161	available	N	O
162	for	N	O
163	79	N	O
164	of	N	O
165	81	N	O
166	evaluable	N	O
167	patients	N	O
168	(	N	O
169	98	N	O
170	%	N	O
171	)	N	O
172	who	N	O
173	completed	N	O
174	the	N	O
175	treatment/observation	N	O
176	period	N	O
177	.	N	O

178	The	N	I-Premise
179	trial	N	I-Premise
180	was	N	I-Premise
181	stopped	N	I-Premise
182	early	N	I-Premise
183	because	N	I-Premise
184	of	N	I-Premise
185	poor	N	I-Premise
186	accrual	N	I-Premise
187	before	N	I-Premise
188	the	N	I-Premise
189	target	N	I-Premise
190	of	N	I-Premise
191	123	N	I-Premise
192	evaluable	N	I-Premise
193	patients	N	I-Premise
194	was	N	I-Premise
195	met	N	I-Premise
196	.	N	I-Premise

197	A	N	I-Premise
198	mean	N	I-Premise
199	of	N	I-Premise
200	10.6	N	I-Premise
201	units	N	I-Premise
202	of	N	I-Premise
203	PRBCs	N	I-Premise
204	over	N	I-Premise
205	5	N	I-Premise
206	months	N	I-Premise
207	were	N	I-Premise
208	administered	N	I-Premise
209	to	N	I-Premise
210	those	N	I-Premise
211	who	N	I-Premise
212	received	N	I-Premise
213	epoetin	N	I-Premise
214	alpha	N	I-Premise
215	compared	N	I-Premise
216	with	N	I-Premise
217	13	N	I-Premise
218	units	N	I-Premise
219	for	N	I-Premise
220	those	N	I-Premise
221	who	N	I-Premise
222	did	N	I-Premise
223	not	N	I-Premise
224	receive	N	I-Premise
225	epoetin	N	I-Premise
226	(	N	I-Premise
227	P	N	I-Premise
228	=	N	I-Premise
229	.04	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	There	N	I-Premise
233	was	N	I-Premise
234	no	N	I-Premise
235	significant	N	I-Premise
236	difference	N	I-Premise
237	in	N	I-Premise
238	QOL	N	I-Premise
239	as	N	I-Premise
240	assessed	N	I-Premise
241	by	N	I-Premise
242	the	N	I-Premise
243	FACT-Anemia	N	I-Premise
244	or	N	I-Premise
245	ESAS	N	I-Premise
246	instruments	N	I-Premise
247	.	N	I-Premise

248	The	N	I-Premise
249	CR	N	I-Premise
250	rate	N	I-Premise
251	and	N	I-Premise
252	the	N	I-Premise
253	3-year	N	I-Premise
254	CR	N	I-Premise
255	duration	N	I-Premise
256	were	N	I-Premise
257	not	N	I-Premise
258	affected	N	I-Premise
259	adversely	N	I-Premise
260	by	N	I-Premise
261	use	N	I-Premise
262	of	N	I-Premise
263	epoetin	N	I-Premise
264	alpha	N	I-Premise
265	.	N	I-Premise

266	Epoetin	N	I-Claim
267	alpha	N	I-Claim
268	decreased	N	I-Claim
269	the	N	I-Claim
270	number	N	I-Claim
271	of	N	I-Claim
272	PRBC	N	I-Claim
273	transfusions	N	I-Claim
274	and	N	I-Claim
275	did	N	I-Claim
276	not	N	I-Claim
277	appear	N	I-Claim
278	to	N	I-Claim
279	have	N	I-Claim
280	a	N	I-Claim
281	negative	N	I-Claim
282	impact	N	I-Claim
283	on	N	I-Claim
284	remission	N	I-Claim
285	duration	N	I-Claim
286	.	N	I-Claim

287	No	N	I-Claim
288	difference	N	I-Claim
289	in	N	I-Claim
290	QOL	N	I-Claim
291	was	N	I-Claim
292	observed	N	I-Claim
293	.	N	I-Claim

1	The	N	I-MajorClaim
2	generalizability	N	I-MajorClaim
3	of	N	I-MajorClaim
4	palliative	N	I-MajorClaim
5	care	N	I-MajorClaim
6	intervention	N	I-MajorClaim
7	research	N	I-MajorClaim
8	is	N	I-MajorClaim
9	often	N	I-MajorClaim
10	limited	N	I-MajorClaim
11	by	N	I-MajorClaim
12	high	N	I-MajorClaim
13	rates	N	I-MajorClaim
14	of	N	I-MajorClaim
15	study	N	I-MajorClaim
16	attrition	N	I-MajorClaim
17	.	N	I-MajorClaim

18	This	N	O
19	study	N	O
20	examined	N	O
21	factors	N	O
22	associated	N	O
23	with	N	O
24	attrition	N	O
25	from	N	O
26	a	N	O
27	randomized	N	O
28	controlled	N	O
29	trial	N	O
30	comparing	N	O
31	meaning-centered	N	O
32	group	N	O
33	psychotherapy	N	O
34	(	N	O
35	MCGP	N	O
36	)	N	O
37	,	N	O
38	an	N	O
39	intervention	N	O
40	designed	N	O
41	to	N	O
42	help	N	O
43	advanced	N	O
44	cancer	N	O
45	patients	N	O
46	sustain	N	O
47	or	N	O
48	enhance	N	O
49	their	N	O
50	sense	N	O
51	of	N	O
52	meaning	N	O
53	to	N	O
54	the	N	O
55	supportive	N	O
56	group	N	O
57	psychotherapy	N	O
58	(	N	O
59	SGP	N	O
60	)	N	O
61	,	N	O
62	a	N	O
63	standardized	N	O
64	support	N	O
65	group	N	O
66	.	N	O

67	Patients	N	O
68	with	N	O
69	advanced	N	O
70	solid	N	O
71	tumor	N	O
72	cancers	N	O
73	(	N	O
74	n	N	O
75	=	N	O
76	153	N	O
77	)	N	O
78	were	N	O
79	randomized	N	O
80	to	N	O
81	eight	N	O
82	sessions	N	O
83	of	N	O
84	either	N	O
85	the	N	O
86	MCGP	N	O
87	or	N	O
88	SGP	N	O
89	.	N	O

90	They	N	O
91	completed	N	O
92	assessments	N	O
93	of	N	O
94	psychosocial	N	O
95	,	N	O
96	spiritual	N	O
97	,	N	O
98	and	N	O
99	physical	N	O
100	well-being	N	O
101	pretreatment	N	O
102	,	N	O
103	midtreatment	N	O
104	,	N	O
105	and	N	O
106	2	N	O
107	months	N	O
108	post-treatment	N	O
109	.	N	O

110	Attrition	N	O
111	was	N	O
112	assessed	N	O
113	in	N	O
114	terms	N	O
115	of	N	O
116	the	N	O
117	percent	N	O
118	of	N	O
119	participants	N	O
120	who	N	O
121	failed	N	O
122	to	N	O
123	complete	N	O
124	these	N	O
125	assessments	N	O
126	,	N	O
127	and	N	O
128	demographic	N	O
129	,	N	O
130	psychiatric	N	O
131	,	N	O
132	medical	N	O
133	,	N	O
134	and	N	O
135	study-related	N	O
136	correlates	N	O
137	of	N	O
138	attrition	N	O
139	were	N	O
140	examined	N	O
141	for	N	O
142	the	N	O
143	participants	N	O
144	in	N	O
145	each	N	O
146	of	N	O
147	these	N	O
148	categories	N	O
149	.	N	O

150	The	N	I-Premise
151	rates	N	I-Premise
152	of	N	I-Premise
153	attrition	N	I-Premise
154	at	N	I-Premise
155	these	N	I-Premise
156	time	N	I-Premise
157	points	N	I-Premise
158	were	N	I-Premise
159	28.1	N	I-Premise
160	%	N	I-Premise
161	,	N	I-Premise
162	17.7	N	I-Premise
163	%	N	I-Premise
164	,	N	I-Premise
165	and	N	I-Premise
166	11.1	N	I-Premise
167	%	N	I-Premise
168	,	N	I-Premise
169	respectively	N	I-Premise
170	;	N	I-Premise
171	43.1	N	I-Premise
172	%	N	I-Premise
173	of	N	I-Premise
174	the	N	I-Premise
175	participants	N	I-Premise
176	(	N	I-Premise
177	66	N	I-Premise
178	of	N	I-Premise
179	153	N	I-Premise
180	)	N	I-Premise
181	completed	N	I-Premise
182	the	N	I-Premise
183	entire	N	I-Premise
184	study	N	I-Premise
185	.	N	I-Premise

186	The	N	I-Premise
187	most	N	I-Premise
188	common	N	I-Premise
189	reason	N	I-Premise
190	for	N	I-Premise
191	dropout	N	I-Premise
192	was	N	I-Premise
193	patients	N	I-Premise
194	feeling	N	I-Premise
195	too	N	I-Premise
196	ill	N	I-Premise
197	.	N	I-Premise

198	Attrition	N	I-Premise
199	rates	N	I-Premise
200	did	N	I-Premise
201	not	N	I-Premise
202	vary	N	I-Premise
203	significantly	N	I-Premise
204	between	N	I-Premise
205	study	N	I-Premise
206	arms	N	I-Premise
207	.	N	I-Premise

208	The	N	O
209	participants	N	O
210	who	N	O
211	dropped	N	O
212	out	N	O
213	pretreatment	N	O
214	reported	N	O
215	less	N	O
216	financial	N	O
217	concerns	N	O
218	than	N	O
219	post-treatment	N	O
220	dropouts	N	O
221	,	N	O
222	and	N	O
223	the	N	O
224	participants	N	O
225	who	N	O
226	dropped	N	O
227	out	N	O
228	of	N	O
229	the	N	O
230	study	N	O
231	midtreatment	N	O
232	had	N	O
233	poorer	N	O
234	physical	N	O
235	health	N	O
236	than	N	O
237	treatment	N	O
238	completers	N	O
239	.	N	O

240	There	N	I-Premise
241	were	N	I-Premise
242	no	N	I-Premise
243	other	N	I-Premise
244	significant	N	I-Premise
245	associations	N	I-Premise
246	between	N	I-Premise
247	attrition	N	I-Premise
248	and	N	I-Premise
249	any	N	I-Premise
250	demographic	N	I-Premise
251	,	N	I-Premise
252	medical	N	I-Premise
253	,	N	I-Premise
254	psychiatric	N	I-Premise
255	,	N	I-Premise
256	or	N	I-Premise
257	study-related	N	I-Premise
258	variables	N	I-Premise
259	.	N	I-Premise

260	These	N	I-Claim
261	findings	N	I-Claim
262	highlight	N	I-Claim
263	the	N	I-Claim
264	challenge	N	I-Claim
265	of	N	I-Claim
266	maintaining	N	I-Claim
267	advanced	N	I-Claim
268	cancer	N	I-Claim
269	patients	N	I-Claim
270	in	N	I-Claim
271	longitudinal	N	I-Claim
272	research	N	I-Claim
273	and	N	I-Claim
274	suggest	N	I-Claim
275	the	N	I-Claim
276	need	N	I-Claim
277	to	N	I-Claim
278	consider	N	I-Claim
279	alternative	N	I-Claim
280	approaches	N	I-Claim
281	(	N	I-Claim
282	e.g.	N	I-Claim
283	,	N	I-Claim
284	telemedicine	N	I-Claim
285	)	N	I-Claim
286	for	N	I-Claim
287	patients	N	I-Claim
288	who	N	I-Claim
289	might	N	I-Claim
290	benefit	N	I-Claim
291	from	N	I-Claim
292	group	N	I-Claim
293	interventions	N	I-Claim
294	but	N	I-Claim
295	are	N	I-Claim
296	too	N	I-Claim
297	ill	N	I-Claim
298	to	N	I-Claim
299	travel	N	I-Claim
300	.	N	I-Claim

1	For	N	I-Claim
2	men	N	I-Claim
3	with	N	I-Claim
4	localised	N	I-Claim
5	prostate	N	I-Claim
6	cancer	N	I-Claim
7	,	N	I-Claim
8	surgery	N	I-Claim
9	provides	N	I-Claim
10	a	N	I-Claim
11	survival	N	I-Claim
12	benefit	N	I-Claim
13	compared	N	I-Claim
14	with	N	I-Claim
15	watchful	N	I-Claim
16	waiting	N	I-Claim
17	.	N	I-Claim

18	Treatments	N	O
19	are	N	O
20	associated	N	O
21	with	N	O
22	morbidity	N	O
23	.	N	O

24	Results	N	O
25	for	N	O
26	functional	N	O
27	outcome	N	O
28	and	N	O
29	quality	N	O
30	of	N	O
31	life	N	O
32	are	N	O
33	rarely	N	O
34	reported	N	O
35	beyond	N	O
36	10	N	O
37	years	N	O
38	and	N	O
39	are	N	O
40	lacking	N	O
41	from	N	O
42	randomised	N	O
43	settings	N	O
44	.	N	O

45	We	N	O
46	report	N	O
47	results	N	O
48	for	N	O
49	quality	N	O
50	of	N	O
51	life	N	O
52	for	N	O
53	men	N	O
54	in	N	O
55	the	N	O
56	Scandinavian	N	O
57	Prostate	N	O
58	Cancer	N	O
59	Group	N	O
60	Study	N	O
61	Number	N	O
62	4	N	O
63	(	N	O
64	SPCG-4	N	O
65	)	N	O
66	after	N	O
67	a	N	O
68	median	N	O
69	follow-up	N	O
70	of	N	O
71	more	N	O
72	than	N	O
73	12	N	O
74	years	N	O
75	.	N	O

76	All	N	O
77	living	N	O
78	Swedish	N	O
79	and	N	O
80	Finnish	N	O
81	men	N	O
82	(	N	O
83	400	N	O
84	of	N	O
85	695	N	O
86	)	N	O
87	randomly	N	O
88	assigned	N	O
89	to	N	O
90	radical	N	O
91	prostatectomy	N	O
92	or	N	O
93	watchful	N	O
94	waiting	N	O
95	in	N	O
96	SPCG-4	N	O
97	from	N	O
98	1989	N	O
99	to	N	O
100	1999	N	O
101	were	N	O
102	included	N	O
103	in	N	O
104	our	N	O
105	analysis	N	O
106	.	N	O

107	An	N	O
108	additional	N	O
109	281	N	O
110	men	N	O
111	were	N	O
112	included	N	O
113	in	N	O
114	a	N	O
115	population-based	N	O
116	control	N	O
117	group	N	O
118	matched	N	O
119	for	N	O
120	region	N	O
121	and	N	O
122	age	N	O
123	.	N	O

124	Physical	N	O
125	symptoms	N	O
126	,	N	O
127	symptom-induced	N	O
128	stress	N	O
129	,	N	O
130	and	N	O
131	self-assessed	N	O
132	quality	N	O
133	of	N	O
134	life	N	O
135	were	N	O
136	evaluated	N	O
137	with	N	O
138	a	N	O
139	study-specific	N	O
140	questionnaire	N	O
141	.	N	O

142	Longitudinal	N	O
143	data	N	O
144	were	N	O
145	available	N	O
146	for	N	O
147	166	N	O
148	Swedish	N	O
149	men	N	O
150	who	N	O
151	had	N	O
152	answered	N	O
153	quality-of-life	N	O
154	questionnaires	N	O
155	at	N	O
156	an	N	O
157	earlier	N	O
158	timepoint	N	O
159	.	N	O

160	182	N	O
161	(	N	O
162	88	N	O
163	%	N	O
164	)	N	O
165	of	N	O
166	208	N	O
167	men	N	O
168	in	N	O
169	the	N	O
170	radical	N	O
171	prostatectomy	N	O
172	group	N	O
173	,	N	O
174	167	N	O
175	(	N	O
176	87	N	O
177	%	N	O
178	)	N	O
179	of	N	O
180	192	N	O
181	men	N	O
182	in	N	O
183	the	N	O
184	watchful-waiting	N	O
185	group	N	O
186	,	N	O
187	and	N	O
188	214	N	O
189	(	N	O
190	76	N	O
191	%	N	O
192	)	N	O
193	of	N	O
194	281	N	O
195	men	N	O
196	in	N	O
197	the	N	O
198	population-based	N	O
199	control	N	O
200	group	N	O
201	answered	N	O
202	the	N	O
203	questionnaire	N	O
204	.	N	O

205	Men	N	O
206	in	N	O
207	SPCG-4	N	O
208	had	N	O
209	a	N	O
210	median	N	O
211	follow-up	N	O
212	of	N	O
213	122	N	O
214	years	N	O
215	(	N	O
216	range	N	O
217	7-17	N	O
218	)	N	O
219	and	N	O
220	a	N	O
221	median	N	O
222	age	N	O
223	of	N	O
224	770	N	O
225	years	N	O
226	(	N	O
227	range	N	O
228	61-88	N	O
229	)	N	O
230	.	N	O

231	High	N	I-Premise
232	self-assessed	N	I-Premise
233	quality	N	I-Premise
234	of	N	I-Premise
235	life	N	I-Premise
236	was	N	I-Premise
237	reported	N	I-Premise
238	by	N	I-Premise
239	62	N	I-Premise
240	(	N	I-Premise
241	35	N	I-Premise
242	%	N	I-Premise
243	)	N	I-Premise
244	of	N	I-Premise
245	179	N	I-Premise
246	men	N	I-Premise
247	allocated	N	I-Premise
248	radical	N	I-Premise
249	prostatectomy	N	I-Premise
250	,	N	I-Premise
251	55	N	I-Premise
252	(	N	I-Premise
253	34	N	I-Premise
254	%	N	I-Premise
255	)	N	I-Premise
256	of	N	I-Premise
257	160	N	I-Premise
258	men	N	I-Premise
259	assigned	N	I-Premise
260	to	N	I-Premise
261	watchful	N	I-Premise
262	waiting	N	I-Premise
263	,	N	I-Premise
264	and	N	I-Premise
265	93	N	I-Premise
266	(	N	I-Premise
267	45	N	I-Premise
268	%	N	I-Premise
269	)	N	I-Premise
270	of	N	I-Premise
271	208	N	I-Premise
272	men	N	I-Premise
273	in	N	I-Premise
274	the	N	I-Premise
275	control	N	I-Premise
276	group	N	I-Premise
277	.	N	I-Premise

278	Anxiety	N	I-Premise
279	was	N	I-Premise
280	higher	N	I-Premise
281	in	N	I-Premise
282	the	N	I-Premise
283	SPCG-4	N	I-Premise
284	groups	N	I-Premise
285	(	N	I-Premise
286	77	N	I-Premise
287	[	N	I-Premise
288	43	N	I-Premise
289	%	N	I-Premise
290	]	N	I-Premise
291	of	N	I-Premise
292	178	N	I-Premise
293	and	N	I-Premise
294	69	N	I-Premise
295	[	N	I-Premise
296	43	N	I-Premise
297	%	N	I-Premise
298	]	N	I-Premise
299	of	N	I-Premise
300	161	N	I-Premise
301	men	N	I-Premise
302	)	N	I-Premise
303	than	N	I-Premise
304	in	N	I-Premise
305	the	N	I-Premise
306	control	N	I-Premise
307	group	N	I-Premise
308	(	N	I-Premise
309	68	N	I-Premise
310	[	N	I-Premise
311	33	N	I-Premise
312	%	N	I-Premise
313	]	N	I-Premise
314	of	N	I-Premise
315	208	N	I-Premise
316	men	N	I-Premise
317	;	N	I-Premise
318	relative	N	I-Premise
319	risk	N	I-Premise
320	142	N	I-Premise
321	,	N	I-Premise
322	95	N	I-Premise
323	%	N	I-Premise
324	CI	N	I-Premise
325	107-188	N	I-Premise
326	)	N	I-Premise
327	.	N	I-Premise

328	Prevalence	N	I-Premise
329	of	N	I-Premise
330	erectile	N	I-Premise
331	dysfunction	N	I-Premise
332	was	N	I-Premise
333	84	N	I-Premise
334	%	N	I-Premise
335	(	N	I-Premise
336	146	N	I-Premise
337	of	N	I-Premise
338	173	N	I-Premise
339	men	N	I-Premise
340	)	N	I-Premise
341	in	N	I-Premise
342	the	N	I-Premise
343	radical	N	I-Premise
344	prostatectomy	N	I-Premise
345	group	N	I-Premise
346	,	N	I-Premise
347	80	N	I-Premise
348	%	N	I-Premise
349	(	N	I-Premise
350	122	N	I-Premise
351	of	N	I-Premise
352	153	N	I-Premise
353	)	N	I-Premise
354	in	N	I-Premise
355	the	N	I-Premise
356	watchful-waiting	N	I-Premise
357	group	N	I-Premise
358	,	N	I-Premise
359	and	N	I-Premise
360	46	N	I-Premise
361	%	N	I-Premise
362	(	N	I-Premise
363	95	N	I-Premise
364	of	N	I-Premise
365	208	N	I-Premise
366	)	N	I-Premise
367	in	N	I-Premise
368	the	N	I-Premise
369	control	N	I-Premise
370	group	N	I-Premise
371	and	N	I-Premise
372	prevalence	N	I-Premise
373	of	N	I-Premise
374	urinary	N	I-Premise
375	leakage	N	I-Premise
376	was	N	I-Premise
377	41	N	I-Premise
378	%	N	I-Premise
379	(	N	I-Premise
380	71	N	I-Premise
381	of	N	I-Premise
382	173	N	I-Premise
383	)	N	I-Premise
384	,	N	I-Premise
385	11	N	I-Premise
386	%	N	I-Premise
387	(	N	I-Premise
388	18	N	I-Premise
389	of	N	I-Premise
390	164	N	I-Premise
391	)	N	I-Premise
392	,	N	I-Premise
393	and	N	I-Premise
394	3	N	I-Premise
395	%	N	I-Premise
396	(	N	I-Premise
397	six	N	I-Premise
398	of	N	I-Premise
399	209	N	I-Premise
400	)	N	I-Premise
401	,	N	I-Premise
402	respectively	N	I-Premise
403	.	N	I-Premise

404	Distress	N	I-Premise
405	caused	N	I-Premise
406	by	N	I-Premise
407	these	N	I-Premise
408	symptoms	N	I-Premise
409	was	N	I-Premise
410	reported	N	I-Premise
411	significantly	N	I-Premise
412	more	N	I-Premise
413	often	N	I-Premise
414	by	N	I-Premise
415	men	N	I-Premise
416	allocated	N	I-Premise
417	radical	N	I-Premise
418	prostatectomy	N	I-Premise
419	than	N	I-Premise
420	by	N	I-Premise
421	men	N	I-Premise
422	assigned	N	I-Premise
423	to	N	I-Premise
424	watchful	N	I-Premise
425	waiting	N	I-Premise
426	.	N	I-Premise

427	In	N	I-Premise
428	a	N	I-Premise
429	longitudinal	N	I-Premise
430	analysis	N	I-Premise
431	of	N	I-Premise
432	men	N	I-Premise
433	in	N	I-Premise
434	SPCG-4	N	I-Premise
435	who	N	I-Premise
436	provided	N	I-Premise
437	information	N	I-Premise
438	at	N	I-Premise
439	two	N	I-Premise
440	follow-up	N	I-Premise
441	points	N	I-Premise
442	9	N	I-Premise
443	years	N	I-Premise
444	apart	N	I-Premise
445	,	N	I-Premise
446	38	N	I-Premise
447	(	N	I-Premise
448	45	N	I-Premise
449	%	N	I-Premise
450	)	N	I-Premise
451	of	N	I-Premise
452	85	N	I-Premise
453	men	N	I-Premise
454	allocated	N	I-Premise
455	radical	N	I-Premise
456	prostatectomy	N	I-Premise
457	and	N	I-Premise
458	48	N	I-Premise
459	(	N	I-Premise
460	60	N	I-Premise
461	%	N	I-Premise
462	)	N	I-Premise
463	of	N	I-Premise
464	80	N	I-Premise
465	men	N	I-Premise
466	allocated	N	I-Premise
467	watchful	N	I-Premise
468	waiting	N	I-Premise
469	reported	N	I-Premise
470	an	N	I-Premise
471	increase	N	I-Premise
472	in	N	I-Premise
473	number	N	I-Premise
474	of	N	I-Premise
475	physical	N	I-Premise
476	symptoms	N	I-Premise
477	;	N	I-Premise
478	50	N	I-Premise
479	(	N	I-Premise
480	61	N	I-Premise
481	%	N	I-Premise
482	)	N	I-Premise
483	of	N	I-Premise
484	82	N	I-Premise
485	and	N	I-Premise
486	47	N	I-Premise
487	(	N	I-Premise
488	64	N	I-Premise
489	%	N	I-Premise
490	)	N	I-Premise
491	of	N	I-Premise
492	74	N	I-Premise
493	men	N	I-Premise
494	,	N	I-Premise
495	respectively	N	I-Premise
496	,	N	I-Premise
497	reported	N	I-Premise
498	a	N	I-Premise
499	reduction	N	I-Premise
500	in	N	I-Premise
501	quality	N	I-Premise
502	of	N	I-Premise
503	life	N	I-Premise
504	.	N	I-Premise

505	For	N	I-Premise
506	men	N	I-Premise
507	in	N	I-Premise
508	SPCG-4	N	I-Premise
509	,	N	I-Premise
510	negative	N	I-Premise
511	side-effects	N	I-Premise
512	were	N	I-Premise
513	common	N	I-Premise
514	and	N	I-Premise
515	added	N	I-Premise
516	more	N	I-Premise
517	stress	N	I-Premise
518	than	N	I-Premise
519	was	N	I-Premise
520	reported	N	I-Premise
521	in	N	I-Premise
522	the	N	I-Premise
523	control	N	I-Premise
524	population	N	I-Premise
525	.	N	I-Premise

526	In	N	I-Claim
527	the	N	I-Claim
528	radical	N	I-Claim
529	prostatectomy	N	I-Claim
530	group	N	I-Claim
531	,	N	I-Claim
532	erectile	N	I-Claim
533	dysfunction	N	I-Claim
534	and	N	I-Claim
535	urinary	N	I-Claim
536	leakage	N	I-Claim
537	were	N	I-Claim
538	often	N	I-Claim
539	consequences	N	I-Claim
540	of	N	I-Claim
541	surgery	N	I-Claim
542	.	N	I-Claim

543	In	N	I-Claim
544	the	N	I-Claim
545	watchful-waiting	N	I-Claim
546	group	N	I-Claim
547	,	N	I-Claim
548	side-effects	N	I-Claim
549	can	N	I-Claim
550	be	N	I-Claim
551	caused	N	I-Claim
552	by	N	I-Claim
553	tumour	N	I-Claim
554	progression	N	I-Claim
555	.	N	I-Claim

556	The	N	I-Claim
557	number	N	I-Claim
558	and	N	I-Claim
559	severity	N	I-Claim
560	of	N	I-Claim
561	side-effects	N	I-Claim
562	changes	N	I-Claim
563	over	N	I-Claim
564	time	N	I-Claim
565	at	N	I-Claim
566	a	N	I-Claim
567	higher	N	I-Claim
568	rate	N	I-Claim
569	than	N	I-Claim
570	is	N	I-Claim
571	caused	N	I-Claim
572	by	N	I-Claim
573	normal	N	I-Claim
574	ageing	N	I-Claim
575	and	N	I-Claim
576	a	N	I-Claim
577	loss	N	I-Claim
578	of	N	I-Claim
579	sexual	N	I-Claim
580	ability	N	I-Claim
581	is	N	I-Claim
582	a	N	I-Claim
583	persistent	N	I-Claim
584	psychological	N	I-Claim
585	problem	N	I-Claim
586	for	N	I-Claim
587	both	N	I-Claim
588	interventions	N	I-Claim
589	.	N	I-Claim

590	An	N	O
591	understanding	N	O
592	of	N	O
593	the	N	O
594	patterns	N	O
595	of	N	O
596	side-effects	N	O
597	and	N	O
598	time	N	O
599	dimension	N	O
600	of	N	O
601	their	N	O
602	occurrence	N	O
603	for	N	O
604	each	N	O
605	treatment	N	O
606	is	N	O
607	important	N	O
608	for	N	O
609	full	N	O
610	patient	N	O
611	information	N	O
612	.	N	O

1	This	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	assessed	N	O
6	the	N	O
7	effect	N	O
8	of	N	O
9	a	N	O
10	SMART	N	O
11	(	N	O
12	Stress	N	O
13	Management	N	O
14	and	N	O
15	Resiliency	N	O
16	Training	N	O
17	)	N	O
18	program	N	O
19	among	N	O
20	25	N	O
21	women	N	O
22	diagnosed	N	O
23	with	N	O
24	breast	N	O
25	cancer	N	O
26	.	N	O

27	Resilience	N	O
28	,	N	O
29	perceived	N	O
30	stress	N	O
31	,	N	O
32	anxiety	N	O
33	,	N	O
34	and	N	O
35	quality	N	O
36	of	N	O
37	life	N	O
38	improved	N	O
39	at	N	O
40	12	N	O
41	weeks	N	O
42	in	N	O
43	the	N	O
44	active	N	O
45	but	N	O
46	not	N	O
47	the	N	O
48	control	N	O
49	arm	N	O
50	.	N	O

51	A	N	O
52	brief	N	O
53	training	N	O
54	in	N	O
55	the	N	O
56	SMART	N	O
57	program	N	O
58	can	N	O
59	enhance	N	O
60	resilience	N	O
61	and	N	O
62	quality	N	O
63	of	N	O
64	life	N	O
65	and	N	O
66	decrease	N	O
67	stress	N	O
68	and	N	O
69	anxiety	N	O
70	.	N	O

71	Patients	N	O
72	with	N	O
73	breast	N	O
74	cancer	N	O
75	experience	N	O
76	stress	N	O
77	and	N	O
78	anxiety	N	O
79	related	N	O
80	to	N	O
81	their	N	O
82	diagnosis	N	O
83	,	N	O
84	with	N	O
85	resulting	N	O
86	lower	N	O
87	quality	N	O
88	of	N	O
89	life	N	O
90	.	N	O

91	The	N	O
92	purpose	N	O
93	of	N	O
94	this	N	O
95	study	N	O
96	was	N	O
97	to	N	O
98	assess	N	O
99	the	N	O
100	effect	N	O
101	of	N	O
102	a	N	O
103	SMART	N	O
104	(	N	O
105	Stress	N	O
106	Management	N	O
107	and	N	O
108	Resiliency	N	O
109	Training	N	O
110	)	N	O
111	program	N	O
112	for	N	O
113	increasing	N	O
114	resiliency	N	O
115	and	N	O
116	for	N	O
117	decreasing	N	O
118	stress	N	O
119	and	N	O
120	anxiety	N	O
121	among	N	O
122	mentors	N	O
123	who	N	O
124	themselves	N	O
125	were	N	O
126	previously	N	O
127	diagnosed	N	O
128	with	N	O
129	breast	N	O
130	cancer	N	O
131	.	N	O

132	The	N	O
133	program	N	O
134	consisted	N	O
135	of	N	O
136	two	N	O
137	90-minute	N	O
138	group	N	O
139	training	N	O
140	sessions	N	O
141	,	N	O
142	a	N	O
143	brief	N	O
144	individual	N	O
145	session	N	O
146	,	N	O
147	and	N	O
148	3	N	O
149	follow-up	N	O
150	telephone	N	O
151	calls	N	O
152	.	N	O

153	Twenty-four	N	O
154	mentors	N	O
155	at	N	O
156	Mayo	N	O
157	Clinic	N	O
158	in	N	O
159	Rochester	N	O
160	,	N	O
161	Minnesota	N	O
162	,	N	O
163	were	N	O
164	randomized	N	O
165	in	N	O
166	a	N	O
167	single-blind	N	O
168	,	N	O
169	wait-list	N	O
170	controlled	N	O
171	clinical	N	O
172	trial	N	O
173	to	N	O
174	either	N	O
175	the	N	O
176	SMART	N	O
177	intervention	N	O
178	or	N	O
179	a	N	O
180	control	N	O
181	group	N	O
182	for	N	O
183	12	N	O
184	weeks	N	O
185	.	N	O

186	Primary	N	O
187	outcome	N	O
188	measures	N	O
189	assessed	N	O
190	at	N	O
191	baseline	N	O
192	and	N	O
193	at	N	O
194	week	N	O
195	12	N	O
196	included	N	O
197	the	N	O
198	Connor	N	O
199	Davidson	N	O
200	Resilience	N	O
201	Scale	N	O
202	,	N	O
203	Perceived	N	O
204	Stress	N	O
205	Scale	N	O
206	,	N	O
207	Smith	N	O
208	Anxiety	N	O
209	Scale	N	O
210	,	N	O
211	and	N	O
212	Linear	N	O
213	Analog	N	O
214	Self	N	O
215	Assessment	N	O
216	Scale	N	O
217	.	N	O

218	Twenty	N	O
219	patients	N	O
220	completed	N	O
221	the	N	O
222	study	N	O
223	.	N	O

224	A	N	I-Premise
225	statistically	N	I-Premise
226	significant	N	I-Premise
227	improvement	N	I-Premise
228	in	N	I-Premise
229	resilience	N	I-Premise
230	,	N	I-Premise
231	perceived	N	I-Premise
232	stress	N	I-Premise
233	,	N	I-Premise
234	anxiety	N	I-Premise
235	,	N	I-Premise
236	and	N	I-Premise
237	overall	N	I-Premise
238	quality	N	I-Premise
239	of	N	I-Premise
240	life	N	I-Premise
241	at	N	I-Premise
242	12	N	I-Premise
243	weeks	N	I-Premise
244	,	N	I-Premise
245	compared	N	I-Premise
246	with	N	I-Premise
247	baseline	N	I-Premise
248	was	N	I-Premise
249	observed	N	I-Premise
250	in	N	I-Premise
251	the	N	I-Premise
252	study	N	I-Premise
253	arm	N	I-Premise
254	.	N	I-Premise

255	No	N	I-Premise
256	significant	N	I-Premise
257	difference	N	I-Premise
258	in	N	I-Premise
259	any	N	I-Premise
260	of	N	I-Premise
261	these	N	I-Premise
262	measures	N	I-Premise
263	was	N	I-Premise
264	noted	N	I-Premise
265	in	N	I-Premise
266	the	N	I-Premise
267	control	N	I-Premise
268	group	N	I-Premise
269	.	N	I-Premise

270	This	N	I-Claim
271	study	N	I-Claim
272	demonstrates	N	I-Claim
273	that	N	I-Claim
274	a	N	I-Claim
275	brief	N	I-Claim
276	,	N	I-Claim
277	predominantly	N	I-Claim
278	group-based	N	I-Claim
279	resilience	N	I-Claim
280	training	N	I-Claim
281	intervention	N	I-Claim
282	is	N	I-Claim
283	feasible	N	I-Claim
284	in	N	I-Claim
285	patients	N	I-Claim
286	with	N	I-Claim
287	previous	N	I-Claim
288	breast	N	I-Claim
289	cancer	N	I-Claim
290	;	N	I-Claim
291	also	N	I-Claim
292	,	N	I-Claim
293	it	N	I-Claim
294	may	N	I-Claim
295	be	N	I-Claim
296	efficacious	N	I-Claim
297	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	health-related	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	,	N	O
8	we	N	O
9	investigated	N	O
10	the	N	O
11	effect	N	O
12	of	N	O
13	adjuvant	N	O
14	chemotherapy	N	O
15	regimens	N	O
16	on	N	O
17	utility	N	O
18	scores	N	O
19	assessed	N	O
20	by	N	O
21	the	N	O
22	EuroQoL-5D	N	O
23	(	N	O
24	EQ-5D	N	O
25	)	N	O
26	instrument	N	O
27	in	N	O
28	a	N	O
29	randomized	N	O
30	,	N	O
31	controlled	N	O
32	trial	N	O
33	for	N	O
34	breast	N	O
35	cancer	N	O
36	patients	N	O
37	after	N	O
38	surgery	N	O
39	.	N	O

40	We	N	O
41	also	N	O
42	investigated	N	O
43	the	N	O
44	relationship	N	O
45	between	N	O
46	Functional	N	O
47	Assessment	N	O
48	of	N	O
49	Cancer	N	O
50	Therapy	N	O
51	(	N	O
52	FACT	N	O
53	)	N	O
54	scale	N	O
55	scores	N	O
56	and	N	O
57	EQ-5D	N	O
58	utilities	N	O
59	.	N	O

60	Patients	N	O
61	were	N	O
62	randomly	N	O
63	assigned	N	O
64	to	N	O
65	the	N	O
66	following	N	O
67	four	N	O
68	chemotherapy	N	O
69	regimens	N	O
70	:	N	O
71	four	N	O
72	cycles	N	O
73	of	N	O
74	anthracycline	N	O
75	followed	N	O
76	by	N	O
77	paclitaxel	N	O
78	(	N	O
79	ACP	N	O
80	)	N	O
81	,	N	O
82	four	N	O
83	cycles	N	O
84	of	N	O
85	anthracycline-containing	N	O
86	regimens	N	O
87	followed	N	O
88	by	N	O
89	docetaxel	N	O
90	(	N	O
91	ACD	N	O
92	)	N	O
93	,	N	O
94	eight	N	O
95	cycles	N	O
96	of	N	O
97	paclitaxel	N	O
98	(	N	O
99	PTX	N	O
100	)	N	O
101	,	N	O
102	and	N	O
103	eight	N	O
104	cycles	N	O
105	of	N	O
106	docetaxel	N	O
107	(	N	O
108	DTX	N	O
109	)	N	O
110	.	N	O

111	Of	N	O
112	1060	N	O
113	registered	N	O
114	,	N	O
115	the	N	O
116	first	N	O
117	300	N	O
118	consecutive	N	O
119	patients	N	O
120	were	N	O
121	included	N	O
122	in	N	O
123	the	N	O
124	current	N	O
125	utility	N	O
126	study	N	O
127	.	N	O

128	Utility	N	O
129	scores	N	O
130	were	N	O
131	assessed	N	O
132	using	N	O
133	the	N	O
134	EQ-5D	N	O
135	instrument	N	O
136	at	N	O
137	baseline	N	O
138	;	N	O
139	cycles	N	O
140	3	N	O
141	,	N	O
142	5	N	O
143	,	N	O
144	and	N	O
145	7	N	O
146	;	N	O
147	7	N	O
148	months	N	O
149	;	N	O
150	and	N	O
151	1	N	O
152	year	N	O
153	.	N	O

154	We	N	O
155	also	N	O
156	evaluated	N	O
157	the	N	O
158	correlation	N	O
159	between	N	O
160	these	N	O
161	scores	N	O
162	and	N	O
163	FACT-G	N	O
164	,	N	O
165	-B	N	O
166	,	N	O
167	and	N	O
168	-Taxane	N	O
169	scores	N	O
170	at	N	O
171	each	N	O
172	time	N	O
173	point	N	O
174	.	N	O

175	Utility	N	I-Premise
176	scores	N	I-Premise
177	were	N	I-Premise
178	significantly	N	I-Premise
179	lower	N	I-Premise
180	in	N	I-Premise
181	the	N	I-Premise
182	DTX	N	I-Premise
183	group	N	I-Premise
184	than	N	I-Premise
185	in	N	I-Premise
186	the	N	I-Premise
187	ACP	N	I-Premise
188	and	N	I-Premise
189	ACD	N	I-Premise
190	groups	N	I-Premise
191	.	N	I-Premise

192	Mean	N	I-Premise
193	utility	N	I-Premise
194	scores	N	I-Premise
195	in	N	I-Premise
196	the	N	I-Premise
197	DTX	N	I-Premise
198	group	N	I-Premise
199	were	N	I-Premise
200	lowest	N	I-Premise
201	at	N	I-Premise
202	7	N	I-Premise
203	months	N	I-Premise
204	and	N	I-Premise
205	tended	N	I-Premise
206	to	N	I-Premise
207	remain	N	I-Premise
208	low	N	I-Premise
209	for	N	I-Premise
210	a	N	I-Premise
211	long	N	I-Premise
212	time	N	I-Premise
213	.	N	I-Premise

214	The	N	I-Premise
215	combined	N	I-Premise
216	anthracycline	N	I-Premise
217	followed	N	I-Premise
218	by	N	I-Premise
219	taxane	N	I-Premise
220	group	N	I-Premise
221	had	N	I-Premise
222	significantly	N	I-Premise
223	higher	N	I-Premise
224	utility	N	I-Premise
225	scores	N	I-Premise
226	that	N	I-Premise
227	the	N	I-Premise
228	taxane-alone	N	I-Premise
229	group	N	I-Premise
230	,	N	I-Premise
231	with	N	I-Premise
232	no	N	I-Premise
233	significant	N	I-Premise
234	difference	N	I-Premise
235	depending	N	I-Premise
236	on	N	I-Premise
237	the	N	I-Premise
238	type	N	I-Premise
239	of	N	I-Premise
240	taxane	N	I-Premise
241	.	N	I-Premise

242	Only	N	I-Premise
243	the	N	I-Premise
244	FACT-G	N	I-Premise
245	social/family	N	I-Premise
246	well-being	N	I-Premise
247	subscale	N	I-Premise
248	had	N	I-Premise
249	no	N	I-Premise
250	relationship	N	I-Premise
251	with	N	I-Premise
252	EQ-5D	N	I-Premise
253	responses	N	I-Premise
254	and	N	I-Premise
255	utility	N	I-Premise
256	scores	N	I-Premise
257	.	N	I-Premise

258	Although	N	I-Claim
259	the	N	I-Claim
260	regimens	N	I-Claim
261	in	N	I-Claim
262	this	N	I-Claim
263	study	N	I-Claim
264	were	N	I-Claim
265	similar	N	I-Claim
266	in	N	I-Claim
267	that	N	I-Claim
268	they	N	I-Claim
269	included	N	I-Claim
270	taxane	N	I-Claim
271	,	N	I-Claim
272	the	N	I-Claim
273	mean	N	I-Claim
274	utility	N	I-Claim
275	scores	N	I-Claim
276	and	N	I-Claim
277	longitudinal	N	I-Claim
278	patterns	N	I-Claim
279	of	N	I-Claim
280	utility	N	I-Claim
281	scores	N	I-Claim
282	were	N	I-Claim
283	different	N	I-Claim
284	among	N	I-Claim
285	regimens	N	I-Claim
286	.	N	I-Claim

1	The	N	I-MajorClaim
2	postoperative	N	I-MajorClaim
3	clinical	N	I-MajorClaim
4	superiority	N	I-MajorClaim
5	of	N	I-MajorClaim
6	the	N	I-MajorClaim
7	interposition	N	I-MajorClaim
8	of	N	I-MajorClaim
9	jejunum	N	I-MajorClaim
10	reconstruction	N	I-MajorClaim
11	(	N	I-MajorClaim
12	INT	N	I-MajorClaim
13	)	N	I-MajorClaim
14	to	N	I-MajorClaim
15	Roux-en-Y	N	I-MajorClaim
16	reconstruction	N	I-MajorClaim
17	(	N	I-MajorClaim
18	RY	N	I-MajorClaim
19	)	N	I-MajorClaim
20	after	N	I-MajorClaim
21	total	N	I-MajorClaim
22	gastrectomy	N	I-MajorClaim
23	has	N	I-MajorClaim
24	not	N	I-MajorClaim
25	been	N	I-MajorClaim
26	clarified	N	I-MajorClaim
27	.	N	I-MajorClaim

28	Postoperative	N	O
29	quality	N	O
30	of	N	O
31	life	N	O
32	(	N	O
33	QOL	N	O
34	)	N	O
35	was	N	O
36	evaluated	N	O
37	between	N	O
38	the	N	O
39	2	N	O
40	methods	N	O
41	by	N	O
42	a	N	O
43	multi-institutional	N	O
44	prospective	N	O
45	randomized	N	O
46	trial	N	O
47	.	N	O

48	A	N	O
49	total	N	O
50	of	N	O
51	103	N	O
52	patients	N	O
53	with	N	O
54	gastric	N	O
55	cancer	N	O
56	were	N	O
57	prospectively	N	O
58	randomly	N	O
59	divided	N	O
60	into	N	O
61	groups	N	O
62	for	N	O
63	RY	N	O
64	(	N	O
65	n	N	O
66	=	N	O
67	51	N	O
68	)	N	O
69	or	N	O
70	INT	N	O
71	reconstruction	N	O
72	(	N	O
73	n	N	O
74	=	N	O
75	52	N	O
76	)	N	O
77	after	N	O
78	total	N	O
79	gastrectomy	N	O
80	.	N	O

81	They	N	O
82	were	N	O
83	stratified	N	O
84	by	N	O
85	sex	N	O
86	,	N	O
87	age	N	O
88	,	N	O
89	institute	N	O
90	,	N	O
91	histology	N	O
92	,	N	O
93	and	N	O
94	degree	N	O
95	of	N	O
96	lymph	N	O
97	node	N	O
98	dissection	N	O
99	.	N	O

100	Postoperatively	N	O
101	,	N	O
102	body	N	O
103	mass	N	O
104	index	N	O
105	(	N	O
106	BMI	N	O
107	)	N	O
108	and	N	O
109	nutritional	N	O
110	conditions	N	O
111	were	N	O
112	measured	N	O
113	serially	N	O
114	,	N	O
115	and	N	O
116	QOL	N	O
117	and	N	O
118	postoperative	N	O
119	squalor	N	O
120	scores	N	O
121	were	N	O
122	evaluated	N	O
123	at	N	O
124	3	N	O
125	,	N	O
126	12	N	O
127	,	N	O
128	and	N	O
129	60	N	O
130	months	N	O
131	and	N	O
132	compared	N	O
133	between	N	O
134	the	N	O
135	2	N	O
136	groups	N	O
137	.	N	O

138	After	N	O
139	removing	N	O
140	patients	N	O
141	who	N	O
142	did	N	O
143	not	N	O
144	complete	N	O
145	the	N	O
146	follow-up	N	O
147	survey	N	O
148	or	N	O
149	censured	N	O
150	cases	N	O
151	,	N	O
152	24	N	O
153	patients	N	O
154	in	N	O
155	the	N	O
156	RY	N	O
157	group	N	O
158	and	N	O
159	18	N	O
160	patients	N	O
161	in	N	O
162	the	N	O
163	INT	N	O
164	group	N	O
165	were	N	O
166	clinically	N	O
167	available	N	O
168	and	N	O
169	their	N	O
170	postoperative	N	O
171	status	N	O
172	was	N	O
173	assessed	N	O
174	.	N	O

175	QOL	N	I-Premise
176	scores	N	I-Premise
177	were	N	I-Premise
178	increased	N	I-Premise
179	and	N	I-Premise
180	complication	N	I-Premise
181	scores	N	I-Premise
182	were	N	I-Premise
183	improved	N	I-Premise
184	in	N	I-Premise
185	the	N	I-Premise
186	postoperative	N	I-Premise
187	periods	N	I-Premise
188	(	N	I-Premise
189	P	N	I-Premise
190	<	N	I-Premise
191	.01	N	I-Premise
192	)	N	I-Premise
193	.	N	I-Premise

194	Postoperative	N	I-Premise
195	BMI	N	I-Premise
196	significantly	N	I-Premise
197	deteriorated	N	I-Premise
198	compared	N	I-Premise
199	with	N	I-Premise
200	preoperative	N	I-Premise
201	BMI	N	I-Premise
202	in	N	I-Premise
203	each	N	I-Premise
204	group	N	I-Premise
205	.	N	I-Premise

206	The	N	I-Premise
207	postoperative	N	I-Premise
208	QOL	N	I-Premise
209	and	N	I-Premise
210	complication	N	I-Premise
211	scores	N	I-Premise
212	at	N	I-Premise
213	60	N	I-Premise
214	months	N	I-Premise
215	after	N	I-Premise
216	surgery	N	I-Premise
217	were	N	I-Premise
218	significantly	N	I-Premise
219	better	N	I-Premise
220	than	N	I-Premise
221	those	N	I-Premise
222	at	N	I-Premise
223	3	N	I-Premise
224	months	N	I-Premise
225	after	N	I-Premise
226	surgery	N	I-Premise
227	in	N	I-Premise
228	each	N	I-Premise
229	group	N	I-Premise
230	(	N	I-Premise
231	P	N	I-Premise
232	<	N	I-Premise
233	.01	N	I-Premise
234	)	N	I-Premise
235	.	N	I-Premise

236	However	N	O
237	,	N	O
238	there	N	I-Premise
239	was	N	I-Premise
240	no	N	I-Premise
241	significant	N	I-Premise
242	difference	N	I-Premise
243	of	N	I-Premise
244	QOL	N	I-Premise
245	scores	N	I-Premise
246	and	N	I-Premise
247	postoperative	N	I-Premise
248	complication	N	I-Premise
249	scores	N	I-Premise
250	between	N	I-Premise
251	the	N	I-Premise
252	2	N	I-Premise
253	reconstruction	N	I-Premise
254	groups	N	I-Premise
255	.	N	I-Premise

256	The	N	I-Premise
257	nutritional	N	I-Premise
258	condition	N	I-Premise
259	in	N	I-Premise
260	the	N	I-Premise
261	INT	N	I-Premise
262	group	N	I-Premise
263	was	N	I-Premise
264	nearly	N	I-Premise
265	the	N	I-Premise
266	same	N	I-Premise
267	as	N	I-Premise
268	that	N	I-Premise
269	in	N	I-Premise
270	the	N	I-Premise
271	RY	N	I-Premise
272	group	N	I-Premise
273	.	N	I-Premise

274	Although	N	I-Premise
275	our	N	I-Premise
276	patient	N	I-Premise
277	sample	N	I-Premise
278	was	N	I-Premise
279	small	N	I-Premise
280	and	N	I-Premise
281	patients	N	I-Premise
282	who	N	I-Premise
283	did	N	I-Premise
284	not	N	I-Premise
285	complete	N	I-Premise
286	the	N	I-Premise
287	follow-up	N	I-Premise
288	survey	N	I-Premise
289	were	N	I-Premise
290	present	N	I-Premise
291	,	N	I-Premise
292	we	N	I-Claim
293	could	N	I-Claim
294	not	N	I-Claim
295	identify	N	I-Claim
296	any	N	I-Claim
297	clinical	N	I-Claim
298	difference	N	I-Claim
299	between	N	I-Claim
300	INT	N	I-Claim
301	and	N	I-Claim
302	RY	N	I-Claim
303	after	N	I-Claim
304	total	N	I-Claim
305	gastrectomy	N	I-Claim
306	60	N	I-Claim
307	months	N	I-Claim
308	after	N	I-Claim
309	surgery	N	I-Claim
310	.	N	I-Claim

311	The	N	I-MajorClaim
312	safer	N	I-MajorClaim
313	and	N	I-MajorClaim
314	simpler	N	I-MajorClaim
315	RY	N	I-MajorClaim
316	method	N	I-MajorClaim
317	may	N	I-MajorClaim
318	be	N	I-MajorClaim
319	a	N	I-MajorClaim
320	more	N	I-MajorClaim
321	suitable	N	I-MajorClaim
322	reconstruction	N	I-MajorClaim
323	method	N	I-MajorClaim
324	than	N	I-MajorClaim
325	INT	N	I-MajorClaim
326	after	N	I-MajorClaim
327	total	N	I-MajorClaim
328	gastrectomy	N	I-MajorClaim
329	.	N	I-MajorClaim

1	Gemcitabine	N	O
2	for	N	O
3	advanced	N	O
4	pancreatic	N	O
5	cancer	N	O
6	(	N	O
7	APC	N	O
8	)	N	O
9	is	N	O
10	palliative	N	O
11	and	N	O
12	the	N	O
13	prognosis	N	O
14	is	N	O
15	poor	N	O
16	,	N	O
17	making	N	O
18	health-related	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	(	N	O
23	HRQOL	N	O
24	)	N	O
25	particularly	N	O
26	important	N	O
27	.	N	O

28	We	N	O
29	evaluated	N	O
30	HRQOL	N	O
31	with	N	O
32	the	N	O
33	EuroQol	N	O
34	(	N	O
35	EQ-5D	N	O
36	)	N	O
37	in	N	O
38	patients	N	O
39	with	N	O
40	APC	N	O
41	participating	N	O
42	in	N	O
43	Cancer	N	O
44	and	N	O
45	Leukemia	N	O
46	Group	N	O
47	B	N	O
48	80303	N	O
49	,	N	O
50	a	N	O
51	multicenter	N	O
52	,	N	O
53	double-blind	N	O
54	,	N	O
55	randomized	N	O
56	trial	N	O
57	comparing	N	O
58	overall	N	O
59	survival	N	O
60	(	N	O
61	OS	N	O
62	)	N	O
63	between	N	O
64	two	N	O
65	treatment	N	O
66	arms	N	O
67	:	N	O
68	gemcitabine	N	O
69	with	N	O
70	bevacizumab	N	O
71	or	N	O
72	gemcitabine	N	O
73	with	N	O
74	placebo	N	O
75	.	N	O

76	A	N	O
77	consecutive	N	O
78	subsample	N	O
79	of	N	O
80	patients	N	O
81	was	N	O
82	invited	N	O
83	to	N	O
84	complete	N	O
85	the	N	O
86	EQ-5D	N	O
87	surveys	N	O
88	.	N	O

89	Because	N	O
90	neither	N	O
91	clinical	N	O
92	nor	N	O
93	HRQOL	N	O
94	outcomes	N	O
95	differed	N	O
96	based	N	O
97	on	N	O
98	the	N	O
99	study	N	O
100	arm	N	O
101	,	N	O
102	analyses	N	O
103	were	N	O
104	pooled	N	O
105	.	N	O

106	Changes	N	O
107	in	N	O
108	mean	N	O
109	scores	N	O
110	from	N	O
111	baseline	N	O
112	to	N	O
113	eight	N	O
114	weeks	N	O
115	and	N	O
116	the	N	O
117	prognostic	N	O
118	value	N	O
119	of	N	O
120	the	N	O
121	EQ-5D	N	O
122	were	N	O
123	evaluated	N	O
124	.	N	O

125	Mean	N	I-Premise
126	index	N	I-Premise
127	scores	N	I-Premise
128	remained	N	I-Premise
129	stable	N	I-Premise
130	(	N	I-Premise
131	0.78	N	I-Premise
132	at	N	I-Premise
133	baseline	N	I-Premise
134	[	N	I-Premise
135	n=267	N	I-Premise
136	]	N	I-Premise
137	,	N	I-Premise
138	0.79	N	I-Premise
139	at	N	I-Premise
140	eight	N	I-Premise
141	weeks	N	I-Premise
142	[	N	I-Premise
143	n=186	N	I-Premise
144	]	N	I-Premise
145	,	N	I-Premise
146	P=0.34	N	I-Premise
147	,	N	I-Premise
148	Wilcoxon	N	I-Premise
149	signed	N	I-Premise
150	rank	N	I-Premise
151	test	N	I-Premise
152	)	N	I-Premise
153	,	N	I-Premise
154	attributable	N	I-Premise
155	to	N	I-Premise
156	a	N	I-Premise
157	modest	N	I-Premise
158	deterioration	N	I-Premise
159	of	N	I-Premise
160	physical	N	I-Premise
161	function	N	I-Premise
162	domain	N	I-Premise
163	scores	N	I-Premise
164	coincident	N	I-Premise
165	with	N	I-Premise
166	small	N	I-Premise
167	improvements	N	I-Premise
168	in	N	I-Premise
169	pain	N	I-Premise
170	and	N	I-Premise
171	anxiety/depression	N	I-Premise
172	scores	N	I-Premise
173	.	N	I-Premise

174	A	N	I-Premise
175	small	N	I-Premise
176	decline	N	I-Premise
177	in	N	I-Premise
178	visual	N	I-Premise
179	analogue	N	I-Premise
180	scale	N	I-Premise
181	scores	N	I-Premise
182	was	N	I-Premise
183	observed	N	I-Premise
184	(	N	I-Premise
185	70.7	N	I-Premise
186	vs.	N	I-Premise
187	68.2	N	I-Premise
188	,	N	I-Premise
189	P=0.026	N	I-Premise
190	)	N	I-Premise
191	.	N	I-Premise

192	HRQOL	N	I-Premise
193	changes	N	I-Premise
194	within	N	I-Premise
195	chemotherapy	N	I-Premise
196	response	N	I-Premise
197	strata	N	I-Premise
198	revealed	N	I-Premise
199	stable	N	I-Premise
200	index	N	I-Premise
201	scores	N	I-Premise
202	but	N	I-Premise
203	a	N	I-Premise
204	trend	N	I-Premise
205	of	N	I-Premise
206	worsened	N	I-Premise
207	physical	N	I-Premise
208	function	N	I-Premise
209	among	N	I-Premise
210	patients	N	I-Premise
211	with	N	I-Premise
212	disease	N	I-Premise
213	progression	N	I-Premise
214	compared	N	I-Premise
215	with	N	I-Premise
216	those	N	I-Premise
217	with	N	I-Premise
218	stable	N	I-Premise
219	or	N	I-Premise
220	improved	N	I-Premise
221	disease	N	I-Premise
222	.	N	I-Premise

223	Visual	N	I-Premise
224	analogue	N	I-Premise
225	scale	N	I-Premise
226	scores	N	I-Premise
227	trended	N	I-Premise
228	downward	N	I-Premise
229	over	N	I-Premise
230	time	N	I-Premise
231	irrespective	N	I-Premise
232	of	N	I-Premise
233	chemotherapy	N	I-Premise
234	response	N	I-Premise
235	status	N	I-Premise
236	,	N	I-Premise
237	with	N	I-Premise
238	a	N	I-Premise
239	statistically	N	I-Premise
240	meaningful	N	I-Premise
241	deterioration	N	I-Premise
242	in	N	I-Premise
243	patients	N	I-Premise
244	who	N	I-Premise
245	progressed	N	I-Premise
246	(	N	I-Premise
247	68.9	N	I-Premise
248	vs.	N	I-Premise
249	64.4	N	I-Premise
250	,	N	I-Premise
251	P=0.029	N	I-Premise
252	)	N	I-Premise
253	.	N	I-Premise

254	Baseline	N	O
255	scores	N	O
256	from	N	O
257	both	N	O
258	EQ-5D	N	O
259	scales	N	O
260	were	N	O
261	significant	N	O
262	predictors	N	O
263	of	N	O
264	OS	N	O
265	in	N	O
266	Cox	N	O
267	proportional	N	O
268	hazard	N	O
269	models	N	O
270	.	N	O

271	Response	N	I-Claim
272	to	N	I-Claim
273	gemcitabine	N	I-Claim
274	treatment	N	I-Claim
275	in	N	I-Claim
276	APC	N	I-Claim
277	is	N	I-Claim
278	not	N	I-Claim
279	associated	N	I-Claim
280	with	N	I-Claim
281	appreciable	N	I-Claim
282	improvement	N	I-Claim
283	of	N	I-Claim
284	global	N	I-Claim
285	HRQOL	N	I-Claim
286	.	N	I-Claim

287	Small	N	O
288	improvements	N	O
289	in	N	O
290	pain	N	O
291	and	N	O
292	mood	N	O
293	are	N	O
294	observed	N	O
295	despite	N	O
296	progressive	N	O
297	functional	N	O
298	decline	N	O
299	.	N	O

300	Those	N	I-Claim
301	who	N	I-Claim
302	respond	N	I-Claim
303	to	N	I-Claim
304	gemcitabine	N	I-Claim
305	may	N	I-Claim
306	experience	N	I-Claim
307	a	N	I-Claim
308	slight	N	I-Claim
309	slowing	N	I-Claim
310	of	N	I-Claim
311	functional	N	I-Claim
312	deterioration	N	I-Claim
313	.	N	I-Claim

1	Observational	N	O
2	studies	N	O
3	demonstrate	N	O
4	an	N	O
5	association	N	O
6	between	N	O
7	physical	N	O
8	activity	N	O
9	and	N	O
10	improved	N	O
11	outcomes	N	O
12	in	N	O
13	breast	N	O
14	and	N	O
15	colon	N	O
16	cancer	N	O
17	survivors	N	O
18	.	N	O

19	To	N	O
20	test	N	O
21	these	N	O
22	observations	N	O
23	with	N	O
24	a	N	O
25	large	N	O
26	,	N	O
27	randomized	N	O
28	clinical	N	O
29	trial	N	O
30	,	N	O
31	an	N	O
32	intervention	N	O
33	that	N	O
34	significantly	N	O
35	impacts	N	O
36	physical	N	O
37	activity	N	O
38	in	N	O
39	these	N	O
40	patients	N	O
41	is	N	O
42	needed	N	O
43	.	N	O

44	The	N	O
45	Active	N	O
46	After	N	O
47	Cancer	N	O
48	Trial	N	O
49	(	N	O
50	AACT	N	O
51	)	N	O
52	was	N	O
53	a	N	O
54	multicenter	N	O
55	pilot	N	O
56	study	N	O
57	evaluating	N	O
58	the	N	O
59	feasibility	N	O
60	of	N	O
61	a	N	O
62	telephone-based	N	O
63	exercise	N	O
64	intervention	N	O
65	in	N	O
66	a	N	O
67	cooperative	N	O
68	group	N	O
69	setting	N	O
70	.	N	O

71	Sedentary	N	O
72	(	N	O
73	engaging	N	O
74	in	N	O
75	<	N	O
76	60	N	O
77	min	N	O
78	of	N	O
79	recreational	N	O
80	activity/week	N	O
81	)	N	O
82	breast	N	O
83	and	N	O
84	colorectal	N	O
85	cancer	N	O
86	survivors	N	O
87	were	N	O
88	randomized	N	O
89	to	N	O
90	a	N	O
91	telephone-based	N	O
92	exercise	N	O
93	intervention	N	O
94	or	N	O
95	usual	N	O
96	care	N	O
97	control	N	O
98	group	N	O
99	.	N	O

100	The	N	O
101	intervention	N	O
102	was	N	O
103	delivered	N	O
104	through	N	O
105	the	N	O
106	University	N	O
107	of	N	O
108	California	N	O
109	at	N	O
110	San	N	O
111	Diego	N	O
112	;	N	O
113	participants	N	O
114	received	N	O
115	ten	N	O
116	phone	N	O
117	calls	N	O
118	over	N	O
119	the	N	O
120	course	N	O
121	of	N	O
122	the	N	O
123	16-week	N	O
124	intervention	N	O
125	.	N	O

126	All	N	O
127	participants	N	O
128	underwent	N	O
129	assessment	N	O
130	of	N	O
131	physical	N	O
132	activity	N	O
133	,	N	O
134	fitness	N	O
135	,	N	O
136	physical	N	O
137	functioning	N	O
138	,	N	O
139	fatigue	N	O
140	and	N	O
141	exercise	N	O
142	self-efficacy	N	O
143	at	N	O
144	baseline	N	O
145	and	N	O
146	after	N	O
147	the	N	O
148	16-week	N	O
149	intervention	N	O
150	.	N	O

151	One	N	O
152	hundred	N	O
153	and	N	O
154	twenty-one	N	O
155	patients	N	O
156	were	N	O
157	enrolled	N	O
158	through	N	O
159	ten	N	O
160	Cancer	N	O
161	and	N	O
162	Leukemia	N	O
163	Group	N	O
164	B	N	O
165	(	N	O
166	CALGB	N	O
167	)	N	O
168	institutions	N	O
169	;	N	O
170	100	N	O
171	patients	N	O
172	had	N	O
173	breast	N	O
174	cancer	N	O
175	and	N	O
176	21	N	O
177	had	N	O
178	colorectal	N	O
179	cancer	N	O
180	.	N	O

181	Participants	N	I-Premise
182	randomized	N	I-Premise
183	to	N	I-Premise
184	the	N	I-Premise
185	exercise	N	I-Premise
186	group	N	I-Premise
187	increased	N	I-Premise
188	physical	N	I-Premise
189	activity	N	I-Premise
190	by	N	I-Premise
191	more	N	I-Premise
192	than	N	I-Premise
193	100	N	I-Premise
194	versus	N	I-Premise
195	22	N	I-Premise
196	%	N	I-Premise
197	in	N	I-Premise
198	controls	N	I-Premise
199	(	N	I-Premise
200	54.5	N	I-Premise
201	vs.	N	I-Premise
202	14.6	N	I-Premise
203	min	N	I-Premise
204	,	N	I-Premise
205	P	N	I-Premise
206	=	N	I-Premise
207	0.13	N	I-Premise
208	)	N	I-Premise
209	,	N	I-Premise
210	and	N	I-Premise
211	experienced	N	I-Premise
212	significant	N	I-Premise
213	increases	N	I-Premise
214	in	N	I-Premise
215	fitness	N	I-Premise
216	(	N	I-Premise
217	increased	N	I-Premise
218	6-min	N	I-Premise
219	walk	N	I-Premise
220	test	N	I-Premise
221	distance	N	I-Premise
222	by	N	I-Premise
223	186.9	N	I-Premise
224	vs.	N	I-Premise
225	81.9	N	I-Premise
226	feet	N	I-Premise
227	,	N	I-Premise
228	P	N	I-Premise
229	=	N	I-Premise
230	0.006	N	I-Premise
231	)	N	I-Premise
232	and	N	I-Premise
233	physical	N	I-Premise
234	functioning	N	I-Premise
235	(	N	I-Premise
236	7.1	N	I-Premise
237	vs.	N	I-Premise
238	2.6	N	I-Premise
239	,	N	I-Premise
240	P	N	I-Premise
241	=	N	I-Premise
242	0.04	N	I-Premise
243	)	N	I-Premise
244	as	N	I-Premise
245	compared	N	I-Premise
246	to	N	I-Premise
247	the	N	I-Premise
248	control	N	I-Premise
249	group	N	I-Premise
250	.	N	I-Premise

251	Breast	N	I-Claim
252	and	N	I-Claim
253	colorectal	N	I-Claim
254	cancer	N	I-Claim
255	survivors	N	I-Claim
256	enrolled	N	I-Claim
257	in	N	I-Claim
258	a	N	I-Claim
259	multicenter	N	I-Claim
260	,	N	I-Claim
261	telephone-based	N	I-Claim
262	physical	N	I-Claim
263	activity	N	I-Claim
264	intervention	N	I-Claim
265	increased	N	I-Claim
266	physical	N	I-Claim
267	activity	N	I-Claim
268	and	N	I-Claim
269	experienced	N	I-Claim
270	significant	N	I-Claim
271	improvements	N	I-Claim
272	in	N	I-Claim
273	fitness	N	I-Claim
274	and	N	I-Claim
275	physical	N	I-Claim
276	functioning	N	I-Claim
277	.	N	I-Claim

278	Lifestyle	N	I-MajorClaim
279	intervention	N	I-MajorClaim
280	research	N	I-MajorClaim
281	is	N	I-MajorClaim
282	feasible	N	I-MajorClaim
283	in	N	I-MajorClaim
284	a	N	I-MajorClaim
285	cooperative	N	I-MajorClaim
286	group	N	I-MajorClaim
287	setting	N	I-MajorClaim
288	.	N	I-MajorClaim

1	This	N	O
2	study	N	O
3	sought	N	O
4	to	N	O
5	evaluate	N	O
6	effectiveness	N	O
7	of	N	O
8	autologous	N	O
9	dendritic	N	O
10	cell	N	O
11	vaccine	N	O
12	(	N	O
13	immunotherapy	N	O
14	)	N	O
15	for	N	O
16	glioblastoma	N	O
17	multiforme	N	O
18	(	N	O
19	GBM	N	O
20	)	N	O
21	.	N	O

22	Patients	N	O
23	14	N	O
24	to	N	O
25	70	N	O
26	years	N	O
27	of	N	O
28	age	N	O
29	with	N	O
30	newly	N	O
31	diagnosed	N	O
32	GBM	N	O
33	and	N	O
34	Karnofsky	N	O
35	Performance	N	O
36	Scale	N	O
37	(	N	O
38	KPS	N	O
39	)	N	O
40	score	N	O
41	>	N	O
42	70	N	O
43	who	N	O
44	were	N	O
45	receiving	N	O
46	initial	N	O
47	treatment	N	O
48	were	N	O
49	enrolled	N	O
50	and	N	O
51	were	N	O
52	randomized	N	O
53	into	N	O
54	2	N	O
55	groups	N	O
56	during	N	O
57	the	N	O
58	5-year	N	O
59	study	N	O
60	period	N	O
61	.	N	O

62	Eighteen	N	O
63	patients	N	O
64	underwent	N	O
65	conventional	N	O
66	treatment	N	O
67	(	N	O
68	surgery	N	O
69	,	N	O
70	radiotherapy	N	O
71	,	N	O
72	and	N	O
73	chemotherapy	N	O
74	)	N	O
75	and	N	O
76	received	N	O
77	adjuvant	N	O
78	autologous	N	O
79	dendritic	N	O
80	cell	N	O
81	vaccine	N	O
82	,	N	O
83	and	N	O
84	16	N	O
85	patients	N	O
86	(	N	O
87	control	N	O
88	group	N	O
89	)	N	O
90	underwent	N	O
91	conventional	N	O
92	treatment	N	O
93	only	N	O
94	.	N	O

95	Administration	N	O
96	of	N	O
97	the	N	O
98	vaccine	N	O
99	was	N	O
100	begun	N	O
101	within	N	O
102	1	N	O
103	to	N	O
104	2	N	O
105	months	N	O
106	postoperatively	N	O
107	,	N	O
108	with	N	O
109	10	N	O
110	inoculations	N	O
111	given	N	O
112	over	N	O
113	6	N	O
114	months	N	O
115	.	N	O

116	Outcome	N	O
117	measures	N	O
118	were	N	O
119	overall	N	O
120	survival	N	O
121	(	N	O
122	OS	N	O
123	)	N	O
124	;	N	O
125	progression-free	N	O
126	survival	N	O
127	(	N	O
128	PFS	N	O
129	)	N	O
130	;	N	O
131	1-	N	O
132	,	N	O
133	2-	N	O
134	,	N	O
135	and	N	O
136	3-year	N	O
137	survival	N	O
138	rates	N	O
139	,	N	O
140	and	N	O
141	quality	N	O
142	of	N	O
143	life	N	O
144	(	N	O
145	QoL	N	O
146	)	N	O
147	.	N	O

148	Follow-up	N	O
149	time	N	O
150	ranged	N	O
151	from	N	O
152	14	N	O
153	to	N	O
154	56	N	O
155	months	N	O
156	(	N	O
157	median	N	O
158	,	N	O
159	33	N	O
160	months	N	O
161	)	N	O
162	.	N	O

163	The	N	I-Premise
164	1-	N	I-Premise
165	,	N	I-Premise
166	2-	N	I-Premise
167	,	N	I-Premise
168	and	N	I-Premise
169	3-year	N	I-Premise
170	survival	N	I-Premise
171	rates	N	I-Premise
172	were	N	I-Premise
173	88.9	N	I-Premise
174	%	N	I-Premise
175	,	N	I-Premise
176	44.4	N	I-Premise
177	%	N	I-Premise
178	,	N	I-Premise
179	and	N	I-Premise
180	16.7	N	I-Premise
181	%	N	I-Premise
182	for	N	I-Premise
183	the	N	I-Premise
184	vaccine	N	I-Premise
185	group	N	I-Premise
186	,	N	I-Premise
187	respectively	N	I-Premise
188	,	N	I-Premise
189	and	N	I-Premise
190	75.0	N	I-Premise
191	%	N	I-Premise
192	,	N	I-Premise
193	18.8	N	I-Premise
194	%	N	I-Premise
195	,	N	I-Premise
196	and	N	I-Premise
197	0	N	I-Premise
198	%	N	I-Premise
199	,	N	I-Premise
200	respectively	N	I-Premise
201	,	N	I-Premise
202	for	N	I-Premise
203	the	N	I-Premise
204	control	N	I-Premise
205	group	N	I-Premise
206	,	N	I-Premise
207	(	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	0.299	N	I-Premise
211	,	N	I-Premise
212	0.0035	N	I-Premise
213	,	N	I-Premise
214	0.0014	N	I-Premise
215	,	N	I-Premise
216	respectively	N	I-Premise
217	)	N	I-Premise
218	.	N	I-Premise

219	The	N	I-Premise
220	median	N	I-Premise
221	OS	N	I-Premise
222	for	N	I-Premise
223	the	N	I-Premise
224	vaccine	N	I-Premise
225	group	N	I-Premise
226	was	N	I-Premise
227	31.9	N	I-Premise
228	months	N	I-Premise
229	and	N	I-Premise
230	for	N	I-Premise
231	the	N	I-Premise
232	control	N	I-Premise
233	group	N	I-Premise
234	was	N	I-Premise
235	15.0	N	I-Premise
236	months	N	I-Premise
237	(	N	I-Premise
238	P	N	I-Premise
239	<	N	I-Premise
240	0.002	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	The	N	I-Premise
244	median	N	I-Premise
245	progression-free	N	I-Premise
246	survival	N	I-Premise
247	(	N	I-Premise
248	PFS	N	I-Premise
249	)	N	I-Premise
250	for	N	I-Premise
251	the	N	I-Premise
252	vaccine	N	I-Premise
253	group	N	I-Premise
254	was	N	I-Premise
255	8.5	N	I-Premise
256	months	N	I-Premise
257	,	N	I-Premise
258	and	N	I-Premise
259	8.0	N	I-Premise
260	months	N	I-Premise
261	for	N	I-Premise
262	the	N	I-Premise
263	control	N	I-Premise
264	group	N	I-Premise
265	(	N	I-Premise
266	P	N	I-Premise
267	=	N	I-Premise
268	0.075	N	I-Premise
269	)	N	I-Premise
270	.	N	I-Premise

271	The	N	I-Premise
272	surviving	N	I-Premise
273	fraction	N	I-Premise
274	was	N	I-Premise
275	significantly	N	I-Premise
276	higher	N	I-Premise
277	in	N	I-Premise
278	the	N	I-Premise
279	vaccine	N	I-Premise
280	group	N	I-Premise
281	based	N	I-Premise
282	on	N	I-Premise
283	Kaplan-Meier	N	I-Premise
284	analysis	N	I-Premise
285	.	N	I-Premise

286	Adjuvant	N	I-Claim
287	immunotherapy	N	I-Claim
288	with	N	I-Claim
289	whole-cell	N	I-Claim
290	lysate	N	I-Claim
291	dendritic	N	I-Claim
292	cell	N	I-Claim
293	vaccine	N	I-Claim
294	may	N	I-Claim
295	improve	N	I-Claim
296	short-term	N	I-Claim
297	survival	N	I-Claim
298	.	N	I-Claim

299	It	N	I-Claim
300	seems	N	I-Claim
301	to	N	I-Claim
302	be	N	I-Claim
303	safe	N	I-Claim
304	,	N	I-Claim
305	and	N	I-Claim
306	its	N	I-Claim
307	long-term	N	I-Claim
308	effectiveness	N	I-Claim
309	is	N	I-Claim
310	worthy	N	I-Claim
311	of	N	I-Claim
312	further	N	I-Claim
313	investigation	N	I-Claim
314	.	N	I-Claim

1	Molecular	N	O
2	markers	N	O
3	to	N	O
4	predict	N	O
5	response	N	O
6	to	N	O
7	5-fluorouracil	N	O
8	(	N	O
9	FU	N	O
10	)	N	O
11	-based	N	O
12	treatment	N	O
13	of	N	O
14	recurrent	N	O
15	or	N	O
16	metastasised	N	O
17	colorectal	N	O
18	cancer	N	O
19	(	N	O
20	mCRC	N	O
21	)	N	O
22	are	N	O
23	not	N	O
24	established	N	O
25	.	N	O

26	The	N	O
27	aim	N	O
28	of	N	O
29	this	N	O
30	trial	N	O
31	was	N	O
32	to	N	O
33	determine	N	O
34	the	N	O
35	value	N	O
36	of	N	O
37	thymidylate	N	O
38	synthase	N	O
39	(	N	O
40	TS	N	O
41	)	N	O
42	,	N	O
43	a	N	O
44	key	N	O
45	enzyme	N	O
46	of	N	O
47	DNA	N	O
48	synthesis	N	O
49	and	N	O
50	target	N	O
51	of	N	O
52	5-FU	N	O
53	,	N	O
54	to	N	O
55	predict	N	O
56	response	N	O
57	to	N	O
58	chemotherapy	N	O
59	of	N	O
60	mCRC	N	O
61	.	N	O

62	Tumour	N	O
63	tissue	N	O
64	was	N	O
65	obtained	N	O
66	from	N	O
67	168	N	O
68	patients	N	O
69	with	N	O
70	mCRC	N	O
71	for	N	O
72	relative	N	O
73	thymidylate	N	O
74	synthase	N	O
75	(	N	O
76	TS	N	O
77	)	N	O
78	mRNA	N	O
79	quantitation	N	O
80	.	N	O

81	Patients	N	O
82	were	N	O
83	randomised	N	O
84	to	N	O
85	receive	N	O
86	either	N	O
87	5-FU/folinic	N	O
88	acid	N	O
89	(	N	O
90	FA	N	O
91	,	N	O
92	FUFA	N	O
93	)	N	O
94	alone	N	O
95	or	N	O
96	in	N	O
97	combination	N	O
98	with	N	O
99	irinotecan	N	O
100	5-fluorouracil/folinic	N	O
101	acid	N	O
102	and	N	O
103	irinotecan	N	O
104	(	N	O
105	FOLFIRI	N	O
106	)	N	O
107	stratified	N	O
108	by	N	O
109	TS	N	O
110	(	N	O
111	low	N	O
112	versus	N	O
113	high	N	O
114	)	N	O
115	.	N	O

116	Primary	N	O
117	end-point	N	O
118	was	N	O
119	overall	N	O
120	response	N	O
121	to	N	O
122	first-line	N	O
123	treatment	N	O
124	among	N	O
125	TS	N	O
126	high	N	O
127	patients	N	O
128	.	N	O

129	All	N	O
130	parties	N	O
131	,	N	O
132	except	N	O
133	for	N	O
134	the	N	O
135	randomisation	N	O
136	centre	N	O
137	,	N	O
138	were	N	O
139	blinded	N	O
140	for	N	O
141	TS	N	O
142	status	N	O
143	.	N	O

144	Biopsies	N	O
145	(	N	O
146	n=168	N	O
147	)	N	O
148	were	N	O
149	taken	N	O
150	without	N	O
151	complications	N	O
152	.	N	O

153	TS	N	O
154	levels	N	O
155	were	N	O
156	available	N	O
157	for	N	O
158	147	N	O
159	patients	N	O
160	(	N	O
161	87.5	N	O
162	%	N	O
163	)	N	O
164	.	N	O

165	Analysing	N	I-Premise
166	response	N	I-Premise
167	to	N	I-Premise
168	FUFA	N	I-Premise
169	and	N	I-Premise
170	FOLFIRI	N	I-Premise
171	in	N	I-Premise
172	the	N	I-Premise
173	per	N	I-Premise
174	protocol	N	I-Premise
175	set	N	I-Premise
176	(	N	I-Premise
177	n=119	N	I-Premise
178	)	N	I-Premise
179	after	N	I-Premise
180	un-blinding	N	I-Premise
181	TS	N	I-Premise
182	in	N	I-Premise
183	the	N	I-Premise
184	data	N	I-Premise
185	base	N	I-Premise
186	revealed	N	I-Premise
187	a	N	I-Premise
188	trend	N	I-Premise
189	to	N	I-Premise
190	better	N	I-Premise
191	overall	N	I-Premise
192	response	N	I-Premise
193	to	N	I-Premise
194	FOLFIRI	N	I-Premise
195	(	N	I-Premise
196	9/19	N	I-Premise
197	,	N	I-Premise
198	47	N	I-Premise
199	%	N	I-Premise
200	)	N	I-Premise
201	in	N	I-Premise
202	TS	N	I-Premise
203	high	N	I-Premise
204	compared	N	I-Premise
205	to	N	I-Premise
206	FUFA	N	I-Premise
207	(	N	I-Premise
208	5/23	N	I-Premise
209	,	N	I-Premise
210	22	N	I-Premise
211	%	N	I-Premise
212	,	N	I-Premise
213	p=0.077	N	I-Premise
214	)	N	I-Premise
215	.	N	I-Premise

216	In	N	I-Premise
217	patients	N	I-Premise
218	with	N	I-Premise
219	biopsies	N	I-Premise
220	taken	N	I-Premise
221	from	N	I-Premise
222	liver	N	I-Premise
223	lesions	N	I-Premise
224	(	N	I-Premise
225	n=91	N	I-Premise
226	)	N	I-Premise
227	overall	N	I-Premise
228	response	N	I-Premise
229	to	N	I-Premise
230	FOLFIRI	N	I-Premise
231	and	N	I-Premise
232	FUFA	N	I-Premise
233	in	N	I-Premise
234	TS	N	I-Premise
235	high	N	I-Premise
236	was	N	I-Premise
237	53	N	I-Premise
238	%	N	I-Premise
239	(	N	I-Premise
240	9/17	N	I-Premise
241	)	N	I-Premise
242	and	N	I-Premise
243	18	N	I-Premise
244	%	N	I-Premise
245	(	N	I-Premise
246	3/17	N	I-Premise
247	)	N	I-Premise
248	,	N	I-Premise
249	respectively	N	I-Premise
250	(	N	I-Premise
251	p=0.035	N	I-Premise
252	)	N	I-Premise
253	.	N	I-Premise

254	In	N	I-Premise
255	patients	N	I-Premise
256	with	N	I-Premise
257	low	N	I-Premise
258	TS	N	I-Premise
259	,	N	I-Premise
260	no	N	I-Premise
261	remarkable	N	I-Premise
262	difference	N	I-Premise
263	in	N	I-Premise
264	overall	N	I-Premise
265	response	N	I-Premise
266	to	N	I-Premise
267	FOLFIRI	N	I-Premise
268	and	N	I-Premise
269	FUFA	N	I-Premise
270	was	N	I-Premise
271	observed	N	I-Premise
272	.	N	I-Premise

273	Taking	N	I-Claim
274	a	N	I-Claim
275	pre-treatment	N	I-Claim
276	biopsy	N	I-Claim
277	is	N	I-Claim
278	a	N	I-Claim
279	safe	N	I-Claim
280	and	N	I-Claim
281	feasible	N	I-Claim
282	procedure	N	I-Claim
283	in	N	I-Claim
284	mCRC	N	I-Claim
285	.	N	I-Claim

286	After	N	I-Claim
287	validation	N	I-Claim
288	of	N	I-Claim
289	our	N	I-Claim
290	data	N	I-Claim
291	in	N	I-Claim
292	a	N	I-Claim
293	larger	N	I-Claim
294	group	N	I-Claim
295	TS	N	I-Claim
296	determination	N	I-Claim
297	may	N	I-Claim
298	have	N	I-Claim
299	the	N	I-Claim
300	potential	N	I-Claim
301	to	N	I-Claim
302	better	N	I-Claim
303	help	N	I-Claim
304	direct	N	I-Claim
305	systemic	N	I-Claim
306	treatment	N	I-Claim
307	in	N	I-Claim
308	patients	N	I-Claim
309	with	N	I-Claim
310	primarily	N	I-Claim
311	non-resectable	N	I-Claim
312	mCRC	N	I-Claim
313	.	N	I-Claim

1	The	N	O
2	primary	N	O
3	objective	N	O
4	of	N	O
5	this	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	compare	N	O
10	the	N	O
11	response	N	O
12	rates	N	O
13	of	N	O
14	elderly	N	O
15	,	N	O
16	chemonaive	N	O
17	patients	N	O
18	with	N	O
19	advanced	N	O
20	non-small	N	O
21	cell	N	O
22	lung	N	O
23	cancer	N	O
24	(	N	O
25	NSCLC	N	O
26	)	N	O
27	treated	N	O
28	with	N	O
29	daily	N	O
30	oral	N	O
31	erlotinib	N	O
32	versus	N	O
33	oral	N	O
34	vinorelbine	N	O
35	.	N	O

36	Chemonaive	N	O
37	Taiwanese	N	O
38	patients	N	O
39	aged	N	O
40	70	N	O
41	years	N	O
42	or	N	O
43	older	N	O
44	who	N	O
45	had	N	O
46	advanced	N	O
47	NSCLC	N	O
48	were	N	O
49	randomized	N	O
50	to	N	O
51	receive	N	O
52	either	N	O
53	oral	N	O
54	erlotinib	N	O
55	150	N	O
56	mg	N	O
57	(	N	O
58	E	N	O
59	)	N	O
60	daily	N	O
61	or	N	O
62	oral	N	O
63	vinorelbine	N	O
64	60	N	O
65	mg/m	N	O
66	(	N	O
67	V	N	O
68	)	N	O
69	on	N	O
70	days	N	O
71	1	N	O
72	and	N	O
73	8	N	O
74	every	N	O
75	3	N	O
76	weeks	N	O
77	.	N	O

78	From	N	O
79	February	N	O
80	2007	N	O
81	to	N	O
82	July	N	O
83	2008	N	O
84	,	N	O
85	116	N	O
86	patients	N	O
87	were	N	O
88	enrolled	N	O
89	and	N	O
90	113	N	O
91	were	N	O
92	included	N	O
93	in	N	O
94	the	N	O
95	intent-to-treat	N	O
96	population	N	O
97	:	N	O
98	57	N	O
99	patients	N	O
100	in	N	O
101	the	N	O
102	E	N	O
103	group	N	O
104	and	N	O
105	56	N	O
106	patients	N	O
107	in	N	O
108	the	N	O
109	V	N	O
110	group	N	O
111	.	N	O

112	Objective	N	I-Premise
113	response	N	I-Premise
114	rates	N	I-Premise
115	were	N	I-Premise
116	22.8	N	I-Premise
117	%	N	I-Premise
118	(	N	I-Premise
119	13	N	I-Premise
120	of	N	I-Premise
121	57	N	I-Premise
122	)	N	I-Premise
123	in	N	I-Premise
124	E	N	I-Premise
125	and	N	I-Premise
126	8.9	N	I-Premise
127	%	N	I-Premise
128	(	N	I-Premise
129	5	N	I-Premise
130	of	N	I-Premise
131	56	N	I-Premise
132	)	N	I-Premise
133	in	N	I-Premise
134	V	N	I-Premise
135	(	N	I-Premise
136	p	N	I-Premise
137	=	N	I-Premise
138	0.0388	N	I-Premise
139	)	N	I-Premise
140	.	N	I-Premise

141	Median	N	I-Premise
142	progression-free	N	I-Premise
143	survival	N	I-Premise
144	(	N	I-Premise
145	PFS	N	I-Premise
146	)	N	I-Premise
147	was	N	I-Premise
148	4.57	N	I-Premise
149	months	N	I-Premise
150	in	N	I-Premise
151	E	N	I-Premise
152	and	N	I-Premise
153	2.53	N	I-Premise
154	months	N	I-Premise
155	in	N	I-Premise
156	V	N	I-Premise
157	(	N	I-Premise
158	p	N	I-Premise
159	=	N	I-Premise
160	0.0287	N	I-Premise
161	)	N	I-Premise
162	,	N	I-Premise
163	with	N	I-Premise
164	an	N	I-Premise
165	80.6	N	I-Premise
166	%	N	I-Premise
167	increase	N	I-Premise
168	in	N	I-Premise
169	median	N	I-Premise
170	PFS	N	I-Premise
171	for	N	I-Premise
172	E	N	I-Premise
173	compared	N	I-Premise
174	with	N	I-Premise
175	V.	N	I-Premise
176	Median	N	I-Premise
177	survival	N	I-Premise
178	time	N	I-Premise
179	was	N	I-Premise
180	11.67	N	I-Premise
181	months	N	I-Premise
182	in	N	I-Premise
183	E	N	I-Premise
184	and	N	I-Premise
185	9.3	N	I-Premise
186	months	N	I-Premise
187	in	N	I-Premise
188	V	N	I-Premise
189	(	N	I-Premise
190	p	N	I-Premise
191	=	N	I-Premise
192	0.6975	N	I-Premise
193	)	N	I-Premise
194	.	N	I-Premise

195	Toxicities	N	I-Premise
196	were	N	I-Premise
197	generally	N	I-Premise
198	mild	N	I-Premise
199	in	N	I-Premise
200	both	N	I-Premise
201	groups	N	I-Premise
202	.	N	I-Premise

203	Median	N	I-Premise
204	PFS	N	I-Premise
205	was	N	I-Premise
206	longest	N	I-Premise
207	for	N	I-Premise
208	epidermal	N	I-Premise
209	growth	N	I-Premise
210	factor	N	I-Premise
211	receptor	N	I-Premise
212	gene	N	I-Premise
213	(	N	I-Premise
214	EGFR	N	I-Premise
215	)	N	I-Premise
216	-mutated	N	I-Premise
217	patients	N	I-Premise
218	in	N	I-Premise
219	the	N	I-Premise
220	E	N	I-Premise
221	group	N	I-Premise
222	,	N	I-Premise
223	followed	N	I-Premise
224	by	N	I-Premise
225	EGFR-mutated	N	I-Premise
226	patients	N	I-Premise
227	in	N	I-Premise
228	V	N	I-Premise
229	,	N	I-Premise
230	EGFR	N	I-Premise
231	wild	N	I-Premise
232	type	N	I-Premise
233	in	N	I-Premise
234	E	N	I-Premise
235	,	N	I-Premise
236	and	N	I-Premise
237	EGFR	N	I-Premise
238	wild	N	I-Premise
239	type	N	I-Premise
240	in	N	I-Premise
241	V	N	I-Premise
242	(	N	I-Premise
243	p	N	I-Premise
244	=	N	I-Premise
245	0.0034	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	Overall	N	I-Premise
249	survival	N	I-Premise
250	was	N	I-Premise
251	longer	N	I-Premise
252	for	N	I-Premise
253	EGFR-mutated	N	I-Premise
254	patients	N	I-Premise
255	than	N	I-Premise
256	for	N	I-Premise
257	EGFR	N	I-Premise
258	wild-type	N	I-Premise
259	patients	N	I-Premise
260	(	N	I-Premise
261	p	N	I-Premise
262	<	N	I-Premise
263	0.0001	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	Erlotinib	N	I-Claim
267	is	N	I-Claim
268	highly	N	I-Claim
269	effective	N	I-Claim
270	compared	N	I-Claim
271	with	N	I-Claim
272	oral	N	I-Claim
273	vinorelbine	N	I-Claim
274	in	N	I-Claim
275	elderly	N	I-Claim
276	,	N	I-Claim
277	chemonaive	N	I-Claim
278	,	N	I-Claim
279	Taiwanese	N	I-Claim
280	patients	N	I-Claim
281	with	N	I-Claim
282	NSCLC	N	I-Claim
283	.	N	I-Claim

284	EGFR-mutated	N	I-Claim
285	patients	N	I-Claim
286	had	N	I-Claim
287	better	N	I-Claim
288	survival	N	I-Claim
289	than	N	I-Claim
290	those	N	I-Claim
291	with	N	I-Claim
292	EGFR	N	I-Claim
293	wild-type	N	I-Claim
294	disease	N	I-Claim
295	,	N	I-Claim
296	regardless	N	I-Claim
297	of	N	I-Claim
298	the	N	I-Claim
299	treatment	N	I-Claim
300	received	N	I-Claim
301	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	low-frequency	N	O
7	low-intensity	N	O
8	electrotherapy	N	O
9	and	N	O
10	manual	N	O
11	lymphatic	N	O
12	drainage	N	O
13	in	N	O
14	the	N	O
15	treatment	N	O
16	of	N	O
17	chronic	N	O
18	upper	N	O
19	limb	N	O
20	breast	N	O
21	cancer-related	N	O
22	lymphoedema	N	O
23	.	N	O

24	Cross-over	N	O
25	single-blind	N	O
26	random	N	O
27	clinical	N	O
28	trial	N	O
29	.	N	O

30	Rehabilitation	N	O
31	service	N	O
32	.	N	O

33	Thirty-six	N	O
34	women	N	O
35	with	N	O
36	chronic	N	O
37	upper	N	O
38	limb	N	O
39	breast	N	O
40	cancer-related	N	O
41	lymphoedema	N	O
42	.	N	O

43	Patients	N	O
44	were	N	O
45	randomized	N	O
46	to	N	O
47	undergo	N	O
48	10	N	O
49	sessions	N	O
50	of	N	O
51	manual	N	O
52	lymphatic	N	O
53	drainage	N	O
54	followed	N	O
55	by	N	O
56	10	N	O
57	sessions	N	O
58	of	N	O
59	low-frequency	N	O
60	low-intensity	N	O
61	electrotherapy	N	O
62	or	N	O
63	to	N	O
64	undergo	N	O
65	first	N	O
66	low-frequency	N	O
67	low-intensity	N	O
68	electrotherapy	N	O
69	followed	N	O
70	by	N	O
71	manual	N	O
72	lymphatic	N	O
73	drainage	N	O
74	.	N	O

75	There	N	O
76	was	N	O
77	a	N	O
78	month	N	O
79	of	N	O
80	washout	N	O
81	time	N	O
82	between	N	O
83	treatments	N	O
84	.	N	O

85	Each	N	O
86	patient	N	O
87	was	N	O
88	examined	N	O
89	just	N	O
90	before	N	O
91	and	N	O
92	after	N	O
93	each	N	O
94	treatment	N	O
95	.	N	O

96	Researchers	N	O
97	and	N	O
98	outcome	N	O
99	assessors	N	O
100	were	N	O
101	blinded	N	O
102	for	N	O
103	assigned	N	O
104	treatment	N	O
105	.	N	O

106	Outcomes	N	O
107	were	N	O
108	lymphoedema	N	O
109	volume	N	O
110	,	N	O
111	pain	N	O
112	,	N	O
113	heaviness	N	O
114	and	N	O
115	tightness	N	O
116	,	N	O
117	and	N	O
118	health-related	N	O
119	quality	N	O
120	of	N	O
121	life	N	O
122	measured	N	O
123	with	N	O
124	the	N	O
125	Functional	N	O
126	Assessment	N	O
127	of	N	O
128	Cancer	N	O
129	Therapy	N	O
130	Questionnaire	N	O
131	for	N	O
132	Breast	N	O
133	Cancer	N	O
134	version	N	O
135	4	N	O
136	(	N	O
137	FACT-B+4	N	O
138	)	N	O
139	.	N	O

140	Carry-over	N	O
141	,	N	O
142	period	N	O
143	and	N	O
144	treatment	N	O
145	effects	N	O
146	were	N	O
147	analysed	N	O
148	.	N	O

149	Treatment	N	O
150	effect	N	O
151	was	N	O
152	assessed	N	O
153	using	N	O
154	paired	N	O
155	t-test	N	O
156	.	N	O

157	Thirty	N	O
158	patients	N	O
159	finalized	N	O
160	treatment	N	O
161	.	N	O

162	Comparing	N	I-Premise
163	the	N	I-Premise
164	changes	N	I-Premise
165	in	N	I-Premise
166	low-frequency	N	I-Premise
167	low-intensity	N	I-Premise
168	electrotherapy	N	I-Premise
169	with	N	I-Premise
170	manual	N	I-Premise
171	lymphatic	N	I-Premise
172	drainage	N	I-Premise
173	changes	N	I-Premise
174	,	N	I-Premise
175	there	N	I-Premise
176	were	N	I-Premise
177	no	N	I-Premise
178	significant	N	I-Premise
179	differences	N	I-Premise
180	.	N	I-Premise

181	Low-frequency	N	I-Premise
182	low-intensity	N	I-Premise
183	electrotherapy	N	I-Premise
184	did	N	I-Premise
185	not	N	I-Premise
186	reduce	N	I-Premise
187	lymphoedema	N	I-Premise
188	volume	N	I-Premise
189	(	N	I-Premise
190	mean	N	I-Premise
191	of	N	I-Premise
192	change	N	I-Premise
193	=	N	I-Premise
194	19.77	N	I-Premise
195	mL	N	I-Premise
196	,	N	I-Premise
197	P	N	I-Premise
198	=	N	I-Premise
199	0.36	N	I-Premise
200	)	N	I-Premise
201	,	N	I-Premise
202	but	N	O
203	significant	N	I-Premise
204	reductions	N	I-Premise
205	were	N	I-Premise
206	observed	N	I-Premise
207	in	N	I-Premise
208	pain	N	I-Premise
209	,	N	I-Premise
210	heaviness	N	I-Premise
211	and	N	I-Premise
212	tightness	N	I-Premise
213	(	N	I-Premise
214	mean	N	I-Premise
215	of	N	I-Premise
216	change	N	I-Premise
217	=	N	I-Premise
218	13.1	N	I-Premise
219	,	N	I-Premise
220	16.2	N	I-Premise
221	and	N	I-Premise
222	6.4	N	I-Premise
223	mm	N	I-Premise
224	,	N	I-Premise
225	respectively	N	I-Premise
226	)	N	I-Premise
227	,	N	I-Premise
228	and	N	I-Premise
229	FACT-B+4	N	I-Premise
230	summaries	N	I-Premise
231	improved	N	I-Premise
232	significantly	N	I-Premise
233	(	N	I-Premise
234	Trial	N	I-Premise
235	Outcome	N	I-Premise
236	Index	N	I-Premise
237	mean	N	I-Premise
238	of	N	I-Premise
239	change	N	I-Premise
240	=	N	I-Premise
241	5.4	N	I-Premise
242	,	N	I-Premise
243	P	N	I-Premise
244	=	N	I-Premise
245	0.015	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	Manual	N	I-Premise
249	lymphatic	N	I-Premise
250	drainage	N	I-Premise
251	showed	N	I-Premise
252	no	N	I-Premise
253	significant	N	I-Premise
254	changes	N	I-Premise
255	in	N	I-Premise
256	any	N	I-Premise
257	of	N	I-Premise
258	the	N	I-Premise
259	outcomes	N	I-Premise
260	.	N	I-Premise

261	Although	N	I-Claim
262	there	N	I-Claim
263	are	N	I-Claim
264	no	N	I-Claim
265	significant	N	I-Claim
266	differences	N	I-Claim
267	between	N	I-Claim
268	treatment	N	I-Claim
269	changes	N	I-Claim
270	,	N	I-Claim
271	the	N	I-Claim
272	observed	N	I-Claim
273	trend	N	I-Claim
274	towards	N	I-Claim
275	a	N	I-Claim
276	better	N	I-Claim
277	health-related	N	I-Claim
278	quality	N	I-Claim
279	of	N	I-Claim
280	life	N	I-Claim
281	is	N	I-Claim
282	remarkable	N	I-Claim
283	in	N	I-Claim
284	low-frequency	N	I-Claim
285	low-intensity	N	I-Claim
286	electrotherapy	N	I-Claim
287	.	N	I-Claim

1	Gynecological	N	O
2	neoplastic	N	O
3	disease	N	O
4	progression	N	O
5	is	N	O
6	characterized	N	O
7	by	N	O
8	specific	N	O
9	energy	N	O
10	metabolism	N	O
11	alterations	N	O
12	and	N	O
13	by	N	O
14	symptoms	N	O
15	including	N	O
16	fatigue	N	O
17	,	N	O
18	anorexia	N	O
19	,	N	O
20	nausea	N	O
21	,	N	O
22	anemia	N	O
23	,	N	O
24	and	N	O
25	immunodepression	N	O
26	,	N	O
27	which	N	O
28	result	N	O
29	in	N	O
30	a	N	O
31	cachexia	N	O
32	syndrome	N	O
33	and	N	O
34	a	N	O
35	marked	N	O
36	decrease	N	O
37	in	N	O
38	patient	N	O
39	quality	N	O
40	of	N	O
41	life	N	O
42	(	N	O
43	QoL	N	O
44	)	N	O
45	.	N	O

46	Therapeutic	N	O
47	protocols	N	O
48	associated	N	O
49	with	N	O
50	appropriate	N	O
51	and	N	O
52	effective	N	O
53	psychological	N	O
54	and	N	O
55	social	N	O
56	support	N	O
57	systems	N	O
58	are	N	O
59	essential	N	O
60	to	N	O
61	counteract	N	O
62	the	N	O
63	symptoms	N	O
64	of	N	O
65	neoplastic	N	O
66	disease	N	O
67	in	N	O
68	incurable	N	O
69	patients	N	O
70	.	N	O

71	A	N	O
72	phase	N	O
73	III	N	O
74	randomized	N	O
75	study	N	O
76	was	N	O
77	performed	N	O
78	to	N	O
79	establish	N	O
80	the	N	O
81	most	N	O
82	effective	N	O
83	and	N	O
84	safest	N	O
85	treatment	N	O
86	to	N	O
87	improve	N	O
88	the	N	O
89	key	N	O
90	symptoms	N	O
91	in	N	O
92	advanced	N	O
93	gynecological	N	O
94	cancer	N	O
95	patients	N	O
96	,	N	O
97	i.e.	N	O
98	,	N	O
99	lean	N	O
100	body	N	O
101	mass	N	O
102	(	N	O
103	LBM	N	O
104	)	N	O
105	,	N	O
106	resting	N	O
107	energy	N	O
108	expenditure	N	O
109	(	N	O
110	REE	N	O
111	)	N	O
112	,	N	O
113	fatigue	N	O
114	,	N	O
115	and	N	O
116	QoL	N	O
117	.	N	O

118	In	N	O
119	addition	N	O
120	,	N	O
121	the	N	O
122	impact	N	O
123	of	N	O
124	the	N	O
125	treatment	N	O
126	arms	N	O
127	on	N	O
128	the	N	O
129	main	N	O
130	metabolic	N	O
131	and	N	O
132	inflammatory	N	O
133	parameters	N	O
134	,	N	O
135	including	N	O
136	C-reactive	N	O
137	protein	N	O
138	(	N	O
139	CRP	N	O
140	)	N	O
141	,	N	O
142	interleukin	N	O
143	(	N	O
144	IL	N	O
145	)	N	O
146	-6	N	O
147	,	N	O
148	tumor	N	O
149	necrosis	N	O
150	factor	N	O
151	(	N	O
152	TNF	N	O
153	)	N	O
154	-	N	O
155	,	N	O
156	leptin	N	O
157	,	N	O
158	reactive	N	O
159	oxygen	N	O
160	species	N	O
161	(	N	O
162	ROS	N	O
163	)	N	O
164	,	N	O
165	and	N	O
166	glutathione	N	O
167	peroxidase	N	O
168	,	N	O
169	was	N	O
170	evaluated	N	O
171	.	N	O

172	The	N	O
173	change	N	O
174	in	N	O
175	the	N	O
176	Glasgow	N	O
177	Prognostic	N	O
178	Score	N	O
179	(	N	O
180	GPS	N	O
181	)	N	O
182	during	N	O
183	treatment	N	O
184	was	N	O
185	also	N	O
186	assessed	N	O
187	.	N	O

188	A	N	O
189	total	N	O
190	of	N	O
191	104	N	O
192	advanced-stage	N	O
193	gynecological	N	O
194	cancer	N	O
195	patients	N	O
196	were	N	O
197	enrolled	N	O
198	and	N	O
199	randomly	N	O
200	assigned	N	O
201	to	N	O
202	receive	N	O
203	either	N	O
204	megestrol	N	O
205	acetate	N	O
206	(	N	O
207	MA	N	O
208	)	N	O
209	plus	N	O
210	l-carnitine	N	O
211	,	N	O
212	celecoxib	N	O
213	,	N	O
214	and	N	O
215	antioxidants	N	O
216	(	N	O
217	arm	N	O
218	1	N	O
219	)	N	O
220	or	N	O
221	MA	N	O
222	alone	N	O
223	(	N	O
224	arm	N	O
225	2	N	O
226	)	N	O
227	.	N	O

228	The	N	O
229	treatment	N	O
230	duration	N	O
231	was	N	O
232	4	N	O
233	months	N	O
234	.	N	O

235	The	N	I-Premise
236	combination	N	I-Premise
237	arm	N	I-Premise
238	was	N	I-Premise
239	more	N	I-Premise
240	effective	N	I-Premise
241	than	N	I-Premise
242	arm	N	I-Premise
243	2	N	I-Premise
244	with	N	I-Premise
245	respect	N	I-Premise
246	to	N	I-Premise
247	LBM	N	I-Premise
248	,	N	I-Premise
249	REE	N	I-Premise
250	,	N	I-Premise
251	fatigue	N	I-Premise
252	,	N	I-Premise
253	and	N	I-Premise
254	global	N	I-Premise
255	QoL	N	I-Premise
256	.	N	I-Premise

257	As	N	I-Premise
258	for	N	I-Premise
259	the	N	I-Premise
260	secondary	N	I-Premise
261	efficacy	N	I-Premise
262	endpoints	N	I-Premise
263	,	N	I-Premise
264	patient	N	I-Premise
265	appetite	N	I-Premise
266	increased	N	I-Premise
267	,	N	I-Premise
268	and	N	I-Premise
269	ECOG	N	I-Premise
270	PS	N	I-Premise
271	decreased	N	I-Premise
272	significantly	N	I-Premise
273	in	N	I-Premise
274	both	N	I-Premise
275	arms	N	I-Premise
276	.	N	I-Premise

277	The	N	I-Premise
278	inflammation	N	I-Premise
279	and	N	I-Premise
280	oxidative	N	I-Premise
281	stress	N	I-Premise
282	parameters	N	I-Premise
283	IL-6	N	I-Premise
284	,	N	I-Premise
285	TNF-	N	I-Premise
286	,	N	I-Premise
287	CRP	N	I-Premise
288	,	N	I-Premise
289	and	N	I-Premise
290	ROS	N	I-Premise
291	decreased	N	I-Premise
292	significantly	N	I-Premise
293	in	N	I-Premise
294	arm	N	I-Premise
295	1	N	I-Premise
296	,	N	I-Premise
297	while	N	I-Premise
298	no	N	I-Premise
299	significant	N	I-Premise
300	change	N	I-Premise
301	was	N	I-Premise
302	observed	N	I-Premise
303	in	N	I-Premise
304	arm	N	I-Premise
305	2	N	I-Premise
306	.	N	I-Premise

307	The	N	I-Claim
308	combined	N	I-Claim
309	treatment	N	I-Claim
310	improved	N	I-Claim
311	both	N	I-Claim
312	immunometabolic	N	I-Claim
313	alterations	N	I-Claim
314	and	N	I-Claim
315	patient	N	I-Claim
316	QoL	N	I-Claim
317	.	N	I-Claim

318	Multimodality	N	I-MajorClaim
319	therapies	N	I-MajorClaim
320	for	N	I-MajorClaim
321	cachexia	N	I-MajorClaim
322	ideally	N	I-MajorClaim
323	should	N	I-MajorClaim
324	be	N	I-MajorClaim
325	introduced	N	I-MajorClaim
326	within	N	I-MajorClaim
327	a	N	I-MajorClaim
328	context	N	I-MajorClaim
329	of	N	I-MajorClaim
330	``	N	I-MajorClaim
331	best	N	I-MajorClaim
332	supportive	N	I-MajorClaim
333	care	N	I-MajorClaim
334	''	N	I-MajorClaim
335	that	N	I-MajorClaim
336	includes	N	I-MajorClaim
337	optimal	N	I-MajorClaim
338	symptom	N	I-MajorClaim
339	management	N	I-MajorClaim
340	and	N	I-MajorClaim
341	careful	N	I-MajorClaim
342	psychosocial	N	I-MajorClaim
343	counseling	N	I-MajorClaim
344	.	N	I-MajorClaim

1	Pain	N	O
2	is	N	O
3	1	N	O
4	of	N	O
5	the	N	O
6	most	N	O
7	common	N	O
8	symptoms	N	O
9	that	N	O
10	a	N	O
11	cancer	N	O
12	patient	N	O
13	would	N	O
14	experience	N	O
15	.	N	O

16	A	N	O
17	significant	N	O
18	barrier	N	O
19	to	N	O
20	positive	N	O
21	pain	N	O
22	management	N	O
23	is	N	O
24	patients	N	O
25	'	N	O
26	misconceptions	N	O
27	regarding	N	O
28	analgesics	N	O
29	and	N	O
30	inadequate	N	O
31	use	N	O
32	of	N	O
33	nonpharmacological	N	O
34	strategies	N	O
35	as	N	O
36	pain	N	O
37	relief	N	O
38	.	N	O

39	The	N	O
40	purpose	N	O
41	of	N	O
42	this	N	O
43	study	N	O
44	was	N	O
45	to	N	O
46	investigate	N	O
47	the	N	O
48	effectiveness	N	O
49	of	N	O
50	a	N	O
51	pain	N	O
52	management	N	O
53	program	N	O
54	(	N	O
55	PMP	N	O
56	)	N	O
57	on	N	O
58	pain	N	O
59	intensity	N	O
60	,	N	O
61	use	N	O
62	of	N	O
63	PRN	N	O
64	drugs	N	O
65	and	N	O
66	nonpharmacological	N	O
67	strategies	N	O
68	as	N	O
69	pain	N	O
70	relief	N	O
71	,	N	O
72	and	N	O
73	barriers	N	O
74	to	N	O
75	managing	N	O
76	pain	N	O
77	in	N	O
78	cancer	N	O
79	patients	N	O
80	.	N	O

81	The	N	O
82	study	N	O
83	was	N	O
84	conducted	N	O
85	in	N	O
86	the	N	O
87	palliative	N	O
88	care	N	O
89	and	N	O
90	hospice	N	O
91	ward	N	O
92	of	N	O
93	a	N	O
94	public	N	O
95	hospital	N	O
96	in	N	O
97	Hong	N	O
98	Kong	N	O
99	.	N	O

100	Patients	N	O
101	were	N	O
102	randomized	N	O
103	to	N	O
104	either	N	O
105	an	N	O
106	experimental	N	O
107	group	N	O
108	(	N	O
109	receiving	N	O
110	the	N	O
111	PMP	N	O
112	)	N	O
113	or	N	O
114	a	N	O
115	control	N	O
116	group	N	O
117	(	N	O
118	routine	N	O
119	care	N	O
120	)	N	O
121	.	N	O

122	There	N	O
123	were	N	O
124	38	N	O
125	hospitalized	N	O
126	patients	N	O
127	,	N	O
128	with	N	O
129	20	N	O
130	(	N	O
131	13	N	O
132	males	N	O
133	and	N	O
134	7	N	O
135	females	N	O
136	)	N	O
137	in	N	O
138	the	N	O
139	experimental	N	O
140	group	N	O
141	and	N	O
142	18	N	O
143	(	N	O
144	11	N	O
145	males	N	O
146	and	N	O
147	7	N	O
148	females	N	O
149	)	N	O
150	in	N	O
151	the	N	O
152	control	N	O
153	group	N	O
154	;	N	O
155	mean	N	O
156	age	N	O
157	was	N	O
158	61.95	N	O
159	years	N	O
160	(	N	O
161	experimental	N	O
162	group	N	O
163	)	N	O
164	to	N	O
165	63.94	N	O
166	years	N	O
167	(	N	O
168	control	N	O
169	group	N	O
170	)	N	O
171	.	N	O

172	Upon	N	I-Premise
173	the	N	I-Premise
174	completion	N	I-Premise
175	of	N	I-Premise
176	PMP	N	I-Premise
177	,	N	I-Premise
178	pain	N	I-Premise
179	scores	N	I-Premise
180	were	N	I-Premise
181	significantly	N	I-Premise
182	reduced	N	I-Premise
183	in	N	I-Premise
184	both	N	I-Premise
185	groups	N	I-Premise
186	,	N	I-Premise
187	yet	N	I-Premise
188	patients	N	I-Premise
189	in	N	I-Premise
190	the	N	I-Premise
191	experimental	N	I-Premise
192	group	N	I-Premise
193	showed	N	I-Premise
194	a	N	I-Premise
195	significant	N	I-Premise
196	increase	N	I-Premise
197	in	N	I-Premise
198	the	N	I-Premise
199	use	N	I-Premise
200	of	N	I-Premise
201	PRN	N	I-Premise
202	analgesics	N	I-Premise
203	and	N	I-Premise
204	nonpharmacological	N	I-Premise
205	strategies	N	I-Premise
206	to	N	I-Premise
207	relieve	N	I-Premise
208	pain	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	<	N	I-Premise
212	.05	N	I-Premise
213	)	N	I-Premise
214	and	N	I-Premise
215	significantly	N	I-Premise
216	reduce	N	I-Premise
217	barriers	N	I-Premise
218	to	N	I-Premise
219	managing	N	I-Premise
220	their	N	I-Premise
221	cancer	N	I-Premise
222	pain	N	I-Premise
223	(	N	I-Premise
224	P	N	I-Premise
225	<	N	I-Premise
226	.05	N	I-Premise
227	)	N	I-Premise
228	compared	N	I-Premise
229	with	N	I-Premise
230	the	N	I-Premise
231	control	N	I-Premise
232	group	N	I-Premise
233	.	N	I-Premise

234	Cancer	N	I-Claim
235	patients	N	I-Claim
236	should	N	I-Claim
237	be	N	I-Claim
238	empowered	N	I-Claim
239	with	N	I-Claim
240	pain	N	I-Claim
241	management	N	I-Claim
242	education	N	I-Claim
243	to	N	I-Claim
244	gain	N	I-Claim
245	knowledge	N	I-Claim
246	and	N	I-Claim
247	correct	N	I-Claim
248	misconceptions	N	I-Claim
249	in	N	I-Claim
250	managing	N	I-Claim
251	their	N	I-Claim
252	cancer	N	I-Claim
253	pain	N	I-Claim
254	.	N	I-Claim

255	Integration	N	I-Claim
256	of	N	I-Claim
257	the	N	I-Claim
258	PMP	N	I-Claim
259	into	N	I-Claim
260	routine	N	I-Claim
261	clinical	N	I-Claim
262	work	N	I-Claim
263	may	N	I-Claim
264	help	N	I-Claim
265	to	N	I-Claim
266	improve	N	I-Claim
267	the	N	I-Claim
268	standard	N	I-Claim
269	of	N	I-Claim
270	care	N	I-Claim
271	for	N	I-Claim
272	cancer	N	I-Claim
273	patients	N	I-Claim
274	.	N	I-Claim

275	It	N	O
276	is	N	O
277	recommended	N	O
278	to	N	O
279	provide	N	O
280	pain	N	O
281	management	N	O
282	education	N	O
283	to	N	O
284	all	N	O
285	cancer	N	O
286	patients	N	O
287	.	N	O

1	Health-related	N	O
2	quality	N	O
3	of	N	O
4	life	N	O
5	(	N	O
6	HRQOL	N	O
7	)	N	O
8	,	N	O
9	symptoms	N	O
10	of	N	O
11	depression	N	O
12	,	N	O
13	and	N	O
14	adverse	N	O
15	events	N	O
16	(	N	O
17	AEs	N	O
18	)	N	O
19	were	N	O
20	compared	N	O
21	between	N	O
22	Japanese	N	O
23	postmenopausal	N	O
24	patients	N	O
25	with	N	O
26	hormone-sensitive	N	O
27	breast	N	O
28	cancer	N	O
29	(	N	O
30	BC	N	O
31	)	N	O
32	who	N	O
33	received	N	O
34	adjuvant	N	O
35	tamoxifen	N	O
36	,	N	O
37	exemestane	N	O
38	,	N	O
39	or	N	O
40	anastrozole	N	O
41	in	N	O
42	an	N	O
43	open-labeled	N	O
44	,	N	O
45	randomized	N	O
46	,	N	O
47	multicenter	N	O
48	trial	N	O
49	designated	N	O
50	as	N	O
51	the	N	O
52	National	N	O
53	Surgical	N	O
54	Adjuvant	N	O
55	Study	N	O
56	of	N	O
57	Breast	N	O
58	Cancer	N	O
59	(	N	O
60	N-SAS	N	O
61	BC	N	O
62	)	N	O
63	04	N	O
64	substudy	N	O
65	of	N	O
66	the	N	O
67	Tamoxifen	N	O
68	Exemestane	N	O
69	Adjuvant	N	O
70	Multinational	N	O
71	(	N	O
72	TEAM	N	O
73	)	N	O
74	trial	N	O
75	.	N	O

76	During	N	O
77	the	N	O
78	first	N	O
79	year	N	O
80	of	N	O
81	treatment	N	O
82	,	N	O
83	HRQOL	N	O
84	and	N	O
85	symptoms	N	O
86	of	N	O
87	depression	N	O
88	were	N	O
89	analyzed	N	O
90	using	N	O
91	the	N	O
92	Functional	N	O
93	Assessment	N	O
94	of	N	O
95	Cancer	N	O
96	Therapy-Breast	N	O
97	(	N	O
98	FACT-B	N	O
99	)	N	O
100	and	N	O
101	its	N	O
102	Endocrine	N	O
103	Symptom	N	O
104	Subscale	N	O
105	(	N	O
106	ES	N	O
107	)	N	O
108	,	N	O
109	and	N	O
110	the	N	O
111	Center	N	O
112	for	N	O
113	Epidemiologic	N	O
114	Studies	N	O
115	Depression	N	O
116	Scale	N	O
117	(	N	O
118	CES-D	N	O
119	)	N	O
120	,	N	O
121	respectively	N	O
122	.	N	O

123	In	N	O
124	addition	N	O
125	,	N	O
126	predefined	N	O
127	AEs	N	O
128	were	N	O
129	analyzed	N	O
130	.	N	O

131	A	N	O
132	total	N	O
133	of	N	O
134	166	N	O
135	eligible	N	O
136	patients	N	O
137	were	N	O
138	randomly	N	O
139	assigned	N	O
140	to	N	O
141	receive	N	O
142	adjuvant	N	O
143	tamoxifen	N	O
144	,	N	O
145	exemestane	N	O
146	,	N	O
147	or	N	O
148	anastrozole	N	O
149	.	N	O

150	FACT-B	N	I-Premise
151	scores	N	I-Premise
152	increased	N	I-Premise
153	after	N	I-Premise
154	treatment	N	I-Premise
155	began	N	I-Premise
156	and	N	I-Premise
157	remained	N	I-Premise
158	significantly	N	I-Premise
159	higher	N	I-Premise
160	in	N	I-Premise
161	the	N	I-Premise
162	tamoxifen	N	I-Premise
163	group	N	I-Premise
164	than	N	I-Premise
165	in	N	I-Premise
166	the	N	I-Premise
167	exemestane	N	I-Premise
168	group	N	I-Premise
169	or	N	I-Premise
170	anastrozole	N	I-Premise
171	group	N	I-Premise
172	during	N	I-Premise
173	the	N	I-Premise
174	first	N	I-Premise
175	year	N	I-Premise
176	(	N	I-Premise
177	P	N	I-Premise
178	=	N	I-Premise
179	0.045	N	I-Premise
180	)	N	I-Premise
181	.	N	I-Premise

182	FACT-B	N	I-Premise
183	scores	N	I-Premise
184	were	N	I-Premise
185	similar	N	I-Premise
186	in	N	I-Premise
187	the	N	I-Premise
188	exemestane	N	I-Premise
189	group	N	I-Premise
190	and	N	I-Premise
191	anastrozole	N	I-Premise
192	group	N	I-Premise
193	.	N	I-Premise

194	ES	N	I-Premise
195	scores	N	I-Premise
196	and	N	I-Premise
197	CES-D	N	I-Premise
198	scores	N	I-Premise
199	were	N	I-Premise
200	similar	N	I-Premise
201	in	N	I-Premise
202	all	N	I-Premise
203	treatment	N	I-Premise
204	groups	N	I-Premise
205	.	N	I-Premise

206	Arthralgia	N	I-Premise
207	and	N	I-Premise
208	fatigue	N	I-Premise
209	were	N	I-Premise
210	less	N	I-Premise
211	frequent	N	I-Premise
212	,	N	I-Premise
213	but	N	I-Premise
214	vaginal	N	I-Premise
215	discharge	N	I-Premise
216	was	N	I-Premise
217	more	N	I-Premise
218	frequent	N	I-Premise
219	in	N	I-Premise
220	the	N	I-Premise
221	tamoxifen	N	I-Premise
222	group	N	I-Premise
223	than	N	I-Premise
224	in	N	I-Premise
225	the	N	I-Premise
226	exemestane	N	I-Premise
227	group	N	I-Premise
228	or	N	I-Premise
229	anastrozole	N	I-Premise
230	group	N	I-Premise
231	.	N	I-Premise

232	HRQOL	N	I-Claim
233	was	N	I-Claim
234	better	N	I-Claim
235	in	N	I-Claim
236	Japanese	N	I-Claim
237	postmenopausal	N	I-Claim
238	women	N	I-Claim
239	treated	N	I-Claim
240	with	N	I-Claim
241	tamoxifen	N	I-Claim
242	than	N	I-Claim
243	those	N	I-Claim
244	treated	N	I-Claim
245	with	N	I-Claim
246	exemestane	N	I-Claim
247	or	N	I-Claim
248	anastrozole	N	I-Claim
249	.	N	I-Claim

250	HRQOL	N	I-Claim
251	and	N	I-Claim
252	AEs	N	I-Claim
253	were	N	I-Claim
254	similar	N	I-Claim
255	with	N	I-Claim
256	exemestane	N	I-Claim
257	and	N	I-Claim
258	anastrozole	N	I-Claim
259	.	N	I-Claim

260	Given	N	I-Claim
261	the	N	I-Claim
262	results	N	I-Claim
263	of	N	I-Claim
264	the	N	I-Claim
265	TEAM	N	I-Claim
266	trial	N	I-Claim
267	,	N	I-Claim
268	upfront	N	I-Claim
269	use	N	I-Claim
270	of	N	I-Claim
271	tamoxifen	N	I-Claim
272	followed	N	I-Claim
273	by	N	I-Claim
274	an	N	I-Claim
275	aromatase	N	I-Claim
276	inhibitor	N	I-Claim
277	(	N	I-Claim
278	AI	N	I-Claim
279	)	N	I-Claim
280	may	N	I-Claim
281	be	N	I-Claim
282	an	N	I-Claim
283	important	N	I-Claim
284	option	N	I-Claim
285	for	N	I-Claim
286	adjuvant	N	I-Claim
287	endocrine	N	I-Claim
288	therapy	N	I-Claim
289	in	N	I-Claim
290	Japanese	N	I-Claim
291	postmenopausal	N	I-Claim
292	women	N	I-Claim
293	.	N	I-Claim

1	Cisplatin	N	I-MajorClaim
2	reduces	N	I-MajorClaim
3	plasma	N	I-MajorClaim
4	ghrelin	N	I-MajorClaim
5	levels	N	I-MajorClaim
6	through	N	I-MajorClaim
7	the	N	I-MajorClaim
8	5-hydroxytryptamine	N	I-MajorClaim
9	(	N	I-MajorClaim
10	5-HT	N	I-MajorClaim
11	)	N	I-MajorClaim
12	receptor	N	I-MajorClaim
13	.	N	I-MajorClaim

14	This	N	O
15	may	N	O
16	cause	N	O
17	cisplatin-induced	N	O
18	gastrointestinal	N	O
19	disorders	N	O
20	and	N	O
21	hinders	N	O
22	the	N	O
23	continuation	N	O
24	of	N	O
25	chemotherapy	N	O
26	.	N	O

27	The	N	O
28	authors	N	O
29	of	N	O
30	this	N	O
31	report	N	O
32	conducted	N	O
33	a	N	O
34	prospective	N	O
35	,	N	O
36	randomized	N	O
37	phase	N	O
38	2	N	O
39	trial	N	O
40	to	N	O
41	evaluate	N	O
42	the	N	O
43	effects	N	O
44	of	N	O
45	exogenous	N	O
46	ghrelin	N	O
47	during	N	O
48	cisplatin-based	N	O
49	chemotherapy	N	O
50	.	N	O

51	Forty-two	N	O
52	patients	N	O
53	with	N	O
54	esophageal	N	O
55	cancer	N	O
56	who	N	O
57	were	N	O
58	receiving	N	O
59	cisplatin-based	N	O
60	neoadjuvant	N	O
61	chemotherapy	N	O
62	were	N	O
63	assigned	N	O
64	to	N	O
65	either	N	O
66	a	N	O
67	ghrelin	N	O
68	group	N	O
69	(	N	O
70	n	N	O
71	=	N	O
72	21	N	O
73	)	N	O
74	or	N	O
75	a	N	O
76	placebo	N	O
77	group	N	O
78	(	N	O
79	n	N	O
80	=	N	O
81	21	N	O
82	)	N	O
83	.	N	O

84	They	N	O
85	received	N	O
86	either	N	O
87	intravenous	N	O
88	infusions	N	O
89	of	N	O
90	synthetic	N	O
91	human	N	O
92	ghrelin	N	O
93	(	N	O
94	3	N	O
95	g/kg	N	O
96	)	N	O
97	or	N	O
98	saline	N	O
99	twice	N	O
100	daily	N	O
101	for	N	O
102	1	N	O
103	week	N	O
104	with	N	O
105	cisplatin	N	O
106	administration	N	O
107	.	N	O

108	The	N	O
109	primary	N	O
110	endpoint	N	O
111	was	N	O
112	changes	N	O
113	in	N	O
114	oral	N	O
115	calorie	N	O
116	intake	N	O
117	,	N	O
118	and	N	O
119	the	N	O
120	secondary	N	O
121	endpoints	N	O
122	were	N	O
123	chemotherapy-related	N	O
124	adverse	N	O
125	events	N	O
126	;	N	O
127	appetite	N	O
128	visual	N	O
129	analog	N	O
130	scale	N	O
131	(	N	O
132	VAS	N	O
133	)	N	O
134	scores	N	O
135	;	N	O
136	changes	N	O
137	in	N	O
138	gastrointestinal	N	O
139	hormones	N	O
140	and	N	O
141	nutritional	N	O
142	status	N	O
143	,	N	O
144	including	N	O
145	rapid	N	O
146	turnover	N	O
147	proteins	N	O
148	,	N	O
149	and	N	O
150	quality	N	O
151	of	N	O
152	life	N	O
153	(	N	O
154	QoL	N	O
155	)	N	O
156	estimated	N	O
157	with	N	O
158	the	N	O
159	European	N	O
160	Organization	N	O
161	for	N	O
162	Research	N	O
163	and	N	O
164	Treatment	N	O
165	of	N	O
166	Cancer	N	O
167	QoL	N	O
168	core	N	O
169	questionnaire	N	O
170	(	N	O
171	QLQ-C30	N	O
172	)	N	O
173	.	N	O

174	Two	N	O
175	patients	N	O
176	were	N	O
177	excluded	N	O
178	from	N	O
179	the	N	O
180	final	N	O
181	analysis	N	O
182	:	N	O
183	One	N	O
184	patient	N	O
185	suspended	N	O
186	ghrelin	N	O
187	administration	N	O
188	because	N	O
189	of	N	O
190	excessive	N	O
191	diaphoresis	N	O
192	,	N	O
193	and	N	O
194	another	N	O
195	patient	N	O
196	in	N	O
197	the	N	O
198	placebo	N	O
199	group	N	O
200	failed	N	O
201	to	N	O
202	monitor	N	O
203	the	N	O
204	self-questionnaire	N	O
205	.	N	O

206	Food	N	I-Premise
207	intake	N	I-Premise
208	and	N	I-Premise
209	appetite	N	I-Premise
210	VAS	N	I-Premise
211	scores	N	I-Premise
212	were	N	I-Premise
213	significantly	N	I-Premise
214	higher	N	I-Premise
215	in	N	I-Premise
216	the	N	I-Premise
217	ghrelin	N	I-Premise
218	group	N	I-Premise
219	than	N	I-Premise
220	in	N	I-Premise
221	the	N	I-Premise
222	placebo	N	I-Premise
223	group	N	I-Premise
224	(	N	I-Premise
225	18.2	N	I-Premise
226		N	I-Premise
227	5.2	N	I-Premise
228	kcal/kg/day	N	I-Premise
229	vs	N	I-Premise
230	12.7	N	I-Premise
231		N	I-Premise
232	3.4	N	I-Premise
233	kcal/kg/day	N	I-Premise
234	[	N	I-Premise
235	P	N	I-Premise
236	=	N	I-Premise
237	.001	N	I-Premise
238	]	N	I-Premise
239	and	N	I-Premise
240	6.2	N	I-Premise
241		N	I-Premise
242	0.9	N	I-Premise
243	vs	N	I-Premise
244	4.1	N	I-Premise
245		N	I-Premise
246	0.9	N	I-Premise
247	[	N	I-Premise
248	P	N	I-Premise
249	<	N	I-Premise
250	.0001	N	I-Premise
251	]	N	I-Premise
252	,	N	I-Premise
253	respectively	N	I-Premise
254	)	N	I-Premise
255	.	N	I-Premise

256	Patients	N	I-Premise
257	in	N	I-Premise
258	the	N	I-Premise
259	ghrelin	N	I-Premise
260	group	N	I-Premise
261	had	N	I-Premise
262	fewer	N	I-Premise
263	adverse	N	I-Premise
264	events	N	I-Premise
265	during	N	I-Premise
266	chemotherapy	N	I-Premise
267	related	N	I-Premise
268	to	N	I-Premise
269	anorexia	N	I-Premise
270	and	N	I-Premise
271	nausea	N	I-Premise
272	than	N	I-Premise
273	patients	N	I-Premise
274	in	N	I-Premise
275	the	N	I-Premise
276	control	N	I-Premise
277	group	N	I-Premise
278	.	N	I-Premise

279	Significant	N	I-Premise
280	deterioration	N	I-Premise
281	was	N	I-Premise
282	noted	N	I-Premise
283	after	N	I-Premise
284	chemotherapy	N	I-Premise
285	in	N	I-Premise
286	the	N	I-Premise
287	placebo	N	I-Premise
288	group	N	I-Premise
289	in	N	I-Premise
290	QoL	N	I-Premise
291	scores	N	I-Premise
292	,	N	I-Premise
293	appetite	N	I-Premise
294	,	N	I-Premise
295	nausea	N	I-Premise
296	and	N	I-Premise
297	vomiting	N	I-Premise
298	,	N	I-Premise
299	and	N	I-Premise
300	global	N	I-Premise
301	health	N	I-Premise
302	status	N	I-Premise
303	.	N	I-Premise

304	Short-term	N	I-Claim
305	administration	N	I-Claim
306	of	N	I-Claim
307	exogenous	N	I-Claim
308	ghrelin	N	I-Claim
309	at	N	I-Claim
310	the	N	I-Claim
311	start	N	I-Claim
312	of	N	I-Claim
313	cisplatin-based	N	I-Claim
314	chemotherapy	N	I-Claim
315	stimulated	N	I-Claim
316	food	N	I-Claim
317	intake	N	I-Claim
318	and	N	I-Claim
319	minimized	N	I-Claim
320	adverse	N	I-Claim
321	events	N	I-Claim
322	.	N	I-Claim

1	This	N	O
2	study	N	O
3	aims	N	O
4	to	N	O
5	examine	N	O
6	the	N	O
7	effectiveness	N	O
8	of	N	O
9	a	N	O
10	self-management	N	O
11	multimodal	N	O
12	comprehensive	N	O
13	coping	N	O
14	strategy	N	O
15	program	N	O
16	(	N	O
17	CCSP	N	O
18	)	N	O
19	on	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QOL	N	O
25	)	N	O
26	among	N	O
27	breast	N	O
28	cancer	N	O
29	patients	N	O
30	1	N	O
31	year	N	O
32	after	N	O
33	treatment	N	O
34	.	N	O

35	Patients	N	O
36	(	N	O
37	n	N	O
38	=	N	O
39	110	N	O
40	)	N	O
41	with	N	O
42	stage	N	O
43	II	N	O
44	,	N	O
45	III	N	O
46	,	N	O
47	or	N	O
48	IV	N	O
49	breast	N	O
50	cancer	N	O
51	scheduled	N	O
52	to	N	O
53	receive	N	O
54	high	N	O
55	dose	N	O
56	chemotherapy	N	O
57	and	N	O
58	autologous	N	O
59	hematopoietic	N	O
60	stem	N	O
61	cell	N	O
62	transplantation	N	O
63	were	N	O
64	randomized	N	O
65	to	N	O
66	either	N	O
67	CCSP	N	O
68	treatment	N	O
69	or	N	O
70	control	N	O
71	group	N	O
72	.	N	O

73	The	N	O
74	CCSP	N	O
75	intervention	N	O
76	was	N	O
77	taught	N	O
78	2	N	O
79	week	N	O
80	before	N	O
81	hospital	N	O
82	admission	N	O
83	with	N	O
84	reinforcement	N	O
85	at	N	O
86	specified	N	O
87	times	N	O
88	during	N	O
89	treatment	N	O
90	and	N	O
91	3	N	O
92	months	N	O
93	after	N	O
94	discharge	N	O
95	.	N	O

96	The	N	O
97	CCSP	N	O
98	components	N	O
99	included	N	O
100	educational	N	O
101	information	N	O
102	,	N	O
103	cognitive	N	O
104	restructuring	N	O
105	,	N	O
106	coping	N	O
107	skills	N	O
108	enhancement	N	O
109	,	N	O
110	and	N	O
111	relaxation	N	O
112	with	N	O
113	guided	N	O
114	imagery	N	O
115	.	N	O

116	Instruments	N	O
117	administered	N	O
118	at	N	O
119	baseline	N	O
120	included	N	O
121	the	N	O
122	following	N	O
123	:	N	O
124	Quality	N	O
125	of	N	O
126	Life	N	O
127	Index-Cancer	N	O
128	Version	N	O
129	(	N	O
130	QOLI-CV	N	O
131	)	N	O
132	,	N	O
133	State-Trait	N	O
134	Anxiety	N	O
135	Inventory	N	O
136	,	N	O
137	Beck	N	O
138	Depression	N	O
139	Inventory	N	O
140	,	N	O
141	and	N	O
142	Coping	N	O
143	Strategies	N	O
144	Questionnaire	N	O
145	.	N	O

146	At	N	O
147	1-year	N	O
148	follow-up	N	O
149	,	N	O
150	patients	N	O
151	(	N	O
152	n	N	O
153	=	N	O
154	73	N	O
155	)	N	O
156	completed	N	O
157	and	N	O
158	returned	N	O
159	the	N	O
160	follow-up	N	O
161	QOLI-CV	N	O
162	.	N	O

163	Patients	N	O
164	were	N	O
165	mainly	N	O
166		N	O
167	40	N	O
168	years	N	O
169	of	N	O
170	age	N	O
171	,	N	O
172	married	N	O
173	,	N	O
174	Caucasian	N	O
175	,	N	O
176	and	N	O
177	diagnosed	N	O
178	with	N	O
179	advanced	N	O
180	breast	N	O
181	cancer	N	O
182	.	N	O

183	A	N	I-Premise
184	model	N	I-Premise
185	measuring	N	I-Premise
186	effectiveness	N	I-Premise
187	of	N	I-Premise
188	CCSP	N	I-Premise
189	on	N	I-Premise
190	QOL	N	I-Premise
191	(	N	I-Premise
192	total	N	I-Premise
193	and	N	I-Premise
194	subscale	N	I-Premise
195	)	N	I-Premise
196	at	N	I-Premise
197	1-year	N	I-Premise
198	follow-up	N	I-Premise
199	showed	N	I-Premise
200	that	N	I-Premise
201	the	N	I-Premise
202	CCSP	N	I-Premise
203	group	N	I-Premise
204	(	N	I-Premise
205	n	N	I-Premise
206	=	N	I-Premise
207	38	N	I-Premise
208	)	N	I-Premise
209	had	N	I-Premise
210	significant	N	I-Premise
211	improvement	N	I-Premise
212	in	N	I-Premise
213	overall	N	I-Premise
214	QOL	N	I-Premise
215	(	N	I-Premise
216	p	N	I-Premise
217	<	N	I-Premise
218	0.01	N	I-Premise
219	)	N	I-Premise
220	,	N	I-Premise
221	health	N	I-Premise
222	and	N	I-Premise
223	functioning	N	I-Premise
224	(	N	I-Premise
225	p	N	I-Premise
226	<	N	I-Premise
227	0.05	N	I-Premise
228	)	N	I-Premise
229	,	N	I-Premise
230	and	N	I-Premise
231	socioeconomic	N	I-Premise
232	(	N	I-Premise
233	p	N	I-Premise
234	<	N	I-Premise
235	0.05	N	I-Premise
236	)	N	I-Premise
237	and	N	I-Premise
238	psychological/spiritual	N	I-Premise
239	well-being	N	I-Premise
240	(	N	I-Premise
241	p	N	I-Premise
242	<	N	I-Premise
243	0.01	N	I-Premise
244	)	N	I-Premise
245	compared	N	I-Premise
246	with	N	I-Premise
247	the	N	I-Premise
248	control	N	I-Premise
249	group	N	I-Premise
250	(	N	I-Premise
251	n	N	I-Premise
252	=	N	I-Premise
253	35	N	I-Premise
254	)	N	I-Premise
255	.	N	I-Premise

256	The	N	I-Premise
257	CCSP	N	I-Premise
258	patients	N	I-Premise
259	frequently	N	I-Premise
260	used	N	I-Premise
261	the	N	I-Premise
262	CCSP	N	I-Premise
263	to	N	I-Premise
264	manage	N	I-Premise
265	psychological	N	I-Premise
266	(	N	I-Premise
267	51	N	I-Premise
268	%	N	I-Premise
269	)	N	I-Premise
270	and	N	I-Premise
271	sleep	N	I-Premise
272	problems	N	I-Premise
273	(	N	I-Premise
274	60	N	I-Premise
275	%	N	I-Premise
276	)	N	I-Premise
277	.	N	I-Premise

278	The	N	I-Premise
279	CCSP	N	I-Premise
280	improved	N	I-Premise
281	QOL	N	I-Premise
282	for	N	I-Premise
283	patients	N	I-Premise
284	at	N	I-Premise
285	1-year	N	I-Premise
286	follow-up	N	I-Premise
287	.	N	I-Premise

288	Patients	N	I-Premise
289	overwhelmingly	N	I-Premise
290	reported	N	I-Premise
291	that	N	I-Premise
292	CCSP	N	I-Premise
293	was	N	I-Premise
294	beneficial	N	I-Premise
295	.	N	I-Premise

296	The	N	I-Claim
297	CCSP	N	I-Claim
298	as	N	I-Claim
299	an	N	I-Claim
300	effective	N	I-Claim
301	coping	N	I-Claim
302	intervention	N	I-Claim
303	has	N	I-Claim
304	potential	N	I-Claim
305	as	N	I-Claim
306	a	N	I-Claim
307	self-management	N	I-Claim
308	program	N	I-Claim
309	for	N	I-Claim
310	breast	N	I-Claim
311	cancer	N	I-Claim
312	survivors	N	I-Claim
313	.	N	I-Claim

1	Few	N	O
2	intervention	N	O
3	programs	N	O
4	assist	N	O
5	patients	N	O
6	and	N	O
7	their	N	O
8	family	N	O
9	caregivers	N	O
10	to	N	O
11	manage	N	O
12	advanced	N	O
13	cancer	N	O
14	and	N	O
15	maintain	N	O
16	their	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QOL	N	O
22	)	N	O
23	.	N	O

24	This	N	O
25	study	N	O
26	examined	N	O
27	(	N	O
28	i	N	O
29	)	N	O
30	whether	N	O
31	patient-caregiver	N	O
32	dyads	N	O
33	(	N	O
34	i.e.	N	O
35	,	N	O
36	pairs	N	O
37	)	N	O
38	randomly	N	O
39	assigned	N	O
40	to	N	O
41	a	N	O
42	brief	N	O
43	or	N	O
44	extensive	N	O
45	dyadic	N	O
46	intervention	N	O
47	(	N	O
48	the	N	O
49	FOCUS	N	O
50	Program	N	O
51	)	N	O
52	had	N	O
53	better	N	O
54	outcomes	N	O
55	than	N	O
56	dyads	N	O
57	randomly	N	O
58	assigned	N	O
59	to	N	O
60	usual	N	O
61	care	N	O
62	and	N	O
63	(	N	O
64	ii	N	O
65	)	N	O
66	whether	N	O
67	patients	N	O
68	'	N	O
69	risk	N	O
70	for	N	O
71	distress	N	O
72	and	N	O
73	other	N	O
74	factors	N	O
75	moderated	N	O
76	the	N	O
77	effect	N	O
78	of	N	O
79	the	N	O
80	brief	N	O
81	or	N	O
82	extensive	N	O
83	program	N	O
84	on	N	O
85	outcomes	N	O
86	.	N	O

87	Advanced	N	O
88	cancer	N	O
89	patients	N	O
90	and	N	O
91	their	N	O
92	caregivers	N	O
93	(	N	O
94	N	N	O
95	=	N	O
96	484	N	O
97	dyads	N	O
98	)	N	O
99	were	N	O
100	stratified	N	O
101	by	N	O
102	patients	N	O
103	'	N	O
104	baseline	N	O
105	risk	N	O
106	for	N	O
107	distress	N	O
108	(	N	O
109	high	N	O
110	versus	N	O
111	low	N	O
112	)	N	O
113	,	N	O
114	cancer	N	O
115	type	N	O
116	(	N	O
117	lung	N	O
118	,	N	O
119	colorectal	N	O
120	,	N	O
121	breast	N	O
122	,	N	O
123	or	N	O
124	prostate	N	O
125	)	N	O
126	,	N	O
127	and	N	O
128	research	N	O
129	site	N	O
130	and	N	O
131	then	N	O
132	randomly	N	O
133	assigned	N	O
134	to	N	O
135	a	N	O
136	brief	N	O
137	(	N	O
138	three-session	N	O
139	)	N	O
140	or	N	O
141	extensive	N	O
142	(	N	O
143	six-session	N	O
144	)	N	O
145	intervention	N	O
146	or	N	O
147	control	N	O
148	.	N	O

149	The	N	O
150	interventions	N	O
151	offered	N	O
152	dyads	N	O
153	information	N	O
154	and	N	O
155	support	N	O
156	.	N	O

157	Intermediary	N	O
158	outcomes	N	O
159	were	N	O
160	appraisals	N	O
161	(	N	O
162	i.e.	N	O
163	,	N	O
164	appraisal	N	O
165	of	N	O
166	illness/caregiving	N	O
167	,	N	O
168	uncertainty	N	O
169	,	N	O
170	and	N	O
171	hopelessness	N	O
172	)	N	O
173	and	N	O
174	resources	N	O
175	(	N	O
176	i.e.	N	O
177	,	N	O
178	coping	N	O
179	,	N	O
180	interpersonal	N	O
181	relationships	N	O
182	,	N	O
183	and	N	O
184	self-efficacy	N	O
185	)	N	O
186	.	N	O

187	The	N	O
188	primary	N	O
189	outcome	N	O
190	was	N	O
191	QOL	N	O
192	.	N	O

193	Data	N	O
194	were	N	O
195	collected	N	O
196	prior	N	O
197	to	N	O
198	intervention	N	O
199	and	N	O
200	post-intervention	N	O
201	(	N	O
202	3	N	O
203	and	N	O
204	6	N	O
205	months	N	O
206	from	N	O
207	baseline	N	O
208	)	N	O
209	.	N	O

210	The	N	O
211	final	N	O
212	sample	N	O
213	was	N	O
214	302	N	O
215	dyads	N	O
216	.	N	O

217	Repeated	N	O
218	measures	N	O
219	MANCOVA	N	O
220	was	N	O
221	used	N	O
222	to	N	O
223	evaluate	N	O
224	outcomes	N	O
225	.	N	O

226	Significant	N	I-Premise
227	group	N	I-Premise
228	by	N	I-Premise
229	time	N	I-Premise
230	interactions	N	I-Premise
231	showed	N	I-Premise
232	that	N	I-Premise
233	there	N	I-Premise
234	was	N	I-Premise
235	an	N	I-Premise
236	improvement	N	I-Premise
237	in	N	I-Premise
238	dyads	N	I-Premise
239	'	N	I-Premise
240	coping	N	I-Premise
241	(	N	I-Premise
242	p	N	I-Premise
243	<	N	I-Premise
244	0.05	N	I-Premise
245	)	N	I-Premise
246	,	N	I-Premise
247	self-efficacy	N	I-Premise
248	(	N	I-Premise
249	p	N	I-Premise
250	<	N	I-Premise
251	0.05	N	I-Premise
252	)	N	I-Premise
253	,	N	I-Premise
254	and	N	I-Premise
255	social	N	I-Premise
256	QOL	N	I-Premise
257	(	N	I-Premise
258	p	N	I-Premise
259	<	N	I-Premise
260	0.01	N	I-Premise
261	)	N	I-Premise
262	and	N	I-Premise
263	in	N	I-Premise
264	caregivers	N	I-Premise
265	'	N	I-Premise
266	emotional	N	I-Premise
267	QOL	N	I-Premise
268	(	N	I-Premise
269	p	N	I-Premise
270	<	N	I-Premise
271	0.05	N	I-Premise
272	)	N	I-Premise
273	.	N	I-Premise

274	Effects	N	O
275	varied	N	O
276	by	N	O
277	intervention	N	O
278	dose	N	O
279	.	N	O

280	Most	N	O
281	effects	N	O
282	were	N	O
283	found	N	O
284	at	N	O
285	3	N	O
286	months	N	O
287	only	N	O
288	.	N	O

289	Risk	N	I-Premise
290	for	N	I-Premise
291	distress	N	I-Premise
292	accounted	N	I-Premise
293	for	N	I-Premise
294	very	N	I-Premise
295	few	N	I-Premise
296	moderation	N	I-Premise
297	effects	N	I-Premise
298	.	N	I-Premise

299	Both	N	I-Premise
300	brief	N	I-Premise
301	and	N	I-Premise
302	extensive	N	I-Premise
303	programs	N	I-Premise
304	had	N	I-Premise
305	positive	N	I-Premise
306	outcomes	N	I-Premise
307	for	N	I-Premise
308	patient-caregiver	N	I-Premise
309	dyads	N	I-Premise
310	,	N	I-Premise
311	but	N	I-Premise
312	few	N	I-Premise
313	sustained	N	I-Premise
314	effects	N	I-Premise
315	.	N	I-Premise

316	Patient-caregiver	N	I-Claim
317	dyads	N	I-Claim
318	benefit	N	I-Claim
319	when	N	I-Claim
320	viewed	N	I-Claim
321	as	N	I-Claim
322	the	N	I-Claim
323	'unit	N	I-Claim
324	of	N	I-Claim
325	care	N	I-Claim
326	'	N	I-Claim
327	.	N	I-Claim

1	As	N	O
2	patients	N	O
3	with	N	O
4	pancreas	N	O
5	and	N	O
6	periampullary	N	O
7	cancer	N	O
8	(	N	O
9	PPC	N	O
10	)	N	O
11	experience	N	O
12	improved	N	O
13	survival	N	O
14	rates	N	O
15	and	N	O
16	longevity	N	O
17	,	N	O
18	the	N	O
19	focus	N	O
20	shifts	N	O
21	toward	N	O
22	living	N	O
23	life	N	O
24	while	N	O
25	surviving	N	O
26	cancer	N	O
27	.	N	O

28	Fatigue	N	O
29	is	N	O
30	the	N	O
31	most	N	O
32	commonly	N	O
33	reported	N	O
34	symptom	N	O
35	in	N	O
36	all	N	O
37	cancer	N	O
38	patients	N	O
39	.	N	O

40	Exercise	N	O
41	has	N	O
42	been	N	O
43	found	N	O
44	to	N	O
45	effectively	N	O
46	decrease	N	O
47	fatigue	N	O
48	levels	N	O
49	and	N	O
50	improve	N	O
51	physical	N	O
52	functioning	N	O
53	in	N	O
54	cancer	N	O
55	patients	N	O
56	.	N	O

57	One	N	O
58	hundred	N	O
59	two	N	O
60	patients	N	O
61	with	N	O
62	resected	N	O
63	PPC	N	O
64	consented	N	O
65	to	N	O
66	participate	N	O
67	in	N	O
68	this	N	O
69	study	N	O
70	and	N	O
71	were	N	O
72	randomized	N	O
73	to	N	O
74	either	N	O
75	an	N	O
76	intervention	N	O
77	group	N	O
78	(	N	O
79	IG	N	O
80	)	N	O
81	or	N	O
82	a	N	O
83	usual	N	O
84	care	N	O
85	group	N	O
86	(	N	O
87	UCG	N	O
88	)	N	O
89	.	N	O

90	Subjects	N	O
91	completed	N	O
92	visual	N	O
93	analog	N	O
94	scales	N	O
95	,	N	O
96	the	N	O
97	FACIT-Fatigue	N	O
98	Scale	N	O
99	and	N	O
100	the	N	O
101	Short	N	O
102	Form-36v2	N	O
103	after	N	O
104	surgery	N	O
105	and	N	O
106	again	N	O
107	3	N	O
108	to	N	O
109	6	N	O
110	months	N	O
111	after	N	O
112	hospital	N	O
113	discharge	N	O
114	.	N	O

115	Patients	N	O
116	in	N	O
117	the	N	O
118	IG	N	O
119	and	N	O
120	UCG	N	O
121	were	N	O
122	comparable	N	O
123	with	N	O
124	regard	N	O
125	to	N	O
126	demographics	N	O
127	,	N	O
128	comorbidities	N	O
129	,	N	O
130	cancer	N	O
131	type	N	O
132	and	N	O
133	staging	N	O
134	,	N	O
135	type	N	O
136	of	N	O
137	resection	N	O
138	,	N	O
139	preoperative	N	O
140	fatigue	N	O
141	and	N	O
142	pain	N	O
143	levels	N	O
144	,	N	O
145	adjuvant	N	O
146	therapy	N	O
147	,	N	O
148	and	N	O
149	baseline	N	O
150	walking	N	O
151	distance	N	O
152	.	N	O

153	Patients	N	I-Premise
154	in	N	I-Premise
155	the	N	I-Premise
156	IG	N	I-Premise
157	had	N	I-Premise
158	significantly	N	I-Premise
159	improved	N	I-Premise
160	scores	N	I-Premise
161	on	N	I-Premise
162	the	N	I-Premise
163	FACIT-Fatigue	N	I-Premise
164	Scale	N	I-Premise
165	at	N	I-Premise
166	study	N	I-Premise
167	completion	N	I-Premise
168	,	N	I-Premise
169	improved	N	I-Premise
170	fatigue	N	I-Premise
171	and	N	I-Premise
172	pain	N	I-Premise
173	scores	N	I-Premise
174	,	N	I-Premise
175	as	N	I-Premise
176	well	N	I-Premise
177	as	N	I-Premise
178	overall	N	I-Premise
179	physical	N	I-Premise
180	functioning	N	I-Premise
181	and	N	I-Premise
182	mental	N	I-Premise
183	health	N	I-Premise
184	composite	N	I-Premise
185	scores	N	I-Premise
186	.	N	I-Premise

187	At	N	I-Premise
188	study	N	I-Premise
189	completion	N	I-Premise
190	,	N	I-Premise
191	participants	N	I-Premise
192	in	N	I-Premise
193	the	N	I-Premise
194	IG	N	I-Premise
195	were	N	I-Premise
196	walking	N	I-Premise
197	twice	N	I-Premise
198	as	N	I-Premise
199	far	N	I-Premise
200	and	N	I-Premise
201	were	N	I-Premise
202	significantly	N	I-Premise
203	more	N	I-Premise
204	likely	N	I-Premise
205	to	N	I-Premise
206	have	N	I-Premise
207	continued	N	I-Premise
208	walking	N	I-Premise
209	or	N	I-Premise
210	another	N	I-Premise
211	form	N	I-Premise
212	of	N	I-Premise
213	exercise	N	I-Premise
214	as	N	I-Premise
215	compared	N	I-Premise
216	with	N	I-Premise
217	the	N	I-Premise
218	UCG	N	I-Premise
219	.	N	I-Premise

220	Using	N	O
221	hierarchical	N	O
222	cluster	N	O
223	analysis	N	O
224	,	N	O
225	3	N	O
226	mutually	N	O
227	exclusive	N	O
228	symptom	N	O
229	groupings	N	O
230	were	N	O
231	identified	N	O
232	in	N	O
233	the	N	O
234	cohort	N	O
235	.	N	O

236	Kaplan-Meier	N	I-Premise
237	survival	N	I-Premise
238	analysis	N	I-Premise
239	did	N	I-Premise
240	not	N	I-Premise
241	indicate	N	I-Premise
242	an	N	I-Premise
243	overall	N	I-Premise
244	survival	N	I-Premise
245	benefit	N	I-Premise
246	for	N	I-Premise
247	the	N	I-Premise
248	IG	N	I-Premise
249	.	N	I-Premise

250	This	N	I-Claim
251	is	N	I-Claim
252	the	N	I-Claim
253	first	N	I-Claim
254	prospective	N	I-Claim
255	,	N	I-Claim
256	randomized	N	I-Claim
257	controlled	N	I-Claim
258	trial	N	I-Claim
259	to	N	I-Claim
260	report	N	I-Claim
261	that	N	I-Claim
262	participation	N	I-Claim
263	in	N	I-Claim
264	a	N	I-Claim
265	home	N	I-Claim
266	walking	N	I-Claim
267	program	N	I-Claim
268	confers	N	I-Claim
269	a	N	I-Claim
270	significant	N	I-Claim
271	benefit	N	I-Claim
272	in	N	I-Claim
273	resected	N	I-Claim
274	PPC	N	I-Claim
275	patients	N	I-Claim
276	with	N	I-Claim
277	regard	N	I-Claim
278	to	N	I-Claim
279	fatigue	N	I-Claim
280	levels	N	I-Claim
281	,	N	I-Claim
282	physical	N	I-Claim
283	functioning	N	I-Claim
284	,	N	I-Claim
285	and	N	I-Claim
286	health-related	N	I-Claim
287	quality	N	I-Claim
288	of	N	I-Claim
289	life	N	I-Claim
290	.	N	I-Claim

1	Pemetrexed	N	O
2	maintenance	N	O
3	therapy	N	O
4	significantly	N	O
5	improved	N	O
6	overall	N	O
7	survival	N	O
8	and	N	O
9	progression-free	N	O
10	survival	N	O
11	compared	N	O
12	with	N	O
13	placebo	N	O
14	,	N	O
15	and	N	O
16	had	N	O
17	a	N	O
18	good	N	O
19	safety	N	O
20	profile	N	O
21	in	N	O
22	a	N	O
23	phase	N	O
24	3	N	O
25	placebo-controlled	N	O
26	study	N	O
27	in	N	O
28	patients	N	O
29	with	N	O
30	advanced	N	O
31	non-small-cell	N	O
32	lung	N	O
33	cancer	N	O
34	(	N	O
35	NSCLC	N	O
36	)	N	O
37	.	N	O

38	Results	N	O
39	for	N	O
40	quality	N	O
41	of	N	O
42	life	N	O
43	,	N	O
44	symptom	N	O
45	palliation	N	O
46	,	N	O
47	and	N	O
48	tolerability	N	O
49	are	N	O
50	presented	N	O
51	here	N	O
52	.	N	O

53	After	N	O
54	four	N	O
55	cycles	N	O
56	of	N	O
57	platinum-based	N	O
58	induction	N	O
59	therapy	N	O
60	,	N	O
61	663	N	O
62	patients	N	O
63	with	N	O
64	stage	N	O
65	IIIB	N	O
66	or	N	O
67	stage	N	O
68	IV	N	O
69	NSCLC	N	O
70	and	N	O
71	Eastern	N	O
72	Cooperative	N	O
73	Oncology	N	O
74	Group	N	O
75	performance	N	O
76	status	N	O
77	of	N	O
78	0	N	O
79	or	N	O
80	1	N	O
81	were	N	O
82	randomly	N	O
83	assigned	N	O
84	(	N	O
85	in	N	O
86	a	N	O
87	2:1	N	O
88	ratio	N	O
89	)	N	O
90	from	N	O
91	March	N	O
92	15	N	O
93	,	N	O
94	2005	N	O
95	,	N	O
96	to	N	O
97	July	N	O
98	20	N	O
99	,	N	O
100	2007	N	O
101	,	N	O
102	using	N	O
103	the	N	O
104	Pocock	N	O
105	and	N	O
106	Simon	N	O
107	minimisation	N	O
108	method	N	O
109	to	N	O
110	receive	N	O
111	pemetrexed	N	O
112	(	N	O
113	500	N	O
114	mg/m	N	O
115	(	N	O
116	2	N	O
117	)	N	O
118	every	N	O
119	21	N	O
120	days	N	O
121	;	N	O
122	n=441	N	O
123	)	N	O
124	or	N	O
125	placebo	N	O
126	(	N	O
127	n=222	N	O
128	)	N	O
129	plus	N	O
130	best	N	O
131	supportive	N	O
132	care	N	O
133	until	N	O
134	disease	N	O
135	progression	N	O
136	.	N	O

137	The	N	O
138	primary	N	O
139	efficacy	N	O
140	data	N	O
141	have	N	O
142	been	N	O
143	reported	N	O
144	previously	N	O
145	.	N	O

146	Patients	N	O
147	completed	N	O
148	the	N	O
149	Lung	N	O
150	Cancer	N	O
151	Symptom	N	O
152	Scale	N	O
153	(	N	O
154	LCSS	N	O
155	)	N	O
156	at	N	O
157	baseline	N	O
158	,	N	O
159	after	N	O
160	each	N	O
161	cycle	N	O
162	,	N	O
163	and	N	O
164	post-discontinuation	N	O
165	.	N	O

166	Worsening	N	O
167	of	N	O
168	symptoms	N	O
169	was	N	O
170	defined	N	O
171	as	N	O
172	an	N	O
173	increase	N	O
174	of	N	O
175	15	N	O
176	mm	N	O
177	or	N	O
178	more	N	O
179	from	N	O
180	baseline	N	O
181	on	N	O
182	a	N	O
183	100	N	O
184	mm	N	O
185	scale	N	O
186	for	N	O
187	each	N	O
188	LCSS	N	O
189	item	N	O
190	.	N	O

191	The	N	O
192	primary	N	O
193	outcome	N	O
194	for	N	O
195	these	N	O
196	quality-of-life	N	O
197	analyses	N	O
198	was	N	O
199	time	N	O
200	to	N	O
201	worsening	N	O
202	of	N	O
203	symptoms	N	O
204	,	N	O
205	analysed	N	O
206	for	N	O
207	all	N	O
208	randomised	N	O
209	patients	N	O
210	.	N	O

211	Baseline	N	O
212	characteristics	N	O
213	,	N	O
214	including	N	O
215	LCSS	N	O
216	scores	N	O
217	,	N	O
218	were	N	O
219	well	N	O
220	balanced	N	O
221	between	N	O
222	groups	N	O
223	.	N	O

224	Baseline	N	O
225	LCSS	N	O
226	scores	N	O
227	were	N	O
228	low	N	O
229	,	N	O
230	indicating	N	O
231	low	N	O
232	symptom	N	O
233	burden	N	O
234	for	N	O
235	patients	N	O
236	without	N	O
237	disease	N	O
238	progression	N	O
239	after	N	O
240	completion	N	O
241	of	N	O
242	first-line	N	O
243	treatment	N	O
244	.	N	O

245	Longer	N	I-Premise
246	time	N	I-Premise
247	to	N	I-Premise
248	worsening	N	I-Premise
249	was	N	I-Premise
250	recorded	N	I-Premise
251	for	N	I-Premise
252	pain	N	I-Premise
253	(	N	I-Premise
254	hazard	N	I-Premise
255	ratio	N	I-Premise
256	[	N	I-Premise
257	HR	N	I-Premise
258	]	N	I-Premise
259	076	N	I-Premise
260	,	N	I-Premise
261	95	N	I-Premise
262	%	N	I-Premise
263	CI	N	I-Premise
264	059-099	N	I-Premise
265	;	N	I-Premise
266	p=0041	N	I-Premise
267	)	N	I-Premise
268	and	N	I-Premise
269	haemoptysis	N	I-Premise
270	(	N	I-Premise
271	HR	N	I-Premise
272	058	N	I-Premise
273	,	N	I-Premise
274	95	N	I-Premise
275	%	N	I-Premise
276	CI	N	I-Premise
277	034-097	N	I-Premise
278	;	N	I-Premise
279	p=0038	N	I-Premise
280	)	N	I-Premise
281	with	N	I-Premise
282	pemetrexed	N	I-Premise
283	than	N	I-Premise
284	with	N	I-Premise
285	placebo	N	I-Premise
286	;	N	I-Premise
287	no	N	I-Premise
288	other	N	I-Premise
289	significant	N	I-Premise
290	differences	N	I-Premise
291	in	N	I-Premise
292	analyses	N	I-Premise
293	of	N	I-Premise
294	time	N	I-Premise
295	to	N	I-Premise
296	worsening	N	I-Premise
297	were	N	I-Premise
298	noted	N	I-Premise
299	.	N	I-Premise

300	Additional	N	I-Premise
301	longitudinal	N	I-Premise
302	analyses	N	I-Premise
303	showed	N	I-Premise
304	a	N	I-Premise
305	greater	N	I-Premise
306	increase	N	I-Premise
307	in	N	I-Premise
308	loss	N	I-Premise
309	of	N	I-Premise
310	appetite	N	I-Premise
311	in	N	I-Premise
312	the	N	I-Premise
313	pemetrexed	N	I-Premise
314	group	N	I-Premise
315	than	N	I-Premise
316	in	N	I-Premise
317	the	N	I-Premise
318	placebo	N	I-Premise
319	group	N	I-Premise
320	(	N	I-Premise
321	43	N	I-Premise
322	mm	N	I-Premise
323	vs	N	I-Premise
324	02	N	I-Premise
325	mm	N	I-Premise
326	;	N	I-Premise
327	p=0028	N	I-Premise
328	)	N	I-Premise
329	.	N	I-Premise

330	Rates	N	I-Premise
331	of	N	I-Premise
332	resource	N	I-Premise
333	use	N	I-Premise
334	were	N	I-Premise
335	statistically	N	I-Premise
336	higher	N	I-Premise
337	for	N	I-Premise
338	pemetrexed	N	I-Premise
339	than	N	I-Premise
340	for	N	I-Premise
341	placebo	N	I-Premise
342	:	N	I-Premise
343	admissions	N	I-Premise
344	to	N	I-Premise
345	hospital	N	I-Premise
346	for	N	I-Premise
347	drug-related	N	I-Premise
348	adverse	N	I-Premise
349	events	N	I-Premise
350	(	N	I-Premise
351	19	N	I-Premise
352	[	N	I-Premise
353	4	N	I-Premise
354	%	N	I-Premise
355	]	N	I-Premise
356	vs	N	I-Premise
357	none	N	I-Premise
358	;	N	I-Premise
359	p=0001	N	I-Premise
360	)	N	I-Premise
361	,	N	I-Premise
362	transfusions	N	I-Premise
363	(	N	I-Premise
364	42	N	I-Premise
365	[	N	I-Premise
366	10	N	I-Premise
367	%	N	I-Premise
368	]	N	I-Premise
369	vs	N	I-Premise
370	seven	N	I-Premise
371	[	N	I-Premise
372	3	N	I-Premise
373	%	N	I-Premise
374	]	N	I-Premise
375	;	N	I-Premise
376	p=0003	N	I-Premise
377	)	N	I-Premise
378	,	N	I-Premise
379	and	N	I-Premise
380	erythropoiesis-stimulating	N	I-Premise
381	agents	N	I-Premise
382	(	N	I-Premise
383	26	N	I-Premise
384	[	N	I-Premise
385	6	N	I-Premise
386	%	N	I-Premise
387	]	N	I-Premise
388	vs	N	I-Premise
389	four	N	I-Premise
390	[	N	I-Premise
391	2	N	I-Premise
392	%	N	I-Premise
393	]	N	I-Premise
394	;	N	I-Premise
395	p=0017	N	I-Premise
396	)	N	I-Premise
397	.	N	I-Premise

398	Quality	N	I-Claim
399	of	N	I-Claim
400	life	N	I-Claim
401	during	N	I-Claim
402	maintenance	N	I-Claim
403	therapy	N	I-Claim
404	with	N	I-Claim
405	pemetrexed	N	I-Claim
406	is	N	I-Claim
407	similar	N	I-Claim
408	to	N	I-Claim
409	placebo	N	I-Claim
410	,	N	I-Claim
411	except	N	I-Claim
412	for	N	I-Claim
413	a	N	I-Claim
414	small	N	I-Claim
415	increase	N	I-Claim
416	in	N	I-Claim
417	loss	N	I-Claim
418	of	N	I-Claim
419	appetite	N	I-Claim
420	,	N	I-Claim
421	and	N	I-Claim
422	significantly	N	I-Claim
423	delayed	N	I-Claim
424	worsening	N	I-Claim
425	of	N	I-Claim
426	pain	N	I-Claim
427	and	N	I-Claim
428	haemoptysis	N	I-Claim
429	.	N	I-Claim

430	In	N	O
431	view	N	O
432	of	N	O
433	the	N	O
434	improvements	N	O
435	in	N	O
436	overall	N	O
437	and	N	O
438	progression-free	N	O
439	survival	N	O
440	noted	N	O
441	with	N	O
442	pemetrexed	N	O
443	maintenance	N	O
444	therapy	N	O
445	,	N	O
446	such	N	I-MajorClaim
447	treatment	N	I-MajorClaim
448	is	N	I-MajorClaim
449	an	N	I-MajorClaim
450	option	N	I-MajorClaim
451	for	N	I-MajorClaim
452	patients	N	I-MajorClaim
453	with	N	I-MajorClaim
454	advanced	N	I-MajorClaim
455	non-squamous	N	I-MajorClaim
456	NSCLC	N	I-MajorClaim
457	who	N	I-MajorClaim
458	have	N	I-MajorClaim
459	not	N	I-MajorClaim
460	progressed	N	I-MajorClaim
461	after	N	I-MajorClaim
462	platinum-based	N	I-MajorClaim
463	induction	N	I-MajorClaim
464	therapy	N	I-MajorClaim
465	.	N	I-MajorClaim

1	Topical	N	O
2	photodynamic	N	O
3	therapy	N	O
4	(	N	O
5	PDT	N	O
6	)	N	O
7	with	N	O
8	aminolevulinic	N	O
9	acid	N	O
10	(	N	O
11	ALA	N	O
12	)	N	O
13	and	N	O
14	5	N	O
15	%	N	O
16	imiquimod	N	O
17	cream	N	O
18	are	N	O
19	effective	N	O
20	therapies	N	O
21	for	N	O
22	the	N	O
23	treatment	N	O
24	of	N	O
25	actinic	N	O
26	keratoses	N	O
27	(	N	O
28	AKs	N	O
29	)	N	O
30	,	N	O
31	but	N	O
32	no	N	O
33	split-face	N	O
34	studies	N	O
35	directly	N	O
36	comparing	N	O
37	these	N	O
38	treatment	N	O
39	options	N	O
40	are	N	O
41	available	N	O
42	in	N	O
43	the	N	O
44	literature	N	O
45	.	N	O

46	To	N	O
47	compare	N	O
48	the	N	O
49	efficacy	N	O
50	and	N	O
51	tolerability	N	O
52	of	N	O
53	ALA-PDT	N	O
54	and	N	O
55	imiquimod	N	O
56	5	N	O
57	%	N	O
58	cream	N	O
59	for	N	O
60	the	N	O
61	treatment	N	O
62	of	N	O
63	AKs	N	O
64	.	N	O

65	Sixty-one	N	O
66	patients	N	O
67	were	N	O
68	enrolled	N	O
69	from	N	O
70	the	N	O
71	Salt	N	O
72	Lake	N	O
73	City	N	O
74	Veterans	N	O
75	Affairs	N	O
76	Hospital	N	O
77	;	N	O
78	51	N	O
79	completed	N	O
80	the	N	O
81	study	N	O
82	and	N	O
83	were	N	O
84	included	N	O
85	in	N	O
86	the	N	O
87	analysis	N	O
88	.	N	O

89	All	N	O
90	patients	N	O
91	were	N	O
92	randomized	N	O
93	to	N	O
94	receive	N	O
95	half	N	O
96	of	N	O
97	a	N	O
98	sachet	N	O
99	of	N	O
100	imiquimod	N	O
101	5	N	O
102	%	N	O
103	cream	N	O
104	twice	N	O
105	weekly	N	O
106	on	N	O
107	half	N	O
108	of	N	O
109	their	N	O
110	face	N	O
111	and	N	O
112	two	N	O
113	sessions	N	O
114	of	N	O
115	PDT	N	O
116	with	N	O
117	20	N	O
118	%	N	O
119	solution	N	O
120	of	N	O
121	ALA	N	O
122	applied	N	O
123	for	N	O
124	1	N	O
125	hour	N	O
126	to	N	O
127	the	N	O
128	other	N	O
129	side	N	O
130	of	N	O
131	the	N	O
132	face	N	O
133	.	N	O

134	The	N	I-Premise
135	75	N	I-Premise
136	%	N	I-Premise
137	AK	N	I-Premise
138	clearance	N	I-Premise
139	rate	N	I-Premise
140	was	N	I-Premise
141	34.6	N	I-Premise
142	%	N	I-Premise
143	for	N	I-Premise
144	ALA-PDT	N	I-Premise
145	and	N	I-Premise
146	25	N	I-Premise
147	%	N	I-Premise
148	for	N	I-Premise
149	imiquimod	N	I-Premise
150	5	N	I-Premise
151	%	N	I-Premise
152	cream	N	I-Premise
153	(	N	I-Premise
154	p	N	I-Premise
155	=	N	I-Premise
156	.30	N	I-Premise
157	)	N	I-Premise
158	.	N	I-Premise

159	The	N	I-Premise
160	mean	N	I-Premise
161	reduction	N	I-Premise
162	in	N	I-Premise
163	AK	N	I-Premise
164	count	N	I-Premise
165	was	N	I-Premise
166	59.2	N	I-Premise
167	%	N	I-Premise
168	for	N	I-Premise
169	ALA-PDT	N	I-Premise
170	and	N	I-Premise
171	41.4	N	I-Premise
172	%	N	I-Premise
173	for	N	I-Premise
174	imiquimod	N	I-Premise
175	5	N	I-Premise
176	%	N	I-Premise
177	cream	N	I-Premise
178	(	N	I-Premise
179	p	N	I-Premise
180	=	N	I-Premise
181	.002	N	I-Premise
182	)	N	I-Premise
183	.	N	I-Premise

184	Dermatology	N	I-Premise
185	Life	N	I-Premise
186	Quality	N	I-Premise
187	Index	N	I-Premise
188	(	N	I-Premise
189	DLQI	N	I-Premise
190	)	N	I-Premise
191	scores	N	I-Premise
192	were	N	I-Premise
193	assessed	N	I-Premise
194	for	N	I-Premise
195	each	N	I-Premise
196	treatment	N	I-Premise
197	modality	N	I-Premise
198	at	N	I-Premise
199	week	N	I-Premise
200	4	N	I-Premise
201	and	N	I-Premise
202	were	N	I-Premise
203	1.95	N	I-Premise
204	and	N	I-Premise
205	1.38	N	I-Premise
206	,	N	I-Premise
207	respectively	N	I-Premise
208	(	N	I-Premise
209	p	N	I-Premise
210	=	N	I-Premise
211	.20	N	I-Premise
212	)	N	I-Premise
213	.	N	I-Premise

214	The	N	I-Premise
215	sample	N	I-Premise
216	size	N	I-Premise
217	was	N	I-Premise
218	small	N	I-Premise
219	,	N	I-Premise
220	and	N	I-Premise
221	patients	N	I-Premise
222	applied	N	I-Premise
223	a	N	I-Premise
224	small	N	I-Premise
225	amount	N	I-Premise
226	of	N	I-Premise
227	imiquimod	N	I-Premise
228	5	N	I-Premise
229	%	N	I-Premise
230	cream	N	I-Premise
231	(	N	I-Premise
232	half	N	I-Premise
233	a	N	I-Premise
234	sachet	N	I-Premise
235	)	N	I-Premise
236	to	N	I-Premise
237	a	N	I-Premise
238	large	N	I-Premise
239	surface	N	I-Premise
240	area	N	I-Premise
241	.	N	I-Premise

242	There	N	I-Claim
243	was	N	I-Claim
244	no	N	I-Claim
245	statistically	N	I-Claim
246	significant	N	I-Claim
247	difference	N	I-Claim
248	in	N	I-Claim
249	treatment	N	I-Claim
250	response	N	I-Claim
251	when	N	I-Claim
252	the	N	I-Claim
253	100	N	I-Claim
254	%	N	I-Claim
255	or	N	I-Claim
256	75	N	I-Claim
257	%	N	I-Claim
258	clearance	N	I-Claim
259	rate	N	I-Claim
260	cutoff	N	I-Claim
261	was	N	I-Claim
262	used	N	I-Claim
263	,	N	I-Claim
264	but	N	I-Claim
265	our	N	I-Claim
266	secondary	N	I-Claim
267	outcome	N	I-Claim
268	suggests	N	I-Claim
269	that	N	I-Claim
270	two	N	I-Claim
271	sessions	N	I-Claim
272	of	N	I-Claim
273	ALA-PDT	N	I-Claim
274	is	N	I-Claim
275	superior	N	I-Claim
276	to	N	I-Claim
277	imiquimod	N	I-Claim
278	5	N	I-Claim
279	%	N	I-Claim
280	cream	N	I-Claim
281	for	N	I-Claim
282	the	N	I-Claim
283	treatment	N	I-Claim
284	of	N	I-Claim
285	AKs	N	I-Claim
286	.	N	I-Claim

287	There	N	I-Claim
288	was	N	I-Claim
289	no	N	I-Claim
290	statistically	N	I-Claim
291	significant	N	I-Claim
292	difference	N	I-Claim
293	in	N	I-Claim
294	effect	N	I-Claim
295	on	N	I-Claim
296	quality	N	I-Claim
297	of	N	I-Claim
298	life	N	I-Claim
299	as	N	I-Claim
300	assessed	N	I-Claim
301	using	N	I-Claim
302	the	N	I-Claim
303	DLQI	N	I-Claim
304	.	N	I-Claim

1	Hot	N	O
2	flushes	N	O
3	and	N	O
4	night	N	O
5	sweats	N	O
6	(	N	O
7	HFNS	N	O
8	)	N	O
9	affect	N	O
10	65-85	N	O
11	%	N	O
12	of	N	O
13	women	N	O
14	after	N	O
15	breast	N	O
16	cancer	N	O
17	treatment	N	O
18	;	N	O
19	they	N	O
20	are	N	O
21	distressing	N	O
22	,	N	O
23	causing	N	O
24	sleep	N	O
25	problems	N	O
26	and	N	O
27	decreased	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	.	N	O

32	Hormone	N	I-MajorClaim
33	replacement	N	I-MajorClaim
34	therapy	N	I-MajorClaim
35	is	N	I-MajorClaim
36	often	N	I-MajorClaim
37	either	N	I-MajorClaim
38	undesirable	N	I-MajorClaim
39	or	N	I-MajorClaim
40	contraindicated	N	I-MajorClaim
41	.	N	I-MajorClaim

42	Safe	N	I-MajorClaim
43	,	N	I-MajorClaim
44	effective	N	I-MajorClaim
45	non-hormonal	N	I-MajorClaim
46	treatments	N	I-MajorClaim
47	are	N	I-MajorClaim
48	needed	N	I-MajorClaim
49	.	N	I-MajorClaim

50	We	N	O
51	investigated	N	O
52	whether	N	O
53	cognitive	N	O
54	behavioural	N	O
55	therapy	N	O
56	(	N	O
57	CBT	N	O
58	)	N	O
59	can	N	O
60	help	N	O
61	breast	N	O
62	cancer	N	O
63	survivors	N	O
64	to	N	O
65	effectively	N	O
66	manage	N	O
67	HFNS	N	O
68	.	N	O

69	In	N	O
70	this	N	O
71	randomised	N	O
72	controlled	N	O
73	trial	N	O
74	,	N	O
75	we	N	O
76	recruited	N	O
77	women	N	O
78	from	N	O
79	breast	N	O
80	clinics	N	O
81	in	N	O
82	London	N	O
83	,	N	O
84	UK	N	O
85	,	N	O
86	who	N	O
87	had	N	O
88	problematic	N	O
89	HFNS	N	O
90	(	N	O
91	minimum	N	O
92	ten	N	O
93	problematic	N	O
94	episodes	N	O
95	a	N	O
96	week	N	O
97	)	N	O
98	after	N	O
99	breast-cancer	N	O
100	treatment	N	O
101	.	N	O

102	Participants	N	O
103	were	N	O
104	randomly	N	O
105	allocated	N	O
106	to	N	O
107	receive	N	O
108	either	N	O
109	usual	N	O
110	care	N	O
111	or	N	O
112	usual	N	O
113	care	N	O
114	plus	N	O
115	group	N	O
116	CBT	N	O
117	(	N	O
118	1:1	N	O
119	)	N	O
120	.	N	O

121	Randomisation	N	O
122	was	N	O
123	done	N	O
124	in	N	O
125	blocks	N	O
126	of	N	O
127	12-20	N	O
128	participants	N	O
129	,	N	O
130	stratifying	N	O
131	by	N	O
132	age	N	O
133	(	N	O
134	younger	N	O
135	than	N	O
136	50	N	O
137	years	N	O
138	,	N	O
139	50	N	O
140	years	N	O
141	or	N	O
142	older	N	O
143	)	N	O
144	,	N	O
145	and	N	O
146	was	N	O
147	done	N	O
148	with	N	O
149	a	N	O
150	computer-generated	N	O
151	sequence	N	O
152	.	N	O

153	The	N	O
154	trial	N	O
155	statistician	N	O
156	and	N	O
157	researchers	N	O
158	collecting	N	O
159	outcome	N	O
160	measures	N	O
161	were	N	O
162	masked	N	O
163	to	N	O
164	group	N	O
165	allocation	N	O
166	.	N	O

167	Group	N	O
168	CBT	N	O
169	comprised	N	O
170	one	N	O
171	90	N	O
172	min	N	O
173	session	N	O
174	a	N	O
175	week	N	O
176	for	N	O
177	6	N	O
178	weeks	N	O
179	,	N	O
180	and	N	O
181	included	N	O
182	psycho-education	N	O
183	,	N	O
184	paced	N	O
185	breathing	N	O
186	,	N	O
187	and	N	O
188	cognitive	N	O
189	and	N	O
190	behavioural	N	O
191	strategies	N	O
192	to	N	O
193	manage	N	O
194	HFNS	N	O
195	.	N	O

196	Assessments	N	O
197	were	N	O
198	done	N	O
199	at	N	O
200	baseline	N	O
201	,	N	O
202	9	N	O
203	weeks	N	O
204	,	N	O
205	and	N	O
206	26	N	O
207	weeks	N	O
208	after	N	O
209	randomisation	N	O
210	.	N	O

211	The	N	O
212	primary	N	O
213	outcome	N	O
214	was	N	O
215	the	N	O
216	adjusted	N	O
217	mean	N	O
218	difference	N	O
219	in	N	O
220	HFNS	N	O
221	problem	N	O
222	rating	N	O
223	(	N	O
224	1-10	N	O
225	)	N	O
226	between	N	O
227	CBT	N	O
228	and	N	O
229	usual	N	O
230	care	N	O
231	groups	N	O
232	at	N	O
233	9	N	O
234	weeks	N	O
235	after	N	O
236	randomisation	N	O
237	.	N	O

238	Analysis	N	O
239	of	N	O
240	the	N	O
241	primary	N	O
242	endpoint	N	O
243	was	N	O
244	done	N	O
245	by	N	O
246	modified	N	O
247	intention	N	O
248	to	N	O
249	treat	N	O
250	.	N	O

251	The	N	O
252	trial	N	O
253	is	N	O
254	registered	N	O
255	,	N	O
256	ISRCTN13771934	N	O
257	,	N	O
258	and	N	O
259	was	N	O
260	closed	N	O
261	March	N	O
262	15	N	O
263	,	N	O
264	2011	N	O
265	.	N	O

266	Between	N	O
267	May	N	O
268	5	N	O
269	,	N	O
270	2009	N	O
271	,	N	O
272	and	N	O
273	Aug	N	O
274	27	N	O
275	,	N	O
276	2010	N	O
277	,	N	O
278	96	N	O
279	women	N	O
280	were	N	O
281	randomly	N	O
282	allocated	N	O
283	to	N	O
284	group	N	O
285	CBT	N	O
286	(	N	O
287	n=47	N	O
288	)	N	O
289	or	N	O
290	usual	N	O
291	care	N	O
292	(	N	O
293	n=49	N	O
294	)	N	O
295	.	N	O

296	Group	N	I-Premise
297	CBT	N	I-Premise
298	significantly	N	I-Premise
299	reduced	N	I-Premise
300	HFNS	N	I-Premise
301	problem	N	I-Premise
302	rating	N	I-Premise
303	at	N	I-Premise
304	9	N	I-Premise
305	weeks	N	I-Premise
306	after	N	I-Premise
307	randomisation	N	I-Premise
308	compared	N	I-Premise
309	with	N	I-Premise
310	usual	N	I-Premise
311	care	N	I-Premise
312	(	N	I-Premise
313	mean	N	I-Premise
314	difference	N	I-Premise
315	-167	N	I-Premise
316	,	N	I-Premise
317	95	N	I-Premise
318	%	N	I-Premise
319	CI	N	I-Premise
320	-243	N	I-Premise
321	to	N	I-Premise
322	-091	N	I-Premise
323	;	N	I-Premise
324	p	N	I-Premise
325	<	N	I-Premise
326	00001	N	I-Premise
327	)	N	I-Premise
328	and	N	I-Premise
329	improvements	N	I-Premise
330	were	N	I-Premise
331	maintained	N	I-Premise
332	at	N	I-Premise
333	26	N	I-Premise
334	weeks	N	I-Premise
335	(	N	I-Premise
336	mean	N	I-Premise
337	difference	N	I-Premise
338	-176	N	I-Premise
339	,	N	I-Premise
340	-254	N	I-Premise
341	to	N	I-Premise
342	-099	N	I-Premise
343	;	N	I-Premise
344	p	N	I-Premise
345	<	N	I-Premise
346	00001	N	I-Premise
347	)	N	I-Premise
348	.	N	I-Premise

349	We	N	I-Premise
350	recorded	N	I-Premise
351	no	N	I-Premise
352	CBT-related	N	I-Premise
353	adverse	N	I-Premise
354	events	N	I-Premise
355	.	N	I-Premise

356	Group	N	I-Claim
357	CBT	N	I-Claim
358	seems	N	I-Claim
359	to	N	I-Claim
360	be	N	I-Claim
361	a	N	I-Claim
362	safe	N	I-Claim
363	and	N	I-Claim
364	effective	N	I-Claim
365	treatment	N	I-Claim
366	for	N	I-Claim
367	women	N	I-Claim
368	who	N	I-Claim
369	have	N	I-Claim
370	problematic	N	I-Claim
371	HFNS	N	I-Claim
372	after	N	I-Claim
373	breast	N	I-Claim
374	cancer	N	I-Claim
375	treatment	N	I-Claim
376	with	N	I-Claim
377	additional	N	I-Claim
378	benefits	N	I-Claim
379	to	N	I-Claim
380	mood	N	I-Claim
381	,	N	I-Claim
382	sleep	N	I-Claim
383	,	N	I-Claim
384	and	N	I-Claim
385	quality	N	I-Claim
386	of	N	I-Claim
387	life	N	I-Claim
388	.	N	I-Claim

389	The	N	O
390	treatment	N	O
391	could	N	O
392	be	N	O
393	incorporated	N	O
394	into	N	O
395	breast	N	O
396	cancer	N	O
397	survivorship	N	O
398	programmes	N	O
399	and	N	O
400	delivered	N	O
401	by	N	O
402	trained	N	O
403	breast	N	O
404	cancer	N	O
405	nurses	N	O
406	.	N	O

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	analgesic	N	O
5	effect	N	O
6	,	N	O
7	safety	N	O
8	,	N	O
9	and	N	O
10	cost-effectiveness	N	O
11	of	N	O
12	controlled-release	N	O
13	oxycodone	N	O
14	(	N	O
15	CRO	N	O
16	)	N	O
17	to	N	O
18	control	N	O
19	postoperative	N	O
20	pain	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	liver	N	O
25	cancer	N	O
26	who	N	O
27	are	N	O
28	undergoing	N	O
29	transarterial	N	O
30	chemoembolization	N	O
31	.	N	O

32	This	N	O
33	randomized	N	O
34	,	N	O
35	double-blind	N	O
36	,	N	O
37	placebo-controlled	N	O
38	,	N	O
39	prospective	N	O
40	clinical	N	O
41	study	N	O
42	received	N	O
43	institutional	N	O
44	review	N	O
45	board	N	O
46	approval	N	O
47	.	N	O

48	After	N	O
49	written	N	O
50	informed	N	O
51	consent	N	O
52	was	N	O
53	obtained	N	O
54	,	N	O
55	210	N	O
56	patients	N	O
57	with	N	O
58	liver	N	O
59	cancer	N	O
60	were	N	O
61	randomized	N	O
62	into	N	O
63	three	N	O
64	groups	N	O
65	of	N	O
66	70	N	O
67	patients	N	O
68	.	N	O

69	Group	N	O
70	1	N	O
71	received	N	O
72	20	N	O
73	mg	N	O
74	of	N	O
75	CRO	N	O
76	,	N	O
77	group	N	O
78	2	N	O
79	received	N	O
80	10	N	O
81	mg	N	O
82	of	N	O
83	CRO	N	O
84	,	N	O
85	and	N	O
86	group	N	O
87	3	N	O
88	received	N	O
89	a	N	O
90	placebo	N	O
91	at	N	O
92	1	N	O
93	hour	N	O
94	before	N	O
95	transarterial	N	O
96	chemoembolization	N	O
97	(	N	O
98	T	N	O
99	(	N	O
100	0	N	O
101	)	N	O
102	)	N	O
103	and	N	O
104	12	N	O
105	(	N	O
106	T	N	O
107	(	N	O
108	12	N	O
109	)	N	O
110	)	N	O
111	and	N	O
112	24	N	O
113	(	N	O
114	T	N	O
115	(	N	O
116	24	N	O
117	)	N	O
118	)	N	O
119	hours	N	O
120	after	N	O
121	T	N	O
122	(	N	O
123	0	N	O
124	)	N	O
125	.	N	O

126	Pain	N	O
127	intensity	N	O
128	on	N	O
129	a	N	O
130	numeric	N	O
131	rating	N	O
132	scale	N	O
133	,	N	O
134	percentage	N	O
135	of	N	O
136	patients	N	O
137	with	N	O
138	each	N	O
139	degree	N	O
140	of	N	O
141	pain	N	O
142	,	N	O
143	quality	N	O
144	of	N	O
145	life	N	O
146	,	N	O
147	adverse	N	O
148	reactions	N	O
149	,	N	O
150	analgesic	N	O
151	costs	N	O
152	,	N	O
153	and	N	O
154	hospital	N	O
155	stays	N	O
156	were	N	O
157	evaluated	N	O
158	and	N	O
159	compared	N	O
160	among	N	O
161	the	N	O
162	three	N	O
163	groups	N	O
164	.	N	O

165	Numeric	N	I-Premise
166	rating	N	I-Premise
167	scale	N	I-Premise
168	scores	N	I-Premise
169	for	N	I-Premise
170	pain	N	I-Premise
171	intensity	N	I-Premise
172	in	N	I-Premise
173	group	N	I-Premise
174	1	N	I-Premise
175	and	N	I-Premise
176	group	N	I-Premise
177	2	N	I-Premise
178	were	N	I-Premise
179	significantly	N	I-Premise
180	lower	N	I-Premise
181	than	N	I-Premise
182	those	N	I-Premise
183	in	N	I-Premise
184	group	N	I-Premise
185	3	N	I-Premise
186	at	N	I-Premise
187	T	N	I-Premise
188	(	N	I-Premise
189	0-12	N	I-Premise
190	)	N	I-Premise
191	(	N	I-Premise
192	P	N	I-Premise
193	<	N	I-Premise
194	.001	N	I-Premise
195	)	N	I-Premise
196	;	N	I-Premise
197	T	N	I-Premise
198	(	N	I-Premise
199	12-24	N	I-Premise
200	)	N	I-Premise
201	(	N	I-Premise
202	P	N	I-Premise
203	<	N	I-Premise
204	.001	N	I-Premise
205	)	N	I-Premise
206	;	N	I-Premise
207	and	N	I-Premise
208	T	N	I-Premise
209	(	N	I-Premise
210	24-48	N	I-Premise
211	)	N	I-Premise
212	(	N	I-Premise
213	P	N	I-Premise
214	<	N	I-Premise
215	.001	N	I-Premise
216	)	N	I-Premise
217	.	N	I-Premise

218	When	N	I-Premise
219	group	N	I-Premise
220	1	N	I-Premise
221	with	N	I-Premise
222	group	N	I-Premise
223	2	N	I-Premise
224	were	N	I-Premise
225	compared	N	I-Premise
226	,	N	I-Premise
227	numeric	N	I-Premise
228	rating	N	I-Premise
229	scale	N	I-Premise
230	scores	N	I-Premise
231	were	N	I-Premise
232	significantly	N	I-Premise
233	lower	N	I-Premise
234	in	N	I-Premise
235	group	N	I-Premise
236	1	N	I-Premise
237	than	N	I-Premise
238	in	N	I-Premise
239	group	N	I-Premise
240	2	N	I-Premise
241	during	N	I-Premise
242	the	N	I-Premise
243	period	N	I-Premise
244	of	N	I-Premise
245	T	N	I-Premise
246	(	N	I-Premise
247	0-12	N	I-Premise
248	)	N	I-Premise
249	(	N	I-Premise
250	P	N	I-Premise
251	<	N	I-Premise
252	.001	N	I-Premise
253	)	N	I-Premise
254	but	N	I-Premise
255	were	N	I-Premise
256	not	N	I-Premise
257	significantly	N	I-Premise
258	different	N	I-Premise
259	at	N	I-Premise
260	T	N	I-Premise
261	(	N	I-Premise
262	12-24	N	I-Premise
263	)	N	I-Premise
264	(	N	I-Premise
265	P	N	I-Premise
266	=	N	I-Premise
267	.68	N	I-Premise
268	)	N	I-Premise
269	and	N	I-Premise
270	T	N	I-Premise
271	(	N	I-Premise
272	24-48	N	I-Premise
273	)	N	I-Premise
274	(	N	I-Premise
275	P	N	I-Premise
276	=	N	I-Premise
277	.10	N	I-Premise
278	)	N	I-Premise
279	.	N	I-Premise

280	Analgesic	N	I-Premise
281	cost	N	I-Premise
282	and	N	I-Premise
283	hospital	N	I-Premise
284	stay	N	I-Premise
285	were	N	I-Premise
286	significantly	N	I-Premise
287	lower	N	I-Premise
288	in	N	I-Premise
289	treated	N	I-Premise
290	groups	N	I-Premise
291	than	N	I-Premise
292	in	N	I-Premise
293	the	N	I-Premise
294	placebo	N	I-Premise
295	group	N	I-Premise
296	.	N	I-Premise

297	No	N	I-Premise
298	significant	N	I-Premise
299	difference	N	I-Premise
300	was	N	I-Premise
301	observed	N	I-Premise
302	in	N	I-Premise
303	quality	N	I-Premise
304	of	N	I-Premise
305	life	N	I-Premise
306	and	N	I-Premise
307	adverse	N	I-Premise
308	events	N	I-Premise
309	between	N	I-Premise
310	the	N	I-Premise
311	treated	N	I-Premise
312	groups	N	I-Premise
313	and	N	I-Premise
314	the	N	I-Premise
315	placebo	N	I-Premise
316	group	N	I-Premise
317	.	N	I-Premise

318	CRO	N	I-Claim
319	is	N	I-Claim
320	effective	N	I-Claim
321	,	N	I-Claim
322	safe	N	I-Claim
323	,	N	I-Claim
324	and	N	I-Claim
325	cost-effective	N	I-Claim
326	in	N	I-Claim
327	the	N	I-Claim
328	control	N	I-Claim
329	of	N	I-Claim
330	postoperative	N	I-Claim
331	pain	N	I-Claim
332	after	N	I-Claim
333	transarterial	N	I-Claim
334	chemoembolization	N	I-Claim
335	for	N	I-Claim
336	patients	N	I-Claim
337	with	N	I-Claim
338	inoperable	N	I-Claim
339	liver	N	I-Claim
340	cancer	N	I-Claim
341	.	N	I-Claim

1	Gefitinib	N	O
2	has	N	O
3	shown	N	O
4	high	N	O
5	response	N	O
6	rate	N	O
7	and	N	O
8	improved	N	O
9	progression-free	N	O
10	survival	N	O
11	(	N	O
12	PFS	N	O
13	)	N	O
14	in	N	O
15	never-smokers	N	O
16	with	N	O
17	lung	N	O
18	adenocarcinoma	N	O
19	(	N	O
20	NSLAs	N	O
21	)	N	O
22	.	N	O

23	We	N	O
24	compared	N	O
25	efficacy	N	O
26	of	N	O
27	gefitinib	N	O
28	with	N	O
29	gemcitabine	N	O
30	and	N	O
31	cisplatin	N	O
32	(	N	O
33	GP	N	O
34	)	N	O
35	chemotherapy	N	O
36	in	N	O
37	this	N	O
38	group	N	O
39	of	N	O
40	patients	N	O
41	as	N	O
42	first-line	N	O
43	therapy	N	O
44	.	N	O

45	In	N	O
46	this	N	O
47	randomized	N	O
48	phase	N	O
49	III	N	O
50	trial	N	O
51	,	N	O
52	a	N	O
53	total	N	O
54	of	N	O
55	313	N	O
56	Korean	N	O
57	never-smokers	N	O
58	with	N	O
59	stage	N	O
60	IIIB	N	O
61	or	N	O
62	IV	N	O
63	lung	N	O
64	adenocarcinoma	N	O
65	,	N	O
66	Eastern	N	O
67	Cooperative	N	O
68	Oncology	N	O
69	Group	N	O
70	performance	N	O
71	status	N	O
72	0	N	O
73	to	N	O
74	2	N	O
75	,	N	O
76	and	N	O
77	adequate	N	O
78	organ	N	O
79	function	N	O
80	were	N	O
81	randomly	N	O
82	assigned	N	O
83	to	N	O
84	receive	N	O
85	either	N	O
86	gefitinib	N	O
87	(	N	O
88	250	N	O
89	mg	N	O
90	daily	N	O
91	)	N	O
92	or	N	O
93	GP	N	O
94	chemotherapy	N	O
95	(	N	O
96	gemcitabine	N	O
97	1,250	N	O
98	mg/m	N	O
99	(	N	O
100	2	N	O
101	)	N	O
102	on	N	O
103	days	N	O
104	1	N	O
105	and	N	O
106	8	N	O
107	;	N	O
108	cisplatin	N	O
109	80	N	O
110	mg/m	N	O
111	(	N	O
112	2	N	O
113	)	N	O
114	on	N	O
115	day	N	O
116	1	N	O
117	every	N	O
118	3	N	O
119	weeks	N	O
120	,	N	O
121	for	N	O
122	up	N	O
123	to	N	O
124	nine	N	O
125	courses	N	O
126	)	N	O
127	.	N	O

128	The	N	O
129	primary	N	O
130	objective	N	O
131	was	N	O
132	to	N	O
133	demonstrate	N	O
134	better	N	O
135	overall	N	O
136	survival	N	O
137	(	N	O
138	OS	N	O
139	)	N	O
140	for	N	O
141	gefitinib	N	O
142	compared	N	O
143	with	N	O
144	GP	N	O
145	in	N	O
146	chemotherapy-naive	N	O
147	NSLAs	N	O
148	.	N	O

149	Three	N	O
150	hundred	N	O
151	nine	N	O
152	patients	N	O
153	were	N	O
154	analyzed	N	O
155	per	N	O
156	protocol	N	O
157	(	N	O
158	gefitinib	N	O
159	arm	N	O
160	,	N	O
161	n	N	O
162	=	N	O
163	159	N	O
164	;	N	O
165	GP	N	O
166	arm	N	O
167	,	N	O
168	n	N	O
169	=	N	O
170	150	N	O
171	)	N	O
172	.	N	O

173	Gefitinib	N	I-Premise
174	did	N	I-Premise
175	not	N	I-Premise
176	show	N	I-Premise
177	better	N	I-Premise
178	OS	N	I-Premise
179	compared	N	I-Premise
180	with	N	I-Premise
181	GP	N	I-Premise
182	(	N	I-Premise
183	hazard	N	I-Premise
184	ratio	N	I-Premise
185	[	N	I-Premise
186	HR	N	I-Premise
187	]	N	I-Premise
188	,	N	I-Premise
189	0.932	N	I-Premise
190	;	N	I-Premise
191	95	N	I-Premise
192	%	N	I-Premise
193	CI	N	I-Premise
194	,	N	I-Premise
195	0.716	N	I-Premise
196	to	N	I-Premise
197	1.213	N	I-Premise
198	;	N	I-Premise
199	P	N	I-Premise
200	=	N	I-Premise
201	.604	N	I-Premise
202	;	N	I-Premise
203	median	N	I-Premise
204	OS	N	I-Premise
205	,	N	I-Premise
206	22.3	N	I-Premise
207	v	N	I-Premise
208	22.9	N	I-Premise
209	months	N	I-Premise
210	,	N	I-Premise
211	respectively	N	I-Premise
212	)	N	I-Premise
213	.	N	I-Premise

214	The	N	I-Premise
215	1-year	N	I-Premise
216	PFS	N	I-Premise
217	rates	N	I-Premise
218	were	N	I-Premise
219	16.7	N	I-Premise
220	%	N	I-Premise
221	with	N	I-Premise
222	gefitinib	N	I-Premise
223	and	N	I-Premise
224	2.8	N	I-Premise
225	%	N	I-Premise
226	with	N	I-Premise
227	GP	N	I-Premise
228	(	N	I-Premise
229	HR	N	I-Premise
230	,	N	I-Premise
231	1.198	N	I-Premise
232	;	N	I-Premise
233	95	N	I-Premise
234	%	N	I-Premise
235	CI	N	I-Premise
236	,	N	I-Premise
237	0.944	N	I-Premise
238	to	N	I-Premise
239	1.520	N	I-Premise
240	)	N	I-Premise
241	.	N	I-Premise

242	Response	N	I-Premise
243	rates	N	I-Premise
244	were	N	I-Premise
245	55	N	I-Premise
246	%	N	I-Premise
247	with	N	I-Premise
248	gefitinib	N	I-Premise
249	and	N	I-Premise
250	46	N	I-Premise
251	%	N	I-Premise
252	with	N	I-Premise
253	GP	N	I-Premise
254	(	N	I-Premise
255	P	N	I-Premise
256	=	N	I-Premise
257	.101	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	Myelosuppression	N	I-Premise
261	,	N	I-Premise
262	renal	N	I-Premise
263	insufficiency	N	I-Premise
264	,	N	I-Premise
265	and	N	I-Premise
266	fatigue	N	I-Premise
267	were	N	I-Premise
268	more	N	I-Premise
269	common	N	I-Premise
270	in	N	I-Premise
271	the	N	I-Premise
272	GP	N	I-Premise
273	arm	N	I-Premise
274	,	N	I-Premise
275	but	N	O
276	skin	N	I-Premise
277	toxicities	N	I-Premise
278	and	N	I-Premise
279	liver	N	I-Premise
280	dysfunction	N	I-Premise
281	were	N	I-Premise
282	more	N	I-Premise
283	common	N	I-Premise
284	in	N	I-Premise
285	the	N	I-Premise
286	gefitinib	N	I-Premise
287	arm	N	I-Premise
288	.	N	I-Premise

289	Two	N	I-Premise
290	patients	N	I-Premise
291	(	N	I-Premise
292	1.3	N	I-Premise
293	%	N	I-Premise
294	)	N	I-Premise
295	in	N	I-Premise
296	the	N	I-Premise
297	gefitinib	N	I-Premise
298	arm	N	I-Premise
299	developed	N	I-Premise
300	interstitial	N	I-Premise
301	lung	N	I-Premise
302	disease	N	I-Premise
303	and	N	I-Premise
304	died	N	I-Premise
305	.	N	I-Premise

306	Gefitinib	N	I-Claim
307	failed	N	I-Claim
308	to	N	I-Claim
309	demonstrate	N	I-Claim
310	superior	N	I-Claim
311	OS	N	I-Claim
312	compared	N	I-Claim
313	with	N	I-Claim
314	GP	N	I-Claim
315	as	N	I-Claim
316	first-line	N	I-Claim
317	therapy	N	I-Claim
318	for	N	I-Claim
319	NSLAs	N	I-Claim
320	.	N	I-Claim

1	Spiritual	N	O
2	well-being	N	O
3	and	N	O
4	sense	N	O
5	of	N	O
6	meaning	N	O
7	are	N	O
8	important	N	O
9	concerns	N	O
10	for	N	O
11	clinicians	N	O
12	who	N	O
13	care	N	O
14	for	N	O
15	patients	N	O
16	with	N	O
17	cancer	N	O
18	.	N	O

19	We	N	O
20	developed	N	O
21	Individual	N	O
22	Meaning-Centered	N	O
23	Psychotherapy	N	O
24	(	N	O
25	IMCP	N	O
26	)	N	O
27	to	N	O
28	address	N	O
29	the	N	O
30	need	N	O
31	for	N	O
32	brief	N	O
33	interventions	N	O
34	targeting	N	O
35	spiritual	N	O
36	well-being	N	O
37	and	N	O
38	meaning	N	O
39	for	N	O
40	patients	N	O
41	with	N	O
42	advanced	N	O
43	cancer	N	O
44	.	N	O

45	Patients	N	O
46	with	N	O
47	stage	N	O
48	III	N	O
49	or	N	O
50	IV	N	O
51	cancer	N	O
52	(	N	O
53	N	N	O
54	=	N	O
55	120	N	O
56	)	N	O
57	were	N	O
58	randomly	N	O
59	assigned	N	O
60	to	N	O
61	seven	N	O
62	sessions	N	O
63	of	N	O
64	either	N	O
65	IMCP	N	O
66	or	N	O
67	therapeutic	N	O
68	massage	N	O
69	(	N	O
70	TM	N	O
71	)	N	O
72	.	N	O

73	Patients	N	O
74	were	N	O
75	assessed	N	O
76	before	N	O
77	and	N	O
78	after	N	O
79	completing	N	O
80	the	N	O
81	intervention	N	O
82	and	N	O
83	2	N	O
84	months	N	O
85	postintervention	N	O
86	.	N	O

87	Primary	N	O
88	outcome	N	O
89	measures	N	O
90	assessed	N	O
91	spiritual	N	O
92	well-being	N	O
93	and	N	O
94	quality	N	O
95	of	N	O
96	life	N	O
97	;	N	O
98	secondary	N	O
99	outcomes	N	O
100	included	N	O
101	anxiety	N	O
102	,	N	O
103	depression	N	O
104	,	N	O
105	hopelessness	N	O
106	,	N	O
107	symptom	N	O
108	burden	N	O
109	,	N	O
110	and	N	O
111	symptom-related	N	O
112	distress	N	O
113	.	N	O

114	Of	N	O
115	the	N	O
116	120	N	O
117	participants	N	O
118	randomly	N	O
119	assigned	N	O
120	,	N	O
121	78	N	O
122	(	N	O
123	65	N	O
124	%	N	O
125	)	N	O
126	completed	N	O
127	the	N	O
128	post-treatment	N	O
129	assessment	N	O
130	and	N	O
131	67	N	O
132	(	N	O
133	56	N	O
134	%	N	O
135	)	N	O
136	completed	N	O
137	the	N	O
138	2-month	N	O
139	follow-up	N	O
140	.	N	O

141	At	N	I-Premise
142	the	N	I-Premise
143	post-treatment	N	I-Premise
144	assessment	N	I-Premise
145	,	N	I-Premise
146	IMCP	N	I-Premise
147	participants	N	I-Premise
148	demonstrated	N	I-Premise
149	significantly	N	I-Premise
150	greater	N	I-Premise
151	improvement	N	I-Premise
152	than	N	I-Premise
153	the	N	I-Premise
154	control	N	I-Premise
155	condition	N	I-Premise
156	for	N	I-Premise
157	the	N	I-Premise
158	primary	N	I-Premise
159	outcomes	N	I-Premise
160	of	N	I-Premise
161	spiritual	N	I-Premise
162	well-being	N	I-Premise
163	(	N	I-Premise
164	b	N	I-Premise
165	=	N	I-Premise
166	0.39	N	I-Premise
167	;	N	I-Premise
168	P	N	I-Premise
169	<	N	I-Premise
170	.001	N	I-Premise
171	,	N	I-Premise
172	including	N	I-Premise
173	both	N	I-Premise
174	components	N	I-Premise
175	of	N	I-Premise
176	spiritual	N	I-Premise
177	well-being	N	I-Premise
178	(	N	I-Premise
179	sense	N	I-Premise
180	of	N	I-Premise
181	meaning	N	I-Premise
182	:	N	I-Premise
183	b	N	I-Premise
184	=	N	I-Premise
185	0.34	N	I-Premise
186	;	N	I-Premise
187	P	N	I-Premise
188	=	N	I-Premise
189	.003	N	I-Premise
190	and	N	I-Premise
191	faith	N	I-Premise
192	:	N	I-Premise
193	b	N	I-Premise
194	=	N	I-Premise
195	0.42	N	I-Premise
196	;	N	I-Premise
197	P	N	I-Premise
198	=	N	I-Premise
199	.03	N	I-Premise
200	)	N	I-Premise
201	,	N	I-Premise
202	and	N	I-Premise
203	quality	N	I-Premise
204	of	N	I-Premise
205	life	N	I-Premise
206	(	N	I-Premise
207	b	N	I-Premise
208	=	N	I-Premise
209	0.76	N	I-Premise
210	;	N	I-Premise
211	P	N	I-Premise
212	=	N	I-Premise
213	.013	N	I-Premise
214	)	N	I-Premise
215	.	N	I-Premise

216	Significantly	N	I-Premise
217	greater	N	I-Premise
218	improvements	N	I-Premise
219	for	N	I-Premise
220	IMCP	N	I-Premise
221	patients	N	I-Premise
222	were	N	I-Premise
223	also	N	I-Premise
224	observed	N	I-Premise
225	for	N	I-Premise
226	the	N	I-Premise
227	secondary	N	I-Premise
228	outcomes	N	I-Premise
229	of	N	I-Premise
230	symptom	N	I-Premise
231	burden	N	I-Premise
232	(	N	I-Premise
233	b	N	I-Premise
234	=	N	I-Premise
235	-6.56	N	I-Premise
236	;	N	I-Premise
237	P	N	I-Premise
238	<	N	I-Premise
239	.001	N	I-Premise
240	)	N	I-Premise
241	and	N	I-Premise
242	symptom-related	N	I-Premise
243	distress	N	I-Premise
244	(	N	I-Premise
245	b	N	I-Premise
246	=	N	I-Premise
247	-0.47	N	I-Premise
248	;	N	I-Premise
249	P	N	I-Premise
250	<	N	I-Premise
251	.001	N	I-Premise
252	)	N	I-Premise
253	but	N	I-Premise
254	not	N	I-Premise
255	for	N	I-Premise
256	anxiety	N	I-Premise
257	,	N	I-Premise
258	depression	N	I-Premise
259	,	N	I-Premise
260	or	N	I-Premise
261	hopelessness	N	I-Premise
262	.	N	I-Premise

263	At	N	I-Premise
264	the	N	I-Premise
265	2-month	N	I-Premise
266	follow-up	N	I-Premise
267	assessment	N	I-Premise
268	,	N	I-Premise
269	the	N	I-Premise
270	improvements	N	I-Premise
271	observed	N	I-Premise
272	for	N	I-Premise
273	the	N	I-Premise
274	IMCP	N	I-Premise
275	group	N	I-Premise
276	were	N	I-Premise
277	no	N	I-Premise
278	longer	N	I-Premise
279	significantly	N	I-Premise
280	greater	N	I-Premise
281	than	N	I-Premise
282	those	N	I-Premise
283	observed	N	I-Premise
284	for	N	I-Premise
285	the	N	I-Premise
286	TM	N	I-Premise
287	group	N	I-Premise
288	.	N	I-Premise

289	IMCP	N	I-Claim
290	has	N	I-Claim
291	clear	N	I-Claim
292	short-term	N	I-Claim
293	benefits	N	I-Claim
294	for	N	I-Claim
295	spiritual	N	I-Claim
296	suffering	N	I-Claim
297	and	N	I-Claim
298	quality	N	I-Claim
299	of	N	I-Claim
300	life	N	I-Claim
301	in	N	I-Claim
302	patients	N	I-Claim
303	with	N	I-Claim
304	advanced	N	I-Claim
305	cancer	N	I-Claim
306	.	N	I-Claim

307	Clinicians	N	O
308	working	N	O
309	with	N	O
310	patients	N	O
311	who	N	O
312	have	N	O
313	advanced	N	O
314	cancer	N	O
315	should	N	O
316	consider	N	O
317	IMCP	N	O
318	as	N	O
319	an	N	O
320	approach	N	O
321	to	N	O
322	enhance	N	O
323	quality	N	O
324	of	N	O
325	life	N	O
326	and	N	O
327	spiritual	N	O
328	well-being	N	O
329	.	N	O

1	To	N	O
2	determine	N	O
3	whether	N	O
4	an	N	O
5	Internet-based	N	I-Claim
6	tailored	N	I-Claim
7	education	N	I-Claim
8	program	N	I-Claim
9	is	N	I-Claim
10	effective	N	I-Claim
11	for	N	I-Claim
12	disease-free	N	I-Claim
13	cancer	N	I-Claim
14	survivors	N	I-Claim
15	with	N	I-Claim
16	cancer-related	N	I-Claim
17	fatigue	N	I-Claim
18	(	N	I-Claim
19	CRF	N	I-Claim
20	)	N	I-Claim
21	.	N	I-Claim

22	We	N	O
23	randomly	N	O
24	assigned	N	O
25	patients	N	O
26	who	N	O
27	had	N	O
28	completed	N	O
29	primary	N	O
30	cancer	N	O
31	treatment	N	O
32	within	N	O
33	the	N	O
34	past	N	O
35	24	N	O
36	months	N	O
37	in	N	O
38	any	N	O
39	of	N	O
40	four	N	O
41	Korean	N	O
42	hospitals	N	O
43	and	N	O
44	had	N	O
45	reported	N	O
46	moderate	N	O
47	to	N	O
48	severe	N	O
49	fatigue	N	O
50	for	N	O
51	at	N	O
52	least	N	O
53	1	N	O
54	week	N	O
55	to	N	O
56	participate	N	O
57	in	N	O
58	a	N	O
59	12-week	N	O
60	,	N	O
61	Internet-based	N	O
62	,	N	O
63	individually	N	O
64	tailored	N	O
65	CRF	N	O
66	education	N	O
67	program	N	O
68	or	N	O
69	to	N	O
70	receive	N	O
71	routine	N	O
72	care	N	O
73	.	N	O

74	We	N	O
75	based	N	O
76	the	N	O
77	program	N	O
78	on	N	O
79	the	N	O
80	CRF	N	O
81	guidelines	N	O
82	of	N	O
83	the	N	O
84	National	N	O
85	Comprehensive	N	O
86	Cancer	N	O
87	Network	N	O
88	(	N	O
89	NCCN	N	O
90	)	N	O
91	and	N	O
92	incorporated	N	O
93	the	N	O
94	transtheoretic	N	O
95	model	N	O
96	(	N	O
97	TTM	N	O
98	)	N	O
99	.	N	O

100	At	N	O
101	baseline	N	O
102	and	N	O
103	12	N	O
104	weeks	N	O
105	,	N	O
106	we	N	O
107	used	N	O
108	the	N	O
109	Brief	N	O
110	Fatigue	N	O
111	Inventory	N	O
112	(	N	O
113	BFI	N	O
114	)	N	O
115	and	N	O
116	Fatigue	N	O
117	Severity	N	O
118	Scale	N	O
119	(	N	O
120	FSS	N	O
121	)	N	O
122	as	N	O
123	primary	N	O
124	outcomes	N	O
125	and	N	O
126	the	N	O
127	Hospital	N	O
128	Anxiety	N	O
129	and	N	O
130	Depression	N	O
131	Scale	N	O
132	(	N	O
133	HADS	N	O
134	)	N	O
135	and	N	O
136	European	N	O
137	Organisation	N	O
138	for	N	O
139	Research	N	O
140	and	N	O
141	Treatment	N	O
142	of	N	O
143	Cancer	N	O
144	Quality	N	O
145	of	N	O
146	Life	N	O
147	Questionnaire	N	O
148	C30	N	O
149	(	N	O
150	EORTC	N	O
151	QLQ-C30	N	O
152	)	N	O
153	for	N	O
154	secondary	N	O
155	outcomes	N	O
156	.	N	O

157	We	N	O
158	recruited	N	O
159	273	N	O
160	participants	N	O
161	and	N	O
162	randomly	N	O
163	assigned	N	O
164	136	N	O
165	to	N	O
166	the	N	O
167	intervention	N	O
168	group	N	O
169	.	N	O

170	Compared	N	I-Premise
171	with	N	I-Premise
172	the	N	I-Premise
173	control	N	I-Premise
174	group	N	I-Premise
175	,	N	I-Premise
176	the	N	I-Premise
177	intervention	N	I-Premise
178	group	N	I-Premise
179	had	N	I-Premise
180	an	N	I-Premise
181	improvement	N	I-Premise
182	in	N	I-Premise
183	fatigue	N	I-Premise
184	as	N	I-Premise
185	shown	N	I-Premise
186	by	N	I-Premise
187	a	N	I-Premise
188	significantly	N	I-Premise
189	greater	N	I-Premise
190	decrease	N	I-Premise
191	in	N	I-Premise
192	BFI	N	I-Premise
193	global	N	I-Premise
194	score	N	I-Premise
195	(	N	I-Premise
196	-0.66	N	I-Premise
197	points	N	I-Premise
198	;	N	I-Premise
199	95	N	I-Premise
200	%	N	I-Premise
201	CI	N	I-Premise
202	-1.04	N	I-Premise
203	to	N	I-Premise
204	-0.27	N	I-Premise
205	)	N	I-Premise
206	and	N	I-Premise
207	FSS	N	I-Premise
208	total	N	I-Premise
209	score	N	I-Premise
210	(	N	I-Premise
211	-0.49	N	I-Premise
212	;	N	I-Premise
213	95	N	I-Premise
214	%	N	I-Premise
215	CI	N	I-Premise
216	,	N	I-Premise
217	-0.78	N	I-Premise
218	to	N	I-Premise
219	-0.21	N	I-Premise
220	)	N	I-Premise
221	.	N	I-Premise

222	In	N	I-Premise
223	secondary	N	I-Premise
224	outcomes	N	I-Premise
225	,	N	I-Premise
226	the	N	I-Premise
227	intervention	N	I-Premise
228	group	N	I-Premise
229	experienced	N	I-Premise
230	a	N	I-Premise
231	significantly	N	I-Premise
232	greater	N	I-Premise
233	decrease	N	I-Premise
234	in	N	I-Premise
235	HADS	N	I-Premise
236	anxiety	N	I-Premise
237	score	N	I-Premise
238	(	N	I-Premise
239	-0.90	N	I-Premise
240	;	N	I-Premise
241	95	N	I-Premise
242	%	N	I-Premise
243	CI	N	I-Premise
244	,	N	I-Premise
245	-1.51	N	I-Premise
246	to	N	I-Premise
247	-0.29	N	I-Premise
248	)	N	I-Premise
249	as	N	I-Premise
250	well	N	I-Premise
251	as	N	I-Premise
252	global	N	I-Premise
253	quality	N	I-Premise
254	of	N	I-Premise
255	life	N	I-Premise
256	(	N	I-Premise
257	5.22	N	I-Premise
258	;	N	I-Premise
259	95	N	I-Premise
260	%	N	I-Premise
261	CI	N	I-Premise
262	,	N	I-Premise
263	0.93	N	I-Premise
264	to	N	I-Premise
265	9.50	N	I-Premise
266	)	N	I-Premise
267	and	N	I-Premise
268	several	N	I-Premise
269	functioning	N	I-Premise
270	scores	N	I-Premise
271	of	N	I-Premise
272	the	N	I-Premise
273	EORTC	N	I-Premise
274	QLQ-C30	N	I-Premise
275	.	N	I-Premise

276	An	N	I-Claim
277	Internet-based	N	I-Claim
278	education	N	I-Claim
279	program	N	I-Claim
280	based	N	I-Claim
281	on	N	I-Claim
282	NCCN	N	I-Claim
283	guidelines	N	I-Claim
284	and	N	I-Claim
285	TTM	N	I-Claim
286	may	N	I-Claim
287	help	N	I-Claim
288	patients	N	I-Claim
289	manage	N	I-Claim
290	CRF	N	I-Claim
291	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	effectiveness	N	O
5	of	N	O
6	mindfulness-based	N	O
7	stress	N	O
8	reduction	N	O
9	(	N	O
10	MBSR	N	O
11	)	N	O
12	for	N	O
13	mood	N	O
14	,	N	O
15	breast-	N	O
16	and	N	O
17	endocrine-specific	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	,	N	O
22	and	N	O
23	well-being	N	O
24	after	N	O
25	hospital	N	O
26	treatment	N	O
27	in	N	O
28	women	N	O
29	with	N	O
30	stage	N	O
31	0	N	O
32	to	N	O
33	III	N	O
34	breast	N	O
35	cancer	N	O
36	.	N	O

37	A	N	O
38	randomized	N	O
39	,	N	O
40	wait-listed	N	O
41	,	N	O
42	controlled	N	O
43	trial	N	O
44	was	N	O
45	carried	N	O
46	out	N	O
47	in	N	O
48	229	N	O
49	women	N	O
50	after	N	O
51	surgery	N	O
52	,	N	O
53	chemotherapy	N	O
54	,	N	O
55	and	N	O
56	radiotherapy	N	O
57	for	N	O
58	breast	N	O
59	cancer	N	O
60	.	N	O

61	Patients	N	O
62	were	N	O
63	randomly	N	O
64	assigned	N	O
65	to	N	O
66	the	N	O
67	8-week	N	O
68	MBSR	N	O
69	program	N	O
70	or	N	O
71	standard	N	O
72	care	N	O
73	.	N	O

74	Profile	N	O
75	of	N	O
76	Mood	N	O
77	States	N	O
78	(	N	O
79	POMS	N	O
80	;	N	O
81	primary	N	O
82	outcome	N	O
83	)	N	O
84	,	N	O
85	Functional	N	O
86	Assessment	N	O
87	of	N	O
88	Cancer	N	O
89	Therapy-Breast	N	O
90	(	N	O
91	FACT-B	N	O
92	)	N	O
93	,	N	O
94	Functional	N	O
95	Assessment	N	O
96	of	N	O
97	Cancer	N	O
98	Therapy-Endocrine	N	O
99	Symptoms	N	O
100	(	N	O
101	FACT-ES	N	O
102	)	N	O
103	scales	N	O
104	and	N	O
105	the	N	O
106	WHO	N	O
107	five-item	N	O
108	well-being	N	O
109	questionnaire	N	O
110	(	N	O
111	WHO-5	N	O
112	)	N	O
113	evaluated	N	O
114	mood	N	O
115	,	N	O
116	quality	N	O
117	of	N	O
118	life	N	O
119	,	N	O
120	and	N	O
121	well-being	N	O
122	at	N	O
123	weeks	N	O
124	0	N	O
125	,	N	O
126	8	N	O
127	,	N	O
128	and	N	O
129	12	N	O
130	.	N	O

131	For	N	O
132	each	N	O
133	outcome	N	O
134	measure	N	O
135	,	N	O
136	a	N	O
137	repeated-measures	N	O
138	analysis	N	O
139	of	N	O
140	variance	N	O
141	model	N	O
142	,	N	O
143	which	N	O
144	incorporated	N	O
145	week	N	O
146	0	N	O
147	measurements	N	O
148	as	N	O
149	a	N	O
150	covariate	N	O
151	,	N	O
152	was	N	O
153	used	N	O
154	to	N	O
155	compare	N	O
156	treatment	N	O
157	groups	N	O
158	at	N	O
159	8	N	O
160	and	N	O
161	12	N	O
162	weeks	N	O
163	.	N	O

164	There	N	I-Premise
165	were	N	I-Premise
166	statistically	N	I-Premise
167	significant	N	I-Premise
168	improvements	N	I-Premise
169	in	N	I-Premise
170	outcome	N	I-Premise
171	in	N	I-Premise
172	the	N	I-Premise
173	experimental	N	I-Premise
174	group	N	I-Premise
175	compared	N	I-Premise
176	with	N	I-Premise
177	control	N	I-Premise
178	group	N	I-Premise
179	at	N	I-Premise
180	both	N	I-Premise
181	8	N	I-Premise
182	and	N	I-Premise
183	12	N	I-Premise
184	weeks	N	I-Premise
185	(	N	I-Premise
186	except	N	I-Premise
187	as	N	I-Premise
188	indicated	N	I-Premise
189	)	N	I-Premise
190	for	N	I-Premise
191	POMS	N	I-Premise
192	total	N	I-Premise
193	mood	N	I-Premise
194	disturbance	N	I-Premise
195	(	N	I-Premise
196	and	N	I-Premise
197	its	N	I-Premise
198	subscales	N	I-Premise
199	of	N	I-Premise
200	anxiety	N	I-Premise
201	,	N	I-Premise
202	depression	N	I-Premise
203	[	N	I-Premise
204	8	N	I-Premise
205	weeks	N	I-Premise
206	only	N	I-Premise
207	]	N	I-Premise
208	,	N	I-Premise
209	anger	N	I-Premise
210	[	N	I-Premise
211	12	N	I-Premise
212	weeks	N	I-Premise
213	only	N	I-Premise
214	]	N	I-Premise
215	,	N	I-Premise
216	vigor	N	I-Premise
217	,	N	I-Premise
218	fatigue	N	I-Premise
219	,	N	I-Premise
220	and	N	I-Premise
221	confusion	N	I-Premise
222	[	N	I-Premise
223	8	N	I-Premise
224	weeks	N	I-Premise
225	only	N	I-Premise
226	]	N	I-Premise
227	)	N	I-Premise
228	,	N	I-Premise
229	FACT-B	N	I-Premise
230	,	N	I-Premise
231	FACT-ES	N	I-Premise
232	,	N	I-Premise
233	(	N	I-Premise
234	and	N	I-Premise
235	Functional	N	I-Premise
236	Assessment	N	I-Premise
237	of	N	I-Premise
238	Cancer	N	I-Premise
239	Therapy	N	I-Premise
240	subscales	N	I-Premise
241	of	N	I-Premise
242	physical	N	I-Premise
243	,	N	I-Premise
244	social	N	I-Premise
245	[	N	I-Premise
246	8	N	I-Premise
247	weeks	N	I-Premise
248	only	N	I-Premise
249	]	N	I-Premise
250	,	N	I-Premise
251	emotional	N	I-Premise
252	,	N	I-Premise
253	and	N	I-Premise
254	functional	N	I-Premise
255	well-being	N	I-Premise
256	)	N	I-Premise
257	,	N	I-Premise
258	and	N	I-Premise
259	WHO-5	N	I-Premise
260	.	N	I-Premise

261	MSBR	N	I-Premise
262	improved	N	I-Premise
263	mood	N	I-Premise
264	,	N	I-Premise
265	breast-	N	I-Premise
266	and	N	I-Premise
267	endocrine-related	N	I-Premise
268	quality	N	I-Premise
269	of	N	I-Premise
270	life	N	I-Premise
271	,	N	I-Premise
272	and	N	I-Premise
273	well-being	N	I-Premise
274	more	N	I-Premise
275	effectively	N	I-Premise
276	than	N	I-Premise
277	standard	N	I-Premise
278	care	N	I-Premise
279	in	N	I-Premise
280	women	N	I-Premise
281	with	N	I-Premise
282	stage	N	I-Premise
283	0	N	I-Premise
284	to	N	I-Premise
285	III	N	I-Premise
286	breast	N	I-Premise
287	cancer	N	I-Premise
288	,	N	I-Premise
289	and	N	I-Premise
290	these	N	I-Premise
291	results	N	I-Premise
292	persisted	N	I-Premise
293	at	N	I-Premise
294	three	N	I-Premise
295	months	N	I-Premise
296	.	N	I-Premise

297	To	N	I-Claim
298	our	N	I-Claim
299	knowledge	N	I-Claim
300	,	N	I-Claim
301	this	N	I-Claim
302	study	N	I-Claim
303	provided	N	I-Claim
304	novel	N	I-Claim
305	evidence	N	I-Claim
306	that	N	I-Claim
307	MBSR	N	I-Claim
308	can	N	I-Claim
309	help	N	I-Claim
310	alleviate	N	I-Claim
311	long-term	N	I-Claim
312	emotional	N	I-Claim
313	and	N	I-Claim
314	physical	N	I-Claim
315	adverse	N	I-Claim
316	effects	N	I-Claim
317	of	N	I-Claim
318	medical	N	I-Claim
319	treatments	N	I-Claim
320	,	N	I-Claim
321	including	N	I-Claim
322	endocrine	N	I-Claim
323	treatments	N	I-Claim
324	.	N	I-Claim

325	MBSR	N	I-MajorClaim
326	is	N	I-MajorClaim
327	recommended	N	I-MajorClaim
328	to	N	I-MajorClaim
329	support	N	I-MajorClaim
330	survivors	N	I-MajorClaim
331	of	N	I-MajorClaim
332	breast	N	I-MajorClaim
333	cancer	N	I-MajorClaim
334	.	N	I-MajorClaim

1	This	N	O
2	study	N	O
3	examined	N	O
4	the	N	O
5	feasibility	N	O
6	and	N	O
7	acceptability	N	O
8	of	N	O
9	an	N	O
10	Individual	N	O
11	Internet	N	O
12	Intervention	N	O
13	(	N	O
14	III	N	O
15	)	N	O
16	embedded	N	O
17	and	N	O
18	integrated	N	O
19	into	N	O
20	an	N	O
21	Internet	N	O
22	Support	N	O
23	Group	N	O
24	(	N	O
25	ISG	N	O
26	)	N	O
27	with	N	O
28	the	N	O
29	ultimate	N	O
30	goal	N	O
31	of	N	O
32	enhancing	N	O
33	adherence	N	O
34	and	N	O
35	learning	N	O
36	,	N	O
37	compared	N	O
38	with	N	O
39	an	N	O
40	individual	N	O
41	internet	N	O
42	invention	N	O
43	alone	N	O
44	.	N	O

45	Thirty-one	N	O
46	posttreatment	N	O
47	cancer	N	O
48	survivors	N	O
49	were	N	O
50	randomized	N	O
51	in	N	O
52	groups	N	O
53	of	N	O
54	seven	N	O
55	to	N	O
56	nine	N	O
57	to	N	O
58	either	N	O
59	the	N	O
60	8-week	N	O
61	III	N	O
62	+	N	O
63	ISG	N	O
64	intervention	N	O
65	or	N	O
66	the	N	O
67	8-week	N	O
68	III	N	O
69	condition	N	O
70	.	N	O

71	Seventeen	N	O
72	participants	N	O
73	met	N	O
74	the	N	O
75	Hospital	N	O
76	Anxiety	N	O
77	and	N	O
78	Depression	N	O
79	Scale	N	O
80	(	N	O
81	HADS	N	O
82	)	N	O
83	criteria	N	O
84	for	N	O
85	depressive	N	O
86	symptoms	N	O
87	(	N	O
88	HADS	N	O
89		N	O
90	8	N	O
91	)	N	O
92	.	N	O

93	Among	N	O
94	all	N	O
95	participants	N	O
96	,	N	O
97	the	N	O
98	mean	N	O
99	number	N	O
100	of	N	O
101	logins	N	O
102	over	N	O
103	8	N	O
104	weeks	N	O
105	was	N	O
106	20.8	N	O
107		N	O
108	17.7	N	O
109	logins	N	O
110	for	N	O
111	the	N	O
112	III	N	O
113	+	N	O
114	ISG	N	O
115	compared	N	O
116	with	N	O
117	12.5	N	O
118		N	O
119	12.5	N	O
120	in	N	O
121	III-only	N	O
122	(	N	O
123	p	N	O
124	=	N	O
125	0.15	N	O
126	)	N	O
127	.	N	O

128	Two	N	O
129	participants	N	O
130	in	N	O
131	the	N	O
132	III	N	O
133	+	N	O
134	ISG	N	O
135	dropped	N	O
136	out	N	O
137	,	N	O
138	compared	N	O
139	with	N	O
140	five	N	O
141	in	N	O
142	III	N	O
143	(	N	O
144	p	N	O
145	=	N	O
146	0.39	N	O
147	)	N	O
148	.	N	O

149	Among	N	I-Premise
150	the	N	I-Premise
151	17	N	I-Premise
152	participants	N	I-Premise
153	with	N	I-Premise
154	depressive	N	I-Premise
155	symptoms	N	I-Premise
156	at	N	I-Premise
157	baseline	N	I-Premise
158	,	N	I-Premise
159	both	N	I-Premise
160	the	N	I-Premise
161	Onward	N	I-Premise
162	and	N	I-Premise
163	the	N	I-Premise
164	III-only	N	I-Premise
165	condition	N	I-Premise
166	showed	N	I-Premise
167	large	N	I-Premise
168	reductions	N	I-Premise
169	in	N	I-Premise
170	the	N	I-Premise
171	depression	N	I-Premise
172	scale	N	I-Premise
173	of	N	I-Premise
174	HADS	N	I-Premise
175	(	N	I-Premise
176	d	N	I-Premise
177	=	N	I-Premise
178	1.27	N	I-Premise
179	and	N	I-Premise
180	0.89	N	I-Premise
181	,	N	I-Premise
182	respectively	N	I-Premise
183	)	N	I-Premise
184	.	N	I-Premise

185	Improvement	N	I-Premise
186	over	N	I-Premise
187	time	N	I-Premise
188	and	N	I-Premise
189	time	N	I-Premise
190	x	N	I-Premise
191	treatment	N	I-Premise
192	effects	N	I-Premise
193	only	N	I-Premise
194	reached	N	I-Premise
195	trend	N	I-Premise
196	significance	N	I-Premise
197	levels	N	I-Premise
198	(	N	I-Premise
199	ps	N	I-Premise
200	=	N	I-Premise
201	0.07	N	I-Premise
202	&	N	I-Premise
203	amp	N	I-Premise
204	;	N	I-Premise
205	0.12	N	I-Premise
206	)	N	I-Premise
207	as	N	I-Premise
208	this	N	I-Premise
209	pilot	N	I-Premise
210	was	N	I-Premise
211	not	N	I-Premise
212	powered	N	I-Premise
213	to	N	I-Premise
214	detect	N	I-Premise
215	these	N	I-Premise
216	differences	N	I-Premise
217	.	N	I-Premise

218	Both	N	I-Claim
219	the	N	I-Claim
220	III	N	I-Claim
221	+	N	I-Claim
222	ISG	N	I-Claim
223	and	N	I-Claim
224	III-only	N	I-Claim
225	demonstrated	N	I-Claim
226	pre-post	N	I-Claim
227	reductions	N	I-Claim
228	in	N	I-Claim
229	depressive	N	I-Claim
230	symptoms	N	I-Claim
231	and	N	I-Claim
232	high	N	I-Claim
233	rates	N	I-Claim
234	of	N	I-Claim
235	utilization	N	I-Claim
236	compared	N	I-Claim
237	with	N	I-Claim
238	other	N	I-Claim
239	web-based	N	I-Claim
240	treatments	N	I-Claim
241	for	N	I-Claim
242	depression	N	I-Claim
243	.	N	I-Claim

244	Although	N	I-Claim
245	it	N	I-Claim
246	is	N	I-Claim
247	premature	N	I-Claim
248	to	N	I-Claim
249	make	N	I-Claim
250	any	N	I-Claim
251	determination	N	I-Claim
252	as	N	I-Claim
253	to	N	I-Claim
254	the	N	I-Claim
255	efficacy	N	I-Claim
256	of	N	I-Claim
257	the	N	I-Claim
258	interventions	N	I-Claim
259	tested	N	I-Claim
260	in	N	I-Claim
261	this	N	I-Claim
262	feasibility	N	I-Claim
263	study	N	I-Claim
264	,	N	I-Claim
265	these	N	I-Claim
266	results	N	I-Claim
267	indicate	N	I-Claim
268	that	N	I-Claim
269	pursuing	N	I-Claim
270	the	N	I-Claim
271	III	N	I-Claim
272	+	N	I-Claim
273	ISG	N	I-Claim
274	model	N	I-Claim
275	,	N	I-Claim
276	as	N	I-Claim
277	well	N	I-Claim
278	as	N	I-Claim
279	standard	N	I-Claim
280	IIIs	N	I-Claim
281	,	N	I-Claim
282	may	N	I-Claim
283	be	N	I-Claim
284	fruitful	N	I-Claim
285	areas	N	I-Claim
286	of	N	I-Claim
287	future	N	I-Claim
288	research	N	I-Claim
289	.	N	I-Claim

1	The	N	O
2	phase	N	O
3	3	N	O
4	VISTA	N	O
5	study	N	O
6	in	N	O
7	transplant-ineligible	N	O
8	myeloma	N	O
9	patients	N	O
10	demonstrated	N	O
11	superior	N	O
12	efficacy	N	O
13	with	N	O
14	bortezomib-melphalan-prednisone	N	O
15	(	N	O
16	VMP	N	O
17	;	N	O
18	nine	N	O
19	6-wk	N	O
20	cycles	N	O
21	)	N	O
22	vs.	N	O
23	melphalan-prednisone	N	O
24	(	N	O
25	MP	N	O
26	)	N	O
27	but	N	O
28	also	N	O
29	increased	N	O
30	toxicity	N	O
31	.	N	O

32	Health-related	N	O
33	quality	N	O
34	of	N	O
35	life	N	O
36	(	N	O
37	HRQoL	N	O
38	;	N	O
39	exploratory	N	O
40	endpoint	N	O
41	)	N	O
42	was	N	O
43	evaluated	N	O
44	using	N	O
45	the	N	O
46	European	N	O
47	Organization	N	O
48	for	N	O
49	Research	N	O
50	and	N	O
51	Treatment	N	O
52	of	N	O
53	Cancer	N	O
54	(	N	O
55	EORTC	N	O
56	)	N	O
57	Quality	N	O
58	of	N	O
59	Life	N	O
60	Questionnaire	N	O
61	(	N	O
62	QLQ-C30	N	O
63	)	N	O
64	.	N	O

65	The	N	O
66	phase	N	O
67	3	N	O
68	VISTA	N	O
69	study	N	O
70	in	N	O
71	transplant-ineligible	N	O
72	myeloma	N	O
73	patients	N	O
74	demonstrated	N	O
75	superior	N	O
76	efficacy	N	O
77	with	N	O
78	bortezomib-melphalan-prednisone	N	O
79	(	N	O
80	VMP	N	O
81	;	N	O
82	nine	N	O
83	6-wk	N	O
84	cycles	N	O
85	)	N	O
86	vs.	N	O
87	melphalan-prednisone	N	O
88	(	N	O
89	MP	N	O
90	)	N	O
91	but	N	O
92	also	N	O
93	increased	N	O
94	toxicity	N	O
95	.	N	O

96	Health-related	N	O
97	quality	N	O
98	of	N	O
99	life	N	O
100	(	N	O
101	HRQoL	N	O
102	;	N	O
103	exploratory	N	O
104	endpoint	N	O
105	)	N	O
106	was	N	O
107	evaluated	N	O
108	using	N	O
109	the	N	O
110	European	N	O
111	Organization	N	O
112	for	N	O
113	Research	N	O
114	and	N	O
115	Treatment	N	O
116	of	N	O
117	Cancer	N	O
118	(	N	O
119	EORTC	N	O
120	)	N	O
121	Quality	N	O
122	of	N	O
123	Life	N	O
124	Questionnaire	N	O
125	(	N	O
126	QLQ-C30	N	O
127	)	N	O
128	.	N	O

129	EORTC	N	O
130	QLQ-C30	N	O
131	was	N	O
132	administered	N	O
133	at	N	O
134	screening	N	O
135	,	N	O
136	on	N	O
137	day	N	O
138	1	N	O
139	of	N	O
140	each	N	O
141	cycle	N	O
142	,	N	O
143	at	N	O
144	the	N	O
145	end-of-treatment	N	O
146	visit	N	O
147	,	N	O
148	and	N	O
149	every	N	O
150	8	N	O
151	wk	N	O
152	until	N	O
153	progression	N	O
154	.	N	O

155	EORTC	N	O
156	QLQ-C30	N	O
157	scores	N	O
158	were	N	O
159	evaluated	N	O
160	among	N	O
161	patients	N	O
162	with	N	O
163	a	N	O
164	valid	N	O
165	baseline	N	O
166	and	N	O
167	at	N	O
168	least	N	O
169	one	N	O
170	post-baseline	N	O
171	HRQoL	N	O
172	assessment	N	O
173	.	N	O

174	At	N	O
175	baseline	N	O
176	,	N	O
177	domain	N	O
178	scores	N	O
179	were	N	O
180	similar	N	O
181	between	N	O
182	arms	N	O
183	.	N	O

184	By	N	I-Premise
185	cycle	N	I-Premise
186	4	N	I-Premise
187	,	N	I-Premise
188	mean	N	I-Premise
189	differences	N	I-Premise
190	were	N	I-Premise
191	clinically	N	I-Premise
192	meaningful	N	I-Premise
193	for	N	I-Premise
194	most	N	I-Premise
195	domains	N	I-Premise
196	,	N	I-Premise
197	indicating	N	I-Premise
198	poorer	N	I-Premise
199	health	N	I-Premise
200	status	N	I-Premise
201	with	N	I-Premise
202	VMP	N	I-Premise
203	.	N	I-Premise

204	From	N	I-Premise
205	cycle	N	I-Premise
206	5	N	I-Premise
207	onwards	N	I-Premise
208	,	N	I-Premise
209	improvements	N	I-Premise
210	relative	N	I-Premise
211	to	N	I-Premise
212	baseline/MP	N	I-Premise
213	were	N	I-Premise
214	observed	N	I-Premise
215	for	N	I-Premise
216	all	N	I-Premise
217	domains	N	I-Premise
218	with	N	I-Premise
219	VMP	N	I-Premise
220	.	N	I-Premise

221	Mean	N	I-Premise
222	scores	N	I-Premise
223	were	N	I-Premise
224	generally	N	I-Premise
225	improved	N	I-Premise
226	by	N	I-Premise
227	the	N	I-Premise
228	end-of-treatment	N	I-Premise
229	assessment	N	I-Premise
230	vs.	N	I-Premise
231	baseline	N	I-Premise
232	in	N	I-Premise
233	both	N	I-Premise
234	arms	N	I-Premise
235	.	N	I-Premise

236	Among	N	I-Premise
237	responding	N	I-Premise
238	patients	N	I-Premise
239	,	N	I-Premise
240	mean	N	I-Premise
241	scores	N	I-Premise
242	generally	N	I-Premise
243	improved	N	I-Premise
244	from	N	I-Premise
245	time	N	I-Premise
246	of	N	I-Premise
247	response	N	I-Premise
248	to	N	I-Premise
249	end-of-treatment	N	I-Premise
250	assessment	N	I-Premise
251	,	N	I-Premise
252	substantially	N	I-Premise
253	driven	N	I-Premise
254	by	N	I-Premise
255	patients	N	I-Premise
256	achieving	N	I-Premise
257	complete	N	I-Premise
258	response	N	I-Premise
259	(	N	I-Premise
260	CR	N	I-Premise
261	)	N	I-Premise
262	.	N	I-Premise

263	Multivariate	N	I-Premise
264	analysis	N	I-Premise
265	showed	N	I-Premise
266	a	N	I-Premise
267	significant	N	I-Premise
268	impact	N	I-Premise
269	of	N	I-Premise
270	duration	N	I-Premise
271	of	N	I-Premise
272	response/CR	N	I-Premise
273	on	N	I-Premise
274	improving	N	I-Premise
275	global	N	I-Premise
276	health	N	I-Premise
277	status	N	I-Premise
278	,	N	I-Premise
279	pain	N	I-Premise
280	,	N	I-Premise
281	and	N	I-Premise
282	appetite	N	I-Premise
283	loss	N	I-Premise
284	scores	N	I-Premise
285	.	N	I-Premise

286	Analyses	N	I-Claim
287	by	N	I-Claim
288	bortezomib	N	I-Claim
289	dose	N	I-Claim
290	intensity	N	I-Claim
291	indicated	N	I-Claim
292	better	N	I-Claim
293	HRQoL	N	I-Claim
294	in	N	I-Claim
295	patients	N	I-Claim
296	receiving	N	I-Claim
297	lower	N	I-Claim
298	dose	N	I-Claim
299	intensity	N	I-Claim
300	.	N	I-Claim

301	These	N	I-Claim
302	findings	N	I-Claim
303	demonstrate	N	I-Claim
304	clinically	N	I-Claim
305	meaningful	N	I-Claim
306	,	N	I-Claim
307	transitory	N	I-Claim
308	HRQoL	N	I-Claim
309	decrements	N	I-Claim
310	with	N	I-Claim
311	VMP	N	I-Claim
312	and	N	I-Claim
313	relatively	N	I-Claim
314	lower	N	I-Claim
315	HRQoL	N	I-Claim
316	vs.	N	I-Claim
317	MP	N	I-Claim
318	during	N	I-Claim
319	early	N	I-Claim
320	treatment	N	I-Claim
321	cycles	N	I-Claim
322	,	N	I-Claim
323	associated	N	I-Claim
324	with	N	I-Claim
325	the	N	I-Claim
326	expected	N	I-Claim
327	additional	N	I-Claim
328	toxicities	N	I-Claim
329	.	N	I-Claim

330	However	N	I-Claim
331	,	N	I-Claim
332	HRQoL	N	I-Claim
333	is	N	I-Claim
334	not	N	I-Claim
335	compromised	N	I-Claim
336	in	N	I-Claim
337	the	N	I-Claim
338	long	N	I-Claim
339	term	N	I-Claim
340	,	N	I-Claim
341	recovering	N	I-Claim
342	by	N	I-Claim
343	the	N	I-Claim
344	end-of-treatment	N	I-Claim
345	visit	N	I-Claim
346	to	N	I-Claim
347	be	N	I-Claim
348	comparable	N	I-Claim
349	vs.	N	I-Claim
350	MP	N	I-Claim
351	.	N	I-Claim

1	Maintenance	N	O
2	therapy	N	O
3	,	N	O
4	commenced	N	O
5	immediately	N	O
6	after	N	O
7	the	N	O
8	completion	N	O
9	of	N	O
10	first-line	N	O
11	chemotherapy	N	O
12	,	N	O
13	is	N	O
14	a	N	O
15	promising	N	O
16	strategy	N	O
17	for	N	O
18	improving	N	O
19	treatment	N	O
20	outcomes	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	non-small-cell	N	O
25	lung	N	O
26	cancer	N	O
27	(	N	O
28	NSCLC	N	O
29	)	N	O
30	.	N	O

31	The	N	O
32	global	N	O
33	phase	N	O
34	III	N	O
35	SequentiAl	N	O
36	Tarceva	N	O
37	in	N	O
38	UnResectable	N	O
39	NSCLC	N	O
40	(	N	O
41	SATURN	N	O
42	)	N	O
43	study	N	O
44	evaluated	N	O
45	the	N	O
46	efficacy	N	O
47	and	N	O
48	safety	N	O
49	of	N	O
50	the	N	O
51	epidermal	N	O
52	growth	N	O
53	factor	N	O
54	receptor	N	O
55	(	N	O
56	EGFR	N	O
57	)	N	O
58	tyrosine-kinase	N	O
59	inhibitor	N	O
60	erlotinib	N	O
61	as	N	O
62	maintenance	N	O
63	treatment	N	O
64	in	N	O
65	NSCLC	N	O
66	patients	N	O
67	without	N	O
68	progression	N	O
69	after	N	O
70	first-line	N	O
71	chemotherapy	N	O
72	.	N	O

73	We	N	O
74	report	N	O
75	a	N	O
76	retrospective	N	O
77	subanalysis	N	O
78	of	N	O
79	Asian	N	O
80	patients	N	O
81	enrolled	N	O
82	in	N	O
83	SATURN	N	O
84	.	N	O

85	Patients	N	O
86	with	N	O
87	advanced	N	O
88	NSCLC	N	O
89	with	N	O
90	no	N	O
91	evidence	N	O
92	of	N	O
93	progression	N	O
94	after	N	O
95	four	N	O
96	cycles	N	O
97	of	N	O
98	chemotherapy	N	O
99	were	N	O
100	randomized	N	O
101	to	N	O
102	receive	N	O
103	erlotinib	N	O
104	150	N	O
105	mg/day	N	O
106	or	N	O
107	placebo	N	O
108	,	N	O
109	until	N	O
110	progressive	N	O
111	disease	N	O
112	or	N	O
113	limiting	N	O
114	toxicity	N	O
115	.	N	O

116	The	N	O
117	co-primary	N	O
118	endpoints	N	O
119	of	N	O
120	SATURN	N	O
121	were	N	O
122	progression-free	N	O
123	survival	N	O
124	(	N	O
125	PFS	N	O
126	)	N	O
127	in	N	O
128	all	N	O
129	patients	N	O
130	and	N	O
131	in	N	O
132	those	N	O
133	with	N	O
134	positive	N	O
135	EGFR	N	O
136	immunohistochemistry	N	O
137	(	N	O
138	IHC	N	O
139	)	N	O
140	status	N	O
141	.	N	O

142	Secondary	N	O
143	endpoints	N	O
144	included	N	O
145	overall	N	O
146	survival	N	O
147	(	N	O
148	OS	N	O
149	)	N	O
150	,	N	O
151	disease	N	O
152	control	N	O
153	rate	N	O
154	,	N	O
155	safety	N	O
156	,	N	O
157	quality	N	O
158	of	N	O
159	life	N	O
160	(	N	O
161	QoL	N	O
162	)	N	O
163	and	N	O
164	biomarker	N	O
165	analyses	N	O
166	.	N	O

167	In	N	O
168	total	N	O
169	,	N	O
170	126	N	O
171	patients	N	O
172	from	N	O
173	East	N	O
174	and	N	O
175	South-East	N	O
176	Asian	N	O
177	centers	N	O
178	were	N	O
179	randomized	N	O
180	(	N	O
181	14	N	O
182	%	N	O
183	of	N	O
184	the	N	O
185	intent-to-treat	N	O
186	population	N	O
187	)	N	O
188	:	N	O
189	88	N	O
190	from	N	O
191	Korea	N	O
192	,	N	O
193	28	N	O
194	from	N	O
195	China	N	O
196	and	N	O
197	10	N	O
198	from	N	O
199	Malaysia	N	O
200	;	N	O
201	one	N	O
202	patient	N	O
203	was	N	O
204	excluded	N	O
205	from	N	O
206	this	N	O
207	analysis	N	O
208	due	N	O
209	to	N	O
210	Indian	N	O
211	ethnicity	N	O
212	.	N	O

213	PFS	N	I-Premise
214	was	N	I-Premise
215	significantly	N	I-Premise
216	prolonged	N	I-Premise
217	in	N	I-Premise
218	the	N	I-Premise
219	erlotinib	N	I-Premise
220	treatment	N	I-Premise
221	arm	N	I-Premise
222	,	N	I-Premise
223	both	N	I-Premise
224	overall	N	I-Premise
225	(	N	I-Premise
226	hazard	N	I-Premise
227	ratio	N	I-Premise
228	[	N	I-Premise
229	HR	N	I-Premise
230	]	N	I-Premise
231	:	N	I-Premise
232	0.57	N	I-Premise
233	;	N	I-Premise
234	p=0.0067	N	I-Premise
235	)	N	I-Premise
236	and	N	I-Premise
237	in	N	I-Premise
238	patients	N	I-Premise
239	with	N	I-Premise
240	EGFR	N	I-Premise
241	IHC-positive	N	I-Premise
242	disease	N	I-Premise
243	(	N	I-Premise
244	HR=0.50	N	I-Premise
245	;	N	I-Premise
246	p=0.0057	N	I-Premise
247	)	N	I-Premise
248	.	N	I-Premise

249	There	N	I-Premise
250	was	N	I-Premise
251	a	N	I-Premise
252	trend	N	I-Premise
253	towards	N	I-Premise
254	an	N	I-Premise
255	increase	N	I-Premise
256	in	N	I-Premise
257	OS	N	I-Premise
258	,	N	I-Premise
259	which	N	I-Premise
260	reached	N	I-Premise
261	statistical	N	I-Premise
262	significance	N	I-Premise
263	in	N	I-Premise
264	the	N	I-Premise
265	EGFR	N	I-Premise
266	IHC-positive	N	I-Premise
267	subgroup	N	I-Premise
268	(	N	I-Premise
269	p=0.0233	N	I-Premise
270	)	N	I-Premise
271	.	N	I-Premise

272	The	N	I-Premise
273	overall	N	I-Premise
274	response	N	I-Premise
275	rate	N	I-Premise
276	was	N	I-Premise
277	significantly	N	I-Premise
278	higher	N	I-Premise
279	with	N	I-Premise
280	erlotinib	N	I-Premise
281	compared	N	I-Premise
282	with	N	I-Premise
283	placebo	N	I-Premise
284	(	N	I-Premise
285	24	N	I-Premise
286	%	N	I-Premise
287	versus	N	I-Premise
288	5	N	I-Premise
289	%	N	I-Premise
290	;	N	I-Premise
291	p=0.0025	N	I-Premise
292	)	N	I-Premise
293	.	N	I-Premise

294	Erlotinib	N	I-Claim
295	was	N	I-Claim
296	generally	N	I-Claim
297	well	N	I-Claim
298	tolerated	N	I-Claim
299	and	N	I-Claim
300	had	N	I-Claim
301	no	N	I-Claim
302	negative	N	I-Claim
303	impact	N	I-Claim
304	on	N	I-Claim
305	QoL	N	I-Claim
306	in	N	I-Claim
307	this	N	I-Claim
308	subpopulation	N	I-Claim
309	.	N	I-Claim

310	The	N	I-Premise
311	most	N	I-Premise
312	common	N	I-Premise
313	treatment-related	N	I-Premise
314	adverse	N	I-Premise
315	events	N	I-Premise
316	were	N	I-Premise
317	rash	N	I-Premise
318	,	N	I-Premise
319	diarrhea	N	I-Premise
320	and	N	I-Premise
321	pruritus	N	I-Premise
322	.	N	I-Premise

323	Erlotinib	N	I-Claim
324	was	N	I-Claim
325	effective	N	I-Claim
326	and	N	I-Claim
327	well	N	I-Claim
328	tolerated	N	I-Claim
329	in	N	I-Claim
330	Asian	N	I-Claim
331	patients	N	I-Claim
332	,	N	I-Claim
333	producing	N	I-Claim
334	benefits	N	I-Claim
335	consistent	N	I-Claim
336	with	N	I-Claim
337	those	N	I-Claim
338	observed	N	I-Claim
339	in	N	I-Claim
340	the	N	I-Claim
341	overall	N	I-Claim
342	SATURN	N	I-Claim
343	population	N	I-Claim
344	.	N	I-Claim

345	Maintenance	N	I-MajorClaim
346	treatment	N	I-MajorClaim
347	with	N	I-MajorClaim
348	erlotinib	N	I-MajorClaim
349	appears	N	I-MajorClaim
350	to	N	I-MajorClaim
351	be	N	I-MajorClaim
352	a	N	I-MajorClaim
353	useful	N	I-MajorClaim
354	option	N	I-MajorClaim
355	for	N	I-MajorClaim
356	the	N	I-MajorClaim
357	management	N	I-MajorClaim
358	of	N	I-MajorClaim
359	Asian	N	I-MajorClaim
360	patients	N	I-MajorClaim
361	with	N	I-MajorClaim
362	advanced	N	I-MajorClaim
363	NSCLC	N	I-MajorClaim
364	without	N	I-MajorClaim
365	progression	N	I-MajorClaim
366	after	N	I-MajorClaim
367	first-line	N	I-MajorClaim
368	chemotherapy	N	I-MajorClaim
369	.	N	I-MajorClaim

1	Study	N	O
2	Type	N	O
3	--	N	O
4	Therapy	N	O
5	(	N	O
6	RCT	N	O
7	)	N	O
8	Level	N	O
9	of	N	O
10	Evidence	N	O
11	1b	N	O
12	.	N	O

13	What	N	O
14	's	N	O
15	known	N	O
16	on	N	O
17	the	N	O
18	subject	N	O
19	?	N	O

20	and	N	O
21	What	N	O
22	does	N	O
23	the	N	O
24	study	N	O
25	add	N	O
26	?	N	O

27	Androgen	N	O
28	deprivation	N	O
29	therapy	N	O
30	(	N	O
31	ADT	N	O
32	)	N	O
33	is	N	O
34	commonly	N	O
35	used	N	O
36	as	N	O
37	a	N	O
38	primary	N	O
39	treatment	N	O
40	for	N	O
41	patients	N	O
42	with	N	O
43	prostate	N	O
44	cancer	N	O
45	(	N	O
46	PCa	N	O
47	)	N	O
48	who	N	O
49	are	N	O
50	not	N	O
51	eligible	N	O
52	for	N	O
53	radical	N	O
54	treatment	N	O
55	options	N	O
56	.	N	O

57	ADT	N	O
58	is	N	O
59	also	N	O
60	used	N	O
61	in	N	O
62	patients	N	O
63	with	N	O
64	PCa	N	O
65	as	N	O
66	neo-adjuvant	N	O
67	hormone	N	O
68	therapy	N	O
69	to	N	O
70	reduce	N	O
71	prostate	N	O
72	volume	N	O
73	and	N	O
74	down-stage	N	O
75	the	N	O
76	disease	N	O
77	before	N	O
78	radiotherapy	N	O
79	with	N	O
80	curative	N	O
81	intent	N	O
82	.	N	O

83	The	N	O
84	present	N	O
85	study	N	O
86	showed	N	O
87	that	N	O
88	ADT	N	O
89	with	N	O
90	the	N	O
91	gonadotropin	N	O
92	hormone-releasing	N	O
93	hormone	N	O
94	(	N	O
95	GhRH	N	O
96	)	N	O
97	antagonist	N	O
98	degarelix	N	O
99	is	N	O
100	non-inferior	N	O
101	to	N	O
102	combined	N	O
103	treatment	N	O
104	with	N	O
105	the	N	O
106	LHRH	N	O
107	agonist	N	O
108	goserelin	N	O
109	and	N	O
110	bicalutamide	N	O
111	in	N	O
112	terms	N	O
113	of	N	O
114	reducing	N	O
115	prostate	N	O
116	volume	N	O
117	during	N	O
118	the	N	O
119	treatment	N	O
120	period	N	O
121	of	N	O
122	3	N	O
123	months	N	O
124	.	N	O

125	Degarelix	N	O
126	treatment	N	O
127	evokes	N	O
128	,	N	O
129	however	N	O
130	,	N	O
131	significantly	N	O
132	better	N	O
133	relief	N	O
134	of	N	O
135	lower	N	O
136	urinary	N	O
137	tract	N	O
138	symptoms	N	O
139	in	N	O
140	patients	N	O
141	having	N	O
142	moderate	N	O
143	and	N	O
144	severe	N	O
145	voiding	N	O
146	problems	N	O
147	.	N	O

148	To	N	O
149	assess	N	O
150	the	N	O
151	efficacy	N	O
152	of	N	O
153	monthly	N	O
154	degarelix	N	O
155	treatment	N	O
156	for	N	O
157	reduction	N	O
158	of	N	O
159	total	N	O
160	prostate	N	O
161	volume	N	O
162	(	N	O
163	TPV	N	O
164	)	N	O
165	,	N	O
166	relief	N	O
167	of	N	O
168	lower	N	O
169	urinary	N	O
170	tract	N	O
171	symptoms	N	O
172	(	N	O
173	LUTS	N	O
174	)	N	O
175	and	N	O
176	improvement	N	O
177	of	N	O
178	quality	N	O
179	of	N	O
180	life	N	O
181	(	N	O
182	QoL	N	O
183	)	N	O
184	in	N	O
185	patients	N	O
186	with	N	O
187	prostate	N	O
188	cancer	N	O
189	(	N	O
190	PCa	N	O
191	)	N	O
192	using	N	O
193	monthly	N	O
194	goserelin	N	O
195	as	N	O
196	active	N	O
197	control	N	O
198	.	N	O

199	This	N	O
200	was	N	O
201	a	N	O
202	randomized	N	O
203	,	N	O
204	parallel-arm	N	O
205	,	N	O
206	active-controlled	N	O
207	,	N	O
208	open-label	N	O
209	,	N	O
210	multicentre	N	O
211	trial	N	O
212	on	N	O
213	182	N	O
214	patients	N	O
215	treated	N	O
216	with	N	O
217	either	N	O
218	monthly	N	O
219	degarelix	N	O
220	(	N	O
221	240/80	N	O
222	mg	N	O
223	)	N	O
224	or	N	O
225	goserelin	N	O
226	(	N	O
227	3.6	N	O
228	mg	N	O
229	)	N	O
230	for	N	O
231	12	N	O
232	weeks	N	O
233	.	N	O

234	For	N	O
235	flare	N	O
236	protection	N	O
237	,	N	O
238	goserelin-treated	N	O
239	patients	N	O
240	also	N	O
241	received	N	O
242	daily	N	O
243	bicalutamide	N	O
244	(	N	O
245	50	N	O
246	mg	N	O
247	)	N	O
248	during	N	O
249	the	N	O
250	initial	N	O
251	28	N	O
252	days	N	O
253	.	N	O

254	Key	N	O
255	trial	N	O
256	variables	N	O
257	monitored	N	O
258	monthly	N	O
259	were	N	O
260	TPV	N	O
261	(	N	O
262	primary	N	O
263	endpoint	N	O
264	)	N	O
265	,	N	O
266	serum	N	O
267	testosterone	N	O
268	,	N	O
269	prostate-specific	N	O
270	antigen	N	O
271	(	N	O
272	PSA	N	O
273	)	N	O
274	,	N	O
275	the	N	O
276	International	N	O
277	Prostate	N	O
278	Symptom	N	O
279	Score	N	O
280	(	N	O
281	IPSS	N	O
282	)	N	O
283	and	N	O
284	the	N	O
285	Benign	N	O
286	Prostate	N	O
287	Hyperplasia	N	O
288	Impact	N	O
289	Index	N	O
290	.	N	O

291	In	N	O
292	all	N	O
293	,	N	O
294	175	N	O
295	patients	N	O
296	completed	N	O
297	the	N	O
298	trial	N	O
299	(	N	O
300	96.1	N	O
301	%	N	O
302	)	N	O
303	.	N	O

304	At	N	I-Premise
305	week	N	I-Premise
306	12	N	I-Premise
307	,	N	I-Premise
308	changes	N	I-Premise
309	in	N	I-Premise
310	TPV	N	I-Premise
311	for	N	I-Premise
312	degarelix	N	I-Premise
313	and	N	I-Premise
314	goserelin	N	I-Premise
315	were	N	I-Premise
316	similar	N	I-Premise
317	(	N	I-Premise
318	-37.2	N	I-Premise
319	%	N	I-Premise
320	vs	N	I-Premise
321	-39.0	N	I-Premise
322	%	N	I-Premise
323	)	N	I-Premise
324	and	N	I-Premise
325	met	N	I-Premise
326	the	N	I-Premise
327	predefined	N	I-Premise
328	non-inferiority	N	I-Premise
329	criterion	N	I-Premise
330	.	N	I-Premise

331	Decreases	N	I-Premise
332	in	N	I-Premise
333	IPSS	N	I-Premise
334	were	N	I-Premise
335	greater	N	I-Premise
336	in	N	I-Premise
337	degarelix	N	I-Premise
338	than	N	I-Premise
339	in	N	I-Premise
340	goserelin-treated	N	I-Premise
341	patients	N	I-Premise
342	,	N	I-Premise
343	differences	N	I-Premise
344	being	N	I-Premise
345	statistically	N	I-Premise
346	significant	N	I-Premise
347	in	N	I-Premise
348	patients	N	I-Premise
349	with	N	I-Premise
350	baseline	N	I-Premise
351	IPSS	N	I-Premise
352	>	N	I-Premise
353	13	N	I-Premise
354	(	N	I-Premise
355	-6.7	N	I-Premise
356		N	I-Premise
357	1.8	N	I-Premise
358	vs	N	I-Premise
359	-4.0	N	I-Premise
360		N	I-Premise
361	1.0	N	I-Premise
362	;	N	I-Premise
363	P	N	I-Premise
364	=	N	I-Premise
365	0.02	N	I-Premise
366	)	N	I-Premise
367	.	N	I-Premise

368	The	N	I-Premise
369	number	N	I-Premise
370	of	N	I-Premise
371	patients	N	I-Premise
372	with	N	I-Premise
373	an	N	I-Premise
374	IPSS	N	I-Premise
375	change	N	I-Premise
376	of	N	I-Premise
377		N	I-Premise
378	3	N	I-Premise
379	over	N	I-Premise
380	baseline	N	I-Premise
381	was	N	I-Premise
382	also	N	I-Premise
383	significantly	N	I-Premise
384	higher	N	I-Premise
385	in	N	I-Premise
386	patients	N	I-Premise
387	treated	N	I-Premise
388	with	N	I-Premise
389	degarelix	N	I-Premise
390	(	N	I-Premise
391	61.0	N	I-Premise
392	vs	N	I-Premise
393	44.3	N	I-Premise
394	%	N	I-Premise
395	,	N	I-Premise
396	P	N	I-Premise
397	=	N	I-Premise
398	0.02	N	I-Premise
399	)	N	I-Premise
400	.	N	I-Premise

401	Both	N	I-Claim
402	treatments	N	I-Claim
403	were	N	I-Claim
404	safe	N	I-Claim
405	and	N	I-Claim
406	well	N	I-Claim
407	tolerated	N	I-Claim
408	.	N	I-Claim

409	Medical	N	I-Claim
410	castration	N	I-Claim
411	reduces	N	I-Claim
412	TPV	N	I-Claim
413	and	N	I-Claim
414	could	N	I-Claim
415	also	N	I-Claim
416	improve	N	I-Claim
417	LUTS	N	I-Claim
418	in	N	I-Claim
419	patients	N	I-Claim
420	with	N	I-Claim
421	PCa	N	I-Claim
422	.	N	I-Claim

423	While	N	O
424	the	N	I-Claim
425	short-term	N	I-Claim
426	efficacy	N	I-Claim
427	of	N	I-Claim
428	degarelix	N	I-Claim
429	and	N	I-Claim
430	goserelin	N	I-Claim
431	+	N	I-Claim
432	bicalutamide	N	I-Claim
433	was	N	I-Claim
434	the	N	I-Claim
435	same	N	I-Claim
436	in	N	I-Claim
437	terms	N	I-Claim
438	of	N	I-Claim
439	TPV	N	I-Claim
440	reduction	N	I-Claim
441	,	N	I-Claim
442	degarelix	N	I-Claim
443	showed	N	I-Claim
444	superiority	N	I-Claim
445	in	N	I-Claim
446	LUTS	N	I-Claim
447	relief	N	I-Claim
448	in	N	I-Claim
449	symptomatic	N	I-Claim
450	patients	N	I-Claim
451	,	N	I-Claim
452	which	N	I-Claim
453	could	N	I-Claim
454	highlight	N	I-Claim
455	the	N	I-Claim
456	different	N	I-Claim
457	actions	N	I-Claim
458	of	N	I-Claim
459	these	N	I-Claim
460	drugs	N	I-Claim
461	on	N	I-Claim
462	extrapituitary	N	I-Claim
463	gonadotrophin-releasing	N	I-Claim
464	hormone	N	I-Claim
465	(	N	I-Claim
466	GnRH	N	I-Claim
467	)	N	I-Claim
468	receptors	N	I-Claim
469	in	N	I-Claim
470	the	N	I-Claim
471	bladder	N	I-Claim
472	and/or	N	I-Claim
473	the	N	I-Claim
474	prostate	N	I-Claim
475	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	prophylactic	N	O
7	swallowing	N	O
8	exercises	N	O
9	on	N	O
10	swallowing	N	O
11	function	N	O
12	in	N	O
13	patients	N	O
14	undergoing	N	O
15	chemoradiation	N	O
16	therapy	N	O
17	(	N	O
18	CRT	N	O
19	)	N	O
20	for	N	O
21	head	N	O
22	and	N	O
23	neck	N	O
24	cancer	N	O
25	.	N	O

26	Randomized	N	O
27	controlled	N	O
28	trial	N	O
29	.	N	O

30	Tertiary	N	O
31	care	N	O
32	,	N	O
33	academic	N	O
34	medical	N	O
35	center	N	O
36	.	N	O

37	Twenty-six	N	O
38	patients	N	O
39	with	N	O
40	head	N	O
41	and	N	O
42	neck	N	O
43	cancer	N	O
44	receiving	N	O
45	CRT	N	O
46	.	N	O

47	Patients	N	O
48	performed	N	O
49	5	N	O
50	targeted	N	O
51	swallowing	N	O
52	exercises	N	O
53	throughout	N	O
54	their	N	O
55	CRT	N	O
56	and	N	O
57	participated	N	O
58	in	N	O
59	weekly	N	O
60	swallowing	N	O
61	therapy	N	O
62	sessions	N	O
63	to	N	O
64	promote	N	O
65	adherence	N	O
66	and	N	O
67	accurate	N	O
68	technique	N	O
69	.	N	O

70	Controls	N	O
71	had	N	O
72	no	N	O
73	prophylactic	N	O
74	exercises	N	O
75	and	N	O
76	were	N	O
77	referred	N	O
78	for	N	O
79	swallowing	N	O
80	treatment	N	O
81	after	N	O
82	completion	N	O
83	of	N	O
84	CRT	N	O
85	if	N	O
86	indicated	N	O
87	.	N	O

88	Swallowing	N	O
89	function	N	O
90	was	N	O
91	assessed	N	O
92	with	N	O
93	the	N	O
94	Functional	N	O
95	Oral	N	O
96	Intake	N	O
97	Scale	N	O
98	(	N	O
99	FOIS	N	O
100	)	N	O
101	and	N	O
102	the	N	O
103	Performance	N	O
104	Status	N	O
105	Scale	N	O
106	for	N	O
107	Head	N	O
108	and	N	O
109	Neck	N	O
110	Cancer	N	O
111	Patients	N	O
112	(	N	O
113	PSS-H	N	O
114	&	N	O
115	N	N	O
116	)	N	O
117	at	N	O
118	baseline	N	O
119	,	N	O
120	immediately	N	O
121	after	N	O
122	CRT	N	O
123	,	N	O
124	and	N	O
125	at	N	O
126	3	N	O
127	,	N	O
128	6	N	O
129	,	N	O
130	9	N	O
131	,	N	O
132	and	N	O
133	12	N	O
134	months	N	O
135	after	N	O
136	CRT	N	O
137	.	N	O

138	There	N	I-Premise
139	were	N	I-Premise
140	no	N	I-Premise
141	statistically	N	I-Premise
142	significant	N	I-Premise
143	differences	N	I-Premise
144	in	N	I-Premise
145	FOIS	N	I-Premise
146	scores	N	I-Premise
147	between	N	I-Premise
148	intervention	N	I-Premise
149	and	N	I-Premise
150	control	N	I-Premise
151	patients	N	I-Premise
152	immediately	N	I-Premise
153	after	N	I-Premise
154	CRT	N	I-Premise
155	(	N	I-Premise
156	immediately	N	I-Premise
157	after	N	I-Premise
158	CRT	N	I-Premise
159	:	N	I-Premise
160	intervention	N	I-Premise
161	group	N	I-Premise
162	median	N	I-Premise
163	score	N	I-Premise
164	,	N	I-Premise
165	3	N	I-Premise
166	[	N	I-Premise
167	range	N	I-Premise
168	,	N	I-Premise
169	1-7	N	I-Premise
170	]	N	I-Premise
171	,	N	I-Premise
172	vs	N	I-Premise
173	median	N	I-Premise
174	control	N	I-Premise
175	score	N	I-Premise
176	,	N	I-Premise
177	4	N	I-Premise
178	[	N	I-Premise
179	range	N	I-Premise
180	,	N	I-Premise
181	1-6	N	I-Premise
182	]	N	I-Premise
183	(	N	I-Premise
184	P	N	I-Premise
185	=	N	I-Premise
186	.88	N	I-Premise
187	)	N	I-Premise
188	.	N	I-Premise

189	However	N	O
190	,	N	O
191	intervention	N	I-Premise
192	patients	N	I-Premise
193	had	N	I-Premise
194	significantly	N	I-Premise
195	better	N	I-Premise
196	scores	N	I-Premise
197	at	N	I-Premise
198	months	N	I-Premise
199	3	N	I-Premise
200	and	N	I-Premise
201	6	N	I-Premise
202	(	N	I-Premise
203	median	N	I-Premise
204	3-month	N	I-Premise
205	intervention	N	I-Premise
206	score	N	I-Premise
207	,	N	I-Premise
208	7	N	I-Premise
209	[	N	I-Premise
210	range	N	I-Premise
211	,	N	I-Premise
212	5-7	N	I-Premise
213	]	N	I-Premise
214	,	N	I-Premise
215	vs	N	I-Premise
216	median	N	I-Premise
217	control	N	I-Premise
218	score	N	I-Premise
219	,	N	I-Premise
220	5	N	I-Premise
221	[	N	I-Premise
222	range	N	I-Premise
223	,	N	I-Premise
224	3-7	N	I-Premise
225	]	N	I-Premise
226	[	N	I-Premise
227	P	N	I-Premise
228	=	N	I-Premise
229	.03	N	I-Premise
230	]	N	I-Premise
231	;	N	I-Premise
232	median	N	I-Premise
233	6-month	N	I-Premise
234	intervention	N	I-Premise
235	score	N	I-Premise
236	,	N	I-Premise
237	7	N	I-Premise
238	[	N	I-Premise
239	range	N	I-Premise
240	,	N	I-Premise
241	6-7	N	I-Premise
242	]	N	I-Premise
243	,	N	I-Premise
244	vs	N	I-Premise
245	median	N	I-Premise
246	control	N	I-Premise
247	score	N	I-Premise
248	,	N	I-Premise
249	6	N	I-Premise
250	[	N	I-Premise
251	range	N	I-Premise
252	,	N	I-Premise
253	3-7	N	I-Premise
254	]	N	I-Premise
255	[	N	I-Premise
256	P	N	I-Premise
257	=	N	I-Premise
258	.009	N	I-Premise
259	]	N	I-Premise
260	)	N	I-Premise
261	.	N	I-Premise

262	There	N	I-Premise
263	was	N	I-Premise
264	no	N	I-Premise
265	significant	N	I-Premise
266	difference	N	I-Premise
267	in	N	I-Premise
268	scores	N	I-Premise
269	at	N	I-Premise
270	months	N	I-Premise
271	9	N	I-Premise
272	and	N	I-Premise
273	12	N	I-Premise
274	(	N	I-Premise
275	P	N	I-Premise
276	=	N	I-Premise
277	.24	N	I-Premise
278	and	N	I-Premise
279	P	N	I-Premise
280	=	N	I-Premise
281	.93	N	I-Premise
282	,	N	I-Premise
283	respectively	N	I-Premise
284	)	N	I-Premise
285	.	N	I-Premise

286	The	N	I-Premise
287	same	N	I-Premise
288	pattern	N	I-Premise
289	between	N	I-Premise
290	intervention	N	I-Premise
291	and	N	I-Premise
292	control	N	I-Premise
293	patients	N	I-Premise
294	was	N	I-Premise
295	observed	N	I-Premise
296	for	N	I-Premise
297	scores	N	I-Premise
298	on	N	I-Premise
299	the	N	I-Premise
300	PSS-H	N	I-Premise
301	&	N	I-Premise
302	N	N	I-Premise
303	.	N	I-Premise

304	Patients	N	I-Claim
305	who	N	I-Claim
306	performed	N	I-Claim
307	prophylactic	N	I-Claim
308	swallowing	N	I-Claim
309	exercises	N	I-Claim
310	had	N	I-Claim
311	improved	N	I-Claim
312	swallowing	N	I-Claim
313	function	N	I-Claim
314	at	N	I-Claim
315	3	N	I-Claim
316	and	N	I-Claim
317	6	N	I-Claim
318	months	N	I-Claim
319	after	N	I-Claim
320	CRT	N	I-Claim
321	but	N	I-Claim
322	not	N	I-Claim
323	immediately	N	I-Claim
324	after	N	I-Claim
325	CRT	N	I-Claim
326	or	N	I-Claim
327	at	N	I-Claim
328	9	N	I-Claim
329	and	N	I-Claim
330	12	N	I-Claim
331	months	N	I-Claim
332	after	N	I-Claim
333	CRT	N	I-Claim
334	.	N	I-Claim

335	The	N	I-Claim
336	small	N	I-Claim
337	sample	N	I-Claim
338	size	N	I-Claim
339	may	N	I-Claim
340	have	N	I-Claim
341	limited	N	I-Claim
342	our	N	I-Claim
343	ability	N	I-Claim
344	to	N	I-Claim
345	detect	N	I-Claim
346	significant	N	I-Claim
347	differences	N	I-Claim
348	beyond	N	I-Claim
349	6	N	I-Claim
350	months	N	I-Claim
351	of	N	I-Claim
352	observation	N	I-Claim
353	as	N	I-Claim
354	well	N	I-Claim
355	as	N	I-Claim
356	additional	N	I-Claim
357	significant	N	I-Claim
358	differences	N	I-Claim
359	in	N	I-Claim
360	our	N	I-Claim
361	study	N	I-Claim
362	.	N	I-Claim

1	Patients	N	O
2	with	N	O
3	lymphoma	N	O
4	experience	N	O
5	sleep	N	O
6	problems	N	O
7	that	N	O
8	may	N	O
9	be	N	O
10	managed	N	O
11	with	N	O
12	aerobic	N	O
13	exercise	N	O
14	but	N	O
15	no	N	O
16	previous	N	O
17	study	N	O
18	has	N	O
19	examined	N	O
20	this	N	O
21	issue	N	O
22	.	N	O

23	We	N	O
24	randomized	N	O
25	122	N	O
26	patients	N	O
27	with	N	O
28	lymphoma	N	O
29	to	N	O
30	usual	N	O
31	care	N	O
32	(	N	O
33	n	N	O
34	=	N	O
35	62	N	O
36	)	N	O
37	or	N	O
38	12	N	O
39	weeks	N	O
40	of	N	O
41	supervised	N	O
42	aerobic	N	O
43	exercise	N	O
44	training	N	O
45	(	N	O
46	AET	N	O
47	;	N	O
48	n	N	O
49	=	N	O
50	60	N	O
51	)	N	O
52	.	N	O

53	Our	N	O
54	primary	N	O
55	sleep	N	O
56	endpoint	N	O
57	was	N	O
58	global	N	O
59	sleep	N	O
60	quality	N	O
61	assessed	N	O
62	by	N	O
63	the	N	O
64	Pittsburgh	N	O
65	Sleep	N	O
66	Quality	N	O
67	Index	N	O
68	(	N	O
69	PSQI	N	O
70	)	N	O
71	.	N	O

72	Secondary	N	O
73	endpoints	N	O
74	were	N	O
75	the	N	O
76	PSQI	N	O
77	component	N	O
78	scores	N	O
79	.	N	O

80	Planned	N	O
81	subgroup	N	O
82	analyses	N	O
83	were	N	O
84	also	N	O
85	conducted	N	O
86	.	N	O

87	Intention-to-treat	N	I-Premise
88	analyses	N	I-Premise
89	indicated	N	I-Premise
90	that	N	I-Premise
91	AET	N	I-Premise
92	resulted	N	I-Premise
93	in	N	I-Premise
94	a	N	I-Premise
95	nonsignificant	N	I-Premise
96	(	N	I-Premise
97	P	N	I-Premise
98	=	N	I-Premise
99	0.16	N	I-Premise
100	)	N	I-Premise
101	improvement	N	I-Premise
102	in	N	I-Premise
103	global	N	I-Premise
104	sleep	N	I-Premise
105	quality	N	I-Premise
106	compared	N	I-Premise
107	with	N	I-Premise
108	usual	N	I-Premise
109	care	N	I-Premise
110	[	N	I-Premise
111	mean	N	I-Premise
112	group	N	I-Premise
113	difference	N	I-Premise
114	=	N	I-Premise
115	-0.64	N	I-Premise
116	;	N	I-Premise
117	95	N	I-Premise
118	%	N	I-Premise
119	confidence	N	I-Premise
120	interval	N	I-Premise
121	(	N	I-Premise
122	CI	N	I-Premise
123	)	N	I-Premise
124	,	N	I-Premise
125	-1.56	N	I-Premise
126	to	N	I-Premise
127	+0.27	N	I-Premise
128	]	N	I-Premise
129	.	N	I-Premise

130	In	N	I-Premise
131	planned	N	I-Premise
132	subgroup	N	I-Premise
133	analyses	N	I-Premise
134	,	N	I-Premise
135	statistically	N	I-Premise
136	significant	N	I-Premise
137	or	N	I-Premise
138	borderline	N	I-Premise
139	significant	N	I-Premise
140	interactions	N	I-Premise
141	were	N	I-Premise
142	identified	N	I-Premise
143	for	N	I-Premise
144	type	N	I-Premise
145	of	N	I-Premise
146	lymphoma	N	I-Premise
147	(	N	I-Premise
148	P	N	I-Premise
149	(	N	I-Premise
150	interaction	N	I-Premise
151	)	N	I-Premise
152	=	N	I-Premise
153	0.006	N	I-Premise
154	)	N	I-Premise
155	,	N	I-Premise
156	current	N	I-Premise
157	treatment	N	I-Premise
158	status	N	I-Premise
159	(	N	I-Premise
160	P	N	I-Premise
161	(	N	I-Premise
162	interaction	N	I-Premise
163	)	N	I-Premise
164	=	N	I-Premise
165	0.036	N	I-Premise
166	)	N	I-Premise
167	,	N	I-Premise
168	time	N	I-Premise
169	since	N	I-Premise
170	diagnosis	N	I-Premise
171	(	N	I-Premise
172	P	N	I-Premise
173	(	N	I-Premise
174	interaction	N	I-Premise
175	)	N	I-Premise
176	=	N	I-Premise
177	0.010	N	I-Premise
178	)	N	I-Premise
179	,	N	I-Premise
180	body	N	I-Premise
181	mass	N	I-Premise
182	index	N	I-Premise
183	(	N	I-Premise
184	P	N	I-Premise
185	(	N	I-Premise
186	interaction	N	I-Premise
187	)	N	I-Premise
188	=	N	I-Premise
189	0.075	N	I-Premise
190	)	N	I-Premise
191	,	N	I-Premise
192	and	N	I-Premise
193	baseline	N	I-Premise
194	sleep	N	I-Premise
195	quality	N	I-Premise
196	(	N	I-Premise
197	P	N	I-Premise
198	(	N	I-Premise
199	interaction	N	I-Premise
200	)	N	I-Premise
201	=	N	I-Premise
202	0.041	N	I-Premise
203	)	N	I-Premise
204	.	N	I-Premise

205	Specifically	N	O
206	,	N	O
207	AET	N	I-Premise
208	improved	N	I-Premise
209	global	N	I-Premise
210	sleep	N	I-Premise
211	quality	N	I-Premise
212	in	N	I-Premise
213	patients	N	I-Premise
214	with	N	I-Premise
215	lymphoma	N	I-Premise
216	who	N	I-Premise
217	had	N	I-Premise
218	indolent	N	I-Premise
219	non-Hodgkin	N	I-Premise
220	lymphoma	N	I-Premise
221	(	N	I-Premise
222	P	N	I-Premise
223	=	N	I-Premise
224	0.001	N	I-Premise
225	)	N	I-Premise
226	,	N	I-Premise
227	were	N	I-Premise
228	receiving	N	I-Premise
229	chemotherapy	N	I-Premise
230	(	N	I-Premise
231	P	N	I-Premise
232	=	N	I-Premise
233	0.013	N	I-Premise
234	)	N	I-Premise
235	,	N	I-Premise
236	were	N	I-Premise
237	<	N	I-Premise
238	2	N	I-Premise
239	years	N	I-Premise
240	post-diagnosis	N	I-Premise
241	(	N	I-Premise
242	P	N	I-Premise
243	=	N	I-Premise
244	0.005	N	I-Premise
245	)	N	I-Premise
246	,	N	I-Premise
247	were	N	I-Premise
248	obese	N	I-Premise
249	(	N	I-Premise
250	P	N	I-Premise
251	=	N	I-Premise
252	0.025	N	I-Premise
253	)	N	I-Premise
254	,	N	I-Premise
255	and	N	I-Premise
256	were	N	I-Premise
257	poor	N	I-Premise
258	sleepers	N	I-Premise
259	at	N	I-Premise
260	baseline	N	I-Premise
261	(	N	I-Premise
262	P	N	I-Premise
263	=	N	I-Premise
264	0.007	N	I-Premise
265	)	N	I-Premise
266	.	N	I-Premise

267	AET	N	I-Claim
268	did	N	I-Claim
269	not	N	I-Claim
270	significantly	N	I-Claim
271	improve	N	I-Claim
272	sleep	N	I-Claim
273	quality	N	I-Claim
274	in	N	I-Claim
275	this	N	I-Claim
276	heterogeneous	N	I-Claim
277	sample	N	I-Claim
278	of	N	I-Claim
279	patients	N	I-Claim
280	with	N	I-Claim
281	lymphoma	N	I-Claim
282	;	N	I-Claim
283	however	N	I-Claim
284	,	N	I-Claim
285	clinically	N	I-Claim
286	identifiable	N	I-Claim
287	subgroups	N	I-Claim
288	appeared	N	I-Claim
289	to	N	I-Claim
290	benefit	N	I-Claim
291	.	N	I-Claim

292	Future	N	O
293	exercise	N	O
294	trials	N	O
295	targeting	N	O
296	these	N	O
297	responsive	N	O
298	subgroups	N	O
299	are	N	O
300	needed	N	O
301	to	N	O
302	confirm	N	O
303	these	N	O
304	findings	N	O
305	.	N	O

306	If	N	O
307	replicated	N	O
308	in	N	O
309	larger	N	O
310	and	N	O
311	more	N	O
312	focused	N	O
313	trials	N	O
314	,	N	O
315	aerobic	N	O
316	exercise	N	O
317	may	N	O
318	be	N	O
319	an	N	O
320	attractive	N	O
321	option	N	O
322	to	N	O
323	manage	N	O
324	sleep	N	O
325	dysfunction	N	O
326	in	N	O
327	patients	N	O
328	with	N	O
329	cancer	N	O
330	because	N	O
331	of	N	O
332	its	N	O
333	favorable	N	O
334	safety	N	O
335	profile	N	O
336	and	N	O
337	other	N	O
338	documented	N	O
339	health	N	O
340	benefits	N	O
341	.	N	O

1	Treosulfan	N	O
2	,	N	O
3	an	N	O
4	alkylating	N	O
5	agent	N	O
6	,	N	O
7	has	N	O
8	demonstrated	N	O
9	activity	N	O
10	in	N	O
11	recurrent	N	O
12	ovarian	N	O
13	carcinoma	N	O
14	.	N	O

15	It	N	O
16	is	N	O
17	equieffective	N	O
18	as	N	O
19	oral	N	O
20	(	N	O
21	p.o	N	O
22	.	N	O

23	)	N	O
24	and	N	O
25	intravenous	N	O
26	(	N	O
27	i.v	N	O
28	.	N	O

29	)	N	O
30	formulation	N	O
31	.	N	O

32	To	N	O
33	explore	N	O
34	the	N	O
35	preference	N	O
36	and	N	O
37	compliance	N	O
38	of	N	O
39	elderly	N	O
40	patients	N	O
41	regarding	N	O
42	p.o	N	O
43	.	N	O

44	or	N	O
45	i.v	N	O
46	.	N	O

47	treosulfan	N	O
48	for	N	O
49	the	N	O
50	treatment	N	O
51	of	N	O
52	relapsed	N	O
53	ovarian	N	O
54	carcinoma	N	O
55	,	N	O
56	women	N	O
57	aged	N	O
58	65	N	O
59	years	N	O
60	or	N	O
61	older	N	O
62	were	N	O
63	included	N	O
64	in	N	O
65	this	N	O
66	prospective	N	O
67	multicenter	N	O
68	study	N	O
69	.	N	O

70	Since	N	O
71	elderly	N	O
72	patients	N	O
73	usually	N	O
74	have	N	O
75	several	N	O
76	concomitant	N	O
77	diseases	N	O
78	and	N	O
79	experience	N	O
80	more	N	O
81	treatment	N	O
82	toxicity	N	O
83	,	N	O
84	an	N	O
85	interim	N	O
86	safety	N	O
87	analysis	N	O
88	was	N	O
89	planned	N	O
90	and	N	O
91	performed	N	O
92	after	N	O
93	25	N	O
94	patients	N	O
95	finished	N	O
96	therapy	N	O
97	to	N	O
98	assess	N	O
99	the	N	O
100	tolerability	N	O
101	of	N	O
102	the	N	O
103	treatment	N	O
104	regimens	N	O
105	.	N	O

106	Patients	N	O
107	had	N	O
108	a	N	O
109	free	N	O
110	choice	N	O
111	of	N	O
112	treosulfan	N	O
113	i.v	N	O
114	.	N	O

115	(	N	O
116	7,000	N	O
117	mg/m	N	O
118	(	N	O
119	2	N	O
120	)	N	O
121	day	N	O
122	1	N	O
123	of	N	O
124	a	N	O
125	28-day	N	O
126	cycle	N	O
127	)	N	O
128	or	N	O
129	p.o	N	O
130	.	N	O

131	(	N	O
132	600	N	O
133	mg/m	N	O
134	(	N	O
135	2	N	O
136	)	N	O
137	day	N	O
138	1-28	N	O
139	of	N	O
140	a	N	O
141	56-day	N	O
142	cycle	N	O
143	)	N	O
144	for	N	O
145	a	N	O
146	maximum	N	O
147	of	N	O
148	12	N	O
149	cycles	N	O
150	(	N	O
151	i.v	N	O
152	.	N	O

153	)	N	O
154	or	N	O
155	12	N	O
156	months	N	O
157	(	N	O
158	p.o.	N	O
159	)	N	O
160	.	N	O

161	Indecisive	N	O
162	patients	N	O
163	were	N	O
164	randomized	N	O
165	.	N	O

166	Toxicity	N	O
167	was	N	O
168	evaluated	N	O
169	according	N	O
170	to	N	O
171	the	N	O
172	NCI-CTC	N	O
173	version	N	O
174	2.0	N	O
175	.	N	O

176	Twenty-five	N	O
177	of	N	O
178	51	N	O
179	recruited	N	O
180	patients	N	O
181	completed	N	O
182	therapy	N	O
183	at	N	O
184	the	N	O
185	time	N	O
186	of	N	O
187	the	N	O
188	planned	N	O
189	interim	N	O
190	analysis	N	O
191	(	N	O
192	median	N	O
193	age	N	O
194	,	N	O
195	75	N	O
196	years	N	O
197	;	N	O
198	range	N	O
199	,	N	O
200	70-82	N	O
201	)	N	O
202	.	N	O

203	Median	N	O
204	ECOG	N	O
205	was	N	O
206	1	N	O
207	,	N	O
208	and	N	O
209	median	N	O
210	number	N	O
211	of	N	O
212	prior	N	O
213	chemotherapy	N	O
214	regimens	N	O
215	was	N	O
216	2	N	O
217	.	N	O

218	A	N	O
219	median	N	O
220	number	N	O
221	of	N	O
222	4	N	O
223	cycles	N	O
224	(	N	O
225	range	N	O
226	,	N	O
227	1-12	N	O
228	)	N	O
229	were	N	O
230	administered	N	O
231	per	N	O
232	patient	N	O
233	.	N	O

234	Anemia	N	I-Premise
235	was	N	I-Premise
236	the	N	I-Premise
237	most	N	I-Premise
238	common	N	I-Premise
239	hematological	N	I-Premise
240	toxicity	N	I-Premise
241	(	N	I-Premise
242	88	N	I-Premise
243	%	N	I-Premise
244	of	N	I-Premise
245	patients	N	I-Premise
246	)	N	I-Premise
247	.	N	I-Premise

248	Most	N	I-Premise
249	frequent	N	I-Premise
250	non-hematological	N	I-Premise
251	toxicities	N	I-Premise
252	were	N	I-Premise
253	nausea	N	I-Premise
254	(	N	I-Premise
255	76	N	I-Premise
256	%	N	I-Premise
257	)	N	I-Premise
258	,	N	I-Premise
259	constipation	N	I-Premise
260	(	N	I-Premise
261	68	N	I-Premise
262	%	N	I-Premise
263	)	N	I-Premise
264	,	N	I-Premise
265	and	N	I-Premise
266	fatigue	N	I-Premise
267	(	N	I-Premise
268	64	N	I-Premise
269	%	N	I-Premise
270	)	N	I-Premise
271	.	N	I-Premise

272	Treatment	N	I-Claim
273	was	N	I-Claim
274	generally	N	I-Claim
275	well	N	I-Claim
276	tolerated	N	I-Claim
277	despite	N	I-Claim
278	the	N	I-Claim
279	fact	N	I-Claim
280	that	N	I-Claim
281	most	N	I-Claim
282	patients	N	I-Claim
283	suffered	N	I-Claim
284	from	N	I-Claim
285	multiple	N	I-Claim
286	comorbidities	N	I-Claim
287	and	N	I-Claim
288	were	N	I-Claim
289	heavily	N	I-Claim
290	pretreated	N	I-Claim
291	.	N	I-Claim

292	There	N	I-Claim
293	were	N	I-Claim
294	no	N	I-Claim
295	unexpected	N	I-Claim
296	hematological	N	I-Claim
297	or	N	I-Claim
298	non-hematological	N	I-Claim
299	toxicities	N	I-Claim
300	.	N	I-Claim

301	Based	N	O
302	on	N	O
303	this	N	O
304	safety	N	O
305	analysis	N	O
306	,	N	O
307	the	N	O
308	next	N	O
309	step	N	O
310	of	N	O
311	study	N	O
312	recruitment	N	O
313	was	N	O
314	continued	N	O
315	.	N	O

1	This	N	O
2	study	N	O
3	examined	N	O
4	whether	N	O
5	changes	N	O
6	in	N	O
7	self-efficacy	N	O
8	explain	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	a	N	O
13	mailed	N	O
14	print	N	O
15	intervention	N	O
16	on	N	O
17	long-term	N	O
18	dietary	N	O
19	practices	N	O
20	of	N	O
21	breast	N	O
22	and	N	O
23	prostate	N	O
24	cancer	N	O
25	survivors	N	O
26	.	N	O

27	The	N	O
28	relationship	N	O
29	between	N	O
30	change	N	O
31	in	N	O
32	self-efficacy	N	O
33	and	N	O
34	long-term	N	O
35	physical	N	O
36	activity	N	O
37	(	N	O
38	PA	N	O
39	)	N	O
40	also	N	O
41	was	N	O
42	examined	N	O
43	.	N	O

44	Breast	N	O
45	and	N	O
46	prostate	N	O
47	cancer	N	O
48	survivors	N	O
49	(	N	O
50	N	N	O
51	=	N	O
52	543	N	O
53	)	N	O
54	from	N	O
55	39	N	O
56	US	N	O
57	states	N	O
58	and	N	O
59	two	N	O
60	Canadian	N	O
61	provinces	N	O
62	participated	N	O
63	in	N	O
64	the	N	O
65	FRESH	N	O
66	START	N	O
67	intervention	N	O
68	trial	N	O
69	.	N	O

70	Participants	N	O
71	were	N	O
72	randomly	N	O
73	assigned	N	O
74	to	N	O
75	receive	N	O
76	a	N	O
77	10-month	N	O
78	program	N	O
79	of	N	O
80	mailed	N	O
81	print	N	O
82	materials	N	O
83	on	N	O
84	diet	N	O
85	and	N	O
86	PA	N	O
87	available	N	O
88	in	N	O
89	the	N	O
90	public	N	O
91	domain	N	O
92	or	N	O
93	a	N	O
94	10-month	N	O
95	program	N	O
96	of	N	O
97	tailored	N	O
98	materials	N	O
99	designed	N	O
100	to	N	O
101	increase	N	O
102	fruit	N	O
103	and	N	O
104	vegetable	N	O
105	(	N	O
106	F	N	O
107	&	N	O
108	V	N	O
109	)	N	O
110	intake	N	O
111	,	N	O
112	decrease	N	O
113	fat	N	O
114	intake	N	O
115	,	N	O
116	and/or	N	O
117	increase	N	O
118	PA.	N	O
119	Changes	N	O
120	in	N	O
121	self-efficacy	N	O
122	for	N	O
123	F	N	O
124	&	N	O
125	V	N	O
126	intake	N	O
127	and	N	O
128	fat	N	O
129	restriction	N	O
130	were	N	O
131	analyzed	N	O
132	as	N	O
133	potential	N	O
134	mediators	N	O
135	of	N	O
136	the	N	O
137	intervention	N	O
138	's	N	O
139	effects	N	O
140	on	N	O
141	diet	N	O
142	at	N	O
143	2-year	N	O
144	follow-up	N	O
145	.	N	O

146	Because	N	O
147	we	N	O
148	previously	N	O
149	found	N	O
150	that	N	O
151	change	N	O
152	in	N	O
153	self-efficacy	N	O
154	for	N	O
155	PA	N	O
156	did	N	O
157	not	N	O
158	vary	N	O
159	by	N	O
160	group	N	O
161	assignment	N	O
162	,	N	O
163	the	N	O
164	relationship	N	O
165	between	N	O
166	change	N	O
167	in	N	O
168	self-efficacy	N	O
169	and	N	O
170	PA	N	O
171	at	N	O
172	2-year	N	O
173	follow-up	N	O
174	was	N	O
175	examined	N	O
176	across	N	O
177	study	N	O
178	conditions	N	O
179	.	N	O

180	Results	N	I-Claim
181	suggest	N	I-Claim
182	that	N	I-Claim
183	change	N	I-Claim
184	in	N	I-Claim
185	self-efficacy	N	I-Claim
186	for	N	I-Claim
187	fat	N	I-Claim
188	restriction	N	I-Claim
189	partially	N	I-Claim
190	explained	N	I-Claim
191	the	N	I-Claim
192	intervention	N	I-Claim
193	's	N	I-Claim
194	effect	N	I-Claim
195	on	N	I-Claim
196	fat	N	I-Claim
197	intake	N	I-Claim
198	(	N	I-Claim
199	mean	N	I-Claim
200	indirect	N	I-Claim
201	effect	N	I-Claim
202	=	N	I-Claim
203	-0.28	N	I-Claim
204	)	N	I-Claim
205	,	N	I-Claim
206	and	N	I-Claim
207	change	N	I-Claim
208	in	N	I-Claim
209	self-efficacy	N	I-Claim
210	for	N	I-Claim
211	F	N	I-Claim
212	&	N	I-Claim
213	V	N	I-Claim
214	consumption	N	I-Claim
215	partially	N	I-Claim
216	explained	N	I-Claim
217	the	N	I-Claim
218	intervention	N	I-Claim
219	's	N	I-Claim
220	effect	N	I-Claim
221	on	N	I-Claim
222	daily	N	I-Claim
223	F	N	I-Claim
224	&	N	I-Claim
225	V	N	I-Claim
226	intake	N	I-Claim
227	(	N	I-Claim
228	mean	N	I-Claim
229	indirect	N	I-Claim
230	effect	N	I-Claim
231	=	N	I-Claim
232	.11	N	I-Claim
233	)	N	I-Claim
234	.	N	I-Claim

235	Change	N	I-Premise
236	in	N	I-Premise
237	self-efficacy	N	I-Premise
238	for	N	I-Premise
239	fat	N	I-Premise
240	restriction	N	I-Premise
241	partially	N	I-Premise
242	accounted	N	I-Premise
243	for	N	I-Premise
244	the	N	I-Premise
245	intervention	N	I-Premise
246	's	N	I-Premise
247	impact	N	I-Premise
248	on	N	I-Premise
249	overall	N	I-Premise
250	diet	N	I-Premise
251	quality	N	I-Premise
252	among	N	I-Premise
253	men	N	I-Premise
254	only	N	I-Premise
255	(	N	I-Premise
256	mean	N	I-Premise
257	indirect	N	I-Premise
258	effect	N	I-Premise
259	=	N	I-Premise
260	0.60	N	I-Premise
261	)	N	I-Premise
262	.	N	I-Premise

263	Finally	N	O
264	,	N	O
265	change	N	O
266	in	N	O
267	self-efficacy	N	O
268	for	N	O
269	PA	N	O
270	predicted	N	O
271	PA	N	O
272	at	N	O
273	2-year	N	O
274	follow-up	N	O
275	.	N	O

276	Findings	N	I-Claim
277	suggest	N	I-Claim
278	that	N	I-Claim
279	self-efficacy	N	I-Claim
280	may	N	I-Claim
281	influence	N	I-Claim
282	long-term	N	I-Claim
283	maintenance	N	I-Claim
284	of	N	I-Claim
285	healthy	N	I-Claim
286	lifestyle	N	I-Claim
287	practices	N	I-Claim
288	among	N	I-Claim
289	cancer	N	I-Claim
290	survivors	N	I-Claim
291	.	N	I-Claim

1	It	N	O
2	is	N	O
3	not	N	O
4	clear	N	O
5	whether	N	O
6	the	N	O
7	administration	N	O
8	of	N	O
9	radioiodine	N	O
10	provides	N	O
11	any	N	O
12	benefit	N	O
13	to	N	O
14	patients	N	O
15	with	N	O
16	low-risk	N	O
17	thyroid	N	O
18	cancer	N	O
19	after	N	O
20	a	N	O
21	complete	N	O
22	surgical	N	O
23	resection	N	O
24	.	N	O

25	The	N	O
26	administration	N	O
27	of	N	O
28	the	N	O
29	smallest	N	O
30	possible	N	O
31	amount	N	O
32	of	N	O
33	radioiodine	N	O
34	would	N	O
35	improve	N	O
36	care	N	O
37	.	N	O

38	In	N	O
39	our	N	O
40	randomized	N	O
41	,	N	O
42	phase	N	O
43	3	N	O
44	trial	N	O
45	,	N	O
46	we	N	O
47	compared	N	O
48	two	N	O
49	thyrotropin-stimulation	N	O
50	methods	N	O
51	(	N	O
52	thyroid	N	O
53	hormone	N	O
54	withdrawal	N	O
55	and	N	O
56	use	N	O
57	of	N	O
58	recombinant	N	O
59	human	N	O
60	thyrotropin	N	O
61	)	N	O
62	and	N	O
63	two	N	O
64	radioiodine	N	O
65	(	N	O
66	(	N	O
67	131	N	O
68	)	N	O
69	I	N	O
70	)	N	O
71	doses	N	O
72	(	N	O
73	i.e.	N	O
74	,	N	O
75	administered	N	O
76	activities	N	O
77	)	N	O
78	(	N	O
79	1.1	N	O
80	GBq	N	O
81	and	N	O
82	3.7	N	O
83	GBq	N	O
84	)	N	O
85	in	N	O
86	a	N	O
87	2-by-2	N	O
88	design	N	O
89	.	N	O

90	Inclusion	N	O
91	criteria	N	O
92	were	N	O
93	an	N	O
94	age	N	O
95	of	N	O
96	18	N	O
97	years	N	O
98	or	N	O
99	older	N	O
100	;	N	O
101	total	N	O
102	thyroidectomy	N	O
103	for	N	O
104	differentiated	N	O
105	thyroid	N	O
106	carcinoma	N	O
107	;	N	O
108	tumor-node-metastasis	N	O
109	(	N	O
110	TNM	N	O
111	)	N	O
112	stage	N	O
113	,	N	O
114	ascertained	N	O
115	on	N	O
116	pathological	N	O
117	examination	N	O
118	(	N	O
119	p	N	O
120	)	N	O
121	of	N	O
122	a	N	O
123	surgical	N	O
124	specimen	N	O
125	,	N	O
126	of	N	O
127	pT1	N	O
128	(	N	O
129	with	N	O
130	tumor	N	O
131	diameter	N	O
132	1	N	O
133	cm	N	O
134	)	N	O
135	and	N	O
136	N1	N	O
137	or	N	O
138	Nx	N	O
139	,	N	O
140	pT1	N	O
141	(	N	O
142	with	N	O
143	tumor	N	O
144	diameter	N	O
145	>	N	O
146	1	N	O
147	to	N	O
148	2	N	O
149	cm	N	O
150	)	N	O
151	and	N	O
152	any	N	O
153	N	N	O
154	stage	N	O
155	,	N	O
156	or	N	O
157	pT2N0	N	O
158	;	N	O
159	absence	N	O
160	of	N	O
161	distant	N	O
162	metastasis	N	O
163	;	N	O
164	and	N	O
165	no	N	O
166	iodine	N	O
167	contamination	N	O
168	.	N	O

169	Thyroid	N	O
170	ablation	N	O
171	was	N	O
172	assessed	N	O
173	8	N	O
174	months	N	O
175	after	N	O
176	radioiodine	N	O
177	administration	N	O
178	by	N	O
179	neck	N	O
180	ultrasonography	N	O
181	and	N	O
182	measurement	N	O
183	of	N	O
184	recombinant	N	O
185	human	N	O
186	thyrotropin-stimulated	N	O
187	thyroglobulin	N	O
188	.	N	O

189	Comparisons	N	O
190	were	N	O
191	based	N	O
192	on	N	O
193	an	N	O
194	equivalence	N	O
195	framework	N	O
196	.	N	O

197	There	N	O
198	were	N	O
199	752	N	O
200	patients	N	O
201	enrolled	N	O
202	between	N	O
203	2007	N	O
204	and	N	O
205	2010	N	O
206	;	N	O
207	92	N	O
208	%	N	O
209	had	N	O
210	papillary	N	O
211	cancer	N	O
212	.	N	O

213	There	N	I-Premise
214	were	N	I-Premise
215	no	N	I-Premise
216	unexpected	N	I-Premise
217	serious	N	I-Premise
218	adverse	N	I-Premise
219	events	N	I-Premise
220	.	N	I-Premise

221	In	N	I-Premise
222	the	N	I-Premise
223	684	N	I-Premise
224	patients	N	I-Premise
225	with	N	I-Premise
226	data	N	I-Premise
227	that	N	I-Premise
228	could	N	I-Premise
229	be	N	I-Premise
230	evaluated	N	I-Premise
231	,	N	I-Premise
232	ultrasonography	N	I-Premise
233	of	N	I-Premise
234	the	N	I-Premise
235	neck	N	I-Premise
236	was	N	I-Premise
237	normal	N	I-Premise
238	in	N	I-Premise
239	652	N	I-Premise
240	(	N	I-Premise
241	95	N	I-Premise
242	%	N	I-Premise
243	)	N	I-Premise
244	,	N	I-Premise
245	and	N	I-Premise
246	the	N	I-Premise
247	stimulated	N	I-Premise
248	thyroglobulin	N	I-Premise
249	level	N	I-Premise
250	was	N	I-Premise
251	1.0	N	I-Premise
252	ng	N	I-Premise
253	per	N	I-Premise
254	milliliter	N	I-Premise
255	or	N	I-Premise
256	less	N	I-Premise
257	in	N	I-Premise
258	621	N	I-Premise
259	of	N	I-Premise
260	the	N	I-Premise
261	652	N	I-Premise
262	patients	N	I-Premise
263	(	N	I-Premise
264	95	N	I-Premise
265	%	N	I-Premise
266	)	N	I-Premise
267	without	N	I-Premise
268	detectable	N	I-Premise
269	thyroglobulin	N	I-Premise
270	antibodies	N	I-Premise
271	.	N	I-Premise

272	Thyroid	N	I-Premise
273	ablation	N	I-Premise
274	was	N	I-Premise
275	complete	N	I-Premise
276	in	N	I-Premise
277	631	N	I-Premise
278	of	N	I-Premise
279	the	N	I-Premise
280	684	N	I-Premise
281	patients	N	I-Premise
282	(	N	I-Premise
283	92	N	I-Premise
284	%	N	I-Premise
285	)	N	I-Premise
286	.	N	I-Premise

287	The	N	I-Premise
288	ablation	N	I-Premise
289	rate	N	I-Premise
290	was	N	I-Premise
291	equivalent	N	I-Premise
292	between	N	I-Premise
293	the	N	I-Premise
294	(	N	I-Premise
295	131	N	I-Premise
296	)	N	I-Premise
297	I	N	I-Premise
298	doses	N	I-Premise
299	and	N	I-Premise
300	between	N	I-Premise
301	the	N	I-Premise
302	thyrotropin-stimulation	N	I-Premise
303	methods	N	I-Premise
304	.	N	I-Premise

305	The	N	I-Claim
306	use	N	I-Claim
307	of	N	I-Claim
308	recombinant	N	I-Claim
309	human	N	I-Claim
310	thyrotropin	N	I-Claim
311	and	N	I-Claim
312	low-dose	N	I-Claim
313	(	N	I-Claim
314	1.1	N	I-Claim
315	GBq	N	I-Claim
316	)	N	I-Claim
317	postoperative	N	I-Claim
318	radioiodine	N	I-Claim
319	ablation	N	I-Claim
320	may	N	I-Claim
321	be	N	I-Claim
322	sufficient	N	I-Claim
323	for	N	I-Claim
324	the	N	I-Claim
325	management	N	I-Claim
326	of	N	I-Claim
327	low-risk	N	I-Claim
328	thyroid	N	I-Claim
329	cancer	N	I-Claim
330	.	N	I-Claim

1	It	N	O
2	is	N	O
3	not	N	O
4	known	N	O
5	whether	N	O
6	low-dose	N	O
7	radioiodine	N	O
8	(	N	O
9	1.1	N	O
10	GBq	N	O
11	[	N	O
12	30	N	O
13	mCi	N	O
14	]	N	O
15	)	N	O
16	is	N	O
17	as	N	O
18	effective	N	O
19	as	N	O
20	high-dose	N	O
21	radioiodine	N	O
22	(	N	O
23	3.7	N	O
24	GBq	N	O
25	[	N	O
26	100	N	O
27	mCi	N	O
28	]	N	O
29	)	N	O
30	for	N	O
31	treating	N	O
32	patients	N	O
33	with	N	O
34	differentiated	N	O
35	thyroid	N	O
36	cancer	N	O
37	or	N	O
38	whether	N	O
39	the	N	O
40	effects	N	O
41	of	N	O
42	radioiodine	N	O
43	(	N	O
44	especially	N	O
45	at	N	O
46	a	N	O
47	low	N	O
48	dose	N	O
49	)	N	O
50	are	N	O
51	influenced	N	O
52	by	N	O
53	using	N	O
54	either	N	O
55	recombinant	N	O
56	human	N	O
57	thyrotropin	N	O
58	(	N	O
59	thyrotropin	N	O
60	alfa	N	O
61	)	N	O
62	or	N	O
63	thyroid	N	O
64	hormone	N	O
65	withdrawal	N	O
66	.	N	O

67	At	N	O
68	29	N	O
69	centers	N	O
70	in	N	O
71	the	N	O
72	United	N	O
73	Kingdom	N	O
74	,	N	O
75	we	N	O
76	conducted	N	O
77	a	N	O
78	randomized	N	O
79	noninferiority	N	O
80	trial	N	O
81	comparing	N	O
82	low-dose	N	O
83	and	N	O
84	high-dose	N	O
85	radioiodine	N	O
86	,	N	O
87	each	N	O
88	in	N	O
89	combination	N	O
90	with	N	O
91	either	N	O
92	thyrotropin	N	O
93	alfa	N	O
94	or	N	O
95	thyroid	N	O
96	hormone	N	O
97	withdrawal	N	O
98	before	N	O
99	ablation	N	O
100	.	N	O

101	Patients	N	O
102	(	N	O
103	age	N	O
104	range	N	O
105	,	N	O
106	16	N	O
107	to	N	O
108	80	N	O
109	years	N	O
110	)	N	O
111	had	N	O
112	tumor	N	O
113	stage	N	O
114	T1	N	O
115	to	N	O
116	T3	N	O
117	,	N	O
118	with	N	O
119	possible	N	O
120	spread	N	O
121	to	N	O
122	nearby	N	O
123	lymph	N	O
124	nodes	N	O
125	but	N	O
126	without	N	O
127	metastasis	N	O
128	.	N	O

129	End	N	O
130	points	N	O
131	were	N	O
132	the	N	O
133	rate	N	O
134	of	N	O
135	success	N	O
136	of	N	O
137	ablation	N	O
138	at	N	O
139	6	N	O
140	to	N	O
141	9	N	O
142	months	N	O
143	,	N	O
144	adverse	N	O
145	events	N	O
146	,	N	O
147	quality	N	O
148	of	N	O
149	life	N	O
150	,	N	O
151	and	N	O
152	length	N	O
153	of	N	O
154	hospital	N	O
155	stay	N	O
156	.	N	O

157	A	N	O
158	total	N	O
159	of	N	O
160	438	N	O
161	patients	N	O
162	underwent	N	O
163	randomization	N	O
164	;	N	O
165	data	N	O
166	could	N	O
167	be	N	O
168	analyzed	N	O
169	for	N	O
170	421	N	O
171	.	N	O

172	Ablation	N	I-Premise
173	success	N	I-Premise
174	rates	N	I-Premise
175	were	N	I-Premise
176	85.0	N	I-Premise
177	%	N	I-Premise
178	in	N	I-Premise
179	the	N	I-Premise
180	group	N	I-Premise
181	receiving	N	I-Premise
182	low-dose	N	I-Premise
183	radioiodine	N	I-Premise
184	versus	N	I-Premise
185	88.9	N	I-Premise
186	%	N	I-Premise
187	in	N	I-Premise
188	the	N	I-Premise
189	group	N	I-Premise
190	receiving	N	I-Premise
191	the	N	I-Premise
192	high	N	I-Premise
193	dose	N	I-Premise
194	and	N	I-Premise
195	87.1	N	I-Premise
196	%	N	I-Premise
197	in	N	I-Premise
198	the	N	I-Premise
199	thyrotropin	N	I-Premise
200	alfa	N	I-Premise
201	group	N	I-Premise
202	versus	N	I-Premise
203	86.7	N	I-Premise
204	%	N	I-Premise
205	in	N	I-Premise
206	the	N	I-Premise
207	group	N	I-Premise
208	undergoing	N	I-Premise
209	thyroid	N	I-Premise
210	hormone	N	I-Premise
211	withdrawal	N	I-Premise
212	.	N	I-Premise

213	All	N	I-Premise
214	95	N	I-Premise
215	%	N	I-Premise
216	confidence	N	I-Premise
217	intervals	N	I-Premise
218	for	N	I-Premise
219	the	N	I-Premise
220	differences	N	I-Premise
221	were	N	I-Premise
222	within	N	I-Premise
223	10	N	I-Premise
224	percentage	N	I-Premise
225	points	N	I-Premise
226	,	N	I-Premise
227	indicating	N	I-Premise
228	noninferiority	N	I-Premise
229	.	N	I-Premise

230	Similar	N	I-Premise
231	results	N	I-Premise
232	were	N	I-Premise
233	found	N	I-Premise
234	for	N	I-Premise
235	low-dose	N	I-Premise
236	radioiodine	N	I-Premise
237	plus	N	I-Premise
238	thyrotropin	N	I-Premise
239	alfa	N	I-Premise
240	(	N	I-Premise
241	84.3	N	I-Premise
242	%	N	I-Premise
243	)	N	I-Premise
244	versus	N	I-Premise
245	high-dose	N	I-Premise
246	radioiodine	N	I-Premise
247	plus	N	I-Premise
248	thyroid	N	I-Premise
249	hormone	N	I-Premise
250	withdrawal	N	I-Premise
251	(	N	I-Premise
252	87.6	N	I-Premise
253	%	N	I-Premise
254	)	N	I-Premise
255	or	N	I-Premise
256	high-dose	N	I-Premise
257	radioiodine	N	I-Premise
258	plus	N	I-Premise
259	thyrotropin	N	I-Premise
260	alfa	N	I-Premise
261	(	N	I-Premise
262	90.2	N	I-Premise
263	%	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	More	N	I-Premise
267	patients	N	I-Premise
268	in	N	I-Premise
269	the	N	I-Premise
270	high-dose	N	I-Premise
271	group	N	I-Premise
272	than	N	I-Premise
273	in	N	I-Premise
274	the	N	I-Premise
275	low-dose	N	I-Premise
276	group	N	I-Premise
277	were	N	I-Premise
278	hospitalized	N	I-Premise
279	for	N	I-Premise
280	at	N	I-Premise
281	least	N	I-Premise
282	3	N	I-Premise
283	days	N	I-Premise
284	(	N	I-Premise
285	36.3	N	I-Premise
286	%	N	I-Premise
287	vs.	N	I-Premise
288	13.0	N	I-Premise
289	%	N	I-Premise
290	,	N	I-Premise
291	P	N	I-Premise
292	<	N	I-Premise
293	0.001	N	I-Premise
294	)	N	I-Premise
295	.	N	I-Premise

296	The	N	I-Premise
297	proportions	N	I-Premise
298	of	N	I-Premise
299	patients	N	I-Premise
300	with	N	I-Premise
301	adverse	N	I-Premise
302	events	N	I-Premise
303	were	N	I-Premise
304	21	N	I-Premise
305	%	N	I-Premise
306	in	N	I-Premise
307	the	N	I-Premise
308	low-dose	N	I-Premise
309	group	N	I-Premise
310	versus	N	I-Premise
311	33	N	I-Premise
312	%	N	I-Premise
313	in	N	I-Premise
314	the	N	I-Premise
315	high-dose	N	I-Premise
316	group	N	I-Premise
317	(	N	I-Premise
318	P=0.007	N	I-Premise
319	)	N	I-Premise
320	and	N	I-Premise
321	23	N	I-Premise
322	%	N	I-Premise
323	in	N	I-Premise
324	the	N	I-Premise
325	thyrotropin	N	I-Premise
326	alfa	N	I-Premise
327	group	N	I-Premise
328	versus	N	I-Premise
329	30	N	I-Premise
330	%	N	I-Premise
331	in	N	I-Premise
332	the	N	I-Premise
333	group	N	I-Premise
334	undergoing	N	I-Premise
335	thyroid	N	I-Premise
336	hormone	N	I-Premise
337	withdrawal	N	I-Premise
338	(	N	I-Premise
339	P=0.11	N	I-Premise
340	)	N	I-Premise
341	.	N	I-Premise

342	Low-dose	N	I-Claim
343	radioiodine	N	I-Claim
344	plus	N	I-Claim
345	thyrotropin	N	I-Claim
346	alfa	N	I-Claim
347	was	N	I-Claim
348	as	N	I-Claim
349	effective	N	I-Claim
350	as	N	I-Claim
351	high-dose	N	I-Claim
352	radioiodine	N	I-Claim
353	,	N	I-Claim
354	with	N	I-Claim
355	a	N	I-Claim
356	lower	N	I-Claim
357	rate	N	I-Claim
358	of	N	I-Claim
359	adverse	N	I-Claim
360	events	N	I-Claim
361	.	N	I-Claim

1	Surgical	N	O
2	resection	N	O
3	is	N	O
4	regarded	N	O
5	as	N	O
6	the	N	O
7	only	N	O
8	curative	N	O
9	option	N	O
10	for	N	O
11	resectable	N	O
12	oesophageal	N	O
13	cancer	N	O
14	,	N	O
15	but	N	O
16	pulmonary	N	O
17	complications	N	O
18	occurring	N	O
19	in	N	O
20	more	N	O
21	than	N	O
22	half	N	O
23	of	N	O
24	patients	N	O
25	after	N	O
26	open	N	O
27	oesophagectomy	N	O
28	are	N	O
29	a	N	O
30	great	N	O
31	concern	N	O
32	.	N	O

33	We	N	O
34	assessed	N	O
35	whether	N	O
36	minimally	N	O
37	invasive	N	O
38	oesophagectomy	N	O
39	reduces	N	O
40	morbidity	N	O
41	compared	N	O
42	with	N	O
43	open	N	O
44	oesophagectomy	N	O
45	.	N	O

46	We	N	O
47	did	N	O
48	a	N	O
49	multicentre	N	O
50	,	N	O
51	open-label	N	O
52	,	N	O
53	randomised	N	O
54	controlled	N	O
55	trial	N	O
56	at	N	O
57	five	N	O
58	study	N	O
59	centres	N	O
60	in	N	O
61	three	N	O
62	countries	N	O
63	between	N	O
64	June	N	O
65	1	N	O
66	,	N	O
67	2009	N	O
68	,	N	O
69	and	N	O
70	March	N	O
71	31	N	O
72	,	N	O
73	2011	N	O
74	.	N	O

75	Patients	N	O
76	aged	N	O
77	18-75	N	O
78	years	N	O
79	with	N	O
80	resectable	N	O
81	cancer	N	O
82	of	N	O
83	the	N	O
84	oesophagus	N	O
85	or	N	O
86	gastro-oesophageal	N	O
87	junction	N	O
88	were	N	O
89	randomly	N	O
90	assigned	N	O
91	via	N	O
92	a	N	O
93	computer-generated	N	O
94	randomisation	N	O
95	sequence	N	O
96	to	N	O
97	receive	N	O
98	either	N	O
99	open	N	O
100	transthoracic	N	O
101	or	N	O
102	minimally	N	O
103	invasive	N	O
104	transthoracic	N	O
105	oesophagectomy	N	O
106	.	N	O

107	Randomisation	N	O
108	was	N	O
109	stratified	N	O
110	by	N	O
111	centre	N	O
112	.	N	O

113	Patients	N	O
114	,	N	O
115	and	N	O
116	investigators	N	O
117	undertaking	N	O
118	interventions	N	O
119	,	N	O
120	assessing	N	O
121	outcomes	N	O
122	,	N	O
123	and	N	O
124	analysing	N	O
125	data	N	O
126	,	N	O
127	were	N	O
128	not	N	O
129	masked	N	O
130	to	N	O
131	group	N	O
132	assignment	N	O
133	.	N	O

134	The	N	O
135	primary	N	O
136	outcome	N	O
137	was	N	O
138	pulmonary	N	O
139	infection	N	O
140	within	N	O
141	the	N	O
142	first	N	O
143	2	N	O
144	weeks	N	O
145	after	N	O
146	surgery	N	O
147	and	N	O
148	during	N	O
149	the	N	O
150	whole	N	O
151	stay	N	O
152	in	N	O
153	hospital	N	O
154	.	N	O

155	Analysis	N	O
156	was	N	O
157	by	N	O
158	intention	N	O
159	to	N	O
160	treat	N	O
161	.	N	O

162	This	N	O
163	trial	N	O
164	is	N	O
165	registered	N	O
166	with	N	O
167	the	N	O
168	Netherlands	N	O
169	Trial	N	O
170	Register	N	O
171	,	N	O
172	NTR	N	O
173	TC	N	O
174	2452	N	O
175	.	N	O

176	We	N	O
177	randomly	N	O
178	assigned	N	O
179	56	N	O
180	patients	N	O
181	to	N	O
182	the	N	O
183	open	N	O
184	oesophagectomy	N	O
185	group	N	O
186	and	N	O
187	59	N	O
188	to	N	O
189	the	N	O
190	minimally	N	O
191	invasive	N	O
192	oesophagectomy	N	O
193	group	N	O
194	.	N	O

195	16	N	I-Premise
196	(	N	I-Premise
197	29	N	I-Premise
198	%	N	I-Premise
199	)	N	I-Premise
200	patients	N	I-Premise
201	in	N	I-Premise
202	the	N	I-Premise
203	open	N	I-Premise
204	oesophagectomy	N	I-Premise
205	group	N	I-Premise
206	had	N	I-Premise
207	pulmonary	N	I-Premise
208	infection	N	I-Premise
209	in	N	I-Premise
210	the	N	I-Premise
211	first	N	I-Premise
212	2	N	I-Premise
213	weeks	N	I-Premise
214	compared	N	I-Premise
215	with	N	I-Premise
216	five	N	I-Premise
217	(	N	I-Premise
218	9	N	I-Premise
219	%	N	I-Premise
220	)	N	I-Premise
221	in	N	I-Premise
222	the	N	I-Premise
223	minimally	N	I-Premise
224	invasive	N	I-Premise
225	group	N	I-Premise
226	(	N	I-Premise
227	relative	N	I-Premise
228	risk	N	I-Premise
229	[	N	I-Premise
230	RR	N	I-Premise
231	]	N	I-Premise
232	030	N	I-Premise
233	,	N	I-Premise
234	95	N	I-Premise
235	%	N	I-Premise
236	CI	N	I-Premise
237	012-076	N	I-Premise
238	;	N	I-Premise
239	p=0005	N	I-Premise
240	)	N	I-Premise
241	.	N	I-Premise

242	19	N	I-Premise
243	(	N	I-Premise
244	34	N	I-Premise
245	%	N	I-Premise
246	)	N	I-Premise
247	patients	N	I-Premise
248	in	N	I-Premise
249	the	N	I-Premise
250	open	N	I-Premise
251	oesophagectomy	N	I-Premise
252	group	N	I-Premise
253	had	N	I-Premise
254	pulmonary	N	I-Premise
255	infection	N	I-Premise
256	in-hospital	N	I-Premise
257	compared	N	I-Premise
258	with	N	I-Premise
259	seven	N	I-Premise
260	(	N	I-Premise
261	12	N	I-Premise
262	%	N	I-Premise
263	)	N	I-Premise
264	in	N	I-Premise
265	the	N	I-Premise
266	minimally	N	I-Premise
267	invasive	N	I-Premise
268	group	N	I-Premise
269	(	N	I-Premise
270	035	N	I-Premise
271	,	N	I-Premise
272	016-078	N	I-Premise
273	;	N	I-Premise
274	p=0005	N	I-Premise
275	)	N	I-Premise
276	.	N	I-Premise

277	For	N	I-Premise
278	in-hospital	N	I-Premise
279	mortality	N	I-Premise
280	,	N	I-Premise
281	one	N	I-Premise
282	patient	N	I-Premise
283	in	N	I-Premise
284	the	N	I-Premise
285	open	N	I-Premise
286	oesophagectomy	N	I-Premise
287	group	N	I-Premise
288	died	N	I-Premise
289	from	N	I-Premise
290	anastomotic	N	I-Premise
291	leakage	N	I-Premise
292	and	N	I-Premise
293	two	N	I-Premise
294	in	N	I-Premise
295	the	N	I-Premise
296	minimally	N	I-Premise
297	invasive	N	I-Premise
298	group	N	I-Premise
299	from	N	I-Premise
300	aspiration	N	I-Premise
301	and	N	I-Premise
302	mediastinitis	N	I-Premise
303	after	N	I-Premise
304	anastomotic	N	I-Premise
305	leakage	N	I-Premise
306	.	N	I-Premise

307	These	N	I-Claim
308	findings	N	I-Claim
309	provide	N	I-Claim
310	evidence	N	I-Claim
311	for	N	I-Claim
312	the	N	I-Claim
313	short-term	N	I-Claim
314	benefits	N	I-Claim
315	of	N	I-Claim
316	minimally	N	I-Claim
317	invasive	N	I-Claim
318	oesophagectomy	N	I-Claim
319	for	N	I-Claim
320	patients	N	I-Claim
321	with	N	I-Claim
322	resectable	N	I-Claim
323	oesophageal	N	I-Claim
324	cancer	N	I-Claim
325	.	N	I-Claim

1	Phase	N	O
2	III	N	O
3	EGF104900	N	O
4	data	N	O
5	demonstrated	N	O
6	that	N	O
7	lapatinib	N	O
8	plus	N	O
9	trastuzumab	N	O
10	significantly	N	O
11	improved	N	O
12	progression-free	N	O
13	survival	N	O
14	(	N	O
15	PFS	N	O
16	)	N	O
17	and	N	O
18	clinical	N	O
19	benefit	N	O
20	rate	N	O
21	versus	N	O
22	lapatinib	N	O
23	monotherapy	N	O
24	,	N	O
25	offering	N	O
26	a	N	O
27	chemotherapy-free	N	O
28	option	N	O
29	for	N	O
30	patients	N	O
31	with	N	O
32	heavily	N	O
33	pretreated	N	O
34	human	N	O
35	epidermal	N	O
36	growth	N	O
37	factor	N	O
38	receptor	N	O
39	2	N	O
40	(	N	O
41	HER2	N	O
42	)	N	O
43	-positive	N	O
44	metastatic	N	O
45	breast	N	O
46	cancer	N	O
47	(	N	O
48	MBC	N	O
49	)	N	O
50	.	N	O

51	Final	N	O
52	planned	N	O
53	overall	N	O
54	survival	N	O
55	(	N	O
56	OS	N	O
57	)	N	O
58	analysis	N	O
59	from	N	O
60	EGF104900	N	O
61	is	N	O
62	reported	N	O
63	here	N	O
64	.	N	O

65	Patients	N	O
66	with	N	O
67	HER2-positive	N	O
68	MBC	N	O
69	whose	N	O
70	disease	N	O
71	progressed	N	O
72	during	N	O
73	prior	N	O
74	trastuzumab-based	N	O
75	therapies	N	O
76	were	N	O
77	randomly	N	O
78	assigned	N	O
79	to	N	O
80	receive	N	O
81	lapatinib	N	O
82	monotherapy	N	O
83	or	N	O
84	lapatinib	N	O
85	in	N	O
86	combination	N	O
87	with	N	O
88	trastuzumab	N	O
89	.	N	O

90	OS	N	O
91	and	N	O
92	updated	N	O
93	PFS	N	O
94	data	N	O
95	are	N	O
96	presented	N	O
97	using	N	O
98	Kaplan-Meier	N	O
99	curves	N	O
100	and	N	O
101	log-rank	N	O
102	tests	N	O
103	stratified	N	O
104	for	N	O
105	hormone	N	O
106	receptor	N	O
107	and	N	O
108	visceral	N	O
109	disease	N	O
110	status	N	O
111	.	N	O

112	Subgroup	N	O
113	analyses	N	O
114	were	N	O
115	conducted	N	O
116	to	N	O
117	identify	N	O
118	characteristics	N	O
119	of	N	O
120	patients	N	O
121	deriving	N	O
122	the	N	O
123	greatest	N	O
124	clinical	N	O
125	benefit	N	O
126	.	N	O

127	In	N	I-Premise
128	this	N	I-Premise
129	updated	N	I-Premise
130	final	N	I-Premise
131	analysis	N	I-Premise
132	of	N	I-Premise
133	all	N	I-Premise
134	patients	N	I-Premise
135	randomly	N	I-Premise
136	assigned	N	I-Premise
137	with	N	I-Premise
138	strata	N	I-Premise
139	(	N	I-Premise
140	n	N	I-Premise
141	=	N	I-Premise
142	291	N	I-Premise
143	)	N	I-Premise
144	,	N	I-Premise
145	lapatinib	N	I-Premise
146	plus	N	I-Premise
147	trastuzumab	N	I-Premise
148	continued	N	I-Premise
149	to	N	I-Premise
150	show	N	I-Premise
151	superiority	N	I-Premise
152	to	N	I-Premise
153	lapatinib	N	I-Premise
154	monotherapy	N	I-Premise
155	in	N	I-Premise
156	PFS	N	I-Premise
157	(	N	I-Premise
158	hazard	N	I-Premise
159	ratio	N	I-Premise
160	[	N	I-Premise
161	HR	N	I-Premise
162	]	N	I-Premise
163	,	N	I-Premise
164	0.74	N	I-Premise
165	;	N	I-Premise
166	95	N	I-Premise
167	%	N	I-Premise
168	CI	N	I-Premise
169	,	N	I-Premise
170	0.58	N	I-Premise
171	to	N	I-Premise
172	0.94	N	I-Premise
173	;	N	I-Premise
174	P	N	I-Premise
175	=	N	I-Premise
176	.011	N	I-Premise
177	)	N	I-Premise
178	and	N	I-Premise
179	offered	N	I-Premise
180	significant	N	I-Premise
181	OS	N	I-Premise
182	benefit	N	I-Premise
183	(	N	I-Premise
184	HR	N	I-Premise
185	,	N	I-Premise
186	0.74	N	I-Premise
187	;	N	I-Premise
188	95	N	I-Premise
189	%	N	I-Premise
190	CI	N	I-Premise
191	,	N	I-Premise
192	0.57	N	I-Premise
193	to	N	I-Premise
194	0.97	N	I-Premise
195	;	N	I-Premise
196	P	N	I-Premise
197	=	N	I-Premise
198	.026	N	I-Premise
199	)	N	I-Premise
200	.	N	I-Premise

201	Improvements	N	I-Premise
202	in	N	I-Premise
203	absolute	N	I-Premise
204	OS	N	I-Premise
205	rates	N	I-Premise
206	were	N	I-Premise
207	10	N	I-Premise
208	%	N	I-Premise
209	at	N	I-Premise
210	6	N	I-Premise
211	months	N	I-Premise
212	and	N	I-Premise
213	15	N	I-Premise
214	%	N	I-Premise
215	at	N	I-Premise
216	12	N	I-Premise
217	months	N	I-Premise
218	in	N	I-Premise
219	the	N	I-Premise
220	combination	N	I-Premise
221	arm	N	I-Premise
222	compared	N	I-Premise
223	with	N	I-Premise
224	the	N	I-Premise
225	monotherapy	N	I-Premise
226	arm	N	I-Premise
227	.	N	I-Premise

228	Multiple	N	I-Premise
229	baseline	N	I-Premise
230	factors	N	I-Premise
231	,	N	I-Premise
232	including	N	I-Premise
233	Eastern	N	I-Premise
234	Cooperative	N	I-Premise
235	Oncology	N	I-Premise
236	Group	N	I-Premise
237	performance	N	I-Premise
238	status	N	I-Premise
239	of	N	I-Premise
240	0	N	I-Premise
241	,	N	I-Premise
242	nonvisceral	N	I-Premise
243	disease	N	I-Premise
244	,	N	I-Premise
245	<	N	I-Premise
246	three	N	I-Premise
247	metastatic	N	I-Premise
248	sites	N	I-Premise
249	,	N	I-Premise
250	and	N	I-Premise
251	less	N	I-Premise
252	time	N	I-Premise
253	from	N	I-Premise
254	initial	N	I-Premise
255	diagnosis	N	I-Premise
256	until	N	I-Premise
257	random	N	I-Premise
258	assignment	N	I-Premise
259	,	N	I-Premise
260	were	N	I-Premise
261	associated	N	I-Premise
262	with	N	I-Premise
263	improved	N	I-Premise
264	OS	N	I-Premise
265	.	N	I-Premise

266	Incidence	N	I-Premise
267	of	N	I-Premise
268	adverse	N	I-Premise
269	events	N	I-Premise
270	was	N	I-Premise
271	consistent	N	I-Premise
272	with	N	I-Premise
273	previously	N	I-Premise
274	reported	N	I-Premise
275	rates	N	I-Premise
276	.	N	I-Premise

277	These	N	I-Claim
278	data	N	I-Claim
279	demonstrated	N	I-Claim
280	a	N	I-Claim
281	significant	N	I-Claim
282	4.5-month	N	I-Claim
283	median	N	I-Claim
284	OS	N	I-Claim
285	advantage	N	I-Claim
286	with	N	I-Claim
287	the	N	I-Claim
288	lapatinib	N	I-Claim
289	and	N	I-Claim
290	trastuzumab	N	I-Claim
291	combination	N	I-Claim
292	and	N	I-Claim
293	support	N	I-Claim
294	dual	N	I-Claim
295	HER2	N	I-Claim
296	blockade	N	I-Claim
297	in	N	I-Claim
298	patients	N	I-Claim
299	with	N	I-Claim
300	heavily	N	I-Claim
301	pretreated	N	I-Claim
302	HER2-positive	N	I-Claim
303	MBC	N	I-Claim
304	.	N	I-Claim

1	This	N	O
2	study	N	O
3	tested	N	O
4	hyperbaric	N	O
5	oxygen	N	O
6	(	N	O
7	HBO	N	O
8	)	N	O
9	as	N	O
10	an	N	O
11	adjunct	N	O
12	to	N	O
13	surgery	N	O
14	and	N	O
15	antibiotics	N	O
16	in	N	O
17	the	N	O
18	treatment	N	O
19	of	N	O
20	bisphosphonate-related	N	O
21	osteonecrosis	N	O
22	of	N	O
23	the	N	O
24	jaw	N	O
25	(	N	O
26	ONJ	N	O
27	)	N	O
28	and	N	O
29	evaluated	N	O
30	its	N	O
31	effects	N	O
32	on	N	O
33	gingival	N	O
34	healing	N	O
35	,	N	O
36	pain	N	O
37	,	N	O
38	and	N	O
39	quality	N	O
40	of	N	O
41	life	N	O
42	.	N	O

43	The	N	O
44	investigators	N	O
45	implemented	N	O
46	a	N	O
47	randomized	N	O
48	controlled	N	O
49	trial	N	O
50	and	N	O
51	enrolled	N	O
52	a	N	O
53	sample	N	O
54	composed	N	O
55	of	N	O
56	patients	N	O
57	with	N	O
58	ONJ	N	O
59	,	N	O
60	where	N	O
61	the	N	O
62	predictor	N	O
63	variable	N	O
64	was	N	O
65	HBO	N	O
66	administered	N	O
67	at	N	O
68	2	N	O
69	atm	N	O
70	twice	N	O
71	a	N	O
72	day	N	O
73	for	N	O
74	40	N	O
75	treatments	N	O
76	as	N	O
77	an	N	O
78	adjunct	N	O
79	to	N	O
80	conventional	N	O
81	therapy	N	O
82	of	N	O
83	surgery	N	O
84	and	N	O
85	antibiotics	N	O
86	versus	N	O
87	conventional	N	O
88	therapy	N	O
89	alone	N	O
90	.	N	O

91	Over	N	O
92	the	N	O
93	next	N	O
94	24	N	O
95	months	N	O
96	,	N	O
97	oral	N	O
98	lesion	N	O
99	size	N	O
100	and	N	O
101	number	N	O
102	,	N	O
103	pain	N	O
104	,	N	O
105	and	N	O
106	quality	N	O
107	of	N	O
108	life	N	O
109	were	N	O
110	assessed	N	O
111	.	N	O

112	Forty-six	N	O
113	patients	N	O
114	(	N	O
115	mean	N	O
116	age	N	O
117	,	N	O
118	66	N	O
119	yrs	N	O
120	;	N	O
121	57	N	O
122	%	N	O
123	women	N	O
124	)	N	O
125	contributed	N	O
126	data	N	O
127	to	N	O
128	the	N	O
129	trial	N	O
130	.	N	O

131	There	N	O
132	were	N	O
133	no	N	O
134	statistically	N	O
135	significant	N	O
136	differences	N	O
137	in	N	O
138	the	N	O
139	distribution	N	O
140	of	N	O
141	variables	N	O
142	used	N	O
143	to	N	O
144	assess	N	O
145	randomization	N	O
146	success	N	O
147	between	N	O
148	the	N	O
149	HBO	N	O
150	and	N	O
151	standard	N	O
152	treatment	N	O
153	groups	N	O
154	.	N	O

155	Seventeen	N	I-Premise
156	of	N	I-Premise
157	25	N	I-Premise
158	HBO-treated	N	I-Premise
159	patients	N	I-Premise
160	(	N	I-Premise
161	68	N	I-Premise
162	%	N	I-Premise
163	)	N	I-Premise
164	improved	N	I-Premise
165	versus	N	I-Premise
166	8	N	I-Premise
167	of	N	I-Premise
168	21	N	I-Premise
169	controls	N	I-Premise
170	(	N	I-Premise
171	38.1	N	I-Premise
172	%	N	I-Premise
173	;	N	I-Premise
174	P	N	I-Premise
175	=	N	I-Premise
176	.043	N	I-Premise
177	,	N	I-Premise
178		N	I-Premise
179	(	N	I-Premise
180	2	N	I-Premise
181	)	N	I-Premise
182	test	N	I-Premise
183	)	N	I-Premise
184	.	N	I-Premise

185	Mean	N	I-Premise
186	time	N	I-Premise
187	to	N	I-Premise
188	improvement	N	I-Premise
189	was	N	I-Premise
190	39.7	N	I-Premise
191	weeks	N	I-Premise
192	(	N	I-Premise
193	95	N	I-Premise
194	%	N	I-Premise
195	confidence	N	I-Premise
196	interval	N	I-Premise
197	[	N	I-Premise
198	CI	N	I-Premise
199	]	N	I-Premise
200	,	N	I-Premise
201	22.4	N	I-Premise
202	to	N	I-Premise
203	57.0	N	I-Premise
204	weeks	N	I-Premise
205	)	N	I-Premise
206	for	N	I-Premise
207	HBO-treated	N	I-Premise
208	patients	N	I-Premise
209	versus	N	I-Premise
210	67.9	N	I-Premise
211	weeks	N	I-Premise
212	(	N	I-Premise
213	95	N	I-Premise
214	CI	N	I-Premise
215	,	N	I-Premise
216	48.4	N	I-Premise
217	to	N	I-Premise
218	87.5	N	I-Premise
219	weeks	N	I-Premise
220	)	N	I-Premise
221	for	N	I-Premise
222	controls	N	I-Premise
223	(	N	I-Premise
224	P	N	I-Premise
225	=	N	I-Premise
226	.03	N	I-Premise
227	,	N	I-Premise
228	log-rank	N	I-Premise
229	test	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	However	N	I-Premise
233	,	N	I-Premise
234	complete	N	I-Premise
235	gingival	N	I-Premise
236	healing	N	I-Premise
237	occurred	N	I-Premise
238	in	N	I-Premise
239	only	N	I-Premise
240	14	N	I-Premise
241	of	N	I-Premise
242	25	N	I-Premise
243	HBO-treated	N	I-Premise
244	patients	N	I-Premise
245	(	N	I-Premise
246	52	N	I-Premise
247	%	N	I-Premise
248	)	N	I-Premise
249	versus	N	I-Premise
250	7	N	I-Premise
251	of	N	I-Premise
252	21	N	I-Premise
253	controls	N	I-Premise
254	(	N	I-Premise
255	33.3	N	I-Premise
256	%	N	I-Premise
257	;	N	I-Premise
258	P	N	I-Premise
259	=	N	I-Premise
260	.203	N	I-Premise
261	,	N	I-Premise
262		N	I-Premise
263	(	N	I-Premise
264	2	N	I-Premise
265	)	N	I-Premise
266	test	N	I-Premise
267	)	N	I-Premise
268	,	N	I-Premise
269	and	N	I-Premise
270	time	N	I-Premise
271	to	N	I-Premise
272	healing	N	I-Premise
273	was	N	I-Premise
274	59	N	I-Premise
275	weeks	N	I-Premise
276	(	N	I-Premise
277	95	N	I-Premise
278	%	N	I-Premise
279	CI	N	I-Premise
280	,	N	I-Premise
281	42.8	N	I-Premise
282	%	N	I-Premise
283	to	N	I-Premise
284	75.8	N	I-Premise
285	%	N	I-Premise
286	)	N	I-Premise
287	for	N	I-Premise
288	HBO-treated	N	I-Premise
289	patients	N	I-Premise
290	versus	N	I-Premise
291	70	N	I-Premise
292	weeks	N	I-Premise
293	(	N	I-Premise
294	95	N	I-Premise
295	CI	N	I-Premise
296	,	N	I-Premise
297	52.2	N	I-Premise
298	%	N	I-Premise
299	to	N	I-Premise
300	88.36	N	I-Premise
301	%	N	I-Premise
302	)	N	I-Premise
303	for	N	I-Premise
304	controls	N	I-Premise
305	(	N	I-Premise
306	P	N	I-Premise
307	=	N	I-Premise
308	.32	N	I-Premise
309	,	N	I-Premise
310	log-rank	N	I-Premise
311	test	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	Pain	N	I-Premise
315	decreased	N	I-Premise
316	faster	N	I-Premise
317	for	N	I-Premise
318	HBO-treated	N	I-Premise
319	subjects	N	I-Premise
320	(	N	I-Premise
321	P	N	I-Premise
322	<	N	I-Premise
323	.01	N	I-Premise
324	,	N	I-Premise
325	linear	N	I-Premise
326	regression	N	I-Premise
327	)	N	I-Premise
328	.	N	I-Premise

329	Quality-of-life	N	I-Premise
330	scores	N	I-Premise
331	for	N	I-Premise
332	physical	N	I-Premise
333	health	N	I-Premise
334	(	N	I-Premise
335	P	N	I-Premise
336	=	N	I-Premise
337	.002	N	I-Premise
338	)	N	I-Premise
339	and	N	I-Premise
340	perceived	N	I-Premise
341	health	N	I-Premise
342	(	N	I-Premise
343	P	N	I-Premise
344	=	N	I-Premise
345	.043	N	I-Premise
346	)	N	I-Premise
347	decreased	N	I-Premise
348	at	N	I-Premise
349	6	N	I-Premise
350	months	N	I-Premise
351	for	N	I-Premise
352	control	N	I-Premise
353	group	N	I-Premise
354	but	N	I-Premise
355	for	N	I-Premise
356	not	N	I-Premise
357	the	N	I-Premise
358	HBO	N	I-Premise
359	group	N	I-Premise
360	.	N	I-Premise

361	ONJ	N	I-Claim
362	is	N	I-Claim
363	multifactorial	N	I-Claim
364	and	N	I-Claim
365	no	N	I-Claim
366	single	N	I-Claim
367	treatment	N	I-Claim
368	modality	N	I-Claim
369	is	N	I-Claim
370	likely	N	I-Claim
371	to	N	I-Claim
372	reverse	N	I-Claim
373	it	N	I-Claim
374	;	N	I-Claim
375	however	N	I-Claim
376	,	N	I-Claim
377	it	N	I-Claim
378	is	N	I-Claim
379	treatable	N	I-Claim
380	and	N	I-Claim
381	even	N	I-Claim
382	advanced	N	I-Claim
383	presentations	N	I-Claim
384	can	N	I-Claim
385	improve	N	I-Claim
386	with	N	I-Claim
387	intensive	N	I-Claim
388	multimodal	N	I-Claim
389	therapy	N	I-Claim
390	.	N	I-Claim

391	Clinically	N	I-Claim
392	,	N	I-Claim
393	HBO	N	I-Claim
394	appears	N	I-Claim
395	to	N	I-Claim
396	be	N	I-Claim
397	a	N	I-Claim
398	useful	N	I-Claim
399	adjunct	N	I-Claim
400	to	N	I-Claim
401	ONJ	N	I-Claim
402	treatment	N	I-Claim
403	,	N	I-Claim
404	particularly	N	I-Claim
405	for	N	I-Claim
406	more	N	I-Claim
407	severe	N	I-Claim
408	cases	N	I-Claim
409	,	N	I-Claim
410	although	N	I-Claim
411	this	N	I-Claim
412	study	N	I-Claim
413	was	N	I-Claim
414	underpowered	N	I-Claim
415	to	N	I-Claim
416	fully	N	I-Claim
417	support	N	I-Claim
418	this	N	I-Claim
419	claim	N	I-Claim
420	.	N	I-Claim

1	Older	N	O
2	breast	N	O
3	cancer	N	O
4	survivors	N	O
5	(	N	O
6	BCSs	N	O
7	)	N	O
8	are	N	O
9	at	N	O
10	risk	N	O
11	for	N	O
12	late	N	O
13	and	N	O
14	long-term	N	O
15	treatment	N	O
16	effects	N	O
17	on	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	(	N	O
22	QOL	N	O
23	)	N	O
24	,	N	O
25	including	N	O
26	lower	N	O
27	physical	N	O
28	functioning	N	O
29	and	N	O
30	fear	N	O
31	of	N	O
32	recurrence	N	O
33	.	N	O

34	Two	N	O
35	promising	N	O
36	approaches	N	O
37	to	N	O
38	address	N	O
39	this	N	O
40	include	N	O
41	dance/movement	N	O
42	therapy	N	O
43	and	N	O
44	mindfulness	N	O
45	.	N	O

46	The	N	O
47	purpose	N	O
48	of	N	O
49	this	N	O
50	2-group	N	O
51	randomized	N	O
52	controlled	N	O
53	pilot	N	O
54	feasibility	N	O
55	study	N	O
56	was	N	O
57	to	N	O
58	test	N	O
59	short-term	N	O
60	effects	N	O
61	of	N	O
62	a	N	O
63	12-week	N	O
64	Mindful	N	O
65	Movement	N	O
66	Program	N	O
67	(	N	O
68	MMP	N	O
69	)	N	O
70	intervention	N	O
71	combining	N	O
72	mindfulness	N	O
73	with	N	O
74	self-directed	N	O
75	movement	N	O
76	on	N	O
77	QOL	N	O
78	and	N	O
79	mindfulness	N	O
80	in	N	O
81	female	N	O
82	BCSs	N	O
83	50	N	O
84	years	N	O
85	or	N	O
86	older	N	O
87	and	N	O
88	at	N	O
89	12	N	O
90	months	N	O
91	or	N	O
92	more	N	O
93	following	N	O
94	treatment	N	O
95	.	N	O

96	Consented	N	O
97	participants	N	O
98	were	N	O
99	randomized	N	O
100	to	N	O
101	an	N	O
102	experimental	N	O
103	group	N	O
104	(	N	O
105	EG	N	O
106	)	N	O
107	(	N	O
108	12	N	O
109	weekly	N	O
110	MMP	N	O
111	sessions	N	O
112	)	N	O
113	or	N	O
114	a	N	O
115	control	N	O
116	group	N	O
117	(	N	O
118	no	N	O
119	sessions	N	O
120	)	N	O
121	.	N	O

122	All	N	O
123	completed	N	O
124	questionnaires	N	O
125	3	N	O
126	times	N	O
127	.	N	O

128	The	N	O
129	EG	N	O
130	participants	N	O
131	kept	N	O
132	home	N	O
133	practice	N	O
134	diaries	N	O
135	.	N	O

136	Analysis	N	O
137	was	N	O
138	conducted	N	O
139	after	N	O
140	intervention	N	O
141	for	N	O
142	immediate	N	O
143	effects	N	O
144	on	N	O
145	outcome	N	O
146	variables	N	O
147	and	N	O
148	6	N	O
149	weeks	N	O
150	later	N	O
151	for	N	O
152	maintenance	N	O
153	of	N	O
154	effects	N	O
155	.	N	O

156	Participants	N	O
157	(	N	O
158	n	N	O
159	=	N	O
160	49	N	O
161	)	N	O
162	ranged	N	O
163	in	N	O
164	age	N	O
165	from	N	O
166	50	N	O
167	to	N	O
168	90	N	O
169	years	N	O
170	(	N	O
171	average	N	O
172	,	N	O
173	65.6	N	O
174	years	N	O
175	)	N	O
176	and	N	O
177	were	N	O
178	at	N	O
179	9.8	N	O
180	years	N	O
181	since	N	O
182	diagnosis	N	O
183	(	N	O
184	range	N	O
185	,	N	O
186	1-32	N	O
187	years	N	O
188	)	N	O
189	,	N	O
190	and	N	O
191	the	N	O
192	majority	N	O
193	were	N	O
194	white	N	O
195	,	N	O
196	unpartnered	N	O
197	,	N	O
198	and	N	O
199	retired	N	O
200	.	N	O

201	After	N	I-Premise
202	intervention	N	I-Premise
203	,	N	I-Premise
204	EG	N	I-Premise
205	participants	N	I-Premise
206	showed	N	I-Premise
207	improved	N	I-Premise
208	QOL	N	I-Premise
209	via	N	I-Premise
210	decreased	N	I-Premise
211	fear	N	I-Premise
212	of	N	I-Premise
213	recurrence	N	I-Premise
214	and	N	I-Premise
215	increased	N	I-Premise
216	mindfulness	N	I-Premise
217	attitude	N	I-Premise
218	.	N	I-Premise

219	At	N	I-Premise
220	6	N	I-Premise
221	weeks	N	I-Premise
222	,	N	I-Premise
223	initial	N	I-Premise
224	effects	N	I-Premise
225	were	N	I-Premise
226	retained	N	I-Premise
227	.	N	I-Premise

228	The	N	I-Premise
229	MMP	N	I-Premise
230	appears	N	I-Premise
231	to	N	I-Premise
232	benefit	N	I-Premise
233	older	N	I-Premise
234	BCSs	N	I-Premise
235	by	N	I-Premise
236	reducing	N	I-Premise
237	fear	N	I-Premise
238	of	N	I-Premise
239	recurrence	N	I-Premise
240	and	N	I-Premise
241	improving	N	I-Premise
242	mindfulness	N	I-Premise
243	attitude	N	I-Premise
244	.	N	I-Premise

245	Although	N	I-Claim
246	these	N	I-Claim
247	findings	N	I-Claim
248	are	N	I-Claim
249	promising	N	I-Claim
250	,	N	I-Claim
251	a	N	I-Claim
252	larger	N	I-Claim
253	study	N	I-Claim
254	is	N	I-Claim
255	needed	N	I-Claim
256	to	N	I-Claim
257	determine	N	I-Claim
258	more	N	I-Claim
259	specifically	N	I-Claim
260	what	N	I-Claim
261	short-	N	I-Claim
262	and	N	I-Claim
263	long-term	N	I-Claim
264	effects	N	I-Claim
265	are	N	I-Claim
266	possible	N	I-Claim
267	.	N	I-Claim

268	The	N	I-Claim
269	combination	N	I-Claim
270	of	N	I-Claim
271	self-directed	N	I-Claim
272	movement	N	I-Claim
273	and	N	I-Claim
274	mindfulness	N	I-Claim
275	,	N	I-Claim
276	as	N	I-Claim
277	tested	N	I-Claim
278	here	N	I-Claim
279	,	N	I-Claim
280	may	N	I-Claim
281	be	N	I-Claim
282	a	N	I-Claim
283	valuable	N	I-Claim
284	tool	N	I-Claim
285	for	N	I-Claim
286	promoting	N	I-Claim
287	health	N	I-Claim
288	and	N	I-Claim
289	well-being	N	I-Claim
290	in	N	I-Claim
291	older	N	I-Claim
292	long-term	N	I-Claim
293	survivors	N	I-Claim
294	of	N	I-Claim
295	breast	N	I-Claim
296	cancer	N	I-Claim
297	.	N	I-Claim

1	Research	N	O
2	has	N	O
3	shown	N	O
4	that	N	O
5	self-directed	N	O
6	stress	N	O
7	management	N	O
8	training	N	O
9	improves	N	O
10	mental	N	O
11	well-being	N	O
12	in	N	O
13	patients	N	O
14	undergoing	N	O
15	chemotherapy	N	O
16	.	N	O

17	The	N	O
18	present	N	O
19	study	N	O
20	extends	N	O
21	this	N	O
22	work	N	O
23	by	N	O
24	evaluating	N	O
25	separate	N	O
26	and	N	O
27	combined	N	O
28	effects	N	O
29	of	N	O
30	stress	N	O
31	management	N	O
32	training	N	O
33	and	N	O
34	home-based	N	O
35	exercise	N	O
36	.	N	O

37	Following	N	O
38	assessment	N	O
39	of	N	O
40	mental	N	O
41	and	N	O
42	physical	N	O
43	well-being	N	O
44	,	N	O
45	depression	N	O
46	,	N	O
47	anxiety	N	O
48	,	N	O
49	exercise	N	O
50	,	N	O
51	and	N	O
52	stress	N	O
53	reduction	N	O
54	activity	N	O
55	before	N	O
56	chemotherapy	N	O
57	started	N	O
58	,	N	O
59	patients	N	O
60	were	N	O
61	randomized	N	O
62	to	N	O
63	stress	N	O
64	management	N	O
65	training	N	O
66	(	N	O
67	SM	N	O
68	)	N	O
69	,	N	O
70	exercise	N	O
71	(	N	O
72	EX	N	O
73	)	N	O
74	,	N	O
75	combined	N	O
76	stress	N	O
77	management	N	O
78	and	N	O
79	exercise	N	O
80	(	N	O
81	SMEX	N	O
82	)	N	O
83	,	N	O
84	or	N	O
85	usual	N	O
86	care	N	O
87	only	N	O
88	(	N	O
89	UCO	N	O
90	)	N	O
91	.	N	O

92	Outcomes	N	O
93	were	N	O
94	reassessed	N	O
95	6	N	O
96	and	N	O
97	12	N	O
98	weeks	N	O
99	after	N	O
100	chemotherapy	N	O
101	started	N	O
102	.	N	O

103	Significance	N	O
104	testing	N	O
105	of	N	O
106	group-by-time	N	O
107	interactions	N	O
108	in	N	O
109	286	N	O
110	patients	N	O
111	who	N	O
112	completed	N	O
113	all	N	O
114	assessments	N	O
115	was	N	O
116	used	N	O
117	to	N	O
118	evaluate	N	O
119	intervention	N	O
120	efficacy	N	O
121	.	N	O

122	Interaction	N	I-Premise
123	effects	N	I-Premise
124	for	N	I-Premise
125	mental	N	I-Premise
126	and	N	I-Premise
127	physical	N	I-Premise
128	well-being	N	I-Premise
129	scores	N	I-Premise
130	were	N	I-Premise
131	not	N	I-Premise
132	significant	N	I-Premise
133	.	N	I-Premise

134	Depression	N	I-Premise
135	scores	N	I-Premise
136	yielded	N	I-Premise
137	a	N	I-Premise
138	linear	N	I-Premise
139	interaction	N	I-Premise
140	comparing	N	I-Premise
141	UCO	N	I-Premise
142	and	N	I-Premise
143	SMEX	N	I-Premise
144	(	N	I-Premise
145	p	N	I-Premise
146	=	N	I-Premise
147	0.019	N	I-Premise
148	)	N	I-Premise
149	,	N	I-Premise
150	with	N	I-Premise
151	decreases	N	I-Premise
152	in	N	I-Premise
153	SMEX	N	I-Premise
154	but	N	I-Premise
155	not	N	I-Premise
156	UCO	N	I-Premise
157	.	N	I-Premise

158	Anxiety	N	I-Premise
159	scores	N	I-Premise
160	yielded	N	I-Premise
161	a	N	I-Premise
162	quadratic	N	I-Premise
163	interaction	N	I-Premise
164	comparing	N	I-Premise
165	UCO	N	I-Premise
166	and	N	I-Premise
167	SMEX	N	I-Premise
168	(	N	I-Premise
169	p	N	I-Premise
170	=	N	I-Premise
171	0.049	N	I-Premise
172	)	N	I-Premise
173	,	N	I-Premise
174	with	N	I-Premise
175	trends	N	I-Premise
176	for	N	I-Premise
177	changes	N	I-Premise
178	in	N	I-Premise
179	SMEX	N	I-Premise
180	but	N	I-Premise
181	not	N	I-Premise
182	UCO	N	I-Premise
183	.	N	I-Premise

184	Additional	N	I-Premise
185	analyses	N	I-Premise
186	yielded	N	I-Premise
187	quadratic	N	I-Premise
188	interactions	N	I-Premise
189	for	N	I-Premise
190	exercise	N	I-Premise
191	activity	N	I-Premise
192	comparing	N	I-Premise
193	UCO	N	I-Premise
194	and	N	I-Premise
195	SMEX	N	I-Premise
196	(	N	I-Premise
197	p	N	I-Premise
198	=	N	I-Premise
199	0.022	N	I-Premise
200	)	N	I-Premise
201	,	N	I-Premise
202	with	N	I-Premise
203	positive	N	I-Premise
204	changes	N	I-Premise
205	in	N	I-Premise
206	SMEX	N	I-Premise
207	but	N	I-Premise
208	not	N	I-Premise
209	UCO	N	I-Premise
210	,	N	I-Premise
211	and	N	I-Premise
212	for	N	I-Premise
213	stress	N	I-Premise
214	management	N	I-Premise
215	activity	N	I-Premise
216	comparing	N	I-Premise
217	UCO	N	I-Premise
218	and	N	I-Premise
219	SM	N	I-Premise
220	(	N	I-Premise
221	p	N	I-Premise
222	<	N	I-Premise
223	0.001	N	I-Premise
224	)	N	I-Premise
225	and	N	I-Premise
226	UCO	N	I-Premise
227	and	N	I-Premise
228	SMEX	N	I-Premise
229	(	N	I-Premise
230	p	N	I-Premise
231	=	N	I-Premise
232	0.013	N	I-Premise
233	)	N	I-Premise
234	,	N	I-Premise
235	with	N	I-Premise
236	positive	N	I-Premise
237	changes	N	I-Premise
238	in	N	I-Premise
239	SM	N	I-Premise
240	and	N	I-Premise
241	SMEX	N	I-Premise
242	but	N	I-Premise
243	not	N	I-Premise
244	UCO	N	I-Premise
245	.	N	I-Premise

246	Only	N	I-Claim
247	the	N	I-Claim
248	combined	N	I-Claim
249	intervention	N	I-Claim
250	yielded	N	I-Claim
251	effects	N	I-Claim
252	on	N	I-Claim
253	quality	N	I-Claim
254	of	N	I-Claim
255	life	N	I-Claim
256	outcomes	N	I-Claim
257	,	N	I-Claim
258	and	N	I-Claim
259	these	N	I-Claim
260	were	N	I-Claim
261	limited	N	I-Claim
262	to	N	I-Claim
263	anxiety	N	I-Claim
264	and	N	I-Claim
265	depression	N	I-Claim
266	.	N	I-Claim

267	These	N	I-Premise
268	findings	N	I-Premise
269	are	N	I-Premise
270	consistent	N	I-Premise
271	with	N	I-Premise
272	evidence	N	I-Premise
273	that	N	I-Premise
274	only	N	I-Premise
275	the	N	I-Premise
276	combined	N	I-Premise
277	intervention	N	I-Premise
278	yielded	N	I-Premise
279	increases	N	I-Premise
280	in	N	I-Premise
281	both	N	I-Premise
282	exercise	N	I-Premise
283	and	N	I-Premise
284	stress	N	I-Premise
285	management	N	I-Premise
286	activity	N	I-Premise
287	.	N	I-Premise

288	Future	N	O
289	research	N	O
290	should	N	O
291	investigate	N	O
292	ways	N	O
293	to	N	O
294	augment	N	O
295	this	N	O
296	intervention	N	O
297	to	N	O
298	enhance	N	O
299	its	N	O
300	benefits	N	O
301	.	N	O

1	The	N	I-MajorClaim
2	incidence	N	I-MajorClaim
3	and	N	I-MajorClaim
4	development	N	I-MajorClaim
5	of	N	I-MajorClaim
6	cancer	N	I-MajorClaim
7	are	N	I-MajorClaim
8	closely	N	I-MajorClaim
9	related	N	I-MajorClaim
10	to	N	I-MajorClaim
11	dysfunction	N	I-MajorClaim
12	of	N	I-MajorClaim
13	immune	N	I-MajorClaim
14	function	N	I-MajorClaim
15	.	N	I-MajorClaim

16	The	N	O
17	immune	N	O
18	system	N	O
19	can	N	O
20	not	N	O
21	identify	N	O
22	and	N	O
23	remove	N	O
24	malignant	N	O
25	and	N	O
26	mutant	N	O
27	cells	N	O
28	,	N	O
29	which	N	O
30	cause	N	O
31	tumor	N	O
32	cells	N	O
33	to	N	O
34	escape	N	O
35	from	N	O
36	surveillance	N	O
37	and	N	O
38	clearance	N	O
39	of	N	O
40	the	N	O
41	immune	N	O
42	system	N	O
43	.	N	O

44	Immunobiological	N	O
45	cancer	N	O
46	therapy	N	O
47	plays	N	O
48	an	N	O
49	important	N	O
50	role	N	O
51	in	N	O
52	strengthening	N	O
53	body	N	O
54	immunological	N	O
55	surveillance	N	O
56	function	N	O
57	and	N	O
58	killing	N	O
59	remaining	N	O
60	tumor	N	O
61	cells	N	O
62	in	N	O
63	the	N	O
64	body	N	O
65	.	N	O

66	We	N	O
67	investigated	N	O
68	the	N	O
69	role	N	O
70	of	N	O
71	DC/CIK	N	O
72	(	N	O
73	dendritic	N	O
74	cell/cytokine-induced	N	O
75	killer	N	O
76	cells	N	O
77	)	N	O
78	immunobiological	N	O
79	cancer	N	O
80	therapy	N	O
81	in	N	O
82	maintenance	N	O
83	therapy	N	O
84	of	N	O
85	advanced	N	O
86	non-small	N	O
87	cell	N	O
88	lung	N	O
89	cancer	N	O
90	.	N	O

91	When	N	O
92	60	N	O
93	cases	N	O
94	of	N	O
95	non-small	N	O
96	cell	N	O
97	lung	N	O
98	cancer	N	O
99	patients	N	O
100	in	N	O
101	stage	N	O
102	IIIb	N	O
103	and	N	O
104	IV	N	O
105	reached	N	O
106	stable	N	O
107	disease	N	O
108	after	N	O
109	treatment	N	O
110	with	N	O
111	4	N	O
112	cycles	N	O
113	of	N	O
114	a	N	O
115	two-drug	N	O
116	regimen	N	O
117	with	N	O
118	platinum	N	O
119	,	N	O
120	they	N	O
121	were	N	O
122	randomly	N	O
123	divided	N	O
124	into	N	O
125	two	N	O
126	groups	N	O
127	.	N	O

128	One	N	O
129	group	N	O
130	was	N	O
131	treated	N	O
132	with	N	O
133	DC/CIK	N	O
134	immunobiological	N	O
135	cancer	N	O
136	therapy	N	O
137	,	N	O
138	and	N	O
139	the	N	O
140	other	N	O
141	was	N	O
142	taken	N	O
143	as	N	O
144	a	N	O
145	control	N	O
146	group	N	O
147	.	N	O

148	Finally	N	O
149	,	N	O
150	cancer	N	O
151	progression	N	O
152	time	N	O
153	and	N	O
154	toxicity	N	O
155	reaction	N	O
156	of	N	O
157	the	N	O
158	two	N	O
159	groups	N	O
160	were	N	O
161	evaluated	N	O
162	.	N	O

163	DC/CIK	N	I-Premise
164	treatment	N	I-Premise
165	prolongs	N	I-Premise
166	progression-free	N	I-Premise
167	survival	N	I-Premise
168	(	N	I-Premise
169	3.20	N	I-Premise
170	months	N	I-Premise
171	[	N	I-Premise
172	95	N	I-Premise
173	%	N	I-Premise
174	CI	N	I-Premise
175	,	N	I-Premise
176	2.94-3.50	N	I-Premise
177	]	N	I-Premise
178	vs	N	I-Premise
179	2.56	N	I-Premise
180	months	N	I-Premise
181	[	N	I-Premise
182	95	N	I-Premise
183	%	N	I-Premise
184	CI	N	I-Premise
185	,	N	I-Premise
186	2.39-2.73	N	I-Premise
187	]	N	I-Premise
188	;	N	I-Premise
189	P	N	I-Premise
190	<	N	I-Premise
191	0.05	N	I-Premise
192	)	N	I-Premise
193	.	N	I-Premise

194	In	N	I-Premise
195	the	N	I-Premise
196	treatment	N	I-Premise
197	group	N	I-Premise
198	,	N	I-Premise
199	the	N	I-Premise
200	proportion	N	I-Premise
201	of	N	I-Premise
202	NK	N	I-Premise
203	cells	N	I-Premise
204	,	N	I-Premise
205	T-cell	N	I-Premise
206	subgroups	N	I-Premise
207	CD3+	N	I-Premise
208	,	N	I-Premise
209	CD4+	N	I-Premise
210	and	N	I-Premise
211	CD8+	N	I-Premise
212	had	N	I-Premise
213	a	N	I-Premise
214	significant	N	I-Premise
215	change	N	I-Premise
216	before	N	I-Premise
217	and	N	I-Premise
218	after	N	I-Premise
219	treatment	N	I-Premise
220	.	N	I-Premise

221	Liver	N	I-Premise
222	and	N	I-Premise
223	kidney	N	I-Premise
224	function	N	I-Premise
225	and	N	I-Premise
226	blood	N	I-Premise
227	tests	N	I-Premise
228	of	N	I-Premise
229	the	N	I-Premise
230	treatment	N	I-Premise
231	group	N	I-Premise
232	were	N	I-Premise
233	within	N	I-Premise
234	the	N	I-Premise
235	normal	N	I-Premise
236	range	N	I-Premise
237	before	N	I-Premise
238	and	N	I-Premise
239	after	N	I-Premise
240	treatment	N	I-Premise
241	.	N	I-Premise

242	In	N	I-Premise
243	the	N	I-Premise
244	treatment	N	I-Premise
245	group	N	I-Premise
246	,	N	I-Premise
247	1	N	I-Premise
248	case	N	I-Premise
249	suffered	N	I-Premise
250	from	N	I-Premise
251	chest	N	I-Premise
252	distress	N	I-Premise
253	,	N	I-Premise
254	3	N	I-Premise
255	cases	N	I-Premise
256	suffered	N	I-Premise
257	from	N	I-Premise
258	acratia	N	I-Premise
259	,	N	I-Premise
260	and	N	I-Premise
261	4	N	I-Premise
262	cases	N	I-Premise
263	suffered	N	I-Premise
264	from	N	I-Premise
265	pyrexia	N	I-Premise
266	.	N	I-Premise

267	DC/CIK	N	I-Claim
268	treatment	N	I-Claim
269	had	N	I-Claim
270	potential	N	I-Claim
271	benefit	N	I-Claim
272	for	N	I-Claim
273	patients	N	I-Claim
274	with	N	I-Claim
275	advanced	N	I-Claim
276	non-small	N	I-Claim
277	cell	N	I-Claim
278	lung	N	I-Claim
279	cancer	N	I-Claim
280	compared	N	I-Claim
281	with	N	I-Claim
282	the	N	I-Claim
283	control	N	I-Claim
284	group	N	I-Claim
285	and	N	I-Claim
286	had	N	I-Claim
287	no	N	I-Claim
288	obvious	N	I-Claim
289	side	N	I-Claim
290	effects	N	I-Claim
291	.	N	I-Claim

292	DC/CIK	N	I-Claim
293	treatment	N	I-Claim
294	is	N	I-Claim
295	a	N	I-Claim
296	safe	N	I-Claim
297	and	N	I-Claim
298	effective	N	I-Claim
299	method	N	I-Claim
300	for	N	I-Claim
301	maintenance	N	I-Claim
302	therapy	N	I-Claim
303	of	N	I-Claim
304	advanced	N	I-Claim
305	non-small	N	I-Claim
306	cell	N	I-Claim
307	lung	N	I-Claim
308	cancer	N	I-Claim
309	.	N	I-Claim

1	Nocturnal	N	O
2	administration	N	O
3	of	N	O
4	branched-chain	N	O
5	amino	N	O
6	acid	N	O
7	(	N	O
8	BCAA	N	O
9	)	N	O
10	granules	N	O
11	improves	N	O
12	serum	N	O
13	albumin	N	O
14	levels	N	O
15	in	N	O
16	patients	N	O
17	with	N	O
18	cirrhosis	N	O
19	.	N	O

20	However	N	O
21	,	N	O
22	it	N	O
23	is	N	O
24	unclear	N	O
25	whether	N	O
26	or	N	O
27	not	N	O
28	this	N	O
29	administration	N	O
30	method	N	O
31	can	N	O
32	improve	N	O
33	the	N	O
34	patients	N	O
35	'	N	O
36	quality	N	O
37	of	N	O
38	life	N	O
39	(	N	O
40	QOL	N	O
41	)	N	O
42	.	N	O

43	In	N	O
44	this	N	O
45	study	N	O
46	,	N	O
47	we	N	O
48	aimed	N	O
49	to	N	O
50	investigate	N	O
51	the	N	O
52	efficacy	N	O
53	of	N	O
54	BCAA	N	O
55	granules	N	O
56	,	N	O
57	given	N	O
58	nocturnally	N	O
59	,	N	O
60	in	N	O
61	improving	N	O
62	QOL	N	O
63	in	N	O
64	these	N	O
65	patients	N	O
66	.	N	O

67	We	N	O
68	performed	N	O
69	a	N	O
70	multicenter	N	O
71	,	N	O
72	randomized	N	O
73	controlled	N	O
74	trial	N	O
75	examining	N	O
76	the	N	O
77	comparative	N	O
78	effects	N	O
79	of	N	O
80	BCAA	N	O
81	granules	N	O
82	given	N	O
83	orally	N	O
84	for	N	O
85	3	N	O
86	months	N	O
87	with	N	O
88	daytime	N	O
89	or	N	O
90	nocturnal	N	O
91	administration	N	O
92	in	N	O
93	patients	N	O
94	with	N	O
95	compensated	N	O
96	cirrhosis	N	O
97	.	N	O

98	Health-related	N	O
99	QOL	N	O
100	was	N	O
101	measured	N	O
102	by	N	O
103	a	N	O
104	Japanese	N	O
105	version	N	O
106	of	N	O
107	the	N	O
108	questionnaire	N	O
109	on	N	O
110	subjective	N	O
111	and	N	O
112	objective	N	O
113	symptoms	N	O
114	,	N	O
115	and	N	O
116	the	N	O
117	Short	N	O
118	Form-8	N	O
119	(	N	O
120	SF-8	N	O
121	)	N	O
122	questionnaire	N	O
123	.	N	O

124	Twenty-one	N	O
125	patients	N	O
126	received	N	O
127	BCAA	N	O
128	granules	N	O
129	three	N	O
130	times	N	O
131	a	N	O
132	day	N	O
133	(	N	O
134	one	N	O
135	sachet	N	O
136	after	N	O
137	each	N	O
138	meal	N	O
139	:	N	O
140	the	N	O
141	daytime	N	O
142	group	N	O
143	)	N	O
144	,	N	O
145	and	N	O
146	16	N	O
147	patients	N	O
148	received	N	O
149	the	N	O
150	granules	N	O
151	twice	N	O
152	a	N	O
153	day	N	O
154	(	N	O
155	one	N	O
156	sachet	N	O
157	after	N	O
158	breakfast	N	O
159	,	N	O
160	and	N	O
161	two	N	O
162	sachets	N	O
163	before	N	O
164	bedtime	N	O
165	:	N	O
166	the	N	O
167	nocturnal	N	O
168	group	N	O
169	)	N	O
170	.	N	O

171	Baseline	N	O
172	characteristics	N	O
173	did	N	O
174	not	N	O
175	differ	N	O
176	between	N	O
177	the	N	O
178	groups	N	O
179	(	N	O
180	whole	N	O
181	cohort	N	O
182	:	N	O
183	Child-Pugh	N	O
184	grade	N	O
185	A/B	N	O
186	,	N	O
187	21/16	N	O
188	;	N	O
189	mean	N	O
190	age	N	O
191	,	N	O
192	68.2	N	O
193	years	N	O
194	)	N	O
195	.	N	O

196	There	N	I-Premise
197	was	N	I-Premise
198	no	N	I-Premise
199	significant	N	I-Premise
200	difference	N	I-Premise
201	in	N	I-Premise
202	any	N	I-Premise
203	of	N	I-Premise
204	the	N	I-Premise
205	subjects	N	I-Premise
206	revealed	N	I-Premise
207	by	N	I-Premise
208	the	N	I-Premise
209	questionnaire	N	I-Premise
210	regarding	N	I-Premise
211	subjective	N	I-Premise
212	or	N	I-Premise
213	objective	N	I-Premise
214	symptoms	N	I-Premise
215	,	N	I-Premise
216	or	N	I-Premise
217	by	N	I-Premise
218	the	N	I-Premise
219	SF-8	N	I-Premise
220	between	N	I-Premise
221	the	N	I-Premise
222	daytime	N	I-Premise
223	group	N	I-Premise
224	and	N	I-Premise
225	the	N	I-Premise
226	nocturnal	N	I-Premise
227	group	N	I-Premise
228	after	N	I-Premise
229	3	N	I-Premise
230	months	N	I-Premise
231	of	N	I-Premise
232	treatment	N	I-Premise
233	.	N	I-Premise

234	The	N	I-Premise
235	daytime	N	I-Premise
236	group	N	I-Premise
237	showed	N	I-Premise
238	a	N	I-Premise
239	significant	N	I-Premise
240	effect	N	I-Premise
241	on	N	I-Premise
242	general	N	I-Premise
243	health	N	I-Premise
244	,	N	I-Premise
245	vitality	N	I-Premise
246	,	N	I-Premise
247	social	N	I-Premise
248	functioning	N	I-Premise
249	,	N	I-Premise
250	mental	N	I-Premise
251	health	N	I-Premise
252	,	N	I-Premise
253	and	N	I-Premise
254	role	N	I-Premise
255	emotional	N	I-Premise
256	as	N	I-Premise
257	revealed	N	I-Premise
258	on	N	I-Premise
259	the	N	I-Premise
260	SF-8	N	I-Premise
261	.	N	I-Premise

262	Conversely	N	I-Premise
263	,	N	I-Premise
264	the	N	I-Premise
265	nocturnal	N	I-Premise
266	group	N	I-Premise
267	exhibited	N	I-Premise
268	a	N	I-Premise
269	significant	N	I-Premise
270	decrease	N	I-Premise
271	in	N	I-Premise
272	the	N	I-Premise
273	occurrence	N	I-Premise
274	of	N	I-Premise
275	muscle	N	I-Premise
276	cramps	N	I-Premise
277	in	N	I-Premise
278	the	N	I-Premise
279	legs	N	I-Premise
280	(	N	I-Premise
281	P	N	I-Premise
282	=	N	I-Premise
283	0.014	N	I-Premise
284	)	N	I-Premise
285	and	N	I-Premise
286	significantly	N	I-Premise
287	improved	N	I-Premise
288	Fisher	N	I-Premise
289	's	N	I-Premise
290	ratio	N	I-Premise
291	after	N	I-Premise
292	3	N	I-Premise
293	months	N	I-Premise
294	(	N	I-Premise
295	P	N	I-Premise
296	=	N	I-Premise
297	0.04	N	I-Premise
298	)	N	I-Premise
299	.	N	I-Premise

300	Nocturnal	N	I-Claim
301	administration	N	I-Claim
302	of	N	I-Claim
303	BCAA	N	I-Claim
304	granules	N	I-Claim
305	in	N	I-Claim
306	patients	N	I-Claim
307	with	N	I-Claim
308	cirrhosis	N	I-Claim
309	reduced	N	I-Claim
310	the	N	I-Claim
311	occurrence	N	I-Claim
312	of	N	I-Claim
313	muscle	N	I-Claim
314	cramps	N	I-Claim
315	in	N	I-Claim
316	the	N	I-Claim
317	leg	N	I-Claim
318	but	N	I-Claim
319	did	N	I-Claim
320	not	N	I-Claim
321	improve	N	I-Claim
322	the	N	I-Claim
323	patients	N	I-Claim
324	'	N	I-Claim
325	QOL	N	I-Claim
326	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	prospective	N	O
6	controlled	N	O
7	study	N	O
8	was	N	O
9	to	N	O
10	assess	N	O
11	the	N	O
12	efficacy	N	O
13	of	N	O
14	two	N	O
15	different	N	O
16	combination	N	O
17	treatment	N	O
18	modalities	N	O
19	of	N	O
20	lymphedema	N	O
21	(	N	O
22	LE	N	O
23	)	N	O
24	.	N	O

25	Manual	N	O
26	lymphatic	N	O
27	drainage	N	O
28	(	N	O
29	MLD	N	O
30	)	N	O
31	and	N	O
32	compression	N	O
33	bandage	N	O
34	combination	N	O
35	(	N	O
36	complex	N	O
37	decongestive	N	O
38	therapy	N	O
39	)	N	O
40	have	N	O
41	been	N	O
42	compared	N	O
43	with	N	O
44	intermittent	N	O
45	pneumatic	N	O
46	compression	N	O
47	(	N	O
48	IPC	N	O
49	)	N	O
50	plus	N	O
51	self-lymphatic	N	O
52	drainage	N	O
53	(	N	O
54	SLD	N	O
55	)	N	O
56	.	N	O

57	Both	N	O
58	MLD	N	O
59	with	N	O
60	compression	N	O
61	bandage	N	O
62	(	N	O
63	complex	N	O
64	decongestive	N	O
65	therapy	N	O
66	)	N	O
67	group	N	O
68	(	N	O
69	Group	N	O
70	I	N	O
71	,	N	O
72	n=15	N	O
73	)	N	O
74	and	N	O
75	IPC	N	O
76	with	N	O
77	SLD	N	O
78	group	N	O
79	(	N	O
80	Group	N	O
81	II	N	O
82	,	N	O
83	n=15	N	O
84	)	N	O
85	received	N	O
86	treatment	N	O
87	for	N	O
88	LE	N	O
89	3	N	O
90	days	N	O
91	in	N	O
92	a	N	O
93	week	N	O
94	and	N	O
95	every	N	O
96	other	N	O
97	day	N	O
98	for	N	O
99	6	N	O
100	weeks	N	O
101	.	N	O

102	Arm	N	O
103	circumferences	N	O
104	were	N	O
105	measured	N	O
106	before	N	O
107	and	N	O
108	the	N	O
109	1st	N	O
110	,	N	O
111	3rd	N	O
112	,	N	O
113	and	N	O
114	6th	N	O
115	weeks	N	O
116	of	N	O
117	the	N	O
118	treatment	N	O
119	.	N	O

120	EORTC-QLQ	N	O
121	and	N	O
122	ASES-tests	N	O
123	were	N	O
124	performed	N	O
125	to	N	O
126	assess	N	O
127	the	N	O
128	quality	N	O
129	of	N	O
130	life	N	O
131	before	N	O
132	and	N	O
133	after	N	O
134	6	N	O
135	week-treatment	N	O
136	.	N	O

137	Patients	N	O
138	in	N	O
139	both	N	O
140	groups	N	O
141	had	N	O
142	similar	N	O
143	demographic	N	O
144	and	N	O
145	clinical	N	O
146	characteristics	N	O
147	.	N	O

148	Even	N	O
149	though	N	O
150	both	N	I-Premise
151	treatment	N	I-Premise
152	modalities	N	I-Premise
153	resulted	N	I-Premise
154	in	N	I-Premise
155	significant	N	I-Premise
156	decrease	N	I-Premise
157	in	N	I-Premise
158	the	N	I-Premise
159	total	N	I-Premise
160	arm	N	I-Premise
161	volume	N	I-Premise
162	(	N	I-Premise
163	12.2	N	I-Premise
164	%	N	I-Premise
165	decrease	N	I-Premise
166	in	N	I-Premise
167	Group	N	I-Premise
168	II	N	I-Premise
169	and	N	I-Premise
170	14.9	N	I-Premise
171	%	N	I-Premise
172	decrease	N	I-Premise
173	in	N	I-Premise
174	Group	N	I-Premise
175	I	N	I-Premise
176	)	N	I-Premise
177	(	N	I-Premise
178	p	N	I-Premise
179	<	N	I-Premise
180	0.001	N	I-Premise
181	)	N	I-Premise
182	,	N	I-Premise
183	no	N	I-Premise
184	significant	N	I-Premise
185	difference	N	I-Premise
186	(	N	I-Premise
187	p=0.582	N	I-Premise
188	)	N	I-Premise
189	was	N	I-Premise
190	found	N	I-Premise
191	between	N	I-Premise
192	those	N	I-Premise
193	two	N	I-Premise
194	groups	N	I-Premise
195	.	N	I-Premise

196	Similarly	N	I-Premise
197	,	N	I-Premise
198	ASES	N	I-Premise
199	scores	N	I-Premise
200	were	N	I-Premise
201	significantly	N	I-Premise
202	(	N	I-Premise
203	p=0.001	N	I-Premise
204	)	N	I-Premise
205	improved	N	I-Premise
206	in	N	I-Premise
207	both	N	I-Premise
208	Group	N	I-Premise
209	I	N	I-Premise
210	and	N	I-Premise
211	II	N	I-Premise
212	without	N	I-Premise
213	any	N	I-Premise
214	significant	N	I-Premise
215	difference	N	I-Premise
216	between	N	I-Premise
217	the	N	I-Premise
218	groups	N	I-Premise
219	.	N	I-Premise

220	While	N	I-Premise
221	emotional	N	I-Premise
222	functioning	N	I-Premise
223	,	N	I-Premise
224	fatigue	N	I-Premise
225	,	N	I-Premise
226	and	N	I-Premise
227	pain	N	I-Premise
228	scores	N	I-Premise
229	were	N	I-Premise
230	significantly	N	I-Premise
231	improved	N	I-Premise
232	in	N	I-Premise
233	both	N	I-Premise
234	groups	N	I-Premise
235	,	N	I-Premise
236	global	N	I-Premise
237	health	N	I-Premise
238	status	N	I-Premise
239	,	N	I-Premise
240	functional	N	I-Premise
241	and	N	I-Premise
242	cognitive	N	I-Premise
243	functioning	N	I-Premise
244	scores	N	I-Premise
245	appeared	N	I-Premise
246	to	N	I-Premise
247	be	N	I-Premise
248	improved	N	I-Premise
249	only	N	I-Premise
250	in	N	I-Premise
251	patients	N	I-Premise
252	of	N	I-Premise
253	group	N	I-Premise
254	I	N	I-Premise
255	.	N	I-Premise

256	Different	N	I-Claim
257	treatment	N	I-Claim
258	modalities	N	I-Claim
259	consisting	N	I-Claim
260	of	N	I-Claim
261	MLD	N	I-Claim
262	and	N	I-Claim
263	compression	N	I-Claim
264	bandage	N	I-Claim
265	(	N	I-Claim
266	complex	N	I-Claim
267	decongestive	N	I-Claim
268	therapy	N	I-Claim
269	)	N	I-Claim
270	or	N	I-Claim
271	IPC	N	I-Claim
272	and	N	I-Claim
273	SLD	N	I-Claim
274	appear	N	I-Claim
275	to	N	I-Claim
276	be	N	I-Claim
277	effective	N	I-Claim
278	in	N	I-Claim
279	the	N	I-Claim
280	treatment	N	I-Claim
281	of	N	I-Claim
282	LE	N	I-Claim
283	with	N	I-Claim
284	similar	N	I-Claim
285	therapeutic	N	I-Claim
286	efficacy	N	I-Claim
287	in	N	I-Claim
288	patients	N	I-Claim
289	with	N	I-Claim
290	breast	N	I-Claim
291	cancer	N	I-Claim
292	.	N	I-Claim

293	However	N	I-Claim
294	,	N	I-Claim
295	combination	N	I-Claim
296	modalities	N	I-Claim
297	including	N	I-Claim
298	IPC	N	I-Claim
299	and	N	I-Claim
300	SLD	N	I-Claim
301	may	N	I-Claim
302	be	N	I-Claim
303	the	N	I-Claim
304	preferred	N	I-Claim
305	choices	N	I-Claim
306	for	N	I-Claim
307	their	N	I-Claim
308	applicability	N	I-Claim
309	at	N	I-Claim
310	home	N	I-Claim
311	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	demonstrate	N	O
9	that	N	O
10	intrapatient	N	O
11	dose	N	O
12	escalation	N	O
13	of	N	O
14	carboplatin	N	O
15	would	N	O
16	improve	N	O
17	the	N	O
18	outcome	N	O
19	in	N	O
20	ovarian	N	O
21	cancer	N	O
22	compared	N	O
23	with	N	O
24	flat	N	O
25	dosing	N	O
26	.	N	O

27	Patients	N	O
28	with	N	O
29	untreated	N	O
30	stage	N	O
31	IC-IV	N	O
32	ovarian	N	O
33	cancer	N	O
34	received	N	O
35	six	N	O
36	cycles	N	O
37	of	N	O
38	carboplatin	N	O
39	area	N	O
40	under	N	O
41	the	N	O
42	curve	N	O
43	6	N	O
44	(	N	O
45	AUC	N	O
46	6	N	O
47	)	N	O
48	3	N	O
49	weekly	N	O
50	either	N	O
51	with	N	O
52	no	N	O
53	dose	N	O
54	modification	N	O
55	except	N	O
56	for	N	O
57	toxicity	N	O
58	(	N	O
59	Arm	N	O
60	A	N	O
61	)	N	O
62	or	N	O
63	with	N	O
64	dose	N	O
65	escalations	N	O
66	in	N	O
67	cycles	N	O
68	2-6	N	O
69	based	N	O
70	on	N	O
71	nadir	N	O
72	neutrophil	N	O
73	and	N	O
74	platelet	N	O
75	counts	N	O
76	(	N	O
77	Arm	N	O
78	B	N	O
79	)	N	O
80	.	N	O

81	The	N	O
82	primary	N	O
83	end-point	N	O
84	was	N	O
85	progression-free	N	O
86	survival	N	O
87	(	N	O
88	PFS	N	O
89	)	N	O
90	.	N	O

91	Nine	N	O
92	hundred	N	O
93	and	N	O
94	sixty-four	N	O
95	patients	N	O
96	were	N	O
97	recruited	N	O
98	from	N	O
99	71	N	O
100	centers	N	O
101	.	N	O

102	Dose	N	O
103	escalation	N	O
104	was	N	O
105	achieved	N	O
106	in	N	O
107	77	N	O
108	%	N	O
109	of	N	O
110	patients	N	O
111	who	N	O
112	had	N	O
113	1	N	O
114	cycle	N	O
115	.	N	O

116	The	N	I-Premise
117	median	N	I-Premise
118	AUCs	N	I-Premise
119	(	N	I-Premise
120	cycle	N	I-Premise
121	2-6	N	I-Premise
122	)	N	I-Premise
123	received	N	I-Premise
124	were	N	I-Premise
125	6.0	N	I-Premise
126	(	N	I-Premise
127	Arm	N	I-Premise
128	A	N	I-Premise
129	)	N	I-Premise
130	and	N	I-Premise
131	7.2	N	I-Premise
132	(	N	I-Premise
133	Arm	N	I-Premise
134	B	N	I-Premise
135	)	N	I-Premise
136	(	N	I-Premise
137	P	N	I-Premise
138	<	N	I-Premise
139	0.001	N	I-Premise
140	)	N	I-Premise
141	.	N	I-Premise

142	Grade	N	I-Premise
143	3/4	N	I-Premise
144	non-hematological	N	I-Premise
145	toxicity	N	I-Premise
146	was	N	I-Premise
147	higher	N	I-Premise
148	in	N	I-Premise
149	Arm	N	I-Premise
150	B	N	I-Premise
151	(	N	I-Premise
152	31	N	I-Premise
153	%	N	I-Premise
154	versus	N	I-Premise
155	22	N	I-Premise
156	%	N	I-Premise
157	P	N	I-Premise
158	=	N	I-Premise
159	0.001	N	I-Premise
160	)	N	I-Premise
161	.	N	I-Premise

162	The	N	I-Premise
163	median	N	I-Premise
164	PFS	N	I-Premise
165	was	N	I-Premise
166	12.1	N	I-Premise
167	months	N	I-Premise
168	in	N	I-Premise
169	Arm	N	I-Premise
170	A	N	I-Premise
171	and	N	I-Premise
172	B	N	I-Premise
173	[	N	I-Premise
174	hazard	N	I-Premise
175	ratio	N	I-Premise
176	(	N	I-Premise
177	HR	N	I-Premise
178	)	N	I-Premise
179	0.99	N	I-Premise
180	;	N	I-Premise
181	95	N	I-Premise
182	%	N	I-Premise
183	confidence	N	I-Premise
184	interval	N	I-Premise
185	(	N	I-Premise
186	CI	N	I-Premise
187	)	N	I-Premise
188	0.85-1.15	N	I-Premise
189	;	N	I-Premise
190	P	N	I-Premise
191	=	N	I-Premise
192	0.93	N	I-Premise
193	]	N	I-Premise
194	.	N	I-Premise

195	The	N	I-Premise
196	median	N	I-Premise
197	overall	N	I-Premise
198	survival	N	I-Premise
199	(	N	I-Premise
200	OS	N	I-Premise
201	)	N	I-Premise
202	was	N	I-Premise
203	34.1	N	I-Premise
204	and	N	I-Premise
205	30.7	N	I-Premise
206	months	N	I-Premise
207	in	N	I-Premise
208	Arms	N	I-Premise
209	A	N	I-Premise
210	and	N	I-Premise
211	B	N	I-Premise
212	,	N	I-Premise
213	respectively	N	I-Premise
214	(	N	I-Premise
215	HR	N	I-Premise
216	0.98	N	I-Premise
217	;	N	I-Premise
218	95	N	I-Premise
219	%	N	I-Premise
220	CI	N	I-Premise
221	0.81-1.18	N	I-Premise
222	,	N	I-Premise
223	P	N	I-Premise
224	=	N	I-Premise
225	0.82	N	I-Premise
226	)	N	I-Premise
227	.	N	I-Premise

228	In	N	I-Premise
229	multivariate	N	I-Premise
230	analysis	N	I-Premise
231	,	N	I-Premise
232	baseline	N	I-Premise
233	neutrophil	N	I-Premise
234	(	N	I-Premise
235	P	N	I-Premise
236	<	N	I-Premise
237	0.001	N	I-Premise
238	)	N	I-Premise
239	,	N	I-Premise
240	baseline	N	I-Premise
241	platelet	N	I-Premise
242	counts	N	I-Premise
243	(	N	I-Premise
244	P	N	I-Premise
245	<	N	I-Premise
246	0.001	N	I-Premise
247	)	N	I-Premise
248	and	N	I-Premise
249	the	N	I-Premise
250	difference	N	I-Premise
251	between	N	I-Premise
252	white	N	I-Premise
253	blood	N	I-Premise
254	cell	N	I-Premise
255	(	N	I-Premise
256	WBC	N	I-Premise
257	)	N	I-Premise
258	and	N	I-Premise
259	neutrophil	N	I-Premise
260	count	N	I-Premise
261	(	N	I-Premise
262	P	N	I-Premise
263	=	N	I-Premise
264	0.009	N	I-Premise
265	)	N	I-Premise
266	had	N	I-Premise
267	a	N	I-Premise
268	significant	N	I-Premise
269	adverse	N	I-Premise
270	prognostic	N	I-Premise
271	value	N	I-Premise
272	.	N	I-Premise

273	Intrapatient	N	I-Claim
274	dose	N	I-Claim
275	escalation	N	I-Claim
276	of	N	I-Claim
277	carboplatin	N	I-Claim
278	based	N	I-Claim
279	on	N	I-Claim
280	nadir	N	I-Claim
281	blood	N	I-Claim
282	counts	N	I-Claim
283	is	N	I-Claim
284	feasible	N	I-Claim
285	and	N	I-Claim
286	safe	N	I-Claim
287	.	N	I-Claim

288	However	N	I-Claim
289	,	N	I-Claim
290	it	N	I-Claim
291	provided	N	I-Claim
292	no	N	I-Claim
293	improvement	N	I-Claim
294	in	N	I-Claim
295	PFS	N	I-Claim
296	or	N	I-Claim
297	OS	N	I-Claim
298	compared	N	I-Claim
299	with	N	I-Claim
300	flat	N	I-Claim
301	dosing	N	I-Claim
302	.	N	I-Claim

303	Baseline	N	O
304	neutrophils	N	O
305	over-ride	N	O
306	nadir	N	O
307	counts	N	O
308	in	N	O
309	prognostic	N	O
310	significance	N	O
311	.	N	O

312	These	N	O
313	data	N	O
314	may	N	O
315	have	N	O
316	wider	N	O
317	implications	N	O
318	particularly	N	O
319	in	N	O
320	respect	N	O
321	of	N	O
322	the	N	O
323	management	N	O
324	of	N	O
325	chemotherapy-induced	N	O
326	neutropenia	N	O
327	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	our	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	evaluate	N	O
9	the	N	O
10	effect	N	O
11	of	N	O
12	cognitive	N	O
13	behavioral	N	O
14	therapy	N	O
15	(	N	O
16	CBT	N	O
17	)	N	O
18	,	N	O
19	physical	N	O
20	exercise	N	O
21	(	N	O
22	PE	N	O
23	)	N	O
24	,	N	O
25	and	N	O
26	of	N	O
27	these	N	O
28	two	N	O
29	interventions	N	O
30	combined	N	O
31	(	N	O
32	CBT/PE	N	O
33	)	N	O
34	on	N	O
35	menopausal	N	O
36	symptoms	N	O
37	(	N	O
38	primary	N	O
39	outcome	N	O
40	)	N	O
41	,	N	O
42	body	N	O
43	image	N	O
44	,	N	O
45	sexual	N	O
46	functioning	N	O
47	,	N	O
48	psychological	N	O
49	well-being	N	O
50	,	N	O
51	and	N	O
52	health-related	N	O
53	quality	N	O
54	of	N	O
55	life	N	O
56	(	N	O
57	secondary	N	O
58	outcomes	N	O
59	)	N	O
60	in	N	O
61	patients	N	O
62	with	N	O
63	breast	N	O
64	cancer	N	O
65	experiencing	N	O
66	treatment-induced	N	O
67	menopause	N	O
68	.	N	O

69	Patients	N	O
70	with	N	O
71	breast	N	O
72	cancer	N	O
73	reporting	N	O
74	treatment-induced	N	O
75	menopausal	N	O
76	symptoms	N	O
77	(	N	O
78	N=422	N	O
79	)	N	O
80	were	N	O
81	randomly	N	O
82	assigned	N	O
83	to	N	O
84	CBT	N	O
85	(	N	O
86	n=109	N	O
87	)	N	O
88	,	N	O
89	PE	N	O
90	(	N	O
91	n=104	N	O
92	)	N	O
93	,	N	O
94	CBT/PE	N	O
95	(	N	O
96	n=106	N	O
97	)	N	O
98	,	N	O
99	or	N	O
100	to	N	O
101	a	N	O
102	waiting	N	O
103	list	N	O
104	control	N	O
105	group	N	O
106	(	N	O
107	n=103	N	O
108	)	N	O
109	.	N	O

110	Self-report	N	O
111	questionnaires	N	O
112	were	N	O
113	completed	N	O
114	at	N	O
115	baseline	N	O
116	,	N	O
117	12	N	O
118	weeks	N	O
119	,	N	O
120	and	N	O
121	6	N	O
122	months	N	O
123	.	N	O

124	Multilevel	N	O
125	procedures	N	O
126	were	N	O
127	used	N	O
128	to	N	O
129	compare	N	O
130	the	N	O
131	intervention	N	O
132	groups	N	O
133	with	N	O
134	the	N	O
135	control	N	O
136	group	N	O
137	over	N	O
138	time	N	O
139	.	N	O

140	Compared	N	I-Premise
141	with	N	I-Premise
142	the	N	I-Premise
143	control	N	I-Premise
144	group	N	I-Premise
145	,	N	I-Premise
146	the	N	I-Premise
147	intervention	N	I-Premise
148	groups	N	I-Premise
149	had	N	I-Premise
150	a	N	I-Premise
151	significant	N	I-Premise
152	decrease	N	I-Premise
153	in	N	I-Premise
154	levels	N	I-Premise
155	of	N	I-Premise
156	endocrine	N	I-Premise
157	symptoms	N	I-Premise
158	(	N	I-Premise
159	Functional	N	I-Premise
160	Assessment	N	I-Premise
161	of	N	I-Premise
162	Cancer	N	I-Premise
163	Therapy-Endocrine	N	I-Premise
164	Symptoms	N	I-Premise
165	;	N	I-Premise
166	P	N	I-Premise
167	<	N	I-Premise
168	.001	N	I-Premise
169	;	N	I-Premise
170	effect	N	I-Premise
171	size	N	I-Premise
172	,	N	I-Premise
173	0.31-0.52	N	I-Premise
174	)	N	I-Premise
175	and	N	I-Premise
176	urinary	N	I-Premise
177	symptoms	N	I-Premise
178	(	N	I-Premise
179	Bristol	N	I-Premise
180	Female	N	I-Premise
181	Lower	N	I-Premise
182	Urinary	N	I-Premise
183	Tract	N	I-Premise
184	Symptoms	N	I-Premise
185	Questionnaire	N	I-Premise
186	;	N	I-Premise
187	P=.002	N	I-Premise
188	;	N	I-Premise
189	effect	N	I-Premise
190	size	N	I-Premise
191	,	N	I-Premise
192	0.29-0.33	N	I-Premise
193	)	N	I-Premise
194	,	N	I-Premise
195	and	N	I-Premise
196	they	N	I-Premise
197	showed	N	I-Premise
198	an	N	I-Premise
199	improvement	N	I-Premise
200	in	N	I-Premise
201	physical	N	I-Premise
202	functioning	N	I-Premise
203	(	N	I-Premise
204	36-Item	N	I-Premise
205	Short	N	I-Premise
206	Form	N	I-Premise
207	Health	N	I-Premise
208	Survey	N	I-Premise
209	physical	N	I-Premise
210	functioning	N	I-Premise
211	subscale	N	I-Premise
212	;	N	I-Premise
213	P=.002	N	I-Premise
214	;	N	I-Premise
215	effect	N	I-Premise
216	size	N	I-Premise
217	,	N	I-Premise
218	0.37-0.46	N	I-Premise
219	)	N	I-Premise
220	.	N	I-Premise

221	The	N	I-Premise
222	groups	N	I-Premise
223	that	N	I-Premise
224	included	N	I-Premise
225	CBT	N	I-Premise
226	also	N	I-Premise
227	showed	N	I-Premise
228	a	N	I-Premise
229	significant	N	I-Premise
230	decrease	N	I-Premise
231	in	N	I-Premise
232	the	N	I-Premise
233	perceived	N	I-Premise
234	burden	N	I-Premise
235	of	N	I-Premise
236	hot	N	I-Premise
237	flashes	N	I-Premise
238	and	N	I-Premise
239	night	N	I-Premise
240	sweats	N	I-Premise
241	(	N	I-Premise
242	problem	N	I-Premise
243	rating	N	I-Premise
244	scale	N	I-Premise
245	of	N	I-Premise
246	the	N	I-Premise
247	Hot	N	I-Premise
248	Flush	N	I-Premise
249	Rating	N	I-Premise
250	Scale	N	I-Premise
251	;	N	I-Premise
252	P	N	I-Premise
253	<	N	I-Premise
254	.001	N	I-Premise
255	;	N	I-Premise
256	effect	N	I-Premise
257	size	N	I-Premise
258	,	N	I-Premise
259	0.39-0.56	N	I-Premise
260	)	N	I-Premise
261	and	N	I-Premise
262	an	N	I-Premise
263	increase	N	I-Premise
264	in	N	I-Premise
265	sexual	N	I-Premise
266	activity	N	I-Premise
267	(	N	I-Premise
268	Sexual	N	I-Premise
269	Activity	N	I-Premise
270	Questionnaire	N	I-Premise
271	habit	N	I-Premise
272	subscale	N	I-Premise
273	;	N	I-Premise
274	P=.027	N	I-Premise
275	;	N	I-Premise
276	effect	N	I-Premise
277	size	N	I-Premise
278	,	N	I-Premise
279	0.65	N	I-Premise
280	)	N	I-Premise
281	.	N	I-Premise

282	Most	N	O
283	of	N	O
284	these	N	O
285	effects	N	O
286	were	N	O
287	observed	N	O
288	at	N	O
289	both	N	O
290	the	N	O
291	12-week	N	O
292	and	N	O
293	6-month	N	O
294	follow-ups	N	O
295	.	N	O

296	CBT	N	I-Claim
297	and	N	I-Claim
298	PE	N	I-Claim
299	can	N	I-Claim
300	have	N	I-Claim
301	salutary	N	I-Claim
302	effects	N	I-Claim
303	on	N	I-Claim
304	endocrine	N	I-Claim
305	symptoms	N	I-Claim
306	and	N	I-Claim
307	,	N	I-Claim
308	to	N	I-Claim
309	a	N	I-Claim
310	lesser	N	I-Claim
311	degree	N	I-Claim
312	,	N	I-Claim
313	on	N	I-Claim
314	sexuality	N	I-Claim
315	and	N	I-Claim
316	physical	N	I-Claim
317	functioning	N	I-Claim
318	of	N	I-Claim
319	patients	N	I-Claim
320	with	N	I-Claim
321	breast	N	I-Claim
322	cancer	N	I-Claim
323	experiencing	N	I-Claim
324	treatment-induced	N	I-Claim
325	menopause	N	I-Claim
326	.	N	I-Claim

327	Future	N	I-Claim
328	work	N	I-Claim
329	is	N	I-Claim
330	needed	N	I-Claim
331	to	N	I-Claim
332	improve	N	I-Claim
333	the	N	I-Claim
334	design	N	I-Claim
335	and	N	I-Claim
336	the	N	I-Claim
337	planning	N	I-Claim
338	of	N	I-Claim
339	these	N	I-Claim
340	interventions	N	I-Claim
341	to	N	I-Claim
342	improve	N	I-Claim
343	program	N	I-Claim
344	adherence	N	I-Claim
345	.	N	I-Claim

1	To	N	O
2	report	N	O
3	5-year	N	O
4	contrast-enhanced	N	O
5	magnetic	N	O
6	resonance	N	O
7	imaging	N	O
8	findings	N	O
9	of	N	O
10	the	N	O
11	REST	N	O
12	trial	N	O
13	recruits	N	O
14	who	N	O
15	underwent	N	O
16	either	N	O
17	uterine	N	O
18	artery	N	O
19	embolization	N	O
20	(	N	O
21	UAE	N	O
22	)	N	O
23	or	N	O
24	myomectomy	N	O
25	.	N	O

26	A	N	O
27	total	N	O
28	of	N	O
29	157	N	O
30	patients	N	O
31	were	N	O
32	randomized	N	O
33	to	N	O
34	UAE	N	O
35	or	N	O
36	surgery	N	O
37	(	N	O
38	hysterectomy	N	O
39	or	N	O
40	myomectomy	N	O
41	)	N	O
42	.	N	O

43	Ninety-nine	N	O
44	patients	N	O
45	who	N	O
46	had	N	O
47	UAE	N	O
48	and	N	O
49	eight	N	O
50	patients	N	O
51	who	N	O
52	had	N	O
53	myomectomy	N	O
54	were	N	O
55	analyzed	N	O
56	.	N	O

57	MRI	N	O
58	scans	N	O
59	at	N	O
60	baseline	N	O
61	,	N	O
62	6	N	O
63	months	N	O
64	,	N	O
65	and	N	O
66	5	N	O
67	years	N	O
68	were	N	O
69	independently	N	O
70	interpreted	N	O
71	by	N	O
72	two	N	O
73	radiologists	N	O
74	.	N	O

75	Dominant	N	O
76	fibroid	N	O
77	diameter	N	O
78	,	N	O
79	uterine	N	O
80	volume	N	O
81	,	N	O
82	total	N	O
83	fibroid	N	O
84	infarction	N	O
85	(	N	O
86	complete	N	O
87	100	N	O
88	%	N	O
89	,	N	O
90	almost	N	O
91	complete	N	O
92	90-99	N	O
93	%	N	O
94	,	N	O
95	partial	N	O
96	<	N	O
97	90	N	O
98	%	N	O
99	)	N	O
100	,	N	O
101	and	N	O
102	new	N	O
103	fibroid	N	O
104	formation	N	O
105	were	N	O
106	the	N	O
107	main	N	O
108	parameters	N	O
109	assessed	N	O
110	and	N	O
111	related	N	O
112	to	N	O
113	the	N	O
114	need	N	O
115	for	N	O
116	reintervention	N	O
117	.	N	O

118	In	N	I-Premise
119	the	N	I-Premise
120	UAE	N	I-Premise
121	group	N	I-Premise
122	,	N	I-Premise
123	mean	N	I-Premise
124		N	I-Premise
125	standard	N	I-Premise
126	deviation	N	I-Premise
127	uterine	N	I-Premise
128	volume	N	I-Premise
129	was	N	I-Premise
130	670	N	I-Premise
131		N	I-Premise
132	503	N	I-Premise
133	,	N	I-Premise
134	422	N	I-Premise
135		N	I-Premise
136	353	N	I-Premise
137	,	N	I-Premise
138	and	N	I-Premise
139	292	N	I-Premise
140		N	I-Premise
141	287	N	I-Premise
142	mL	N	I-Premise
143	at	N	I-Premise
144	baseline	N	I-Premise
145	,	N	I-Premise
146	6	N	I-Premise
147	months	N	I-Premise
148	,	N	I-Premise
149	and	N	I-Premise
150	5	N	I-Premise
151	years	N	I-Premise
152	,	N	I-Premise
153	respectively	N	I-Premise
154	.	N	I-Premise

155	Mean	N	I-Premise
156	dominant	N	I-Premise
157	fibroid	N	I-Premise
158	diameter	N	I-Premise
159	was	N	I-Premise
160	7.6	N	I-Premise
161		N	I-Premise
162	3.0	N	I-Premise
163	,	N	I-Premise
164	5.8	N	I-Premise
165		N	I-Premise
166	2.9	N	I-Premise
167	,	N	I-Premise
168	and	N	I-Premise
169	5	N	I-Premise
170		N	I-Premise
171	2.9	N	I-Premise
172	cm	N	I-Premise
173	at	N	I-Premise
174	baseline	N	I-Premise
175	,	N	I-Premise
176	6	N	I-Premise
177	months	N	I-Premise
178	,	N	I-Premise
179	and	N	I-Premise
180	5	N	I-Premise
181	years	N	I-Premise
182	.	N	I-Premise

183	Fibroid	N	I-Premise
184	infarction	N	I-Premise
185	at	N	I-Premise
186	6	N	I-Premise
187	months	N	I-Premise
188	was	N	I-Premise
189	complete	N	I-Premise
190	in	N	I-Premise
191	35	N	I-Premise
192	%	N	I-Premise
193	of	N	I-Premise
194	women	N	I-Premise
195	,	N	I-Premise
196	almost	N	I-Premise
197	complete	N	I-Premise
198	in	N	I-Premise
199	29	N	I-Premise
200	%	N	I-Premise
201	,	N	I-Premise
202	and	N	I-Premise
203	partial	N	I-Premise
204	in	N	I-Premise
205	36	N	I-Premise
206	%	N	I-Premise
207	.	N	I-Premise

208	Need	N	I-Premise
209	for	N	I-Premise
210	reintervention	N	I-Premise
211	was	N	I-Premise
212	19	N	I-Premise
213	,	N	I-Premise
214	10	N	I-Premise
215	,	N	I-Premise
216	and	N	I-Premise
217	33	N	I-Premise
218	%	N	I-Premise
219	in	N	I-Premise
220	these	N	I-Premise
221	groups	N	I-Premise
222	,	N	I-Premise
223	respectively	N	I-Premise
224	(	N	I-Premise
225	p	N	I-Premise
226	=	N	I-Premise
227	0.123	N	I-Premise
228	)	N	I-Premise
229	.	N	I-Premise

230	No	N	I-Premise
231	myomectomy	N	I-Premise
232	cases	N	I-Premise
233	had	N	I-Premise
234	further	N	I-Premise
235	intervention	N	I-Premise
236	.	N	I-Premise

237	At	N	I-Premise
238	5	N	I-Premise
239	years	N	I-Premise
240	,	N	I-Premise
241	the	N	I-Premise
242	prevalence	N	I-Premise
243	of	N	I-Premise
244	new	N	I-Premise
245	fibroid	N	I-Premise
246	was	N	I-Premise
247	60	N	I-Premise
248	%	N	I-Premise
249	in	N	I-Premise
250	the	N	I-Premise
251	myomectomy	N	I-Premise
252	group	N	I-Premise
253	and	N	I-Premise
254	7	N	I-Premise
255	%	N	I-Premise
256	in	N	I-Premise
257	the	N	I-Premise
258	UAE	N	I-Premise
259	group	N	I-Premise
260	(	N	I-Premise
261	p	N	I-Premise
262	=	N	I-Premise
263	0.008	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	There	N	I-Premise
267	is	N	I-Premise
268	a	N	I-Premise
269	further	N	I-Premise
270	significant	N	I-Premise
271	reduction	N	I-Premise
272	in	N	I-Premise
273	both	N	I-Premise
274	uterine	N	I-Premise
275	volume	N	I-Premise
276	and	N	I-Premise
277	dominant	N	I-Premise
278	fibroid	N	I-Premise
279	diameter	N	I-Premise
280	between	N	I-Premise
281	6	N	I-Premise
282	months	N	I-Premise
283	and	N	I-Premise
284	5	N	I-Premise
285	years	N	I-Premise
286	after	N	I-Premise
287	UAE	N	I-Premise
288	.	N	I-Premise

289	Complete	N	I-Claim
290	fibroid	N	I-Claim
291	infarction	N	I-Claim
292	does	N	I-Claim
293	not	N	I-Claim
294	translate	N	I-Claim
295	into	N	I-Claim
296	total	N	I-Claim
297	freedom	N	I-Claim
298	from	N	I-Claim
299	a	N	I-Claim
300	subsequent	N	I-Claim
301	reintervention	N	I-Claim
302	.	N	I-Claim

303	New	N	I-Claim
304	fibroid	N	I-Claim
305	formation	N	I-Claim
306	is	N	I-Claim
307	significantly	N	I-Claim
308	higher	N	I-Claim
309	after	N	I-Claim
310	myomectomy	N	I-Claim
311	.	N	I-Claim

1	Due	N	O
2	to	N	O
3	the	N	O
4	various	N	O
5	inter-individual	N	O
6	differences	N	O
7	in	N	O
8	the	N	O
9	biological	N	O
10	characteristics	N	O
11	of	N	O
12	tumor	N	O
13	cells	N	O
14	,	N	O
15	as	N	O
16	well	N	O
17	as	N	O
18	issues	N	O
19	on	N	O
20	the	N	O
21	efficacy	N	O
22	,	N	O
23	adverse	N	O
24	reactions	N	O
25	,	N	O
26	and	N	O
27	defects	N	O
28	of	N	O
29	existing	N	O
30	drugs	N	O
31	,	N	O
32	we	N	O
33	compared	N	O
34	the	N	O
35	clinical	N	O
36	efficacy	N	O
37	and	N	O
38	toxicity	N	O
39	of	N	O
40	pemetrexed	N	O
41	and	N	O
42	gemcitabine	N	O
43	combined	N	O
44	with	N	O
45	cisplatin	N	O
46	for	N	O
47	the	N	O
48	treatment	N	O
49	of	N	O
50	previously	N	O
51	untreated	N	O
52	advanced	N	O
53	non-small	N	O
54	cell	N	O
55	lung	N	O
56	cancer	N	O
57	(	N	O
58	NSCLC	N	O
59	)	N	O
60	.	N	O

61	251	N	O
62	patients	N	O
63	were	N	O
64	randomly	N	O
65	divided	N	O
66	into	N	O
67	pemetrexed	N	O
68	combined	N	O
69	with	N	O
70	cisplatin	N	O
71	group	N	O
72	(	N	O
73	PP	N	O
74	group	N	O
75	)	N	O
76	with	N	O
77	127	N	O
78	cases	N	O
79	and	N	O
80	gemcitabine	N	O
81	combined	N	O
82	with	N	O
83	cisplatin	N	O
84	group	N	O
85	(	N	O
86	GP	N	O
87	group	N	O
88	)	N	O
89	with	N	O
90	124	N	O
91	cases	N	O
92	.	N	O

93	PP	N	O
94	group	N	O
95	received	N	O
96	pemetrexed	N	O
97	500	N	O
98	mg/m	N	O
99	iv	N	O
100	infusion	N	O
101	d1	N	O
102	and	N	O
103	cisplatin	N	O
104	75	N	O
105	mg/m	N	O
106	iv	N	O
107	infusion	N	O
108	d1	N	O
109	,	N	O
110	whereas	N	O
111	GP	N	O
112	group	N	O
113	received	N	O
114	gemcitabine	N	O
115	1,000	N	O
116	mg/m	N	O
117	iv	N	O
118	infusion	N	O
119	d1,8	N	O
120	and	N	O
121	cisplatin	N	O
122	75	N	O
123	mg/m	N	O
124	iv	N	O
125	infusion	N	O
126	d1	N	O
127	.	N	O

128	The	N	O
129	treatment	N	O
130	cycle	N	O
131	was	N	O
132	once	N	O
133	every	N	O
134	three	N	O
135	weeks	N	O
136	.	N	O

137	In	N	O
138	addition	N	O
139	,	N	O
140	folic	N	O
141	acid	N	O
142	,	N	O
143	vitamin	N	O
144	B12	N	O
145	,	N	O
146	and	N	O
147	dexamethasone	N	O
148	were	N	O
149	administered	N	O
150	in	N	O
151	both	N	O
152	groups	N	O
153	.	N	O

154	The	N	I-Premise
155	total	N	I-Premise
156	clinical	N	I-Premise
157	effective	N	I-Premise
158	rates	N	I-Premise
159	in	N	I-Premise
160	PP	N	I-Premise
161	group	N	I-Premise
162	and	N	I-Premise
163	GP	N	I-Premise
164	group	N	I-Premise
165	were	N	I-Premise
166	25.20	N	I-Premise
167	%	N	I-Premise
168	and	N	I-Premise
169	17.74	N	I-Premise
170	%	N	I-Premise
171	,	N	I-Premise
172	respectively	N	I-Premise
173	.	N	I-Premise

174	The	N	I-Premise
175	total	N	I-Premise
176	efficiencies	N	I-Premise
177	of	N	I-Premise
178	non-squamous	N	I-Premise
179	cell	N	I-Premise
180	carcinoma	N	I-Premise
181	were	N	I-Premise
182	27.62	N	I-Premise
183	%	N	I-Premise
184	and	N	I-Premise
185	16.00	N	I-Premise
186	%	N	I-Premise
187	.	N	I-Premise

188	The	N	I-Premise
189	tumor	N	I-Premise
190	progression	N	I-Premise
191	duration	N	I-Premise
192	in	N	I-Premise
193	these	N	I-Premise
194	two	N	I-Premise
195	groups	N	I-Premise
196	was	N	I-Premise
197	6.5	N	I-Premise
198	and	N	I-Premise
199	5.6	N	I-Premise
200	months	N	I-Premise
201	,	N	I-Premise
202	respectively	N	I-Premise
203	.	N	I-Premise

204	The	N	I-Premise
205	median	N	I-Premise
206	survival	N	I-Premise
207	time	N	I-Premise
208	in	N	I-Premise
209	the	N	I-Premise
210	two	N	I-Premise
211	groups	N	I-Premise
212	was	N	I-Premise
213	16.9	N	I-Premise
214	and	N	I-Premise
215	17.0	N	I-Premise
216	months	N	I-Premise
217	,	N	I-Premise
218	respectively	N	I-Premise
219	,	N	I-Premise
220	with	N	I-Premise
221	59.62	N	I-Premise
222	%	N	I-Premise
223	and	N	I-Premise
224	65.87	N	I-Premise
225	%	N	I-Premise
226	survival	N	I-Premise
227	rates	N	I-Premise
228	of	N	I-Premise
229	1	N	I-Premise
230	year	N	I-Premise
231	and	N	I-Premise
232	27.28	N	I-Premise
233	%	N	I-Premise
234	and	N	I-Premise
235	27.93	N	I-Premise
236	%	N	I-Premise
237	survival	N	I-Premise
238	rates	N	I-Premise
239	of	N	I-Premise
240	2	N	I-Premise
241	years	N	I-Premise
242	,	N	I-Premise
243	respectively	N	I-Premise
244	.	N	I-Premise

245	The	N	I-Premise
246	total	N	I-Premise
247	efficacy	N	I-Premise
248	of	N	I-Premise
249	non-squamous	N	I-Premise
250	cell	N	I-Premise
251	carcinoma	N	I-Premise
252	in	N	I-Premise
253	the	N	I-Premise
254	PP	N	I-Premise
255	group	N	I-Premise
256	was	N	I-Premise
257	significantly	N	I-Premise
258	higher	N	I-Premise
259	than	N	I-Premise
260	that	N	I-Premise
261	in	N	I-Premise
262	GP	N	I-Premise
263	group	N	I-Premise
264	.	N	I-Premise

265	The	N	I-Premise
266	results	N	I-Premise
267	were	N	I-Premise
268	statistically	N	I-Premise
269	significant	N	I-Premise
270	.	N	I-Premise

271	However	N	O
272	,	N	O
273	there	N	O
274	were	N	O
275	no	N	O
276	significant	N	O
277	differences	N	O
278	in	N	O
279	total	N	O
280	response	N	O
281	rates	N	O
282	,	N	O
283	tumor	N	O
284	progression	N	O
285	duration	N	O
286	,	N	O
287	and	N	O
288	median	N	O
289	survival	N	O
290	rates	N	O
291	of	N	O
292	1	N	O
293	and	N	O
294	2	N	O
295	years	N	O
296	.	N	O

297	The	N	I-Premise
298	rate	N	I-Premise
299	of	N	I-Premise
300	adverse	N	I-Premise
301	reactions	N	I-Premise
302	,	N	I-Premise
303	including	N	I-Premise
304	white	N	I-Premise
305	blood	N	I-Premise
306	cell	N	I-Premise
307	reduction	N	I-Premise
308	,	N	I-Premise
309	lower	N	I-Premise
310	platelet	N	I-Premise
311	count	N	I-Premise
312	,	N	I-Premise
313	lower	N	I-Premise
314	hemoglobin	N	I-Premise
315	,	N	I-Premise
316	and	N	I-Premise
317	hair	N	I-Premise
318	loss	N	I-Premise
319	in	N	I-Premise
320	the	N	I-Premise
321	PP	N	I-Premise
322	group	N	I-Premise
323	was	N	I-Premise
324	significantly	N	I-Premise
325	lower	N	I-Premise
326	than	N	I-Premise
327	that	N	I-Premise
328	in	N	I-Premise
329	the	N	I-Premise
330	GP	N	I-Premise
331	group	N	I-Premise
332	.	N	I-Premise

333	The	N	I-Premise
334	results	N	I-Premise
335	were	N	I-Premise
336	statistically	N	I-Premise
337	significant	N	I-Premise
338	.	N	I-Premise

339	The	N	I-Claim
340	clinical	N	I-Claim
341	efficacy	N	I-Claim
342	of	N	I-Claim
343	pemetrexed	N	I-Claim
344	and	N	I-Claim
345	gemcitabine	N	I-Claim
346	combined	N	I-Claim
347	with	N	I-Claim
348	cisplatin	N	I-Claim
349	for	N	I-Claim
350	the	N	I-Claim
351	treatment	N	I-Claim
352	of	N	I-Claim
353	previously	N	I-Claim
354	untreated	N	I-Claim
355	advanced	N	I-Claim
356	NSCLC	N	I-Claim
357	was	N	I-Claim
358	roughly	N	I-Claim
359	the	N	I-Claim
360	same	N	I-Claim
361	,	N	I-Claim
362	but	N	I-Claim
363	the	N	I-Claim
364	adverse	N	I-Claim
365	reactions	N	I-Claim
366	decreased	N	I-Claim
367	significantly	N	I-Claim
368	in	N	I-Claim
369	the	N	I-Claim
370	PP	N	I-Claim
371	group	N	I-Claim
372	compared	N	I-Claim
373	with	N	I-Claim
374	those	N	I-Claim
375	in	N	I-Claim
376	the	N	I-Claim
377	GP	N	I-Claim
378	group	N	I-Claim
379	.	N	I-Claim

380	Therefore	N	I-MajorClaim
381	,	N	I-MajorClaim
382	pemetrexed	N	I-MajorClaim
383	combined	N	I-MajorClaim
384	with	N	I-MajorClaim
385	cisplatin	N	I-MajorClaim
386	can	N	I-MajorClaim
387	be	N	I-MajorClaim
388	used	N	I-MajorClaim
389	as	N	I-MajorClaim
390	a	N	I-MajorClaim
391	safe	N	I-MajorClaim
392	and	N	I-MajorClaim
393	effective	N	I-MajorClaim
394	drug	N	I-MajorClaim
395	for	N	I-MajorClaim
396	clinical	N	I-MajorClaim
397	first-line	N	I-MajorClaim
398	treatment	N	I-MajorClaim
399	for	N	I-MajorClaim
400	previously	N	I-MajorClaim
401	untreated	N	I-MajorClaim
402	NSCLC	N	I-MajorClaim
403	.	N	I-MajorClaim

1	Cancer	N	O
2	related	N	O
3	fatigue	N	O
4	(	N	O
5	CRF	N	O
6	)	N	O
7	is	N	O
8	a	N	O
9	common	N	O
10	problem	N	O
11	for	N	O
12	cancer	N	O
13	patients	N	O
14	across	N	O
15	diagnoses	N	O
16	during	N	O
17	chemotherapy	N	O
18	and	N	O
19	is	N	O
20	associated	N	O
21	with	N	O
22	physical	N	O
23	inactivity	N	O
24	,	N	O
25	lower	N	O
26	functional	N	O
27	level	N	O
28	and	N	O
29	lack	N	O
30	of	N	O
31	energy	N	O
32	.	N	O

33	Few	N	O
34	RCT	N	O
35	exercise	N	O
36	intervention	N	O
37	studies	N	O
38	have	N	O
39	included	N	O
40	cancer	N	O
41	patients	N	O
42	undergoing	N	O
43	chemotherapy	N	O
44	.	N	O

45	The	N	O
46	objective	N	O
47	of	N	O
48	this	N	O
49	study	N	O
50	is	N	O
51	to	N	O
52	evaluate	N	O
53	whether	N	O
54	a	N	O
55	six-week	N	O
56	supervised	N	O
57	multimodal	N	O
58	exercise	N	O
59	intervention	N	O
60	,	N	O
61	adjunct	N	O
62	to	N	O
63	chemotherapy	N	O
64	and	N	O
65	standard	N	O
66	care	N	O
67	,	N	O
68	can	N	O
69	reduce	N	O
70	the	N	O
71	patient	N	O
72	's	N	O
73	CRF	N	O
74	level	N	O
75	.	N	O

76	Data	N	O
77	is	N	O
78	based	N	O
79	on	N	O
80	analyses	N	O
81	of	N	O
82	a	N	O
83	prospective	N	O
84	randomised	N	O
85	controlled	N	O
86	trial	N	O
87	'The	N	O
88	Body	N	O
89	Cancer	N	O
90	Trial	N	O
91	'	N	O
92	.	N	O

93	213	N	O
94	cancer	N	O
95	patients	N	O
96	with	N	O
97	different	N	O
98	diagnoses	N	O
99	were	N	O
100	randomised	N	O
101	into	N	O
102	an	N	O
103	intervention	N	O
104	group	N	O
105	or	N	O
106	wait-list	N	O
107	control	N	O
108	group	N	O
109	.	N	O

110	The	N	O
111	primary	N	O
112	outcome	N	O
113	,	N	O
114	Fatigue	N	O
115	score	N	O
116	(	N	O
117	CRF	N	O
118	)	N	O
119	,	N	O
120	was	N	O
121	evaluated	N	O
122	by	N	O
123	the	N	O
124	Functional	N	O
125	Assessment	N	O
126	of	N	O
127	Cancer	N	O
128	Therapy-Anaemia	N	O
129	Questionnaire	N	O
130	(	N	O
131	FACT-An-	N	O
132	)	N	O
133	(	N	O
134	FACT-G	N	O
135	score	N	O
136	&	N	O
137	FACT-An	N	O
138	Anemia	N	O
139	subscale	N	O
140	)	N	O
141	.	N	O

142	Supervised	N	O
143	exercise	N	O
144	,	N	O
145	comprising	N	O
146	high-intensity	N	O
147	cardiovascular	N	O
148	and	N	O
149	heavy	N	O
150	resistance	N	O
151	training	N	O
152	,	N	O
153	relaxation-	N	O
154	and	N	O
155	body	N	O
156	awareness	N	O
157	training	N	O
158	and	N	O
159	massage	N	O
160	,	N	O
161	9	N	O
162	h	N	O
163	weekly	N	O
164	for	N	O
165	6	N	O
166	weeks	N	O
167	.	N	O

168	CRF	N	I-Premise
169	was	N	I-Premise
170	significantly	N	I-Premise
171	reduced	N	I-Premise
172	in	N	I-Premise
173	the	N	I-Premise
174	intervention	N	I-Premise
175	group	N	I-Premise
176	,	N	I-Premise
177	corresponding	N	I-Premise
178	to	N	I-Premise
179	a	N	I-Premise
180	Fatigue	N	I-Premise
181	score	N	I-Premise
182	reduction	N	I-Premise
183	of	N	I-Premise
184	3.04	N	I-Premise
185	(	N	I-Premise
186	effect	N	I-Premise
187	size	N	I-Premise
188	of	N	I-Premise
189	0.44	N	I-Premise
190	,	N	I-Premise
191	95	N	I-Premise
192	%	N	I-Premise
193	CI	N	I-Premise
194	0.17-0.72	N	I-Premise
195	)	N	I-Premise
196	(	N	I-Premise
197	P	N	I-Premise
198	=	N	I-Premise
199	.002	N	I-Premise
200	)	N	I-Premise
201	,	N	I-Premise
202	the	N	I-Premise
203	FACT-An	N	I-Premise
204	score	N	I-Premise
205	by	N	I-Premise
206	5.40	N	I-Premise
207	(	N	I-Premise
208	P	N	I-Premise
209	=	N	I-Premise
210	.015	N	I-Premise
211	)	N	I-Premise
212	,	N	I-Premise
213	the	N	I-Premise
214	FACT-An	N	I-Premise
215	Toi	N	I-Premise
216	score	N	I-Premise
217	by	N	I-Premise
218	5.22	N	I-Premise
219	(	N	I-Premise
220	P	N	I-Premise
221	=	N	I-Premise
222	.009	N	I-Premise
223	)	N	I-Premise
224	and	N	I-Premise
225	the	N	I-Premise
226	Anaemia-ANS	N	I-Premise
227	by	N	I-Premise
228	3.76	N	I-Premise
229	(	N	I-Premise
230	P	N	I-Premise
231	=	N	I-Premise
232	.002	N	I-Premise
233	)	N	I-Premise
234	.	N	I-Premise

235	There	N	I-Premise
236	was	N	I-Premise
237	no	N	I-Premise
238	statistically	N	I-Premise
239	significant	N	I-Premise
240	effect	N	I-Premise
241	on	N	I-Premise
242	the	N	I-Premise
243	General	N	I-Premise
244	Quality	N	I-Premise
245	of	N	I-Premise
246	Life	N	I-Premise
247	score	N	I-Premise
248	(	N	I-Premise
249	FACT-G	N	I-Premise
250	)	N	I-Premise
251	or	N	I-Premise
252	on	N	I-Premise
253	any	N	I-Premise
254	of	N	I-Premise
255	the	N	I-Premise
256	individual	N	I-Premise
257	wellbeing	N	I-Premise
258	scores	N	I-Premise
259	;	N	I-Premise
260	Physical	N	I-Premise
261	(	N	I-Premise
262	P	N	I-Premise
263	=	N	I-Premise
264	.13	N	I-Premise
265	)	N	I-Premise
266	,	N	I-Premise
267	Emotional	N	I-Premise
268	(	N	I-Premise
269	P	N	I-Premise
270	=	N	I-Premise
271	.87	N	I-Premise
272	)	N	I-Premise
273	,	N	I-Premise
274	Social	N	I-Premise
275	(	N	I-Premise
276	P	N	I-Premise
277	=	N	I-Premise
278	.83	N	I-Premise
279	)	N	I-Premise
280	and	N	I-Premise
281	Functional	N	I-Premise
282	(	N	I-Premise
283	P	N	I-Premise
284	=	N	I-Premise
285	.26	N	I-Premise
286	)	N	I-Premise
287	.	N	I-Premise

288	In	N	I-Claim
289	summary	N	I-Claim
290	,	N	I-Claim
291	this	N	I-Claim
292	six-week	N	I-Claim
293	supervised	N	I-Claim
294	multimodal	N	I-Claim
295	exercise	N	I-Claim
296	intervention	N	I-Claim
297	can	N	I-Claim
298	lead	N	I-Claim
299	to	N	I-Claim
300	significant	N	I-Claim
301	reduction	N	I-Claim
302	in	N	I-Claim
303	self-reported	N	I-Claim
304	CRF	N	I-Claim
305	in	N	I-Claim
306	cancer	N	I-Claim
307	patients	N	I-Claim
308	undergoing	N	I-Claim
309	chemotherapy	N	I-Claim
310	.	N	I-Claim

1	We	N	O
2	aimed	N	O
3	to	N	O
4	assess	N	O
5	the	N	O
6	effectiveness	N	O
7	of	N	O
8	acupuncture	N	O
9	for	N	O
10	cancer-related	N	O
11	fatigue	N	O
12	(	N	O
13	CRF	N	O
14	)	N	O
15	in	N	O
16	patients	N	O
17	with	N	O
18	breast	N	O
19	cancer	N	O
20	.	N	O

21	We	N	O
22	conducted	N	O
23	a	N	O
24	pragmatic	N	O
25	,	N	O
26	randomized	N	O
27	controlled	N	O
28	trial	N	O
29	comparing	N	O
30	acupuncture	N	O
31	with	N	O
32	enhanced	N	O
33	usual	N	O
34	care	N	O
35	.	N	O

36	Three	N	O
37	hundred	N	O
38	two	N	O
39	outpatients	N	O
40	with	N	O
41	breast	N	O
42	cancer	N	O
43	participated	N	O
44	.	N	O

45	We	N	O
46	randomly	N	O
47	assigned	N	O
48	75	N	O
49	patients	N	O
50	to	N	O
51	usual	N	O
52	care	N	O
53	and	N	O
54	227	N	O
55	patients	N	O
56	to	N	O
57	acupuncture	N	O
58	plus	N	O
59	usual	N	O
60	care	N	O
61	(	N	O
62	random	N	O
63	assignment	N	O
64	of	N	O
65	1:3	N	O
66	respectively	N	O
67	)	N	O
68	with	N	O
69	minimization	N	O
70	controlling	N	O
71	for	N	O
72	baseline	N	O
73	general	N	O
74	fatigue	N	O
75	and	N	O
76	maintenance	N	O
77	treatment	N	O
78	.	N	O

79	Treatment	N	O
80	was	N	O
81	delivered	N	O
82	by	N	O
83	acupuncturists	N	O
84	once	N	O
85	a	N	O
86	week	N	O
87	for	N	O
88	6	N	O
89	weeks	N	O
90	through	N	O
91	needling	N	O
92	three	N	O
93	pairs	N	O
94	of	N	O
95	acupoints	N	O
96	.	N	O

97	The	N	O
98	usual	N	O
99	care	N	O
100	group	N	O
101	received	N	O
102	a	N	O
103	booklet	N	O
104	with	N	O
105	information	N	O
106	about	N	O
107	fatigue	N	O
108	and	N	O
109	its	N	O
110	management	N	O
111	.	N	O

112	Primary	N	O
113	outcome	N	O
114	was	N	O
115	general	N	O
116	fatigue	N	O
117	at	N	O
118	6	N	O
119	weeks	N	O
120	,	N	O
121	measured	N	O
122	with	N	O
123	the	N	O
124	Multidimensional	N	O
125	Fatigue	N	O
126	Inventory	N	O
127	(	N	O
128	MFI	N	O
129	)	N	O
130	.	N	O

131	Other	N	O
132	measurements	N	O
133	included	N	O
134	the	N	O
135	Hospital	N	O
136	Anxiety	N	O
137	and	N	O
138	Depression	N	O
139	Scale	N	O
140	,	N	O
141	Functional	N	O
142	Assessment	N	O
143	of	N	O
144	Cancer	N	O
145	Therapy-General	N	O
146	quality-of-life	N	O
147	scale	N	O
148	,	N	O
149	and	N	O
150	expectation	N	O
151	of	N	O
152	acupuncture	N	O
153	effect	N	O
154	.	N	O

155	Analyses	N	O
156	were	N	O
157	by	N	O
158	intention	N	O
159	to	N	O
160	treat	N	O
161	.	N	O

162	Two	N	O
163	hundred	N	O
164	forty-six	N	O
165	of	N	O
166	302	N	O
167	patients	N	O
168	randomly	N	O
169	assigned	N	O
170	provided	N	O
171	complete	N	O
172	data	N	O
173	at	N	O
174	6	N	O
175	weeks	N	O
176	.	N	O

177	The	N	I-Premise
178	difference	N	I-Premise
179	in	N	I-Premise
180	the	N	I-Premise
181	mean	N	I-Premise
182	General	N	I-Premise
183	Fatigue	N	I-Premise
184	score	N	I-Premise
185	,	N	I-Premise
186	between	N	I-Premise
187	those	N	I-Premise
188	who	N	I-Premise
189	received	N	I-Premise
190	the	N	I-Premise
191	intervention	N	I-Premise
192	and	N	I-Premise
193	those	N	I-Premise
194	who	N	I-Premise
195	did	N	I-Premise
196	not	N	I-Premise
197	,	N	I-Premise
198	was	N	I-Premise
199	-3.11	N	I-Premise
200	(	N	I-Premise
201	95	N	I-Premise
202	%	N	I-Premise
203	CI	N	I-Premise
204	,	N	I-Premise
205	-3.97	N	I-Premise
206	to	N	I-Premise
207	-2.25	N	I-Premise
208	;	N	I-Premise
209	P	N	I-Premise
210	<	N	I-Premise
211	.001	N	I-Premise
212	)	N	I-Premise
213	.	N	I-Premise

214	The	N	I-Premise
215	intervention	N	I-Premise
216	also	N	I-Premise
217	improved	N	I-Premise
218	all	N	I-Premise
219	other	N	I-Premise
220	fatigue	N	I-Premise
221	aspects	N	I-Premise
222	measured	N	I-Premise
223	by	N	I-Premise
224	MFI	N	I-Premise
225	,	N	I-Premise
226	including	N	I-Premise
227	Physical	N	I-Premise
228	Fatigue	N	I-Premise
229	and	N	I-Premise
230	Mental	N	I-Premise
231	Fatigue	N	I-Premise
232	(	N	I-Premise
233	acupuncture	N	I-Premise
234	effect	N	I-Premise
235	,	N	I-Premise
236	-2.36	N	I-Premise
237	and	N	I-Premise
238	-1.94	N	I-Premise
239	,	N	I-Premise
240	respectively	N	I-Premise
241	;	N	I-Premise
242	both	N	I-Premise
243	at	N	I-Premise
244	P	N	I-Premise
245	<	N	I-Premise
246	.001	N	I-Premise
247	)	N	I-Premise
248	,	N	I-Premise
249	anxiety	N	I-Premise
250	and	N	I-Premise
251	depression	N	I-Premise
252	(	N	I-Premise
253	acupuncture	N	I-Premise
254	effect	N	I-Premise
255	,	N	I-Premise
256	-1.83	N	I-Premise
257	and	N	I-Premise
258	-2.13	N	I-Premise
259	,	N	I-Premise
260	respectively	N	I-Premise
261	;	N	I-Premise
262	both	N	I-Premise
263	at	N	I-Premise
264	P	N	I-Premise
265	<	N	I-Premise
266	.001	N	I-Premise
267	)	N	I-Premise
268	,	N	I-Premise
269	and	N	I-Premise
270	quality	N	I-Premise
271	of	N	I-Premise
272	life	N	I-Premise
273	(	N	I-Premise
274	Physical	N	I-Premise
275	Well-Being	N	I-Premise
276	effect	N	I-Premise
277	,	N	I-Premise
278	3.30	N	I-Premise
279	;	N	I-Premise
280	Functional	N	I-Premise
281	Well-Being	N	I-Premise
282	effect	N	I-Premise
283	,	N	I-Premise
284	3.57	N	I-Premise
285	;	N	I-Premise
286	both	N	I-Premise
287	at	N	I-Premise
288	P	N	I-Premise
289	<	N	I-Premise
290	.001	N	I-Premise
291	;	N	I-Premise
292	Emotional	N	I-Premise
293	Well-Being	N	I-Premise
294	effect	N	I-Premise
295	,	N	I-Premise
296	1.93	N	I-Premise
297	;	N	I-Premise
298	P	N	I-Premise
299	=	N	I-Premise
300	.001	N	I-Premise
301	;	N	I-Premise
302	and	N	I-Premise
303	Social	N	I-Premise
304	Functioning	N	I-Premise
305	Well-Being	N	I-Premise
306	effect	N	I-Premise
307	,	N	I-Premise
308	1.05	N	I-Premise
309	;	N	I-Premise
310	P	N	I-Premise
311	<	N	I-Premise
312	.05	N	I-Premise
313	)	N	I-Premise
314	.	N	I-Premise

315	Acupuncture	N	I-Claim
316	is	N	I-Claim
317	an	N	I-Claim
318	effective	N	I-Claim
319	intervention	N	I-Claim
320	for	N	I-Claim
321	managing	N	I-Claim
322	the	N	I-Claim
323	symptom	N	I-Claim
324	of	N	I-Claim
325	CRF	N	I-Claim
326	and	N	I-Claim
327	improving	N	I-Claim
328	patients	N	I-Claim
329	'	N	I-Claim
330	quality	N	I-Claim
331	of	N	I-Claim
332	life	N	I-Claim
333	.	N	I-Claim

1	Exercise	N	O
2	for	N	O
3	Health	N	O
4	was	N	O
5	a	N	O
6	randomized	N	O
7	,	N	O
8	controlled	N	O
9	trial	N	O
10	designed	N	O
11	to	N	O
12	evaluate	N	O
13	two	N	O
14	modes	N	O
15	of	N	O
16	delivering	N	O
17	(	N	O
18	face-to-face	N	O
19	[	N	O
20	FtF	N	O
21	]	N	O
22	and	N	O
23	over-the-telephone	N	O
24	[	N	O
25	Tel	N	O
26	]	N	O
27	)	N	O
28	an	N	O
29	8-month	N	O
30	translational	N	O
31	exercise	N	O
32	intervention	N	O
33	,	N	O
34	commencing	N	O
35	6-weeks	N	O
36	post-breast	N	O
37	cancer	N	O
38	surgery	N	O
39	(	N	O
40	PS	N	O
41	)	N	O
42	.	N	O

43	Outcomes	N	O
44	included	N	O
45	quality	N	O
46	of	N	O
47	life	N	O
48	(	N	O
49	QoL	N	O
50	)	N	O
51	,	N	O
52	function	N	O
53	(	N	O
54	fitness	N	O
55	and	N	O
56	upper	N	O
57	body	N	O
58	)	N	O
59	and	N	O
60	treatment-related	N	O
61	side	N	O
62	effects	N	O
63	(	N	O
64	fatigue	N	O
65	,	N	O
66	lymphoedema	N	O
67	,	N	O
68	body	N	O
69	mass	N	O
70	index	N	O
71	,	N	O
72	menopausal	N	O
73	symptoms	N	O
74	,	N	O
75	anxiety	N	O
76	,	N	O
77	depression	N	O
78	and	N	O
79	pain	N	O
80	)	N	O
81	.	N	O

82	Generalised	N	O
83	estimating	N	O
84	equation	N	O
85	modelling	N	O
86	determined	N	O
87	time	N	O
88	(	N	O
89	baseline	N	O
90	[	N	O
91	5	N	O
92	weeks	N	O
93	PS	N	O
94	]	N	O
95	,	N	O
96	mid-intervention	N	O
97	[	N	O
98	6	N	O
99	months	N	O
100	PS	N	O
101	]	N	O
102	,	N	O
103	post-intervention	N	O
104	[	N	O
105	12	N	O
106	months	N	O
107	PS	N	O
108	]	N	O
109	)	N	O
110	,	N	O
111	group	N	O
112	(	N	O
113	FtF	N	O
114	,	N	O
115	Tel	N	O
116	,	N	O
117	Usual	N	O
118	Care	N	O
119	[	N	O
120	UC	N	O
121	]	N	O
122	)	N	O
123	and	N	O
124	time-by-group	N	O
125	effects	N	O
126	.	N	O

127	194	N	O
128	women	N	O
129	representative	N	O
130	of	N	O
131	the	N	O
132	breast	N	O
133	cancer	N	O
134	population	N	O
135	were	N	O
136	randomised	N	O
137	to	N	O
138	the	N	O
139	FtF	N	O
140	(	N	O
141	n	N	O
142	=	N	O
143	67	N	O
144	)	N	O
145	,	N	O
146	Tel	N	O
147	(	N	O
148	n	N	O
149	=	N	O
150	67	N	O
151	)	N	O
152	and	N	O
153	UC	N	O
154	(	N	O
155	n	N	O
156	=	N	O
157	60	N	O
158	)	N	O
159	groups	N	O
160	.	N	O

161	There	N	I-Premise
162	were	N	I-Premise
163	significant	N	I-Premise
164	(	N	I-Premise
165	p	N	I-Premise
166	<	N	I-Premise
167	0.05	N	I-Premise
168	)	N	I-Premise
169	interaction	N	I-Premise
170	effects	N	I-Premise
171	on	N	I-Premise
172	QoL	N	I-Premise
173	,	N	I-Premise
174	fitness	N	I-Premise
175	and	N	I-Premise
176	fatigue	N	I-Premise
177	with	N	I-Premise
178	differences	N	I-Premise
179	being	N	I-Premise
180	observed	N	I-Premise
181	between	N	I-Premise
182	the	N	I-Premise
183	treatment	N	I-Premise
184	groups	N	I-Premise
185	and	N	I-Premise
186	the	N	I-Premise
187	UC	N	I-Premise
188	group	N	I-Premise
189	.	N	I-Premise

190	Trends	N	I-Premise
191	observed	N	I-Premise
192	for	N	I-Premise
193	the	N	I-Premise
194	treatment	N	I-Premise
195	groups	N	I-Premise
196	were	N	I-Premise
197	similar	N	I-Premise
198	.	N	I-Premise

199	The	N	I-Premise
200	treatment	N	I-Premise
201	groups	N	I-Premise
202	reported	N	I-Premise
203	improved	N	I-Premise
204	QoL	N	I-Premise
205	,	N	I-Premise
206	fitness	N	I-Premise
207	and	N	I-Premise
208	fatigue	N	I-Premise
209	over	N	I-Premise
210	time	N	I-Premise
211	and	N	I-Premise
212	changes	N	I-Premise
213	observed	N	I-Premise
214	between	N	I-Premise
215	baseline	N	I-Premise
216	and	N	I-Premise
217	post-intervention	N	I-Premise
218	were	N	I-Premise
219	clinically	N	I-Premise
220	relevant	N	I-Premise
221	.	N	I-Premise

222	In	N	I-Premise
223	contrast	N	I-Premise
224	,	N	I-Premise
225	the	N	I-Premise
226	UC	N	I-Premise
227	group	N	I-Premise
228	experienced	N	I-Premise
229	no	N	I-Premise
230	change	N	I-Premise
231	,	N	I-Premise
232	or	N	I-Premise
233	worsening	N	I-Premise
234	QoL	N	I-Premise
235	,	N	I-Premise
236	fitness	N	I-Premise
237	and	N	I-Premise
238	fatigue	N	I-Premise
239	,	N	I-Premise
240	mid-intervention	N	I-Premise
241	.	N	I-Premise

242	Although	N	I-Premise
243	improvements	N	I-Premise
244	in	N	I-Premise
245	the	N	I-Premise
246	UC	N	I-Premise
247	group	N	I-Premise
248	occurred	N	I-Premise
249	by	N	I-Premise
250	12-months	N	I-Premise
251	post-surgery	N	I-Premise
252	,	N	I-Premise
253	the	N	I-Premise
254	change	N	I-Premise
255	did	N	I-Premise
256	not	N	I-Premise
257	meet	N	I-Premise
258	the	N	I-Premise
259	clinically	N	I-Premise
260	relevant	N	I-Premise
261	threshold	N	I-Premise
262	.	N	I-Premise

263	There	N	I-Premise
264	were	N	I-Premise
265	no	N	I-Premise
266	differences	N	I-Premise
267	in	N	I-Premise
268	other	N	I-Premise
269	treatment-related	N	I-Premise
270	side	N	I-Premise
271	effects	N	I-Premise
272	between	N	I-Premise
273	groups	N	I-Premise
274	.	N	I-Premise

275	This	N	I-Claim
276	translational	N	I-Claim
277	intervention	N	I-Claim
278	trial	N	I-Claim
279	,	N	I-Claim
280	delivered	N	I-Claim
281	either	N	I-Claim
282	FtF	N	I-Claim
283	or	N	I-Claim
284	Tel	N	I-Claim
285	,	N	I-Claim
286	supports	N	I-Claim
287	exercise	N	I-Claim
288	as	N	I-Claim
289	a	N	I-Claim
290	form	N	I-Claim
291	of	N	I-Claim
292	adjuvant	N	I-Claim
293	breast	N	I-Claim
294	cancer	N	I-Claim
295	therapy	N	I-Claim
296	that	N	I-Claim
297	can	N	I-Claim
298	prevent	N	I-Claim
299	declines	N	I-Claim
300	in	N	I-Claim
301	fitness	N	I-Claim
302	and	N	I-Claim
303	function	N	I-Claim
304	during	N	I-Claim
305	treatment	N	I-Claim
306	and	N	I-Claim
307	optimise	N	I-Claim
308	recovery	N	I-Claim
309	post-treatment	N	I-Claim
310	.	N	I-Claim

1	Two	N	O
2	million	N	O
3	people	N	O
4	across	N	O
5	the	N	O
6	U.K.	N	O
7	are	N	O
8	living	N	O
9	with	N	O
10	cancer	N	O
11	,	N	O
12	often	N	O
13	experienced	N	O
14	as	N	O
15	a	N	O
16	long-term	N	O
17	condition	N	O
18	.	N	O

19	They	N	O
20	may	N	O
21	have	N	O
22	unmet	N	O
23	needs	N	O
24	after	N	O
25	active	N	O
26	treatment	N	O
27	.	N	O

28	Rehabilitation	N	O
29	aims	N	O
30	to	N	O
31	address	N	O
32	these	N	O
33	needs	N	O
34	,	N	O
35	maximize	N	O
36	psychological	N	O
37	and	N	O
38	physical	N	O
39	function	N	O
40	,	N	O
41	and	N	O
42	enable	N	O
43	minimum	N	O
44	dependency	N	O
45	regardless	N	O
46	of	N	O
47	life	N	O
48	expectancy	N	O
49	.	N	O

50	We	N	O
51	aimed	N	O
52	to	N	O
53	test	N	O
54	,	N	O
55	in	N	O
56	a	N	O
57	randomized	N	O
58	controlled	N	O
59	trial	N	O
60	,	N	O
61	the	N	O
62	clinical	N	O
63	and	N	O
64	cost	N	O
65	effectiveness	N	O
66	of	N	O
67	a	N	O
68	rehabilitation	N	O
69	intervention	N	O
70	for	N	O
71	patients	N	O
72	with	N	O
73	advanced	N	O
74	,	N	O
75	recurrent	N	O
76	cancer	N	O
77	.	N	O

78	We	N	O
79	conducted	N	O
80	a	N	O
81	two-arm	N	O
82	,	N	O
83	wait-list	N	O
84	control	N	O
85	,	N	O
86	randomized	N	O
87	trial	N	O
88	of	N	O
89	a	N	O
90	complex	N	O
91	rehabilitation	N	O
92	intervention	N	O
93	delivered	N	O
94	by	N	O
95	a	N	O
96	hospice-based	N	O
97	multidisciplinary	N	O
98	team	N	O
99	vs.	N	O
100	usual	N	O
101	care	N	O
102	for	N	O
103	active	N	O
104	,	N	O
105	progressive	N	O
106	,	N	O
107	recurrent	N	O
108	hematological	N	O
109	and	N	O
110	breast	N	O
111	malignancies	N	O
112	,	N	O
113	with	N	O
114	a	N	O
115	follow-up	N	O
116	at	N	O
117	three	N	O
118	months	N	O
119	.	N	O

120	The	N	O
121	primary	N	O
122	outcome	N	O
123	was	N	O
124	the	N	O
125	psychological	N	O
126	subscale	N	O
127	of	N	O
128	the	N	O
129	Supportive	N	O
130	Care	N	O
131	Needs	N	O
132	Survey	N	O
133	(	N	O
134	SCNS	N	O
135	)	N	O
136	.	N	O

137	Secondary	N	O
138	outcomes	N	O
139	were	N	O
140	other	N	O
141	domains	N	O
142	of	N	O
143	the	N	O
144	SCNS	N	O
145	,	N	O
146	psychological	N	O
147	status	N	O
148	,	N	O
149	continuity	N	O
150	of	N	O
151	care	N	O
152	,	N	O
153	quality	N	O
154	of	N	O
155	life	N	O
156	,	N	O
157	and	N	O
158	resource	N	O
159	use	N	O
160	.	N	O

161	Forty-one	N	O
162	participants	N	O
163	were	N	O
164	enrolled	N	O
165	and	N	O
166	36	N	O
167	completed	N	O
168	the	N	O
169	trial	N	O
170	.	N	O

171	The	N	I-Premise
172	primary	N	I-Premise
173	outcome	N	I-Premise
174	was	N	I-Premise
175	significantly	N	I-Premise
176	lower	N	I-Premise
177	in	N	I-Premise
178	the	N	I-Premise
179	intervention	N	I-Premise
180	arm	N	I-Premise
181	(	N	I-Premise
182	adjusted	N	I-Premise
183	difference	N	I-Premise
184	-16.8	N	I-Premise
185	,	N	I-Premise
186	95	N	I-Premise
187	%	N	I-Premise
188	CI	N	I-Premise
189	-28.34	N	I-Premise
190	to	N	I-Premise
191	-5.3	N	I-Premise
192	;	N	I-Premise
193	P	N	I-Premise
194	=	N	I-Premise
195	0.006	N	I-Premise
196	)	N	I-Premise
197	.	N	I-Premise

198	The	N	I-Premise
199	SCNS	N	I-Premise
200	physical	N	I-Premise
201	and	N	I-Premise
202	patient	N	I-Premise
203	care	N	I-Premise
204	subscales	N	I-Premise
205	(	N	I-Premise
206	-14.2	N	I-Premise
207	,	N	I-Premise
208	95	N	I-Premise
209	%	N	I-Premise
210	CI	N	I-Premise
211	-26.2	N	I-Premise
212	to	N	I-Premise
213	-2.2	N	I-Premise
214	;	N	I-Premise
215	P	N	I-Premise
216	=	N	I-Premise
217	0.02	N	I-Premise
218	and	N	I-Premise
219	-7.4	N	I-Premise
220	,	N	I-Premise
221	95	N	I-Premise
222	%	N	I-Premise
223	CI	N	I-Premise
224	-13.7	N	I-Premise
225	to	N	I-Premise
226	-1.1	N	I-Premise
227	;	N	I-Premise
228	P	N	I-Premise
229	=	N	I-Premise
230	0.02	N	I-Premise
231	,	N	I-Premise
232	respectively	N	I-Premise
233	)	N	I-Premise
234	and	N	I-Premise
235	self-reported	N	I-Premise
236	health	N	I-Premise
237	state	N	I-Premise
238	(	N	I-Premise
239	12.8	N	I-Premise
240	,	N	I-Premise
241	95	N	I-Premise
242	%	N	I-Premise
243	CI	N	I-Premise
244	3.2	N	I-Premise
245	to	N	I-Premise
246	22.4	N	I-Premise
247	;	N	I-Premise
248	P	N	I-Premise
249	=	N	I-Premise
250	0.01	N	I-Premise
251	)	N	I-Premise
252	also	N	I-Premise
253	differed	N	I-Premise
254	significantly	N	I-Premise
255	.	N	I-Premise

256	The	N	I-Premise
257	incremental	N	I-Premise
258	cost-effectiveness	N	I-Premise
259	ratio	N	I-Premise
260	was	N	I-Premise
261	19,390	N	I-Premise
262	per	N	I-Premise
263	quality-adjusted	N	I-Premise
264	life	N	I-Premise
265	year	N	I-Premise
266	.	N	I-Premise

267	This	N	I-Claim
268	intervention	N	I-Claim
269	significantly	N	I-Claim
270	reduced	N	I-Claim
271	the	N	I-Claim
272	unmet	N	I-Claim
273	needs	N	I-Claim
274	of	N	I-Claim
275	cancer	N	I-Claim
276	survivors	N	I-Claim
277	and	N	I-Claim
278	it	N	I-Claim
279	is	N	I-Claim
280	likely	N	I-Claim
281	that	N	I-Claim
282	it	N	I-Claim
283	is	N	I-Claim
284	cost-effective	N	I-Claim
285	.	N	I-Claim

286	Despite	N	I-Claim
287	small	N	I-Claim
288	numbers	N	I-Claim
289	,	N	I-Claim
290	the	N	I-Claim
291	main	N	I-Claim
292	effect	N	I-Claim
293	size	N	I-Claim
294	was	N	I-Claim
295	robust	N	I-Claim
296	.	N	I-Claim

297	We	N	I-Claim
298	recommend	N	I-Claim
299	implementation	N	I-Claim
300	alongside	N	I-Claim
301	evaluation	N	I-Claim
302	in	N	I-Claim
303	wider	N	I-Claim
304	clinical	N	I-Claim
305	settings	N	I-Claim
306	and	N	I-Claim
307	patient	N	I-Claim
308	populations	N	I-Claim
309	.	N	I-Claim

1	To	N	O
2	study	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	Fuzheng	N	O
7	Jianpi	N	O
8	Decoction	N	O
9	(	N	O
10	FJD	N	O
11	)	N	O
12	combined	N	O
13	chemotherapy	N	O
14	on	N	O
15	the	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	QOL	N	O
21	)	N	O
22	and	N	O
23	the	N	O
24	survival	N	O
25	time	N	O
26	of	N	O
27	children	N	O
28	with	N	O
29	solid	N	O
30	tumor	N	O
31	.	N	O

32	Recruited	N	O
33	were	N	O
34	167	N	O
35	solid	N	O
36	tumor	N	O
37	children	N	O
38	patients	N	O
39	at	N	O
40	Department	N	O
41	of	N	O
42	Tumor	N	O
43	,	N	O
44	Beijing	N	O
45	Children	N	O
46	's	N	O
47	Hospital	N	O
48	.	N	O

49	They	N	O
50	were	N	O
51	randomly	N	O
52	assigned	N	O
53	to	N	O
54	the	N	O
55	treatment	N	O
56	group	N	O
57	(	N	O
58	83	N	O
59	cases	N	O
60	)	N	O
61	and	N	O
62	the	N	O
63	control	N	O
64	group	N	O
65	(	N	O
66	84	N	O
67	cases	N	O
68	)	N	O
69	according	N	O
70	to	N	O
71	the	N	O
72	random	N	O
73	digit	N	O
74	table	N	O
75	.	N	O

76	All	N	O
77	had	N	O
78	chemotherapy	N	O
79	.	N	O

80	Those	N	O
81	in	N	O
82	the	N	O
83	treatment	N	O
84	group	N	O
85	additionally	N	O
86	took	N	O
87	FJD	N	O
88	,	N	O
89	50	N	O
90	-100	N	O
91	mL	N	O
92	each	N	O
93	time	N	O
94	,	N	O
95	twice	N	O
96	daily	N	O
97	.	N	O

98	After	N	O
99	chemotherapy	N	O
100	those	N	O
101	in	N	O
102	the	N	O
103	treatment	N	O
104	group	N	O
105	took	N	O
106	modified	N	O
107	FJD	N	O
108	.	N	O

109	The	N	O
110	WBC	N	O
111	,	N	O
112	Hb	N	O
113	,	N	O
114	and	N	O
115	PLT	N	O
116	were	N	O
117	detected	N	O
118	in	N	O
119	all	N	O
120	patients	N	O
121	before	N	O
122	treatment	N	O
123	,	N	O
124	6	N	O
125	months	N	O
126	after	N	O
127	treatment	N	O
128	,	N	O
129	and	N	O
130	1	N	O
131	year	N	O
132	after	N	O
133	treatment	N	O
134	.	N	O

135	The	N	O
136	1-	N	O
137	,	N	O
138	2-	N	O
139	,	N	O
140	and	N	O
141	3-year	N	O
142	QOL	N	O
143	,	N	O
144	3-year	N	O
145	survival	N	O
146	rate	N	O
147	,	N	O
148	and	N	O
149	the	N	O
150	survival	N	O
151	life	N	O
152	of	N	O
153	dead	N	O
154	children	N	O
155	patients	N	O
156	were	N	O
157	observed	N	O
158	.	N	O

159	Compared	N	I-Premise
160	with	N	I-Premise
161	the	N	I-Premise
162	control	N	I-Premise
163	group	N	I-Premise
164	of	N	I-Premise
165	the	N	I-Premise
166	same	N	I-Premise
167	period	N	I-Premise
168	,	N	I-Premise
169	the	N	I-Premise
170	6-month	N	I-Premise
171	and	N	I-Premise
172	1-year	N	I-Premise
173	WBC	N	I-Premise
174	and	N	I-Premise
175	Hb	N	I-Premise
176	increased	N	I-Premise
177	,	N	I-Premise
178	the	N	I-Premise
179	1-year	N	I-Premise
180	PLT	N	I-Premise
181	increased	N	I-Premise
182	in	N	I-Premise
183	the	N	I-Premise
184	treatment	N	I-Premise
185	group	N	I-Premise
186	,	N	I-Premise
187	showing	N	I-Premise
188	statistical	N	I-Premise
189	difference	N	I-Premise
190	(	N	I-Premise
191	P	N	I-Premise
192	<	N	I-Premise
193	0.05	N	I-Premise
194	,	N	I-Premise
195	P	N	I-Premise
196	<	N	I-Premise
197	0.01	N	I-Premise
198	)	N	I-Premise
199	.	N	I-Premise

200	Compared	N	I-Premise
201	with	N	I-Premise
202	1-year	N	I-Premise
203	treatment	N	I-Premise
204	in	N	I-Premise
205	the	N	I-Premise
206	treatment	N	I-Premise
207	group	N	I-Premise
208	,	N	I-Premise
209	the	N	I-Premise
210	2-and	N	I-Premise
211	3-year	N	I-Premise
212	psychological	N	I-Premise
213	functions	N	I-Premise
214	and	N	I-Premise
215	the	N	I-Premise
216	general	N	I-Premise
217	symptoms	N	I-Premise
218	scores	N	I-Premise
219	decreased	N	I-Premise
220	(	N	I-Premise
221	P	N	I-Premise
222	<	N	I-Premise
223	0.05	N	I-Premise
224	,	N	I-Premise
225	P	N	I-Premise
226	<	N	I-Premise
227	0.01	N	I-Premise
228	)	N	I-Premise
229	.	N	I-Premise

230	Compared	N	I-Premise
231	with	N	I-Premise
232	the	N	I-Premise
233	control	N	I-Premise
234	group	N	I-Premise
235	of	N	I-Premise
236	the	N	I-Premise
237	same	N	I-Premise
238	period	N	I-Premise
239	,	N	I-Premise
240	the	N	I-Premise
241	2-and	N	I-Premise
242	3-year	N	I-Premise
243	somatic	N	I-Premise
244	functions	N	I-Premise
245	,	N	I-Premise
246	psychological	N	I-Premise
247	functions	N	I-Premise
248	,	N	I-Premise
249	and	N	I-Premise
250	the	N	I-Premise
251	general	N	I-Premise
252	symptoms	N	I-Premise
253	scores	N	I-Premise
254	decreased	N	I-Premise
255	in	N	I-Premise
256	the	N	I-Premise
257	treatment	N	I-Premise
258	group	N	I-Premise
259	;	N	I-Premise
260	the	N	I-Premise
261	2-year	N	I-Premise
262	somatic	N	I-Premise
263	functions	N	I-Premise
264	and	N	I-Premise
265	psychological	N	I-Premise
266	functions	N	I-Premise
267	decreased	N	I-Premise
268	in	N	I-Premise
269	the	N	I-Premise
270	treatment	N	I-Premise
271	group	N	I-Premise
272	;	N	I-Premise
273	the	N	I-Premise
274	3-year	N	I-Premise
275	psychological	N	I-Premise
276	functions	N	I-Premise
277	and	N	I-Premise
278	the	N	I-Premise
279	general	N	I-Premise
280	symptoms	N	I-Premise
281	scores	N	I-Premise
282	decreased	N	I-Premise
283	in	N	I-Premise
284	the	N	I-Premise
285	treatment	N	I-Premise
286	group	N	I-Premise
287	,	N	I-Premise
288	all	N	I-Premise
289	with	N	I-Premise
290	statistical	N	I-Premise
291	difference	N	I-Premise
292	(	N	I-Premise
293	all	N	I-Premise
294	P	N	I-Premise
295	<	N	I-Premise
296	0.05	N	I-Premise
297	)	N	I-Premise
298	.	N	I-Premise

299	Compared	N	I-Premise
300	with	N	I-Premise
301	the	N	I-Premise
302	control	N	I-Premise
303	group	N	I-Premise
304	,	N	I-Premise
305	the	N	I-Premise
306	death	N	I-Premise
307	number	N	I-Premise
308	decreased	N	I-Premise
309	,	N	I-Premise
310	the	N	I-Premise
311	survival	N	I-Premise
312	rate	N	I-Premise
313	increased	N	I-Premise
314	,	N	I-Premise
315	the	N	I-Premise
316	life	N	I-Premise
317	span	N	I-Premise
318	of	N	I-Premise
319	dead	N	I-Premise
320	children	N	I-Premise
321	was	N	I-Premise
322	prolonged	N	I-Premise
323	in	N	I-Premise
324	the	N	I-Premise
325	treatment	N	I-Premise
326	group	N	I-Premise
327	,	N	I-Premise
328	showing	N	I-Premise
329	statistical	N	I-Premise
330	difference	N	I-Premise
331	(	N	I-Premise
332	P	N	I-Premise
333	<	N	I-Premise
334	0.05	N	I-Premise
335	)	N	I-Premise
336	.	N	I-Premise

337	FJD	N	I-Claim
338	combined	N	I-Claim
339	chemotherapy	N	I-Claim
340	could	N	I-Claim
341	effectively	N	I-Claim
342	improve	N	I-Claim
343	the	N	I-Claim
344	QOL	N	I-Claim
345	of	N	I-Claim
346	solid	N	I-Claim
347	tumor	N	I-Claim
348	children	N	I-Claim
349	patients	N	I-Claim
350	,	N	I-Claim
351	elevate	N	I-Claim
352	their	N	I-Claim
353	survival	N	I-Claim
354	rate	N	I-Claim
355	,	N	I-Claim
356	and	N	I-Claim
357	prolong	N	I-Claim
358	their	N	I-Claim
359	life	N	I-Claim
360	spans	N	I-Claim
361	.	N	I-Claim

1	Over	N	O
2	30	N	O
3	%	N	O
4	of	N	O
5	patients	N	O
6	with	N	O
7	non-small	N	O
8	cell	N	O
9	lung	N	O
10	cancer	N	O
11	(	N	O
12	NSCLC	N	O
13	)	N	O
14	develop	N	O
15	brain	N	O
16	metastases	N	O
17	.	N	O

18	If	N	O
19	inoperable	N	O
20	,	N	O
21	optimal	N	O
22	supportive	N	O
23	care	N	O
24	(	N	O
25	OSC	N	O
26	)	N	O
27	,	N	O
28	including	N	O
29	steroids	N	O
30	,	N	O
31	and	N	O
32	whole	N	O
33	brain	N	O
34	radiotherapy	N	O
35	(	N	O
36	WBRT	N	O
37	)	N	O
38	are	N	O
39	generally	N	O
40	considered	N	O
41	to	N	O
42	be	N	O
43	standard	N	O
44	care	N	O
45	,	N	O
46	although	N	O
47	there	N	O
48	is	N	O
49	no	N	O
50	randomised	N	O
51	evidence	N	O
52	demonstrating	N	O
53	that	N	O
54	the	N	O
55	addition	N	O
56	of	N	O
57	WBRT	N	O
58	to	N	O
59	OSC	N	O
60	improves	N	O
61	survival	N	O
62	or	N	O
63	quality	N	O
64	of	N	O
65	life	N	O
66	.	N	O

67	QUARTZ	N	O
68	is	N	O
69	a	N	O
70	randomised	N	O
71	,	N	O
72	non-inferiority	N	O
73	,	N	O
74	phase	N	O
75	III	N	O
76	trial	N	O
77	comparing	N	O
78	OSC	N	O
79	+	N	O
80	WBRT	N	O
81	versus	N	O
82	OSC	N	O
83	in	N	O
84	patients	N	O
85	with	N	O
86	inoperable	N	O
87	brain	N	O
88	metastases	N	O
89	from	N	O
90	NSCLC	N	O
91	.	N	O

92	The	N	O
93	primary	N	O
94	outcome	N	O
95	measure	N	O
96	is	N	O
97	quality-adjusted	N	O
98	life	N	O
99	years	N	O
100	(	N	O
101	QALYs	N	O
102	)	N	O
103	.	N	O

104	QUARTZ	N	O
105	was	N	O
106	threatened	N	O
107	with	N	O
108	both	N	O
109	loss	N	O
110	of	N	O
111	funding	N	O
112	and	N	O
113	early	N	O
114	closure	N	O
115	due	N	O
116	to	N	O
117	poor	N	O
118	accrual	N	O
119	.	N	O

120	A	N	O
121	lack	N	O
122	of	N	O
123	preliminary	N	O
124	randomised	N	O
125	data	N	O
126	supporting	N	O
127	the	N	O
128	trial	N	O
129	's	N	O
130	hypotheses	N	O
131	was	N	O
132	thought	N	O
133	to	N	O
134	underlie	N	O
135	the	N	O
136	poor	N	O
137	accrual	N	O
138	,	N	O
139	so	N	O
140	,	N	O
141	with	N	O
142	no	N	O
143	knowledge	N	O
144	of	N	O
145	the	N	O
146	data	N	O
147	,	N	O
148	the	N	O
149	independent	N	O
150	trial	N	O
151	steering	N	O
152	committee	N	O
153	agreed	N	O
154	to	N	O
155	the	N	O
156	unusual	N	O
157	step	N	O
158	of	N	O
159	releasing	N	O
160	interim	N	O
161	data	N	O
162	.	N	O

163	Between	N	O
164	March	N	O
165	2007	N	O
166	and	N	O
167	April	N	O
168	2010	N	O
169	,	N	O
170	151	N	O
171	(	N	O
172	of	N	O
173	the	N	O
174	planned	N	O
175	534	N	O
176	)	N	O
177	patients	N	O
178	were	N	O
179	randomised	N	O
180	(	N	O
181	75	N	O
182	OSC	N	O
183	+	N	O
184	WBRT	N	O
185	,	N	O
186	76	N	O
187	OSC	N	O
188	)	N	O
189	.	N	O

190	Participants	N	O
191	'	N	O
192	baseline	N	O
193	demographics	N	O
194	included	N	O
195	median	N	O
196	age	N	O
197	67	N	O
198	years	N	O
199	(	N	O
200	interquartile	N	O
201	range	N	O
202	62-73	N	O
203	)	N	O
204	,	N	O
205	60	N	O
206	%	N	O
207	male	N	O
208	,	N	O
209	50	N	O
210	%	N	O
211	with	N	O
212	a	N	O
213	Karnofsky	N	O
214	performance	N	O
215	status	N	O
216	<	N	O
217	70	N	O
218	;	N	O
219	steroid	N	O
220	usage	N	O
221	was	N	O
222	similar	N	O
223	in	N	O
224	the	N	O
225	two	N	O
226	groups	N	O
227	;	N	O
228	64/75	N	O
229	(	N	O
230	85	N	O
231	%	N	O
232	)	N	O
233	received	N	O
234	WBRT	N	O
235	(	N	O
236	20	N	O
237	Gy	N	O
238	in	N	O
239	five	N	O
240	fractions	N	O
241	)	N	O
242	.	N	O

243	Median	N	I-Premise
244	survival	N	I-Premise
245	was	N	I-Premise
246	:	N	I-Premise
247	OSC	N	I-Premise
248	+	N	I-Premise
249	WBRT	N	I-Premise
250	49	N	I-Premise
251	days	N	I-Premise
252	(	N	I-Premise
253	95	N	I-Premise
254	%	N	I-Premise
255	confidence	N	I-Premise
256	interval	N	I-Premise
257	39-61	N	I-Premise
258	)	N	I-Premise
259	,	N	I-Premise
260	OSC	N	I-Premise
261	51	N	I-Premise
262	days	N	I-Premise
263	(	N	I-Premise
264	95	N	I-Premise
265	%	N	I-Premise
266	confidence	N	I-Premise
267	interval	N	I-Premise
268	27-57	N	I-Premise
269	)	N	I-Premise
270	-	N	I-Premise
271	hazard	N	I-Premise
272	ratio	N	I-Premise
273	1.11	N	I-Premise
274	(	N	I-Premise
275	95	N	I-Premise
276	%	N	I-Premise
277	confidence	N	I-Premise
278	interval	N	I-Premise
279	0.80-1.53	N	I-Premise
280	)	N	I-Premise
281	in	N	I-Premise
282	favour	N	I-Premise
283	of	N	I-Premise
284	WBRT	N	I-Premise
285	.	N	I-Premise

286	Quality	N	I-Premise
287	of	N	I-Premise
288	life	N	I-Premise
289	assessed	N	I-Premise
290	using	N	I-Premise
291	EQ-5D	N	I-Premise
292	showed	N	I-Premise
293	no	N	I-Premise
294	evidence	N	I-Premise
295	of	N	I-Premise
296	a	N	I-Premise
297	difference	N	I-Premise
298	.	N	I-Premise

299	The	N	I-Premise
300	estimated	N	I-Premise
301	mean	N	I-Premise
302	QALYs	N	I-Premise
303	was	N	I-Premise
304	:	N	I-Premise
305	OSC	N	I-Premise
306	+	N	I-Premise
307	WBRT	N	I-Premise
308	31	N	I-Premise
309	days	N	I-Premise
310	and	N	I-Premise
311	OSC	N	I-Premise
312	30	N	I-Premise
313	days	N	I-Premise
314	,	N	I-Premise
315	difference	N	I-Premise
316	-1	N	I-Premise
317	day	N	I-Premise
318	(	N	I-Premise
319	95	N	I-Premise
320	%	N	I-Premise
321	confidence	N	I-Premise
322	interval	N	I-Premise
323	-12.0	N	I-Premise
324	to	N	I-Premise
325	+13.2	N	I-Premise
326	days	N	I-Premise
327	)	N	I-Premise
328	.	N	I-Premise

329	These	N	I-Claim
330	interim	N	I-Claim
331	data	N	I-Claim
332	indicate	N	I-Claim
333	no	N	I-Claim
334	early	N	I-Claim
335	evidence	N	I-Claim
336	of	N	I-Claim
337	detriment	N	I-Claim
338	to	N	I-Claim
339	quality	N	I-Claim
340	of	N	I-Claim
341	life	N	I-Claim
342	,	N	I-Claim
343	overall	N	I-Claim
344	survival	N	I-Claim
345	or	N	I-Claim
346	QALYs	N	I-Claim
347	for	N	I-Claim
348	patients	N	I-Claim
349	allocated	N	I-Claim
350	to	N	I-Claim
351	OSC	N	I-Claim
352	alone	N	I-Claim
353	.	N	I-Claim

354	They	N	O
355	provide	N	O
356	key	N	O
357	information	N	O
358	for	N	O
359	discussing	N	O
360	the	N	O
361	trial	N	O
362	with	N	O
363	patients	N	O
364	and	N	O
365	strengthen	N	O
366	the	N	O
367	argument	N	O
368	for	N	O
369	continuing	N	O
370	QUARTZ	N	O
371	to	N	O
372	definitively	N	O
373	answer	N	O
374	this	N	O
375	important	N	O
376	clinical	N	O
377	question	N	O
378	.	N	O

1	Chemoradiotherapy	N	O
2	(	N	O
3	CRT	N	O
4	)	N	O
5	-induced	N	O
6	oral	N	O
7	mucositis	N	O
8	(	N	O
9	OM	N	O
10	)	N	O
11	adversely	N	O
12	affects	N	O
13	a	N	O
14	patient	N	O
15	's	N	O
16	oral	N	O
17	functions	N	O
18	and	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	(	N	O
23	QOL	N	O
24	)	N	O
25	.	N	O

26	Low-level	N	O
27	laser	N	O
28	therapy	N	O
29	(	N	O
30	LLLT	N	O
31	)	N	O
32	showed	N	O
33	some	N	O
34	preventive	N	O
35	and	N	O
36	curative	N	O
37	effects	N	O
38	against	N	O
39	clinically	N	O
40	reported	N	O
41	objective	N	O
42	measures	N	O
43	of	N	O
44	OM	N	O
45	in	N	O
46	few	N	O
47	trials	N	O
48	including	N	O
49	our	N	O
50	recently	N	O
51	published	N	O
52	study	N	O
53	.	N	O

54	There	N	O
55	is	N	O
56	dearth	N	O
57	of	N	O
58	evidence	N	O
59	regarding	N	O
60	the	N	O
61	effects	N	O
62	of	N	O
63	LLLT	N	O
64	on	N	O
65	patient	N	O
66	's	N	O
67	subjective	N	O
68	experience	N	O
69	of	N	O
70	OM	N	O
71	and	N	O
72	QOL	N	O
73	.	N	O

74	Hence	N	O
75	,	N	O
76	we	N	O
77	did	N	O
78	this	N	O
79	study	N	O
80	to	N	O
81	evaluate	N	O
82	the	N	O
83	effects	N	O
84	of	N	O
85	LLLT	N	O
86	on	N	O
87	a	N	O
88	patient	N	O
89	's	N	O
90	reported	N	O
91	measures	N	O
92	of	N	O
93	OM	N	O
94	and	N	O
95	QOL	N	O
96	in	N	O
97	head	N	O
98	and	N	O
99	neck	N	O
100	cancer	N	O
101	(	N	O
102	HNC	N	O
103	)	N	O
104	patients	N	O
105	receiving	N	O
106	CRT	N	O
107	.	N	O

108	This	N	O
109	triple	N	O
110	blinded	N	O
111	study	N	O
112	randomized	N	O
113	220	N	O
114	HNC	N	O
115	patients	N	O
116	scheduled	N	O
117	for	N	O
118	CRT	N	O
119	(	N	O
120	three	N	O
121	weekly	N	O
122	Cisplatin	N	O
123	+	N	O
124	RT	N	O
125	=	N	O
126	66	N	O
127	Gray	N	O
128	(	N	O
129	2	N	O
130	Gy/session	N	O
131	)	N	O
132	,	N	O
133	five	N	O
134	fractions/week	N	O
135	for	N	O
136	6.5	N	O
137	weeks	N	O
138	,	N	O
139	total	N	O
140	33	N	O
141	fractions	N	O
142	)	N	O
143	into	N	O
144	laser	N	O
145	(	N	O
146	110	N	O
147	)	N	O
148	and	N	O
149	placebo	N	O
150	(	N	O
151	110	N	O
152	)	N	O
153	groups	N	O
154	.	N	O

155	The	N	O
156	laser	N	O
157	group	N	O
158	received	N	O
159	LLLT	N	O
160	(	N	O
161	Technomed	N	O
162	Electronics	N	O
163	Advanced	N	O
164	Laser	N	O
165	Therapy	N	O
166	1000	N	O
167	,	N	O
168	He-Ne	N	O
169	,	N	O
170		N	O
171	=	N	O
172	632.8	N	O
173	nm	N	O
174	,	N	O
175	power	N	O
176	density	N	O
177	=	N	O
178	24	N	O
179	mW/cm	N	O
180	(	N	O
181	2	N	O
182	)	N	O
183	,	N	O
184	dosage	N	O
185	=	N	O
186	3.0	N	O
187	J	N	O
188	at	N	O
189	each	N	O
190	point	N	O
191	,	N	O
192	total	N	O
193	dose/session	N	O
194	=	N	O
195	36-40	N	O
196	J	N	O
197	,	N	O
198	spot	N	O
199	size	N	O
200	1	N	O
201	cm	N	O
202	(	N	O
203	2	N	O
204	)	N	O
205	,	N	O
206	irradiation	N	O
207	time/point	N	O
208	125	N	O
209	s	N	O
210	)	N	O
211	before	N	O
212	each	N	O
213	radiation	N	O
214	session	N	O
215	,	N	O
216	while	N	O
217	the	N	O
218	placebo	N	O
219	group	N	O
220	did	N	O
221	not	N	O
222	receive	N	O
223	laser	N	O
224	therapy	N	O
225	.	N	O

226	Methodology	N	O
227	was	N	O
228	similar	N	O
229	to	N	O
230	our	N	O
231	recently	N	O
232	published	N	O
233	study	N	O
234	(	N	O
235	Gautam	N	O
236	et	N	O
237	al	N	O
238	.	N	O

239	Radiother	N	O
240	Oncol	N	O
241	104:349-354	N	O
242	,	N	O
243	2012	N	O
244	)	N	O
245	.	N	O

246	In	N	O
247	this	N	O
248	part	N	O
249	of	N	O
250	our	N	O
251	study	N	O
252	,	N	O
253	a	N	O
254	blinded	N	O
255	assessor	N	O
256	collected	N	O
257	subjective	N	O
258	outcomes	N	O
259	of	N	O
260	the	N	O
261	patient	N	O
262	's	N	O
263	reported	N	O
264	measures	N	O
265	of	N	O
266	OM	N	O
267	using	N	O
268	Oral	N	O
269	Mucositis	N	O
270	Weekly	N	O
271	Questionnaire-Head	N	O
272	and	N	O
273	Neck	N	O
274	(	N	O
275	OMWQ-HN	N	O
276	)	N	O
277	and	N	O
278	QOL	N	O
279	using	N	O
280	Functional	N	O
281	Assessment	N	O
282	of	N	O
283	Cancer	N	O
284	Treatment-Head	N	O
285	and	N	O
286	Neck	N	O
287	(	N	O
288	FACT-HN	N	O
289	)	N	O
290	Questionnaire	N	O
291	.	N	O

292	Data	N	O
293	were	N	O
294	analyzed	N	O
295	using	N	O
296	repeated	N	O
297	measure	N	O
298	ANOVA	N	O
299	through	N	O
300	general	N	O
301	linear	N	O
302	model	N	O
303	.	N	O

304	Statistical	N	O
305	significance	N	O
306	was	N	O
307	kept	N	O
308	at	N	O
309	p	N	O
310	<	N	O
311	0.05	N	O
312	.	N	O

313	Results	N	I-Premise
314	analysis	N	I-Premise
315	revealed	N	I-Premise
316	that	N	I-Premise
317	OMWQ-HN	N	I-Premise
318	(	N	I-Premise
319	F	N	I-Premise
320	=	N	I-Premise
321	12.199	N	I-Premise
322	,	N	I-Premise
323	df	N	I-Premise
324	=	N	I-Premise
325	6,1314	N	I-Premise
326	,	N	I-Premise
327	p	N	I-Premise
328	<	N	I-Premise
329	0.001	N	I-Premise
330	)	N	I-Premise
331	and	N	I-Premise
332	FACT-HN	N	I-Premise
333	(	N	I-Premise
334	p	N	I-Premise
335	<	N	I-Premise
336	0.05	N	I-Premise
337	)	N	I-Premise
338	scores	N	I-Premise
339	were	N	I-Premise
340	significantly	N	I-Premise
341	lower	N	I-Premise
342	in	N	I-Premise
343	LLLT	N	I-Premise
344	than	N	I-Premise
345	placebo	N	I-Premise
346	group	N	I-Premise
347	patients	N	I-Premise
348	.	N	I-Premise

349	Also	N	O
350	,	N	O
351	a	N	I-Premise
352	significant	N	I-Premise
353	reduction	N	I-Premise
354	(	N	I-Premise
355	p	N	I-Premise
356	<	N	I-Premise
357	0.001	N	I-Premise
358	)	N	I-Premise
359	in	N	I-Premise
360	incidence	N	I-Premise
361	of	N	I-Premise
362	severe	N	I-Premise
363	OM	N	I-Premise
364	,	N	I-Premise
365	need	N	I-Premise
366	for	N	I-Premise
367	opioid	N	I-Premise
368	analgesics	N	I-Premise
369	,	N	I-Premise
370	and	N	I-Premise
371	total	N	I-Premise
372	parenteral	N	I-Premise
373	nutrition	N	I-Premise
374	was	N	I-Premise
375	observed	N	I-Premise
376	.	N	I-Premise

377	LLLT	N	I-Claim
378	was	N	I-Claim
379	effective	N	I-Claim
380	in	N	I-Claim
381	improving	N	I-Claim
382	the	N	I-Claim
383	patient	N	I-Claim
384	's	N	I-Claim
385	subjective	N	I-Claim
386	experience	N	I-Claim
387	of	N	I-Claim
388	OM	N	I-Claim
389	and	N	I-Claim
390	QOL	N	I-Claim
391	in	N	I-Claim
392	HNC	N	I-Claim
393	patients	N	I-Claim
394	receiving	N	I-Claim
395	CRT	N	I-Claim
396	.	N	I-Claim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	blinded	N	O
6	,	N	O
7	randomized	N	O
8	clinical	N	O
9	trial	N	O
10	was	N	O
11	to	N	O
12	compare	N	O
13	two	N	O
14	topical	N	O
15	agents	N	O
16	(	N	O
17	Calendula	N	O
18	Weleda	N	O
19	cream	N	O
20	vs.	N	O
21	Essex	N	O
22	cream	N	O
23	)	N	O
24	in	N	O
25	reducing	N	O
26	the	N	O
27	risk	N	O
28	of	N	O
29	severe	N	O
30	acute	N	O
31	radiation	N	O
32	skin	N	O
33	reactions	N	O
34	(	N	O
35	ARSR	N	O
36	)	N	O
37	in	N	O
38	relation	N	O
39	to	N	O
40	adjuvant	N	O
41	radiotherapy	N	O
42	(	N	O
43	RT	N	O
44	)	N	O
45	for	N	O
46	breast	N	O
47	cancer	N	O
48	.	N	O

49	The	N	O
50	primary	N	O
51	endpoint	N	O
52	was	N	O
53	the	N	O
54	difference	N	O
55	in	N	O
56	proportion	N	O
57	of	N	O
58	patients	N	O
59	with	N	O
60	ARSR	N	O
61	,	N	O
62	assessed	N	O
63	with	N	O
64	the	N	O
65	Radiation	N	O
66	Therapy	N	O
67	Oncology	N	O
68	Group/The	N	O
69	Organization	N	O
70	for	N	O
71	Research	N	O
72	and	N	O
73	Treatment	N	O
74	of	N	O
75	Cancer	N	O
76	Acute	N	O
77	Radiation	N	O
78	Morbidity	N	O
79	Scoring	N	O
80	Criteria	N	O
81	(	N	O
82	RTOG/EORTC	N	O
83	scale	N	O
84	)	N	O
85	at	N	O
86	follow-up	N	O
87	.	N	O

88	The	N	O
89	secondary	N	O
90	endpoints	N	O
91	included	N	O
92	patient	N	O
93	reported	N	O
94	outcome	N	O
95	measures	N	O
96	;	N	O
97	Quality	N	O
98	of	N	O
99	Life	N	O
100	Questionnaire	N	O
101	(	N	O
102	QLQ-C30	N	O
103	)	N	O
104	,	N	O
105	Sleep	N	O
106	disturbances	N	O
107	(	N	O
108	MOS-sleep	N	O
109	questionnaire	N	O
110	)	N	O
111	and	N	O
112	symptoms	N	O
113	from	N	O
114	the	N	O
115	irradiated	N	O
116	area	N	O
117	(	N	O
118	visual	N	O
119	analogue	N	O
120	scale	N	O
121	)	N	O
122	.	N	O

123	Patients	N	O
124	'	N	O
125	experiences	N	O
126	and	N	O
127	adherence	N	O
128	to	N	O
129	the	N	O
130	topical	N	O
131	agents	N	O
132	were	N	O
133	also	N	O
134	evaluated	N	O
135	.	N	O

136	A	N	O
137	total	N	O
138	of	N	O
139	420	N	O
140	patients	N	O
141	were	N	O
142	randomised	N	O
143	and	N	O
144	411	N	O
145	were	N	O
146	analysed	N	O
147	.	N	O

148	With	N	O
149	the	N	O
150	exception	N	O
151	of	N	O
152	previous	N	O
153	chemotherapy	N	O
154	,	N	O
155	the	N	O
156	treatment	N	O
157	groups	N	O
158	were	N	O
159	well	N	O
160	balanced	N	O
161	,	N	O
162	both	N	O
163	regarding	N	O
164	treatment-	N	O
165	and	N	O
166	patient-related	N	O
167	factors	N	O
168	.	N	O

169	The	N	I-Premise
170	incidence	N	I-Premise
171	of	N	I-Premise
172	severe	N	I-Premise
173	ARSR	N	I-Premise
174	(	N	I-Premise
175	RTOG/EORTC	N	I-Premise
176	grade	N	I-Premise
177	2	N	I-Premise
178	)	N	I-Premise
179	at	N	I-Premise
180	the	N	I-Premise
181	follow-up	N	I-Premise
182	visit	N	I-Premise
183	was	N	I-Premise
184	23	N	I-Premise
185	%	N	I-Premise
186	(	N	I-Premise
187	n	N	I-Premise
188	=	N	I-Premise
189	45	N	I-Premise
190	)	N	I-Premise
191	in	N	I-Premise
192	the	N	I-Premise
193	Calendula	N	I-Premise
194	group	N	I-Premise
195	and	N	I-Premise
196	19	N	I-Premise
197	%	N	I-Premise
198	(	N	I-Premise
199	n	N	I-Premise
200	=	N	I-Premise
201	38	N	I-Premise
202	)	N	I-Premise
203	in	N	I-Premise
204	the	N	I-Premise
205	Essex	N	I-Premise
206	group	N	I-Premise
207	.	N	I-Premise

208	We	N	I-Premise
209	found	N	I-Premise
210	no	N	I-Premise
211	difference	N	I-Premise
212	in	N	I-Premise
213	severe	N	I-Premise
214	ARSR	N	I-Premise
215	between	N	I-Premise
216	the	N	I-Premise
217	groups	N	I-Premise
218	at	N	I-Premise
219	any	N	I-Premise
220	point	N	I-Premise
221	of	N	I-Premise
222	assessment	N	I-Premise
223	.	N	I-Premise

224	The	N	I-Premise
225	patients	N	I-Premise
226	reported	N	I-Premise
227	low	N	I-Premise
228	levels	N	I-Premise
229	of	N	I-Premise
230	skin	N	I-Premise
231	related	N	I-Premise
232	symptoms	N	I-Premise
233	and	N	I-Premise
234	no	N	I-Premise
235	statistically	N	I-Premise
236	significant	N	I-Premise
237	differences	N	I-Premise
238	between	N	I-Premise
239	the	N	I-Premise
240	groups	N	I-Premise
241	were	N	I-Premise
242	found	N	I-Premise
243	.	N	I-Premise

244	No	N	I-Claim
245	differences	N	I-Claim
246	in	N	I-Claim
247	ARSR	N	I-Claim
248	between	N	I-Claim
249	patients	N	I-Claim
250	randomised	N	I-Claim
251	to	N	I-Claim
252	Calendula	N	I-Claim
253	or	N	I-Claim
254	Essex	N	I-Claim
255	cream	N	I-Claim
256	was	N	I-Claim
257	found	N	I-Claim
258	.	N	I-Claim

259	ARSR	N	I-Claim
260	seem	N	I-Claim
261	to	N	I-Claim
262	be	N	I-Claim
263	a	N	I-Claim
264	relatively	N	I-Claim
265	limited	N	I-Claim
266	problem	N	I-Claim
267	,	N	I-Claim
268	probably	N	I-Claim
269	more	N	I-Claim
270	influenced	N	I-Claim
271	by	N	I-Claim
272	treatment	N	I-Claim
273	related	N	I-Claim
274	factors	N	I-Claim
275	than	N	I-Claim
276	by	N	I-Claim
277	choice	N	I-Claim
278	of	N	I-Claim
279	skin	N	I-Claim
280	care	N	I-Claim
281	products	N	I-Claim
282	in	N	I-Claim
283	this	N	I-Claim
284	patient	N	I-Claim
285	group	N	I-Claim
286	.	N	I-Claim

1	With	N	O
2	the	N	O
3	adoption	N	O
4	of	N	O
5	enhanced	N	O
6	recovery	N	O
7	and	N	O
8	emerging	N	O
9	new	N	O
10	modalities	N	O
11	of	N	O
12	analgesia	N	O
13	after	N	O
14	laparoscopic	N	O
15	colorectal	N	O
16	resection	N	O
17	(	N	O
18	LCR	N	O
19	)	N	O
20	,	N	O
21	the	N	O
22	role	N	O
23	of	N	O
24	epidural	N	O
25	analgesia	N	O
26	has	N	O
27	been	N	O
28	questioned	N	O
29	.	N	O

30	This	N	O
31	pilot	N	O
32	trial	N	O
33	assessed	N	O
34	the	N	O
35	feasibility	N	O
36	of	N	O
37	a	N	O
38	randomized	N	O
39	controlled	N	O
40	trial	N	O
41	(	N	O
42	RCT	N	O
43	)	N	O
44	comparing	N	O
45	epidural	N	O
46	analgesia	N	O
47	and	N	O
48	use	N	O
49	of	N	O
50	a	N	O
51	local	N	O
52	anaesthetic	N	O
53	wound	N	O
54	infusion	N	O
55	catheter	N	O
56	(	N	O
57	WIC	N	O
58	)	N	O
59	following	N	O
60	LCR	N	O
61	.	N	O

62	Between	N	O
63	April	N	O
64	2010	N	O
65	and	N	O
66	May	N	O
67	2011	N	O
68	,	N	O
69	patients	N	O
70	undergoing	N	O
71	elective	N	O
72	LCR	N	O
73	in	N	O
74	two	N	O
75	centres	N	O
76	were	N	O
77	randomized	N	O
78	to	N	O
79	analgesia	N	O
80	via	N	O
81	epidural	N	O
82	or	N	O
83	WIC	N	O
84	.	N	O

85	Sham	N	O
86	procedures	N	O
87	were	N	O
88	used	N	O
89	to	N	O
90	blind	N	O
91	surgeons	N	O
92	,	N	O
93	patients	N	O
94	and	N	O
95	outcome	N	O
96	assessors	N	O
97	.	N	O

98	The	N	O
99	primary	N	O
100	outcome	N	O
101	was	N	O
102	the	N	O
103	feasibility	N	O
104	of	N	O
105	a	N	O
106	large	N	O
107	RCT	N	O
108	,	N	O
109	and	N	O
110	all	N	O
111	outcomes	N	O
112	for	N	O
113	a	N	O
114	definitive	N	O
115	trial	N	O
116	were	N	O
117	tested	N	O
118	.	N	O

119	The	N	O
120	success	N	O
121	of	N	O
122	blinding	N	O
123	was	N	O
124	assessed	N	O
125	using	N	O
126	a	N	O
127	mixed-methods	N	O
128	approach	N	O
129	.	N	O

130	Forty-five	N	O
131	patients	N	O
132	were	N	O
133	eligible	N	O
134	,	N	O
135	of	N	O
136	whom	N	O
137	34	N	O
138	were	N	O
139	randomized	N	O
140	(	N	O
141	mean	N	O
142	(	N	O
143	s.d	N	O
144	.	N	O

145	)	N	O
146	age	N	O
147	70	N	O
148	(	N	O
149	118	N	O
150	)	N	O
151	years	N	O
152	)	N	O
153	.	N	O

154	Patients	N	O
155	were	N	O
156	followed	N	O
157	up	N	O
158	per-protocol	N	O
159	;	N	O
160	there	N	O
161	were	N	O
162	no	N	O
163	deaths	N	O
164	,	N	O
165	and	N	O
166	five	N	O
167	patients	N	O
168	had	N	O
169	a	N	O
170	total	N	O
171	of	N	O
172	six	N	O
173	complications	N	O
174	.	N	O

175	Challenges	N	O
176	with	N	O
177	capturing	N	O
178	pain	N	O
179	data	N	O
180	were	N	O
181	identified	N	O
182	and	N	O
183	resolved	N	O
184	.	N	O

185	Mean	N	I-Premise
186	(	N	I-Premise
187	s.d	N	I-Premise
188	.	N	I-Premise

189	)	N	I-Premise
190	pain	N	I-Premise
191	scores	N	I-Premise
192	on	N	I-Premise
193	the	N	I-Premise
194	day	N	I-Premise
195	of	N	I-Premise
196	discharge	N	I-Premise
197	were	N	I-Premise
198	19	N	I-Premise
199	(	N	I-Premise
200	31	N	I-Premise
201	)	N	I-Premise
202	in	N	I-Premise
203	the	N	I-Premise
204	epidural	N	I-Premise
205	group	N	I-Premise
206	and	N	I-Premise
207	07	N	I-Premise
208	(	N	I-Premise
209	07	N	I-Premise
210	)	N	I-Premise
211	in	N	I-Premise
212	the	N	I-Premise
213	WIC	N	I-Premise
214	group	N	I-Premise
215	.	N	I-Premise

216	Median	N	I-Premise
217	length	N	I-Premise
218	of	N	I-Premise
219	stay	N	I-Premise
220	was	N	I-Premise
221	4	N	I-Premise
222	(	N	I-Premise
223	range	N	I-Premise
224	2-35	N	I-Premise
225	,	N	I-Premise
226	interquartile	N	I-Premise
227	range	N	I-Premise
228	3-5	N	I-Premise
229	)	N	I-Premise
230	days	N	I-Premise
231	.	N	I-Premise

232	Mean	N	I-Premise
233	use	N	I-Premise
234	of	N	I-Premise
235	additional	N	I-Premise
236	analgesia	N	I-Premise
237	(	N	I-Premise
238	intravenous	N	I-Premise
239	morphine	N	I-Premise
240	equivalents	N	I-Premise
241	)	N	I-Premise
242	was	N	I-Premise
243	12	N	I-Premise
244	mg	N	I-Premise
245	in	N	I-Premise
246	the	N	I-Premise
247	WIC	N	I-Premise
248	arm	N	I-Premise
249	and	N	I-Premise
250	9	N	I-Premise
251	mg	N	I-Premise
252	in	N	I-Premise
253	the	N	I-Premise
254	epidural	N	I-Premise
255	arm	N	I-Premise
256	.	N	I-Premise

257	Patient	N	O
258	blinding	N	O
259	was	N	O
260	successful	N	O
261	in	N	O
262	both	N	O
263	arms	N	O
264	.	N	O

265	Qualitative	N	I-Claim
266	interviews	N	I-Claim
267	suggested	N	I-Claim
268	that	N	I-Claim
269	patients	N	I-Claim
270	found	N	I-Claim
271	participation	N	I-Claim
272	in	N	I-Claim
273	the	N	I-Claim
274	trial	N	I-Claim
275	acceptable	N	I-Claim
276	and	N	I-Claim
277	that	N	I-Claim
278	they	N	I-Claim
279	would	N	I-Claim
280	consider	N	I-Claim
281	participating	N	I-Claim
282	in	N	I-Claim
283	a	N	I-Claim
284	future	N	I-Claim
285	trial	N	I-Claim
286	.	N	I-Claim

287	A	N	I-Claim
288	blinded	N	I-Claim
289	RCT	N	I-Claim
290	investigating	N	I-Claim
291	the	N	I-Claim
292	role	N	I-Claim
293	of	N	I-Claim
294	epidural	N	I-Claim
295	and	N	I-Claim
296	WIC	N	I-Claim
297	administration	N	I-Claim
298	for	N	I-Claim
299	postoperative	N	I-Claim
300	analgesia	N	I-Claim
301	following	N	I-Claim
302	LCR	N	I-Claim
303	is	N	I-Claim
304	feasible	N	I-Claim
305	.	N	I-Claim

306	Rigorous	N	I-MajorClaim
307	standard	N	I-MajorClaim
308	operating	N	I-MajorClaim
309	procedures	N	I-MajorClaim
310	for	N	I-MajorClaim
311	data	N	I-MajorClaim
312	collection	N	I-MajorClaim
313	are	N	I-MajorClaim
314	required	N	I-MajorClaim
315	.	N	I-MajorClaim

1	Several	N	O
2	guidelines	N	O
3	on	N	O
4	the	N	O
5	treatment	N	O
6	of	N	O
7	cancer-related	N	O
8	fatigue	N	O
9	recommend	N	O
10	optimizing	N	O
11	treatment	N	O
12	of	N	O
13	accompanying	N	O
14	symptoms	N	O
15	.	N	O

16	However	N	O
17	,	N	O
18	evidence	N	O
19	for	N	O
20	this	N	O
21	recommendation	N	O
22	from	N	O
23	randomized	N	O
24	clinical	N	O
25	trials	N	O
26	is	N	O
27	lacking	N	O
28	.	N	O

29	We	N	O
30	investigated	N	O
31	whether	N	O
32	monitoring	N	O
33	and	N	O
34	protocolized	N	O
35	treatment	N	O
36	of	N	O
37	physical	N	O
38	symptoms	N	O
39	alleviates	N	O
40	fatigue	N	O
41	.	N	O

42	In	N	O
43	all	N	O
44	,	N	O
45	152	N	O
46	fatigued	N	O
47	patients	N	O
48	with	N	O
49	advanced	N	O
50	cancer	N	O
51	were	N	O
52	randomly	N	O
53	assigned	N	O
54	to	N	O
55	protocolized	N	O
56	patient-tailored	N	O
57	treatment	N	O
58	(	N	O
59	PPT	N	O
60	)	N	O
61	of	N	O
62	symptoms	N	O
63	or	N	O
64	care	N	O
65	as	N	O
66	usual	N	O
67	.	N	O

68	The	N	O
69	PPT	N	O
70	group	N	O
71	had	N	O
72	four	N	O
73	appointments	N	O
74	with	N	O
75	a	N	O
76	nurse	N	O
77	who	N	O
78	assessed	N	O
79	nine	N	O
80	symptoms	N	O
81	on	N	O
82	a	N	O
83	0	N	O
84	to	N	O
85	10	N	O
86	numeric	N	O
87	rating	N	O
88	scale	N	O
89	(	N	O
90	NRS	N	O
91	)	N	O
92	.	N	O

93	Patients	N	O
94	received	N	O
95	a	N	O
96	nonpharmacologic	N	O
97	intervention	N	O
98	for	N	O
99	symptoms	N	O
100	with	N	O
101	a	N	O
102	score	N	O
103		N	O
104	1	N	O
105	and	N	O
106	a	N	O
107	medical	N	O
108	intervention	N	O
109	for	N	O
110	symptoms	N	O
111	with	N	O
112	a	N	O
113	score	N	O
114		N	O
115	4	N	O
116	.	N	O

117	Fatigue	N	O
118	dimensions	N	O
119	,	N	O
120	fatigue	N	O
121	NRS	N	O
122	score	N	O
123	,	N	O
124	interference	N	O
125	of	N	O
126	fatigue	N	O
127	with	N	O
128	daily	N	O
129	life	N	O
130	,	N	O
131	symptom	N	O
132	burden	N	O
133	,	N	O
134	quality	N	O
135	of	N	O
136	life	N	O
137	,	N	O
138	anxiety	N	O
139	,	N	O
140	and	N	O
141	depression	N	O
142	were	N	O
143	measured	N	O
144	at	N	O
145	baseline	N	O
146	and	N	O
147	after	N	O
148	1	N	O
149	,	N	O
150	2	N	O
151	,	N	O
152	and	N	O
153	3	N	O
154	months	N	O
155	.	N	O

156	Differences	N	O
157	between	N	O
158	the	N	O
159	groups	N	O
160	over	N	O
161	time	N	O
162	were	N	O
163	assessed	N	O
164	by	N	O
165	using	N	O
166	mixed	N	O
167	modeling	N	O
168	.	N	O

169	Seventy-six	N	O
170	patients	N	O
171	were	N	O
172	randomly	N	O
173	assigned	N	O
174	to	N	O
175	each	N	O
176	study	N	O
177	arm	N	O
178	.	N	O

179	Mean	N	O
180	age	N	O
181	was	N	O
182	58	N	O
183		N	O
184	10	N	O
185	years	N	O
186	,	N	O
187	57	N	O
188	%	N	O
189	were	N	O
190	female	N	O
191	,	N	O
192	and	N	O
193	65	N	O
194	%	N	O
195	were	N	O
196	given	N	O
197	palliative	N	O
198	chemotherapy	N	O
199	.	N	O

200	We	N	I-Premise
201	found	N	I-Premise
202	significant	N	I-Premise
203	improvements	N	I-Premise
204	over	N	I-Premise
205	time	N	I-Premise
206	in	N	I-Premise
207	favor	N	I-Premise
208	of	N	I-Premise
209	PPT	N	I-Premise
210	for	N	I-Premise
211	the	N	I-Premise
212	primary	N	I-Premise
213	outcome	N	I-Premise
214	general	N	I-Premise
215	fatigue	N	I-Premise
216	(	N	I-Premise
217	P	N	I-Premise
218	=	N	I-Premise
219	.01	N	I-Premise
220	)	N	I-Premise
221	,	N	I-Premise
222	with	N	I-Premise
223	significant	N	I-Premise
224	group	N	I-Premise
225	differences	N	I-Premise
226	at	N	I-Premise
227	month	N	I-Premise
228	1	N	I-Premise
229	(	N	I-Premise
230	effect	N	I-Premise
231	size	N	I-Premise
232	,	N	I-Premise
233	0.26	N	I-Premise
234	;	N	I-Premise
235	P	N	I-Premise
236	=	N	I-Premise
237	.007	N	I-Premise
238	)	N	I-Premise
239	and	N	I-Premise
240	month	N	I-Premise
241	2	N	I-Premise
242	(	N	I-Premise
243	effect	N	I-Premise
244	size	N	I-Premise
245	,	N	I-Premise
246	0.35	N	I-Premise
247	;	N	I-Premise
248	P	N	I-Premise
249	=	N	I-Premise
250	.005	N	I-Premise
251	)	N	I-Premise
252	.	N	I-Premise

253	Improvements	N	I-Premise
254	in	N	I-Premise
255	favor	N	I-Premise
256	of	N	I-Premise
257	PPT	N	I-Premise
258	were	N	I-Premise
259	also	N	I-Premise
260	found	N	I-Premise
261	for	N	I-Premise
262	the	N	I-Premise
263	following	N	I-Premise
264	secondary	N	I-Premise
265	outcomes	N	I-Premise
266	:	N	I-Premise
267	fatigue	N	I-Premise
268	dimensions	N	I-Premise
269	``	N	I-Premise
270	reduced	N	I-Premise
271	activity	N	I-Premise
272	''	N	I-Premise
273	and	N	I-Premise
274	``	N	I-Premise
275	reduced	N	I-Premise
276	motivation	N	I-Premise
277	,	N	I-Premise
278	''	N	I-Premise
279	fatigue	N	I-Premise
280	NRS	N	I-Premise
281	,	N	I-Premise
282	symptom	N	I-Premise
283	burden	N	I-Premise
284	,	N	I-Premise
285	interference	N	I-Premise
286	of	N	I-Premise
287	fatigue	N	I-Premise
288	with	N	I-Premise
289	daily	N	I-Premise
290	life	N	I-Premise
291	,	N	I-Premise
292	and	N	I-Premise
293	anxiety	N	I-Premise
294	(	N	I-Premise
295	all	N	I-Premise
296	P	N	I-Premise
297		N	I-Premise
298	.03	N	I-Premise
299	)	N	I-Premise
300	.	N	I-Premise

301	In	N	I-Claim
302	fatigued	N	I-Claim
303	patients	N	I-Claim
304	with	N	I-Claim
305	advanced	N	I-Claim
306	cancer	N	I-Claim
307	,	N	I-Claim
308	nurse-led	N	I-Claim
309	monitoring	N	I-Claim
310	and	N	I-Claim
311	protocolized	N	I-Claim
312	treatment	N	I-Claim
313	of	N	I-Claim
314	physical	N	I-Claim
315	symptoms	N	I-Claim
316	is	N	I-Claim
317	effective	N	I-Claim
318	in	N	I-Claim
319	alleviating	N	I-Claim
320	fatigue	N	I-Claim
321	.	N	I-Claim

1	Behavioral	N	O
2	symptoms	N	O
3	are	N	O
4	common	N	O
5	in	N	O
6	breast	N	O
7	cancer	N	O
8	survivors	N	O
9	,	N	O
10	including	N	O
11	disturbances	N	O
12	in	N	O
13	energy	N	O
14	,	N	O
15	sleep	N	O
16	,	N	O
17	and	N	O
18	mood	N	O
19	,	N	O
20	though	N	O
21	few	N	O
22	risk	N	O
23	factors	N	O
24	for	N	O
25	these	N	O
26	negative	N	O
27	outcomes	N	O
28	have	N	O
29	been	N	O
30	identified	N	O
31	.	N	O

32	Our	N	O
33	study	N	O
34	examined	N	O
35	intrusive	N	O
36	thoughts	N	O
37	as	N	O
38	a	N	O
39	predictor	N	O
40	of	N	O
41	lingering	N	O
42	symptoms	N	O
43	in	N	O
44	breast	N	O
45	cancer	N	O
46	survivors	N	O
47	in	N	O
48	the	N	O
49	year	N	O
50	following	N	O
51	treatment	N	O
52	.	N	O

53	Data	N	O
54	come	N	O
55	from	N	O
56	the	N	O
57	Moving	N	O
58	Beyond	N	O
59	Cancer	N	O
60	psychoeducational	N	O
61	intervention	N	O
62	trial	N	O
63	,	N	O
64	aimed	N	O
65	at	N	O
66	easing	N	O
67	the	N	O
68	transition	N	O
69	from	N	O
70	patient	N	O
71	to	N	O
72	survivor	N	O
73	.	N	O

74	Women	N	O
75	(	N	O
76	n	N	O
77	=	N	O
78	558	N	O
79	)	N	O
80	completed	N	O
81	psychosocial	N	O
82	questionnaires	N	O
83	within	N	O
84	4	N	O
85	weeks	N	O
86	posttreatment	N	O
87	and	N	O
88	again	N	O
89	2	N	O
90	,	N	O
91	6	N	O
92	,	N	O
93	and	N	O
94	12	N	O
95	months	N	O
96	later	N	O
97	.	N	O

98	We	N	O
99	examined	N	O
100	intrusive	N	O
101	thoughts	N	O
102	about	N	O
103	cancer	N	O
104	at	N	O
105	the	N	O
106	baseline	N	O
107	assessment	N	O
108	as	N	O
109	a	N	O
110	predictor	N	O
111	of	N	O
112	fatigue	N	O
113	,	N	O
114	sleep	N	O
115	problems	N	O
116	,	N	O
117	pain	N	O
118	,	N	O
119	breast	N	O
120	cancer-specific	N	O
121	symptoms	N	O
122	,	N	O
123	depressive	N	O
124	symptoms	N	O
125	,	N	O
126	negative	N	O
127	affect	N	O
128	,	N	O
129	and	N	O
130	quality	N	O
131	of	N	O
132	life	N	O
133	using	N	O
134	growth	N	O
135	curve	N	O
136	modeling	N	O
137	,	N	O
138	controlling	N	O
139	for	N	O
140	study	N	O
141	condition	N	O
142	and	N	O
143	other	N	O
144	covariates	N	O
145	.	N	O

146	Intrusive	N	I-Premise
147	thoughts	N	I-Premise
148	were	N	I-Premise
149	associated	N	I-Premise
150	with	N	I-Premise
151	higher	N	I-Premise
152	levels	N	I-Premise
153	of	N	I-Premise
154	all	N	I-Premise
155	symptoms	N	I-Premise
156	at	N	I-Premise
157	baseline	N	I-Premise
158	and	N	I-Premise
159	at	N	I-Premise
160	the	N	I-Premise
161	12-month	N	I-Premise
162	assessment	N	I-Premise
163	.	N	I-Premise

164	Intrusive	N	I-Premise
165	thoughts	N	I-Premise
166	also	N	I-Premise
167	influenced	N	I-Premise
168	the	N	I-Premise
169	trajectory	N	I-Premise
170	of	N	I-Premise
171	pain	N	I-Premise
172	,	N	I-Premise
173	depressive	N	I-Premise
174	symptoms	N	I-Premise
175	,	N	I-Premise
176	negative	N	I-Premise
177	affect	N	I-Premise
178	,	N	I-Premise
179	and	N	I-Premise
180	physical	N	I-Premise
181	functioning	N	I-Premise
182	over	N	I-Premise
183	time	N	I-Premise
184	;	N	I-Premise
185	women	N	I-Premise
186	with	N	I-Premise
187	higher	N	I-Premise
188	intrusions	N	I-Premise
189	at	N	I-Premise
190	baseline	N	I-Premise
191	started	N	I-Premise
192	worse	N	I-Premise
193	and	N	I-Premise
194	improved	N	I-Premise
195	over	N	I-Premise
196	time	N	I-Premise
197	,	N	I-Premise
198	whereas	N	I-Premise
199	those	N	I-Premise
200	with	N	I-Premise
201	lower	N	I-Premise
202	intrusions	N	I-Premise
203	remained	N	I-Premise
204	at	N	I-Premise
205	a	N	I-Premise
206	constant	N	I-Premise
207	,	N	I-Premise
208	lower	N	I-Premise
209	level	N	I-Premise
210	over	N	I-Premise
211	time	N	I-Premise
212	.	N	I-Premise

213	Intrusions	N	I-Premise
214	were	N	I-Premise
215	not	N	I-Premise
216	associated	N	I-Premise
217	with	N	I-Premise
218	the	N	I-Premise
219	trajectory	N	I-Premise
220	of	N	I-Premise
221	fatigue	N	I-Premise
222	,	N	I-Premise
223	sleep	N	I-Premise
224	,	N	I-Premise
225	breast	N	I-Premise
226	cancer-specific	N	I-Premise
227	symptoms	N	I-Premise
228	,	N	I-Premise
229	or	N	I-Premise
230	mental	N	I-Premise
231	functioning	N	I-Premise
232	;	N	I-Premise
233	women	N	I-Premise
234	with	N	I-Premise
235	higher	N	I-Premise
236	intrusions	N	I-Premise
237	at	N	I-Premise
238	baseline	N	I-Premise
239	started	N	I-Premise
240	worse	N	I-Premise
241	and	N	I-Premise
242	remained	N	I-Premise
243	worse	N	I-Premise
244	over	N	I-Premise
245	time	N	I-Premise
246	.	N	I-Premise

247	Intrusive	N	I-Claim
248	thoughts	N	I-Claim
249	are	N	I-Claim
250	associated	N	I-Claim
251	with	N	I-Claim
252	enduring	N	I-Claim
253	elevations	N	I-Claim
254	in	N	I-Claim
255	behavioral	N	I-Claim
256	symptoms	N	I-Claim
257	and	N	I-Claim
258	impaired	N	I-Claim
259	quality	N	I-Claim
260	of	N	I-Claim
261	life	N	I-Claim
262	in	N	I-Claim
263	the	N	I-Claim
264	year	N	I-Claim
265	after	N	I-Claim
266	breast	N	I-Claim
267	cancer	N	I-Claim
268	treatment	N	I-Claim
269	and	N	I-Claim
270	may	N	I-Claim
271	be	N	I-Claim
272	a	N	I-Claim
273	risk	N	I-Claim
274	factor	N	I-Claim
275	for	N	I-Claim
276	poor	N	I-Claim
277	outcomes	N	I-Claim
278	.	N	I-Claim

1	The	N	O
2	management	N	O
3	of	N	O
4	cancer-related	N	O
5	anorexia/cachexia	N	O
6	syndrome	N	O
7	(	N	O
8	CACS	N	O
9	)	N	O
10	is	N	O
11	a	N	O
12	great	N	O
13	challenge	N	O
14	in	N	O
15	clinical	N	O
16	practice	N	O
17	.	N	O

18	To	N	O
19	date	N	O
20	,	N	O
21	practice	N	O
22	guidelines	N	O
23	for	N	O
24	the	N	O
25	prevention	N	O
26	and	N	O
27	treatment	N	O
28	of	N	O
29	CACS	N	O
30	are	N	O
31	lacking	N	O
32	.	N	O

33	The	N	O
34	authors	N	O
35	conducted	N	O
36	a	N	O
37	randomized	N	O
38	study	N	O
39	to	N	O
40	confirm	N	O
41	the	N	O
42	effectiveness	N	O
43	and	N	O
44	safety	N	O
45	of	N	O
46	treatment	N	O
47	of	N	O
48	CACS	N	O
49	utilizing	N	O
50	megestrol	N	O
51	acetate	N	O
52	(	N	O
53	MA	N	O
54	)	N	O
55	plus	N	O
56	thalidomide	N	O
57	.	N	O

58	One	N	O
59	hundred	N	O
60	and	N	O
61	two	N	O
62	candidates	N	O
63	with	N	O
64	CACS	N	O
65	were	N	O
66	randomly	N	O
67	assigned	N	O
68	to	N	O
69	two	N	O
70	treatment	N	O
71	groups	N	O
72	(	N	O
73	trial	N	O
74	group	N	O
75	and	N	O
76	control	N	O
77	group	N	O
78	)	N	O
79	:	N	O
80	the	N	O
81	trial	N	O
82	group	N	O
83	received	N	O
84	MA	N	O
85	(	N	O
86	160	N	O
87	mg	N	O
88	po	N	O
89	,	N	O
90	bid	N	O
91	)	N	O
92	plus	N	O
93	thalidomide	N	O
94	(	N	O
95	50	N	O
96	mg	N	O
97	po	N	O
98	,	N	O
99	bid	N	O
100	)	N	O
101	,	N	O
102	while	N	O
103	the	N	O
104	control	N	O
105	group	N	O
106	received	N	O
107	MA	N	O
108	(	N	O
109	160	N	O
110	mg	N	O
111	po	N	O
112	,	N	O
113	bid	N	O
114	)	N	O
115	alone	N	O
116	.	N	O

117	Treatment	N	O
118	duration	N	O
119	was	N	O
120	8	N	O
121	weeks	N	O
122	.	N	O

123	Analysis	N	I-Premise
124	of	N	I-Premise
125	the	N	I-Premise
126	trial	N	I-Premise
127	group	N	I-Premise
128	demonstrated	N	I-Premise
129	a	N	I-Premise
130	significant	N	I-Premise
131	increase	N	I-Premise
132	from	N	I-Premise
133	baseline	N	I-Premise
134	in	N	I-Premise
135	body	N	I-Premise
136	weight	N	I-Premise
137	(	N	I-Premise
138	<	N	I-Premise
139	0.01	N	I-Premise
140	)	N	I-Premise
141	,	N	I-Premise
142	quality	N	I-Premise
143	of	N	I-Premise
144	life	N	I-Premise
145	(	N	I-Premise
146	p	N	I-Premise
147	=	N	I-Premise
148	0.02	N	I-Premise
149	)	N	I-Premise
150	,	N	I-Premise
151	appetite	N	I-Premise
152	(	N	I-Premise
153	p	N	I-Premise
154	=	N	I-Premise
155	0.01	N	I-Premise
156	)	N	I-Premise
157	,	N	I-Premise
158	and	N	I-Premise
159	grip	N	I-Premise
160	strength	N	I-Premise
161	(	N	I-Premise
162	p	N	I-Premise
163	=	N	I-Premise
164	0.01	N	I-Premise
165	)	N	I-Premise
166	,	N	I-Premise
167	and	N	I-Premise
168	a	N	I-Premise
169	significant	N	I-Premise
170	decrease	N	I-Premise
171	in	N	I-Premise
172	fatigue	N	I-Premise
173	,	N	I-Premise
174	Glasgow	N	I-Premise
175	Prognostic	N	I-Premise
176	Score	N	I-Premise
177	(	N	I-Premise
178	p	N	I-Premise
179	=	N	I-Premise
180	0.05	N	I-Premise
181	)	N	I-Premise
182	,	N	I-Premise
183	Eastern	N	I-Premise
184	Cooperative	N	I-Premise
185	Oncology	N	I-Premise
186	Group	N	I-Premise
187	performance	N	I-Premise
188	status	N	I-Premise
189	(	N	I-Premise
190	p	N	I-Premise
191	=	N	I-Premise
192	0.03	N	I-Premise
193	)	N	I-Premise
194	,	N	I-Premise
195	IL-6	N	I-Premise
196	(	N	I-Premise
197	p	N	I-Premise
198	<	N	I-Premise
199	0.01	N	I-Premise
200	)	N	I-Premise
201	,	N	I-Premise
202	and	N	I-Premise
203	tumor	N	I-Premise
204	necrosis	N	I-Premise
205	factor-	N	I-Premise
206	(	N	I-Premise
207	p	N	I-Premise
208	=	N	I-Premise
209	0.02	N	I-Premise
210	)	N	I-Premise
211	.	N	I-Premise

212	In	N	I-Premise
213	contrast	N	I-Premise
214	,	N	I-Premise
215	in	N	I-Premise
216	the	N	I-Premise
217	control	N	I-Premise
218	group	N	I-Premise
219	,	N	I-Premise
220	endpoints	N	I-Premise
221	with	N	I-Premise
222	a	N	I-Premise
223	significant	N	I-Premise
224	improvement	N	I-Premise
225	from	N	I-Premise
226	baseline	N	I-Premise
227	included	N	I-Premise
228	body	N	I-Premise
229	weight	N	I-Premise
230	(	N	I-Premise
231	p	N	I-Premise
232	<	N	I-Premise
233	0.02	N	I-Premise
234	)	N	I-Premise
235	and	N	I-Premise
236	appetite	N	I-Premise
237	(	N	I-Premise
238	p	N	I-Premise
239	=	N	I-Premise
240	0.02	N	I-Premise
241	)	N	I-Premise
242	.	N	I-Premise

243	The	N	I-Premise
244	mean	N	I-Premise
245	changes	N	I-Premise
246	in	N	I-Premise
247	the	N	I-Premise
248	endpoints	N	I-Premise
249	from	N	I-Premise
250	baseline	N	I-Premise
251	in	N	I-Premise
252	the	N	I-Premise
253	trial	N	I-Premise
254	group	N	I-Premise
255	were	N	I-Premise
256	significantly	N	I-Premise
257	greater	N	I-Premise
258	compared	N	I-Premise
259	with	N	I-Premise
260	the	N	I-Premise
261	control	N	I-Premise
262	group	N	I-Premise
263	:	N	I-Premise
264	in	N	I-Premise
265	the	N	I-Premise
266	primary	N	I-Premise
267	endpoints	N	I-Premise
268	,	N	I-Premise
269	body	N	I-Premise
270	weight	N	I-Premise
271	(	N	I-Premise
272	p	N	I-Premise
273	=	N	I-Premise
274	0.05	N	I-Premise
275	)	N	I-Premise
276	,	N	I-Premise
277	fatigue	N	I-Premise
278	(	N	I-Premise
279	p	N	I-Premise
280	<	N	I-Premise
281	0.01	N	I-Premise
282	)	N	I-Premise
283	and	N	I-Premise
284	quality	N	I-Premise
285	of	N	I-Premise
286	life	N	I-Premise
287	(	N	I-Premise
288	p	N	I-Premise
289	=	N	I-Premise
290	0.01	N	I-Premise
291	)	N	I-Premise
292	,	N	I-Premise
293	and	N	I-Premise
294	in	N	I-Premise
295	the	N	I-Premise
296	secondary	N	I-Premise
297	endpoints	N	I-Premise
298	,	N	I-Premise
299	grip	N	I-Premise
300	strength	N	I-Premise
301	(	N	I-Premise
302	p	N	I-Premise
303	=	N	I-Premise
304	0.05	N	I-Premise
305	)	N	I-Premise
306	,	N	I-Premise
307	Glasgow	N	I-Premise
308	Prognostic	N	I-Premise
309	Score	N	I-Premise
310	(	N	I-Premise
311	p	N	I-Premise
312	=	N	I-Premise
313	0.02	N	I-Premise
314	)	N	I-Premise
315	,	N	I-Premise
316	Eastern	N	I-Premise
317	Cooperative	N	I-Premise
318	Oncology	N	I-Premise
319	Group	N	I-Premise
320	performance	N	I-Premise
321	status	N	I-Premise
322	(	N	I-Premise
323	p	N	I-Premise
324	=	N	I-Premise
325	0.02	N	I-Premise
326	)	N	I-Premise
327	,	N	I-Premise
328	IL-6	N	I-Premise
329	(	N	I-Premise
330	p	N	I-Premise
331	<	N	I-Premise
332	0.01	N	I-Premise
333	)	N	I-Premise
334	and	N	I-Premise
335	tumor	N	I-Premise
336	necrosis	N	I-Premise
337	factor-	N	I-Premise
338	(	N	I-Premise
339	p	N	I-Premise
340	=	N	I-Premise
341	0.01	N	I-Premise
342	)	N	I-Premise
343	.	N	I-Premise

344	Toxicity	N	I-Premise
345	was	N	I-Premise
346	found	N	I-Premise
347	to	N	I-Premise
348	be	N	I-Premise
349	relatively	N	I-Premise
350	negligible	N	I-Premise
351	in	N	I-Premise
352	both	N	I-Premise
353	groups	N	I-Premise
354	.	N	I-Premise

355	A	N	I-Claim
356	combination	N	I-Claim
357	regimen	N	I-Claim
358	of	N	I-Claim
359	MA	N	I-Claim
360	and	N	I-Claim
361	thalidomide	N	I-Claim
362	is	N	I-Claim
363	more	N	I-Claim
364	effective	N	I-Claim
365	than	N	I-Claim
366	MA	N	I-Claim
367	alone	N	I-Claim
368	in	N	I-Claim
369	the	N	I-Claim
370	treatment	N	I-Claim
371	of	N	I-Claim
372	CACS	N	I-Claim
373	.	N	I-Claim

1	Prior	N	O
2	studies	N	O
3	have	N	O
4	suggested	N	O
5	that	N	O
6	melatonin	N	O
7	,	N	O
8	a	N	O
9	frequently	N	O
10	used	N	O
11	integrative	N	O
12	medicine	N	O
13	,	N	O
14	can	N	O
15	attenuate	N	O
16	weight	N	O
17	loss	N	O
18	,	N	O
19	anorexia	N	O
20	,	N	O
21	and	N	O
22	fatigue	N	O
23	in	N	O
24	patients	N	O
25	with	N	O
26	cancer	N	O
27	.	N	O

28	These	N	O
29	studies	N	O
30	were	N	O
31	limited	N	O
32	by	N	O
33	a	N	O
34	lack	N	O
35	of	N	O
36	blinding	N	O
37	and	N	O
38	absence	N	O
39	of	N	O
40	placebo	N	O
41	controls	N	O
42	.	N	O

43	The	N	O
44	primary	N	O
45	purpose	N	O
46	of	N	O
47	this	N	O
48	study	N	O
49	was	N	O
50	to	N	O
51	compare	N	O
52	melatonin	N	O
53	with	N	O
54	placebo	N	O
55	for	N	O
56	appetite	N	O
57	improvement	N	O
58	in	N	O
59	patients	N	O
60	with	N	O
61	cancer	N	O
62	cachexia	N	O
63	.	N	O

64	We	N	O
65	performed	N	O
66	a	N	O
67	randomized	N	O
68	,	N	O
69	double-blind	N	O
70	,	N	O
71	28-day	N	O
72	trial	N	O
73	of	N	O
74	melatonin	N	O
75	20	N	O
76	mg	N	O
77	versus	N	O
78	placebo	N	O
79	in	N	O
80	patients	N	O
81	with	N	O
82	advanced	N	O
83	lung	N	O
84	or	N	O
85	GI	N	O
86	cancer	N	O
87	,	N	O
88	appetite	N	O
89	scores	N	O
90		N	O
91	4	N	O
92	on	N	O
93	a	N	O
94	0	N	O
95	to	N	O
96	10	N	O
97	scale	N	O
98	(	N	O
99	10	N	O
100	=	N	O
101	worst	N	O
102	appetite	N	O
103	)	N	O
104	,	N	O
105	and	N	O
106	history	N	O
107	of	N	O
108	weight	N	O
109	loss	N	O
110		N	O
111	5	N	O
112	%	N	O
113	.	N	O

114	Assessments	N	O
115	included	N	O
116	weight	N	O
117	,	N	O
118	symptoms	N	O
119	by	N	O
120	the	N	O
121	Edmonton	N	O
122	Symptom	N	O
123	Assessment	N	O
124	Scale	N	O
125	,	N	O
126	and	N	O
127	quality	N	O
128	of	N	O
129	life	N	O
130	by	N	O
131	the	N	O
132	Functional	N	O
133	Assessment	N	O
134	of	N	O
135	Anorexia/Cachexia	N	O
136	Therapy	N	O
137	(	N	O
138	FAACT	N	O
139	)	N	O
140	questionnaire	N	O
141	.	N	O

142	Differences	N	O
143	between	N	O
144	groups	N	O
145	from	N	O
146	baseline	N	O
147	to	N	O
148	day	N	O
149	28	N	O
150	were	N	O
151	analyzed	N	O
152	using	N	O
153	one-sided	N	O
154	,	N	O
155	two-sample	N	O
156	t	N	O
157	tests	N	O
158	or	N	O
159	Wilcoxon	N	O
160	two-sample	N	O
161	tests	N	O
162	.	N	O

163	Interim	N	O
164	analysis	N	O
165	halfway	N	O
166	through	N	O
167	the	N	O
168	trial	N	O
169	had	N	O
170	a	N	O
171	Lan-DeMets	N	O
172	monitoring	N	O
173	boundary	N	O
174	with	N	O
175	an	N	O
176	O'Brien-Fleming	N	O
177	stopping	N	O
178	rule	N	O
179	.	N	O

180	Decision	N	O
181	boundaries	N	O
182	were	N	O
183	to	N	O
184	accept	N	O
185	the	N	O
186	null	N	O
187	hypothesis	N	O
188	of	N	O
189	futility	N	O
190	if	N	O
191	the	N	O
192	test	N	O
193	statistic	N	O
194	z	N	O
195	<	N	O
196	0.39	N	O
197	(	N	O
198	P	N	O
199		N	O
200	.348	N	O
201	)	N	O
202	and	N	O
203	reject	N	O
204	the	N	O
205	null	N	O
206	hypothesis	N	O
207	if	N	O
208	z	N	O
209	>	N	O
210	2.54	N	O
211	(	N	O
212	P	N	O
213		N	O
214	.0056	N	O
215	)	N	O
216	.	N	O

217	After	N	O
218	interim	N	O
219	analysis	N	O
220	of	N	O
221	48	N	O
222	patients	N	O
223	,	N	O
224	the	N	O
225	study	N	O
226	was	N	O
227	closed	N	O
228	for	N	O
229	futility	N	O
230	.	N	O

231	There	N	I-Premise
232	were	N	I-Premise
233	no	N	I-Premise
234	significant	N	I-Premise
235	differences	N	I-Premise
236	between	N	I-Premise
237	groups	N	I-Premise
238	for	N	I-Premise
239	appetite	N	I-Premise
240	(	N	I-Premise
241	P	N	I-Premise
242	=	N	I-Premise
243	.78	N	I-Premise
244	)	N	I-Premise
245	or	N	I-Premise
246	other	N	I-Premise
247	symptoms	N	I-Premise
248	,	N	I-Premise
249	weight	N	I-Premise
250	(	N	I-Premise
251	P	N	I-Premise
252	=	N	I-Premise
253	.17	N	I-Premise
254	)	N	I-Premise
255	,	N	I-Premise
256	FAACT	N	I-Premise
257	score	N	I-Premise
258	(	N	I-Premise
259	P	N	I-Premise
260	=	N	I-Premise
261	.95	N	I-Premise
262	)	N	I-Premise
263	,	N	I-Premise
264	toxicity	N	I-Premise
265	,	N	I-Premise
266	or	N	I-Premise
267	survival	N	I-Premise
268	from	N	I-Premise
269	baseline	N	I-Premise
270	to	N	I-Premise
271	day	N	I-Premise
272	28	N	I-Premise
273	.	N	I-Premise

274	In	N	I-Claim
275	cachectic	N	I-Claim
276	patients	N	I-Claim
277	with	N	I-Claim
278	advanced	N	I-Claim
279	cancer	N	I-Claim
280	,	N	I-Claim
281	oral	N	I-Claim
282	melatonin	N	I-Claim
283	20	N	I-Claim
284	mg	N	I-Claim
285	at	N	I-Claim
286	night	N	I-Claim
287	did	N	I-Claim
288	not	N	I-Claim
289	improve	N	I-Claim
290	appetite	N	I-Claim
291	,	N	I-Claim
292	weight	N	I-Claim
293	,	N	I-Claim
294	or	N	I-Claim
295	quality	N	I-Claim
296	of	N	I-Claim
297	life	N	I-Claim
298	compared	N	I-Claim
299	with	N	I-Claim
300	placebo	N	I-Claim
301	.	N	I-Claim

1	Treatment	N	O
2	of	N	O
3	patients	N	O
4	with	N	O
5	advanced	N	O
6	or	N	O
7	metastatic	N	O
8	esophagogastric	N	O
9	adenocarcinoma	N	O
10	should	N	O
11	not	N	O
12	only	N	O
13	prolong	N	O
14	life	N	O
15	but	N	O
16	also	N	O
17	provide	N	O
18	relief	N	O
19	of	N	O
20	symptoms	N	O
21	and	N	O
22	improve	N	O
23	quality	N	O
24	of	N	O
25	life	N	O
26	(	N	O
27	QOL	N	O
28	)	N	O
29	.	N	O

30	Esophagogastric	N	O
31	adenocarcinoma	N	O
32	mainly	N	O
33	occurs	N	O
34	in	N	O
35	elderly	N	O
36	patients	N	O
37	,	N	O
38	but	N	O
39	they	N	O
40	are	N	O
41	underrepresented	N	O
42	in	N	O
43	most	N	O
44	clinical	N	O
45	trials	N	O
46	and	N	O
47	often	N	O
48	do	N	O
49	not	N	O
50	receive	N	O
51	effective	N	O
52	combination	N	O
53	chemotherapy	N	O
54	,	N	O
55	most	N	O
56	probably	N	O
57	for	N	O
58	fear	N	O
59	of	N	O
60	intolerance	N	O
61	.	N	O

62	Using	N	O
63	validated	N	O
64	instruments	N	O
65	,	N	O
66	we	N	O
67	prospectively	N	O
68	assessed	N	O
69	QOL	N	O
70	within	N	O
71	the	N	O
72	randomized	N	O
73	FLOT65+	N	O
74	phase	N	O
75	II	N	O
76	trial	N	O
77	.	N	O

78	Within	N	O
79	the	N	O
80	FLOT65+	N	O
81	trial	N	O
82	,	N	O
83	a	N	O
84	total	N	O
85	of	N	O
86	143	N	O
87	patients	N	O
88	aged	N	O
89	65	N	O
90	years	N	O
91	were	N	O
92	randomly	N	O
93	allocated	N	O
94	to	N	O
95	receive	N	O
96	biweekly	N	O
97	oxaliplatin	N	O
98	plus	N	O
99	5-fluorouracil	N	O
100	(	N	O
101	5-FU	N	O
102	)	N	O
103	continuous	N	O
104	infusion	N	O
105	and	N	O
106	folinic	N	O
107	acid	N	O
108	(	N	O
109	FLO	N	O
110	)	N	O
111	or	N	O
112	the	N	O
113	same	N	O
114	regimen	N	O
115	in	N	O
116	combination	N	O
117	with	N	O
118	docetaxel	N	O
119	50	N	O
120	mg/m	N	O
121	(	N	O
122	2	N	O
123	)	N	O
124	(	N	O
125	FLOT	N	O
126	)	N	O
127	.	N	O

128	The	N	O
129	European	N	O
130	Organisation	N	O
131	for	N	O
132	Research	N	O
133	and	N	O
134	Treatment	N	O
135	of	N	O
136	Cancer	N	O
137	Quality	N	O
138	of	N	O
139	Life	N	O
140	Questionnaire	N	O
141	C30	N	O
142	(	N	O
143	EORTC	N	O
144	QLQ-C30	N	O
145	)	N	O
146	and	N	O
147	the	N	O
148	gastric	N	O
149	module	N	O
150	STO22	N	O
151	were	N	O
152	administered	N	O
153	every	N	O
154	8	N	O
155	weeks	N	O
156	until	N	O
157	progression	N	O
158	.	N	O

159	Time	N	O
160	to	N	O
161	definitive	N	O
162	deterioration	N	O
163	of	N	O
164	QOL	N	O
165	parameters	N	O
166	was	N	O
167	analyzed	N	O
168	and	N	O
169	compared	N	O
170	within	N	O
171	the	N	O
172	treatment	N	O
173	arms	N	O
174	.	N	O

175	The	N	O
176	median	N	O
177	age	N	O
178	of	N	O
179	patients	N	O
180	was	N	O
181	70	N	O
182	years	N	O
183	.	N	O

184	Patients	N	I-Premise
185	receiving	N	I-Premise
186	FLOT	N	I-Premise
187	exhibited	N	I-Premise
188	higher	N	I-Premise
189	response	N	I-Premise
190	rates	N	I-Premise
191	and	N	I-Premise
192	had	N	I-Premise
193	improved	N	I-Premise
194	disease-free	N	I-Premise
195	and	N	I-Premise
196	progression-free	N	I-Premise
197	survival	N	I-Premise
198	(	N	I-Premise
199	PFS	N	I-Premise
200	)	N	I-Premise
201	.	N	I-Premise

202	The	N	O
203	proportions	N	O
204	of	N	O
205	patients	N	O
206	with	N	O
207	evaluable	N	O
208	baseline	N	O
209	EORTC	N	O
210	QLQ-C30	N	O
211	and	N	O
212	STO22	N	O
213	questionnaires	N	O
214	were	N	O
215	balanced	N	O
216	(	N	O
217	83	N	O
218	%	N	O
219	in	N	O
220	FLOT	N	O
221	and	N	O
222	89	N	O
223	%	N	O
224	in	N	O
225	FLO	N	O
226	)	N	O
227	.	N	O

228	Considering	N	O
229	evaluable	N	O
230	patients	N	O
231	with	N	O
232	assessable	N	O
233	questionnaires	N	O
234	(	N	O
235	n	N	O
236	=	N	O
237	123	N	O
238	)	N	O
239	,	N	O
240	neither	N	O
241	functioning	N	O
242	nor	N	O
243	symptom	N	O
244	parameters	N	O
245	differed	N	O
246	significantly	N	O
247	in	N	O
248	favor	N	O
249	of	N	O
250	one	N	O
251	of	N	O
252	the	N	O
253	two	N	O
254	treatment	N	O
255	groups	N	O
256	.	N	O

257	Particularly	N	O
258	,	N	O
259	there	N	I-Premise
260	was	N	I-Premise
261	no	N	I-Premise
262	significant	N	I-Premise
263	difference	N	I-Premise
264	regarding	N	I-Premise
265	time	N	I-Premise
266	to	N	I-Premise
267	definitive	N	I-Premise
268	deterioration	N	I-Premise
269	of	N	I-Premise
270	global	N	I-Premise
271	health	N	I-Premise
272	status/quality	N	I-Premise
273	of	N	I-Premise
274	life	N	I-Premise
275	from	N	I-Premise
276	baseline	N	I-Premise
277	(	N	I-Premise
278	primary	N	I-Premise
279	endpoint	N	I-Premise
280	)	N	I-Premise
281	.	N	I-Premise

282	Notably	N	O
283	,	N	O
284	patients	N	I-Premise
285	receiving	N	I-Premise
286	FLO	N	I-Premise
287	or	N	I-Premise
288	FLOT	N	I-Premise
289	as	N	I-Premise
290	palliative	N	I-Premise
291	treatment	N	I-Premise
292	(	N	I-Premise
293	n	N	I-Premise
294	=	N	I-Premise
295	98	N	I-Premise
296	)	N	I-Premise
297	achieved	N	I-Premise
298	comparable	N	I-Premise
299	QOL	N	I-Premise
300	results	N	I-Premise
301	.	N	I-Premise

302	Although	N	I-Premise
303	toxicity	N	I-Premise
304	was	N	I-Premise
305	higher	N	I-Premise
306	in	N	I-Premise
307	patients	N	I-Premise
308	receiving	N	I-Premise
309	FLOT	N	I-Premise
310	,	N	I-Premise
311	no	N	I-Premise
312	negative	N	I-Premise
313	impact	N	I-Premise
314	of	N	I-Premise
315	the	N	I-Premise
316	addition	N	I-Premise
317	of	N	I-Premise
318	docetaxel	N	I-Premise
319	on	N	I-Premise
320	QOL	N	I-Premise
321	parameters	N	I-Premise
322	could	N	I-Premise
323	be	N	I-Premise
324	demonstrated	N	I-Premise
325	.	N	I-Premise

326	Thus	N	O
327	,	N	O
328	elderly	N	I-Claim
329	patients	N	I-Claim
330	in	N	I-Claim
331	need	N	I-Claim
332	of	N	I-Claim
333	intensified	N	I-Claim
334	chemotherapy	N	I-Claim
335	may	N	I-Claim
336	receive	N	I-Claim
337	FLOT	N	I-Claim
338	without	N	I-Claim
339	compromising	N	I-Claim
340	patient-reported	N	I-Claim
341	outcome	N	I-Claim
342	parameters	N	I-Claim
343	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	dose-volume	N	O
4	histogram	N	O
5	variables	N	O
6	for	N	O
7	the	N	O
8	internal	N	O
9	and	N	O
10	external	N	O
11	urinary	N	O
12	sphincters	N	O
13	(	N	O
14	IUS/EUS	N	O
15	)	N	O
16	with	N	O
17	urinary	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	after	N	O
22	prostate	N	O
23	brachytherapy	N	O
24	.	N	O

25	Subjects	N	O
26	were	N	O
27	42	N	O
28	consecutive	N	O
29	men	N	O
30	from	N	O
31	a	N	O
32	prospective	N	O
33	study	N	O
34	of	N	O
35	brachytherapy	N	O
36	as	N	O
37	monotherapy	N	O
38	with	N	O
39	(	N	O
40	125	N	O
41	)	N	O
42	I	N	O
43	for	N	O
44	intermediate-risk	N	O
45	localized	N	O
46	prostate	N	O
47	cancer	N	O
48	.	N	O

49	No	N	O
50	patient	N	O
51	received	N	O
52	hormonal	N	O
53	therapy	N	O
54	.	N	O

55	Preplanning	N	O
56	constraints	N	O
57	included	N	O
58	prostate	N	O
59	V100	N	O
60	higher	N	O
61	than	N	O
62	95	N	O
63	%	N	O
64	,	N	O
65	V150	N	O
66	lower	N	O
67	than	N	O
68	60	N	O
69	%	N	O
70	,	N	O
71	and	N	O
72	V200	N	O
73	lower	N	O
74	than	N	O
75	20	N	O
76	%	N	O
77	and	N	O
78	rectal	N	O
79	R100	N	O
80	less	N	O
81	than	N	O
82	1cm	N	O
83	(	N	O
84	3	N	O
85	)	N	O
86	.	N	O

87	Patients	N	O
88	completed	N	O
89	the	N	O
90	Expanded	N	O
91	Prostate	N	O
92	Cancer	N	O
93	Index	N	O
94	Composite	N	O
95	quality-of-life	N	O
96	questionnaire	N	O
97	before	N	O
98	and	N	O
99	at	N	O
100	1	N	O
101	,	N	O
102	4	N	O
103	,	N	O
104	8	N	O
105	,	N	O
106	and	N	O
107	12	N	O
108	months	N	O
109	after	N	O
110	implantation	N	O
111	,	N	O
112	and	N	O
113	urinary	N	O
114	domain	N	O
115	scores	N	O
116	were	N	O
117	analyzed	N	O
118	.	N	O

119	All	N	O
120	structures	N	O
121	including	N	O
122	the	N	O
123	IUS	N	O
124	and	N	O
125	EUS	N	O
126	were	N	O
127	contoured	N	O
128	on	N	O
129	T2-weighted	N	O
130	MRI	N	O
131	at	N	O
132	day	N	O
133	30	N	O
134	,	N	O
135	and	N	O
136	doses	N	O
137	received	N	O
138	were	N	O
139	calculated	N	O
140	from	N	O
141	identification	N	O
142	of	N	O
143	seeds	N	O
144	on	N	O
145	CT.	N	O
146	Spearman	N	O
147	's	N	O
148	(	N	O
149	nonparametric	N	O
150	)	N	O
151	rank	N	O
152	correlation	N	O
153	coefficient	N	O
154	(	N	O
155		N	O
156	)	N	O
157	was	N	O
158	used	N	O
159	for	N	O
160	statistical	N	O
161	analyses	N	O
162	.	N	O

163	Overall	N	O
164	urinary	N	O
165	morbidity	N	O
166	was	N	O
167	worst	N	O
168	at	N	O
169	1	N	O
170	month	N	O
171	after	N	O
172	the	N	O
173	implant	N	O
174	.	N	O

175	Urinary	N	I-Premise
176	function	N	I-Premise
177	declined	N	I-Premise
178	when	N	I-Premise
179	the	N	I-Premise
180	IUS	N	I-Premise
181	V285	N	I-Premise
182	was	N	I-Premise
183	0.4	N	I-Premise
184	%	N	I-Premise
185	(	N	I-Premise
186	=-0.32	N	I-Premise
187	,	N	I-Premise
188	p=0.04	N	I-Premise
189	)	N	I-Premise
190	;	N	I-Premise
191	bother	N	I-Premise
192	worsened	N	I-Premise
193	when	N	I-Premise
194	the	N	I-Premise
195	IUS	N	I-Premise
196	V35	N	I-Premise
197	was	N	I-Premise
198	99	N	I-Premise
199	%	N	I-Premise
200	(	N	I-Premise
201	=-0.31	N	I-Premise
202	,	N	I-Premise
203	p=0.05	N	I-Premise
204	)	N	I-Premise
205	or	N	I-Premise
206	the	N	I-Premise
207	EUS	N	I-Premise
208	V240	N	I-Premise
209	was	N	I-Premise
210	63	N	I-Premise
211	%	N	I-Premise
212	(	N	I-Premise
213	=-0.31	N	I-Premise
214	,	N	I-Premise
215	p=0.05	N	I-Premise
216	)	N	I-Premise
217	;	N	I-Premise
218	irritation	N	I-Premise
219	increased	N	I-Premise
220	when	N	I-Premise
221	the	N	I-Premise
222	IUS	N	I-Premise
223	V35	N	I-Premise
224	was	N	I-Premise
225	95	N	I-Premise
226	%	N	I-Premise
227	(	N	I-Premise
228	=-0.37	N	I-Premise
229	,	N	I-Premise
230	p=0.02	N	I-Premise
231	)	N	I-Premise
232	and	N	I-Premise
233	the	N	I-Premise
234	EUS	N	I-Premise
235	V265	N	I-Premise
236	was	N	I-Premise
237	24	N	I-Premise
238	%	N	I-Premise
239	(	N	I-Premise
240	=-0.32	N	I-Premise
241	,	N	I-Premise
242	p=0.04	N	I-Premise
243	)	N	I-Premise
244	;	N	I-Premise
245	and	N	O
246	urgency	N	I-Premise
247	worsened	N	I-Premise
248	when	N	I-Premise
249	the	N	I-Premise
250	IUS	N	I-Premise
251	V35	N	I-Premise
252	was	N	I-Premise
253	99.5	N	I-Premise
254	%	N	I-Premise
255	(	N	I-Premise
256	=-0.38	N	I-Premise
257	,	N	I-Premise
258	p=0.02	N	I-Premise
259	)	N	I-Premise
260	.	N	I-Premise

261	Incontinence	N	I-Premise
262	did	N	I-Premise
263	not	N	I-Premise
264	correlate	N	I-Premise
265	with	N	I-Premise
266	EUS	N	I-Premise
267	or	N	I-Premise
268	IUS	N	I-Premise
269	dose	N	I-Premise
270	.	N	I-Premise

271	Doses	N	I-Claim
272	to	N	I-Claim
273	the	N	I-Claim
274	IUS	N	I-Claim
275	and	N	I-Claim
276	EUS	N	I-Claim
277	on	N	I-Claim
278	MRI/CT	N	I-Claim
279	predicted	N	I-Claim
280	worse	N	I-Claim
281	urinary	N	I-Claim
282	function	N	I-Claim
283	,	N	I-Claim
284	with	N	I-Claim
285	greater	N	I-Claim
286	bother	N	I-Claim
287	,	N	I-Claim
288	irritative	N	I-Claim
289	symptoms	N	I-Claim
290	,	N	I-Claim
291	and	N	I-Claim
292	urgency	N	I-Claim
293	.	N	I-Claim

294	Incorporating	N	I-MajorClaim
295	MRI-based	N	I-MajorClaim
296	dose-volume	N	I-MajorClaim
297	histogram	N	I-MajorClaim
298	analysis	N	I-MajorClaim
299	into	N	I-MajorClaim
300	the	N	I-MajorClaim
301	treatment	N	I-MajorClaim
302	planning	N	I-MajorClaim
303	process	N	I-MajorClaim
304	may	N	I-MajorClaim
305	reduce	N	I-MajorClaim
306	acute	N	I-MajorClaim
307	urinary	N	I-MajorClaim
308	morbidity	N	I-MajorClaim
309	after	N	I-MajorClaim
310	brachytherapy	N	I-MajorClaim
311	.	N	I-MajorClaim

1	Maintenance	N	O
2	therapy	N	O
3	can	N	O
4	delay	N	O
5	progression	N	O
6	and	N	O
7	prolong	N	O
8	survival	N	O
9	in	N	O
10	metastatic	N	O
11	non-small-cell	N	O
12	lung	N	O
13	cancer	N	O
14	(	N	O
15	mNSCLC	N	O
16	)	N	O
17	.	N	O

18	As	N	O
19	treatment	N	O
20	for	N	O
21	mNSCLC	N	O
22	is	N	O
23	non-curative	N	O
24	,	N	O
25	its	N	O
26	impact	N	O
27	on	N	O
28	patient	N	O
29	health-related	N	O
30	quality	N	O
31	of	N	O
32	life	N	O
33	(	N	O
34	HRQoL	N	O
35	)	N	O
36	is	N	O
37	an	N	O
38	important	N	O
39	consideration	N	O
40	.	N	O

41	SATURN	N	O
42	(	N	O
43	Sequential	N	O
44	Tarceva	N	O
45	in	N	O
46	Unresectable	N	O
47	NSCLC	N	O
48	)	N	O
49	was	N	O
50	a	N	O
51	randomised	N	O
52	,	N	O
53	double-blind	N	O
54	,	N	O
55	placebo-controlled	N	O
56	,	N	O
57	multicentre	N	O
58	study	N	O
59	investigating	N	O
60	the	N	O
61	impact	N	O
62	of	N	O
63	erlotinib	N	O
64	maintenance	N	O
65	therapy	N	O
66	on	N	O
67	HRQoL	N	O
68	in	N	O
69	patients	N	O
70	with	N	O
71	locally	N	O
72	advanced	N	O
73	or	N	O
74	recurrent	N	O
75	NSCLC	N	O
76	.	N	O

77	Eligible	N	O
78	patients	N	O
79	who	N	O
80	had	N	O
81	previously	N	O
82	completed	N	O
83	four	N	O
84	cycles	N	O
85	of	N	O
86	platinum-based	N	O
87	chemotherapy	N	O
88	were	N	O
89	randomised	N	O
90	1:1	N	O
91	to	N	O
92	receive	N	O
93	erlotinib	N	O
94	150	N	O
95	mg/day	N	O
96	or	N	O
97	placebo	N	O
98	until	N	O
99	disease	N	O
100	progression	N	O
101	,	N	O
102	unacceptable	N	O
103	toxicity	N	O
104	or	N	O
105	death	N	O
106	.	N	O

107	Patient	N	O
108	HRQoL	N	O
109	was	N	O
110	assessed	N	O
111	using	N	O
112	the	N	O
113	Functional	N	O
114	Assessment	N	O
115	of	N	O
116	Cancer	N	O
117	Therapy-Lung	N	O
118	questionnaire	N	O
119	,	N	O
120	in	N	O
121	terms	N	O
122	of	N	O
123	time	N	O
124	to	N	O
125	symptom	N	O
126	progression	N	O
127	(	N	O
128	TSP	N	O
129	)	N	O
130	,	N	O
131	time	N	O
132	to	N	O
133	deterioration	N	O
134	(	N	O
135	TTD	N	O
136	)	N	O
137	in	N	O
138	Trial	N	O
139	Outcome	N	O
140	Index	N	O
141	(	N	O
142	TOI	N	O
143	)	N	O
144	and	N	O
145	TTD	N	O
146	.	N	O

147	Exploratory	N	O
148	analysis	N	O
149	was	N	O
150	based	N	O
151	on	N	O
152	time	N	O
153	to	N	O
154	analgesia	N	O
155	and	N	O
156	appearance	N	O
157	of	N	O
158	key	N	O
159	symptoms	N	O
160	(	N	O
161	pain	N	O
162	,	N	O
163	cough	N	O
164	and	N	O
165	dyspnoea	N	O
166	)	N	O
167	.	N	O

168	Compared	N	I-Premise
169	with	N	I-Premise
170	placebo	N	I-Premise
171	,	N	I-Premise
172	erlotinib	N	I-Premise
173	maintenance	N	I-Premise
174	therapy	N	I-Premise
175	prolonged	N	I-Premise
176	progression-free	N	I-Premise
177	and	N	I-Premise
178	overall	N	I-Premise
179	survival	N	I-Premise
180	by	N	I-Premise
181	41	N	I-Premise
182	%	N	I-Premise
183	and	N	I-Premise
184	23	N	I-Premise
185	%	N	I-Premise
186	,	N	I-Premise
187	respectively	N	I-Premise
188	.	N	I-Premise

189	At	N	O
190	baseline	N	O
191	,	N	O
192	HRQoL	N	O
193	measures	N	O
194	were	N	O
195	comparable	N	O
196	between	N	O
197	the	N	O
198	two	N	O
199	treatment	N	O
200	groups	N	O
201	.	N	O

202	Maintenance	N	I-Premise
203	therapy	N	I-Premise
204	with	N	I-Premise
205	erlotinib	N	I-Premise
206	did	N	I-Premise
207	not	N	I-Premise
208	impact	N	I-Premise
209	on	N	I-Premise
210	deterioration	N	I-Premise
211	in	N	I-Premise
212	HRQoL	N	I-Premise
213	:	N	I-Premise
214	TSP	N	I-Premise
215	(	N	I-Premise
216	hazard	N	I-Premise
217	ratio	N	I-Premise
218	[	N	I-Premise
219	HR	N	I-Premise
220	]	N	I-Premise
221	=0.91	N	I-Premise
222	[	N	I-Premise
223	95	N	I-Premise
224	%	N	I-Premise
225	confidence	N	I-Premise
226	interval	N	I-Premise
227	(	N	I-Premise
228	CI	N	I-Premise
229	)	N	I-Premise
230	0.74-1.12	N	I-Premise
231	]	N	I-Premise
232	;	N	I-Premise
233	n=785	N	I-Premise
234	)	N	I-Premise
235	,	N	I-Premise
236	TTD	N	I-Premise
237	in	N	I-Premise
238	TOI	N	I-Premise
239	(	N	I-Premise
240	HR=1.06	N	I-Premise
241	[	N	I-Premise
242	95	N	I-Premise
243	%	N	I-Premise
244	CI	N	I-Premise
245	0.87-1.31	N	I-Premise
246	]	N	I-Premise
247	;	N	I-Premise
248	n=781	N	I-Premise
249	)	N	I-Premise
250	and	N	I-Premise
251	TTD	N	I-Premise
252	in	N	I-Premise
253	HRQoL	N	I-Premise
254	(	N	I-Premise
255	HR=0.96	N	I-Premise
256	[	N	I-Premise
257	95	N	I-Premise
258	%	N	I-Premise
259	CI	N	I-Premise
260	0.79-1.16	N	I-Premise
261	]	N	I-Premise
262	;	N	I-Premise
263	n=776	N	I-Premise
264	)	N	I-Premise
265	.	N	I-Premise

266	Time	N	I-Premise
267	to	N	I-Premise
268	pain	N	I-Premise
269	and	N	I-Premise
270	time	N	I-Premise
271	to	N	I-Premise
272	analgesic	N	I-Premise
273	use	N	I-Premise
274	were	N	I-Premise
275	significantly	N	I-Premise
276	delayed	N	I-Premise
277	in	N	I-Premise
278	patients	N	I-Premise
279	receiving	N	I-Premise
280	erlotinib	N	I-Premise
281	compared	N	I-Premise
282	with	N	I-Premise
283	placebo	N	I-Premise
284	(	N	I-Premise
285	HR=0.61	N	I-Premise
286	[	N	I-Premise
287	95	N	I-Premise
288	%	N	I-Premise
289	CI	N	I-Premise
290	0.42-0.88	N	I-Premise
291	]	N	I-Premise
292	;	N	I-Premise
293	p=0.0080	N	I-Premise
294	and	N	I-Premise
295	HR=0.66	N	I-Premise
296	[	N	I-Premise
297	95	N	I-Premise
298	%	N	I-Premise
299	CI	N	I-Premise
300	0.46-0.94	N	I-Premise
301	]	N	I-Premise
302	;	N	I-Premise
303	p=0.0199	N	I-Premise
304	,	N	I-Premise
305	respectively	N	I-Premise
306	)	N	I-Premise
307	.	N	I-Premise

308	A	N	I-Premise
309	non-significant	N	I-Premise
310	trend	N	I-Premise
311	towards	N	I-Premise
312	delayed	N	I-Premise
313	time	N	I-Premise
314	to	N	I-Premise
315	cough	N	I-Premise
316	and	N	I-Premise
317	time	N	I-Premise
318	to	N	I-Premise
319	dyspnoea	N	I-Premise
320	(	N	I-Premise
321	HR=0.77	N	I-Premise
322	[	N	I-Premise
323	95	N	I-Premise
324	%	N	I-Premise
325	CI	N	I-Premise
326	0.49-1.21	N	I-Premise
327	]	N	I-Premise
328	and	N	I-Premise
329	HR=0.75	N	I-Premise
330	[	N	I-Premise
331	95	N	I-Premise
332	%	N	I-Premise
333	CI	N	I-Premise
334	0.48-1.17	N	I-Premise
335	]	N	I-Premise
336	,	N	I-Premise
337	respectively	N	I-Premise
338	)	N	I-Premise
339	was	N	I-Premise
340	also	N	I-Premise
341	observed	N	I-Premise
342	.	N	I-Premise

343	Erlotinib	N	I-Claim
344	maintenance	N	I-Claim
345	therapy	N	I-Claim
346	significantly	N	I-Claim
347	extends	N	I-Claim
348	progression-free	N	I-Claim
349	survival	N	I-Claim
350	without	N	I-Claim
351	compromising	N	I-Claim
352	patient	N	I-Claim
353	HRQoL	N	I-Claim
354	in	N	I-Claim
355	comparison	N	I-Claim
356	with	N	I-Claim
357	placebo	N	I-Claim
358	,	N	I-Claim
359	with	N	I-Claim
360	some	N	I-Claim
361	improvement	N	I-Claim
362	in	N	I-Claim
363	symptoms	N	I-Claim
364	.	N	I-Claim

1	The	N	O
2	randomized	N	O
3	,	N	O
4	controlled	N	O
5	BOLERO-2	N	O
6	(	N	O
7	Breast	N	O
8	Cancer	N	O
9	Trials	N	O
10	of	N	O
11	Oral	N	O
12	Everolimus	N	O
13	)	N	O
14	trial	N	O
15	demonstrated	N	O
16	significantly	N	O
17	improved	N	O
18	progression-free	N	O
19	survival	N	O
20	with	N	O
21	the	N	O
22	use	N	O
23	of	N	O
24	everolimus	N	O
25	plus	N	O
26	exemestane	N	O
27	(	N	O
28	EVE	N	O
29	+	N	O
30	EXE	N	O
31	)	N	O
32	versus	N	O
33	placebo	N	O
34	plus	N	O
35	exemestane	N	O
36	(	N	O
37	PBO	N	O
38	+	N	O
39	EXE	N	O
40	)	N	O
41	in	N	O
42	patients	N	O
43	with	N	O
44	advanced	N	O
45	breast	N	O
46	cancer	N	O
47	who	N	O
48	developed	N	O
49	disease	N	O
50	progression	N	O
51	after	N	O
52	treatment	N	O
53	with	N	O
54	nonsteroidal	N	O
55	aromatase	N	O
56	inhibitors	N	O
57	.	N	O

58	This	N	O
59	analysis	N	O
60	investigated	N	O
61	the	N	O
62	treatment	N	O
63	effects	N	O
64	on	N	O
65	health-related	N	O
66	quality	N	O
67	of	N	O
68	life	N	O
69	(	N	O
70	HRQOL	N	O
71	)	N	O
72	.	N	O

73	Using	N	O
74	the	N	O
75	European	N	O
76	Organisation	N	O
77	for	N	O
78	Research	N	O
79	and	N	O
80	Treatment	N	O
81	of	N	O
82	Cancer	N	O
83	Quality	N	O
84	of	N	O
85	Life	N	O
86	Questionnaire-Core	N	O
87	30	N	O
88	(	N	O
89	EORTC	N	O
90	QLQ-C30	N	O
91	)	N	O
92	questionnaire	N	O
93	,	N	O
94	HRQOL	N	O
95	was	N	O
96	assessed	N	O
97	at	N	O
98	baseline	N	O
99	and	N	O
100	every	N	O
101	6	N	O
102	weeks	N	O
103	thereafter	N	O
104	until	N	O
105	disease	N	O
106	progression	N	O
107	and/or	N	O
108	treatment	N	O
109	discontinuation	N	O
110	.	N	O

111	The	N	O
112	30	N	O
113	items	N	O
114	in	N	O
115	15	N	O
116	subscales	N	O
117	of	N	O
118	the	N	O
119	QLQ-C30	N	O
120	include	N	O
121	global	N	O
122	health	N	O
123	status	N	O
124	wherein	N	O
125	higher	N	O
126	scores	N	O
127	(	N	O
128	range	N	O
129	,	N	O
130	0-100	N	O
131	)	N	O
132	indicate	N	O
133	better	N	O
134	HRQOL	N	O
135	.	N	O

136	This	N	O
137	analysis	N	O
138	included	N	O
139	a	N	O
140	protocol-specified	N	O
141	time	N	O
142	to	N	O
143	definitive	N	O
144	deterioration	N	O
145	(	N	O
146	TDD	N	O
147	)	N	O
148	analysis	N	O
149	at	N	O
150	a	N	O
151	5	N	O
152	%	N	O
153	decrease	N	O
154	in	N	O
155	HRQOL	N	O
156	versus	N	O
157	baseline	N	O
158	,	N	O
159	with	N	O
160	no	N	O
161	subsequent	N	O
162	increase	N	O
163	above	N	O
164	this	N	O
165	threshold	N	O
166	.	N	O

167	The	N	O
168	authors	N	O
169	report	N	O
170	additional	N	O
171	sensitivity	N	O
172	analyses	N	O
173	using	N	O
174	10-point	N	O
175	minimal	N	O
176	important	N	O
177	difference	N	O
178	decreases	N	O
179	in	N	O
180	the	N	O
181	global	N	O
182	health	N	O
183	status	N	O
184	score	N	O
185	versus	N	O
186	baseline	N	O
187	.	N	O

188	Treatment	N	O
189	arms	N	O
190	were	N	O
191	compared	N	O
192	using	N	O
193	the	N	O
194	stratified	N	O
195	log-rank	N	O
196	test	N	O
197	and	N	O
198	Cox	N	O
199	proportional	N	O
200	hazards	N	O
201	model	N	O
202	adjusted	N	O
203	for	N	O
204	trial	N	O
205	stratum	N	O
206	(	N	O
207	visceral	N	O
208	metastases	N	O
209	,	N	O
210	previous	N	O
211	hormone	N	O
212	sensitivity	N	O
213	)	N	O
214	,	N	O
215	age	N	O
216	,	N	O
217	sex	N	O
218	,	N	O
219	race	N	O
220	,	N	O
221	baseline	N	O
222	global	N	O
223	health	N	O
224	status	N	O
225	score	N	O
226	and	N	O
227	Eastern	N	O
228	Cooperative	N	O
229	Oncology	N	O
230	Group	N	O
231	performance	N	O
232	status	N	O
233	,	N	O
234	prognostic	N	O
235	risk	N	O
236	factors	N	O
237	,	N	O
238	and	N	O
239	treatment	N	O
240	history	N	O
241	.	N	O

242	Baseline	N	O
243	global	N	O
244	health	N	O
245	status	N	O
246	scores	N	O
247	were	N	O
248	found	N	O
249	to	N	O
250	be	N	O
251	similar	N	O
252	between	N	O
253	treatment	N	O
254	groups	N	O
255	(	N	O
256	64.7	N	O
257	vs	N	O
258	65.3	N	O
259	)	N	O
260	.	N	O

261	The	N	I-Premise
262	median	N	I-Premise
263	TDD	N	I-Premise
264	in	N	I-Premise
265	HRQOL	N	I-Premise
266	was	N	I-Premise
267	8.3	N	I-Premise
268	months	N	I-Premise
269	with	N	I-Premise
270	EVE	N	I-Premise
271	+	N	I-Premise
272	EXE	N	I-Premise
273	versus	N	I-Premise
274	5.8	N	I-Premise
275	months	N	I-Premise
276	with	N	I-Premise
277	PBO	N	I-Premise
278	+	N	I-Premise
279	EXE	N	I-Premise
280	(	N	I-Premise
281	hazard	N	I-Premise
282	ratio	N	I-Premise
283	,	N	I-Premise
284	0.74	N	I-Premise
285	;	N	I-Premise
286	P	N	I-Premise
287	=	N	I-Premise
288	.0084	N	I-Premise
289	)	N	I-Premise
290	.	N	I-Premise

291	At	N	I-Premise
292	the	N	I-Premise
293	10-point	N	I-Premise
294	minimal	N	I-Premise
295	important	N	I-Premise
296	difference	N	I-Premise
297	,	N	I-Premise
298	the	N	I-Premise
299	median	N	I-Premise
300	TDD	N	I-Premise
301	with	N	I-Premise
302	EVE	N	I-Premise
303	+	N	I-Premise
304	EXE	N	I-Premise
305	was	N	I-Premise
306	11.7	N	I-Premise
307	months	N	I-Premise
308	versus	N	I-Premise
309	8.4	N	I-Premise
310	months	N	I-Premise
311	with	N	I-Premise
312	PBO	N	I-Premise
313	+	N	I-Premise
314	EXE	N	I-Premise
315	(	N	I-Premise
316	hazard	N	I-Premise
317	ratio	N	I-Premise
318	,	N	I-Premise
319	0.80	N	I-Premise
320	;	N	I-Premise
321	P	N	I-Premise
322	=	N	I-Premise
323	.1017	N	I-Premise
324	)	N	I-Premise
325	.	N	I-Premise

326	In	N	I-Claim
327	patients	N	I-Claim
328	with	N	I-Claim
329	advanced	N	I-Claim
330	breast	N	I-Claim
331	cancer	N	I-Claim
332	who	N	I-Claim
333	develop	N	I-Claim
334	disease	N	I-Claim
335	progression	N	I-Claim
336	after	N	I-Claim
337	treatment	N	I-Claim
338	with	N	I-Claim
339	nonsteroidal	N	I-Claim
340	aromatase	N	I-Claim
341	inhibitors	N	I-Claim
342	,	N	I-Claim
343	EVE	N	I-Claim
344	+	N	I-Claim
345	EXE	N	I-Claim
346	was	N	I-Claim
347	associated	N	I-Claim
348	with	N	I-Claim
349	a	N	I-Claim
350	longer	N	I-Claim
351	TDD	N	I-Claim
352	in	N	I-Claim
353	global	N	I-Claim
354	HRQOL	N	I-Claim
355	versus	N	I-Claim
356	PBO	N	I-Claim
357	+	N	I-Claim
358	EXE	N	I-Claim
359	.	N	I-Claim

1	Malignant	N	I-MajorClaim
2	pleural	N	I-MajorClaim
3	effusion	N	I-MajorClaim
4	(	N	I-MajorClaim
5	MPE	N	I-MajorClaim
6	)	N	I-MajorClaim
7	is	N	I-MajorClaim
8	a	N	I-MajorClaim
9	common	N	I-MajorClaim
10	complication	N	I-MajorClaim
11	of	N	I-MajorClaim
12	advanced	N	I-MajorClaim
13	non-small	N	I-MajorClaim
14	cell	N	I-MajorClaim
15	lung	N	I-MajorClaim
16	cancer	N	I-MajorClaim
17	(	N	I-MajorClaim
18	NSCLC	N	I-MajorClaim
19	)	N	I-MajorClaim
20	.	N	I-MajorClaim

21	Bevacizumab	N	I-MajorClaim
22	,	N	I-MajorClaim
23	a	N	I-MajorClaim
24	humanized	N	I-MajorClaim
25	monoclonal	N	I-MajorClaim
26	antibody	N	I-MajorClaim
27	against	N	I-MajorClaim
28	vascular	N	I-MajorClaim
29	endothelial	N	I-MajorClaim
30	growth	N	I-MajorClaim
31	factor	N	I-MajorClaim
32	(	N	I-MajorClaim
33	VEGF	N	I-MajorClaim
34	)	N	I-MajorClaim
35	,	N	I-MajorClaim
36	has	N	I-MajorClaim
37	been	N	I-MajorClaim
38	shown	N	I-MajorClaim
39	to	N	I-MajorClaim
40	be	N	I-MajorClaim
41	efficient	N	I-MajorClaim
42	in	N	I-MajorClaim
43	suppressing	N	I-MajorClaim
44	the	N	I-MajorClaim
45	accumulation	N	I-MajorClaim
46	of	N	I-MajorClaim
47	pleural	N	I-MajorClaim
48	fluid	N	I-MajorClaim
49	.	N	I-MajorClaim

50	However	N	O
51	,	N	O
52	whether	N	O
53	intrapleural	N	O
54	delivery	N	O
55	of	N	O
56	bevacizumab	N	O
57	can	N	O
58	be	N	O
59	used	N	O
60	to	N	O
61	treat	N	O
62	MPE	N	O
63	remains	N	O
64	unknown	N	O
65	.	N	O

66	The	N	O
67	aim	N	O
68	of	N	O
69	the	N	O
70	present	N	O
71	study	N	O
72	was	N	O
73	to	N	O
74	evaluate	N	O
75	the	N	O
76	efficacy	N	O
77	and	N	O
78	safety	N	O
79	of	N	O
80	combined	N	O
81	intrapleural	N	O
82	therapy	N	O
83	with	N	O
84	bevacizumab	N	O
85	and	N	O
86	cisplatin	N	O
87	,	N	O
88	an	N	O
89	antineoplastic	N	O
90	agent	N	O
91	,	N	O
92	in	N	O
93	controlling	N	O
94	MPE	N	O
95	.	N	O

96	A	N	O
97	total	N	O
98	of	N	O
99	72	N	O
100	NSCLC	N	O
101	study	N	O
102	subjects	N	O
103	with	N	O
104	MPE	N	O
105	were	N	O
106	randomly	N	O
107	assigned	N	O
108	to	N	O
109	one	N	O
110	of	N	O
111	two	N	O
112	groups	N	O
113	.	N	O

114	The	N	O
115	first	N	O
116	group	N	O
117	received	N	O
118	intrapleural	N	O
119	bevacizumab	N	O
120	(	N	O
121	300	N	O
122	mg	N	O
123	)	N	O
124	with	N	O
125	cisplatin	N	O
126	(	N	O
127	30	N	O
128	mg	N	O
129	)	N	O
130	therapy	N	O
131	and	N	O
132	the	N	O
133	second	N	O
134	group	N	O
135	received	N	O
136	intrapleural	N	O
137	cisplatin	N	O
138	(	N	O
139	30	N	O
140	mg	N	O
141	)	N	O
142	therapy	N	O
143	alone	N	O
144	.	N	O

145	Pleural	N	O
146	fluid	N	O
147	was	N	O
148	collected	N	O
149	from	N	O
150	both	N	O
151	groups	N	O
152	prior	N	O
153	to	N	O
154	and	N	O
155	following	N	O
156	treatment	N	O
157	.	N	O

158	The	N	O
159	levels	N	O
160	of	N	O
161	VEGF	N	O
162	and	N	O
163	carcinoembryonic	N	O
164	antigen	N	O
165	(	N	O
166	CEA	N	O
167	)	N	O
168	in	N	O
169	the	N	O
170	pleural	N	O
171	fluid	N	O
172	were	N	O
173	determined	N	O
174	by	N	O
175	ELISA	N	O
176	.	N	O

177	In	N	I-Premise
178	70	N	I-Premise
179	evaluable	N	I-Premise
180	study	N	I-Premise
181	subjects	N	I-Premise
182	,	N	I-Premise
183	the	N	I-Premise
184	curative	N	I-Premise
185	efficacy	N	I-Premise
186	in	N	I-Premise
187	the	N	I-Premise
188	bevacizumab	N	I-Premise
189	group	N	I-Premise
190	was	N	I-Premise
191	significantly	N	I-Premise
192	higher	N	I-Premise
193	than	N	I-Premise
194	that	N	I-Premise
195	found	N	I-Premise
196	in	N	I-Premise
197	the	N	I-Premise
198	cisplatin	N	I-Premise
199	group	N	I-Premise
200	(	N	I-Premise
201	83.33	N	I-Premise
202	vs.	N	I-Premise
203	50.00	N	I-Premise
204	%	N	I-Premise
205	,	N	I-Premise
206	respectively	N	I-Premise
207	;	N	I-Premise
208	p	N	I-Premise
209	<	N	I-Premise
210	0.05	N	I-Premise
211	)	N	I-Premise
212	.	N	I-Premise

213	Therapy	N	I-Premise
214	with	N	I-Premise
215	combined	N	I-Premise
216	bevacizumab	N	I-Premise
217	plus	N	I-Premise
218	cisplatin	N	I-Premise
219	significantly	N	I-Premise
220	reduced	N	I-Premise
221	VEGF	N	I-Premise
222	levels	N	I-Premise
223	in	N	I-Premise
224	the	N	I-Premise
225	pleural	N	I-Premise
226	fluid	N	I-Premise
227	(	N	I-Premise
228	p	N	I-Premise
229	<	N	I-Premise
230	0.01	N	I-Premise
231	)	N	I-Premise
232	.	N	I-Premise

233	In	N	I-Premise
234	the	N	I-Premise
235	bevacizumab	N	I-Premise
236	group	N	I-Premise
237	,	N	I-Premise
238	the	N	I-Premise
239	levels	N	I-Premise
240	of	N	I-Premise
241	VEGF	N	I-Premise
242	in	N	I-Premise
243	the	N	I-Premise
244	pleural	N	I-Premise
245	fluid	N	I-Premise
246	were	N	I-Premise
247	significantly	N	I-Premise
248	lower	N	I-Premise
249	compared	N	I-Premise
250	to	N	I-Premise
251	those	N	I-Premise
252	of	N	I-Premise
253	the	N	I-Premise
254	cisplatin	N	I-Premise
255	group	N	I-Premise
256	after	N	I-Premise
257	treatment	N	I-Premise
258	,	N	I-Premise
259	which	N	I-Premise
260	showed	N	I-Premise
261	greater	N	I-Premise
262	efficacy	N	I-Premise
263	(	N	I-Premise
264	p	N	I-Premise
265	<	N	I-Premise
266	0.01	N	I-Premise
267	)	N	I-Premise
268	.	N	I-Premise

269	In	N	I-Premise
270	addition	N	I-Premise
271	,	N	I-Premise
272	combination	N	I-Premise
273	therapy	N	I-Premise
274	showed	N	I-Premise
275	greater	N	I-Premise
276	efficacy	N	I-Premise
277	in	N	I-Premise
278	the	N	I-Premise
279	patients	N	I-Premise
280	with	N	I-Premise
281	high	N	I-Premise
282	levels	N	I-Premise
283	of	N	I-Premise
284	VEGF	N	I-Premise
285	expression	N	I-Premise
286	(	N	I-Premise
287	p	N	I-Premise
288	<	N	I-Premise
289	0.01	N	I-Premise
290	)	N	I-Premise
291	.	N	I-Premise

292	There	N	I-Premise
293	was	N	I-Premise
294	no	N	I-Premise
295	significant	N	I-Premise
296	difference	N	I-Premise
297	in	N	I-Premise
298	grade	N	I-Premise
299	III/IV	N	I-Premise
300	adverse	N	I-Premise
301	events	N	I-Premise
302	between	N	I-Premise
303	the	N	I-Premise
304	two	N	I-Premise
305	groups	N	I-Premise
306	.	N	I-Premise

307	All	N	I-Premise
308	procedures	N	I-Premise
309	were	N	I-Premise
310	well	N	I-Premise
311	tolerated	N	I-Premise
312	by	N	I-Premise
313	the	N	I-Premise
314	patients	N	I-Premise
315	.	N	I-Premise

316	Combined	N	I-Claim
317	intrapleural	N	I-Claim
318	therapy	N	I-Claim
319	with	N	I-Claim
320	bevacizumab	N	I-Claim
321	and	N	I-Claim
322	cisplatin	N	I-Claim
323	was	N	I-Claim
324	effective	N	I-Claim
325	and	N	I-Claim
326	safe	N	I-Claim
327	in	N	I-Claim
328	managing	N	I-Claim
329	NSCLC-mediated	N	I-Claim
330	MPE	N	I-Claim
331	.	N	I-Claim

332	We	N	I-MajorClaim
333	propose	N	I-MajorClaim
334	that	N	I-MajorClaim
335	VEGF	N	I-MajorClaim
336	expression	N	I-MajorClaim
337	levels	N	I-MajorClaim
338	in	N	I-MajorClaim
339	MPE	N	I-MajorClaim
340	could	N	I-MajorClaim
341	serve	N	I-MajorClaim
342	as	N	I-MajorClaim
343	a	N	I-MajorClaim
344	prognostic	N	I-MajorClaim
345	marker	N	I-MajorClaim
346	for	N	I-MajorClaim
347	bevacizumab	N	I-MajorClaim
348	therapy	N	I-MajorClaim
349	.	N	I-MajorClaim

1	There	N	O
2	are	N	O
3	no	N	O
4	known	N	O
5	effective	N	O
6	treatments	N	O
7	for	N	O
8	painful	N	O
9	chemotherapy-induced	N	O
10	peripheral	N	O
11	neuropathy	N	O
12	.	N	O

13	To	N	O
14	determine	N	O
15	the	N	O
16	effect	N	O
17	of	N	O
18	duloxetine	N	O
19	,	N	O
20	60	N	O
21	mg	N	O
22	daily	N	O
23	,	N	O
24	on	N	O
25	average	N	O
26	pain	N	O
27	severity	N	O
28	.	N	O

29	Randomized	N	O
30	,	N	O
31	double-blind	N	O
32	,	N	O
33	placebo-controlled	N	O
34	crossover	N	O
35	trial	N	O
36	at	N	O
37	8	N	O
38	National	N	O
39	Cancer	N	O
40	Institute	N	O
41	(	N	O
42	NCI	N	O
43	)	N	O
44	-funded	N	O
45	cooperative	N	O
46	research	N	O
47	networks	N	O
48	that	N	O
49	enrolled	N	O
50	231	N	O
51	patients	N	O
52	who	N	O
53	were	N	O
54	25	N	O
55	years	N	O
56	or	N	O
57	older	N	O
58	being	N	O
59	treated	N	O
60	at	N	O
61	community	N	O
62	and	N	O
63	academic	N	O
64	settings	N	O
65	between	N	O
66	April	N	O
67	2008	N	O
68	and	N	O
69	March	N	O
70	2011	N	O
71	.	N	O

72	Study	N	O
73	follow-up	N	O
74	was	N	O
75	completed	N	O
76	July	N	O
77	2012	N	O
78	.	N	O

79	Stratified	N	O
80	by	N	O
81	chemotherapeutic	N	O
82	drug	N	O
83	and	N	O
84	comorbid	N	O
85	pain	N	O
86	risk	N	O
87	,	N	O
88	patients	N	O
89	were	N	O
90	randomized	N	O
91	to	N	O
92	receive	N	O
93	either	N	O
94	duloxetine	N	O
95	followed	N	O
96	by	N	O
97	placebo	N	O
98	or	N	O
99	placebo	N	O
100	followed	N	O
101	by	N	O
102	duloxetine	N	O
103	.	N	O

104	Eligibility	N	O
105	required	N	O
106	that	N	O
107	patients	N	O
108	have	N	O
109	grade	N	O
110	1	N	O
111	or	N	O
112	higher	N	O
113	sensory	N	O
114	neuropathy	N	O
115	according	N	O
116	to	N	O
117	the	N	O
118	NCI	N	O
119	Common	N	O
120	Terminology	N	O
121	Criteria	N	O
122	for	N	O
123	Adverse	N	O
124	Events	N	O
125	and	N	O
126	at	N	O
127	least	N	O
128	4	N	O
129	on	N	O
130	a	N	O
131	scale	N	O
132	of	N	O
133	0	N	O
134	to	N	O
135	10	N	O
136	,	N	O
137	representing	N	O
138	average	N	O
139	chemotherapy-induced	N	O
140	pain	N	O
141	,	N	O
142	after	N	O
143	paclitaxel	N	O
144	,	N	O
145	other	N	O
146	taxane	N	O
147	,	N	O
148	or	N	O
149	oxaliplatin	N	O
150	treatment	N	O
151	.	N	O

152	The	N	O
153	initial	N	O
154	treatment	N	O
155	consisted	N	O
156	of	N	O
157	taking	N	O
158	1	N	O
159	capsule	N	O
160	daily	N	O
161	of	N	O
162	either	N	O
163	30	N	O
164	mg	N	O
165	of	N	O
166	duloxetine	N	O
167	or	N	O
168	placebo	N	O
169	for	N	O
170	the	N	O
171	first	N	O
172	week	N	O
173	and	N	O
174	2	N	O
175	capsules	N	O
176	of	N	O
177	either	N	O
178	30	N	O
179	mg	N	O
180	of	N	O
181	duloxetine	N	O
182	or	N	O
183	placebo	N	O
184	daily	N	O
185	for	N	O
186	4	N	O
187	additional	N	O
188	weeks	N	O
189	.	N	O

190	The	N	O
191	primary	N	O
192	hypothesis	N	O
193	was	N	O
194	that	N	O
195	duloxetine	N	O
196	would	N	O
197	be	N	O
198	more	N	O
199	effective	N	O
200	than	N	O
201	placebo	N	O
202	in	N	O
203	decreasing	N	O
204	chemotherapy-induced	N	O
205	peripheral	N	O
206	neuropathic	N	O
207	pain	N	O
208	.	N	O

209	Pain	N	O
210	severity	N	O
211	was	N	O
212	assessed	N	O
213	using	N	O
214	the	N	O
215	Brief	N	O
216	Pain	N	O
217	Inventory-Short	N	O
218	Form	N	O
219	``	N	O
220	average	N	O
221	pain	N	O
222	''	N	O
223	item	N	O
224	with	N	O
225	0	N	O
226	representing	N	O
227	no	N	O
228	pain	N	O
229	and	N	O
230	10	N	O
231	representing	N	O
232	as	N	O
233	bad	N	O
234	as	N	O
235	can	N	O
236	be	N	O
237	imagined	N	O
238	.	N	O

239	Individuals	N	I-Premise
240	receiving	N	I-Premise
241	duloxetine	N	I-Premise
242	as	N	I-Premise
243	their	N	I-Premise
244	initial	N	I-Premise
245	5-week	N	I-Premise
246	treatment	N	I-Premise
247	reported	N	I-Premise
248	a	N	I-Premise
249	mean	N	I-Premise
250	decrease	N	I-Premise
251	in	N	I-Premise
252	average	N	I-Premise
253	pain	N	I-Premise
254	of	N	I-Premise
255	1.06	N	I-Premise
256	(	N	I-Premise
257	95	N	I-Premise
258	%	N	I-Premise
259	CI	N	I-Premise
260	,	N	I-Premise
261	0.72-1.40	N	I-Premise
262	)	N	I-Premise
263	vs	N	I-Premise
264	0.34	N	I-Premise
265	(	N	I-Premise
266	95	N	I-Premise
267	%	N	I-Premise
268	CI	N	I-Premise
269	,	N	I-Premise
270	0.01-0.66	N	I-Premise
271	)	N	I-Premise
272	among	N	I-Premise
273	those	N	I-Premise
274	who	N	I-Premise
275	received	N	I-Premise
276	placebo	N	I-Premise
277	(	N	I-Premise
278	P	N	I-Premise
279	=	N	I-Premise
280	.003	N	I-Premise
281	;	N	I-Premise
282	effect	N	I-Premise
283	size	N	I-Premise
284	,	N	I-Premise
285	0.513	N	I-Premise
286	)	N	I-Premise
287	.	N	I-Premise

288	The	N	I-Premise
289	observed	N	I-Premise
290	mean	N	I-Premise
291	difference	N	I-Premise
292	in	N	I-Premise
293	the	N	I-Premise
294	average	N	I-Premise
295	pain	N	I-Premise
296	score	N	I-Premise
297	between	N	I-Premise
298	duloxetine	N	I-Premise
299	and	N	I-Premise
300	placebo	N	I-Premise
301	was	N	I-Premise
302	0.73	N	I-Premise
303	(	N	I-Premise
304	95	N	I-Premise
305	%	N	I-Premise
306	CI	N	I-Premise
307	,	N	I-Premise
308	0.26-1.20	N	I-Premise
309	)	N	I-Premise
310	.	N	I-Premise

311	Fifty-nine	N	I-Premise
312	percent	N	I-Premise
313	of	N	I-Premise
314	those	N	I-Premise
315	initially	N	I-Premise
316	receiving	N	I-Premise
317	duloxetine	N	I-Premise
318	vs	N	I-Premise
319	38	N	I-Premise
320	%	N	I-Premise
321	of	N	I-Premise
322	those	N	I-Premise
323	initially	N	I-Premise
324	receiving	N	I-Premise
325	placebo	N	I-Premise
326	reported	N	I-Premise
327	decreased	N	I-Premise
328	pain	N	I-Premise
329	of	N	I-Premise
330	any	N	I-Premise
331	amount	N	I-Premise
332	.	N	I-Premise

333	Among	N	I-Claim
334	patients	N	I-Claim
335	with	N	I-Claim
336	painful	N	I-Claim
337	chemotherapy-induced	N	I-Claim
338	peripheral	N	I-Claim
339	neuropathy	N	I-Claim
340	,	N	I-Claim
341	the	N	I-Claim
342	use	N	I-Claim
343	of	N	I-Claim
344	duloxetine	N	I-Claim
345	compared	N	I-Claim
346	with	N	I-Claim
347	placebo	N	I-Claim
348	for	N	I-Claim
349	5	N	I-Claim
350	weeks	N	I-Claim
351	resulted	N	I-Claim
352	in	N	I-Claim
353	a	N	I-Claim
354	greater	N	I-Claim
355	reduction	N	I-Claim
356	in	N	I-Claim
357	pain	N	I-Claim
358	.	N	I-Claim

1	Sexual	N	O
2	dysfunction	N	O
3	represents	N	O
4	a	N	O
5	complex	N	O
6	and	N	O
7	multifactorial	N	O
8	construct	N	O
9	that	N	O
10	can	N	O
11	affect	N	O
12	both	N	O
13	men	N	O
14	and	N	O
15	women	N	O
16	and	N	O
17	has	N	O
18	been	N	O
19	noted	N	O
20	to	N	O
21	often	N	O
22	deteriorate	N	O
23	significantly	N	O
24	after	N	O
25	treatment	N	O
26	for	N	O
27	rectal	N	O
28	and	N	O
29	anal	N	O
30	cancer	N	O
31	.	N	O

32	Despite	N	O
33	this	N	O
34	,	N	O
35	it	N	O
36	remains	N	O
37	an	N	O
38	understudied	N	O
39	,	N	O
40	underreported	N	O
41	,	N	O
42	and	N	O
43	undertreated	N	O
44	issue	N	O
45	in	N	O
46	the	N	O
47	field	N	O
48	of	N	O
49	cancer	N	O
50	survivorship	N	O
51	.	N	O

52	This	N	O
53	study	N	O
54	examined	N	O
55	the	N	O
56	characteristics	N	O
57	of	N	O
58	women	N	O
59	enrolled	N	O
60	in	N	O
61	an	N	O
62	intervention	N	O
63	trial	N	O
64	to	N	O
65	treat	N	O
66	sexual	N	O
67	dysfunction	N	O
68	,	N	O
69	and	N	O
70	explored	N	O
71	the	N	O
72	relationship	N	O
73	between	N	O
74	sexual	N	O
75	functioning	N	O
76	and	N	O
77	psychological	N	O
78	well-being	N	O
79	.	N	O

80	There	N	O
81	were	N	O
82	70	N	O
83	female	N	O
84	posttreatment	N	O
85	anal	N	O
86	or	N	O
87	rectal	N	O
88	cancer	N	O
89	survivors	N	O
90	assessed	N	O
91	as	N	O
92	part	N	O
93	of	N	O
94	the	N	O
95	current	N	O
96	study	N	O
97	.	N	O

98	Participants	N	O
99	were	N	O
100	enrolled	N	O
101	in	N	O
102	a	N	O
103	randomized	N	O
104	intervention	N	O
105	trial	N	O
106	to	N	O
107	treat	N	O
108	sexual	N	O
109	dysfunction	N	O
110	and	N	O
111	completed	N	O
112	outcome	N	O
113	measures	N	O
114	prior	N	O
115	to	N	O
116	randomization	N	O
117	.	N	O

118	The	N	O
119	main	N	O
120	outcome	N	O
121	measures	N	O
122	are	N	O
123	quality	N	O
124	of	N	O
125	life	N	O
126	(	N	O
127	QOL	N	O
128	)	N	O
129	(	N	O
130	European	N	O
131	Organization	N	O
132	for	N	O
133	Research	N	O
134	and	N	O
135	Treatment	N	O
136	of	N	O
137	Cancer	N	O
138	Core	N	O
139	Quality	N	O
140	of	N	O
141	Life	N	O
142	Questionnaire	N	O
143	[	N	O
144	EORTC-QLQ-C30	N	O
145	]	N	O
146	and	N	O
147	Colorectal	N	O
148	Cancer-Specific	N	O
149	Module	N	O
150	[	N	O
151	QLQ-CR38	N	O
152	]	N	O
153	)	N	O
154	,	N	O
155	sexual	N	O
156	functioning	N	O
157	(	N	O
158	Female	N	O
159	Sexual	N	O
160	Functioning	N	O
161	Index	N	O
162	)	N	O
163	,	N	O
164	and	N	O
165	psychological	N	O
166	well-being	N	O
167	(	N	O
168	Brief	N	O
169	Symptom	N	O
170	Inventory	N	O
171	Depression/Anxiety	N	O
172	,	N	O
173	Impact	N	O
174	of	N	O
175	Events	N	O
176	Scale-Revised	N	O
177	,	N	O
178	CR-38	N	O
179	Body	N	O
180	Image	N	O
181	)	N	O
182	.	N	O

183	Women	N	O
184	enrolled	N	O
185	in	N	O
186	the	N	O
187	study	N	O
188	intervention	N	O
189	were	N	O
190	on	N	O
191	average	N	O
192	55	N	O
193	years	N	O
194	old	N	O
195	,	N	O
196	predominantly	N	O
197	Caucasian	N	O
198	(	N	O
199	79	N	O
200	%	N	O
201	)	N	O
202	,	N	O
203	married	N	O
204	(	N	O
205	57	N	O
206	%	N	O
207	)	N	O
208	,	N	O
209	and	N	O
210	a	N	O
211	median	N	O
212	of	N	O
213	4	N	O
214	years	N	O
215	postprimary	N	O
216	treatment	N	O
217	.	N	O

218	For	N	O
219	those	N	O
220	reporting	N	O
221	sexual	N	O
222	activity	N	O
223	at	N	O
224	baseline	N	O
225	(	N	O
226	N=41	N	O
227	)	N	O
228	,	N	O
229	sexual	N	O
230	dysfunction	N	O
231	was	N	O
232	associated	N	O
233	with	N	O
234	a	N	O
235	range	N	O
236	of	N	O
237	specific	N	O
238	measures	N	O
239	of	N	O
240	psychological	N	O
241	well-being	N	O
242	,	N	O
243	all	N	O
244	in	N	O
245	the	N	O
246	hypothesized	N	O
247	direction	N	O
248	.	N	O

249	The	N	I-Premise
250	Sexual/Relationship	N	I-Premise
251	Satisfaction	N	I-Premise
252	subscale	N	I-Premise
253	was	N	I-Premise
254	associated	N	I-Premise
255	with	N	I-Premise
256	all	N	I-Premise
257	measures	N	I-Premise
258	of	N	I-Premise
259	psychological	N	I-Premise
260	well-being	N	I-Premise
261	(	N	I-Premise
262	r=-0.45	N	I-Premise
263	to	N	I-Premise
264	-0.70	N	I-Premise
265	,	N	I-Premise
266	all	N	I-Premise
267	P	N	I-Premise
268	<	N	I-Premise
269	0.01	N	I-Premise
270	)	N	I-Premise
271	.	N	I-Premise

272	Body	N	I-Premise
273	image	N	I-Premise
274	,	N	I-Premise
275	anxiety	N	I-Premise
276	,	N	I-Premise
277	and	N	I-Premise
278	cancer-specific	N	I-Premise
279	posttraumatic	N	I-Premise
280	distress	N	I-Premise
281	were	N	I-Premise
282	notable	N	I-Premise
283	in	N	I-Premise
284	their	N	I-Premise
285	association	N	I-Premise
286	with	N	I-Premise
287	subscales	N	I-Premise
288	of	N	I-Premise
289	sexual	N	I-Premise
290	functioning	N	I-Premise
291	,	N	I-Premise
292	while	N	I-Premise
293	a	N	I-Premise
294	global	N	I-Premise
295	QOL	N	I-Premise
296	measure	N	I-Premise
297	was	N	I-Premise
298	largely	N	I-Premise
299	unrelated	N	I-Premise
300	.	N	I-Premise

301	For	N	I-Premise
302	sexually	N	I-Premise
303	active	N	I-Premise
304	female	N	I-Premise
305	rectal	N	I-Premise
306	and	N	I-Premise
307	anal	N	I-Premise
308	cancer	N	I-Premise
309	survivors	N	I-Premise
310	enrolled	N	I-Premise
311	in	N	I-Premise
312	a	N	I-Premise
313	sexual	N	I-Premise
314	health	N	I-Premise
315	intervention	N	I-Premise
316	,	N	I-Premise
317	sexual	N	I-Premise
318	dysfunction	N	I-Premise
319	was	N	I-Premise
320	significantly	N	I-Premise
321	and	N	I-Premise
322	consistently	N	I-Premise
323	associated	N	I-Premise
324	with	N	I-Premise
325	specific	N	I-Premise
326	measures	N	I-Premise
327	of	N	I-Premise
328	psychological	N	I-Premise
329	well-being	N	I-Premise
330	,	N	I-Premise
331	most	N	I-Premise
332	notably	N	I-Premise
333	Sexual/Relationship	N	I-Premise
334	Satisfaction	N	I-Premise
335	.	N	I-Premise

336	These	N	I-Claim
337	results	N	I-Claim
338	suggest	N	I-Claim
339	that	N	I-Claim
340	sexual	N	I-Claim
341	functioning	N	I-Claim
342	may	N	I-Claim
343	require	N	I-Claim
344	focused	N	I-Claim
345	assessment	N	I-Claim
346	by	N	I-Claim
347	providers	N	I-Claim
348	,	N	I-Claim
349	beyond	N	I-Claim
350	broad	N	I-Claim
351	QOL	N	I-Claim
352	assessments	N	I-Claim
353	,	N	I-Claim
354	and	N	O
355	that	N	O
356	attention	N	I-Claim
357	to	N	I-Claim
358	Sexual/Relationship	N	I-Claim
359	Satisfaction	N	I-Claim
360	may	N	I-Claim
361	be	N	I-Claim
362	critical	N	I-Claim
363	in	N	I-Claim
364	the	N	I-Claim
365	development	N	I-Claim
366	and	N	I-Claim
367	implementation	N	I-Claim
368	of	N	I-Claim
369	interventions	N	I-Claim
370	for	N	I-Claim
371	this	N	I-Claim
372	cohort	N	I-Claim
373	of	N	I-Claim
374	patients	N	I-Claim
375	.	N	I-Claim

1	To	N	O
2	prospectively	N	O
3	evaluate	N	O
4	and	N	O
5	compare	N	O
6	health-related	N	O
7	quality-of-life	N	O
8	(	N	O
9	QOL	N	O
10	)	N	O
11	outcomes	N	O
12	in	N	O
13	patients	N	O
14	with	N	O
15	head-neck	N	O
16	squamous	N	O
17	cell	N	O
18	carcinoma	N	O
19	randomized	N	O
20	to	N	O
21	either	N	O
22	intensity-modulated	N	O
23	radiation	N	O
24	therapy	N	O
25	(	N	O
26	IMRT	N	O
27	)	N	O
28	or	N	O
29	three-dimensional	N	O
30	conformal	N	O
31	radiotherapy	N	O
32	(	N	O
33	3D-CRT	N	O
34	)	N	O
35	and	N	O
36	assess	N	O
37	serial	N	O
38	longitudinal	N	O
39	change	N	O
40	in	N	O
41	QOL	N	O
42	over	N	O
43	time	N	O
44	.	N	O

45	QOL	N	O
46	outcomes	N	O
47	were	N	O
48	assessed	N	O
49	using	N	O
50	the	N	O
51	European	N	O
52	Organization	N	O
53	for	N	O
54	Research	N	O
55	and	N	O
56	Treatment	N	O
57	of	N	O
58	Cancer	N	O
59	(	N	O
60	EORTC	N	O
61	)	N	O
62	QOL	N	O
63	questionnaire	N	O
64	(	N	O
65	QLQ-C30	N	O
66	)	N	O
67	and	N	O
68	Head-Neck	N	O
69	module	N	O
70	(	N	O
71	HN-35	N	O
72	)	N	O
73	at	N	O
74	baseline	N	O
75	(	N	O
76	pre-treatment	N	O
77	)	N	O
78	and	N	O
79	subsequently	N	O
80	periodically	N	O
81	on	N	O
82	follow-up	N	O
83	.	N	O

84	Mean	N	O
85	scores	N	O
86	of	N	O
87	individual	N	O
88	domains/scales	N	O
89	of	N	O
90	3D-CRT	N	O
91	and	N	O
92	IMRT	N	O
93	were	N	O
94	compared	N	O
95	using	N	O
96	't	N	O
97	'	N	O
98	test	N	O
99	at	N	O
100	each	N	O
101	time	N	O
102	point	N	O
103	;	N	O
104	while	N	O
105	longitudinal	N	O
106	change	N	O
107	in	N	O
108	mean	N	O
109	scores	N	O
110	of	N	O
111	both	N	O
112	groups	N	O
113	over	N	O
114	time	N	O
115	was	N	O
116	evaluated	N	O
117	by	N	O
118	repeated	N	O
119	measurement	N	O
120	analysis	N	O
121	of	N	O
122	variance	N	O
123	.	N	O

124	Fifty	N	O
125	eight	N	O
126	of	N	O
127	the	N	O
128	60	N	O
129	randomized	N	O
130	patients	N	O
131	who	N	O
132	filled	N	O
133	the	N	O
134	QOL	N	O
135	questionnaire	N	O
136	at	N	O
137	least	N	O
138	at	N	O
139	one	N	O
140	time	N	O
141	point	N	O
142	were	N	O
143	included	N	O
144	in	N	O
145	the	N	O
146	analysis	N	O
147	.	N	O

148	Several	N	O
149	general	N	O
150	(	N	O
151	emotional	N	O
152	functioning	N	O
153	,	N	O
154	role	N	O
155	functioning	N	O
156	,	N	O
157	social	N	O
158	contact	N	O
159	)	N	O
160	as	N	O
161	well	N	O
162	as	N	O
163	head	N	O
164	and	N	O
165	neck	N	O
166	cancer-specific	N	O
167	(	N	O
168	dry	N	O
169	mouth	N	O
170	,	N	O
171	opening	N	O
172	mouth	N	O
173	,	N	O
174	sticky	N	O
175	saliva	N	O
176	,	N	O
177	pain	N	O
178	,	N	O
179	senses	N	O
180	)	N	O
181	QOL	N	O
182	domains	N	O
183	were	N	O
184	better	N	O
185	preserved	N	O
186	with	N	O
187	IMRT	N	O
188	compared	N	O
189	to	N	O
190	3D-CRT	N	O
191	at	N	O
192	different	N	O
193	time	N	O
194	points	N	O
195	.	N	O

196	Importantly	N	O
197	,	N	O
198	none	N	O
199	of	N	O
200	the	N	O
201	QOL	N	O
202	domains	N	O
203	were	N	O
204	worse	N	O
205	with	N	O
206	IMRT	N	O
207	at	N	O
208	any	N	O
209	time	N	O
210	point	N	O
211	.	N	O

212	There	N	I-Premise
213	was	N	I-Premise
214	substantial	N	I-Premise
215	deterioration	N	I-Premise
216	in	N	I-Premise
217	QOL	N	I-Premise
218	scores	N	I-Premise
219	immediate	N	I-Premise
220	post-treatment	N	I-Premise
221	(	N	I-Premise
222	3-months	N	I-Premise
223	)	N	I-Premise
224	in	N	I-Premise
225	both	N	I-Premise
226	arms	N	I-Premise
227	.	N	I-Premise

228	However	N	I-Premise
229	,	N	I-Premise
230	QOL	N	I-Premise
231	scores	N	I-Premise
232	gradually	N	I-Premise
233	but	N	I-Premise
234	definitely	N	I-Premise
235	improved	N	I-Premise
236	over	N	I-Premise
237	time	N	I-Premise
238	for	N	I-Premise
239	most	N	I-Premise
240	domains	N	I-Premise
241	.	N	I-Premise

242	Global	N	I-Premise
243	QOL	N	I-Premise
244	,	N	I-Premise
245	emotional/role	N	I-Premise
246	functioning	N	I-Premise
247	,	N	I-Premise
248	nausea/vomiting	N	I-Premise
249	,	N	I-Premise
250	pain	N	I-Premise
251	,	N	I-Premise
252	swallowing	N	I-Premise
253	,	N	I-Premise
254	speech	N	I-Premise
255	,	N	I-Premise
256	social	N	I-Premise
257	contact/eating	N	I-Premise
258	,	N	I-Premise
259	insomnia	N	I-Premise
260	showed	N	I-Premise
261	rapid	N	I-Premise
262	recovery	N	I-Premise
263	(	N	I-Premise
264	<	N	I-Premise
265	6months	N	I-Premise
266	)	N	I-Premise
267	while	N	I-Premise
268	physical/cognitive	N	I-Premise
269	functioning	N	I-Premise
270	,	N	I-Premise
271	dry	N	I-Premise
272	mouth	N	I-Premise
273	,	N	I-Premise
274	sticky	N	I-Premise
275	saliva	N	I-Premise
276	,	N	I-Premise
277	fatigue	N	I-Premise
278	,	N	I-Premise
279	senses	N	I-Premise
280	showed	N	I-Premise
281	delayed	N	I-Premise
282	recovery	N	I-Premise
283	(	N	I-Premise
284	>	N	I-Premise
285	6months	N	I-Premise
286	)	N	I-Premise
287	.	N	I-Premise

288	There	N	I-Premise
289	were	N	I-Premise
290	no	N	I-Premise
291	significant	N	I-Premise
292	differences	N	I-Premise
293	in	N	I-Premise
294	loco-regional	N	I-Premise
295	or	N	I-Premise
296	survival	N	I-Premise
297	between	N	I-Premise
298	the	N	I-Premise
299	two	N	I-Premise
300	arms	N	I-Premise
301	.	N	I-Premise

302	There	N	I-Claim
303	is	N	I-Claim
304	substantial	N	I-Claim
305	deterioration	N	I-Claim
306	in	N	I-Claim
307	QOL	N	I-Claim
308	after	N	I-Claim
309	curative-intent	N	I-Claim
310	head-neck	N	I-Claim
311	irradiation	N	I-Claim
312	that	N	I-Claim
313	gradually	N	I-Claim
314	improves	N	I-Claim
315	over	N	I-Claim
316	time	N	I-Claim
317	.	N	I-Claim

318	IMRT	N	I-Claim
319	results	N	I-Claim
320	in	N	I-Claim
321	clinically	N	I-Claim
322	meaningful	N	I-Claim
323	and	N	I-Claim
324	statistically	N	I-Claim
325	better	N	I-Claim
326	QOL	N	I-Claim
327	scores	N	I-Claim
328	for	N	I-Claim
329	some	N	I-Claim
330	domains	N	I-Claim
331	compared	N	I-Claim
332	to	N	I-Claim
333	3D-CRT	N	I-Claim
334	at	N	I-Claim
335	several	N	I-Claim
336	time	N	I-Claim
337	points	N	I-Claim
338	with	N	I-Claim
339	comparable	N	I-Claim
340	disease	N	I-Claim
341	outcomes	N	I-Claim
342	that	N	I-Claim
343	could	N	I-Claim
344	support	N	I-Claim
345	its	N	I-Claim
346	widespread	N	I-Claim
347	adoption	N	I-Claim
348	in	N	I-Claim
349	routine	N	I-Claim
350	clinical	N	I-Claim
351	practice	N	I-Claim
352	.	N	I-Claim

1	The	N	O
2	AVEREL	N	O
3	trial	N	O
4	[	N	O
5	A	N	O
6	Study	N	O
7	of	N	O
8	Avastin	N	O
9	(	N	O
10	Bevacizumab	N	O
11	)	N	O
12	in	N	O
13	Combination	N	O
14	With	N	O
15	Herceptin	N	O
16	(	N	O
17	Trastuzumab	N	O
18	)	N	O
19	/Docetaxel	N	O
20	in	N	O
21	Patients	N	O
22	With	N	O
23	HER2-Positive	N	O
24	Metastatic	N	O
25	Breast	N	O
26	Cancer	N	O
27	]	N	O
28	evaluated	N	O
29	first-line	N	O
30	bevacizumab-containing	N	O
31	therapy	N	O
32	for	N	O
33	human	N	O
34	epidermal	N	O
35	growth	N	O
36	factor	N	O
37	receptor	N	O
38	2	N	O
39	(	N	O
40	HER2	N	O
41	)	N	O
42	-positive	N	O
43	locally	N	O
44	recurrent/metastatic	N	O
45	breast	N	O
46	cancer	N	O
47	(	N	O
48	LR/MBC	N	O
49	)	N	O
50	.	N	O

51	Patients	N	O
52	with	N	O
53	measurable/evaluable	N	O
54	HER2-positive	N	O
55	LR/MBC	N	O
56	who	N	O
57	had	N	O
58	not	N	O
59	received	N	O
60	trastuzumab	N	O
61	or	N	O
62	chemotherapy	N	O
63	for	N	O
64	LR/MBC	N	O
65	were	N	O
66	stratified	N	O
67	by	N	O
68	prior	N	O
69	adjuvant	N	O
70	trastuzumab	N	O
71	,	N	O
72	prior	N	O
73	(	N	O
74	neo	N	O
75	)	N	O
76	adjuvant	N	O
77	taxane	N	O
78	,	N	O
79	hormone	N	O
80	receptor	N	O
81	status	N	O
82	,	N	O
83	and	N	O
84	measurable	N	O
85	disease	N	O
86	and	N	O
87	were	N	O
88	randomly	N	O
89	assigned	N	O
90	to	N	O
91	receive	N	O
92	docetaxel	N	O
93	100	N	O
94	mg/m	N	O
95	(	N	O
96	2	N	O
97	)	N	O
98	plus	N	O
99	trastuzumab	N	O
100	8	N	O
101	mg/kg	N	O
102	loading	N	O
103	dose	N	O
104	followed	N	O
105	by	N	O
106	6	N	O
107	mg/kg	N	O
108	either	N	O
109	with	N	O
110	bevacizumab	N	O
111	15	N	O
112	mg/kg	N	O
113	or	N	O
114	without	N	O
115	bevacizumab	N	O
116	,	N	O
117	all	N	O
118	administered	N	O
119	every	N	O
120	3	N	O
121	weeks	N	O
122	.	N	O

123	The	N	O
124	primary	N	O
125	end	N	O
126	point	N	O
127	was	N	O
128	progression-free	N	O
129	survival	N	O
130	(	N	O
131	PFS	N	O
132	)	N	O
133	.	N	O

134	Additional	N	O
135	end	N	O
136	points	N	O
137	included	N	O
138	overall	N	O
139	survival	N	O
140	,	N	O
141	response	N	O
142	rate	N	O
143	(	N	O
144	RR	N	O
145	)	N	O
146	,	N	O
147	safety	N	O
148	,	N	O
149	quality	N	O
150	of	N	O
151	life	N	O
152	,	N	O
153	and	N	O
154	translational	N	O
155	research	N	O
156	.	N	O

157	Results	N	O
158	Baseline	N	O
159	characteristics	N	O
160	of	N	O
161	the	N	O
162	424	N	O
163	patients	N	O
164	were	N	O
165	balanced	N	O
166	between	N	O
167	treatment	N	O
168	arms	N	O
169	.	N	O

170	Most	N	O
171	patients	N	O
172	had	N	O
173	visceral	N	O
174	metastases	N	O
175	,	N	O
176	43	N	O
177	%	N	O
178	had	N	O
179	a	N	O
180	disease-free	N	O
181	interval	N	O
182	less	N	O
183	than	N	O
184	12	N	O
185	months	N	O
186	,	N	O
187	and	N	O
188	85	N	O
189	%	N	O
190	had	N	O
191	measurable	N	O
192	disease	N	O
193	.	N	O

194	Median	N	O
195	follow-up	N	O
196	was	N	O
197	26	N	O
198	months	N	O
199	.	N	O

200	The	N	I-Premise
201	hazard	N	I-Premise
202	ratio	N	I-Premise
203	for	N	I-Premise
204	investigator-assessed	N	I-Premise
205	PFS	N	I-Premise
206	was	N	I-Premise
207	0.82	N	I-Premise
208	(	N	I-Premise
209	95	N	I-Premise
210	%	N	I-Premise
211	CI	N	I-Premise
212	,	N	I-Premise
213	0.65	N	I-Premise
214	to	N	I-Premise
215	1.02	N	I-Premise
216	;	N	I-Premise
217	P	N	I-Premise
218	=	N	I-Premise
219	.0775	N	I-Premise
220	;	N	I-Premise
221	median	N	I-Premise
222	PFS	N	I-Premise
223	,	N	I-Premise
224	13.7	N	I-Premise
225	v	N	I-Premise
226	16.5	N	I-Premise
227	months	N	I-Premise
228	in	N	I-Premise
229	the	N	I-Premise
230	non-bevacizumab	N	I-Premise
231	and	N	I-Premise
232	bevacizumab	N	I-Premise
233	arms	N	I-Premise
234	,	N	I-Premise
235	respectively	N	I-Premise
236	;	N	I-Premise
237	PFS	N	I-Premise
238	events	N	I-Premise
239	in	N	I-Premise
240	72	N	I-Premise
241	%	N	I-Premise
242	)	N	I-Premise
243	.	N	I-Premise

244	The	N	I-Premise
245	Independent	N	I-Premise
246	Review	N	I-Premise
247	Committee-assessed	N	I-Premise
248	PFS	N	I-Premise
249	hazard	N	I-Premise
250	ratio	N	I-Premise
251	was	N	I-Premise
252	0.72	N	I-Premise
253	(	N	I-Premise
254	95	N	I-Premise
255	%	N	I-Premise
256	CI	N	I-Premise
257	,	N	I-Premise
258	0.54	N	I-Premise
259	to	N	I-Premise
260	0.94	N	I-Premise
261	;	N	I-Premise
262	P	N	I-Premise
263	=	N	I-Premise
264	.0162	N	I-Premise
265	;	N	I-Premise
266	median	N	I-Premise
267	PFS	N	I-Premise
268	,	N	I-Premise
269	13.9	N	I-Premise
270	v	N	I-Premise
271	16.8	N	I-Premise
272	months	N	I-Premise
273	,	N	I-Premise
274	respectively	N	I-Premise
275	;	N	I-Premise
276	PFS	N	I-Premise
277	events	N	I-Premise
278	in	N	I-Premise
279	53	N	I-Premise
280	%	N	I-Premise
281	)	N	I-Premise
282	.	N	I-Premise

283	The	N	I-Premise
284	RR	N	I-Premise
285	was	N	I-Premise
286	70	N	I-Premise
287	%	N	I-Premise
288	versus	N	I-Premise
289	74	N	I-Premise
290	%	N	I-Premise
291	,	N	I-Premise
292	respectively	N	I-Premise
293	(	N	I-Premise
294	P	N	I-Premise
295	=	N	I-Premise
296	.3492	N	I-Premise
297	)	N	I-Premise
298	.	N	I-Premise

299	Grade	N	I-Claim
300		N	I-Claim
301	3	N	I-Claim
302	febrile	N	I-Claim
303	neutropenia	N	I-Claim
304	and	N	I-Claim
305	hypertension	N	I-Claim
306	were	N	I-Claim
307	more	N	I-Claim
308	common	N	I-Claim
309	with	N	I-Claim
310	bevacizumab-containing	N	I-Claim
311	therapy	N	I-Claim
312	.	N	I-Claim

313	High	N	I-Premise
314	baseline	N	I-Premise
315	plasma	N	I-Premise
316	vascular	N	I-Premise
317	endothelial	N	I-Premise
318	growth	N	I-Premise
319	factor	N	I-Premise
320	A	N	I-Premise
321	(	N	I-Premise
322	VEGF-A	N	I-Premise
323	)	N	I-Premise
324	concentrations	N	I-Premise
325	were	N	I-Premise
326	associated	N	I-Premise
327	with	N	I-Premise
328	greater	N	I-Premise
329	bevacizumab	N	I-Premise
330	benefit	N	I-Premise
331	(	N	I-Premise
332	not	N	I-Premise
333	statistically	N	I-Premise
334	significant	N	I-Premise
335	)	N	I-Premise
336	.	N	I-Premise

337	Combining	N	I-Claim
338	bevacizumab	N	I-Claim
339	with	N	I-Claim
340	docetaxel	N	I-Claim
341	and	N	I-Claim
342	trastuzumab	N	I-Claim
343	did	N	I-Claim
344	not	N	I-Claim
345	significantly	N	I-Claim
346	improve	N	I-Claim
347	investigator-assessed	N	I-Claim
348	PFS	N	I-Claim
349	.	N	I-Claim

350	The	N	O
351	potential	N	O
352	predictive	N	O
353	value	N	O
354	of	N	O
355	plasma	N	O
356	VEGF-A	N	O
357	is	N	O
358	consistent	N	O
359	with	N	O
360	findings	N	O
361	in	N	O
362	HER2-negative	N	O
363	LR/MBC	N	O
364	,	N	O
365	warranting	N	O
366	prospective	N	O
367	evaluation	N	O
368	.	N	O

1	This	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	evaluate	N	O
7	efficacy	N	O
8	,	N	O
9	toxicity	N	O
10	,	N	O
11	and	N	O
12	adverse	N	O
13	effects	N	O
14	of	N	O
15	combination	N	O
16	of	N	O
17	chemotherapy	N	O
18	drugs	N	O
19	and	N	O
20	intraperitoneal	N	O
21	perfusion	N	O
22	of	N	O
23	verapamil	N	O
24	in	N	O
25	the	N	O
26	treatment	N	O
27	of	N	O
28	malignant	N	O
29	ascites	N	O
30	.	N	O

31	Seventy-two	N	O
32	patients	N	O
33	with	N	O
34	malignant	N	O
35	ascites	N	O
36	were	N	O
37	divided	N	O
38	into	N	O
39	two	N	O
40	study	N	O
41	groups	N	O
42	.	N	O

43	Patients	N	O
44	in	N	O
45	control	N	O
46	group	N	O
47	(	N	O
48	31	N	O
49	cases	N	O
50	)	N	O
51	received	N	O
52	conventional	N	O
53	chemotherapy	N	O
54	,	N	O
55	whereas	N	O
56	patients	N	O
57	in	N	O
58	the	N	O
59	combined	N	O
60	treatment	N	O
61	group	N	O
62	(	N	O
63	41	N	O
64	cases	N	O
65	)	N	O
66	were	N	O
67	given	N	O
68	verapamil	N	O
69	intraperitoneally	N	O
70	in	N	O
71	addition	N	O
72	to	N	O
73	chemotherapy	N	O
74	drugs	N	O
75	.	N	O

76	Thirty	N	O
77	days	N	O
78	after	N	O
79	the	N	O
80	treatment	N	O
81	,	N	O
82	efficacy	N	O
83	,	N	O
84	toxicity	N	O
85	,	N	O
86	and	N	O
87	adverse	N	O
88	effects	N	O
89	were	N	O
90	assessed	N	O
91	in	N	O
92	both	N	O
93	study	N	O
94	groups	N	O
95	.	N	O

96	The	N	I-Premise
97	treatment	N	I-Premise
98	of	N	I-Premise
99	control	N	I-Premise
100	group	N	I-Premise
101	led	N	I-Premise
102	to	N	I-Premise
103	1	N	I-Premise
104	case	N	I-Premise
105	of	N	I-Premise
106	complete	N	I-Premise
107	remission	N	I-Premise
108	and	N	I-Premise
109	2	N	I-Premise
110	cases	N	I-Premise
111	of	N	I-Premise
112	partial	N	I-Premise
113	remission	N	I-Premise
114	,	N	I-Premise
115	making	N	I-Premise
116	the	N	I-Premise
117	rate	N	I-Premise
118	of	N	I-Premise
119	efficacy	N	I-Premise
120	(	N	I-Premise
121	complete	N	I-Premise
122	+	N	I-Premise
123	partial	N	I-Premise
124	remission	N	I-Premise
125	)	N	I-Premise
126	of	N	I-Premise
127	9.7	N	I-Premise
128	%	N	I-Premise
129	.	N	I-Premise

130	The	N	I-Premise
131	combined	N	I-Premise
132	treatment	N	I-Premise
133	group	N	I-Premise
134	demonstrated	N	I-Premise
135	13	N	I-Premise
136	cases	N	I-Premise
137	of	N	I-Premise
138	complete	N	I-Premise
139	remission	N	I-Premise
140	and	N	I-Premise
141	22	N	I-Premise
142	cases	N	I-Premise
143	of	N	I-Premise
144	partial	N	I-Premise
145	remission	N	I-Premise
146	.	N	I-Premise

147	Thus	N	O
148	,	N	O
149	the	N	I-Premise
150	rate	N	I-Premise
151	of	N	I-Premise
152	efficacy	N	I-Premise
153	was	N	I-Premise
154	significantly	N	I-Premise
155	higher	N	I-Premise
156	in	N	I-Premise
157	the	N	I-Premise
158	combined	N	I-Premise
159	treatment	N	I-Premise
160	group	N	I-Premise
161	(	N	I-Premise
162	85.36	N	I-Premise
163	%	N	I-Premise
164	;	N	I-Premise
165	p	N	I-Premise
166	<	N	I-Premise
167	0.05	N	I-Premise
168	vs.	N	I-Premise
169	control	N	I-Premise
170	group	N	I-Premise
171	)	N	I-Premise
172	.	N	I-Premise

173	Using	N	O
174	KPS	N	O
175	scores	N	O
176	,	N	O
177	changes	N	O
178	in	N	O
179	quality	N	O
180	of	N	O
181	life	N	O
182	were	N	O
183	compared	N	O
184	before	N	O
185	and	N	O
186	after	N	O
187	the	N	O
188	treatment	N	O
189	.	N	O

190	The	N	I-Premise
191	quality	N	I-Premise
192	of	N	I-Premise
193	life	N	I-Premise
194	improved	N	I-Premise
195	in	N	I-Premise
196	control	N	I-Premise
197	group	N	I-Premise
198	by	N	I-Premise
199	13.7	N	I-Premise
200	%	N	I-Premise
201	,	N	I-Premise
202	while	N	I-Premise
203	combined	N	I-Premise
204	treatment	N	I-Premise
205	group	N	I-Premise
206	showed	N	I-Premise
207	improvement	N	I-Premise
208	of	N	I-Premise
209	83.5	N	I-Premise
210	%	N	I-Premise
211	(	N	I-Premise
212	p	N	I-Premise
213	<	N	I-Premise
214	0.05	N	I-Premise
215	vs.	N	I-Premise
216	control	N	I-Premise
217	group	N	I-Premise
218	)	N	I-Premise
219	.	N	I-Premise

220	Further	N	O
221	,	N	O
222	cumulative	N	I-Premise
223	survival	N	I-Premise
224	rate	N	I-Premise
225	was	N	I-Premise
226	also	N	I-Premise
227	significantly	N	I-Premise
228	higher	N	I-Premise
229	in	N	I-Premise
230	the	N	I-Premise
231	combined	N	I-Premise
232	treatment	N	I-Premise
233	group	N	I-Premise
234	.	N	I-Premise

235	Treatment	N	I-Premise
236	toxicity	N	I-Premise
237	and	N	I-Premise
238	the	N	I-Premise
239	rate	N	I-Premise
240	of	N	I-Premise
241	adverse	N	I-Premise
242	effects	N	I-Premise
243	and	N	I-Premise
244	intestinal	N	I-Premise
245	adhesion	N	I-Premise
246	were	N	I-Premise
247	not	N	I-Premise
248	significantly	N	I-Premise
249	different	N	I-Premise
250	between	N	I-Premise
251	study	N	I-Premise
252	groups	N	I-Premise
253	.	N	I-Premise

254	Intraperitoneal	N	I-Claim
255	perfusion	N	I-Claim
256	of	N	I-Claim
257	verapamil	N	I-Claim
258	enhances	N	I-Claim
259	the	N	I-Claim
260	efficacy	N	I-Claim
261	of	N	I-Claim
262	chemotherapy	N	I-Claim
263	drugs	N	I-Claim
264	,	N	I-Claim
265	prolongs	N	I-Claim
266	survival	N	I-Claim
267	,	N	I-Claim
268	and	N	I-Claim
269	improves	N	I-Claim
270	the	N	I-Claim
271	quality	N	I-Claim
272	of	N	I-Claim
273	life	N	I-Claim
274	.	N	I-Claim

275	Intraperitoneal	N	I-Claim
276	administration	N	I-Claim
277	limits	N	I-Claim
278	cardiotoxicity	N	I-Claim
279	of	N	I-Claim
280	verapamil	N	I-Claim
281	.	N	I-Claim

1	Many	N	O
2	patients	N	O
3	with	N	O
4	cancer	N	O
5	experience	N	O
6	depression	N	O
7	and	N	O
8	anxiety	N	O
9	,	N	O
10	and	N	O
11	an	N	O
12	associated	N	O
13	decrease	N	O
14	in	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QOL	N	O
20	)	N	O
21	during	N	O
22	radiation	N	O
23	therapy	N	O
24	(	N	O
25	RT	N	O
26	)	N	O
27	.	N	O

28	The	N	O
29	main	N	O
30	objective	N	O
31	of	N	O
32	the	N	O
33	study	N	O
34	was	N	O
35	to	N	O
36	determine	N	O
37	the	N	O
38	benefits	N	O
39	of	N	O
40	psychosocial	N	O
41	interventions	N	O
42	for	N	O
43	cancer	N	O
44	patients	N	O
45	who	N	O
46	received	N	O
47	RT	N	O
48	.	N	O

49	Patients	N	O
50	with	N	O
51	cancer	N	O
52	(	N	O
53	n	N	O
54	=	N	O
55	178	N	O
56	)	N	O
57	who	N	O
58	agreed	N	O
59	to	N	O
60	participate	N	O
61	in	N	O
62	the	N	O
63	study	N	O
64	were	N	O
65	randomized	N	O
66	to	N	O
67	the	N	O
68	intervention	N	O
69	arm	N	O
70	(	N	O
71	n	N	O
72	=	N	O
73	89	N	O
74	)	N	O
75	or	N	O
76	the	N	O
77	control	N	O
78	arm	N	O
79	(	N	O
80	n	N	O
81	=	N	O
82	89	N	O
83	)	N	O
84	.	N	O

85	Patients	N	O
86	in	N	O
87	the	N	O
88	intervention	N	O
89	group	N	O
90	received	N	O
91	psychosocial	N	O
92	care	N	O
93	during	N	O
94	RT	N	O
95	,	N	O
96	whereas	N	O
97	the	N	O
98	control	N	O
99	group	N	O
100	received	N	O
101	RT	N	O
102	only	N	O
103	.	N	O

104	The	N	O
105	benefits	N	O
106	of	N	O
107	the	N	O
108	intervention	N	O
109	were	N	O
110	evaluated	N	O
111	using	N	O
112	the	N	O
113	Zung	N	O
114	Self-rating	N	O
115	Depression	N	O
116	Scale	N	O
117	(	N	O
118	SDS	N	O
119	)	N	O
120	to	N	O
121	measure	N	O
122	depression	N	O
123	,	N	O
124	the	N	O
125	Self-rating	N	O
126	Anxiety	N	O
127	Scale	N	O
128	(	N	O
129	SAS	N	O
130	)	N	O
131	to	N	O
132	assess	N	O
133	anxiety	N	O
134	,	N	O
135	and	N	O
136	the	N	O
137	European	N	O
138	Organization	N	O
139	for	N	O
140	Research	N	O
141	and	N	O
142	Treatment	N	O
143	of	N	O
144	Cancer	N	O
145	Quality	N	O
146	of	N	O
147	Life	N	O
148	Questionnaire-Core	N	O
149	30	N	O
150	(	N	O
151	EORTC	N	O
152	QLQ-C30	N	O
153	)	N	O
154	to	N	O
155	survey	N	O
156	health-related	N	O
157	QOL	N	O
158	.	N	O

159	The	N	O
160	association	N	O
161	between	N	O
162	intervention	N	O
163	and	N	O
164	survival	N	O
165	was	N	O
166	also	N	O
167	assessed	N	O
168	.	N	O

169	Patients	N	I-Premise
170	randomly	N	I-Premise
171	assigned	N	I-Premise
172	to	N	I-Premise
173	the	N	I-Premise
174	intervention	N	I-Premise
175	arm	N	I-Premise
176	showed	N	I-Premise
177	significant	N	I-Premise
178	improvements	N	I-Premise
179	on	N	I-Premise
180	symptoms	N	I-Premise
181	of	N	I-Premise
182	depression	N	I-Premise
183	(	N	I-Premise
184	p	N	I-Premise
185	<	N	I-Premise
186	0.05	N	I-Premise
187	)	N	I-Premise
188	and	N	I-Premise
189	anxiety	N	I-Premise
190	(	N	I-Premise
191	p	N	I-Premise
192	<	N	I-Premise
193	0.05	N	I-Premise
194	)	N	I-Premise
195	,	N	I-Premise
196	health-related	N	I-Premise
197	QOL	N	I-Premise
198	(	N	I-Premise
199	p	N	I-Premise
200	<	N	I-Premise
201	0.05	N	I-Premise
202	)	N	I-Premise
203	(	N	I-Premise
204	i.e	N	I-Premise
205	.	N	I-Premise

206	better	N	I-Premise
207	global	N	I-Premise
208	health	N	I-Premise
209	status	N	I-Premise
210	,	N	I-Premise
211	and	N	I-Premise
212	physical	N	I-Premise
213	and	N	I-Premise
214	emotional	N	I-Premise
215	functioning	N	I-Premise
216	,	N	I-Premise
217	and	N	I-Premise
218	less	N	I-Premise
219	insomnia	N	I-Premise
220	)	N	I-Premise
221	when	N	I-Premise
222	compared	N	I-Premise
223	with	N	I-Premise
224	controls	N	I-Premise
225	.	N	I-Premise

226	In	N	I-Claim
227	the	N	I-Claim
228	subset	N	I-Claim
229	analysis	N	I-Claim
230	,	N	I-Claim
231	female	N	I-Claim
232	patients	N	I-Claim
233	,	N	I-Claim
234	those	N	I-Claim
235	that	N	I-Claim
236	received	N	I-Claim
237	high	N	I-Claim
238	dose	N	I-Claim
239	irradiation	N	I-Claim
240	,	N	I-Claim
241	and	N	I-Claim
242	those	N	I-Claim
243	that	N	I-Claim
244	underwent	N	I-Claim
245	adjuvant	N	I-Claim
246	chemotherapy	N	I-Claim
247	could	N	I-Claim
248	benefit	N	I-Claim
249	more	N	I-Claim
250	from	N	I-Claim
251	psychosocial	N	I-Claim
252	intervention	N	I-Claim
253	.	N	I-Claim

254	There	N	I-Premise
255	was	N	I-Premise
256	no	N	I-Premise
257	difference	N	I-Premise
258	between	N	I-Premise
259	the	N	I-Premise
260	two	N	I-Premise
261	groups	N	I-Premise
262	in	N	I-Premise
263	disease-free	N	I-Premise
264	survival	N	I-Premise
265	(	N	I-Premise
266	DFS	N	I-Premise
267	)	N	I-Premise
268	(	N	I-Premise
269	2-year	N	I-Premise
270	DFS	N	I-Premise
271	79.8	N	I-Premise
272	%	N	I-Premise
273	in	N	I-Premise
274	the	N	I-Premise
275	intervention	N	I-Premise
276	arm	N	I-Premise
277	and	N	I-Premise
278	76.4	N	I-Premise
279	%	N	I-Premise
280	in	N	I-Premise
281	the	N	I-Premise
282	control	N	I-Premise
283	arm	N	I-Premise
284	;	N	I-Premise
285	p	N	I-Premise
286	=	N	I-Premise
287	0.527	N	I-Premise
288	)	N	I-Premise
289	and	N	I-Premise
290	overall	N	I-Premise
291	survival	N	I-Premise
292	(	N	I-Premise
293	OS	N	I-Premise
294	)	N	I-Premise
295	(	N	I-Premise
296	2-year	N	I-Premise
297	OS	N	I-Premise
298	83.1	N	I-Premise
299	%	N	I-Premise
300	in	N	I-Premise
301	the	N	I-Premise
302	intervention	N	I-Premise
303	arm	N	I-Premise
304	and	N	I-Premise
305	84.3	N	I-Premise
306	%	N	I-Premise
307	in	N	I-Premise
308	the	N	I-Premise
309	control	N	I-Premise
310	arm	N	I-Premise
311	;	N	I-Premise
312	p	N	I-Premise
313	=	N	I-Premise
314	0.925	N	I-Premise
315	)	N	I-Premise
316	.	N	I-Premise

317	Psychosocial	N	I-Claim
318	intervention	N	I-Claim
319	is	N	I-Claim
320	a	N	I-Claim
321	cost-effective	N	I-Claim
322	approach	N	I-Claim
323	that	N	I-Claim
324	can	N	I-Claim
325	improve	N	I-Claim
326	a	N	I-Claim
327	patient	N	I-Claim
328	's	N	I-Claim
329	mood	N	I-Claim
330	and	N	I-Claim
331	QOL	N	I-Claim
332	both	N	I-Claim
333	during	N	I-Claim
334	and	N	I-Claim
335	after	N	I-Claim
336	RT	N	I-Claim
337	.	N	I-Claim

338	However	N	I-Claim
339	,	N	I-Claim
340	the	N	I-Claim
341	intervention	N	I-Claim
342	was	N	I-Claim
343	not	N	I-Claim
344	found	N	I-Claim
345	to	N	I-Claim
346	reduce	N	I-Claim
347	the	N	I-Claim
348	risk	N	I-Claim
349	of	N	I-Claim
350	cancer	N	I-Claim
351	recurrence	N	I-Claim
352	and	N	I-Claim
353	death	N	I-Claim
354	.	N	I-Claim

1	It	N	O
2	is	N	O
3	well	N	O
4	documented	N	O
5	that	N	O
6	stress	N	O
7	is	N	O
8	associated	N	O
9	with	N	O
10	negative	N	O
11	health	N	O
12	outcomes	N	O
13	in	N	O
14	cancer	N	O
15	patients	N	O
16	.	N	O

17	The	N	O
18	purpose	N	O
19	of	N	O
20	this	N	O
21	study	N	O
22	was	N	O
23	to	N	O
24	assess	N	O
25	the	N	O
26	effects	N	O
27	of	N	O
28	a	N	O
29	novel	N	O
30	mindfulness	N	O
31	intervention	N	O
32	called	N	O
33	mindfulness-based	N	O
34	art	N	O
35	therapy	N	O
36	(	N	O
37	MBAT	N	O
38	)	N	O
39	versus	N	O
40	standard	N	O
41	educational	N	O
42	support	N	O
43	,	N	O
44	on	N	O
45	indices	N	O
46	of	N	O
47	stress	N	O
48	and	N	O
49	quality	N	O
50	of	N	O
51	life	N	O
52	in	N	O
53	breast	N	O
54	cancer	N	O
55	patients	N	O
56	with	N	O
57	high	N	O
58	stress	N	O
59	levels	N	O
60	.	N	O

61	A	N	O
62	total	N	O
63	of	N	O
64	191	N	O
65	women	N	O
66	were	N	O
67	enrolled	N	O
68	,	N	O
69	stratified	N	O
70	by	N	O
71	age	N	O
72	and	N	O
73	stress	N	O
74	level	N	O
75	,	N	O
76	and	N	O
77	randomized	N	O
78	to	N	O
79	receive	N	O
80	either	N	O
81	an	N	O
82	8-week	N	O
83	MBAT	N	O
84	intervention	N	O
85	or	N	O
86	a	N	O
87	breast	N	O
88	cancer	N	O
89	educational	N	O
90	support	N	O
91	program	N	O
92	of	N	O
93	equal	N	O
94	time	N	O
95	and	N	O
96	duration	N	O
97	.	N	O

98	Psychosocial	N	O
99	stress	N	O
100	was	N	O
101	measured	N	O
102	using	N	O
103	the	N	O
104	Symptoms	N	O
105	Checklist-90-Revised	N	O
106	,	N	O
107	and	N	O
108	quality	N	O
109	of	N	O
110	life	N	O
111	was	N	O
112	measured	N	O
113	using	N	O
114	the	N	O
115	Medical	N	O
116	Outcomes	N	O
117	Study	N	O
118	Short-Form	N	O
119	Health	N	O
120	Survey	N	O
121	at	N	O
122	baseline	N	O
123	,	N	O
124	immediately	N	O
125	post-intervention	N	O
126	,	N	O
127	and	N	O
128	at	N	O
129	6	N	O
130	months	N	O
131	.	N	O

132	Results	N	I-Premise
133	showed	N	I-Premise
134	overall	N	I-Premise
135	significant	N	I-Premise
136	improvements	N	I-Premise
137	in	N	I-Premise
138	psychosocial	N	I-Premise
139	stress	N	I-Premise
140	and	N	I-Premise
141	quality	N	I-Premise
142	of	N	I-Premise
143	life	N	I-Premise
144	in	N	I-Premise
145	both	N	I-Premise
146	the	N	I-Premise
147	MBAT	N	I-Premise
148	and	N	I-Premise
149	educational	N	I-Premise
150	support	N	I-Premise
151	groups	N	I-Premise
152	immediately	N	I-Premise
153	post-intervention	N	I-Premise
154	;	N	I-Premise
155	however	N	I-Premise
156	,	N	I-Premise
157	participants	N	I-Premise
158	with	N	I-Premise
159	high	N	I-Premise
160	stress	N	I-Premise
161	levels	N	I-Premise
162	at	N	I-Premise
163	baseline	N	I-Premise
164	had	N	I-Premise
165	significantly	N	I-Premise
166	improved	N	I-Premise
167	overall	N	I-Premise
168	outcomes	N	I-Premise
169	only	N	I-Premise
170	in	N	I-Premise
171	the	N	I-Premise
172	MBAT	N	I-Premise
173	group	N	I-Premise
174	,	N	I-Premise
175	both	N	I-Premise
176	immediately	N	I-Premise
177	post-intervention	N	I-Premise
178	and	N	I-Premise
179	at	N	I-Premise
180	6	N	I-Premise
181	months	N	I-Premise
182	.	N	I-Premise

183	In	N	O
184	addition	N	O
185	,	N	O
186	at	N	I-Premise
187	6	N	I-Premise
188	months	N	I-Premise
189	follow-up	N	I-Premise
190	,	N	I-Premise
191	participants	N	I-Premise
192	attending	N	I-Premise
193	five	N	I-Premise
194	or	N	I-Premise
195	more	N	I-Premise
196	sessions	N	I-Premise
197	trended	N	I-Premise
198	toward	N	I-Premise
199	retaining	N	I-Premise
200	treatment	N	I-Premise
201	effects	N	I-Premise
202	better	N	I-Premise
203	in	N	I-Premise
204	the	N	I-Premise
205	MBAT	N	I-Premise
206	than	N	I-Premise
207	in	N	I-Premise
208	the	N	I-Premise
209	control	N	I-Premise
210	group	N	I-Premise
211	.	N	I-Premise

212	Finally	N	O
213	,	N	O
214	black	N	I-Premise
215	women	N	I-Premise
216	and	N	I-Premise
217	white	N	I-Premise
218	women	N	I-Premise
219	were	N	I-Premise
220	similar	N	I-Premise
221	in	N	I-Premise
222	terms	N	I-Premise
223	of	N	I-Premise
224	how	N	I-Premise
225	they	N	I-Premise
226	benefited	N	I-Premise
227	from	N	I-Premise
228	the	N	I-Premise
229	MBAT	N	I-Premise
230	intervention	N	I-Premise
231	,	N	I-Premise
232	even	N	I-Premise
233	though	N	I-Premise
234	white	N	I-Premise
235	participants	N	I-Premise
236	tended	N	I-Premise
237	to	N	I-Premise
238	have	N	I-Premise
239	higher	N	I-Premise
240	educational	N	I-Premise
241	level	N	I-Premise
242	and	N	I-Premise
243	marital	N	I-Premise
244	status	N	I-Premise
245	.	N	I-Premise

246	In	N	I-Claim
247	conclusion	N	I-Claim
248	,	N	I-Claim
249	MBAT	N	I-Claim
250	is	N	I-Claim
251	associated	N	I-Claim
252	with	N	I-Claim
253	significant	N	I-Claim
254	,	N	I-Claim
255	sustained	N	I-Claim
256	benefits	N	I-Claim
257	across	N	I-Claim
258	a	N	I-Claim
259	diverse	N	I-Claim
260	range	N	I-Claim
261	of	N	I-Claim
262	breast	N	I-Claim
263	cancer	N	I-Claim
264	patients	N	I-Claim
265	,	N	I-Claim
266	particularly	N	I-Claim
267	those	N	I-Claim
268	with	N	I-Claim
269	high	N	I-Claim
270	stress	N	I-Claim
271	levels	N	I-Claim
272	.	N	I-Claim

1	The	N	O
2	current	N	O
3	study	N	O
4	examined	N	O
5	the	N	O
6	effect	N	O
7	of	N	O
8	recombinant	N	O
9	human	N	O
10	deoxyribonuclease	N	O
11	(	N	O
12	rhDNase	N	O
13	)	N	O
14	on	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QOL	N	O
20	)	N	O
21	measures	N	O
22	,	N	O
23	clinical	N	O
24	improvement	N	O
25	,	N	O
26	and	N	O
27	DNA	N	O
28	content	N	O
29	of	N	O
30	thick	N	O
31	oropharyngeal	N	O
32	secretions	N	O
33	(	N	O
34	OPS	N	O
35	)	N	O
36	in	N	O
37	patients	N	O
38	with	N	O
39	head-and-neck	N	O
40	(	N	O
41	H	N	O
42	&	N	O
43	N	N	O
44	)	N	O
45	cancers	N	O
46	.	N	O

47	Thirty-six	N	O
48	patients	N	O
49	with	N	O
50	local-regional	N	O
51	advanced	N	O
52	H	N	O
53	&	N	O
54	amp	N	O
55	;	N	O
56	N	N	O
57	cancer	N	O
58	receiving	N	O
59	chemoradiationtherapy	N	O
60	(	N	O
61	CRT	N	O
62	)	N	O
63	were	N	O
64	randomized	N	O
65	to	N	O
66	receive	N	O
67	either	N	O
68	placebo	N	O
69	or	N	O
70	rhDNase	N	O
71	.	N	O

72	Endpoints	N	O
73	included	N	O
74	MD	N	O
75	Anderson	N	O
76	Symptom	N	O
77	Inventory-Head	N	O
78	and	N	O
79	Neck	N	O
80	(	N	O
81	MDASI-HN	N	O
82	)	N	O
83	and	N	O
84	Functional	N	O
85	Assessment	N	O
86	of	N	O
87	Cancer	N	O
88	Therapy-Head	N	O
89	and	N	O
90	Neck	N	O
91	(	N	O
92	FACT-NH	N	O
93	)	N	O
94	scores	N	O
95	,	N	O
96	along	N	O
97	with	N	O
98	clinical	N	O
99	assessment	N	O
100	and	N	O
101	DNA	N	O
102	concentration	N	O
103	of	N	O
104	OPS	N	O
105	.	N	O

106	There	N	I-Premise
107	were	N	I-Premise
108	no	N	I-Premise
109	statistically	N	I-Premise
110	significant	N	I-Premise
111	differences	N	I-Premise
112	in	N	I-Premise
113	patients	N	I-Premise
114	'	N	I-Premise
115	QOL	N	I-Premise
116	outcomes	N	I-Premise
117	over	N	I-Premise
118	the	N	I-Premise
119	study	N	I-Premise
120	period	N	I-Premise
121	.	N	I-Premise

122	Both	N	I-Premise
123	groups	N	I-Premise
124	showed	N	I-Premise
125	an	N	I-Premise
126	increase	N	I-Premise
127	in	N	I-Premise
128	symptom	N	I-Premise
129	and	N	I-Premise
130	interference	N	I-Premise
131	scores	N	I-Premise
132	,	N	I-Premise
133	although	N	O
134	patients	N	I-Premise
135	in	N	I-Premise
136	the	N	I-Premise
137	rhDNase	N	I-Premise
138	group	N	I-Premise
139	showed	N	I-Premise
140	a	N	I-Premise
141	greater	N	I-Premise
142	decline	N	I-Premise
143	in	N	I-Premise
144	both	N	I-Premise
145	scores	N	I-Premise
146	during	N	I-Premise
147	the	N	I-Premise
148	3	N	I-Premise
149	months	N	I-Premise
150	posttreatment	N	I-Premise
151	.	N	I-Premise

152	Similarly	N	I-Premise
153	,	N	I-Premise
154	both	N	I-Premise
155	groups	N	I-Premise
156	showed	N	I-Premise
157	a	N	I-Premise
158	decline	N	I-Premise
159	in	N	I-Premise
160	physical	N	I-Premise
161	and	N	I-Premise
162	functional	N	I-Premise
163	well	N	I-Premise
164	being	N	I-Premise
165	but	N	I-Premise
166	recovered	N	I-Premise
167	in	N	I-Premise
168	the	N	I-Premise
169	3	N	I-Premise
170	months	N	I-Premise
171	posttreatment	N	I-Premise
172	follow-up	N	I-Premise
173	,	N	I-Premise
174	with	N	I-Premise
175	the	N	I-Premise
176	rhDNase	N	I-Premise
177	group	N	I-Premise
178	exhibiting	N	I-Premise
179	speedier	N	I-Premise
180	recovery	N	I-Premise
181	.	N	I-Premise

182	Patients	N	I-Premise
183	in	N	I-Premise
184	the	N	I-Premise
185	rhDNase	N	I-Premise
186	group	N	I-Premise
187	exhibited	N	I-Premise
188	significant	N	I-Premise
189	clinical	N	I-Premise
190	improvement	N	I-Premise
191	in	N	I-Premise
192	OPS	N	I-Premise
193	,	N	I-Premise
194	blindly	N	I-Premise
195	assessed	N	I-Premise
196	by	N	I-Premise
197	a	N	I-Premise
198	physician	N	I-Premise
199	,	N	I-Premise
200	compared	N	I-Premise
201	with	N	I-Premise
202	the	N	I-Premise
203	placebo	N	I-Premise
204	group	N	I-Premise
205	(	N	I-Premise
206	67	N	I-Premise
207	%	N	I-Premise
208	vs	N	I-Premise
209	27	N	I-Premise
210	%	N	I-Premise
211	,	N	I-Premise
212	respectively	N	I-Premise
213	;	N	I-Premise
214	P=.046	N	I-Premise
215	)	N	I-Premise
216	.	N	I-Premise

217	The	N	I-Premise
218	rhDNase	N	I-Premise
219	group	N	I-Premise
220	showed	N	I-Premise
221	no	N	I-Premise
222	change	N	I-Premise
223	in	N	I-Premise
224	OPS-DNA	N	I-Premise
225	concentration	N	I-Premise
226	,	N	I-Premise
227	although	N	O
228	the	N	I-Premise
229	placebo	N	I-Premise
230	group	N	I-Premise
231	showed	N	I-Premise
232	a	N	I-Premise
233	significant	N	I-Premise
234	increase	N	I-Premise
235	in	N	I-Premise
236	DNA	N	I-Premise
237	concentration	N	I-Premise
238	during	N	I-Premise
239	the	N	I-Premise
240	drug	N	I-Premise
241	trial	N	I-Premise
242	(	N	I-Premise
243	P=.045	N	I-Premise
244	)	N	I-Premise
245	.	N	I-Premise

246	There	N	I-Claim
247	was	N	I-Claim
248	no	N	I-Claim
249	differences	N	I-Claim
250	in	N	I-Claim
251	acute	N	I-Claim
252	toxicities	N	I-Claim
253	between	N	I-Claim
254	the	N	I-Claim
255	2	N	I-Claim
256	groups	N	I-Claim
257	.	N	I-Claim

258	Our	N	I-Claim
259	preliminary	N	I-Claim
260	data	N	I-Claim
261	suggest	N	I-Claim
262	that	N	I-Claim
263	rhDNase	N	I-Claim
264	did	N	I-Claim
265	not	N	I-Claim
266	significantly	N	I-Claim
267	improve	N	I-Claim
268	study	N	I-Claim
269	primary	N	I-Claim
270	endpoints	N	I-Claim
271	of	N	I-Claim
272	QOL	N	I-Claim
273	measures	N	I-Claim
274	compared	N	I-Claim
275	with	N	I-Claim
276	the	N	I-Claim
277	placebo	N	I-Claim
278	group	N	I-Claim
279	.	N	I-Claim

280	However	N	O
281	,	N	O
282	there	N	I-Claim
283	was	N	I-Claim
284	a	N	I-Claim
285	significant	N	I-Claim
286	improvement	N	I-Claim
287	in	N	I-Claim
288	secondary	N	I-Claim
289	endpoints	N	I-Claim
290	of	N	I-Claim
291	clinically	N	I-Claim
292	assessed	N	I-Claim
293	OPS	N	I-Claim
294	and	N	I-Claim
295	DNA	N	I-Claim
296	concentration	N	I-Claim
297	compared	N	I-Claim
298	with	N	I-Claim
299	placebo	N	I-Claim
300	in	N	I-Claim
301	H	N	I-Claim
302	&	N	I-Claim
303	N	N	I-Claim
304	cancer	N	I-Claim
305	patients	N	I-Claim
306	treated	N	I-Claim
307	with	N	I-Claim
308	CRT	N	I-Claim
309	.	N	I-Claim

310	Further	N	O
311	investigation	N	O
312	in	N	O
313	larger	N	O
314	numbers	N	O
315	of	N	O
316	patients	N	O
317	is	N	O
318	warranted	N	O
319	.	N	O

1	Due	N	O
2	to	N	O
3	concerns	N	O
4	of	N	O
5	fragility	N	O
6	fracture	N	O
7	,	N	O
8	exercise	N	O
9	is	N	O
10	a	N	O
11	perceived	N	O
12	contraindication	N	O
13	for	N	O
14	prostate	N	O
15	cancer	N	O
16	patients	N	O
17	with	N	O
18	bone	N	O
19	metastases	N	O
20	.	N	O

21	These	N	O
22	patients	N	O
23	experience	N	O
24	significant	N	O
25	functional	N	O
26	impairment	N	O
27	and	N	O
28	muscle	N	O
29	atrophy	N	O
30	,	N	O
31	which	N	O
32	may	N	O
33	lead	N	O
34	to	N	O
35	an	N	O
36	increased	N	O
37	likelihood	N	O
38	of	N	O
39	skeletal	N	O
40	complicaTIOns	N	O
41	(	N	O
42	i.e.	N	O
43	,	N	O
44	pathological	N	O
45	fracture	N	O
46	,	N	O
47	bone	N	O
48	pain	N	O
49	)	N	O
50	and/or	N	O
51	falls	N	O
52	.	N	O

53	Safe	N	O
54	resistance	N	O
55	exercise	N	O
56	prescription	N	O
57	may	N	O
58	counteract	N	O
59	this	N	O
60	effect	N	O
61	.	N	O

62	The	N	O
63	aim	N	O
64	of	N	O
65	this	N	O
66	feasibility	N	O
67	trial	N	O
68	was	N	O
69	to	N	O
70	determine	N	O
71	the	N	O
72	safety	N	O
73	and	N	O
74	efficacy	N	O
75	of	N	O
76	resistance	N	O
77	exercise	N	O
78	by	N	O
79	prostate	N	O
80	cancer	N	O
81	survivors	N	O
82	with	N	O
83	bone	N	O
84	metastatic	N	O
85	disease	N	O
86	.	N	O

87	Twenty	N	O
88	men	N	O
89	with	N	O
90	established	N	O
91	bone	N	O
92	metastases	N	O
93	secondary	N	O
94	to	N	O
95	prostate	N	O
96	cancer	N	O
97	were	N	O
98	randomly	N	O
99	assigned	N	O
100	to	N	O
101	a	N	O
102	12-week	N	O
103	resistance	N	O
104	exercise	N	O
105	program	N	O
106	in	N	O
107	which	N	O
108	exercise	N	O
109	prescription	N	O
110	was	N	O
111	based	N	O
112	on	N	O
113	the	N	O
114	location	N	O
115	of	N	O
116	bone	N	O
117	lesions	N	O
118	(	N	O
119	n=10	N	O
120	)	N	O
121	or	N	O
122	usual	N	O
123	care	N	O
124	(	N	O
125	n=10	N	O
126	)	N	O
127	.	N	O

128	Outcomes	N	O
129	included	N	O
130	safety	N	O
131	and	N	O
132	tolerance	N	O
133	of	N	O
134	the	N	O
135	exercise	N	O
136	program	N	O
137	,	N	O
138	physical	N	O
139	function	N	O
140	,	N	O
141	physical	N	O
142	activity	N	O
143	level	N	O
144	,	N	O
145	body	N	O
146	composition	N	O
147	,	N	O
148	fatigue	N	O
149	,	N	O
150	quality	N	O
151	of	N	O
152	life	N	O
153	and	N	O
154	psychological	N	O
155	distress	N	O
156	.	N	O

157	Outcomes	N	O
158	were	N	O
159	compared	N	O
160	between	N	O
161	groups	N	O
162	using	N	O
163	analysis	N	O
164	of	N	O
165	covariance	N	O
166	adjusted	N	O
167	for	N	O
168	baseline	N	O
169	values	N	O
170	.	N	O

171	Participants	N	O
172	had	N	O
173	significant	N	O
174	disease	N	O
175	load	N	O
176	with	N	O
177	65	N	O
178	%	N	O
179	of	N	O
180	participants	N	O
181	presenting	N	O
182	with	N	O
183	two	N	O
184	or	N	O
185	more	N	O
186	regions	N	O
187	affected	N	O
188	by	N	O
189	bone	N	O
190	metastases	N	O
191	and	N	O
192	an	N	O
193	average	N	O
194	Gleason	N	O
195	score	N	O
196	of	N	O
197	8.20.9	N	O
198	.	N	O

199	Five	N	O
200	participants	N	O
201	(	N	O
202	exercise=2	N	O
203	;	N	O
204	usual	N	O
205	care=3	N	O
206	)	N	O
207	did	N	O
208	not	N	O
209	complete	N	O
210	the	N	O
211	intervention	N	O
212	,	N	O
213	three	N	O
214	of	N	O
215	which	N	O
216	were	N	O
217	due	N	O
218	to	N	O
219	advancing	N	O
220	disease	N	O
221	(	N	O
222	exercise=2	N	O
223	;	N	O
224	usual	N	O
225	care=1	N	O
226	)	N	O
227	.	N	O

228	No	N	I-Premise
229	adverse	N	I-Premise
230	events	N	I-Premise
231	or	N	I-Premise
232	skeletal	N	I-Premise
233	complications	N	I-Premise
234	occurred	N	I-Premise
235	during	N	I-Premise
236	the	N	I-Premise
237	supervised	N	I-Premise
238	exercise	N	I-Premise
239	sessions	N	I-Premise
240	.	N	I-Premise

241	The	N	I-Premise
242	exercise	N	I-Premise
243	program	N	I-Premise
244	was	N	I-Premise
245	well	N	I-Premise
246	tolerated	N	I-Premise
247	as	N	I-Premise
248	evidenced	N	I-Premise
249	by	N	I-Premise
250	high	N	I-Premise
251	attendance	N	I-Premise
252	(	N	I-Premise
253	83	N	I-Premise
254	%	N	I-Premise
255	)	N	I-Premise
256	and	N	I-Premise
257	compliance	N	I-Premise
258	rates	N	I-Premise
259	(	N	I-Premise
260	93	N	I-Premise
261	%	N	I-Premise
262	)	N	I-Premise
263	,	N	I-Premise
264	and	N	I-Premise
265	the	N	I-Premise
266	ability	N	I-Premise
267	of	N	I-Premise
268	the	N	I-Premise
269	participants	N	I-Premise
270	to	N	I-Premise
271	exercise	N	I-Premise
272	at	N	I-Premise
273	an	N	I-Premise
274	intensity	N	I-Premise
275	within	N	I-Premise
276	the	N	I-Premise
277	target	N	I-Premise
278	range	N	I-Premise
279	for	N	I-Premise
280	cancer	N	I-Premise
281	survivors	N	I-Premise
282	(	N	I-Premise
283	rating	N	I-Premise
284	of	N	I-Premise
285	perceived	N	I-Premise
286	exertion	N	I-Premise
287	=13.81.5	N	I-Premise
288	)	N	I-Premise
289	.	N	I-Premise

290	The	N	I-Premise
291	change	N	I-Premise
292	in	N	I-Premise
293	physical	N	I-Premise
294	function	N	I-Premise
295	(	N	I-Premise
296	muscle	N	I-Premise
297	strength	N	I-Premise
298	11	N	I-Premise
299	%	N	I-Premise
300	;	N	I-Premise
301	submaximal	N	I-Premise
302	aerobic	N	I-Premise
303	exercise	N	I-Premise
304	capacity	N	I-Premise
305	5	N	I-Premise
306	%	N	I-Premise
307	and	N	I-Premise
308	ambulation	N	I-Premise
309	12	N	I-Premise
310	%	N	I-Premise
311	)	N	I-Premise
312	,	N	I-Premise
313	physical	N	I-Premise
314	activity	N	I-Premise
315	level	N	I-Premise
316	(	N	I-Premise
317	24	N	I-Premise
318	%	N	I-Premise
319	)	N	I-Premise
320	and	N	I-Premise
321	lean	N	I-Premise
322	mass	N	I-Premise
323	(	N	I-Premise
324	3	N	I-Premise
325	%	N	I-Premise
326	)	N	I-Premise
327	differed	N	I-Premise
328	significantly	N	I-Premise
329	between	N	I-Premise
330	groups	N	I-Premise
331	following	N	I-Premise
332	the	N	I-Premise
333	intervention	N	I-Premise
334	,	N	I-Premise
335	with	N	I-Premise
336	favorable	N	I-Premise
337	changes	N	I-Premise
338	in	N	I-Premise
339	the	N	I-Premise
340	exercise	N	I-Premise
341	group	N	I-Premise
342	compared	N	I-Premise
343	with	N	I-Premise
344	the	N	I-Premise
345	usual	N	I-Premise
346	care	N	I-Premise
347	group	N	I-Premise
348	.	N	I-Premise

349	No	N	I-Premise
350	significant	N	I-Premise
351	between-group	N	I-Premise
352	differences	N	I-Premise
353	were	N	I-Premise
354	observed	N	I-Premise
355	for	N	I-Premise
356	fatigue	N	I-Premise
357	,	N	I-Premise
358	quality	N	I-Premise
359	of	N	I-Premise
360	life	N	I-Premise
361	or	N	I-Premise
362	psychological	N	I-Premise
363	distress	N	I-Premise
364	.	N	I-Premise

365	This	N	I-Claim
366	initial	N	I-Claim
367	evidence	N	I-Claim
368	involving	N	I-Claim
369	a	N	I-Claim
370	small	N	I-Claim
371	sample	N	I-Claim
372	size	N	I-Claim
373	suggests	N	I-Claim
374	that	N	I-Claim
375	appropriately	N	I-Claim
376	designed	N	I-Claim
377	and	N	I-Claim
378	supervised	N	I-Claim
379	resistance	N	I-Claim
380	exercise	N	I-Claim
381	may	N	I-Claim
382	be	N	I-Claim
383	safe	N	I-Claim
384	and	N	I-Claim
385	well	N	I-Claim
386	tolerated	N	I-Claim
387	by	N	I-Claim
388	prostate	N	I-Claim
389	cancer	N	I-Claim
390	patients	N	I-Claim
391	with	N	I-Claim
392	bone	N	I-Claim
393	metastatic	N	I-Claim
394	disease	N	I-Claim
395	and	N	I-Claim
396	can	N	I-Claim
397	lead	N	I-Claim
398	to	N	I-Claim
399	improvements	N	I-Claim
400	in	N	I-Claim
401	physical	N	I-Claim
402	function	N	I-Claim
403	,	N	I-Claim
404	physical	N	I-Claim
405	activity	N	I-Claim
406	levels	N	I-Claim
407	and	N	I-Claim
408	lean	N	I-Claim
409	mass	N	I-Claim
410	.	N	I-Claim

411	Future	N	I-Claim
412	trials	N	I-Claim
413	involving	N	I-Claim
414	larger	N	I-Claim
415	sample	N	I-Claim
416	sizes	N	I-Claim
417	are	N	I-Claim
418	required	N	I-Claim
419	to	N	I-Claim
420	expand	N	I-Claim
421	these	N	I-Claim
422	preliminary	N	I-Claim
423	findings	N	I-Claim
424	.	N	I-Claim

1	Gefitinib	N	O
2	and	N	O
3	Pemetrexed	N	O
4	are	N	O
5	drugs	N	O
6	used	N	O
7	as	N	O
8	second-line	N	O
9	therapy	N	O
10	for	N	O
11	advanced	N	O
12	non-small	N	O
13	cell	N	O
14	lung	N	O
15	cancer	N	O
16	(	N	O
17	NSCLC	N	O
18	)	N	O
19	,	N	O
20	although	N	O
21	studies	N	O
22	comparing	N	O
23	the	N	O
24	two	N	O
25	drugs	N	O
26	are	N	O
27	limited	N	O
28	.	N	O

29	The	N	O
30	aim	N	O
31	of	N	O
32	this	N	O
33	study	N	O
34	is	N	O
35	to	N	O
36	explore	N	O
37	the	N	O
38	effects	N	O
39	,	N	O
40	safety	N	O
41	,	N	O
42	and	N	O
43	quality	N	O
44	of	N	O
45	life	N	O
46	(	N	O
47	QoL	N	O
48	)	N	O
49	of	N	O
50	Gefitinib	N	O
51	and	N	O
52	Pemetrexed	N	O
53	on	N	O
54	patients	N	O
55	with	N	O
56	advanced	N	O
57	non-squamous	N	O
58	NSCLC	N	O
59	.	N	O

60	Forty-six	N	O
61	advanced	N	O
62	non-squamous	N	O
63	NSCLC	N	O
64	patients	N	O
65	who	N	O
66	failed	N	O
67	to	N	O
68	first-line	N	O
69	therapy	N	O
70	were	N	O
71	randomly	N	O
72	divided	N	O
73	into	N	O
74	two	N	O
75	groups	N	O
76	with	N	O
77	23	N	O
78	patients	N	O
79	each	N	O
80	,	N	O
81	one	N	O
82	using	N	O
83	oral	N	O
84	Gefitinib	N	O
85	(	N	O
86	Gefitinib	N	O
87	group	N	O
88	)	N	O
89	and	N	O
90	the	N	O
91	other	N	O
92	using	N	O
93	intravenous	N	O
94	injection	N	O
95	Pemetrexed	N	O
96	(	N	O
97	Pemetrexed	N	O
98	group	N	O
99	)	N	O
100	.	N	O

101	The	N	O
102	effects	N	O
103	,	N	O
104	safety	N	O
105	,	N	O
106	and	N	O
107	QoL	N	O
108	were	N	O
109	determined	N	O
110	and	N	O
111	analyzed	N	O
112	.	N	O

113	For	N	I-Premise
114	the	N	I-Premise
115	Pemetrexed	N	I-Premise
116	group	N	I-Premise
117	,	N	I-Premise
118	objective	N	I-Premise
119	response	N	I-Premise
120	rate	N	I-Premise
121	(	N	I-Premise
122	ORR	N	I-Premise
123	)	N	I-Premise
124	was	N	I-Premise
125	13.0	N	I-Premise
126	%	N	I-Premise
127	(	N	I-Premise
128	3/23	N	I-Premise
129	)	N	I-Premise
130	,	N	I-Premise
131	disease	N	I-Premise
132	control	N	I-Premise
133	rate	N	I-Premise
134	(	N	I-Premise
135	DCR	N	I-Premise
136	)	N	I-Premise
137	was	N	I-Premise
138	30.4	N	I-Premise
139	%	N	I-Premise
140	(	N	I-Premise
141	7/23	N	I-Premise
142	)	N	I-Premise
143	,	N	I-Premise
144	and	N	I-Premise
145	median	N	I-Premise
146	progression-free	N	I-Premise
147	survival	N	I-Premise
148	(	N	I-Premise
149	mPFS	N	I-Premise
150	)	N	I-Premise
151	was	N	I-Premise
152	3.1	N	I-Premise
153	months	N	I-Premise
154	.	N	I-Premise

155	In	N	I-Premise
156	the	N	I-Premise
157	Gefitinib	N	I-Premise
158	group	N	I-Premise
159	,	N	I-Premise
160	ORR	N	I-Premise
161	was	N	I-Premise
162	17.3	N	I-Premise
163	%	N	I-Premise
164	(	N	I-Premise
165	4/23	N	I-Premise
166	)	N	I-Premise
167	,	N	I-Premise
168	DCR	N	I-Premise
169	was	N	I-Premise
170	39.1	N	I-Premise
171	%	N	I-Premise
172	(	N	I-Premise
173	9/23	N	I-Premise
174	)	N	I-Premise
175	,	N	I-Premise
176	and	N	I-Premise
177	mPFS	N	I-Premise
178	was	N	I-Premise
179	4.4	N	I-Premise
180	months	N	I-Premise
181	.	N	I-Premise

182	Compared	N	I-Premise
183	with	N	I-Premise
184	the	N	I-Premise
185	Pemetrexed	N	I-Premise
186	group	N	I-Premise
187	,	N	I-Premise
188	the	N	I-Premise
189	ORR	N	I-Premise
190	,	N	I-Premise
191	DCR	N	I-Premise
192	,	N	I-Premise
193	and	N	I-Premise
194	mPFS	N	I-Premise
195	in	N	I-Premise
196	the	N	I-Premise
197	Gefitinib	N	I-Premise
198	group	N	I-Premise
199	exhibited	N	I-Premise
200	no	N	I-Premise
201	statistical	N	I-Premise
202	significance	N	I-Premise
203	(	N	I-Premise
204	P	N	I-Premise
205	>	N	I-Premise
206	0.05	N	I-Premise
207	)	N	I-Premise
208	.	N	I-Premise

209	Furthermore	N	O
210	,	N	O
211	the	N	I-Premise
212	most	N	I-Premise
213	common	N	I-Premise
214	toxicities	N	I-Premise
215	in	N	I-Premise
216	the	N	I-Premise
217	Pemetrexed	N	I-Premise
218	group	N	I-Premise
219	were	N	I-Premise
220	neutropenia	N	I-Premise
221	(	N	I-Premise
222	n=9	N	I-Premise
223	,	N	I-Premise
224	39.13	N	I-Premise
225	%	N	I-Premise
226	)	N	I-Premise
227	and	N	I-Premise
228	fatigue	N	I-Premise
229	(	N	I-Premise
230	n=8	N	I-Premise
231	,	N	I-Premise
232	34.78	N	I-Premise
233	%	N	I-Premise
234	)	N	I-Premise
235	,	N	I-Premise
236	whereas	N	I-Premise
237	those	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	in	N	I-Premise
241	Gefitinib	N	I-Premise
242	group	N	I-Premise
243	were	N	I-Premise
244	skin	N	I-Premise
245	rash	N	I-Premise
246	(	N	I-Premise
247	n=8	N	I-Premise
248	,	N	I-Premise
249	34.78	N	I-Premise
250	%	N	I-Premise
251	)	N	I-Premise
252	and	N	I-Premise
253	diarrhea	N	I-Premise
254	(	N	I-Premise
255	n=4	N	I-Premise
256	,	N	I-Premise
257	17.39	N	I-Premise
258	%	N	I-Premise
259	)	N	I-Premise
260	.	N	I-Premise

261	Compared	N	I-Premise
262	with	N	I-Premise
263	baseline	N	I-Premise
264	,	N	I-Premise
265	the	N	I-Premise
266	QoL	N	I-Premise
267	improved	N	I-Premise
268	in	N	I-Premise
269	both	N	I-Premise
270	groups	N	I-Premise
271	but	N	I-Premise
272	to	N	I-Premise
273	different	N	I-Premise
274	degrees	N	I-Premise
275	.	N	I-Premise

276	Likewise	N	O
277	,	N	O
278	emotional	N	I-Premise
279	,	N	I-Premise
280	functional	N	I-Premise
281	well-being	N	I-Premise
282	,	N	I-Premise
283	and	N	I-Premise
284	QoL	N	I-Premise
285	aspects	N	I-Premise
286	specifically	N	I-Premise
287	related	N	I-Premise
288	to	N	I-Premise
289	lung	N	I-Premise
290	cancer	N	I-Premise
291	were	N	I-Premise
292	better	N	I-Premise
293	improved	N	I-Premise
294	in	N	I-Premise
295	the	N	I-Premise
296	Gefitinib	N	I-Premise
297	group	N	I-Premise
298	than	N	I-Premise
299	in	N	I-Premise
300	the	N	I-Premise
301	Pemetrexed	N	I-Premise
302	group	N	I-Premise
303	(	N	I-Premise
304	P	N	I-Premise
305	<	N	I-Premise
306	0.05	N	I-Premise
307	)	N	I-Premise
308	.	N	I-Premise

309	The	N	I-Claim
310	effects	N	I-Claim
311	of	N	I-Claim
312	Pemetrexed	N	I-Claim
313	and	N	I-Claim
314	Gefitinib	N	I-Claim
315	as	N	I-Claim
316	second	N	I-Claim
317	line	N	I-Claim
318	therapy	N	I-Claim
319	were	N	I-Claim
320	similar	N	I-Claim
321	,	N	I-Claim
322	although	N	I-Premise
323	with	N	I-Premise
324	different	N	I-Premise
325	AEs	N	I-Premise
326	.	N	I-Premise

327	Both	N	I-Claim
328	drugs	N	I-Claim
329	could	N	I-Claim
330	improve	N	I-Claim
331	the	N	I-Claim
332	QoL	N	I-Claim
333	,	N	I-Claim
334	but	N	O
335	Gefitinib	N	I-Claim
336	showed	N	I-Claim
337	better	N	I-Claim
338	overall	N	I-Claim
339	results	N	I-Claim
340	than	N	I-Claim
341	Pemetrexed	N	I-Claim
342	.	N	I-Claim

1	Everolimus	N	O
2	(	N	O
3	EVE	N	O
4	)	N	O
5	+exemestane	N	O
6	(	N	O
7	EXE	N	O
8	;	N	O
9	n	N	O
10	=	N	O
11	485	N	O
12	)	N	O
13	more	N	O
14	than	N	O
15	doubled	N	O
16	median	N	O
17	progression-free	N	O
18	survival	N	O
19	versus	N	O
20	placebo	N	O
21	(	N	O
22	PBO	N	O
23	)	N	O
24	+	N	O
25	EXE	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	239	N	O
30	)	N	O
31	,	N	O
32	with	N	O
33	a	N	O
34	manageable	N	O
35	safety	N	O
36	profile	N	O
37	and	N	O
38	no	N	O
39	deterioration	N	O
40	in	N	O
41	health-related	N	O
42	quality-of-life	N	O
43	(	N	O
44	HRQOL	N	O
45	)	N	O
46	in	N	O
47	patients	N	O
48	with	N	O
49	hormone-receptor-positive	N	O
50	(	N	O
51	HR	N	O
52	(	N	O
53	+	N	O
54	)	N	O
55	)	N	O
56	advanced	N	O
57	breast	N	O
58	cancer	N	O
59	(	N	O
60	ABC	N	O
61	)	N	O
62	who	N	O
63	recurred	N	O
64	or	N	O
65	progressed	N	O
66	on/after	N	O
67	nonsteroidal	N	O
68	aromatase	N	O
69	inhibitor	N	O
70	(	N	O
71	NSAI	N	O
72	)	N	O
73	therapy	N	O
74	.	N	O

75	To	N	O
76	further	N	O
77	evaluate	N	O
78	EVE	N	O
79	+	N	O
80	EXE	N	O
81	impact	N	O
82	on	N	O
83	disease	N	O
84	burden	N	O
85	,	N	O
86	we	N	O
87	conducted	N	O
88	additional	N	O
89	post-hoc	N	O
90	analyses	N	O
91	of	N	O
92	patient-reported	N	O
93	HRQOL	N	O
94	.	N	O

95	HRQOL	N	O
96	was	N	O
97	assessed	N	O
98	using	N	O
99	EORTC	N	O
100	QLQ-C30	N	O
101	and	N	O
102	QLQ-BR23	N	O
103	questionnaires	N	O
104	at	N	O
105	baseline	N	O
106	and	N	O
107	every	N	O
108	6	N	O
109	weeks	N	O
110	thereafter	N	O
111	until	N	O
112	treatment	N	O
113	discontinuation	N	O
114	because	N	O
115	of	N	O
116	disease	N	O
117	progression	N	O
118	,	N	O
119	toxicity	N	O
120	,	N	O
121	or	N	O
122	consent	N	O
123	withdrawal	N	O
124	.	N	O

125	Endpoints	N	O
126	included	N	O
127	the	N	O
128	QLQ-C30	N	O
129	Global	N	O
130	Health	N	O
131	Status	N	O
132	(	N	O
133	QL2	N	O
134	)	N	O
135	scale	N	O
136	,	N	O
137	the	N	O
138	QLQ-BR23	N	O
139	breast	N	O
140	symptom	N	O
141	(	N	O
142	BRBS	N	O
143	)	N	O
144	,	N	O
145	and	N	O
146	arm	N	O
147	symptom	N	O
148	(	N	O
149	BRAS	N	O
150	)	N	O
151	scales	N	O
152	.	N	O

153	Between-group	N	O
154	differences	N	O
155	in	N	O
156	change	N	O
157	from	N	O
158	baseline	N	O
159	were	N	O
160	assessed	N	O
161	using	N	O
162	linear	N	O
163	mixed	N	O
164	models	N	O
165	with	N	O
166	selected	N	O
167	covariates	N	O
168	.	N	O

169	Sensitivity	N	O
170	analysis	N	O
171	using	N	O
172	pattern-mixture	N	O
173	models	N	O
174	determined	N	O
175	the	N	O
176	effect	N	O
177	of	N	O
178	study	N	O
179	discontinuation	N	O
180	on/before	N	O
181	week	N	O
182	24	N	O
183	.	N	O

184	Treatment	N	O
185	arms	N	O
186	were	N	O
187	compared	N	O
188	using	N	O
189	differences	N	O
190	of	N	O
191	least	N	O
192	squares	N	O
193	mean	N	O
194	(	N	O
195	LSM	N	O
196	)	N	O
197	changes	N	O
198	from	N	O
199	baseline	N	O
200	and	N	O
201	95	N	O
202	%	N	O
203	confidence	N	O
204	intervals	N	O
205	(	N	O
206	CIs	N	O
207	)	N	O
208	at	N	O
209	each	N	O
210	timepoint	N	O
211	and	N	O
212	overall	N	O
213	.	N	O

214	Progression-free	N	O
215	survival	N	O
216	,	N	O
217	survival	N	O
218	,	N	O
219	response	N	O
220	rate	N	O
221	,	N	O
222	safety	N	O
223	,	N	O
224	and	N	O
225	HRQOL	N	O
226	.	N	O

227	Linear	N	I-Premise
228	mixed	N	I-Premise
229	models	N	I-Premise
230	(	N	I-Premise
231	primary	N	I-Premise
232	model	N	I-Premise
233	)	N	I-Premise
234	demonstrated	N	I-Premise
235	no	N	I-Premise
236	statistically	N	I-Premise
237	significant	N	I-Premise
238	overall	N	I-Premise
239	difference	N	I-Premise
240	between	N	I-Premise
241	EVE	N	I-Premise
242	+	N	I-Premise
243	EXE	N	I-Premise
244	and	N	I-Premise
245	PBO	N	I-Premise
246	+	N	I-Premise
247	EXE	N	I-Premise
248	for	N	I-Premise
249	QL2	N	I-Premise
250	(	N	I-Premise
251	LSM	N	I-Premise
252	difference	N	I-Premise
253	=	N	I-Premise
254	-1.91	N	I-Premise
255	;	N	I-Premise
256	95	N	I-Premise
257	%	N	I-Premise
258	CI	N	I-Premise
259	=	N	I-Premise
260	-4.61	N	I-Premise
261	,	N	I-Premise
262	0.78	N	I-Premise
263	)	N	I-Premise
264	,	N	I-Premise
265	BRBS	N	I-Premise
266	(	N	I-Premise
267	LSM	N	I-Premise
268	difference	N	I-Premise
269	=	N	I-Premise
270	-0.18	N	I-Premise
271	;	N	I-Premise
272	95	N	I-Premise
273	%	N	I-Premise
274	CI	N	I-Premise
275	=	N	I-Premise
276	-1.98	N	I-Premise
277	,	N	I-Premise
278	1.62	N	I-Premise
279	)	N	I-Premise
280	,	N	I-Premise
281	or	N	I-Premise
282	BRAS	N	I-Premise
283	(	N	I-Premise
284	LSM	N	I-Premise
285	difference	N	I-Premise
286	=	N	I-Premise
287	-0.42	N	I-Premise
288	;	N	I-Premise
289	95	N	I-Premise
290	%	N	I-Premise
291	CI	N	I-Premise
292	=	N	I-Premise
293	-2.94	N	I-Premise
294	,	N	I-Premise
295	2.10	N	I-Premise
296	)	N	I-Premise
297	.	N	I-Premise

298	Based	N	O
299	on	N	O
300	pattern-mixture	N	O
301	models	N	O
302	,	N	O
303	patients	N	O
304	who	N	O
305	dropped	N	O
306	out	N	O
307	early	N	O
308	had	N	O
309	worse	N	O
310	QL2	N	O
311	decline	N	O
312	on	N	O
313	both	N	O
314	treatments	N	O
315	.	N	O

316	In	N	I-Premise
317	the	N	I-Premise
318	expanded	N	I-Premise
319	pattern-mixture	N	I-Premise
320	model	N	I-Premise
321	,	N	I-Premise
322	EVE	N	I-Premise
323	+	N	I-Premise
324	EXE-treated	N	I-Premise
325	patients	N	I-Premise
326	who	N	I-Premise
327	did	N	I-Premise
328	not	N	I-Premise
329	drop	N	I-Premise
330	out	N	I-Premise
331	early	N	I-Premise
332	had	N	I-Premise
333	stable	N	I-Premise
334	BRBS	N	I-Premise
335	and	N	I-Premise
336	BRAS	N	I-Premise
337	relative	N	I-Premise
338	to	N	I-Premise
339	PBO	N	I-Premise
340	+	N	I-Premise
341	EXE	N	I-Premise
342	.	N	I-Premise

343	HRQOL	N	O
344	data	N	O
345	were	N	O
346	not	N	O
347	collected	N	O
348	after	N	O
349	disease	N	O
350	progression	N	O
351	.	N	O

352	These	N	I-Claim
353	analyses	N	I-Claim
354	confirm	N	I-Claim
355	that	N	I-Claim
356	EVE	N	I-Claim
357	+	N	I-Claim
358	EXE	N	I-Claim
359	provides	N	I-Claim
360	clinical	N	I-Claim
361	benefit	N	I-Claim
362	without	N	I-Claim
363	adversely	N	I-Claim
364	impacting	N	I-Claim
365	HRQOL	N	I-Claim
366	in	N	I-Claim
367	patients	N	I-Claim
368	with	N	I-Claim
369	HR	N	I-Claim
370	(	N	I-Claim
371	+	N	I-Claim
372	)	N	I-Claim
373	ABC	N	I-Claim
374	who	N	I-Claim
375	recurred/progressed	N	I-Claim
376	on	N	I-Claim
377	prior	N	I-Claim
378	NSAIs	N	I-Claim
379	versus	N	I-Claim
380	endocrine	N	I-Claim
381	therapy	N	I-Claim
382	alone	N	I-Claim
383	.	N	I-Claim

1	Care	N	O
2	closer	N	O
3	to	N	O
4	home	N	O
5	is	N	O
6	being	N	O
7	explored	N	O
8	as	N	O
9	a	N	O
10	means	N	O
11	of	N	O
12	improving	N	O
13	patient	N	O
14	experience	N	O
15	as	N	O
16	well	N	O
17	as	N	O
18	efficiency	N	O
19	in	N	O
20	terms	N	O
21	of	N	O
22	cost	N	O
23	savings	N	O
24	.	N	O

25	Evidence	N	O
26	that	N	O
27	community	N	O
28	cancer	N	O
29	services	N	O
30	improve	N	O
31	care	N	O
32	quality	N	O
33	and/or	N	O
34	generate	N	O
35	cost	N	O
36	savings	N	O
37	is	N	O
38	currently	N	O
39	limited	N	O
40	.	N	O

41	A	N	O
42	randomised	N	O
43	study	N	O
44	was	N	O
45	undertaken	N	O
46	to	N	O
47	compare	N	O
48	delivery	N	O
49	of	N	O
50	cancer	N	O
51	treatment	N	O
52	in	N	O
53	the	N	O
54	hospital	N	O
55	with	N	O
56	two	N	O
57	different	N	O
58	community	N	O
59	settings	N	O
60	.	N	O

61	Ninety-seven	N	O
62	patients	N	O
63	being	N	O
64	offered	N	O
65	outpatient-based	N	O
66	cancer	N	O
67	treatment	N	O
68	were	N	O
69	randomised	N	O
70	to	N	O
71	treatment	N	O
72	delivered	N	O
73	in	N	O
74	a	N	O
75	hospital	N	O
76	day	N	O
77	unit	N	O
78	,	N	O
79	at	N	O
80	the	N	O
81	patient	N	O
82	's	N	O
83	home	N	O
84	or	N	O
85	in	N	O
86	local	N	O
87	general	N	O
88	practice	N	O
89	(	N	O
90	GP	N	O
91	)	N	O
92	surgeries	N	O
93	.	N	O

94	The	N	O
95	primary	N	O
96	outcome	N	O
97	was	N	O
98	patient-perceived	N	O
99	benefits	N	O
100	,	N	O
101	using	N	O
102	the	N	O
103	emotional	N	O
104	function	N	O
105	domain	N	O
106	of	N	O
107	the	N	O
108	EORTC	N	O
109	quality	N	O
110	of	N	O
111	life	N	O
112	(	N	O
113	QOL	N	O
114	)	N	O
115	QLQC30	N	O
116	questionnaire	N	O
117	evaluated	N	O
118	after	N	O
119	12	N	O
120	weeks	N	O
121	.	N	O

122	Secondary	N	O
123	outcomes	N	O
124	included	N	O
125	additional	N	O
126	QOL	N	O
127	measures	N	O
128	,	N	O
129	patient	N	O
130	satisfaction	N	O
131	,	N	O
132	safety	N	O
133	and	N	O
134	health	N	O
135	economics	N	O
136	.	N	O

137	There	N	I-Premise
138	was	N	I-Premise
139	no	N	I-Premise
140	statistically	N	I-Premise
141	significant	N	I-Premise
142	QOL	N	I-Premise
143	difference	N	I-Premise
144	between	N	I-Premise
145	treatment	N	I-Premise
146	in	N	I-Premise
147	the	N	I-Premise
148	combined	N	I-Premise
149	community	N	I-Premise
150	locations	N	I-Premise
151	relative	N	I-Premise
152	to	N	I-Premise
153	hospital	N	I-Premise
154	(	N	I-Premise
155	difference	N	I-Premise
156	of	N	I-Premise
157	-7.2	N	I-Premise
158	,	N	I-Premise
159	95	N	I-Premise
160	%	N	I-Premise
161	confidence	N	I-Premise
162	interval	N	I-Premise
163	:	N	I-Premise
164	-195	N	I-Premise
165	to	N	I-Premise
166	+52	N	I-Premise
167	,	N	I-Premise
168	P=0.25	N	I-Premise
169	)	N	I-Premise
170	.	N	I-Premise

171	There	N	I-Premise
172	was	N	I-Premise
173	a	N	I-Premise
174	significant	N	I-Premise
175	difference	N	I-Premise
176	between	N	I-Premise
177	the	N	I-Premise
178	two	N	I-Premise
179	community	N	I-Premise
180	locations	N	I-Premise
181	in	N	I-Premise
182	favour	N	I-Premise
183	of	N	I-Premise
184	home	N	I-Premise
185	(	N	I-Premise
186	+152	N	I-Premise
187	,	N	I-Premise
188	13	N	I-Premise
189	to	N	I-Premise
190	291	N	I-Premise
191	,	N	I-Premise
192	P=0.033	N	I-Premise
193	)	N	I-Premise
194	.	N	I-Premise

195	Hospital	N	O
196	anxiety	N	O
197	and	N	O
198	depression	N	O
199	scale	N	O
200	scores	N	O
201	were	N	O
202	consistent	N	O
203	with	N	O
204	the	N	O
205	primary	N	O
206	outcome	N	O
207	measure	N	O
208	.	N	O

209	There	N	I-Premise
210	was	N	I-Premise
211	no	N	I-Premise
212	evidence	N	I-Premise
213	that	N	I-Premise
214	community	N	I-Premise
215	treatment	N	I-Premise
216	compromised	N	I-Premise
217	patient	N	I-Premise
218	safety	N	I-Premise
219	and	N	O
220	no	N	I-Premise
221	significant	N	I-Premise
222	difference	N	I-Premise
223	between	N	I-Premise
224	treatment	N	I-Premise
225	arms	N	I-Premise
226	in	N	I-Premise
227	terms	N	I-Premise
228	of	N	I-Premise
229	overall	N	I-Premise
230	costs	N	I-Premise
231	or	N	I-Premise
232	Quality	N	I-Premise
233	Adjusted	N	I-Premise
234	Life	N	I-Premise
235	Year	N	I-Premise
236	.	N	I-Premise

237	Seventy-eight	N	I-Premise
238	percent	N	I-Premise
239	of	N	I-Premise
240	patients	N	I-Premise
241	expressed	N	I-Premise
242	satisfaction	N	I-Premise
243	with	N	I-Premise
244	their	N	I-Premise
245	treatment	N	I-Premise
246	whatever	N	I-Premise
247	their	N	I-Premise
248	location	N	I-Premise
249	,	N	I-Premise
250	whereas	N	I-Premise
251	57	N	I-Premise
252	%	N	I-Premise
253	of	N	I-Premise
254	patients	N	I-Premise
255	preferred	N	I-Premise
256	future	N	I-Premise
257	treatment	N	I-Premise
258	to	N	I-Premise
259	continue	N	I-Premise
260	at	N	I-Premise
261	the	N	I-Premise
262	hospital	N	I-Premise
263	,	N	I-Premise
264	81	N	I-Premise
265	%	N	I-Premise
266	at	N	I-Premise
267	GP	N	I-Premise
268	surgeries	N	I-Premise
269	and	N	I-Premise
270	90	N	I-Premise
271	%	N	I-Premise
272	at	N	I-Premise
273	home	N	I-Premise
274	.	N	I-Premise

275	Although	N	O
276	initial	N	O
277	pre-trial	N	O
278	interviews	N	O
279	revealed	N	O
280	concerns	N	O
281	among	N	O
282	health-care	N	O
283	professionals	N	O
284	and	N	O
285	some	N	O
286	patients	N	O
287	regarding	N	O
288	community	N	O
289	treatment	N	O
290	,	N	O
291	opinions	N	O
292	were	N	O
293	largely	N	O
294	more	N	O
295	favourable	N	O
296	in	N	O
297	post-trial	N	O
298	interviews	N	O
299	.	N	O

300	Patient	N	I-Claim
301	QOL	N	I-Claim
302	favours	N	I-Claim
303	delivering	N	I-Claim
304	cancer	N	I-Claim
305	treatment	N	I-Claim
306	in	N	I-Claim
307	the	N	I-Claim
308	home	N	I-Claim
309	rather	N	I-Claim
310	than	N	I-Claim
311	GP	N	I-Claim
312	surgeries	N	I-Claim
313	.	N	I-Claim

314	Nevertheless	N	I-Claim
315	,	N	I-Claim
316	both	N	I-Claim
317	community	N	I-Claim
318	settings	N	I-Claim
319	were	N	I-Claim
320	acceptable	N	I-Claim
321	to	N	I-Claim
322	and	N	I-Claim
323	preferred	N	I-Claim
324	by	N	I-Claim
325	patients	N	I-Claim
326	compared	N	I-Claim
327	with	N	I-Claim
328	hospital	N	I-Claim
329	,	N	I-Claim
330	were	N	I-Claim
331	safe	N	I-Claim
332	,	N	I-Claim
333	with	N	I-Claim
334	no	N	I-Claim
335	detrimental	N	I-Claim
336	impact	N	I-Claim
337	on	N	I-Claim
338	overall	N	I-Claim
339	health-care	N	I-Claim
340	costs	N	I-Claim
341	.	N	I-Claim

1	The	N	O
2	optimal	N	O
3	duration	N	O
4	over	N	O
5	which	N	O
6	lung	N	O
7	SBRT	N	O
8	should	N	O
9	be	N	O
10	delivered	N	O
11	is	N	O
12	unknown	N	O
13	.	N	O

14	We	N	O
15	conducted	N	O
16	a	N	O
17	randomized	N	O
18	pilot	N	O
19	study	N	O
20	in	N	O
21	patients	N	O
22	treated	N	O
23	with	N	O
24	four	N	O
25	fractions	N	O
26	of	N	O
27	lung	N	O
28	SBRT	N	O
29	delivered	N	O
30	over	N	O
31	4	N	O
32	or	N	O
33	over	N	O
34	11	N	O
35	days	N	O
36	.	N	O

37	Patients	N	O
38	with	N	O
39	a	N	O
40	peripheral	N	O
41	solitary	N	O
42	lung	N	O
43	tumor	N	O
44	(	N	O
45	NSCLC	N	O
46	or	N	O
47	pulmonary	N	O
48	metastasis	N	O
49	)	N	O
50		N	O
51	5	N	O
52	cm	N	O
53	were	N	O
54	eligible	N	O
55	.	N	O

56	For	N	O
57	NSCLC	N	O
58	lung	N	O
59	tumors	N	O
60		N	O
61	3	N	O
62	cm	N	O
63	,	N	O
64	a	N	O
65	dose	N	O
66	of	N	O
67	48	N	O
68	Gy	N	O
69	in	N	O
70	4	N	O
71	fractions	N	O
72	was	N	O
73	used	N	O
74	,	N	O
75	otherwise	N	O
76	52	N	O
77	Gy	N	O
78	in	N	O
79	4	N	O
80	fractions	N	O
81	was	N	O
82	delivered	N	O
83	.	N	O

84	Patients	N	O
85	were	N	O
86	randomized	N	O
87	to	N	O
88	receive	N	O
89	treatment	N	O
90	over	N	O
91	4	N	O
92	consecutive	N	O
93	days	N	O
94	or	N	O
95	over	N	O
96	11	N	O
97	days	N	O
98	.	N	O

99	The	N	O
100	primary	N	O
101	end-point	N	O
102	was	N	O
103	acute	N	O
104	grade	N	O
105		N	O
106	2	N	O
107	toxicity	N	O
108	.	N	O

109	Secondary	N	O
110	end-points	N	O
111	included	N	O
112	quality	N	O
113	of	N	O
114	life	N	O
115	(	N	O
116	QOL	N	O
117	)	N	O
118	assessed	N	O
119	using	N	O
120	the	N	O
121	EORTC	N	O
122	QLQ-C30	N	O
123	and	N	O
124	QLQ-LC13	N	O
125	questionnaires	N	O
126	.	N	O

127	Fifty	N	O
128	four	N	O
129	patients	N	O
130	were	N	O
131	enrolled	N	O
132	.	N	O

133	More	N	O
134	patients	N	O
135	in	N	O
136	the	N	O
137	11	N	O
138	day	N	O
139	group	N	O
140	had	N	O
141	respiratory	N	O
142	symptoms	N	O
143	at	N	O
144	baseline	N	O
145	.	N	O

146	55.6	N	I-Premise
147	%	N	I-Premise
148	patients	N	I-Premise
149	treated	N	I-Premise
150	over	N	I-Premise
151	4	N	I-Premise
152	days	N	I-Premise
153	and	N	I-Premise
154	33.3	N	I-Premise
155	%	N	I-Premise
156	of	N	I-Premise
157	patients	N	I-Premise
158	treated	N	I-Premise
159	over	N	I-Premise
160	11	N	I-Premise
161	days	N	I-Premise
162	experienced	N	I-Premise
163	acute	N	I-Premise
164	grade	N	I-Premise
165		N	I-Premise
166	2	N	I-Premise
167	toxicity	N	I-Premise
168	(	N	I-Premise
169	p=0.085	N	I-Premise
170	)	N	I-Premise
171	.	N	I-Premise

172	Dyspnea	N	I-Premise
173	,	N	I-Premise
174	fatigue	N	I-Premise
175	and	N	I-Premise
176	coughing	N	I-Premise
177	domains	N	I-Premise
178	were	N	I-Premise
179	worse	N	I-Premise
180	in	N	I-Premise
181	the	N	I-Premise
182	11	N	I-Premise
183	day	N	I-Premise
184	group	N	I-Premise
185	at	N	I-Premise
186	baseline	N	I-Premise
187	.	N	I-Premise

188	At	N	I-Premise
189	1	N	I-Premise
190	and	N	I-Premise
191	4	N	I-Premise
192	months	N	I-Premise
193	,	N	I-Premise
194	more	N	I-Premise
195	patients	N	I-Premise
196	in	N	I-Premise
197	the	N	I-Premise
198	4	N	I-Premise
199	day	N	I-Premise
200	group	N	I-Premise
201	experienced	N	I-Premise
202	a	N	I-Premise
203	clinically	N	I-Premise
204	meaningful	N	I-Premise
205	worsening	N	I-Premise
206	in	N	I-Premise
207	the	N	I-Premise
208	dyspnea	N	I-Premise
209	QOL	N	I-Premise
210	domain	N	I-Premise
211	compared	N	I-Premise
212	to	N	I-Premise
213	the	N	I-Premise
214	11	N	I-Premise
215	day	N	I-Premise
216	group	N	I-Premise
217	(	N	I-Premise
218	44.5	N	I-Premise
219	%	N	I-Premise
220	vs	N	I-Premise
221	15.4	N	I-Premise
222	%	N	I-Premise
223	,	N	I-Premise
224	p=0.02	N	I-Premise
225	;	N	I-Premise
226	38.5	N	I-Premise
227	%	N	I-Premise
228	vs	N	I-Premise
229	12.0	N	I-Premise
230	%	N	I-Premise
231	,	N	I-Premise
232	p=0.03	N	I-Premise
233	,	N	I-Premise
234	respectively	N	I-Premise
235	)	N	I-Premise
236	.	N	I-Premise

237	However	N	I-Premise
238	,	N	I-Premise
239	raw	N	I-Premise
240	QOL	N	I-Premise
241	scores	N	I-Premise
242	were	N	I-Premise
243	not	N	I-Premise
244	different	N	I-Premise
245	at	N	I-Premise
246	these	N	I-Premise
247	time-points	N	I-Premise
248	between	N	I-Premise
249	treatment	N	I-Premise
250	groups	N	I-Premise
251	.	N	I-Premise

252	Grade	N	I-Claim
253	2	N	I-Claim
254	or	N	I-Claim
255	higher	N	I-Claim
256	acute	N	I-Claim
257	toxicity	N	I-Claim
258	was	N	I-Claim
259	more	N	I-Claim
260	common	N	I-Claim
261	in	N	I-Claim
262	the	N	I-Claim
263	4	N	I-Claim
264	day	N	I-Claim
265	group	N	I-Claim
266	,	N	I-Claim
267	approaching	N	I-Claim
268	statistical	N	I-Claim
269	significance	N	I-Claim
270	.	N	I-Claim

271	More	N	I-Claim
272	patients	N	I-Claim
273	treated	N	I-Claim
274	on	N	I-Claim
275	4	N	I-Claim
276	consecutive	N	I-Claim
277	days	N	I-Claim
278	reported	N	I-Claim
279	a	N	I-Claim
280	clinically	N	I-Claim
281	meaningful	N	I-Claim
282	increase	N	I-Claim
283	in	N	I-Claim
284	dyspnea	N	I-Claim
285	,	N	I-Claim
286	although	N	I-Claim
287	interpretation	N	I-Claim
288	of	N	I-Claim
289	these	N	I-Claim
290	results	N	I-Claim
291	is	N	I-Claim
292	challenging	N	I-Claim
293	due	N	I-Claim
294	to	N	I-Claim
295	baseline	N	I-Claim
296	imbalance	N	I-Claim
297	between	N	I-Claim
298	treatment	N	I-Claim
299	groups	N	I-Claim
300	.	N	I-Claim

301	Larger	N	I-Claim
302	studies	N	I-Claim
303	are	N	I-Claim
304	required	N	I-Claim
305	to	N	I-Claim
306	validate	N	I-Claim
307	these	N	I-Claim
308	results	N	I-Claim
309	.	N	I-Claim

1	Patients	N	O
2	experience	N	O
3	reductions	N	O
4	in	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	QOL	N	O
10	)	N	O
11	while	N	O
12	receiving	N	O
13	cancer	N	O
14	treatment	N	O
15	and	N	O
16	several	N	O
17	approaches	N	O
18	have	N	O
19	been	N	O
20	proposed	N	O
21	to	N	O
22	address	N	O
23	QOL	N	O
24	issues	N	O
25	.	N	O

26	In	N	O
27	this	N	O
28	project	N	O
29	,	N	O
30	the	N	O
31	QOL	N	O
32	differences	N	O
33	between	N	O
34	older	N	O
35	adult	N	O
36	(	N	O
37	age	N	O
38	65+	N	O
39	)	N	O
40	and	N	O
41	younger	N	O
42	adult	N	O
43	(	N	O
44	age	N	O
45	18-64	N	O
46	)	N	O
47	advanced	N	O
48	cancer	N	O
49	patients	N	O
50	in	N	O
51	response	N	O
52	to	N	O
53	a	N	O
54	multidisciplinary	N	O
55	intervention	N	O
56	designed	N	O
57	to	N	O
58	improve	N	O
59	QOL	N	O
60	were	N	O
61	examined	N	O
62	.	N	O

63	This	N	O
64	study	N	O
65	was	N	O
66	registered	N	O
67	on	N	O
68	ClinicalTrials.gov	N	O
69	.	N	O

70	Newly	N	O
71	diagnosed	N	O
72	advanced	N	O
73	cancer	N	O
74	patients	N	O
75	undergoing	N	O
76	radiation	N	O
77	therapy	N	O
78	were	N	O
79	randomized	N	O
80	to	N	O
81	active	N	O
82	QOL	N	O
83	intervention	N	O
84	or	N	O
85	control	N	O
86	groups	N	O
87	.	N	O

88	Those	N	O
89	in	N	O
90	the	N	O
91	intervention	N	O
92	group	N	O
93	received	N	O
94	six	N	O
95	multidisciplinary	N	O
96	90-minute	N	O
97	sessions	N	O
98	designed	N	O
99	to	N	O
100	address	N	O
101	the	N	O
102	five	N	O
103	major	N	O
104	domains	N	O
105	of	N	O
106	QOL	N	O
107	.	N	O

108	Outcomes	N	O
109	measured	N	O
110	at	N	O
111	baseline	N	O
112	and	N	O
113	weeks	N	O
114	4	N	O
115	,	N	O
116	27	N	O
117	,	N	O
118	and	N	O
119	52	N	O
120	included	N	O
121	QOL	N	O
122	(	N	O
123	Linear	N	O
124	Analogue	N	O
125	Self-Assessment	N	O
126	(	N	O
127	LASA	N	O
128	)	N	O
129	,	N	O
130	Functional	N	O
131	Assessment	N	O
132	of	N	O
133	Cancer	N	O
134	Therapy-General	N	O
135	(	N	O
136	FACT-G	N	O
137	)	N	O
138	)	N	O
139	and	N	O
140	mood	N	O
141	(	N	O
142	Profile	N	O
143	of	N	O
144	Mood	N	O
145	States	N	O
146	(	N	O
147	POMS	N	O
148	)	N	O
149	)	N	O
150	.	N	O

151	Kruskall-Wallis	N	O
152	methodology	N	O
153	was	N	O
154	used	N	O
155	to	N	O
156	compare	N	O
157	scores	N	O
158	between	N	O
159	older	N	O
160	and	N	O
161	younger	N	O
162	adult	N	O
163	patients	N	O
164	randomized	N	O
165	to	N	O
166	the	N	O
167	intervention	N	O
168	.	N	O

169	Of	N	O
170	131	N	O
171	patients	N	O
172	in	N	O
173	the	N	O
174	larger	N	O
175	randomized	N	O
176	controlled	N	O
177	study	N	O
178	,	N	O
179	we	N	O
180	report	N	O
181	data	N	O
182	on	N	O
183	54	N	O
184	evaluable	N	O
185	patients	N	O
186	(	N	O
187	16	N	O
188	older	N	O
189	adults	N	O
190	and	N	O
191	38	N	O
192	younger	N	O
193	adults	N	O
194	)	N	O
195	randomized	N	O
196	to	N	O
197	the	N	O
198	intervention	N	O
199	.	N	O

200	Older	N	I-Premise
201	adult	N	I-Premise
202	patients	N	I-Premise
203	reported	N	I-Premise
204	better	N	I-Premise
205	overall	N	I-Premise
206	QOL	N	I-Premise
207	(	N	I-Premise
208	LASA	N	I-Premise
209	74.4	N	I-Premise
210	vs.	N	I-Premise
211	62.9	N	I-Premise
212	,	N	I-Premise
213	p	N	I-Premise
214	=	N	I-Premise
215	0.040	N	I-Premise
216	)	N	I-Premise
217	,	N	I-Premise
218	higher	N	I-Premise
219	social	N	I-Premise
220	well-being	N	I-Premise
221	(	N	I-Premise
222	FACT-G	N	I-Premise
223	91.1	N	I-Premise
224	vs.	N	I-Premise
225	83.3	N	I-Premise
226	,	N	I-Premise
227	p	N	I-Premise
228	=	N	I-Premise
229	0.045	N	I-Premise
230	)	N	I-Premise
231	,	N	I-Premise
232	and	N	I-Premise
233	fewer	N	I-Premise
234	problems	N	I-Premise
235	with	N	I-Premise
236	anger	N	I-Premise
237	(	N	I-Premise
238	POMS	N	I-Premise
239	anger-hostility	N	I-Premise
240	95.0	N	I-Premise
241	vs.	N	I-Premise
242	86.4	N	I-Premise
243	,	N	I-Premise
244	p	N	I-Premise
245	=	N	I-Premise
246	0.028	N	I-Premise
247	)	N	I-Premise
248	.	N	I-Premise

249	Long-term	N	I-Premise
250	benefits	N	I-Premise
251	for	N	I-Premise
252	older	N	I-Premise
253	patients	N	I-Premise
254	were	N	I-Premise
255	seen	N	I-Premise
256	in	N	I-Premise
257	the	N	I-Premise
258	anger-hostility	N	I-Premise
259	scale	N	I-Premise
260	at	N	I-Premise
261	week	N	I-Premise
262	27	N	I-Premise
263	(	N	I-Premise
264	92.2	N	I-Premise
265	vs.	N	I-Premise
266	84.2	N	I-Premise
267	,	N	I-Premise
268	p	N	I-Premise
269	=	N	I-Premise
270	0.027	N	I-Premise
271	)	N	I-Premise
272	and	N	I-Premise
273	week	N	I-Premise
274	52	N	I-Premise
275	(	N	I-Premise
276	96.3	N	I-Premise
277	vs.	N	I-Premise
278	85.9	N	I-Premise
279	,	N	I-Premise
280	p	N	I-Premise
281	=	N	I-Premise
282	0.005	N	I-Premise
283	)	N	I-Premise
284	.	N	I-Premise

285	Older	N	I-Claim
286	adult	N	I-Claim
287	patients	N	I-Claim
288	who	N	I-Claim
289	received	N	I-Claim
290	a	N	I-Claim
291	multidisciplinary	N	I-Claim
292	intervention	N	I-Claim
293	to	N	I-Claim
294	improve	N	I-Claim
295	QOL	N	I-Claim
296	while	N	I-Claim
297	undergoing	N	I-Claim
298	advanced	N	I-Claim
299	cancer	N	I-Claim
300	treatments	N	I-Claim
301	benefited	N	I-Claim
302	differently	N	I-Claim
303	in	N	I-Claim
304	some	N	I-Claim
305	QOL	N	I-Claim
306	domains	N	I-Claim
307	,	N	I-Claim
308	compared	N	I-Claim
309	to	N	I-Claim
310	younger	N	I-Claim
311	adult	N	I-Claim
312	patients	N	I-Claim
313	.	N	I-Claim

314	Future	N	O
315	studies	N	O
316	can	N	O
317	provide	N	O
318	further	N	O
319	insight	N	O
320	on	N	O
321	how	N	O
322	to	N	O
323	tailor	N	O
324	QOL	N	O
325	interventions	N	O
326	for	N	O
327	these	N	O
328	age	N	O
329	groups	N	O
330	.	N	O

1	Chronic	N	O
2	gastrointestinal	N	O
3	symptoms	N	O
4	after	N	O
5	pelvic	N	O
6	radiotherapy	N	O
7	are	N	O
8	common	N	O
9	,	N	O
10	multifactorial	N	O
11	in	N	O
12	cause	N	O
13	,	N	O
14	and	N	O
15	affect	N	O
16	patients	N	O
17	'	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	.	N	O

22	We	N	O
23	assessed	N	O
24	whether	N	O
25	such	N	O
26	patients	N	O
27	could	N	O
28	be	N	O
29	helped	N	O
30	if	N	O
31	a	N	O
32	practitioner	N	O
33	followed	N	O
34	an	N	O
35	investigative	N	O
36	and	N	O
37	management	N	O
38	algorithm	N	O
39	,	N	O
40	and	N	O
41	whether	N	O
42	outcomes	N	O
43	differed	N	O
44	by	N	O
45	whether	N	O
46	a	N	O
47	nurse	N	O
48	or	N	O
49	a	N	O
50	gastroenterologist	N	O
51	led	N	O
52	this	N	O
53	algorithm-based	N	O
54	care	N	O
55	.	N	O

56	For	N	O
57	this	N	O
58	three-arm	N	O
59	randomised	N	O
60	controlled	N	O
61	trial	N	O
62	we	N	O
63	recruited	N	O
64	patients	N	O
65	(	N	O
66	aged	N	O
67	18	N	O
68	years	N	O
69	)	N	O
70	from	N	O
71	clinics	N	O
72	in	N	O
73	London	N	O
74	,	N	O
75	UK	N	O
76	,	N	O
77	with	N	O
78	new-onset	N	O
79	gastrointestinal	N	O
80	symptoms	N	O
81	persisting	N	O
82	6	N	O
83	months	N	O
84	after	N	O
85	pelvic	N	O
86	radiotherapy	N	O
87	.	N	O

88	Using	N	O
89	a	N	O
90	computer-generated	N	O
91	randomisation	N	O
92	sequence	N	O
93	,	N	O
94	we	N	O
95	randomly	N	O
96	allocated	N	O
97	patients	N	O
98	to	N	O
99	one	N	O
100	of	N	O
101	three	N	O
102	groups	N	O
103	(	N	O
104	1:1:1	N	O
105	;	N	O
106	stratified	N	O
107	by	N	O
108	tumour	N	O
109	site	N	O
110	[	N	O
111	urological	N	O
112	,	N	O
113	gynaecological	N	O
114	,	N	O
115	or	N	O
116	gastrointestinal	N	O
117	]	N	O
118	,	N	O
119	and	N	O
120	degree	N	O
121	of	N	O
122	bowel	N	O
123	dysfunction	N	O
124	[	N	O
125	IBDQ-B	N	O
126	score	N	O
127	<	N	O
128	60	N	O
129	vs	N	O
130	60-70	N	O
131	]	N	O
132	)	N	O
133	:	N	O
134	usual	N	O
135	care	N	O
136	(	N	O
137	a	N	O
138	detailed	N	O
139	self-help	N	O
140	booklet	N	O
141	)	N	O
142	,	N	O
143	gastroenterologist-led	N	O
144	algorithm-based	N	O
145	treatment	N	O
146	,	N	O
147	or	N	O
148	nurse-led	N	O
149	algorithm-based	N	O
150	treatment	N	O
151	.	N	O

152	The	N	O
153	primary	N	O
154	endpoint	N	O
155	was	N	O
156	change	N	O
157	in	N	O
158	Inflammatory	N	O
159	Bowel	N	O
160	Disease	N	O
161	Questionnaire-Bowel	N	O
162	subset	N	O
163	score	N	O
164	(	N	O
165	IBDQ-B	N	O
166	)	N	O
167	at	N	O
168	6	N	O
169	months	N	O
170	,	N	O
171	analysed	N	O
172	by	N	O
173	intention	N	O
174	to	N	O
175	treat	N	O
176	.	N	O

177	Between	N	O
178	Nov	N	O
179	26	N	O
180	,	N	O
181	2007	N	O
182	,	N	O
183	and	N	O
184	Dec	N	O
185	12	N	O
186	,	N	O
187	2011	N	O
188	,	N	O
189	we	N	O
190	enrolled	N	O
191	and	N	O
192	randomly	N	O
193	allocated	N	O
194	218	N	O
195	patients	N	O
196	to	N	O
197	treatment	N	O
198	:	N	O
199	80	N	O
200	to	N	O
201	the	N	O
202	nurse	N	O
203	group	N	O
204	,	N	O
205	70	N	O
206	to	N	O
207	the	N	O
208	gastroenterologist	N	O
209	group	N	O
210	,	N	O
211	and	N	O
212	68	N	O
213	to	N	O
214	the	N	O
215	booklet	N	O
216	group	N	O
217	(	N	O
218	figure	N	O
219	)	N	O
220	.	N	O

221	Most	N	O
222	had	N	O
223	a	N	O
224	baseline	N	O
225	IBDQ-B	N	O
226	score	N	O
227	indicating	N	O
228	moderate-to-severe	N	O
229	symptoms	N	O
230	.	N	O

231	We	N	I-Premise
232	recorded	N	I-Premise
233	the	N	I-Premise
234	following	N	I-Premise
235	pair-wise	N	I-Premise
236	mean	N	I-Premise
237	difference	N	I-Premise
238	in	N	I-Premise
239	change	N	I-Premise
240	in	N	I-Premise
241	IBDQ-B	N	I-Premise
242	score	N	I-Premise
243	between	N	I-Premise
244	groups	N	I-Premise
245	:	N	I-Premise
246	nurse	N	I-Premise
247	versus	N	I-Premise
248	booklet	N	I-Premise
249	412	N	I-Premise
250	(	N	I-Premise
251	95	N	I-Premise
252	%	N	I-Premise
253	CI	N	I-Premise
254	004-819	N	I-Premise
255	;	N	I-Premise
256	p=004	N	I-Premise
257	)	N	I-Premise
258	,	N	I-Premise
259	gastroenterologist	N	I-Premise
260	versus	N	I-Premise
261	booklet	N	I-Premise
262	547	N	I-Premise
263	(	N	I-Premise
264	114-981	N	I-Premise
265	;	N	I-Premise
266	p=001	N	I-Premise
267	)	N	I-Premise
268	.	N	I-Premise

269	Outcomes	N	I-Premise
270	in	N	I-Premise
271	the	N	I-Premise
272	nurse	N	I-Premise
273	group	N	I-Premise
274	were	N	I-Premise
275	not	N	I-Premise
276	inferior	N	I-Premise
277	to	N	I-Premise
278	outcomes	N	I-Premise
279	in	N	I-Premise
280	the	N	I-Premise
281	gastroenterologist	N	I-Premise
282	group	N	I-Premise
283	(	N	I-Premise
284	mean	N	I-Premise
285	difference	N	I-Premise
286	136	N	I-Premise
287	,	N	I-Premise
288	one	N	I-Premise
289	sided	N	I-Premise
290	95	N	I-Premise
291	%	N	I-Premise
292	CI	N	I-Premise
293	-148	N	I-Premise
294	)	N	I-Premise
295	.	N	I-Premise

296	Patients	N	I-Claim
297	given	N	I-Claim
298	targeted	N	I-Claim
299	intervention	N	I-Claim
300	following	N	I-Claim
301	a	N	I-Claim
302	detailed	N	I-Claim
303	clinical	N	I-Claim
304	algorithm	N	I-Claim
305	had	N	I-Claim
306	better	N	I-Claim
307	improvements	N	I-Claim
308	in	N	I-Claim
309	radiotherapy-induced	N	I-Claim
310	gastrointestinal	N	I-Claim
311	symptoms	N	I-Claim
312	than	N	I-Claim
313	did	N	I-Claim
314	patients	N	I-Claim
315	given	N	I-Claim
316	usual	N	I-Claim
317	care	N	I-Claim
318	.	N	I-Claim

319	Our	N	I-Claim
320	findings	N	I-Claim
321	suggest	N	I-Claim
322	that	N	I-Claim
323	,	N	I-Claim
324	for	N	I-Claim
325	most	N	I-Claim
326	patients	N	I-Claim
327	,	N	I-Claim
328	this	N	I-Claim
329	algorithm-based	N	I-Claim
330	care	N	I-Claim
331	can	N	I-Claim
332	be	N	I-Claim
333	given	N	I-Claim
334	by	N	I-Claim
335	a	N	I-Claim
336	trained	N	I-Claim
337	nurse	N	I-Claim
338	.	N	I-Claim

1	Abiraterone	N	I-Claim
2	acetate	N	I-Claim
3	plus	N	I-Claim
4	prednisone	N	I-Claim
5	significantly	N	I-Claim
6	improves	N	I-Claim
7	radiographic	N	I-Claim
8	progression-free	N	I-Claim
9	survival	N	I-Claim
10	in	N	I-Claim
11	asymptomatic	N	I-Claim
12	or	N	I-Claim
13	mildly	N	I-Claim
14	symptomatic	N	I-Claim
15	,	N	I-Claim
16	chemotherapy-naive	N	I-Claim
17	patients	N	I-Claim
18	with	N	I-Claim
19	metastatic	N	I-Claim
20	castration-resistant	N	I-Claim
21	prostate	N	I-Claim
22	cancer	N	I-Claim
23	compared	N	I-Claim
24	with	N	I-Claim
25	prednisone	N	I-Claim
26	alone	N	I-Claim
27	.	N	I-Claim

28	We	N	O
29	describe	N	O
30	analyses	N	O
31	of	N	O
32	data	N	O
33	for	N	O
34	patient-reported	N	O
35	pain	N	O
36	and	N	O
37	functional	N	O
38	status	N	O
39	in	N	O
40	a	N	O
41	preplanned	N	O
42	interim	N	O
43	analysis	N	O
44	of	N	O
45	a	N	O
46	phase	N	O
47	3	N	O
48	trial	N	O
49	.	N	O

50	Between	N	O
51	April	N	O
52	28	N	O
53	,	N	O
54	2009	N	O
55	,	N	O
56	and	N	O
57	June	N	O
58	23	N	O
59	,	N	O
60	2010	N	O
61	,	N	O
62	patients	N	O
63	with	N	O
64	progressive	N	O
65	,	N	O
66	metastatic	N	O
67	castration-resistant	N	O
68	prostate	N	O
69	cancer	N	O
70	were	N	O
71	enrolled	N	O
72	into	N	O
73	a	N	O
74	multinational	N	O
75	,	N	O
76	double-blind	N	O
77	,	N	O
78	placebo-controlled	N	O
79	trial	N	O
80	.	N	O

81	Patients	N	O
82	were	N	O
83	eligible	N	O
84	if	N	O
85	they	N	O
86	were	N	O
87	asymptomatic	N	O
88	(	N	O
89	score	N	O
90	of	N	O
91	0	N	O
92	or	N	O
93	1	N	O
94	on	N	O
95	item	N	O
96	three	N	O
97	of	N	O
98	the	N	O
99	Brief	N	O
100	Pain	N	O
101	Inventory	N	O
102	Short	N	O
103	Form	N	O
104	[	N	O
105	BPI-SF	N	O
106	]	N	O
107	questionnaire	N	O
108	)	N	O
109	or	N	O
110	mildly	N	O
111	symptomatic	N	O
112	(	N	O
113	score	N	O
114	of	N	O
115	2	N	O
116	or	N	O
117	3	N	O
118	)	N	O
119	and	N	O
120	had	N	O
121	not	N	O
122	previously	N	O
123	received	N	O
124	chemotherapy	N	O
125	.	N	O

126	Patients	N	O
127	were	N	O
128	randomly	N	O
129	assigned	N	O
130	(	N	O
131	1:1	N	O
132	)	N	O
133	to	N	O
134	receive	N	O
135	oral	N	O
136	abiraterone	N	O
137	(	N	O
138	1	N	O
139	g	N	O
140	daily	N	O
141	)	N	O
142	plus	N	O
143	prednisone	N	O
144	(	N	O
145	5	N	O
146	mg	N	O
147	twice	N	O
148	daily	N	O
149	)	N	O
150	or	N	O
151	placebo	N	O
152	plus	N	O
153	prednisone	N	O
154	in	N	O
155	continuous	N	O
156	4-week	N	O
157	cycles	N	O
158	.	N	O

159	Pain	N	O
160	was	N	O
161	assessed	N	O
162	with	N	O
163	the	N	O
164	BPI-SF	N	O
165	questionnaire	N	O
166	,	N	O
167	and	N	O
168	health-related	N	O
169	quality	N	O
170	of	N	O
171	life	N	O
172	(	N	O
173	HRQoL	N	O
174	)	N	O
175	with	N	O
176	the	N	O
177	Functional	N	O
178	Assessment	N	O
179	of	N	O
180	Cancer	N	O
181	Therapy-Prostate	N	O
182	(	N	O
183	FACT-P	N	O
184	)	N	O
185	questionnaire	N	O
186	.	N	O

187	We	N	O
188	analysed	N	O
189	data	N	O
190	with	N	O
191	prespecified	N	O
192	criteria	N	O
193	for	N	O
194	clinically	N	O
195	meaningful	N	O
196	pain	N	O
197	progression	N	O
198	and	N	O
199	deterioration	N	O
200	in	N	O
201	HRQoL	N	O
202	.	N	O

203	All	N	O
204	patients	N	O
205	who	N	O
206	underwent	N	O
207	randomisation	N	O
208	were	N	O
209	included	N	O
210	in	N	O
211	analyses	N	O
212	.	N	O

213	1088	N	O
214	patients	N	O
215	underwent	N	O
216	randomisation	N	O
217	:	N	O
218	546	N	O
219	were	N	O
220	assigned	N	O
221	to	N	O
222	abiraterone	N	O
223	plus	N	O
224	prednisone	N	O
225	and	N	O
226	542	N	O
227	to	N	O
228	placebo	N	O
229	plus	N	O
230	prednisone	N	O
231	.	N	O

232	At	N	O
233	the	N	O
234	time	N	O
235	of	N	O
236	the	N	O
237	second	N	O
238	prespecified	N	O
239	interim	N	O
240	analysis	N	O
241	,	N	O
242	median	N	O
243	follow-up	N	O
244	was	N	O
245	222	N	O
246	months	N	O
247	(	N	O
248	IQR	N	O
249	202-248	N	O
250	)	N	O
251	.	N	O

252	Median	N	I-Premise
253	time	N	I-Premise
254	to	N	I-Premise
255	progression	N	I-Premise
256	of	N	I-Premise
257	mean	N	I-Premise
258	pain	N	I-Premise
259	intensity	N	I-Premise
260	was	N	I-Premise
261	longer	N	I-Premise
262	in	N	I-Premise
263	patients	N	I-Premise
264	assigned	N	I-Premise
265	to	N	I-Premise
266	abiraterone	N	I-Premise
267	plus	N	I-Premise
268	prednisone	N	I-Premise
269	(	N	I-Premise
270	267	N	I-Premise
271	months	N	I-Premise
272	[	N	I-Premise
273	95	N	I-Premise
274	%	N	I-Premise
275	CI	N	I-Premise
276	193-not	N	I-Premise
277	estimable	N	I-Premise
278	]	N	I-Premise
279	)	N	I-Premise
280	than	N	I-Premise
281	in	N	I-Premise
282	those	N	I-Premise
283	assigned	N	I-Premise
284	to	N	I-Premise
285	placebo	N	I-Premise
286	plus	N	I-Premise
287	prednisone	N	I-Premise
288	(	N	I-Premise
289	184	N	I-Premise
290	months	N	I-Premise
291	[	N	I-Premise
292	149-not	N	I-Premise
293	estimable	N	I-Premise
294	]	N	I-Premise
295	;	N	I-Premise
296	hazard	N	I-Premise
297	ratio	N	I-Premise
298	[	N	I-Premise
299	HR	N	I-Premise
300	]	N	I-Premise
301	082	N	I-Premise
302	,	N	I-Premise
303	95	N	I-Premise
304	%	N	I-Premise
305	CI	N	I-Premise
306	067-100	N	I-Premise
307	;	N	I-Premise
308	p=00490	N	I-Premise
309	)	N	I-Premise
310	,	N	I-Premise
311	as	N	I-Premise
312	was	N	I-Premise
313	median	N	I-Premise
314	time	N	I-Premise
315	to	N	I-Premise
316	progression	N	I-Premise
317	of	N	I-Premise
318	pain	N	I-Premise
319	interference	N	I-Premise
320	with	N	I-Premise
321	daily	N	I-Premise
322	activities	N	I-Premise
323	(	N	I-Premise
324	103	N	I-Premise
325	months	N	I-Premise
326	[	N	I-Premise
327	95	N	I-Premise
328	%	N	I-Premise
329	CI	N	I-Premise
330	93-130	N	I-Premise
331	]	N	I-Premise
332	vs	N	I-Premise
333	74	N	I-Premise
334	months	N	I-Premise
335	[	N	I-Premise
336	64-86	N	I-Premise
337	]	N	I-Premise
338	;	N	I-Premise
339	HR	N	I-Premise
340	079	N	I-Premise
341	,	N	I-Premise
342	95	N	I-Premise
343	%	N	I-Premise
344	CI	N	I-Premise
345	067-093	N	I-Premise
346	;	N	I-Premise
347	p=0005	N	I-Premise
348	)	N	I-Premise
349	.	N	I-Premise

350	Median	N	I-Premise
351	time	N	I-Premise
352	to	N	I-Premise
353	progression	N	I-Premise
354	of	N	I-Premise
355	worst	N	I-Premise
356	pain	N	I-Premise
357	was	N	I-Premise
358	also	N	I-Premise
359	longer	N	I-Premise
360	with	N	I-Premise
361	abiraterone	N	I-Premise
362	plus	N	I-Premise
363	prednisone	N	I-Premise
364	(	N	I-Premise
365	267	N	I-Premise
366	months	N	I-Premise
367	[	N	I-Premise
368	95	N	I-Premise
369	%	N	I-Premise
370	CI	N	I-Premise
371	194-not	N	I-Premise
372	estimable	N	I-Premise
373	]	N	I-Premise
374	)	N	I-Premise
375	than	N	I-Premise
376	with	N	I-Premise
377	placebo	N	I-Premise
378	plus	N	I-Premise
379	prednisone	N	I-Premise
380	(	N	I-Premise
381	194	N	I-Premise
382	months	N	I-Premise
383	[	N	I-Premise
384	166-not	N	I-Premise
385	estimable	N	I-Premise
386	]	N	I-Premise
387	)	N	I-Premise
388	,	N	I-Premise
389	but	N	I-Premise
390	the	N	I-Premise
391	difference	N	I-Premise
392	was	N	I-Premise
393	not	N	I-Premise
394	significant	N	I-Premise
395	(	N	I-Premise
396	HR	N	I-Premise
397	085	N	I-Premise
398	,	N	I-Premise
399	95	N	I-Premise
400	%	N	I-Premise
401	CI	N	I-Premise
402	069-104	N	I-Premise
403	;	N	I-Premise
404	p=0109	N	I-Premise
405	)	N	I-Premise
406	.	N	I-Premise

407	Median	N	I-Premise
408	time	N	I-Premise
409	to	N	I-Premise
410	HRQoL	N	I-Premise
411	deterioration	N	I-Premise
412	was	N	I-Premise
413	longer	N	I-Premise
414	in	N	I-Premise
415	patients	N	I-Premise
416	assigned	N	I-Premise
417	to	N	I-Premise
418	abiraterone	N	I-Premise
419	plus	N	I-Premise
420	prednisone	N	I-Premise
421	than	N	I-Premise
422	in	N	I-Premise
423	those	N	I-Premise
424	assigned	N	I-Premise
425	to	N	I-Premise
426	placebo	N	I-Premise
427	plus	N	I-Premise
428	prednisone	N	I-Premise
429	as	N	I-Premise
430	assessed	N	I-Premise
431	by	N	I-Premise
432	the	N	I-Premise
433	FACT-P	N	I-Premise
434	total	N	I-Premise
435	score	N	I-Premise
436	(	N	I-Premise
437	127	N	I-Premise
438	months	N	I-Premise
439	[	N	I-Premise
440	95	N	I-Premise
441	%	N	I-Premise
442	CI	N	I-Premise
443	111-140	N	I-Premise
444	]	N	I-Premise
445	vs	N	I-Premise
446	83	N	I-Premise
447	months	N	I-Premise
448	[	N	I-Premise
449	74-106	N	I-Premise
450	]	N	I-Premise
451	;	N	I-Premise
452	HR	N	I-Premise
453	078	N	I-Premise
454	,	N	I-Premise
455	95	N	I-Premise
456	%	N	I-Premise
457	CI	N	I-Premise
458	066-092	N	I-Premise
459	;	N	I-Premise
460	p=0003	N	I-Premise
461	)	N	I-Premise
462	and	N	I-Premise
463	by	N	I-Premise
464	the	N	I-Premise
465	score	N	I-Premise
466	on	N	I-Premise
467	its	N	I-Premise
468	prostate-cancer-specific	N	I-Premise
469	subscale	N	I-Premise
470	(	N	I-Premise
471	111	N	I-Premise
472	months	N	I-Premise
473	[	N	I-Premise
474	86-138	N	I-Premise
475	]	N	I-Premise
476	vs	N	I-Premise
477	58	N	I-Premise
478	months	N	I-Premise
479	[	N	I-Premise
480	55-83	N	I-Premise
481	]	N	I-Premise
482	;	N	I-Premise
483	HR	N	I-Premise
484	070	N	I-Premise
485	,	N	I-Premise
486	95	N	I-Premise
487	%	N	I-Premise
488	CI	N	I-Premise
489	060-083	N	I-Premise
490	;	N	I-Premise
491	p	N	I-Premise
492	<	N	I-Premise
493	00001	N	I-Premise
494	)	N	I-Premise
495	.	N	I-Premise

496	Abiraterone	N	I-Claim
497	plus	N	I-Claim
498	prednisone	N	I-Claim
499	delays	N	I-Claim
500	patient-reported	N	I-Claim
501	pain	N	I-Claim
502	progression	N	I-Claim
503	and	N	I-Claim
504	HRQoL	N	I-Claim
505	deterioration	N	I-Claim
506	in	N	I-Claim
507	chemotherapy-naive	N	I-Claim
508	patients	N	I-Claim
509	with	N	I-Claim
510	metastatic	N	I-Claim
511	castration-resistant	N	I-Claim
512	prostate	N	I-Claim
513	cancer	N	I-Claim
514	.	N	I-Claim

515	These	N	I-Claim
516	results	N	I-Claim
517	provide	N	I-Claim
518	further	N	I-Claim
519	support	N	I-Claim
520	for	N	I-Claim
521	the	N	I-Claim
522	efficacy	N	I-Claim
523	of	N	I-Claim
524	abiraterone	N	I-Claim
525	in	N	I-Claim
526	this	N	I-Claim
527	population	N	I-Claim
528	.	N	I-Claim

1	Single-agent	N	O
2	therapy	N	O
3	with	N	O
4	bicalutamide	N	O
5	,	N	O
6	a	N	O
7	nonsteroidal	N	O
8	antiandrogen	N	O
9	,	N	O
10	was	N	O
11	compared	N	O
12	with	N	O
13	castration	N	O
14	,	N	O
15	either	N	O
16	surgical	N	O
17	or	N	O
18	medical	N	O
19	,	N	O
20	in	N	O
21	patients	N	O
22	with	N	O
23	untreated	N	O
24	Stage	N	O
25	D2	N	O
26	prostate	N	O
27	cancer	N	O
28	.	N	O

29	In	N	O
30	an	N	O
31	open	N	O
32	,	N	O
33	randomized	N	O
34	,	N	O
35	multicenter	N	O
36	trial	N	O
37	,	N	O
38	patients	N	O
39	were	N	O
40	randomized	N	O
41	to	N	O
42	treatment	N	O
43	with	N	O
44	50	N	O
45	mg	N	O
46	bicalutamide	N	O
47	(	N	O
48	n	N	O
49	=	N	O
50	243	N	O
51	)	N	O
52	once	N	O
53	daily	N	O
54	or	N	O
55	to	N	O
56	castration	N	O
57	(	N	O
58	n	N	O
59	=	N	O
60	243	N	O
61	)	N	O
62	,	N	O
63	either	N	O
64	orchiectomy	N	O
65	or	N	O
66	depot	N	O
67	injection	N	O
68	of	N	O
69	goserelin	N	O
70	acetate	N	O
71	every	N	O
72	28	N	O
73	days	N	O
74	.	N	O

75	Primary	N	O
76	efficacy	N	O
77	endpoints	N	O
78	were	N	O
79	times	N	O
80	to	N	O
81	treatment	N	O
82	failure	N	O
83	and	N	O
84	objective	N	O
85	disease	N	O
86	progression	N	O
87	and	N	O
88	survival	N	O
89	.	N	O

90	Assessments	N	O
91	included	N	O
92	review	N	O
93	of	N	O
94	measurable	N	O
95	metastases	N	O
96	,	N	O
97	prostate	N	O
98	dimensions	N	O
99	,	N	O
100	Eastern	N	O
101	Cooperative	N	O
102	Oncology	N	O
103	Group	N	O
104	performance	N	O
105	status	N	O
106	,	N	O
107	pain	N	O
108	,	N	O
109	analgesic	N	O
110	requirements	N	O
111	,	N	O
112	and	N	O
113	quality	N	O
114	of	N	O
115	life	N	O
116	responses	N	O
117	.	N	O

118	The	N	O
119	median	N	O
120	duration	N	O
121	of	N	O
122	therapy	N	O
123	was	N	O
124	39	N	O
125	weeks	N	O
126	for	N	O
127	bicalutamide-treated	N	O
128	patients	N	O
129	and	N	O
130	42	N	O
131	weeks	N	O
132	for	N	O
133	castrated	N	O
134	patients	N	O
135	;	N	O
136	treatment	N	O
137	failure	N	O
138	occurred	N	O
139	in	N	O
140	53	N	O
141	%	N	O
142	and	N	O
143	42	N	O
144	%	N	O
145	and	N	O
146	disease	N	O
147	progression	N	O
148	in	N	O
149	43	N	O
150	%	N	O
151	and	N	O
152	33	N	O
153	%	N	O
154	,	N	O
155	respectively	N	O
156	.	N	O

157	Treatment	N	I-Premise
158	effects	N	I-Premise
159	favored	N	I-Premise
160	castration	N	I-Premise
161	for	N	I-Premise
162	both	N	I-Premise
163	endpoints	N	I-Premise
164	(	N	I-Premise
165	P	N	I-Premise
166	<	N	I-Premise
167	or	N	I-Premise
168	=	N	I-Premise
169	0.002	N	I-Premise
170	)	N	I-Premise
171	,	N	I-Premise
172	with	N	I-Premise
173	hazard	N	I-Premise
174	ratios	N	I-Premise
175	(	N	I-Premise
176	bicalutamide	N	I-Premise
177	:	N	I-Premise
178	castration	N	I-Premise
179	)	N	I-Premise
180	of	N	I-Premise
181	1.54	N	I-Premise
182	(	N	I-Premise
183	95	N	I-Premise
184	%	N	I-Premise
185	confidence	N	I-Premise
186	interval	N	I-Premise
187	[	N	I-Premise
188	CI	N	I-Premise
189	]	N	I-Premise
190	,	N	I-Premise
191	1.18	N	I-Premise
192	to	N	I-Premise
193	2.00	N	I-Premise
194	)	N	I-Premise
195	for	N	I-Premise
196	time	N	I-Premise
197	to	N	I-Premise
198	treatment	N	I-Premise
199	failure	N	I-Premise
200	and	N	I-Premise
201	1.6	N	I-Premise
202	(	N	I-Premise
203	95	N	I-Premise
204	%	N	I-Premise
205	CI	N	I-Premise
206	,	N	I-Premise
207	1.19	N	I-Premise
208	to	N	I-Premise
209	2.15	N	I-Premise
210	)	N	I-Premise
211	for	N	I-Premise
212	time	N	I-Premise
213	to	N	I-Premise
214	disease	N	I-Premise
215	progression	N	I-Premise
216	.	N	I-Premise

217	From	N	I-Premise
218	the	N	I-Premise
219	1-year	N	I-Premise
220	survival	N	I-Premise
221	analysis	N	I-Premise
222	,	N	I-Premise
223	the	N	I-Premise
224	hazard	N	I-Premise
225	ratio	N	I-Premise
226	for	N	I-Premise
227	probability	N	I-Premise
228	of	N	I-Premise
229	death	N	I-Premise
230	was	N	I-Premise
231	1.29	N	I-Premise
232	(	N	I-Premise
233	95	N	I-Premise
234	%	N	I-Premise
235	CI	N	I-Premise
236	,	N	I-Premise
237	0.96	N	I-Premise
238	to	N	I-Premise
239	1.72	N	I-Premise
240	)	N	I-Premise
241	.	N	I-Premise

242	Thus	N	I-Premise
243	far	N	I-Premise
244	,	N	I-Premise
245	with	N	I-Premise
246	a	N	I-Premise
247	median	N	I-Premise
248	follow-up	N	I-Premise
249	of	N	I-Premise
250	86	N	I-Premise
251	weeks	N	I-Premise
252	,	N	I-Premise
253	median	N	I-Premise
254	survival	N	I-Premise
255	has	N	I-Premise
256	not	N	I-Premise
257	been	N	I-Premise
258	reached	N	I-Premise
259	in	N	I-Premise
260	either	N	I-Premise
261	group	N	I-Premise
262	.	N	I-Premise

263	Changes	N	I-Premise
264	from	N	I-Premise
265	baseline	N	I-Premise
266	in	N	I-Premise
267	several	N	I-Premise
268	quality	N	I-Premise
269	of	N	I-Premise
270	life	N	I-Premise
271	variables	N	I-Premise
272	were	N	I-Premise
273	significantly	N	I-Premise
274	different	N	I-Premise
275	(	N	I-Premise
276	P	N	I-Premise
277	<	N	I-Premise
278	or	N	I-Premise
279	=	N	I-Premise
280	0.01	N	I-Premise
281	)	N	I-Premise
282	between	N	I-Premise
283	treatment	N	I-Premise
284	groups	N	I-Premise
285	periodically	N	I-Premise
286	from	N	I-Premise
287	months	N	I-Premise
288	1	N	I-Premise
289	to	N	I-Premise
290	6	N	I-Premise
291	,	N	I-Premise
292	and	N	I-Premise
293	all	N	I-Premise
294	favored	N	I-Premise
295	bicalutamide	N	I-Premise
296	.	N	I-Premise

297	Overall	N	I-Premise
298	,	N	I-Premise
299	the	N	I-Premise
300	antiandrogen	N	I-Premise
301	was	N	I-Premise
302	well	N	I-Premise
303	tolerated	N	I-Premise
304	compared	N	I-Premise
305	with	N	I-Premise
306	castration	N	I-Premise
307	;	N	I-Premise
308	with	N	I-Premise
309	bicalutamide	N	I-Premise
310	,	N	I-Premise
311	hot	N	I-Premise
312	flushes	N	I-Premise
313	occurred	N	I-Premise
314	less	N	I-Premise
315	often	N	I-Premise
316	and	N	I-Premise
317	breast	N	I-Premise
318	tenderness	N	I-Premise
319	and	N	I-Premise
320	gynecomastia	N	I-Premise
321	more	N	I-Premise
322	often	N	I-Premise
323	.	N	I-Premise

324	Although	N	I-Premise
325	a	N	I-Premise
326	dosage	N	I-Premise
327	of	N	I-Premise
328	50	N	I-Premise
329	mg	N	I-Premise
330	of	N	I-Premise
331	bicalutamide	N	I-Premise
332	once	N	I-Premise
333	daily	N	I-Premise
334	was	N	I-Premise
335	not	N	I-Premise
336	as	N	I-Premise
337	effective	N	I-Premise
338	as	N	I-Premise
339	castration	N	I-Premise
340	,	N	I-Premise
341	the	N	I-Claim
342	favorable	N	I-Claim
343	quality	N	I-Claim
344	of	N	I-Claim
345	life	N	I-Claim
346	outcomes	N	I-Claim
347	and	N	I-Claim
348	the	N	I-Claim
349	low	N	I-Claim
350	incidence	N	I-Claim
351	of	N	I-Claim
352	nonhormonal	N	I-Claim
353	adverse	N	I-Claim
354	events	N	I-Claim
355	provide	N	I-Claim
356	reasons	N	I-Claim
357	to	N	I-Claim
358	evaluate	N	I-Claim
359	bicalutamide	N	I-Claim
360	,	N	I-Claim
361	as	N	I-Claim
362	a	N	I-Claim
363	single	N	I-Claim
364	therapeutic	N	I-Claim
365	agent	N	I-Claim
366	,	N	I-Claim
367	at	N	I-Claim
368	higher	N	I-Claim
369	doses	N	I-Claim
370	.	N	I-Claim

1	An	N	O
2	open	N	O
3	,	N	O
4	randomized	N	O
5	study	N	O
6	was	N	O
7	performed	N	O
8	to	N	O
9	assess	N	O
10	the	N	O
11	effects	N	O
12	of	N	O
13	supportive	N	O
14	pamidronate	N	O
15	treatment	N	O
16	on	N	O
17	morbidity	N	O
18	from	N	O
19	bone	N	O
20	metastases	N	O
21	in	N	O
22	breast	N	O
23	cancer	N	O
24	patients	N	O
25	.	N	O

26	Eighty-one	N	O
27	pamidronate	N	O
28	patients	N	O
29	and	N	O
30	80	N	O
31	control	N	O
32	patients	N	O
33	were	N	O
34	monitored	N	O
35	for	N	O
36	a	N	O
37	median	N	O
38	of	N	O
39	18	N	O
40	and	N	O
41	21	N	O
42	months	N	O
43	,	N	O
44	respectively	N	O
45	,	N	O
46	for	N	O
47	events	N	O
48	of	N	O
49	skeletal	N	O
50	morbidity	N	O
51	and	N	O
52	the	N	O
53	radiologic	N	O
54	course	N	O
55	of	N	O
56	metastatic	N	O
57	bone	N	O
58	disease	N	O
59	.	N	O

60	The	N	O
61	oral	N	O
62	pamidronate	N	O
63	dose	N	O
64	was	N	O
65	600	N	O
66	mg/d	N	O
67	(	N	O
68	high	N	O
69	dose	N	O
70	[	N	O
71	HD	N	O
72	]	N	O
73	)	N	O
74	during	N	O
75	the	N	O
76	earliest	N	O
77	study	N	O
78	years	N	O
79	,	N	O
80	then	N	O
81	changed	N	O
82	to	N	O
83	300	N	O
84	mg/d	N	O
85	(	N	O
86	low	N	O
87	dose	N	O
88	[	N	O
89	LD	N	O
90	]	N	O
91	)	N	O
92	because	N	O
93	of	N	O
94	gastrointestinal	N	O
95	toxicity	N	O
96	.	N	O

97	Twenty-nine	N	O
98	of	N	O
99	81	N	O
100	pamidronate	N	O
101	(	N	O
102	HD/LD	N	O
103	)	N	O
104	patients	N	O
105	first	N	O
106	received	N	O
107	600	N	O
108	mg/d	N	O
109	and	N	O
110	were	N	O
111	then	N	O
112	changed	N	O
113	to	N	O
114	300	N	O
115	mg/d	N	O
116	;	N	O
117	52	N	O
118	of	N	O
119	81	N	O
120	pamidronate	N	O
121	LD	N	O
122	patients	N	O
123	received	N	O
124	300	N	O
125	mg/d	N	O
126	throughout	N	O
127	the	N	O
128	study	N	O
129	.	N	O

130	Tumor	N	O
131	treatment	N	O
132	was	N	O
133	unrestricted	N	O
134	.	N	O

135	An	N	O
136	overall	N	O
137	intent-to-treat	N	O
138	analysis	N	O
139	was	N	O
140	performed	N	O
141	.	N	O

142	In	N	I-Premise
143	the	N	I-Premise
144	pamidronate	N	I-Premise
145	group	N	I-Premise
146	,	N	I-Premise
147	the	N	I-Premise
148	occurrence	N	I-Premise
149	of	N	I-Premise
150	hypercalcemia	N	I-Premise
151	,	N	I-Premise
152	severe	N	I-Premise
153	bone	N	I-Premise
154	pain	N	I-Premise
155	,	N	I-Premise
156	and	N	I-Premise
157	symptomatic	N	I-Premise
158	impending	N	I-Premise
159	fractures	N	I-Premise
160	decreased	N	I-Premise
161	by	N	I-Premise
162	65	N	I-Premise
163	%	N	I-Premise
164	,	N	I-Premise
165	30	N	I-Premise
166	%	N	I-Premise
167	,	N	I-Premise
168	and	N	I-Premise
169	50	N	I-Premise
170	%	N	I-Premise
171	,	N	I-Premise
172	respectively	N	I-Premise
173	;	N	I-Premise
174	event-rates	N	I-Premise
175	of	N	I-Premise
176	systemic	N	I-Premise
177	treatment	N	I-Premise
178	and	N	I-Premise
179	radiotherapy	N	I-Premise
180	decreased	N	I-Premise
181	by	N	I-Premise
182	35	N	I-Premise
183	%	N	I-Premise
184	(	N	I-Premise
185	P	N	I-Premise
186	<	N	I-Premise
187	or	N	I-Premise
188	=	N	I-Premise
189	.02	N	I-Premise
190	)	N	I-Premise
191	.	N	I-Premise

192	The	N	I-Premise
193	event-free	N	I-Premise
194	period	N	I-Premise
195	(	N	I-Premise
196	EFP	N	I-Premise
197	)	N	I-Premise
198	,	N	I-Premise
199	radiologic	N	I-Premise
200	course	N	I-Premise
201	of	N	I-Premise
202	disease	N	I-Premise
203	,	N	I-Premise
204	and	N	I-Premise
205	survival	N	I-Premise
206	did	N	I-Premise
207	not	N	I-Premise
208	improve	N	I-Premise
209	.	N	I-Premise

210	Subgroup	N	I-Claim
211	analyses	N	I-Claim
212	suggested	N	I-Claim
213	a	N	I-Claim
214	dose-dependent	N	I-Claim
215	treatment	N	I-Claim
216	effect	N	I-Claim
217	.	N	I-Claim

218	Compared	N	I-Premise
219	with	N	I-Premise
220	their	N	I-Premise
221	controls	N	I-Premise
222	,	N	I-Premise
223	in	N	I-Premise
224	pamidronate	N	I-Premise
225	HD/LD	N	I-Premise
226	patients	N	I-Premise
227	,	N	I-Premise
228	events	N	I-Premise
229	occurred	N	I-Premise
230	60	N	I-Premise
231	%	N	I-Premise
232	to	N	I-Premise
233	90	N	I-Premise
234	%	N	I-Premise
235	less	N	I-Premise
236	frequently	N	I-Premise
237	(	N	I-Premise
238	P	N	I-Premise
239	<	N	I-Premise
240	or	N	I-Premise
241	=	N	I-Premise
242	.03	N	I-Premise
243	)	N	I-Premise
244	and	N	I-Premise
245	the	N	I-Premise
246	EFP	N	I-Premise
247	was	N	I-Premise
248	prolonged	N	I-Premise
249	(	N	I-Premise
250	P	N	I-Premise
251	=	N	I-Premise
252	.002	N	I-Premise
253	)	N	I-Premise
254	.	N	I-Premise

255	In	N	I-Premise
256	pamidronate	N	I-Premise
257	LD	N	I-Premise
258	patients	N	I-Premise
259	,	N	I-Premise
260	event-rates	N	I-Premise
261	decreased	N	I-Premise
262	by	N	I-Premise
263	15	N	I-Premise
264	%	N	I-Premise
265	to	N	I-Premise
266	45	N	I-Premise
267	%	N	I-Premise
268	(	N	I-Premise
269	P	N	I-Premise
270	<	N	I-Premise
271	or	N	I-Premise
272	=	N	I-Premise
273	.04	N	I-Premise
274	)	N	I-Premise
275	.	N	I-Premise

276	Gastrointestinal	N	I-Premise
277	toxicity	N	I-Premise
278	of	N	I-Premise
279	pamidronate	N	I-Premise
280	caused	N	I-Premise
281	a	N	I-Premise
282	23	N	I-Premise
283	%	N	I-Premise
284	drop-out	N	I-Premise
285	rate	N	I-Premise
286	,	N	I-Premise
287	but	N	I-Claim
288	other	N	I-Claim
289	cancer-associated	N	I-Claim
290	factors	N	I-Claim
291	seemed	N	I-Claim
292	to	N	I-Claim
293	contribute	N	I-Claim
294	to	N	I-Claim
295	this	N	I-Claim
296	toxicity	N	I-Claim
297	.	N	I-Claim

298	Pamidronate	N	I-Claim
299	treatment	N	I-Claim
300	of	N	I-Claim
301	breast	N	I-Claim
302	cancer	N	I-Claim
303	patients	N	I-Claim
304	efficaciously	N	I-Claim
305	reduced	N	I-Claim
306	skeletal	N	I-Claim
307	morbidity	N	I-Claim
308	.	N	I-Claim

309	The	N	I-Claim
310	effect	N	I-Claim
311	appeared	N	I-Claim
312	to	N	I-Claim
313	be	N	I-Claim
314	dose-dependent	N	I-Claim
315	.	N	I-Claim

316	Further	N	I-Claim
317	research	N	I-Claim
318	on	N	I-Claim
319	dose	N	I-Claim
320	and	N	I-Claim
321	mode	N	I-Claim
322	of	N	I-Claim
323	treatment	N	I-Claim
324	is	N	I-Claim
325	mandatory	N	I-Claim
326	.	N	I-Claim

1	From	N	O
2	1984	N	O
3	to	N	O
4	1989	N	O
5	,	N	O
6	the	N	O
7	Swiss	N	O
8	Group	N	O
9	for	N	O
10	Clinical	N	O
11	Cancer	N	O
12	Research	N	O
13	(	N	O
14	SAKK	N	O
15	)	N	O
16	performed	N	O
17	a	N	O
18	randomized	N	O
19	phase	N	O
20	III	N	O
21	trial	N	O
22	comparing	N	O
23	early	N	O
24	versus	N	O
25	late	N	O
26	alternating	N	O
27	chemotherapy	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	small-cell	N	O
32	lung	N	O
33	cancer	N	O
34	.	N	O

35	406	N	O
36	eligible	N	O
37	patients	N	O
38	were	N	O
39	entered	N	O
40	into	N	O
41	the	N	O
42	trial	N	O
43	.	N	O

44	Regimen	N	O
45	A	N	O
46	consisted	N	O
47	of	N	O
48	PAV	N	O
49	(	N	O
50	cisPlatin	N	O
51	,	N	O
52	Adriamycin	N	O
53	,	N	O
54	VP	N	O
55	16-213	N	O
56	,	N	O
57	and	N	O
58	Regimen	N	O
59	B	N	O
60	of	N	O
61	CyMOC	N	O
62	(	N	O
63	Cyclophosphamide	N	O
64	,	N	O
65	Methotrexate	N	O
66	,	N	O
67	Oncovin	N	O
68	,	N	O
69	CCNU	N	O
70	)	N	O
71	.	N	O

72	Cycles	N	O
73	were	N	O
74	repeated	N	O
75	as	N	O
76	rapidly	N	O
77	as	N	O
78	possible	N	O
79	.	N	O

80	patients	N	O
81	were	N	O
82	randomized	N	O
83	to	N	O
84	receive	N	O
85	either	N	O
86	ABABAB	N	O
87	(	N	O
88	early	N	O
89	alternating	N	O
90	chemotherapy	N	O
91	)	N	O
92	or	N	O
93	AAABBB	N	O
94	(	N	O
95	late	N	O
96	alternating	N	O
97	chemotherapy	N	O
98	)	N	O
99	.	N	O

100	After	N	O
101	six	N	O
102	cycles	N	O
103	patients	N	O
104	with	N	O
105	limited	N	O
106	disease	N	O
107	in	N	O
108	complete	N	O
109	or	N	O
110	partial	N	O
111	remission	N	O
112	and	N	O
113	those	N	O
114	with	N	O
115	extensive	N	O
116	disease	N	O
117	in	N	O
118	complete	N	O
119	remission	N	O
120	received	N	O
121	irradiation	N	O
122	to	N	O
123	the	N	O
124	primary	N	O
125	(	N	O
126	45	N	O
127	Gy	N	O
128	)	N	O
129	and	N	O
130	the	N	O
131	CNS	N	O
132	(	N	O
133	36	N	O
134	Gy	N	O
135	)	N	O
136	.	N	O

137	The	N	I-Premise
138	overall	N	I-Premise
139	remission	N	I-Premise
140	rate	N	I-Premise
141	was	N	I-Premise
142	87	N	I-Premise
143	%	N	I-Premise
144	with	N	I-Premise
145	31	N	I-Premise
146	%	N	I-Premise
147	complete	N	I-Premise
148	remissions	N	I-Premise
149	.	N	I-Premise

150	The	N	I-Premise
151	median	N	I-Premise
152	survival	N	I-Premise
153	of	N	I-Premise
154	all	N	I-Premise
155	406	N	I-Premise
156	eligible	N	I-Premise
157	patients	N	I-Premise
158	was	N	I-Premise
159	346	N	I-Premise
160	days	N	I-Premise
161	with	N	I-Premise
162	15	N	I-Premise
163	%	N	I-Premise
164	of	N	I-Premise
165	the	N	I-Premise
166	patients	N	I-Premise
167	alive	N	I-Premise
168	at	N	I-Premise
169	two	N	I-Premise
170	years	N	I-Premise
171	.	N	I-Premise

172	The	N	I-Premise
173	overall	N	I-Premise
174	remission	N	I-Premise
175	rate	N	I-Premise
176	,	N	I-Premise
177	the	N	I-Premise
178	rate	N	I-Premise
179	of	N	I-Premise
180	complete	N	I-Premise
181	remission	N	I-Premise
182	,	N	I-Premise
183	the	N	I-Premise
184	median	N	I-Premise
185	survival	N	I-Premise
186	and	N	I-Premise
187	the	N	I-Premise
188	rate	N	I-Premise
189	of	N	I-Premise
190	long-term	N	I-Premise
191	survival	N	I-Premise
192	were	N	I-Premise
193	not	N	I-Premise
194	significantly	N	I-Premise
195	different	N	I-Premise
196	in	N	I-Premise
197	the	N	I-Premise
198	two	N	I-Premise
199	treatment	N	I-Premise
200	arms	N	I-Premise
201	.	N	I-Premise

202	In	N	I-Premise
203	limited	N	I-Premise
204	disease	N	I-Premise
205	the	N	I-Premise
206	estimated	N	I-Premise
207	percentages	N	I-Premise
208	of	N	I-Premise
209	survival	N	I-Premise
210	at	N	I-Premise
211	2	N	I-Premise
212	years	N	I-Premise
213	were	N	I-Premise
214	33	N	I-Premise
215	%	N	I-Premise
216	in	N	I-Premise
217	the	N	I-Premise
218	early	N	I-Premise
219	and	N	I-Premise
220	24	N	I-Premise
221	%	N	I-Premise
222	in	N	I-Premise
223	the	N	I-Premise
224	late	N	I-Premise
225	alternating	N	I-Premise
226	chemotherapy	N	I-Premise
227	arms	N	I-Premise
228	.	N	I-Premise

229	Patients	N	I-Premise
230	with	N	I-Premise
231	extensive	N	I-Premise
232	disease	N	I-Premise
233	survived	N	I-Premise
234	significantly	N	I-Premise
235	longer	N	I-Premise
236	with	N	I-Premise
237	late	N	I-Premise
238	alternating	N	I-Premise
239	chemotherapy	N	I-Premise
240	than	N	I-Premise
241	on	N	I-Premise
242	the	N	I-Premise
243	early	N	I-Premise
244	alternation	N	I-Premise
245	regimen	N	I-Premise
246	(	N	I-Premise
247	median	N	I-Premise
248	survival	N	I-Premise
249	336	N	I-Premise
250	days	N	I-Premise
251	versus	N	I-Premise
252	301	N	I-Premise
253	days	N	I-Premise
254	,	N	I-Premise
255	p	N	I-Premise
256	=	N	I-Premise
257	0.01	N	I-Premise
258	)	N	I-Premise
259	.	N	I-Premise

260	In	N	I-Premise
261	the	N	I-Premise
262	latter	N	I-Premise
263	patients	N	I-Premise
264	the	N	I-Premise
265	received	N	I-Premise
266	dose	N	I-Premise
267	intensities	N	I-Premise
268	(	N	I-Premise
269	RDI	N	I-Premise
270	)	N	I-Premise
271	of	N	I-Premise
272	cisplatin	N	I-Premise
273	,	N	I-Premise
274	adriamycin	N	I-Premise
275	and	N	I-Premise
276	etoposide	N	I-Premise
277	were	N	I-Premise
278	significantly	N	I-Premise
279	higher	N	I-Premise
280	in	N	I-Premise
281	the	N	I-Premise
282	late-alternation	N	I-Premise
283	arm	N	I-Premise
284	.	N	I-Premise

285	Patients	N	I-Premise
286	treated	N	I-Premise
287	with	N	I-Premise
288	early	N	I-Premise
289	alternating	N	I-Premise
290	chemotherapy	N	I-Premise
291	rated	N	I-Premise
292	their	N	I-Premise
293	tumor	N	I-Premise
294	symptoms	N	I-Premise
295	,	N	I-Premise
296	functional	N	I-Premise
297	states	N	I-Premise
298	,	N	I-Premise
299	fatigue/malaise	N	I-Premise
300	and	N	I-Premise
301	restriction	N	I-Premise
302	of	N	I-Premise
303	social	N	I-Premise
304	activity	N	I-Premise
305	significantly	N	I-Premise
306	better	N	I-Premise
307	,	N	I-Premise
308	reflecting	N	I-Premise
309	an	N	I-Premise
310	improved	N	I-Premise
311	subjective	N	I-Premise
312	adjustment	N	I-Premise
313	.	N	I-Premise

314	Alternating	N	I-Claim
315	chemotherapy	N	I-Claim
316	with	N	I-Claim
317	PAV-CyMOC	N	I-Claim
318	plus	N	I-Claim
319	consolidating	N	I-Claim
320	radiotherapy	N	I-Claim
321	is	N	I-Claim
322	a	N	I-Claim
323	feasible	N	I-Claim
324	and	N	I-Claim
325	effective	N	I-Claim
326	treatment	N	I-Claim
327	for	N	I-Claim
328	small-cell	N	I-Claim
329	lung	N	I-Claim
330	cancer	N	I-Claim
331	,	N	I-Claim
332	with	N	I-Claim
333	acceptable	N	I-Claim
334	toxicity	N	I-Claim
335	.	N	I-Claim

336	Whereas	N	O
337	patients	N	I-Claim
338	with	N	I-Claim
339	early	N	I-Claim
340	alternating	N	I-Claim
341	chemotherapy	N	I-Claim
342	achieve	N	I-Claim
343	a	N	I-Claim
344	better	N	I-Claim
345	subjective	N	I-Claim
346	adjustment	N	I-Claim
347	,	N	I-Claim
348	late	N	I-Claim
349	alternating	N	I-Claim
350	chemotherapy	N	I-Claim
351	allows	N	I-Claim
352	for	N	I-Claim
353	a	N	I-Claim
354	higher	N	I-Claim
355	RDI	N	I-Claim
356	of	N	I-Claim
357	cisplatin	N	I-Claim
358	,	N	I-Claim
359	adriamycin	N	I-Claim
360	and	N	I-Claim
361	etoposide	N	I-Claim
362	,	N	I-Claim
363	which	N	I-Claim
364	results	N	I-Claim
365	in	N	I-Claim
366	a	N	I-Claim
367	significantly	N	I-Claim
368	longer	N	I-Claim
369	median	N	I-Claim
370	survival	N	I-Claim
371	of	N	I-Claim
372	patients	N	I-Claim
373	with	N	I-Claim
374	extensive	N	I-Claim
375	disease	N	I-Claim
376	.	N	I-Claim

1	Taxol	N	I-Premise
2	(	N	I-Premise
3	paclitaxel	N	I-Premise
4	;	N	I-Premise
5	Bristol-Myers	N	I-Premise
6	Squibb	N	I-Premise
7	,	N	I-Premise
8	Wallingford	N	I-Premise
9	,	N	I-Premise
10	CT	N	I-Premise
11	)	N	I-Premise
12	is	N	I-Premise
13	a	N	I-Premise
14	new	N	I-Premise
15	anticancer	N	I-Premise
16	agent	N	I-Premise
17	with	N	I-Premise
18	activity	N	I-Premise
19	in	N	I-Premise
20	a	N	I-Premise
21	number	N	I-Premise
22	of	N	I-Premise
23	human	N	I-Premise
24	tumors	N	I-Premise
25	,	N	I-Premise
26	including	N	I-Premise
27	epithelial	N	I-Premise
28	ovarian	N	I-Premise
29	cancer	N	I-Premise
30	.	N	I-Premise

31	In	N	O
32	nonrandomized	N	O
33	trials	N	O
34	,	N	O
35	doses	N	O
36	studied	N	O
37	have	N	O
38	ranged	N	O
39	from	N	O
40	135	N	O
41	mg/m2	N	O
42	to	N	O
43	250	N	O
44	mg/m2	N	O
45	administered	N	O
46	over	N	O
47	24	N	O
48	hours	N	O
49	with	N	O
50	premedication	N	O
51	to	N	O
52	avoid	N	O
53	hypersensitivity	N	O
54	reactions	N	O
55	(	N	O
56	HSRs	N	O
57	)	N	O
58	.	N	O

59	This	N	O
60	study	N	O
61	addressed	N	O
62	two	N	O
63	questions	N	O
64	:	N	O
65	the	N	O
66	dose-response	N	O
67	relationship	N	O
68	of	N	O
69	Taxol	N	O
70	in	N	O
71	relapsed	N	O
72	ovarian	N	O
73	cancer	N	O
74	and	N	O
75	the	N	O
76	safety	N	O
77	of	N	O
78	a	N	O
79	short	N	O
80	infusion	N	O
81	given	N	O
82	with	N	O
83	premedication	N	O
84	.	N	O

85	Women	N	O
86	with	N	O
87	platinum-pretreated	N	O
88	epithelial	N	O
89	ovarian	N	O
90	cancer	N	O
91	and	N	O
92	measurable	N	O
93	recurrent	N	O
94	disease	N	O
95	were	N	O
96	randomized	N	O
97	in	N	O
98	a	N	O
99	bifactorial	N	O
100	design	N	O
101	to	N	O
102	receive	N	O
103	either	N	O
104	175	N	O
105	or	N	O
106	135	N	O
107	mg/m2	N	O
108	of	N	O
109	Taxol	N	O
110	over	N	O
111	either	N	O
112	24	N	O
113	or	N	O
114	3	N	O
115	hours	N	O
116	.	N	O

117	Major	N	O
118	end	N	O
119	points	N	O
120	were	N	O
121	the	N	O
122	frequency	N	O
123	of	N	O
124	significant	N	O
125	HSRs	N	O
126	and	N	O
127	objective	N	O
128	response	N	O
129	rate	N	O
130	.	N	O

131	Secondary	N	O
132	end	N	O
133	points	N	O
134	were	N	O
135	progression-free	N	O
136	and	N	O
137	overall	N	O
138	survival	N	O
139	.	N	O

140	Of	N	O
141	407	N	O
142	patients	N	O
143	randomized	N	O
144	,	N	O
145	391	N	O
146	were	N	O
147	eligible	N	O
148	and	N	O
149	382	N	O
150	assessable	N	O
151	for	N	O
152	response	N	O
153	.	N	O

154	Analysis	N	O
155	was	N	O
156	performed	N	O
157	according	N	O
158	to	N	O
159	the	N	O
160	bifactorial	N	O
161	design	N	O
162	.	N	O

163	Severe	N	I-Premise
164	HSRs	N	I-Premise
165	were	N	I-Premise
166	rare	N	I-Premise
167	(	N	I-Premise
168	1.5	N	I-Premise
169	%	N	I-Premise
170	patients	N	I-Premise
171	)	N	I-Premise
172	and	N	I-Premise
173	were	N	I-Premise
174	not	N	I-Premise
175	affected	N	I-Premise
176	by	N	I-Premise
177	either	N	I-Premise
178	dose	N	I-Premise
179	or	N	I-Premise
180	schedule	N	I-Premise
181	.	N	I-Premise

182	Response	N	I-Premise
183	was	N	I-Premise
184	slightly	N	I-Premise
185	higher	N	I-Premise
186	at	N	I-Premise
187	the	N	I-Premise
188	175-mg/m2	N	I-Premise
189	dose	N	I-Premise
190	(	N	I-Premise
191	20	N	I-Premise
192	%	N	I-Premise
193	)	N	I-Premise
194	than	N	I-Premise
195	at	N	I-Premise
196	135	N	I-Premise
197	mg/m2	N	I-Premise
198	(	N	I-Premise
199	15	N	I-Premise
200	%	N	I-Premise
201	)	N	I-Premise
202	,	N	I-Premise
203	but	N	I-Premise
204	this	N	I-Premise
205	was	N	I-Premise
206	not	N	I-Premise
207	statistically	N	I-Premise
208	significant	N	I-Premise
209	(	N	I-Premise
210	P	N	I-Premise
211	=	N	I-Premise
212	.2	N	I-Premise
213	)	N	I-Premise
214	.	N	I-Premise

215	However	N	I-Premise
216	,	N	I-Premise
217	progression-free	N	I-Premise
218	survival	N	I-Premise
219	was	N	I-Premise
220	significantly	N	I-Premise
221	longer	N	I-Premise
222	in	N	I-Premise
223	the	N	I-Premise
224	high-dose	N	I-Premise
225	group	N	I-Premise
226	(	N	I-Premise
227	19	N	I-Premise
228	v	N	I-Premise
229	14	N	I-Premise
230	weeks	N	I-Premise
231	;	N	I-Premise
232	P	N	I-Premise
233	=	N	I-Premise
234	.02	N	I-Premise
235	)	N	I-Premise
236	.	N	I-Premise

237	Significantly	N	I-Premise
238	more	N	I-Premise
239	neutropenia	N	I-Premise
240	was	N	I-Premise
241	seen	N	I-Premise
242	when	N	I-Premise
243	Taxol	N	I-Premise
244	was	N	I-Premise
245	administered	N	I-Premise
246	as	N	I-Premise
247	a	N	I-Premise
248	24-hour	N	I-Premise
249	infusion	N	I-Premise
250	.	N	I-Premise

251	Response	N	I-Premise
252	rates	N	I-Premise
253	were	N	I-Premise
254	similar	N	I-Premise
255	in	N	I-Premise
256	the	N	I-Premise
257	24-	N	I-Premise
258	and	N	I-Premise
259	3-hour	N	I-Premise
260	groups	N	I-Premise
261	(	N	I-Premise
262	19	N	I-Premise
263	%	N	I-Premise
264	and	N	I-Premise
265	16	N	I-Premise
266	%	N	I-Premise
267	,	N	I-Premise
268	respectively	N	I-Premise
269	;	N	I-Premise
270	P	N	I-Premise
271	=	N	I-Premise
272	.6	N	I-Premise
273	)	N	I-Premise
274	.	N	I-Premise

275	No	N	I-Premise
276	survival	N	I-Premise
277	differences	N	I-Premise
278	were	N	I-Premise
279	noted	N	I-Premise
280	.	N	I-Premise

281	The	N	I-Claim
282	3-hour	N	I-Claim
283	infusion	N	I-Claim
284	of	N	I-Claim
285	Taxol	N	I-Claim
286	is	N	I-Claim
287	safe	N	I-Claim
288	when	N	I-Claim
289	given	N	I-Claim
290	with	N	I-Claim
291	premedication	N	I-Claim
292	and	N	I-Claim
293	is	N	I-Claim
294	associated	N	I-Claim
295	with	N	I-Claim
296	less	N	I-Claim
297	neutropenia	N	I-Claim
298	.	N	I-Claim

299	There	N	O
300	is	N	O
301	a	N	O
302	modest	N	O
303	dose	N	O
304	effect	N	O
305	with	N	O
306	longer	N	O
307	time	N	O
308	to	N	O
309	progression	N	O
310	at	N	O
311	175	N	O
312	mg/m2	N	O
313	.	N	O

314	The	N	I-Claim
315	observation	N	I-Claim
316	that	N	I-Claim
317	longer	N	I-Claim
318	infusion	N	I-Claim
319	produces	N	I-Claim
320	more	N	I-Claim
321	myelosuppression	N	I-Claim
322	but	N	I-Claim
323	does	N	I-Claim
324	not	N	I-Claim
325	yield	N	I-Claim
326	higher	N	I-Claim
327	response	N	I-Claim
328	rates	N	I-Claim
329	should	N	I-Claim
330	lead	N	I-Claim
331	to	N	I-Claim
332	further	N	I-Claim
333	studies	N	I-Claim
334	to	N	I-Claim
335	determine	N	I-Claim
336	the	N	I-Claim
337	optimal	N	I-Claim
338	dose	N	I-Claim
339	and	N	I-Claim
340	schedule	N	I-Claim
341	of	N	I-Claim
342	this	N	I-Claim
343	interesting	N	I-Claim
344	new	N	I-Claim
345	agent	N	I-Claim
346	.	N	I-Claim

1	The	N	O
2	impact	N	O
3	of	N	O
4	the	N	O
5	side	N	O
6	effects	N	O
7	of	N	O
8	megestrol	N	O
9	acetate	N	O
10	on	N	O
11	the	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	of	N	O
16	noncachectic	N	O
17	women	N	O
18	with	N	O
19	advanced	N	O
20	breast	N	O
21	cancer	N	O
22	was	N	O
23	studied	N	O
24	in	N	O
25	a	N	O
26	dose-response	N	O
27	clinical	N	O
28	trial	N	O
29	of	N	O
30	the	N	O
31	Cancer	N	O
32	and	N	O
33	Leukemia	N	O
34	Group	N	O
35	B	N	O
36	(	N	O
37	CALGB	N	O
38	8741	N	O
39	)	N	O
40	.	N	O

41	Side	N	O
42	effects	N	O
43	of	N	O
44	appetite	N	O
45	increase	N	O
46	and	N	O
47	weight	N	O
48	gain	N	O
49	at	N	O
50	higher	N	O
51	doses	N	O
52	were	N	O
53	predicted	N	O
54	to	N	O
55	have	N	O
56	a	N	O
57	negative	N	O
58	effect	N	O
59	on	N	O
60	quality	N	O
61	of	N	O
62	life	N	O
63	.	N	O

64	Stage	N	O
65	IV	N	O
66	breast	N	O
67	cancer	N	O
68	patients	N	O
69	were	N	O
70	randomized	N	O
71	to	N	O
72	receive	N	O
73	either	N	O
74	160	N	O
75	,	N	O
76	800	N	O
77	,	N	O
78	or	N	O
79	1,600	N	O
80	mg/d	N	O
81	of	N	O
82	megestrol	N	O
83	acetate	N	O
84	.	N	O

85	Quality	N	O
86	of	N	O
87	life	N	O
88	was	N	O
89	assessed	N	O
90	in	N	O
91	131	N	O
92	patients	N	O
93	at	N	O
94	trial	N	O
95	entry	N	O
96	and	N	O
97	at	N	O
98	1	N	O
99	and	N	O
100	3	N	O
101	months	N	O
102	while	N	O
103	on	N	O
104	treatment	N	O
105	,	N	O
106	by	N	O
107	telephone	N	O
108	interview	N	O
109	,	N	O
110	using	N	O
111	the	N	O
112	following	N	O
113	measures	N	O
114	:	N	O
115	the	N	O
116	Functional	N	O
117	Living	N	O
118	Index-Cancer	N	O
119	(	N	O
120	FLIC	N	O
121	)	N	O
122	,	N	O
123	Rand	N	O
124	Functional	N	O
125	Limitations	N	O
126	Scale	N	O
127	,	N	O
128	Rand	N	O
129	Mental	N	O
130	Health	N	O
131	Inventory	N	O
132	(	N	O
133	MHI	N	O
134	)	N	O
135	,	N	O
136	the	N	O
137	Body	N	O
138	Image	N	O
139	Subscale	N	O
140	,	N	O
141	and	N	O
142	linear	N	O
143	analog	N	O
144	scales	N	O
145	of	N	O
146	drug	N	O
147	side	N	O
148	effects	N	O
149	.	N	O

150	At	N	I-Premise
151	3	N	I-Premise
152	months	N	I-Premise
153	,	N	I-Premise
154	women	N	I-Premise
155	treated	N	I-Premise
156	with	N	I-Premise
157	160	N	I-Premise
158	mg/d	N	I-Premise
159	reported	N	I-Premise
160	less	N	I-Premise
161	severe	N	I-Premise
162	side	N	I-Premise
163	effects	N	I-Premise
164	(	N	I-Premise
165	P	N	I-Premise
166	<	N	I-Premise
167	.0005	N	I-Premise
168	)	N	I-Premise
169	,	N	I-Premise
170	better	N	I-Premise
171	physical	N	I-Premise
172	functioning	N	I-Premise
173	(	N	I-Premise
174	FLS	N	I-Premise
175	,	N	I-Premise
176	P	N	I-Premise
177	<	N	I-Premise
178	.0005	N	I-Premise
179	)	N	I-Premise
180	,	N	I-Premise
181	less	N	I-Premise
182	psychologic	N	I-Premise
183	distress	N	I-Premise
184	(	N	I-Premise
185	MHI	N	I-Premise
186	,	N	I-Premise
187	P	N	I-Premise
188	=	N	I-Premise
189	.008	N	I-Premise
190	)	N	I-Premise
191	,	N	I-Premise
192	and	N	I-Premise
193	an	N	I-Premise
194	improvement	N	I-Premise
195	in	N	I-Premise
196	overall	N	I-Premise
197	quality	N	I-Premise
198	of	N	I-Premise
199	life	N	I-Premise
200	(	N	I-Premise
201	FLIC	N	I-Premise
202	,	N	I-Premise
203	P	N	I-Premise
204	=	N	I-Premise
205	.003	N	I-Premise
206	)	N	I-Premise
207	from	N	I-Premise
208	the	N	I-Premise
209	time	N	I-Premise
210	of	N	I-Premise
211	study	N	I-Premise
212	entry	N	I-Premise
213	as	N	I-Premise
214	compared	N	I-Premise
215	with	N	I-Premise
216	those	N	I-Premise
217	treated	N	I-Premise
218	with	N	I-Premise
219	1,600	N	I-Premise
220	mg/d	N	I-Premise
221	.	N	I-Premise

222	Patients	N	I-Premise
223	who	N	I-Premise
224	received	N	I-Premise
225	the	N	I-Premise
226	800-mg/d	N	I-Premise
227	dose	N	I-Premise
228	fell	N	I-Premise
229	between	N	I-Premise
230	the	N	I-Premise
231	low-	N	I-Premise
232	and	N	I-Premise
233	high-dose	N	I-Premise
234	arms	N	I-Premise
235	in	N	I-Premise
236	reported	N	I-Premise
237	intensity	N	I-Premise
238	of	N	I-Premise
239	drug	N	I-Premise
240	side	N	I-Premise
241	effects	N	I-Premise
242	,	N	I-Premise
243	but	N	I-Premise
244	responded	N	I-Premise
245	similarly	N	I-Premise
246	to	N	I-Premise
247	those	N	I-Premise
248	in	N	I-Premise
249	the	N	I-Premise
250	160-mg/d	N	I-Premise
251	group	N	I-Premise
252	in	N	I-Premise
253	terms	N	I-Premise
254	of	N	I-Premise
255	physical	N	I-Premise
256	functioning	N	I-Premise
257	,	N	I-Premise
258	psychologic	N	I-Premise
259	distress	N	I-Premise
260	,	N	I-Premise
261	and	N	I-Premise
262	overall	N	I-Premise
263	quality	N	I-Premise
264	of	N	I-Premise
265	life	N	I-Premise
266	.	N	I-Premise

267	Unless	N	I-Claim
268	additional	N	I-Claim
269	follow-up	N	I-Claim
270	data	N	I-Claim
271	demonstrate	N	I-Claim
272	a	N	I-Claim
273	survival	N	I-Claim
274	advantage	N	I-Claim
275	at	N	I-Claim
276	higher	N	I-Claim
277	doses	N	I-Claim
278	,	N	I-Claim
279	the	N	I-Claim
280	160-mg/d	N	I-Claim
281	dose	N	I-Claim
282	is	N	I-Claim
283	optimal	N	I-Claim
284	,	N	I-Claim
285	achieving	N	I-Claim
286	maximal	N	I-Claim
287	treatment	N	I-Claim
288	effect	N	I-Claim
289	with	N	I-Claim
290	the	N	I-Claim
291	fewest	N	I-Claim
292	side	N	I-Claim
293	effects	N	I-Claim
294	and	N	I-Claim
295	better	N	I-Claim
296	quality	N	I-Claim
297	of	N	I-Claim
298	life	N	I-Claim
299	.	N	I-Claim

1	A	N	O
2	single-item	N	O
3	linear	N	O
4	analogue	N	O
5	self-assessment	N	O
6	scale	N	O
7	for	N	O
8	mood	N	O
9	was	N	O
10	compared	N	O
11	with	N	O
12	a	N	O
13	28-item	N	O
14	adjective	N	O
15	checklist	N	O
16	for	N	O
17	emotional	N	O
18	well-being	N	O
19	.	N	O

20	To	N	O
21	confirm	N	O
22	its	N	O
23	concurrent	N	O
24	validity	N	O
25	and	N	O
26	responsiveness	N	O
27	to	N	O
28	treatment	N	O
29	and	N	O
30	recurrence	N	O
31	in	N	O
32	patients	N	O
33	with	N	O
34	breast	N	O
35	cancer	N	O
36	,	N	O
37	emotional	N	O
38	well-being	N	O
39	was	N	O
40	assessed	N	O
41	every	N	O
42	3	N	O
43	months	N	O
44	for	N	O
45	2	N	O
46	years	N	O
47	and	N	O
48	at	N	O
49	1	N	O
50	and	N	O
51	6	N	O
52	months	N	O
53	after	N	O
54	recurrence	N	O
55	in	N	O
56	1,169	N	O
57	patients	N	O
58	who	N	O
59	were	N	O
60	premenopausal	N	O
61	and	N	O
62	960	N	O
63	patients	N	O
64	who	N	O
65	were	N	O
66	postmenopausal	N	O
67	.	N	O

68	These	N	O
69	patients	N	O
70	were	N	O
71	enrolled	N	O
72	in	N	O
73	two	N	O
74	International	N	O
75	Breast	N	O
76	Cancer	N	O
77	Study	N	O
78	Group	N	O
79	randomized	N	O
80	clinical	N	O
81	trials	N	O
82	in	N	O
83	operable	N	O
84	breast	N	O
85	cancer	N	O
86	conducted	N	O
87	from	N	O
88	1986	N	O
89	to	N	O
90	1993	N	O
91	.	N	O

92	To	N	O
93	assess	N	O
94	concurrent	N	O
95	validity	N	O
96	,	N	O
97	Pearson	N	O
98	's	N	O
99	correlation	N	O
100	between	N	O
101	the	N	O
102	linear	N	O
103	analogue	N	O
104	self-assessment	N	O
105	scale	N	O
106	and	N	O
107	the	N	O
108	adjective	N	O
109	checklist	N	O
110	were	N	O
111	calculated	N	O
112	for	N	O
113	each	N	O
114	time-point	N	O
115	within	N	O
116	each	N	O
117	treatment	N	O
118	group	N	O
119	and	N	O
120	for	N	O
121	the	N	O
122	two	N	O
123	assessments	N	O
124	after	N	O
125	recurrence	N	O
126	.	N	O

127	Responsiveness	N	O
128	to	N	O
129	treatment	N	O
130	and	N	O
131	recurrence	N	O
132	were	N	O
133	analyzed	N	O
134	using	N	O
135	paired	N	O
136	t	N	O
137	tests	N	O
138	and	N	O
139	the	N	O
140	squared	N	O
141	ratio	N	O
142	of	N	O
143	these	N	O
144	t	N	O
145	tests	N	O
146	,	N	O
147	an	N	O
148	estimate	N	O
149	of	N	O
150	relative	N	O
151	efficiency	N	O
152	.	N	O

153	Concurrent	N	O
154	validity	N	O
155	of	N	O
156	the	N	O
157	mood	N	O
158	linear	N	O
159	analogue	N	O
160	self-assessment	N	O
161	was	N	O
162	consistently	N	O
163	confirmed	N	O
164	across	N	O
165	four	N	O
166	language	N	O
167	groups	N	O
168	.	N	O

169	Both	N	I-Claim
170	measures	N	I-Claim
171	were	N	I-Claim
172	responsive	N	I-Claim
173	;	N	I-Claim
174	out	N	I-Premise
175	of	N	I-Premise
176	24	N	I-Premise
177	changes	N	I-Premise
178	over	N	I-Premise
179	time	N	I-Premise
180	,	N	I-Premise
181	19	N	I-Premise
182	were	N	I-Premise
183	in	N	I-Premise
184	the	N	I-Premise
185	expected	N	I-Premise
186	direction	N	I-Premise
187	for	N	I-Premise
188	the	N	I-Premise
189	linear	N	I-Premise
190	analogue	N	I-Premise
191	self-assessment	N	I-Premise
192	scale	N	I-Premise
193	(	N	I-Premise
194	p	N	I-Premise
195	<	N	I-Premise
196	or	N	I-Premise
197	=	N	I-Premise
198	0.05	N	I-Premise
199	for	N	I-Premise
200	9	N	I-Premise
201	of	N	I-Premise
202	19	N	I-Premise
203	)	N	I-Premise
204	and	N	I-Premise
205	17	N	I-Premise
206	for	N	I-Premise
207	the	N	I-Premise
208	adjective	N	I-Premise
209	checklist	N	I-Premise
210	(	N	I-Premise
211	p	N	I-Premise
212	<	N	I-Premise
213	or	N	I-Premise
214	=	N	I-Premise
215	0.05	N	I-Premise
216	for	N	I-Premise
217	10	N	I-Premise
218	of	N	I-Premise
219	17	N	I-Premise
220	)	N	I-Premise
221	.	N	I-Premise

222	The	N	I-Premise
223	linear	N	I-Premise
224	analogue	N	I-Premise
225	self-assessment	N	I-Premise
226	scale	N	I-Premise
227	was	N	I-Premise
228	less	N	I-Premise
229	but	N	I-Premise
230	significantly	N	I-Premise
231	efficient	N	I-Premise
232	for	N	I-Premise
233	detection	N	I-Premise
234	of	N	I-Premise
235	treatment	N	I-Premise
236	effects	N	I-Premise
237	,	N	I-Premise
238	with	N	I-Premise
239	relative	N	I-Premise
240	efficiency	N	I-Premise
241	estimates	N	I-Premise
242	ranging	N	I-Premise
243	from	N	I-Premise
244	0.16	N	I-Premise
245	to	N	I-Premise
246	2.45	N	I-Premise
247	and	N	I-Premise
248	a	N	I-Premise
249	median	N	I-Premise
250	of	N	I-Premise
251	0.66	N	I-Premise
252	among	N	I-Premise
253	the	N	I-Premise
254	comparisons	N	I-Premise
255	with	N	I-Premise
256	relatively	N	I-Premise
257	stable	N	I-Premise
258	estimates	N	I-Premise
259	(	N	I-Premise
260	/t/	N	I-Premise
261	>	N	I-Premise
262	or	N	I-Premise
263	=	N	I-Premise
264	1.0	N	I-Premise
265	)	N	I-Premise
266	and	N	I-Premise
267	more	N	I-Premise
268	efficient	N	I-Premise
269	for	N	I-Premise
270	recurrence	N	I-Premise
271	than	N	I-Premise
272	the	N	I-Premise
273	adjective	N	I-Premise
274	checklist	N	I-Premise
275	.	N	I-Premise

276	The	N	I-Claim
277	mood	N	I-Claim
278	linear	N	I-Claim
279	analogue	N	I-Claim
280	self-assessment	N	I-Claim
281	scale	N	I-Claim
282	is	N	I-Claim
283	a	N	I-Claim
284	valid	N	I-Claim
285	indicator	N	I-Claim
286	of	N	I-Claim
287	emotional	N	I-Claim
288	well-being	N	I-Claim
289	in	N	I-Claim
290	patients	N	I-Claim
291	with	N	I-Claim
292	breast	N	I-Claim
293	cancer	N	I-Claim
294	in	N	I-Claim
295	large	N	I-Claim
296	multicenter	N	I-Claim
297	,	N	I-Claim
298	multicultural	N	I-Claim
299	trials	N	I-Claim
300	in	N	I-Claim
301	which	N	I-Claim
302	comprehensive	N	I-Claim
303	scales	N	I-Claim
304	are	N	I-Claim
305	less	N	I-Claim
306	feasible	N	I-Claim
307	.	N	I-Claim

308	This	N	I-Claim
309	investigation	N	I-Claim
310	supports	N	I-Claim
311	the	N	I-Claim
312	clinical	N	I-Claim
313	relevance	N	I-Claim
314	of	N	I-Claim
315	linear	N	I-Claim
316	analogue	N	I-Claim
317	self-assessment	N	I-Claim
318	scales	N	I-Claim
319	as	N	I-Claim
320	indicators	N	I-Claim
321	of	N	I-Claim
322	components	N	I-Claim
323	of	N	I-Claim
324	quality	N	I-Claim
325	of	N	I-Claim
326	life	N	I-Claim
327	in	N	I-Claim
328	cancer	N	I-Claim
329	clinical	N	I-Claim
330	trials	N	I-Claim
331	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	whether	N	O
4	the	N	O
5	administration	N	O
6	of	N	O
7	recombinant	N	O
8	human	N	O
9	erythropoietin	N	O
10	(	N	O
11	r-HuEPO	N	O
12	)	N	O
13	would	N	O
14	increase	N	O
15	the	N	O
16	hematocrit	N	O
17	,	N	O
18	reduce	N	O
19	the	N	O
20	requirement	N	O
21	for	N	O
22	transfusion	N	O
23	,	N	O
24	and	N	O
25	improve	N	O
26	the	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	in	N	O
31	anemic	N	O
32	cancer	N	O
33	patients	N	O
34	receiving	N	O
35	myelosuppressive	N	O
36	,	N	O
37	cisplatin-based	N	O
38	chemotherapy	N	O
39	.	N	O

40	One	N	O
41	hundred	N	O
42	thirty-two	N	O
43	anemic	N	O
44	cancer	N	O
45	patients	N	O
46	receiving	N	O
47	cyclic	N	O
48	,	N	O
49	cisplatin-containing	N	O
50	,	N	O
51	myelosuppressive	N	O
52	chemotherapy	N	O
53	were	N	O
54	evaluated	N	O
55	.	N	O

56	Patients	N	O
57	received	N	O
58	either	N	O
59	r-HuEPO	N	O
60	(	N	O
61	150	N	O
62	U/kg	N	O
63	)	N	O
64	or	N	O
65	placebo	N	O
66	,	N	O
67	subcutaneously	N	O
68	,	N	O
69	three	N	O
70	times	N	O
71	a	N	O
72	week	N	O
73	for	N	O
74	3	N	O
75	months	N	O
76	.	N	O

77	Responses	N	O
78	were	N	O
79	assessed	N	O
80	by	N	O
81	measuring	N	O
82	changes	N	O
83	in	N	O
84	hemoglobin/hematocrit	N	O
85	,	N	O
86	transfusion	N	O
87	requirement	N	O
88	,	N	O
89	and	N	O
90	quality	N	O
91	of	N	O
92	life	N	O
93	.	N	O

94	The	N	I-Premise
95	mean	N	I-Premise
96	hematocrit	N	I-Premise
97	increased	N	I-Premise
98	by	N	I-Premise
99	6.0	N	I-Premise
100	percentage	N	I-Premise
101	points	N	I-Premise
102	in	N	I-Premise
103	the	N	I-Premise
104	r-HuEPO	N	I-Premise
105	group	N	I-Premise
106	versus	N	I-Premise
107	1.3	N	I-Premise
108	in	N	I-Premise
109	the	N	I-Premise
110	placebo	N	I-Premise
111	group	N	I-Premise
112	.	N	I-Premise

113	A	N	I-Premise
114	decrease	N	I-Premise
115	in	N	I-Premise
116	transfusion	N	I-Premise
117	requirement	N	I-Premise
118	did	N	I-Premise
119	not	N	I-Premise
120	reach	N	I-Premise
121	significance	N	I-Premise
122	over	N	I-Premise
123	all	N	I-Premise
124	3	N	I-Premise
125	months	N	I-Premise
126	,	N	I-Premise
127	but	N	I-Premise
128	there	N	I-Premise
129	was	N	I-Premise
130	a	N	I-Premise
131	significant	N	I-Premise
132	reduction	N	I-Premise
133	in	N	I-Premise
134	the	N	I-Premise
135	percentage	N	I-Premise
136	of	N	I-Premise
137	patients	N	I-Premise
138	transfused	N	I-Premise
139	in	N	I-Premise
140	the	N	I-Premise
141	second	N	I-Premise
142	and	N	I-Premise
143	third	N	I-Premise
144	months	N	I-Premise
145	(	N	I-Premise
146	27	N	I-Premise
147	%	N	I-Premise
148	r-HuEPO	N	I-Premise
149	vs.	N	I-Premise
150	56	N	I-Premise
151	%	N	I-Premise
152	placebo	N	I-Premise
153	)	N	I-Premise
154	and	N	I-Premise
155	a	N	I-Premise
156	trend	N	I-Premise
157	toward	N	I-Premise
158	reduction	N	I-Premise
159	in	N	I-Premise
160	the	N	I-Premise
161	mean	N	I-Premise
162	total	N	I-Premise
163	number	N	I-Premise
164	of	N	I-Premise
165	units	N	I-Premise
166	transfused	N	I-Premise
167	(	N	I-Premise
168	1.20	N	I-Premise
169	units	N	I-Premise
170	r-HuEPO	N	I-Premise
171	vs.	N	I-Premise
172	2.02	N	I-Premise
173	units	N	I-Premise
174	placebo	N	I-Premise
175	)	N	I-Premise
176	,	N	I-Premise
177	suggesting	N	I-Premise
178	a	N	I-Premise
179	lag	N	I-Premise
180	of	N	I-Premise
181	1	N	I-Premise
182	month	N	I-Premise
183	before	N	I-Premise
184	r-HuEPO	N	I-Premise
185	can	N	I-Premise
186	affect	N	I-Premise
187	the	N	I-Premise
188	transfusion	N	I-Premise
189	requirement	N	I-Premise
190	.	N	I-Premise

191	Pretreatment	N	I-Premise
192	serum	N	I-Premise
193	erythropoietin	N	I-Premise
194	levels	N	I-Premise
195	were	N	I-Premise
196	lower	N	I-Premise
197	in	N	I-Premise
198	responders	N	I-Premise
199	than	N	I-Premise
200	in	N	I-Premise
201	nonresponders	N	I-Premise
202	(	N	I-Premise
203	73.5	N	I-Premise
204	IU/L	N	I-Premise
205	and	N	I-Premise
206	86.3	N	I-Premise
207	IU/L	N	I-Premise
208	means	N	I-Premise
209	,	N	I-Premise
210	respectively	N	I-Premise
211	)	N	I-Premise
212	.	N	I-Premise

213	However	N	I-Premise
214	,	N	I-Premise
215	the	N	I-Premise
216	magnitude	N	I-Premise
217	of	N	I-Premise
218	this	N	I-Premise
219	difference	N	I-Premise
220	was	N	I-Premise
221	not	N	I-Premise
222	helpful	N	I-Premise
223	in	N	I-Premise
224	defining	N	I-Premise
225	which	N	I-Premise
226	patients	N	I-Premise
227	were	N	I-Premise
228	likely	N	I-Premise
229	to	N	I-Premise
230	respond	N	I-Premise
231	.	N	I-Premise

232	There	N	I-Premise
233	was	N	I-Premise
234	a	N	I-Premise
235	significant	N	I-Premise
236	improvement	N	I-Premise
237	in	N	I-Premise
238	overall	N	I-Premise
239	quality	N	I-Premise
240	of	N	I-Premise
241	life	N	I-Premise
242	between	N	I-Premise
243	the	N	I-Premise
244	two	N	I-Premise
245	treatment	N	I-Premise
246	arms	N	I-Premise
247	in	N	I-Premise
248	favor	N	I-Premise
249	of	N	I-Premise
250	the	N	I-Premise
251	r-HuEPO-treated	N	I-Premise
252	group	N	I-Premise
253	.	N	I-Premise

254	There	N	I-Premise
255	were	N	I-Premise
256	no	N	I-Premise
257	significant	N	I-Premise
258	adverse	N	I-Premise
259	effects	N	I-Premise
260	associated	N	I-Premise
261	with	N	I-Premise
262	r-HuEPO	N	I-Premise
263	.	N	I-Premise

264	r-HuEPO	N	I-Claim
265	is	N	I-Claim
266	safe	N	I-Claim
267	and	N	I-Claim
268	can	N	I-Claim
269	cause	N	I-Claim
270	a	N	I-Claim
271	significant	N	I-Claim
272	improvement	N	I-Claim
273	in	N	I-Claim
274	the	N	I-Claim
275	hematocrit	N	I-Claim
276	and	N	I-Claim
277	quality	N	I-Claim
278	of	N	I-Claim
279	life	N	I-Claim
280	of	N	I-Claim
281	anemic	N	I-Claim
282	cancer	N	I-Claim
283	patients	N	I-Claim
284	receiving	N	I-Claim
285	myelosuppressive	N	I-Claim
286	,	N	I-Claim
287	cisplatin-based	N	I-Claim
288	chemotherapy	N	I-Claim
289	.	N	I-Claim

290	After	N	I-Claim
291	1	N	I-Claim
292	month	N	I-Claim
293	of	N	I-Claim
294	r-HuEPO	N	I-Claim
295	,	N	I-Claim
296	there	N	I-Claim
297	is	N	I-Claim
298	also	N	I-Claim
299	a	N	I-Claim
300	reduction	N	I-Claim
301	in	N	I-Claim
302	transfusion	N	I-Claim
303	requirement	N	I-Claim
304	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	protracted	N	O
4	venous	N	O
5	infusion	N	O
6	(	N	O
7	PVI	N	O
8	)	N	O
9	5-fluorouracil	N	O
10	(	N	O
11	5-FU	N	O
12	)	N	O
13	with	N	O
14	and	N	O
15	without	N	O
16	mitomycin	N	O
17	C	N	O
18	(	N	O
19	MMC	N	O
20	)	N	O
21	in	N	O
22	a	N	O
23	prospectively	N	O
24	randomised	N	O
25	study	N	O
26	and	N	O
27	analyse	N	O
28	for	N	O
29	tumour	N	O
30	response	N	O
31	,	N	O
32	survival	N	O
33	,	N	O
34	toxicity	N	O
35	and	N	O
36	quality	N	O
37	of	N	O
38	life	N	O
39	(	N	O
40	QL	N	O
41	)	N	O
42	.	N	O

43	Two	N	O
44	hundred	N	O
45	patients	N	O
46	with	N	O
47	advanced	N	O
48	colorectal	N	O
49	cancer	N	O
50	received	N	O
51	PVI	N	O
52	5-FU	N	O
53	300	N	O
54	mg/m2/day	N	O
55	for	N	O
56	a	N	O
57	maximum	N	O
58	of	N	O
59	24	N	O
60	weeks	N	O
61	and	N	O
62	were	N	O
63	randomised	N	O
64	to	N	O
65	PVI	N	O
66	5-FU	N	O
67	alone	N	O
68	or	N	O
69	PVI	N	O
70	5-FU	N	O
71	+	N	O
72	MMC	N	O
73	10	N	O
74	mg/m2	N	O
75	(	N	O
76	7	N	O
77	mg/m2	N	O
78	from	N	O
79	June	N	O
80	1995	N	O
81	)	N	O
82	6	N	O
83	weekly	N	O
84	for	N	O
85	4	N	O
86	courses	N	O
87	.	N	O

88	Overall	N	I-Premise
89	response	N	I-Premise
90	was	N	I-Premise
91	54	N	I-Premise
92	%	N	I-Premise
93	(	N	I-Premise
94	95	N	I-Premise
95	%	N	I-Premise
96	confidence	N	I-Premise
97	interval	N	I-Premise
98	[	N	I-Premise
99	CI	N	I-Premise
100	]	N	I-Premise
101	44.1	N	I-Premise
102	%	N	I-Premise
103	-63.9	N	I-Premise
104	%	N	I-Premise
105	)	N	I-Premise
106	with	N	I-Premise
107	PVI	N	I-Premise
108	5-FU	N	I-Premise
109	+	N	I-Premise
110	MMC	N	I-Premise
111	compared	N	I-Premise
112	to	N	I-Premise
113	38	N	I-Premise
114	%	N	I-Premise
115	(	N	I-Premise
116	95	N	I-Premise
117	%	N	I-Premise
118	CI	N	I-Premise
119	:	N	I-Premise
120	28.3	N	I-Premise
121	%	N	I-Premise
122	-47.7	N	I-Premise
123	%	N	I-Premise
124	)	N	I-Premise
125	for	N	I-Premise
126	PVI	N	I-Premise
127	5-FU	N	I-Premise
128	alone	N	I-Premise
129	(	N	I-Premise
130	P	N	I-Premise
131	=	N	I-Premise
132	0.024	N	I-Premise
133	)	N	I-Premise
134	.	N	I-Premise

135	The	N	I-Premise
136	median	N	I-Premise
137	failure	N	I-Premise
138	free	N	I-Premise
139	survival	N	I-Premise
140	was	N	I-Premise
141	7.9	N	I-Premise
142	months	N	I-Premise
143	in	N	I-Premise
144	PVI	N	I-Premise
145	5-FU	N	I-Premise
146	plus	N	I-Premise
147	MMC	N	I-Premise
148	and	N	I-Premise
149	5.4	N	I-Premise
150	months	N	I-Premise
151	with	N	I-Premise
152	PVI	N	I-Premise
153	5-FU	N	I-Premise
154	alone	N	I-Premise
155	(	N	I-Premise
156	P	N	I-Premise
157	=	N	I-Premise
158	0.033	N	I-Premise
159	)	N	I-Premise
160	and	N	I-Premise
161	at	N	I-Premise
162	one	N	I-Premise
163	year	N	I-Premise
164	31.9	N	I-Premise
165	%	N	I-Premise
166	for	N	I-Premise
167	the	N	I-Premise
168	combination	N	I-Premise
169	compared	N	I-Premise
170	to	N	I-Premise
171	17.7	N	I-Premise
172	%	N	I-Premise
173	for	N	I-Premise
174	PVI	N	I-Premise
175	5-FU	N	I-Premise
176	alone	N	I-Premise
177	.	N	I-Premise

178	Median	N	I-Premise
179	survival	N	I-Premise
180	was	N	I-Premise
181	14	N	I-Premise
182	months	N	I-Premise
183	with	N	I-Premise
184	MMC	N	I-Premise
185	and	N	I-Premise
186	15	N	I-Premise
187	months	N	I-Premise
188	in	N	I-Premise
189	5-FU	N	I-Premise
190	alone	N	I-Premise
191	;	N	I-Premise
192	one-year	N	I-Premise
193	survival	N	I-Premise
194	51.7	N	I-Premise
195	%	N	I-Premise
196	vs.	N	I-Premise
197	57.2	N	I-Premise
198	%	N	I-Premise
199	.	N	I-Premise

200	PVI	N	I-Premise
201	5-FU	N	I-Premise
202	+	N	I-Premise
203	MMC	N	I-Premise
204	caused	N	I-Premise
205	more	N	I-Premise
206	overall	N	I-Premise
207	haematological	N	I-Premise
208	toxicity	N	I-Premise
209	but	N	I-Premise
210	CTC	N	I-Premise
211	grades	N	I-Premise
212	3/4	N	I-Premise
213	was	N	I-Premise
214	increased	N	I-Premise
215	only	N	I-Premise
216	for	N	I-Premise
217	thrombocytopaenia	N	I-Premise
218	.	N	I-Premise

219	Two	N	I-Premise
220	patients	N	I-Premise
221	treated	N	I-Premise
222	with	N	I-Premise
223	a	N	I-Premise
224	cumulative	N	I-Premise
225	dose	N	I-Premise
226	of	N	I-Premise
227	MMC	N	I-Premise
228	of	N	I-Premise
229	40	N	I-Premise
230	mg/m2	N	I-Premise
231	developed	N	I-Premise
232	haemolytic	N	I-Premise
233	uraemic	N	I-Premise
234	syndrome	N	I-Premise
235	warranting	N	I-Premise
236	the	N	I-Premise
237	reduction	N	I-Premise
238	in	N	I-Premise
239	cumulative	N	I-Premise
240	MMC	N	I-Premise
241	dose	N	I-Premise
242	to	N	I-Premise
243	28	N	I-Premise
244	mg/m2	N	I-Premise
245	.	N	I-Premise

246	The	N	I-Premise
247	global	N	I-Premise
248	QL	N	I-Premise
249	scores	N	I-Premise
250	were	N	I-Premise
251	better	N	I-Premise
252	for	N	I-Premise
253	PVI	N	I-Premise
254	5-FU	N	I-Premise
255	+	N	I-Premise
256	MMC	N	I-Premise
257	arm	N	I-Premise
258	at	N	I-Premise
259	24	N	I-Premise
260	weeks	N	I-Premise
261	,	N	I-Premise
262	but	N	I-Premise
263	the	N	I-Premise
264	remaining	N	I-Premise
265	QL	N	I-Premise
266	data	N	I-Premise
267	showed	N	I-Premise
268	no	N	I-Premise
269	differences	N	I-Premise
270	.	N	I-Premise

271	PVI	N	I-Claim
272	5-FU	N	I-Claim
273	+	N	I-Claim
274	MMC	N	I-Claim
275	results	N	I-Claim
276	in	N	I-Claim
277	failure-free	N	I-Claim
278	survival	N	I-Claim
279	and	N	I-Claim
280	response	N	I-Claim
281	advantage	N	I-Claim
282	,	N	I-Claim
283	tolerable	N	I-Claim
284	toxicity	N	I-Claim
285	and	N	I-Claim
286	better	N	I-Claim
287	QL	N	I-Claim
288	when	N	I-Claim
289	compared	N	I-Claim
290	to	N	I-Claim
291	PVI	N	I-Claim
292	5-FU	N	I-Claim
293	alone	N	I-Claim
294	but	N	I-Claim
295	no	N	I-Claim
296	overall	N	I-Claim
297	survival	N	I-Claim
298	advantage	N	I-Claim
299	.	N	I-Claim

300	There	N	I-Premise
301	is	N	I-Premise
302	no	N	I-Premise
303	irreversible	N	I-Premise
304	toxicity	N	I-Premise
305	with	N	I-Premise
306	MMC	N	I-Premise
307	at	N	I-Premise
308	a	N	I-Premise
309	cumulative	N	I-Premise
310	dose	N	I-Premise
311	of	N	I-Premise
312	28	N	I-Premise
313	mg/m2	N	I-Premise
314	.	N	I-Premise

1	The	N	O
2	effectiveness	N	O
3	of	N	O
4	a	N	O
5	Pain	N	O
6	Education	N	O
7	Program	N	O
8	in	N	O
9	cancer	N	O
10	patients	N	O
11	with	N	O
12	chronic	N	O
13	pain	N	O
14	offered	N	O
15	by	N	O
16	nurses	N	O
17	was	N	O
18	investigated	N	O
19	in	N	O
20	a	N	O
21	randomized	N	O
22	controlled	N	O
23	clinical	N	O
24	trial	N	O
25	.	N	O

26	A	N	O
27	multi-method	N	O
28	approach	N	O
29	was	N	O
30	used	N	O
31	in	N	O
32	which	N	O
33	verbal	N	O
34	instruction	N	O
35	,	N	O
36	written	N	O
37	material	N	O
38	,	N	O
39	an	N	O
40	audio	N	O
41	cassette	N	O
42	tape	N	O
43	,	N	O
44	and	N	O
45	the	N	O
46	use	N	O
47	of	N	O
48	a	N	O
49	pain	N	O
50	diary	N	O
51	were	N	O
52	combined	N	O
53	to	N	O
54	inform	N	O
55	and	N	O
56	instruct	N	O
57	patients	N	O
58	about	N	O
59	pain	N	O
60	and	N	O
61	pain	N	O
62	management	N	O
63	.	N	O

64	The	N	O
65	Pain	N	O
66	Education	N	O
67	Program	N	O
68	was	N	O
69	tailored	N	O
70	to	N	O
71	the	N	O
72	needs	N	O
73	of	N	O
74	the	N	O
75	individual	N	O
76	patient	N	O
77	and	N	O
78	consisted	N	O
79	of	N	O
80	three	N	O
81	elements	N	O
82	:	N	O
83	(	N	O
84	1	N	O
85	)	N	O
86	educating	N	O
87	patients	N	O
88	about	N	O
89	the	N	O
90	basic	N	O
91	principles	N	O
92	regarding	N	O
93	pain	N	O
94	and	N	O
95	pain	N	O
96	management	N	O
97	;	N	O
98	(	N	O
99	2	N	O
100	)	N	O
101	instructing	N	O
102	patients	N	O
103	how	N	O
104	to	N	O
105	report	N	O
106	their	N	O
107	pain	N	O
108	in	N	O
109	a	N	O
110	pain	N	O
111	diary	N	O
112	;	N	O
113	and	N	O
114	(	N	O
115	3	N	O
116	)	N	O
117	instructing	N	O
118	patients	N	O
119	how	N	O
120	to	N	O
121	communicate	N	O
122	about	N	O
123	pain	N	O
124	and	N	O
125	how	N	O
126	to	N	O
127	contact	N	O
128	health	N	O
129	care	N	O
130	providers	N	O
131	.	N	O

132	Following	N	O
133	pretesting	N	O
134	in	N	O
135	313	N	O
136	patients	N	O
137	,	N	O
138	patients	N	O
139	who	N	O
140	needed	N	O
141	district	N	O
142	nursing	N	O
143	and	N	O
144	who	N	O
145	did	N	O
146	not	N	O
147	need	N	O
148	district	N	O
149	nursing	N	O
150	at	N	O
151	home	N	O
152	were	N	O
153	randomly	N	O
154	assigned	N	O
155	to	N	O
156	a	N	O
157	control	N	O
158	or	N	O
159	intervention	N	O
160	group	N	O
161	.	N	O

162	Intervention	N	O
163	group	N	O
164	patients	N	O
165	received	N	O
166	the	N	O
167	Pain	N	O
168	Education	N	O
169	Program	N	O
170	in	N	O
171	the	N	O
172	hospital	N	O
173	,	N	O
174	and	N	O
175	3	N	O
176	and	N	O
177	7	N	O
178	days	N	O
179	postdischarge	N	O
180	by	N	O
181	telephone	N	O
182	;	N	O
183	this	N	O
184	was	N	O
185	done	N	O
186	by	N	O
187	nurses	N	O
188	who	N	O
189	were	N	O
190	specially	N	O
191	trained	N	O
192	as	N	O
193	pain	N	O
194	counselors	N	O
195	.	N	O

196	Follow-up	N	O
197	assessments	N	O
198	were	N	O
199	at	N	O
200	2	N	O
201	,	N	O
202	4	N	O
203	and	N	O
204	8	N	O
205	weeks	N	O
206	postdischarge	N	O
207	.	N	O

208	Results	N	O
209	of	N	O
210	the	N	O
211	pretest	N	O
212	showed	N	O
213	that	N	O
214	many	N	O
215	patients	N	O
216	lacked	N	O
217	knowledge	N	O
218	about	N	O
219	pain	N	O
220	and	N	O
221	pain	N	O
222	management	N	O
223	.	N	O

224	The	N	O
225	majority	N	O
226	of	N	O
227	pain	N	O
228	topics	N	O
229	had	N	O
230	to	N	O
231	be	N	O
232	discussed	N	O
233	.	N	O

234	The	N	I-Claim
235	Pain	N	I-Claim
236	Education	N	I-Claim
237	Program	N	I-Claim
238	proved	N	I-Claim
239	to	N	I-Claim
240	be	N	I-Claim
241	feasible	N	I-Claim
242	:	N	I-Claim
243	75.0	N	I-Premise
244	%	N	I-Premise
245	of	N	I-Premise
246	the	N	I-Premise
247	patients	N	I-Premise
248	had	N	I-Premise
249	read	N	I-Premise
250	the	N	I-Premise
251	entire	N	I-Premise
252	pain	N	I-Premise
253	brochure	N	I-Premise
254	,	N	I-Premise
255	55.7	N	I-Premise
256	%	N	I-Premise
257	had	N	I-Premise
258	listened	N	I-Premise
259	to	N	I-Premise
260	the	N	I-Premise
261	audio	N	I-Premise
262	cassette	N	I-Premise
263	,	N	I-Premise
264	and	N	I-Premise
265	85.6	N	I-Premise
266	%	N	I-Premise
267	of	N	I-Premise
268	pain	N	I-Premise
269	scores	N	I-Premise
270	were	N	I-Premise
271	completed	N	I-Premise
272	in	N	I-Premise
273	the	N	I-Premise
274	pain	N	I-Premise
275	diary	N	I-Premise
276	.	N	I-Premise

277	Results	N	I-Claim
278	showed	N	I-Claim
279	a	N	I-Claim
280	significant	N	I-Claim
281	increase	N	I-Claim
282	in	N	I-Claim
283	pain	N	I-Claim
284	knowledge	N	I-Claim
285	in	N	I-Claim
286	patients	N	I-Claim
287	who	N	I-Claim
288	received	N	I-Claim
289	the	N	I-Claim
290	Pain	N	I-Claim
291	Education	N	I-Claim
292	Program	N	I-Claim
293	and	N	I-Claim
294	a	N	I-Claim
295	significant	N	I-Claim
296	decrease	N	I-Claim
297	in	N	I-Claim
298	pain	N	I-Claim
299	intensity	N	I-Claim
300	.	N	I-Claim

301	However	N	I-Premise
302	,	N	I-Premise
303	pain	N	I-Premise
304	relief	N	I-Premise
305	was	N	I-Premise
306	mainly	N	I-Premise
307	found	N	I-Premise
308	in	N	I-Premise
309	the	N	I-Premise
310	intervention	N	I-Premise
311	group	N	I-Premise
312	patients	N	I-Premise
313	without	N	I-Premise
314	district	N	I-Premise
315	nursing	N	I-Premise
316	.	N	I-Premise

317	It	N	I-Claim
318	can	N	I-Claim
319	be	N	I-Claim
320	concluded	N	I-Claim
321	that	N	I-Claim
322	the	N	I-Claim
323	tailored	N	I-Claim
324	Pain	N	I-Claim
325	Education	N	I-Claim
326	Program	N	I-Claim
327	is	N	I-Claim
328	effective	N	I-Claim
329	for	N	I-Claim
330	cancer	N	I-Claim
331	patients	N	I-Claim
332	in	N	I-Claim
333	chronic	N	I-Claim
334	pain	N	I-Claim
335	.	N	I-Claim

336	The	N	I-MajorClaim
337	use	N	I-MajorClaim
338	of	N	I-MajorClaim
339	the	N	I-MajorClaim
340	Pain	N	I-MajorClaim
341	Education	N	I-MajorClaim
342	Program	N	I-MajorClaim
343	by	N	I-MajorClaim
344	nurses	N	I-MajorClaim
345	should	N	I-MajorClaim
346	be	N	I-MajorClaim
347	seriously	N	I-MajorClaim
348	considered	N	I-MajorClaim
349	on	N	I-MajorClaim
350	oncology	N	I-MajorClaim
351	units	N	I-MajorClaim
352	.	N	I-MajorClaim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	evaluate	N	O
9	pamidronate	N	O
10	for	N	O
11	bone	N	O
12	pain	N	O
13	in	N	O
14	a	N	O
15	randomised	N	O
16	double-blind	N	O
17	trial	N	O
18	and	N	O
19	to	N	O
20	evaluate	N	O
21	the	N	O
22	contribution	N	O
23	of	N	O
24	new	N	O
25	markers	N	O
26	of	N	O
27	bone	N	O
28	resorption	N	O
29	in	N	O
30	patients	N	O
31	with	N	O
32	bone	N	O
33	metastases	N	O
34	.	N	O

35	Fifty-two	N	O
36	patients	N	O
37	with	N	O
38	painful	N	O
39	bone	N	O
40	metastases	N	O
41	were	N	O
42	randomised	N	O
43	to	N	O
44	receive	N	O
45	a	N	O
46	two-hour	N	O
47	infusion	N	O
48	of	N	O
49	pamidronate	N	O
50	120	N	O
51	mg	N	O
52	or	N	O
53	an	N	O
54	identical	N	O
55	infusion	N	O
56	of	N	O
57	saline	N	O
58	.	N	O

59	Four	N	O
60	weeks	N	O
61	later	N	O
62	,	N	O
63	all	N	O
64	patients	N	O
65	received	N	O
66	pamidronate	N	O
67	120	N	O
68	mg	N	O
69	.	N	O

70	Bone	N	O
71	resorption	N	O
72	markers	N	O
73	measured	N	O
74	included	N	O
75	urinary	N	O
76	calcium	N	O
77	(	N	O
78	uCa	N	O
79	)	N	O
80	,	N	O
81	hydroxyproline	N	O
82	(	N	O
83	Hyp	N	O
84	)	N	O
85	,	N	O
86	and	N	O
87	the	N	O
88	collagen	N	O
89	breakdown	N	O
90	products	N	O
91	:	N	O
92	NTx	N	O
93	,	N	O
94	Crosslaps	N	O
95	and	N	O
96	Free	N	O
97	Dpd	N	O
98	.	N	O

99	Symptomatic	N	I-Premise
100	response	N	I-Premise
101	during	N	I-Premise
102	the	N	I-Premise
103	first	N	I-Premise
104	four	N	I-Premise
105	weeks	N	I-Premise
106	was	N	I-Premise
107	seen	N	I-Premise
108	after	N	I-Premise
109	pamidronate	N	I-Premise
110	,	N	I-Premise
111	but	N	I-Premise
112	not	N	I-Premise
113	with	N	I-Premise
114	placebo	N	I-Premise
115	(	N	I-Premise
116	P	N	I-Premise
117	<	N	I-Premise
118	0.05	N	I-Premise
119	)	N	I-Premise
120	.	N	I-Premise

121	Quality	N	I-Premise
122	of	N	I-Premise
123	life	N	I-Premise
124	was	N	I-Premise
125	maintained	N	I-Premise
126	with	N	I-Premise
127	pamidronate	N	I-Premise
128	and	N	I-Premise
129	deteriorated	N	I-Premise
130	after	N	I-Premise
131	placebo	N	I-Premise
132	(	N	I-Premise
133	P	N	I-Premise
134	<	N	I-Premise
135	0.05	N	I-Premise
136	)	N	I-Premise
137	.	N	I-Premise

138	Resorption	N	I-Premise
139	markers	N	I-Premise
140	did	N	I-Premise
141	not	N	I-Premise
142	decrease	N	I-Premise
143	after	N	I-Premise
144	placebo	N	I-Premise
145	,	N	I-Premise
146	but	N	I-Premise
147	NTx	N	I-Premise
148	and	N	I-Premise
149	Crosslaps	N	I-Premise
150	both	N	I-Premise
151	decreased	N	I-Premise
152	by	N	I-Premise
153	70	N	I-Premise
154	%	N	I-Premise
155	after	N	I-Premise
156	pamidronate	N	I-Premise
157	(	N	I-Premise
158	P	N	I-Premise
159	=	N	I-Premise
160	0.001	N	I-Premise
161	)	N	I-Premise
162	.	N	I-Premise

163	A	N	I-Premise
164	second	N	I-Premise
165	infusion	N	I-Premise
166	of	N	I-Premise
167	pamidronate	N	I-Premise
168	did	N	I-Premise
169	not	N	I-Premise
170	decrease	N	I-Premise
171	resorption	N	I-Premise
172	further	N	I-Premise
173	,	N	I-Premise
174	but	N	I-Premise
175	maintained	N	I-Premise
176	the	N	I-Premise
177	suppression	N	I-Premise
178	of	N	I-Premise
179	resorption	N	I-Premise
180	at	N	I-Premise
181	similar	N	I-Premise
182	levels	N	I-Premise
183	for	N	I-Premise
184	a	N	I-Premise
185	further	N	I-Premise
186	four	N	I-Premise
187	weeks	N	I-Premise
188	.	N	I-Premise

189	Symptomatic	N	I-Premise
190	response	N	I-Premise
191	to	N	I-Premise
192	pamidronate	N	I-Premise
193	correlated	N	I-Premise
194	closely	N	I-Premise
195	with	N	I-Premise
196	the	N	I-Premise
197	rate	N	I-Premise
198	of	N	I-Premise
199	bone	N	I-Premise
200	resorption	N	I-Premise
201	;	N	I-Premise
202	it	N	I-Premise
203	was	N	I-Premise
204	more	N	I-Premise
205	frequent	N	I-Premise
206	in	N	I-Premise
207	those	N	I-Premise
208	patients	N	I-Premise
209	with	N	I-Premise
210	an	N	I-Premise
211	initial	N	I-Premise
212	NTx	N	I-Premise
213	value	N	I-Premise
214	of	N	I-Premise
215	<	N	I-Premise
216	2	N	I-Premise
217	times	N	I-Premise
218	the	N	I-Premise
219	upper	N	I-Premise
220	limit	N	I-Premise
221	of	N	I-Premise
222	normal	N	I-Premise
223	(	N	I-Premise
224	17	N	I-Premise
225	of	N	I-Premise
226	27	N	I-Premise
227	,	N	I-Premise
228	62	N	I-Premise
229	%	N	I-Premise
230	)	N	I-Premise
231	and	N	I-Premise
232	in	N	I-Premise
233	those	N	I-Premise
234	where	N	I-Premise
235	the	N	I-Premise
236	level	N	I-Premise
237	of	N	I-Premise
238	Ntx	N	I-Premise
239	returned	N	I-Premise
240	to	N	I-Premise
241	normal	N	I-Premise
242	(	N	I-Premise
243	19	N	I-Premise
244	of	N	I-Premise
245	32	N	I-Premise
246	,	N	I-Premise
247	59	N	I-Premise
248	%	N	I-Premise
249	)	N	I-Premise
250	,	N	I-Premise
251	than	N	I-Premise
252	in	N	I-Premise
253	the	N	I-Premise
254	patients	N	I-Premise
255	with	N	I-Premise
256	either	N	I-Premise
257	high	N	I-Premise
258	baseline	N	I-Premise
259	values	N	I-Premise
260	of	N	I-Premise
261	NTx	N	I-Premise
262	(	N	I-Premise
263	>	N	I-Premise
264	2	N	I-Premise
265	times	N	I-Premise
266	the	N	I-Premise
267	upper	N	I-Premise
268	limit	N	I-Premise
269	of	N	I-Premise
270	normal	N	I-Premise
271	)	N	I-Premise
272	or	N	I-Premise
273	Ntx	N	I-Premise
274	levels	N	I-Premise
275	which	N	I-Premise
276	failed	N	I-Premise
277	to	N	I-Premise
278	normalise	N	I-Premise
279	for	N	I-Premise
280	whom	N	I-Premise
281	the	N	I-Premise
282	response	N	I-Premise
283	frequencies	N	I-Premise
284	were	N	I-Premise
285	2	N	I-Premise
286	of	N	I-Premise
287	16	N	I-Premise
288	(	N	I-Premise
289	13	N	I-Premise
290	%	N	I-Premise
291	)	N	I-Premise
292	and	N	I-Premise
293	0	N	I-Premise
294	of	N	I-Premise
295	11	N	I-Premise
296	(	N	I-Premise
297	0	N	I-Premise
298	%	N	I-Premise
299	)	N	I-Premise
300	,	N	I-Premise
301	respectively	N	I-Premise
302	.	N	I-Premise

303	Subjective	N	I-Claim
304	benefit	N	I-Claim
305	after	N	I-Claim
306	intravenous	N	I-Claim
307	pamidronate	N	I-Claim
308	is	N	I-Claim
309	confirmed	N	I-Claim
310	in	N	I-Claim
311	this	N	I-Claim
312	placebo-controlled	N	I-Claim
313	study	N	I-Claim
314	.	N	I-Claim

315	The	N	I-Claim
316	new	N	I-Claim
317	bone	N	I-Claim
318	resorption	N	I-Claim
319	markers	N	I-Claim
320	of	N	I-Claim
321	collagen	N	I-Claim
322	breakdown	N	I-Claim
323	were	N	I-Claim
324	able	N	I-Claim
325	to	N	I-Claim
326	predict	N	I-Claim
327	clinical	N	I-Claim
328	response	N	I-Claim
329	to	N	I-Claim
330	pamidronate	N	I-Claim
331	.	N	I-Claim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	prospective	N	O
5	,	N	O
6	randomized	N	O
7	,	N	O
8	multicentre	N	O
9	clinical	N	O
10	trial	N	O
11	comparing	N	O
12	the	N	O
13	effects	N	O
14	and	N	O
15	costs	N	O
16	of	N	O
17	GM-CSF	N	O
18	as	N	O
19	an	N	O
20	adjunct	N	O
21	to	N	O
22	intensive	N	O
23	chemotherapy	N	O
24	in	N	O
25	elderly	N	O
26	patients	N	O
27	with	N	O
28	acute	N	O
29	myeloid	N	O
30	leukaemia	N	O
31	(	N	O
32	AML	N	O
33	)	N	O
34	.	N	O

35	The	N	O
36	patients	N	O
37	were	N	O
38	randomized	N	O
39	to	N	O
40	either	N	O
41	daunomycin-cytosine	N	O
42	arabinoside	N	O
43	(	N	O
44	control	N	O
45	arm	N	O
46	:	N	O
47	n	N	O
48	=	N	O
49	161	N	O
50	)	N	O
51	or	N	O
52	daunomycin-cytosine	N	O
53	arabinoside	N	O
54	with	N	O
55	GM-CSF	N	O
56	(	N	O
57	GM-CSF	N	O
58	arm	N	O
59	:	N	O
60	n	N	O
61	=	N	O
62	157	N	O
63	)	N	O
64	.	N	O

65	The	N	O
66	primary	N	O
67	end-point	N	O
68	was	N	O
69	the	N	O
70	effect	N	O
71	of	N	O
72	GM-CSF	N	O
73	on	N	O
74	the	N	O
75	percentage	N	O
76	of	N	O
77	complete	N	O
78	remissions	N	O
79	(	N	O
80	CR	N	O
81	)	N	O
82	.	N	O

83	Survival	N	O
84	duration	N	O
85	,	N	O
86	disease-free	N	O
87	survival	N	O
88	,	N	O
89	quality	N	O
90	of	N	O
91	life	N	O
92	and	N	O
93	costs	N	O
94	were	N	O
95	evaluated	N	O
96	separately	N	O
97	.	N	O

98	CR	N	I-Premise
99	after	N	I-Premise
100	remission	N	I-Premise
101	induction	N	I-Premise
102	treatment	N	I-Premise
103	was	N	I-Premise
104	achieved	N	I-Premise
105	in	N	I-Premise
106	55	N	I-Premise
107	%	N	I-Premise
108	of	N	I-Premise
109	the	N	I-Premise
110	patients	N	I-Premise
111	in	N	I-Premise
112	the	N	I-Premise
113	control	N	I-Premise
114	group	N	I-Premise
115	and	N	I-Premise
116	in	N	I-Premise
117	56	N	I-Premise
118	%	N	I-Premise
119	of	N	I-Premise
120	the	N	I-Premise
121	patients	N	I-Premise
122	in	N	I-Premise
123	the	N	I-Premise
124	GM-CSF	N	I-Premise
125	group	N	I-Premise
126	(	N	I-Premise
127	P	N	I-Premise
128	=	N	I-Premise
129	NS	N	I-Premise
130	)	N	I-Premise
131	.	N	I-Premise

132	The	N	I-Premise
133	duration	N	I-Premise
134	of	N	I-Premise
135	survival	N	I-Premise
136	and	N	I-Premise
137	disease-free	N	I-Premise
138	survival	N	I-Premise
139	at	N	I-Premise
140	2	N	I-Premise
141	years	N	I-Premise
142	after	N	I-Premise
143	randomization	N	I-Premise
144	were	N	I-Premise
145	estimated	N	I-Premise
146	at	N	I-Premise
147	22	N	I-Premise
148	%	N	I-Premise
149	and	N	I-Premise
150	19	N	I-Premise
151	%	N	I-Premise
152	for	N	I-Premise
153	the	N	I-Premise
154	control	N	I-Premise
155	group	N	I-Premise
156	and	N	I-Premise
157	22	N	I-Premise
158	%	N	I-Premise
159	and	N	I-Premise
160	14	N	I-Premise
161	%	N	I-Premise
162	for	N	I-Premise
163	the	N	I-Premise
164	GM-CSF	N	I-Premise
165	group	N	I-Premise
166	(	N	I-Premise
167	P	N	I-Premise
168	=	N	I-Premise
169	NS	N	I-Premise
170	)	N	I-Premise
171	.	N	I-Premise

172	Considering	N	I-Premise
173	the	N	I-Premise
174	short-term	N	I-Premise
175	quality	N	I-Premise
176	of	N	I-Premise
177	life	N	I-Premise
178	,	N	I-Premise
179	the	N	I-Premise
180	administration	N	I-Premise
181	of	N	I-Premise
182	GM-CSF	N	I-Premise
183	resulted	N	I-Premise
184	in	N	I-Premise
185	more	N	I-Premise
186	problems	N	I-Premise
187	with	N	I-Premise
188	regard	N	I-Premise
189	to	N	I-Premise
190	depressed	N	I-Premise
191	mood	N	I-Premise
192	,	N	I-Premise
193	diarrhoea	N	I-Premise
194	and	N	I-Premise
195	rash/eczema	N	I-Premise
196	.	N	I-Premise

197	With	N	I-Premise
198	regard	N	I-Premise
199	to	N	I-Premise
200	the	N	I-Premise
201	long-term	N	I-Premise
202	quality	N	I-Premise
203	of	N	I-Premise
204	life	N	I-Premise
205	there	N	I-Premise
206	were	N	I-Premise
207	no	N	I-Premise
208	significant	N	I-Premise
209	differences	N	I-Premise
210	between	N	I-Premise
211	the	N	I-Premise
212	two	N	I-Premise
213	groups	N	I-Premise
214	.	N	I-Premise

215	The	N	I-Premise
216	average	N	I-Premise
217	costs	N	I-Premise
218	of	N	I-Premise
219	the	N	I-Premise
220	primary	N	I-Premise
221	treatment	N	I-Premise
222	were	N	I-Premise
223	higher	N	I-Premise
224	in	N	I-Premise
225	GM-CSF-treated	N	I-Premise
226	patients	N	I-Premise
227	than	N	I-Premise
228	in	N	I-Premise
229	the	N	I-Premise
230	control	N	I-Premise
231	group	N	I-Premise
232	,	N	I-Premise
233	i.e	N	I-Premise
234	.	N	I-Premise

235	US	N	I-Premise
236	$	N	I-Premise
237	40782	N	I-Premise
238	and	N	I-Premise
239	US	N	I-Premise
240	$	N	I-Premise
241	34465	N	I-Premise
242	,	N	I-Premise
243	respectively	N	I-Premise
244	(	N	I-Premise
245	P	N	I-Premise
246	<	N	I-Premise
247	0.01	N	I-Premise
248	)	N	I-Premise
249	.	N	I-Premise

250	The	N	I-Premise
251	costs	N	I-Premise
252	during	N	I-Premise
253	the	N	I-Premise
254	follow-up	N	I-Premise
255	period	N	I-Premise
256	did	N	I-Premise
257	not	N	I-Premise
258	differ	N	I-Premise
259	between	N	I-Premise
260	the	N	I-Premise
261	two	N	I-Premise
262	groups	N	I-Premise
263	.	N	I-Premise

264	The	N	I-Claim
265	results	N	I-Claim
266	of	N	I-Claim
267	this	N	I-Claim
268	randomized	N	I-Claim
269	clinical	N	I-Claim
270	trial	N	I-Claim
271	indicate	N	I-Claim
272	that	N	I-Claim
273	daunomycin-cytosine	N	I-Claim
274	arabinoside	N	I-Claim
275	plus	N	I-Claim
276	GM-CSF	N	I-Claim
277	is	N	I-Claim
278	not	N	I-Claim
279	a	N	I-Claim
280	cost-effective	N	I-Claim
281	treatment	N	I-Claim
282	strategy	N	I-Claim
283	when	N	I-Claim
284	compared	N	I-Claim
285	with	N	I-Claim
286	daunomycin-cytosine	N	I-Claim
287	arabinoside	N	I-Claim
288	alone	N	I-Claim
289	.	N	I-Claim

1	Although	N	O
2	many	N	O
3	drug	N	O
4	combination	N	O
5	therapies	N	O
6	have	N	O
7	been	N	O
8	proposed	N	O
9	,	N	O
10	there	N	I-MajorClaim
11	is	N	I-MajorClaim
12	no	N	I-MajorClaim
13	standard	N	I-MajorClaim
14	therapy	N	I-MajorClaim
15	for	N	I-MajorClaim
16	patients	N	I-MajorClaim
17	with	N	I-MajorClaim
18	advanced	N	I-MajorClaim
19	gastric	N	I-MajorClaim
20	carcinoma	N	I-MajorClaim
21	.	N	I-MajorClaim

22	The	N	I-Claim
23	superiority	N	I-Claim
24	of	N	I-Claim
25	combination	N	I-Claim
26	therapy	N	I-Claim
27	over	N	I-Claim
28	monochemotherapy	N	I-Claim
29	has	N	I-Claim
30	not	N	I-Claim
31	been	N	I-Claim
32	demonstrated	N	I-Claim
33	convincingly	N	I-Claim
34	.	N	I-Claim

35	To	N	O
36	explore	N	O
37	the	N	O
38	role	N	O
39	of	N	O
40	monochemotherapy	N	O
41	,	N	O
42	the	N	O
43	authors	N	O
44	evaluated	N	O
45	5-fluorouracil	N	O
46	(	N	O
47	5-FU	N	O
48	)	N	O
49	,	N	O
50	modulated	N	O
51	by	N	O
52	6S-leucovorin	N	O
53	(	N	O
54	6S-LV	N	O
55	)	N	O
56	and	N	O
57	a	N	O
58	cisplatin-containing	N	O
59	regimen	N	O
60	,	N	O
61	which	N	O
62	was	N	O
63	comprised	N	O
64	of	N	O
65	epirubicin	N	O
66	,	N	O
67	etoposide	N	O
68	,	N	O
69	and	N	O
70	cisplatin	N	O
71	with	N	O
72	the	N	O
73	addition	N	O
74	of	N	O
75	the	N	O
76	reversal	N	O
77	agent	N	O
78	lonidamine	N	O
79	(	N	O
80	EEP-L	N	O
81	)	N	O
82	.	N	O

83	After	N	O
84	stratification	N	O
85	according	N	O
86	to	N	O
87	performance	N	O
88	status	N	O
89	(	N	O
90	PS	N	O
91	)	N	O
92	and	N	O
93	resection	N	O
94	of	N	O
95	the	N	O
96	primary	N	O
97	tumor	N	O
98	,	N	O
99	72	N	O
100	patients	N	O
101	with	N	O
102	advanced	N	O
103	gastric	N	O
104	carcinoma	N	O
105	were	N	O
106	randomized	N	O
107	to	N	O
108	2	N	O
109	parallel	N	O
110	Phase	N	O
111	II	N	O
112	trials	N	O
113	with	N	O
114	5-FU/6S-LV	N	O
115	and	N	O
116	EEP-L	N	O
117	,	N	O
118	respectively	N	O
119	.	N	O

120	Thirty-six	N	O
121	patients	N	O
122	in	N	O
123	Study	N	O
124	A	N	O
125	received	N	O
126	bolus	N	O
127	6S-LV	N	O
128	,	N	O
129	100	N	O
130	mg/m2	N	O
131	,	N	O
132	followed	N	O
133	by	N	O
134	bolus	N	O
135	5-FU	N	O
136	,	N	O
137	370	N	O
138	mg/m2	N	O
139	,	N	O
140	on	N	O
141	Days	N	O
142	1-5	N	O
143	and	N	O
144	36	N	O
145	others	N	O
146	in	N	O
147	Study	N	O
148	B	N	O
149	received	N	O
150	epirubicin	N	O
151	,	N	O
152	30	N	O
153	mg/m2	N	O
154	,	N	O
155	on	N	O
156	Days	N	O
157	1	N	O
158	and	N	O
159	5	N	O
160	;	N	O
161	etoposide	N	O
162	,	N	O
163	100	N	O
164	mg/m2	N	O
165	,	N	O
166	on	N	O
167	Days	N	O
168	1	N	O
169	,	N	O
170	3	N	O
171	,	N	O
172	and	N	O
173	5	N	O
174	;	N	O
175	cisplatin	N	O
176	,	N	O
177	30	N	O
178	mg/m2	N	O
179	,	N	O
180	on	N	O
181	Days	N	O
182	2	N	O
183	and	N	O
184	4	N	O
185	;	N	O
186	and	N	O
187	lonidamine	N	O
188	,	N	O
189	150	N	O
190	mg/day	N	O
191	.	N	O

192	There	N	O
193	were	N	O
194	6	N	O
195	partial	N	O
196	responses	N	O
197	(	N	O
198	18.2	N	O
199	%	N	O
200	)	N	O
201	(	N	O
202	95	N	O
203	%	N	O
204	confidence	N	O
205	interval	N	O
206	[	N	O
207	CI	N	O
208	]	N	O
209	+/-	N	O
210	13.2	N	O
211	)	N	O
212	in	N	O
213	Study	N	O
214	A	N	O
215	and	N	O
216	7	N	O
217	partial	N	O
218	responses	N	O
219	(	N	O
220	21.9	N	O
221	%	N	O
222	)	N	O
223	(	N	O
224	95	N	O
225	%	N	O
226	CI	N	O
227	+/-	N	O
228	14.3	N	O
229	)	N	O
230	in	N	O
231	Study	N	O
232	B	N	O
233	.	N	O

234	Partial	N	O
235	responses	N	O
236	were	N	O
237	more	N	O
238	frequent	N	O
239	in	N	O
240	patients	N	O
241	with	N	O
242	resected	N	O
243	tumors	N	O
244	or	N	O
245	with	N	O
246	an	N	O
247	Eastern	N	O
248	Cooperative	N	O
249	Oncology	N	O
250	Group	N	O
251	PS	N	O
252	of	N	O
253	0-1	N	O
254	.	N	O

255	The	N	I-Premise
256	median	N	I-Premise
257	duration	N	I-Premise
258	of	N	I-Premise
259	response	N	I-Premise
260	was	N	I-Premise
261	8.8	N	I-Premise
262	and	N	I-Premise
263	8.3	N	I-Premise
264	months	N	I-Premise
265	,	N	I-Premise
266	respectively	N	I-Premise
267	,	N	I-Premise
268	in	N	I-Premise
269	Study	N	I-Premise
270	A	N	I-Premise
271	and	N	I-Premise
272	Study	N	I-Premise
273	B	N	I-Premise
274	.	N	I-Premise

275	The	N	I-Premise
276	median	N	I-Premise
277	survival	N	I-Premise
278	reached	N	I-Premise
279	8	N	I-Premise
280	months	N	I-Premise
281	in	N	I-Premise
282	Study	N	I-Premise
283	A	N	I-Premise
284	and	N	I-Premise
285	9	N	I-Premise
286	months	N	I-Premise
287	in	N	I-Premise
288	Study	N	I-Premise
289	B	N	I-Premise
290	.	N	I-Premise

291	In	N	I-Premise
292	the	N	I-Premise
293	whole	N	I-Premise
294	population	N	I-Premise
295	of	N	I-Premise
296	patients	N	I-Premise
297	survival	N	I-Premise
298	was	N	I-Premise
299	significantly	N	I-Premise
300	higher	N	I-Premise
301	in	N	I-Premise
302	patients	N	I-Premise
303	with	N	I-Premise
304	a	N	I-Premise
305	PS	N	I-Premise
306	of	N	I-Premise
307	0-1	N	I-Premise
308	(	N	I-Premise
309	P	N	I-Premise
310	<	N	I-Premise
311	0.05	N	I-Premise
312	)	N	I-Premise
313	.	N	I-Premise

314	Patients	N	I-Premise
315	with	N	I-Premise
316	a	N	I-Premise
317	PS	N	I-Premise
318	of	N	I-Premise
319	0-1	N	I-Premise
320	and	N	I-Premise
321	a	N	I-Premise
322	resected	N	I-Premise
323	tumor	N	I-Premise
324	had	N	I-Premise
325	the	N	I-Premise
326	significantly	N	I-Premise
327	longest	N	I-Premise
328	survival	N	I-Premise
329	both	N	I-Premise
330	in	N	I-Premise
331	EEP-L	N	I-Premise
332	treated	N	I-Premise
333	patients	N	I-Premise
334	and	N	I-Premise
335	in	N	I-Premise
336	all	N	I-Premise
337	evaluable	N	I-Premise
338	patients	N	I-Premise
339	in	N	I-Premise
340	the	N	I-Premise
341	two	N	I-Premise
342	studies	N	I-Premise
343	.	N	I-Premise

344	The	N	I-Premise
345	most	N	I-Premise
346	frequent	N	I-Premise
347	World	N	I-Premise
348	Health	N	I-Premise
349	Organization	N	I-Premise
350	Grade	N	I-Premise
351	3-4	N	I-Premise
352	toxic	N	I-Premise
353	effects	N	I-Premise
354	were	N	I-Premise
355	gastrointestinal	N	I-Premise
356	in	N	I-Premise
357	Study	N	I-Premise
358	A	N	I-Premise
359	and	N	I-Premise
360	hematologic	N	I-Premise
361	in	N	I-Premise
362	Study	N	I-Premise
363	B	N	I-Premise
364	.	N	I-Premise

365	No	N	I-Premise
366	treatment-related	N	I-Premise
367	death	N	I-Premise
368	was	N	I-Premise
369	observed	N	I-Premise
370	.	N	I-Premise

371	The	N	I-Claim
372	efficacy	N	I-Claim
373	of	N	I-Claim
374	5-FU	N	I-Claim
375	,	N	I-Claim
376	modulated	N	I-Claim
377	with	N	I-Claim
378	6S-LV	N	I-Claim
379	,	N	I-Claim
380	is	N	I-Claim
381	moderate	N	I-Claim
382	in	N	I-Claim
383	patients	N	I-Claim
384	with	N	I-Claim
385	advanced	N	I-Claim
386	gastric	N	I-Claim
387	carcinoma	N	I-Claim
388	,	N	I-Claim
389	similar	N	I-Claim
390	to	N	I-Claim
391	cisplatin-containing	N	I-Claim
392	regimens	N	I-Claim
393	.	N	I-Claim

394	PS	N	I-Claim
395	and	N	I-Claim
396	other	N	I-Claim
397	prognostic	N	I-Claim
398	factors	N	I-Claim
399	could	N	I-Claim
400	influence	N	I-Claim
401	the	N	I-Claim
402	response	N	I-Claim
403	rate	N	I-Claim
404	,	N	I-Claim
405	which	N	I-Claim
406	does	N	I-Claim
407	not	N	I-Claim
408	appear	N	I-Claim
409	to	N	I-Claim
410	be	N	I-Claim
411	a	N	I-Claim
412	reliable	N	I-Claim
413	parameter	N	I-Claim
414	for	N	I-Claim
415	evaluating	N	I-Claim
416	the	N	I-Claim
417	outcome	N	I-Claim
418	of	N	I-Claim
419	chemotherapy	N	I-Claim
420	trials	N	I-Claim
421	.	N	I-Claim

1	The	N	O
2	Intergroup	N	O
3	conducted	N	O
4	this	N	O
5	breast	N	O
6	cancer	N	O
7	adjuvant	N	O
8	trial	N	O
9	to	N	O
10	compare	N	O
11	an	N	O
12	investigational	N	O
13	16-week	N	O
14	regimen	N	O
15	with	N	O
16	cyclophosphamide	N	O
17	,	N	O
18	doxorubicin	N	O
19	,	N	O
20	and	N	O
21	fluorouracil	N	O
22	(	N	O
23	5-FU	N	O
24	;	N	O
25	CAF	N	O
26	)	N	O
27	.	N	O

28	The	N	O
29	16-week	N	O
30	regimen	N	O
31	features	N	O
32	greater	N	O
33	doxorubicin	N	O
34	and	N	O
35	5-FU	N	O
36	dose-intensity	N	O
37	than	N	O
38	CAF	N	O
39	and	N	O
40	improved	N	O
41	scheduling	N	O
42	of	N	O
43	antimetabolites	N	O
44	with	N	O
45	sequential	N	O
46	methotrexate	N	O
47	and	N	O
48	5-FU	N	O
49	,	N	O
50	as	N	O
51	well	N	O
52	as	N	O
53	infusion	N	O
54	5-FU	N	O
55	.	N	O

56	A	N	O
57	total	N	O
58	of	N	O
59	646	N	O
60	node-positive	N	O
61	,	N	O
62	receptor-negative	N	O
63	patients	N	O
64	were	N	O
65	randomly	N	O
66	assigned	N	O
67	to	N	O
68	receive	N	O
69	either	N	O
70	the	N	O
71	1	N	O
72	6-week	N	O
73	regimen	N	O
74	or	N	O
75	six	N	O
76	cycles	N	O
77	of	N	O
78	CAF	N	O
79	.	N	O

80	Breast	N	O
81	cancer	N	O
82	outcomes	N	O
83	included	N	O
84	recurrence	N	O
85	as	N	O
86	well	N	O
87	as	N	O
88	disease-free	N	O
89	and	N	O
90	overall	N	O
91	survival	N	O
92	.	N	O

93	Toxicity	N	O
94	was	N	O
95	evaluated	N	O
96	by	N	O
97	the	N	O
98	Common	N	O
99	Toxicity	N	O
100	Criteria	N	O
101	(	N	O
102	CTC	N	O
103	)	N	O
104	.	N	O

105	Treatment-related	N	O
106	quality	N	O
107	of	N	O
108	life	N	O
109	was	N	O
110	assessed	N	O
111	by	N	O
112	the	N	O
113	Breast	N	O
114	Chemotherapy	N	O
115	Questionnaire	N	O
116	(	N	O
117	BCQ	N	O
118	)	N	O
119	before	N	O
120	,	N	O
121	during	N	O
122	,	N	O
123	and	N	O
124	4	N	O
125	months	N	O
126	after	N	O
127	treatment	N	O
128	in	N	O
129	163	N	O
130	patients	N	O
131	.	N	O

132	The	N	O
133	trial	N	O
134	was	N	O
135	designed	N	O
136	to	N	O
137	use	N	O
138	one-sided	N	O
139	tests	N	O
140	of	N	O
141	significance	N	O
142	for	N	O
143	power	N	O
144	calculations	N	O
145	,	N	O
146	but	N	O
147	is	N	O
148	now	N	O
149	reported	N	O
150	with	N	O
151	both	N	O
152	one-sided	N	O
153	and	N	O
154	the	N	O
155	traditional	N	O
156	two-sided	N	O
157	tests	N	O
158	of	N	O
159	significance	N	O
160	.	N	O

161	At	N	I-Premise
162	a	N	I-Premise
163	median	N	I-Premise
164	follow-up	N	I-Premise
165	of	N	I-Premise
166	3.9	N	I-Premise
167	years	N	I-Premise
168	,	N	I-Premise
169	the	N	I-Premise
170	estimated	N	I-Premise
171	4-year	N	I-Premise
172	recurrence-free	N	I-Premise
173	survival	N	I-Premise
174	rate	N	I-Premise
175	was	N	I-Premise
176	67.5	N	I-Premise
177	%	N	I-Premise
178	with	N	I-Premise
179	the	N	I-Premise
180	16-week	N	I-Premise
181	regimen	N	I-Premise
182	versus	N	I-Premise
183	62.7	N	I-Premise
184	%	N	I-Premise
185	with	N	I-Premise
186	CAF	N	I-Premise
187	(	N	I-Premise
188	P	N	I-Premise
189	=	N	I-Premise
190	.19	N	I-Premise
191	,	N	I-Premise
192	two-sided	N	I-Premise
193	;	N	I-Premise
194	P	N	I-Premise
195	=	N	I-Premise
196	.095	N	I-Premise
197	,	N	I-Premise
198	one-sided	N	I-Premise
199	)	N	I-Premise
200	.	N	I-Premise

201	The	N	I-Premise
202	estimated	N	I-Premise
203	4-year	N	I-Premise
204	survival	N	I-Premise
205	rate	N	I-Premise
206	was	N	I-Premise
207	78.1	N	I-Premise
208	%	N	I-Premise
209	with	N	I-Premise
210	the	N	I-Premise
211	16-week	N	I-Premise
212	regimen	N	I-Premise
213	versus	N	I-Premise
214	71.4	N	I-Premise
215	%	N	I-Premise
216	with	N	I-Premise
217	CAF	N	I-Premise
218	(	N	I-Premise
219	P	N	I-Premise
220	=	N	I-Premise
221	.10	N	I-Premise
222	,	N	I-Premise
223	two-sided	N	I-Premise
224	;	N	I-Premise
225	P	N	I-Premise
226	=	N	I-Premise
227	.05	N	I-Premise
228	,	N	I-Premise
229	one-sided	N	I-Premise
230	)	N	I-Premise
231	.	N	I-Premise

232	CAF	N	I-Premise
233	produced	N	I-Premise
234	significantly	N	I-Premise
235	higher	N	I-Premise
236	grades	N	I-Premise
237	of	N	I-Premise
238	leukopenia	N	I-Premise
239	,	N	I-Premise
240	granulocytopenia	N	I-Premise
241	,	N	I-Premise
242	and	N	I-Premise
243	thrombocytopenia	N	I-Premise
244	,	N	I-Premise
245	as	N	I-Premise
246	well	N	I-Premise
247	as	N	I-Premise
248	liver	N	I-Premise
249	and	N	I-Premise
250	cardiac	N	I-Premise
251	toxicity	N	I-Premise
252	,	N	I-Premise
253	whereas	N	O
254	the	N	I-Premise
255	16-week	N	I-Premise
256	regimen	N	I-Premise
257	produced	N	I-Premise
258	significantly	N	I-Premise
259	higher	N	I-Premise
260	grades	N	I-Premise
261	of	N	I-Premise
262	anemia	N	I-Premise
263	,	N	I-Premise
264	nausea	N	I-Premise
265	,	N	I-Premise
266	stomatitis	N	I-Premise
267	,	N	I-Premise
268	and	N	I-Premise
269	weight	N	I-Premise
270	loss	N	I-Premise
271	,	N	I-Premise
272	as	N	I-Premise
273	well	N	I-Premise
274	as	N	I-Premise
275	skin	N	I-Premise
276	and	N	I-Premise
277	neurotoxicity	N	I-Premise
278	.	N	I-Premise

279	There	N	I-Premise
280	were	N	I-Premise
281	three	N	I-Premise
282	treatment-related	N	I-Premise
283	deaths	N	I-Premise
284	with	N	I-Premise
285	CAF	N	I-Premise
286	but	N	I-Premise
287	none	N	I-Premise
288	with	N	I-Premise
289	the	N	I-Premise
290	16-week	N	I-Premise
291	regimen	N	I-Premise
292	.	N	I-Premise

293	During	N	I-Premise
294	treatment	N	I-Premise
295	,	N	I-Premise
296	quality	N	I-Premise
297	of	N	I-Premise
298	life	N	I-Premise
299	declined	N	I-Premise
300	significantly	N	I-Premise
301	more	N	I-Premise
302	with	N	I-Premise
303	the	N	I-Premise
304	16-week	N	I-Premise
305	regimen	N	I-Premise
306	than	N	I-Premise
307	CAF	N	I-Premise
308	,	N	I-Premise
309	but	N	I-Premise
310	by	N	I-Premise
311	4	N	I-Premise
312	months	N	I-Premise
313	posttreatment	N	I-Premise
314	,	N	I-Premise
315	there	N	I-Premise
316	was	N	I-Premise
317	no	N	I-Premise
318	difference	N	I-Premise
319	.	N	I-Premise

320	The	N	I-Premise
321	16-week	N	I-Premise
322	regimen	N	I-Premise
323	produced	N	I-Premise
324	marginally	N	I-Premise
325	better	N	I-Premise
326	breast	N	I-Premise
327	cancer	N	I-Premise
328	outcomes	N	I-Premise
329	than	N	I-Premise
330	CAF	N	I-Premise
331	with	N	I-Premise
332	similar	N	I-Premise
333	toxicity	N	I-Premise
334	but	N	I-Premise
335	a	N	I-Premise
336	greater	N	I-Premise
337	reduction	N	I-Premise
338	in	N	I-Premise
339	during-treatment	N	I-Premise
340	quality	N	I-Premise
341	of	N	I-Premise
342	life	N	I-Premise
343	.	N	I-Premise

344	The	N	I-Claim
345	16-week	N	I-Claim
346	regimen	N	I-Claim
347	should	N	I-Claim
348	not	N	I-Claim
349	be	N	I-Claim
350	used	N	I-Claim
351	instead	N	I-Claim
352	of	N	I-Claim
353	a	N	I-Claim
354	standard-dose	N	I-Claim
355	regimen	N	I-Claim
356	without	N	I-Claim
357	careful	N	I-Claim
358	consideration	N	I-Claim
359	of	N	I-Claim
360	the	N	I-Claim
361	16-week	N	I-Claim
362	regimen	N	I-Claim
363	's	N	I-Claim
364	pros	N	I-Claim
365	and	N	I-Claim
366	cons	N	I-Claim
367	,	N	I-Claim
368	which	N	I-Claim
369	include	N	I-Claim
370	its	N	I-Claim
371	complicated	N	I-Claim
372	schedule	N	I-Claim
373	.	N	I-Claim

374	It	N	I-Claim
375	should	N	I-Claim
376	probably	N	I-Claim
377	not	N	I-Claim
378	be	N	I-Claim
379	tested	N	I-Claim
380	further	N	I-Claim
381	,	N	I-Claim
382	but	N	I-Claim
383	its	N	I-Claim
384	antimetabolite	N	I-Claim
385	schedules	N	I-Claim
386	and	N	I-Claim
387	frequent	N	I-Claim
388	drug	N	I-Claim
389	administration	N	I-Claim
390	(	N	I-Claim
391	ie	N	I-Claim
392	,	N	I-Claim
393	dose	N	I-Claim
394	density	N	I-Claim
395	)	N	I-Claim
396	should	N	I-Claim
397	be	N	I-Claim
398	considered	N	I-Claim
399	in	N	I-Claim
400	the	N	I-Claim
401	development	N	I-Claim
402	of	N	I-Claim
403	new	N	I-Claim
404	regimens	N	I-Claim
405	.	N	I-Claim

1	The	N	O
2	finding	N	O
3	of	N	O
4	a	N	O
5	decrease	N	O
6	in	N	O
7	contralateral	N	O
8	breast	N	O
9	cancer	N	O
10	incidence	N	O
11	following	N	O
12	tamoxifen	N	O
13	administration	N	O
14	for	N	O
15	adjuvant	N	O
16	therapy	N	O
17	led	N	O
18	to	N	O
19	the	N	O
20	concept	N	O
21	that	N	O
22	the	N	O
23	drug	N	O
24	might	N	O
25	play	N	O
26	a	N	O
27	role	N	O
28	in	N	O
29	breast	N	O
30	cancer	N	O
31	prevention	N	O
32	.	N	O

33	To	N	O
34	test	N	O
35	this	N	O
36	hypothesis	N	O
37	,	N	O
38	the	N	O
39	National	N	O
40	Surgical	N	O
41	Adjuvant	N	O
42	Breast	N	O
43	and	N	O
44	Bowel	N	O
45	Project	N	O
46	initiated	N	O
47	the	N	O
48	Breast	N	O
49	Cancer	N	O
50	Prevention	N	O
51	Trial	N	O
52	(	N	O
53	P-1	N	O
54	)	N	O
55	in	N	O
56	1992	N	O
57	.	N	O

58	Women	N	O
59	(	N	O
60	N=13388	N	O
61	)	N	O
62	at	N	O
63	increased	N	O
64	risk	N	O
65	for	N	O
66	breast	N	O
67	cancer	N	O
68	because	N	O
69	they	N	O
70	1	N	O
71	)	N	O
72	were	N	O
73	60	N	O
74	years	N	O
75	of	N	O
76	age	N	O
77	or	N	O
78	older	N	O
79	,	N	O
80	2	N	O
81	)	N	O
82	were	N	O
83	35-59	N	O
84	years	N	O
85	of	N	O
86	age	N	O
87	with	N	O
88	a	N	O
89	5-year	N	O
90	predicted	N	O
91	risk	N	O
92	for	N	O
93	breast	N	O
94	cancer	N	O
95	of	N	O
96	at	N	O
97	least	N	O
98	1.66	N	O
99	%	N	O
100	,	N	O
101	or	N	O
102	3	N	O
103	)	N	O
104	had	N	O
105	a	N	O
106	history	N	O
107	of	N	O
108	lobular	N	O
109	carcinoma	N	O
110	in	N	O
111	situ	N	O
112	were	N	O
113	randomly	N	O
114	assigned	N	O
115	to	N	O
116	receive	N	O
117	placebo	N	O
118	(	N	O
119	n=6707	N	O
120	)	N	O
121	or	N	O
122	20	N	O
123	mg/day	N	O
124	tamoxifen	N	O
125	(	N	O
126	n=6681	N	O
127	)	N	O
128	for	N	O
129	5	N	O
130	years	N	O
131	.	N	O

132	Gail	N	O
133	's	N	O
134	algorithm	N	O
135	,	N	O
136	based	N	O
137	on	N	O
138	a	N	O
139	multivariate	N	O
140	logistic	N	O
141	regression	N	O
142	model	N	O
143	using	N	O
144	combinations	N	O
145	of	N	O
146	risk	N	O
147	factors	N	O
148	,	N	O
149	was	N	O
150	used	N	O
151	to	N	O
152	estimate	N	O
153	the	N	O
154	probability	N	O
155	(	N	O
156	risk	N	O
157	)	N	O
158	of	N	O
159	occurrence	N	O
160	of	N	O
161	breast	N	O
162	cancer	N	O
163	over	N	O
164	time	N	O
165	.	N	O

166	Tamoxifen	N	I-Premise
167	reduced	N	I-Premise
168	the	N	I-Premise
169	risk	N	I-Premise
170	of	N	I-Premise
171	invasive	N	I-Premise
172	breast	N	I-Premise
173	cancer	N	I-Premise
174	by	N	I-Premise
175	49	N	I-Premise
176	%	N	I-Premise
177	(	N	I-Premise
178	two-sided	N	I-Premise
179	P	N	I-Premise
180	<	N	I-Premise
181	.00001	N	I-Premise
182	)	N	I-Premise
183	,	N	I-Premise
184	with	N	I-Premise
185	cumulative	N	I-Premise
186	incidence	N	I-Premise
187	through	N	I-Premise
188	69	N	I-Premise
189	months	N	I-Premise
190	of	N	I-Premise
191	follow-up	N	I-Premise
192	of	N	I-Premise
193	43.4	N	I-Premise
194	versus	N	I-Premise
195	22.0	N	I-Premise
196	per	N	I-Premise
197	1000	N	I-Premise
198	women	N	I-Premise
199	in	N	I-Premise
200	the	N	I-Premise
201	placebo	N	I-Premise
202	and	N	I-Premise
203	tamoxifen	N	I-Premise
204	groups	N	I-Premise
205	,	N	I-Premise
206	respectively	N	I-Premise
207	.	N	I-Premise

208	The	N	O
209	decreased	N	O
210	risk	N	O
211	occurred	N	O
212	in	N	O
213	women	N	O
214	aged	N	O
215	49	N	O
216	years	N	O
217	or	N	O
218	younger	N	O
219	(	N	O
220	44	N	O
221	%	N	O
222	)	N	O
223	,	N	O
224	50-59	N	O
225	years	N	O
226	(	N	O
227	51	N	O
228	%	N	O
229	)	N	O
230	,	N	O
231	and	N	O
232	60	N	O
233	years	N	O
234	or	N	O
235	older	N	O
236	(	N	O
237	55	N	O
238	%	N	O
239	)	N	O
240	;	N	O
241	risk	N	I-Premise
242	was	N	I-Premise
243	also	N	I-Premise
244	reduced	N	I-Premise
245	in	N	I-Premise
246	women	N	I-Premise
247	with	N	I-Premise
248	a	N	I-Premise
249	history	N	I-Premise
250	of	N	I-Premise
251	lobular	N	I-Premise
252	carcinoma	N	I-Premise
253	in	N	I-Premise
254	situ	N	I-Premise
255	(	N	I-Premise
256	56	N	I-Premise
257	%	N	I-Premise
258	)	N	I-Premise
259	or	N	I-Premise
260	atypical	N	I-Premise
261	hyperplasia	N	I-Premise
262	(	N	I-Premise
263	86	N	I-Premise
264	%	N	I-Premise
265	)	N	I-Premise
266	and	N	I-Premise
267	in	N	I-Premise
268	those	N	I-Premise
269	with	N	I-Premise
270	any	N	I-Premise
271	category	N	I-Premise
272	of	N	I-Premise
273	predicted	N	I-Premise
274	5-year	N	I-Premise
275	risk	N	I-Premise
276	.	N	I-Premise

277	Tamoxifen	N	I-Premise
278	reduced	N	I-Premise
279	the	N	I-Premise
280	risk	N	I-Premise
281	of	N	I-Premise
282	noninvasive	N	I-Premise
283	breast	N	I-Premise
284	cancer	N	I-Premise
285	by	N	I-Premise
286	50	N	I-Premise
287	%	N	I-Premise
288	(	N	I-Premise
289	two-sided	N	I-Premise
290	P	N	I-Premise
291	<	N	I-Premise
292	.002	N	I-Premise
293	)	N	I-Premise
294	.	N	I-Premise

295	Tamoxifen	N	I-Premise
296	reduced	N	I-Premise
297	the	N	I-Premise
298	occurrence	N	I-Premise
299	of	N	I-Premise
300	estrogen	N	I-Premise
301	receptor-positive	N	I-Premise
302	tumors	N	I-Premise
303	by	N	I-Premise
304	69	N	I-Premise
305	%	N	I-Premise
306	,	N	I-Premise
307	but	N	I-Premise
308	no	N	I-Premise
309	difference	N	I-Premise
310	in	N	I-Premise
311	the	N	I-Premise
312	occurrence	N	I-Premise
313	of	N	I-Premise
314	estrogen	N	I-Premise
315	receptor-negative	N	I-Premise
316	tumors	N	I-Premise
317	was	N	I-Premise
318	seen	N	I-Premise
319	.	N	I-Premise

320	Tamoxifen	N	I-Premise
321	administration	N	I-Premise
322	did	N	I-Premise
323	not	N	I-Premise
324	alter	N	I-Premise
325	the	N	I-Premise
326	average	N	I-Premise
327	annual	N	I-Premise
328	rate	N	I-Premise
329	of	N	I-Premise
330	ischemic	N	I-Premise
331	heart	N	I-Premise
332	disease	N	I-Premise
333	;	N	I-Premise
334	however	N	I-Premise
335	,	N	I-Premise
336	a	N	I-Premise
337	reduction	N	I-Premise
338	in	N	I-Premise
339	hip	N	I-Premise
340	,	N	I-Premise
341	radius	N	I-Premise
342	(	N	I-Premise
343	Colles	N	I-Premise
344	'	N	I-Premise
345	)	N	I-Premise
346	,	N	I-Premise
347	and	N	I-Premise
348	spine	N	I-Premise
349	fractures	N	I-Premise
350	was	N	I-Premise
351	observed	N	I-Premise
352	.	N	I-Premise

353	The	N	I-Premise
354	rate	N	I-Premise
355	of	N	I-Premise
356	endometrial	N	I-Premise
357	cancer	N	I-Premise
358	was	N	I-Premise
359	increased	N	I-Premise
360	in	N	I-Premise
361	the	N	I-Premise
362	tamoxifen	N	I-Premise
363	group	N	I-Premise
364	(	N	I-Premise
365	risk	N	I-Premise
366	ratio	N	I-Premise
367	=	N	I-Premise
368	2.53	N	I-Premise
369	;	N	I-Premise
370	95	N	I-Premise
371	%	N	I-Premise
372	confidence	N	I-Premise
373	interval	N	I-Premise
374	=	N	I-Premise
375	1.35-4.97	N	I-Premise
376	)	N	I-Premise
377	;	N	I-Premise
378	this	N	I-Premise
379	increased	N	I-Premise
380	risk	N	I-Premise
381	occurred	N	I-Premise
382	predominantly	N	I-Premise
383	in	N	I-Premise
384	women	N	I-Premise
385	aged	N	I-Premise
386	50	N	I-Premise
387	years	N	I-Premise
388	or	N	I-Premise
389	older	N	I-Premise
390	.	N	I-Premise

391	All	N	O
392	endometrial	N	O
393	cancers	N	O
394	in	N	O
395	the	N	O
396	tamoxifen	N	O
397	group	N	O
398	were	N	O
399	stage	N	O
400	I	N	O
401	(	N	O
402	localized	N	O
403	disease	N	O
404	)	N	O
405	;	N	O
406	no	N	I-Premise
407	endometrial	N	I-Premise
408	cancer	N	I-Premise
409	deaths	N	I-Premise
410	have	N	I-Premise
411	occurred	N	I-Premise
412	in	N	I-Premise
413	this	N	I-Premise
414	group	N	I-Premise
415	.	N	I-Premise

416	No	N	I-Premise
417	liver	N	I-Premise
418	cancers	N	I-Premise
419	or	N	I-Premise
420	increase	N	I-Premise
421	in	N	I-Premise
422	colon	N	I-Premise
423	,	N	I-Premise
424	rectal	N	I-Premise
425	,	N	I-Premise
426	ovarian	N	I-Premise
427	,	N	I-Premise
428	or	N	I-Premise
429	other	N	I-Premise
430	tumors	N	I-Premise
431	was	N	I-Premise
432	observed	N	I-Premise
433	in	N	I-Premise
434	the	N	I-Premise
435	tamoxifen	N	I-Premise
436	group	N	I-Premise
437	.	N	I-Premise

438	The	N	I-Premise
439	rates	N	I-Premise
440	of	N	I-Premise
441	stroke	N	I-Premise
442	,	N	I-Premise
443	pulmonary	N	I-Premise
444	embolism	N	I-Premise
445	,	N	I-Premise
446	and	N	I-Premise
447	deep-vein	N	I-Premise
448	thrombosis	N	I-Premise
449	were	N	I-Premise
450	elevated	N	I-Premise
451	in	N	I-Premise
452	the	N	I-Premise
453	tamoxifen	N	I-Premise
454	group	N	I-Premise
455	;	N	I-Premise
456	these	N	I-Premise
457	events	N	I-Premise
458	occurred	N	I-Premise
459	more	N	I-Premise
460	frequently	N	I-Premise
461	in	N	I-Premise
462	women	N	I-Premise
463	aged	N	I-Premise
464	50	N	I-Premise
465	years	N	I-Premise
466	or	N	I-Premise
467	older	N	I-Premise
468	.	N	I-Premise

469	Tamoxifen	N	I-Claim
470	decreases	N	I-Claim
471	the	N	I-Claim
472	incidence	N	I-Claim
473	of	N	I-Claim
474	invasive	N	I-Claim
475	and	N	I-Claim
476	noninvasive	N	I-Claim
477	breast	N	I-Claim
478	cancer	N	I-Claim
479	.	N	I-Claim

480	Despite	N	I-Claim
481	side	N	I-Claim
482	effects	N	I-Claim
483	resulting	N	I-Claim
484	from	N	I-Claim
485	administration	N	I-Claim
486	of	N	I-Claim
487	tamoxifen	N	I-Claim
488	,	N	I-Claim
489	its	N	I-Claim
490	use	N	I-Claim
491	as	N	I-Claim
492	a	N	I-Claim
493	breast	N	I-Claim
494	cancer	N	I-Claim
495	preventive	N	I-Claim
496	agent	N	I-Claim
497	is	N	I-Claim
498	appropriate	N	I-Claim
499	in	N	I-Claim
500	many	N	I-Claim
501	women	N	I-Claim
502	at	N	I-Claim
503	increased	N	I-Claim
504	risk	N	I-Claim
505	for	N	I-Claim
506	the	N	I-Claim
507	disease	N	I-Claim
508	.	N	I-Claim

1	For	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	metastatic	N	I-Claim
5	prostate	N	I-Claim
6	cancer	N	I-Claim
7	,	N	I-Claim
8	treatment	N	I-Claim
9	is	N	I-Claim
10	primarily	N	I-Claim
11	palliative	N	I-Claim
12	,	N	I-Claim
13	relying	N	I-Claim
14	mainly	N	I-Claim
15	on	N	I-Claim
16	the	N	I-Claim
17	suppression	N	I-Claim
18	of	N	I-Claim
19	systemic	N	I-Claim
20	androgen	N	I-Claim
21	hormone	N	I-Claim
22	levels	N	I-Claim
23	.	N	I-Claim

24	To	N	O
25	help	N	O
26	document	N	O
27	the	N	O
28	achievement	N	O
29	of	N	O
30	palliation	N	O
31	and	N	O
32	to	N	O
33	characterize	N	O
34	positive	N	O
35	and	N	O
36	negative	N	O
37	effects	N	O
38	of	N	O
39	treatment	N	O
40	,	N	O
41	we	N	O
42	evaluated	N	O
43	quality-of-life	N	O
44	(	N	O
45	QOL	N	O
46	)	N	O
47	parameters	N	O
48	in	N	O
49	patients	N	O
50	with	N	O
51	metastatic	N	O
52	prostate	N	O
53	cancer	N	O
54	who	N	O
55	were	N	O
56	randomly	N	O
57	assigned	N	O
58	to	N	O
59	two	N	O
60	methods	N	O
61	of	N	O
62	androgen	N	O
63	deprivation	N	O
64	.	N	O

65	Patients	N	O
66	(	N	O
67	n	N	O
68	=	N	O
69	739	N	O
70	)	N	O
71	with	N	O
72	stage	N	O
73	M1	N	O
74	(	N	O
75	bone	N	O
76	or	N	O
77	soft	N	O
78	tissue	N	O
79	metastasis	N	O
80	)	N	O
81	prostate	N	O
82	cancer	N	O
83	were	N	O
84	enrolled	N	O
85	in	N	O
86	a	N	O
87	QOL	N	O
88	protocol	N	O
89	that	N	O
90	was	N	O
91	a	N	O
92	companion	N	O
93	to	N	O
94	Southwest	N	O
95	Oncology	N	O
96	Group	N	O
97	INT-0105	N	O
98	,	N	O
99	a	N	O
100	randomized	N	O
101	double-blind	N	O
102	trial	N	O
103	comparing	N	O
104	treatment	N	O
105	with	N	O
106	bilateral	N	O
107	orchiectomy	N	O
108	(	N	O
109	surgical	N	O
110	castration	N	O
111	)	N	O
112	plus	N	O
113	either	N	O
114	flutamide	N	O
115	or	N	O
116	placebo	N	O
117	.	N	O

118	Patients	N	O
119	completed	N	O
120	a	N	O
121	comprehensive	N	O
122	battery	N	O
123	of	N	O
124	QOL	N	O
125	questionnaires	N	O
126	at	N	O
127	random	N	O
128	assignment	N	O
129	to	N	O
130	treatment	N	O
131	and	N	O
132	at	N	O
133	1	N	O
134	,	N	O
135	3	N	O
136	,	N	O
137	and	N	O
138	6	N	O
139	months	N	O
140	later	N	O
141	.	N	O

142	Data	N	O
143	were	N	O
144	collected	N	O
145	on	N	O
146	three	N	O
147	treatment-specific	N	O
148	symptoms	N	O
149	(	N	O
150	diarrhea	N	O
151	,	N	O
152	gas	N	O
153	pain	N	O
154	,	N	O
155	and	N	O
156	body	N	O
157	image	N	O
158	)	N	O
159	,	N	O
160	on	N	O
161	physical	N	O
162	functioning	N	O
163	,	N	O
164	and	N	O
165	on	N	O
166	emotional	N	O
167	functioning	N	O
168	.	N	O

169	All	N	O
170	P	N	O
171	values	N	O
172	are	N	O
173	two-sided	N	O
174	.	N	O

175	Questionnaire	N	O
176	return	N	O
177	rates	N	O
178	for	N	O
179	this	N	O
180	study	N	O
181	never	N	O
182	dropped	N	O
183	below	N	O
184	80	N	O
185	%	N	O
186	;	N	O
187	only	N	O
188	2	N	O
189	%	N	O
190	of	N	O
191	the	N	O
192	patients	N	O
193	did	N	O
194	not	N	O
195	submit	N	O
196	baseline	N	O
197	QOL	N	O
198	assessments	N	O
199	.	N	O

200	Cross-sectional	N	I-Premise
201	analyses	N	I-Premise
202	(	N	I-Premise
203	corrected	N	I-Premise
204	for	N	I-Premise
205	multiple	N	I-Premise
206	testing	N	I-Premise
207	)	N	I-Premise
208	identified	N	I-Premise
209	statistically	N	I-Premise
210	significant	N	I-Premise
211	differences	N	I-Premise
212	that	N	I-Premise
213	favored	N	I-Premise
214	orchiectomy	N	I-Premise
215	plus	N	I-Premise
216	placebo	N	I-Premise
217	for	N	I-Premise
218	two	N	I-Premise
219	of	N	I-Premise
220	the	N	I-Premise
221	five	N	I-Premise
222	primary	N	I-Premise
223	QOL	N	I-Premise
224	parameters	N	I-Premise
225	as	N	I-Premise
226	follows	N	I-Premise
227	:	N	I-Premise
228	patients	N	I-Premise
229	receiving	N	I-Premise
230	flutamide	N	I-Premise
231	reported	N	I-Premise
232	more	N	I-Premise
233	diarrhea	N	I-Premise
234	at	N	I-Premise
235	3	N	I-Premise
236	months	N	I-Premise
237	(	N	I-Premise
238	P	N	I-Premise
239	=	N	I-Premise
240	.001	N	I-Premise
241	)	N	I-Premise
242	and	N	I-Premise
243	worse	N	I-Premise
244	emotional	N	I-Premise
245	functioning	N	I-Premise
246	at	N	I-Premise
247	3	N	I-Premise
248	and	N	I-Premise
249	6	N	I-Premise
250	months	N	I-Premise
251	(	N	I-Premise
252	both	N	I-Premise
253	P	N	I-Premise
254	<	N	I-Premise
255	.003	N	I-Premise
256	)	N	I-Premise
257	.	N	I-Premise

258	Longitudinal	N	I-Premise
259	analyses	N	I-Premise
260	replicated	N	I-Premise
261	these	N	I-Premise
262	findings	N	I-Premise
263	.	N	I-Premise

264	Other	N	I-Premise
265	analyzed	N	I-Premise
266	QOL	N	I-Premise
267	parameters	N	I-Premise
268	favored	N	I-Premise
269	the	N	I-Premise
270	group	N	I-Premise
271	receiving	N	I-Premise
272	placebo	N	I-Premise
273	but	N	I-Premise
274	were	N	I-Premise
275	not	N	I-Premise
276	statistically	N	I-Premise
277	significant	N	I-Premise
278	after	N	I-Premise
279	adjustment	N	I-Premise
280	for	N	I-Premise
281	multiple	N	I-Premise
282	testing	N	I-Premise
283	.	N	I-Premise

284	We	N	I-Claim
285	found	N	I-Claim
286	a	N	I-Claim
287	consistent	N	I-Claim
288	pattern	N	I-Claim
289	of	N	I-Claim
290	better	N	I-Claim
291	QOL	N	I-Claim
292	outcomes	N	I-Claim
293	at	N	I-Claim
294	each	N	I-Claim
295	follow-up	N	I-Claim
296	assessment	N	I-Claim
297	during	N	I-Claim
298	the	N	I-Claim
299	first	N	I-Claim
300	6	N	I-Claim
301	months	N	I-Claim
302	of	N	I-Claim
303	treatment	N	I-Claim
304	for	N	I-Claim
305	orchiectomized	N	I-Claim
306	patients	N	I-Claim
307	with	N	I-Claim
308	metastatic	N	I-Claim
309	prostate	N	I-Claim
310	cancer	N	I-Claim
311	who	N	I-Claim
312	received	N	I-Claim
313	placebo	N	I-Claim
314	versus	N	I-Claim
315	flutamide	N	I-Claim
316	.	N	I-Claim

317	Improvement	N	I-Claim
318	over	N	I-Claim
319	time	N	I-Claim
320	was	N	I-Claim
321	evident	N	I-Claim
322	in	N	I-Claim
323	both	N	I-Claim
324	treatment	N	I-Claim
325	groups	N	I-Claim
326	but	N	I-Claim
327	more	N	I-Claim
328	so	N	I-Claim
329	for	N	I-Claim
330	patients	N	I-Claim
331	receiving	N	I-Claim
332	placebo	N	I-Claim
333	.	N	I-Claim

1	In	N	O
2	phase	N	O
3	II	N	O
4	studies	N	O
5	,	N	O
6	irinotecan	N	O
7	is	N	O
8	active	N	O
9	in	N	O
10	metastatic	N	O
11	colorectal	N	O
12	cancer	N	O
13	,	N	O
14	but	N	O
15	the	N	O
16	overall	N	O
17	benefit	N	O
18	has	N	O
19	not	N	O
20	been	N	O
21	assessed	N	O
22	in	N	O
23	a	N	O
24	randomised	N	O
25	clinical	N	O
26	trial	N	O
27	.	N	O

28	Patients	N	O
29	with	N	O
30	proven	N	O
31	metastatic	N	O
32	colorectal	N	O
33	cancer	N	O
34	,	N	O
35	which	N	O
36	had	N	O
37	progressed	N	O
38	within	N	O
39	6	N	O
40	months	N	O
41	of	N	O
42	treatment	N	O
43	with	N	O
44	fluorouracil	N	O
45	,	N	O
46	were	N	O
47	randomly	N	O
48	assigned	N	O
49	either	N	O
50	300-350	N	O
51	mg/m2	N	O
52	irinotecan	N	O
53	every	N	O
54	3	N	O
55	weeks	N	O
56	with	N	O
57	supportive	N	O
58	care	N	O
59	or	N	O
60	supportive	N	O
61	care	N	O
62	alone	N	O
63	,	N	O
64	in	N	O
65	a	N	O
66	2:1	N	O
67	ratio	N	O
68	.	N	O

69	189	N	O
70	patients	N	O
71	were	N	O
72	allocated	N	O
73	irinotecan	N	O
74	and	N	O
75	supportive	N	O
76	care	N	O
77	and	N	O
78	90	N	O
79	supportive	N	O
80	care	N	O
81	alone	N	O
82	.	N	O

83	The	N	O
84	mean	N	O
85	age	N	O
86	of	N	O
87	the	N	O
88	participants	N	O
89	was	N	O
90	58.8	N	O
91	years	N	O
92	;	N	O
93	181	N	O
94	(	N	O
95	65	N	O
96	%	N	O
97	)	N	O
98	were	N	O
99	men	N	O
100	and	N	O
101	98	N	O
102	(	N	O
103	35	N	O
104	%	N	O
105	)	N	O
106	were	N	O
107	women	N	O
108	.	N	O

109	WHO	N	O
110	performance	N	O
111	status	N	O
112	was	N	O
113	0	N	O
114	in	N	O
115	79	N	O
116	(	N	O
117	42	N	O
118	%	N	O
119	)	N	O
120	patients	N	O
121	,	N	O
122	1	N	O
123	in	N	O
124	77	N	O
125	(	N	O
126	41	N	O
127	%	N	O
128	)	N	O
129	patients	N	O
130	,	N	O
131	and	N	O
132	2	N	O
133	in	N	O
134	32	N	O
135	(	N	O
136	17	N	O
137	%	N	O
138	)	N	O
139	patients	N	O
140	.	N	O

141	Tumour-related	N	O
142	symptoms	N	O
143	were	N	O
144	present	N	O
145	in	N	O
146	134	N	O
147	(	N	O
148	71	N	O
149	%	N	O
150	)	N	O
151	patients	N	O
152	and	N	O
153	weight	N	O
154	loss	N	O
155	of	N	O
156	more	N	O
157	than	N	O
158	5	N	O
159	%	N	O
160	was	N	O
161	seen	N	O
162	in	N	O
163	15	N	O
164	(	N	O
165	8	N	O
166	%	N	O
167	)	N	O
168	patients	N	O
169	.	N	O

170	With	N	I-Premise
171	a	N	I-Premise
172	median	N	I-Premise
173	follow-up	N	I-Premise
174	of	N	I-Premise
175	13	N	I-Premise
176	months	N	I-Premise
177	,	N	I-Premise
178	the	N	I-Premise
179	overall	N	I-Premise
180	survival	N	I-Premise
181	was	N	I-Premise
182	significantly	N	I-Premise
183	better	N	I-Premise
184	in	N	I-Premise
185	the	N	I-Premise
186	irinotecan	N	I-Premise
187	group	N	I-Premise
188	(	N	I-Premise
189	p=0.0001	N	I-Premise
190	)	N	I-Premise
191	,	N	I-Premise
192	with	N	I-Premise
193	36.2	N	I-Premise
194	%	N	I-Premise
195	1-year	N	I-Premise
196	survival	N	I-Premise
197	in	N	I-Premise
198	the	N	I-Premise
199	irinotecan	N	I-Premise
200	group	N	I-Premise
201	versus	N	I-Premise
202	13.8	N	I-Premise
203	%	N	I-Premise
204	in	N	I-Premise
205	the	N	I-Premise
206	supportive-care	N	I-Premise
207	group	N	I-Premise
208	.	N	I-Premise

209	The	N	I-Premise
210	survival	N	I-Premise
211	benefit	N	I-Premise
212	,	N	I-Premise
213	adjusted	N	I-Premise
214	for	N	I-Premise
215	prognostic	N	I-Premise
216	factors	N	I-Premise
217	in	N	I-Premise
218	a	N	I-Premise
219	multivariate	N	I-Premise
220	analysis	N	I-Premise
221	,	N	I-Premise
222	remained	N	I-Premise
223	significant	N	I-Premise
224	(	N	I-Premise
225	p=0.001	N	I-Premise
226	)	N	I-Premise
227	.	N	I-Premise

228	Survival	N	I-Premise
229	without	N	I-Premise
230	performance-status	N	I-Premise
231	deterioration	N	I-Premise
232	(	N	I-Premise
233	p=0.0001	N	I-Premise
234	)	N	I-Premise
235	,	N	I-Premise
236	without	N	I-Premise
237	weight	N	I-Premise
238	loss	N	I-Premise
239	of	N	I-Premise
240	more	N	I-Premise
241	than	N	I-Premise
242	5	N	I-Premise
243	%	N	I-Premise
244	(	N	I-Premise
245	p=0.018	N	I-Premise
246	)	N	I-Premise
247	,	N	I-Premise
248	and	N	I-Premise
249	pain-free	N	I-Premise
250	survival	N	I-Premise
251	(	N	I-Premise
252	p=0.003	N	I-Premise
253	)	N	I-Premise
254	were	N	I-Premise
255	significantly	N	I-Premise
256	better	N	I-Premise
257	in	N	I-Premise
258	the	N	I-Premise
259	patients	N	I-Premise
260	given	N	I-Premise
261	irinotecan	N	I-Premise
262	.	N	I-Premise

263	In	N	I-Premise
264	a	N	I-Premise
265	quality-of-life	N	I-Premise
266	analysis	N	I-Premise
267	,	N	I-Premise
268	all	N	I-Premise
269	significant	N	I-Premise
270	differences	N	I-Premise
271	,	N	I-Premise
272	except	N	I-Premise
273	on	N	I-Premise
274	diarrhoea	N	I-Premise
275	score	N	I-Premise
276	,	N	I-Premise
277	were	N	I-Premise
278	in	N	I-Premise
279	favour	N	I-Premise
280	of	N	I-Premise
281	the	N	I-Premise
282	irinotecan	N	I-Premise
283	group	N	I-Premise
284	.	N	I-Premise

285	Our	N	I-Claim
286	study	N	I-Claim
287	shows	N	I-Claim
288	that	N	I-Claim
289	despite	N	I-Claim
290	the	N	I-Claim
291	side-effects	N	I-Claim
292	of	N	I-Claim
293	treatment	N	I-Claim
294	,	N	I-Claim
295	patients	N	I-Claim
296	who	N	I-Claim
297	have	N	I-Claim
298	metastatic	N	I-Claim
299	colorectal	N	I-Claim
300	cancer	N	I-Claim
301	,	N	I-Claim
302	and	N	I-Claim
303	for	N	I-Claim
304	whom	N	I-Claim
305	fluorouracil	N	I-Claim
306	has	N	I-Claim
307	failed	N	I-Claim
308	,	N	I-Claim
309	have	N	I-Claim
310	a	N	I-Claim
311	longer	N	I-Claim
312	survival	N	I-Claim
313	,	N	I-Claim
314	fewer	N	I-Claim
315	tumour-related	N	I-Claim
316	symptoms	N	I-Claim
317	,	N	I-Claim
318	and	N	I-Claim
319	a	N	I-Claim
320	better	N	I-Claim
321	quality	N	I-Claim
322	of	N	I-Claim
323	life	N	I-Claim
324	when	N	I-Claim
325	treated	N	I-Claim
326	with	N	I-Claim
327	irinotecan	N	I-Claim
328	than	N	I-Claim
329	with	N	I-Claim
330	supportive	N	I-Claim
331	care	N	I-Claim
332	alone	N	I-Claim
333	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	present	N	O
6	trial	N	O
7	was	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	effects	N	O
12	of	N	O
13	chemotherapy	N	O
14	on	N	O
15	the	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	and	N	O
20	survival	N	O
21	of	N	O
22	patients	N	O
23	with	N	O
24	advanced	N	O
25	non-small	N	O
26	cell	N	O
27	lung	N	O
28	cancer	N	O
29	(	N	O
30	NSCLC	N	O
31	)	N	O
32	(	N	O
33	stage	N	O
34	IIIB	N	O
35	or	N	O
36	IV	N	O
37	)	N	O
38	.	N	O

39	In	N	O
40	a	N	O
41	controlled	N	O
42	multicentre	N	O
43	trial	N	O
44	,	N	O
45	patients	N	O
46	were	N	O
47	randomised	N	O
48	to	N	O
49	receive	N	O
50	supportive	N	O
51	care	N	O
52	only	N	O
53	or	N	O
54	supportive	N	O
55	care	N	O
56	plus	N	O
57	chemotherapy	N	O
58	.	N	O

59	Chemotherapy	N	O
60	consisted	N	O
61	of	N	O
62	intravenous	N	O
63	(	N	O
64	i.v	N	O
65	.	N	O

66	)	N	O
67	carboplatin	N	O
68	300	N	O
69	mg/m2	N	O
70	on	N	O
71	day	N	O
72	1	N	O
73	and	N	O
74	etoposide	N	O
75	120	N	O
76	mg/m2	N	O
77	orally	N	O
78	on	N	O
79	days	N	O
80	1-5	N	O
81	every	N	O
82	4	N	O
83	weeks	N	O
84	for	N	O
85	a	N	O
86	maximum	N	O
87	of	N	O
88	eight	N	O
89	courses	N	O
90	.	N	O

91	Quality	N	O
92	of	N	O
93	life	N	O
94	was	N	O
95	measured	N	O
96	at	N	O
97	randomisation	N	O
98	and	N	O
99	prior	N	O
100	to	N	O
101	each	N	O
102	treatment	N	O
103	course	N	O
104	and	N	O
105	at	N	O
106	corresponding	N	O
107	4-week	N	O
108	intervals	N	O
109	in	N	O
110	the	N	O
111	control	N	O
112	arm	N	O
113	,	N	O
114	using	N	O
115	the	N	O
116	EORTC	N	O
117	QLQ-C30	N	O
118	+	N	O
119	LC13	N	O
120	questionnaire	N	O
121	.	N	O

122	48	N	O
123	patients	N	O
124	were	N	O
125	randomised	N	O
126	(	N	O
127	supportive	N	O
128	care	N	O
129	26	N	O
130	,	N	O
131	chemotherapy	N	O
132	22	N	O
133	)	N	O
134	,	N	O
135	being	N	O
136	eligible	N	O
137	for	N	O
138	comparative	N	O
139	analyses	N	O
140	.	N	O

141	Another	N	O
142	102	N	O
143	patients	N	O
144	,	N	O
145	97	N	O
146	of	N	O
147	which	N	O
148	received	N	O
149	chemotherapy	N	O
150	,	N	O
151	were	N	O
152	subsequently	N	O
153	included	N	O
154	in	N	O
155	the	N	O
156	study	N	O
157	on	N	O
158	an	N	O
159	individual	N	O
160	treatment	N	O
161	preference	N	O
162	basis	N	O
163	.	N	O

164	Data	N	O
165	from	N	O
166	these	N	O
167	patients	N	O
168	were	N	O
169	used	N	O
170	for	N	O
171	confirmative	N	O
172	purposes	N	O
173	.	N	O

174	Patients	N	I-Premise
175	in	N	I-Premise
176	the	N	I-Premise
177	chemotherapy	N	I-Premise
178	group	N	I-Premise
179	reported	N	I-Premise
180	better	N	I-Premise
181	overall	N	I-Premise
182	physical	N	I-Premise
183	functioning	N	I-Premise
184	and	N	I-Premise
185	symptom	N	I-Premise
186	control	N	I-Premise
187	compared	N	I-Premise
188	with	N	I-Premise
189	the	N	I-Premise
190	supportive	N	I-Premise
191	care	N	I-Premise
192	group	N	I-Premise
193	.	N	I-Premise

194	Group	N	I-Premise
195	differences	N	I-Premise
196	were	N	I-Premise
197	smaller	N	I-Premise
198	within	N	I-Premise
199	the	N	I-Premise
200	psychosocial	N	I-Premise
201	domain	N	I-Premise
202	,	N	I-Premise
203	although	N	I-Premise
204	trends	N	I-Premise
205	were	N	I-Premise
206	seen	N	I-Premise
207	in	N	I-Premise
208	favour	N	I-Premise
209	of	N	I-Premise
210	the	N	I-Premise
211	chemotherapy	N	I-Premise
212	group	N	I-Premise
213	.	N	I-Premise

214	No	N	I-Premise
215	significant	N	I-Premise
216	differences	N	I-Premise
217	were	N	I-Premise
218	seen	N	I-Premise
219	in	N	I-Premise
220	favour	N	I-Premise
221	of	N	I-Premise
222	the	N	I-Premise
223	supportive	N	I-Premise
224	care	N	I-Premise
225	group	N	I-Premise
226	,	N	I-Premise
227	except	N	I-Premise
228	for	N	I-Premise
229	hair	N	I-Premise
230	loss	N	I-Premise
231	.	N	I-Premise

232	Median	N	I-Premise
233	survival	N	I-Premise
234	times	N	I-Premise
235	were	N	I-Premise
236	29	N	I-Premise
237	weeks	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	chemotherapy	N	I-Premise
241	group	N	I-Premise
242	versus	N	I-Premise
243	11	N	I-Premise
244	weeks	N	I-Premise
245	in	N	I-Premise
246	the	N	I-Premise
247	supportive	N	I-Premise
248	care	N	I-Premise
249	group	N	I-Premise
250	,	N	I-Premise
251	and	N	I-Premise
252	1-year	N	I-Premise
253	survival	N	I-Premise
254	rates	N	I-Premise
255	were	N	I-Premise
256	28	N	I-Premise
257	%	N	I-Premise
258	versus	N	I-Premise
259	8	N	I-Premise
260	%	N	I-Premise
261	.	N	I-Premise

262	Quality	N	I-Premise
263	of	N	I-Premise
264	life	N	I-Premise
265	and	N	I-Premise
266	survival	N	I-Premise
267	outcomes	N	I-Premise
268	were	N	I-Premise
269	similar	N	I-Premise
270	in	N	I-Premise
271	the	N	I-Premise
272	randomised	N	I-Premise
273	and	N	I-Premise
274	non-randomised	N	I-Premise
275	patients	N	I-Premise
276	receiving	N	I-Premise
277	chemotherapy	N	I-Premise
278	.	N	I-Premise

279	No	N	I-Premise
280	treatment-related	N	I-Premise
281	deaths	N	I-Premise
282	occurred	N	I-Premise
283	.	N	I-Premise

284	In	N	I-Claim
285	conclusion	N	I-Claim
286	,	N	I-Claim
287	treatment	N	I-Claim
288	with	N	I-Claim
289	carboplatin	N	I-Claim
290	and	N	I-Claim
291	etoposide	N	I-Claim
292	can	N	I-Claim
293	improve	N	I-Claim
294	both	N	I-Claim
295	the	N	I-Claim
296	quality	N	I-Claim
297	of	N	I-Claim
298	life	N	I-Claim
299	and	N	I-Claim
300	the	N	I-Claim
301	survival	N	I-Claim
302	of	N	I-Claim
303	patients	N	I-Claim
304	with	N	I-Claim
305	advanced	N	I-Claim
306	NSCLC	N	I-Claim
307	.	N	I-Claim

1	The	N	O
2	second	N	O
3	International	N	O
4	Society	N	O
5	of	N	O
6	Paediatric	N	O
7	Oncology	N	O
8	(	N	O
9	SIOP	N	O
10	)	N	O
11	study	N	O
12	for	N	O
13	rhabdomyosarcoma	N	O
14	(	N	O
15	MMT84	N	O
16	)	N	O
17	had	N	O
18	several	N	O
19	goals	N	O
20	.	N	O

21	The	N	O
22	two	N	O
23	principal	N	O
24	aims	N	O
25	were	N	O
26	:	N	O
27	(	N	O
28	1	N	O
29	)	N	O
30	to	N	O
31	improve	N	O
32	the	N	O
33	survival	N	O
34	of	N	O
35	children	N	O
36	with	N	O
37	rhabdomyosarcoma	N	O
38	;	N	O
39	and	N	O
40	(	N	O
41	2	N	O
42	)	N	O
43	to	N	O
44	reduce	N	O
45	the	N	O
46	late	N	O
47	effects	N	O
48	from	N	O
49	therapy	N	O
50	by	N	O
51	restricting	N	O
52	the	N	O
53	indications	N	O
54	for	N	O
55	surgery	N	O
56	and/or	N	O
57	radiotherapy	N	O
58	after	N	O
59	good	N	O
60	response	N	O
61	to	N	O
62	initial	N	O
63	chemotherapy	N	O
64	.	N	O

65	A	N	O
66	further	N	O
67	aim	N	O
68	was	N	O
69	to	N	O
70	investigate	N	O
71	the	N	O
72	role	N	O
73	of	N	O
74	high-dose	N	O
75	chemotherapy	N	O
76	in	N	O
77	young	N	O
78	patients	N	O
79	with	N	O
80	parameningeal	N	O
81	primary	N	O
82	tumours	N	O
83	.	N	O

84	186	N	O
85	previously	N	O
86	untreated	N	O
87	eligible	N	O
88	patients	N	O
89	entered	N	O
90	the	N	O
91	study	N	O
92	.	N	O

93	Patients	N	O
94	with	N	O
95	completely	N	O
96	resected	N	O
97	primary	N	O
98	tumour	N	O
99	received	N	O
100	three	N	O
101	courses	N	O
102	of	N	O
103	IVA	N	O
104	(	N	O
105	ifosfamide	N	O
106	,	N	O
107	vincristine	N	O
108	and	N	O
109	actinomycin	N	O
110	D	N	O
111	)	N	O
112	.	N	O

113	Patients	N	O
114	with	N	O
115	incompletely	N	O
116	resected	N	O
117	tumour	N	O
118	received	N	O
119	six	N	O
120	to	N	O
121	10	N	O
122	courses	N	O
123	of	N	O
124	IVA	N	O
125	according	N	O
126	to	N	O
127	stage	N	O
128	.	N	O

129	Patients	N	O
130	achieving	N	O
131	complete	N	O
132	remission	N	O
133	with	N	O
134	chemotherapy	N	O
135	alone	N	O
136	did	N	O
137	not	N	O
138	usually	N	O
139	receive	N	O
140	radiotherapy	N	O
141	or	N	O
142	undergo	N	O
143	extensive	N	O
144	surgery	N	O
145	,	N	O
146	but	N	O
147	patients	N	O
148	remaining	N	O
149	in	N	O
150	partial	N	O
151	remission	N	O
152	received	N	O
153	local	N	O
154	therapy	N	O
155	with	N	O
156	surgery	N	O
157	and/or	N	O
158	radiotherapy	N	O
159	.	N	O

160	Only	N	O
161	patients	N	O
162	over	N	O
163	5	N	O
164	years	N	O
165	of	N	O
166	age	N	O
167	with	N	O
168	parameningeal	N	O
169	disease	N	O
170	and	N	O
171	patients	N	O
172	over	N	O
173	12	N	O
174	years	N	O
175	with	N	O
176	tumours	N	O
177	at	N	O
178	any	N	O
179	site	N	O
180	were	N	O
181	given	N	O
182	systematic	N	O
183	irradiation	N	O
184	.	N	O

185	Complete	N	I-Premise
186	remission	N	I-Premise
187	was	N	I-Premise
188	achieved	N	I-Premise
189	in	N	I-Premise
190	91	N	I-Premise
191	%	N	I-Premise
192	(	N	I-Premise
193	170/186	N	I-Premise
194	)	N	I-Premise
195	of	N	I-Premise
196	all	N	I-Premise
197	patients	N	I-Premise
198	.	N	I-Premise

199	With	N	I-Premise
200	a	N	I-Premise
201	median	N	I-Premise
202	follow-up	N	I-Premise
203	of	N	I-Premise
204	8	N	I-Premise
205	years	N	I-Premise
206	,	N	I-Premise
207	the	N	I-Premise
208	5-year	N	I-Premise
209	overall	N	I-Premise
210	survival	N	I-Premise
211	was	N	I-Premise
212	68	N	I-Premise
213	%	N	I-Premise
214	(	N	I-Premise
215	+/-	N	I-Premise
216	3	N	I-Premise
217	%	N	I-Premise
218	standard	N	I-Premise
219	error	N	I-Premise
220	of	N	I-Premise
221	the	N	I-Premise
222	mean	N	I-Premise
223	(	N	I-Premise
224	SEM	N	I-Premise
225	)	N	I-Premise
226	and	N	I-Premise
227	the	N	I-Premise
228	5-year	N	I-Premise
229	event-free	N	I-Premise
230	survival	N	I-Premise
231	53	N	I-Premise
232	%	N	I-Premise
233	(	N	I-Premise
234	+/-	N	I-Premise
235	4	N	I-Premise
236	%	N	I-Premise
237	SEM	N	I-Premise
238	)	N	I-Premise
239	.	N	I-Premise

240	These	N	I-Premise
241	results	N	I-Premise
242	show	N	I-Premise
243	an	N	I-Premise
244	improvement	N	I-Premise
245	over	N	I-Premise
246	previous	N	I-Premise
247	SIOP	N	I-Premise
248	study	N	I-Premise
249	(	N	I-Premise
250	RMS75	N	I-Premise
251	)	N	I-Premise
252	in	N	I-Premise
253	which	N	I-Premise
254	survival	N	I-Premise
255	was	N	I-Premise
256	52	N	I-Premise
257	%	N	I-Premise
258	and	N	I-Premise
259	event-free	N	I-Premise
260	survival	N	I-Premise
261	was	N	I-Premise
262	47	N	I-Premise
263	%	N	I-Premise
264	.	N	I-Premise

265	Among	N	I-Premise
266	the	N	I-Premise
267	54	N	I-Premise
268	patients	N	I-Premise
269	who	N	I-Premise
270	exhibited	N	I-Premise
271	isolated	N	I-Premise
272	local	N	I-Premise
273	relapse	N	I-Premise
274	,	N	I-Premise
275	35	N	I-Premise
276	%	N	I-Premise
277	(	N	I-Premise
278	19/54	N	I-Premise
279	)	N	I-Premise
280	survived	N	I-Premise
281	in	N	I-Premise
282	further	N	I-Premise
283	remission	N	I-Premise
284	longer	N	I-Premise
285	than	N	I-Premise
286	2	N	I-Premise
287	years	N	I-Premise
288	after	N	I-Premise
289	retreatment	N	I-Premise
290	,	N	I-Premise
291	including	N	I-Premise
292	local	N	I-Premise
293	therapy	N	I-Premise
294	(	N	I-Premise
295	surgery	N	I-Premise
296	+/-	N	I-Premise
297	radiotherapy	N	I-Premise
298	)	N	I-Premise
299	.	N	I-Premise

300	Analysis	N	O
301	of	N	O
302	the	N	O
303	overall	N	O
304	burden	N	O
305	of	N	O
306	therapy	N	O
307	received	N	O
308	by	N	O
309	all	N	O
310	surviving	N	O
311	children	N	O
312	(	N	O
313	including	N	O
314	primary	N	O
315	treatment	N	O
316	and	N	O
317	treatment	N	O
318	for	N	O
319	relapse	N	O
320	if	N	O
321	required	N	O
322	)	N	O
323	showed	N	O
324	that	N	O
325	24	N	O
326	%	N	O
327	(	N	O
328	28/116	N	O
329	)	N	O
330	were	N	O
331	treated	N	O
332	by	N	O
333	limited	N	O
334	surgery	N	O
335	followed	N	O
336	by	N	O
337	three	N	O
338	courses	N	O
339	of	N	O
340	IVA	N	O
341	,	N	O
342	29	N	O
343	%	N	O
344	(	N	O
345	34/116	N	O
346	)	N	O
347	were	N	O
348	treated	N	O
349	by	N	O
350	chemotherapy	N	O
351	alone	N	O
352	(	N	O
353	after	N	O
354	initial	N	O
355	biopsy	N	O
356	)	N	O
357	and	N	O
358	13	N	O
359	%	N	O
360	(	N	O
361	15/116	N	O
362	)	N	O
363	received	N	O
364	chemotherapy	N	O
365	plus	N	O
366	conservative	N	O
367	local	N	O
368	treatment	N	O
369	(	N	O
370	limited	N	O
371	surgery	N	O
372	or	N	O
373	radiotherapy	N	O
374	for	N	O
375	residual	N	O
376	disease	N	O
377	)	N	O
378	.	N	O

379	Only	N	O
380	34	N	O
381	%	N	O
382	(	N	O
383	39/116	N	O
384	)	N	O
385	received	N	O
386	intensive	N	O
387	local	N	O
388	therapy	N	O
389	defined	N	O
390	as	N	O
391	radical	N	O
392	wide	N	O
393	field	N	O
394	radiotherapy	N	O
395	or	N	O
396	radical	N	O
397	surgery	N	O
398	or	N	O
399	both	N	O
400	.	N	O

401	Compared	N	I-Claim
402	with	N	I-Claim
403	the	N	I-Claim
404	results	N	I-Claim
405	obtained	N	I-Claim
406	in	N	I-Claim
407	the	N	I-Claim
408	previous	N	I-Claim
409	SIOP	N	I-Claim
410	study	N	I-Claim
411	,	N	I-Claim
412	treatment	N	I-Claim
413	in	N	I-Claim
414	MMT84	N	I-Claim
415	was	N	I-Claim
416	based	N	I-Claim
417	on	N	I-Claim
418	response	N	I-Claim
419	to	N	I-Claim
420	initial	N	I-Claim
421	chemotherapy	N	I-Claim
422	and	N	I-Claim
423	,	N	I-Claim
424	despite	N	I-Claim
425	an	N	I-Claim
426	overall	N	I-Claim
427	reduction	N	I-Claim
428	of	N	I-Claim
429	the	N	I-Claim
430	use	N	I-Claim
431	of	N	I-Claim
432	local	N	I-Claim
433	therapy	N	I-Claim
434	,	N	I-Claim
435	significantly	N	I-Claim
436	improved	N	I-Claim
437	survival	N	I-Claim
438	for	N	I-Claim
439	patients	N	I-Claim
440	with	N	I-Claim
441	non-metastatic	N	I-Claim
442	disease	N	I-Claim
443	.	N	I-Claim

444	This	N	I-Claim
445	trial	N	I-Claim
446	,	N	I-Claim
447	also	N	I-Claim
448	for	N	I-Claim
449	the	N	I-Claim
450	first	N	I-Claim
451	time	N	I-Claim
452	,	N	I-Claim
453	provides	N	I-Claim
454	evidence	N	I-Claim
455	that	N	I-Claim
456	retreatment	N	I-Claim
457	after	N	I-Claim
458	local	N	I-Claim
459	relapse	N	I-Claim
460	can	N	I-Claim
461	achieve	N	I-Claim
462	long-term	N	I-Claim
463	second	N	I-Claim
464	remissions	N	I-Claim
465	.	N	I-Claim

1	We	N	O
2	report	N	O
3	results	N	O
4	of	N	O
5	a	N	O
6	randomized	N	O
7	prospective	N	O
8	study	N	O
9	that	N	O
10	compared	N	O
11	single	N	O
12	agents	N	O
13	of	N	O
14	low	N	O
15	toxicity	N	O
16	given	N	O
17	both	N	O
18	as	N	O
19	the	N	O
20	first-line	N	O
21	and	N	O
22	second-line	N	O
23	chemotherapy	N	O
24	with	N	O
25	combination	N	O
26	chemotherapy	N	O
27	in	N	O
28	advanced	N	O
29	breast	N	O
30	cancer	N	O
31	with	N	O
32	distant	N	O
33	metastases	N	O
34	.	N	O

35	Patients	N	O
36	in	N	O
37	the	N	O
38	single-agent	N	O
39	arm	N	O
40	(	N	O
41	n	N	O
42	=	N	O
43	153	N	O
44	)	N	O
45	received	N	O
46	weekly	N	O
47	epirubicin	N	O
48	(	N	O
49	E	N	O
50	)	N	O
51	20	N	O
52	mg/m2	N	O
53	until	N	O
54	progression	N	O
55	or	N	O
56	until	N	O
57	the	N	O
58	cumulative	N	O
59	dose	N	O
60	of	N	O
61	1,000	N	O
62	mg/m2	N	O
63	,	N	O
64	followed	N	O
65	by	N	O
66	mitomycin	N	O
67	(	N	O
68	M	N	O
69	)	N	O
70	8	N	O
71	mg/m2	N	O
72	every	N	O
73	4	N	O
74	weeks	N	O
75	,	N	O
76	and	N	O
77	those	N	O
78	in	N	O
79	the	N	O
80	combination	N	O
81	chemotherapy	N	O
82	arm	N	O
83	(	N	O
84	n	N	O
85	=	N	O
86	150	N	O
87	)	N	O
88	were	N	O
89	first	N	O
90	given	N	O
91	cyclophosphamide	N	O
92	500	N	O
93	mg/m2	N	O
94	,	N	O
95	E	N	O
96	60	N	O
97	mg/m2	N	O
98	,	N	O
99	and	N	O
100	fluorouracil	N	O
101	500	N	O
102	mg/m2	N	O
103	three	N	O
104	times	N	O
105	per	N	O
106	week	N	O
107	(	N	O
108	CEF	N	O
109	)	N	O
110	followed	N	O
111	by	N	O
112	M	N	O
113	8	N	O
114	mg/m2	N	O
115	plus	N	O
116	vinblastine	N	O
117	(	N	O
118	V	N	O
119	)	N	O
120	6	N	O
121	mg/m2	N	O
122	every	N	O
123	4	N	O
124	weeks	N	O
125	.	N	O

126	Exclusion	N	O
127	criteria	N	O
128	included	N	O
129	age	N	O
130	greater	N	O
131	than	N	O
132	70	N	O
133	years	N	O
134	,	N	O
135	World	N	O
136	Health	N	O
137	Organization	N	O
138	(	N	O
139	WHO	N	O
140	)	N	O
141	performance	N	O
142	status	N	O
143	greater	N	O
144	than	N	O
145	2	N	O
146	,	N	O
147	prior	N	O
148	chemotherapy	N	O
149	for	N	O
150	metastatic	N	O
151	disease	N	O
152	,	N	O
153	and	N	O
154	presence	N	O
155	of	N	O
156	liver	N	O
157	metastases	N	O
158	in	N	O
159	patients	N	O
160	younger	N	O
161	than	N	O
162	50	N	O
163	.	N	O

164	An	N	I-Premise
165	objective	N	I-Premise
166	response	N	I-Premise
167	(	N	I-Premise
168	complete	N	I-Premise
169	[	N	I-Premise
170	CR	N	I-Premise
171	]	N	I-Premise
172	or	N	I-Premise
173	partial	N	I-Premise
174	[	N	I-Premise
175	PR	N	I-Premise
176	]	N	I-Premise
177	)	N	I-Premise
178	was	N	I-Premise
179	obtained	N	I-Premise
180	in	N	I-Premise
181	55	N	I-Premise
182	%	N	I-Premise
183	,	N	I-Premise
184	48	N	I-Premise
185	%	N	I-Premise
186	,	N	I-Premise
187	16	N	I-Premise
188	%	N	I-Premise
189	,	N	I-Premise
190	and	N	I-Premise
191	7	N	I-Premise
192	%	N	I-Premise
193	of	N	I-Premise
194	patients	N	I-Premise
195	treated	N	I-Premise
196	with	N	I-Premise
197	CEF	N	I-Premise
198	,	N	I-Premise
199	E	N	I-Premise
200	,	N	I-Premise
201	M	N	I-Premise
202	,	N	I-Premise
203	and	N	I-Premise
204	MV	N	I-Premise
205	,	N	I-Premise
206	respectively	N	I-Premise
207	.	N	I-Premise

208	A	N	I-Premise
209	response	N	I-Premise
210	to	N	I-Premise
211	CEF	N	I-Premise
212	tended	N	I-Premise
213	to	N	I-Premise
214	last	N	I-Premise
215	longer	N	I-Premise
216	than	N	I-Premise
217	a	N	I-Premise
218	response	N	I-Premise
219	to	N	I-Premise
220	E	N	I-Premise
221	(	N	I-Premise
222	median	N	I-Premise
223	,	N	I-Premise
224	12	N	I-Premise
225	v	N	I-Premise
226	10.5	N	I-Premise
227	months	N	I-Premise
228	;	N	I-Premise
229	P	N	I-Premise
230	=	N	I-Premise
231	.07	N	I-Premise
232	)	N	I-Premise
233	.	N	I-Premise

234	Treatment-related	N	I-Premise
235	toxicity	N	I-Premise
236	was	N	I-Premise
237	less	N	I-Premise
238	in	N	I-Premise
239	the	N	I-Premise
240	single-agent	N	I-Premise
241	arm	N	I-Premise
242	and	N	I-Premise
243	quality-of-life	N	I-Premise
244	(	N	I-Premise
245	QOL	N	I-Premise
246	)	N	I-Premise
247	analysis	N	I-Premise
248	favored	N	I-Premise
249	the	N	I-Premise
250	single-agent	N	I-Premise
251	arm	N	I-Premise
252	.	N	I-Premise

253	No	N	I-Premise
254	significant	N	I-Premise
255	difference	N	I-Premise
256	in	N	I-Premise
257	time	N	I-Premise
258	to	N	I-Premise
259	progression	N	I-Premise
260	or	N	I-Premise
261	survival	N	I-Premise
262	was	N	I-Premise
263	found	N	I-Premise
264	between	N	I-Premise
265	the	N	I-Premise
266	two	N	I-Premise
267	arms	N	I-Premise
268	.	N	I-Premise

269	Similarly	N	I-Premise
270	,	N	I-Premise
271	no	N	I-Premise
272	difference	N	I-Premise
273	in	N	I-Premise
274	survival	N	I-Premise
275	was	N	I-Premise
276	found	N	I-Premise
277	when	N	I-Premise
278	the	N	I-Premise
279	patients	N	I-Premise
280	who	N	I-Premise
281	received	N	I-Premise
282	both	N	I-Premise
283	the	N	I-Premise
284	planned	N	I-Premise
285	first-and	N	I-Premise
286	second-line	N	I-Premise
287	treatments	N	I-Premise
288	were	N	I-Premise
289	compared	N	I-Premise
290	or	N	I-Premise
291	when	N	I-Premise
292	survival	N	I-Premise
293	was	N	I-Premise
294	calculated	N	I-Premise
295	from	N	I-Premise
296	the	N	I-Premise
297	beginning	N	I-Premise
298	of	N	I-Premise
299	the	N	I-Premise
300	second-line	N	I-Premise
301	therapy	N	I-Premise
302	.	N	I-Premise

303	Patients	N	I-Claim
304	treated	N	I-Claim
305	with	N	I-Claim
306	single-agent	N	I-Claim
307	E	N	I-Claim
308	followed	N	I-Claim
309	by	N	I-Claim
310	single-agent	N	I-Claim
311	M	N	I-Claim
312	had	N	I-Claim
313	similar	N	I-Claim
314	survival	N	I-Claim
315	,	N	I-Claim
316	but	N	I-Claim
317	less	N	I-Claim
318	treatment-related	N	I-Claim
319	toxicity	N	I-Claim
320	and	N	I-Claim
321	better	N	I-Claim
322	QOL	N	I-Claim
323	as	N	I-Claim
324	compared	N	I-Claim
325	with	N	I-Claim
326	those	N	I-Claim
327	treated	N	I-Claim
328	with	N	I-Claim
329	CEF	N	I-Claim
330	followed	N	I-Claim
331	by	N	I-Claim
332	MV	N	I-Claim
333	.	N	I-Claim

1	Vinorelbine	N	I-Claim
2	,	N	I-Claim
3	a	N	I-Claim
4	semisynthetic	N	I-Claim
5	vinca	N	I-Claim
6	alkaloid	N	I-Claim
7	,	N	I-Claim
8	represents	N	I-Claim
9	a	N	I-Claim
10	well-tolerated	N	I-Claim
11	treatment	N	I-Claim
12	for	N	I-Claim
13	elderly	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	advanced	N	I-Claim
17	non-small-cell	N	I-Claim
18	lung	N	I-Claim
19	cancer	N	I-Claim
20	(	N	I-Claim
21	NSCLC	N	I-Claim
22	)	N	I-Claim
23	.	N	I-Claim

24	We	N	O
25	explored	N	O
26	the	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	(	N	O
31	QoL	N	O
32	)	N	O
33	of	N	O
34	such	N	O
35	patients	N	O
36	in	N	O
37	a	N	O
38	multicenter	N	O
39	randomized	N	O
40	trial	N	O
41	that	N	O
42	compared	N	O
43	vinorelbine	N	O
44	treatment	N	O
45	with	N	O
46	supportive	N	O
47	care	N	O
48	alone	N	O
49	.	N	O

50	Eligible	N	O
51	patients	N	O
52	were	N	O
53	70	N	O
54	years	N	O
55	of	N	O
56	age	N	O
57	or	N	O
58	older	N	O
59	,	N	O
60	had	N	O
61	stage	N	O
62	IV	N	O
63	or	N	O
64	IIIB	N	O
65	NSCLC	N	O
66	that	N	O
67	was	N	O
68	ineligible	N	O
69	for	N	O
70	radiotherapy	N	O
71	,	N	O
72	and	N	O
73	had	N	O
74	a	N	O
75	performance	N	O
76	status	N	O
77	of	N	O
78	0-2	N	O
79	(	N	O
80	a	N	O
81	status	N	O
82	of	N	O
83	fully	N	O
84	active	N	O
85	to	N	O
86	a	N	O
87	status	N	O
88	of	N	O
89	capable	N	O
90	of	N	O
91	all	N	O
92	self-care	N	O
93	but	N	O
94	unable	N	O
95	to	N	O
96	work	N	O
97	)	N	O
98	.	N	O

99	Vinorelbine	N	O
100	was	N	O
101	given	N	O
102	intravenously	N	O
103	on	N	O
104	days	N	O
105	1	N	O
106	and	N	O
107	8	N	O
108	of	N	O
109	a	N	O
110	21-day	N	O
111	treatment	N	O
112	cycle	N	O
113	,	N	O
114	for	N	O
115	a	N	O
116	total	N	O
117	of	N	O
118	six	N	O
119	cycles	N	O
120	.	N	O

121	QoL	N	O
122	was	N	O
123	evaluated	N	O
124	with	N	O
125	European	N	O
126	Organization	N	O
127	for	N	O
128	Research	N	O
129	and	N	O
130	Treatment	N	O
131	of	N	O
132	Cancer	N	O
133	questionnaires	N	O
134	QLQ-C30	N	O
135	and	N	O
136	QLQ-LC13	N	O
137	,	N	O
138	and	N	O
139	the	N	O
140	QoL	N	O
141	data	N	O
142	were	N	O
143	analyzed	N	O
144	by	N	O
145	fitting	N	O
146	a	N	O
147	linear	N	O
148	mixed	N	O
149	model	N	O
150	for	N	O
151	each	N	O
152	QoL	N	O
153	scale	N	O
154	.	N	O

155	Survival	N	O
156	curves	N	O
157	were	N	O
158	plotted	N	O
159	and	N	O
160	were	N	O
161	compared	N	O
162	with	N	O
163	the	N	O
164	Mantel-Haenszel	N	O
165	test	N	O
166	.	N	O

167	Relative	N	O
168	hazards	N	O
169	of	N	O
170	death	N	O
171	and	N	O
172	95	N	O
173	%	N	O
174	confidence	N	O
175	intervals	N	O
176	(	N	O
177	CIs	N	O
178	)	N	O
179	were	N	O
180	estimated	N	O
181	by	N	O
182	the	N	O
183	Cox	N	O
184	model	N	O
185	.	N	O

186	Investigators	N	O
187	,	N	O
188	blinded	N	O
189	to	N	O
190	the	N	O
191	results	N	O
192	,	N	O
193	stopped	N	O
194	the	N	O
195	trial	N	O
196	early	N	O
197	because	N	O
198	of	N	O
199	a	N	O
200	low	N	O
201	enrollment	N	O
202	rate	N	O
203	.	N	O

204	(	N	O
205	From	N	O
206	April	N	O
207	1996	N	O
208	to	N	O
209	November	N	O
210	1997	N	O
211	,	N	O
212	191	N	O
213	of	N	O
214	the	N	O
215	350	N	O
216	targeted	N	O
217	patients	N	O
218	were	N	O
219	randomly	N	O
220	assigned	N	O
221	.	N	O

222	)	N	O
223	Data	N	O
224	from	N	O
225	161	N	O
226	patients	N	O
227	have	N	O
228	been	N	O
229	analyzed	N	O
230	.	N	O

231	Vinorelbine-treated	N	I-Premise
232	patients	N	I-Premise
233	scored	N	I-Premise
234	better	N	I-Premise
235	than	N	I-Premise
236	control	N	I-Premise
237	patients	N	I-Premise
238	on	N	I-Premise
239	QoL	N	I-Premise
240	functioning	N	I-Premise
241	scales	N	I-Premise
242	,	N	I-Premise
243	and	N	I-Premise
244	they	N	I-Premise
245	reported	N	I-Premise
246	fewer	N	I-Premise
247	lung	N	I-Premise
248	cancer-related	N	I-Premise
249	symptoms	N	I-Premise
250	but	N	I-Premise
251	reported	N	I-Premise
252	worse	N	I-Premise
253	toxicity-related	N	I-Premise
254	symptoms	N	I-Premise
255	.	N	I-Premise

256	There	N	I-Premise
257	was	N	I-Premise
258	a	N	I-Premise
259	statistically	N	I-Premise
260	significant	N	I-Premise
261	(	N	I-Premise
262	two-sided	N	I-Premise
263	P	N	I-Premise
264	=	N	I-Premise
265	.03	N	I-Premise
266	)	N	I-Premise
267	survival	N	I-Premise
268	advantage	N	I-Premise
269	for	N	I-Premise
270	patients	N	I-Premise
271	receiving	N	I-Premise
272	vinorelbine	N	I-Premise
273	;	N	I-Premise
274	median	N	I-Premise
275	survival	N	I-Premise
276	increased	N	I-Premise
277	from	N	I-Premise
278	21	N	I-Premise
279	to	N	I-Premise
280	28	N	I-Premise
281	weeks	N	I-Premise
282	in	N	I-Premise
283	the	N	I-Premise
284	vinorelbine-treated	N	I-Premise
285	group	N	I-Premise
286	.	N	I-Premise

287	The	N	I-Premise
288	relative	N	I-Premise
289	hazard	N	I-Premise
290	of	N	I-Premise
291	death	N	I-Premise
292	for	N	I-Premise
293	vinorelbine-treated	N	I-Premise
294	patients	N	I-Premise
295	was	N	I-Premise
296	0.65	N	I-Premise
297	(	N	I-Premise
298	95	N	I-Premise
299	%	N	I-Premise
300	CI	N	I-Premise
301	=	N	I-Premise
302	0.45-0.93	N	I-Premise
303	)	N	I-Premise
304	.	N	I-Premise

305	Vinorelbine	N	I-Claim
306	improves	N	I-Claim
307	survival	N	I-Claim
308	of	N	I-Claim
309	elderly	N	I-Claim
310	patients	N	I-Claim
311	with	N	I-Claim
312	advanced	N	I-Claim
313	NSCLC	N	I-Claim
314	and	N	I-Claim
315	possibly	N	I-Claim
316	improves	N	I-Claim
317	overall	N	I-Claim
318	QoL	N	I-Claim
319	.	N	I-Claim

